PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Marsit, CJ; Liu, M; Nelson, HH; Posner, M; Suzuki, M; Kelsey, KT				Marsit, CJ; Liu, M; Nelson, HH; Posner, M; Suzuki, M; Kelsey, KT			Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival	ONCOGENE			English	Article						methylation; NSCLC; HNSCC; Fanconi anemia; BRCA	PROMOTER HYPERMETHYLATION; DNA METHYLATION; OVARIAN-TUMORS; BRCA1 PROMOTER; CPG ISLANDS; GENE; SUSCEPTIBILITY; EXPOSURE; BREAST; ASSOCIATION	Inactivation of the FANC-BRCA pathway via promoter methylation of the FANCF gene renders cells sensitive to DNA crosslinking agents, and has been identified in ovarian cancer cell lines and sporadic primary tumor tissues. We investigated epigenetic alterations in the FANC-BRCA pathway in head and neck squamous cell carcinomas (HNSCC) and non-small-cell lung cancers (NSCLC) using methylation-specific PCR. Promoter methylation of FANCF occurred in 15% (13/89) of HNSCCs and 14% (22/158) of NSCLCs. Methylation of BRCA1 occurred only in 6/158 NSCLC, and was limited to adenocarcinomas and large-cell carcinomas of the lung. No methylation of BRCA2 was detected. FANCF methylation was associated with a shorter duration of tobacco use (P=0.03) and a younger age of starting smoking (P = 0.06) in NSCLC, and with a greater number of years of alcohol drinking (P=0.02) in HNSCC. In adenocarcinomas of the lung, FANCF promoter methylation was a significant predictor of poor survival with a hazard ratio of 3.1 (95% Cl 1.2-7.9). This study demonstrates that inactivation of the FANC-BRCA pathway is relatively common in solid tumors and may be related to tobacco and alcohol exposure and survival of these patients.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Med Oncol, Boston, MA 02115 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol, Dallas, TX USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kelsey, KT (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave, Boston, MA 02115 USA.	kelsey@hsph.harvard.edu	Kelsey, Karl T/I-1252-2014	Marsit, Carmen/0000-0003-4566-150X; Nelson, Heather/0000-0003-1901-9513	NCI NIH HHS [T32CA09078, CA78609] Funding Source: Medline; NIEHS NIH HHS [ES00002] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078609, T32CA009078] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alter BP, 1996, AM J HEMATOL, V53, P99, DOI 10.1002/(SICI)1096-8652(199610)53:2<99::AID-AJH7>3.3.CO;2-M; AUERBACH AD, 1976, NATURE, V261, P494, DOI 10.1038/261494a0; Baldwin RL, 2000, CANCER RES, V60, P5329; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Esteller M, 2001, CANCER RES, V61, P3225; Fang JY, 2001, J GASTROEN HEPATOL, V16, P960, DOI 10.1046/j.1440-1746.2001.02554.x; Gras E, 2001, CANCER-AM CANCER SOC, V92, P787, DOI 10.1002/1097-0142(20010815)92:4<787::AID-CNCR1384>3.0.CO;2-4; Hasegawa M, 2002, ONCOGENE, V21, P4231, DOI 10.1038/sj.onc.1205528; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; ISHIDA R, 1982, CANCER RES, V42, P4000; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Kim DH, 2001, CANCER RES, V61, P3419; Kim DH, 2001, ONCOGENE, V20, P1765, DOI 10.1038/sj.onc.1204302; Kutler DI, 2003, BLOOD, V101, P1249, DOI 10.1182/blood-2002-07-2170; Miyamoto K, 2002, JPN J CLIN ONCOL, V32, P79, DOI 10.1093/jjco/hyf020; Nelson HH, 1999, J NATL CANCER I, V91, P2032, DOI 10.1093/jnci/91.23.2032; Olshan AF, 1997, ONCOGENE, V14, P811, DOI 10.1038/sj.onc.1200892; Phelps RM, 1996, J CELL BIOCHEM, P32; Potter JD, 1999, JNCI-J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916; Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761; ROTHMAN K, 1972, J CHRON DIS, V25, P711, DOI 10.1016/0021-9681(72)90006-9; SASAKI MS, 1973, CANCER RES, V33, P1829; Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852; WANG X, 1995, CANCER EPIDEM BIOMAR, V4, P543	26	181	197	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					1000	1004		10.1038/sj.onc.1207256	http://dx.doi.org/10.1038/sj.onc.1207256			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647419				2022-12-17	WOS:000188486600016
J	Berchem, G; Glondu, M; Gleizes, M; Brouillet, JP; Vignon, F; Garcia, M; Liaudet-Coopman, E				Berchem, G; Glondu, M; Gleizes, M; Brouillet, JP; Vignon, F; Garcia, M; Liaudet-Coopman, E			Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis	ONCOGENE			English	Article						cathepsin-D; cancer; proliferation; angiogenesis; apoptosis	BREAST-CANCER CELLS; CARCINOMA; GROWTH; METASTASIS; PROTEASE; MATRIX	Cathepsin-D is an independent marker of poor prognosis in human breast cancer. We previously showed that human wild-type cathepsin-D, as well as its mutated form devoid of proteolytic activity stably transfected in 3Y1-Ad12 cancer cells, stimulated tumor growth. To investigate the mechanisms by which human cathepsin-D and its catalytically-inactive counterpart promoted tumor growth in vivo, we quantified the expression of proliferating cell nuclear antigen, the number of blood vessels and of apoptotic cells in M-AM tumor xenografts. We first verified that both human wild-type and mutated cathepsin-D were expressed at a high level in cathepsin-D xenografts, whereas no human cathepsin-D was detected in control xenografts. Our immunohistochemical studies then revealed that both wild-type cathepsin-D and catalytically-inactive cathepsin-D, increased proliferating cell nuclear antigen expression and tumor angiogenesis. Interestingly, wild-type cathepsin-D significantly inhibited tumor apoptosis, whereas catalytically-inactive cathepsin-D did not. We therefore propose that human. cathepsin-D stimulates tumor growth by acting-directly or indirectly-as a mitogenic factor on both cancer and endothelial cells independently of its catalytic activity. Our overall results provide the first mechanistic evidences on the essential role of cathepsin-D at multiple tumor progression steps, affecting cell proliferation, angiogenesis and apoptosis.	Univ Montpellier 1, INSERM, U540, F-34090 Montpellier, France; CHU A Villeneuve, Biol Cellulaire Lab, F-34295 Montpellier 5, France; Ctr Hosp Luxembourg 4, Lab Hemato Cancerol, L-1210 Luxembourg, Luxembourg	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; Luxembourg Hospital Center	Liaudet-Coopman, E (corresponding author), Univ Montpellier 1, INSERM, U540, 60 rue Navacelles, F-34090 Montpellier, France.		Berchem, Guy/C-9364-2014; Liaudet-Coopman, Emmanuelle/N-4744-2017	Berchem, Guy/0000-0003-0157-2257; Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690				BARRETT AJ, 1970, BIOCHEM J, V117, P601, DOI 10.1042/bj1170601; BRIOZZO P, 1991, EXP CELL RES, V194, P252, DOI 10.1016/0014-4827(91)90362-X; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Ferrandina G, 1997, BRIT J CANCER, V76, P661, DOI 10.1038/bjc.1997.442; Foekens JA, 1999, BRIT J CANCER, V79, P300, DOI 10.1038/sj.bjc.6990048; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; GARCIA M, 1990, ONCOGENE, V5, P1809; GARCIA M, 1985, CANCER RES, V45, P709; Glondu M, 2001, ONCOGENE, V20, P6920, DOI 10.1038/sj.onc.1204843; Gonzalez-Vela MC, 1999, HISTOPATHOLOGY, V34, P35; Kagedal K, 2001, FASEB J, V15, P1592, DOI 10.1096/fj.00-0708fje; LIAUDET E, 1994, ONCOGENE, V9, P1145; LIAUDET E, 1995, CELL GROWTH DIFFER, V6, P1045; LiaudetCoopman EDE, 1997, CLIN CANCER RES, V3, P179; Morikawa W, 2000, J BIOL CHEM, V275, P38912, DOI 10.1074/jbc.M005402200; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; ROCHEFORT H, 1987, J CELL BIOCHEM, V35, P17, DOI 10.1002/jcb.240350103; Rochefort H, 1999, APMIS, V107, P86, DOI 10.1111/j.1699-0463.1999.tb01530.x; ROCHEFORT H, 1992, EUR J CANCER, V28A, P1780, DOI 10.1016/0959-8049(92)90003-K; ROGER P, 1994, HUM PATHOL, V25, P863, DOI 10.1016/0046-8177(94)90004-3; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Tsukuba T, 2000, MOL CELLS, V10, P601, DOI 10.1007/s100590000019; VIGNON F, 1986, ENDOCRINOLOGY, V118, P1537, DOI 10.1210/endo-118-4-1537; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755	24	181	195	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5951	5955		10.1038/sj.onc.1205745	http://dx.doi.org/10.1038/sj.onc.1205745			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185597				2022-12-17	WOS:000177520900017
J	Zhang, TD; Chen, GQ; Wang, ZG; Wang, ZY; Chen, SJ; Chen, Z				Zhang, TD; Chen, GQ; Wang, ZG; Wang, ZY; Chen, SJ; Chen, Z			Arsenic trioxide, a therapeutic agent for APL	ONCOGENE			English	Article						arsenic trioxide (AS(2)O(3)); acute promyelocytic leukemia (APL); apoptosis; differentiation; PML-RAR alpha	ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; PML/RAR-ALPHA PROTEIN; PML-RAR-ALPHA; IN-VITRO; MEDIATED APOPTOSIS; GROWTH-INHIBITION; CLINICAL-EFFICACY; CELL APOPTOSIS; RESISTANT	Acute promyelocytic leukemia (APL) is an interesting model in cancer research, because it can respond to the differentiation/apoptosis induction therapy using all-traps retinoic acid (ATRA) and arsenic trioxide (As2O3). Over the past 5 years, it has been well demonstrated that As2O3 induces a high complete remission (CR) rate in both primary and relapsed APL patients (around 85 similar to 90%). The side effects are mild to moderate in relapsed patients, while severe hepatic lesions have been found in some primary cases. After CR obtained in relapsed patients, chemotherapy in combination with As2O3 as post-remission therapy has given better survival than those treated with As2O3 alone. The effect of As2O3 has been shown to be related to the expression of APL-specific PML-RAR alpha oncoprotein, and there is a synergistic effect between As2O3 and ATRA in an APL mouse model. Cell biology studies have revealed that As2O3 exerts dose-dependent dual effects on APL cells. Apoptosis is evident when cells are treated with 0.5 similar to2.0 muM of As2O3 while partial differentiation is observed using low concentrations (0.1 similar to0.5 muM) of the drug. The apoptosis-inducing effect is associated with the collapse of mitochondrial transmembrane potentials in a thiol-dependent manner, whereas the mechanisms underlying APL cell differentiation induced by low dose arsenic remain to be explored. Interestingly, As2O3 over a wide range of concentration (0.1 similar to2.0 mum) induces degradation of a key leukemogenic protein, PML-RAR alpha, as well as the wild-type PML, thus setting up a good example of targeting therapy for human cancers.	Shanghai Med Univ 2, Rui Jin Hosp, Shanghai Inst Hematol, Shanghai 200025, Peoples R China; Harbin Med Univ, Hosp 1, Harbin 150001, Peoples R China	Shanghai Jiao Tong University; Harbin Medical University	Chen, Z (corresponding author), Shanghai Med Univ 2, Rui Jin Hosp, Shanghai Inst Hematol, 194 Rui Jin Rd II, Shanghai 200025, Peoples R China.	zchen@ms.stn.sh.cn		chen, guo qiang/0000-0003-4936-2363				Agis H, 1999, ANN HEMATOL, V78, P329, DOI 10.1007/s002770050523; Akao Y, 1999, FEBS LETT, V455, P59, DOI 10.1016/S0014-5793(99)00841-8; Andre C, 1996, EXP CELL RES, V229, P253, DOI 10.1006/excr.1996.0368; Barbui T, 1998, BLOOD, V91, P3093, DOI 10.1182/blood.V91.9.3093.3093_3093_3102; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Cai X, 2000, LEUKEMIA, V14, P262, DOI 10.1038/sj.leu.2401650; Camacho LH, 2000, J CLIN ONCOL, V18, P2620, DOI 10.1200/JCO.2000.18.13.2620; Chen GQ, 1997, BLOOD, V89, P3345; Chen GQ, 1996, BLOOD, V88, P1052; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Chen Z, 2001, SEMIN HEMATOL, V38, P26, DOI 10.1053/shem.2001.20863; Cheng GX, 1999, P NATL ACAD SCI USA, V96, P6318, DOI 10.1073/pnas.96.11.6318; Cohen MH, 2001, ONCOLOGIST, V6, P4, DOI 10.1634/theoncologist.6-1-4; Conrad ME, 1999, NEW ENGL J MED, V340, P1043; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; Deaglio S, 2001, LEUKEMIA RES, V25, P227, DOI 10.1016/S0145-2126(00)00105-3; Galimberti S, 1999, BONE MARROW TRANSPL, V24, P345, DOI 10.1038/sj.bmt.1701875; Gallagher RE, 1998, NEW ENGL J MED, V339, P1389, DOI 10.1056/NEJM199811053391909; Gianni M, 1999, LEUKEMIA, V13, P739, DOI 10.1038/sj.leu.2401419; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; Huang CH, 1999, PACE, V22, P965, DOI 10.1111/j.1540-8159.1999.tb06826.x; Huang CS, 1999, CANCER RES, V59, P3053; Huang SC, 2000, BIOCHEM PHARMACOL, V60, P771, DOI 10.1016/S0006-2952(00)00397-X; Huang SY, 1998, BRIT J HAEMATOL, V103, P1092, DOI 10.1046/j.1365-2141.1998.01079.x; Huff J, 2000, TOXICOL SCI, V55, P17, DOI 10.1093/toxsci/55.1.17; Jiang XH, 2001, INT J CANCER, V91, P173, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1039>3.0.CO;2-D; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Jing YK, 2001, BLOOD, V97, P264, DOI 10.1182/blood.V97.1.264; Kinjo K, 2000, LEUKEMIA, V14, P431, DOI 10.1038/sj.leu.2401646; Kitamura K, 2000, BRIT J HAEMATOL, V108, P696, DOI 10.1046/j.1365-2141.2000.01933.x; Kitamura K, 1997, INT J HEMATOL, V65, P179; Kitamura K, 2000, LEUKEMIA, V14, P1743, DOI 10.1038/sj.leu.2401900; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; Kroemer G, 1999, JNCI-J NATL CANCER I, V91, P743, DOI 10.1093/jnci/91.9.743; Kwong YL, 1997, BLOOD, V89, P3487, DOI 10.1182/blood.V89.9.3487; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Li YM, 1999, CANCER RES, V59, P776; Lin CP, 2000, LEUKEMIA LYMPHOMA, V38, P191, DOI 10.3109/10428190009060333; Lin CP, 2000, LEUKEMIA LYMPHOMA, V38, P195, DOI 10.3109/10428190009060334; Look AT, 1998, J NATL CANCER I, V90, P86, DOI 10.1093/jnci/90.2.86; McCabe MJ, 2000, J PHARMACOL EXP THER, V295, P724; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mervis J, 1996, SCIENCE, V273, P578, DOI 10.1126/science.273.5275.578; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Ohnishi K, 2000, ANN INTERN MED, V133, P881, DOI 10.7326/0003-4819-133-11-200012050-00012; Ohsawa M, 2000, LEUKEMIA, V14, P941, DOI 10.1038/sj.leu.2401755; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Roboz GJ, 2000, BLOOD, V96, P1525, DOI 10.1182/blood.V96.4.1525.h8001525_1525_1530; Seol JG, 2001, INT J ONCOL, V18, P249; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Shen Y, 2001, LEUKEMIA, V15, P735, DOI 10.1038/sj.leu.2402106; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Shen ZY, 1999, INT J MOL MED, V4, P33; Slack JL, 2000, ANN HEMATOL, V79, P227, DOI 10.1007/s002770050585; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Sternsdorf T, 1999, MOL CELL BIOL, V19, P5170; Sun H. D., 1992, CHIN J INTEGRAT CHIN, V12, P170; Tallman MS, 1999, SEMIN THROMB HEMOST, V25, P209, DOI 10.1055/s-2007-994922; Tamm I, 1999, NEW ENGL J MED, V340, P1043; Uslu R, 2000, CLIN CANCER RES, V6, P4957; Wang Z Y, 2000, Lancet Oncol, V1, P101, DOI 10.1016/S1470-2045(00)00017-6; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Warrell R P Jr, 1999, Haematologica, V84 Suppl EHA-4, P75; ZHANG P, 1996, CHIN J HEMATOL, V17, P58; Zhang T, 2000, MODERN PATHOL, V13, P954, DOI 10.1038/modpathol.3880174; Zhang W, 1998, LEUKEMIA, V12, P1383, DOI 10.1038/sj.leu.2401112; Zhu J, 1999, LEUKEMIA, V13, P1062, DOI 10.1038/sj.leu.2401448; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978; Zhu XH, 1999, J NATL CANCER I, V91, P772, DOI 10.1093/jnci/91.9.772	73	181	201	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7146	7153		10.1038/sj.onc.1204762	http://dx.doi.org/10.1038/sj.onc.1204762			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704843				2022-12-17	WOS:000171891900003
J	Li, RZ; Pei, HP; Watson, DK				Li, RZ; Pei, HP; Watson, DK			Regulation of Ets function by protein-protein interactions	ONCOGENE			English	Review						protein-protein interaction; Ets; transcriptional modulation; combinatorial control	SERUM RESPONSE FACTOR; NF-KAPPA-B; TRANSCRIPTION FACTORS PU.1; TERNARY COMPLEX FACTORS; CORE-BINDING-FACTOR; DNA-BINDING; GENE-EXPRESSION; PHYSICAL INTERACTIONS; FUSION PROTEIN; C-FOS	Ets proteins are a family of transcription factors that share an 85 amino acid conserved DNA binding domain, the ETS domain. Over 25 mammalian Ets family members control important biological processes, including cellular proliferation, differentiation, lymphocyte development and activation, transformation and apoptosis by recognizing the GGA core motif in the promoter or enhancer of their target genes, Protein-protein interactions regulates DNA binding, subcellular localization, target gene selection and transcriptional activity of Ets proteins. Combinatorial control is a characteristic property of Ets family members, involving interaction between Ets and other key transcriptional factors such as AP-1, NF kappaB and Pax family members. Specific domains of Ets proteins interact with many protein motifs such as bHLH, bZipper and Paired domain. Such interactions coordinate cellular processes in response to diverse signals including cytokines, growth factors, antigen and cellular stresses.	Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Ctr Mol & Struct Biol, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Li, RZ (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, 86 Jonathan Lucas St,Room 315, Charleston, SC 29425 USA.				NCI NIH HHS [P01CA78582] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aittomaki S, 2000, J IMMUNOL, V164, P5689, DOI 10.4049/jimmunol.164.11.5689; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; BERGELSON S, 1994, BIOCHEM BIOPH RES CO, V200, P290, DOI 10.1006/bbrc.1994.1447; Bhat NK, 1996, INT J ONCOL, V8, P841; BHAT NK, 1994, CHALLENGES MODERN ME, V5, P63; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; Bradford AP, 2000, J BIOL CHEM, V275, P3100, DOI 10.1074/jbc.275.5.3100; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Buttice G, 1996, ONCOGENE, V13, P2297; Carrere S, 1998, ONCOGENE, V16, P3261, DOI 10.1038/sj.onc.1201868; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chakrabarti SR, 1999, P NATL ACAD SCI USA, V96, P7467, DOI 10.1073/pnas.96.13.7467; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Dalgleish P, 2000, NUCLEIC ACIDS RES, V28, P560, DOI 10.1093/nar/28.2.560; Dang W, 1998, MOL CELL BIOL, V18, P1477, DOI 10.1128/MCB.18.3.1477; Darby TG, 1997, ONCOGENE, V15, P3067, DOI 10.1038/sj.onc.1201503; Day RN, 1998, J BIOL CHEM, V273, P31909, DOI 10.1074/jbc.273.48.31909; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; Drewett V, 2000, J BIOL CHEM, V275, P1757, DOI 10.1074/jbc.275.3.1757; Eichbaum Q, 1997, BLOOD, V90, P4135, DOI 10.1182/blood.V90.10.4135; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; FISHER RJ, 1994, PROTEIN SCI, V3, P257; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GHYSDAEL J, 1997, ETS FAMILY TRANSCRIP; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; GITLIN SD, 1993, J VIROL, V67, P7307, DOI 10.1128/JVI.67.12.7307-7316.1993; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GOLDBERG Y, 1994, J BIOL CHEM, V269, P16566; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOTTSCHALK LR, 1993, J EXP MED, V178, P1681, DOI 10.1084/jem.178.5.1681; Graves BJ, 1998, COLD SPRING HARB SYM, V63, P621, DOI 10.1101/sqb.1998.63.621; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Gri G, 1998, J BIOL CHEM, V273, P6431, DOI 10.1074/jbc.273.11.6431; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Ho JMY, 1999, BLOOD, V93, P4354, DOI 10.1182/blood.V93.12.4354.412k30_4354_4364; JANKNECHT R, 1994, ONCOGENE, V9, P1273; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; JOHN S, 1995, MOL CELL BIOL, V15, P1786; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; Konishi Y, 1999, ONCOGENE, V18, P6795, DOI 10.1038/sj.onc.1203118; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; Ling Y, 1998, J BIOL CHEM, V273, P10506, DOI 10.1074/jbc.273.17.10506; Ling Y, 1997, EMBO J, V16, P2431, DOI 10.1093/emboj/16.9.2431; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MagnaghiJaulin L, 1996, NUCLEIC ACIDS RES, V24, P1052, DOI 10.1093/nar/24.6.1052; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; Mao SF, 1999, MOL CELL BIOL, V19, P3635; MAY M, 1993, BIOCHEMISTRY-US, V32, P11734, DOI 10.1021/bi00094a033; Mayall TP, 1997, GENE DEV, V11, P887, DOI 10.1101/gad.11.7.887; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NOTHIAS JY, 1993, J VIROL, V67, P3036, DOI 10.1128/JVI.67.6.3036-3047.1993; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Ortiz MA, 1999, P NATL ACAD SCI USA, V96, P2740, DOI 10.1073/pnas.96.6.2740; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Perkel JM, 1998, J IMMUNOL, V160, P241; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Rameil P, 2000, ONCOGENE, V19, P2086, DOI 10.1038/sj.onc.1203542; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1993, CANCER RES, V53, P215; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; SAWADA J, 1994, EMBO J, V13, P1396, DOI 10.1002/j.1460-2075.1994.tb06393.x; SEELER JS, 1993, VIROLOGY, V196, P442, DOI 10.1006/viro.1993.1500; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SHERIDAN PL, 1995, GENE DEV, V9, P2090, DOI 10.1101/gad.9.17.2090; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; Suzuki F, 1998, J BIOL CHEM, V273, P29302, DOI 10.1074/jbc.273.45.29302; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; Tian G, 1999, MOL CELL BIOL, V19, P2946; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; Wara-Aswapati N, 1999, MOL CELL BIOL, V19, P6803; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; WATSON DK, 2001, ENCY CANC; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Wheat W, 1999, MOL CELL BIOL, V19, P2231; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Yang ZY, 2000, J BIOL CHEM, V275, P21272, DOI 10.1074/jbc.M000145200; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zhao B, 2000, J VIROL, V74, P5151, DOI 10.1128/JVI.74.11.5151-5160.2000	135	181	183	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2000	19	55					6514	6523		10.1038/sj.onc.1204035	http://dx.doi.org/10.1038/sj.onc.1204035			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175367				2022-12-17	WOS:000166595000013
J	Ghosh, AK; Yuan, W; Mori, Y; Varga, J				Ghosh, AK; Yuan, W; Mori, Y; Varga, J			Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-beta involves functional cooperation with p300/CBP transcriptional coactivators	ONCOGENE			English	Article						type I collagen; transforming growth factor-beta; coactivators; p300/CBP; signal transduction; Smads	GROWTH-FACTOR-BETA; ADENOVIRAL ONCOPROTEIN E1A; HISTONE ACETYLTRANSFERASES; MOLECULAR-CLONING; TUMOR-SUPPRESSOR; BINDING-PROTEIN; RETINOIC ACID; DNA-BINDING; F9 CELLS; CBP	Transforming growth factor-beta (TGF-beta) stimulation of Type I collagen gene (COL1A2) transcription involves the Smad signal transduction pathway, but the mechanisms of Smad-mediated transcriptional activation are not fully understood. We now demonstrate that the ubiquitous transcriptional coactivators p300 and CREB-binding protein (CBP) enhanced basal as well as TGF-beta- or Smad3-induced COL1A2 promoter activity, and stimulated the expression of endogenous Type I collagen. The adenoviral E1A oncoprotein abrogated stimulation of COL1A2 activity in transfected fibroblasts, and reduced the basal level of collagen gene expression. This effect was due to specific interaction of E1A with cellular p300/CBP because (a) a mutant form of EIA defective in p300 binding failed to abrogate stimulation, and (b) forced expression of D300/CBP restored the ability of TGF-beta to stimulate COL1A2 promoter activity in the presence of EIA, The effect of p300 on COL1A2, transcription appeared to be due, in part, to its intrinsic acetyltransferase activity, as stimulation induced by a histone acetyltransferase-deficient mutant p300 was substantially reduced. Transactivation of COL1A2 by p300 involved the Smad signaling pathway, as Smad4-deficient cells failed to respond to p300, and stimulation nas rescued by overexpression of Smad4, Furthermore, minimal constructs containing only the Smad-binding CAGACA element of COL1A2 were transactivated by p300 in the presence of TGF-beta, These results indicate, for the first time, that the multifunctional p300/CBP coactivators play a major role in Smad-dependent TGF-beta stimulation of collagen gene expression in fibroblasts.	Univ Illinois, Coll Med, Sect Rheumatol MC733, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Varga, J (corresponding author), Univ Illinois, Coll Med, Sect Rheumatol MC733, 1158 Mol Biol Res Bldg,900 S Ashland Ave, Chicago, IL 60607 USA.				NIAMS NIH HHS [AR-46390, AR-42309] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR046390, R01AR042309] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; CHIRIVIA JC, 1993, NATURE, V365, P855; COUSSENS LM, 1994, J CELL PHYSIOL, V160, P435, DOI 10.1002/jcp.1041600306; Datto MB, 1997, MOL CELL BIOL, V17, P2030, DOI 10.1128/MCB.17.4.2030; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DYSON N, 1992, CANCER SURV, V12, P161; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kawabata M, 1999, J BIOCHEM, V125, P9, DOI 10.1093/oxfordjournals.jbchem.a022273; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Kon A, 1999, ONCOGENE, V18, P1837, DOI 10.1038/sj.onc.1202495; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; LI LY, 1995, GENE, V164, P229, DOI 10.1016/0378-1119(95)00508-4; Liu B, 1999, MOL CELL BIOL, V19, P424; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; Morozov A, 1997, J VIROL, V71, P3451, DOI 10.1128/JVI.71.5.3451-3457.1997; Muraoka M, 1996, ONCOGENE, V12, P1565; MYERS JC, 1981, P NATL ACAD SCI-BIOL, V78, P3516, DOI 10.1073/pnas.78.6.3516; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Padgett RW, 1998, BIOESSAYS, V20, P382, DOI 10.1002/(SICI)1521-1878(199805)20:5&lt;382::AID-BIES5&gt;3.0.CO;2-Q; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Schutte M, 1996, CANCER RES, V56, P2527; SOBULO OM, 1997, P NATL ACAD SCI USA, V94, P10215; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; VARGA J, 1987, BIOCHEM J, V247, P597, DOI 10.1042/bj2470597; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Waltzer L, 1999, EMBO J, V18, P1630, DOI 10.1093/emboj/18.6.1630; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	63	181	191	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3546	3555		10.1038/sj.onc.1203693	http://dx.doi.org/10.1038/sj.onc.1203693			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918613				2022-12-17	WOS:000088346500011
J	Smith, LM; Wise, SC; Hendricks, DT; Sabichi, AL; Bos, T; Reddy, P; Brown, PH; Birrer, MJ				Smith, LM; Wise, SC; Hendricks, DT; Sabichi, AL; Bos, T; Reddy, P; Brown, PH; Birrer, MJ			cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype	ONCOGENE			English	Article						cJun; AP-1; breast cancer; tumorigenicity; invasion; hormone resistance	RAT EMBRYO CELLS; C-JUN; AP-1 ACTIVITY; DNA-BINDING; GLUCOCORTICOID RECEPTOR; MALIGNANT PROGRESSION; INDEPENDENT GROWTH; MESSENGER-RNA; EXPRESSION; PROTEIN	We have previously demonstrated decreased Jun/AP-1 activity in the breast cancer cell line MCF-7 when compared to normal or immortalized mammary epithelial cells. In this paper, we overexpress Jun in MCF-7 cells (MCF7Jun) and demonstrate that it results in diverse biologic and biochemical changes, which mimic those seen clinically in breast cancer. Overexpression of Jun causes significant alterations in the composition of AP-1, decreased junB and increased fr a-l expression and results in an increased biologic aggressiveness. MCF7Jun cells exhibit increased cellular motility, increased expression of a matrix degrading enzyme MMP-9, increased in vitro chemoinvasion and tumor formation in nude mice in the absence of exogenous estrogens. Furthermore, MCF7Jun cells are unresponsive to the growth stimulating effects of estrogen and growth inhibitory effects of tamoxifen. Analysis of the estrogen receptor (ER) expression and activity showed that the MCF7Jun cells have no detectable ER. MCF-7 cells overexpressing mutant forms of cJun were responsive to the growth stimulatory effects of estrogen indicating that full-length cJun is required to acquire the estrogen-independent phenotype in breast cancer cells.	NCI, Med Branch, Dept Cell & Canc Biol, NIH, Rockville, MD 20850 USA; Eastern Virginia Med Sch, Dept Microbiol & Immunol, Norfolk, VA USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Eastern Virginia Medical School; University of Texas System; University of Texas Health San Antonio	Birrer, MJ (corresponding author), 9610 Med Ctr Dr,Room 300, Rockville, MD 20850 USA.							ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BIGNON E, 1989, J MED CHEM, V32, P2092, DOI 10.1021/jm00129a013; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; CLARKE R, 1989, J ENDOCRINOL, V122, P331, DOI 10.1677/joe.0.1220331; CLARKE R, 1989, P NATL ACAD SCI USA, V86, P3649, DOI 10.1073/pnas.86.10.3649; CLARKE R, 1990, ANN ONCOL, V1, P401, DOI 10.1093/oxfordjournals.annonc.a057790; DARBON JM, 1986, BIOCHEM PHARMACOL, V35, P2683, DOI 10.1016/0006-2952(86)90175-9; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DICKSON RB, 1995, MOL BIOL CANC MED, P241; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; Dumont JA, 1996, CELL GROWTH DIFFER, V7, P351; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; HolstHansen C, 1996, CLIN EXP METASTAS, V14, P297; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Lambert PA, 1997, SURGERY, V122, P372, DOI 10.1016/S0039-6060(97)90029-5; LEONESSA F, 1992, ACTA ONCOL, V31, P115, DOI 10.3109/02841869209088890; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; RITKE MK, 1994, BIOCHEM PHARMACOL, V48, P525, DOI 10.1016/0006-2952(94)90282-8; SACEDA M, 1991, J BIOL CHEM, V266, P17809; SATO H, 1993, ONCOGENE, V8, P395; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Smith LM, 1997, CANCER RES, V57, P3046; STANIER RY, 1976, MICROBIAL WORLD, P276; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; Szabo E, 1996, CANCER RES, V56, P305; Tang ZQ, 1997, MOL CELL BIOL, V17, P1274, DOI 10.1128/MCB.17.3.1274; THOMPSON EW, 1993, CLIN EXP METASTAS, V11, P15, DOI 10.1007/BF00880062; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; Uht RM, 1997, ENDOCRINOLOGY, V138, P2900, DOI 10.1210/en.138.7.2900; VIG E, 1994, MOL ENDOCRINOL, V8, P1336, DOI 10.1210/me.8.10.1336; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Yang LM, 1997, CANCER RES, V57, P4652; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972	44	181	190	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	1999	18	44					6063	6070		10.1038/sj.onc.1202989	http://dx.doi.org/10.1038/sj.onc.1202989			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557095				2022-12-17	WOS:000083359100012
J	Klesse, LJ; Meyers, KA; Marshall, CJ; Parada, LF				Klesse, LJ; Meyers, KA; Marshall, CJ; Parada, LF			Nerve growth factor induces survival and differentiation through two distinct signaling cascades in PC12 cells	ONCOGENE			English	Article						PC12 cells; nerve growth factor; map kinase; phosphatidylinositol 3-kinase	ADENOVIRUS-MEDIATED TRANSFER; TRK PROTOONCOGENE PRODUCT; TYROSINE KINASE-ACTIVITY; RAT SYMPATHETIC NEURONS; PHOSPHATIDYLINOSITOL 3-KINASE; PHEOCHROMOCYTOMA CELLS; PHOSPHOINOSITIDE 3-KINASE; NEUROTROPHIN RECEPTORS; AKT PROTOONCOGENE; BINDING-SITES	Nerve growth factor induces differentiation and survival of rat PC12 pheochromocytoma cells. The activation of the erk cascade has been implicated in transducing the multitude of signals induced by NGF. In order to explore the role of this signaling cascade in NGF mediated survival, differentiation and proliferation, we generated recombinant adenoviruses which express the intermediates of the erk cascade in their wild type, dominant negative and constitutively activated forms. We show that differentiation of PC12 cells requires activity of the ras/erk pathway, whereas inhibition of this pathway had no effect on survival or proliferation. Constitutively active forms of ras, raf and mek induced PC12 cell differentiation, while dominant interfering forms inhibited differentiation. Survival of PC12 cells in serum-free medium did not require activity of the ras/erk pathway. Instead, PI3 Kinase signaling was necessary for PC12 cell survival. Interestingly, constitutively activated versions of raf and mek were able to promote survival, but again this was dependent on activation of PI3 Kinase. Therefore, at least two distinct signaling pathways are required in PC12 cells for mediation of NGF functions.	Univ Texas, SW Med Ctr, Ctr Dev Biol, Dallas, TX 75235 USA; Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Parada, LF (corresponding author), Univ Texas, SW Med Ctr, Ctr Dev Biol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Parada, luis F/B-9400-2014	Klesse, Laura/0000-0003-1323-7720	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034296] Funding Source: NIH RePORTER; NINDS NIH HHS [R0I NS 34296] Funding Source: Medline; PHS HHS [T326M08203] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BORASIO GD, 1993, J CELL BIOL, V121, P665, DOI 10.1083/jcb.121.3.665; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EDWARDS SN, 1994, J CELL BIOL, V124, P537, DOI 10.1083/jcb.124.4.537; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Jackson TR, 1996, J CELL SCI, V109, P289; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Nakamura T, 1996, ONCOGENE, V13, P1111; Nobes CD, 1996, NEUROSCIENCE, V70, P1067, DOI 10.1016/0306-4522(95)00420-3; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; Rinkenberger JL, 1997, CURR OPIN GENET DEV, V7, P589, DOI 10.1016/S0959-437X(97)80004-4; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Snider WD, 1996, PHILOS T ROY SOC B, V351, P395, DOI 10.1098/rstb.1996.0034; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SZEBERENYI J, 1992, ONCOGENE, V7, P2105; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TISCHLER AS, 1975, NATURE, V258, P341, DOI 10.1038/258341a0; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOGEL KS, 1995, CELL, V82, P733, DOI 10.1016/0092-8674(95)90470-0; Wang JK, 1996, ONCOGENE, V13, P721; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yan CYI, 1998, J NEUROSCI, V18, P4042; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	72	181	186	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	1999	18	12					2055	2068		10.1038/sj.onc.1202524	http://dx.doi.org/10.1038/sj.onc.1202524			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321730				2022-12-17	WOS:000079346200003
J	Goldberg, Y; Nassif, II; Pittas, A; Tsai, LL; Dynlacht, BD; Rigas, B; Shiff, SJ				Goldberg, Y; Nassif, II; Pittas, A; Tsai, LL; Dynlacht, BD; Rigas, B; Shiff, SJ			The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: Alterations in tumor suppressor and cell cycle-regulatory proteins	ONCOGENE			English	Article						NSAIDs; colon cancer; cyclin-dependent kinases; p21(WAF-1); cyclins; tumor suppressor proteins	SODIUM-BUTYRATE; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; P53 MUTATIONS; GENE; LINE; PHOSPHORYLATION; TRANSFORMATION; INDUCTION; POLYPOSIS	Nonsteroidal anti-inflammatory drugs lower the incidence of and mortality from colon cancer. Sulindac reduces the number and size of polyps in patients with. familial adenomatous polyposis. We have shown that sulindac and sulindac sulfide reversibly reduce the proliferation rate of HT-29 colon cancer cells, alter their morphology, induce them to accumulate in the G(0)/ G(1) phase of the cell cycle, and sulindac sulfide induces cell death by apoptosis. In this study we confirmed that sulindac and sulindac sulfide prevent HT-29 cells from progressing from the G(0)/G(1) into the S phase. This block in cell cycle progression is associated with an initial rise, then an abrupt decrease in the levels of p34(cdc2) protein. Sulindac and sulindac sulfide decrease the levels of mitotic cyclins, induce the levels of p21(WAF-1/cip1), and reduce the total levels of pRB, with a relative increase in the amount of the underphosphorylated form of pRB in a time- and concentration-dependent manner. In addition, these compounds reduce the levels of mutant p53. These responses are not associated with intestinal cell differentiation and occur independent of the ability of these compounds to induce apoptosis. We conclude that sulindac and sulindac sulfide reduce the levels of major components of the molecular cell cycle machinery and alter the levels of several tumor suppressor proteins in a manner consistent with cell cycle quiescence. These mechanisms may be operative in vivo to account, in part, for the anti-neoplastic effects of these compounds.	ROCKEFELLER UNIV HOSP,HUMAN BEHAV & METAB LAB,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MED,NEW YORK,NY 10021; HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Rockefeller University; Cornell University; Harvard University								CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARKE AR, 1994, ONCOGENE, V9, P1767; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DUGGAN DE, 1980, DRUG METAB DISPOS, V8, P241; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FRITSCHE M, 1993, ONCOGENE, V8, P307; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GOPE R, 1993, CELL MOL BIOL, V39, P589; GOPE R, 1992, MOL CELL BIOCHEM, V110, P123, DOI 10.1007/BF02454189; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HANIF R, 1995, GASTROENTEROLOGY, V108, pA478; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HERZ F, 1981, ARCH BIOCHEM BIOPHYS, V210, P581, DOI 10.1016/0003-9861(81)90224-1; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; INSEL P A, 1990, P638; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG HP, 1995, ONCOGENE, V10, P1855; KASTAN MB, 1991, CANCER RES, V51, P6304; KIM YS, 1980, CANCER-AM CANCER SOC, V45, P1185, DOI 10.1002/1097-0142(19800315)45:5+<1185::AID-CNCR2820451324>3.0.CO;2-W; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PAGANINHILL A, 1994, SEMIN SURG ONCOL, V10, P158, DOI 10.1002/ssu.2980100303; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PIAZZA GA, 1995, CANCER RES, V55, P3110; RAO CV, 1995, CANCER RES, V55, P1464; RAZVI ES, 1995, ADV VIRUS RES, V45, P1, DOI 10.1016/S0065-3527(08)60057-3; RIGAS B, 1993, J LAB CLIN MED, V122, P518; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SCHROY PC, 1994, J CELL PHYSIOL, V161, P111, DOI 10.1002/jcp.1041610114; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; SHIFF SJ, 1996, EXP CELL RES, V222; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TSAI LH, 1993, ONCOGENE, V8, P1593; TURNER D, 1993, CAN MED ASSOC J, V149, P595; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119; WADDELL WR, 1983, J SURG ONCOL, V22, P197, DOI 10.1002/jso.2930220314; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG W, 1995, CANCER RES, V55, P668	62	181	186	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					893	901						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632912				2022-12-17	WOS:A1996TW68600021
J	BLAGOSKLONNY, MV; TORETSKY, J; NECKERS, L				BLAGOSKLONNY, MV; TORETSKY, J; NECKERS, L			GELDANAMYCIN SELECTIVELY DESTABILIZES AND CONFORMATIONALLY ALTERS MUTATED P53	ONCOGENE			English	Article						BENZOQUINONE ANSAMYCINS; GELDANAMYCIN; MUTATED P53; PROTEIN STABILITY	TUMOR-SUPPRESSOR PROTEIN; CANCER CELL-LINES; MUTANT P53; ACTIVATING MUTATIONS; BINDING-SITE; DNA-DAMAGE; COS CELLS; WILD-TYPE; GENE; TRANSFORMATION	Mutated p53 proteins interfere in the function of wild type p53 and may also serve as a dominant oncogene, The vast majority of p53 mutations result in a protein of altered conformation and prolonged half-life. We sought to examine whether geldanamycin, a drug capable of destabilizing several oncogene and proto-oncogene products, could alter the stability and DNA binding characteristics of several mutated p53 proteins, Brief exposure to GA destabilized the p53 protein of several breast, prostate and leukemic cell lines harboring mutated p53 alleles, resulting in a significant reduction in p53 steady state level and half-life. In contrast to its effects on mutated p53, GA altered neither steady state level nor inducibility of the wild type protein. In addition to its effects on protein stability, GA also altered the conformation of mutated p53, so that it was no longer detectable with a mutant conformation-specific antibody. Finally, mutated p53 protein isolated from GA-treated cells regained partial ability to bind a wild type-specific p53 DNA consensus sequence, These data indicate the feasability of pharmacologic intervention for altering the mutated p53 phenotype.	NCI,CLIN PHARMACOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AVILA MA, 1994, CANCER RES, V54, P2424; BARTEK J, 1990, ONCOGENE, V5, P893; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSIAO M, 1994, AM J PATHOL, V145, P702; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LU X, 1991, CELL, V70, P153; MILLER P, 1994, BIOCHEM BIOPH RES CO, V201, P1313, DOI 10.1006/bbrc.1994.1847; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MILNER J, 1990, ONCOGENE, V5, P1683; MURAKAMI Y, 1994, BIOCHEM J, V301, P63, DOI 10.1042/bj3010063; NEGRINI M, 1994, CANCER RES, V54, P1818; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PRICE BD, 1993, ONCOGENE, V8, P3055; RYAN JJ, 1994, LEUKEMIA RES, V18, P617, DOI 10.1016/0145-2126(94)90043-4; SHUE G, 1994, J BIOL CHEM, V269, P2702; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; UEHARA Y, 1989, CANCER RES, V49, P780; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZHANG W, 1992, ONCOGENE, V7, P1645	52	181	184	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					933	939						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675452				2022-12-17	WOS:A1995RU79800014
J	JIANG, HP; LIN, J; SU, ZZ; HERLYN, M; KERBEL, RS; WEISSMAN, BE; WELCH, DR; FISHER, PB				JIANG, HP; LIN, J; SU, ZZ; HERLYN, M; KERBEL, RS; WEISSMAN, BE; WELCH, DR; FISHER, PB			THE MELANOMA DIFFERENTIATION-ASSOCIATED GENE MDA-6, WHICH ENCODES THE CYCLIN-DEPENDENT KINASE INHIBITOR P21, IS DIFFERENTIALLY EXPRESSED DURING GROWTH, DIFFERENTIATION AND PROGRESSION IN HUMAN-MELANOMA CELLS	ONCOGENE			English	Article						TERMINAL CELL DIFFERENTIATION; GROWTH CONTROL; MATRIGEL-ASSISTED PROGRESSION; METASTASIS SUPPRESSION	HUMAN-MALIGNANT MELANOMA; GLIOBLASTOMA-MULTIFORME CELLS; RECOMBINANT HUMAN FIBROBLAST; POLYMERASE CHAIN-REACTION; WILD-TYPE P53; ANTIGENIC PHENOTYPE; TRANSFORMED PHENOTYPE; IMMUNE INTERFERON; MESSENGER-RNA; SUPPRESSION	The combination of recombinant human fibroblast interferon (IFN-beta) and the antileukemic compound mezerein (MEZ) induces terminal differentiation with an irreversible loss of proliferative capacity in human melanoma cells, Using subtraction hybridization, cDNAs were identified that display enhanced expression in terminally differentiated and growth arrested human melanoma cells (Jiang and Fisher, 1993; Jiang et al., 1994a), A specific melanoma differentiation-associated (mda) cDNA, mda-6, is described whose expression inversely correlates with melanoma progression and growth, mda-6 is identical to WAF1/CIP1/SDI1 that encodes the M-r 21 000 protein (p21) that is an inhibitor of cyclin-dependent kinases, Actively growing normal melanocyte, SV40-immortalized human melanocyte and dysplastic nevus cell. lines synthesize elevated levels of mda-6 mRNA; whereas, actively proliferating radial and early vertical growth phase primary melanomas as well as metastatic human melanoma cells produce reduced levels of mda-6 mRNA, Treatment of primary and metastatic human melanoma cells with IFN-beta+MEZ results in growth inhibition and an increase in mda-6 expression, mda-6 expression also increases when human melanoma cells are grown to high saturation densities or when grown in serum-free medium, Using anti-p53 and anti-p21 antibodies, an inverse correlation is found between p53 and p21 protein levels during growth arrest and differentiation, Induction of growth arrest and terminal differentiation in H0-1 human melanoma cells by IFN-beta+MEZ results in a temporal decrease in wildtype p53 protein levels with a corresponding increase in p21 levels, In the Matrigel-assisted melanoma progression model, mda-6 expression decreases in early vertical growth phase primary human melanoma cells selected for autonomous or enhanced tumor formation in nude mice, In metastatic human melanoma cells displaying a loss of metastatic potential resulting from introduction of a normal human chromosome 6, mda-6 mRNA levels increase, Taken together, these studies indicate that mda-6 (p21) may function as a negative regulator of melanoma growth, progression and metastasis.	COLUMBIA UNIV, COLL PHYS & SURG,INST CANC RES,DEPT PATHOL, CTR COMPREHENS CANC, NEW YORK, NY 10027 USA; COLUMBIA UNIV, COLL PHYS & SURG,INST CANC RES,DEPT UROL, CTR COMPREHENS CANC, NEW YORK, NY 10027 USA; WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA; SUNNYBROOK HLTH SCI CTR, DIV CANC RES, TORONTO, ON M4N 3M5, CANADA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, DEPT PATHOL, CHAPEL HILL, NC 27599 USA; PENN STATE UNIV, COLL MED,MILTON S HERSHEY MED CTR,DEPT PATHOL, DIV EXPTL PATHOL, HERSHEY, PA 17033 USA	Columbia University; Columbia University; The Wistar Institute; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of North Carolina; University of North Carolina Chapel Hill; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NATIONAL CANCER INSTITUTE [R01CA043208, P01CA025874, R01CA035675] Funding Source: NIH RePORTER; NCI NIH HHS [CA43208, CA25874, CA35675] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; CLARK WH, 1991, BRIT J CANCER, V64, P631, DOI 10.1038/bjc.1991.375; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DUIGOU GJ, 1991, ONCOGENE, V6, P1813; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1986, ANTICANCER RES, V6, P765; FISHER PB, 1991, STATUS DIFFERENTIATI, V2, P201; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIOVANELLA BC, 1976, J NATL CANCER I, V56, P1131, DOI 10.1093/jnci/56.6.1131; GRAHAM GM, 1991, CANCER IMMUNOL IMMUN, V32, P382, DOI 10.1007/BF01741333; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUARINI L, 1992, PIGM CELL RES, P123; GUARINI L, 1989, CANCER IMMUNOL IMMUN, V30, P262, DOI 10.1007/BF01744892; HARPER JW, 1993, CELL, V75, P805; HAYES TE, 1991, NEW BIOL, V3, P259; Herlyn M, 1990, Adv Cancer Res, V54, P213, DOI 10.1016/S0065-230X(08)60812-X; HERLYN M, 1990, CANCER METAST REV, V9, P101, DOI 10.1007/BF00046337; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG HP, 1992, INT J ONCOL, V1, P227; JIMENEZ JJ, 1987, SCIENCE, V238, P1278, DOI 10.1126/science.3685979; Kerbel R S, 1990, Adv Cancer Res, V55, P87, DOI 10.1016/S0065-230X(08)60469-8; KHOCHBIN S, 1988, J MOL BIOL, V200, P55, DOI 10.1016/0022-2836(88)90333-6; KOBAYASHI H, 1994, AM J PATHOL, V144, P776; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LI Y, 1994, ONCOGENE, V9, P2261; LIN J, 1994, INT J ONCOL, V5, P5; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Loganzo Frank Jr., 1994, Molecular and Cellular Differentiation, V2, P23; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; LOTAN R, 1993, RETINOIDS ONCOLOGY, P43; Lu Chao, 1994, Current Opinion in Oncology, V6, P212, DOI 10.1097/00001622-199403000-00015; MacDougall John R., 1993, Molecular and Cellular Differentiation, V1, P21; MANCIANTI ML, 1988, J INVEST DERMATOL, V90, P134, DOI 10.1111/1523-1747.ep12462099; MELBER K, 1989, CANCER RES, V49, P3650; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MICHIELI P, 1994, CANCER RES, V54, P3391; MILLIKIN D, 1991, CANCER RES, V51, P5449; MONTANO X, 1994, ONCOGENE, V9, P1455; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; REDDY PG, 1991, J NATL CANCER I, V83, P1307, DOI 10.1093/jnci/83.18.1307; RICHON VM, 1989, ONCOGENE, V4, P165; RON D, 1994, P NATL ACAD SCI USA, V91, P1985, DOI 10.1073/pnas.91.6.1985; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN DW, 1983, P NATL ACAD SCI-BIOL, V80, P5919, DOI 10.1073/pnas.80.19.5919; SHOBAT O, 1987, ONCOGENE, V1, P277; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SU ZZ, 1991, MOL CARCINOGEN, V4, P231, DOI 10.1002/mc.2940040310; SU ZZ, 1993, CANCER RES, V53, P1929; TOKUNAGA K, 1987, CANCER RES, V47, P5616; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOLKENANDT M, 1991, PIGM CELL RES, V4, P35, DOI 10.1111/j.1600-0749.1991.tb00311.x; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAXMAN S, 1988, STATUS DIFFERENTIATI, V1; WAXMAN S, 1991, STATUS DIFFERENTIATI, V2; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; WELCH DR, 1994, ONCOGENE, V9, P255; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	73	181	192	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1855	1864						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753561				2022-12-17	WOS:A1995QX46900019
J	MIZUNO, K; OKANO, I; OHASHI, K; NUNOUE, K; KUMA, K; MIYATA, T; NAKAMURA, T				MIZUNO, K; OKANO, I; OHASHI, K; NUNOUE, K; KUMA, K; MIYATA, T; NAKAMURA, T			IDENTIFICATION OF A HUMAN CDNA-ENCODING A NOVEL PROTEIN-KINASE WITH 2 REPEATS OF THE LIM DOUBLE ZINC-FINGER MOTIF	ONCOGENE			English	Article							CYSTEINE-RICH PROTEIN; TYROSINE KINASE; CONSERVED FEATURES; CATALYTIC DOMAIN; ACTIVIN RECEPTOR; SERINE KINASE; INSULIN GENE; FAMILY; SEQUENCE; MEMBER	By low-stringency screening of a human hepatoma HepG2 cell cDNA library, using the genomic fragment of chick c-sea receptor tyrosine kinase as a probe, we isolated overlapping cDNAs encoding a novel protein kinase, which we termed LIM-kinase (LIMK). The predicted open reading frame encodes a 647-amino-acid polypeptide containing a putative protein kinase structure in the C-terminal half. In addition, LIMK has two repeats of cysteine-rich LIM/double zinc finger motif at the most N-terminus. To our knowledge, this is the first protein kinase seen to contain the LIM motif(s) in the molecule. Although the protein kinase domain of LIMK has highly conserved sequence elements of protein kinases, phylogenetic analysis revealed that LIMK cannot be classified into any subfamily of known protein kinases. Northern blot analysis revealed that the single species of LIMK mRNA of 3.3 kb was expressed in various human epithelial and hematopoietic cell lines. In rat tissues, LIMK mRNA was expressed in the brain, at the highest level. LIM is suggested to be involved in protein-protein interactions by binding to another LIM motif. As the LIM domain is frequently present in the homeodomain-containing transcriptional regulators and oncogenic nuclear proteins, LIMK may be involved in developmental or oncogenic processes through interactions with these LIM-containing proteins.	KYOTO UNIV, FAC SCI, DEPT BIOPHYS, KYOTO 60601, JAPAN; OSAKA UNIV, SCH MED, BIOMED RES CTR, OSAKA 565, JAPAN	Kyoto University; Osaka University	MIZUNO, K (corresponding author), KYUSHU UNIV, FAC SCI, DEPT BIOL, FUKUOKA 812, JAPAN.		Mizuno, Kensaku/G-8631-2015	Ohashi, Kazumasa/0000-0001-7617-403X				BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1328; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; NAKAMURA T, 1992, J BIOL CHEM, V267, P18924; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHASHI K, 1994, ONCOGENE, V9, P699; OKANO I, 1993, FEBS LETT, V333, P51, DOI 10.1016/0014-5793(93)80373-3; RABBITTS TH, 1990, NATURE, V346, P418, DOI 10.1038/346418a0; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TAN JL, 1990, MOL CELL BIOL, V10, P3578, DOI 10.1128/MCB.10.7.3578; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WANG XK, 1992, J BIOL CHEM, V267, P9176; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057	42	181	190	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1605	1612						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183554				2022-12-17	WOS:A1994NL81500011
J	GARCIA, M; DEROCQ, D; PUJOL, P; ROCHEFORT, H				GARCIA, M; DEROCQ, D; PUJOL, P; ROCHEFORT, H			OVEREXPRESSION OF TRANSFECTED CATHEPSIN-D IN TRANSFORMED-CELLS INCREASES THEIR MALIGNANT PHENOTYPE AND METASTATIC POTENCY	ONCOGENE			English	Article							BREAST-CANCER CELLS; PLASMINOGEN-ACTIVATOR; EXTRACELLULAR-MATRIX; MURINE FIBROBLASTS; PROTEIN; SECRETION; ACID; CARCINOGENESIS; STIMULATION; ANTIBODIES	Cathepsin D, an aspartic lysosomal proteinase, is over-expressed by breast cancer cells and highly correlated with the occurrence of metastasis in patients. We used an adenovirus transformed rat cell line that does not secrete cathepsin D, to study the consequences of transfecting human cathepsin D cDNA. Overexpression of human cathepsin D in stable transfectant clones, results in higher initial growth rates in low serum conditions, overgrowth at high cell densities resulting in stellate aggregates, and greater anchorage-independent growth in soft agar. The metastatic activity (mostly in liver) of cathepsin D clones injected into athymic mice was significantly higher than that of control clones. These results show that over-expression of cathepsin D increases the transformed phenotype of malignant cells in vitro and their metastatic potency in vivo.	UNIV MONTPELLIER,FAC MED,INSERM,U148,UNITE HORMONES & CANC,60 RUE NAVACELLES,F-34090 MONTPELLIER,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier								AUGEREAU P, 1988, MOL ENDOCRINOL, V2, P186, DOI 10.1210/mend-2-2-186; Barrett A, 1977, PROTEINASES MAMMALIA, P209; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BRIOZZO P, 1988, CANCER RES, V48, P3688; CAPONY F, 1989, CANCER RES, V49, P3904; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; CONNER GE, 1989, BIOCHEMISTRY-US, V28, P3530, DOI 10.1021/bi00434a057; DENHARDT DT, 1987, ONCOGENE, V2, P55; Fidler I J, 1978, Adv Cancer Res, V28, P149, DOI 10.1016/S0065-230X(08)60648-X; FIDLER IJ, 1973, EUR J CANCER, V9, P223, DOI 10.1016/S0014-2964(73)80022-2; GARCIA M, 1985, CANCER RES, V45, P709; GOTTESMAN MM, 1978, P NATL ACAD SCI USA, V75, P2767, DOI 10.1073/pnas.75.6.2767; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; KANE SE, 1988, MOL CELL BIOL, V8, P3316, DOI 10.1128/MCB.8.8.3316; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; LIOTTA LA, 1986, CANCER RES, V46, P1; MONTCOURRIER P, 1990, CANCER RES, V50, P6045; OHARE K, 1981, P NATL ACAD SCI-BIOL, V78, P1527, DOI 10.1073/pnas.78.3.1527; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; RECKLIES AD, 1980, CANCER RES, V40, P550; ROCHEFORT H, 1987, J CELL BIOCHEM, V35, P17, DOI 10.1002/jcb.240350103; SLOANE BF, 1984, CANCER METAST REV, V3, P249, DOI 10.1007/BF00048388; SPYRATOS F, 1989, LANCET, V2, P1115; SULLIVAN LM, 1986, CELL, V45, P905, DOI 10.1016/0092-8674(86)90565-9; TANDON AK, 1990, NEW ENGL J MED, V322, P297, DOI 10.1056/NEJM199002013220504; TANIGUCHI S, 1990, BIOCHEM BIOPH RES CO, V168, P520, DOI 10.1016/0006-291X(90)92352-Z; THORPE SM, 1989, CANCER RES, V49, P6008; UEDA H, 1985, CANCER RES, V45, P3332; VIGNON F, 1986, ENDOCRINOLOGY, V118, P1537, DOI 10.1210/endo-118-4-1537; WEINBERG RA, 1989, CANCER RES, V49, P3713; YAMASHITA T, 1980, INT J CANCER, V26, P435, DOI 10.1002/ijc.2910260408	33	181	188	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1990	5	12					1809	1814						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET436	2284099				2022-12-17	WOS:A1990ET43600010
J	Chen, J; Weiss, WA				Chen, J.; Weiss, W. A.			Alternative splicing in cancer: implications for biology and therapy	ONCOGENE			English	Review						alternative splicing; aberrant splicing; p53; BARD1; AR	HUMAN ANDROGEN RECEPTOR; WILD-TYPE P53; PRE-MESSENGER-RNA; DOMAIN BARD1 GENE; TUMOR-SUPPRESSOR; PYRUVATE-KINASE; SOLUBLE-FAS; IN-VIVO; TRANSCRIPTIONAL ACTIVATION; CELL SENESCENCE	Alternative splicing has critical roles in normal development and can promote growth and survival in cancer. Aberrant splicing, the production of noncanonical and cancer-specific mRNA transcripts, can lead to loss-of-function in tumor suppressors or activation of oncogenes and cancer pathways. Emerging data suggest that aberrant splicing products and loss of canonically spliced variants correlate with stage and progression in malignancy. Here, we review the splicing landscape of TP53, BARD1 and AR to illuminate roles for alternative splicing in cancer. We also examine the intersection between alternative splicing pathways and novel therapeutic approaches.	[Chen, J.] Univ Calif San Francisco, Biomed Sci Grad Program, San Francisco, CA 94158 USA; [Chen, J.; Weiss, W. A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA; [Weiss, W. A.] Univ Calif San Francisco, Dept Neurol Surg & Pediat, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Chen, J (corresponding author), Univ Calif San Francisco, Dept Neurol, Box 0520,1450 3rd St HD-220, San Francisco, CA 94158 USA.	justin.chen@ucsf.edu		Weiss, William/0000-0003-2230-9132; Chen, Justin/0000-0002-1661-4547	NIH [CA176287, CA82104, CA133091, CA102321, CA148699, CA159859, CA163155, CA081403]; Cure Search Foundation; Katie Dougherty Foundation; Pediatric Brain Tumor Foundation; St Baldricks Foundation; Samuel G Waxman Foundation; NATIONAL CANCER INSTITUTE [R01CA159859, U54CA163155, P01CA081403, R01CA102321, U01CA176287, R01CA082104, R01CA133091, R01CA148699] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cure Search Foundation; Katie Dougherty Foundation; Pediatric Brain Tumor Foundation; St Baldricks Foundation; Samuel G Waxman Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Clay Gustafson, Miller Huang and Erin Simonds for reviewing the manuscript. The Weiss lab is supported by NIH grants CA176287, CA82104, CA133091, CA102321, CA148699, CA159859, CA163155 and CA081403; and the Cure Search, Katie Dougherty, Pediatric Brain Tumor, St Baldricks and Samuel G Waxman Foundations.	Ahrens-Fath I, 2005, FEBS J, V272, P74, DOI 10.1111/j.1432-1033.2004.04395.x; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; Attard G, 2009, CANCER RES, V69, P4937, DOI 10.1158/0008-5472.CAN-08-4531; Avery-Kiejda KA, 2008, CLIN CANCER RES, V14, P1659, DOI 10.1158/1078-0432.CCR-07-1422; Babic I, 2013, CELL METAB, V17, P1000, DOI 10.1016/j.cmet.2013.04.013; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bonnal S, 2012, NAT REV DRUG DISCOV, V11, P847, DOI 10.1038/nrd3823; Bosse KR, 2012, CANCER RES, V72, P2068, DOI 10.1158/0008-5472.CAN-11-3703; Bouillet P, 2009, NAT REV IMMUNOL, V9, P514, DOI 10.1038/nri2570; Boukakis G, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-434; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Bourdon JC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2811; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; Brinkmann AO, 2001, MOL CELL ENDOCRINOL, V179, P105, DOI 10.1016/S0303-7207(01)00466-X; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Bruggenwirth HT, 1997, AM J HUM GENET, V61, P1067, DOI 10.1086/301605; Burge C.B., 1999, RNA WORLD, V37, P525; Candeias MM, 2006, ONCOGENE, V25, P6936, DOI 10.1038/sj.onc.1209996; Capasso M, 2013, CARCINOGENESIS, V34, P605, DOI 10.1093/carcin/bgs380; Capasso M, 2009, NAT GENET, V41, P718, DOI 10.1038/ng.374; Cappellari M, 2013, ONCOGENE, P1; CASCINO I, 1995, J IMMUNOL, V154, P2706; Chan SC, 2012, J BIOL CHEM, V287, P19736, DOI 10.1074/jbc.M112.352930; Chen J, 2009, GENE DEV, V23, P278, DOI 10.1101/gad.1761609; Chen M, 2009, NAT REV MOL CELL BIO, V10, P741, DOI 10.1038/nrm2777; Chen P, 2007, J FIRE SCI, V25, P5, DOI 10.1177/0734904107062356; Cheng CH, 2006, MOL CELL BIOL, V26, P362, DOI 10.1128/MCB.26.1.362-370.2006; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; COCQUERELLE C, 1992, EMBO J, V11, P1095, DOI 10.1002/j.1460-2075.1992.tb05148.x; Corrionero A, 2011, GENE DEV, V25, P445, DOI 10.1101/gad.2014311; Coulter LR, 1997, MOL CELL BIOL, V17, P2143, DOI 10.1128/MCB.17.4.2143; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Crawford JB, 2006, MOL CELL BIOL, V26, P8791, DOI 10.1128/MCB.01677-06; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Dizin E, 2010, INT J BIOCHEM CELL B, V42, P693, DOI 10.1016/j.biocel.2009.12.025; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Ellis JD, 2012, MOL CELL, V46, P884, DOI 10.1016/j.molcel.2012.05.037; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fairbrother WG, 2004, NUCLEIC ACIDS RES, V32, pW187, DOI 10.1093/nar/gkh393; Fairbrother WG, 2002, SCIENCE, V297, P1007, DOI 10.1126/science.1073774; Fan LY, 2011, ACS CHEM BIOL, V6, P582, DOI 10.1021/cb100356k; Feki A, 2005, ONCOGENE, V24, P3726, DOI 10.1038/sj.onc.1208491; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Flaman JM, 1996, ONCOGENE, V12, P813; Folco EG, 2011, GENE DEV, V25, P440, DOI 10.1101/gad.2009411; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Furumai R, 2010, CANCER SCI, V101, P2483, DOI 10.1111/j.1349-7006.2010.01686.x; Ghigna C, 1998, CANCER RES, V58, P5818; Ghimenti C, 2002, GENE CHROMOSOME CANC, V33, P235, DOI 10.1002/gcc.1223; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Graveley BR, 2001, RNA, V7, P806, DOI 10.1017/S1355838201010317; Guo X, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-35; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Hafsi H, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-134; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hellwinkel OJC, 1999, J STEROID BIOCHEM, V68, P1, DOI 10.1016/S0960-0760(98)00157-5; Hellwinkel OJC, 2001, J CLIN ENDOCR METAB, V86, P2569, DOI 10.1210/jc.86.6.2569; Heyd F, 2011, TRENDS BIOCHEM SCI, V36, P397, DOI 10.1016/j.tibs.2011.04.003; Hofstetter G, 2010, ONCOGENE, V29, P1997, DOI 10.1038/onc.2009.482; Holmila R, 2003, Hum Mutat, V21, P101, DOI 10.1002/humu.9104; Hong X, 2006, MOL BIOL EVOL, V23, P2392, DOI 10.1093/molbev/msl111; Hu R, 2011, PROSTATE, V71, P1656, DOI 10.1002/pros.21382; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Hua YM, 2011, NATURE, V478, P123, DOI 10.1038/nature10485; Huggins C, 1941, CANCER RES, V1, P293; Hui LJ, 2004, ONCOGENE, V23, P3013, DOI 10.1038/sj.onc.1207362; Ikonen T, 1998, FEBS LETT, V430, P393, DOI 10.1016/S0014-5793(98)00701-7; Irminger-Finger I, 2006, NAT REV CANCER, V6, P382, DOI 10.1038/nrc1878; Irminger-Finger I, 2001, MOL CELL, V8, P1255, DOI 10.1016/S1097-2765(01)00406-3; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; Jagla M, 2007, ENDOCRINOLOGY, V148, P4334, DOI 10.1210/en.2007-0446; Jefford CE, 2004, ONCOGENE, V23, P3509, DOI 10.1038/sj.onc.1207427; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Kaida D, 2007, NAT CHEM BIOL, V3, P576, DOI 10.1038/nchembio.2007.18; Kalsotra A, 2011, NAT REV GENET, V12, P715, DOI 10.1038/nrg3052; Karni R, 2008, P NATL ACAD SCI USA, V105, P15323, DOI 10.1073/pnas.0801376105; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Karppinen SM, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.020669; Keren H, 2010, NAT REV GENET, V11, P345, DOI 10.1038/nrg2776; Knudsen KE, 2009, CLIN CANCER RES, V15, P4792, DOI 10.1158/1078-0432.CCR-08-2660; Kondera-Anasz Z, 2005, APOPTOSIS, V10, P1143, DOI 10.1007/s10495-005-1018-9; Kotake Y, 2007, NAT CHEM BIOL, V3, P570, DOI 10.1038/nchembio.2007.16; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LeFave CV, 2011, EMBO J, V30, P4084, DOI 10.1038/emboj.2011.259; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li L, 2007, CANCER RES, V67, P11876, DOI 10.1158/0008-5472.CAN-07-2370; Li XL, 2005, CELL, V122, P365, DOI 10.1016/j.cell.2005.06.008; Libertini SJ, 2007, CANCER RES, V67, P9001, DOI 10.1158/0008-5472.CAN-07-1072; Lim J, 1997, MOL CELL ENDOCRINOL, V131, P205, DOI 10.1016/S0303-7207(97)00109-3; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Liu HX, 2000, MOL CELL BIOL, V20, P1063, DOI 10.1128/MCB.20.3.1063-1071.2000; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Liu JH, 2002, BLOOD, V100, P1449, DOI 10.1182/blood.V100.4.1449.h81602001449_1449_1453; Lorson CL, 2010, HUM MOL GENET, V19, pR111, DOI 10.1093/hmg/ddq147; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Marabese M, 2008, EUR J CANCER, V44, P131, DOI 10.1016/j.ejca.2007.10.011; Marcel V, 2010, ONCOGENE, V29, P2691, DOI 10.1038/onc.2010.26; Marcel V, 2010, FEBS LETT, V584, P4463, DOI 10.1016/j.febslet.2010.10.005; Marcias G, 2010, HUM MUTAT, V31, P74, DOI 10.1002/humu.21138; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MATLASHEWSKI G, 1987, ONCOGENE RES, V1, P77; Matlin AJ, 2005, NAT REV MOL CELL BIO, V6, P386, DOI 10.1038/nrm1645; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; Mazurek S, 2005, SEMIN CANCER BIOL, V15, P300, DOI 10.1016/j.semcancer.2005.04.009; McCarthy EE, 2003, MOL CELL BIOL, V23, P5056, DOI 10.1128/MCB.23.14.5056-5063.2003; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILLERWIDEMAN M, 1992, J ANTIBIOT, V45, P914, DOI 10.7164/antibiotics.45.914; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Nakajima H, 1996, J ANTIBIOT, V49, P1204; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Piekielko-Witkowska A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013690; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RISSTALPERS C, 1994, AM J HUM GENET, V54, P609; Ryser S, 2009, CANCER RES, V69, P1125, DOI 10.1158/0008-5472.CAN-08-2134; Sakai T, 2004, J ANTIBIOT, V57, P173, DOI 10.7164/antibiotics.57.173; Salzman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030733; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shaffer PL, 2004, P NATL ACAD SCI USA, V101, P4758, DOI 10.1073/pnas.0401123101; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Sheen-Chen SM, 2003, WORLD J SURG, V27, P10, DOI 10.1007/s00268-002-6378-5; Sporn JC, 2011, CLIN CANCER RES, V17, P5451, DOI 10.1158/1078-0432.CCR-11-0263; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Takehara T, 2001, HEPATOLOGY, V34, P55, DOI 10.1053/jhep.2001.25387; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tang Y, 2013, ONCOGENE, V32, P2792, DOI 10.1038/onc.2012.288; Taplin ME, 2007, NAT CLIN PRACT ONCOL, V4, P236, DOI 10.1038/ncponc0765; Tepper CG, 2002, CANCER RES, V62, P6606; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Thorsen K, 2008, MOL CELL PROTEOMICS, V7, P1214, DOI 10.1074/mcp.M700590-MCP200; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Tsuzuki M, 2006, CANCER LETT, V233, P108, DOI 10.1016/j.canlet.2005.03.012; Venables JP, 2009, NAT STRUCT MOL BIOL, V16, P670, DOI 10.1038/nsmb.1608; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009; Wang K, 2011, NATURE, V469, P216, DOI 10.1038/nature09609; Wang Y, 2012, NAT STRUCT MOL BIOL, V19, P1044, DOI 10.1038/nsmb.2377; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Webb TR, 2013, DRUG DISCOV TODAY, V18, P43, DOI 10.1016/j.drudis.2012.07.013; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Wu JQ, 2010, P NATL ACAD SCI USA, V107, P5254, DOI 10.1073/pnas.0914114107; Wu JY, 2006, INT J CANCER, V118, P1215, DOI 10.1002/ijc.21428; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xerri L, 1996, BRIT J HAEMATOL, V92, P900, DOI 10.1046/j.1365-2141.1996.423958.x; Xu Q, 2003, NUCLEIC ACIDS RES, V31, P5635, DOI 10.1093/nar/gkg786; Yeo G, 2004, P NATL ACAD SCI USA, V101, P15700, DOI 10.1073/pnas.0404901101; Yeo GW, 2007, PLOS GENET, V3, P814, DOI 10.1371/journal.pgen.0030085; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Yoshida K, 2011, NATURE, V478, P64, DOI 10.1038/nature10496; Zhang XT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027970; Zhang YQ, 2012, BRIT J CANCER, V107, P675, DOI 10.1038/bjc.2012.297; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	175	180	189	0	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					1	14		10.1038/onc.2013.570	http://dx.doi.org/10.1038/onc.2013.570			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24441040				2022-12-17	WOS:000349740100001
J	He, BA; Reguart, N; You, L; Mazieres, J; Xu, ZD; Lee, AY; Mikami, I; McCormick, F; Jablons, DM				He, BA; Reguart, N; You, L; Mazieres, J; Xu, ZD; Lee, AY; Mikami, I; McCormick, F; Jablons, DM			Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations	ONCOGENE			English	Article						human; Wnt-1; colorectal cancer; apoptosis	HUMAN LUNG-CANCER; BETA-CATENIN; MONOCLONAL-ANTIBODY; COLON-CARCINOMA; EXPRESSION; DOCETAXEL; PATHWAY; GENES; HYPERMETHYLATION; ACTIVATION	Aberrant Wnt signaling, mainly through mutations of APC and in some cases of CTNNB1 or AXIN2, has been found in the majority of colorectal cancers. Recently, frequent promoter hypermethylation was identified to cause silencing of the secreted frizzled-related protein ( sFRP) family in colorectal cancer. Restoration of sFRP in colorectal cancer cells attenuates Wnt signaling even in the presence of downstream mutations. Here we show that Wnt inhibitory factor-1 (WIF-1), a different secreted antagonist of Wnt signaling, is also silenced by promoter hypermethylation in colorectal cancer cells. Restoration of WIF-1 function, Wnt-1 siRNA, or a monoclonal anti-Wnt-1 antibody that we developed attenuates Wnt-1 signaling and induces significant apoptosis in these cells containing downstream mutations and expressing Wnt-1. In addition, this monoclonal anti-Wnt-1 antibody showed synergistic effects with docetaxel in treating these colorectal cancer cells and great efficacy in treating primary colorectal cancer cultures freshly prepared from patients. Therefore, our data support the hypothesis that constitutive Wnt signaling may be required to complement downstream mutations in the evolution of colorectal cancer. Furthermore, our results suggest that blockade of the Wnt signal may have a therapeutic role in the treatment of colorectal cancer.	Univ Calif San Francisco, Ctr Comprehens Canc, Dept Surg, Thorac Oncol Lab, San Francisco, CA 94115 USA; Hosp Germans Trias & Pujol, Inst Catala Oncol, Med Oncol Serv, Barcelona, Spain; Inst Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM, U563, F-31052 Toulouse, France	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Catalan Institute of Oncology; Hospital Germans Trias i Pujol; UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Jablons, DM (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, Dept Surg, Thorac Oncol Lab, 1600 Divisadero St,C322C,Box 1674, San Francisco, CA 94115 USA.	jablonsd@surgery.ucsf.edu	MAZIERES, JULIEN/M-3986-2014	MAZIERES, JULIEN/0000-0002-5921-7613	NCI NIH HHS [R01 CA093708, R01 CA093708-01A3] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093708] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISSERY MC, 1991, CANCER RES, V51, P4845; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Ciani L, 2004, J CELL BIOL, V164, P243, DOI 10.1083/jcb.200309096; Clark TB, 1998, CANCER INVEST, V16, P314, DOI 10.3109/07357909809084650; Dimitriadis A, 2001, CANCER LETT, V166, P185, DOI 10.1016/S0304-3835(01)00428-1; Dunne AL, 2004, ONCOL RES, V14, P447, DOI 10.3727/0965040041791455; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; He B, 2004, NEOPLASIA, V6, P7, DOI 10.1016/S1476-5586(04)80048-4; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Heighway J, 2002, ONCOGENE, V21, P7749, DOI 10.1038/sj.onc.1205979; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Karantanis E, 1994, Eur J Surg Oncol, V20, P653; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lin KM, 1997, P NATL ACAD SCI USA, V94, P11196, DOI 10.1073/pnas.94.21.11196; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; STERNBERG CN, 1994, BRIT J CANCER, V70, P376, DOI 10.1038/bjc.1994.309; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449; You L, 2004, CANCER RES, V64, P5385, DOI 10.1158/0008-5472.CAN-04-1227	30	180	192	0	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3054	3058		10.1038/sj.onc.1208511	http://dx.doi.org/10.1038/sj.onc.1208511			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735684				2022-12-17	WOS:000228649500015
J	Hoon, DSB; Spugnardi, M; Kuo, C; Huang, SK; Morton, DL; Taback, B				Hoon, DSB; Spugnardi, M; Kuo, C; Huang, SK; Morton, DL; Taback, B			Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients	ONCOGENE			English	Article						MGMT; RAR-beta 2; RASSF1A; methylation; melanoma	ABERRANT PROMOTER METHYLATION; CPG ISLAND HYPERMETHYLATION; POLYMERASE-CHAIN-REACTION; DNA METHYLATION; PROGNOSTIC-SIGNIFICANCE; MULTIPLE GENES; CANCER; RASSF1A; EXPRESSION; MARKERS	Aberrant methylation of CpG islands in promoter regions of tumor suppressor genes (TSG) has been demonstrated in epithelial origin tumors. However, the methylation pro. ling of tumor-related gene promoter regions in cutaneous melanoma tumors has not been reported. Seven known or candidate TSGs that are frequently hypermethylated in carcinomas were assessed by methylation-specific polymerase chain reaction (MSP) in 15 melanoma cell lines and 130 cutaneous melanoma tumors. Four TSGs were frequently hypermethylated in 86 metastatic tumor specimens: retinoic acid receptor-beta2 (RAR-beta2) (70%), RAS association domain family protein 1A (RASSF1A) (57%), and O-6-methylguanine DNA methylatransferase (MGMT) (34%), and death-associated protein kinase (DAPK) (19%). Hypermethylation of MGMT, RASSF1A, and DAPK was significantly lower in primary melanomas (n = 20) compared to metastatic melanomas. However, hypermethylation of RAR-beta2 was 70% in both primary and metastatic melanomas. Cell lines had hypermethylation profiles similar to those of metastatic melanomas. The analysis of these four markers of metastatic tumors demonstrated that 97% had greater than or equal to1 gene(s) and 59% had greater than or equal to2 genes hypermethylated. The methylation of genes was verified by bisulfite sequencing. The mRNA transcripts could be re-expressed in melanoma cell lines having hypermethylated genes following treatment with 5'-aza 2'-deoxycytidine (5Aza-dC). Analysis of melanoma patients' plasma (preoperative blood; n = 31) demonstrated circulating hypermethylated MGMT, RAR-beta2, and RASSF1A DNA for at least one of the markers in 29% of the patients. Our findings indicate that the incidence of TSG hypermethylation increases during tumor progression. Methylation of TSG may play a significant role in cutaneous melanoma progression.	St Johns Hlth Ctr, John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA; St Johns Hlth Ctr, John Wayne Canc Inst, Div Surg Oncol, Santa Monica, CA 90404 USA	John Wayne Cancer Institute; John Wayne Cancer Institute	Hoon, DSB (corresponding author), St Johns Hlth Ctr, John Wayne Canc Inst, Dept Mol Oncol, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.	hoon@jwci.org	Hoon, Dave SB/C-7146-2018	Hoon, Dave SB/0000-0003-1915-3683	NCI NIH HHS [P01 CA029605, P01 CA029605-270006, R21 CA100314, P0 CA 13917, P0 CA 29605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA029605, R21CA100314] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bostick PJ, 1999, J CLIN ONCOL, V17, P3238, DOI 10.1200/JCO.1999.17.10.3238; Chen CM, 2003, AM J PATHOL, V163, P37, DOI 10.1016/S0002-9440(10)63628-0; Christmann M, 2001, INT J CANCER, V92, P123, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1160>3.3.CO;2-M; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Demary K, 2001, ENDOCRINOLOGY, V142, P2600, DOI 10.1210/en.142.6.2600; Eads CA, 1999, CANCER RES, V59, P2302; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Esteller M, 2001, CANCER RES, V61, P3225; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; Fujiwara Y, 1999, CANCER RES, V59, P1567; Goessl C, 2000, CANCER RES, V60, P5941; Harden SV, 2003, CLIN CANCER RES, V9, P1370; Jeronimo C, 2001, J NATL CANCER I, V93, P1747, DOI 10.1093/jnci/93.22.1747; Johnson PJ, 2002, CLIN CHEM, V48, P1186; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kurie JM, 2003, J NATL CANCER I, V95, P206, DOI 10.1093/jnci/95.3.206; Lo KW, 2001, CANCER RES, V61, P3877; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Maruyama R, 2001, CANCER RES, V61, P8659; Paz MF, 2003, CANCER RES, V63, P1114; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Rosas SLB, 2001, CANCER RES, V61, P939; Shi HD, 2003, CANCER RES, V63, P2164; Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755; Sirchia SM, 2002, CANCER RES, V62, P2455; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; Spanjaard RA, 1997, J BIOL CHEM, V272, P18990, DOI 10.1074/jbc.272.30.18990; Spugnardi M, 2003, CANCER RES, V63, P1639; Taback B, 2001, CANCER RES, V61, P5723; Takeuchi H, 2003, CANCER RES, V63, P441; Toyooka S, 2003, INT J CANCER, V103, P153, DOI 10.1002/ijc.10787; Ueki T, 2000, CANCER RES, V60, P1835; Usadel H, 2002, CANCER RES, V62, P371; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	40	180	200	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					4014	4022		10.1038/sj.onc.1207505	http://dx.doi.org/10.1038/sj.onc.1207505			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15064737	Green Accepted			2022-12-17	WOS:000221382000014
J	Hu, L; Lau, SH; Tzang, CH; Wen, JM; Wang, WS; Xie, D; Huang, MH; Wang, Y; Wu, MC; Huang, JF; Zeng, WF; Sham, JST; Yang, MS; Guan, XY				Hu, L; Lau, SH; Tzang, CH; Wen, JM; Wang, WS; Xie, D; Huang, MH; Wang, Y; Wu, MC; Huang, JF; Zeng, WF; Sham, JST; Yang, MS; Guan, XY			Association of Vimentin overexpression and hepatocellular carcinoma metastasis	ONCOGENE			English	Article						Vimentin; hepatocellular carcinoma; metastasis; microarray	TISSUE MICROARRAY; BREAST-CARCINOMA; EXPRESSION; PROTEIN; CELLS; CLUSTERIN; CANCER; RNA	The poor prognosis of hepatocellular carcinoma (HCC) has been associated with recurrence and metastasis. Recently, we established a pair of HCC cell lines from a primary (H2-P) and its matched metastatic (H2-M) HCC tumors. A high density of cDNA microarray with 9184 human cDNA was used to identify the differentially expressed genes between H2-P and H2-M. Comparing with H2-P, eight upregulated and six downregulated genes were detected in H2-M. One interesting finding is the overexpression of Vimentin (VIM), a well-defined intermediate filament, which has been linked to a more aggressive status in various tumors. The correlation of overexpression of VIM and HCC metastasis was studied by immunohistochemistry using a tissue microarray with 200 primary HCCs and 60 pairs of primary and matched metastatic HCC samples. Tissue microarray demonstrated that the overexpression of VIM was significantly associated with HCC metastasis (P<0.01). This finding strongly suggests that the overexpression of VIM may play an important role in the metastasis of HCC.	Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; City Univ Hong Kong, Dept Biol & Chem, Hong Kong, Hong Kong, Peoples R China; Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou, Peoples R China; Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hepatobilliary Surg, Guangzhou, Peoples R China; Second Mil Med Univ, Eastern Hepatobilliary Surg Hosp, Shanghai, Peoples R China	University of Hong Kong; City University of Hong Kong; Sun Yat Sen University; Sun Yat Sen University; Naval Medical University	Guan, XY (corresponding author), Univ Hong Kong, Dept Clin Oncol, Room 109,1-F,Sch Chinese Med Bldg,10 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	xyguan@hkucc.hku.hk	Yang, Mengsu/I-5750-2015; Guan, Xin-Yuan/A-3639-2009; /A-3639-2009	Yang, Mengsu/0000-0003-2083-2296; Guan, Xin-Yuan/0000-0002-4485-6017; /0000-0003-1874-9805				Aguayo A, 2001, SEMIN ONCOL, V28, P503, DOI 10.1053/sonc.2001.26953; Aldamassi M., 2001, PRACTICAL GUIDE MICR; BENZEEV A, 1985, CANCER RES, V45, P2632; Byrne JA, 1996, GENOMICS, V35, P523, DOI 10.1006/geno.1996.0393; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; DOMAGALA W, 1994, EUR J CANCER, V30A, P1527, DOI 10.1016/0959-8049(94)00288-G; FAN C, 1995, ONCOLOGY, V52, P498; Gilles C, 1999, J CELL SCI, V112, P4615; Gilles C, 1996, J PATHOL, V180, P175, DOI 10.1002/(SICI)1096-9896(199610)180:2<175::AID-PATH630>3.0.CO;2-G; Guan XY, 2000, GENE CHROMOSOME CANC, V29, P110; Guan XY, 1996, NAT GENET, V12, P10, DOI 10.1038/ng0196-10; Hendrix MJC, 1997, AM J PATHOL, V150, P483; Iwatsuki H, 1999, ACTA HISTOCHEM, V101, P369, DOI 10.1016/S0065-1281(99)80038-5; Lang SH, 2002, PROSTATE, V52, P253, DOI 10.1002/pros.10088; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lelievre V, 2001, J BIOL CHEM, V276, P43668, DOI 10.1074/jbc.M107341200; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; Qin LX, 1999, CANCER RES, V59, P5662; Redondo M, 2000, AM J PATHOL, V157, P393, DOI 10.1016/S0002-9440(10)64552-X; Tang ZY, 2001, WORLD J GASTROENTERO, V7, P445; THOMASSALGAR S, 1994, J BIOL CHEM, V269, P17879; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Wang Y, 2002, J PATHOL, V197, P610, DOI 10.1002/path.1150; Wen JM, 2002, CANCER GENET CYTOGEN, V135, P91, DOI 10.1016/S0165-4608(01)00636-7	24	180	201	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					298	302		10.1038/sj.onc.1206483	http://dx.doi.org/10.1038/sj.onc.1206483			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14647434				2022-12-17	WOS:000187895300031
J	Al Moustafa, AE; Alaoui-Jamali, MA; Batist, G; Hernandez-Perez, M; Serruya, C; Alpert, L; Black, MJ; Sladek, R; Foulkes, WD				Al Moustafa, AE; Alaoui-Jamali, MA; Batist, G; Hernandez-Perez, M; Serruya, C; Alpert, L; Black, MJ; Sladek, R; Foulkes, WD			Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cells	ONCOGENE			English	Article						cDNA microarray; gene expression; head and neck cancer	BETA-CATENIN EXPRESSION; S-TRANSFERASE-PI; E-CADHERIN; DIFFERENTIAL EXPRESSION; INTERMEDIATE-FILAMENTS; ADHESION; PROTEIN; CYTOKERATIN; COMBINATION; SUBTRACTION	In order to identify genes involved in head and neck carcinogenesis, we compared the gene expression profile in matched primary normal epithelial cells and primary head and neck cancer cells from the same patients. A cDNA microarray analysis consisting of 12530 human genes revealed significant changes in the expression of 213 genes, with 91 genes being up-regulated and 122 being dowm-regulated. This comprehensive list of genes includes those associated with signal transduction (growth factors), cell structure, cell cycle, transcription, apoptosis, and cell-cell adhesion. Further analysis of nine genes involved in cell-cell interaction, using Western blot and/or reverse transcription (RT)-PCR of four paired cell lines supported the reliability of our microarray analysis. More specifically, our study provides the first evidence that claudin-7 and connexin 31.1 are down-regulated in head and neck squamous cell carcinomas (HNSCC) compared to normal cells. These findings provide a large body of information regarding gene expression profiles associated with head and neck carcinogenesis, and also represent a source of potential targets for HNSCC prevention and/or therapeutics.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Oncol, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Pathol, Montreal, PQ H3T 1E2, Canada; McGill Ctr Translat Res Canc, Montreal, PQ H3T 1E2, Canada; Sir MB Davis Jewish Gen Hosp, Dept Surg, Div Head & Neck Surg, Montreal, PQ, Canada; McGill Univ, Ctr Hlth, Inst Res, Montreal, PQ, Canada; McGill Univ, Montreal Genome Ctr, Montreal, PQ, Canada; McGill Univ, Program Canc Genet, Dept Human Genet, Montreal, PQ, Canada; McGill Univ, Program Canc Genet, Dept Oncol, Montreal, PQ, Canada	Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; McGill University; McGill University; McGill University; McGill University; McGill University	Al Moustafa, AE (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, Montreal, PQ H3T 1E2, Canada.	aalmoust@ldi.jgh.mcgill.ca; malaou@po-box.mcgill.ca	Sladek, Robert/R-2391-2019; Foulkes, William D./AAR-9586-2021	Sladek, Robert/0000-0002-2730-1204; Foulkes, William D./0000-0001-7427-4651				ALMOUSTAFA AE, 2002, IN PRESS LUNG CANC; Anttonen A, 1999, BRIT J CANCER, V79, P558, DOI 10.1038/sj.bjc.6690088; Bagutti C, 1998, J PATHOL, V186, P8, DOI 10.1002/(SICI)1096-9896(199809)186:1<8::AID-PATH156>3.0.CO;2-H; Bentz BG, 2000, LARYNGOSCOPE, V110, P1642, DOI 10.1097/00005537-200010000-00013; BEYER EC, 1990, J MEMBRANE BIOL, V3, P187; Bishop AJR, 2001, BBA-REV CANCER, V1471, pM109, DOI 10.1016/S0304-419X(01)00018-X; BRISSETTE JL, 1994, P NATL ACAD SCI USA, V91, P6453, DOI 10.1073/pnas.91.14.6453; BUDUNOVA IV, 1995, CARCINOGENESIS, V16, P2717, DOI 10.1093/carcin/16.11.2717; Chen Z, 1999, CLIN CANCER RES, V5, P1369; Chu YW, 1996, AM J PATHOL, V148, P63; Clavel CE, 2001, J PATHOL, V194, P20, DOI 10.1002/path.868; Duffey DC, 2000, BRIT J CANCER, V83, P1367, DOI 10.1054/bjoc.2000.1423; Gofuku J, 1999, AM J CLIN PATHOL, V111, P29; Grunwald GB, 1993, CURR OPIN CELL BIOL, V5, P797, DOI 10.1016/0955-0674(93)90028-O; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Heiskala M, 2001, TRAFFIC, V2, P92, DOI 10.1034/j.1600-0854.2001.020203.x; Jeffries S, 2001, ORAL ONCOL, V37, P115, DOI 10.1016/S1368-8375(00)00065-8; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Li G, 2000, MOL MED TODAY, V6, P163, DOI 10.1016/S1357-4310(00)01692-0; Li Z, 1998, J CELL SCI, V111, P1005; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; MILLER AC, 1993, INT J CANCER, V53, P302, DOI 10.1002/ijc.2910530222; Miura K, 1997, JPN J CANCER RES, V88, P143, DOI 10.1111/j.1349-7006.1997.tb00359.x; Morifuji M, 2000, AM J PATHOL, V156, P1317, DOI 10.1016/S0002-9440(10)65002-X; Ninomiya I, 2000, INT J CANCER, V85, P757, DOI 10.1002/(SICI)1097-0215(20000315)85:6<757::AID-IJC3>3.0.CO;2-O; Ono K, 2000, CANCER RES, V60, P5007; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; Paterson IC, 2001, J PATHOL, V193, P458, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH822>3.0.CO;2-V; Pukkila MJ, 2001, J CLIN PATHOL, V54, P42, DOI 10.1136/jcp.54.1.42; Reid BC, 2000, ORAL ONCOL, V36, P414, DOI 10.1016/S1368-8375(00)00028-2; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.bi.59.070190.001321; Tomson AM, 1996, CLIN EXP METASTAS, V14, P501, DOI 10.1007/BF00115110; Villaret DB, 2000, LARYNGOSCOPE, V110, P374, DOI 10.1097/00005537-200003000-00008; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Wang T, 2000, ONCOGENE, V19, P1519, DOI 10.1038/sj.onc.1203457; Witt CJ, 2000, OTOLARYNG HEAD NECK, V122, P721, DOI 10.1016/S0194-5998(00)70204-X; Wong DTW, 1996, CRIT REV ORAL BIOL M, V7, P319, DOI 10.1177/10454411960070040201; Yamasaki H, 1999, CANCER DETECT PREV, V23, P273, DOI 10.1046/j.1525-1500.1999.99037.x; Yang YM, 1997, AM J PATHOL, V150, P693; Yokoyama K, 2001, ORAL ONCOL, V37, P65, DOI 10.1016/S1368-8375(00)00059-2	43	180	189	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2634	2640		10.1038/sj.onc.1205351	http://dx.doi.org/10.1038/sj.onc.1205351			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965536				2022-12-17	WOS:000174996500003
J	Kawada, M; Yamagoe, S; Murakami, Y; Suzuki, K; Mizuno, S; Uehara, Y				Kawada, M; Yamagoe, S; Murakami, Y; Suzuki, K; Mizuno, S; Uehara, Y			Induction of p27(Kip1) degradation and anchorage independence by Ras through the MAP kinase signaling pathway	ONCOGENE			English	Article						ras; anchorage independence; cell cycle; p27(Kip1)	CELL-CYCLE ARREST; PROTEIN-KINASE; G1 PHASE; POTENTIAL MEDIATOR; TRANSFORMED-CELLS; CDK6 INHIBITOR; GROWTH; PROGRESSION; ACTIVATION; LINKS	While most untransformed cells require substrate attachment for growth (anchorage dependence), the oncogenic transformed cells lack this requirement (anchorage independence) and are often tumorigenic. However, the mechanism of loss of anchorage dependence is not fully understood. When rat normal fibroblasts were cultured in suspension without substrate attachment, the cell cycle arrested in G1 phase and the cyclin-dependent kinase inhibitor p27(Kip1) protein and its mRNA accumulated. Conditional expression of oncogenic Ras induced the G1-S transition of the cell cycle and significantly shortened the half-life of p27(Kip1) protein without altering its mRNA level. Inhibition of the activation of mitogen-activated protein (MAP) kinase by cyclic AMP-elevating agents and a MEK inhibitor prevented the oncogenic Ras-induced degradation of p27(KiP1). These results suggest that the loss of substrate attachment induces the cell cycle arrest through the upregulation of p27(Kip1) mRNA, but the oncogenic Ras confers anchorage independence by accelerating p27(Kip1) degradation through the activation of the MAP kinase signaling pathway. Furthermore, we have found that p27(Kip1) is phosphorylated by MAP kinase in vitro and the phosphorylated p27(Kip1) cannot bind to and inhibit cdk2.	NATL INST HLTH,DEPT BIOACT MOL,SHINJUKU KU,TOKYO 162,JAPAN					Kawada, Manabu/0000-0001-9348-4240				BARRETT JF, 1995, J BIOL CHEM, V270, P15923, DOI 10.1074/jbc.270.27.15923; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FUKAZAWA H, 1995, ANAL BIOCHEM, V228, P83, DOI 10.1006/abio.1995.1318; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Kang JS, 1996, MOL CELL BIOL, V16, P3370; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LOVEC H, 1994, ONCOGENE, V9, P323; Luo Y, 1996, MOL CELL BIOL, V16, P6744; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; Maki CG, 1996, CANCER RES, V56, P2649; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Nakajima T, 1996, J BIOL CHEM, V271, P24842, DOI 10.1074/jbc.271.40.24842; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Schulze A, 1996, MOL CELL BIOL, V16, P4632; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SOUTHGATE J, 1995, BRIT J CANCER, V72, P1214, DOI 10.1038/bjc.1995.488; Spirin KS, 1996, CANCER RES, V56, P2400; Takeuchi S, 1996, CANCER RES, V56, P738; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Winston JT, 1996, ONCOGENE, V12, P127; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	56	180	184	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					629	637		10.1038/sj.onc.1201228	http://dx.doi.org/10.1038/sj.onc.1201228			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264403				2022-12-17	WOS:A1997XP68300002
J	SCHNEIDER, R; SCHWEIGER, M				SCHNEIDER, R; SCHWEIGER, M			A NOVEL MODULAR MOSAIC OF CELL-ADHESION MOTIFS IN THE EXTRACELLULAR DOMAINS OF THE NEUROGENIC TRK AND TRKB TYROSINE KINASE RECEPTORS	ONCOGENE			English	Article							IMMUNOGLOBULIN SUPERFAMILY; PROTEIN; GENE; EXPRESSION; SEQUENCES; ONCOGENE; PROTOONCOGENE; ACTIVATION; CONTAINS; FAMILY	The extracellular domains of the human trk proto-oncogene and the closely homologous murine trkB share two highly conserved regions as well as several invariant cysteines which are supposed to be important for ligand recognition. Detailed comparative sequence analyses have now revealed the presence of a novel combination of distinct cell adhesion motifs corresponding precisely with these conserved regions. The N-terminal part consists of an array of three tandem leucine-rich motifs of 24 amino acids which is flanked by two distinct cysteine clusters. Significantly homologous structural features are found in the toll gene product of Drosophila, a transmembrane protein mediating specific cell adhesion events involved in the dorsoventral embryonic pattern formation. Directly adjacent to these structures we additionally identified two repeats of the immunoglobulin-like C2 type, which are significantly similar to repeats found in the neural cell adhesion molecules (N-CAMs) and in the platelet-derived growth factor receptor (PDGFR)-like tyrosine kinase receptor family. Our findings indicate that the trk/trkB protein tyrosine kinase receptors are involved in the transmembrane signalling of growth factor binding as well as of specific cell adhesion events during neuronal development. Additionally, we propose that the specifically expressed truncated forms of the trkB receptor, lacking the tyrosine kinase domain, are functioning as neural cell adhesion molecules. The knowledge of this domain structure will facilitate the elucidation of the molecular reasons why alterations in the extracellular region lead to oncogenic activation of the human trk proto-oncogene, which is a major cause of papillary thyroid carcinoma.			SCHNEIDER, R (corresponding author), UNIV INNSBRUCK,INST BIOCHEM,PETER MAYR STR 1A,A-6020 INNSBRUCK,AUSTRIA.							Barton D E, 1988, Oncogene Res, V3, P323; BONGARZONE I, 1989, ONCOGENE, V4, P1457; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HERZOG H, 1989, P NATL ACAD SCI USA, V86, P3514, DOI 10.1073/pnas.86.10.3514; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; HUNDKAPILLER T, 1988, ADV IMMUNOL, V44, P1; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KEITH FJ, 1990, EMBO J, V9, P4299, DOI 10.1002/j.1460-2075.1990.tb07878.x; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MIKOL DD, 1990, J CELL BIOL, V110, P471, DOI 10.1083/jcb.110.2.471; MIOZZO M, 1990, ONCOGENE, V5, P1411; REBSTOCK S, 1990, J BIOL CHEM, V265, P7872; REYES AA, 1991, MOL CELL BIOL, V11, P1654, DOI 10.1128/MCB.11.3.1654; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; SCHNEIDER R, 1991, FEBS LETT, V283, P203, DOI 10.1016/0014-5793(91)80588-T; SCHNEIDER R, 1988, EMBO J, V7, P4151, DOI 10.1002/j.1460-2075.1988.tb03310.x; SCHOFIELD PR, 1989, EMBO J, V8, P489, DOI 10.1002/j.1460-2075.1989.tb03402.x; WILLIAMS AF, 1987, J EXP MED, V165, P368, DOI 10.1084/jem.165.2.368; WILLIAMS AF, 1987, IMMUNOL TODAY, V8, P298, DOI 10.1016/0167-5699(87)90016-8; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	33	180	188	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1807	1811						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1656363				2022-12-17	WOS:A1991GX11800013
J	SASSONECORSI, P; RANSONE, LJ; VERMA, IM				SASSONECORSI, P; RANSONE, LJ; VERMA, IM			CROSS-TALK IN SIGNAL TRANSDUCTION - TPA-INDUCIBLE FACTOR JUN/AP-1 ACTIVATES CAMP-RESPONSIVE ENHANCER ELEMENTS	ONCOGENE			English	Note									SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,SAN DIEGO,CA 92138	Salk Institute	SASSONECORSI, P (corresponding author), CNRS,GENET MOLEC EUCARYOTES LAB,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE.		Messier, Claude/A-2322-2008; Sassone-Corsi, Paolo/H-6182-2011	Messier, Claude/0000-0002-4791-1763; 				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BELL JD, 1985, J BIOL CHEM, V260, P2625; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; CURRAN T, 1985, MOL CELL BIOL, V5, P162; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DELI E, 1988, FEBS LETT, V231, P407, DOI 10.1016/0014-5793(88)80860-3; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; KELLEHER DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4316, DOI 10.1073/pnas.81.14.4316; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; QUANTIN B, 1988, NATURE, V334, P537; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOEFFLER JP, 1988, SCIENCE, V242, P1430; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0	43	180	181	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					427	431						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	2107494				2022-12-17	WOS:A1990CW41500023
J	TSUJIMOTO, Y; IKEGAKI, N; CROCE, CM				TSUJIMOTO, Y; IKEGAKI, N; CROCE, CM			CHARACTERIZATION OF THE PROTEIN PRODUCT OF BCL-2, THE GENE INVOLVED IN HUMAN FOLLICULAR LYMPHOMA	ONCOGENE			English	Article									UNIV PENN,SCH MED,DEPT HUMAN GENET,PHILADELPHIA,PA 19104	University of Pennsylvania	TSUJIMOTO, Y (corresponding author), WISTAR INST ANAT & BIOL,3601 SPRUCE ST,PHILADELPHIA,PA 19104, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	NCI NIH HHS [CA 25875, CA 69805] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA025875] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; FUKUHARA S, 1979, CANCER RES, V39, P3119; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; YUNIS JJ, 1982, NEW ENGL J MED, V307, P1231, DOI 10.1056/NEJM198211113072002	15	180	186	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	2	1					3	7						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	L4813	3325884				2022-12-17	WOS:A1987L481300001
J	Schabath, MB; Welsh, EA; Fulp, WJ; Chen, L; Teer, JK; Thompson, ZJ; Engel, BE; Xie, M; Berglund, AE; Creelan, BC; Antonia, SJ; Gray, JE; Eschrich, SA; Chen, DT; Cress, WD; Haura, EB; Beg, AA				Schabath, M. B.; Welsh, E. A.; Fulp, W. J.; Chen, L.; Teer, J. K.; Thompson, Z. J.; Engel, B. E.; Xie, M.; Berglund, A. E.; Creelan, B. C.; Antonia, S. J.; Gray, J. E.; Eschrich, S. A.; Chen, D-T; Cress, W. D.; Haura, E. B.; Beg, A. A.			Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma	ONCOGENE			English	Article							NF-KAPPA-B; TUMOR MICROENVIRONMENT; CANCER-IMMUNOTHERAPY; SOMATIC MUTATIONS; T-CELLS; LKB1; SIGNATURE; METASTASIS; SURVIVAL; INNATE	While mutations in the KRAS oncogene are among the most prevalent in human cancer, there are few successful treatments to target these tumors. It is also likely that heterogeneity in KRAS-mutant tumor biology significantly contributes to the response to therapy. We hypothesized that the presence of commonly co-occurring mutations in STK11 and TP53 tumor suppressors may represent a significant source of heterogeneity in KRAS-mutant tumors. To address this, we utilized a large cohort of resected tumors from 442 lung adenocarcinoma patients with data including annotation of prevalent driver mutations (KRAS and EGFR) and tumor suppressor mutations (STK11 and TP53), microarray-based gene expression and clinical covariates, including overall survival (OS). Specifically, we determined impact of STK11 and TP53 mutations on a new KRAS mutation-associated gene expression signature as well as previously defined signatures of tumor cell proliferation and immune surveillance responses. Interestingly, STK11, but not TP53 mutations, were associated with highly elevated expression of KRAS mutation-associated genes. Mutations in TP53 and STK11 also impacted tumor biology regardless of KRAS status, with TP53 strongly associated with enhanced proliferation and STK11 with suppression of immune surveillance. These findings illustrate the remarkably distinct ways through which tumor suppressor mutations may contribute to heterogeneity in KRAS-mutant tumor biology. In addition, these studies point to novel associations between gene mutations and immune surveillance that could impact the response to immunotherapy.	[Schabath, M. B.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL 33612 USA; [Welsh, E. A.; Teer, J. K.; Berglund, A. E.; Eschrich, S. A.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Bioinformat, Tampa, FL 33612 USA; [Fulp, W. J.; Chen, L.; Thompson, Z. J.; Chen, D-T] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Biostat, Tampa, FL 33612 USA; [Engel, B. E.; Xie, M.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Canc Biol Grad Program, Tampa, FL 33612 USA; [Creelan, B. C.; Antonia, S. J.; Gray, J. E.; Haura, E. B.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL 33612 USA; [Cress, W. D.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA; [Beg, A. A.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Immunol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Schabath, MB; Beg, AA (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.	matthew.schabath@moffitt.org; amer.beg@moffitt.org	Fulp, William/AAD-2369-2022; Schabath, Matthew B./J-3763-2016; Eschrich, Steven/K-6848-2013	Schabath, Matthew B./0000-0003-3241-3216; Eschrich, Steven/0000-0002-9833-2788; Fulp, William/0000-0001-6888-0794; Creelan, Ben/0000-0002-2728-8070; Berglund, Anders/0000-0002-0393-3530	National Institutes of Health SPORE Grant [P50 CA119997]; DeBartolo Family; Cancer Center Support Grant (CCSG grant) at the H. Lee Moffitt Cancer Center and Research Institute, a National Cancer Institute-designated Comprehensive Cancer Center [P30-CA76292]; NATIONAL CANCER INSTITUTE [R25CA174664, P50CA119997, P30CA076292, P50CA070907] Funding Source: NIH RePORTER	National Institutes of Health SPORE Grant; DeBartolo Family; Cancer Center Support Grant (CCSG grant) at the H. Lee Moffitt Cancer Center and Research Institute, a National Cancer Institute-designated Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a National Institutes of Health SPORE Grant (P50 CA119997). We would also like to thank Mr Andrew 'Ross' Myers, Anastasia Belock, Mercedes Rodriguez, Edward T Chwieseni, Marek Wloch, Hiba Gohar, and Moffitt's Tissue Core facility, Moffitt's Cancer Registry (Director: Karen A Coyne), Research Information Technology (IT) group, and the Data Management and Integration Technology (DMIT) group. Total Cancer Care is enabled, in part, by the generous support of the DeBartolo Family, and we thank the many patients who provided data and tissue to the Total Cancer Care Consortium. Our study also received valuable assistance from the following Core Facilities at the Moffitt Cancer Center: Biostatistics and Cancer Informatics, Tissue, and Molecular Genomics. This work has been supported in part by a Cancer Center Support Grant (CCSG grant P30-CA76292) at the H. Lee Moffitt Cancer Center and Research Institute, a National Cancer Institute-designated Comprehensive Cancer Center.	Baker NM, 2014, CLIN CANCER RES, V20, P4740, DOI 10.1158/1078-0432.CCR-13-1727; Bang D, 2013, CANCER DISCOV, V3, P690, DOI 10.1158/2159-8290.CD-12-0541; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Carretero J, 2010, CANCER CELL, V17, P547, DOI 10.1016/j.ccr.2010.04.026; Chen DT, 2011, JNCI-J NATL CANCER I, V103, P1859, DOI 10.1093/jnci/djr420; Chen DT, 2010, BREAST CANCER RES TR, V119, P335, DOI 10.1007/s10549-009-0344-y; Cox Adrienne D, 2010, Small GTPases, V1, P2; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Fridman WH, 2011, CANCER RES, V71, P5601, DOI 10.1158/0008-5472.CAN-11-1316; Fuertes MB, 2013, TRENDS IMMUNOL, V34, P67, DOI 10.1016/j.it.2012.10.004; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Gajewski TF, 2013, CURR OPIN IMMUNOL, V25, P259, DOI 10.1016/j.coi.2013.03.008; Gajewski TF, 2013, CURR OPIN IMMUNOL, V25, P268, DOI 10.1016/j.coi.2013.02.009; Gao YJ, 2011, PROTEIN CELL, V2, P99, DOI 10.1007/s13238-011-1021-6; Gao YJ, 2010, P NATL ACAD SCI USA, V107, P18892, DOI 10.1073/pnas.1004952107; Gibbons DL, 2014, MOL CANCER RES, V12, P3, DOI 10.1158/1541-7786.MCR-13-0539; Hopewell EL, 2013, J CLIN INVEST, V123, P2509, DOI 10.1172/JCI67250; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Ji RR, 2012, CANCER IMMUNOL IMMUN, V61, P1019, DOI 10.1007/s00262-011-1172-6; Kaufman JM, 2014, J THORAC ONCOL, V9, P794, DOI 10.1097/JTO.0000000000000173; Kim HS, 2013, CELL, V155, P552, DOI 10.1016/j.cell.2013.09.041; Loboda A, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-26; Matsumoto S, 2007, ONCOGENE, V26, P5911, DOI 10.1038/sj.onc.1210418; Meng DQ, 2013, LUNG CANCER, V81, P1, DOI 10.1016/j.lungcan.2013.03.019; Mitin N, 2005, CURR BIOL, V15, pR563, DOI 10.1016/j.cub.2005.07.010; O'Neill GM, 2007, CANCER RES, V67, P8975, DOI 10.1158/0008-5472.CAN-07-1328; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Pao W, 2011, LANCET ONCOL, V12, P175, DOI 10.1016/S1470-2045(10)70087-5; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sanchez-Cespedes M, 2011, FAM CANCER, V10, P447, DOI 10.1007/s10689-011-9443-0; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shah U, 2008, CANCER RES, V68, P3562, DOI 10.1158/0008-5472.CAN-07-6620; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Sos ML, 2009, J CLIN INVEST, V119, P1727, DOI 10.1172/JCI37127; Ulloa-Montoya F, 2013, J CLIN ONCOL, V31, P2388, DOI 10.1200/JCO.2012.44.3762; Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177	46	179	184	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3209	3216		10.1038/onc.2015.375	http://dx.doi.org/10.1038/onc.2015.375			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26477306	Green Accepted			2022-12-17	WOS:000378092700012
J	Weizman, N; Krelin, Y; Shabtay-Orbach, A; Amit, M; Binenbaum, Y; Wong, RJ; Gil, Z				Weizman, N.; Krelin, Y.; Shabtay-Orbach, A.; Amit, M.; Binenbaum, Y.; Wong, R. J.; Gil, Z.			Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase	ONCOGENE			English	Article						pancreatic ductal adenocarcinoma; chemotherapy; gemcitabine; resistance; macrophages; cytidine deaminase	PHASE-III TRIAL; TUMOR MICROENVIRONMENT; CELL-MIGRATION; DUCTAL ADENOCARCINOMA; DRUG-RESISTANCE; BREAST-CANCER; MOUSE MODEL; EXPRESSION; INVASION; CHEMOTHERAPY	Resistance to pharmacologic agents used in chemotherapy is common in most human carcinomas, including pancreatic ductal adenocarcinoma (PDA), which is resistant to almost all drugs, including gemcitabine, a nucleoside analog used as a first-line treatment. Poor survival rates of PDA patients have, therefore, not changed much over 4 decades. Recent data indicated that tumor-associated macrophages (TAMs), which are abundant in the microenvironment of several tumors, including PDA, secrete pro-tumorigenic factors that contribute to cancer progression and dissemination. In this study, we show for the first time that TAMs can also induce chemoresistance of PDA by reducing gemcitabine-induced apoptosis. Macrophages co-cultured with cancer cells or TAM-conditioned medium significantly reduced apoptosis and activation of the caspase-3 pathway during gemcitabine treatment. In vivo PDA models of mice, which have reduced macrophage recruitment and activation, demonstrated improved response to gemcitabine compared with controls. Similarly, inhibition of monocytes/macrophages trafficking by a CSF1-receptor antagonist GW2580 augmented the effect of gemcitabine in a transgenic mouse PDA model that was resistant to gemcitabine alone. Analysis of multiple proteins involved in gemcitabine delivery and metabolism revealed that TAMs induced upregulation of cytidine deaminase (CDA), the enzyme that metabolizes the drug following its transport into the cell. Decreasing CDA expression by PDA cells blocked the protective effect of TAMs against gemcitabine. These results provide the first evidence of a paracrine effect of TAMs, which mediates acquired resistance of cancer cells to chemotherapy. Modulation of macrophage trafficking or inhibition of CDA may offer a new strategy for augmenting the response of PDA to chemotherapy.	[Weizman, N.; Krelin, Y.; Shabtay-Orbach, A.; Amit, M.; Binenbaum, Y.; Gil, Z.] Rambam Med Ctr, Dept Otolaryngol Head & Neck Surg, Lab Appl Canc Res, IL-31096 Haifa, Israel; [Amit, M.; Gil, Z.] Rambam Med Ctr, Technion Israel Inst Technol, Dept Otolaryngol Head & Neck Surg, IL-31096 Haifa, Israel; [Wong, R. J.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA	Rambam Health Care Campus; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Memorial Sloan Kettering Cancer Center	Gil, Z (corresponding author), Rambam Med Ctr, Technion Israel Inst Technol, Dept Otolaryngol Head & Neck Surg, 6 Haaliya St,POB 9602, IL-31096 Haifa, Israel.	ziv@baseofskull.org			Israel Science Foundation; Israel Cancer Association; Israeli Ministry of Health [3-7355]; Rambam Medical Center; ICRF Barbara S Goodman endowed research career development award in Pancreatic Cancer [2011-601-BGPC]; US-Israel Binational Science Foundation	Israel Science Foundation(Israel Science Foundation); Israel Cancer Association; Israeli Ministry of Health; Rambam Medical Center; ICRF Barbara S Goodman endowed research career development award in Pancreatic Cancer; US-Israel Binational Science Foundation(US-Israel Binational Science Foundation)	Esther Eshkol is thanked for editorial assistance. This research was supported by the Legacy Heritage Biomedical Science Partnership Program of the Israel Science Foundation, the Israel Cancer Association (grant donated by Ellen and Emanuel Kronitz in memory of Dr Leon Kronitz), the Israeli Ministry of Health (No. 3-7355), the Rambam Medical Center Intramural Grant, the ICRF Barbara S Goodman endowed research career development award in Pancreatic Cancer (2011-601-BGPC) all to ZG, and the US-Israel Binational Science Foundation to ZG and RJW.	Ahn GO, 2010, P NATL ACAD SCI USA, V107, P8363, DOI 10.1073/pnas.0911378107; Akita H, 2009, ONCOGENE, V28, P2903, DOI 10.1038/onc.2009.158; Andre F, 2010, CURR OPIN ONCOL, V22, P547, DOI 10.1097/CCO.0b013e32833fb384; Bhutia YD, 2011, CANCER RES, V71, P1825, DOI 10.1158/0008-5472.CAN-10-2736; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Cavel O, 2012, CANCER RES, V72, P5733, DOI 10.1158/0008-5472.CAN-12-0764; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; Colucci G, 2010, J CLIN ONCOL, V28, P1645, DOI 10.1200/JCO.2009.25.4433; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Cunningham D, 2009, J CLIN ONCOL, V27, P5513, DOI 10.1200/JCO.2009.24.2446; De Palma M, 2011, NATURE, V472, P303, DOI 10.1038/472303a; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; Dijkgraaf EM, 2013, CANCER RES, V73, P2480, DOI 10.1158/0008-5472.CAN-12-3542; Esposito I, 2004, J CLIN PATHOL, V57, P630, DOI 10.1136/jcp.2003.014498; Ferrandina G, 2008, J CLIN ONCOL, V26, P890, DOI 10.1200/JCO.2007.13.6606; Gil Z, 2010, J NATL CANCER I, V102, P107, DOI 10.1093/jnci/djp456; Gilbert LA, 2011, CANCER RES, V71, P5062, DOI 10.1158/0008-5472.CAN-11-0277; Giovannetti E, 2006, MOL CANCER THER, V5, P1387, DOI 10.1158/1535-7163.MCT-06-0004; Green CE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006713; Greten FR, 2002, GASTROENTEROLOGY, V123, P2052, DOI 10.1053/gast.2002.37075; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Jinushi M, 2011, P NATL ACAD SCI USA, V108, P12425, DOI 10.1073/pnas.1106645108; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Korc M, 2007, AM J SURG, V194, pS84, DOI 10.1016/j.amjsurg.2007.05.004; Kozin SV, 2010, CANCER RES, V70, P5679, DOI 10.1158/0008-5472.CAN-09-4446; Loehrer PJ, 2011, J CLIN ONCOL, V29, P4105, DOI 10.1200/JCO.2011.34.8904; Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009; Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078-0432.CCR-07-2223; Mitchem JB, 2013, CANCER RES, V73, P1128, DOI 10.1158/0008-5472.CAN-12-2731; Morgan MA, 2005, CANCER RES, V65, P6835, DOI 10.1158/0008-5472.CAN-04-2246; Nefedova Y, 2003, LEUKEMIA, V17, P1175, DOI 10.1038/sj.leu.2402924; Niedergethmann M, 2007, BRIT J CANCER, V97, P1432, DOI 10.1038/sj.bjc.6604031; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Pahler J, 2008, NEOPLASIA, V10, P329, DOI 10.1593/neo.07871; Riccil F, 2005, CANCER BIOL THER, V4, P302, DOI 10.4161/cbt.4.3.1501; Schafer H, 2013, ONCOGENE, V32, P180, DOI 10.1038/onc.2012.44; Shree T, 2011, GENE DEV, V25, P2465, DOI 10.1101/gad.180331.111; Singh S, 2010, BRIT J CANCER, V103, P1671, DOI 10.1038/sj.bjc.6605968; STAROSELSKY AN, 1990, CANCER RES, V50, P7775; Steube KG, 1998, INT J CANCER, V78, P120, DOI 10.1002/(SICI)1097-0215(19980925)78:1<120::AID-IJC19>3.3.CO;2-J; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Summy JM, 2005, PANCREAS, V31, P263, DOI 10.1097/01.mpa.0000178280.50534.0c; Tempero M, 2003, J CLIN ONCOL, V21, P3402, DOI 10.1200/JCO.2003.09.140; Vakkila J, 2004, NAT REV IMMUNOL, V4, P641, DOI 10.1038/nri1415; van Rooijen N, 2003, METHOD ENZYMOL, V373, P3; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; YAMASHINA K, 1986, CANCER RES, V46, P2396; Zhang J, 2010, JNCI-J NATL CANCER I, V102, P522, DOI 10.1093/jnci/djq044; Zheng YH, 2009, BLOOD, V114, P3625, DOI 10.1182/blood-2009-05-220285	49	179	187	2	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3812	3819		10.1038/onc.2013.357	http://dx.doi.org/10.1038/onc.2013.357			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	23995783				2022-12-17	WOS:000339394100007
J	van Jaarsveld, MTM; Helleman, J; Boersma, AWM; van Kuijk, PF; van IJcken, WF; Despierre, E; Vergote, I; Mathijssen, RHJ; Berns, EMJJ; Verweij, J; Pothof, J; Wiemer, EAC				van Jaarsveld, M. T. M.; Helleman, J.; Boersma, A. W. M.; van Kuijk, P. F.; van IJcken, W. F.; Despierre, E.; Vergote, I.; Mathijssen, R. H. J.; Berns, E. M. J. J.; Verweij, J.; Pothof, J.; Wiemer, E. A. C.			miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells	ONCOGENE			English	Article						cisplatin; drug resistance; KEAP1; miR-141; ovarian cancer	MICRORNA EXPRESSION PROFILES; MIR-200 FAMILY; MESENCHYMAL TRANSITION; PLATINUM RESISTANCE; CONFERS RESISTANCE; CLINICAL-TRIALS; REPRESSORS ZEB1; DOWN-REGULATION; TRANSCRIPTION; ACTIVATION	Epithelial ovarian cancer is the most lethal gynecological malignancy in the Western world. A major impediment for the successful treatment is the development of drug resistance. The molecular processes that contribute to resistance have been extensively studied; however, there is not much known about regulation by microRNAs (miRNAs). We compared miRNA expression profiles of an isogenic cisplatin-sensitive and -resistant ovarian cancer cell line pair (A2780/A2780 DDP) and found 27 miRNAs to be differentially expressed (>= 2-fold). Five of these, including the family members miR-141/200c, showed a correlation with cisplatin sensitivity in the NCI-60 panel. Overexpression of miR-141 resulted in enhanced resistance to cisplatin in ovarian cancer cell lines. We next correlated the expression level of miR-141 in 132 primary ovarian tumors (108 serous and 24 non-serous) with response to platinum-based chemotherapy. Although no differences were observed in the serous tumors, miR-141 levels were higher in non-serous ovarian tumors that did not respond well to therapy (platinum-free interval <6 months). We demonstrate that miR-141 directly targets KEAP1, and that downregulation of KEAP1 induces cisplatin resistance. Conversely, overexpression of KEAP1 significantly enhanced cisplatin sensitivity. Expression of KEAP1 with its 3'-UTR, and a 3'-UTR in which the miR-141 target site has been mutated, revealed that miR-141 regulates KEAP1 upon exposure to cisplatin. Finally, we show that the NF-kappa B pathway, which can be regulated by KEAP1, is activated upon miR-141 overexpression, and that inhibition of this pathway partially reverses miR-141-mediated cisplatin resistance. These findings demonstrate that the miR-141-mediated regulation of KEAP1 has a crucial role in the cellular response to cisplatin.	[van Jaarsveld, M. T. M.; Helleman, J.; Boersma, A. W. M.; van Kuijk, P. F.; Mathijssen, R. H. J.; Berns, E. M. J. J.; Verweij, J.; Wiemer, E. A. C.] Erasmus Univ, Daniel den Hoed Canc Ctr, Med Ctr, Dept Med Oncol, NL-3015 GE Rotterdam, Netherlands; [van IJcken, W. F.] Erasmus MC, Erasmus Ctr Biom, Rotterdam, Netherlands; [Despierre, E.; Vergote, I.] Univ Hosp Leuven, Dept Obstet & Gynecol, European Union, Louvain, Belgium; [Despierre, E.; Vergote, I.] Univ Hosp Leuven, Leuven Canc Inst, Div Gynecol Oncol, European Union, Louvain, Belgium; [Pothof, J.] Erasmus MC, Dept Genet, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; Erasmus University Rotterdam; Erasmus MC	Wiemer, EAC (corresponding author), Erasmus Univ, Daniel den Hoed Canc Ctr, Med Ctr, Dept Med Oncol, Room Be422,Dr Molewaterplein 50, NL-3015 GE Rotterdam, Netherlands.	e.wiemer@erasmusmc.nl	van ijcken, willem/N-9805-2018	van ijcken, willem/0000-0002-0421-8301; Wiemer, Erik/0000-0002-0673-7236	Dutch Cancer Society EMCR [2007-3794]	Dutch Cancer Society EMCR	We thank Dr Kevin Scanlon (Keck Graduate Institute of Applied Life Sciences, Claremont, USA) for the kind gift of the cisplatin-sensitive/resistant A2780 cell line pair. We thank Mariel Brok and Kirsten Ruigrok-Ritstier for technical assistance, Andrea Sacchetti for FACS-sorting KEAP1-transfected cells and Herman Burger for critical comments on the manuscript. This project is supported by a grant from the Dutch Cancer Society EMCR 2007-3794.	Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Blower PE, 2007, MOL CANCER THER, V6, P1483, DOI 10.1158/1535-7163.MCT-07-0009; Brozovic A, 2007, CANCER LETT, V251, P1, DOI 10.1016/j.canlet.2006.10.007; Burger H, 2011, DRUG RESIST UPDATE, V14, P22, DOI 10.1016/j.drup.2010.12.002; Campbell KJ, 2006, CANCER RES, V66, P929, DOI 10.1158/0008-5472.CAN-05-2234; CARMICHAEL J, 1987, CANCER RES, V47, P936; Cochrane DR, 2010, J ONCOL, V2010, DOI 10.1155/2010/821717; Cochrane DR, 2009, MOL CANCER THER, V8, P1055, DOI 10.1158/1535-7163.MCT-08-1046; Devling TWP, 2005, P NATL ACAD SCI USA, V102, P7280, DOI 10.1073/pnas.0501475102; Eades G, 2011, J BIOL CHEM, V286, P40725, DOI 10.1074/jbc.M111.275495; Eberle KE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021496; Ferlay J, 2010, EUR J CANCER, V46, P765, DOI 10.1016/j.ejca.2009.12.014; Friedlander M, 2011, INT J GYNECOL CANCER, V21, P771, DOI 10.1097/IGC.0b013e31821bb8aa; Gallagher MF, 2009, J OVARIAN RES, V2, DOI 10.1186/1757-2215-2-19; Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698; Giudice A, 2010, METHODS MOL BIOL, V647, P37, DOI 10.1007/978-1-60761-738-9_3; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; Imanaka Y, 2011, J HUM GENET, V56, P270, DOI 10.1038/jhg.2011.1; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Kim JE, 2010, CELL SIGNAL, V22, P1645, DOI 10.1016/j.cellsig.2010.06.004; Kong FF, 2011, J HUAZHONG U SCI-MED, V31, P543, DOI 10.1007/s11596-011-0487-z; Konstantinopoulos PA, 2011, CANCER RES, V71, P5081, DOI 10.1158/0008-5472.CAN-10-4668; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Ledermann JA, 2011, INT J GYNECOL CANCER, V21, P763, DOI 10.1097/IGC.0b013e31821b2669; Lee DF, 2009, MOL CELL, V36, P131, DOI 10.1016/j.molcel.2009.07.025; Lee YS, 2005, J BIOL CHEM, V280, P16635, DOI 10.1074/jbc.M412247200; Mabuchi S, 2004, J BIOL CHEM, V279, P23477, DOI 10.1074/jbc.M313709200; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; Martin LP, 2008, CLIN CANCER RES, V14, P1291, DOI 10.1158/1078-0432.CCR-07-2238; Mateescu B, 2011, NAT MED, V17, P1627, DOI 10.1038/nm.2512; McLellan LI, 1999, DRUG RESIST UPDATE, V2, P153, DOI 10.1054/drup.1999.0083; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731; OZOLS RF, 2005, PRINCIPLES PRACTICE; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pectasides D, 2006, ONCOLOGIST, V11, P1089, DOI 10.1634/theoncologist.11-10-1089; Pothof J, 2009, EMBO J, V28, P2090, DOI 10.1038/emboj.2009.156; Reichard JF, 2007, NUCLEIC ACIDS RES, V35, P7074, DOI 10.1093/nar/gkm638; SCHMIDT W, 1993, CANCER RES, V53, P799; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Stewart DJ, 2007, CRIT REV ONCOL HEMAT, V63, P12, DOI 10.1016/j.critrevonc.2007.02.001; Venkatraman M, 2005, MOL CARCINOGEN, V44, P51, DOI 10.1002/mc.20116; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Wang YL, 1999, J BIOL CHEM, V274, P22095, DOI 10.1074/jbc.274.31.22095; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wyman SK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005311; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yang N, 2008, CANCER RES, V68, P10307, DOI 10.1158/0008-5472.CAN-08-1954; Ye G, 2011, J CELL SCI, V124, P359, DOI 10.1242/jcs.072223	50	179	181	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2013	32	36					4284	4293		10.1038/onc.2012.433	http://dx.doi.org/10.1038/onc.2012.433			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23045278				2022-12-17	WOS:000324168000010
J	Kato, M; Paranjape, T; Ullrich, R; Nallur, S; Gillespie, E; Keane, K; Esquela-Kerscher, A; Weidhaas, JB; Slack, FJ				Kato, M.; Paranjape, T.; Ullrich, R.; Nallur, S.; Gillespie, E.; Keane, K.; Esquela-Kerscher, A.; Weidhaas, J. B.; Slack, F. J.			The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells	ONCOGENE			English	Article						miRNA; DNA damage response; radiation; cancer; C. elegans	P53 NETWORK; RESISTANCE; APOPTOSIS	MicroRNAs (miRNAs) are important regulators of cell fate determination and homeostasis. Expression of these small RNA genes is tightly regulated during development and in normal tissues, but they are often misregulated in cancer. MiRNA expression is also affected by DNA damaging agents, such as radiation. In particular, mammalian miR-34 is upregulated by p53 in response to radiation, but little is known about the role of this miRNA in vivo. Here we show that Caenorhabditis elegans with loss-of-function mutations in the mir-34 gene have an abnormal cellular survival response to radiation; these animals are highly radiosensitive in the soma and radioresistant in the germline. These findings show a role for mir-34 in both apoptotic and non-apoptotic cell death in vivo, much like that of cep-1, the C. elegans p53 homolog. These results have been additionally validated in vitro in breast cancer cells, wherein exogenous addition of miR-34 alters cell survival post-radiation. These observations confirm that mir-34 is required for a normal cellular response to DNA damage in vivo resulting in altered cellular survival post-irradiation, and point to a potential therapeutic use for anti-miR-34 as a radio-sensitizing agent in p53-mutant breast cancer. Oncogene (2009) 28, 2419-2424; doi:10.1038/onc.2009.106; published online 4 May 2009	[Kato, M.; Esquela-Kerscher, A.; Slack, F. J.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; [Paranjape, T.; Ullrich, R.; Nallur, S.; Gillespie, E.; Keane, K.; Weidhaas, J. B.] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA	Yale University; Yale University	Slack, FJ (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, KBT 936,POB 208103,266 Whitney Ave, New Haven, CT 06520 USA.	joanne.weidhaas@yale.edu; frank.slack@yale.edu	Paranjape, Trupti/E-4338-2012; Gillespie, Erin/AAZ-8543-2021	Gillespie, Erin/0000-0002-1386-1542; Weidhaas, Joanne/0000-0002-5096-3281; Slack, Frank/0000-0001-8263-0409	Uehara Life Science Foundation; Breast Cancer Alliance; NIH [CA124484, CA131301-01A1]; American Cancer Society Institutional Research; ASTRO Junior Faculty Career Research Training Award; Ellison Medical Foundation; NATIONAL CANCER INSTITUTE [R01CA131301, K08CA124484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM071157] Funding Source: NIH RePORTER	Uehara Life Science Foundation; Breast Cancer Alliance; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society Institutional Research(American Cancer Society); ASTRO Junior Faculty Career Research Training Award; Ellison Medical Foundation(Lawrence Ellison Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the CGC for strains. MK was supported by a postdoctoral fellowship from the Uehara Life Science Foundation. JW was supported by the Breast Cancer Alliance and a K08 grant (CA124484) from the NIH and by an American Cancer Society Institutional Research Grant to the Yale Cancer Center and by the ASTRO Junior Faculty Career Research Training Award. FS was supported by a grant from the Ellison Medical Foundation. FS and JW were supported by a grant from the NIH (CA131301-01A1).	Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Gartner A, 2000, MOL CELL, V5, P435, DOI 10.1016/S1097-2765(00)80438-4; He L, 2007, NAT REV CANCER, V7, P819, DOI 10.1038/nrc2232; Hui L, 2006, ONCOGENE, V25, P7305, DOI 10.1038/sj.onc.1209735; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Ljungman M, 2004, NAT REV CANCER, V4, P727, DOI 10.1038/nrc1435; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Miska EA, 2007, PLOS GENET, V3, P2395, DOI 10.1371/journal.pgen.0030215; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; Salter KH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001908; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weidhaas JB, 2006, P NATL ACAD SCI USA, V103, P9946, DOI 10.1073/pnas.0603791103; Weidhaas JB, 2007, CANCER RES, V67, P11111, DOI 10.1158/0008-5472.CAN-07-2858	17	179	191	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	25					2419	2424		10.1038/onc.2009.106	http://dx.doi.org/10.1038/onc.2009.106			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462HS	19421141	Green Accepted			2022-12-17	WOS:000267342400006
J	Hodawadekar, SC; Marmorstein, R				Hodawadekar, S. C.; Marmorstein, R.			Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design	ONCOGENE			English	Review						histone acetyltransferases (HAT); histone deacetylases (HDAC); post-translational histone modifications	SIR2 HISTONE/PROTEIN DEACETYLASES; GCN5 TRANSCRIPTIONAL COACTIVATOR; SMALL-MOLECULE ACTIVATORS; CRYSTAL-STRUCTURE; CATALYTIC MECHANISM; COENZYME-A; NICOTINAMIDE INHIBITION; CHROMATIN TRANSCRIPTION; CALORIE RESTRICTION; ANTITUMOR-ACTIVITY	The post-translational modi. cation of histones plays an important role in chromatin regulation, a process that insures the fidelity of gene expression and other DNA transactions. Of the enzymes that mediate post-translation modi. cation, the histone acetyltransferase ( HAT) and histone deacetylase ( HDAC) proteins that add and remove acetyl groups to and from target lysine residues within histones, respectively, have been the most extensively studied at both the functional and structural levels. Not surprisingly, the aberrant activity of several of these enzymes have been implicated in human diseases such as cancer and metabolic disorders, thus making them important drug targets. Significant mechanistic insights into the function of HATs and HDACs have come from the X-ray crystal structures of these enzymes both alone and in liganded complexes, along with associated enzymatic and biochemical studies. In this review, we will discuss what we have learned from the structures and related biochemistry of HATs and HDACs and the implications of these findings for the design of protein effectors to regulate gene expression and treat disease.	Univ Penn, Dept Chem, Wistar Inst, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania	Marmorstein, R (corresponding author), Univ Penn, Dept Chem, Wistar Inst, 3601 Spruce St,Room 327, Philadelphia, PA 19104 USA.	marmor@wistar.org						Anekonda TS, 2006, J NEUROCHEM, V96, P305, DOI 10.1111/j.1471-4159.2005.03492.x; Avalos JL, 2005, MOL CELL, V17, P855, DOI 10.1016/j.molcel.2005.02.022; Avalos JL, 2004, MOL CELL, V13, P639, DOI 10.1016/S1097-2765(04)00082-6; Balasubramanyam K, 2004, J BIOL CHEM, V279, P51163, DOI 10.1074/jbc.M409024200; Balasubramanyam K, 2004, J BIOL CHEM, V279, P33716, DOI 10.1074/jbc.M402839200; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Berndsen CE, 2007, BIOCHEMISTRY-US, V46, P623, DOI 10.1021/bi602513x; Biel M, 2005, ANGEW CHEM INT EDIT, V44, P3186, DOI 10.1002/anie.200461346; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Clements A, 2003, METHOD ENZYMOL, V371, P545; Clements A, 1999, EMBO J, V18, P3521, DOI 10.1093/emboj/18.13.3521; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Gallinari P, 2007, CELL RES, V17, P195, DOI 10.1038/sj.cr.7310149; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gregoretti IV, 2004, J MOL BIOL, V338, P17, DOI 10.1016/j.jmb.2004.02.006; Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506; Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057; Heltweg B, 2006, CANCER RES, V66, P4368, DOI 10.1158/0008-5472.CAN-05-3617; Hideshima T, 2005, P NATL ACAD SCI USA, V102, P8567, DOI 10.1073/pnas.0503221102; Hoff KG, 2006, STRUCTURE, V14, P1231, DOI 10.1016/j.str.2006.06.006; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Imai S, 2000, COLD SPRING HARB SYM, V65, P297, DOI 10.1101/sqb.2000.65.297; Jackson AD, 2002, J BIOL CHEM, V277, P18535, DOI 10.1074/jbc.M200671200; Jackson MD, 2003, J BIOL CHEM, V278, P50985, DOI 10.1074/jbc.M306552200; Kaeberlein M, 2005, J BIOL CHEM, V280, P17038, DOI 10.1074/jbc.M500655200; Kelly WK, 2002, EXPERT OPIN INV DRUG, V11, P1695, DOI 10.1517/13543784.11.12.1695; Kelly WK, 2003, CLIN CANCER RES, V9, P3578; Khan AN, 2006, J BIOL CHEM, V281, P11702, DOI 10.1074/jbc.M511482200; Kiviranta PH, 2006, J MED CHEM, V49, P7907, DOI 10.1021/jm060566j; Kobayashi Y, 2005, INT J MOL MED, V16, P237; Kumagai T, 2007, INT J CANCER, V121, P656, DOI 10.1002/ijc.22558; Lau OD, 2000, J BIOL CHEM, V275, P21953, DOI 10.1074/jbc.M003219200; Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9; Lin HY, 2006, MED RES REV, V26, P397, DOI 10.1002/med.20056; Lin YX, 1999, NATURE, V400, P86, DOI 10.1038/21922; Liszt G, 2005, J BIOL CHEM, V280, P21313, DOI 10.1074/jbc.M413296200; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Manson MM, 2005, RECENT RESULTS CANC, V166, P257; Marks PA, 2005, CELL CYCLE, V4, P549, DOI 10.4161/cc.4.4.1564; Marmorstein R, 2001, CELL MOL LIFE SCI, V58, P693, DOI 10.1007/PL00000893; Marmorstein R, 2004, BIOCHEM SOC T, V32, P904, DOI 10.1042/BST0320904; Marmorstein R, 2001, STRUCTURE, V9, P1127, DOI 10.1016/S0969-2126(01)00690-6; Marmorstein R, 2001, CURR OPIN GENET DEV, V11, P155, DOI 10.1016/S0959-437X(00)00173-8; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Moreth K, 2007, BIOCHEM J, V401, P659, DOI 10.1042/BJ20061239; Muraoka M, 1996, ONCOGENE, V12, P1565; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Nielsen TK, 2007, ACTA CRYSTALLOGR F, V63, P270, DOI 10.1107/S1744309107012377; Nielsen TK, 2005, J MOL BIOL, V354, P107, DOI 10.1016/j.jmb.2005.09.065; Nightingale KP, 2006, CURR OPIN GENET DEV, V16, P125, DOI 10.1016/j.gde.2006.02.015; Parker JA, 2005, NAT GENET, V37, P349, DOI 10.1038/ng1534; Parthun MR, 2007, ONCOGENE, V26, P5319, DOI 10.1038/sj.onc.1210602; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Posakony J, 2004, J MED CHEM, V47, P2635, DOI 10.1021/jm030473r; Poux AN, 2003, BIOCHEMISTRY-US, V42, P14366, DOI 10.1021/bi035632n; Poux AN, 2002, P NATL ACAD SCI USA, V99, P14065, DOI 10.1073/pnas.222373899; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Sagar V, 2004, BIOORGAN MED CHEM, V12, P3383, DOI 10.1016/j.bmc.2004.03.070; Sanders BD, 2007, MOL CELL, V25, P463, DOI 10.1016/j.molcel.2006.12.022; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Sauve AA, 2003, BIOCHEMISTRY-US, V42, P9249, DOI 10.1021/bi034959l; Sauve AA, 2001, BIOCHEMISTRY-US, V40, P15456, DOI 10.1021/bi011858j; Sauve AA, 2006, ANNU REV BIOCHEM, V75, P435, DOI 10.1146/annurev.biochem.74.082803.133500; Schuetz A, 2007, STRUCTURE, V15, P377, DOI 10.1016/j.str.2007.02.002; Serrador JM, 2004, IMMUNITY, V20, P417, DOI 10.1016/S1074-7613(04)00078-0; Smith BC, 2007, J AM CHEM SOC, V129, P5802, DOI 10.1021/ja070162w; Somoza JR, 2004, STRUCTURE, V12, P1325, DOI 10.1016/j.str.2004.04.012; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Thompson PR, 2004, NAT STRUCT MOL BIOL, V11, P308, DOI 10.1038/nsmb740; Timmermann S, 2001, CELL MOL LIFE SCI, V58, P728, DOI 10.1007/PL00000896; Trievel RC, 1999, P NATL ACAD SCI USA, V96, P8931, DOI 10.1073/pnas.96.16.8931; Vannini A, 2004, P NATL ACAD SCI USA, V101, P15064, DOI 10.1073/pnas.0404603101; Vanommeslaeghe K, 2005, BIOORGAN MED CHEM, V13, P3987, DOI 10.1016/j.bmc.2005.04.001; Varga-Weisz PD, 2006, CURR OPIN GENET DEV, V16, P151, DOI 10.1016/j.gde.2006.02.006; Varier RA, 2004, BIOCHEM PHARMACOL, V68, P1215, DOI 10.1016/j.bcp.2004.05.038; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Woodcock CL, 2006, CURR OPIN STRUC BIOL, V16, P213, DOI 10.1016/j.sbi.2006.02.005; Yan Y, 2000, MOL CELL, V6, P1195, DOI 10.1016/S1097-2765(00)00116-7; Yan Y, 2002, NAT STRUCT BIOL, V9, P862, DOI 10.1038/nsb849; Zhang K, 2005, J CELL BIOCHEM, V96, P1137, DOI 10.1002/jcb.20615; Zhao KH, 2004, P NATL ACAD SCI USA, V101, P8563, DOI 10.1073/pnas.0401057101; Zheng YJ, 2004, METHOD ENZYMOL, V376, P188	93	179	184	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5528	5540		10.1038/sj.onc.1210619	http://dx.doi.org/10.1038/sj.onc.1210619			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694092				2022-12-17	WOS:000248674300019
J	De Ferrari, GV; Moon, RT				De Ferrari, G. V.; Moon, R. T.			The ups and downs of Wnt signaling in prevalent neurological disorders	ONCOGENE			English	Review						Wnt signaling; autism; schizophrenia; Alzheimer's disease; apolipoprotein E; genetic variation	GLYCOGEN-SYNTHASE KINASE-3-BETA; FETAL VALPROATE SYNDROME; SINGLE NUCLEOTIDE POLYMORPHISM; HOMEOBOX-TRANSCRIPTION-FACTOR; DISEASE-LIKE PHOSPHORYLATION; AMYLOID PRECURSOR PROTEIN; ONSET ALZHEIMER-DISEASE; GENOME-WIDE SCAN; ALPHA-T-CATENIN; BETA-CATENIN	In order to function properly, the brain must be wired correctly during critical periods in early development. Mistakes in this process are hypothesized to occur in disorders like autism and schizophrenia. Later in life, signaling pathways are essential in maintaining proper communication between neuronal and non-neuronal cells, and disrupting this balance may result in disorders like Alzheimer's disease. The Wnt/beta-catenin pathway has a well-established role in cancer. Here, we review recent evidence showing the involvement of Wnt/beta-catenin signaling in neurodevelopment as well as in neurodegenerative diseases. We suggest that the onset/development of such pathological conditions may involve the additive effect of genetic variation within Wnt signaling components and of molecules that modulate the activity of this signaling cascade.	Univ Washington, Sch Med, Howard Hughes Med Inst, Dept Pharmacol, Seattle, WA 98115 USA; Univ Washington, Sch Med, Inst Stem Cell & Regenerat Med, Seattle, WA 98115 USA; Univ Concepcion, Fac Ciencias Biol, Dept Bioquim & Biol Mol, Concepcion, Chile	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Universidad de Concepcion	De Ferrari, GV (corresponding author), Univ Washington, Sch Med, Howard Hughes Med Inst, Dept Pharmacol, Seattle, WA 98115 USA.	gdeferrari@udec.cl; rtmoon@u.washington.edu	Moon, Randall/M-5605-2019; Moon, Randall T/B-1743-2014	Moon, Randall/0000-0002-9352-1408; Moon, Randall T/0000-0002-9352-1408; De Ferrari, Giancarlo/0000-0003-0932-125X				Abu-Khalil A, 2004, J COMP NEUROL, V474, P276, DOI 10.1002/cne.20112; Ahn YM, 2005, INT J NEUROPSYCHOPH, V8, P607, DOI 10.1017/S1461145705005353; Alimohamad H, 2005, J NEUROCHEM, V95, P513, DOI 10.1111/j.1471-4159.2005.03388.x; Alimohamad H, 2005, BIOL PSYCHIAT, V57, P533, DOI 10.1016/j.biopsych.2004.11.036; Alvarez AR, 2004, EXP CELL RES, V297, P186, DOI 10.1016/j.yexcr.2004.02.028; Alvarez G, 2002, BIPOLAR DISORD, V4, P153, DOI 10.1034/j.1399-5618.2002.01150.x; Baader SL, 1998, J NEUROSCI, V18, P1763; Bailer U, 2002, BIOL PSYCHIAT, V52, P40, DOI 10.1016/S0006-3223(02)01320-3; Bailey A, 1998, HUM MOL GENET, V7, P571; Barrett S, 1999, AM J MED GENET, V88, P609; Bartlett CW, 2005, INT J DEV NEUROSCI, V23, P221, DOI 10.1016/j.ijdevneu.2004.10.004; Beasley C, 2001, NEUROSCI LETT, V302, P117, DOI 10.1016/S0304-3940(01)01688-3; Benayed R, 2005, AM J HUM GENET, V77, P851, DOI 10.1086/497705; Benedetti F, 2005, NEUROSCI LETT, V376, P51, DOI 10.1016/j.neulet.2004.11.022; Benedetti F, 2004, NEUROSCI LETT, V368, P123, DOI 10.1016/j.neulet.2004.06.050; Benedetti F, 2004, NEUROSCI LETT, V355, P37, DOI 10.1016/j.neulet.2003.10.021; Blacker D, 2003, HUM MOL GENET, V12, P23, DOI 10.1093/hmg/ddg007; Blomqvist MEL, 2004, NEUROSCI LETT, V358, P220, DOI 10.1016/j.neulet.2004.01.032; Blouin JL, 1998, NAT GENET, V20, P70, DOI 10.1038/1734; Brown SP, 1998, J AGING PHYS ACTIV, V6, P248, DOI 10.1123/japa.6.3.248; Bug G, 2005, CANCER RES, V65, P2537, DOI 10.1158/0008-5472.CAN-04-3011; Busby V, 2004, NEUROMOL MED, V5, P133, DOI 10.1385/NMM:5:2:133; Buxbaum JD, 2001, AM J HUM GENET, V68, P1514, DOI 10.1086/320588; Caricasole A, 2004, J NEUROSCI, V24, P6021, DOI 10.1523/JNEUROSCI.1381-04.2004; Caricasole A, 2003, TRENDS PHARMACOL SCI, V24, P233, DOI 10.1016/S0165-6147(03)00100-7; Chakravarti A, 2001, NATURE, V409, P822, DOI 10.1038/35057281; Chen G, 1999, J NEUROCHEM, V72, P1327, DOI 10.1046/j.1471-4159.2000.0721327.x; Chen JY, 2006, J BIOL CHEM, V281, P11910, DOI 10.1074/jbc.M511920200; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; Chenn A, 2003, CEREB CORTEX, V13, P599, DOI 10.1093/cercor/13.6.599; CHRISTIANSON AL, 1994, DEV MED CHILD NEUROL, V36, P361; Ciani L, 2005, NAT REV NEUROSCI, V6, P351, DOI 10.1038/nrn1665; Collaborative Linkage Study of Autism, 2001, Am J Med Genet, V105, P609; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Cotter D, 1998, NEUROREPORT, V9, P1379, DOI 10.1097/00001756-199805110-00024; Courchesne E, 2004, CURR OPIN NEUROL, V17, P489, DOI 10.1097/01.wco.0000137542.14610.b4; Courchesne E, 2003, JAMA-J AM MED ASSOC, V290, P337, DOI 10.1001/jama.290.3.337; Courchesne E, 2001, NEUROLOGY, V57, P245, DOI 10.1212/WNL.57.2.245; Daw EW, 2000, AM J HUM GENET, V66, P196, DOI 10.1086/302710; De Ferrari GV, 2003, MOL PSYCHIATR, V8, P195, DOI 10.1038/sj.mp.4001208; De Ferrari GV, 2000, BRAIN RES REV, V33, P1, DOI 10.1016/S0165-0173(00)00021-7; Emamian ES, 2004, NAT GENET, V36, P131, DOI 10.1038/ng1296; Ertekin-Taner N, 2003, HUM MOL GENET, V12, P3133, DOI 10.1093/hmg/ddg343; Fatemi SH, 2002, CELL MOL NEUROBIOL, V22, P171, DOI 10.1023/A:1019861721160; Folstein S. E., 2003, NOVART FDN SYMP, V251, P281; Folstein S. E., 2003, NOVART FDN SYMP, V251, P80; Folstein S. E., 2003, NOVART FDN SYMP, V251, P109; Folstein SE, 2001, NAT REV GENET, V2, P943, DOI 10.1038/35103559; Folstein SE, 2003, NOVART FDN SYMP, V251, P70; Ftouh S, 2005, J NEUROCHEM, V94, P520, DOI 10.1111/j.1471-4159.2005.03239.x; Gharani N, 2004, MOL PSYCHIATR, V9, P474, DOI 10.1038/sj.mp.4001498; Grove EA, 1998, DEVELOPMENT, V125, P2315; Gurling HMD, 2001, AM J HUM GENET, V68, P661, DOI 10.1086/318788; Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116; Hall AC, 2002, MOL CELL NEUROSCI, V20, P257, DOI 10.1006/mcne.2002.1117; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Herz J, 2001, NEURON, V29, P571, DOI 10.1016/S0896-6273(01)00234-3; Hey PJ, 1998, GENE, V216, P103, DOI 10.1016/S0378-1119(98)00311-4; Houart C, 2002, NEURON, V35, P255, DOI 10.1016/S0896-6273(02)00751-1; Hu-Lince D, 2005, AM J PHARMACOGENOMIC, V5, P233, DOI 10.2165/00129785-200505040-00004; Ide M, 2004, BIOL PSYCHIAT, V56, P462, DOI 10.1016/j.biopsych.2004.06.039; Ingram JL, 2000, NEUROTOXICOL TERATOL, V22, P319, DOI 10.1016/S0892-0362(99)00083-5; Jeong SH, 2006, PSYCHIAT RES, V143, P1, DOI 10.1016/j.psychres.2005.07.026; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; Katsu T, 2003, NEUROSCI LETT, V353, P53, DOI 10.1016/j.neulet.2003.09.017; Kehoe P, 1999, HUM MOL GENET, V8, P237, DOI 10.1093/hmg/8.2.237; Kendler KS, 2000, AM J PSYCHIAT, V157, P402, DOI 10.1176/appi.ajp.157.3.402; Kim DH, 1998, J BIOCHEM-TOKYO, V124, P1072, DOI 10.1093/oxfordjournals.jbchem.a022223; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kozlovsky N, 2000, AM J PSYCHIAT, V157, P831, DOI 10.1176/appi.ajp.157.5.831; Kozlovsky N, 2001, SCHIZOPHR RES, V52, P101, DOI 10.1016/S0920-9964(00)00174-2; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; Lako M, 1998, HUM MOL GENET, V7, P813, DOI 10.1093/hmg/7.5.813; Lau KF, 1999, J PEPT RES, V54, P85, DOI 10.1034/j.1399-3011.1999.00083.x; Lee SMK, 2000, DEVELOPMENT, V127, P457; Leroy K, 1999, J CHEM NEUROANAT, V16, P279, DOI 10.1016/S0891-0618(99)00012-5; Li J, 2004, AM J MED GENET B, V126B, P51, DOI 10.1002/ajmg.b.20122; Li X, 2006, J NEURAL TRANSM, V113, P93, DOI 10.1007/s00702-005-0303-7; Li YH, 2001, MOL NEUROBIOL, V23, P53; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Magoori K, 2003, J BIOL CHEM, V278, P11331, DOI 10.1074/jbc.M211987200; Mak BC, 2005, AM J PATHOL, V167, P107, DOI 10.1016/S0002-9440(10)62958-6; Mak BC, 2004, CANCER INVEST, V22, P588, DOI 10.1081/CNV-200027144; Mak BC, 2003, J BIOL CHEM, V278, P5947, DOI 10.1074/jbc.C200473200; Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Mateo I, 2006, DEMENT GERIATR COGN, V21, P228, DOI 10.1159/000091044; Mayeux R, 2002, AM J HUM GENET, V70, P237, DOI 10.1086/324773; McCoy PA, 2002, AM J MED GENET, V114, P106, DOI 10.1002/ajmg.10182; McGrew LL, 1999, MECH DEVELOP, V87, P21, DOI 10.1016/S0925-4773(99)00136-7; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MILLEN KJ, 1994, DEVELOPMENT, V120, P695; Miyaoka T, 1999, SCHIZOPHR RES, V38, P1, DOI 10.1016/S0920-9964(98)00179-0; Miyazaki K, 2005, INT J DEV NEUROSCI, V23, P287, DOI 10.1016/j.ijdevneu.2004.05.004; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Moore SJ, 2000, J MED GENET, V37, P489, DOI 10.1136/jmg.37.7.489; Mudher A, 2002, TRENDS NEUROSCI, V25, P22, DOI 10.1016/S0166-2236(00)02031-2; Mudher A, 2001, J NEUROSCI, V21, P4987, DOI 10.1523/JNEUROSCI.21-14-04987.2001; Myers A, 2002, AM J MED GENET, V114, P235, DOI 10.1002/ajmg.10183; Packard M, 2002, CELL, V111, P319, DOI 10.1016/S0092-8674(02)01047-4; Palferman S, 2001, AM J HUM GENET, V69, P570; Panakova D, 2005, NATURE, V435, P58, DOI 10.1038/nature03504; Pei JJ, 1999, J NEUROPATH EXP NEUR, V58, P1010, DOI 10.1097/00005072-199909000-00011; PericakVance MA, 1997, JAMA-J AM MED ASSOC, V278, P1237, DOI 10.1001/jama.278.15.1237; PETIT E, 1995, J MED GENET, V32, P269, DOI 10.1136/jmg.32.4.269; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Philippe A, 1999, HUM MOL GENET, V8, P805, DOI 10.1093/hmg/8.5.805; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; PULVER AE, 1995, AM J MED GENET, V60, P252, DOI 10.1002/ajmg.1320600316; Rapoport JL, 2005, MOL PSYCHIATR, V10, P434, DOI 10.1038/sj.mp.4001642; Rebeck GW, 2002, J ALZHEIMERS DIS, V4, P145, DOI 10.3233/JAD-2002-4304; Risch N, 1999, AM J HUM GENET, V65, P493, DOI 10.1086/302497; RITVO ER, 1986, AM J PSYCHIAT, V143, P862; Rodier PM, 1997, REPROD TOXICOL, V11, P417, DOI 10.1016/S0890-6238(97)80001-U; Rogaeva E, 1998, JAMA-J AM MED ASSOC, V280, P614, DOI 10.1001/jama.280.7.614; Russ C, 2002, MOL PSYCHIATR, V7, P104, DOI 10.1038/sj/mp/4000941; Russ C, 2001, MOL PSYCHIATR, V6, P320, DOI 10.1038/sj.mp.4000852; Sala CF, 2000, BIOCHEM BIOPH RES CO, V273, P27, DOI 10.1006/bbrc.2000.2882; Salinas PC, 1999, BIOCHEM SOC SYMP, V65, P101; Salinas PC, 2005, J NEUROBIOL, V64, P435, DOI 10.1002/neu.20159; Sato S, 2002, J BIOL CHEM, V277, P42060, DOI 10.1074/jbc.M202241200; Saunders AJ, 2003, HUM MOL GENET, V12, P2765, DOI 10.1093/hmg/ddg310; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Scassellati C, 2004, NEUROPSYCHOBIOLOGY, V50, P16, DOI 10.1159/000077936; Schumann CM, 2004, J NEUROSCI, V24, P6392, DOI 10.1523/JNEUROSCI.1297-04.2004; Scott WK, 2000, AM J HUM GENET, V66, P922, DOI 10.1086/302828; Serajee FJ, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.4.e42; SHAW A, 1998, CHINA NEW INVESTOR, V3, P3; Sparks BF, 2002, NEUROLOGY, V59, P184, DOI 10.1212/WNL.59.2.184; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sun X, 2002, NEUROSCI LETT, V321, P61, DOI 10.1016/S0304-3940(01)02583-6; Svenningsson P, 2003, SCIENCE, V302, P1412, DOI 10.1126/science.1089681; Takashima A, 1998, NEUROSCI RES, V31, P317, DOI 10.1016/S0168-0102(98)00061-3; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tavazoie SF, 2005, NAT NEUROSCI, V8, P1727, DOI 10.1038/nn1566; Teter B, 2002, J ALZHEIMERS DIS, V4, P155, DOI 10.3233/JAD-2002-4305; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; van Meurs JBJ, 2006, J BONE MINER RES, V21, P141, DOI 10.1359/JBMR.050904; Vogel MW, 1996, DEV BRAIN RES, V96, P210; Vorstman JAS, 2006, MOL PSYCHIATR, V11, P18, DOI 10.1038/sj.mp.4001757; Wang JM, 2003, NAT NEUROSCI, V6, P1017, DOI 10.1038/nn1128; Wang YS, 2002, J NEUROSCI, V22, P8563; Wassink TH, 2001, AM J MED GENET, V105, P406, DOI 10.1002/ajmg.1401; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Williams G, 2001, DEV MED CHILD NEUROL, V43, P202, DOI 10.1017/S001216220100038X; Williams PG, 1997, DEV MED CHILD NEUROL, V39, P632; Wilson SW, 2004, DEV CELL, V6, P167, DOI 10.1016/S1534-5807(04)00027-9; Wiznitzer M, 2004, J CHILD NEUROL, V19, P675, DOI 10.1177/08830738040190090701; Wu WS, 1998, JAMA-J AM MED ASSOC, V280, P619, DOI 10.1001/jama.280.7.619; Yang JZ, 2003, BIOL PSYCHIAT, V54, P1298, DOI 10.1016/S0006-3223(03)00291-9; Ylisaukko-oja T, 2004, MOL PSYCHIATR, V9, P161, DOI 10.1038/sj.mp.4001385; Zhang YB, 2004, AM J MED GENET B, V129B, P16, DOI 10.1002/ajmg.b.30076; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zhou CJ, 2004, J NEUROSCI, V24, P7632, DOI 10.1523/JNEUROSCI.2123-04.2004; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	164	179	209	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2006	25	57					7545	7553		10.1038/sj.onc.1210064	http://dx.doi.org/10.1038/sj.onc.1210064			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GX	17143299				2022-12-17	WOS:000242514900013
J	Nicotera, P; Merlino, G				Nicotera, P; Merlino, G			Regulation of the apoptosis-necrosis switch	ONCOGENE			English	Review						apoptosis; necrosis; ATP; NO; nitric oxide; neurons	NEURONAL CELL-DEATH; METHYL-D-ASPARTATE; NITRIC-OXIDE NO; MITOCHONDRIAL RESPIRATORY-CHAIN; NF-KAPPA-B; S-NITROSYLATION; NEUROBLASTOMA-CELLS; INHIBITS APOPTOSIS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; LIPID-PEROXIDATION	Execution of the apoptotic program involves a relatively limited number of pathways. According to a general view, these would converge to activate the caspase family of proteases. However, there is increasing evidence that apoptotic-like features can also be found when caspases are inhibited. Moreover, under pathological conditions, apoptosis and nonapoptotic death paradigms are often interwined, which suggest that, in vivo, cells may use diverging execution pathways. Molecular switches between apoptosis and necrosis include adenosine triphosphate-dependent steps in the activation of caspases or steps sensitive to reactive oxygen/nitrogen species. In turn, caspase activation can cause necrosis by promoting ion overload.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Fdn S Lucia, I-00179 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Rome, Italy	University of Leicester; IRCCS Santa Lucia; University of Rome Tor Vergata	Nicotera, P (corresponding author), Univ Leicester, MRC, Toxicol Unit, Hodgkin Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England.	pn10@le.ac.uk			Telethon [E.1224] Funding Source: Medline	Telethon(Fondazione Telethon)		Adjei PN, 1996, J CLIN INVEST, V98, P2588, DOI 10.1172/JCI119078; ANKARCRONA M, 1994, EXP CELL RES, V213, P172, DOI 10.1006/excr.1994.1187; BAGETTA G, 1993, BIOCHEM BIOPH RES CO, V197, P1132, DOI 10.1006/bbrc.1993.2595; Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; Bernassola F, 2001, J CELL BIOCHEM, V82, P123, DOI 10.1002/jcb.1143; Bernassola F, 1999, ANN NY ACAD SCI, V887, P83, DOI 10.1111/j.1749-6632.1999.tb07924.x; BLANCO FJ, 1995, AM J PATHOL, V146, P75; BOLANOS JP, 1995, J NEUROCHEM, V64, P1965; Bonfoco E, 1996, J NEUROCHEM, V67, P2484; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Bossy-Wetzel E, 2003, CELL DEATH DIFFER, V10, P757, DOI 10.1038/sj.cdd.4401244; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brune B, 1997, J BIOL CHEM, V272, P7253, DOI 10.1074/jbc.272.11.7253; Brune B, 1999, CELL DEATH DIFFER, V6, P969, DOI 10.1038/sj.cdd.4400582; Catani MV, 1998, BIOCHEM BIOPH RES CO, V249, P275, DOI 10.1006/bbrc.1998.9130; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Clementi E, 1996, LIFE SCI, V59, P389, DOI 10.1016/0024-3205(96)00317-7; CORASANITI MT, 1994, NEUROPHARMACOLOGY, V33, P1071, DOI 10.1016/0028-3908(94)90145-7; CORASANITI MT, 1992, NEUROSCI LETT, V147, P221, DOI 10.1016/0304-3940(92)90600-C; CORASANITI MT, 1995, NEURODEGENERATION, V4, P315, DOI 10.1016/1055-8330(95)90021-7; Dimmeler S, 1999, CELL DEATH DIFFER, V6, P964, DOI 10.1038/sj.cdd.4400581; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Enikolopov G, 1999, CELL DEATH DIFFER, V6, P956, DOI 10.1038/sj.cdd.4400577; Eu JP, 2003, P NATL ACAD SCI USA, V100, P15229, DOI 10.1073/pnas.2433468100; FEHSEL K, 1995, J IMMUNOL, V155, P2858; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KANETO H, 1995, DIABETES, V44, P733, DOI 10.2337/diabetes.44.7.733; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim WK, 1999, NEURON, V24, P461, DOI 10.1016/S0896-6273(00)80859-4; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; KIM YM, 1995, J BIOL CHEM, V270, P5710, DOI 10.1074/jbc.270.11.5710; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LEIST M, 1995, J IMMUNOL, V154, P1307; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Leist M, 1998, EXP CELL RES, V239, P183, DOI 10.1006/excr.1997.4026; Leist M, 1999, EXP CELL RES, V249, P396, DOI 10.1006/excr.1999.4514; Li JR, 1999, CELL DEATH DIFFER, V6, P952, DOI 10.1038/sj.cdd.4400579; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Lipton SA, 1999, CELL DEATH DIFFER, V6, P943, DOI 10.1038/sj.cdd.4400580; Liu LM, 1999, CELL DEATH DIFFER, V6, P937, DOI 10.1038/sj.cdd.4400578; LOCKSHIN RICHARD A., 1965, J INSECT PHYSIOL, V11, P123, DOI 10.1016/0022-1910(65)90099-5; Lovat PE, 2003, J CELL BIOCHEM, V89, P698, DOI 10.1002/jcb.10551; Maccarrone M, 2000, J BIOL CHEM, V275, P31938, DOI 10.1074/jbc.M005722200; Maccarrone M, 1998, FEBS LETT, V434, P421, DOI 10.1016/S0014-5793(98)01026-6; Manabe S, 2003, INVEST OPHTH VIS SCI, V44, P385, DOI 10.1167/iovs.02-0187; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Matsumoto A, 2003, SCIENCE, V301, P657, DOI 10.1126/science.1079319; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Melino G, 2000, CELL MOL LIFE SCI, V57, P612, DOI 10.1007/PL00000723; Melino G, 2000, CANCER RES, V60, P2377; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; Messmer UK, 1996, EUR J PHARMACOL, V302, P171, DOI 10.1016/0014-2999(96)00055-6; Mohr S, 1996, J BIOL CHEM, V271, P4209; MONCADA S, 1991, PHARMACOL REV, V43, P109; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicotera P, 1999, TRENDS PHARMACOL SCI, V20, P46, DOI 10.1016/S0165-6147(99)01304-8; Nicotera P, 1997, Adv Neurol, V72, P95; Nicotera P, 1999, CELL DEATH DIFFER, V6, P931, DOI 10.1038/sj.cdd.4400583; Petersen A, 2001, HUM MOL GENET, V10, P1243, DOI 10.1093/hmg/10.12.1243; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Rossi A, 2000, J INVEST DERMATOL, V115, P731, DOI 10.1046/j.1523-1747.2000.00116.x; ROY B, 1995, BIOCHEMISTRY-US, V34, P5411, DOI 10.1021/bi00016a012; RUBBO H, 1994, J BIOL CHEM, V269, P26066; SALGO MG, 1995, ARCH BIOCHEM BIOPHYS, V322, P500, DOI 10.1006/abbi.1995.1493; Sarin A, 1997, IMMUNITY, V6, P209, DOI 10.1016/S1074-7613(00)80427-6; Schneiderhan N, 2003, ONCOGENE, V22, P2857, DOI 10.1038/sj.onc.1206431; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; SCHWARZ MA, 1995, P NATL ACAD SCI USA, V92, P4452, DOI 10.1073/pnas.92.10.4452; SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306; Sciorati C, 1997, J BIOL CHEM, V272, P23211, DOI 10.1074/jbc.272.37.23211; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; So HS, 1998, BIOCHEM BIOPH RES CO, V247, P809, DOI 10.1006/bbrc.1998.8788; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Stamler JS, 2001, PHYSIOL REV, V81, P209, DOI 10.1152/physrev.2001.81.1.209; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Stamler JS, 1996, J CLIN INVEST, V97, P2165, DOI 10.1172/JCI118656; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Suschek CV, 1999, J BIOL CHEM, V274, P6130, DOI 10.1074/jbc.274.10.6130; Suzuki H, 2003, NEURON, V39, P1005, DOI 10.1016/j.neuron.2003.08.015; Syntichaki P, 2002, NATURE, V419, P939, DOI 10.1038/nature01108; TABUCHI A, 1994, FEBS LETT, V351, P123, DOI 10.1016/0014-5793(94)00839-6; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Volbracht C, 2001, MOL MED, V7, P36, DOI 10.1007/BF03401837; Volbracht C, 1999, MOL MED, V5, P477; Wang X, 2003, CELL DEATH DIFFER, V10, P468, DOI 10.1038/sj.cdd.4401181; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; WELSH N, 1991, ENDOCRINOLOGY, V129, P3167, DOI 10.1210/endo-129-6-3167; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; Xu Keli, 2001, ScientificWorldJournal, V1, P129, DOI 10.1100/tsw.2001.224; Yasuda Masahiro, 1998, Journal of Toxicological Sciences, V23, P389; Yuan J, 2003, NEURON, V40, P401, DOI 10.1016/S0896-6273(03)00601-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	122	179	191	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2757	2765		10.1038/sj.onc.1207559	http://dx.doi.org/10.1038/sj.onc.1207559			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077139	Green Submitted			2022-12-17	WOS:000220799600003
J	Tauchi, T; Shin-ya, K; Sashida, G; Sumi, M; Nakajima, A; Shimamoto, T; Ohyashiki, JH; Ohyashiki, K				Tauchi, T; Shin-ya, K; Sashida, G; Sumi, M; Nakajima, A; Shimamoto, T; Ohyashiki, JH; Ohyashiki, K			Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways	ONCOGENE			English	Article						telomerase inhibition; ATM; telomere dysfunction	ABL TYROSINE KINASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN TUMOR-CELLS; ATAXIA-TELANGIECTASIA; CATIONIC PORPHYRINS; CATALYTIC SUBUNIT; CANCER-CELLS; IN-VITRO; CHECKPOINT; GROWTH	The telomerase complex is responsible for telomere maintenance and represents a promising neoplasia therapeutic target. In order to determine whether G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), might have effects on telomere dynamics and to evaluate the clinical utility, we assessed the effects of telomestatin on BCR-ABL-positive human leukemia cells. We found that treatment with telomestatin reproducibly inhibited telomerase activity in the BCR-ABL-positive leukemic cell lines OM9;22 and K562, resulting in telomere shortening. Inhibition of telomerase activity by telomestatin disrupts' telomere maintenance and ultimately results in telomere dysfunction. Telomestatin completely suppressed the plating efficiency of K562 cells at 1 muM; however, telomestatin had less effects on BFU-Es and CFU-GMs colony formation from normal bone marrow CD34-positive cells. Enhanced chemosensitivity toward imatinib and chemotherapeutic agents was also observed in telomestatin-treated K562 cells. Further, the combination of telomestatin plus imatinib more: effectively inhibited hematopoietic colony formation by primary human chronic myelogenous leukemia. cells. Last, telomestatin induced the activation of ATM and Chk2, and subsequently increased the expression of, p21(CIP1) and p27(KIP1). These results demonstrate that telomere dysfunction induced by telomestatin activates the ATM-dependent DNA damage response. We conclude that telomerase inhibitors combined with the use, of imatinib and other chemotherapeutic agents may be very useful for the treatment of human leukemia.	Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, Tokyo 1600023, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Tokyo Med Univ, Intractable Dis Res Ctr, Shinjuku Ku, Tokyo 1600023, Japan	Tokyo Medical University; University of Tokyo; Tokyo Medical University	Tauchi, T (corresponding author), Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan.		Sashida, Goro/N-5259-2014	Sashida, Goro/0000-0003-2318-5987				Bearss DJ, 2000, ONCOGENE, V19, P6632, DOI 10.1038/sj.onc.1204092; Blackburn EH, 1995, TELOMERES; Blasco Maria A., 1999, Genes and Development, V13, P2353, DOI 10.1101/gad.13.18.2353; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chaves-Dias C, 2001, J IMMUNOL, V166, P6647, DOI 10.4049/jimmunol.166.11.6647; Chehab NH, 2000, GENE DEV, V14, P278; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Delhommeau FO, 2002, ONCOGENE, V21, P8262, DOI 10.1038/sj.onc.1206054; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Glukhov AI, 1998, BIOCHEM BIOPH RES CO, V248, P368, DOI 10.1006/bbrc.1998.8801; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hisatomi H, 1999, INT J ONCOL, V14, P727; Izbicka E, 1999, CANCER RES, V59, P639; Kharbanda S, 2000, CURR BIOL, V10, P568, DOI 10.1016/S0960-9822(00)00483-8; Kim MM, 2001, P NATL ACAD SCI USA, V98, P7982, DOI 10.1073/pnas.131211098; KIM MY, 2002, J AM CHEM SOC, V123, P1262; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lee KH, 2001, P NATL ACAD SCI USA, V98, P3381, DOI 10.1073/pnas.051629198; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; Meyerson M, 2000, J CLIN ONCOL, V18, P2626, DOI 10.1200/JCO.2000.18.13.2626; Nakajima A, 2003, LEUKEMIA, V17, P560, DOI 10.1038/sj.leu.2402825; Nakajima A, 2001, LEUKEMIA, V15, P989, DOI 10.1038/sj.leu.2402137; Ohyashiki JH, 2002, ONCOGENE, V21, P680, DOI 10.1038/sj.onc.1205075; OHYASHIKI K, 1993, LEUKEMIA, V7, P1034; Perry, 1999, Expert Opin Investig Drugs, V8, P1981, DOI 10.1517/13543784.8.12.1981; Sachsinger J, 2001, CANCER RES, V61, P5580; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Shi DF, 2001, J MED CHEM, V44, P4509, DOI 10.1021/jm010246u; Shieh SY, 2000, GENE DEV, V14, P289; Shin-ya K, 2001, J AM CHEM SOC, V123, P1262, DOI 10.1021/ja005780q; Sun DY, 1997, J MED CHEM, V40, P2113, DOI 10.1021/jm970199z; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; Tauchi T, 2002, CLIN CANCER RES, V8, P3341; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wheelhouse RT, 1998, J AM CHEM SOC, V120, P3261, DOI 10.1021/ja973792e; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	47	179	189	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5338	5347		10.1038/sj.onc.1206833	http://dx.doi.org/10.1038/sj.onc.1206833			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917635				2022-12-17	WOS:000184734900013
J	Afaq, F; Adhami, VM; Ahmad, N; Mukhtar, H				Afaq, F; Adhami, VM; Ahmad, N; Mukhtar, H			Inhibition of ultraviolet B-mediated activation of nuclear factor kappa B in normal human epidermal keratinocytes by green tea Constituent (-)-epigallocatechin-3-gallate	ONCOGENE			English	Article						photochemopreventive; EGCG; NF-kappa B; NHEK; UVB	HUMAN SKIN; MOUSE SKIN; TRANSCRIPTION FACTOR; PYRIMIDINE DIMERS; IN-VITRO; CANCER; RADIATION; LIGHT; PROTEIN; KINASE	Epigallocatechin-3-gallate (EGCG), the major constituent of green tea, possesses significant anti-inflammatory and cancer chemopreventive properties. Studies have shown the photochemopreventive effects of green tea and EGCG in cell culture, animal models, and human skin. The molecular mechanism(s) of photochemopreventive effects of EGCG are incompletely understood. We recently showed that EGCG treatment of the normal human epidermal keratinocytes (NHEK) inhibits ultraviolet (UV)B-mediated activation of the mitogen-activated protein kinase (MAPK) pathway. In this study, we evaluated the effect of EGCG on UVB-mediated modulation of the nuclear factor kappa B (NF-kappaB) pathway, which is known to play a critical role in a variety of physiological functions and is involved in inflammation and development of cancer. Immunoblot analysis demonstrated that the treatment of NHEK with EGCG (10-40 mum) for 24 h resulted in a significant inhibition of UVB (40mJ/cm(2))-mediated degradation and phosphorylation of IkappaBalpha and activation of IKKalpha, in a dose-dependent manner. UVB-mediated degradation and phosphorylation of IkappaBalpha and activation of IKKalpha was also observed in a time-dependent protocol (15 and 30min, 1, 2, 3, 6, 12h post-UVB exposure). Employing immunoblot analysis, enzyme-linked immunosorbent assay, and gel shift assay, we demonstrate that EGCG treatment of the cells resulted in a significant dose- and time-dependent inhibition of UVB-mediated activation and nuclear translocation of a NF-kappaB/p65. Our data suggest that EGCG protects against the adverse effects of UV radiation via modulations in NF-kappaB pathway, and provide a molecular basis for the photochemopreventive effect of EGCG.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Madison, WI 53706 USA; Case Western Reserve Univ, Dept Dermatol, Cleveland, OH 44106 USA	University of Wisconsin System; University of Wisconsin Madison; Case Western Reserve University	Mukhtar, H (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Room B25,1300 Univ Ave, Madison, WI 53706 USA.	hmukhtar@wisc.edu	Adhami, Vaqar/AAY-2837-2020	Adhami, Vaqar/0000-0002-2048-4570				Afaq F, 2002, FRONT BIOSCI-LANDMRK, V7, pD784, DOI 10.2741/afaq; Afaq F, 2001, J PHOTOCH PHOTOBIO B, V63, P61, DOI 10.1016/S1011-1344(01)00217-2; Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Ahmad N, 2001, SKIN PHARMACOL APPL, V14, P69, DOI 10.1159/000056336; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BLOCK G, 1993, J NATL CANCER I, V85, P846, DOI 10.1093/jnci/85.11.846; Breuer-McHam J, 2001, PHOTOCHEM PHOTOBIOL, V74, P805, DOI 10.1562/0031-8655(2001)074&lt;0805:AOHIHS&gt;2.0.CO;2; Burren R, 1998, INT J CANCER, V76, P201, DOI 10.1002/(SICI)1097-0215(19980413)76:2<201::AID-IJC6>3.0.CO;2-0; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; de Gruijl FR, 1999, EUR J CANCER, V35, P2003, DOI 10.1016/S0959-8049(99)00283-X; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; Elmets CA, 2001, J AM ACAD DERMATOL, V44, P425, DOI 10.1067/mjd.2001.112919; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilchrest BA, 1996, PHOTOCHEM PHOTOBIOL, V63, P1, DOI 10.1111/j.1751-1097.1996.tb02988.x; GoihmanYahr M, 1996, CLIN DERMATOL, V14, P153, DOI 10.1016/0738-081X(95)00150-E; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Griffiths HR, 1998, CRIT REV CL LAB SCI, V35, P189, DOI 10.1080/10408369891234192; Haas AF, 1998, FREE RADICAL BIO MED, V25, P998, DOI 10.1016/S0891-5849(98)00135-X; Helenius M, 1999, EXP CELL RES, V248, P194, DOI 10.1006/excr.1999.4393; Hong JT, 2001, MOL CARCINOGEN, V31, P152, DOI 10.1002/mc.1050; Ikeda M, 2002, J DERMATOL SCI, V28, P159, DOI 10.1016/S0923-1811(01)00164-5; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Katiyar SK, 2000, CLIN CANCER RES, V6, P3864; Katiyar SK, 2001, TOXICOL APPL PHARM, V176, P110, DOI 10.1006/taap.2001.9276; Katiyar SK, 2001, CARCINOGENESIS, V22, P287, DOI 10.1093/carcin/22.2.287; Katiyar SK, 2001, J LEUKOCYTE BIOL, V69, P719; Katiyar SK, 1997, JNCI-J NATL CANCER I, V89, P556, DOI 10.1093/jnci/89.8.556; Katiyar SK, 1997, CARCINOGENESIS, V18, P497, DOI 10.1093/carcin/18.3.497; Kaufman CK, 2000, J CELL BIOL, V149, P999, DOI 10.1083/jcb.149.5.999; Kim J, 2001, SKIN PHARMACOL APPL, V14, P11, DOI 10.1159/000056329; KLIGMAN LH, 1980, J AM ACAD DERMATOL, V3, P30, DOI 10.1016/S0190-9622(80)80221-0; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KRIPKE ML, 1992, P NATL ACAD SCI USA, V89, P7516, DOI 10.1073/pnas.89.16.7516; Lefort K, 2001, ONCOGENE, V20, P7375, DOI 10.1038/sj.onc.1204923; Legrand-Poels S, 1998, J PHOTOCH PHOTOBIO B, V45, P1, DOI 10.1016/S1011-1344(98)00118-3; Lu YP, 2000, CANCER RES, V60, P4785; Majumdar S, 2002, J IMMUNOL, V168, P2644, DOI 10.4049/jimmunol.168.6.2644; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Morita A, 1997, J EXP MED, V186, P1763, DOI 10.1084/jem.186.10.1763; Mukhtar H, 1996, PHOTOCHEM PHOTOBIOL, V63, P355, DOI 10.1111/j.1751-1097.1996.tb03040.x; Naylor MF, 1997, ARCH DERMATOL, V133, P373, DOI 10.1001/archderm.133.3.373; Nomura M, 2000, CARCINOGENESIS, V21, P1885, DOI 10.1093/carcin/21.10.1885; Nomura M, 2001, J BIOL CHEM, V276, P46624, DOI 10.1074/jbc.M107897200; Okabe S, 1999, JPN J CANCER RES, V90, P733, DOI 10.1111/j.1349-7006.1999.tb00808.x; Pfundt R, 2001, J PATHOL, V193, P248; Rice-Evans C, 1999, P SOC EXP BIOL MED, V220, P262, DOI 10.1046/j.1525-1373.1999.d01-45.x; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Saliou C, 1999, FREE RADICAL BIO MED, V26, P174, DOI 10.1016/S0891-5849(98)00212-3; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VILE GF, 1995, PHOTOCHEM PHOTOBIOL, V62, P463, DOI 10.1111/j.1751-1097.1995.tb02369.x; Vink AA, 1997, P NATL ACAD SCI USA, V94, P5255, DOI 10.1073/pnas.94.10.5255; Yamazaki S, 2001, J BIOL CHEM, V276, P27657, DOI 10.1074/jbc.M103426200; Yang FJ, 1998, J NUTR, V128, P2334, DOI 10.1093/jn/128.12.2334	64	179	193	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2003	22	7					1035	1044		10.1038/sj.onc.1206206	http://dx.doi.org/10.1038/sj.onc.1206206			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592390				2022-12-17	WOS:000180926100009
J	Pages, V; Fuchs, RPP				Pages, V; Fuchs, RPP			How DNA lesions are turned into mutations within cells?	ONCOGENE			English	Article						DNA damage tolerance; lesion bypass polymerases; error-prone DNA repair; origin of mutations; mutagens and carcinogens	POLYMERASE-III HOLOENZYME; THYMINE-THYMINE DIMER; ESCHERICHIA-COLI; XERODERMA-PIGMENTOSUM; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; ERROR-PRONE; TRANSLESION SYNTHESIS; GENE ENCODES; Y-FAMILY	Genomes of all living organisms are constantly injured by endogenous and exogenous agents that modify the chemical integrity of DNA and in turn challenge its informational content. Despite the efficient action of numerous repair systems that remove lesions in DNA in an error-free manner, some lesions, that escape these repair mechanisms, are present when DNA is being replicated. Although replicative DNA polymerases are usually unable to copy past such lesions, it was recently discovered that cells are equipped with specialized DNA polymerases that will assist the replicative polymerase during the process of Translesion Synthesis (TLS). These TLS polymerases exhibit relaxed fidelity that allows them to copy past lesions in DNA with an inherent risk of generating mutations at high frequency. We present recent aspects related to the genetics and biochemistry of TLS and highlight some of the remaining hot topics of this field.	Univ Strasbourg 1, UPR 9003 CNRS, ESBS, UPR Conventionnee, F-67400 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Fuchs, RPP (corresponding author), Univ Strasbourg 1, UPR 9003 CNRS, ESBS, UPR Conventionnee, Blvd S Brant, F-67400 Strasbourg, France.		Pagès, Vincent/L-8455-2016	Pagès, Vincent/0000-0002-3059-2903				Baynton K, 1998, MOL CELL BIOL, V18, P960, DOI 10.1128/MCB.18.2.960; Becherel OJ, 2002, DNA REPAIR, V1, P703, DOI 10.1016/S1568-7864(02)00106-4; Becherel OJ, 2001, P NATL ACAD SCI USA, V98, P8566, DOI 10.1073/pnas.141113398; Bresson A, 2002, EMBO J, V21, P3881, DOI 10.1093/emboj/cdf363; Cordonnier AM, 1999, MUTAT RES-DNA REPAIR, V435, P111, DOI 10.1016/S0921-8777(99)00047-6; Cordonnier AM, 1999, MOL CELL BIOL, V19, P2206; Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398; de Saro FJL, 2001, P NATL ACAD SCI USA, V98, P8376, DOI 10.1073/pnas.121009498; FUCHS RPP, 1981, NATURE, V294, P657, DOI 10.1038/294657a0; Fuchs RPP, 2001, BIOCHEM SOC T, V29, P191, DOI 10.1042/BST0290191; Haracska L, 2002, MOL CELL BIOL, V22, P784, DOI 10.1128/MCB.22.3.784-791.2002; Haracska L, 2001, P NATL ACAD SCI USA, V98, P14256, DOI 10.1073/pnas.261560798; Haracska L, 2001, MOL CELL BIOL, V21, P7199, DOI 10.1128/MCB.21.21.7199-7206.2001; Haracska L, 2001, GENE DEV, V15, P945, DOI 10.1101/gad.882301; HUGHES AJ, 1991, J BIOL CHEM, V266, P4568; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; KATO T, 1977, MOL GEN GENET, V156, P121, DOI 10.1007/BF00283484; Kim DR, 1996, J BIOL CHEM, V271, P20699, DOI 10.1074/jbc.271.34.20699; KoffelSchwartz N, 1996, P NATL ACAD SCI USA, V93, P7805, DOI 10.1073/pnas.93.15.7805; LARIMER FW, 1989, J BACTERIOL, V171, P230, DOI 10.1128/jb.171.1.230-237.1989; Lawrence CW, 2002, DNA REPAIR, V1, P425, DOI 10.1016/S1568-7864(02)00038-1; LEMONTT JF, 1971, MUTAT RES, V13, P319, DOI 10.1016/0027-5107(71)90042-X; Lenne-Samuel N, 2000, MOL MICROBIOL, V38, P299, DOI 10.1046/j.1365-2958.2000.02116.x; Lenne-Samuel N, 2002, EMBO REP, V3, P45, DOI 10.1093/embo-reports/kvf007; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; MILLER JH, 1983, ANNU REV GENET, V17, P215, DOI 10.1146/annurev.ge.17.120183.001243; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Reuven NB, 1999, J BIOL CHEM, V274, P31763, DOI 10.1074/jbc.274.45.31763; Silvian LF, 2001, NAT STRUCT BIOL, V8, P984, DOI 10.1038/nsb1101-984; STEINBORN G, 1978, MOL GEN GENET, V165, P87, DOI 10.1007/BF00270380; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; Wagner J, 2002, DNA REPAIR, V1, P159, DOI 10.1016/S1568-7864(01)00012-X; Wagner J, 2000, EMBO REP, V1, P484; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0	43	179	181	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	2002	21	58					8957	8966		10.1038/sj.onc.1206006	http://dx.doi.org/10.1038/sj.onc.1206006			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483512				2022-12-17	WOS:000179889500007
J	Rane, SG; Reddy, EP				Rane, SG; Reddy, EP			JAKs, STATs and Src kinases in hematopoiesis	ONCOGENE			English	Review						hematopoiesis; Src kinases; JAK kinases; STATs; ras; PI3K	COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASE; DNA-BINDING ACTIVITY; RECEPTOR-ALPHA CHAIN; COMMON BETA-SUBUNIT; SIGNAL-TRANSDUCTION PATHWAYS; LEUKEMIA INHIBITORY FACTOR; GROWTH-HORMONE RECEPTOR; SEVERE COMBINED IMMUNODEFICIENCY; DEFECTIVE LYMPHOID DEVELOPMENT	Hematopoiesis is the cumulative result of intricately regulated signal transduction cascades that are mediated by cytokines and their cognate receptors. Proper culmination of these diverse signaling pathways forms the basis for an orderly generation of different cell types and aberrations in these pathways is an underlying cause for diseases such as leukemias and other myeloproliferative and lympho proliferative disorders. Over the past decade, downstream signal transduction events initiated upon cytokine/growth factor stimulation have been a major focus of basic and applied biomedical research. As a result, several key concepts have emerged allowing a better understanding of the complex signaling processes. A group of transcription factors, termed signal transducers and activators of transcription (STATs) appear to orchestrate the downstream events propagated by cytokine/growth factor interactions with their cognate receptors. Similarly, cytoplasmic Janus protein tyrosine kinases (JAKs) and Src family of kinases seem to play a critical role in diverse signal transduction pathways that govern cellular survival, proliferation, differentiation and apoptosis. Accumulating evidence suggests that STAT protein activation may be mediated by members of both JAK and Src family members following cytokine/growth factor stimulation. In addition, JAK kinases appear to be essential for the phosphorylation of the cytokine receptors which results in the creation of docking sites on the receptors for binding of SH2-containing proteins such as STATs, Src-kinases and other signaling intermediates. Cell and tissue-speciticity of cytokine action appears to be determined by the nature of signal transduction pathways activated by cytokine/receptor interactions. The integration of these diverse signaling cues from active JAK kinases, members of the Src-family kinases and STAT proteins, leads to cell proliferation, cell survival and differentiation, the end-point of the cytokine/growth factor stimulus.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	reddy@unix.temple.edu	Reddy, E. Premkumar/F-6233-2011		NIEHS NIH HHS [ES09225] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009225] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; AlShami A, 1997, BLOOD, V89, P1035, DOI 10.1182/blood.V89.3.1035; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Bagley CJ, 1997, BLOOD, V89, P1471, DOI 10.1182/blood.V89.5.1471.1471_1471_1482; Barber DL, 2001, BLOOD, V97, P2230, DOI 10.1182/blood.V97.8.2230; Barry SC, 1997, BLOOD, V89, P842, DOI 10.1182/blood.V89.3.842; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; Bittorf T, 1999, BIOL CHEM, V380, P1201, DOI 10.1515/BC.1999.152; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bromberg J, 2001, METHOD ENZYMOL, V333, P138; Cacalano NA, 1999, EMBO J, V18, P1549, DOI 10.1093/emboj/18.6.1549; CALDENHOVEN E, 1995, J BIOL CHEM, V270, P25778, DOI 10.1074/jbc.270.43.25778; Callus BA, 1998, BLOOD, V91, P3182, DOI 10.1182/blood.V91.9.3182.3182_3182_3192; CALVO V, 1994, EUR J IMMUNOL, V24, P2664, DOI 10.1002/eji.1830241115; Candotti F, 1997, BLOOD, V90, P3996, DOI 10.1182/blood.V90.10.3996; Cantor AB, 2001, CURR OPIN GENET DEV, V11, P513, DOI 10.1016/S0959-437X(00)00226-4; Cao XM, 1996, MOL CELL BIOL, V16, P1595; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carter BZ, 2001, BLOOD, V97, P2784, DOI 10.1182/blood.V97.9.2784; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Chen M, 1997, P NATL ACAD SCI USA, V94, P6910, DOI 10.1073/pnas.94.13.6910; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Coffer PJ, 1998, BLOOD, V91, P2547, DOI 10.1182/blood.V91.7.2547.2547_2547_2557; Coffer PJ, 1998, BIOCHEM J, V329, P121; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; CORNELIS S, 1995, EUR J IMMUNOL, V25, P1857, DOI 10.1002/eji.1830250710; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Darnell JE, 1998, J INTERF CYTOK RES, V18, P549, DOI 10.1089/jir.1998.18.549; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DASILVA L, 1994, J BIOL CHEM, V269, P18267; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVID M, 1995, MOL CELL BIOL, V15, P7050; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; deGroot RP, 1997, J BIOL CHEM, V272, P2319; DEL PL, 1997, SCIENCE, V278, P687; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; DUHE RJ, 1995, J BIOL CHEM, V270, P23084, DOI 10.1074/jbc.270.39.23084; Durstin M, 1996, J IMMUNOL, V157, P534; EDER M, 1994, J BIOL CHEM, V269, P30173; Eilers A, 1996, CELL GROWTH DIFFER, V7, P833; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Flores-Morales A, 1998, MOL CELL ENDOCRINOL, V138, P1, DOI 10.1016/S0303-7207(98)00054-9; Foltz IN, 1997, BLOOD, V89, P3092, DOI 10.1182/blood.V89.9.3092; Frank DA, 1996, LEUKEMIA, V10, P1724; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; Gauzzi MC, 1996, J BIOL CHEM, V271, P20494, DOI 10.1074/jbc.271.34.20494; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; Grossman WJ, 1999, BLOOD, V94, P932, DOI 10.1182/blood.V94.3.932.415k30_932_939; HACKETT RH, 1995, J BIOL CHEM, V270, P21326, DOI 10.1074/jbc.270.36.21326; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; Ihle JN, 1997, STEM CELLS, V15, P105, DOI 10.1002/stem.5530150814; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IHLE JN, 1997, STEM CELLS S1, V15, P112; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; INHORN RC, 1995, P NATL ACAD SCI USA, V92, P8665, DOI 10.1073/pnas.92.19.8665; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; Iwamoto T, 2000, ONCOGENE, V19, P4795, DOI 10.1038/sj.onc.1203829; Jaster R, 1997, MOL CELL BIOL, V17, P3364, DOI 10.1128/MCB.17.6.3364; Jiang N, 1996, J BIOL CHEM, V271, P16472, DOI 10.1074/jbc.271.28.16472; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; JUBINSKY PT, 1993, BLOOD, V81, P587; JUCKER M, 1995, J BIOL CHEM, V270, P27817; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; Kazansky AV, 2001, CELL GROWTH DIFFER, V12, P1; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Kotenko SV, 1996, J BIOL CHEM, V271, P17174, DOI 10.1074/jbc.271.29.17174; Kouro T, 1996, INT IMMUNOL, V8, P237, DOI 10.1093/intimm/8.2.237; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; KREIDER BL, 1990, MOL CELL BIOL, V10, P4846, DOI 10.1128/MCB.10.9.4846; Krishnan K, 1997, EUR J BIOCHEM, V247, P298, DOI 10.1111/j.1432-1033.1997.00298.x; KRUGER A, 1991, ONCOGENE, V6, P245; Lacronique V, 2000, BLOOD, V95, P2076, DOI 10.1182/blood.V95.6.2076; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LANEUVILLE P, 1991, ONCOGENE, V6, P275; Leonard WJ, 2000, J ALLERGY CLIN IMMUN, V105, P877, DOI 10.1067/mai.2000.106899; Leonard WJ, 1996, ANNU REV MED, V47, P229; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Lim CP, 2001, J BIOL CHEM, V276, P21004, DOI 10.1074/jbc.M007592200; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu KD, 1997, CURR BIOL, V7, P817, DOI 10.1016/S0960-9822(06)00369-1; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; McLemore ML, 2001, IMMUNITY, V14, P193, DOI 10.1016/S1074-7613(01)00101-7; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; Migone TS, 1998, P NATL ACAD SCI USA, V95, P3845, DOI 10.1073/pnas.95.7.3845; MIURA O, 1994, BLOOD, V84, P1501; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MUI ALF, 1995, J LEUKOCYTE BIOL, V57, P799, DOI 10.1002/jlb.57.5.799; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Nagata Y, 1997, BLOOD, V90, P929, DOI 10.1182/blood.V90.3.929.929_929_934; Nagata Y, 1997, BLOOD, V89, P2664, DOI 10.1182/blood.V89.8.2664; Naka T, 1999, TRENDS BIOCHEM SCI, V24, P394, DOI 10.1016/S0968-0004(99)01454-1; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nelson BH, 1996, MOL CELL BIOL, V16, P309; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Nicholson SE, 1998, J LEUKOCYTE BIOL, V63, P665, DOI 10.1002/jlb.63.6.665; Nicola NA, 1996, BLOOD, V87, P2665, DOI 10.1182/blood.V87.7.2665.bloodjournal8772665; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; OKUDA K, 1992, BLOOD, V79, P2880; Okutani Y, 2001, ONCOGENE, V20, P6643, DOI 10.1038/sj.onc.1204807; OShea JJ, 1997, J CLIN IMMUNOL, V17, P431, DOI 10.1023/A:1027388508570; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Pallen Catherine J., 1992, Current Opinion in Cell Biology, V4, P1000, DOI 10.1016/0955-0674(92)90132-V; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Park SY, 1995, IMMUNITY, V3, P771, DOI 10.1016/1074-7613(95)90066-7; Paulson R F, 1995, Semin Immunol, V7, P267, DOI 10.1006/smim.1995.0031; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAZDRAK K, 1995, J IMMUNOL, V155, P397; Pazdrak K, 1997, J EXP MED, V186, P561, DOI 10.1084/jem.186.4.561; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pellegrini M, 1999, J CLIN IMMUNOL, V19, P365, DOI 10.1023/A:1020598632068; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PIERCE JH, 1989, BIOCHIM BIOPHYS ACTA, V989, P179, DOI 10.1016/0304-419X(89)90042-5; Pratt JC, 1996, J BIOL CHEM, V271, P12137, DOI 10.1074/jbc.271.21.12137; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; Quelle FW, 1998, GENE DEV, V12, P1099, DOI 10.1101/gad.12.8.1099; RAINES MA, 1992, BLOOD, V79, P3350; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; ROVERA G, 1987, ONCOGENE, V1, P29; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; Sattler M, 1996, ONCOGENE, V12, P839; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Smith A, 1997, EMBO J, V16, P451, DOI 10.1093/emboj/16.3.451; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; TAKAKI S, 1994, INT ARCH ALLERGY IMM, V104, P36, DOI 10.1159/000236746; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; Tanuma N, 2000, J BIOL CHEM, V275, P28216; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; TORIGOE T, 1992, BLOOD, V80, P617; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Uchida K, 1997, CYTOGENET CELL GENET, V78, P209, DOI 10.1159/000134658; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; vanDijk TB, 1997, FEBS LETT, V412, P161, DOI 10.1016/S0014-5793(97)00768-0; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; Ward AC, 2000, BLOOD, V95, P19; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Woodcock JM, 1999, INT J BIOCHEM CELL B, V31, P1017, DOI 10.1016/S1357-2725(99)00084-9; Woodcock JM, 1996, J BIOL CHEM, V271, P25999, DOI 10.1074/jbc.271.42.25999; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yetter D, 1995, Nurs Manage, V26, P60; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; Yoshimura A, 1998, LEUKEMIA, V12, P1851, DOI 10.1038/sj.leu.2401238; Yoshimura A, 1998, CYTOKINE GROWTH F R, V9, P197, DOI 10.1016/S1359-6101(98)00019-7; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345; Zhou YJ, 1997, P NATL ACAD SCI USA, V94, P13850, DOI 10.1073/pnas.94.25.13850; ZON LI, 1995, BLOOD, V86, P2876	253	179	197	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3334	3358		10.1038/sj.onc.1205398	http://dx.doi.org/10.1038/sj.onc.1205398			25	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032773				2022-12-17	WOS:000175633300008
J	Xue, LY; Chiu, SM; Oleinick, NL				Xue, LY; Chiu, SM; Oleinick, NL			Photochemical destruction of the Bcl-2 oncoprotein during photodynamic therapy with the phthalocyanine photosensitizer Pc 4	ONCOGENE			English	Article						Bcl-2; apoptosis; photodynamic therapy; Pc 4	PROSTATE-CANCER CELLS; CYTOCHROME-C; INDUCED APOPTOSIS; CASPASE ACTIVATION; TYROSINE KINASE; SINGLET OXYGEN; RELEASE; DEATH; MITOCHONDRIA; CLEAVAGE	Photodynamic therapy (PDT), utilizing a photosensitizer and visible light, causes localized oxidative damage. With the mitochondrial photosensitizer Pc 4, PDT induces apoptosis, yet its molecular targets are not known, Here, the anti-apoptotic protein Bcl-2 is shown to be highly sensitive to PDT, as judged on Western blots by the disappearance of anti-Bcl-2-reactive material from the position of the native 26 kDa protein. The loss of Bcl-2 was PDT dose dependent and was observed for both endogenous and overexpressed Bcl-2 in several cell lines, immediately after PDT, and with chilled cells. It was accompanied by a trace of a 23-kDa cleavage product as well as high-molecular weight products that may result from photochemical crosslinking. PDT-induced Bcl-2 loss occurred in MCF-7 cells that do not express caspase-3 or in the presence of protease inhibitors, but was prevented, along with the induction of apoptosis, by the singlet oxygen scavenger L-histidine. Loss of FLAG-Bcl-2 was observed with both anti-FLAG and anti-Bcl-2 antibodies, indicating loss of native protein rather than simple BCL-2-epitope destruction. Photochemical damage was not observed in Bcl-x(L), Bax, Bad, the voltage-dependent anion channel, or the adenine nucleotide translocator. Therefore, Bcl-2 is one target of PDT with Pc 4, and PDT damage to Bcl-2 contributes to its efficient induction of apoptosis.	Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, CWRU Ireland Comprehens Canc Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Oleinick, NL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, BRB-324,10900 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [P30CA043703, P01CA048735, R01CA083917] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA48735, R01 CA83917, P30 CA43703] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL R, 1991, CANCER LETT, V56, P125, DOI 10.1016/0304-3835(91)90086-W; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Carthy CM, 1999, LAB INVEST, V79, P953; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Colussi VC, 1999, PHOTOCHEM PHOTOBIOL, V69, P236, DOI 10.1562/0031-8655(1999)069<0236:PPTOHO>2.3.CO;2; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; Fadeel B, 1999, LEUKEMIA, V13, P719, DOI 10.1038/sj.leu.2401411; Fujita N, 1998, BIOCHEM BIOPH RES CO, V246, P484, DOI 10.1006/bbrc.1998.8587; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Granville DJ, 1999, BRIT J CANCER, V79, P95, DOI 10.1038/sj.bjc.6690017; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Haldar S, 1996, CANCER RES, V56, P1253; HALLIWELL B, 1989, FREE RADICAL BIO MED, P66; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; He J, 1997, PHOTOCHEM PHOTOBIOL, V65, P581; He J, 1996, PHOTOCHEM PHOTOBIOL, V64, P845, DOI 10.1111/j.1751-1097.1996.tb01845.x; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; Kim HRC, 1999, CANCER RES, V59, P3429; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1999, CANCER RES, V59, P1693; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lavie G, 1999, BRIT J CANCER, V79, P423, DOI 10.1038/sj.bjc.6690066; MOAN J, 1992, PHOTOCHEM PHOTOBIOL, V55, P931, DOI 10.1111/j.1751-1097.1992.tb08541.x; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Trivedi NS, 2000, PHOTOCHEM PHOTOBIOL, V71, P634, DOI 10.1562/0031-8655(2000)071<0634:QAOPLI>2.0.CO;2; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Tudor G, 2000, CELL DEATH DIFFER, V7, P574, DOI 10.1038/sj.cdd.4400688; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; WEISHAUPT KR, 1976, CANCER RES, V36, P2326; Wuerzberger SM, 1998, CANCER RES, V58, P1876; Xue LY, 2001, EXP CELL RES, V263, P145, DOI 10.1006/excr.2000.5108; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang WG, 1999, PHOTOCHEM PHOTOBIOL, V69, P582, DOI 10.1562/0031-8655(1999)069<0582:ABRVIT>2.3.CO;2	44	179	197	1	18	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2001	20	26					3420	3427		10.1038/sj.onc.1204441	http://dx.doi.org/10.1038/sj.onc.1204441			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423992				2022-12-17	WOS:000169248800012
J	Reddy, EP; Korapati, A; Chaturvedi, P; Rane, S				Reddy, EP; Korapati, A; Chaturvedi, P; Rane, S			IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled	ONCOGENE			English	Review						IL-3/GM-CSF/IL-5; JAKs; STATs; Src kinases; signal transduction	COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASE; COMMON BETA-SUBUNIT; GM-CSF RECEPTOR; PROGENITOR-CELL LINE; DNA-BINDING ACTIVITY; INTERLEUKIN-5 TRANSDUCE SIGNALS; HEMATOPOIETIC GROWTH-FACTORS; MEMBRANE-PROXIMAL DOMAIN; MURINE LEUKEMIA-VIRUS	Hematopoiesis is the cumulative result of intricately regulated signal transduction cascades that are mediated by cytokines and their cognate receptors, Proper culmination of these diverse signaling pathways forms the basis for an orderly generation of different cell types and aberrations in these pathways is an underlying cause for diseases such as cancer. Over the past several years, downstream events initiated upon cytokine/growth factor stimulation have been a major focus of biomedical research. As a result, several hey concepts have emerged allowing a better understanding of the complex signaling processes, A group of novel transcription factors, termed signal transducers and activators of transcription (STATs) appear to orchestrate the downstream events propagated by cytokine/growth factor interactions with their cognate receptors, Until recently, the JAK proteins were considered to be the tyrosine kinases, which dictated the levels of phosphorylation and activation of STAT proteins, forming the basis of the JAK-STAT model. However, over the past few years, increasing evidence has accumulated which indicates that at least some of the STAT protein activation may be mediated by members of the Src gene family following cytokine/growth factor stimulation. Studies have demonstrated that the Src-family of tyrosine kinases can phosphorylate and activate certain STAT proteins, in lieu of JAK kinases, In such a scenario, JAK kinases may be more crucial to phosphorylation of the cytokine/growth factor receptors and in the process create docking sites on the receptors for binding of SH2-containing proteins such as STATs, Src-kinases and other signaling intermediates, Tyrosine phosphorylation and activation of STAT proteins can be achieved either by JAKs or Src-kinases depending on the nature of STAT that is being activated. This forms the basis for the JAK-Src-STAT model proposed in this review, The concerted action of JAK kinases, members of the Src-kinase family and STAT proteins, leads to cell proliferation and cell survival, the end-point of the cytokine/growth factor stimulus.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; SmithKline Beecham Pharmaceut, King Of Prussia, PA 19406 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; GlaxoSmithKline	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.		Claret, Francois X/R-2104-2016; Reddy, E. Premkumar/F-6233-2011	Claret, Francois X/0000-0003-4629-6495; 	NATIONAL CANCER INSTITUTE [R01CA098239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009225] Funding Source: NIH RePORTER; NCI NIH HHS [CA98239] Funding Source: Medline; NIEHS NIH HHS [ES09225] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; AlShami A, 1997, BLOOD, V89, P1035, DOI 10.1182/blood.V89.3.1035; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Bagley CJ, 1997, BLOOD, V89, P1471, DOI 10.1182/blood.V89.5.1471.1471_1471_1482; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; BARRY SC, 1994, J BIOL CHEM, V269, P8488; Barry SC, 1997, BLOOD, V89, P842, DOI 10.1182/blood.V89.3.842; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; CALDENHOVEN E, 1995, J BIOL CHEM, V270, P25778, DOI 10.1074/jbc.270.43.25778; CALVO V, 1994, EUR J IMMUNOL, V24, P2664, DOI 10.1002/eji.1830241115; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Chen M, 1997, P NATL ACAD SCI USA, V94, P6910, DOI 10.1073/pnas.94.13.6910; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Coffer PJ, 1998, BLOOD, V91, P2547, DOI 10.1182/blood.V91.7.2547.2547_2547_2557; Coffer PJ, 1998, BIOCHEM J, V329, P121; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; CORNELIS S, 1995, EUR J IMMUNOL, V25, P1857, DOI 10.1002/eji.1830250710; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; deGroot RP, 1997, J BIOL CHEM, V272, P2319; delPeso L, 1997, SCIENCE, V278, P687; Doyle SE, 1998, BLOOD, V92, P867; Durstin M, 1996, J IMMUNOL, V157, P534; Evans CA, 1999, BLOOD, V94, P1504, DOI 10.1182/blood.V94.5.1504.417a27_1504_1514; Flores-Morales A, 1998, MOL CELL ENDOCRINOL, V138, P1, DOI 10.1016/S0303-7207(98)00054-9; Foltz IN, 1997, BLOOD, V89, P3092, DOI 10.1182/blood.V89.9.3092; Frank DA, 1996, LEUKEMIA, V10, P1724; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GORMAN DM, 1992, J BIOL CHEM, V267, P15842; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; HERCUS TR, 1994, BLOOD, V83, P3500; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IHLE JN, 1983, J IMMUNOL, V131, P282; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; INHORN RC, 1995, P NATL ACAD SCI USA, V92, P8665, DOI 10.1073/pnas.92.19.8665; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; Jaster R, 1997, MOL CELL BIOL, V17, P3364, DOI 10.1128/MCB.17.6.3364; JUCKER M, 1995, J BIOL CHEM, V270, P27817; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; KING FJ, 1990, ONCOGENE, V5, P337; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Kotenko SV, 1996, J BIOL CHEM, V271, P17174, DOI 10.1074/jbc.271.29.17174; Kouro T, 1996, INT IMMUNOL, V8, P237, DOI 10.1093/intimm/8.2.237; KREIDER BL, 1990, MOL CELL BIOL, V10, P4846, DOI 10.1128/MCB.10.9.4846; KREMER E, 1993, BLOOD, V82, P22, DOI 10.1182/blood.V82.1.22.bloodjournal82122; Krishnan K, 1997, EUR J BIOCHEM, V247, P298, DOI 10.1111/j.1432-1033.1997.00298.x; KRUGER A, 1991, ONCOGENE, V6, P245; LANEUVILLE P, 1991, ONCOGENE, V6, P275; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu JJ, 1998, J BIOMED SCI, V5, P446, DOI 10.1007/BF02255934; Liu L, 1997, J BIOL CHEM, V272, P10998; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MATSUDA T, 1994, BLOOD, V83, P3457; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIYAJIMA A, 1993, BLOOD, V82, P1960; MUI ALF, 1995, J LEUKOCYTE BIOL, V57, P799, DOI 10.1002/jlb.57.5.799; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; Nagata Y, 1997, BLOOD, V90, P929, DOI 10.1182/blood.V90.3.929.929_929_934; Nagata Y, 1997, BLOOD, V89, P2664, DOI 10.1182/blood.V89.8.2664; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; Nicola NA, 1996, BLOOD, V87, P2665, DOI 10.1182/blood.V87.7.2665.bloodjournal8772665; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Nishinakamura R, 1996, BLOOD, V88, P2458, DOI 10.1182/blood.V88.7.2458.bloodjournal8872458; NISHINAKAMURA R, 1995, IMMUNITY, V2, P211, DOI 10.1016/1074-7613(95)90046-2; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; OKUDA K, 1992, BLOOD, V79, P2880; Orban PC, 1999, BLOOD, V94, P1614, DOI 10.1182/blood.V94.5.1614.417k22_1614_1622; Paulson R F, 1995, Semin Immunol, V7, P267, DOI 10.1006/smim.1995.0031; PAZDRAK K, 1995, J IMMUNOL, V155, P397; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PIERCE JH, 1989, BIOCHIM BIOPHYS ACTA, V989, P179, DOI 10.1016/0304-419X(89)90042-5; Pratt JC, 1996, J BIOL CHEM, V271, P12137, DOI 10.1074/jbc.271.21.12137; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; RAINES MA, 1992, BLOOD, V79, P3350; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; ROBB L, 1995, P NATL ACAD SCI USA, V92, P9565, DOI 10.1073/pnas.92.21.9565; ROVERA G, 1987, ONCOGENE, V1, P29; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; Sattler M, 1996, ONCOGENE, V12, P839; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHANAFELT AB, 1992, J BIOL CHEM, V267, P25466; SHEN Y, 1992, CYTOGENET CELL GENET, V61, P175, DOI 10.1159/000133401; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Smith A, 1997, EMBO J, V16, P451, DOI 10.1093/emboj/16.3.451; Smith PD, 1998, BIOCHEM J, V331, P381, DOI 10.1042/bj3310381; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; Stomski FC, 1999, BLOOD, V94, P1933; TAKAKI S, 1994, INT ARCH ALLERGY IMM, V104, P36, DOI 10.1159/000236746; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; Tian SS, 1996, BLOOD, V88, P4435, DOI 10.1182/blood.V88.12.4435.bloodjournal88124435; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; TORIGOE T, 1992, BLOOD, V80, P617; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VALTIERI M, 1987, J IMMUNOL, V138, P3829; vanDijk TB, 1997, FEBS LETT, V412, P161, DOI 10.1016/S0014-5793(97)00768-0; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WATANABE S, 1995, MOL BIOL CELL, V6, P627, DOI 10.1091/mbc.6.6.627; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; Woodcock JM, 1999, INT J BIOCHEM CELL B, V31, P1017, DOI 10.1016/S1357-2725(99)00084-9; Woodcock JM, 1996, J BIOL CHEM, V271, P25999, DOI 10.1074/jbc.271.42.25999; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yoshimura A, 1998, LEUKEMIA, V12, P1851, DOI 10.1038/sj.leu.2401238; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345; ZON LI, 1995, BLOOD, V86, P2876	172	179	187	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2532	2547		10.1038/sj.onc.1203594	http://dx.doi.org/10.1038/sj.onc.1203594			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851052				2022-12-17	WOS:000087459400009
J	Xu, XL; Brodie, SG; Yang, X; Im, YH; Parks, WT; Chen, L; Zhou, YX; Weinstein, M; Kim, SJ; Deng, CX				Xu, XL; Brodie, SG; Yang, X; Im, YH; Parks, WT; Chen, L; Zhou, YX; Weinstein, M; Kim, SJ; Deng, CX			Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice	ONCOGENE			English	Article						Smad4; Dpc4; juvenile polyposis; gastric cancer; TGF beta 1; cyclin D1	GROWTH-FACTOR-BETA; CYCLIN D1; TGF-BETA; JUVENILE POLYPOSIS; COLORECTAL-CANCER; TRANSFORMING GROWTH-FACTOR-BETA-1; HELICOBACTER-FELIS; CHROMOSOME 18Q21.1; MESODERM INDUCTION; EPITHELIAL-CELLS	The tumor suppressor SMAD4, also known as DPC4, deleted in pancreatic cancer, is a central mediator of TGF-P signaling. It was previously shown that mice homozygous for a null mutation of Smad4 (Smad4(-/-)) died prior to gastrulation displaying impaired extra-embryonic membrane formation and endoderm differentiation. Here we show that Smad4(+/-) mice began to develop polyposis in the fundus and antrum when they were over 6-12 months old, and in the duodenum and cecum in older animals at a lower frequency, With increasing age, polyps in the antrum show sequential changes from hyperplasia, to dysplasia, in-situ carcinoma, and finally invasion. These alterations are initiated by a dramatic expansion of the gastric epithelium where Smad4 is expressed. However, loss of the remaining Smad4 wild-type allele was detected only in later stages of tumor progression, suggesting that haploinsufficiency of Smad4 is sufficient for tumor initiation. Our data also showed that overexpression of TGF-beta 1 and Cyclin D1 was associated with increased proliferation of gastric polyps and tumors. These studies demonstrate that Smad4 functions as a tumor suppressor in the gastrointestinal tract and also provide a valuable model for screening factors that promote or prevent gastric tumorigenesis.	NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; NCI, Cell Regulat & Carcinogenesis Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Deng, CX (corresponding author), NIDDKD, Genet Dev & Dis Branch, NIH, 10-9N105, Bethesda, MD 20892 USA.		deng, chuxia/N-6713-2016; XIAO, YANG/GPW-5529-2022	Parks, W. Tony/0000-0001-7341-3277; Yang, Xiao/0000-0002-0298-9831	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056001, Z01DK056001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chang H, 1999, DEVELOPMENT, V126, P1631; CORREA P, 1992, CANCER RES, V52, P6735; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Fox JG, 1997, CANCER RES, V57, P3972; Fox JG, 1996, GASTROENTEROLOGY, V110, P155, DOI 10.1053/gast.1996.v110.pm8536852; Friedl W, 1999, GENE CHROMOSOME CANC, V25, P403, DOI 10.1002/(SICI)1098-2264(199908)25:4<403::AID-GCC15>3.0.CO;2-P; Grady WM, 1999, CANCER RES, V59, P320; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Howe JR, 1998, AM J HUM GENET, V62, P1129, DOI 10.1086/301840; ITO M, 1992, CANCER RES, V52, P295; JARVINEN H, 1984, GUT, V25, P792, DOI 10.1136/gut.25.7.792; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Moss SF, 1998, ALIMENT PHARM THER, V12, P91, DOI 10.1111/j.1365-2036.1998.00002.x; MYEROFF LL, 1995, CANCER RES, V55, P5545; Naef M, 1997, INT J CANCER, V71, P131; Nagatake M, 1996, CANCER RES, V56, P2718; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; OSWALD F, 1994, ONCOGENE, V9, P2029; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PISANI P, 1993, INT J CANCER, V55, P891, DOI 10.1002/ijc.2910550604; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SCHULZE A, 1994, ONCOGENE, V9, P3475; Schutte M, 1996, CANCER RES, V56, P2527; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; TAHARA E, 1995, WORLD J SURG, V19, P484, DOI 10.1007/BF00294705; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tamura G, 1996, J PATHOL, V180, P371, DOI 10.1002/(SICI)1096-9896(199612)180:4<371::AID-PATH704>3.0.CO;2-2; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Weinstein M, 1998, P NATL ACAD SCI USA, V95, P9378, DOI 10.1073/pnas.95.16.9378; Yamamoto M, 1996, CANCER-AM CANCER SOC, V77, P1628, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1628::AID-CNCR31>3.3.CO;2-Z; Yang HK, 1999, ONCOGENE, V18, P2213, DOI 10.1038/sj.onc.1202535; Yang X, 1999, DEVELOPMENT, V126, P1571; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; YOSHIDA K, 1989, INT J CANCER, V44, P394, DOI 10.1002/ijc.2910440303; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	48	179	199	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 6	2000	19	15					1868	1874		10.1038/sj.onc.1203504	http://dx.doi.org/10.1038/sj.onc.1203504			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773876				2022-12-17	WOS:000086424300002
J	Wang, Q; Zhang, HT; Kajino, K; Greene, MI				Wang, Q; Zhang, HT; Kajino, K; Greene, MI			BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells	ONCOGENE			English	Article						BRCA1; breast cancer; c-Myc; transcription; transformation	ORNITHINE DECARBOXYLASE GENE; EPIDERMAL GROWTH-FACTOR; NUCLEAR PHOSPHOPROTEIN; EMBRYO FIBROBLASTS; PROTEIN COMPLEX; TRANSGENIC MICE; BREAST-CANCER; IN-VIVO; EXPRESSION; CYCLE	c-Myc, a proto-oncogene that is implicated in tumorigenesis, embryonic development and apoptosis, can physically associate with BRCA1. We have found that BRCA1 interacts with c-Myc in yeast, in in vitro assays and in mammalian cells. Endogenous interactions between BRCA1 and c-Myc were also observed. Efficient BRCA1-Myc association requires the intact helix-loop-helix region of c-Myc, a motif involved in Myc-Max dimerization. BRCA1 does not however bind to Max. Our studies revealed that BRCA1 represses Myc-mediated transcription while having no effect on some other transcriptional activities. Furthermore, BRCA1 reverses the phenotype of embryonic fibroblasts transformed by the activation of Myc and Ras, but only minimally affects the transformed phenotype induced by SV40 virus. These data indicate that BRCA1 may function as a tumor suppressor by regulating the behavior of c-Myc and provide a molecular explanation for some of the effects of the BRCA1 gene product.	Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19104 USA	University of Pennsylvania	Greene, MI (corresponding author), Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19104 USA.		Wang, Qiang/N-7310-2015; Kajino, Kiichi/F-6873-2012	Wang, Qiang/0000-0001-9409-0251; Zhang, Hongtao/0000-0001-9173-0049				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen YM, 1996, CANCER RES, V56, P3168; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; EASTON DF, 1995, AM J HUM GENET, V56, P265; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GREENE MI, 1982, J IMMUNOL, V128, P732; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Hou XY, 1996, CANCER RES, V56, P2616; KARN J, 1989, ONCOGENE, V4, P773; KIRKLAND JL, 1992, ENDOCRINOLOGY, V130, P3223, DOI 10.1210/en.130.6.3223; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEMAITRE JM, 1996, ADV CANC RES, V70; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; MacGregor D, 1996, J CELL PHYSIOL, V167, P95, DOI 10.1002/(SICI)1097-4652(199604)167:1<95::AID-JCP11>3.3.CO;2-Q; MAI S, 1995, GENOME, V38, P780, DOI 10.1139/g95-099; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; MOSHIER JA, 1995, CANCER RES, V55, P5358; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; PENA A, 1993, J BIOL CHEM, V268, P27277; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Rao VN, 1996, ONCOGENE, V12, P523; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; SANDGREN EP, 1995, CANCER RES, V55, P3915; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shao NS, 1996, ONCOGENE, V13, P1; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wang SC, 1997, BIOCHEM BIOPH RES CO, V234, P247, DOI 10.1006/bbrc.1997.6544; Wilson CA, 1996, NAT GENET, V13, P264, DOI 10.1038/ng0796-264; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Wu SJ, 1996, ONCOGENE, V12, P621; Xu CF, 1997, GENE CHROMOSOME CANC, V18, P102, DOI 10.1002/(SICI)1098-2264(199702)18:2<102::AID-GCC4>3.3.CO;2-A; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang HT, 1997, ONCOGENE, V14, P2863, DOI 10.1038/sj.onc.1201140	71	179	182	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1939	1948		10.1038/sj.onc.1202403	http://dx.doi.org/10.1038/sj.onc.1202403			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788437				2022-12-17	WOS:000076423500007
J	Davies, MPA; Rudland, PS; Robertson, L; Parry, EW; Jolicoeur, P; Barraclough, R				Davies, MPA; Rudland, PS; Robertson, L; Parry, EW; Jolicoeur, P; Barraclough, R			Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic mice induces metastasis of mammary tumours	ONCOGENE			English	Article						p9Ka; S100A4; c-neu; breast cancer; metastasis; transgenic mice	HUMAN-BREAST-CANCER; NONMUSCLE MYOSIN; CELL-LINES; GENE; RAT; ONCOGENE; INDUCTION; MTS1; TUMORS; ADENOCARCINOMA	Increased levels of S100A4 (p9Ka) confer metastatic ability on a normally non-metastatic epithelial cell line. To find out whether S100A4 can induce metastasis in vivo, transgenic mice expressing high levels of S100A4, but which show no phenotypic effect, have been mated with MMTV-neu transgenic mice which succumb to stochastic mammary neoplasia related to expression of the MMTV-neu transgene. Resultant bitransgenic, multiparous, female progeny expressing both S100A4 and Neu have a slightly earlier incidence of palpable mammary tumours than the MMTV-neu offspring and specifically exhibit macroscopic metastatic lesions in the lungs. The S100A4 transgene is expressed in primary and secondary lesions of bitransgenic offspring and its expression is particularly associated with regions of invasion of primary lesions and metastases.	UNIV LIVERPOOL,DEPT BIOCHEM,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,DEPT HUMAN ANAT & CELL BIOL,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; CLIN RES INST MONTREAL,MONTREAL,PQ H2W 1R7,CANADA	University of Liverpool; University of Liverpool; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Davies, Michael/GWV-2527-2022; Barraclough, Roger/AAH-6516-2020	Barraclough, Roger/0000-0002-7203-1194; Davies, Michael Peter Alan/0000-0002-7609-4977				BARRACLOUGH R, 1987, J CELL PHYSIOL, V131, P393, DOI 10.1002/jcp.1041310311; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BARRACLOUGH R, 1994, EUR J CANCER, V30A, P1570, DOI 10.1016/0959-8049(94)00320-5; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V21, P8097; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOMBS LM, 1990, ANAL BIOCHEM, V188, P338, DOI 10.1016/0003-2697(90)90617-I; DAVIES BR, 1993, ONCOGENE, V8, P999; DAVIES M, 1995, DNA CELL BIOL, V14, P825, DOI 10.1089/dna.1995.14.825; DAVIES MPA, 1993, THESIS U LIVERPOOL; DEVOUGE MW, 1992, ONCOGENE, V7, P109; DUNNINGTON DJ, 1984, CANCER RES, V44, P5338; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; FORD HL, 1995, ONCOGENE, V11, P2067; FORD HL, 1995, ONCOGENE, V10, P1597; GIBBS FEM, 1995, J HISTOCHEM CYTOCHEM, V43, P169, DOI 10.1177/43.2.7822773; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GRIGORIAN MS, 1993, GENE, V135, P229, DOI 10.1016/0378-1119(93)90070-J; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hogan B., 1986, MANIPULATING MOUSE E; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; LAEMMLI UK, 1970, NATURE, V227, P2678; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PEDROCCHI M, 1994, INT J CANCER, V57, P684, DOI 10.1002/ijc.2910570513; Sambrook J, 1989, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TAKENAGA K, 1994, JPN J CANCER RES, V85, P831, DOI 10.1111/j.1349-7006.1994.tb02955.x; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D	32	179	183	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1631	1637						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895508				2022-12-17	WOS:A1996VM88700007
J	Dorfman, K; Carrasco, D; Gruda, M; Ryan, C; Lira, SA; Bravo, R				Dorfman, K; Carrasco, D; Gruda, M; Ryan, C; Lira, SA; Bravo, R			Disruption of the erp/mkp-1 gene does not affect mouse development: Normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts	ONCOGENE			English	Article						erp; mkp-1 knockout; development; Erk1, Erk2 MAP kinases	PROTEIN-TYROSINE-PHOSPHATASE; DUAL-SPECIFICITY PHOSPHATASE; IMMEDIATE-EARLY GENE; EMBRYONIC STEM-CELLS; HEAT-SHOCK; IN-VIVO; MESODERM INDUCTION; GROWTH-FACTORS; EXPRESSION; ACTIVATION	Externally regulated phosphatase (ERP or MKP-1) is a dual specificity phosphatase that has been implicated in the dephosphorylation of mitogen activated protein kinases (MAP kinases), MAP kinase is activated in response to external signals and in turn phosphorylates proteins essential to the regulation of cell growth, To study the role of ERP/MKP-1 protein in mammalian development and its function in signal transduction we have generated mice, embryonic stem (ES), cells and mouse embryo fibroblasts (MEFs) that are deficient in the ERP/MKP-1 protein, ERP/MKP-1-deficient mice are born at normal frequency, are fertile and present no phenotypic or histologic abnormalities, MAP kinase activity and the induction of c-fos mRNA is unaltered in MEFs lacking the ERP/MKP-1 protein, indicating no alteration of the MAP kinase pathway, In addition, ERP/MKP-1 deficient MEFs grow and enter DNA synthesis at the same rate as control cells, Our results demonstrate that the activity of ERP/MKP-1 is not essential for embryo development and indicate that the lack of ERP/MKP-1 activity can be compensated by other phosphatases in vivo.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT ONCOL, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb								ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; BURKERT U, 1991, NEW BIOL, V3, P698; CARRASCO D, 1993, CELL GROWTH DIFFER, V4, P849; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; DUFF JL, 1993, J BIOL CHEM, V268, P26037; EMSLIE EA, 1994, HUM GENET, V93, P513; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KWAK SP, 1994, J BIOL CHEM, V269, P3596; LABONNE C, 1995, DEVELOPMENT, V121, P1475; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WILES MV, 1991, DEVELOPMENT, V111, P259; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5; Wurst W., 1993, Gene targeting: a practical approach., P33; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	49	179	182	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	1996	13	5					925	931						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806681				2022-12-17	WOS:A1996VG76600005
J	HALABAN, R; RUBIN, JS; FUNASAKA, Y; COBB, M; BOULTON, T; FALETTO, D; ROSEN, E; CHAN, A; YOKO, K; WHITE, W; COOK, C; MOELLMANN, G				HALABAN, R; RUBIN, JS; FUNASAKA, Y; COBB, M; BOULTON, T; FALETTO, D; ROSEN, E; CHAN, A; YOKO, K; WHITE, W; COOK, C; MOELLMANN, G			MET AND HEPATOCYTE GROWTH-FACTOR SCATTER FACTOR SIGNAL TRANSDUCTION IN NORMAL MELANOCYTES AND MELANOMA-CELLS	ONCOGENE			English	Article							AUTOCRINE MOTILITY FACTOR; TYROSINE KINASE RECEPTOR; HUMAN GASTRIC-CARCINOMA; C-MET; MOLECULAR-CLONING; MURINE MELANOCYTES; EPITHELIAL-CELLS; REGULATED KINASES; TRANSFORMING GENE; PROTEIN-KINASES	The proto-oncogene c-MET encodes a transmembrane tyrosine kinase receptor for hepatocyte growth factor/scatter factor (HGF/SF). HGF/SF stimulates the proliferation and motility of various cell types. Because HGF/SF is also a melanocyte mitogen, we investigated the biological role of HGF/SF, including c-Met expression, activation and signal transduction, in normal and malignant human melanocytes. We show that HGF/SF is mitogenic in the presence of synergistic factors, such as basic fibroblast growth factor (bFGF) and mast cell growth factor (MGF) and that, by itself, it stimulates the motility of normal human melanocytes. The ligand also maintained high levels of tyrosinase activity and melanin content in theses cells. Signal transduction by HGF/SF included phosphorylation of tyrosyl residues on c-Met, a cascade of tyrosine phosphorylations on several other proteins and activation of microtubule-associated protein kinase/extracellular signal-regulated kinase. Met expression and activity are normal in human melanomas, and constitutive activity of HGF/SF in retrovirally infected autonomously proliferative mouse melanocytes is insufficient to confer the malignant phenotype. Our findings suggest that activation of Met in response to HGF/SF may contribute to malignant progression synergistically with the aberrant expression of bFGF in malignant melanocytes and that, in addition, the peptide may promote dispersion of factor-dependent melanocytes from early stages of primary melanomas to ectopic sites.	NCI,FREDERICK CANC RES & DEV,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PATHOL,WINSTON SALEM,NC 27103; YALE UNIV,SCH MED,DEPT RADIAT THERAPY,NEW HAVEN,CT 06510; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; YALE UNIV,SCH MED,DEPT PLAST SURG,NEW HAVEN,CT 06510; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Wake Forest University; Wake Forest Baptist Medical Center; Yale University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Yale University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HALABAN, R (corresponding author), YALE UNIV,SCH MED,DEPT DERMATOL,333 CEDAR ST,POB 3333,NEW HAVEN,CT 06510, USA.		Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew Man-Lok/0000-0001-9923-5464; Cobb, Melanie/0000-0003-0833-5473	NATIONAL CANCER INSTITUTE [R29CA044542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039848] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034128, R37DK034128] Funding Source: NIH RePORTER; NCI NIH HHS [5-R29-CA44542] Funding Source: Medline; NIAMS NIH HHS [1RO1-AR39848] Funding Source: Medline; NIDDK NIH HHS [DK 34128] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AHN NG, 1990, J BIOL CHEM, V265, P11495; ALBINO AP, 1991, CANCER RES, V51, P4815; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; BAIRD A, 1991, CANCER CELL-MON REV, V3, P239; BEAN MA, 1975, CANCER RES, V35, P2902; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BHARGAVA J, 1992, CELL GROWTH DIFFER, V3, P11; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BRADL M, 1991, P NATL ACAD SCI USA, V88, P6447, DOI 10.1073/pnas.88.15.6447; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CEPKO CL, 1984, CELL, V37, P1043; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; FALETTO DL, 1992, ONCOGENE, V7, P1149; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; FURLONG RA, 1991, J CELL SCI, V100, P173; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GREGORY J, 1989, J BIOL CHEM, V264, P18377; HALABAN R, 1992, J IMMUNOTHER, V12, P154, DOI 10.1097/00002371-199210000-00002; HALABAN R, 1986, J INVEST DERMATOL, V87, P95, DOI 10.1111/1523-1747.ep12523594; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HALABAN R, 1991, Critical Reviews in Oncogenesis, V2, P247; HALABAN R, 1988, ONCOGENE RES, V3, P177; HALABAN R, 1991, ANN NY ACAD SCI, V638, P232, DOI 10.1111/j.1749-6632.1991.tb49034.x; HALABAN R, 1983, J CELL BIOL, V97, P480, DOI 10.1083/jcb.97.2.480; HALABAN R, 1977, EXP CELL RES, V108, P119, DOI 10.1016/S0014-4827(77)80017-7; HALABAN R, 1991, CANCER METAST REV, V10, P129, DOI 10.1007/BF00049410; HERLYN M, 1985, CANCER RES, V45, P5670; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; JAMBROSIC J, 1989, INT J CANCER, V44, P1117, DOI 10.1002/ijc.2910440630; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; LEE RM, 1992, J BIOL CHEM, V267, P1088; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P45, DOI 10.1016/0006-291X(91)90887-D; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1988, P NATL ACAD SCI USA, V85, P2667, DOI 10.1073/pnas.85.8.2667; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RODECK U, 1991, J INVEST DERMATOL, V97, P20, DOI 10.1111/1523-1747.ep12477822; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SILLETTI S, 1991, CANCER RES, V51, P3507; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAMURA A, 1987, IN VITRO CELL DEV B, V23, P519; WATANABE H, 1991, J BIOL CHEM, V266, P13442; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WILSON RE, 1989, CANCER RES, V49, P711; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	73	179	183	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2195	2206						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1331934				2022-12-17	WOS:A1992JW66500012
J	Galavotti, S; Bartesaghi, S; Faccenda, D; Shaked-Rabi, M; Sanzone, S; McEvoy, A; Dinsdale, D; Condorelli, F; Brandner, S; Campanella, M; Grose, R; Jones, C; Salomoni, P				Galavotti, S.; Bartesaghi, S.; Faccenda, D.; Shaked-Rabi, M.; Sanzone, S.; McEvoy, A.; Dinsdale, D.; Condorelli, F.; Brandner, S.; Campanella, M.; Grose, R.; Jones, C.; Salomoni, P.			The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells	ONCOGENE			English	Article						autophagy; cancer stem cell; invasion	MALIGNANT GLIOMA-CELLS; HUMAN BRAIN-TUMORS; INDUCED CYTOTOXICITY; GENE-EXPRESSION; GLUCOSE TRANSPORTERS; IONIZING-RADIATION; MYELOID-LEUKEMIA; CANCER; DEATH; CHLOROQUINE	The aggressiveness of glioblastoma multiforme (GBM) is defined by local invasion and resistance to therapy. Within established GBM, a subpopulation of tumor-initiating cells with stem-like properties (GBM stem cells, GSCs) is believed to underlie resistance to therapy. The metabolic pathway autophagy has been implicated in the regulation of survival in GBM. However, the status of autophagy in GBM and its role in the cancer stem cell fraction is currently unclear. We found that a number of autophagy regulators are highly expressed in GBM tumors carrying a mesenchymal signature, which defines aggressiveness and invasion, and are associated with components of the MAPK pathway. This autophagy signature included the autophagy-associated genes DRAM1 and SQSTM1, which encode a key regulator of selective autophagy, p62. High levels of DRAM1 were associated with shorter overall survival in GBM patients. In GSCs, DRAM? and SQSTM1 expression correlated with activation of MAPK and expression of the mesenchymal marker c-MET. DRAM1 knockdown decreased p62 localization to autophagosomes and its autophagy-mediated degradation, thus suggesting a role for DRAM1 in p62-mediated autophagy. In contrast, autophagy induced by starvation or inhibition of mTOR/PI-3K was not affected by either DRAM1 or p62 downregulation. Functionally, DRAM1 and p62 regulate cell motility and invasion in GSCs. This was associated with alterations of energy metabolism, in particular reduced ATP and lactate levels. Taken together, these findings shed new light on the role of autophagy in GBM and reveal a novel function of the autophagy regulators DRAM1 and p62 in control of migration/invasion in cancer stem cells. Oncogene (2013) 32, 699-712; doi:10.1038/onc.2012.111; published online 23 April 2012	[Galavotti, S.; Bartesaghi, S.; Salomoni, P.] UCL Canc Inst, Samantha Dickson Brain Canc Unit, London WC1E 6BT, England; [Faccenda, D.; Campanella, M.] Univ London Royal Vet Coll, London, England; [Shaked-Rabi, M.; Brandner, S.] UCL, Neurol Inst, London, England; [Sanzone, S.; Condorelli, F.] Univ Piemonte Orientale, Novara, Italy; [McEvoy, A.] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England; [Dinsdale, D.] MRC Toxicol Unit, Leicester, Leics, England; [Campanella, M.] UCL Consortium Mitochondrial Res, London, England; [Grose, R.] Barts Canc Inst, London, England; [Jones, C.] Inst Canc Res, London SW3 6JB, England	University of London; University College London; University of London; University of London Royal Veterinary College; University of London; University College London; University of Eastern Piedmont Amedeo Avogadro; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; Queen Mary University London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Salomoni, P (corresponding author), UCL Canc Inst, Samantha Dickson Brain Canc Unit, London WC1E 6BT, England.	p.salomoni@ucl.ac.uk	Brandner, Sebastian/J-4562-2014; Condorelli, Fabrizio/AAT-1953-2020; Jones, Chris/ABE-6059-2021; Bartesaghi, Stefano/G-1916-2015	Brandner, Sebastian/0000-0002-9821-0342; Condorelli, Fabrizio/0000-0002-9943-0857; Jones, Chris/0000-0001-8118-2296; Bartesaghi, Stefano/0000-0002-2083-7807; Grose, Richard/0000-0002-4738-0173	Samantha Dickson Brain Tumour Trust [SDK-I-0805]; University of Modena and Reggio Emilia, Modena, Italy; NHS; Cancer Research UK [C8851/A10844]; National Hospital Development foundation; UCLH CBRC [31]; BBSRC [BB/I013695/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/I013695/1] Funding Source: researchfish; The Brain Tumour Charity [8/47] Funding Source: researchfish	Samantha Dickson Brain Tumour Trust; University of Modena and Reggio Emilia, Modena, Italy; NHS; Cancer Research UK(Cancer Research UK); National Hospital Development foundation; UCLH CBRC; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); The Brain Tumour Charity	We thank Susan Short, Sergio Quezada, Steven Pollard and Daniel Hochhauser (UCL Cancer Institute, London, UK), Sharon Tooze (CRUK London Research Institute, London, UK), Bruno Calabretta (Kimmel Cancer Center, Philadelphia, USA), Andrea Cossarizza and Paola Loria (University of Modena and Reggio Emilia, Italy) for reagents and critical discussion. We also thank other members of PS lab (UCL Cancer Institute) and Melania Capasso (Bans and the London, UK). We thank Carol Mercer and Pat Dennis (University of Cincinnati, USA) for the BHMT plasmid, and Scott Lowe (CSHL, USA) for the hRAS-V12 IRES GFP plasmid (Addgene). Finally, we thank the UCL Scientific Services and in particular Tomas Adejumo for support with flow cytometry. PS is supported by the Samantha Dickson Brain Tumour Trust and a generous donation by David Hunter and Wendy Tansey in memory of Peter Clark. SG is recipient of a PhD studentship from the University of Modena and Reggio Emilia, Modena, Italy. CJ acknowledges NHS funding to the NIHR Biomedical Research Centre. ET acknowledges Cancer Research UK funding to his laboratory (C8851/A10844). MSR is funded by the National Hospital Development foundation and SB (Institute of Neurology, loN) received support from UCLH CBRC (Ref 31) and the Samantha Dickson Brain tumor trust (Ref SDK-I-0805). SB (IoN) acknowledges the Neurosurgical team at the National Hospital for their continued support of the brain tumor bank.	Beckner ME, 2010, INT J CANCER, V126, P2282, DOI 10.1002/ijc.24918; Beckner ME, 2005, LAB INVEST, V85, P316, DOI 10.1038/labinvest.3700239; Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204; Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660; Bilir A, 2008, INT J ONCOL, V32, P829; BOADO RJ, 1994, MOL BRAIN RES, V27, P51, DOI 10.1016/0169-328X(94)90183-X; Briceno Eduardo, 2003, Neurosurg Focus, V14, pe3; BROOKS DJ, 1986, J CEREBR BLOOD F MET, V6, P230, DOI 10.1038/jcbfm.1986.36; Campanella M, 2008, CELL METAB, V8, P13, DOI 10.1016/j.cmet.2008.06.001; Campello S, 2006, J EXP MED, V203, P2879, DOI 10.1084/jem.20061877; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chen HC, 2007, CELL, V130, P548, DOI 10.1016/j.cell.2007.06.026; Cheng Y, 2011, CANCER RES, V71, P2654, DOI 10.1158/0008-5472.CAN-10-2889; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Crighton D, 2007, AUTOPHAGY, V3, P72, DOI 10.4161/auto.3438; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Dang LN, 2010, TRENDS MOL MED, V16, P387, DOI 10.1016/j.molmed.2010.07.002; Day SE, 2011, MAGN RESON MED, V65, P557, DOI 10.1002/mrm.22698; De Bacco F, 2011, J NATL CANCER I, V103, P645, DOI 10.1093/jnci/djr093; Dikic I, 2010, CANCER RES, V70, P3431, DOI 10.1158/0008-5472.CAN-09-4027; Fan QW, 2011, AUTOPHAGY, V7, P536, DOI 10.4161/auto.7.5.14779; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Geng Y, 2010, NEURO-ONCOLOGY, V12, P473, DOI 10.1093/neuonc/nop048; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Hoyer-Hansen M, 2008, AUTOPHAGY, V4, P574, DOI 10.4161/auto.5921; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Kanzawa T, 2003, CANCER RES, V63, P2103; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Katayama M, 2007, CELL DEATH DIFFER, V14, P548, DOI 10.1038/sj.cdd.4402030; Kim MJ, 2011, J BIOL CHEM, V286, P12924, DOI 10.1074/jbc.M110.138958; KIRSCH WM, 1967, J NEUROSURG, V27, P45, DOI 10.3171/jns.1967.27.1.0045; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Kroemer G, 2010, CURR OPIN CELL BIOL, V22, P121, DOI 10.1016/j.ceb.2010.02.003; Lee Y, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-52; Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269; Llaguno SA, 2009, CANCER CELL, V15, P45, DOI 10.1016/j.ccr.2008.12.006; Lock R, 2011, CELL CYCLE, V10, P1516, DOI 10.4161/cc.10.10.15434; Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500; Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512; Lusa L, 2007, JNCI-J NATL CANCER I, V99, P1715, DOI 10.1093/jnci/djm216; Martinou M, 2011, CANCER GENOM PROTEOM, V8, P33; Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008; Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023; Munshi A, 2009, CANCER, V115, P2380, DOI 10.1002/cncr.24288; NAGAMATSU S, 1993, J NEUROCHEM, V61, P2048, DOI 10.1111/j.1471-4159.1993.tb07441.x; Natsumeda M, 2011, NEUROPATHOLOGY, V31, P486, DOI 10.1111/j.1440-1789.2010.01197.x; NISHIOKA T, 1992, CANCER RES, V52, P3972; Paugh BS, 2010, J CLIN ONCOL, V28, P3061, DOI 10.1200/JCO.2009.26.7252; Perou CM, 2010, LANCET ONCOL, V11, P718, DOI 10.1016/S1470-2045(10)70176-5; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pollard SM, 2009, CELL STEM CELL, V4, P568, DOI 10.1016/j.stem.2009.03.014; Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009; Reitman ZJ, 2010, JNCI-J NATL CANCER I, V102, P932, DOI 10.1093/jnci/djq187; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Salomoni P, 2009, AUTOPHAGY, V5, P1050, DOI 10.4161/auto.5.7.9509; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Shima Y, 2007, BIOCHEM BIOPH RES CO, V353, P60, DOI 10.1016/j.bbrc.2006.11.137; Shingu T, 2009, AUTOPHAGY, V5, P537, DOI 10.4161/auto.5.4.8164; Shingu T, 2009, INT J CANCER, V124, P1060, DOI 10.1002/ijc.24030; Siegelin MD, 2011, J CLIN INVEST, V121, P1349, DOI 10.1172/JCI44855; Singh R, 2011, CELL METAB, V13, P495, DOI 10.1016/j.cmet.2011.04.004; Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003-4819-144-5-200603070-00008; Tatsuta T, 2008, EMBO J, V27, P306, DOI 10.1038/sj.emboj.7601972; Terpstra M, 1998, CANCER RES, V58, P5083; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Wild-Bode C, 2001, CANCER RES, V61, P2744; Wolf A, 2011, NEUROBIOL DIS, V44, P84, DOI 10.1016/j.nbd.2011.06.007; Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137	77	178	190	4	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2013	32	6					699	712		10.1038/onc.2012.111	http://dx.doi.org/10.1038/onc.2012.111			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22525272	Green Published			2022-12-17	WOS:000315746700004
J	Kawada, K; Hosogi, H; Sonoshita, M; Sakashita, H; Manabe, T; Shimahara, Y; Sakai, Y; Takabayashi, A; Oshima, M; Taketo, MM				Kawada, K.; Hosogi, H.; Sonoshita, M.; Sakashita, H.; Manabe, T.; Shimahara, Y.; Sakai, Y.; Takabayashi, A.; Oshima, M.; Taketo, M. M.			Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes	ONCOGENE			English	Article						CXCR3; colon cancer; lymph node; metastasis	COLORECTAL-CANCER; ENDOTHELIAL-CELLS; BREAST-CANCER; IFN-GAMMA; EPITHELIAL-CELLS; CUTTING EDGE; PIVOTAL ROLE; T-CELLS; EXPRESSION; CC	Chemokines and their receptors are essential for leukocyte trafficking, and also implicated in cancer metastasis to specific organs. We have recently demonstrated that CXCR3 plays a critical role in metastasis of mouse melanoma cells to lymph nodes. Here, we show that some human colon cancer cell lines express CXCR3 constitutively. We constructed cells that expressed CXCR3 cDNA (`DLD-1-CXCR3'), and compared with nonexpressing controls by rectal transplantation in nude mice. Although both cell lines disseminated to lymph nodes at similar frequencies at 2 weeks, DLD-1-CXCR3 expanded more rapidly than the control in 4 weeks. In 6 weeks, 59% of mice inoculated with DLD1-CXCR3 showed macroscopic metastasis in para-aortic lymph nodes, whereas only 14% of those with the control (P < 0.05). In contrast, metastasis to the liver or lung was rare, and unaffected by CXCR3 expression. In clinical colon cancer samples, we found expression of CXCR3 in 34% cases, most of which had lymph node metastasis. Importantly, patients with CXCR3-positive cancer showed significantly poorer prognosis than those without CXCR3, or those expressing CXCR4 or CCR7. These results indicate that activation of CXCR3 with its ligands stimulates colon cancer metastasis preferentially to the draining lymph nodes with poorer prognosis.	Kyoto Univ, Grad Sch Med, Dept Pharmacol, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Dept Surg, Kyoto, Japan; Kyoto Univ, Grad Sch Med, Dept Clin Pathol, Kyoto, Japan; Kitano Hosp, Inst Med, Osaka, Japan	Kyoto University; Kyoto University; Kyoto University; Kitano Hospital	Taketo, MM (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pharmacol, Kyoto 6068501, Japan.	taketo@mfour.med.kyoto-u.ac.jp	Sonoshita, Masahiro/AAE-5516-2019; Hosogi, Hisahiro/AAK-2585-2020; Oshima, Masanobu/F-9958-2014; SONOSHITA, MASAHIRO/Q-1571-2019	Oshima, Masanobu/0000-0002-3304-0004; SONOSHITA, MASAHIRO/0000-0003-2890-336X				Amichay D, 1996, J IMMUNOL, V157, P4511; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bao SD, 2004, CANCER CELL, V5, P329, DOI 10.1016/S1535-6108(04)00081-9; Cella M, 1999, NAT MED, V5, P919, DOI 10.1038/11360; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; Dijkstra IM, 2004, J IMMUNOL, V172, P2744, DOI 10.4049/jimmunol.172.5.2744; Dwinell MB, 2001, GASTROENTEROLOGY, V120, P49, DOI 10.1053/gast.2001.20914; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; Flatmark K, 2004, EUR J CANCER, V40, P1593, DOI 10.1016/j.ejca.2004.02.023; FLEMING JB, 1997, AJCC CANC STAGING MA, P83; GATTASS CR, 1994, J EXP MED, V179, P1373, DOI 10.1084/jem.179.4.1373; Janatpour MJ, 2001, J EXP MED, V194, P1375, DOI 10.1084/jem.194.9.1375; Jordan NJ, 1999, J CLIN INVEST, V104, P1061, DOI 10.1172/JCI6685; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kashtan H, 1992, Surg Oncol, V1, P251, DOI 10.1016/0960-7404(92)90072-S; Kawada K, 2004, CANCER RES, V64, P4010, DOI 10.1158/0008-5472.CAN-03-1757; Kim J, 2005, J CLIN ONCOL, V23, P2744, DOI 10.1200/JCO.2005.07.078; Luther SA, 2000, P NATL ACAD SCI USA, V97, P12694, DOI 10.1073/pnas.97.23.12694; Mancardi S, 2003, IMMUNOLOGY, V108, P523, DOI 10.1046/j.1365-2567.2003.01613.x; Martin-Fontecha A, 2004, NAT IMMUNOL, V5, P1260, DOI 10.1038/ni1138; Mashino K, 2002, CANCER RES, V62, P2937; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Ninomiya I, 2004, INT J CANCER, V112, P135, DOI 10.1002/ijc.20360; Ochsenbein AF, 2001, NATURE, V411, P1058, DOI 10.1038/35082583; Palframan RT, 2001, J EXP MED, V194, P1361, DOI 10.1084/jem.194.9.1361; Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470; Poggi A, 2004, BLOOD, V103, P2205, DOI 10.1182/blood-2003-08-2928; Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200; Saeki H, 1999, J IMMUNOL, V162, P2472; Schimanski CC, 2005, CLIN CANCER RES, V11, P1743, DOI 10.1158/1078-0432.CCR-04-1195; Soejima K, 2001, J IMMUNOL, V167, P6576, DOI 10.4049/jimmunol.167.11.6576; Soto H, 1998, P NATL ACAD SCI USA, V95, P8205, DOI 10.1073/pnas.95.14.8205; Tannenbaum CS, 1998, J IMMUNOL, V161, P927; Trentin L, 1999, J CLIN INVEST, V104, P115, DOI 10.1172/JCI7335; Tsutsumi S, 2001, CANCER LETT, V169, P77, DOI 10.1016/S0304-3835(00)00622-4; Vicari AP, 2000, J IMMUNOL, V165, P1992, DOI 10.4049/jimmunol.165.4.1992; Vlahakis SR, 2002, J IMMUNOL, V169, P5546, DOI 10.4049/jimmunol.169.10.5546; von Andrian UH, 2003, NAT REV IMMUNOL, V3, P867, DOI 10.1038/nri1222; Walser TC, 2006, CANCER RES, V66, P7701, DOI 10.1158/0008-5472.CAN-06-0709; Wiley HE, 2001, J NATL CANCER I, V93, P1638, DOI 10.1093/jnci/93.21.1638; Yoneyama H, 2002, J EXP MED, V195, P1257, DOI 10.1084/jem.20011983; Zeelenberg IS, 2003, CANCER RES, V63, P3833; Zhang R, 1997, ONCOGENE, V14, P1607, DOI 10.1038/sj.onc.1200957	44	178	189	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2007	26	32					4679	4688		10.1038/sj.onc.1210267	http://dx.doi.org/10.1038/sj.onc.1210267			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297455				2022-12-17	WOS:000248037900008
J	Shah, NP; Sawyers, CL				Shah, NP; Sawyers, CL			Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias	ONCOGENE			English	Review						tyrosine kinase inhibitor; BCR-ABL; imatinib; gleevec; mutation	CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; KINASE INHIBITOR STI571; ABL TYROSINE KINASE; CYTOGENETIC RESPONSES; POSITIVE CELLS; GENE MUTATION; BLAST CRISIS; STI-571; DOMAIN	Philadelphia chromosome-associated leukemias are among the most well-understood human malignancies. The importance of BCR-ABL enzymatic activity in the proliferation of the leukemic clone has been confirmed by the high response rates of these leukemias to the ABL-selective tyrosine kinase inhibitor STI571, even in advanced disease phases, which are characterized by increased genetic heterogeneity. Disease relapse has been observed in a subset of patients who had initially responded to STI571. Evidence suggests that BCR-ABL activity is restored in the majority of these cases of acquired resistance. Molecular studies of resistant leukemia cells isolated from patients have implicated BCR-ABL kinase domain point mutation as the most common mechanism of resistance. Additionally, genomic amplification of the BCR-ABL gene can occasionally be detected. This review will highlight mechanisms of STI571 resistance in clinical samples as well as preclinical models.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med & Mol Pharmacol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Sawyers, CL (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.	csawyers@mednet.ucla.edu	Sawyers, Charles/G-5327-2016					Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Gambacorti-Passerini C, 2000, JNCI-J NATL CANCER I, V92, P1641, DOI 10.1093/jnci/92.20.1641; GambacortiPasserini C, 1997, BLOOD CELL MOL DIS, V23, P380, DOI 10.1006/bcmd.1997.0155; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; GRAEBER T, UNPUB; Hochhaus A, 2002, LEUKEMIA, V16, P2190, DOI 10.1038/sj.leu.2402741; Hochhaus A, 2001, SCIENCE, V293, P2163; Hofmann WK, 2002, BLOOD, V99, P1860, DOI 10.1182/blood.V99.5.1860; Jorgensen HG, 2002, BLOOD, V99, P713, DOI 10.1182/blood.V99.2.713; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; le Coutre P, 2000, BLOOD, V95, P1758, DOI 10.1182/blood.V95.5.1758.005a41_1758_1766; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Nagar B, 2002, CANCER RES, V62, P4236; NOWELL PC, 1960, SCIENCE, V132, P1497; Ricci C, 2002, CANCER RES, V62, P5995; Roche-Lestienne C, 2002, BLOOD, V100, P1014, DOI 10.1182/blood.V100.3.1014; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505	23	178	184	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7389	7395		10.1038/sj.onc.1206942	http://dx.doi.org/10.1038/sj.onc.1206942			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576846				2022-12-17	WOS:000186112500011
J	Fehrmann, F; Laimins, LA				Fehrmann, F; Laimins, LA			Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation	ONCOGENE			English	Review						HPV; cervical cancer; Oncoproteins; E6; E7; E5	RETINOBLASTOMA TUMOR-SUPPRESSOR; GROWTH-FACTOR RECEPTOR; E6 PROTEINS TARGET; HUMAN KERATINOCYTES; TYPE-16 E6; TELOMERASE ACTIVATION; E7 ONCOPROTEIN; E5 GENE; DEPENDENT ACTIVATION; ADENOVIRUS E4-ORF1	Human papillomavirus (HPV) infections play a crucial role in the pathogenesis of cervical neoplasia. Insights into the mechanisms by which HPV infection can, in a small numbers of cases, result in malignancy, comes from the observation that three proteins encoded by high-risk genital HPVs, E6, E7 and to a lesser extent E5, target factors that control the cell cycle and proliferation These interactions result in abrogation of cell cycle control, chromosomal alterations, telomerase activation, and eventual cell immortalization. In this review, we discuss the functions of E6, E7, and E5 proteins that are most relevant to the malignant progression of HPV-transformed cells.	Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Laimins, LA (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, 303 E Chicago Ave, Chicago, IL 60611 USA.	l-laimins@northwestern.edu						ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BOUVARD V, 1994, VIROLOGY, V203, P73, DOI 10.1006/viro.1994.1456; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; BUBB V, 1988, VIROLOGY, V163, P243, DOI 10.1016/0042-6822(88)90259-0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHIANG CM, 1992, P NATL ACAD SCI USA, V89, P5799, DOI 10.1073/pnas.89.13.5799; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Crusius K, 1998, EXP CELL RES, V241, P76, DOI 10.1006/excr.1998.4024; Crusius K, 1997, ONCOGENE, V15, P1437, DOI 10.1038/sj.onc.1201312; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; de Villiers E M, 1994, Curr Top Microbiol Immunol, V186, P1; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; DIPAOLO JA, 1989, ONCOGENE, V4, P395; Doorbar J, 1997, VIROLOGY, V238, P40, DOI 10.1006/viro.1997.8768; DOORBAR J, 1991, NATURE, V352, P824, DOI 10.1038/352824a0; DURST M, 1989, VIROLOGY, V173, P767, DOI 10.1016/0042-6822(89)90595-3; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Fehrmann F, 2003, J VIROL, V77, P2819, DOI 10.1128/JVI.77.5.2819-2831.2003; FRATTINI MG, 1994, VIROLOGY, V204, P799, DOI 10.1006/viro.1994.1596; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gewin L, 2001, J VIROL, V75, P7198, DOI 10.1128/JVI.75.15.7198-7201.2001; Giarre M, 2001, J VIROL, V75, P4705, DOI 10.1128/JVI.75.10.4705-4712.2001; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; GU ZM, 1995, J VIROL, V69, P8051, DOI 10.1128/JVI.69.12.8051-8056.1995; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HALBERT CL, 1988, J VIROL, V62, P1071, DOI 10.1128/JVI.62.3.1071-1075.1988; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARPER JW, 1993, CELL, V75, P805; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Helt AM, 2002, J VIROL, V76, P10559, DOI 10.1128/JVI.76.20.10559-10568.2002; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HILDESHEIM A, 1994, J INFECT DIS, V169, P235, DOI 10.1093/infdis/169.2.235; Howley PM, 2001, VIROLOGY, P2197; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Jones DL, 1999, VIROLOGY, V258, P406, DOI 10.1006/viro.1999.9733; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; LAIMINS LA, 1993, INFECT AGENT DIS, V2, P74; Laimins LA, 1996, SEMIN VIROL, V7, P305, DOI 10.1006/smvy.1996.0038; LAMBERT PF, 1991, J VIROL, V65, P3417, DOI 10.1128/JVI.65.7.3417-3420.1991; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; Lepik D, 2000, J VIROL, V74, P4688, DOI 10.1128/JVI.74.10.4688-4697.2000; Lepik D, 1998, J VIROL, V72, P6822, DOI 10.1128/JVI.72.8.6822-6831.1998; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Noya F, 2001, J VIROL, V75, P6121, DOI 10.1128/JVI.75.13.6121-6134.2001; Oh ST, 2001, J VIROL, V75, P5559, DOI 10.1128/JVI.75.12.5559-5566.2001; Ozbun MA, 2002, J VIROL, V76, P11291, DOI 10.1128/JVI.76.22.11291-11300.2002; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIM D, 1992, ONCOGENE, V7, P27; Reddel RR, 1998, BIOESSAYS, V20, P977, DOI 10.1002/(SICI)1521-1878(199812)20:12<977::AID-BIES3>3.0.CO;2-E; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Stubenrauch F, 1999, SEMIN CANCER BIOL, V9, P379, DOI 10.1006/scbi.1999.0141; Stubenrauch F, 1998, J VIROL, V72, P8115, DOI 10.1128/JVI.72.10.8115-8123.1998; THIERRY F, 1987, EMBO J, V6, P3391, DOI 10.1002/j.1460-2075.1987.tb02662.x; Thomas JT, 2001, J VIROL, V75, P7564, DOI 10.1128/JVI.75.16.7564-7571.2001; Thomas JT, 1998, J VIROL, V72, P1131, DOI 10.1128/JVI.72.2.1131-1137.1998; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; VALLE GF, 1995, J GEN VIROL, V76, P1239, DOI 10.1099/0022-1317-76-5-1239; VANOORTMARSSEN GJ, 1995, INT J EPIDEMIOL, V24, P300; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; VOUSDEN KH, 1994, ADV CANCER RES, V64, P1, DOI 10.1016/S0065-230X(08)60833-7; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wallin KL, 1999, NEW ENGL J MED, V341, P1633, DOI 10.1056/NEJM199911253412201; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; ZerfassThome K, 1996, ONCOGENE, V13, P2323; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	119	178	197	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2003	22	33					5201	5207		10.1038/sj.onc.1206554	http://dx.doi.org/10.1038/sj.onc.1206554			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709FL	12910257				2022-12-17	WOS:000184615100011
J	Hendrix, MJC; Seftor, EA; Hess, AR; Seftor, REB				Hendrix, MJC; Seftor, EA; Hess, AR; Seftor, REB			Molecular plasticity of human melanoma cells	ONCOGENE			English	Article						melanoma; plasticity; vasculogenic mimicry; VE-cadherin; EphA2	HUMAN UVEAL MELANOMA; VASCULOGENIC MIMICRY; ENDOTHELIAL SURVIVAL; VE-CADHERIN; STEM-CELLS; ANGIOGENESIS; EXPRESSION; GENE; LAMININ-5; ADHESION	The molecular analysis of tumors, such as melanoma, has benefited significantly from microarray technology that can facilitate the classification of tumors based on the differential expression of genes. The data summarized in this review describe the molecular profile of aggressive cutaneous and uveal melanoma cells as that of multiple phenotypes similar to a pluripotent, embryonic-like stem cell. A noteworthy example of the plasticity of the aggressive melanoma cell phenotype is demonstrated by the ability of these tumor cells to engage in vasculogenic mimicry and neovascularization. A review of the current evidence demonstrating important cellular and molecular determinants of melanoma vasculogenic mimicry is presented. In addition, novel signaling pathways are discussed, involving VE-cadherin, EphA2, FAK, and PI 3-kinase, which promote cell migration, invasion, and matrix remodeling. The observations summarized in this review describe some of the key molecular events that regulate the process of melanoma vasculogenic mimicry and identify new signal transduction pathways that can serve as putative targets for therapeutic intervention.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA	University of Iowa	Hendrix, MJC (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Holden Comprehens Canc Ctr, Bowen Sci Bldg,51 Newton Rd, Iowa City, IA 52242 USA.				NATIONAL CANCER INSTITUTE [R37CA059702, R01CA059702, T32CA079445, R01CA080318, R01CA088043] Funding Source: NIH RePORTER; NCI NIH HHS [CA59702, CA79445-03, CA80318, CA88043-02S1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bayless KJ, 2002, J CELL SCI, V115, P1123; Bazzoni G, 1999, CURR OPIN CELL BIOL, V11, P573, DOI 10.1016/S0955-0674(99)00023-X; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chan TO, 2002, CANCER CELL, V1, P181, DOI 10.1016/S1535-6108(02)00033-8; Clarijs R, 2002, INVEST OPHTH VIS SCI, V43, P912; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; D'Amour KA, 2002, NAT MED, V8, P213, DOI 10.1038/nm0302-213; Folberg R, 2000, AM J PATHOL, V156, P361, DOI 10.1016/S0002-9440(10)64739-6; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hendrix MJC, 2002, CANCER RES, V62, P665; Hendrix MJC, 2001, P NATL ACAD SCI USA, V98, P8018, DOI 10.1073/pnas.131209798; Hess AR, 2001, CANCER RES, V61, P3250; HESS AR, 2002, THESIS U IOWA IOWA C, P1; HESS AR, 2002, CANCER RES, V43, P36; Holden C, 2002, SCIENCE, V296, P2126, DOI 10.1126/science.296.5576.2126; Hynes RO, 1992, CURR OPIN GENET DEV, V2, P621, DOI 10.1016/S0959-437X(05)80182-0; Kemler R, 1992, Semin Cell Biol, V3, P149; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Khan J, 1998, CANCER RES, V58, P5009; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Kumar R, 1998, IN VIVO, V12, P27; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Liotta L, 2000, NAT REV GENET, V1, P48, DOI 10.1038/35049567; Malinda KM, 1999, FASEB J, V13, P53, DOI 10.1096/fasebj.13.1.53; Malinda KM, 1996, INT J BIOCHEM CELL B, V28, P957, DOI 10.1016/1357-2725(96)00042-8; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Maniotis AJ, 2002, LAB INVEST, V82, P1031, DOI 10.1097/01.LAB.0000024362.12721.67; PANDEY A, 1994, J BIOL CHEM, V269, P30154; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; Rak J, 1996, CANCER METAST REV, V15, P231, DOI 10.1007/BF00437476; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rosenberg IM, 1997, AM J PHYSIOL-GASTR L, V273, pG824, DOI 10.1152/ajpgi.1997.273.4.G824; Seftor EA, 2002, CLIN EXP METASTAS, V19, P233, DOI 10.1023/A:1015591624171; Seftor REB, 2001, CANCER RES, V61, P6322; Straume O, 2002, AM J PATHOL, V160, P1009, DOI 10.1016/S0002-9440(10)64922-X; Vogel G, 2002, SCIENCE, V295, P1989, DOI 10.1126/science.295.5562.1989; Warso MA, 2001, CLIN CANCER RES, V7, P473; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X	45	178	199	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 19	2003	22	20					3070	3075		10.1038/sj.onc.1206447	http://dx.doi.org/10.1038/sj.onc.1206447			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789282				2022-12-17	WOS:000183096600007
J	Shao, ZM; Nguyen, M; Barsky, SH				Shao, ZM; Nguyen, M; Barsky, SH			Human breast carcinoma desmoplasia is PDGF initiated	ONCOGENE			English	Article						PDGF; desmoplasia; breast carcinoma; paracrine growth factors; dominant-negative mutants; c-ras(H)	GROWTH-FACTOR-II; DOMINANT-NEGATIVE MUTANTS; MESSENGER-RNA EXPRESSION; MCF-7 CELLS; TUMOR-GROWTH; NUDE-MICE; IN-VIVO; CANCER; RECEPTOR; GENE	The desmoplastic response to human breast carcinoma is a host myofibroblast-mediated collagenous response exhibiting synergistic effects on tumor progression. Although many paracrine interactions between breast carcinoma cells and myofibroblasts have been characterized, the event(s) which initiate desmoplasia have remained undefined. Our studies utilized c-ras(H) transfected MCF-7 cells which overexpress ras p21 and which are weakly tumorigenic in ovariectomized nude mice. The xenografts are desmoplastic and comprised of 30% myofibroblasts and 60 mg/g of interstitial collagen. III sits hybridization studies of these xenografts reveal a stromal gene expression pattern (stromelysin-3, IGF-II and TIMP-1) identical to that observed in human tumor desmoplasia. 17-beta estradiol increases c-ras(H) MCF-7 growth but abolishes desmoplasia. c-ras(H) MCF-7 in vitro constitutively produce myofibroblast mitogenic activity which competes with PDGF in a receptor binding assay. This myofibroblast mitogenic activity is unaltered by 17-beta estradiol/tamoxifen pretreatment irt vitro. Transfection of c-ras(H) MCF-7,vith a PDGF-A dominant negative mutant, 1308, produced by site-directed mutagenesis (serine -->cystcine(129)) reduces both homo- and heterodimer secretion of PDGF by as much as 90% but does not interfere with the secretion of other growth factors. Clones with low PDGF, though tumorigenic, are nondesmoplastic. Our results suggest that breast carcinoma-secreted PDGF is the major initiator of tumor desmoplasia.	Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Surg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Revlon Breast Ctr, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Barsky, SH (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA.				NCI NIH HHS [CA01351, CA40225, CA71195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA071195, R01CA040225] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS EF, 1988, BREAST CANCER RES TR, V11, P165, DOI 10.1007/BF01805840; ARTEAGA CL, 1989, CANCER RES, V49, P6237; BARSKY SH, 1987, CANCER RES, V47, P1663; BARSKY SH, 1987, BIOCHEM BIOPH RES CO, V149, P1125, DOI 10.1016/0006-291X(87)90525-0; BARSKY SH, 1984, AM J PATHOL, V115, P329; Barsky SH, 1997, ONCOGENE, V15, P2077, DOI 10.1038/sj.onc.1201379; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BERGMAN I, 1963, ANAL CHEM, V35, P1961, DOI 10.1021/ac60205a053; BRONZERT DA, 1987, P NATL ACAD SCI USA, V84, P5763, DOI 10.1073/pnas.84.16.5763; CULLEN KJ, 1991, CANCER RES, V51, P4978; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DVORAK HF, 1979, JNCI-J NATL CANCER I, V62, P1459; DVORAK HF, 1981, J NATL CANCER I, V67, P335; DVORAK HF, 1981, SCIENCE, V212, P923, DOI 10.1126/science.7195067; GOUSTIN AS, 1986, CANCER RES, V46, P1015; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HELDIN CH, 1981, P NATL ACAD SCI-BIOL, V78, P3664, DOI 10.1073/pnas.78.6.3664; HORGAN K, 1987, BRIT J SURG, V74, P227, DOI 10.1002/bjs.1800740326; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; LIEUBEAU B, 1994, CANCER RES, V54, P6526; MALIK R, 1991, CANCER RES, V51, P5626; MANNI A, 1994, CANCER RES, V54, P2934; MERCOLA M, 1990, GENE DEV, V4, P2333, DOI 10.1101/gad.4.12b.2333; MIURA M, 1994, CANCER RES, V54, P2472; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NAUNDORF H, 1992, J CANCER RES CLIN, V119, P35, DOI 10.1007/BF01209485; NOGUCHI M, 1993, MOL CELL ENDOCRINOL, V92, P69, DOI 10.1016/0303-7207(93)90076-V; O'Connell JT, 1998, HUM PATHOL, V29, P1517, DOI 10.1016/S0046-8177(98)90024-7; OSBORNE CK, 1990, BREAST CANCER RES TR, V15, P3, DOI 10.1007/BF01811884; OSBORNE CK, 1989, MOL ENDOCRINOL, V3, P1701, DOI 10.1210/mend-3-11-1701; PERES R, 1987, CANCER RES, V47, P3425; Povlsen C O, 1980, Antibiot Chemother (1971), V28, P15; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; SINGER C, 1995, CANCER RES, V55, P2448; SOMMERS CL, 1990, CANCER RES, V50, P67; Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949; Tomlinson J, 1999, CLIN CANCER RES, V5, P3516; YEE D, 1988, CANCER RES, V48, P6691; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509	40	178	182	0	12	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4337	4345		10.1038/sj.onc.1203785	http://dx.doi.org/10.1038/sj.onc.1203785			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980609	Bronze			2022-12-17	WOS:000089271900004
J	Calin, GA; di Iasio, MG; Caprini, E; Vorechovsky, I; Natali, PG; Sozzi, G; Croce, CM; Barbanti-Brodano, G; Russo, G; Negrini, M				Calin, GA; di Iasio, MG; Caprini, E; Vorechovsky, I; Natali, PG; Sozzi, G; Croce, CM; Barbanti-Brodano, G; Russo, G; Negrini, M			Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms	ONCOGENE			English	Article						PPP2R1A; PPP2R1B; mutations; human neoplasms	TUMOR-SUPPRESSOR GENE; PROTEIN PHOSPHATASE-2A; ATAXIA-TELANGIECTASIA; OVARIAN-CANCER; BREAST-CANCER; ATM GENE; HETEROZYGOSITY; REGIONS; REFINEMENT; LEUKEMIA	The phosphatase 2A (PP2A) is one of the major cellular serine-threonine phosphatases, It was recently shown that the gene encoding for the beta isoform of its subunit A, PPP2R1B, is altered in human lung and colorectal carcinomas, suggesting a role in human tumorigenesis, Here, we report the detection of mutations in breast, lung carcinomas and melanomas in the genes of both alpha (PPP2R1A) and beta isoforms, Mutations affecting PPP2R1B were found in four breast carcinomas, while mutations in PPP2R1A were found in carcinomas of the breast and of the lung and in one melanoma. Most of the mutations affecting PPP2R1B were exons deletions, suggesting abnormal splicing. These splicing abnormalities were detected in tumor samples in the absence of the normal splicing product, and were not found in several normal controls. In one case, a homozygous deletion present in tumor DNA, and not in the matched normal control was demonstrated. Mutations affecting the PPP2R1A gene were nucleotide substitutions changing highly conserved amino acids and one frame-shift. Although the frequency of alterations is low, the inclusion of both isoforms of subunit A in the genes mutated in human cancer and the addition of breast cancer to the list of neoplasms in which PPP2R1B is altered, strengthen the potential role of PP2A in human tumorogenesis.	Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, Sez Microbiol, I-44100 Ferrara, Italy; Ist Dermopat Immacolata, I-00167 Rome, Italy; Novum, Karolinska Inst, Dept Biosci, S-14157 Huddinge, Sweden; Ist Nazl Tumori, I-23133 Milan, Italy; Regina Elena Canc Inst, Immunol Lab, I-00158 Rome, Italy; Thomas Jefferson Univ, Kimmel Canc Ctr, Kimmel Canc Inst, Philadelphia, PA 19107 USA	University of Ferrara; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Karolinska Institutet; Fondazione IRCCS Istituto Nazionale Tumori Milan; Jefferson University	Negrini, M (corresponding author), Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, Sez Microbiol, Via Luigi Borsari 46, I-44100 Ferrara, Italy.		Russo, Giandomenico/K-9566-2016; Negrini, Massimo/J-2377-2016; Calin, George/E-9390-2011; Young, Richard A/F-6495-2012; sozzi, gabriella/G-8259-2011	Russo, Giandomenico/0000-0002-7718-9687; Negrini, Massimo/0000-0002-0007-1920; Young, Richard A/0000-0001-8855-8647; sozzi, gabriella/0000-0001-9360-6914; Calin, George/0000-0001-6704-5615				Baysal BE, 1998, GENE, V217, P107, DOI 10.1016/S0378-1119(98)00350-3; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Davis M, 1996, CANCER RES, V56, P741; di Iasio MG, 1999, ONCOGENE, V18, P1635, DOI 10.1038/sj.onc.1202453; Dohner H, 1997, BLOOD, V89, P2516, DOI 10.1182/blood.V89.7.2516; Gabra H, 1996, CANCER RES, V56, P950; HAMPTON GM, 1994, CANCER RES, V54, P4586; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; Hayashi K, 1996, LABORATORY PROTOCOLS FOR MUTATION DETECTION, P14; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HERBST RA, 1995, CANCER RES, V55, P2494; IIZUKA M, 1995, GENE CHROMOSOME CANC, V13, P40; Kerangueven F, 1997, ONCOGENE, V14, P339, DOI 10.1038/sj.onc.1200818; Maniatis T., 1982, MOL CLONING LAB MANU; NEGRINI M, 1995, CANCER RES, V55, P3003; RASIO D, 1995, CANCER RES, V55, P3988; Rosenberg JE, 1996, ONCOGENE, V13, P2483; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Sparks AB, 1998, CANCER RES, V58, P1130; Stilgenbauer S, 1997, NAT MED, V3, P1155, DOI 10.1038/nm1097-1155; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; Vorechovsky I, 1996, CANCER RES, V56, P2726; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	30	178	186	0	18	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2000	19	9					1191	1195		10.1038/sj.onc.1203389	http://dx.doi.org/10.1038/sj.onc.1203389			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713707				2022-12-17	WOS:000085567800009
J	Tuck, AB; Arsenault, DM; O'Malley, FP; Hota, C; Ling, MC; Wilson, SM; Chambers, AF				Tuck, AB; Arsenault, DM; O'Malley, FP; Hota, C; Ling, MC; Wilson, SM; Chambers, AF			Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells	ONCOGENE			English	Article						osteopontin (OPN); invasion; plasminogen activator; urokinase; mammary epithelial cells; breast cancer	BREAST-CANCER; NEOPLASTIC TRANSFORMATION; BOVINE OSTEOPONTIN; TUMOR PROGRESSION; GENE-EXPRESSION; IV COLLAGENASE; METASTASIS; TRANSGLUTAMINASE; ADHESION; CLONING	Osteopontin (OPN) has been associated with enhanced malignancy in breast cancer, but its functional role in this disease is poorly understood. To study the effect of OPN on cellular invasiveness, basal OPN expression was first assessed in members of a progression series of human mammary epithelial cell lines (21PT: immortalized, non-tumorigenic; 21NT: weakly tumorigenic; 21MT-1: tumorigenic, weakly metastatic; MDA-MB-435 cells: tumorigenic, highly metastatic). The two lines which expressed lowest basal levels of OPN (21PT, 21NT) were then examined for up-regulation of invasive behavior in response to exogenous or transfected (endogenous) OPN. Both 21PT and 21NT showed increased invasiveness through Matrigel when human recombinant (hr)OPN was added to the lower chamber of trans wells. Both also showed a cell migration response to hrOPN. Populations of 21PT and 21NT cells stably transfected with an OPN-expression vector showed higher levels of cell invasiness than control vector transfectants. Examination of transfectants for mRNA of a number of secreted proteases showed that only urokinase-type plasminogen activator (uPA) expression was closely associated with OPN expression and cellular invasiveness, Treatment of the parental 21PT and 21NT cells with exogenous hrOPN resulted in increased uPA mRNA expression and increased urokinase activity of the conditioned media. Both increased cell migration and induction of uPA expression are thus potential mechanisms of increased invasiness of breast epithelial cells in response to OPN.	Univ Western Ontario, Dept Pathol, London Hlth Sci Ctr, London, ON N6A 4G5, Canada; Univ Western Ontario, Dept Oncol, London Hlth Sci Ctr, London, ON N6A 4G5, Canada; Univ Western Ontario, Dept Surg, London Hlth Sci Ctr, London, ON N6A 4G5, Canada; London Reg Canc Ctr, London, ON N6A 4L6, Canada	London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); Western University (University of Western Ontario)	Tuck, AB (corresponding author), Univ Western Ontario, Dept Pathol, London Hlth Sci Ctr, Victoria Campus,375 S St, London, ON N6A 4G5, Canada.		Chambers, Ann F/L-6285-2015	Chambers, Ann F/0000-0002-9509-5123				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; ASCHLIMANN D, 1996, SEMIN THROMB HEMOST, V22, P437; AUGEREAU P, 1988, MOL ENDOCRINOL, V2, P186, DOI 10.1210/mend-2-2-186; BAND V, 1990, CANCER RES, V50, P7351; BARICOS WH, 1995, KIDNEY INT, V47, P1039, DOI 10.1038/ki.1995.150; Bautista DS, 1996, CLIN BIOCHEM, V29, P231, DOI 10.1016/0009-9120(96)84728-A; BAUTISTA DS, 1994, J BIOL CHEM, V269, P23280; BEHREND EI, 1994, CANCER RES, V54, P832; BELLAHCENE A, 1995, AM J PATHOL, V146, P95; BENINATI S, 1994, J BIOCHEM-TOKYO, V115, P675, DOI 10.1093/oxfordjournals.jbchem.a124395; BROWN LF, 1994, AM J PATHOL, V145, P610; CAO LQ, 1994, GENE, V139, P163, DOI 10.1016/0378-1119(94)90750-1; Chellaiah M, 1996, MOL BIOL CELL, V7, P743, DOI 10.1091/mbc.7.5.743; Chen HJ, 1997, ONCOGENE, V14, P1581, DOI 10.1038/sj.onc.1200993; DENHARD DT, 1995, ANN NY ACAD SCI, V760; FENG B, 1995, CLIN EXP METASTAS, V13, P453, DOI 10.1007/BF00118184; GARDNER HAR, 1994, ONCOGENE, V9, P2321; HIROTA S, 1995, LAB INVEST, V72, P64; HRUSKA KA, 1995, ANN NY ACAD SCI, V760, P151, DOI 10.1111/j.1749-6632.1995.tb44627.x; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; MENTER DG, 1991, CELL BIOPHYS, V18, P123, DOI 10.1007/BF02989810; MORRIS VL, 1993, CLIN EXP METASTAS, V11, P103, DOI 10.1007/BF00880071; Oates AJ, 1996, ONCOGENE, V13, P97; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PRICE JE, 1990, CANCER RES, V50, P717; PRINCE CW, 1991, BIOCHEM BIOPH RES CO, V177, P1205, DOI 10.1016/0006-291X(91)90669-X; REPONEN P, 1992, J BIOL CHEM, V267, P7856; RICCIO A, 1985, NUCLEIC ACIDS RES, V13, P2759, DOI 10.1093/nar/13.8.2759; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SAAVEDRA RA, 1995, ANN NY ACAD SCI, V760, P35, DOI 10.1111/j.1749-6632.1995.tb44618.x; Sambrook J, 1989, MOL CLONING LAB MANU; SENGER DR, 1983, NATURE, V302, P714, DOI 10.1038/302714a0; Senger DR, 1996, BBA-MOL CELL RES, V1314, P13, DOI 10.1016/S0167-4889(96)00067-5; SENGER DR, 1988, CANCER RES, V48, P5770; Shanmugam V, 1997, BIOCHEMISTRY-US, V36, P5729, DOI 10.1021/bi961687w; Simon C, 1996, CANCER RES, V56, P5369; Singhal H, 1997, CLIN CANCER RES, V3, P605; SORENSEN ES, 1995, ANN NY ACAD SCI, V760, P363, DOI 10.1111/j.1749-6632.1995.tb44658.x; SORENSEN ES, 1994, BIOCHEM J, V304, P13, DOI 10.1042/bj3040013; Teti A, 1998, INT J CANCER, V77, P82; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; TUCK AB, 1991, J NATL CANCER I, V83, P485; TUCK AB, 1990, CLIN EXP METASTAS, V8, P417, DOI 10.1007/BF00058153; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; XUAN JW, 1995, J CELL BIOCHEM, V57, P680, DOI 10.1002/jcb.240570413; XUAN JW, 1994, J CELL BIOCHEM, V54, P247, DOI 10.1002/jcb.240540213; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V	49	178	187	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4237	4246		10.1038/sj.onc.1202799	http://dx.doi.org/10.1038/sj.onc.1202799			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435636				2022-12-17	WOS:000081542400007
J	Kissil, JL; Feinstein, E; Cohen, O; Jones, PA; Tsai, YC; Knowles, MA; Eydmann, ME; Kimchi, A				Kissil, JL; Feinstein, E; Cohen, O; Jones, PA; Tsai, YC; Knowles, MA; Eydmann, ME; Kimchi, A			DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene	ONCOGENE			English	Article						serine/threonine kinase; death gene; tumor suppressor; methylation; 5'-azadeoxycytidine	HUMAN BLADDER-CANCER; DNA-METHYLATION; DEATH; APOPTOSIS; MEDIATOR; LEUKEMIA; BCL-2; P16	DAP-kinase is a novel calmodulin dependent serine/threonine kinase that carries ankyrin repeats and the death domain. It was recently isolated, by a functional selection approach of gene cloning, as a positive mediator of programmed cell death. In this study the expression of DAP-kinase was examined in the cell lines derived from various human neoplasms, DAP-kinase mRNA and protein expression were below the limit of detection in eight out of ten neoplastic derived B-cell lines. In six out of 14 examined bladder carcinoma, in three out of five renal cell carcinoma, and in four out of ten tested breast carcinoma cell lines, the DAP-kinase protein levels were below detection limits or lower than 1% compared to the positive cell lines. Interestingly, DAP-kinase expression could be restored in some of the negative bladder carcinoma and B-cell lines by treatment of cells with 5'-azadeoxycytidine that causes DNA demethylation. The high frequency of loss of DAP-kinase expression in human tumor cell lines, and the occasional involvement of methylation in this process raise the possibility that this novel mediator of cell death may function as a tumor suppressor gene.	WEIZMANN INST SCI, DEPT MOL GENET, IL-76100 REHOVOT, ISRAEL; UNIV SO CALIF, KENNETH NORRIS JR COMPREHENS CANC CTR, LOS ANGELES, CA 90033 USA; MARIE CURIE RES INST, MOL GENET LAB, OXTED RH8 0TL, SURREY, ENGLAND	Weizmann Institute of Science; University of Southern California				Knowles, Margaret/0000-0002-9363-8657	NCI NIH HHS [CA49758] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN A, 1991, BLOOD, V78, P94; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ERIKSON J, 1986, P NATL ACAD SCI USA, V83, P1807, DOI 10.1073/pnas.83.6.1807; FEINSTEIN E, 1995, GENOMICS, V29, P305, DOI 10.1006/geno.1995.1255; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; KISSIL JL, 1995, J BIOL CHEM, V270, P27932, DOI 10.1074/jbc.270.46.27932; KNOWLES MA, 1994, CANCER RES, V54, P531; KNOWLES MA, 1993, LANCET, V342, P1184, DOI 10.1016/0140-6736(93)92169-T; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SAKAI T, 1991, AM J HUM GENET, V48, P880; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SHEAFF RJ, 1995, CURR BIOL, V5, P28, DOI 10.1016/S0960-9822(95)00009-1; Simcha I, 1996, J CELL BIOL, V133, P199, DOI 10.1083/jcb.133.1.199; SKOLNICK MH, 1994, EUR J CANCER, V30A, P1991, DOI 10.1016/0959-8049(94)00392-I; TSAI YC, 1990, CANCER RES, V50, P44; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; TULCHINSKY E, 1995, BBA-GENE STRUCT EXPR, V1261, P243, DOI 10.1016/0167-4781(95)00013-7; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; WILLIAMSON MP, 1995, HUM MOL GENET, V4, P1569, DOI 10.1093/hmg/4.9.1569	30	178	195	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	1997	15	4					403	407		10.1038/sj.onc.1201172	http://dx.doi.org/10.1038/sj.onc.1201172			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242376				2022-12-17	WOS:A1997XM23800004
J	Grammer, TC; Blenis, J				Grammer, TC; Blenis, J			Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases	ONCOGENE			English	Article						MAPK; MEK; phosphatidylinositol-3 kinase; protein kinase C	GLYCOGEN-SYNTHASE KINASE-3; PROTEIN-KINASE; CYCLIC-AMP; INSULIN; PHOSPHORYLATION; TYROSINE; WORTMANNIN; PP90RSK; CELLS; IDENTIFICATION	The mitogen-activated protein kinases (MAPKs) ERK-1 and ERK-2 are activated by a wide variety of oncogenes and extracellular stimuli. The MAPKs participate in a signalling cascade downstream of growth factor/cytokine receptors, Ras, Raf, and MEK. However, MAPK activation is more complicated than a simple linear pathway, and the evidence presented here supports a model of multiple, temporally distinct pathways converging on MAPK which are differentially utilized by various stimuli and cell types. In addition to MEK-dependent MAPK activation, we provide evidence for MEK-independent regulation of the MAPKs. Our results suggest that phosphatidylinositol-3-kinases (PI(3)K) or conventional protein kinase C isoforms (cPKCs) partially contribute to MEK-dependent activation. Importantly, we also find that PI3K and cPKCs play a major role in the MEK-independent, prolonged MAPK activation by platelet-derived growth factor signalling. This finding is of interest as the maintained activation of MAPK has been correlated by others to the regulation of cell proliferation and differentiation.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School								BLENIS J, 1986, P NATL ACAD SCI USA, V83, P1733, DOI 10.1073/pnas.83.6.1733; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FERBY IM, 1994, J BIOL CHEM, V269, P30485; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; VANRENTERGHEM B, 1994, J BIOL CHEM, V269, P24666; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; YANG YC, 1993, FEBS LETT, V333, P287, DOI 10.1016/0014-5793(93)80672-H	26	178	179	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	1997	14	14					1635	1642		10.1038/sj.onc.1201000	http://dx.doi.org/10.1038/sj.onc.1201000			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135064				2022-12-17	WOS:A1997WR89300001
J	Bottger, V; Bottger, A; Howard, SF; Picksley, SM; Chene, P; GarciaEcheverria, C; Hochkeppel, HK; Lane, DP				Bottger, V; Bottger, A; Howard, SF; Picksley, SM; Chene, P; GarciaEcheverria, C; Hochkeppel, HK; Lane, DP			Identification of novel mdm2 binding peptides by phage display	ONCOGENE			English	Article						mdm2; hdm2; p53; phage display library; peptide inhibitors	TRANSCRIPTIONAL ACTIVATION; IMMUNOCHEMICAL ANALYSIS; MONOCLONAL-ANTIBODIES; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; SYNTHETIC PEPTIDES; EPITOPE LIBRARY; P53; LIGANDS; PROTEIN	The oncogene mdm2 and its human homologue hdm2 bind to the tumour suppressor protein p53 and inactivate its function as a transcription factor. This has been implied as a possible mechanism for cancer development in several tumours including human sarcomas. The mdm2-p53 interaction is therefore a much persued target for the development of anti-cancer drugs. In order to find novel high affinity ligands for hdm2 which would interfere with its binding to p53 we screened phage display peptide libraries for mdm2 binding phage. We found a series of 12 and 15mer peptides which interact strongly with hdm2. The peptide sequences show striking homology with the previously established mdm2 binding site on p53, confirming that the peptide defined (18)TFSDLW(23) region is crucial for the interaction but that contact between the two molecules extends to position L(26) On p53. Free synthetic peptides derived from the phage selected sequences proved to be up to 100 times stronger inhibitors of the p53-mdm2 interaction than the p53 derived wt-peptide in several ELISA-assays. This illustrates the potency of phage display libraries in the search for new peptide based lead structures designed to mimic or inhibit therapeutically important protein-protein interactions.	UNIV DUNDEE, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND; CIBA GEIGY AG, CH-4002 BASEL, SWITZERLAND	University of Dundee; Novartis			Lane, David P/C-4920-2008	Bottger, Angelika/0000-0003-3273-9558; Lane, David/0000-0003-0551-3545				BOTTGER V, 1995, J MOL BIOL, V247, P932, DOI 10.1006/jmbi.1995.0191; BOTTGER V, 1994, J MOL BIOL, V235, P61, DOI 10.1016/S0022-2836(05)80013-0; CHAN S, 1987, MOL CELL PROBE, V1, P73, DOI 10.1016/0890-8508(87)90008-9; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; LENG P, 1995, ONCOGENE, V10, P1275; LUNA RMD, 1995, NATURE, V378, P203; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SNYDER LC, 1987, SOMAT CELL MOLEC GEN, V13, P235; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	28	178	196	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2141	2147						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950981				2022-12-17	WOS:A1996VV14500011
J	Carbone, M; Rizzo, P; Procopio, A; Giuliano, M; Pass, HI; Gebhardt, MC; Mangham, C; Hansen, M; Malkin, DF; Bushart, G; Pompetti, F; Picci, P; Levine, AS; Bergsagel, JD; Garcea, RL				Carbone, M; Rizzo, P; Procopio, A; Giuliano, M; Pass, HI; Gebhardt, MC; Mangham, C; Hansen, M; Malkin, DF; Bushart, G; Pompetti, F; Picci, P; Levine, AS; Bergsagel, JD; Garcea, RL			SV40-like sequences in human bone tumors	ONCOGENE			English	Article						SV40; human bone tumors	HUMAN-BRAIN-TUMORS; T-DELETION MUTANTS; SIMIAN-VIRUS 40; GROWTH-FACTOR-I; SV40; ANTIGEN; SIMIAN-VIRUS-40; MICE; GENE; TRANSFORMATION	Simian virus 40 (SV40) is a monkey virus that induces ependymomas, choroid plexus tumors, mesotheliomas, osteosarcomas, sarcomas and true histiocytic lymphomas when injected in hamsters. Recently, approximately 60% of human ependymomas, choroid plexus tumors and mesotheliomas were reported to contain and express SV40-like sequences (N. Engl. J. Med., 1992, 36, 988-993; Oncogene, 1994, 9, 1781-1790). In this study the presence of SV40-like sequences was investigated in additional types of human tumors. Initially, 200 tumor and normal tissue DNA samples were analysed by polymerase chain reaction (PCR) with primers that were analysed by with primers that amplify a 574 base pair region of SV40 large T antigen (Tag), which includes the Rb-pocket binding domain and the intron of Tag. PCR amplification and Southern blot hybridization with a probe specific for SV40 Tag revealed that 18/200 samples contained SV40-like sequences and, unexpectedly, 11/18 were from patients with osteosarcomas. Additional DNA samples from bone tumors were then analysed. In 40/126 osteosarcomas, and 14/34 other bone-related tumors, Tag sequences could be amplified. Sequence analysis of the DNA amplified from seven different tumors confirmed that the amplified sequences corresponded to SV40 Tag, with some demonstrating deletions in the intron region but not in the Rb-pocket binding domain. The extent of SV40 genome sequences present in the DNA samples was further analysed in two osteosarcomas. PCR amplification, Southern blot hybridization, and sequence analysis revealed that these samples also contained sequences for the carboxy-terminal domain of Tag, the viral regulatory region, and the VP1 capsid protein. These results indicate that SV40-like sequences are present in human bone tumors.	NIH, SECT DNA REPLICAT REPAIR & MUTAGENESIS, BETHESDA, MD 20892 USA; UNIV G DANNUNZIO, EXPT CTR GENE THERAPY & DIAG, CHIETI, ITALY; NCI, THORAC ONCOL SECT, BETHESDA, MD 20892 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, BOSTON, MA 02115 USA; BOSTON UNIV, BOSTON, MA 02215 USA; HOSP SICK CHILDREN, TORONTO, ON M5G 1X8, CANADA; UNIV ULM, D-7900 ULM, GERMANY; IST ORTOPED RIZZOLI, BOLOGNA, ITALY; SCOTTISH RITE HOSP, ATLANTA, GA USA; CHILDRENS HOSP, DENVER, CO 80218 USA	National Institutes of Health (NIH) - USA; G d'Annunzio University of Chieti-Pescara; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Boston Children's Hospital; Harvard Medical School; Boston University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Ulm University; IRCCS Istituto Ortopedico Rizzoli; Children's Hospital Colorado	Carbone, M (corresponding author), UNIV CHICAGO, DEPT PATHOL, 5841 S MARYLAND AVE, MC3083, ROOM S-342, CHICAGO, IL 60637 USA.		Procopio, Antonio Domenico/AAB-2451-2021; Bergsagel, Daniel John/I-6464-2019; Malkin, David/AAW-8715-2021; Picci, Piero/J-5979-2016	Procopio, Antonio Domenico/0000-0001-6897-8724; rizzo, paola/0000-0001-7174-9674; Pass, Harvey/0000-0003-3222-3471; Picci, Piero/0000-0002-8519-4101; Giuliano, Mariateresa/0000-0002-7338-9200				ABRAMCZUK J, 1984, J VIROL, V49, P540, DOI 10.1128/JVI.49.2.540-548.1984; AVANTAGGIATI ML, IN PRESS EMBO J; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; BRIGHT RK, 1994, J IMMUNOL, V153, P2064; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; BUCHMAN AR, 1981, DNA TUMOR VIRUSES 2, P799; BUTEL JS, 1994, ENCY VIROLOGY, V2, P1322; CARBONE M, 1994, ONCOGENE, V9, P1781; CARBONE M, 1989, CANCER RES, V49, P1565; CARBONE M, 1991, MOL BASIS HUMAN CANC, P191; CARBONE M, 1995, DNA TUMOR VIRUSES ON, P75; CICALA C, 1993, AM J PATHOL, V142, P1524; CICALA C, 1992, VIROLOGY, V190, P475, DOI 10.1016/0042-6822(92)91237-O; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Cristaudo A., 1995, Journal of Environmental Pathology Toxicology and Oncology, V14, P29; DEMATTEI M, 1995, INT J CANCER, V61, P756, DOI 10.1002/ijc.2910610603; DIAMANDOPOULOS GT, 1972, SCIENCE, V176, P173, DOI 10.1126/science.176.4031.173; DIXON K, 1982, NATURE, V296, P672, DOI 10.1038/296672a0; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; GEISSLER E, 1983, HUM GENET, V63, P1, DOI 10.1007/BF00285389; GEISSLER E, 1990, PROG MED VIROL, V37, P211; GERBER P, 1962, VIROLOGY, V18, P582, DOI 10.1016/0042-6822(62)90061-2; ILYINSKII PO, 1992, J VIROL, V66, P6353, DOI 10.1128/JVI.66.11.6353-6360.1992; JENSEN F, 1964, J NATL CANCER I, V29, P1123; KE Y, 1989, AM J PATHOL, V134, P979; KOPROWSKI H, 1962, J CELL COMPAR PHYSL, V59, P281, DOI 10.1002/jcp.1030590308; KRIEG P, 1981, P NATL ACAD SCI-BIOL, V78, P6446, DOI 10.1073/pnas.78.10.6446; KRIEG P, 1984, VIROLOGY, V138, P336, DOI 10.1016/0042-6822(84)90357-X; LEDNICKY JA, 1995, VIROLOGY, V212, P710, DOI 10.1006/viro.1995.1529; LEDNICKY JA, 1995, VIRUS RES, V35, P143, DOI 10.1016/0168-1702(94)00093-R; LEWIS AM, 1979, P NATL ACAD SCI USA, V76, P4299, DOI 10.1073/pnas.76.9.4299; LEWIS AM, 1973, BIOHAZARDS BIOL RES, P96; MARTIN JD, 1991, VIRUS RES, V19, P163, DOI 10.1016/0168-1702(91)90043-U; MARTINI F, 1995, J NATL CANCER I, V87, P1331, DOI 10.1093/jnci/87.17.1331; MAYOL X, 1993, ONCOGENE, V8, P2561; MELNICK JL, 1962, P SOC EXP BIOL MED, V109, P965, DOI 10.3181/00379727-109-27392; MORRIS JA, 1961, P SOC EXP BIOL MED, V108, P56, DOI 10.3181/00379727-108-26843; PASS HI, IN PRESS IMPORTANT A; PASS HI, IN PRESS CANC RES; POMPETTI F, IN PRESS J CELL BIOC; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; RABSON AS, 1962, J NATL CANCER I, V29, P1123; Ray F.A., 1995, DNA TUMOR VIRUSES ON, P15; REDDEL RR, 1989, J NATL CANCER I, V81, P945, DOI 10.1093/jnci/81.12.945; SAMBROOK S, 1989, MOL CLONING, V2; SHAH K, 1976, AM J EPIDEMIOL, V103, P1; SHEIN HM, 1962, P NATL ACAD SCI USA, V48, P1164, DOI 10.1073/pnas.48.7.1164; SIMMONS DT, 1995, DNA TUMOR VIRUSES ON, P27; SORIANO F, 1974, NATURE, V249, P421, DOI 10.1038/249421a0; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; TIEMANN F, 1994, ONCOGENE, V9, P1907; TODARO GJ, 1967, P SOC EXP BIOL MED, V124, P1232; VALENTINIS B, 1994, ONCOGENE, V9, P825; WALKER DL, 1986, PAPOVAVIRIDAE, V1, P327; WALSH JW, 1982, NEUROSURGERY, V10, P643, DOI 10.1227/00006123-198205000-00018; WANG R, 1991, J VIROL, V65, P5174, DOI 10.1128/JVI.65.10.5174-5183.1991; WEINER LP, 1972, NEW ENGL J MED, V305, P1517; WILKIE TM, 1994, ONCOGENE, V9, P2889; YOSHIIKE K, 1986, PAPOVAVIRIDAE, V1, P295	60	178	182	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	1996	13	3					527	535						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760294				2022-12-17	WOS:A1996VB32800010
J	HU, LF; CHEN, F; ZHENG, X; ERNBERG, I; CAO, SL; CHRISTENSSON, B; KLEIN, G; WINBERG, G				HU, LF; CHEN, F; ZHENG, X; ERNBERG, I; CAO, SL; CHRISTENSSON, B; KLEIN, G; WINBERG, G			CLONABILITY AND TUMORIGENICITY OF HUMAN EPITHELIAL-CELLS EXPRESSING THE EBV ENCODED MEMBRANE-PROTEIN LMP1	ONCOGENE			English	Article							EPSTEIN-BARR-VIRUS; NASOPHARYNGEAL CARCINOMA; HUMAN KERATINOCYTES; NEOPLASTIC TRANSFORMATION; NUCLEAR ANTIGEN; BNLF-1 GENE; B-CELLS; ONCOGENE; GENOME; DEATH	Two isolates of the EBV-LMP1 gene were compared for their ability to induce phenotypic changes in a non-tumorigenic human keratinocyte line, Rhek-1, immortalized with an adenovirus 12-SV40 hybrid virus. One isolate, designated B-LMP1, was derived from B95-8, a B-cell line of marmoset origin, that carries a viral strain from a mononucleosis patient. The other, designated C-LMP1, originated from a nude mouse passaged Chinese NPC tumor, CAO. Both types of transfectants were less serum dependent than the non-transfected and the vector-transfected controls. The ability to grow on low serum increased with increasing LMP1 expression. All transfectants were more highly clonable than the non-transfected or vector-transfected controls. Clonability in soft agarose increased with increasing LMP1 expression. Nine of 24 C-LMP1 transfectants produced tumors in SCID mice. Seven of them grew invasively into the surrounding tissue. Only one of 12 B-LMP1 transfected Rhek-1 clones was tumorigenic. It did not grow invasively. All tumorigenic transfectants expressed LMP1 at high or moderate levels. All tumors were found to express LMP1. Transfectants with low LMP1 expression did not produce tumors. The untransfected Rhek-1 cells and six vector control clones failed to produce tumors.	KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT PATHOL,S-14186 HUDDINGE,SWEDEN; SHANGHAI MED UNIV,TUMOR HOSP,SHANGHAI,PEOPLES R CHINA; FRED HUTCHINSON CANC RES CTR,PROGRAMME CANC BIOL,SEATTLE,WA 98104	Karolinska Institutet; Karolinska Institutet; Fudan University; Fred Hutchinson Cancer Center			Winberg, Gosta/I-5686-2013	Winberg, Gosta/0000-0002-3371-4056	NATIONAL CANCER INSTITUTE [R01CA030264] Funding Source: NIH RePORTER; NCI NIH HHS [2RQI CA30264-10] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSONANVRET M, 1977, INT J CANCER, V20, P486, DOI 10.1002/ijc.2910200403; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1989, ONCOGENE, V4, P67; CHEN ML, 1992, ONCOGENE, V7, P2131; CUOMO L, 1993, IN PRESS INT J CANCE; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FIDLER IJ, 1991, ANTICANCER RES, V11, P17; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; Hausen H., 1970, NATURE, V228, P1056; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HENLE W, 1970, J NATL CANCER I, V44, P225; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P4737, DOI 10.1073/pnas.71.12.4737; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBOWITZ D, 1992, J VIROL, V66, P4612, DOI 10.1128/JVI.66.7.4612-4616.1992; MANN KP, 1987, J VIROL, V61, P2100, DOI 10.1128/JVI.61.7.2100-2108.1987; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; RHIM JS, 1989, ANTICANCER RES, V9, P1345; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RYMO L, 1985, P NATL ACAD SCI USA, V82, P3435, DOI 10.1073/pnas.82.10.3435; SALCEDO R, 1991, J VIROL, V65, P5558, DOI 10.1128/JVI.65.10.5558-5563.1991; Sambrook J., 1989, MOL CLONING LAB MANU; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WOLF H, 1973, NATURE-NEW BIOL, V244, P245, DOI 10.1038/newbio244245a0; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; ZHANG RD, 1991, CANCER RES, V51, P2029	34	178	205	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1575	1583						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389032				2022-12-17	WOS:A1993LE06400021
J	OROURKE, RW; MILLER, CW; KATO, GJ; SIMON, KJ; CHEN, DL; DANG, CV; KOEFFLER, HP				OROURKE, RW; MILLER, CW; KATO, GJ; SIMON, KJ; CHEN, DL; DANG, CV; KOEFFLER, HP			A POTENTIAL TRANSCRIPTIONAL ACTIVATION ELEMENT IN THE P53-PROTEIN	ONCOGENE			English	Article							TUMOR-ANTIGEN; GENE-PRODUCT; T-ANTIGEN; P53; TRANSFORMATION; PROTEIN; CELLS; EXPRESSION; MUTATIONS; ONCOGENE	The human p53 gene codes for a 393 amino acid nuclear phosphoprotein. p53 is most commonly described as a tumor suppressor, or anti-oncogene, although its role in vivo remains unclear. We report that GAL4-p53 fusion protein can activate transcription of a CAT reporter gene downstream of a GAL4-DNA binding site. We tested both the amino terminal 160 amino acids and the carboxy terminal 233 amino acids of the p53 protein and found that the transcriptional activating (TA) region was restricted to the amino terminal fragment. These results imply that p53 may be a transcriptional activating factor (TAF); furthermore, these data lend support to the hypothesis of p53 as a positive regulator of transcription which might mediate its tumor suppressor role by inducing expression of a set of genes with a negative effect on cellular growth.	UNIV CALIF LOS ANGELES,SCH MED,DIV HEMATOL ONCOL,11-240 FACTOR BLDG,10833 LE CONTE AVE,LOS ANGELES,CA 90024; JOHNS HOPKINS UNIV,JOHNS HOPKINS ONCOL CTR,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,JOHNS HOPKINS ONCOL CTR,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,JOHNS HOPKINS ONCOL CTR,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine			Kato, Gregory J/I-7615-2014; Dang, Chi/Y-3375-2019	Kato, Gregory J/0000-0003-4465-3217; O'Rourke, Robert/0000-0002-4038-4198; Dang, Chi/0000-0002-4031-2522	NCI NIH HHS [CA 26038, CA 33936] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033936, R01CA026038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CANN AJ, 1988, ONCOGENE, V3, P123; DICKSON D, 1978, NATURE, V273, P260, DOI 10.1038/273260a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LANE DP, 1983, CELL BIOL INT REP, V7, P513, DOI 10.1016/0309-1651(83)90154-6; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LINZER D, 1979, CELL, V17, P143; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; SADOWSKI I, 1988, NATURE, V335, P653; Sambrook J., 1989, MOL CLONING; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WARNESS BA, 1990, SCIENCE, V248, P76; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	34	178	179	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1990	5	12					1829	1832						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET436	2284102				2022-12-17	WOS:A1990ET43600013
J	ISHIZAKA, Y; ITOH, F; TAHIRA, T; IKEDA, I; SUGIMURA, T; TUCKER, J; FERTITTA, A; CARRANO, AV; NAGAO, M				ISHIZAKA, Y; ITOH, F; TAHIRA, T; IKEDA, I; SUGIMURA, T; TUCKER, J; FERTITTA, A; CARRANO, AV; NAGAO, M			HUMAN RET PROTO-ONCOGENE MAPPED TO CHROMOSOME 10Q11.2	ONCOGENE			English	Note									UNIV CALIF LAWRENCE LIVERMORE NATL LAB,DIV BIOMED SCI,LIVERMORE,CA 94550	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	ISHIZAKA, Y (corresponding author), NATL CANC CTR,RES INST,DIV CARCINOGENESIS,1-1 TSUKIJI 5,CHUO KU,TOKYO 104,JAPAN.							DONGHI R, 1989, ONCOGENE, V4, P521; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; HARPER ME, 1981, P NATL ACAD SCI-BIOL, V78, P4458, DOI 10.1073/pnas.78.7.4458; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; JELINEK WR, 1980, P NATL ACAD SCI-BIOL, V77, P1398, DOI 10.1073/pnas.77.3.1398; LANDEGENT JE, 1987, HUM GENET, V77, P366, DOI 10.1007/BF00291428; LIOU GI, 1987, NUCLEIC ACIDS RES, V15, P3196, DOI 10.1093/nar/15.7.3196; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; Pearse A G, 1974, Pathol Annu, V9, P27; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; SIMPSON NE, 1987, NATURE, V328, P528, DOI 10.1038/328528a0; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; TAHIRA T, IN PRESS ONCOGENE; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TUCKER JD, 1988, CYTOGENET CELL GENET, V48, P103, DOI 10.1159/000132600	18	178	192	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1989	4	12					1519	1521						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2687772				2022-12-17	WOS:A1989CB65900016
J	BROWNELL, E; MITTEREDER, N; RICE, NR				BROWNELL, E; MITTEREDER, N; RICE, NR			A HUMAN REL PROTO-ONCOGENE CDNA CONTAINING AN ALU FRAGMENT AS A POTENTIAL CODING EXON	ONCOGENE			English	Article									NCI,FREDERICK CANC RES FACIL,MOLEC VIROL & CARCINOGENESIS,BRI BASIC RES PROGRAM,POB B,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; BROWNELL E, 1988, ONCOGENE, V3, P93; BROWNELL E, 1986, AM J HUM GENET, V39, P194; BROWNELL E, 1985, MOL CELL BIOL, V5, P2826, DOI 10.1128/MCB.5.10.2826; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CARAS IW, 1987, NATURE, V325, P545, DOI 10.1038/325545a0; CHEN ISY, 1983, J VIROL, V45, P104, DOI 10.1128/JVI.45.1.104-113.1983; DEININGER PL, 1988, MOL CELL BIOL, V8, P4566, DOI 10.1128/MCB.8.10.4566; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HERZOG NK, 1986, J VIROL, V57, P371, DOI 10.1128/JVI.57.1.371-375.1986; HERZOG NK, 1986, P NATL ACAD SCI USA, V83, P812, DOI 10.1073/pnas.83.3.812; JURKA J, 1988, P NATL ACAD SCI USA, V85, P4775, DOI 10.1073/pnas.85.13.4775; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1988, MOL CELL BIOL, V8, P2737, DOI 10.1128/MCB.8.7.2737; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LUNDWALL AB, 1985, J BIOL CHEM, V260, P2108; Maxam A M, 1980, Methods Enzymol, V65, P499; MILES JS, 1988, NUCLEIC ACIDS RES, V16, P5783, DOI 10.1093/nar/16.13.5783; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NICHOLLS RD, 1987, CELL, V49, P369, DOI 10.1016/0092-8674(87)90289-3; RICE NR, 1986, VIROLOGY, V149, P217, DOI 10.1016/0042-6822(86)90123-6; RICE NR, 1987, J VIROL, V61, P1577, DOI 10.1128/JVI.61.5.1577-1585.1987; RICE NR, 1988, ONCOGENE HDB, P495; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID CW, 1982, SCIENCE, V216, P1065, DOI 10.1126/science.6281889; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHARMA S, 1987, SCIENCE, V235, P1489, DOI 10.1126/science.3547651; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMEK S, 1988, ONCOGENE RES, V2, P103; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; SRIVASTAVA R, 1987, P NATL ACAD SCI USA, V84, P4224, DOI 10.1073/pnas.84.12.4224; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; WALRO DS, 1987, VIROLOGY, V160, P433, DOI 10.1016/0042-6822(87)90015-8; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WILLARD C, 1987, J MOL EVOL, V26, P180, DOI 10.1007/BF02099850	40	178	179	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					935	942						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2666912				2022-12-17	WOS:A1989AE58400018
J	Rebecca, VW; Amaravadi, RK				Rebecca, V. W.; Amaravadi, R. K.			Emerging strategies to effectively target autophagy in cancer	ONCOGENE			English	Review							STRESS-INDUCED AUTOPHAGY; ADVANCED SOLID TUMORS; PHASE-I TRIAL; CELL-SURVIVAL; REGULATE AUTOPHAGY; LINKS AUTOPHAGY; UP-REGULATION; INHIBITOR; HYDROXYCHLOROQUINE; P53	Autophagy serves a dichotomous role in cancer and recent advances have helped delineate the appropriate settings where inhibiting or promoting autophagy may confer therapeutic efficacy in patients. Our evolving understanding of the molecular machinery responsible for the tightly controlled regulation of this homeostatic mechanism has begun to bear fruit in the way of autophagy-oriented clinical trials and promising lead compounds to modulate autophagy for therapeutic benefit. In this manuscript we review the recent preclinical and clinical therapeutic strategies that involve autophagy modulation in cancer.	[Amaravadi, R. K.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19063 USA; [Amaravadi, R. K.] Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19063 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Amaravadi, RK (corresponding author), Univ Penn, Sch Med, Dept Med, 16 Penn Tower,3400 Spruce St, Philadelphia, PA 19063 USA.	ravi.amaravadi@uphs.upenn.edu			National Institutes of Health [R01 CA169134]; NATIONAL CANCER INSTITUTE [P01CA114046, R01CA169134] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by R01 CA169134 (RKA) from the National Institutes of Health.	Amaravadi R, 2014, CANCER DISCOV, V4, P873, DOI 10.1158/2159-8290.CD-14-0618; Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Backer JM, 2008, BIOCHEM J, V410, P1, DOI 10.1042/BJ20071427; Barnard RA, 2014, AUTOPHAGY, V10, P1415, DOI 10.4161/auto.29165; Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204; Bowman CJ, 2014, NAT CELL BIOL, V16, P1202, DOI 10.1038/ncb3062; Bray K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041831; Broz DK, 2013, GENE DEV, V27, P1016, DOI 10.1101/gad.212282.112; Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260; Cecconi F, 2007, AUTOPHAGY, V3, P506; Chang ZX, 2013, INT J MOL MED, V31, P1449, DOI 10.3892/ijmm.2013.1351; Chen M, 2014, NAT MED, V20, P507, DOI 10.1038/nm.3521; Cheng Y, 2012, MOL CANCER THER, V11, P154, DOI 10.1158/1535-7163.MCT-11-0606; Cherra SJ, 2010, J CELL BIOL, V190, P533, DOI 10.1083/jcb.201002108; Cianfanelli V, 2015, NAT CELL BIOL, V17, P20, DOI 10.1038/ncb3072; Codogno P, 2012, NAT REV MOL CELL BIO, V13, P7, DOI 10.1038/nrm3249; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Denton D, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3916; Deretic V, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a018481; Doria A, 2013, NEW ENGL J MED, V368, P1845, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]; Dowdle WE, 2014, NAT CELL BIOL, V16, P1069, DOI 10.1038/ncb3053; Duran RV, 2012, MOL CELL, V47, P349, DOI 10.1016/j.molcel.2012.05.043; Eisenberg T, 2014, AUTOPHAGY, V10, P1143, DOI 10.4161/auto.28767; Eisenberg T, 2014, CELL METAB, V19, P431, DOI 10.1016/j.cmet.2014.02.010; Elgendy M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6637; Fujita KI, 2011, P NATL ACAD SCI USA, V108, P1427, DOI 10.1073/pnas.1014156108; Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458; Fullgrabe J, 2014, NAT REV MOL CELL BIO, V15, P65, DOI 10.1038/nrm3716; Fullgrabe J, 2013, NATURE, V500, P468, DOI 10.1038/nature12313; Galluzzi L, 2015, CELL DEATH DIFFER, V22, P58, DOI 10.1038/cdd.2014.137; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006; Goodall ML, 2014, AUTOPHAGY, V10, P1120, DOI 10.4161/auto.28594; Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019; Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113; Hailey DW, 2010, CELL, V141, P656, DOI 10.1016/j.cell.2010.04.009; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harder LM, 2014, AUTOPHAGY, V10, P339, DOI 10.4161/auto.26863; Hayashi-Nishino M, 2009, NAT CELL BIOL, V11, P1433, DOI 10.1038/ncb1991; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Horikawa I, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5706; Iacobuzio-Donahue CA, 2014, NEW ENGL J MED, V370, P1352, DOI 10.1056/NEJMcibr1400189; Jewell JL, 2013, NAT REV MOL CELL BIO, V14, P133, DOI 10.1038/nrm3522; Karsli-Uzunbas G, 2014, CANCER DISCOV, V4, P914, DOI 10.1158/2159-8290.CD-14-0363; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Kim S, 2014, CANCER IMMUNOL IMMUN, V63, P1009, DOI 10.1007/s00262-014-1573-4; Kishi-Itakura C, 2014, J CELL SCI, V127, P4089, DOI 10.1242/jcs.156034; Klionsky DJ, 2010, AUTOPHAGY, V6, P438, DOI 10.4161/auto.6.4.12244; Kraya AA, 2015, AUTOPHAGY, V11, P60, DOI 10.4161/15548627.2014.984273; Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380; Kuang ES, 2013, TRENDS BIOCHEM SCI, V38, P453, DOI 10.1016/j.tibs.2013.06.008; Laddha SV, 2014, MOL CANCER RES, V12, P485, DOI 10.1158/1541-7786.MCR-13-0614; Lan YY, 2014, CELL REP, V9, P180, DOI 10.1016/j.celrep.2014.08.074; Levy JMM, 2014, CANCER DISCOV, V4, P773, DOI 10.1158/2159-8290.CD-14-0049; Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037; Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Ma XH, 2014, J CLIN INVEST, V124, P1406, DOI 10.1172/JCI70454; Ma XH, 2011, CLIN CANCER RES, V17, P3478, DOI 10.1158/1078-0432.CCR-10-2372; Maes H, 2014, CANCER CELL, V26, P190, DOI 10.1016/j.ccr.2014.06.025; Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231; Mandell MA, 2014, DEV CELL, V30, P394, DOI 10.1016/j.devcel.2014.06.013; Marino G, 2014, MOL CELL, V53, P710, DOI 10.1016/j.molcel.2014.01.016; Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735; Martins I, 2014, CELL DEATH DIFFER, V21, P79, DOI 10.1038/cdd.2013.75; Mathew R, 2011, COLD SH Q B, V76, P389, DOI 10.1101/sqb.2012.76.011015; Mathew R, 2014, MOL CELL, V55, P916, DOI 10.1016/j.molcel.2014.07.019; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109; McLendon PM, 2014, P NATL ACAD SCI USA, V111, pE5178, DOI 10.1073/pnas.1415589111; Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347; Mijaljica D, 2011, AUTOPHAGY, V7, P666, DOI 10.4161/auto.7.6.15812; Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455; Pike LRG, 2013, BIOCHEM J, V449, P389, DOI 10.1042/BJ20120972; Platta HW, 2012, BIOCHEM J, V441, P399, DOI 10.1042/BJ20111424; Qiu LY, 2012, J LIPOSOME RES, V22, P245, DOI 10.3109/08982104.2012.684150; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Ramakrishnan R, 2012, CANCER RES, V72, P5483, DOI 10.1158/0008-5472.CAN-12-2236; Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119; Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118; Rao S, 2014, AUTOPHAGY, V10, P529, DOI 10.4161/auto.27643; Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056; Ravikumar B, 2008, J CELL SCI, V121, P1649, DOI 10.1242/jcs.025726; Ravikumar B, 2010, NAT CELL BIOL, V12, P747, DOI 10.1038/ncb2078; Rebecca VW, 2014, PIGM CELL MELANOMA R, V27, P465, DOI 10.1111/pcmr.12227; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Ronan B, 2014, NAT CHEM BIOL, V10, P1013, DOI 10.1038/nchembio.1681; Rong YG, 2011, P NATL ACAD SCI USA, V108, P7826, DOI 10.1073/pnas.1013800108; Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Rothe K, 2014, BLOOD, V123, P3622, DOI 10.1182/blood-2013-07-516807; Sarraf SA, 2013, NATURE, V496, P372, DOI 10.1038/nature12043; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; Shukla S, 2014, J BIOL CHEM, V289, P22306, DOI 10.1074/jbc.M114.567032; Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Tanida I, 2011, ANTIOXID REDOX SIGN, V14, P2201, DOI 10.1089/ars.2010.3482; Thorburn J, 2014, CELL REP, V7, P45, DOI 10.1016/j.celrep.2014.02.036; Tomar D, 2012, BBA-MOL CELL RES, V1823, P316, DOI 10.1016/j.bbamcr.2011.11.015; Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611; Vogl DT, 2014, AUTOPHAGY, V10, P1380, DOI 10.4161/auto.29264; Wang K, 2011, AUTOPHAGY, V7, P297, DOI 10.4161/auto.7.3.14502; Wani WY, 2015, LAB INVEST, V95, P14, DOI 10.1038/labinvest.2014.131; Wei HJ, 2014, GENE DEV, V28, P1204, DOI 10.1101/gad.237354.113; Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011; Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015; Wolpin BM, 2014, ONCOLOGIST, V19, P637, DOI 10.1634/theoncologist.2014-0086; Wong PM, 2013, AUTOPHAGY, V9, P124, DOI 10.4161/auto.23323; Wong YC, 2014, P NATL ACAD SCI USA, V111, pE4439, DOI 10.1073/pnas.1405752111; Wu H, 2014, AUTOPHAGY, V10, P1712, DOI 10.4161/auto.29568; Xie XQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055096; Xu XJ, 2014, NAT IMMUNOL, V15, P1152, DOI 10.1038/ni.3025; Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zoncu R, 2011, SCIENCE, V334, P678, DOI 10.1126/science.1207056; Zou CG, 2014, P NATL ACAD SCI USA, V111, P12480, DOI 10.1073/pnas.1405032111	122	177	186	2	89	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					1	11		10.1038/onc.2015.99	http://dx.doi.org/10.1038/onc.2015.99			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25893285	Green Accepted			2022-12-17	WOS:000367812400001
J	Freudlsperger, C; Bian, Y; Wise, SC; Burnett, J; Coupar, J; Yang, X; Chen, Z; Van Waes, C				Freudlsperger, C.; Bian, Y.; Wise, S. Contag; Burnett, J.; Coupar, J.; Yang, X.; Chen, Z.; Van Waes, C.			TGF-beta and NF-kappa B signal pathway cross-talk is mediated through TAK1 and SMAD7 in a subset of head and neck cancers	ONCOGENE			English	Article						TGF-beta TAK1; NF-kappa B; SMAD7; celastrol; head and neck cancer	SQUAMOUS-CELL CARCINOMA; INDUCED APOPTOSIS; GENE-EXPRESSION; KINASE TAK1; GROWTH; ACTIVATION; RECEPTOR; PROTEIN; PROLIFERATION; INHIBITOR	Transforming growth factor-beta (TGF-beta) has a dual role in epithelial malignancies, including head and neck squamous cell carcinoma (HNSCC). Attenuation of canonical TGF-beta signaling enhances de novo tumor development, whereas TGF-beta overexpression and signaling paradoxically promotes malignant progression. We recently observed that TGF-beta-induced growth arrest response is attenuated, in association with aberrant activation of nuclear factor-kappa B (NF-kappa B), a transcription factor, which promotes malignant progression in HNSCC. However, what role cross-talk between components of the TGF-beta and NF-kappa B pathways plays in altered activation of these pathways has not been established. Here, we show TGF-beta receptor II and TGF-beta-activated kinase 1 (TAK1) are predominantly expressed in a subset of HNSCC tumors with nuclear activation of NF-kappa B family member RELA (p65). Further, TGF-beta 1 treatment induced sequential phosphorylation of TAK1, IKK, I kappa B alpha and RELA in human HNSCC lines. TAK1 enhances TGF-beta-induced NF-kappa B activation, as TAK1 siRNA knockdown decreased TGF-beta 1-induced phosphorylation of IKK, I kappa B and RELA, degradation of I kappa B alpha, RELA nuclear translocation and DNA binding, and NF-kappa B-induced reporter and target gene transcription. Functionally, TAK1 siRNA inhibited cell proliferation, migration and invasion. Celastrol, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-beta 1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-beta 1- and tumor necrosis factor-alpha (TNF-alpha)-induced NF-kappa B reporter gene activity. Celastrol also inhibited cell proliferation, while increasing sub-G0 DNA fragmentation and Annexin V markers of apoptosis. Furthermore, TGF-beta and RELA activation promoted SMAD7 expression. In turn, SMAD7 preferentially suppressed TGF-beta-induced SMAD and NF-kappa B reporters when compared with constitutive or TNF-alpha-induced NF-kappa B reporter gene activation. Thus, cross-talk by TGF-beta via TAK1 and NF-kappa B promotes the malignant phenotype of HNSCC. Moreover, NF-kappa B may contribute to the downstream attenuation of canonical TGF-beta signaling through increased SMAD7 expression. Celastrol highlights the therapeutic potential of agents targeting TAK1 as a key node in this pro-oncogenic TGF-beta-NF-kappa B signal pathway. Oncogene (2013) 32, 1549-1559; doi:10.1038/onc.2012.171; published online 28 May 2012	[Freudlsperger, C.; Bian, Y.; Wise, S. Contag; Burnett, J.; Coupar, J.; Yang, X.; Chen, Z.; Van Waes, C.] Natl Inst Deafness & Other Commun Disorders, Tumor Biol Sect, Head & Neck Surg Branch, NIH, Bethesda, MD 20892 USA; [Freudlsperger, C.] Univ Hosp Tuebingen, Dept Oral & Maxillofacial Surg, Tubingen, Germany	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Chen, Z (corresponding author), Natl Inst Deafness & Other Commun Disorders, Tumor Biol Sect, Head & Neck Surg Branch, NIH, 10 Ctr Dr,MSC 1462,Bldg 10,Rm 4-2732, Bethesda, MD 20892 USA.	chenz@nidcd.nih.gov; vanwaesc@nidcd.nih.gov	Freudlsperger, Christian/ABE-2926-2020	Freudlsperger, Christian/0000-0002-4289-0457	National Institute on Deafness and Other Communication Disorders, NIH [ZIA-DC-000016, ZIA-DC-000073]; Clinical Research Training Program; NIH; Pfizer Inc.; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000016, ZIADC000073] Funding Source: NIH RePORTER	National Institute on Deafness and Other Communication Disorders, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Clinical Research Training Program; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pfizer Inc.(Pfizer); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	Supported by intramural projects ZIA-DC-000016 and ZIA-DC-000073 from the National Institute on Deafness and Other Communication Disorders, NIH. Dr Contag Wise was supported by the Clinical Research Training Program, a public-private partnership supported jointly by the NIH and Pfizer Inc. The authors wish to thank Dr Ning T Yeh (NIDCD/NIH) and Chris Silvin (NHGRI/NIH) for their technical assistance. We would like to thank Drs Adam Glick and Ashok Kulkarni for review of the manuscript and helpful comments.	Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Arsura M, 1997, CELL GROWTH DIFFER, V8, P1049; Arsura M, 2003, HEPATOLOGY, V38, P1540; Attisano L, 2001, GENOME BIOL, V2; Azuma M, 1999, EXP CELL RES, V250, P213, DOI 10.1006/excr.1999.4503; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bancroft CC, 2002, INT J CANCER, V99, P538, DOI 10.1002/ijc.10398; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bian YS, 2009, CANCER RES, V69, P5918, DOI 10.1158/0008-5472.CAN-08-4623; Bitzer M, 2000, GENE DEV, V14, P187; Bornstein S, 2009, J CLIN INVEST, V119, P3408, DOI 10.1172/JCI38854; Brenner JC, 2010, HEAD NECK-J SCI SPEC, V32, P1195; Calixto Joao B., 2004, Planta Medica, V70, P93, DOI 10.1055/s-2004-815483; Chatterjee A, 2010, CANCER RES, V70, P1419, DOI 10.1158/0008-5472.CAN-09-2613; Cohen J, 2009, CANCER RES, V69, P3415, DOI 10.1158/0008-5472.CAN-08-3704; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dowdy SC, 2003, J BIOL CHEM, V278, P44377, DOI 10.1074/jbc.M307202200; Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037; Friedman J, 2007, CLIN CANCER RES, V13, P6568, DOI 10.1158/1078-0432.CCR-07-1591; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hong S, 2007, CANCER RES, V67, P9577, DOI 10.1158/0008-5472.CAN-07-1179; Hong S, 2007, NAT IMMUNOL, V8, P504, DOI 10.1038/ni1451; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; Jackson-Bernitsas DG, 2007, ONCOGENE, V26, P1385, DOI 10.1038/sj.onc.1209945; Jadrich JL, 2003, GENE EXPR PATTERNS, V3, P131, DOI 10.1016/S1567-133X(03)00012-7; Lam LT, 2005, CLIN CANCER RES, V11, P28; Lee TL, 2008, INT J CANCER, V122, P1987, DOI 10.1002/ijc.23324; Li H, 2005, EUR J PHARMACOL, V512, P231, DOI 10.1016/j.ejphar.2005.02.030; Lu SL, 2006, GENE DEV, V20, P1331, DOI 10.1101/gad.1413306; Lu T, 2004, P NATL ACAD SCI USA, V101, P7112, DOI 10.1073/pnas.0402048101; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mu YB, 2012, CELL TISSUE RES, V347, P11, DOI 10.1007/s00441-011-1201-y; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; REISS M, 1990, CANCER COMMUN, V2, P363, DOI 10.3727/095535490820874029; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Sethi G, 2007, BLOOD, V109, P2727, DOI 10.1182/blood-2006-10-050807; Setty AR, 2005, SEMIN ARTHRITIS RHEU, V34, P773, DOI 10.1016/j.semarthrit.2005.01.011; Sheng HM, 1999, ONCOGENE, V18, P855, DOI 10.1038/sj.onc.1202397; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Solt LA, 2008, IMMUNOL RES, V42, P3, DOI 10.1007/s12026-008-8025-1; Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780; Sovak MA, 1999, CELL GROWTH DIFFER, V10, P537; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Tao XL, 2002, ARTHRITIS RHEUM, V46, P1735, DOI 10.1002/art.10411; Van Waes C, 2007, CLIN CANCER RES, V13, P1076, DOI 10.1158/1078-0432.CCR-06-2221; Wang WS, 2005, J AM SOC NEPHROL, V16, P1371, DOI 10.1681/ASN.2004121070; White RA, 2010, ONCOGENE, V29, P5437, DOI 10.1038/onc.2010.306; Wolf JS, 2001, CLIN CANCER RES, V7, P1812; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xie W, 2003, ONCOL RES, V14, P61, DOI 10.3727/000000003108748612; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002; Yan B, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r78; Yang HJ, 2006, CANCER RES, V66, P4758, DOI 10.1158/0008-5472.CAN-05-4529; Yasui T, 2011, J BONE MINER RES, V26, P1447, DOI 10.1002/jbmr.357; Zhang PL, 2005, MODERN PATHOL, V18, P924, DOI 10.1038/modpathol.3800372; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328	61	177	183	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2013	32	12					1549	1559		10.1038/onc.2012.171	http://dx.doi.org/10.1038/onc.2012.171			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22641218	Green Accepted			2022-12-17	WOS:000316456000008
J	Basu-Roy, U; Seo, E; Ramanathapuram, L; Rapp, TB; Perry, JA; Orkin, SH; Mansukhani, A; Basilico, C				Basu-Roy, U.; Seo, E.; Ramanathapuram, L.; Rapp, T. B.; Perry, J. A.; Orkin, S. H.; Mansukhani, A.; Basilico, C.			Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas	ONCOGENE			English	Article						osteosarcoma; wnt signaling; cancer stem cell; mesenchymal tumors; differentiation; sarcosphere	CANCER STEM-CELLS; TRANSCRIPTION FACTOR SOX2; OSTEOBLAST DIFFERENTIATION; PROGENITOR CELLS; BETA-CATENIN; MOUSE MODEL; WNT; GROWTH; SARCOMA; LINEAGE	Tumors are thought to be sustained by a reservoir of self-renewing cells, termed tumor-initiating cells or cancer stem cells. Osteosarcomas are high-grade sarcomas derived from osteoblast progenitor cells and are the most common pediatric bone malignancy. In this report we show that the stem cell transcription factor Sox2 is highly expressed in human and murine osteosarcoma (mOS) cell lines as well as in the tumor samples. Osteosarcoma cells have increased ability to grow in suspension as osteospheres, that are greatly enriched in expression of Sox2 and the stem cell marker, Sca-1. Depletion of Sox2 by short-hairpin RNAs in independent mOS-derived cells drastically reduces their transformed properties in vitro and their ability to form tumors. Sox2-depleted osteosarcoma cells can no longer form osteospheres and differentiate into mature osteoblasts. Concomitantly, they exhibit decreased Sca-1 expression and upregulation of the Wnt signaling pathway. Thus, despite other mutations, these cells maintain a requirement for Sox2 for tumorigenicity. Our data indicate that Sox2 is required for osteosarcoma cell self renewal, and that Sox2 antagonizes the pro-differentiation Wnt pathway that can in turn reduce Sox2 expression. These studies define Sox2 as a survival factor and a novel biomarker of self renewal in osteosarcomas, and support a tumor suppressive role for the Wnt pathway in tumors of mesenchymal origin. Our findings could provide the basis for novel therapeutic strategies based on inhibiting Sox2 or enhancing Wnt signaling for the treatment of osteosarcomas. Oncogene (2012) 31, 2270-2282; doi:10.1038/onc.2011.405; published online 19 September 2011	[Basu-Roy, U.; Seo, E.; Mansukhani, A.; Basilico, C.] NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; [Ramanathapuram, L.] NYU, Coll Dent, New York, NY 10016 USA; [Rapp, T. B.] NYU, Sch Med, Dept Orthoped Surg, New York, NY 10016 USA; [Perry, J. A.; Orkin, S. H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Harvard Stem Cell Inst, Boston, MA 02115 USA; [Perry, J. A.; Orkin, S. H.] Howard Hughes Med Inst, Boston, MA 02115 USA; [Perry, J. A.; Orkin, S. H.] Harvard Univ, Sch Med, Div Hematol Oncol, Childrens Hosp Boston, Boston, MA USA	New York University; New York University; New York University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard Medical School	Mansukhani, A (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.	Alka.Mansukhani@med.nyu.edu; Claudio.Basilico@med.nyu.edu		Mansukhani, Alka/0000-0003-1020-3242; , Tim/0000-0002-1444-0803	PHS from the NIAMS [AR051358]; NIDCR [DE013745]; NCI; Children's Cancer Research Fund; St Baldrick's Foundation; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051358] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013745] Funding Source: NIH RePORTER	PHS from the NIAMS; NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Children's Cancer Research Fund; St Baldrick's Foundation; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr E De Stanchina (Antitumor Assessment Facility, Memorial Sloan Kettering Cancer Center, New York, NY) for excellent services and advice with the xenograft assays. Thanks to Dr J Durbin, NYU TABS, for help with tissue acquisition. This investigation was supported by PHS Grants AR051358 from the NIAMS and DE013745 from the NIDCR, and by an NCI UO1 award (to SHO). UBR is a recipient of a fellowship from The Children's Cancer Research Fund in memory of Dr A Rausen. AM is a recipient of a research grant from St Baldrick's Foundation. JAP is a postdoctoral fellow of the American Cancer Society. SHO is an Investigator of the Howard Hughes Medical Institute.	Adams JM, 2008, COLD SH Q B, V73, P451, DOI 10.1101/sqb.2008.73.004; Ambrosetti D, 2008, MOL CELL BIOL, V28, P4759, DOI 10.1128/MCB.01849-07; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Basu-Roy U, 2010, CELL DEATH DIFFER, V17, P1345, DOI 10.1038/cdd.2010.57; Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Buzzeo MP, 2007, LEUKEMIA, V21, P1619, DOI 10.1038/sj.leu.2404768; Cai YP, 2010, J PATHOL, V220, P24, DOI 10.1002/path.2628; Calo E, 2010, NATURE, V466, P1110, DOI 10.1038/nature09264; Cantiani L, 2007, CANCER RES, V67, P7675, DOI 10.1158/0008-5472.CAN-06-4697; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Cleton-Jansen AM, 2009, BRIT J CANCER, V101, P1909, DOI 10.1038/sj.bjc.6605405; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cormier JN, 2004, CA-CANCER J CLIN, V54, P94, DOI 10.3322/canjclin.54.2.94; Douglas D, 2008, CANCER RES, V68, P6507, DOI 10.1158/0008-5472.CAN-07-6152; Fujii H, 2009, INT J ONCOL, V34, P1381, DOI 10.3892/ijo_00000265; Gangemi RMR, 2009, STEM CELLS, V27, P40, DOI 10.1634/stemcells.2008-0493; Gibbs CP, 2005, NEOPLASIA, V7, P967, DOI 10.1593/neo.05394; Gillette JM, 2008, IN VITRO CELL DEV-AN, V44, P87, DOI 10.1007/s11626-007-9075-8; Gong C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015630; Gutierrez GM, 2008, P NATL ACAD SCI USA, V105, P18402, DOI 10.1073/pnas.0805925105; Heare T, 2009, CURR OPIN PEDIATR, V21, P365, DOI 10.1097/MOP.0b013e32832b1111; Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168; Hong JH, 2006, CELL CYCLE, V5, P176, DOI 10.4161/cc.5.2.2362; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Jia SF, 1999, CLIN EXP METASTAS, V17, P501, DOI 10.1023/A:1006623001465; Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; Kim CF, 2008, CELL STEM CELL, V3, P147, DOI 10.1016/j.stem.2008.07.012; Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551; Lefebvre V, 2007, INT J BIOCHEM CELL B, V39, P2195, DOI 10.1016/j.biocel.2007.05.019; Levings PP, 2009, CANCER RES, V69, P5648, DOI 10.1158/0008-5472.CAN-08-3580; Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297; Mansukhani A, 2005, J CELL BIOL, V168, P1065, DOI 10.1083/jcb.200409182; Marie PJ, 2003, GENE, V316, P23, DOI 10.1016/S0378-1119(03)00748-0; Matushansky I, 2007, J CLIN INVEST, V117, P3248, DOI 10.1172/JCI31377; Milat F, 2009, MOL CELL ENDOCRINOL, V310, P52, DOI 10.1016/j.mce.2009.06.002; Morikawa S, 2009, J EXP MED, V206, P2483, DOI 10.1084/jem.20091046; Niwa H, 2007, DEVELOPMENT, V134, P635, DOI 10.1242/dev.02787; Pevny LH, 2010, INT J BIOCHEM CELL B, V42, P421, DOI 10.1016/j.biocel.2009.08.018; Que JW, 2009, DEVELOPMENT, V136, P1899, DOI 10.1242/dev.034629; Rainusso N, 2011, CANCER BIOL THER, V12, P278, DOI 10.4161/cbt.12.4.15951; Riggi N, 2010, GENE DEV, V24, P916, DOI 10.1101/gad.1899710; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017; TABONE MD, 1994, J CLIN ONCOL, V12, P2614, DOI 10.1200/JCO.1994.12.12.2614; Taelman VF, 2010, CELL, V143, P1136, DOI 10.1016/j.cell.2010.11.034; Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137; Takenobu H, 2011, ONCOGENE, V30, P97, DOI 10.1038/onc.2010.383; Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999-008-0335-z; Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187; Tirino V, 2011, FASEB J, V25, P2022, DOI 10.1096/fj.10-179036; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; WADAYAMA B, 1994, CANCER RES, V54, P3042; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Xiang R, 2011, BRIT J CANCER, V104, P1410, DOI 10.1038/bjc.2011.94; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	59	177	187	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	18					2270	2282		10.1038/onc.2011.405	http://dx.doi.org/10.1038/onc.2011.405			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	936SR	21927024	Green Submitted, Green Accepted			2022-12-17	WOS:000303610800003
J	Lehen'kyi, V; Flourakis, M; Skryma, R; Prevarskaya, N				Lehen'kyi, V.; Flourakis, M.; Skryma, R.; Prevarskaya, N.			TRPV6 channel controls prostate cancer cell proliferation via Ca2+/NFAT-dependent pathways	ONCOGENE			English	Article						prostate cancer; TRPV6; Ca2+ uptake; NFAT; proliferation; LNCaP cells	OPERATED CA2+ CURRENT; EPITHELIAL-CELLS; ANDROGEN RECEPTOR; APOPTOTIC RESISTANCE; STORE DEPLETION; EXPRESSION; HOMEOSTASIS; GROWTH; INVOLVEMENT; PROGRESSION	The transient receptor potential channel, subfamily V, member 6 (TRPV6), is strongly expressed in advanced prostate cancer and significantly correlates with the Gleason > 7 grading, being undetectable in healthy and benign prostate tissues. However, the role of TRPV6 as a highly Ca2+-selective channel in prostate carcinogenesis remains poorly understood. Here, we report that TRPV6 is directly involved in the control of prostate cancer cell (LNCaP cell line) proliferation by decreasing: (i) proliferation rate; (ii) cell accumulation in the S-phase of cell cycle and (iii) proliferating cell nuclear antigen (PCNA) expression. We demonstrate that the Ca2+ uptake into LNCaP cells is mediated by TRPV6, with the subsequent downstream activation of the nuclear factor of activated T-cell transcription factor (NFAT). TRPV6-mediated Ca2+ entry is also involved in apoptosis resistance of LNCaP cells. Our results suggest that TRPV6 expression in LNCaP cells is regulated by androgen receptor, however, in a ligand-independent manner. We conclude that the upregulation of TRPV6 Ca2+ channel in prostate cancer cells may represent a mechanism for maintaining a higher proliferation rate, increasing cell survival and apoptosis resistance as well.	Univ Sci & Tech Lille, INSERM, Lab Cell Physiol, Villeneuve Dascq, France; INSERM, Equipe Ligue Natl Contre Canc, Villeneuve Dascq, France; Univ Sci & Tech Lille, Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Prevarskaya, N (corresponding author), Univ Sci & Tech Lille, INSERM, Lab Cell Physiol, Bat SN3, Villeneuve Dascq, France.	natacha.prevarskaya@univ-lille1.fr		Flourakis, Matthieu/0000-0002-5366-9125; LEHEN'KYI, V'yacheslav/0000-0003-0806-8766; Prevarskaya, natacha/0000-0003-0316-197X				Bidaux G, 2005, ENDOCR-RELAT CANCER, V12, P367, DOI 10.1677/erc.1.00969; Bodding M, 2004, J BIOL CHEM, V279, P36546, DOI 10.1074/jbc.M404679200; Bodding M, 2003, J BIOL CHEM, V278, P50872, DOI 10.1074/jbc.M308800200; Burnstein KL, 2005, J CELL BIOCHEM, V95, P657, DOI 10.1002/jcb.20460; Cooperberg MR, 2005, J CLIN ONCOL, V23, P8146, DOI 10.1200/JCO.2005.02.9751; Fixemer T, 2003, ONCOGENE, V22, P7858, DOI 10.1038/sj.onc.1206895; Korkmaz KS, 2002, J BIOL CHEM, V277, P36689, DOI 10.1074/jbc.M202414200; Legrand G, 2001, J BIOL CHEM, V276, P47608, DOI 10.1074/jbc.M107011200; Lipskaia L, 2004, BIOL CELL, V96, P55, DOI 10.1016/j.biolcel.2003.11.001; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Peng JB, 2001, BIOCHEM BIOPH RES CO, V282, P729, DOI 10.1006/bbrc.2001.4638; Prevarskaya N, 2004, BIOCHEM BIOPH RES CO, V322, P1326, DOI 10.1016/j.bbrc.2004.08.037; Schindl R, 2002, J BIOL CHEM, V277, P26950, DOI 10.1074/jbc.M203700200; Schwarz EC, 2006, CELL CALCIUM, V39, P163, DOI 10.1016/j.ceca.2005.10.006; Skryma R, 2000, J PHYSIOL-LONDON, V527, P71, DOI 10.1111/j.1469-7793.2000.00071.x; Thebault S, 2006, CANCER RES, V66, P2038, DOI 10.1158/0008-5472.CAN-05-0376; Vanden Abeele F, 2004, J BIOL CHEM, V279, P30326, DOI 10.1074/jbc.M400106200; Vanden Abeele F, 2002, CANCER CELL, V1, P169; Vanden Abeele F, 2003, J BIOL CHEM, V278, P15381, DOI 10.1074/jbc.M212106200; Vanoverberghe K, 2004, CELL DEATH DIFFER, V11, P321, DOI 10.1038/sj.cdd.4401375; Wang LG, 1999, BIOCHEM BIOPH RES CO, V259, P21, DOI 10.1006/bbrc.1999.0655; Wang TT, 2005, MOL ENDOCRINOL, V19, P2685, DOI 10.1210/me.2005-0106; Wissenbach U, 2004, BIOCHEM BIOPH RES CO, V322, P1359, DOI 10.1016/j.bbrc.2004.08.042; Xiao F, 2005, MOL ENDOCRINOL, V19, P2964, DOI 10.1210/me.2004-0408	24	177	184	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2007	26	52					7380	7385		10.1038/sj.onc.1210545	http://dx.doi.org/10.1038/sj.onc.1210545			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17533368	Green Submitted			2022-12-17	WOS:000250955700010
J	Sims-Mourtada, J; Izzo, JG; Ajani, J; Chao, KSC				Sims-Mourtada, J.; Izzo, J. G.; Ajani, J.; Chao, K. S. C.			Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport	ONCOGENE			English	Article						hedgehog; multiple drug resistance; drug transport; chemoresistance	MULTIDRUG-RESISTANCE; STEM-CELLS; MUTATIONS; PTCH	A major obstacle to successful chemotherapy is intrinsic or acquired multi-drug resistance (MDR). The most common cause of MDR involves increased drug efflux from cancer cells mediated by members of the ATP-binding cassette (ABC) transporter family. The regulation of ABC transporters in the context of cancer is poorly understood, and clinical efforts to inhibit their function have not been fruitful. Constitutive activation of the Hedgehog (Hh) pathway has been shown to contribute to the growth and maintenance of various cancers. Here, we show that inhibition of Hh signaling increases the response of cancer cells to multiple structurally unrelated chemotherapies. We further show that Hh pathway activation induces chemoresistance in part by increasing drug efflux in an ABC transporter-dependent manner. We found that Hh signaling regulates the expression of the ABC transporter proteins multi-drug resistance protein-1 (MDR1, ABCB1, P-glycoprotein) and (BCRP, ABCG2), and that targeted knockdown of MDR1 and BCRP expression by small interfering RNA partially reverses Hh-induced chemoresistance. These results suggest that the Hh pathway may be a target to overcome MDR and increase chemotherapeutic response.	Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Chao, KSC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, 1515 Holcombe Blvd,Unit 97, Houston, TX 77030 USA.	cchao@mdanderson.org			NATIONAL CANCER INSTITUTE [R21CA121551, P50CA097007, R01CA089198] Funding Source: NIH RePORTER; NCI NIH HHS [CA89198, P50 CA97007, CA121551] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Bunting KD, 2000, BLOOD, V96, P902, DOI 10.1182/blood.V96.3.902.015k40_902_909; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chintamani, 2005, WORLD J SURG ONCOL, V3, P61; Doyle LA, 2003, ONCOGENE, V22, P7340, DOI 10.1038/sj.onc.1206938; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Kubo A, 2004, AM J GASTROENTEROL, V99, P582, DOI 10.1111/j.1572-0241.2004.04131.x; Lindstrom E, 2006, HUM MUTAT, V27, P215, DOI 10.1002/humu.20296; Okano-Uchida T, 2004, P NATL ACAD SCI USA, V101, P1211, DOI 10.1073/pnas.0307972100; Perez-Tomas R, 2006, CURR MED CHEM, V13, P1859, DOI 10.2174/092986706777585077; Reifenberger J, 2005, BRIT J DERMATOL, V152, P43, DOI 10.1111/J.1365-2133.2005.06353.X; Ruel L, 2003, NAT CELL BIOL, V5, P907, DOI 10.1038/ncb1052; Sims-Mourtada J, 2006, CLIN CANCER RES, V12, P6565, DOI 10.1158/1078-0432.CCR-06-0176; Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984; Takara K, 2006, CURR PHARM DESIGN, V12, P273, DOI 10.2174/138161206775201965; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	17	177	185	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	38					5674	5679		10.1038/sj.onc.1210356	http://dx.doi.org/10.1038/sj.onc.1210356			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17353904				2022-12-17	WOS:000248801900014
J	Chauhan, D; Velankar, M; Brahmandam, M; Hideshima, T; Podar, K; Richardson, P; Schlossman, R; Ghobrial, I; Raje, N; Munshi, N; Anderson, KC				Chauhan, D.; Velankar, M.; Brahmandam, M.; Hideshima, T.; Podar, K.; Richardson, P.; Schlossman, R.; Ghobrial, I.; Raje, N.; Munshi, N.; Anderson, K. C.			A novel Bcl-2/Bcl-X-L/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma	ONCOGENE			English	Article						multiple myeloma; mitochondria; apoptosis; Bcl-2	BCL-2 FAMILY; INDUCED APOPTOSIS; CELLS; DEXAMETHASONE; ACTIVATION; MCL-1	Bcl-2 or Bcl-X-L confers resistance to chemotherapy in multiple myeloma ( MM). Here we characterized the effects of ABT-737, a potent small-molecule inhibitor of antiapoptotic proteins Bcl-2, Bcl-X-L and Bcl-w with markedly higher affinity than previously reported compounds, on human MM cells. ABT-737 induces apoptosis in MM cells, including those resistant to conventional therapy. Examination of purified patient MM cells demonstrated similar results, without significant toxicity against normal peripheral blood mononuclear cells and MM bone marrow stromal cells. Importantly, ABT-737 decreases the viability of bortezomib-, dexamethasone-(Dex) and thalidomide-refractory patient MM cells. Additionally, ABT-737 abrogates MM cell growth triggered by interleukin-6 or insulin-like growth factor-1. Mechanistic studies show that ABT-737-induced apoptosis is associated with activation of caspase-8, caspase-9 and caspase-3, followed by poly(ADP-ribose) polymerase cleavage. Combining ABT- 737 with proteasome inhibitor bortezomib, melphalan or dexamethasone induces additive anti-MM activity. Taken together, our study provides the rationale for clinical protocols evaluating ABT-737, alone and together with botezomib, mephalan or dexamethasone, to enhance MM cell killing, overcome drug resistance conferred by Bcl-2 and improve patient outcome in MM.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Anderson, KC (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.	Kenneth_anderson@dfci.harvard.edu	Munshi, Nikhil/ABE-2338-2021; Podar, Klaus/ABD-1112-2020	Podar, Klaus/0000-0002-7414-3632	NATIONAL CANCER INSTITUTE [R01CA050947] Funding Source: NIH RePORTER; NCI NIH HHS [IP50CA10070, P0-1 CA 78373, R0-1 CA50947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bossy-Wetzel E, 1999, MUTAT RES-DNA REPAIR, V434, P243, DOI 10.1016/S0921-8777(99)00032-4; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chauhan D, 2005, CANCER CELL, V8, P407, DOI 10.1016/j.ccr.2005.10.013; Chauhan D, 2005, ANNU REV PHARMACOL, V45, P465, DOI 10.1146/annurev.pharmtox.45.120403.100037; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cory S, 2005, CANCER CELL, V8, P5, DOI 10.1016/j.ccr.2005.06.012; Dalton WS, 2002, CLIN CANCER RES, V8, P3643; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Gazitt Y, 1998, INT J ONCOL, V13, P397; HARDIN J, 1994, BLOOD, V84, P3063; Jelinek DF, 1997, J IMMUNOL, V159, P487; Kluck RM, 1997, APOPTOSIS, V2, P337; Le Gouill S, 2004, BLOOD, V104, P2886, DOI 10.1182/blood-2004-05-1760; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Liu Q, 2003, BLOOD, V101, P4105, DOI 10.1182/blood-2002-10-3067; Mitsiades N, 2003, BLOOD, V101, P4055, DOI 10.1182/blood-2002-11-3514; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Perez-Galan P, 2006, BLOOD, V107, P257, DOI 10.1182/blood-2005-05-2091; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; van de Donk NWCJ, 2003, LEUKEMIA, V17, P211, DOI 10.1038/sj.leu.2402768; Wuilleme-Toumi S, 2005, LEUKEMIA, V19, P1248, DOI 10.1038/sj.leu.2403784; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xu FH, 1997, BRIT J HAEMATOL, V97, P429, DOI 10.1046/j.1365-2141.1997.592708.x; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	27	177	183	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2374	2380		10.1038/sj.onc.1210028	http://dx.doi.org/10.1038/sj.onc.1210028			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016430				2022-12-17	WOS:000245466000013
J	Curry, CL; Reed, LL; Golde, TE; Miele, L; Nickoloff, BJ; Foreman, KE				Curry, CL; Reed, LL; Golde, TE; Miele, L; Nickoloff, BJ; Foreman, KE			Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells	ONCOGENE			English	Article						Kaposi's sarcoma; Notch; gamma-secretase; apoptosis; growth arrest; KSHV	NF-KAPPA-B; EMBRYONIC LETHALITY; HUMAN KERATINOCYTES; ENDOTHELIAL-CELLS; MAMMALIAN NOTCH; EXPRESSION; DIFFERENTIATION; PATHWAY; GENE; TRANSFORMATION	Kaposi's sarcoma (KS) is a common neoplasm in HIV-1-infected individuals causing significant morbidity and mortality. Despite recent advances, the pathogenesis of this potentially life-threatening neoplasm remains unclear, and there is currently no cure for KS. Notch proteins are known to play a fundamental role in cell fate decisions including proliferation, differentiation, and apoptosis. It is, therefore, not surprising that Notch proteins have been implicated in tumorigenesis and appear to function as either oncogenes or tumor suppressor proteins depending on cellular context. In this report, we demonstrate elevated levels of activated Notch-1, -2, and -4 in KS tumor cells in vivo and in vitro compared to endothelial cells, the precursor of the KS cell. Notch activation was confirmed through luciferase reporter assays and localization of Hes (Hairy/Enhancer of Split)-1 and Hey (Hairy/Enhancer of Split related with YRPW)1 (primary targets of the Notch pathway) in KS cell nuclei. Studies using gamma-secretase inhibitors (GSI and LY- 411,575), which block Notch activation, resulted in apoptosis in primary and immortalized KS cells. Similar studies injecting GSI into established KS cell tumors on mice demonstrated growth inhibition or tumor regression that was characterized by apoptosis in treated, but not control tumors. The results indicate that KS cells overexpress activated Notch and interruption of Notch signaling inhibits KS cell growth. Thus, targeting Notch signaling may be of therapeutic value in KS patients.	Loyola Univ, Med Ctr, Dept Pathol, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Inst Oncol, Maywood, IL USA; Loyola Univ, Med Ctr, Dept Microbiol & Immunol, Maywood, IL USA; Mayo Clin, Dept Neurosci, Jacksonville, FL USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; Mayo Clinic	Foreman, KE (corresponding author), Loyola Univ, Med Ctr, Dept Pathol, 2160 S 1st Ave, Maywood, IL 60153 USA.	kforema@lumc.edu		Curry, Christine L/0000-0003-4783-9623; Miele, Lucio/0000-0002-5853-7287	NATIONAL CANCER INSTITUTE [P01CA059327, R21CA108450] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA59327, CA108450] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Cheng PY, 2001, J IMMUNOL, V167, P4458, DOI 10.4049/jimmunol.167.8.4458; da Costa CA, 2004, J NEUROCHEM, V90, P800, DOI 10.1111/j.1471-4159.2004.02512.x; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Foreman KE, 1996, AM J PATHOL, V149, P795; Gallahan D, 1996, CANCER RES, V56, P1775; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Hayward SD, 2004, SEMIN CANCER BIOL, V14, P387, DOI 10.1016/j.semcancer.2004.04.018; HERNDIER BG, 1994, AIDS, V8, P575, DOI 10.1097/00002030-199405000-00002; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Iso T, 2002, J BIOL CHEM, V277, P6598, DOI 10.1074/jbc.M110495200; Iso T, 2001, MOL CELL BIOL, V21, P6080, DOI 10.1128/MCB.21.17.6080-6089.2001; Jang MS, 2004, J CELL PHYSIOL, V199, P418, DOI 10.1002/jcp.10467; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Lanz TA, 2004, J PHARMACOL EXP THER, V309, P49, DOI 10.1124/jpet.103.060715; Lathion S, 2003, CANCER RES, V63, P8687; Leimeister C, 2000, MECH DEVELOP, V98, P175, DOI 10.1016/S0925-4773(00)00459-7; Lu C, 2002, ARCH PATHOL LAB MED, V126, P941; Luo B, 1997, MOL CELL BIOL, V17, P6057, DOI 10.1128/MCB.17.10.6057; Maier MM, 2000, BIOCHEM BIOPH RES CO, V275, P652, DOI 10.1006/bbrc.2000.3354; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Qin JZ, 2004, MOL CANCER THER, V3, P895; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Shimazaki T, 2001, J NEUROSCI, V21, P7642, DOI 10.1523/JNEUROSCI.21-19-07642.2001; Shutter JR, 2000, GENE DEV, V14, P1313; Soriano JV, 2000, INT J CANCER, V86, P652; Tang J, 2003, J VIROL, V77, P5975, DOI 10.1128/JVI.77.10.5975-5984.2003; Tsai S, 2000, BLOOD, V96, P950, DOI 10.1182/blood.V96.3.950.015k43_950_957; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Weijzen S, 2003, J CELL PHYSIOL, V194, P356, DOI 10.1002/jcp.10217; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	49	177	204	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6333	6344		10.1038/sj.onc.1208783	http://dx.doi.org/10.1038/sj.onc.1208783			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	15940249				2022-12-17	WOS:000232038200001
J	Sutherland, KD; Lindeman, GJ; Choong, DYH; Wittlin, S; Brentzell, L; Phillips, W; Campbell, IG; Visvader, JE				Sutherland, KD; Lindeman, GJ; Choong, DYH; Wittlin, S; Brentzell, L; Phillips, W; Campbell, IG; Visvader, JE			Differential hypermethylation of SOCS genes in ovarian and breast carcinomas	ONCOGENE			English	Article						suppressor of cytokine signaling (SOCS); ovary; breast; carcinoma; tumor suppressor	CONSTITUTIVE EXPRESSION; NEGATIVE REGULATOR; METHYLATION; PROTEIN; GROWTH; SUPPRESSOR; BINDING; KINASE; BOX	Suppressor of cytokine signaling ( SOCS) proteins have emerged as critical attenuators of cytokine-mediated processes, suggesting a role in the suppression of tumorigenesis. In the ovary and mammary gland, cytokines such as prolactin and IL-6 are important regulators of growth and differentiation. We have investigated whether silencing or inactivation of SOCS genes occurs in ovarian and breast carcinomas. The SOCS1 and SOCS2 CpG islands were found to be hypermethylated in 23 and 14% of primary ovarian cancers, respectively, whereas only SOCS1 was methylated in breast cancers (9%). Methylation of these genes did not occur in normal tissues. No correlation was apparent between methylation and loss of heterozygosity, and no somatic mutations were found in a large panel of carcinomas. Aberrant methylation of these SOCS genes correlated with transcriptional silencing in ovarian and breast cancer cell lines, since expression was induced by the demethylating agent 5-azadeoxycytidine. SOCS3 was not hypermethylated in either cancer type. Consistent with this data, SOCS1 and SOCS2 but not SOCS3 suppressed the growth of ovarian and breast cancer cells. Hypermethylation and silencing of specific SOCS genes in the ovary, and to a lesser extent in breast, may augment cytokine responsiveness in these tissues, thereby contributing to oncogenesis.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Bone Marrow Res Labs, Parkville, Vic 3050, Australia; Peter MacCallum Canc Ctr, Melbourne, Vic 8006, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; Peter Maccallum Cancer Center	Visvader, JE (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia.	visvader@wehi.edu.au	campbell, Ian G/F-6006-2011; Phillips, Wayne A/H-8070-2013	Phillips, Wayne A/0000-0002-7961-638X; Sutherland, Kate/0000-0002-7453-3366; Lindeman, Geoffrey/0000-0001-9386-2416; Campbell, Ian/0000-0002-7773-4155				Brender C, 2001, BLOOD, V97, P1056, DOI 10.1182/blood.V97.4.1056; Catteau A, 2002, SEMIN CANCER BIOL, V12, P359, DOI 10.1016/S1044-579X(02)00056-1; CHAUBERT P, 1993, BIOTECHNIQUES, V15, P586; Chen CY, 2003, GENE CHROMOSOME CANC, V37, P300, DOI 10.1002/gcc.10222; Dobrovic A, 2002, METHODS, V27, P134, DOI 10.1016/S1046-2023(02)00065-8; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Fukushima N, 2003, BRIT J CANCER, V89, P338, DOI 10.1038/sj.bjc.6601039; Galm O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735; GRAFF JR, 1995, CANCER RES, V55, P5195; Grosdemouge Isabelle, 2003, Reprod Biol Endocrinol, V1, P12, DOI 10.1186/1477-7827-1-12; Guilleret I, 2002, INT J CANCER, V101, P335, DOI 10.1002/ijc.10593; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Helman D, 1998, FEBS LETT, V441, P287, DOI 10.1016/S0014-5793(98)01555-5; Herman JG, 1996, CANCER RES, V56, P722; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Horseman ND, 1997, EMBO J, V16, P6926, DOI 10.1093/emboj/16.23.6926; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kaulsay KK, 1999, EXP CELL RES, V250, P35, DOI 10.1006/excr.1999.4492; Lindeman GJ, 2001, GENE DEV, V15, P1631, DOI 10.1101/gad.880801; MACHELON V, 1994, CELL MOL BIOL, V40, P373; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nash MA, 1999, ENDOCR-RELAT CANCER, V6, P93, DOI 10.1677/erc.0.0060093; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Pezet A, 1999, J BIOL CHEM, V274, P24497, DOI 10.1074/jbc.274.35.24497; Raccurt M, 2003, BRIT J CANCER, V89, P524, DOI 10.1038/sj.bjc.6601115; Ram PK, 2000, J BIOL CHEM, V275, P39487, DOI 10.1074/jbc.M004755200; Rottapel R, 2002, ONCOGENE, V21, P4351, DOI 10.1038/sj.onc.1205537; Sakai I, 2002, BLOOD, V100, P2926, DOI 10.1182/blood-2002-01-0073; SILBERSTEIN GB, 1987, J DAIRY SCI, V70, P1981, DOI 10.3168/jds.S0022-0302(87)80240-0; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tam SP, 2001, ENDOCRINOLOGY, V142, P5015, DOI 10.1210/en.142.11.5015; Tomic S, 1999, MOL CELL ENDOCRINOL, V158, P45, DOI 10.1016/S0303-7207(99)00180-X; Xiao WZ, 2001, HUM MUTAT, V17, P439, DOI 10.1002/humu.1130.abs; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zhao L, 2002, MOL ENDOCRINOL, V16, P2902, DOI 10.1210/me.2001-0330	38	177	192	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7726	7733		10.1038/sj.onc.1207787	http://dx.doi.org/10.1038/sj.onc.1207787			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361843				2022-12-17	WOS:000224306700014
J	Luo, AP; Kong, JP; Hu, GX; Liew, CC; Xiong, MM; Wang, XQ; Ji, JF; Wang, T; Zhi, HY; Wu, M; Liu, ZH				Luo, AP; Kong, JP; Hu, GX; Liew, CC; Xiong, MM; Wang, XQ; Ji, JF; Wang, T; Zhi, HY; Wu, M; Liu, ZH			Discovery of Ca2+-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray	ONCOGENE			English	Article						differentiation; calcium; cell envelope; esophageal squamous cell carcinoma; cDNA microarray	PROLINE-RICH PROTEINS; ANNEXIN-I; TERMINAL DIFFERENTIATION; TRANSCRIPTION FACTORS; CORNIFIED ENVELOPE; BARRIER FUNCTION; KERATIN 4; EXPRESSION; CANCER; OVEREXPRESSION	To identify genes that are differentially expressed in human esophageal squamous cell carcinoma (ESCC), we have developed a cDNA microarray representing 34 176 clones to analyse gene expression profiles in ESCC. A total of 77 genes ( including 31 novel genes) were downregulated, and 15 genes ( including one novel gene) were upregulated in cancer tissues compared with their normal counterparts. Immunohistochemistry and Northern blot analysis were carried out to verify the cDNA microarray results. It was revealed that genes involved in squamous cell differentiation were coordinately downregulated, including annexin I, small proline-rich proteins (SPRRs), calcium-binding S100 proteins (S100A8, S100A9), transglutaminase (TGM3), cytokeratins (KRT4, KRT13), gut-enriched Krupple-like factor ( GKLF) and cystatin A. Interestingly, most of the downregulated genes encoded Ca2+-binding or - modulating proteins that constitute the cell envelope (CE). Moreover, genes associated with invasion or proliferation were upregulated, including genes such as fibronectin, secreted protein acidic and rich in cystein ( SPARC), cathepsin B and KRT17. Functional analysis of the alteration in the expression of GKLF suggested that GKLF might be able to regulate the expression of SPRR1A, SPRR2A and KRT4 in ESCC. This study provides new insights into the role of squamous cell differentiation-associated genes in ESCC initiation and progression.	Chinese Acad Med Sci, Inst Canc, Natl Lab Mol Oncol, Beijing 100021, Peoples R China; Peking Union Med Coll, Beijing 100021, Peoples R China; Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Univ Texas, Ctr Human Genet, Houston, TX 77030 USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Texas System	Liu, ZH (corresponding author), Chinese Acad Med Sci, Inst Canc, Natl Lab Mol Oncol, Beijing 100021, Peoples R China.	liuzh@pubem.cicams.ac.cn						Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; BANKSSCHLEGEL SP, 1986, CANCER RES, V46, P250; Bikle DD, 2001, MOL CELL ENDOCRINOL, V177, P161, DOI 10.1016/S0303-7207(01)00452-X; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; Busatto G, 1998, J CLIN PATHOL-MOL PA, V51, P80, DOI 10.1136/mp.51.2.80; Chang S, 1999, Wei Sheng Yan Jiu, V28, P364; Dotto GP, 1999, CRIT REV ORAL BIOL M, V10, P442; Fischer DF, 1999, GENOMICS, V55, P88, DOI 10.1006/geno.1998.5622; Frey BM, 1999, FASEB J, V13, P2235, DOI 10.1096/fasebj.13.15.2235; Gebhardt C, 2002, ONCOGENE, V21, P4266, DOI 10.1038/sj.onc.1205521; Geboes K, 1978, Front Gastrointest Res, V3, P1; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Hu YC, 2001, CLIN CANCER RES, V7, P2213; Ishizuka T, 2002, BIOCHEM BIOPH RES CO, V296, P152, DOI 10.1016/S0006-291X(02)00836-7; JANKOWSKI J, 1993, EUR J GASTROEN HEPAT, V5, P235, DOI 10.1097/00042737-199304000-00008; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; Jones SJ, 1997, J INVEST DERMATOL, V109, P187, DOI 10.1111/1523-1747.ep12319308; Katz JP, 2002, DEVELOPMENT, V129, P2619; Kerkhoff C, 1998, BBA-MOL CELL RES, V1448, P200, DOI 10.1016/S0167-4889(98)00144-X; Koch PJ, 2000, J CELL BIOL, V151, P389, DOI 10.1083/jcb.151.2.389; Lam KY, 1997, INT J CANCER, V74, P212, DOI 10.1002/(SICI)1097-0215(19970422)74:2<212::AID-IJC13>3.3.CO;2-U; Li W, 1998, Wei Sheng Yan Jiu, V27, P69; Liew CC, 1997, MOL CELL BIOCHEM, V172, P81, DOI 10.1023/A:1006811403996; Lu JY, 2001, INT J CANCER, V91, P288, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1063>3.0.CO;2-S; Ma SH, 1997, GENE EXPRESSION, V6, P361; Marenholz I, 1996, GENOMICS, V37, P295, DOI 10.1006/geno.1996.0563; Montesano R, 1996, INT J CANCER, V69, P225, DOI 10.1002/(SICI)1097-0215(19960621)69:3<225::AID-IJC13>3.0.CO;2-6; Moore RC, 1998, CELL MOTIL CYTOSKEL, V41, P168, DOI 10.1002/(SICI)1097-0169(1998)41:2<168::AID-CM7>3.0.CO;2-A; Nagasawa S, 2001, J SURG ONCOL, V78, P208, DOI 10.1002/jso.1152; Ness SL, 1998, J BIOL CHEM, V273, P23904, DOI 10.1074/jbc.273.37.23904; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; Seery JP, 2000, CURR BIOL, V10, P1447, DOI 10.1016/S0960-9822(00)00803-4; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Steinert PM, 1998, J BIOL CHEM, V273, P11758, DOI 10.1074/jbc.273.19.11758; STEVEN AC, 1994, J CELL SCI, V107, P693; Suzuki H, 1997, CANCER INVEST, V15, P411, DOI 10.3109/07357909709047579; THIEL C, 1992, J CELL SCI, V103, P733; Turksen K, 2002, DEVELOPMENT, V129, P1775; van Dorst EBL, 1998, J CLIN PATHOL, V51, P679, DOI 10.1136/jcp.51.9.679; Wang Q, 2002, CANCER LETT, V179, P71, DOI 10.1016/S0304-3835(01)00846-1; Xia SH, 2002, ONCOGENE, V21, P6641, DOI 10.1038/sj.onc.1205818; Xu L, 2001, CANCER RES, V61, P3176; Xu Y, 2002, CANCER RES, V62, P3493; Yamazaki M, 1997, DNA SEQUENCE, V8, P71, DOI 10.3109/10425179709020888; Zhang WH, 2000, AM J HUM GENET, V67, P110, DOI 10.1086/302970	49	177	203	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1291	1299		10.1038/sj.onc.1207218	http://dx.doi.org/10.1038/sj.onc.1207218			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647409				2022-12-17	WOS:000188892200014
J	Evans, JR; Mitchell, SA; Spriggs, KA; Ostrowski, J; Bomsztyk, K; Ostarek, D; Willis, AE				Evans, JR; Mitchell, SA; Spriggs, KA; Ostrowski, J; Bomsztyk, K; Ostarek, D; Willis, AE			Members of the poly (rC) binding protein family stimulate the activity of the c-myc internal ribosome entry segment in vitro and in vivo	ONCOGENE			English	Article						c-myc; translation; internal ribosome entry; IRES; poly (rC) binding proteins	NUCLEAR RIBONUCLEOPROTEIN-K; SITE-MEDIATED TRANSLATION; DOMAIN PROTEINS; HNRNP K; INITIATION; IRES; REGION; ONCOGENE; LEADS; GENE	The 5' untranslated region of the proto-oncogene c-myc contains an internal ribosome entry segment and c-Myc translation can be initiated by cap-independent as well as cap-dependent mechanisms. In contrast to the process of cap-dependent initiation, the trans-acting factor requirements for cellular internal ribosome entry are poorly understood. Here, we show that members of the poly (rC) binding protein family, poly (rC) binding protein 1 (PCBP1), poly (rC) binding protein 2 (PCBP2) and hnRNPK were able to activate the IRES in vitro up to threefold when added in combination with upstream of N-ras and unr-interacting protein. The interactions of PCBP1, PCBP2 and hnRNPK with c-myc-IRES-RNA were shown to be specific by ultraviolet crosslinking analysis and electrophoretic mobility shift assays, while immunoprecipitation of the three proteins using specific antibodies followed by reverse transcriptase-polymerase chain reaction showed that they were able to bind c-myc mRNA. c-myc-IRES-mediated translation from the reporter vector was stimulated by cotransfection of plasmids encoding PCBP1, PCBP2 and hnRNPK. Interestingly, the mutated version of the c-myc IRES that is prevalent in patients with multiple myeloma bound hnRNPK more efficiently in vitro and was stimulated by hnRNPK to a greater extent in vivo.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Washington, Seattle, WA 98195 USA; Univ Halle Wittenberg, Dept Biochem, D-06210 Halle An Der Saale, Germany	University of Leicester; University of Washington; University of Washington Seattle; Martin Luther University Halle Wittenberg	Willis, AE (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	aew5@le.ac.uk		Ostrowski, Jerzy/0000-0003-1363-3766; Ostareck, Dirk/0000-0001-9406-7190; Willis, Anne/0000-0002-1470-8531				Andino R, 1999, TRENDS MICROBIOL, V7, P76, DOI 10.1016/S0966-842X(98)01446-2; BLACK DL, 1998, ELECTROPHORETIC MOBI; Chappell SA, 2000, ONCOGENE, V19, P4437, DOI 10.1038/sj.onc.1203791; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; Creancier L, 2001, MOL CELL BIOL, V21, P1833, DOI 10.1128/MCB.21.5.1833-1840.2001; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Gamarnik AV, 1997, RNA, V3, P882; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Henis-Korenblit S, 2002, P NATL ACAD SCI USA, V99, P5400, DOI 10.1073/pnas.082102499; Holcik M, 2003, MOL CELL BIOL, V23, P280, DOI 10.1128/MCB.23.1.280-288.2003; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Holcik M, 1997, P NATL ACAD SCI USA, V94, P2410, DOI 10.1073/pnas.94.6.2410; Hunt SL, 1999, GENE DEV, V13, P437, DOI 10.1101/gad.13.4.437; Jopling CL, 2001, ONCOGENE, V20, P2664, DOI 10.1038/sj.onc.1204404; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kim JH, 2000, J MOL BIOL, V298, P395, DOI 10.1006/jmbi.2000.3687; Le Quesne JPC, 2001, J MOL BIOL, V310, P111, DOI 10.1006/jmbi.2001.4745; Lomakin IB, 2000, MOL CELL BIOL, V20, P6019, DOI 10.1128/MCB.20.16.6019-6029.2000; Makeyev AV, 2002, RNA, V8, P265, DOI 10.1017/S1355838202024627; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; Mitchell SA, 2003, MOL CELL, V11, P757, DOI 10.1016/S1097-2765(03)00093-5; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; NIESVIZKY R, 1993, BLOOD REV, V7, P24, DOI 10.1016/0268-960X(93)90021-U; Niranjanakumari S, 2002, METHODS, V26, P182, DOI 10.1016/S1046-2023(02)00021-X; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Ostareck-Lederer A, 1998, TRENDS BIOCHEM SCI, V23, P409, DOI 10.1016/S0968-0004(98)01301-2; Ostrowski J, 2002, J BIOL CHEM, V277, P6303, DOI 10.1074/jbc.M110267200; Paulin FEM, 1996, ONCOGENE, V13, P505; Paulin FEM, 1998, NUCLEIC ACIDS RES, V26, P3097, DOI 10.1093/nar/26.13.3097; Pilipenko EV, 2000, GENE DEV, V14, P2028; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; STONELEY M, 1998, THESIS U LEICESTER; Thisted T, 2001, J BIOL CHEM, V276, P17484, DOI 10.1074/jbc.M010594200; VANSEUNINGEN I, 1995, BIOCHEMISTRY-US, V34, P5644, DOI 10.1021/bi00016a040; Walter BL, 1999, RNA, V5, P1570, DOI 10.1017/S1355838299991483; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; West MJ, 1995, ONCOGENE, V11, P2515	43	177	187	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					8012	8020		10.1038/sj.onc.1206645	http://dx.doi.org/10.1038/sj.onc.1206645			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970749				2022-12-17	WOS:000185388200016
J	Grant, DS; Yenisey, C; Rose, RW; Tootell, M; Santra, M; Iozzo, RV				Grant, DS; Yenisey, C; Rose, RW; Tootell, M; Santra, M; Iozzo, RV			Decorin suppresses tumor cell-mediated angiogenesis	ONCOGENE			English	Article						decorin proteoglycan; angiogenesis; migration, attachment; vascular endothelial cell growth factor	GROWTH-FACTOR-RECEPTOR; HEPARAN-SULFATE PROTEOGLYCANS; CAPILLARY ENDOTHELIAL-CELLS; CYCLIN-DEPENDENT KINASES; PROTEIN CORE; GENE-EXPRESSION; COLLAGEN FIBRILLOGENESIS; RIBONUCLEASE INHIBITOR; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION	The progressive growth of most neoplasms is dependent upon the establishment of new blood vessels, a process regulated by tumor-secreted factors and matrix proteins. We examined the in vitro and in vivo angiogenic ability of conditioned media obtained from fibrosarcoma, carcinoma, and osteosarcoma cells and their decorin-transfected counterparts. Human endothelial cells were investigated in vitro by evaluating three essential steps of angiogenesis: migration, attachment, and differentiation. On the whole, wild-type tumor cell-secretions enhanced endothelial cell attachment, migration, and differentiation, whereas their decorin-expressing forms inhibited these processes. Similarly, decorin-containing media suppressed endothelial cell sprouting in an ex vivo aortic ring assay. Since angiogenesis is an important component of tumor expansion, the growth rate of these cells as tumor xenografts was examined by implantation in nude mice. In vivo, the decorin-expressing tumor xenografts grew at markedly lower rates and showed a significant suppression of neovascularization. Immunohistochemical, Northern and Western blot analyses indicated that the decorin-expressing cells produced vascular endothelial growth factor (VEGF) at markedly reduced rates vis-a-vis their wild-type counterparts. Specificity of this process was confirmed by experiments where addition of recombinant decorin to the wild-type tumor cells caused 80-95% suppression of VEGF mRNA and protein. These results provide a novel mechanism of action for decorin, and indicate that decorin could adversely affect in vivo tumor growth by suppressing the endogenous tumor cell production of a powerful angiogenic stimulus.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Dept Med, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Room 249 Jefferson Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.		Iozzo, Renato/AAS-1980-2020	Yenisey, Cigdem/0000-0001-7693-641X; Iozzo, Renato/0000-0002-5908-5112	NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA47282, R01 CA39481] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE T, 1993, J CLIN INVEST, V92, P54, DOI 10.1172/JCI116599; ADANY R, 1990, J BIOL CHEM, V265, P11389; ALBINI A, 1987, CANCER RES, V47, P3239; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; Balsari A, 1999, LAB INVEST, V79, P897; BIANCO P, 1993, DERMATAN SULPHATE PR, P193; BIDANSET DJ, 1992, J CELL BIOL, V118, P1523, DOI 10.1083/jcb.118.6.1523; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; COPPOCK DL, 1993, CELL GROWTH DIFFER, V4, P483; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Davies CD, 2001, MICROVASC RES, V62, P26, DOI 10.1006/mvre.2001.2311; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; GARRIDO T, 1995, BRIT J CANCER, V71, P770, DOI 10.1038/bjc.1995.149; Ghiselli G, 2001, BIOCHEM J, V359, P153, DOI 10.1042/0264-6021:3590153; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; JARVELAINEN HT, 1992, EXP CELL RES, V203, P395, DOI 10.1016/0014-4827(92)90013-X; JARVELAINEN HT, 1991, J BIOL CHEM, V266, P23274; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; Kinsella MG, 2000, J BIOL CHEM, V275, P13924, DOI 10.1074/jbc.275.18.13924; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; Klezovitch O, 1998, J BIOL CHEM, V273, P23856, DOI 10.1074/jbc.273.37.23856; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Kresse H, 2001, J CELL PHYSIOL, V189, P266, DOI 10.1002/jcp.10030; MANN DM, 1990, J BIOL CHEM, V265, P5317; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; Mongiat M, 2000, J BIOL CHEM, V275, P7095, DOI 10.1074/jbc.275.10.7095; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Nelimarkka L, 2001, AM J PATHOL, V158, P345, DOI 10.1016/S0002-9440(10)63975-2; NICOSIA RF, 1990, LAB INVEST, V63, P115; NICOSIA RF, 1987, AM J PATHOL, V128, P78; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Petit AMV, 1997, AM J PATHOL, V151, P1523; POLAKOWSKI IJ, 1993, AM J PATHOL, V143, P507; Reed CC, 2002, ONCOGENE, V21, P3688, DOI 10.1038/sj.onc.1205470; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sage EH, 1997, TRENDS CELL BIOL, V7, P182; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; SCHOLZEN T, 1994, J BIOL CHEM, V269, P28270; Schonherr E, 1999, EUR J CELL BIOL, V78, P44, DOI 10.1016/S0171-9335(99)80006-5; Schonherr E, 2001, J BIOL CHEM, V276, P40687, DOI 10.1074/jbc.M105426200; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEIDNER N, 1993, AM J PATHOL, V143, P401; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; Yang VWC, 1999, J BIOL CHEM, V274, P12454, DOI 10.1074/jbc.274.18.12454	65	177	185	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4765	4777		10.1038/sj.onc.1205595	http://dx.doi.org/10.1038/sj.onc.1205595			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101415				2022-12-17	WOS:000176716300006
J	Coffer, PJ; Koenderman, L; de Groot, RP				Coffer, PJ; Koenderman, L; de Groot, RP			The role of STATs in myeloid differentiation and leukemia	ONCOGENE			English	Review						STAT; cytokine; myeloid; Bcr-Abl; differentiation; leukemia	COLONY-STIMULATING FACTOR; CHRONIC MYELOGENOUS LEUKEMIA; DNA-BINDING ACTIVITY; INDUCED ERYTHROID-DIFFERENTIATION; ERYTHROLEUKEMIA CELL-LINE; MAMMARY-GLAND DEVELOPMENT; HEMATOPOIETIC STEM-CELLS; PERIPHERAL-BLOOD CELLS; ACUTE-PHASE RESPONSE; C-MYC TRANSCRIPTION	Myeloid differentiation is a highly regulated process governed by various cytokines, such as EPO, TPO, G-CSF, IL-3, IL-5 and GM-CSF, These cytokines act in part through activation of the STAT transcription factor family. Tn particular, various isoforms of STAT3 and STAT5 are activated during myeloid differentiation in a cell-type and maturation-state dependent fashion. In vitro studies hale shown that STAT proteins are essential for cytokine-regulated processes such as cellular proliferation, differentiation as well as survival. Similarly, various STAT knock-outs have highlighted the role of STATs in myeloid differentiation in vivo. STATs also appear to play an important role in various myeloid malignancies, which are characterized by arrested maturation and cytokine-independent proliferation of myeloid progenitors. Constitutive activation of STAT3 and/or STAT5 resulting in enhanced transcription of anti-apoptotic-cell-cycle progression genes is likely to contribute to the pathogenesis of various myeloid leukemia's.	Univ Utrecht, Med Ctr, Dept Pulm Dis, NL-3584 CX Utrecht, Netherlands	Utrecht University	de Groot, RP (corresponding author), SRON, Sorbennelaan 2, NL-3584 CA Utrecht, Netherlands.		Koenderman, Leo/AAE-7870-2020; Coffer, Paul J/A-5769-2009; Coffer, Paul/AAF-7970-2020	Koenderman, Leo/0000-0002-5636-6453; 				AFAR DEH, 1995, P NATL ACAD SCI USA, V92, P9540, DOI 10.1073/pnas.92.21.9540; AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Al-Shami A, 1998, J BIOL CHEM, V273, P1058, DOI 10.1074/jbc.273.2.1058; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Aronica MG, 1996, ONCOGENE, V13, P1017; Azam M, 1997, IMMUNITY, V6, P691, DOI 10.1016/S1074-7613(00)80445-8; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Belhoussine R, 1999, ADV EXP MED BIOL, V457, P365; Biethahn S, 1999, EXP HEMATOL, V27, P885, DOI 10.1016/S0301-472X(99)00017-X; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; Bovolenta C, 1996, FEBS LETT, V386, P239, DOI 10.1016/0014-5793(96)00453-X; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Caldenhoven E, 1999, Mol Cell Biol Res Commun, V1, P95, DOI 10.1006/mcbr.1999.0114; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; Caldenhoven E, 1998, STEM CELLS, V16, P397, DOI 10.1002/stem.160397; Caldenhoven E, 1999, J LEUKOCYTE BIOL, V65, P391, DOI 10.1002/jlb.65.3.391; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; CARROLL M, 1995, P NATL ACAD SCI USA, V92, P2869, DOI 10.1073/pnas.92.7.2869; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chai SK, 1997, J IMMUNOL, V159, P4720; Chakraborty A, 1998, LEUKEMIA LYMPHOMA, V30, P433, DOI 10.3109/10428199809057555; Chakraborty A, 1998, J LEUKOCYTE BIOL, V64, P675, DOI 10.1002/jlb.64.5.675; Chakraborty A, 1999, BLOOD, V94, p471A; Chakraborty A, 1996, BLOOD, V88, P2442, DOI 10.1182/blood.V88.7.2442.bloodjournal8872442; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; Dorsch M, 1999, BLOOD, V94, P2676, DOI 10.1182/blood.V94.8.2676.420k28_2676_2685; Dorsch M, 1997, J EXP MED, V186, P1947, DOI 10.1084/jem.186.12.1947; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; Frank DA, 1996, LEUKEMIA, V10, P1724; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Hamasaki A, 1998, J EXP MED, V188, P1985, DOI 10.1084/jem.188.11.1985; Hayakawa F, 1998, BRIT J HAEMATOL, V101, P521, DOI 10.1046/j.1365-2141.1998.00720.x; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; JIANG HP, 1994, ONCOGENE, V9, P3397; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kaplan MH, 1998, MOL CELL BIOL, V18, P1996, DOI 10.1128/MCB.18.4.1996; KAZANSKY AV, 1995, MOL ENDOCRINOL, V9, P1598, DOI 10.1210/me.9.11.1598; Kirito K, 1998, BLOOD, V92, P462, DOI 10.1182/blood.V92.2.462.414k15_462_471; Kirito K, 1997, J BIOL CHEM, V272, P16507, DOI 10.1074/jbc.272.26.16507; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; Krosl J, 1996, J BIOL CHEM, V271, P27432, DOI 10.1074/jbc.271.44.27432; KRUGER A, 1991, ONCOGENE, V6, P245; LAMB P, 1995, NUCLEIC ACIDS RES, V23, P3283, DOI 10.1093/nar/23.16.3283; Lee C, 1999, J BIOL CHEM, V274, P26767, DOI 10.1074/jbc.274.38.26767; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LIESCHKE GJ, 1994, BLOOD, V84, P1737; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Lokuta MA, 1998, J IMMUNOL, V161, P1594; LOWENBERG B, 1993, BLOOD, V81, P281; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Meyer J, 1998, BLOOD, V91, P1901, DOI 10.1182/blood.V91.6.1901.1901_1901_1908; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Moriggl R, 1999, IMMUNITY, V11, P225, DOI 10.1016/S1074-7613(00)80097-7; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1999, CELL MOL LIFE SCI, V55, P1547, DOI 10.1007/s000180050394; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Naik SM, 1997, J BIOL CHEM, V272, P1283, DOI 10.1074/jbc.272.2.1283; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Narimatsu M, 1997, BIOCHEM BIOPH RES CO, V238, P764, DOI 10.1006/bbrc.1997.7387; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Niu GL, 1999, CANCER RES, V59, P5059; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; OGAWA M, 1993, BLOOD, V81, P2844; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Orlofsky A, 1999, J IMMUNOL, V163, P412; Pinto A, 1998, CRIT REV ONCOL HEMAT, V27, P161, DOI 10.1016/S1040-8428(97)10029-4; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; Rosen RL, 1996, BLOOD, V88, P1206, DOI 10.1182/blood.V88.4.1206.bloodjournal8841206; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Schuringa JJ, 1999, BLOOD, V94, p475A; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; Shuai K, 1996, ONCOGENE, V13, P247; Smithgall TE, 1998, PHARMACOL REV, V50, P1; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; STEWART MJ, 1995, LEUKEMIA, V9, P1499; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; VANDERBRUGGEN T, 1995, BLOOD, V85, P1442, DOI 10.1182/blood.V85.6.1442.bloodjournal8561442; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Ward AC, 1999, J BIOL CHEM, V274, P14956, DOI 10.1074/jbc.274.21.14956; Ward AC, 1999, BLOOD, V93, P113, DOI 10.1182/blood.V93.1.113.401k33_113_124; Weber-Nordt RM, 1999, BLOOD, V94, p75A; WeberNordt RM, 1996, BLOOD, V88, P809; Welte T, 1997, EUR J IMMUNOL, V27, P2737, DOI 10.1002/eji.1830271038; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Williamson EA, 1997, LEUKEMIA, V11, P73, DOI 10.1038/sj.leu.2400551; Woldman I, 1997, J IMMUNOL, V159, P877; Xia Z, 1998, CANCER RES, V58, P3173; Yamada H, 1996, INT J HEMATOL, V65, P31; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; Yoshimura A, 1998, LEUKEMIA, V12, P1851, DOI 10.1038/sj.leu.2401238; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	138	177	193	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2511	2522		10.1038/sj.onc.1203479	http://dx.doi.org/10.1038/sj.onc.1203479			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851050				2022-12-17	WOS:000087459400007
J	Lynch, DK; Ellis, CA; Edwards, PAW; Hiles, ID				Lynch, DK; Ellis, CA; Edwards, PAW; Hiles, ID			Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism	ONCOGENE			English	Article						Akt; ErbB4; integrin-linked kinase; phosphatidylinositol 3-kinase; protein kinase B; site-directed mutagenesis	GLYCOGEN-SYNTHASE KINASE-3; NATRIURETIC-PEPTIDE RECEPTOR; PLECKSTRIN HOMOLOGY DOMAIN; PROMOTES CELL-SURVIVAL; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT; PHOSPHOINOSITIDE 3-KINASE; MOLECULAR-CLONING; SIGNALING PATHWAY; INDUCED APOPTOSIS	The serine threonine kinase protein kinase B regulates cellular activities as diverse as glycogen metabolism and apoptosis, Full activation of protein kinase B requires 3-phosphoinositides and dual phosphorylation on threonine-308 and serine-473, CaM-K kinase and 3-phosphoinositide dependent-kinase-l phosphorylate threonine-308, Integrin-linked kinase reportedly phophorylates serine-473, Consistent,vith this, in a model COS cell system we show that expression of wild-type integrin-linked kinase promotes the wortmannin sensitive phosphorylation of serine-473 of protein kinase B and its downstream substrates, and inhibits C-2-ceramide induced apoptosis, In contrast, integrin-linked kinase mutated in a lysine residue critical for function in protein kinases is inactive in these experiments, and furthermore, acts dominantly to block serine-473 phosphorylation induced by ErbB4, However, alignment of analogous sequences from different species demonstrates that integrin-linked kinase is not a typical protein kinase and identifies a conserved serine residue which potentially regulates kinase activity in a phosphorylation dependent manner, Mutation of this serine to aspartate or glutamate, but not alanine, in combination with the inactivating lysine mutation restores integrin-linked kinase dependent phosphorylation of serine-473 of protein kinase, These data strongly suggest that integrin-linked kinase does not possess serine-473 kinase activity but functions as an adaptor to recruit a serine-473 kinase or phosphatase.	Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Mol Pharmacol Unit, Stevenage SG1 2NY, Herts, England	GlaxoSmithKline	Hiles, ID (corresponding author), Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Mol Pharmacol Unit, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England.		Edwards, Paul A/M-8291-2014	Edwards, Paul A/0000-0002-4789-3374				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Coffer PJ, 1998, BIOCHEM J, V335, P1; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Elenius K, 1999, ONCOGENE, V18, P2607, DOI 10.1038/sj.onc.1202612; Foster DC, 1998, J BIOL CHEM, V273, P16311, DOI 10.1074/jbc.273.26.16311; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; PEARSON RB, 1995, EMBO J, V14, P5278; Potter LR, 1998, MOL CELL BIOL, V18, P2164, DOI 10.1128/MCB.18.4.2164; Sambrook J, 1987, MOL CLONING LAB MANU; Sawyer C, 1998, ONCOGENE, V17, P919, DOI 10.1038/sj.onc.1202015; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	57	177	187	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					8024	8032		10.1038/sj.onc.1203258	http://dx.doi.org/10.1038/sj.onc.1203258			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637513				2022-12-17	WOS:000084634600011
J	Dievart, A; Beaulieu, N; Jolicoeur, P				Dievart, A; Beaulieu, N; Jolicoeur, P			Involvement of Notch1 in the development of mouse mammary tumors	ONCOGENE			English	Article						MMTV; oncogene; provirus; transformation	HUMAN-BREAST-CANCER; NEU ONCOGENE; DROSOPHILA NOTCH; TRANSGENIC MICE; HUMAN HOMOLOG; CELL-LINE; GENE; PROTEIN; DOMAIN; TRANSCRIPTION	The MMTV/neu transgenic (Tg) mice spontaneously develop mammary tumors stochastically after a long latent period, suggesting that the c-neu/erbB2 oncogene is not sufficient for tumor formation. To identify putative collaborator(s) of the c-neu/erbB2, we used the provirus insertional mutagenesis approach with mammary tumors arising in MMTV/neu Tg mice infected with the mouse mammary tumor virus (MMTV), The Notch1 gene was identified as a novel target for MMTV provirus insertional activation. In Notch1-rearranged tumors, the Notch1 gene was interrupted by the MMTV provirus insertion upstream of the exons coding for the TM domain. These insertions led to overexpression of novel 5' truncated similar to 7kb RNA coding for 280 kDa mutant protein harboring only the Notch1 ectodomain, N(EC)(mut), These may be involved in tumor formation. Another consequence of these insertions was the expression of truncated 3' Notch1 transcripts (3.5-4.5 kb) and proteins (86-110 kDa) deleted of most of the extracellular sequences (Notch1(intra)). We found that 3' truncated Notch1(intra) can transform HC11 mouse mammary epithelial cells in vitro. Deletion analysis revealed that the ankyrin-repeats and the domain 1 (aa 1751-1821) are required, while a signal peptide, the two conserved cysteines (C-1652 and C-1685) and the OPA and PEST sequences are dispensable for transformation. These results indicate that the N-terminally truncated Notch1(intra) protein behaves as an oncogene in this system.	Clin Res Inst Montreal, Mol Biol Lab, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Med, Montreal, PQ H3J 3J7, Canada; Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3J 3J7, Canada; McGill Univ, Dept Expt Med, Montreal, PQ H3G 1A4, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal; McGill University	Jolicoeur, P (corresponding author), Clin Res Inst Montreal, Mol Biol Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.			Dievart, Anne/0000-0001-9460-4638				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; Aster JC, 1997, J BIOL CHEM, V272, P11336; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Callahan R, 1996, BREAST CANCER RES TR, V39, P33, DOI 10.1007/BF01806076; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Chen YY, 1997, J BIOL CHEM, V272, P14110, DOI 10.1074/jbc.272.22.14110; DELAMO FF, 1993, GENOMICS, V15, P259, DOI 10.1006/geno.1993.1055; DIEDERICH RJ, 1994, DEVELOPMENT, V120, P473; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Guan E, 1996, J EXP MED, V183, P2025, DOI 10.1084/jem.183.5.2025; HOEMANN CD, 1999, UNPUB; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; KOPAN R, 1993, J CELL BIOL, V121, P631, DOI 10.1083/jcb.121.3.631; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Lu FM, 1996, P NATL ACAD SCI USA, V93, P5663, DOI 10.1073/pnas.93.11.5663; MAJORS JE, 1981, NATURE, V289, P253, DOI 10.1038/289253a0; Milner LA, 1996, P NATL ACAD SCI USA, V93, P13014, DOI 10.1073/pnas.93.23.13014; Moore D H, 1979, Adv Cancer Res, V29, P347, DOI 10.1016/S0065-230X(08)60850-7; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NYE JS, 1994, DEVELOPMENT, V120, P2421; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; REAUME AG, 1992, DEV BIOL, V154, P377, DOI 10.1016/0012-1606(92)90076-S; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; ROSENBERG N, 1997, RETROVIRUS PATHOGENE; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Shawber C, 1996, DEVELOPMENT, V122, P3765; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sun X, 1997, DEVELOPMENT, V124, P3439; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; WEBSTER MA, 1994, SEMIN CANCER BIOL, V5, P69; Wettstein DA, 1997, DEVELOPMENT, V124, P693	46	177	183	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	1999	18	44					5973	5981		10.1038/sj.onc.1202991	http://dx.doi.org/10.1038/sj.onc.1202991			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557086	Green Submitted			2022-12-17	WOS:000083359100003
J	Sirma, H; Giannini, C; Poussin, K; Paterlini, P; Kremsdorf, D; Brechot, C				Sirma, H; Giannini, C; Poussin, K; Paterlini, P; Kremsdorf, D; Brechot, C			Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx	ONCOGENE			English	Article						hepatitis B virus X-protein; cell cycle arrest; apoptosis; transactivation; NF-kappa B; HCC	NF-KAPPA-B; PAPILLOMAVIRUS E2 PROTEIN; TRANSGENIC MICE; INDUCED APOPTOSIS; DNA-SYNTHESIS; GENE PRODUCT; CELL-DEATH; IN-VIVO; P53; EXPRESSION	Chronic infection by HBV is the leading cause of hepatocellular carcinoma in man. Several lines of evidence suggest that the viral transactivator HBx plays a critical role in the molecular pathogenesis of HBV-related HCC, To study the actual impact of HBx and the mechanism of its action, we have recently cloned and characterized a set of X-sequences from HCC in patients with chronic infection by HBV, In the present study, we have compared the effects of HBx and its naturally arising mutants on cell growth and viability. We report that HBx inhibits clonal outgrowth of cells and induces apoptosis by a p53-independent pathway. Furthermore, HBx expression induced a late G1 cell cycle block prior to their counterselection by apoptosis, Importantly, mutations in the HBx-gene evolving in hepatocellular carcinoma abolished both HBx-induced growth arrest and apoptosis, Using a panel of engineered mutants me have mapped the growth suppressive effect of HBx to domains shown to be required for its transactivating function. Based on these results, we propose that abrogation of the anti-proliferative and apoptotic effects of HBx by naturally occurring mutations might render the hepatocytes susceptible to uncontrolled growth and contribute to multistep hepatocarcinogenesis associated with HBV-infection.	Hop Necker Enfants Malad, INSERM, U370, F-75730 Paris 15, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Brechot, C (corresponding author), Hop Necker Enfants Malad, INSERM, U370, 156 Rue Vaugirard, F-75730 Paris 15, France.		Kremsdorf, Dina/O-9797-2017					Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Bellas RE, 1997, AM J PATHOL, V151, P891; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; CHLICHLIA K, 1995, ONCOGENE, V10, P269; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FISCHER M, 1995, VIRUS GENES, V10, P99, DOI 10.1007/BF01724303; Goodwin EC, 1998, J VIROL, V72, P3925, DOI 10.1128/JVI.72.5.3925-3934.1998; GOULAOUIC H, 1994, VIROLOGY, V200, P87, DOI 10.1006/viro.1994.1166; Hildt E, 1996, SEMIN VIROL, V7, P333, DOI 10.1006/smvy.1996.0041; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; Huang JK, 1996, J VIROL, V70, P5582, DOI 10.1128/JVI.70.8.5582-5591.1996; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOIKE K, 1994, J CLIN INVEST, V94, P44, DOI 10.1172/JCI117343; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lee Y, 1998, GENE, V207, P111, DOI 10.1016/S0378-1119(97)00603-3; Lin KI, 1998, J CELL BIOL, V141, P1479, DOI 10.1083/jcb.141.7.1479; Lipton SA, 1997, NAT MED, V3, P20, DOI 10.1038/nm0197-20; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; Marianneau P, 1997, J VIROL, V71, P3244, DOI 10.1128/JVI.71.4.3244-3249.1997; MINAMI M, 1995, GENOMICS, V29, P403, DOI 10.1006/geno.1995.9004; Mymryk JS, 1996, ONCOGENE, V13, P1581; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; Ozer A, 1996, GASTROENTEROLOGY, V110, P1519, DOI 10.1053/gast.1996.v110.pm8613059; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; Poussin K, 1999, INT J CANCER, V80, P497, DOI 10.1002/(SICI)1097-0215(19990209)80:4<497::AID-IJC3>3.0.CO;2-8; QUADRI I, 1995, P NATL ACAD SCI USA, V92, P1003; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; RUNKEL L, 1993, VIROLOGY, V197, P529, DOI 10.1006/viro.1993.1626; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; Urban S, 1997, HEPATOLOGY, V26, P1045, DOI 10.1002/hep.510260437; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	58	177	191	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4848	4859		10.1038/sj.onc.1202867	http://dx.doi.org/10.1038/sj.onc.1202867			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490818				2022-12-17	WOS:000082184800009
J	Millar, DS; Ow, KK; Paul, CL; Russell, PJ; Molloy, PL; Clark, SJ				Millar, DS; Ow, KK; Paul, CL; Russell, PJ; Molloy, PL; Clark, SJ			Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer	ONCOGENE			English	Article						DNA methylation; bisulphite genomic sequencing; GSTP1; prostate cancer	DNA METHYLATION; EXPRESSION; CELLS; PATTERNS; PROMOTER; TUMORS; OVEREXPRESSION; CARCINOGENESIS; CARCINOMAS; SEQUENCES	Glutathione-S-Transferases (GSTs) comprise a family of isoenzymes that provide protection to mammalian cells against electrophilic metabolites of carcinogens and reactive oxygen species. Previous studies have shown that the CpG-rich promoter region of the pi-class gene GSTP1 is methylated at single restriction sites in the majority of prostate cancers, In order to understand the nature of abnormal methylation of the GSTP1 gene in prostate cancer we undertook a detailed analysis of methylation at 131 CpG sites spanning the promoter and body of the gene. Our results show that DNA methylation is not confined to specific CpG sites in the promoter region of the GSTP1 gene but is extensive throughout the CpG island in prostate cancer cells. Furthermore we found that both alleles are abnormally methylated in this region. In normal prostate tissue, the entire CpG island was unmethylated, but extensive methylation was found outside the island in the body of the gene. Loss of GSTP1 expression correlated with DNA methylation of the CpG island in both prostate cancer cell lines and cancer tissues whereas methylation outside the CpG island in normal prostate tissue appeared to have no effect on gene expression.	CSIRO, Div Mol Sci, Sydney Lab, N Ryde, NSW 1670, Australia; Royal Prince Alfred Hosp, Kanematsu Labs, Camperdown, NSW 2050, Australia; Prince Wales Hosp, Oncol Res Ctr, Randwick, NSW 2031, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Sydney	Clark, SJ (corresponding author), CSIRO, Div Mol Sci, Sydney Lab, POB 184, N Ryde, NSW 1670, Australia.		Clark, Susan J/B-2272-2008; Molloy, Peter L/H-7931-2013; Russell, Pamela J/G-1685-2010; Russell, Pamela/O-8504-2019; Clark, Susan J/U-7365-2019	Clark, Susan J/0000-0001-5925-5030; Molloy, Peter L/0000-0002-7788-3417; Russell, Pamela J/0000-0002-3995-1239; Clark, Susan J/0000-0001-5925-5030				BATIST G, 1986, J BIOL CHEM, V261, P5544; Baylin SB, 1998, ADV CANCER RES, V72, P141; Clark S. J., 1997, P151; Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9; CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CLARK SJ, 1995, DNA NUCLEOPROTEIN ST, P103; Cookson MS, 1997, J UROLOGY, V157, P673, DOI 10.1016/S0022-5347(01)65248-0; COWELL IG, 1988, BIOCHEM J, V255, P79, DOI 10.1042/bj2550079; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; ISAACS WB, 1995, CANCER SURV, V23, P19; ISHIOKA C, 1991, CANCER, V67, P2560, DOI 10.1002/1097-0142(19910515)67:10<2560::AID-CNCR2820671028>3.0.CO;2-M; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Melki JR, 1998, LEUKEMIA, V12, P311, DOI 10.1038/sj.leu.2400932; Moffat GJ, 1996, J BIOL CHEM, V271, P1054, DOI 10.1074/jbc.271.2.1054; MORROW CS, 1989, GENE, V75, P3, DOI 10.1016/0378-1119(89)90377-6; Moskaluk CA, 1997, CANCER-AM CANCER SOC, V79, P1595, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1595::AID-CNCR23>3.0.CO;2-S; MULDER TPJ, 1995, CANCER RES, V55, P2696; Paul CL, 1996, BIOTECHNIQUES, V21, P126; PETERS WHM, 1990, CARCINOGENESIS, V11, P1593, DOI 10.1093/carcin/11.9.1593; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; Schmutte C, 1996, CANCER RES, V56, P2375; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; Stirzaker C, 1997, CANCER RES, V57, P2229; Stoger R, 1997, HUM MOL GENET, V6, P1791, DOI 10.1093/hmg/6.11.1791; TOMMASI S, 1993, SOMAT CELL MOLEC GEN, V19, P529, DOI 10.1007/BF01233380; TOTH M, 1990, J MOL BIOL, V214, P673, DOI 10.1016/0022-2836(90)90285-T; Wang X, 1997, CLIN CANCER RES, V3, P111; Warnecke PM, 1998, GENOMICS, V51, P182, DOI 10.1006/geno.1998.5371; Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422; Warnecke PM, 1998, DEV GENET, V22, P111, DOI 10.1002/(SICI)1520-6408(1998)22:2&lt;111::AID-DVG1&gt;3.0.CO;2-9	38	177	196	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1313	1324		10.1038/sj.onc.1202415	http://dx.doi.org/10.1038/sj.onc.1202415			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022813				2022-12-17	WOS:000078510900007
J	Velasco-Miguel, S; Buckbinder, L; Jean, P; Gelbert, L; Talbott, R; Laidlaw, J; Seizinger, B; Kley, N				Velasco-Miguel, S; Buckbinder, L; Jean, P; Gelbert, L; Talbott, R; Laidlaw, J; Seizinger, B; Kley, N			PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes	ONCOGENE			English	Article						p53; GADD genes; 6q21; genotoxic stress; serum regulation	NON-HODGKINS-LYMPHOMA; BREAST-CANCER-CELLS; WILD-TYPE P53; MDM-2 ONCOGENE; CHROMOSOME 6Q; PROTEIN; APOPTOSIS; INDUCTION; REGIONS; HETEROZYGOSITY	Exposure of mammalian cells to hypoxia, radiation and certain chemotherapeutic agents promotes cell cycle arrest and/or apoptosis. Activation of p53 responsive genes is believed to play an important role in mediating such responses. In this study we identified a novel gene, PA26, which maps to chromosome 6q21 and encodes at least three transcript isoforms, of which two are differentially induced by genotoxic stress (UV, gamma-irradiation and cytotoxic drugs) in a p53-dependent manner. A functional p53-responsive element was identified in the second intron of the PA26 gene, in consistence with a mechanism of transcriptional induction of the PA26 gene by p53. No clues to its functions were revealed by sequence analysis, although pronounced negative regulation by serum factors argues fbr a potential role of PA26 in growth regulation. Immunological analysis suggests that PA26 protein(s) is localized to the cell nucleus. Our results suggest that the PA26 gene is a novel p53 target gene with properties common to the GADD family of growth arrest and DNA damage-inducible stress-response genes, and, thus, a potential novel regulator of cellular growth.	Bristol Myers Squibb Pharmaceut Res Inst, Dept Oncol, Princeton, NJ 08543 USA; Pfizer Inc, Cent Res, Groton, CT 06340 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08543 USA; Genome Therapeut Corp, Waltham, MA 02154 USA	Bristol-Myers Squibb; Pfizer; Princeton University	Kley, N (corresponding author), Univ Texas, SW Med Ctr, Dept Dev Biol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BROWN JL, 1994, CANCER GENET CYTOGEN, V72, P116, DOI 10.1016/0165-4608(94)90126-0; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; BUCKBINDER L, 1994, P NATL ACAD SCI USA, V91, P10640, DOI 10.1073/pnas.91.22.10640; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chen JD, 1996, MOL CELL BIOL, V16, P2445; COWAN KH, 1986, P NATL ACAD SCI USA, V83, P9328, DOI 10.1073/pnas.83.24.9328; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1474; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Gerard B, 1997, LEUKEMIA, V11, P228, DOI 10.1038/sj.leu.2400566; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; JACKMAN J, 1994, CANCER RES, V54, P5656; JOHANSSON B, 1995, BLOOD, V86, P3905, DOI 10.1182/blood.V86.10.3905.bloodjournal86103905; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Madden SL, 1996, CANCER RES, V56, P5384; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Morelli C, 1997, CANCER RES, V57, P4153; NEGRINI M, 1994, CANCER RES, V54, P1331; Noviello C, 1996, CLIN CANCER RES, V2, P1601; OFFIT K, 1993, BLOOD, V82, P2157; OKAMOTO K, 1994, EMBO J, V13, P4813; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; PEJOVIC T, 1995, ANN MED, V27, P73, DOI 10.3109/07853899509031940; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; RAO PH, 1994, CANCER GENET CYTOGEN, V77, P60, DOI 10.1016/0165-4608(94)90150-3; ROAULT JP, 1996, NAT GENT, V14, P482; Sambrook J, 1989, MOL CLONING LAB MANU; Sandhu AK, 1996, ONCOGENE, V12, P247; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Winkles JA, 1998, PROG NUCLEIC ACID RE, V58, P41; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141	51	177	186	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					127	137		10.1038/sj.onc.1202274	http://dx.doi.org/10.1038/sj.onc.1202274			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926927				2022-12-17	WOS:000078166000014
J	Kondo, S; Kondo, Y; Li, GY; Silverman, RH; Cowell, JK				Kondo, S; Kondo, Y; Li, GY; Silverman, RH; Cowell, JK			Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA	ONCOGENE			English	Article						telomerase; brain tumors; nude mice; RNAse L; apoptosis	IMMORTAL CELLS; TUMOR; ACTIVATION; CHIMERAS	Telomerase is the RNA-protein complex which elongates telomeric DNA (TTAGGG)(n) and appears to play an important role in cellular immortalization. The almost exclusive expression of telomerase in tumor cells, and not in most normal cells, offers an exciting opportunity for therapy by inhibiting its function. Here, we have investigated the effect of inhibition of telomerase on the growth and survival of human malignant glioma cells in vitro and in vivo by using a 19-mer antisense oligonucleotide against human telomerase RNA linked to a 2',5'-oligoadenylate (2-5A), 2-5A antisense functions by activating the endoribonuclease, RNase L, resulting in the degradation of single stranded, targeted RNA. We have shown that the 2-5A antisense treatment effectively suppressed tumor cell growth and survival in vitro. Furthermore, treatment of tumors grown in nude mice with the antisense oligonucleotide inhibited survival of the tumor cells. TUNEL assays suggest that this effect is mediated through the induction of apoptosis. Targeting telomerase RNA with 2-5A antisense, therefore, may represent an effective and novel approach for treatment of a broad range of cancers.	Cleveland Clin Fdn, Dept Neurosurg, Brain Tumor Ctr, Ctr Canc, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Neurosci, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Cowell, JK (corresponding author), Cleveland Clin Fdn, Dept Neurosurg, Brain Tumor Ctr, Ctr Canc, Cleveland, OH 44195 USA.			Cowell, John/0000-0002-2079-5950	NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER; NCI NIH HHS [1 PO1 CA 62220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belair CD, 1997, P NATL ACAD SCI USA, V94, P13677, DOI 10.1073/pnas.94.25.13677; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Cirino NM, 1997, P NATL ACAD SCI USA, V94, P1937, DOI 10.1073/pnas.94.5.1937; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DEEN DF, 1993, J NEURO-ONCOL, V16, P243, DOI 10.1007/BF01057041; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DONG BH, 1994, J BIOL CHEM, V269, P14153; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kondo S., UNPUB; KRAUSE D, 1986, J BIOL CHEM, V261, P6836; LANGFORD LA, 1995, LANCET, V346, P1267, DOI 10.1016/S0140-6736(95)91865-5; LESIAK K, 1993, BIOCONJUGATE CHEM, V4, P467, DOI 10.1021/bc00024a008; MAHALEY MS, 1989, J NEUROSURG, V71, P826, DOI 10.3171/jns.1989.71.6.0826; MAITRA RK, 1995, J BIOL CHEM, V270, P15071, DOI 10.1074/jbc.270.25.15071; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; SALSER W, 1977, COLD SPRING HARB SYM, V42, P985; SCHOENBERG BS, 1983, ONCOLOGY NERVOUS SYS, P1; Silverman R., 1997, RIBONUCLEASES STRUCT, P515; TORRENCE PF, 1993, P NATL ACAD SCI USA, V90, P1300, DOI 10.1073/pnas.90.4.1300; XIAO W, 1994, BIOORG MED CHEM LETT, V4, P2609, DOI 10.1016/S0960-894X(01)80294-8; Xiao W, 1996, ANTISENSE NUCLEIC A, V6, P247, DOI 10.1089/oli.1.1996.6.247; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; ZUKER M, 1989, METHOD ENZYMOL, V180, P262	32	177	202	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 25	1998	16	25					3323	3330		10.1038/sj.onc.1201885	http://dx.doi.org/10.1038/sj.onc.1201885			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681832	Bronze			2022-12-17	WOS:000074343600014
J	OZAKI, T; SAIJO, M; MURAKAMI, K; ENOMOTO, H; TAYA, Y; SAKIYAMA, S				OZAKI, T; SAIJO, M; MURAKAMI, K; ENOMOTO, H; TAYA, Y; SAKIYAMA, S			COMPLEX-FORMATION BETWEEN LAMIN-A AND THE RETINOBLASTOMA GENE-PRODUCT - IDENTIFICATION OF THE DOMAIN ON LAMIN-A REQUIRED FOR ITS INTERACTION	ONCOGENE			English	Article							LARGE T-ANTIGEN; INTERMEDIATE FILAMENT PROTEINS; SV40 LARGE-T; CELL-CYCLE; SUSCEPTIBILITY GENE; NUCLEAR-ENVELOPE; TUMOR SUPPRESSOR; CARCINOMA-CELLS; RB GENE; BINDING	The retinoblastoma susceptibility gene product (pRB) has been known to function as a negative regulator of cell growth. Recent observations suggest that its biological activity might be modulated by an interaction with nuclear structures. By using in vitro binding assays, we have found that pRB can associate with lamin A, which has been known to be one of the major nuclear matrix proteins. A series of GST-lamin A deletion mutants was constructed to define the amino acid sequence required for binding to pRB. A GST-lamin A (247-355) contained an activity to associate with pRB, while the other constructs, such as GST-lamin A (37-244) or GST-lamin A (356-571), could not bind to pRB. Within the pRB-binding domain of lamin A, there exists the short amino acid sequence which is also present in the pRB-binding region of the transcription factor E2F-1. The similar experiments using a set of GST-RB deletion mutants revealed that a region containing the E1A-binding pocket B and the carboxy-terminal portion of pRB was responsible for binding to lamin A.	CHIBA CANC CTR,RES INST,DIV BIOCHEM,CHUOH KU,CHIBA 260,JAPAN; NATL CANC CTR,RES INST,DIV BIOL,CHUOH KU,TOKYO 104,JAPAN	Chiba Cancer Center; National Cancer Center - Japan								AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BURKE B, 1986, CELL, V44, P639, DOI 10.1016/0092-8674(86)90273-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; GLASS CA, 1993, EMBO J, V12, P4413, DOI 10.1002/j.1460-2075.1993.tb06126.x; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P153; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES JA, 1991, EMBO J, V10, P4297; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; Nigg EA, 1989, CURR OPIN CELL BIOL, V1, P435, DOI 10.1016/0955-0674(89)90002-1; OZAKI T, 1992, FEBS LETT, V312, P165, DOI 10.1016/0014-5793(92)80927-9; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SAIJO M, 1994, FEBS LETT, V340, P181, DOI 10.1016/0014-5793(94)80133-9; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TEMPLETON DJ, 1992, MOL CELL BIOL, V12, P435, DOI 10.1128/MCB.12.2.435; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	46	177	180	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2649	2653						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058329				2022-12-17	WOS:A1994PC05400025
J	Yang, S; Li, Y; Gao, J; Zhang, T; Li, S; Luo, A; Chen, H; Ding, F; Wang, X; Liu, Z				Yang, S.; Li, Y.; Gao, J.; Zhang, T.; Li, S.; Luo, A.; Chen, H.; Ding, F.; Wang, X.; Liu, Z.			MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1	ONCOGENE			English	Article						miR-34a; miR-34c; breast cancer; metastasis	NEGATIVE FEEDBACK LOOP; C-MET EXPRESSION; MESENCHYMAL TRANSITION; TUMOR-SUPPRESSOR; GENE-EXPRESSION; DOWN-REGULATION; INHIBITS MIGRATION; MIR-34A; FAMILY; METHYLATION	MicroRNAs have key roles in tumor metastasis. Here, we describe the regulation and function of miR-34a and miR-34c (miR-34a/c) in breast cancer metastasis. Expression analysis verified that miR-34a/c expression is significantly decreased in metastatic breast cancer cells and human primary breast tumors with lymph node metastases. Overexpression of miR-34a/c could inhibit breast cancer cell migration and invasion in vitro and distal pulmonary metastasis in vivo. Further studies revealed that Fos-related antigen 1 (Fra-1 or Fosl1) is a downstream target of miR-34a/c as miR-34a/c bound directly to the 3'untranslated region of Fra-1, subsequently reducing both the mRNA and protein levels of Fra-1. Silencing of Fra-1 recapitulated the effects of miR-34a/c overexpression, whereas enforced expression of Fra-1 reverses the suppressive effects of miR-34a/c. Moreover, significant downregulation of miR-34a in metastatic breast cancer tissues was found to be inversely correlated with Fra-1 expression. Our results demonstrate that miR-34a/c functions as a metastasis suppressor to regulate breast cancer migration and invasion through targeting Fra-1 oncogene and suggest a therapeutic application of miR-34 in breast cancer.	[Yang, S.; Li, Y.; Zhang, T.; Li, S.; Luo, A.; Chen, H.; Ding, F.; Liu, Z.] Chinese Acad Med Sci, State Key Lab Mol Oncol, Canc Inst & Hosp, Beijing 100021, Peoples R China; [Yang, S.; Li, Y.; Gao, J.; Zhang, T.; Li, S.; Luo, A.; Chen, H.; Ding, F.; Wang, X.; Liu, Z.] Peking Union Med Coll, Beijing 100021, Peoples R China; [Gao, J.; Wang, X.] Chinese Acad Med Sci, Dept Abdominal Surg, Canc Inst & Hosp, Beijing 100021, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS	Wang, X (corresponding author), Chinese Acad Med Sci, Dept Abdominal Surg, Canc Inst & Hosp, Beijing 100021, Peoples R China.	xiangw@vip.sina.com; liuzh@cicams.ac.cn	Yang, Shouhui/M-5374-2017	Wang, Xiang/0000-0002-1522-9532; Li, Sheng/0000-0001-8080-9712	National Basic Research Program of China [2011CB504205]; National Natural Science Foundation of China [91019009, 81021061]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Ziqiang Zhang, Yongquan Wang and Zhiyuan Wu for providing technical support. This work was supported by the National Basic Research Program of China (2011CB504205) and National Natural Science Foundation of China (91019009, 81021061).	Bamberger AM, 1999, INT J CANCER, V84, P533, DOI 10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Bieche I, 1999, GENE CHROMOSOME CANC, V24, P255, DOI 10.1002/(SICI)1098-2264(199903)24:3<255::AID-GCC11>3.0.CO;2-2; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Cannell IG, 2010, P NATL ACAD SCI USA, V107, P5375, DOI 10.1073/pnas.0910015107; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chen L, 2009, CANCER RES, V69, P8853, DOI 10.1158/0008-5472.CAN-09-1636; Chiappetta G, 2000, CLIN CANCER RES, V6, P4300; Chim CS, 2010, CARCINOGENESIS, V31, P745, DOI 10.1093/carcin/bgq033; Choi YJ, 2011, NAT CELL BIOL, V13, P1353, DOI 10.1038/ncb2366; Christoffersen NR, 2010, CELL DEATH DIFFER, V17, P236, DOI 10.1038/cdd.2009.109; Debinski W, 2005, MOL CANCER RES, V3, P237; Ellsworth RE, 2008, BREAST CANCER RES TR, V107, P259, DOI 10.1007/s10549-007-9547-2; Ellsworth RE, 2003, CANCER EPIDEM BIOMAR, V12, P915; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Gee HE, 2008, NATURE, V455, DOI 10.1038/nature07362; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guessous F, 2010, CELL CYCLE, V9, P1031, DOI 10.4161/cc.9.6.10987; Hermeking H, 2010, CELL DEATH DIFFER, V17, P193, DOI 10.1038/cdd.2009.56; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Hwang CI, 2011, P NATL ACAD SCI USA, V108, P14240, DOI 10.1073/pnas.1017536108; Ji Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006816; Kim NH, 2011, J CELL BIOL, V195, P417, DOI 10.1083/jcb.201103097; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Li N, 2009, CANCER LETT, V275, P44, DOI 10.1016/j.canlet.2008.09.035; Li Y, 2010, CANCER RES, V70, P7894, DOI 10.1158/0008-5472.CAN-10-1675; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Luo YP, 2010, ONCOGENE, V29, P662, DOI 10.1038/onc.2009.308; Lv Xiao-Bin, 2011, Chin J Cancer, V30, P821, DOI 10.5732/cjc.011.10289; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Mackiewicz M, 2011, BREAST CANCER RES TR, V130, P663, DOI 10.1007/s10549-011-1690-0; Migliore C, 2008, CANCER RES, V68, P10128, DOI 10.1158/0008-5472.CAN-08-2148; Milde-Langosch K, 2004, BREAST CANCER RES TR, V86, P139, DOI 10.1023/B:BREA.0000032982.49024.71; Mudduluru G, 2011, ONCOGENE, V30, P2888, DOI 10.1038/onc.2011.13; NAGAI H, 1995, CANCER RES, V55, P1752; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Osborne RJ, 2000, CANCER RES, V60, P3706; Ramos-Nino ME, 2003, CANCER RES, V63, P3539; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Sayan AE, 2011, ONCOGENE, V25, P8; Serewko MM, 2002, CANCER RES, V62, P3759; Siemens H, 2011, CELL CYCLE, V10, P4256, DOI 10.4161/cc.10.24.18552; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Stinson S, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001538; Sun F, 2008, FEBS LETT, V582, P1564, DOI 10.1016/j.febslet.2008.03.057; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104; Tian YY, 2010, J BIOL CHEM, V285, P7986, DOI 10.1074/jbc.M109.062877; Tkach V, 2003, ONCOGENE, V22, P5045, DOI 10.1038/sj.onc.1206570; Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325; Usui A, 2012, CANCER-AM CANCER SOC, V118, P3387, DOI 10.1002/cncr.26652; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Vial E, 2003, J CELL SCI, V116, P4957, DOI 10.1242/jcs.00812; Wei JS, 2008, ONCOGENE, V27, P5204, DOI 10.1038/onc.2008.154; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; Wiggins JF, 2010, CANCER RES, V70, P5923, DOI 10.1158/0008-5472.CAN-10-0655; WINQVIST R, 1995, CANCER RES, V55, P2660; Wu JM, 2012, CARCINOGENESIS, V33, P519, DOI 10.1093/carcin/bgr304; Wu ZS, 2011, CANCER-AM CANCER SOC, V117, P2842, DOI 10.1002/cncr.25860; Yu FY, 2012, J BIOL CHEM, V287, P465, DOI 10.1074/jbc.M111.280768; Zajchowski DA, 2001, CANCER RES, V61, P5168	67	176	181	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2013	32	36					4294	4303		10.1038/onc.2012.432	http://dx.doi.org/10.1038/onc.2012.432			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23001043				2022-12-17	WOS:000324168000011
J	Hildebrandt, MAT; Gu, J; Lin, J; Ye, Y; Tan, W; Tamboli, P; Wood, CG; Wu, X				Hildebrandt, M. A. T.; Gu, J.; Lin, J.; Ye, Y.; Tan, W.; Tamboli, P.; Wood, C. G.; Wu, X.			Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; microRNA; methylation; metastasis; miR-9	HUMAN BREAST-CANCER; MICRORNAS; EXPRESSION; MIR-9	The long-term prognosis for clear cell renal cell carcinoma (ccRCC) is dramatically altered by the development of metastatic recurrence. However, there are very few indicators that can predict which patient will develop a recurrence. MicroRNAs regulate many cellular processes and have been shown to be associated with cancer development and recurrence. More recently it has been shown that microRNA genes can be epigenetically modified in cancer, resulting in aberrant silencing of microRNA genes with tumor suppressor functions. In this study, we show that two genes encoding for hsa-miR-9 are significantly hypermethylated in ccRCC tumors compared with adjacent normal tissues (P-value <0.001 for both miR-9-1 and miR-9-3) resulting in decreased expression, and that the methylation of these genes was more significant in DNA obtained from the primary tumor for patients who developed a recurrence (P-value: 0.012 and 0.009 for miR-9-1 and miR-9-3, respectively) than in tumors from nonrecurrent patients. Furthermore, methylation of miR-9-3 was significantly associated with an increased risk of recurrence (hazard ratio: 5.85, 95% confidence intervals: 1.30-26.35) and high methylation levels of either miR-9-1 or miR-9-3 resulted in a significant, nearly 30-month decrease in recurrence-free survival time (P-value: 0.034 and 0.007 for miR-9-1 and miR-9-3, respectively). Our results demonstrate that hsa-miR-9 is involved in the development of ccRCC while also having a role in the development of metastatic recurrence. Oncogene (2010) 29, 5724-5728; doi:10.1038/onc.2010.305; published online 2 August 2010	[Wu, X.] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Unit 1340, Houston, TX 77030 USA; [Tamboli, P.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Wood, C. G.] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Wu, X (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Unit 1340, 1155 Pressler Blvd, Houston, TX 77030 USA.	xwu@mdanderson.org	Gu, Jian/Q-4780-2018	Gu, Jian/0000-0003-3499-0973	National Institute of Health [R01 CA098897]; NATIONAL CANCER INSTITUTE [R01CA098897, K07CA134831] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported, in part, by National Institute of Health Grant R01 CA098897.	Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638; Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Hsu PY, 2009, CANCER RES, V69, P5936, DOI 10.1158/0008-5472.CAN-08-4914; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Laios A, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-35; Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Lujambio A, 2007, CELL CYCLE, V6, P1455; Luo HC, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-82; Omura N, 2008, CANCER BIOL THER, V7, P1146, DOI 10.4161/cbt.7.7.6208; Pantuck AJ, 2001, J UROLOGY, V166, P1611, DOI 10.1016/S0022-5347(05)65640-6; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025	15	176	191	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	42					5724	5728		10.1038/onc.2010.305	http://dx.doi.org/10.1038/onc.2010.305			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	668IT	20676129				2022-12-17	WOS:000283262500008
J	Szajnik, M; Szczepanski, MJ; Czystowska, M; Elishaev, E; Mandapathil, M; Nowak-Markwitz, E; Spaczynski, M; Whiteside, TL				Szajnik, M.; Szczepanski, M. J.; Czystowska, M.; Elishaev, E.; Mandapathil, M.; Nowak-Markwitz, E.; Spaczynski, M.; Whiteside, T. L.			TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer	ONCOGENE			English	Article						ovarian cancer; paclitaxel; TLR4; MyD88	TOLL-LIKE RECEPTORS; CELL-LINES; EPITHELIAL-CELLS; CARCINOMA; TAXOL; GENE; EXPRESSION; APOPTOSIS; OVEREXPRESSION; INTERLEUKIN-6	Toll-like receptors (TLRs) expressed on immune cells trigger inflammatory responses. TLRs are also expressed on ovarian cancer (OvCa) cells, but the consequences of signaling by the TLR4/MyD88 pathway in these cells are unclear. Here, TLR4 and MyD88 expression in OvCa tissues (n = 20) and cell lines (OVCAR3, SKOV3, AD10, A2780 and CP70) was evaluated by reverse transcriptase-PCR, western blots and immunohistochemistry. Cell growth, apoptosis, nuclear factor-kappa B (NF-kappa B) translocation, IRAK4 and TRIF expression and cJun phosphorylation were measured following tumor cell exposure to the TLR4 ligands, lipopolysaccharide (LPS) or paclitaxel (PTX). Culture supernatants were tested for cytokine levels. TLR4 was expressed in all tumors, tumor cell lines and normal epithelium. MyD88 was detectable in tumor tissues and in 3/5 OvCa lines but not in normal cells. In MyD88(+) SCOV3 cells, LPS or PTX binding to TLR4 induced IRAK4 activation and cJun phosphorylation, activated the NF-kappa B pathway and promoted interleukin (IL)-8, IL-6, vascular endothelial growth factor and monocyte chemotactic protein-1 production and resistance to drug-induced apoptosis. Silencing of TLR4 in SCOV3 cells with small interference RNA resulted in phosphorylated-cJun (p-cJun) downregulation and a loss of PTX resistance. In PTX-sensitive, MyD88(neg) A2780 cells, TLR4 stimulation upregulated TRIF, and TLR4 silencing eliminated this effect. Thus, TLR4/MyD88 signaling supports OvCa progression and chemoresistance, promoting immune escape. Oncogene (2009) 28, 4353-4363; doi: 10.1038/onc.2009.289; published online 12 October 2009	[Whiteside, T. L.] Univ Pittsburgh, Dept Pathol, Inst Canc, Sch Med, Pittsburgh, PA 15232 USA; [Szajnik, M.; Spaczynski, M.] Poznan Univ Med Sci, Dept Gynecol Oncol, Poznan, Poland; [Szczepanski, M. J.; Nowak-Markwitz, E.] Poznan Univ Med Sci, Dept Clin Immunol, Poznan, Poland	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Poznan University of Medical Sciences; Poznan University of Medical Sciences	Whiteside, TL (corresponding author), Univ Pittsburgh, Dept Pathol, Inst Canc, Sch Med, 5117 Ctr Ave,Suite 1-27, Pittsburgh, PA 15232 USA.	whitesidetl@upmc.edu	Mandapathil, Magis/AFL-3260-2022; Czystowska-Kuźmicz, Małgorzata/U-7933-2018; Czystowska-Kuzmicz, Malgorzata/AAC-6989-2020; Czystowska-Kuźmicz, Małgorzata/ABH-3220-2020	Czystowska-Kuźmicz, Małgorzata/0000-0001-9169-6194; Czystowska-Kuźmicz, Małgorzata/0000-0001-9169-6194	NIH [PO1 CA109688, NO1-HB37165]; National Heart Lung and Blood Institute (NHLBI); NATIONAL CANCER INSTITUTE [P01CA109688] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart Lung and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank B Hilldorfer for technical assistance and the Centre for Biologic Imaging at the University of Pittsburgh for assistance in performing confocal microscopy. This study was supported in part by NIH Grants PO1 CA109688 (TLW) and NO1-HB37165 (TLW) and by Heidi L Browning Ovarian Cancer Research Scholar Fund. Dr Szajnik was supported by the fellowship from the PACT Program of the National Heart Lung and Blood Institute (NHLBI).	Backhed F, 2003, MICROBES INFECT, V5, P951, DOI 10.1016/S1286-4579(03)00189-8; Bayry J, 2004, P NATL ACAD SCI USA, V101, P14210, DOI 10.1073/pnas.0402183101; BEHRENS BC, 1987, CANCER RES, V47, P414; Berek JS, 1999, ANN ONCOL, V10, P87, DOI 10.1023/A:1008323922057; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Brewer MA, 2003, CLIN CANCER RES, V9, P20; Byrd-Leifer CA, 2001, EUR J IMMUNOL, V31, P2448, DOI 10.1002/1521-4141(200108)31:8&lt;2448::AID-IMMU2448&gt;3.0.CO;2-N; Chuang TH, 2001, BBA-GENE STRUCT EXPR, V1518, P157, DOI 10.1016/S0167-4781(00)00289-X; Cimoli G, 2004, BBA-REV CANCER, V1705, P103, DOI 10.1016/j.bbcan.2004.10.001; Cuello M, 2001, GYNECOL ONCOL, V81, P380, DOI 10.1006/gyno.2001.6194; Duan ZF, 1999, GENE, V229, P75, DOI 10.1016/S0378-1119(99)00042-6; Duan ZF, 2003, CLIN CANCER RES, V9, P2778; Eskan MA, 2008, J IMMUNOL, V180, P1818, DOI 10.4049/jimmunol.180.3.1818; Fitzpatrick FA, 2003, INT IMMUNOPHARMACOL, V3, P1699, DOI 10.1016/j.intimp.2003.08.007; Fukata M, 2008, ONCOGENE, V27, P234, DOI 10.1038/sj.onc.1210908; Gallardo D, 1996, CANCER RES, V56, P4891; Girling JE, 2007, IMMUNOL CELL BIOL, V85, P481, DOI 10.1038/sj.icb.7100086; He WG, 2007, MOL IMMUNOL, V44, P2850, DOI 10.1016/j.molimm.2007.01.022; Hefler LA, 2003, CANCER RES, V63, P3066; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; Huang X, 2005, INVEST OPHTH VIS SCI, V46, P4209, DOI 10.1167/iovs.05-0185; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kassim SK, 2004, CLIN BIOCHEM, V37, P363, DOI 10.1016/j.clinbiochem.2004.01.014; Kawasaki K, 2001, J ENDOTOXIN RES, V7, P232, DOI 10.1177/09680519010070030701; Kelly MG, 2006, CANCER RES, V66, P3859, DOI 10.1158/0008-5472.CAN-05-3948; Kreuz S, 2004, J CELL BIOL, V166, P369, DOI 10.1083/jcb.200401036; Landen CN, 2008, J CLIN ONCOL, V26, P995, DOI 10.1200/JCO.2006.07.9970; Lauzon NM, 2006, CELL IMMUNOL, V241, P102, DOI 10.1016/j.cellimm.2006.08.004; Lokshin AE, 2006, GYNECOL ONCOL, V102, P244, DOI 10.1016/j.ygyno.2005.12.011; MacRedmond R, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-116; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Marupudi NI, 2007, EXPERT OPIN DRUG SAF, V6, P609, DOI 10.1517/14740338.6.5.609; MCCLURE N, 1994, LANCET, V344, P235, DOI 10.1016/S0140-6736(94)93001-5; Molteni M, 2006, CANCER LETT, V235, P75, DOI 10.1016/j.canlet.2005.04.006; Penson RT, 2000, INT J GYNECOL CANCER, V10, P33, DOI 10.1046/j.1525-1438.2000.00003.x; Petty R, 1998, Pathol Oncol Res, V4, P97; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Siervo-Sassi RR, 2003, CANCER LETT, V190, P61, DOI 10.1016/S0304-3835(02)00579-7; Strauss L, 2007, J IMMUNOL, V178, P320, DOI 10.4049/jimmunol.178.1.320; Szczepanski M, 2007, EUR ARCH OTO-RHINO-L, V264, P525, DOI 10.1007/s00405-006-0215-7; Szczepanski MJ, 2009, CANCER RES, V69, P3105, DOI 10.1158/0008-5472.CAN-08-3838; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeda K, 2007, SEMIN IMMUNOL, V19, P24; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Tanimura N, 2008, BIOCHEM BIOPH RES CO, V368, P94, DOI 10.1016/j.bbrc.2008.01.061; Taxman DJ, 2003, CANCER RES, V63, P5095; Wang TH, 2006, ONCOGENE, V25, P4857, DOI 10.1038/sj.onc.1209498; Yusuf RZ, 2003, CURR CANCER DRUG TAR, V3, P1, DOI 10.2174/1568009033333754; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	49	176	199	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2009	28	49					4353	4363		10.1038/onc.2009.289	http://dx.doi.org/10.1038/onc.2009.289			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DT	19826413	Green Accepted			2022-12-17	WOS:000272876400004
J	Chitale, D; Gong, Y; Taylor, BS; Broderick, S; Brennan, C; Somwar, R; Golas, B; Wang, L; Motoi, N; Szoke, J; Reinersman, JM; Major, J; Sander, C; Seshan, VE; Zakowski, MF; Rusch, V; Pao, W; Gerald, W; Ladanyi, M				Chitale, D.; Gong, Y.; Taylor, B. S.; Broderick, S.; Brennan, C.; Somwar, R.; Golas, B.; Wang, L.; Motoi, N.; Szoke, J.; Reinersman, J. M.; Major, J.; Sander, C.; Seshan, V. E.; Zakowski, M. F.; Rusch, V.; Pao, W.; Gerald, W.; Ladanyi, M.			An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors	ONCOGENE			English	Article						lung adenocarcinoma; expression profiling; array comparative genomic hybridization; microarray; EGFR; KRAS	SOMATIC MUTATIONS; KRAS MUTATIONS; GENE; ADENOCARCINOMA; GLIOBLASTOMA; PATHWAYS; SPECIFICITY; REGULATORS; SENESCENCE; EXPRESSION	To address the biological heterogeneity of lung cancer, we studied 199 lung adenocarcinomas by integrating genome-wide data on copy number alterations and gene expression with full annotation for major known somatic mutations in this cancer. This showed non-random patterns of copy number alterations significantly linked to EGFR and KRAS mutation status and to distinct clinical outcomes, and led to the discovery of a striking association of EGFR mutations with underexpression of DUSP4, a gene within a broad region of frequent single-copy loss on 8p. DUSP4 is involved in negative feedback control of EGFR signaling, and we provide functional validation for its role as a growth suppressor in EGFR-mutant lung adenocarcinoma. DUSP4 loss also associates with p16/CDKN2A deletion and defines a distinct clinical subset of lung cancer patients. Another novel observation is that of a reciprocal relationship between EGFR and LKB1 mutations. These results highlight the power of integrated genomics to identify candidate driver genes within recurrent broad regions of copy number alteration and to delineate distinct oncogenetic pathways in genetically complex common epithelial cancers. Oncogene (2009) 28, 2773-2783; doi:10.1038/onc.2009.135; published online 15 June 2009	[Chitale, D.; Wang, L.; Motoi, N.; Szoke, J.; Reinersman, J. M.; Zakowski, M. F.; Gerald, W.; Ladanyi, M.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA; [Gong, Y.; Pao, W.; Gerald, W.; Ladanyi, M.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Taylor, B. S.; Major, J.; Sander, C.] Mem Sloan Kettering Canc Ctr, Computat Biol Program, New York, NY 10065 USA; [Broderick, S.; Golas, B.; Rusch, V.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA; [Brennan, C.] Mem Sloan Kettering Canc Ctr, Dept Neurosurg, New York, NY 10065 USA; [Somwar, R.; Seshan, V. E.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA; [Pao, W.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Ladanyi, M (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave,Room S-801, New York, NY 10065 USA.	ladanyim@mskcc.org	Ladanyi, Marc/AAG-8585-2019; Brennan, Cameron/R-7082-2019; Reinersman, Matthew/ABE-3551-2020; Sander, Chris/H-1452-2011; Wang, Lu/N-8128-2018; Motoi, Noriko/AAO-5642-2020; Motoi, Noriko/A-9718-2009	Brennan, Cameron/0000-0003-4064-8891; Reinersman, Matthew/0000-0002-4458-0743; Sander, Chris/0000-0001-6059-6270; Wang, Lu/0000-0002-0073-0666; Motoi, Noriko/0000-0001-7098-3311; Motoi, Noriko/0000-0001-7098-3311; Chitale, Dhananjay/0000-0002-4421-6431; Rusch, Valerie/0000-0003-2345-6900	National Cancer Institute [U01-CA84999, P01-CA129243]; Doris Duke Charitable Foundation; Long Island League to Abolish Cancer; Labrecque Foundation; Lung Cancer Research Foundation; Anbinder Fund; NATIONAL CANCER INSTITUTE [U01CA084999, P01CA129243] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); Long Island League to Abolish Cancer; Labrecque Foundation; Lung Cancer Research Foundation; Anbinder Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Agnes Viale and the MSKCC Genomics Core Laboratory personnel for the generation of microarray data; Dr Laetitia Borsu for assistance with Sequenom assays; Drs Hakim Djaballah and Gabriela E. Sanchez of the MSKCC HTS Core Facility for providing GFP siRNAs; Louis Vargas, Yonghong Xiao and the MSKCC Pathology Core personnel for technical assistance; Drs William Travis, Andre Moreira and David Klimstra for providing pathologic diagnoses; Drs John Minna and Adi Gazdar for providing the human bronchial epithelial cell ( HBEC) lines; Drs Alice H Berger, Marasu Niki and Pier Paolo Pandol. for assistance with reagents and related studies; Dr Roman Thomas for sharing unpublished microarray data, and Dr Harold Varmus for support ( to RS). Barry S Taylor is a graduate student in the Department of Physiology and Biophysics, Weill Cornell Graduate School of Medical Sciences. We acknowledge the support of the National Cancer Institute (U01-CA84999 to WG, P01-CA129243to ML), the Doris Duke Charitable Foundation ( to WP), the Long Island League to Abolish Cancer ( to WP), the Labrecque Foundation ( to WG) and the Lung Cancer Research Foundation ( to ML). The MSKCC Sequenom facility is supported by the Anbinder Fund.	Adams J, 2005, CANCER LETT, V220, P137, DOI 10.1016/j.canlet.2004.06.052; Adler AS, 2006, NAT GENET, V38, P421, DOI 10.1038/ng1752; Amit I, 2007, NAT GENET, V39, P503, DOI 10.1038/ng1987; Armes JE, 2004, ONCOGENE, V23, P5697, DOI 10.1038/sj.onc.1207740; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; Garnis C, 2006, INT J CANCER, V118, P1556, DOI 10.1002/ijc.21491; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; Kobayashi S, 2006, CANCER RES, V66, P11389, DOI 10.1158/0008-5472.CAN-06-2318; Kwei KA, 2008, ONCOGENE, V27, P3635, DOI 10.1038/sj.onc.1211012; Lee SH, 1999, CANCER RES, V59, P5683; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Marks JL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000426; Matsumoto S, 2007, ONCOGENE, V26, P5911, DOI 10.1038/sj.onc.1210418; Meyerson M, 2004, SEMIN ONCOL, V31, P4, DOI 10.1053/j.seminoncol.2003.12.009; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Mounawar M, 2007, CANCER RES, V67, P5667, DOI 10.1158/0008-5472.CAN-06-4229; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Riely GJ, 2008, CLIN CANCER RES, V14, P5731, DOI 10.1158/1078-0432.CCR-08-0646; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sato M, 2006, CANCER RES, V66, P2116, DOI 10.1158/0008-5472.CAN-05-2521; Schulze A, 2004, MOL BIOL CELL, V15, P3450, DOI 10.1091/mbc.E03-11-0807; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shaw AT, 2007, GENE DEV, V21, P694, DOI 10.1101/gad.1526207; Shen WH, 2006, CANCER RES, V66, P6033, DOI 10.1158/0008-5472.CAN-05-3878; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Takano T, 2005, J CLIN ONCOL, V23, P6829, DOI 10.1200/JCO.2005.01.0793; Tanaka H, 2007, CANCER RES, V67, P6007, DOI 10.1158/0008-5472.CAN-06-4774; Tresini M, 2007, J BIOL CHEM, V282, P4136, DOI 10.1074/jbc.M604955200; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Zhu CQ, 2004, CLIN CANCER RES, V10, P1984, DOI 10.1158/1078-0432.CCR-03-0470	38	176	181	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28	31					2773	2783		10.1038/onc.2009.135	http://dx.doi.org/10.1038/onc.2009.135			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479TS	19525976	Green Accepted, Green Submitted			2022-12-17	WOS:000268684400001
J	Wagner, S; Carpentier, I; Rogov, V; Kreike, M; Ikeda, F; Lohr, F; Wu, CJ; Ashwell, JD; Dotsch, V; Dikic, I; Beyaert, R				Wagner, S.; Carpentier, I.; Rogov, V.; Kreike, M.; Ikeda, F.; Loehr, F.; Wu, C-J; Ashwell, J. D.; Doetsch, V.; Dikic, I.; Beyaert, R.			Ubiquitin binding mediates the NF-kappa B inhibitory potential of ABIN proteins	ONCOGENE			English	Article						ABIN; NF-kappa B; ubiquitin; TNF; protein-protein interaction	ADENOVIRAL GENE-TRANSFER; A20-BINDING INHIBITOR; NEMO/IKK-GAMMA; KINASE COMPLEX; ACTIVATION; ALPHA; A20; IKK; RIP	Deregulated nuclear factor kappa B (NF-kappa B) activation plays an important role in inflammation and tumorigenesis. ABIN proteins have been characterized as negative regulators of NF-kappa B signaling. However, their mechanism of NF-kappa B inhibition remained unclear. With the help of a yeast two-hybrid screen, we identified ABIN proteins as novel ubiquitin-interacting proteins. The minimal ubiquitin-binding domain (UBD) corresponds to the ABIN homology domain 2 (AHD2) and is highly conserved in ABIN-1, ABIN-2 and ABIN-3. Moreover, this region is also present in NF-kappa B essential modulator/I kappa B kinase gamma (NEMO/IKK gamma) and the NEMO-like protein optineurin, and is therefore termed UBD in ABIN proteins and NEMO (UBAN). Nuclear magnetic resonance studies of the UBAN domain identify it as a novel type of UBD, with the binding surface on ubiquitin being significantly different from the binding surface of other UBDs. ABIN-1 specifically binds ubiquitinated NEMO via a bipartite interaction involving its UBAN and NEMO-binding domain. Mutations in the UBAN domain led to a loss of ubiquitin binding and impaired the NF-kappa B inhibitory potential of ABINs. Taken together, these data illustrate an important role for ubiquitin binding in the negative regulation of NF-kappa B signaling by ABINs and identify UBAN as a novel UBD.	[Carpentier, I.; Kreike, M.; Beyaert, R.] Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, B-9052 Ghent, Belgium; [Carpentier, I.; Kreike, M.; Beyaert, R.] Univ Ghent, Dept Mol Biol, Zwijnaarde, Belgium; [Wagner, S.; Ikeda, F.; Dikic, I.] Univ Frankfurt, Sch Med, Inst Biochem 2, Frankfurt, Germany; [Rogov, V.; Loehr, F.; Doetsch, V.] Univ Frankfurt, Inst Biophys Chem, Frankfurt, Germany; [Rogov, V.] Russian Acad Sci, Inst Prot Res, Pushchino 142292, Russia; [Wu, C-J; Ashwell, J. D.] NCI, Lab Immune Cell Biol, NIH, Bethesda, MD 20892 USA	Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Goethe University Frankfurt; Goethe University Frankfurt; Russian Academy of Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Beyaert, R (corresponding author), Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, Technologiepk 927, B-9052 Ghent, Belgium.	ivan.dikic@biochem2.de; rudi.beyaert@dmbr.ugent.be	Doetsch, Volker/D-5697-2011; Ikeda, Fumiyo/AAD-3770-2020; Dikic, Ivan/O-4650-2015; Beyaert, Rudi/B-2589-2009; Wagner, Sebastian/B-9056-2012	Ikeda, Fumiyo/0000-0003-0407-2768; Dikic, Ivan/0000-0001-8156-9511; Dotsch, Volker/0000-0001-5720-212X; Beyaert, Rudi/0000-0002-5704-582X	NATIONAL CANCER INSTITUTE [ZIABC010779, Z01BC010779] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agou F, 2004, J BIOL CHEM, V279, P54248, DOI 10.1074/jbc.M406423200; Calzado MA, 2007, CURR MED CHEM, V14, P367, DOI 10.2174/092986707779941113; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; El Bakkouri K, 2005, J BIOL CHEM, V280, P17938, DOI 10.1074/jbc.M413588200; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Heyninck K, 2003, FEBS LETT, V536, P135, DOI 10.1016/S0014-5793(03)00041-3; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; Liu WK, 2004, BIOCHEM J, V378, P867, DOI 10.1042/BJ20031736; Mauro C, 2006, J BIOL CHEM, V281, P18482, DOI 10.1074/jbc.M601502200; Shambharkar PB, 2007, EMBO J, V26, P1794, DOI 10.1038/sj.emboj.7601622; Shembade N, 2007, EMBO J, V26, P3910, DOI 10.1038/sj.emboj.7601823; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Van Huffel S, 2001, J BIOL CHEM, V276, P30216, DOI 10.1074/jbc.M100048200; Weaver BK, 2007, MOL CELL BIOL, V27, P4603, DOI 10.1128/MCB.00223-07; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384; Wullaert A, 2005, HEPATOLOGY, V42, P381, DOI 10.1002/hep.20785; Wullaert A, 2007, J BIOL CHEM, V282, P81, DOI 10.1074/jbc.M607481200; Wullaert A, 2006, TRENDS IMMUNOL, V27, P533, DOI 10.1016/j.it.2006.09.003; Zhou HL, 2005, CANCER CELL, V7, P425, DOI 10.1016/j.ccr.2005.04.012; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273; Zhu G, 2007, CURR BIOL, V17, P1438, DOI 10.1016/j.cub.2007.07.041	21	176	186	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	26					3739	3745		10.1038/sj.onc.1211042	http://dx.doi.org/10.1038/sj.onc.1211042			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18212736				2022-12-17	WOS:000256659300011
J	Evers, B; Jonkers, J				Evers, B.; Jonkers, J.			Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects	ONCOGENE			English	Review						BRCA1; BRCA2; breast cancer; tumor suppressor; mouse model	CANCER SUSCEPTIBILITY GENE; EMBRYONIC CELLULAR PROLIFERATION; DNA-DAMAGE RESPONSE; BREAST-CANCER; SPLICE VARIANT; GENOMIC INSTABILITY; ESTROGEN-RECEPTOR; FAMILIAL BREAST; CENTROSOME AMPLIFICATION; INDUCED TUMORIGENESIS	Germline mutations in BRCA1 and BRCA2 are responsible for a large proportion of hereditary breast and ovarian cancers. Soon after the identification of both genes in the mid-1990s, investigators set out to develop mouse models for the associated disease. Whereas conventional Brca1 and Brca2 mouse mutants did not reveal a strong phenotype in a heterozygous setting, most homozygous mutations caused embryonic lethality. Consequently, development of mouse models for BRCA-associated tumorigenesis required the generation of tissue-specific conditional knockout animals. In this review, we give an overview of the conventional and the conditional mouse models of BRCA1 and BRCA2 deficiency generated over the last decade, as well as the contribution of these models to our understanding of the biological and molecular functions of BRCA1 and BRCA2. The most advanced mouse models for BRCA1- and BRCA2-associated tumorigenesis mimic human disease to the extent that they can be used in studies addressing clinically relevant questions. These models will help to resolve yet unanswered questions and to translate our increasing knowledge of BRCA1 and BRCA2 biology into clinical practice.	Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Jonkers, J (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.jonkers@nki.nl	Jonkers, Jos/AAG-3246-2019	Jonkers, Jos/0000-0002-9264-9792				Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; Bachelier R, 2005, ONCOL REP, V14, P1117; Bae I, 2005, CELL CYCLE, V4, P1641, DOI 10.4161/cc.4.11.2152; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bennett LM, 2000, MOL CARCINOGEN, V28, P174, DOI 10.1002/1098-2744(200007)28:3<174::AID-MC6>3.0.CO;2-C; Berton TR, 2003, ONCOGENE, V22, P5415, DOI 10.1038/sj.onc.1206825; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Cao L, 2003, GENE DEV, V17, P201, DOI 10.1101/gad.1050003; Cao L, 2006, EMBO J, V25, P2167, DOI 10.1038/sj.emboj.7601115; Chandler J, 2001, GENESIS, V29, P72, DOI 10.1002/1526-968X(200102)29:2<72::AID-GENE1007>3.0.CO;2-B; Chappuis PO, 2000, SEMIN SURG ONCOL, V18, P287, DOI 10.1002/(SICI)1098-2388(200006)18:4<287::AID-SSU3>3.3.CO;2-X; Chen FQ, 1997, MUTAT RES-DNA REPAIR, V384, P205, DOI 10.1016/S0921-8777(97)00020-7; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Cheung AMY, 2004, CANCER RES, V64, P1959, DOI 10.1158/0008-5472.CAN-03-2270; Cheung AMY, 2002, CANCER RES, V62, P6194; COLLINS N, 1995, ONCOGENE, V10, P1673; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; Cullinane CA, 2005, INT J CANCER, V117, P988, DOI 10.1002/ijc.21273; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Dekker M, 2006, GENE THER, V13, P686, DOI 10.1038/sj.gt.3302689; Dekker M, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng027; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Donoho G, 2003, GENE CHROMOSOME CANC, V36, P317, DOI 10.1002/gcc.10148; Elledge SJ, 2002, CANCER CELL, V1, P129, DOI 10.1016/S1535-6108(02)00041-7; ElShamy WM, 2004, NAT CELL BIOL, V6, P954, DOI 10.1038/ncb1171; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fortin J, 2005, BBA-GENE STRUCT EXPR, V1731, P57, DOI 10.1016/j.bbaexp.2005.08.011; Friedman LS, 1998, CANCER RES, V58, P1338; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Greenblatt MS, 2001, CANCER RES, V61, P4092; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hay T, 2005, CANCER RES, V65, P10145, DOI 10.1158/0008-5472.CAN-05-1186; Hay T, 2005, ONCOGENE, V24, P3842, DOI 10.1038/sj.onc.1208533; Hohenstein P, 2001, ONCOGENE, V20, P2544, DOI 10.1038/sj.onc.1204363; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Jones LP, 2005, ONCOGENE, V24, P3554, DOI 10.1038/sj.onc.1208426; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Jonkers J, 2002, NAT REV CANCER, V2, P251, DOI 10.1038/nrc777; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kim SS, 2004, MOL CELL BIOL, V24, P9498, DOI 10.1128/MCB.24.21.9498-9507.2004; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lane TF, 2004, CANCER BIOL THER, V3, P528, DOI 10.4161/cbt.3.6.843; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528; Lomonosov M, 2003, GENE DEV, V17, P3017, DOI 10.1101/gad.279003; Lou ZK, 2005, NAT STRUCT MOL BIOL, V12, P589, DOI 10.1038/nsmb953; Lu ML, 1996, CANCER RES, V56, P4578; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Ludwig T, 2001, ONCOGENE, V20, P3937, DOI 10.1038/sj.onc.1204512; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; Mak TW, 2000, NAT IMMUNOL, V1, P77, DOI 10.1038/76950; Mallepell S, 2006, P NATL ACAD SCI USA, V103, P2196, DOI 10.1073/pnas.0510974103; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; McAllister KA, 2002, CANCER RES, V62, P990; McPherson JP, 2006, HUM MOL GENET, V15, P831, DOI 10.1093/hmg/ddl002; McPherson JP, 2004, GENE DEV, V18, P1144, DOI 10.1101/gad.1192704; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Metcalfe K, 2004, J CLIN ONCOL, V22, P2328, DOI 10.1200/JCO.2004.04.033; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mixon M, 2000, ONCOGENE, V19, P5237, DOI 10.1038/sj.onc.1203905; Morimatsu M, 1998, CANCER RES, V58, P3441; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Noruzinia M, 2005, CANCER-AM CANCER SOC, V104, P1567, DOI 10.1002/cncr.21367; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pellegrini L, 2004, TRENDS BIOCHEM SCI, V29, P310, DOI 10.1016/j.tibs.2004.04.009; Phillips KA, 2000, J CLIN ONCOL, V18, p107S; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rebbeck TR, 1999, J NATL CANCER I, V91, P1475, DOI 10.1093/jnci/91.17.1475; Schultz N, 2003, NUCLEIC ACIDS RES, V31, P4959, DOI 10.1093/nar/gkg703; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Selbert S, 1998, TRANSGENIC RES, V7, P387, DOI 10.1023/A:1008848304391; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Shin S, 2003, P NATL ACAD SCI USA, V100, P7201, DOI 10.1073/pnas.1132020100; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Spillman MA, 1996, ONCOGENE, V13, P1639; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Turner JMA, 2004, CURR BIOL, V14, P2135, DOI 10.1016/j.cub.2004.11.032; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Tutt ANJ, 2002, EMBO REP, V3, P255, DOI 10.1093/embo-reports/kvf037; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Wang XY, 2004, J BIOL CHEM, V279, P29606, DOI 10.1074/jbc.M312279200; Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Xu CF, 1997, GENE CHROMOSOME CANC, V18, P102, DOI 10.1002/(SICI)1098-2264(199702)18:2<102::AID-GCC4>3.3.CO;2-A; Xu JW, 2005, ENDOCRINOLOGY, V146, P2031, DOI 10.1210/en.2004-0409; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yan DH, 2004, ONCOGENE, V23, P1896, DOI 10.1038/sj.onc.1207314; Yang YP, 2003, HUM MOL GENET, V12, P2121, DOI 10.1093/hmg/ddg222	121	176	177	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2006	25	43					5885	5897		10.1038/sj.onc.1209871	http://dx.doi.org/10.1038/sj.onc.1209871			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TS	16998503				2022-12-17	WOS:000240765900009
J	Mulholland, DJ; Dedhar, S; Wu, H; Nelson, CC				Mulholland, DJ; Dedhar, S; Wu, H; Nelson, CC			PTEN and GSK3 beta: Key regulators of progression to androgen- independent prostate cancer	ONCOGENE			English	Review						PTEN; GSK3 beta; androgen; independent; prostate cancer	INTEGRIN-LINKED KINASE; GROWTH-FACTOR-I; TUMOR-SUPPRESSOR GENE; NUCLEAR BETA-CATENIN; CELL-CYCLE ARREST; GLYCOGEN-SYNTHASE KINASE-3-BETA; INTRAEPITHELIAL NEOPLASIA; MAMMALIAN TARGET; TRANSCRIPTIONAL ACTIVITY; INCREASED EXPRESSION	Prostate cancer (PrCa) is characterized by progression from an androgen-dependent phenotype to one that is inevitably androgen independent (AI) and lethal. Recent evidence strongly suggests that the phosphatidylinositol-3-kinase/Akt (PI3K/Akt) and androgen receptor (AR) signalling pathways provide prostatic epithelium with the necessary signalling events to escape the apoptotic response associated with androgen withdrawal therapy. Silencing of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) and glycogen synthase kinase beta (GSK3b) are frequently associated with advanced PrCa systems and likely serve critical roles in promoting AR and PI3K/Akt gain-of-function. That PTEN negatively regulates AR and is sufficient to promote metastatic PrCa in murine models strongly implies its role as a gatekeeper of progressive PrCa. In human PrCa, PTEN loss is correlated with substantial increases in Akt(Ser473) and integrin-linked kinase expression, both of which promote Ser(9) phospho-inhibition of GSK3 beta and inactivation of apoptotic factors. Sufficient evidence also suggests that GSK3 beta is not only a critical regulator of proproliferative signalling but also a promiscuous one as PI3K/Akt pools of GSK3 beta are, at least in part, functionally interchangeable with those of the Wnt/beta-catenin pathway. Thus, GSK3 beta may serve not only as a mediator of PI3K/ Akt activation but may also regulate the potent transactivation and proproliferative effects that Wnt3a and beta-catenin confer upon AR. These data suggest that prostate-specific activation of GSK3 beta may serve as a viable pharmacological option. Thus, in this review, we emphasize that temporal changes in GSK3 beta and PTEN expression during progression to AI PrCa are important factors when considering the potential for therapies targeting the oncogenic contributions of PI3K/Akt and AR signalling pathways.	Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Vancouver Gen Hosp, Prostate Ctr, Vancouver, BC, Canada	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of British Columbia	Mulholland, DJ (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, 650 Charles E Young Dr S, Los Angeles, CA 90095 USA.	dmulholland@mednet.ucla.edu		Dedhar, Shoukat/0000-0003-4355-1657				Altuwaijri S, 2004, ENDOCRINE, V25, P27, DOI 10.1385/ENDO:25:1:27; Anna CH, 2003, TOXICOL APPL PHARM, V190, P135, DOI 10.1016/S0041-008X(03)00170-4; Asatiani E, 2005, CANCER RES, V65, P1164, DOI 10.1158/0008-5472.CAN-04-2688; Bernard D, 2003, J CLIN INVEST, V112, P1724; Bierie B, 2003, ONCOGENE, V22, P3875, DOI 10.1038/sj.onc.1206426; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; Bowen C, 2000, CANCER RES, V60, P6111; Campbell RB, 2003, J BIOL CHEM, V278, P33617, DOI 10.1074/jbc.C300296200; Carter Michael D, 2004, J Biomol Tech, V15, P257; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen GP, 2004, CANCER-AM CANCER SOC, V101, P1345, DOI 10.1002/cncr.20518; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Cinar B, 2005, CANCER RES, V65, P2547, DOI 10.1158/0008-5472.CAN-04-3411; Comuzzi B, 2003, AM J PATHOL, V162, P233, DOI 10.1016/S0002-9440(10)63814-X; CULIG Z, 1994, CANCER RES, V54, P5474; Davies MA, 1999, CANCER RES, V59, P2551; de la Taille A, 2003, CLIN CANCER RES, V9, P1801; DeFeo-Jones D, 2005, MOL CANCER THER, V4, P271; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Dreher T, 2004, VIRCHOWS ARCH, V444, P509, DOI 10.1007/s00428-004-1004-6; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Fu MF, 2004, BIOCHEM PHARMACOL, V68, P1199, DOI 10.1016/j.bcp.2004.05.037; Fu MF, 2003, J STEROID BIOCHEM, V85, P133, DOI 10.1016/S0960-0760(03)00223-1; Fu MF, 2003, MOL CELL BIOL, V23, P8563, DOI 10.1128/MCB.23.23.8563-8575.2003; Gao N, 2003, BIOCHEM BIOPH RES CO, V310, P1124, DOI 10.1016/j.bbrc.2003.09.132; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Gingrich JR, 1999, PROSTATE CANCER P D, V2, P70, DOI 10.1038/sj/pcan/4500296; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Gounari F, 2002, ONCOGENE, V21, P4099, DOI 10.1038/sj.onc.1205562; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Graff JR, 2001, CLIN CANCER RES, V7, P1987; Gregory CW, 2001, CANCER RES, V61, P4315; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; He WW, 1997, GENOMICS, V43, P69, DOI 10.1006/geno.1997.4715; Heisler LE, 1997, MOL CELL ENDOCRINOL, V126, P59, DOI 10.1016/S0303-7207(96)03970-6; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Huang HJ, 2004, J BIOL CHEM, V279, P13866, DOI 10.1074/jbc.M314143200; Isaacs W, 2001, EPIDEMIOL REV, V23, P36, DOI 10.1093/oxfordjournals.epirev.a000794; Kalesnikoff J, 2004, REV PHYSIOL BIOCH P, V149, P87, DOI 10.1007/s10254-003-0016-y; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; Kim J, 2004, J CELL BIOCHEM, V93, P233, DOI 10.1002/jcb.20228; Koivisto P, 1997, CANCER RES, V57, P314; Koksal IT, 2004, UROL ONCOL-SEMIN ORI, V22, P307, DOI 10.1016/j.urolonc.2004.01.009; Kreisberg JI, 2004, CANCER RES, V64, P5232, DOI 10.1158/0008-5472.CAN-04-0272; Krueckl SL, 2004, CANCER RES, V64, P8620, DOI 10.1158/0008-5472.CAN-04-2446; Li HW, 2004, J BIOL CHEM, V279, P4212, DOI 10.1074/jbc.M311374200; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Li PF, 2001, J BIOL CHEM, V276, P20444, DOI 10.1074/jbc.M010226200; Liao XB, 2004, ENDOCRINOLOGY, V145, P2941, DOI 10.1210/en.2003-1519; Lin HK, 2004, MOL ENDOCRINOL, V18, P2409, DOI 10.1210/me.2004-0117; Lin HK, 2003, J BIOL CHEM, V278, P50902, DOI 10.1074/jbc.M300676200; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Lin JQ, 1999, CANCER RES, V59, P2891; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Malik SN, 2002, CLIN CANCER RES, V8, P1168; Masiello D, 2004, MOL ENDOCRINOL, V18, P2388, DOI 10.1210/me.2003-0436; MASSENKEIL G, 1994, ANTICANCER RES, V14, P2785; McDavid K, 2004, PUBLIC HEALTH REP, V119, P174, DOI 10.1177/003335490411900211; McMenamin ME, 1999, CANCER RES, V59, P4291; Meijer L, 2004, TRENDS PHARMACOL SCI, V25, P471, DOI 10.1016/j.tips.2004.07.006; Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078-0432.CCR-1146-03; Mulholland DJ, 2003, ONCOGENE, V22, P5602, DOI 10.1038/sj.onc.1206802; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Nan B, 2003, J MOL ENDOCRINOL, V31, P169, DOI 10.1677/jme.0.0310169; Nazareth LV, 1999, MOL ENDOCRINOL, V13, P2065, DOI 10.1210/me.13.12.2065; Nickerson T, 1999, UROLOGY, V54, P1120, DOI 10.1016/S0090-4295(99)00421-5; Nickerson T, 2001, CANCER RES, V61, P6276; Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200; Perez JJ, 2002, CURR MED CHEM, V9, P2209, DOI 10.2174/0929867023368683; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; PHILLIPS SMA, 1994, BRIT J UROL, V73, P390, DOI 10.1111/j.1464-410X.1994.tb07602.x; Qi Xiao-ping, 2005, Zhonghua Nan Ke Xue, V11, P34; Radu A, 2003, MOL CELL BIOL, V23, P6139, DOI 10.1128/MCB.23.17.6139-6149.2003; Ratliff Timothy L, 2005, J Urol, V174, P1149; Salas TR, 2004, J BIOL CHEM, V279, P19191, DOI 10.1074/jbc.M309560200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200; Sharp ZD, 2005, J GERONTOL A-BIOL, V60, P293, DOI 10.1093/gerona/60.3.293; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stiles B, 2004, DEV BIOL, V273, P175, DOI 10.1016/j.ydbio.2004.06.008; Sumitomo M, 2004, CANCER CELL, V5, P67, DOI 10.1016/S1535-6108(03)00331-3; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; THOMPSON TC, 1995, ONCOGENE, V10, P869; Truica CI, 2000, CANCER RES, V60, P4709; Van der Poel HG, 2004, J UROLOGY, V172, P1333, DOI 10.1097/01.ju.0000138829.97838.19; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; Verras M, 2005, MOL ENDOCRINOL, V19, P391, DOI 10.1210/me.2004-0208; Verras M, 2004, CANCER RES, V64, P8860, DOI 10.1158/0008-5472.CAN-04-2370; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang QC, 2004, INT J CANCER, V111, P508, DOI 10.1002/ijc.20286; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Warshamana-Greene GS, 2004, MOL CANCER THER, V3, P527; Wen Y, 2000, CANCER RES, V60, P6841; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; Wong HY, 2004, BIOCHEM J, V383, P267, DOI 10.1042/BJ20040683; Wu LC, 2005, CANCER RES, V65, P2825, DOI 10.1158/0008-5472.CAN-04-3137; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Xin L, 2003, P NATL ACAD SCI USA, V100, P11896, DOI 10.1073/pnas.1734139100; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; YUAN SX, 1993, CANCER RES, V53, P1304; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; Zhang LQ, 2003, CANCER RES, V63, P4552; Zhang XJ, 2000, PROSTATE, V43, P278; Zhao H, 2004, ONCOGENE, V23, P786, DOI 10.1038/sj.onc.1207162; Zhu HN, 2004, CANCER RES, V64, P7918, DOI 10.1158/0008-5472.CAN-04-2704	117	176	180	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					329	337		10.1038/sj.onc.1209020	http://dx.doi.org/10.1038/sj.onc.1209020			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16421604				2022-12-17	WOS:000234714100001
J	Zhang, M; Latham, DE; Delaney, MA; Chakravarti, A				Zhang, M; Latham, DE; Delaney, MA; Chakravarti, A			Survivin mediates resistance to antiandrogen therapy in prostate cancer	ONCOGENE			English	Article						survivin; flutamide; androgen; independent prostate cancer	GROWTH-FACTOR-I; ANDROGEN RECEPTOR MUTATIONS; SIGNALING PATHWAYS; TYROSINE KINASE; PROTEIN-KINASE; LNCAP CELLS; APOPTOSIS; EXPRESSION; GENE; PROLIFERATION	Resistance to antiandrogen therapy in patients with metastatic prostate cancer poses a major challenge, which, if overcome, may lead to significant advances in the treatment of these patients. Hormone resistance of prostate cancer develops, in part, from upregulation of antiapoptotic genes after androgen deprivation. Given the accumulating evidence that Survivin, a new member of the inhibitor of apoptosis (IAP) family, is associated with both cancer progression and drug resistance, we hypothesized that Survivin plays a potentially important role in hormone therapy resistance, and that targeting of Survivin may enhance sensitivity to antiandrogen therapy in prostate cancer. Patterns of Survivin expression were assessed in three prostate cancer cell lines LNCaP, PC-3, and DU-145 using quantitative Western analysis. All three cell lines were found to strongly express Survivin. In LNCaP cells with intact androgen receptors (ARs), it was observed that androgen stimulation with 5 alpha-dihydrotestosterone (DHT) increased Survivin expression. Conversely, treatment with Flutamide decreased Survivin expression in LNCaP cells. We next studied the functional effect of Survivin on sensitivity to Flutamide. LNCaP cells were infected with replication-deficient adenoviruses encoding either wild-type Survivin pAd-S(WT) or a phosphorylation-defective Survivin Thr34 -> Ala dominant-negative mutant pAd-S(T34A), and then treated with Flutamide. Cell viability and apoptosis were assessed in vitro and in vivo. It was determined that Survivin can mediate resistance to such antiandrogen therapies based on our assays. Direct androgen stimulation resulted in pan-cell cycle expression of Survivin, which was found to be mediated by AKT, as it was determined that exogenous insulin-like growth factor-1 (IGF-1), a known activator of AKT signaling, could increase Survivin expression and result in pan-cell cycle expression even in AR-negative prostate cancer cell lines PC-3 and DU-145. Given this alternative mechanism of Survivin expression and our findings that Survivin can mediate resistance to Flutamide treatment, we further investigated whether IGF-1-mediated activation of Survivin via AKT could mediate resistance to antiandrogen therapy. Both in vitro and in vivo, this was found to be the case, supporting a novel mechanism of resistance to antiandrogen therapy. Our study indicates that upregulation of Survivin via IGF-1 signaling confers resistance to Flutamide in prostate cancer cells. Targeted inhibition of Survivin appears to enhance the therapeutic effects of Flutamide in vitro and in vivo, revealing a novel strategy to enhance sensitivity to androgen ablation therapy.	Harvard Univ, Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA	Harvard University; Harvard Medical School	Chakravarti, A (corresponding author), Harvard Univ, Gen Hosp, Sch Med, Dept Radiat Oncol, 100 Blossom St,Founders House,Room 536, Boston, MA 02114 USA.	achakravarti@partners.org						Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Denmeade SR, 2002, NAT REV CANCER, V2, P389, DOI 10.1038/nrc801; Djavan B, 2001, WORLD J UROL, V19, P225, DOI 10.1007/s003450100220; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463; GOLDSPIEL BR, 1990, DICP ANN PHARMAC, V24, P616, DOI 10.1177/106002809002400612; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Isaacs JT, 1999, UROL CLIN N AM, V26, P263, DOI 10.1016/S0094-0143(05)70066-5; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Kassen AE, 2000, PROSTATE, V44, P124, DOI 10.1002/1097-0045(20000701)44:2<124::AID-PROS5>3.0.CO;2-S; Kim IY, 1996, EXP CELL RES, V222, P103, DOI 10.1006/excr.1996.0013; Kishi H, 2004, J UROLOGY, V171, P1855, DOI 10.1097/01.ju.0000120317.88372.03; Koivisto P, 1997, CANCER RES, V57, P314; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KYPRIANOU N, 1990, CANCER RES, V50, P3748; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1999, CANCER RES, V59, P3143; LIMONTA P, 1995, J STEROID BIOCHEM, V53, P401, DOI 10.1016/0960-0760(95)00086-F; Ling X, 2004, J BIOL CHEM, V279, P15196, DOI 10.1074/jbc.M310947200; Marcelli M, 2000, CANCER RES, V60, P944; McEleny KR, 2002, PROSTATE, V51, P133, DOI 10.1002/pros.10061; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Nickerson T, 2001, CANCER RES, V61, P6276; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Oh WK, 1998, J UROLOGY, V160, P1220, DOI 10.1016/S0022-5347(01)62501-1; Okamoto M, 1997, ENDOCRINOLOGY, V138, P5071, DOI 10.1210/en.138.11.5071; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Remacle-Bonnet MM, 2000, CANCER RES, V60, P2007; Ruijter E, 1999, ENDOCR REV, V20, P22, DOI 10.1210/er.20.1.22; Shariat SF, 2004, CANCER, V100, P751, DOI 10.1002/cncr.20039; Shen RQ, 2000, ENDOCRINOLOGY, V141, P1699, DOI 10.1210/en.141.5.1699; Taplin ME, 1999, CANCER RES, V59, P2511; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Tsihlias J, 2000, ONCOGENE, V19, P670, DOI 10.1038/sj.onc.1203369; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287	45	176	186	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2474	2482		10.1038/sj.onc.1208490	http://dx.doi.org/10.1038/sj.onc.1208490			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735703				2022-12-17	WOS:000228180600005
J	Chakravarti, A; Zhai, GG; Zhang, M; Malhotra, R; Latham, DE; Delaney, MA; Robe, P; Nestler, U; Song, QH; Loeffler, J				Chakravarti, A; Zhai, GG; Zhang, M; Malhotra, R; Latham, DE; Delaney, MA; Robe, P; Nestler, U; Song, QH; Loeffler, J			Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms	ONCOGENE			English	Article						Survivin; radiation resistance; primary human glioblastoma	ANTI-APOPTOSIS GENE; MALIGNANT GLIOMA; BRAIN-TUMORS; EXPRESSION; CANCER; PROTEIN; INHIBITOR; PROGNOSIS; PROLIFERATION; NEUROBLASTOMA	The observed radioresistance of human glioblastoma multiforme (GBM) poses a major challenge, which, if overcome, may lead to significant advances in the management of this patient population. There is accumulating evidence from correlative studies that Survivin expression is associated with increased malignant potential of human gliomas. The purpose of this study was to investigate whether Survivin plays a direct role in mediating radiation resistance in primary human glioma cell lines, and, if so, investigating the underlying mechanisms. Our panel of GBM cell lines included two that were relatively radiation resistant (GM20 and GM21) and two that were more radiation sensitive (GM22 and GM23), which demonstrated differential levels of Survivin expression between the two groups. Through the use of adenoviral vectors containing either dominant-negative (pAd-S(T34A)) or wild-type Suvrivin (pAd-S(WT)), we were able to inactivate or overexpress Survivin, respectively. Our findings suggest that Survivin plays a critical role in mediating radiation resistance in primary GBM cells, in part through suppression of apoptotic cell death via a caspase-independent manner. We have identified novel mechanisms by which Survivin may enhance tumor cell survival upon radiation exposure such as regulation of double-strand DNA break repair and tumor cell metabolism, which were most evident in the radiation-resistant cell lines. These differences in Survivin function both in radiation-resistant vs radiation-sensitive cell lines and in the presence vs absence of radiation exposure warrant further investigation and highlight potentially important mechanisms of radiation resistance in these tumors.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA USA; Univ Giessen, Dept Neurosurg, Giessen, Germany	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Justus Liebig University Giessen	Chakravarti, A (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, 100 Blossom St,Founders House,Room 536, Boston, MA 02114 USA.	achakravarti@partners.org	Nestler, Ulf/D-6503-2014; Nestler, Ulf/AHD-3675-2022	Nestler, Ulf/0000-0002-2963-4344; Nestler, Ulf/0000-0002-2963-4344; Malhotra, Rajeev/0000-0003-0120-4630	NCI NIH HHS [KO882163CA] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adida C, 1998, LANCET, V351, P882, DOI 10.1016/S0140-6736(05)70294-4; Adida C, 2000, BLOOD, V96, P1921; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Asanuma K, 2000, JPN J CANCER RES, V91, P1204, DOI 10.1111/j.1349-7006.2000.tb00906.x; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Chakravarti A, 2002, J CLIN ONCOL, V20, P1063, DOI 10.1200/JCO.20.4.1063; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Davis FG, 1999, CANCER, V85, P485, DOI 10.1002/(SICI)1097-0142(19990115)85:2<485::AID-CNCR29>3.0.CO;2-L; Fortugno P, 2002, J CELL SCI, V115, P575; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Hall E, 2000, RADIOBIOLOGY RADIOLO; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Jiang XY, 2001, J CELL BIOCHEM, V83, P342, DOI 10.1002/jcb.1228; Kajiwara Y, 2003, CANCER-AM CANCER SOC, V97, P1077, DOI 10.1002/cncr.11122; Katoh M, 2003, J NEURO-ONCOL, V64, P71, DOI 10.1023/A:1024942127462; Kawasaki H, 1998, CANCER RES, V58, P5071; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Lang-Rollin ICJ, 2003, J NEUROSCI, V23, P11015; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Lu CD, 1998, CANCER RES, V58, P1808; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; MANGIARDI J, 2001, BRAIN TUMORS, P105; Merlo A, 2003, NEUROSURG REV, V26, P145, DOI 10.1007/s10143-003-0267-8; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100; Olie RA, 2000, CANCER RES, V60, P2805; Sasaki T, 2002, ACTA NEUROPATHOL, V104, P105, DOI 10.1007/s00401-002-0532-x; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; Smith SD, 2001, JAMA-J AM MED ASSOC, V285, P324, DOI 10.1001/jama.285.3.324; TAN EC, 1993, J BIOL CHEM, V268, P27291; Tanaka K, 2000, CLIN CANCER RES, V6, P127; WALKER MD, 1978, J NEUROSURG, V49, P333, DOI 10.3171/jns.1978.49.3.0333; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; WESTPHAL M, 1990, CULTURE HUMAN BRAIN, V5; Wright ME, 2000, FEBS LETT, V481, P13, DOI 10.1016/S0014-5793(00)01962-1	38	176	186	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	2004	23	45					7494	7506		10.1038/sj.onc.1208049	http://dx.doi.org/10.1038/sj.onc.1208049			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326475				2022-12-17	WOS:000224176500006
J	Fixemer, T; Wissenbach, U; Flockerzi, V; Bonkhoff, H				Fixemer, T; Wissenbach, U; Flockerzi, V; Bonkhoff, H			Expression of the Ca2+-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression	ONCOGENE			English	Article						prostate cancer; TRPV6; in situ hybridization; prognostic marker; TRP cation channel	CALCIUM-CHANNEL; GLEASON SCORE; PREDICT; BIOPSY; ANTIGEN; STAGE	Members of the TRP superfamily of cation channels have homeostatic and regulatory functions in cells and changes in their expression may contribute to malignant growth. Previously, we have demonstrated that the gene of the Ca2+-selective cation channel CaT-L or TRPV6 is not expressed in benign prostate tissues including benign prostate hyperplasia, but is upregulated in prostate cancer. Here, we report on the differential expression of TRPV6 mRNA in prostate tissue obtained from 140 patients with prostate cancer. Using in situ hybridization, TRPV6 transcripts were undetectable in benign prostate tissue, high-grade prostatic intraepithelial neoplasia (n = 57), incidental adenocarcinoma and all tumors less than 2.3 cubic centimeter (cc). In prostatectomy specimens from 97 clinically organ-confined tumors, TRPV6 expression correlated significantly with the Gleason score (P = 0.032), pathological stage (P<0.001) and extraprostatic extension (P = 0.025). Lymph node metastasis (n = 17) and androgen-insensitive tumors (n = 27) revealed TRPV6 expression in 63 and 67% of cases, respectively. The latter, however, revealed markedly and significantly decreased levels when compared with untreated tumors (P = 0.044). In summary, the data demonstrate that TRPV6 expression is associated with prostate cancer progression. Accordingly, TRPV6 represents a prognostic marker and, as a plasma membrane Ca2+ channel, a promising target for new therapeutic strategies to treat advanced prostate cancer.	Univ Saarland, Inst Expt & Klin Pharmakol & Toxikol, D-66421 Homburg, Germany; Univ Saarland, Inst Allgemeine & Spezielle Pathol, D-66421 Homburg, Germany	Saarland University; Saarland University	Flockerzi, V (corresponding author), Univ Saarland, Inst Expt & Klin Pharmakol & Toxikol, D-66421 Homburg, Germany.							Bonkhoff H, 1999, AM J PATHOL, V155, P641, DOI 10.1016/S0002-9440(10)65160-7; CUPP MR, 1995, J UROLOGY, V153, P1543, DOI 10.1016/S0022-5347(01)67458-5; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Mariot P, 2002, J BIOL CHEM, V277, P10824, DOI 10.1074/jbc.M108754200; NARAYAN P, 1995, UROLOGY, V46, P205, DOI 10.1016/S0090-4295(99)80195-2; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Partin AW, 1997, JAMA-J AM MED ASSOC, V277, P1445, DOI 10.1001/jama.277.18.1445; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Steinberg DM, 1997, AM J SURG PATHOL, V21, P566, DOI 10.1097/00000478-199705000-00010; Toyota M, 1999, CANCER RES, V59, P4535; Wills ML, 1998, UROLOGY, V51, P759, DOI 10.1016/S0090-4295(98)00011-9; Wissenbach U, 2001, J BIOL CHEM, V276, P19461, DOI 10.1074/jbc.M009895200	12	176	191	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7858	7861		10.1038/sj.onc.1206895	http://dx.doi.org/10.1038/sj.onc.1206895			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586412				2022-12-17	WOS:000186240200016
J	Sharpless, NE; Chin, L				Sharpless, NE; Chin, L			The INK4a/ARF locus and melanoma	ONCOGENE			English	Article						p19(ARF); cell cycle; cdk4; cdk6; ultraviolet light	TUMOR-SUPPRESSOR GENE; P53-DEPENDENT APOPTOSIS; ULTRAVIOLET-RADIATION; G(1) ARREST; CYCLIN-E; P16(INK4A); P53; SENESCENCE; EXPRESSION; MUTATIONS	Inactivation of the INK4a/ARF (or CDKN2a) locus is a common and critical genetic event in the development of human and mouse melanoma. This locus engages the Rb and p53 tumor suppressor pathways through its capacity to encode two distinct gene products, p16(INK4a) and p14(ARF). This review highlights the body of evidence supporting a role for both p16(INK4a) and p14(ARF) in the suppression of melanoma, and speculates as to why this locus is preferentially targeted in this tumor type. In addition, the potential importance of these two pathways in mediating UV-induced melanoma genesis will be addressed via genetic and molecular evidence in the mouse.	Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Dept Genet, Chapel Hill, NC 27599 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Harvard University; Dana-Farber Cancer Institute	Chin, L (corresponding author), Harvard Univ, Sch Med, Dept Dermatol, 44 Binney St M413, Boston, MA 02115 USA.	Lynda_Chin@dfci.harvard.edu		Sharpless, Norman/0000-0001-7078-9455				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Atillasoy ES, 1998, AM J PATHOL, V152, P1179; Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Berking C, 2002, CARCINOGENESIS, V23, P181, DOI 10.1093/carcin/23.1.181; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DONAWHO CK, 1991, CANCER RES, V51, P4176; DURO D, 1995, ONCOGENE, V11, P21; Fahraeus R, 1999, EMBO J, V18, P2106, DOI 10.1093/emboj/18.8.2106; Flores JF, 1996, CANCER RES, V56, P5023; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gilchrest BA, 1999, NEW ENGL J MED, V340, P1341, DOI 10.1056/NEJM199904293401707; GLENDENING JM, 1995, CANCER RES, V55, P5531; HARRISON SL, 1994, LANCET, V344, P1529, DOI 10.1016/S0140-6736(94)90348-4; Herlyn M, 1996, AM J PATHOL, V149, P739; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Holland EA, 1995, ONCOGENE, V11, P2289; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Jamal S, 2002, J CLIN INVEST, V110, P443, DOI 10.1172/JCI200213729; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kannan K, 2003, P NATL ACAD SCI USA, V100, P1221, DOI 10.1073/pnas.0336397100; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; LIU L, 1995, ONCOGENE, V11, P405; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; MAO L, 1995, CANCER RES, V55, P2995; Nairn RS, 1996, P NATL ACAD SCI USA, V93, P13042, DOI 10.1073/pnas.93.23.13042; Noonan FP, 2001, NATURE, V413, P271, DOI 10.1038/35095108; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Pavey S, 1999, CANCER RES, V59, P4185; Pavey S, 2001, ONCOGENE, V20, P6103, DOI 10.1038/sj.onc.1204707; Piepkorn M, 2000, J AM ACAD DERMATOL, V42, P741, DOI 10.1067/mjd.2000.103988; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Reznikoff CA, 1996, CANCER RES, V56, P2886; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Schmid M, 1998, ONCOGENE, V17, P2669, DOI 10.1038/sj.onc.1202205; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sharpless NE, 2002, CANCER RES, V62, P2761; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tang L, 1999, MELANOMA RES, V9, P148, DOI 10.1097/00008390-199904000-00006; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; Walker GJ, 1998, GENE CHROMOSOME CANC, V22, P157, DOI 10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N; Wieser RJ, 1999, ONCOGENE, V18, P277, DOI 10.1038/sj.onc.1202270; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; ZANETTI R, 1992, EUR J CANCER, V28A, P1172, DOI 10.1016/0959-8049(92)90480-P; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	76	176	183	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3092	3098		10.1038/sj.onc.1206461	http://dx.doi.org/10.1038/sj.onc.1206461			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789286				2022-12-17	WOS:000183096600011
J	Huang, ZW				Huang, ZW			Bcl-2 family proteins as targets for anticancer drug design	ONCOGENE			English	Article						Bcl-2; apoptosis; caspase; cancer; chemoresistance; drug design	PROGRAMMED CELL-DEATH; CYTOCHROME-C; ISOLATED-MITOCHONDRIA; ANTISENSE THERAPY; TUMOR-CELLS; APOPTOSIS; BCL-X(L); BINDING; DOMAIN; BAX	Bcl-2 family proteins are key regulators of programmed cell death or apoptosis that is implicated in many human diseases, particularly cancer. In recent years, they have attracted intensive interest in both basic research to understand the fundamental principles of cell survival and cell death and drug discovery to develop a new class of anticancer agents. The Bcl-2 family includes both anti-and pro-apoptotic proteins with opposing biological functions in either inhibiting or promoting cell death. High expression of anti-apoptotic members such as Bcl-2 and Bcl-x(L) commonly found in human cancers contributes to neoplastic cell expansion and interferes with the therapeutic action of many chemotherapeutic drugs. The functional blockade of Bcl-2 or Bcl-x(L) could either restore the apoptotic process in tumor cells or sensitize these tumors for chemo- and radiotherapies. This article reviews the recent progress in the design and discovery of small molecules that block the anti-apoptotic function of Bcl-2 or Bcl-x(L). These chemical inhibitors are effective modulators of apoptosis and promising leads for the further development of new anticancer agents.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Huang, ZW (corresponding author), Univ Illinois, Dept Biochem, Urbana, IL 61801 USA.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aritomi M, 1997, J BIOL CHEM, V272, P27886, DOI 10.1074/jbc.272.44.27886; BOYD JM, 1995, ONCOGENE, V11, P1921; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Diaz JL, 1997, J BIOL CHEM, V272, P11350; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Huang ZW, 2000, PHARMACOL THERAPEUT, V86, P201, DOI 10.1016/S0163-7258(00)00052-8; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; MORGAN BA, 2000, 91 ANN M AM ASS CANC, V42, P4693; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nakashima T, 2000, CANCER RES, V60, P1229; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Ottilie S, 1997, J BIOL CHEM, V272, P30866, DOI 10.1074/jbc.272.49.30866; Piche A, 1998, CANCER RES, V58, P2134; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TOKUTAKE N, 1994, BBA-BIOENERGETICS, V1185, P271, DOI 10.1016/0005-2728(94)90241-0; TOMITA F, 1980, J ANTIBIOT, V33, P668, DOI 10.7164/antibiotics.33.668; TZUNG SP, 1999, AACR NCI EORTIC INT, P87; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wang JL, 2000, CANCER RES, V60, P1498; Webb A, 1997, LANCET, V349, P1137, DOI 10.1016/S0140-6736(96)11103-X; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Yu NF, 2000, TETRAHEDRON LETT, V41, P6993, DOI 10.1016/S0040-4039(00)01195-3; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	33	176	191	0	15	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 27	2000	19	56					6627	6631		10.1038/sj.onc.1204087	http://dx.doi.org/10.1038/sj.onc.1204087			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426648				2022-12-17	WOS:000167704000009
J	Kosako, H; Yoshida, T; Matsumura, F; Ishizaki, T; Narumiya, S; Inagaki, M				Kosako, H; Yoshida, T; Matsumura, F; Ishizaki, T; Narumiya, S; Inagaki, M			Rho-kinase/ROCK is involved in cytokinesis through the phosphorylation of myosin light chain and not ezrin/radixin/moesin proteins at the cleavage furrow	ONCOGENE			English	Article						cell cycle; cytokinesis; Rho-kinase; myosin light chain; ERM proteins	ERM PROTEINS; CULTURED-CELLS; ACTIN CYTOSKELETON; SMALL GTPASE; ADHESION; ASSOCIATION; PHOSPHATASE; FILAMENTS; ACTIVATION; MOESIN	The small GTPase Rho and one of its targets, Rho-kinase (also termed ROK or ROCK), are implicated in various cellular functions including stress fiber formation, smooth muscle contraction, tumor cell invasion and cell motility, We have previously reported that Rho-kinase accumulates at the cleavage furrow during cytokinesis in several cultured cells. Here, using Rho-kinase inhibitors, Y-27632 and HA1077, we found that Rho-kinase is responsible for the phosphorylation of myosin regulatory light chain at Ser(19) in the cleavage furrow during cytokinesis. On the other hand, phosphorylation of ezrin/radixin/moesin (ERM) proteins at the cleavage furrow was enhanced by the addition of the above Rho-kinase inhibitors, Treatment with Y-27632 strongly enhanced the accumulation of Rho-kinase but not RhoA and citron kinase at the cleavage furrow. Furthermore, the furrow ingression in cytokinesis was significantly prolonged in the presence of Y-27632, These results suggest that Rho-kinase is involved in the progression of cytokinesis through the phosphorylation of several proteins including myosin light chain at the cleavage furrow.	Univ Tokyo, Grad Sch Med, Dept Neurobiol, Bunkyo Ku, Tokyo 1130033, Japan; Aichi Canc Ctr, Res Inst, Biochem Lab, Nagoya, Aichi 4648681, Japan; Mie Univ, Sch Med, Dept Pathol, Tsu, Mie 5148507, Japan; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08855 USA; Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068315, Japan	University of Tokyo; Aichi Cancer Center; Mie University; Rutgers State University New Brunswick; Kyoto University	Kosako, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Neurobiol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Inagaki, Masaki/B-9920-2016; Yoshida, Toshimichi/H-6204-2013	Yoshida, Toshimichi/0000-0001-8935-8217; Matsumura, Fumio/0000-0002-8204-153X				Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; Gerisch G, 2000, CURR OPIN CELL BIOL, V12, P126, DOI 10.1016/S0955-0674(99)00066-6; Hales KG, 1999, CURR OPIN CELL BIOL, V11, P717, DOI 10.1016/S0955-0674(99)00042-3; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hayashi K, 1999, J CELL SCI, V112, P1149; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; Kosako H, 1999, ONCOGENE, V18, P2783, DOI 10.1038/sj.onc.1202633; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; O'Connell CB, 1999, J CELL BIOL, V144, P305, DOI 10.1083/jcb.144.2.305; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	27	176	181	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					6059	6064		10.1038/sj.onc.1203987	http://dx.doi.org/10.1038/sj.onc.1203987			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146558				2022-12-17	WOS:000165827900013
J	Ravagnan, L; Marzo, I; Costantini, P; Susin, SA; Zamzami, N; Petit, PX; Hirsch, F; Goulbern, M; Poupon, MF; Miccoli, L; Xie, ZH; Reed, JC; Kroemer, G				Ravagnan, L; Marzo, I; Costantini, P; Susin, SA; Zamzami, N; Petit, PX; Hirsch, F; Goulbern, M; Poupon, MF; Miccoli, L; Xie, ZH; Reed, JC; Kroemer, G			Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore	ONCOGENE			English	Article						lonidamine; mitochondrial megachannel; permeability transition; programmed cell death	CERAMIDE-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; ASCITES TUMOR-CELLS; CYTOCHROME-C; NUCLEAR APOPTOSIS; BENZODIAZEPINE RECEPTOR; NEUROBLASTOMA-CELLS; ENERGY-METABOLISM; OXIDATIVE STRESS; DIVALENT-CATIONS	The molecular mode of action of lonidamine, a therapeutic agent employed in cancer chemotherapy, has been elusive. Here we provide evidence that lonidamine (LND) acts on mitochondria to induce apoptosis, LND provokes a disruption of the mitochondrial transmembrane potential which precedes signs of nuclear apoptosis and cytolysis, The mitochondrial and cytocidal effects of LND are not prevented by inhibitors of caspases or of mRNA or protein synthesis. However, they are prevented by transfection-enforced overexpression of Bcl-2, an oncoprotein which inhibits apoptosis by stabilizing the mitochondrial membrane barrier function. Accordingly, the cell death-inducing effect of LND is amplified by simultaneous addition of PK11195, an isoquinoline ligand of the peripheral benzodiazepine receptor which antagonizes the cytoprotective effect of Bcl-2, When added to isolated nuclei, LND fails to provoke DNA degradation unless mitochondria are added simultaneously. In isolated mitochondria, LND causes the dissipation of the mitochondrial inner transmembrane potential and the release of apoptogenic factors capable of inducing nuclear apoptosis in vitro. Thus the mitochondrion is the subcellular target of LND. All effects of LND on isolated mitochondria are counteracted by cyclosporin A, an inhibitor of the mitochondrial PT pore. We therefore tested the effect of LND on the purified PT pore reconstituted into liposomes, LND permeabilizes liposomal membranes containing the PT pore. This effect is prevented by addition of recombinant Bcl-2 protein but not by a mutant Bcl-2 protein that has lost its apoptosis-inhibitory function. Altogether these data indicate that LND represents a novel type of anti-cancer agent which induces apoptosis via a direct effect on the mitochondrial PT pore.	CNRS, Unite Propre Rech 420, F-94801 Villejuif, France; INRA, Ctr Rech Jouy En Josas, F-78352 Jouy En Josas, France; Inst Curie, CNRS, Unite Mixte Rech 147, F-75248 Paris, France; Burnham Inst, La Jolla, CA 92037 USA	Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite; Sanford Burnham Prebys Medical Discovery Institute	Kroemer, G (corresponding author), CNRS, Unite Propre Rech 420, 19 Rue Guy Moquet, F-94801 Villejuif, France.		Susin, Santos A/Q-6754-2017; PETIT, Patrice/A-4453-2008; Kroemer, Guido/AAY-9859-2020; Marzo, Isabel/E-6918-2016; Petit, patrice/AAF-6774-2020; KROEMER, Guido/B-4263-2013; miccoli, laurent/N-6638-2018; Petit, Patrice X./A-3692-2009	Susin, Santos A/0000-0002-3366-1628; Marzo, Isabel/0000-0002-2315-9079; KROEMER, Guido/0000-0002-9334-4405; miccoli, laurent/0000-0002-5242-4388; Petit, Patrice X./0000-0002-5038-9101				Angioli R, 1997, INT J ONCOL, V11, P777; Backway KL, 1997, CANCER RES, V57, P2446; BENHORIN H, 1995, CANCER RES, V55, P2814; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; BRENNER C, 1998, IN PRESS METH ENZYMO; BRENNER C, 1998, IN PRESS FEBS LETT; Brunet CL, 1998, CELL DEATH DIFFER, V5, P107, DOI 10.1038/sj.cdd.4400334; BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699; CASTIGLIONE S, 1993, BIOCHEM PHARMACOL, V46, P330, DOI 10.1016/0006-2952(93)90423-T; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CONNERN CP, 1994, BIOCHEM J, V302, P321, DOI 10.1042/bj3020321; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; De Cesare M, 1998, BRIT J CANCER, V77, P434, DOI 10.1038/bjc.1998.69; Decaudin D, 1997, CANCER RES, V57, P62; DelBufalo D, 1996, J CLIN INVEST, V98, P1165, DOI 10.1172/JCI118900; DeLena M, 1997, J CLIN ONCOL, V15, P3208, DOI 10.1200/JCO.1997.15.10.3208; Dogliotti L, 1998, CANCER CHEMOTH PHARM, V41, P333, DOI 10.1007/s002800050747; Dudak SD, 1996, ANTICANCER RES, V16, P3665; Fanciulli M, 1996, ONCOL RES, V8, P111; FLORIDI A, 1981, CANCER RES, V41, P4661; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1997, CANCER RES, V57, P3823; HAEFFNER A, 1999, IN PRESS EUR J IMMUN; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kantrow SP, 1997, BIOCHEM BIOPH RES CO, V232, P669, DOI 10.1006/bbrc.1997.6353; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer Guido, 1997, P1111; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Macho A, 1997, J IMMUNOL, V158, P4612; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Marchetti P, 1996, J IMMUNOL, V157, P4830; Marchetti P, 1996, CANCER RES, V56, P2033; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; Miccoli L, 1998, J NATL CANCER I, V90, P1400, DOI 10.1093/jnci/90.18.1400; OUDARD S, 1995, INT J CANCER, V62, P216, DOI 10.1002/ijc.2910620218; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pratesi G, 1996, CANCER CHEMOTH PHARM, V38, P123, DOI 10.1007/s002800050459; Pulselli R, 1996, ANTICANCER RES, V16, P419; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; SZABO I, 1992, J BIOL CHEM, V267, P2940; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	66	176	183	1	24	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2537	2546		10.1038/sj.onc.1202625	http://dx.doi.org/10.1038/sj.onc.1202625			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353597				2022-12-17	WOS:000079907100001
J	Wilson, CA; Payton, MN; Elliott, GS; Buaas, FW; Cajulis, EE; Grosshans, D; Ramos, L; Reese, DM; Slamon, DJ; Calzone, FJ				Wilson, CA; Payton, MN; Elliott, GS; Buaas, FW; Cajulis, EE; Grosshans, D; Ramos, L; Reese, DM; Slamon, DJ; Calzone, FJ			Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-Delta 11b	ONCOGENE			English	Article						BRCA1; subcellular localization; alternative splicing	HUMAN CYTOMEGALO-VIRUS; IMMEDIATE EARLY GENE; BREAST-CANCER; OVARIAN-CANCER; MONOCLONAL-ANTIBODIES; KINETIC-MODEL; MUTATIONS; FAMILIES; PROTEIN; TISSUES	The mechanism of BRCA1 tumor suppression in human breast and ovarian cells is the focus investigation. In this report, full length (230 kDa) introduced into cells with CMV promoter constructs was nuclear when transgene expression was low whereas high expression resulted in cytoplasmic accumulation, aberrant nuclear and cell morphology. A nuclear localization signal (NLS) was mapped to BRCA1 amino acid positions 262-570. We describe a splice variant, BRCA1-Delta 11b, missing the majority of exon 11 including the NLS. Exogenous BRCA1-Delta 11b (110 kDa) was cytoplasmic and, unlike the full-length protein, overexpression of the protein encoded by the variant did not appear to be toxic. RNA probe titrations and RT-PCR demonstrated that BRCA1 and Delta 11b transcripts are coexpressed in a wide variety of cells and tissues. Interestingly, BRCA1-Delta 11b message was greatly reduced or absent in several breast and ovarian tumor lines relative to exon 11 transcripts and a Delta 9,10 splice variant. Taken together our results suggest that full-length BRCA1 and BRCA1-Delta 11b may have distinct roles in cell growth regulation and tumorigenesis.	AMGEN INC, AMGEN CTR, THOUSAND OAKS, CA 91320 USA; UNIV CALIF IRVINE, IRVINE, CA 92717 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90095 USA	Amgen; University of California System; University of California Irvine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL CANCER INSTITUTE [R01CA036827] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA36827] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKRIGG A, 1985, VIRUS RES, V2, P107, DOI 10.1016/0168-1702(85)90242-4; BAG J, 1991, TRANSLATION EUKARYOT, P71; BERGMANN JE, 1979, J BIOL CHEM, V254, P1927; Bienstock RJ, 1996, CANCER RES, V56, P2539; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BOYD M, 1995, NATURE, V375, P541, DOI 10.1038/375541b0; Bradley A, 1996, NAT GENET, V13, P268, DOI 10.1038/ng0796-268b; CALZONE FJ, 1991, DEVELOPMENT, V112, P335; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Chen YM, 1996, SCIENCE, V272, P125, DOI 10.1126/science.272.5258.125; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; CORNELIS RS, 1995, GENE CHROMOSOME CANC, V13, P203, DOI 10.1002/gcc.2870130310; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERNIG D, 1994, PROG GROWTH FACTOR R, V4, P353; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GALAU GA, 1977, ARCH BIOCHEM BIOPHYS, V179, P584, DOI 10.1016/0003-9861(77)90147-3; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GODEFROYCOLBURN T, 1981, J BIOL CHEM, V256, P1762; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; GUDAS JM, 1995, CANCER RES, V55, P4561; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Ithier G, 1996, NEW ENGL J MED, V334, P1198; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; Jensen RA, 1996, NAT GENET, V13, P269, DOI 10.1038/ng0796-269; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LEE JJ, 1987, METHOD ENZYMOL, V152, P633; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; Merajver SD, 1995, CLIN CANCER RES, V1, P539; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; PATI UK, 1992, GENE, V114, P285, DOI 10.1016/0378-1119(92)90589-H; Rao VN, 1996, ONCOGENE, V12, P523; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Shattuck-Eidens D, 1995, JAMA-J AM MED ASSOC, V273, P535; Slobin L.I., 1991, TRANSLATION EUKARYOT, P149; Sobol A, 1996, CANCER RES, V56, P3216; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wilson CA, 1996, NAT GENET, V13, P264, DOI 10.1038/ng0796-264	50	176	181	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	1997	14	1					1	16		10.1038/sj.onc.1200924	http://dx.doi.org/10.1038/sj.onc.1200924			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010228				2022-12-17	WOS:A1997WB76000001
J	RUGGERI, B; ZHANG, SY; CAAMANO, J; DIRADO, M; FLYNN, SD; KLEINSZANTO, AJP				RUGGERI, B; ZHANG, SY; CAAMANO, J; DIRADO, M; FLYNN, SD; KLEINSZANTO, AJP			HUMAN PANCREATIC CARCINOMAS AND CELL-LINES REVEAL FREQUENT AND MULTIPLE ALTERATIONS IN THE P53 AND RB-1 TUMOR-SUPPRESSOR GENES	ONCOGENE			English	Article							HUMAN PROSTATE CARCINOMA; HUMAN BREAST-CANCER; RETINOBLASTOMA GENE; LUNG-CANCER; MONOCLONAL-ANTIBODIES; POLYPOSIS-COLI; OVARIAN-CANCER; EXPRESSION; MUTATIONS; TRANSFORMATION	The molecular pathology of human pancreatic cancer is poorly understood, particularly with regard to the role of known tumor-suppressor genes. We have examined the expression of the p53 and Rb-1 tumor-suppressor genes in seven human pancreatic carcinoma cell lines and 10 primary pancreatic carcinomas. Examination of the Rb-1 gene by Northern hybridization and immunoprecipitation analyses revealed the absence of Rb-1 protein expression in two cell lines. Moreover, regions of absent nuclear staining in two primary pancreatic carcinomas were detected by immunohistochemical analysis. Investigation of p53 by Southern, Northern, immunohistochemical and immunoprecipitation analyses revealed multiple abnormalities, including gross rearrangements in two cell lines, the absence of detectable p53 transcript in two cell lines and a truncated transcript in one line. Six cell lines overexpressed p53 protein, while one line revealed the absence of p53 product by immunohistochemical and immunoprecipitation analyses. Sequence analysis of exons 5-8 of the p53 gene confirmed these analyses, revealing missense mutations in all seven cell lines in codons 181, 220, 248, 249, 265, 272 and 273. Of 10 mutations identified, nine were transitions and 50% were in codon 273. Immunohistochemical analyses of frozen primary pancreatic carcinomas revealed positive nuclear staining for p53 in 40% of cases. Mutations were identified in codons 238 and 286 and in intron 9 in several representative specimens. Alterations in the p53 and Rb-1 genes may be important features in the development of human pancreatic cancer.	FOX CHASE CANC INST,INST CANC RES,DEPT PATHOL,7701 BURHOLME AVE,PHILADELPHIA,PA 19111; YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510	Fox Chase Cancer Center; Yale University			Klein-Szanto, A./E-6218-2010; Caamano, Jorge/O-7530-2019; Caamano, Jorge/I-6778-2012	Caamano, Jorge/0000-0003-3530-7056; Caamano, Jorge/0000-0003-3530-7056	NCI NIH HHS [CA-06927, CA-09035-16] Funding Source: Medline; NCRR NIH HHS [RR-05895] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005895] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1991, ONCOGENE, V6, P1699; BARTEK J, 1990, ONCOGENE, V5, P893; BARTON CM, 1991, BRIT J CANCER, V64, P1076, DOI 10.1038/bjc.1991.467; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOS JL, 1989, CANCER RES, V49, P4682; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CAAMANO J, 1991, IN PRESS AM J PATHOL; CANCE WG, 1990, NEW ENGL J MED, V323, P1457, DOI 10.1056/NEJM199011223232105; CELLO JP, 1989, GASTROINTESTINAL DIS, P1872; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIBA I, 1990, ONCOGENE, V5, P1603; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GRAJOWER MM, 1983, ANN INTERN MED, V98, P111, DOI 10.7326/0003-4819-98-1-111_2; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GRUNEWALD K, 1989, INT J CANCER, V43, P1037, DOI 10.1002/ijc.2910430614; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HALL PA, 1990, J PATHOL, V161, P195, DOI 10.1002/path.1711610305; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HENSEL CH, 1990, CANCER RES, V50, P3067; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOLLINGSWORTH RE, 1991, J NATL CANCER I, V83, P91, DOI 10.1093/jnci/83.2.91; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JAGELMAN DG, 1987, CANCER GENET CYTOGEN, V27, P319, DOI 10.1016/0165-4608(87)90014-8; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KONDOLEON S, 1987, NUCLEIC ACIDS RES, V15, P10605, DOI 10.1093/nar/15.24.10605; KORC M, 1986, P NATL ACAD SCI USA, V83, P5141, DOI 10.1073/pnas.83.14.5141; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEMOINE NR, 1990, BAILLIERE CLIN GASTR, V4, P815, DOI 10.1016/0950-3528(90)90021-8; LEMOINE NR, 1992, J PATHOL, V166, P7, DOI 10.1002/path.1711660103; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI SB, 1991, J NATL CANCER I, V83, P637, DOI 10.1093/jnci/83.9.637; LYNCH HT, 1985, BRIT J CANCER, V52, P271, DOI 10.1038/bjc.1985.187; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARKS JR, 1991, CANCER RES, V51, P2979; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MICHELASSI F, 1989, Italian Journal of Surgical Sciences, V19, P341; MILLER CW, 1990, CANCER RES, V50, P7950; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OKAMOTO A, 1991, CANCER RES, V51, P5632; POSTON GJ, 1991, GUT, V32, P800, DOI 10.1136/gut.32.7.800; Sambrook J., 1989, MOL CLONING LAB MANU; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; SMITH JJ, 1987, P NATL ACAD SCI USA, V84, P7567, DOI 10.1073/pnas.84.21.7567; SOUSSI T, 1990, ONCOGENE, V5, P945; STRATTON MR, 1990, ONCOGENE, V5, P1297; TADA M, 1990, CANCER-AM CANCER SOC, V66, P930, DOI 10.1002/1097-0142(19900901)66:5<930::AID-CNCR2820660519>3.0.CO;2-W; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; VARLEY JM, 1989, ONCOGENE, V4, P725; VARLEY JM, 1991, ONCOGENE, V6, P413; WASYLYSHYN ML, 1991, SURGERY, V110, P265; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	74	176	177	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1503	1511						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630814				2022-12-17	WOS:A1992JE81300006
J	BURNS, PA; KEMP, CJ; GANNON, JV; LANE, DP; BREMNER, R; BALMAIN, A				BURNS, PA; KEMP, CJ; GANNON, JV; LANE, DP; BREMNER, R; BALMAIN, A			LOSS OF HETEROZYGOSITY AND MUTATIONAL ALTERATIONS OF THE P53-GENE IN SKIN TUMORS OF INTERSPECIFIC HYBRID MICE	ONCOGENE			English	Article							MOUSE SKIN; CHEMICAL CARCINOGENESIS; P53 PROTEIN; WILD-TYPE; GENE; DNA; ACTIVATION; ONCOGENE; MODEL; RAS	Functional alterations or loss of tumor-suppressor genes are an important feature of neoplastic progression in humans. The employment of suitable animal model systems would greatly facilitate the detection and manipulation of such genes. We describe here an experimental approach to this problem based on the analysis of skin tumors induced in F1 hybrids between Mus musculus and Mus spretus mice. The results show that loss of heterozygosity on chromosome 11 occurred in 4/13 mouse skin carcinomas, but not in premalignant papillomas. Since the murine p53 gene is located on this chromosome, immunoprecipitation and DNA-sequencing studies were carried out on tumorigenic cell lines and primary tumor DNA respectively to determine the status of p53 alleles. These studies revealed the presence of p53 mutations, both frameshifts and missense, some of which are identical to those found in human tumors. Loss of normal p53 function is found in well-differentiated squamous-cell carcinomas and thus does not appear to be directly responsible for further progression to an undifferentiated spindle cell phenotype.	BEATSON INST CANC RES,GARSCUBE ESTATE,SWITCHBACK RD,GLASGOW G61 1BD,SCOTLAND; IMPERIAL CANC RES FUND,CLARE HALL LABS,MOLEC IMMUNOCHEM LAB,POTTERS BAR EN6 3LD,HERTS,ENGLAND; UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,CANC RES CAMPAIGN LABS,DUNDEE DD1 4HN,SCOTLAND; HOSP SICK CHILDREN,DEPT IMMUNOL & CANC,TORONTO M5G 1X8,ONTARIO,CANADA	Beatson Institute; University of Dundee; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Lane, David P/C-4920-2008; Bremner, Rod/I-6490-2012	Bremner, Rod/0000-0001-9184-7212; Lane, David/0000-0003-0551-3545				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BOYD P, 1986, HUM GENET, V73, P171, DOI 10.1007/BF00291609; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BRASH DE, 1991, IN PRESS P NATL ACAD; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUCHMANN A, 1991, CANCER RES, V51, P4097; CHENG SC, 1988, CARCINOGENESIS, V9, P1721, DOI 10.1093/carcin/9.9.1721; CHIBA I, 1990, ONCOGENE, V5, P1603; DIPPLE A, 1983, CANCER RES, V43, P4132; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUSENIG N E, 1973, INSERM (Institut National de la Sante et de la Recherche Medicale) Colloque, V19, P219; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GLASER T, 1990, SCIENCE, V250, P823, DOI 10.1126/science.2173141; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KLEINSZANTO AJP, 1989, CARCINOGENESIS, V10, P2169, DOI 10.1093/carcin/10.11.2169; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MUNKE M, 1987, J MOL EVOL, V25, P134, DOI 10.1007/BF02101755; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; QUINTANILLA M, 1991, IN PRESS CARCINOGENE; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROBERT B, 1985, NATURE, V314, P181, DOI 10.1038/314181a0; SOUSSI T, 1990, ONCOGENE, V5, P945; STONE JC, 1989, GENOMICS, V5, P70, DOI 10.1016/0888-7543(89)90088-8; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	43	176	182	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2363	2369						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766680				2022-12-17	WOS:A1991GX73500028
J	LETWIN, K; YEE, SP; PAWSON, T				LETWIN, K; YEE, SP; PAWSON, T			NOVEL PROTEIN-TYROSINE KINASE CDNAS RELATED TO FPS/FES AND EPH CLONED USING ANTI-PHOSPHOTYROSINE ANTIBODY	ONCOGENE			English	Article									MT SINAI HOSP,RES INST,DIV MOLEC & DEV BIOL,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Pawson, Tony J/E-4578-2013					ARQUINT M, 1987, P NATL ACAD SCI USA, V84, P600, DOI 10.1073/pnas.84.2.600; BARKER WC, 1982, P NATL ACAD SCI-BIOL, V79, P2836, DOI 10.1073/pnas.79.9.2836; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BUECHLER JA, 1988, IN PRESS BIOCHEMISTR; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5394; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; EDWARDS AM, 1988, MOL CELL BIOL, V8, P2655, DOI 10.1128/MCB.8.6.2655; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FELDMAN RA, 1986, MOL CELL BIOL, V6, P1065, DOI 10.1128/MCB.6.4.1065; FOSTER DA, 1986, MOL CELL BIOL, V6, P325, DOI 10.1128/MCB.6.1.325; GREER PA, 1988, MOL CELL BIOL, V8, P578, DOI 10.1128/MCB.8.2.578; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HENKEMEYER MJ, 1988, MOL CELL BIOL, V8, P843, DOI 10.1128/MCB.8.2.843; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; HUANG CC, 1985, J MOL BIOL, V181, P175, DOI 10.1016/0022-2836(85)90083-X; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; LINDBERG RL, 1988, IN PRESS ONCOGENE, V3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P2001; Maniatis T., 1982, MOL CLONING; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MATHEYPREVOT B, 1982, CELL, V28, P297; MAYER BJ, 1988, NATURE, V332, P275; MORAN MF, 1988, IN PRESS ONCOGENE, V3; PAWSON T, 1980, CELL, V22, P767, DOI 10.1016/0092-8674(80)90553-X; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROHRSCHNEIDER LR, 1984, ADV VIRAL ONCOL, V4, P269; RUTA Y, 1988, ONCOGENE, V3, P9; SADOWSKI I, 1987, ONCOGENE, V1, P181; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; STAHL MA, 1986, NATURE, V332, P269; STONE JC, 1984, CELL, V37, P549, DOI 10.1016/0092-8674(84)90385-4; STREBHARDT K, 1987, P NATL ACAD SCI USA, V84, P8778, DOI 10.1073/pnas.84.24.8778; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VOGEL OS, 1988, NATURE, V335, P90; WEINMASTER G, 1986, EMBO J, V5, P69, DOI 10.1002/j.1460-2075.1986.tb04179.x; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; WOOLFORD J, 1984, VIROLOGY, V135, P168, DOI 10.1016/0042-6822(84)90127-2; YACIUK P, 1986, MOL CELL BIOL, V6, P2807, DOI 10.1128/MCB.6.8.2807; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276; ZOLLER MJ, 1981, J BIOL CHEM, V256, P837	65	176	194	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1988	3	6					621	627						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R6460	2485255				2022-12-17	WOS:A1988R646000001
J	Roth, L; Agemy, L; Kotamraju, VR; Braun, G; Teesalu, T; Sugahara, KN; Hamzah, J; Ruoslahti, E				Roth, L.; Agemy, L.; Kotamraju, V. R.; Braun, G.; Teesalu, T.; Sugahara, K. N.; Hamzah, J.; Ruoslahti, E.			Transtumoral targeting enabled by a novel neuropilin-binding peptide	ONCOGENE			English	Article						tumor homing; tumor penetration; breast cancer; nanoparticles	ENDOTHELIAL GROWTH-FACTOR; HOMING PEPTIDE; TUMOR-CELLS; SEMAPHORIN-III; RECEPTOR; NANOPARTICLES; CANCER; PERMEABILITY; DRUGS; VEGF	We have recently described a class of peptides that improve drug delivery by increasing penetration of drugs into solid tumors. These peptides contain a C-terminal Cend Rule (CendR) sequence motif (R/K)XX(R/K), which is responsible for cell internalization and tissue-penetration activity. Tumor-specific CendR peptides contain both a tumor-homing motif and a cryptic CendR motif that is proteolytically unmasked in tumor tissue. A previously described cyclic tumor-homing peptide, LyP-1 (sequence: CGNKRTRGC), contains a CendR element and is capable of tissue penetration. We use here the truncated form of LyP-1, in which the CendR motif is exposed (CGNKRTR; tLyP-1), and show that both LyP-1 and tLyP-1 internalize into cells through the neuropilin-1-dependent CendR internalization pathway. Moreover, we show that neuropilin-2 also binds tLyP-1 and that this binding equally activates the CendR pathway. Fluorescein-labeled tLyP-1 peptide and tLyP-1-conjugated nanoparticles show robust and selective homing to tumors, penetrating from the blood vessels into the tumor parenchyma. The truncated peptide is more potent in this regard than the parent peptide LyP-1. tLyP-1 furthermore improves extravasation of a co-injected nanoparticle into the tumor tissue. These properties make tLyP-1 a promising tool for targeted delivery of therapeutic and diagnostic agents to breast cancers and perhaps other types of tumors. Oncogene (2012) 31, 3754-3763; doi:10.1038/onc.2011.537; published online 19 December 2011	[Roth, L.; Agemy, L.; Kotamraju, V. R.; Teesalu, T.; Hamzah, J.; Ruoslahti, E.] Univ Calif Santa Barbara, Sanford Burnham Med Res Inst, Vasc Mapping Lab, Ctr Nanomed, Santa Barbara, CA 93106 USA; [Roth, L.; Agemy, L.; Kotamraju, V. R.; Teesalu, T.; Sugahara, K. N.; Hamzah, J.; Ruoslahti, E.] La Jolla Canc Res Fdn, Canc Res Ctr, Sanford Burnham Med Res Inst, La Jolla, CA 92037 USA; [Braun, G.] Univ Calif Santa Barbara, Inst Collaborat Biotechnol, Santa Barbara, CA 93106 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California Santa Barbara; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California Santa Barbara	Ruoslahti, E (corresponding author), Univ Calif Santa Barbara, Sanford Burnham Med Res Inst, Vasc Mapping Lab, Ctr Nanomed, UCSB Campus,Biol 2 Bldg,Room 3119, Santa Barbara, CA 93106 USA.	ruoslahti@sanfordburnham.org	Teesalu, Tambet/J-1802-2015; hamzah, juliana/G-3114-2013; Braun, Gary/A-4913-2009	Braun, Gary/0000-0002-6301-0228; Roth, Lise/0000-0001-7555-2916	USAMRAA for the Department of Defense [W81XWH-09-1-0698, W81XWH-08-1-0727]; Susan G Komen for the Cure post-doctoral fellowship [KG091411]; Santa Barbara Cancer Center; Cancer Center Support Grant from the NCI [CA30199]; NATIONAL CANCER INSTITUTE [P30CA030199] Funding Source: NIH RePORTER	USAMRAA for the Department of Defense; Susan G Komen for the Cure post-doctoral fellowship(Susan G. Komen Breast Cancer Foundation); Santa Barbara Cancer Center; Cancer Center Support Grant from the NCI; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Eva Engvall for comments on the manuscript. This work was supported by grant number W81XWH-09-1-0698 and W81XWH-08-1-0727 from the USAMRAA for the Department of Defense (ER). LR was supported by Susan G Komen for the Cure post-doctoral fellowship (KG091411) and GB by a fellowship from the Santa Barbara Cancer Center. ER was supported in part by CA30199 the Cancer Center Support Grant from the NCI.	Acevedo LM, 2008, BLOOD, V111, P2674, DOI 10.1182/blood-2007-08-110205; Agemy L, 2011, P NATL ACAD SCI USA, V108, P17450, DOI 10.1073/pnas.1114518108; Agemy L, 2010, BLOOD, V116, P2847, DOI 10.1182/blood-2010-03-274258; Bagri A, 2009, CLIN CANCER RES, V15, P1860, DOI 10.1158/1078-0432.CCR-08-0563; Becker PM, 2005, CIRC RES, V96, P1257, DOI 10.1161/01.RES.0000171756.13554.49; Caunt M, 2008, CANCER CELL, V13, P331, DOI 10.1016/j.ccr.2008.01.029; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Dallas NA, 2008, CLIN CANCER RES, V14, P8052, DOI 10.1158/1078-0432.CCR-08-1520; Ellis LM, 2006, MOL CANCER THER, V5, P1099, DOI 10.1158/1535-7163.MCT-05-0538; Fogal V, 2008, CANCER RES, V68, P7210, DOI 10.1158/0008-5472.CAN-07-6752; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; Greish K, 2007, J DRUG TARGET, V15, P457, DOI 10.1080/10611860701539584; Guttmann-Raviv N, 2006, CANCER LETT, V231, P1, DOI 10.1016/j.canlet.2004.12.047; Hamzah J, 2011, P NATL ACAD SCI USA, V108, P7154, DOI 10.1073/pnas.1104540108; Haspel N, 2011, BIOCHEMISTRY-US, V50, P1755, DOI 10.1021/bi101662j; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Heldin CH, 2004, NAT REV CANCER, V4, P806, DOI 10.1038/nrc1456; Hoffman JA, 2003, CANCER CELL, V4, P383, DOI 10.1016/S1535-6108(03)00273-3; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jain R, 1999, IEEE MULTIMEDIA, V6, P1, DOI 10.1109/MMUL.1999.809225; Karmali PP, 2009, NANOMED-NANOTECHNOL, V5, P73, DOI 10.1016/j.nano.2008.07.007; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Laakkonen P, 2004, P NATL ACAD SCI USA, V101, P9381, DOI 10.1073/pnas.0403317101; Laakkonen P, 2002, NAT MED, V8, P751, DOI 10.1038/nm720; Liang WC, 2007, J MOL BIOL, V366, P815, DOI 10.1016/j.jmb.2006.11.021; Mamluk Roni, 2005, Angiogenesis, V8, P217, DOI 10.1007/s10456-005-9009-6; Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018; Park JH, 2009, SMALL, V5, P694, DOI 10.1002/smll.200801789; Ruoslahti E, 2002, NAT REV CANCER, V2, P83, DOI 10.1038/nrc724; Ruoslahti E, 2002, DRUG DISCOV TODAY, V7, P1138, DOI 10.1016/S1359-6446(02)02501-1; Ruoslahti E, 2010, J CELL BIOL, V188, P759, DOI 10.1083/jcb.200910104; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sugahara KN, 2010, SCIENCE, V328, P1031, DOI 10.1126/science.1183057; Sugahara KN, 2009, CANCER CELL, V16, P510, DOI 10.1016/j.ccr.2009.10.013; TAKAGI S, 1987, DEV BIOL, V122, P90, DOI 10.1016/0012-1606(87)90335-6; Teesalu T, 2009, P NATL ACAD SCI USA, V106, P16157, DOI 10.1073/pnas.0908201106; Thorek DLJ, 2006, ANN BIOMED ENG, V34, P23, DOI 10.1007/s10439-005-9002-7; Uchida M, 2011, ACS NANO, V5, P2493, DOI 10.1021/nn102863y; von Maltzahn G, 2008, BIOCONJUGATE CHEM, V19, P1570, DOI 10.1021/bc800077y	39	175	191	9	101	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	33					3754	3763		10.1038/onc.2011.537	http://dx.doi.org/10.1038/onc.2011.537			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IU	22179825				2022-12-17	WOS:000307924900002
J	Gotte, M; Mohr, C; Koo, CY; Stock, C; Vaske, AK; Viola, M; Ibrahim, SA; Peddibhotla, S; Teng, YHF; Low, JY; Ebnet, K; Kiesel, L; Yip, GW				Goette, M.; Mohr, C.; Koo, C-Y; Stock, C.; Vaske, A-K; Viola, M.; Ibrahim, S. A.; Peddibhotla, S.; Teng, Y. H-F; Low, J-Y; Ebnet, K.; Kiesel, L.; Yip, G. W.			miR-145-dependent targeting of Junctional Adhesion Molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness	ONCOGENE			English	Article						F11R; microRNA; actin cytoskeleton; metastasis; nuclear rotation; endometrial carcinoma	SUPPRESSIVE MICRORNAS; PROSTATE-CANCER; MIR-145; METASTASIS; MIGRATION; PROTEIN; INVASION; GROWTH; MATURATION; PHENOTYPE	Micro RNAs are small non-coding RNAs, which regulate fundamental cellular and developmental processes at the transcriptional and translational level. In breast cancer, miR-145 expression is downregulated compared with healthy control tissue. As several predicted targets of miR-145 potentially regulate cell motility, we aimed at investigating a potential role for miR-145 in breast cancer cell motility and invasiveness. Assisted by Affymetrix array technology, we demonstrate that overexpression of miR-145 in MDA-MB-231, MCF-7, MDA-MB-468 and SK-BR-3 breast cancer cells and in Ishikawa endometrial carcinoma cells leads to a downregulation of the cell-cell adhesion protein JAM-A and of the actin bundling protein fascin. Moreover, podocalyxin and Serpin E1 mRNA levels were downregulated, and gamma-actin, transgelin and MYL9 were upregulated upon miR-145 overexpression. These miR-145-dependent expression changes drastically decreased cancer cell motility, as revealed by time-lapse video microscopy, scratch wound closure assays and matrigel invasion assays. Immunofluorescence microscopy demonstrated restructuring of the actin cytoskeleton and a change in cell morphology by miR-145 overexpression, resulting in a more cortical actin distribution, and reduced actin stress fiber and filopodia formation. Nuclear rotation was observed in 10% of the pre-miR-145 transfected MDA-MB-231 cells, accompanied by a reduction of perinuclear actin. Luciferase activation assays confirmed direct miR-145-dependent regulation of the 3'UTR of JAM-A, whereas siRNA-mediated knockdown of JAM-A expression resulted in decreased motility and invasiveness of MDA-MB-231 and MCF-7 breast cancer cells. Our data identify JAM-A and fascin as novel targets of miR-145, firmly establishing a role for miR-145 in modulating breast cancer cell motility. Our data provide a rationale for future miR-145-targeted approaches of antimetastatic cancer therapy. Oncogene (2010) 29, 6569-6580; doi:10.1038/onc.2010.386; published online 6 September 2010	[Goette, M.; Mohr, C.; Vaske, A-K; Viola, M.; Ibrahim, S. A.; Kiesel, L.] Munster Univ Hosp, Dept Gynecol & Obstet, D-48149 Munster, Germany; [Yip, G. W.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 117597, Singapore; [Stock, C.] Munster Univ Hosp, Inst Physiol 2, D-48149 Munster, Germany; [Ibrahim, S. A.] Cairo Univ, Fac Sci, Dept Zool, Giza, Egypt; [Peddibhotla, S.; Ebnet, K.] Univ Munster, ZMBE, Inst Med Biochem, Cell Adhes & Cell Polar Grp, Munster, Germany	University of Munster; National University of Singapore; University of Munster; Egyptian Knowledge Bank (EKB); Cairo University; University of Munster	Gotte, M (corresponding author), Munster Univ Hosp, Dept Gynecol & Obstet, Domagkstr 11, D-48149 Munster, Germany.	mgotte@uni-muenster.de; georgeyip@nus.edu.sg	Viola, Manuela/B-7120-2011; Kiesel, Ludwig/ABC-5333-2020; Götte, Martin/G-2254-2018; Gotte, M/Z-5878-2019; Ebnet, Klaus T/C-8314-2009	Viola, Manuela/0000-0002-0634-6390; Kiesel, Ludwig/0000-0002-7247-9247; Götte, Martin/0000-0003-2360-2496; Gotte, M/0000-0003-2360-2496; Ebnet, Klaus T/0000-0002-0417-7888; Ibrahim, Sherif Abdelaziz/0000-0001-6403-7345; Koo, Chuay Yeng/0000-0002-9495-0554	National Medical Research Council, Singapore [NMRC/1023/2005]; German Academic Exchange Service DAAD [A/08/15601, A/06/90277]; Forderkreis Universitat Munster	National Medical Research Council, Singapore(National Medical Research Council, Singapore); German Academic Exchange Service DAAD(Deutscher Akademischer Austausch Dienst (DAAD)); Forderkreis Universitat Munster	We would like to thank Birgit Pers, Ruth Goez, and Barbara Kloke for expert technical assistance, Professor Anna Starzinski-Powitz for providing Ishikawa cells, and Christian Adams MSc, for help with luciferase assays. Funding was provided by Grant NMRC/1023/2005 from the National Medical Research Council, Singapore (to GWY), by German Academic Exchange Service DAAD Grants A/08/15601 (to MV), and A/06/90277 (to SAI), and by the Forderkreis Universitat Munster (to MG).	Baehrecke EH, 2003, CURR BIOL, V13, pR473, DOI 10.1016/S0960-9822(03)00405-6; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Cera MR, 2009, J CELL SCI, V122, P268, DOI 10.1242/jcs.037127; Cheng YH, 2009, CIRC RES, V105, P158, DOI 10.1161/CIRCRESAHA.109.197517; Chiyomaru T, 2010, BRIT J CANCER, V102, P883, DOI 10.1038/sj.bjc.6605570; Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195; Darnel AD, 2009, CLIN CANCER RES, V15, P1376, DOI 10.1158/1078-0432.CCR-08-1789; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Ebnet K, 2004, J CELL SCI, V117, P19, DOI 10.1242/jcs.00930; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Gerashchenko MV, 2009, CELL BIOL INT, V33, P1057, DOI 10.1016/j.cellbi.2009.06.020; Gotte M, 2008, HUM MOL GENET, V17, P996, DOI 10.1093/hmg/ddm372; Gotte M, 2010, AM J PATHOL, V176, P25, DOI 10.2353/ajpath.2010.090775; Gomes ER, 2005, CELL, V121, P451, DOI 10.1016/j.cell.2005.02.022; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Hashimoto Y, 2007, MOL BIOL CELL, V18, P4591, DOI 10.1091/mbc.E07-02-0157; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; ISHIWATA I, 1984, GYNECOL ONCOL, V17, P281, DOI 10.1016/0090-8258(84)90212-9; Kano M, 2010, INT J CANCER, V127, P2804, DOI 10.1002/ijc.25284; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Kim SJ, 2010, GASTROENTEROLOGY, V138, P1035, DOI 10.1053/j.gastro.2009.09.061; KIM SJ, 2009, GASTROENTEROLOGY, V138, pE1; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Larrucea S, 2008, EXP CELL RES, V314, P2004, DOI 10.1016/j.yexcr.2008.03.009; Larsson E, 2009, GENOME MED, V1, DOI 10.1186/gm108; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Levy JR, 2008, J CELL SCI, V121, P3187, DOI 10.1242/jcs.033878; Liu X, 2009, CLIN CANCER RES, V15, P1177, DOI 10.1158/1078-0432.CCR-08-1355; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; McSherry EA, 2009, INT J CANCER, V125, P1343, DOI 10.1002/ijc.24498; Megraw M, 2007, NUCLEIC ACIDS RES, V35, pD149, DOI 10.1093/nar/gkl904; Naik MU, 2008, CANCER RES, V68, P2194, DOI 10.1158/0008-5472.CAN-07-3057; Naik MU, 2003, ARTERIOSCL THROM VAS, V23, P2165, DOI 10.1161/01.ATV.0000093982.84451.87; Nikolova V, 2009, CARCINOGENESIS, V30, P397, DOI 10.1093/carcin/bgp001; Ostenfeld MS, 2010, ONCOGENE, V29, P1073, DOI 10.1038/onc.2009.395; Qualtrough D, 2009, BRIT J CANCER, V101, P1124, DOI 10.1038/sj.bjc.6605286; Quintavalle M, 2010, J CELL BIOL, V189, P13, DOI 10.1083/jcb.200912096; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Seidler DG, 2006, J MOL MED, V84, P583, DOI 10.1007/s00109-006-0046-4; Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019; Sempere LF, 2009, THESCIENTIFICWORLDJO, V9, P626, DOI 10.1100/tsw.2009.88; Severson EA, 2009, MOL BIOL CELL, V20, P1916, DOI 10.1091/mbc.E08-10-1014; Sizemore S, 2007, CANCER RES, V67, P6183, DOI 10.1158/0008-5472.CAN-06-3575; Spizzo R, 2010, CELL DEATH DIFFER, V17, P246, DOI 10.1038/cdd.2009.117; Stuwe L, 2007, J PHYSIOL-LONDON, V585, P351, DOI 10.1113/jphysiol.2007.145185; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Takagi T, 2009, ONCOLOGY-BASEL, V77, P12, DOI 10.1159/000218166; Vignjevic D, 2007, CANCER RES, V67, P6844, DOI 10.1158/0008-5472.CAN-07-0929; Wang SH, 2009, INT J ONCOL, V34, P1461, DOI 10.3892/ijo_00000275; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Xin M, 2009, GENE DEV, V23, P2166, DOI 10.1101/gad.1842409; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Yoder BJ, 2005, CLIN CANCER RES, V11, P186; Zeng L, 2009, P NATL ACAD SCI USA, V106, P17793, DOI 10.1073/pnas.0903693106	56	175	187	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	50					6569	6580		10.1038/onc.2010.386	http://dx.doi.org/10.1038/onc.2010.386			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	695OA	20818426	Bronze			2022-12-17	WOS:000285380200006
J	Swietach, P; Hulikova, A; Vaughan-Jones, RD; Harris, AL				Swietach, P.; Hulikova, A.; Vaughan-Jones, R. D.; Harris, A. L.			New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation	ONCOGENE			English	Review						cancer; pH; carbonic anhydrase IX; acid/base transport; buffers	PIG VENTRICULAR MYOCYTE; H+-ION MOBILITY; INTRACELLULAR PH; EXTRACELLULAR-PH; CELL-GROWTH; MN/CA IX; ANTIPORT ACTIVITY; GENE-EXPRESSION; MELANOMA-CELLS; BREAST-CANCER	In this review, we discuss the role of the tumour-associated carbonic anhydrase isoform IX (CAIX) in the context of pH regulation. We summarise recent experimental findings on the effect of CAIX on cell growth and survival, and present a diffusion-reaction model to help in the assessment of CAIX function under physiological conditions. CAIX emerges as an important facilitator of acid diffusion and acid transport, helping to overcome large cell-to-capillary distances that are characteristic of solid tumours. The source of substrate for CAIX catalysis is likely to be CO2, generated by adequately oxygenated mitochondria or from the titration of metabolic acids with HCO3- taken up from the extracellular milieu. The relative importance of these pathways will depend on oxygen and metabolite availability, the spatiotemporal patterns of the cell's exposure to hypoxia and on the regulation of metabolism by genes. This is now an important avenue for further investigation. The importance of CAIX in regulating tumour pH highlights the protein as a potential target for cancer therapy. Oncogene (2010) 29, 6509-6521; doi: 10.1038/onc.2010.455; published online 4 October 2010	[Swietach, P.; Hulikova, A.; Vaughan-Jones, R. D.] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3PT, England; [Harris, A. L.] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX1 3PT, England	University of Oxford; University of Oxford	Swietach, P (corresponding author), Univ Oxford, Dept Physiol Anat & Genet, Sherrington Bldg,S Parks Rd, Oxford OX1 3PT, England.	pawel.swietach@dpag.ox.ac.uk	Harris, Adrian L/ABA-3343-2020; Swietach, Pawel/AAK-4169-2020	Harris, Adrian L/0000-0003-1376-8409; Swietach, Pawel/0000-0002-9945-9473	Royal Society; Medical Research Council; British Heart Foundation; Cancer Research UK; European Union; MRC [G0700698] Funding Source: UKRI; British Heart Foundation [RG/08/016/26423] Funding Source: researchfish; Medical Research Council [G0700698] Funding Source: researchfish	Royal Society(Royal Society of London); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Cancer Research UK(Cancer Research UK); European Union(European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This study was supported by the Royal Society, Medical Research Council, British Heart Foundation, the Cancer Research UK and the European Union Framework 7 Metoxia.	Ahlskog JKJ, 2009, BIOORG MED CHEM LETT, V19, P4851, DOI 10.1016/j.bmcl.2009.06.022; Airley RE, 2003, INT J CANCER, V104, P85, DOI 10.1002/ijc.10904; Alper SL, 2006, EXP PHYSIOL, V91, P153, DOI 10.1113/expphysiol.2005.031765; Alterio V, 2009, P NATL ACAD SCI USA, V106, P16233, DOI 10.1073/pnas.0908301106; Beasley NJP, 2001, CANCER RES, V61, P5262; Boron WF, 2010, BBA-PROTEINS PROTEOM, V1804, P410, DOI 10.1016/j.bbapap.2009.10.021; Boron WF, 2004, ADV PHYSIOL EDUC, V28, P160, DOI 10.1152/advan.00045.2004; CHAMBARD JC, 1986, EXP CELL RES, V164, P282, DOI 10.1016/0014-4827(86)90029-7; Chegwidden WR, 2000, EXS, V90, P343; Chia SK, 2001, J CLIN ONCOL, V19, P3660, DOI 10.1200/JCO.2001.19.16.3660; Chiche J, 2010, J CELL MOL MED, V14, P771, DOI 10.1111/j.1582-4934.2009.00994.x; Chiche J, 2009, CANCER RES, V69, P358, DOI 10.1158/0008-5472.CAN-08-2470; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; De Simone G, 2010, BBA-PROTEINS PROTEOM, V1804, P404, DOI 10.1016/j.bbapap.2009.07.027; Dorai T, 2005, EUR J CANCER, V41, P2935, DOI 10.1016/j.ejca.2005.09.011; Fang JS, 2008, SEMIN CANCER BIOL, V18, P330, DOI 10.1016/j.semcancer.2008.03.011; FRANCHI A, 1981, INT J CANCER, V27, P819, DOI 10.1002/ijc.2910270614; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Generali D, 2006, ENDOCR-RELAT CANCER, V13, P921, DOI 10.1677/erc.1.01216; Giatromanolaki A, 2001, CANCER RES, V61, P7992; GILLIES R J, 1992, Cellular Physiology and Biochemistry, V2, P159, DOI 10.1159/000154638; Gillies RJ, 2004, IEEE ENG MED BIOL, V23, P57, DOI 10.1109/MEMB.2004.1360409; GILLIES RJ, 1990, P NATL ACAD SCI USA, V87, P7414, DOI 10.1073/pnas.87.19.7414; Giusti I, 2008, NEOPLASIA, V10, P481, DOI 10.1593/neo.08178; Gleadle JM, 1998, MOL MED TODAY, V4, P122, DOI 10.1016/S1357-4310(97)01198-2; Griffiths J R, 2001, Novartis Found Symp, V240, P46; GRIFFITHS JR, 1981, BIOSCIENCE REP, V1, P319, DOI 10.1007/BF01114871; Guler OO, 2010, CURR MED CHEM, V17, P1516, DOI 10.2174/092986710790979999; Haapasalo JA, 2006, CLIN CANCER RES, V12, P473, DOI 10.1158/1078-0432.CCR-05-0848; Haapasalo J, 2008, NEURO-ONCOLOGY, V10, P131, DOI 10.1215/15228517-2007-065; Halestrap AP, 2004, PFLUG ARCH EUR J PHY, V447, P619, DOI 10.1007/s00424-003-1067-2; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HOLM E, 1995, CANCER RES, V55, P1373; Huang WC, 2008, CURR BIOL, V18, P781, DOI 10.1016/j.cub.2008.04.049; Hulikova A, 2009, FEBS LETT, V583, P3563, DOI 10.1016/j.febslet.2009.10.060; Innocenti A, 2009, BIOORG MED CHEM LETT, V19, P5825, DOI 10.1016/j.bmcl.2009.08.088; IRVING M, 1990, BIOPHYS J, V57, P717, DOI 10.1016/S0006-3495(90)82592-3; Ivanov S, 2001, AM J PATHOL, V158, P905, DOI 10.1016/S0002-9440(10)64038-2; KALLINOWSKI F, 1989, CANCER RES, V49, P3759; Koukourakis MI, 2001, CLIN CANCER RES, V7, P3399; Kunz-Schughart L, 2000, AM J PHYSIOL-CELL PH, V278, pC765, DOI 10.1152/ajpcell.2000.278.4.C765; LAGARDE AE, 1988, J CELL BIOCHEM, V36, P249, DOI 10.1002/jcb.240360306; LALLEMAIN G, 1985, J BIOL CHEM, V260, P4877; Lardner A, 2001, J LEUKOCYTE BIOL, V69, P522; Lee AH, 1998, CANCER RES, V58, P1901; Leem CH, 1999, J PHYSIOL-LONDON, V517, P159, DOI 10.1111/j.1469-7793.1999.0159z.x; Liao SY, 2000, CANCER, V88, P1108, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1108::AID-CNCR23>3.0.CO;2-D; Lindner D, 2009, BRIT J CANCER, V100, P1287, DOI 10.1038/sj.bjc.6605022; Loncaster JA, 2001, CANCER RES, V61, P6394; Martinez-Zaguilan R, 1999, BIOCHEM PHARMACOL, V57, P1037, DOI 10.1016/S0006-2952(99)00022-2; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; MartinezZaguilan R, 1996, CLIN EXP METASTAS, V14, P176, DOI 10.1007/BF00121214; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; McLean LA, 2000, AM J PHYSIOL-CELL PH, V278, pC676, DOI 10.1152/ajpcell.2000.278.4.C676; Morgan PE, 2007, AM J PHYSIOL-CELL PH, V293, pC738, DOI 10.1152/ajpcell.00157.2007; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543, DOI 10.1152/ajpcell.1998.274.2.C543; NEWELL K, 1993, P NATL ACAD SCI USA, V90, P1127, DOI 10.1073/pnas.90.3.1127; Niederer SA, 2008, BIOPHYS J, V94, P2385, DOI 10.1529/biophysj.107.118885; Pan PW, 2006, J PHYSIOL-LONDON, V571, P319, DOI 10.1113/jphysiol.2005.102590; PASTOREK J, 1994, ONCOGENE, V9, P2877; Pastorekova S, 1997, GASTROENTEROLOGY, V112, P398, DOI 10.1053/gast.1997.v112.pm9024293; Pastorekova S., 2004, CARBONIC ANHYDRASE I; Potter CPS, 2003, BRIT J CANCER, V89, P2, DOI 10.1038/sj.bjc.6600936; POUYSSEGUR J, 1985, FEBS LETT, V190, P115, DOI 10.1016/0014-5793(85)80439-7; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Romero MF, 2004, PFLUG ARCH EUR J PHY, V447, P495, DOI 10.1007/s00424-003-1180-2; Saarnio J, 1998, AM J PATHOL, V153, P279, DOI 10.1016/S0002-9440(10)65569-1; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; Sauvant C, 2008, INT J CANCER, V123, P2532, DOI 10.1002/ijc.23818; Sennoune SR, 2004, AM J PHYSIOL-CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003; Spitzer KW, 2002, J PHYSIOL-LONDON, V541, P159, DOI 10.1113/jphysiol.2001.013268; Sterling D, 2001, J BIOL CHEM, V276, P47886, DOI 10.1074/jbc.M105959200; Stewart AK, 2009, J BIOL CHEM, V284, P6126, DOI 10.1074/jbc.M802051200; Stock C, 2007, CELL PHYSIOL BIOCHEM, V20, P679, DOI 10.1159/000107550; Sun B, 1996, J PHYSIOL-LONDON, V495, P65, DOI 10.1113/jphysiol.1996.sp021574; Supuran CT, 2008, NAT REV DRUG DISCOV, V7, P168, DOI 10.1038/nrd2467; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; Svastova E, 2003, EXP CELL RES, V290, P332, DOI 10.1016/S0014-4827(03)00351-3; Swietach P, 2003, PROG BIOPHYS MOL BIO, V83, P69, DOI 10.1016/S0079-6107(03)00027-0; Swietach P, 2008, J BIOL CHEM, V283, P20473, DOI 10.1074/jbc.M801330200; Swietach P, 2007, BIOPHYS J, V92, P641, DOI 10.1529/biophysj.106.096560; Swietach P, 2009, J BIOL CHEM, V284, P20299, DOI 10.1074/jbc.M109.006478; THOMAS RC, 1989, NATURE, V337, P601, DOI 10.1038/337601a0; THOMLINSON RH, 1955, BRIT J CANCER, V9, P539, DOI 10.1038/bjc.1955.55; Turner JR, 1997, HUM PATHOL, V28, P740, DOI 10.1016/S0046-8177(97)90185-4; Turner KJ, 2002, BRIT J CANCER, V86, P1276, DOI 10.1038/sj.bjc.6600215; VASSEUR M, 1989, BIOCHEM J, V263, P775, DOI 10.1042/bj2630775; Vaughan-Jones RD, 2002, J PHYSIOL-LONDON, V541, P139, DOI 10.1113/jphysiol.2001.013267; VAUGHANJONES RD, 1990, J PHYSIOL-LONDON, V428, P441, DOI 10.1113/jphysiol.1990.sp018221; VAUPEL P, 1989, CANCER RES, V49, P6449; WOHLHUETER RM, 1981, J BIOL CHEM, V256, P869; Wykoff CC, 2000, CANCER RES, V60, P7075; Xu C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009625; Zavada J, 2000, BRIT J CANCER, V82, P1808, DOI 10.1054/bjoc.2000.1111	95	175	178	2	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2010	29	50					6509	6521		10.1038/onc.2010.455	http://dx.doi.org/10.1038/onc.2010.455			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	695OA	20890298				2022-12-17	WOS:000285380200001
J	Yamamoto, H; Oue, N; Sato, A; Hasegawa, Y; Yamamoto, H; Matsubara, A; Yasui, W; Kikuchi, A				Yamamoto, H.; Oue, N.; Sato, A.; Hasegawa, Y.; Yamamoto, H.; Matsubara, A.; Yasui, W.; Kikuchi, A.			Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase	ONCOGENE			English	Article						Wnt5a; prostate cancer; Gleason score; invasion; MMP-1	RADICAL PROSTATECTOMY; ACTIVATOR PROTEIN-1; TUMOR-FORMATION; CELL-MIGRATION; GASTRIC-CANCER; GROWTH-FACTOR; IN-VITRO; INVASION; PATHWAY; WNT-5A	Wnt5a is a representative ligand that activates the beta-catenin-independent pathway in Wnt signaling. Although it has been reported that abnormal activation of the Wnt/beta-catenin-dependent pathway is often observed in human prostate cancer, the involvement of the b-catenin-independent pathway in this cancer is unclear. Abnormal expression of Wnt5a and beta-catenin was observed in 27 (28%) and 49 (50%) of 98 prostate cancer cases, respectively, by immunohistochemical analyses. Simultaneous expression of Wnt5a and b-catenin was observed in only five cases, suggesting their exclusive expression. The positive detection of Wnt5a was correlated with high Gleason scores and biochemical relapse of prostate cancer, but that of b-catenin was not. Knockdown and overexpression of Wnt5a in human prostate cancer cell lines reduced and stimulated, respectively, their invasion activities, and the invasion activity required Frizzled2 and Ror2 as Wnt receptors. Wnt5a activated Jun-N-terminal kinase through protein kinase D (PKD) and the inhibition of PKD suppressed Wnt5a-dependent cell migration and invasion. In addition, Wnt5a induced the expression of metalloproteinase-1 through the recruitment of JunD to its promoter region. These results suggest that Wnt5a promotes the aggressiveness of prostate cancer and that its expression is involved in relapse after prostatectomy. Oncogene (2010) 29, 2036-2046; doi: 10.1038/onc.2009.496; published online 18 January 2010	[Sato, A.; Yamamoto, H.; Kikuchi, A.] Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; [Yamamoto, H.] Hiroshima Univ, Dept Biochem, Grad Sch Biomed Sci, Hiroshima, Japan; [Yamamoto, H.] Hiroshima Univ, Dept Surg, Grad Sch Biomed Sci, Hiroshima, Japan; [Oue, N.; Yasui, W.] Hiroshima Univ, Dept Mol Pathol, Grad Sch Biomed Sci, Hiroshima, Japan; [Hasegawa, Y.; Matsubara, A.] Hiroshima Univ, Dept Urol, Grad Sch Biomed Sci, Hiroshima, Japan	Osaka University; Hiroshima University; Hiroshima University; Hiroshima University; Hiroshima University	Kikuchi, A (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	akikuchi@molbiobc.med.osaka-u.ac.jp		Yamamoto, Hideki/0000-0003-4919-3483	Ministry of Education, Science, and Culture of Japan (2007, 2008, 2009); The YASUDA Medical Foundation (2006); Uehara Memorial Foundation (2008)	Ministry of Education, Science, and Culture of Japan (2007, 2008, 2009)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); The YASUDA Medical Foundation (2006); Uehara Memorial Foundation (2008)(Uehara Memorial Foundation)	This work was supported by Grants-in-Aid for Scientific Research and for Scientific Research on Priority Areas from the Ministry of Education, Science, and Culture of Japan (2007, 2008, 2009), The YASUDA Medical Foundation (2006) and Uehara Memorial Foundation (2008).	ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Bernard P, 2007, INT J BIOCHEM CELL B, V39, P31, DOI 10.1016/j.biocel.2006.06.007; Cao J, 2008, J BIOL CHEM, V283, P6232, DOI 10.1074/jbc.M705759200; D'Amico AV, 2000, J CLIN ONCOL, V18, P1164, DOI 10.1200/JCO.2000.18.6.1164; Dejmek J, 2005, CANCER RES, V65, P9142, DOI 10.1158/0008-5472.CAN-05-1710; Doyle GAR, 1997, J BIOL CHEM, V272, P11840, DOI 10.1074/jbc.272.18.11840; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; Hall MC, 2003, J BIOL CHEM, V278, P10304, DOI 10.1074/jbc.M212334200; Han M, 2003, J UROLOGY, V169, P517, DOI 10.1016/S0022-5347(05)63946-8; Hart CA, 2002, BRIT J CANCER, V86, P1136, DOI 10.1038/sj/bjc/6600207; Hsing AW, 2000, INT J CANCER, V85, P60, DOI 10.1002/(SICI)1097-0215(20000101)85:1&lt;60::AID-IJC11&gt;3.0.CO;2-B; Huang CL, 2005, J CLIN ONCOL, V23, P8765, DOI 10.1200/JCO.2005.02.2871; Hurlstone A, 2002, EMBO J, V21, P2303, DOI 10.1093/emboj/21.10.2303; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kikuchi A, 2003, CANCER SCI, V94, P225, DOI 10.1111/j.1349-7006.2003.tb01424.x; Kikuchi A, 2008, CANCER SCI, V99, P202, DOI 10.1111/j.1349-7006.2007.00675.x; Kikuchi A, 2009, TRENDS CELL BIOL, V19, P119, DOI 10.1016/j.tcb.2009.01.003; Kobayashi T, 2006, MOL CELL BIOL, V26, P898, DOI 10.1128/MCB.26.3.898-911.2006; Kremenevskaja N, 2005, ONCOGENE, V24, P2144, DOI 10.1038/sj.onc.1208370; Kurayoshi M, 2007, BIOCHEM J, V402, P515, DOI 10.1042/BJ20061476; Kurayoshi M, 2006, CANCER RES, V66, P10439, DOI 10.1158/0008-5472.CAN-06-2359; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Masckauchan TNH, 2006, MOL BIOL CELL, V17, P5163, DOI 10.1091/mbc.E06-04-0320; Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365-2443.2003.00662.x; Partin AW, 1997, JAMA-J AM MED ASSOC, V277, P1445, DOI 10.1001/jama.277.18.1445; Polakis P, 2000, GENE DEV, V14, P1837; Pound CR, 1999, JAMA-J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591; Pukrop T, 2006, P NATL ACAD SCI USA, V103, P5454, DOI 10.1073/pnas.0509703103; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Sato A, 2010, EMBO J, V29, P41, DOI 10.1038/emboj.2009.322; Sobin, 2009, UICC TNM CLASSIFICAT; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Verras M, 2004, CANCER RES, V64, P8860, DOI 10.1158/0008-5472.CAN-04-2370; Wang HY, 2006, CELL SIGNAL, V18, P934, DOI 10.1016/j.cellsig.2005.12.008; Wang Q, 2007, ONCOGENE, V26, P6560, DOI 10.1038/sj.onc.1210472; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Wu JY, 2006, CANCER RES, V66, P5111, DOI 10.1158/0008-5472.CAN-06-0383; Yamamoto H, 2009, GASTROENTEROLOGY, V137, P242, DOI 10.1053/j.gastro.2009.02.003; Yardy GW, 2005, PROSTATE CANCER P D, V8, P119, DOI 10.1038/sj.pcan.4500794; Zeng ZZ, 2006, CANCER RES, V66, P8091, DOI 10.1158/0008-5472.CAN-05-4400	44	175	189	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2010	29	14					2036	2046		10.1038/onc.2009.496	http://dx.doi.org/10.1038/onc.2009.496			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20101234				2022-12-17	WOS:000276402800003
J	Sampath, D; Rao, VA; Plunkett, W				Sampath, D; Rao, VA; Plunkett, W			Mechanisms of apoptosis induction by nucleoside analogs	ONCOGENE			English	Review						DNA damage; sensors; checkpoints; DNA repair	ACTIVATED PROTEIN-KINASE; S-PHASE CHECKPOINT; CHRONIC LYMPHOCYTIC-LEUKEMIA; DRUG-INDUCED APOPTOSIS; DAMAGE-INDUCED APOPTOSIS; HUMAN DNA-POLYMERASES; HAIRY-CELL LEUKEMIA; C-ABL; ARA-C; CYTOCHROME-C	Nucleoside analogs are structurally, metabolically, and pharmacodynamically related agents that nevertheless have diverse biological actions and therapeutic consequences. This class of agents affects the structural integrity of DNA, generally after incorporation during replication or DNA excision repair synthesis, leading to stalled replication forks and chain termination. The DNA damage sensors ATM, ATR and DNA-PK recognize these events. These and other protein kinases activate checkpoint pathways that arrest cell cycle progression, and also signal for DNA repair. In addition, if these survival mechanisms are overwhelmed by the damage caused, a third function of these sensors is to activate signaling pathways that initiate apoptotic processes. A review of the spectrum of responses that are activated by clinically relevant nucleoside analogs begins to provide a mechanistic basis for diverse outcomes in cell viability. Such information, when coupled with an understanding of the intrinsic apoptotic potential of a tumor cell type may provide a rational basis for the design of therapeutic strategies.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Plunkett, W (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd, Houston, TX 77030 USA.	wplunket@mdanderson.org	Sampath, Deepa/T-5069-2019; Sampath, Deepa/J-3298-2016; Rao, V Ashutosh/A-3569-2013	Rao, V Ashutosh/0000-0001-6817-8049; Sampath, Deepa/0000-0002-4366-8436	NATIONAL CANCER INSTITUTE [P01CA081534, R01CA028596, P01CA055164, P20CA081534, R01CA032839] Funding Source: NIH RePORTER; NCI NIH HHS [CA81534, CA55164, CA32839, CA28596] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achanta G, 2001, CANCER RES, V61, P8723; AGARWAL RP, 1982, PHARMACOL THERAPEUT, V17, P399, DOI 10.1016/0163-7258(82)90023-7; Akinaga S, 2000, ANTI-CANCER DRUG DES, V15, P43; Azuma A, 2001, MOL PHARMACOL, V59, P725, DOI 10.1124/mol.59.4.725; Bellosillo B, 2002, BLOOD, V100, P1810, DOI 10.1182/blood-2001-12-0327; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; BIANCHI V, 1992, EXP CELL RES, V199, P120, DOI 10.1016/0014-4827(92)90469-O; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Bullock G, 1996, LEUKEMIA, V10, P1731; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Capasso H, 2002, J CELL SCI, V115, P4555, DOI 10.1242/jcs.00133; CARSON DA, 1988, ADV ENZYME REGUL, V27, P395, DOI 10.1016/0065-2571(88)90028-3; CARSON DA, 1978, CIBA F S, V68, P115; CARTER BZ, 2003, BLOOD; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; CHAN T, 1978, CELL, V14, P523, DOI 10.1016/0092-8674(78)90238-6; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHESON BD, 1997, NUCLEOSIDE ANAL CANC; Chreneik JE, 2003, J BIOL CHEM, V278, P12461, DOI 10.1074/jbc.M212930200; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; COHEN A, 1978, P NATL ACAD SCI USA, V75, P472, DOI 10.1073/pnas.75.1.472; COHEN A, 1976, NEW ENGL J MED, V295, P1449, DOI 10.1056/NEJM197612232952603; COHEN A, 1978, J CLIN INVEST, V61, P1405, DOI 10.1172/JCI109058; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Crews KR, 2002, J CLIN ONCOL, V20, P4217, DOI 10.1200/JCO.2002.10.006; Datta R, 2000, J BIOL CHEM, V275, P31733, DOI 10.1074/jbc.M910231199; Dearden CE, 2000, SEMIN ONCOL, V27, P22; Dewson G, 2003, ONCOGENE, V22, P2643, DOI 10.1038/sj.onc.1206326; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Eastman A, 2002, MOL CANCER THER, V1, P1067; Eggert A, 2001, CANCER RES, V61, P1314; ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979; Eucker J, 2002, ANTI-CANCER DRUG, V13, P907, DOI 10.1097/00001813-200210000-00002; Faderl Stefan, 2002, Cancer Chemother Biol Response Modif, V20, P37; Feng L, 2000, INT J MOL MED, V5, P597; Fink D, 1998, CLIN CANCER RES, V4, P1; Fu WN, 2003, ONCOGENE, V22, P451, DOI 10.1038/sj.onc.1206147; Fukazawa T, 1999, ONCOGENE, V18, P2189, DOI 10.1038/sj.onc.1202561; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Genini D, 2000, BLOOD, V96, P3537; Genini D, 2000, J BIOL CHEM, V275, P29, DOI 10.1074/jbc.275.1.29; GIBLETT ER, 1972, LANCET, V2, P1067; GIBLETT ER, 1975, LANCET, V1, P1010, DOI 10.1016/S0140-6736(75)91950-9; Goodman GR, 2003, J CLIN ONCOL, V21, P891, DOI 10.1200/JCO.2003.05.093; Goodman MF, 2000, TRENDS BIOCHEM SCI, V25, P189, DOI 10.1016/S0968-0004(00)01564-4; Grant S, 1998, ADV CANCER RES, V72, P197; Grem J L, 1999, Cancer Chemother Biol Response Modif, V18, P1; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; GUNJI H, 1991, CANCER RES, V51, P741; HAAF T, 1995, PHARMACOL THERAPEUT, V65, P19, DOI 10.1016/0163-7258(94)00053-6; Harada K, 2002, CANCER RES, V62, P5897; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; HEIDELBERGER C, 1983, ADV ENZYMOL RAMB, V54, P57; HEINEMANN V, 1992, CANCER RES, V52, P533; HEINEMANN V, 1990, MOL PHARMACOL, V38, P567; HENTOSH P, 1990, J BIOL CHEM, V265, P4033; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Huang P, 2000, LEUKEMIA, V14, P1405, DOI 10.1038/sj.leu.2401845; HUANG P, 1991, CANCER RES, V51, P6110; HUANG P, 1995, CANCER CHEMOTH PHARM, V36, P181, DOI 10.1007/BF00685844; HUANG P, 1990, J BIOL CHEM, V265, P16617; HUANG P, 1991, MOL PHARMACOL, V39, P449; Ibrado AM, 1996, CANCER RES, V56, P4743; INGRAHAM HA, 1982, MOL PHARMACOL, V21, P211; Johnson S A, 2001, Expert Opin Pharmacother, V2, P929, DOI 10.1517/14656566.2.6.929; Johnson SA, 2000, CLIN PHARMACOKINET, V39, P5, DOI 10.2165/00003088-200039010-00002; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kamiya K, 1996, J BIOL CHEM, V271, P19428, DOI 10.1074/jbc.271.32.19428; Kastan MB, 2000, COLD SPRING HARB SYM, V65, P521, DOI 10.1101/sqb.2000.65.521; Keating MJ, 1999, SEMIN ONCOL, V26, P107; Keating MJ, 1997, CLIN CANCER RES, V3, P2598; KEATING MJ, 1999, CLIN CANC RES 2, V3, P2598; KEITH FJ, 1995, LEUKEMIA, V9, P131; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kim CN, 1997, CANCER RES, V57, P3115; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kobayashi T, 1998, CELL DEATH DIFFER, V5, P584, DOI 10.1038/sj.cdd.4400382; Kohn EA, 2002, J BIOL CHEM, V277, P26553, DOI 10.1074/jbc.M202040200; Komander D, 2003, BIOCHEM J, V375, P255, DOI 10.1042/BJ20031119; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Konopleva M, 2000, BLOOD, V95, P3929; Konopleva M, 2002, LEUKEMIA, V16, P1713, DOI 10.1038/sj.leu.2402608; Konopleva M, 2002, BRIT J HAEMATOL, V118, P521, DOI 10.1046/j.1365-2141.2002.03637.x; KUFE DW, 1984, MOL PHARMACOL, V25, P322; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Leoni LM, 1998, P NATL ACAD SCI USA, V95, P9567, DOI 10.1073/pnas.95.16.9567; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu QH, 2000, GENE DEV, V14, P1448; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Lopez-Girona A, 2001, P NATL ACAD SCI USA, V98, P11289, DOI 10.1073/pnas.191557598; Massey A, 2001, CURR BIOL, V11, P1142, DOI 10.1016/S0960-9822(01)00272-X; MIYASHITA T, 1993, BLOOD, V81, P151; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; O'Brien SM, 2001, J CLIN ONCOL, V19, P1414, DOI 10.1200/JCO.2001.19.5.1414; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OHNO Y, 1988, CANCER RES, V48, P1494; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PARKER WB, 1990, PHARMACOL THERAPEUT, V48, P381, DOI 10.1016/0163-7258(90)90056-8; PARKER WB, 1988, MOL PHARMACOL, V34, P485; Petak I, 2003, CELL DEATH DIFFER, V10, P211, DOI 10.1038/sj.cdd.4401132; Petak I, 2000, CLIN CANCER RES, V6, P4432; Petak Istvan, 2001, Pathology and Oncology Research, V7, P95; PINEDO HM, 1988, J CLIN ONCOL, V6, P1653, DOI 10.1200/JCO.1988.6.10.1653; Plunkett W, 1996, SEMIN ONCOL, V23, P3; Plunkett W, 2001, Cancer Chemother Biol Response Modif, V19, P21; PLUNKETT W, 1982, CANCER RES, V42, P2092; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Raina D, 2002, MOL PHARMACOL, V61, P1489, DOI 10.1124/mol.61.6.1489; Rao V. Ashutosh, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P797; Rao VA, 2003, CLIN CANCER RES, V9, P3204; Rodriguez CO, 2003, BLOOD, V102, P1842, DOI 10.1182/blood-2003-01-0317; Roos-Mattjus P, 2003, J BIOL CHEM, V278, P24428, DOI 10.1074/jbc.M301544200; Roos-Mattjus P, 2002, J BIOL CHEM, V277, P43809, DOI 10.1074/jbc.M207272200; Sampath D, 2002, MOL PHARMACOL, V62, P680, DOI 10.1124/mol.62.3.680; Sampath D, 2000, CANCER RES, V60, P6408; Sandoval A, 1996, CLIN CANCER RES, V2, P1731; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Santoro A, 2000, J CLIN ONCOL, V18, P2615, DOI 10.1200/JCO.2000.18.13.2615; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; Saven A, 1998, BLOOD, V92, P1918, DOI 10.1182/blood.V92.6.1918; SCHWEITZER BI, 1994, BIOCHEMISTRY-US, V33, P11460, DOI 10.1021/bi00204a008; SETO S, 1985, J CLIN INVEST, V75, P377, DOI 10.1172/JCI111710; SETO S, 1986, J IMMUNOL, V136, P2839; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shao RG, 1997, CANCER RES, V57, P4029; Shi Z, 2001, CANCER RES, V61, P1065; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; SNYDER RD, 1984, CHEM-BIOL INTERACT, V50, P1, DOI 10.1016/0009-2797(84)90127-3; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Storniolo AM, 1999, CANCER, V85, P1261, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1261::AID-CNCR7>3.3.CO;2-K; Sugimoto K, 2000, BRIT J HAEMATOL, V110, P819, DOI 10.1046/j.1365-2141.2000.02304.x; Sugiyama K, 2000, INT J CANCER, V85, P703, DOI 10.1002/(SICI)1097-0215(20000301)85:5<703::AID-IJC17>3.0.CO;2-7; Tempero M, 2003, J CLIN ONCOL, V21, P3402, DOI 10.1200/JCO.2003.09.140; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330; TSENG WC, 1982, MOL PHARMACOL, V21, P474; Ueki T, 2001, INT J CANCER, V91, P673, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1113>3.0.CO;2-U; Wang JL, 2002, CELL CYCLE, V1, P267, DOI 10.4161/cc.1.4.137; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; Yamauchi T, 2001, CLIN CANCER RES, V7, P3580; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YANG SW, 1992, J BIOL CHEM, V267, P2345; Yin MB, 2002, BIOCHEM BIOPH RES CO, V295, P435, DOI 10.1016/S0006-291X(02)00683-6; Yin XM, 2000, CELL RES, V10, P161, DOI 10.1038/sj.cr.7290045; Yoshida K, 2000, MOL CELL BIOL, V20, P5370, DOI 10.1128/MCB.20.15.5370-5380.2000; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; YUAN ZM, 1995, BIOCHEMISTRY-US, V34, P4908, DOI 10.1021/bi00014a048; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhu WG, 2001, CANCER RES, V61, P1327; Zinzani PL, 2000, J CLIN ONCOL, V18, P2603, DOI 10.1200/JCO.2000.18.13.2603; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	168	175	180	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2003	22	56					9063	9074		10.1038/sj.onc.1207229	http://dx.doi.org/10.1038/sj.onc.1207229			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	751GC	14663485				2022-12-17	WOS:000187043600010
J	Wang, S; Fusaro, G; Padmanabhan, J; Chellappan, SP				Wang, S; Fusaro, G; Padmanabhan, J; Chellappan, SP			Prohibitin co-localizes with Rb in the nucleus and recruits N-CoR and HDAC1 for transcriptional repression	ONCOGENE			English	Article						prohibitin; Rb; histone deacetylase 1; IgM; marked box	RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; TUMOR-SUPPRESSOR; ACUTE-LEUKEMIA; CELL-CYCLE; E2F; INTERACTS; RECEPTOR; COMPLEXES; TARGET	The potential tumor suppressor protein prohibitin can prevent cell proliferation and this required its binding to the Rb protein. Prohibitin could repress the transcriptional activity of E2F family members and this required a part of the marked box region of E2F. The sub-cellular localization of prohibitin has been variously attributed to the mitochondria as well as the inner cell membrane. Here we show that a subset of probibitin molecules are present in the nucleus where it co-localizes with the Rb protein. Deletion of a putative amino-terminal membrane-docking domain of prohibitin had no effect on its ability to suppress cell proliferation or inhibit E2F activity. Our experiments show that a 53 amino-acid stretch of E2F1 is sufficient for being targeted by prohibitin; fusion of this region to GAL4-VP16 construct could make it susceptible to prohibitin-mediated, but not Rb-mediated repression. Prohibitin, like Rb, could repress transcription from SV40 and major late promoters when recruited directly to DNA. Prohibitin mediated transcriptional repression required histone-deacetylase activity, but unlike Rb, additional co-repressors like N-CoR are also involved. Repression by prohibitin correlates with histone deacetylation on promoters and this was reversed by IgM stimulation of cells; IgM did not affect Rb-mediated repression or deacetylation of the promoters. Prohibitin thus appears to repress E2F-mediated transcription utilizing different molecular mediators and facilitate channeling of specific signaling pathways to the cell cycle machinery.	Univ S Florida, Dept Interdisciplinary Oncol, H Lee Moffitt Canc Ctr, Tampa, FL 33612 USA; Univ S Florida, Res Inst, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Chellappan, SP (corresponding author), Univ S Florida, Dept Interdisciplinary Oncol, H Lee Moffitt Canc Ctr, 12902 Magnolia Dr, Tampa, FL 33612 USA.	Chellasp@moffitt.usf.edu	Padmanabhan, Jaya/A-4226-2012	Padmanabhan, Jaya/0000-0003-2019-5135	NATIONAL CANCER INSTITUTE [R01CA077301] Funding Source: NIH RePORTER; NCI NIH HHS [CA 77301] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Brehm A, 1999, TRENDS BIOCHEM SCI, V24, P142, DOI 10.1016/S0968-0004(99)01368-7; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Coates PJ, 2001, EXP CELL RES, V265, P262, DOI 10.1006/excr.2001.5166; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; DEDON PC, 1991, ANAL BIOCHEM, V197, P83, DOI 10.1016/0003-2697(91)90359-2; Delage-Mourroux R, 2000, J BIOL CHEM, V275, P35848, DOI 10.1074/jbc.M001327200; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fusaro G, 2002, ONCOGENE, V21, P4539, DOI 10.1038/sj.onc.1205551; Harbour JW, 2000, CURR OPIN CELL BIOL, V12, P685, DOI 10.1016/S0955-0674(00)00152-6; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Howe L, 1999, CRIT REV EUKAR GENE, V9, P231, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.80; IKONEN E, 1995, FEBS LETT, V358, P273, DOI 10.1016/0014-5793(94)01444-6; Johnson David G., 1998, Frontiers in Bioscience, V3, pD447; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Luo RX, 1999, J NATL CANCER I, V91, P1288, DOI 10.1093/jnci/91.15.1288; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; MCCLUNG JK, 1995, EXP GERONTOL, V30, P99, DOI 10.1016/0531-5565(94)00069-7; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; Steglich G, 1999, MOL CELL BIOL, V19, P3435; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; Thompson WE, 1999, ANAT REC, V256, P40, DOI 10.1002/(SICI)1097-0185(19990901)256:1<40::AID-AR6>3.0.CO;2-X; Wang S, 1999, MOL CELL BIOL, V19, P7447; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; ZHANG YH, 1995, ONCOGENE, V10, P2085	46	175	186	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2002	21	55					8388	8396		10.1038/sj.onc.1205944	http://dx.doi.org/10.1038/sj.onc.1205944			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466959				2022-12-17	WOS:000179480100002
J	Slack, JK; Adams, RB; Rovin, JD; Bissonette, EA; Stoker, CE; Parsons, JT				Slack, JK; Adams, RB; Rovin, JD; Bissonette, EA; Stoker, CE; Parsons, JT			Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells	ONCOGENE			English	Article						focal adhesion kinase; Src; cell migration; prostate; signal transduction	PROTEIN-TYROSINE KINASE; SRC FAMILY KINASES; SUBSTRATE P130(CAS); DROSOPHILA HOMOLOG; IN-VIVO; PHOSPHORYLATION; INTEGRIN; CRK; ACTIVATION; PAXILLIN	Focal adhesion kinase (FAK) has been implicated in the regulation of cell migration. In addition, FAK expression is:increased in a number of highly metastatic tumor cell lines. Therefore, we investigated the role of FAK in regulating migration of prostate carcinoma cell lines with increasing metastatic potential. We show that highly tumorigenic PC3 and DU145 cells exhibit intrinsic migratory capacity, while poorly tumorigenic LNCaP cells require a stimulus to migrate, Increased metastatic potential of PC3 and DU145 cells correlates with increased FAK expression, overall tyrosine phosphorylation and activity, as measured by autophosphorylation of tyrosine 397, However, in PC3 and DU145 cells, FAK autophosphorylation is adhesion dependent whereas a second site of tyrosine phosphorylation, tyrosine 861, a Src specific site, is uncoupled from adhesion-dependent signaling events, Finally, inhibiting the FAK/Src signal transduction pathway by over expressing FRNK ((F) under bar ocal adhesion kinase-(R) under bar elated (N) under bar on-(K) under bar inase), an inhibitor of FAK activation, or treatment with PP2, a Src family kinase-inhibitor, significantly inhibited migration of prostate carcinoma cell lines, demonstrating that tumor cell migration continues to be dependent on signals emanating from this pathway.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Surg, Charlottesville, VA 22908 USA; Univ Virginia, Dept Hlth Evaluat Sci, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Parsons, JT (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Box 441, Charlottesville, VA 22908 USA.		Mordwinkin, Nicholas M/A-4347-2010		NATIONAL CANCER INSTITUTE [P01CA076465] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA76465] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Fox GL, 1999, P NATL ACAD SCI USA, V96, P14978, DOI 10.1073/pnas.96.26.14978; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Han NM, 1997, ANN SURG ONCOL, V4, P264, DOI 10.1007/BF02306620; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Judson PL, 1999, CANCER, V86, P1551, DOI 10.1002/(SICI)1097-0142(19991015)86:6<1551::AID-CNCR23>3.0.CO;2-P; KAIGHN ME, 1979, INVEST UROL, V17, P16; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KORNBERG LJ, 1992, J BIOL CHEM, V276, P23439; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MOHLER JL, 1988, CANCER RES, V48, P4312; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; Owen JD, 1999, MOL CELL BIOL, V19, P4806; OWENS LV, 1995, CANCER RES, V55, P2752; Owens LV, 1996, ANN SURG ONCOL, V3, P100, DOI 10.1007/BF02409059; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Taylor JM, 2000, J BIOL CHEM, V275, P19250, DOI 10.1074/jbc.M909099199; Tremblay L, 1996, INT J CANCER, V68, P164, DOI 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W; Tremblay L, 1996, MOL ENDOCRINOL, V10, P1010, DOI 10.1210/me.10.8.1010; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Vuori K, 1996, MOL CELL BIOL, V16, P2606; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Zheng DQ, 1999, CANCER RES, V59, P1655	60	175	180	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1152	1163		10.1038/sj.onc.1204208	http://dx.doi.org/10.1038/sj.onc.1204208			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313859				2022-12-17	WOS:000167570100002
J	Qiu, Y; Kung, HJ				Qiu, Y; Kung, HJ			Signaling network of the Btk family kinases	ONCOGENE			English	Review						PH domain; Btk; tyrosine kinase; apoptosis; motility	BRUTONS-TYROSINE-KINASE; PLECKSTRIN HOMOLOGY DOMAINS; X-LINKED AGAMMAGLOBULINEMIA; CELL ANTIGEN RECEPTOR; BETA-GAMMA-SUBUNITS; PROSTATE-CANCER CELLS; SERUM RESPONSE FACTOR; RI CROSS-LINKING; FACTOR-KAPPA-B; SRC-FAMILY	The Btk family kinases represent new members of nonreceptor tyrosine kinases,which include Btk/Atk, Itk/Emt/Tsk, Bmx/Etk, and Tee. They are characterized by having four structural modules: PH (pleckstrin homology) domain, SH3 (Src homology 3) domain, SH2 (Src homology 2) domain and kinase (Src homology 1) domain. Increasing evidence suggests that, like Src-family kinases, Btk family kinases play central but diverse modulatory roles in various cellular processes, They participate in signal transduction in response to virtually all types of extracellular stimuli which are transmitted by growth factor receptors, cytokine receptors, G-protein coupled receptors, antigen-receptors and integrins, They are regulated by many non-receptor tyrosine kinases such as Src, Jak, Syk and FAK family kinases, In turn, they regulate many of major signaling pathways including those of PI3K, PLC gamma and PKC, Both genetic and biochemical approaches have been used to dissect the signaling pathways and elucidate their roles in growth, differentiation and apoptosis, An emerging new role of this family of kinases is cytoskeletal reorganization and cell motility, The physiological importance of these kinases was amply demonstrated hy their link to the development of immunodeficiency diseases, due to germ-line mutations. The present article attempts to review the structure and functions of Btk family kinases by summarizing our current knowledge on the interacting partners associated with the different modules of the kinases and the diverse signaling pathways in which they are involved.	Univ Calif Davis, Sch Med, Dept Biol Chem, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med, Ctr Canc, Sacramento, CA 95817 USA; Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Kung, HJ (corresponding author), Univ Calif Davis, Sch Med, Dept Biol Chem, 4645 2nd Ave, Sacramento, CA 95817 USA.		Kung, Hsing-Jien/C-7651-2013; Roszak, Joanna/F-4003-2010					Afar DEH, 1996, MOL CELL BIOL, V16, P3465; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Bajpai UD, 2000, J EXP MED, V191, P1735, DOI 10.1084/jem.191.10.1735; Beitz LO, 1999, J BIOL CHEM, V274, P32662, DOI 10.1074/jbc.274.46.32662; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bunnell SC, 1996, J BIOL CHEM, V271, P25646, DOI 10.1074/jbc.271.41.25646; Cao XM, 1996, MOL CELL BIOL, V16, P1595; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Cory GOC, 1996, J IMMUNOL, V157, P3791; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; Craxton A, 1999, J BIOL CHEM, V274, P30644, DOI 10.1074/jbc.274.43.30644; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; Ekman N, 2000, ONCOGENE, V19, P4151, DOI 10.1038/sj.onc.1203763; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Gibson S, 1996, J IMMUNOL, V156, P2716; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; Gu CH, 2000, J BIOL CHEM, V275, P20726, DOI 10.1074/jbc.M000152200; Hata D, 1998, J EXP MED, V187, P1235, DOI 10.1084/jem.187.8.1235; Heyeck SD, 1997, J BIOL CHEM, V272, P25401, DOI 10.1074/jbc.272.40.25401; Hsueh RC, 2000, ADV IMMUNOL, V75, P283, DOI 10.1016/S0065-2776(00)75007-3; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Islam TC, 2000, J GENE MED, V2, P204; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; JUI HY, 2001, IN PRESS J BIOL CHEM; Jurado LAP, 1998, HUM MOL GENET, V7, P325, DOI 10.1093/hmg/7.3.325; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kawakami Y, 2000, P NATL ACAD SCI USA, V97, P7423, DOI 10.1073/pnas.120175097; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3556; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; Kawakami Y, 1998, J IMMUNOL, V161, P1795; Kitaura J, 2000, J EXP MED, V192, P729, DOI 10.1084/jem.192.5.729; Kojima T, 1997, BIOCHEM BIOPH RES CO, V236, P333, DOI 10.1006/bbrc.1997.6947; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; Li TJ, 1997, ONCOGENE, V15, P1375, DOI 10.1038/sj.onc.1201308; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; Liao XC, 1995, IMMUNITY, V3, P757, DOI 10.1016/1074-7613(95)90065-9; Ma YC, 1998, P NATL ACAD SCI USA, V95, P12197, DOI 10.1073/pnas.95.21.12197; MACHIDE M, 1995, ONCOGENE, V11, P619; Mano H, 1998, GENES CELLS, V3, P431, DOI 10.1046/j.1365-2443.1998.00201.x; MANO H, 1995, BLOOD, V85, P343; Mano H, 1999, INT J HEMATOL, V69, P6; MANO H, 1993, ONCOGENE, V8, P417; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; Morrogh LM, 1999, EUR J IMMUNOL, V29, P2269; Nore BF, 2000, EUR J IMMUNOL, V30, P145, DOI 10.1002/1521-4141(200001)30:1<145::AID-IMMU145>3.0.CO;2-0; Novina CD, 1998, J BIOL CHEM, V273, P33443, DOI 10.1074/jbc.273.50.33443; Novina CD, 1999, MOL CELL BIOL, V19, P5014; Ohya K, 1999, P NATL ACAD SCI USA, V96, P11976, DOI 10.1073/pnas.96.21.11976; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Saharinen P, 1997, BLOOD, V90, P4341; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SATO K, 1994, LEUKEMIA, V8, P1663; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; Satterthwaite AB, 2000, P NATL ACAD SCI USA, V97, P6687, DOI 10.1073/pnas.110146697; Satterthwaite AB, 2000, IMMUNOL REV, V175, P120, DOI 10.1034/j.1600-065X.2000.017504.x; Schaeffer EM, 1999, SCIENCE, V284, P638, DOI 10.1126/science.284.5414.638; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; TakahashiTezuka M, 1997, ONCOGENE, V14, P2273, DOI 10.1038/sj.onc.1201071; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; Uckun FM, 1998, BIOCHEM PHARMACOL, V56, P683, DOI 10.1016/S0006-2952(98)00122-1; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Vassilev A, 1999, J BIOL CHEM, V274, P1646, DOI 10.1074/jbc.274.3.1646; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1995, IMMUNOL TODAY, V16, P460, DOI 10.1016/0167-5699(95)80027-1; Vihinen M, 1997, NUCLEIC ACIDS RES, V25, P166, DOI 10.1093/nar/25.1.166; Vihinen M, 1999, HUM MUTAT, V13, P280, DOI 10.1002/(SICI)1098-1004(1999)13:4<280::AID-HUMU3>3.0.CO;2-L; Vihinen Mauno, 1997, Frontiers in Bioscience (online), V2, pD27; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Yamadori T, 1999, P NATL ACAD SCI USA, V96, P6341, DOI 10.1073/pnas.96.11.6341; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; Yang WC, 1999, EUR J IMMUNOL, V29, P1842, DOI 10.1002/(SICI)1521-4141(199906)29:06<1842::AID-IMMU1842>3.0.CO;2-D; Yang WC, 1999, J BIOL CHEM, V274, P607, DOI 10.1074/jbc.274.2.607; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; Yao LB, 1999, J BIOL CHEM, V274, P19752, DOI 10.1074/jbc.274.28.19752; Yoshida K, 2000, J BIOL CHEM, V275, P24945, DOI 10.1074/jbc.M909012199	112	175	210	4	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2000	19	49					5651	5661		10.1038/sj.onc.1203958	http://dx.doi.org/10.1038/sj.onc.1203958			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114746				2022-12-17	WOS:000165659300013
J	Green, JE; Shibata, MA; Yoshidome, K; Liu, ML; Jorcyk, C; Anver, MR; Wigginton, J; Wiltrout, R; Shibata, E; Kaczmarczyk, S; Wang, W; Liu, ZY; Calvo, A; Couldrey, C				Green, JE; Shibata, MA; Yoshidome, K; Liu, ML; Jorcyk, C; Anver, MR; Wigginton, J; Wiltrout, R; Shibata, E; Kaczmarczyk, S; Wang, W; Liu, ZY; Calvo, A; Couldrey, C			The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma	ONCOGENE			English	Article						transgenic mice; C3(1); SV40 T-antigen; mammary cancer; prostate cancer; rat prostate steroid binding protein; tumor progression; DCIS	TUMOR PROGRESSION; BREAST-CANCER; RESPONSE ELEMENTS; MICE; GENE; VIRUS; SV40; PROSTATE; EXPRESSION; BINDING	The 5' flanking region of the C3(1) component of the rat prostate steroid binding protein (PSBP) has been used to successfully target the expression of the SV40 large T-antigen (Tag) to the epithelium of both the mammary and prostate glands resulting in models of mammary and prostate cancers which histologically resemble the human diseases. Atypia of the mammary ductal epithelium develops at about 8 weeks of age, progressing to mammary intraepithelial neoplasia (resembling human ductal carcinoma in situ [DCIS]) at about 12 weeks of age with the development of invasive carcinomas at about 16 weeks of age in 100% of female mice. The carcinomas share features to what has been classified in human breast cancer as infiltrating ductal carcinomas. All FVB/N female mice carrying the transgene develop mammary cancer with about a 15% incidence of lung metastases. Approximately 10% of older male mice develop anaplastic mammary carcinomas. Unlike many other transgenic models in which hormones and pregnancy are used to induce a mammary phenotype, C3(1)/Tag mice develop mammary tumors in the mammary epithelium of virgin animals without hormone supplementation or pregnancy. Although mammary tumor development appears hormone-responsive at early stages, invasive carcinomas are hormone-independent, which corresponds to the loss of estrogen receptor-a expression during tumor progression. Molecular and biologic factors related to mammary tumor progression can be studied in this model since lesions evolve over a predictable time course. Genomic alterations have been identified during tumor progression, including an amplification of the distal portion of chromosome 6 containing ki-ras and loss of heterozygosity (LOH) in other chromosomal regions. We have demonstrated that stage specific alterations in the expression of genes which are critical regulators of the cell cycle and apoptosis are functionally important in vivo. C3(1)/Tag mice appear useful for testing particular therapies since growth of the mammary tumors can be reduced using chemopreventive agents, cytokines, and an anti-angiogenesis agent.	NCI, Transgen Oncogenesis Grp, Lab Cell Regulat & Carcinogneesis, Bethesda, MD 20892 USA; Boise State Univ, Dept Biol, Boise, ID 83725 USA; SAIC, Pathol Histopathol Lab, Frederick, MD 21712 USA; NCI, Lab Expt Immunol, Frederick, MD 21712 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Idaho; Boise State University; Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Green, JE (corresponding author), NCI, Transgen Oncogenesis Grp, Lab Cell Regulat & Carcinogneesis, Bldg 41,Room C629, Bethesda, MD 20892 USA.		Calvo, Alfonso/V-7945-2017; Shibata, Masa-Aki/L-1624-2019	Calvo, Alfonso/0000-0003-4074-4242; Shibata, Masa-Aki/0000-0002-3350-7305	NCI NIH HHS [N01-CO-56000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC009262] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLISON J, 1989, MOL CELL BIOL, V9, P2254, DOI 10.1128/MCB.9.5.2254; Amundadottir LT, 1996, BREAST CANCER RES TR, V39, P119, DOI 10.1007/BF01806083; Carbone M, 1999, J CELL PHYSIOL, V180, P167, DOI 10.1002/(SICI)1097-4652(199908)180:2<167::AID-JCP4>3.0.CO;2-Q; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; CATO ACB, 1989, J STEROID BIOCHEM, V34, P139, DOI 10.1016/0022-4731(89)90074-5; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; CLAESSENS F, 1990, MOL CELL ENDOCRINOL, V74, P203, DOI 10.1016/0303-7207(90)90225-W; COX LA, 1994, BREAST CANCER RES TR, V32, P19, DOI 10.1007/BF00666203; DCOLE CH, 1998, FIELDS VIROLOGY, V2, P1997; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; Furth PA, 1998, DEV BIOL STAND, V94, P281; HEYNS W, 1977, EUR J BIOCHEM, V78, P221, DOI 10.1111/j.1432-1033.1977.tb11733.x; Hodi F S, 1998, Surg Oncol Clin N Am, V7, P471; Hurwitz AA, 1998, P NATL ACAD SCI USA, V95, P10067, DOI 10.1073/pnas.95.17.10067; Liu ML, 1998, ONCOGENE, V17, P2403, DOI 10.1038/sj.onc.1202456; Macleod KF, 1999, J PATHOL, V187, P43, DOI 10.1002/(SICI)1096-9896(199901)187:1<43::AID-PATH246>3.0.CO;2-P; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Maroulakou IG, 1997, MOL CARCINOGEN, V20, P168, DOI 10.1002/(SICI)1098-2744(199710)20:2<168::AID-MC3>3.0.CO;2-J; MAROULAKOU IG, 1999, IN PRESS ONCOGENE; Martini F, 1998, DEV BIOLOGICALS, V94, P55; MERLINO G, 1994, SEMIN CANCER BIOL, V5, P13; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; Moens U, 1997, VIRUS GENES, V15, P135, DOI 10.1023/A:1007962908248; PARKER MG, 1987, J CELL BIOCHEM, V35, P285, DOI 10.1002/jcb.240350403; PITTIUS CW, 1988, MOL ENDOCRINOL, V2, P1027, DOI 10.1210/mend-2-11-1027; RUSHMERE NK, 1987, MOL CELL ENDOCRINOL, V51, P259, DOI 10.1016/0303-7207(87)90036-0; Shibata MA, 1996, CANCER RES, V56, P2998; Shibata MA, 1998, CARCINOGENESIS, V19, P195, DOI 10.1093/carcin/19.1.195; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; Shibata MA, 1998, TOXICOL PATHOL, V26, P177, DOI 10.1177/019262339802600121; Shibata MA, 1996, CANCER RES, V56, P4894; STAMP G, 1992, CELL GROWTH DIFFER, V3, P929; TAN JA, 1992, J BIOL CHEM, V267, P4456; Tehranian A, 1996, AM J PATHOL, V149, P1177; VANAKEN H, 1996, MOL CELL ENDOCRINOL, V121, P1967; VOEST EE, 1995, J NATL CANCER I, V87, P581, DOI 10.1093/jnci/87.8.581; Watson MA, 1996, CANCER RES, V56, P860; YINB C, 1997, NATURE, V385, P637; Zhang XJ, 1997, PROSTATE, V32, P16, DOI 10.1002/(SICI)1097-0045(19970615)32:1<16::AID-PROS3>3.0.CO;2-A	39	175	180	0	15	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1020	1027		10.1038/sj.onc.1203280	http://dx.doi.org/10.1038/sj.onc.1203280			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713685				2022-12-17	WOS:000085796400007
J	Maggiora, P; Marchio, S; Stella, MC; Giai, M; Belfiore, A; De Bortoli, M; Di Renzo, MF; Costantino, A; Sismondi, P; Comoglio, PM				Maggiora, P; Marchio, S; Stella, MC; Giai, M; Belfiore, A; De Bortoli, M; Di Renzo, MF; Costantino, A; Sismondi, P; Comoglio, PM			Overexpression of the RON gene in human breast carcinoma	ONCOGENE			English	Article						protein-tyrosine kinase; RON; breast neoblasts	HEPATOCYTE GROWTH-FACTOR; MACROPHAGE-STIMULATING PROTEIN; RECEPTOR TYROSINE KINASE; SCATTER FACTOR-RECEPTOR; MET PROTOONCOGENE; OVARIAN-CANCER; IDENTIFICATION; CELLS; EXPRESSION; TRANSFORMATION	Constitutive activation of the RON gene, known to code for the tyrosine-kinase receptor for Macrophage Stimulating Protein (also known as Scatter Factor 2), has been shown to induce invasive-metastatic phenotype in vitro. As yet, nothing is known about the expression of this novel member of the MET-oncogene family in spontaneously occurring human cancers. Here we report that Ron is expressed at abnormally high levels in about 50% primary breast carcinomas (35/74 patients). Among these, the expression is increased more than 20-fold in 12 cases and the overexpressed protein is constitutively phosphorylated on tyrosine residues. Notably, Ron is only barely detectable in epithelial cells of the mammary gland, and its expression remains unchanged in benign breast lesions (including adenomas and papillomas). Overexpression was observed in different histotypic variants of carcinomas; it is associated with the disease at any stage and correlates with the post-menopausal status. In breast carcinoma cells grown im vitro, activation of the Ron receptor resulted in proliferation, migration and invasion through reconstituted basement membranes. Altogether, these data suggest a role for the RON gene in progression of human breast carcinomas to the invasive-metastatic phenotype.	Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, I-10060 Turin, Italy; Univ Turin, Sch Med, Dept Gynecol Oncol, I-10060 Turin, Italy; Univ Turin, Dept Biol, LMCB, I-10123 Turin, Italy; Univ Catania, Sch Med, Dept Endocrinol, I-95123 Catania, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; University of Turin; University of Turin; University of Catania	Comoglio, PM (corresponding author), Univ Turin, Sch Med, Inst Canc Res, Str Prov 142,Km 3-95, I-10060 Turin, Italy.		Marchiò, Serena/G-9054-2017; DI RENZO, Maria Flavia/B-6091-2012; Belfiore, Antonino/B-4652-2011; De Bortoli, Michele/B-5418-2013	Marchiò, Serena/0000-0001-8214-0776; DI RENZO, Maria Flavia/0000-0002-5093-3373; Belfiore, Antonino/0000-0002-6181-4193; De Bortoli, Michele/0000-0002-6666-9052; Comoglio, Paolo/0000-0002-7056-5328; Sismondi, Piero/0000-0002-2505-5716				BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; BYERS S, 1994, BREAST CANCER RES TR, V31, P203, DOI 10.1007/BF00666154; Collesi C, 1996, MOL CELL BIOL, V16, P5518; DELGATTO F, 1995, BBA-GENE STRUCT EXPR, V1263, P93, DOI 10.1016/0167-4781(95)00082-R; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FOX SB, 1994, BREAST CANCER RES TR, V29, P41, DOI 10.1007/BF00666180; Gambarotta G, 1996, ONCOGENE, V13, P1911; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gaudino G, 1995, ONCOGENE, V11, P2627; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GIORDANO S, 1997, P NATL ACAD SCI USA, V94, P11445; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; Hartmann A, 1997, TRENDS GENET, V13, P27, DOI 10.1016/S0168-9525(96)10043-3; HENNIPMAN A, 1989, CANCER RES, V49, P516; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; KOBAYASHI H, 1992, CANCER RES, V52, P3610; Kovach JS, 1996, P NATL ACAD SCI USA, V93, P1093, DOI 10.1073/pnas.93.3.1093; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; Lin JC, 1996, ONCOGENE, V13, P2001; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAGY J, 1995, J SURG ONCOL, V60, P95, DOI 10.1002/jso.2930600206; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RONSIN C, 1993, ONCOGENE, V8, P1195; SAINSBURY JRC, 1985, LANCET, V1, P364; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TOI M, 1994, BREAST CANCER RES TR, V29, P51, DOI 10.1007/BF00666181; Tuck AB, 1996, AM J PATHOL, V148, P225; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WERNERT N, 1994, CANCER RES, V54, P5683; YAMASHITA J, 1994, CANCER RES, V54, P1630	42	175	192	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2927	2933		10.1038/sj.onc.1201812	http://dx.doi.org/10.1038/sj.onc.1201812			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671413				2022-12-17	WOS:000073988200011
J	BOND, JA; WYLLIE, FS; WYNFORDTHOMAS, D				BOND, JA; WYLLIE, FS; WYNFORDTHOMAS, D			ESCAPE FROM SENESCENCE IN HUMAN-DIPLOID FIBROBLASTS INDUCED DIRECTLY BY MUTANT P53	ONCOGENE			English	Article							EPITHELIAL-CELLS; P53-DEFICIENT MICE; TUMOR SUPPRESSION; CANCER SYNDROME; IMMORTALIZATION; TRANSFORMATION; ABNORMALITIES; MECHANISMS; RB	Cellular senescence is thought to be a key restraint on the progression of human tumours, escape from which involves loss of function of tumour suppressor genes. The number and nature of the genes involved however is uncertain, in particular the role of p53 mutation, which is commonly correlated with tumour progression. To address this question, we used the novel approach of directly assessing the effect of mutant p53 on 'pre-aged' human diploid fibroblasts (HDF), thereby avoiding the uncertainty of additional cooperating events, inherent in transgenic models. HDF were passaged till near-senescent and then infected with an amphotropic retroviral vector encoding an ala143 human mutant p53. The results show conclusively that p53 mutation alone is sufficient to extend the proliferative lifespan of normal fibroblasts by approximately 17 population doublings, but has no phenotypic effect on 'young' fibroblasts. We conclude that a key tumour-limiting function of wild-type p53 is to mediate growth arrest after a given number of cell divisions, in agreement with data implicating a p53-regulated gene, WAF-1/sdi-1, in cellular senescence. This may be reconciled with its 'guardian of the genome' role, if telomere erosion, a key change in senescence, is perceived by the cell as a form of DNA 'damage'.	UNIV WALES COLL MED,DEPT PATHOL,CANC RES CAMPAIGN,THYROID TUMOUR BIOL GRP,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University								BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; BURNS JS, 1992, MOL CARCINOGEN, V6, P129, DOI 10.1002/mc.2940060208; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARVEY M, 1993, ONCOGENE, V8, P2457; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; NODA A, IN PRESS EXP CELL RE; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1993, ONCOGENE, V8, P1407; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; TSUKADA T, 1993, ONCOGENE, V8, P3313; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; WYLLIE FS, 1991, MOL CELL ENDOCRINOL, V76, P13, DOI 10.1016/0303-7207(91)90255-Q	18	175	184	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1885	1889						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208534				2022-12-17	WOS:A1994NR68500011
J	PONZETTO, C; GIORDANO, S; PEVERALI, F; DELLAVALLE, G; ABATE, ML; VAULA, G; COMOGLIO, PM				PONZETTO, C; GIORDANO, S; PEVERALI, F; DELLAVALLE, G; ABATE, ML; VAULA, G; COMOGLIO, PM			C-MET IS AMPLIFIED BUT NOT MUTATED IN A CELL-LINE WITH AN ACTIVATED MET TYROSINE KINASE	ONCOGENE			English	Article							CYSTIC-FIBROSIS GENE; PROTO-ONCOGENE; AMPLIFICATION; PROTOONCOGENE; EXPRESSION; RECEPTOR; SEQUENCE; OVEREXPRESSION; IDENTIFICATION; FIBROBLASTS	The putative tyrosine kinase receptor encoded by the oncogene c-met is activated (tyrosine-phosphorylated in vivo) in the human gastric carcinoma cell line GTL-16. The corresponding gene is amplified and over-expressed. In this study we show that c-met is part of an amplification unit measuring more than 3000 kb. The multiple copies of the amplicon are located on a novel chromosome different from chromosome 7. We have previously shown that the c-met protein present in GTL-16 cells is indistinguishable from that found in other cells. Kinase activation could be due to over-expression of the normal c-met protein or to the presence of activating mutation(s). To verify the primary structure of the c-met protein in GTL-16 cells we sequenced a series of overlapping cDNAs obtained from GTL-16 cell RNA by reverse transcription and polymerase chain reaction. Two differences were found in the c-met coding region with respect to the published human c-met cDNA: (1) the lack of 54 nucleotides corresponding to a stretch of 18 amino acids located in the extracellular domain of the receptor, and (2) the substitution of the codon specifying alanine 1209 (located in the tyrosine kinase domain) with one coding for glycine. However, we also obtained cDNAs identical to that just described from a number of control cell lines. These results suggest: (1) that the present c-met cDNA presumably reflects the sequence of the most abundant transcript in several cell types, and (2) that overexpression of the normal c-met protein, alone or in combination with an autocrine loop, is most probably responsible for the activation of the c-met kinase in GTL-16 cells.	UNIV PAVIA,DEPT GENET & MICROBIOL,I-27100 PAVIA,ITALY	University of Pavia	PONZETTO, C (corresponding author), UNIV TURIN,DEPT BIOMED SCI & ONCOL,C SO M DAZEGLIO 52,I-10126 TURIN,ITALY.		Giordano, Silvia/J-9858-2018; Peverali, Fiorenzo/J-2660-2012	Giordano, Silvia/0000-0003-1854-1086; Peverali, Fiorenzo/0000-0001-6717-6586; Comoglio, Paolo/0000-0002-7056-5328				AMBROOK J, 1989, MOL CLONING LABORATO; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHAN AML, 1988, ONCOGENE, V2, P593; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CORNAGLIAFERRARIS P, 1990, PEDIATR RES, V27, P1, DOI 10.1203/00006450-199001000-00001; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; ESTIVILL X, 1987, NATURE, V326, P840, DOI 10.1038/326840a0; FARRALL M, 1988, AM J HUM GENET, V43, P471; GIORDANO S, 1988, J CELL BIOCHEM, V38, P229, DOI 10.1002/jcb.240380402; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; HUDZIAK RM, 1990, CELL GROWTH DIFFER, V1, P129; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LAWRENCE JB, 1988, CELL, V52, P51; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; PARK M, 1986, COLD SPRING HARB SYM, V51, P967, DOI 10.1101/SQB.1986.051.01.110; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SOMAN NR, 1990, P NATL ACAD SCI USA, V87, P738, DOI 10.1073/pnas.87.2.738; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5; TRENT JM, 1987, CANCER GENET CYTOGEN, V26, P187, DOI 10.1016/0165-4608(87)90150-6; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x	32	175	187	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					553	559						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1674365				2022-12-17	WOS:A1991FR93900008
J	Roth, M; Chen, WY				Roth, M.; Chen, W. Y.			Sorting out functions of sirtuins in cancer	ONCOGENE			English	Review						acquired resistance; cancer; genetic instability; longevity; sirtuin; SIRT1	ACETYLATION-DEPENDENT REGULATION; STRESS-RESPONSIVE DEACETYLASE; RETRACTED ARTICLE. SEE; FINGER ENCODING GENE; FATTY-ACID OXIDATION; BINDING PROTEIN HUR; HISTONE DEACETYLASE; TUMOR-SUPPRESSOR; REGULATES SIRT1; CELL-SURVIVAL	The sirtuins (SIRT 1-7) comprise a family of NAD(+)-dependent protein-modifying enzymes with activities in lysine deacetylation, adenosinediphospho(ADP)-ribosylation, and/or deacylation. These enzymes are involved in the cell's stress response systems and in regulating gene expression, DNA damage repair, metabolism and survival. Sirtuins have complex roles in both promoting and/or suppressing tumorigenesis. This review presents recent research progress concerning sirtuins and cancer. On one hand, functional loss of sirtuin genes, particularly SIRT1, involved in maintaining genome integrity and DNA repair will promote tumorigenesis because of genomic instability upon their loss. On the other hand, cancer cells tend to require sirtuins for these same processes to allow them to survive, proliferate, repair the otherwise catastrophic genomic events and evolve. The bifurcated roles of SIRT1, and perhaps several other sirtuins, in cancer may be in part a result of the nature of the genes that are involved in the cell's genome maintenance systems. The in-depth understanding of sirtuin functions may have significant implication in designing precise modulation of selective sirtuin members to aid cancer prevention or treatment under defined conditions.	[Roth, M.; Chen, W. Y.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Chen, WY (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, City Hope, Dept Canc Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.	wechen@coh.org	Chen, WenYong/D-6748-2012	Chen, WenYong/0000-0001-6913-5729	National Cancer Institute of the National Institutes of Health [R01 CA143421]; State of California Tobacco Related Disease Research Program (TRDRP) [20XT-0121]; NATIONAL CANCER INSTITUTE [R01CA143421] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); State of California Tobacco Related Disease Research Program (TRDRP)(University of California System); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the research support from the National Cancer Institute of the National Institutes of Health under award number R01 CA143421, and the State of California Tobacco Related Disease Research Program (TRDRP) award 20XT-0121 to WYC. The contents are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health.	Abdelmohsen K, 2007, MOL CELL, V25, P543, DOI 10.1016/j.molcel.2007.01.011; Ahn BH, 2008, P NATL ACAD SCI USA, V105, P14447, DOI 10.1073/pnas.0803790105; Alhazzazi TY, 2011, CANCER-AM CANCER SOC, V117, P1670, DOI 10.1002/cncr.25676; Ashraf N, 2006, BRIT J CANCER, V95, P1056, DOI 10.1038/sj.bjc.6603384; Barber MF, 2012, NATURE, V487, P114, DOI 10.1038/nature11043; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bell EL, 2011, ONCOGENE, V30, P2986, DOI 10.1038/onc.2011.37; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910; Brunelle JK, 2009, J CELL SCI, V122, P437, DOI 10.1242/jcs.031682; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Burnett C, 2011, NATURE, V477, P482, DOI 10.1038/nature10296; Byles V, 2012, ONCOGENE, V31, P4619, DOI 10.1038/onc.2011.612; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cha EJ, 2009, CLIN CANCER RES, V15, P4453, DOI 10.1158/1078-0432.CCR-08-3329; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Chen WY, 2012, ONCOTARGET, V3, P363; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Chu F, 2005, CANCER RES, V65, P10183, DOI 10.1158/0008-5472.CAN-05-2002; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Cooper HM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004986; Dai JM, 2007, J CELL PHYSIOL, V210, P161, DOI 10.1002/jcp.20831; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Dan L, 2012, HAEMATOL-HEMATOL J, V97, P551, DOI 10.3324/haematol.2011.055236; Danilin S, 2010, CARCINOGENESIS, V31, P1018, DOI 10.1093/carcin/bgq052; Dansen TB, 2008, TRENDS CELL BIOL, V18, P421, DOI 10.1016/j.tcb.2008.07.004; Das C, 2009, NATURE, V459, P113, DOI 10.1038/nature07861; de Nigris F, 2002, BRIT J CANCER, V86, P917, DOI 10.1038/sj.bjc.6600156; Dioum EM, 2009, SCIENCE, V324, P1289, DOI 10.1126/science.1169956; Du JT, 2011, SCIENCE, V334, P806, DOI 10.1126/science.1207861; Eades G, 2011, J BIOL CHEM, V286, P25992, DOI 10.1074/jbc.M111.229401; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Ferrari R, 2008, SCIENCE, V321, P1086, DOI 10.1126/science.1155546; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Finley LWS, 2011, CANCER CELL, V19, P416, DOI 10.1016/j.ccr.2011.02.014; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Ford E, 2006, GENE DEV, V20, P1075, DOI 10.1101/gad.1399706; Ford J, 2008, CELL CYCLE, V7, P3091, DOI 10.4161/cc.7.19.6799; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Furuyama T, 2004, CURR BIOL, V14, P1812, DOI 10.1016/j.cub.2004.09.060; Gao ZG, 2011, J BIOL CHEM, V286, P22227, DOI 10.1074/jbc.M111.228874; Guarani V, 2011, NATURE, V473, P234, DOI 10.1038/nature09917; Guarente L, 2000, GENE DEV, V14, P1021; Guo XM, 2010, J BIOL CHEM, V285, P13223, DOI 10.1074/jbc.M110.102574; Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057; Haigis MC, 2010, CANCER RES, V72, P2468; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heinonen M, 2011, J PATHOL, V224, P529, DOI 10.1002/path.2889; Heltweg B, 2006, CANCER RES, V66, P4368, DOI 10.1158/0008-5472.CAN-05-3617; Hennighausen L, 2008, GENE DEV, V22, P711, DOI 10.1101/gad.1643908; Herranz D, 2013, ONCOGENE, V32, P4052, DOI 10.1038/onc.2012.407; Herranz D, 2010, NAT REV CANCER, V10, P819, DOI 10.1038/nrc2962; Herranz D, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1001; Herrero-Yraola A, 2001, EMBO J, V20, P2404, DOI 10.1093/emboj/20.10.2404; Hiratsuka M, 2003, BIOCHEM BIOPH RES CO, V309, P558, DOI 10.1016/j.bbrc.2003.08.029; Hirschey MD, 2010, NATURE, V464, P121, DOI 10.1038/nature08778; Ho KK, 2008, ONCOGENE, V27, P2300, DOI 10.1038/onc.2008.23; Holloway KR, 2010, P NATL ACAD SCI USA, V107, P9216, DOI 10.1073/pnas.0911325107; Horwitz GA, 2008, SCIENCE, V321, P1084, DOI 10.1126/science.1155544; Hou HL, 2012, J CLIN PATHOL, V65, P1088, DOI 10.1136/jclinpath-2012-200940; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Huang JY, 2010, BBA-PROTEINS PROTEOM, V1804, P1645, DOI 10.1016/j.bbapap.2009.12.021; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Inoue T, 2007, ONCOGENE, V26, P945, DOI 10.1038/sj.onc.1209857; Inoue T, 2007, CELL CYCLE, V6, P1011, DOI 10.4161/cc.6.9.4219; Inuzuka H, 2012, CELL, V150, P179, DOI 10.1016/j.cell.2012.05.038; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jang KY, 2008, AM J SURG PATHOL, V32, P1523, DOI 10.1097/PAS.0b013e31816b6478; Jang KY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045119; Jin YH, 2008, BIOCHEM BIOPH RES CO, V368, P690, DOI 10.1016/j.bbrc.2008.01.114; Jing EX, 2007, CELL METAB, V6, P105, DOI 10.1016/j.cmet.2007.07.003; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jung-Hynes B, 2009, J BIOL CHEM, V284, P3823, DOI 10.1074/jbc.M807869200; Kabra N, 2009, J BIOL CHEM, V284, P18210, DOI 10.1074/jbc.M109.000034; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaidi A, 2010, SCIENCE, V329, P1348, DOI 10.1126/science.1192049; Kanfi Y, 2012, NATURE, V483, P218, DOI 10.1038/nature10815; Kawahara TLA, 2009, CELL, V136, P62, DOI 10.1016/j.cell.2008.10.052; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kim EJ, 2007, MOL CELL, V28, P277, DOI 10.1016/j.molcel.2007.08.030; Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004; Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023; Kim JE, 2008, NATURE, V451, P583, DOI 10.1038/nature06500; Kim JK, 2013, HEPATOLOGY, V57, P1055, DOI 10.1002/hep.26101; Koptyra M, 2006, BLOOD, V108, P319, DOI 10.1182/blood-2005-07-2815; Kozako T, 2012, INT J CANCER, V131, P2044, DOI 10.1002/ijc.27481; Kriegl L, 2012, ONCOTARGET, V3, P1182; Krishnan J, 2012, GENE DEV, V26, P259, DOI 10.1101/gad.180406.111; Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102; Laemmle A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033433; Lages E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020600; Lain S, 2008, CANCER CELL, V13, P454, DOI 10.1016/j.ccr.2008.03.004; Lavu S, 2008, NAT REV DRUG DISCOV, V7, P841, DOI 10.1038/nrd2665; Lennerz V, 2005, P NATL ACAD SCI USA, V102, P16013, DOI 10.1073/pnas.0500090102; Li L, 2012, CANCER CELL, V21, P266, DOI 10.1016/j.ccr.2011.12.020; Li SD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010486; Li YZ, 2011, GENES CELLS, V16, P34, DOI 10.1111/j.1365-2443.2010.01460.x; Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023; Liszt G, 2005, J BIOL CHEM, V280, P21313, DOI 10.1074/jbc.M413296200; Liu PY, 2013, CELL DEATH DIFFER, V20, P503, DOI 10.1038/cdd.2012.147; Lombard DB, 2007, MOL CELL BIOL, V27, P8807, DOI 10.1128/MCB.01636-07; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Lu LY, 2008, J BIOL CHEM, V283, P31785, DOI 10.1074/jbc.M805880200; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mao BB, 2011, INT J BIOCHEM CELL B, V43, P1573, DOI 10.1016/j.biocel.2011.07.006; Mao ZY, 2012, P NATL ACAD SCI USA, V109, P11800, DOI 10.1073/pnas.1200583109; Mao ZY, 2011, SCIENCE, V332, P1443, DOI 10.1126/science.1202723; Marshall GM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002135; Mattagajasingh I, 2007, P NATL ACAD SCI USA, V104, P14855, DOI 10.1073/pnas.0704329104; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; McCord RA, 2009, AGING-US, V1, P109, DOI 10.18632/aging.100011; Menssen A, 2012, P NATL ACAD SCI USA, V109, pE187, DOI 10.1073/pnas.1105304109; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Michishita E, 2008, NATURE, V452, P492, DOI 10.1038/nature06736; Michishita E, 2009, CELL CYCLE, V8, P2664, DOI 10.4161/cc.8.16.9367; Monti Elena, 2011, Curr Mol Pharmacol, V4, P62; Morris BJ, 2013, FREE RADICAL BIO MED, V56, P133, DOI 10.1016/j.freeradbiomed.2012.10.525; Mostoslavsky R, 2006, CELL, V124, P315, DOI [10.1016/j.cell.2005.11.044, 10.1016/J.CEL.2005.11.044]; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Murayama A, 2008, CELL, V133, P627, DOI 10.1016/j.cell.2008.03.030; Nahhas F, 2007, MOL CELL BIOCHEM, V303, P221, DOI 10.1007/s11010-007-9478-6; Nakagawa T, 2009, CELL, V137, P560, DOI 10.1016/j.cell.2009.02.026; Narayan N, 2012, NATURE, V492, P199, DOI 10.1038/nature11700; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Newman JC, 2012, J BIOL CHEM, V287, P42436, DOI 10.1074/jbc.R112.404863; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; North BJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000784; North BJ, 2007, J BIOL CHEM, V282, P19546, DOI 10.1074/jbc.M702990200; Nosho K, 2009, MODERN PATHOL, V22, P922, DOI 10.1038/modpathol.2009.49; Nowicki MO, 2004, BLOOD, V104, P3746, DOI 10.1182/blood-2004-05-1941; Nowotarski SL, 2010, J BIOL CHEM, V285, P31885, DOI 10.1074/jbc.M110.148767; O'Hagan HM, 2011, CANCER CELL, V20, P606, DOI 10.1016/j.ccr.2011.09.012; O'Hagan HM, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000155; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; Ogura M, 2010, BIOCHEM BIOPH RES CO, V393, P73, DOI 10.1016/j.bbrc.2010.01.081; Oh WK, 2010, MOL PHARMACOL, V78, P855, DOI 10.1124/mol.110.065961; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Peck B, 2010, MOL CANCER THER, V9, P844, DOI 10.1158/1535-7163.MCT-09-0971; Peng LR, 2011, MOL CELL BIOL, V31, P4720, DOI 10.1128/MCB.06147-11; Peters CJ, 2010, GASTROENTEROLOGY, V139, P1995, DOI 10.1053/j.gastro.2010.05.080; Potente M, 2007, GENE DEV, V21, P2644, DOI 10.1101/gad.435107; Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040; Qiu XL, 2010, CELL METAB, V12, P662, DOI 10.1016/j.cmet.2010.11.015; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Sasaki T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004020; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Scher MB, 2007, GENE DEV, V21, P920, DOI 10.1101/gad.1527307; Schwer B, 2002, J CELL BIOL, V158, P647, DOI 10.1083/jcb.200205057; Sebastian C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047; Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shuai K, 1996, ONCOGENE, V13, P247; Slupianek A, 2006, DNA REPAIR, V5, P243, DOI 10.1016/j.dnarep.2005.10.005; Someya S, 2010, CELL, V143, P802, DOI 10.1016/j.cell.2010.10.002; Sundaresan NR, 2008, MOL CELL BIOL, V28, P6384, DOI 10.1128/MCB.00426-08; Sundaresan NR, 2009, J CLIN INVEST, V119, P2758, DOI 10.1172/JCI39162; Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tiwari N, 2012, SEMIN CANCER BIOL, V22, P194, DOI 10.1016/j.semcancer.2012.02.013; Tudek B, 2010, AM J TRANSL RES, V2, P254; Vakhrusheva O, 2008, CIRC RES, V102, P703, DOI 10.1161/CIRCRESAHA.107.164558; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; Van Meter M, 2011, CELL CYCLE, V10, P3153, DOI 10.4161/cc.10.18.17435; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaquero A, 2007, NATURE, V450, P440, DOI 10.1038/nature06268; Vaquero A, 2006, GENE DEV, V20, P1256, DOI 10.1101/gad.1412706; Vaquero A, 2009, INT J DEV BIOL, V53, P303, DOI 10.1387/ijdb.082675av; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Verdin E, 2010, TRENDS BIOCHEM SCI, V35, P669, DOI 10.1016/j.tibs.2010.07.003; Wang B, 2011, ONCOGENE, V30, P907, DOI 10.1038/onc.2010.468; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Wang F, 2012, ONCOGENE, V31, P1546, DOI 10.1038/onc.2011.347; Wang F, 2007, AGING CELL, V6, P505, DOI 10.1111/j.1474-9726.2007.00304.x; Wang JC, 2011, ONCOLOGY-BASEL, V81, P325, DOI 10.1159/000334577; Wang RH, 2008, MOL CELL, V32, P11, DOI 10.1016/j.molcel.2008.09.011; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Wang SL, 2009, CELL MOL IMMUNOL, V6, P327, DOI 10.1038/cmi.2009.43; Wang X, 2006, ONCOGENE, V25, P7148, DOI 10.1038/sj.onc.1209707; Wang Z, 2013, ONCOGENE, V32, P589, DOI 10.1038/onc.2012.83; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Weinberg RA, 2007, BIOL CANC, P725; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Xiao MT, 2012, GENE DEV, V26, P1326, DOI 10.1101/gad.191056.112; Xie M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045331; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yang HY, 2007, CELL, V130, P1095, DOI 10.1016/j.cell.2007.07.035; Yang YH, 2007, NAT CELL BIOL, V9, P1253, DOI 10.1038/ncb1645; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Yuan HF, 2012, BLOOD, V119, P1904, DOI 10.1182/blood-2011-06-361691; Yuan J, 2009, J CELL BIOL, V185, P203, DOI 10.1083/jcb.200809167; Zhao WH, 2008, NATURE, V451, P587, DOI 10.1038/nature06515; Zhao Y, 2010, NAT CELL BIOL, V12, P665, DOI 10.1038/ncb2069; Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041	212	174	184	0	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1609	1620		10.1038/onc.2013.120	http://dx.doi.org/10.1038/onc.2013.120			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23604120	Green Accepted			2022-12-17	WOS:000334344700001
J	Bourguignon, LYW; Earle, C; Wong, G; Spevak, CC; Krueger, K				Bourguignon, L. Y. W.; Earle, C.; Wong, G.; Spevak, C. C.; Krueger, K.			Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells	ONCOGENE			English	Article						nanog; Stat-3; miR-21; hyaluronan; CD44; head & neck cancer	NF-KAPPA-B; CANCER STATISTICS; GENE-EXPRESSION; TUMOR-CELLS; RHO-KINASE; HYALURONAN; BREAST; PROGRESSION; ACTIVATION; TRANSCRIPTION	MicroRNAs are often associated with the pathogenesis of many cancers, including head and neck squamous cell carcinoma (HNSCC). In particular, microRNA-21 (miR-21) appears to have a critical role in tumor cell survival, chemoresistance and HNSCC progression. In this study, we investigated matrix hyaluronan (HA)-induced CD44 (a primary HA receptor) interaction with the stem cell markers, Nanog and Stat-3, in HNSCC cells (HSC-3 cells). Our results indicate that HA binding to CD44 promotes Nanog-Stat-3 (also tyrosine phosphorylated Stat-3) complex formation, nuclear translocation and transcriptional activation. Further analyses reveal that miR-21 is controlled by an upstream promoter containing Stat-3 binding site(s), while chromatin immunoprecipitation assays demonstrate that stimulation of miR-21 expression by HA/CD44 signaling is Nanog/Stat-3-dependent in HNSCC cells. This process results in a decrease of a tumor suppressor protein (PDCD4), and an upregulation of i nhibitors of the apoptosis family of proteins (IAPs) as well as chemoresistance in HSC-3 cells. Treatment of HSC-3 cells with Nanog- and/or Stat-3-specific small interfering RNAs effectively blocks HA-mediated Nanog-Stat-3 signaling events, abrogates miR-21 production and increases PDCD4 expression. Subsequently, this Nanog-Stat-3 signaling inhibition causes downregulation of survival protein (IAP) expression and enhancement of chemosensitivity. To further evaluate the role of miR-21 in tumor cell-specific functions, HSC-3 cells were also transfected with a specific anti-miR-21 inhibitor in order to silence miR-21 expression and block its target functions. Our results demonstrate that anti-miR-21 inhibitor not only upregulates PDCD4 expression but also decreases IAP expression and enhances chemosensitivity in HA-treated HNSCC cells. Together, these findings indicate that the HA-induced CD44 interaction with Nanog and Stat-3 has a pivotal role in miR-21 production leading to PDCD4 reduction, IAP upregulation and chemoresistance in HNSCC cells. This novel Nanog/Stat-3 signaling pathway-specific mechanism involved in miR-21 production is significant for the formation of future intervention strategies in the treatment of HA/CD44-activated HNSCC. Oncogene (2012) 31, 149-160; doi:10.1038/onc.2011.222; published online 20 June 2011	[Bourguignon, L. Y. W.] Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, San Francisco, CA 94121 USA; San Francisco VA Med Ctr, San Francisco, CA USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Bourguignon, LYW (corresponding author), Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, 4150 Clement St, San Francisco, CA 94121 USA.	lilly.bourguignon@ucsf.edu			Veterans Affairs (VA) Merit Review grant; United States Public Health grants [R01 CA66163, R01 CA78633, P01 AR39448]; NATIONAL CANCER INSTITUTE [R01CA066163, R01CA078633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039448, R01AR050023] Funding Source: NIH RePORTER	Veterans Affairs (VA) Merit Review grant; United States Public Health grants; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We gratefully acknowledge the assistance of Drs Gerard J Bourguignon and Walter M Holleran in the preparation and review of this manuscript. We are grateful for Ms Christina Camacho for her assistance in preparing graphs and illustrations. We would also like to thank for Dr Shaomeng Wang from the University of Michigan for providing us an IAP inhibitor, SM164. This work was supported by Veterans Affairs (VA) Merit Review grant and United States Public Health grants (R01 CA66163, R01 CA78633 and P01 AR39448). LYWB is a VA Senior Research Career Scientist.	Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Bourguignon LYW, 2008, J BIOL CHEM, V283, P17635, DOI 10.1074/jbc.M800109200; Bourguignon LYW, 2008, SEMIN CANCER BIOL, V18, P251, DOI 10.1016/j.semcancer.2008.03.007; Bourguignon LYW, 2010, J BIOL CHEM, V285, P36721, DOI 10.1074/jbc.M110.162305; Bourguignon LYW, 2009, J BIOL CHEM, V284, P26533, DOI 10.1074/jbc.M109.027466; Bourguignon LYW, 2009, J BIOL CHEM, V284, P2657, DOI 10.1074/jbc.M806708200; Chang SS, 2008, INT J CANCER, V123, P2791, DOI 10.1002/ijc.23831; Chiou SH, 2008, CLIN CANCER RES, V14, P4085, DOI 10.1158/1078-0432.CCR-07-4404; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Ezeh UI, 2005, CANCER-AM CANCER SOC, V104, P2255, DOI 10.1002/cncr.21432; Gyrd-Hansen M, 2010, NAT REV CANCER, V10, P561, DOI 10.1038/nrc2889; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Huang SY, 2007, CLIN CANCER RES, V13, P1362, DOI 10.1158/1078-0432.CCR-06-2313; Hunter AM, 2007, APOPTOSIS, V12, P1543, DOI 10.1007/s10495-007-0087-3; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kashyap V, 2009, STEM CELLS DEV, V18, P1093, DOI 10.1089/scd.2009.0113; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; Lu JF, 2008, CANCER RES, V68, P9384, DOI 10.1158/0008-5472.CAN-08-2655; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Nakamura M, 2005, ONCOL REP, V14, P1281; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Toole BP, 2002, AM J PATHOL, V161, P745, DOI 10.1016/S0002-9440(10)64232-0; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Torre C, 2010, ARCH OTOLARYNGOL, V136, P493, DOI 10.1001/archoto.2010.25; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang SJ, 2011, AM J PATHOL, V178, P956, DOI 10.1016/j.ajpath.2010.11.077; Wang SJ, 2009, LARYNGOSCOPE, V119, P1518, DOI 10.1002/lary.20506; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9	30	174	182	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	2					149	160		10.1038/onc.2011.222	http://dx.doi.org/10.1038/onc.2011.222			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	879CN	21685938	Green Accepted, Green Submitted			2022-12-17	WOS:000299307400002
J	Lin, L; Amin, R; Gallicano, GI; Glasgow, E; Jogunoori, W; Jessup, JM; Zasloff, M; Marshall, JL; Shetty, K; Johnson, L; Mishra, L; He, AR				Lin, L.; Amin, R.; Gallicano, G. I.; Glasgow, E.; Jogunoori, W.; Jessup, J. M.; Zasloff, M.; Marshall, J. L.; Shetty, K.; Johnson, L.; Mishra, L.; He, A. R.			The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling	ONCOGENE			English	Article						IL6; stem cell; TGF-beta; STAT3; beta 2SP; hepatocellular carcinoma	LIVER STEM-CELLS; SERINE PHOSPHORYLATION; STEM/PROGENITOR CELLS; GENE-EXPRESSION; CARCINOMA CELLS; MICE; ACTIVATION; PATHWAY; CHEMORESISTANCE; CD133(+)	Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide, with few effective therapeutic options for advanced disease. At least 40% of HCCs are clonal, potentially arising from STAT3+, NANOG+ and OCT3/4+ liver progenitor/stem cell transformation, along with inactivation of transforming growth factor-beta (TGF-beta) signaling. Here we report significantly greater signal transducer and activator of transcription 3 (STAT3) and tyrosine phosphorylated STAT3 in human HCC tissues (P<0.0030 and P<0.0455, respectively) than in human normal liver. Further, in HCC cells with loss of response to TGF-b, NSC 74859, a STAT3-specific inhibitor, markedly suppresses growth. In contrast, CD133(+) status did not affect the response to STAT3 inhibition: both CD133(+) Huh-7 cells and CD133(-) Huh-7 cells are equally sensitive to NSC 74859 treatment and STAT3 inhibition, with an IC50 of 100 mu M. Thus, the TGF-beta/beta2 spectrin (beta 2SP) pathway may reflect a more functional 'stem/progenitor' state than CD133. Furthermore, NSC 74859 treatment of Huh-7 xenografts in nude mice significantly retarded tumor growth, with an effective dose of only 5 mg/kg. Moreover, NSC 74859 inhibited tyrosine phosphorylation of STAT3 in HCC cells in vivo. We conclude that inhibiting interleukin 6 (IL6)/STAT3 in HCCs with inactivation of the TGF-beta/beta 2SP pathway is an effective approach in management of HCCs. Thus, IL6/STAT3, a major signaling pathway in HCC stem cell renewal and proliferation, can provide a novel approach to the treatment of specific HCCs.	[Lin, L.; Glasgow, E.; Marshall, J. L.; He, A. R.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Med & Oncol, Washington, DC 20007 USA; [Lin, L.; Amin, R.; Glasgow, E.; Jogunoori, W.; Zasloff, M.; Shetty, K.; Johnson, L.; Mishra, L.; He, A. R.] Georgetown Univ, Dept Surg, Washington, DC 20007 USA; [Gallicano, G. I.] Georgetown Univ, Med Ctr, Dept Biochem & Mol & Cellular Biol, Washington, DC 20007 USA; [Jessup, J. M.] NCI, Canc Diag Program, Rockville, MD USA; [Shetty, K.; Johnson, L.] Georgetown Univ, Inst Transplant Surg, Dept Surg, Washington, DC USA; [Mishra, L.] Dept Vet Affairs Med Ctr, Washington, DC USA	Georgetown University; Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Georgetown University	He, AR (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Med & Oncol, 3800 Reservoir Rd NW, Washington, DC 20007 USA.	lm229@georgetown.edu; aiwu.r.he@gunet.georgetown.edu		Glasgow, Eric/0000-0001-7729-3954; Mishra, Lopa/0000-0002-6850-0808	NATIONAL CANCER INSTITUTE [P30CA051008, R01CA106614, P01CA130821, R01CA042857, ZIABC011199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056111] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA042857, R01 CA106614-01A2, R01 CA042857-18A1, P30 CA51008-13, P01 CA130821, R01 CA106614A, R01 CA106614, P30 CA051008, R01 CA4285718A] Funding Source: Medline; NIDDK NIH HHS [R01 DK056111, R01 DK56111, R01 DK056111-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Alison MR, 2005, STEM CELL REV, V1, P253, DOI 10.1385/SCR:1:3:253; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cabibbo A, 1998, ONCOGENE, V16, P2935, DOI 10.1038/sj.onc.1201825; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Dando JS, 2005, STEM CELLS, V23, P550, DOI 10.1634/stemcells.2004-0205; Frank NY, 2005, CANCER RES, V65, P4320, DOI 10.1158/0008-5472.CAN-04-3327; Hambardzumyan D, 2006, CANCER CELL, V10, P454, DOI 10.1016/j.ccr.2006.11.008; Im YH, 2001, CANCER RES, V61, P6665; Kanzler S, 2001, ONCOGENE, V20, P5015, DOI 10.1038/sj.onc.1204544; KEW MC, 1971, BMJ-BRIT MED J, V4, P408, DOI 10.1136/bmj.4.5784.408; Kitisin K, 2007, ONCOGENE, V26, P7103, DOI 10.1038/sj.onc.1210513; Kojima H, 2005, P NATL ACAD SCI USA, V102, P4524, DOI 10.1073/pnas.0500679102; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; LaBarge MA, 2008, J CLIN INVEST, V118, P2021, DOI 10.1172/JCI36046; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Lim CP, 2001, J BIOL CHEM, V276, P21004, DOI 10.1074/jbc.M007592200; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Ma S, 2008, ONCOGENE, V27, P1749, DOI 10.1038/sj.onc.1210811; Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025; Manghisi G, 1998, HEPATOLOGY, V28, P751; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Nguyen LN, 2007, HEPATOLOGY, V45, P31, DOI 10.1002/hep.21466; Ohkawara B, 2004, GENE DEV, V18, P381, DOI 10.1101/gad.1166904; Roskams T, 2006, ONCOGENE, V25, P3818, DOI 10.1038/sj.onc.1209558; Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401; Sicklick JK, 2006, AM J PHYSIOL-GASTR L, V290, pG859, DOI 10.1152/ajpgi.00456.2005; Sicklick JK, 2006, CARCINOGENESIS, V27, P748, DOI 10.1093/carcin/bgi292; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; Suetsugi A, 2006, BIOCHEM BIOPH RES CO, V351, P820, DOI 10.1016/j.bbrc.2006.10.128; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tang Y, 2003, SCIENCE, V299, P574, DOI 10.1126/science.1075994; Tang Y, 2008, P NATL ACAD SCI USA, V105, P2445, DOI 10.1073/pnas.0705395105; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; VISTICA DT, 1991, CANCER RES, V51, P2515; Wallner L, 2006, CANCER RES, V66, P3087, DOI 10.1158/0008-5472.CAN-05-3447; Weinstein M, 2000, CYTOKINE GROWTH F R, V11, P49, DOI 10.1016/S1359-6101(99)00028-3; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622; Yang SF, 2007, J CLIN PATHOL, V60, P642, DOI 10.1136/jcp.2006.036970; Yeoh GCT, 2007, HEPATOLOGY, V45, P486, DOI 10.1002/hep.21535; Yin SY, 2007, INT J CANCER, V120, P1444, DOI 10.1002/ijc.22476; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104	45	174	195	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2009	28	7					961	972		10.1038/onc.2008.448	http://dx.doi.org/10.1038/onc.2008.448			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	408TH	19137011	Green Accepted			2022-12-17	WOS:000263457400003
J	Gal, A; Sjoblom, T; Fedorova, L; Imreh, S; Beug, H; Moustakas, A				Gal, A.; Sjoeblom, T.; Fedorova, L.; Imreh, S.; Beug, H.; Moustakas, A.			Sustained TGF beta exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis	ONCOGENE			English	Article						epithelial-mesenchymal transition; metastasis; Smad; signal transduction; TGF beta; tumour suppression	TRANSFORMING GROWTH-FACTOR-BETA-1; TUMOR PROGRESSION; HUMAN CANCER; HA-RAS; METASTASIS; PLASTICITY; PATHWAY; TRANSDIFFERENTIATION; PROLIFERATION; INVASIVENESS	To better understand the dual, tumour-suppressive and tumour-promoting function of transforming growth factor-beta (TGF beta), we analysed mammary epithelial NMuMG cells in response to short and long-term TGFb exposure. NMuMG cells became proliferation-arrested and apoptotic after exposure to TGFb for 2-5 days, whereas surviving cells underwent epithelial-mesenchymal transition (EMT). After chronic TGFb exposure (2-3 weeks), however, NMuMG cells became resistant to proliferation arrest and apoptosis, showing sustained EMT instead (TD cells). EMT was fully reversed by a pharmacologic TGF beta-receptor-I kinase inhibitor or withdrawal of TGFb for 6-12 days. Interestingly, both cell cycle arresting/proapoptotic (Smads, p38 kinase) and antiapoptotic, proliferation and EMT-promoting signalling pathways (PI3K-PKB/Akt, ERK) were co-suppressed to low, but significant levels. Except for PI3K-Akt, TGF beta-dependent downregulation of these signalling pathways in transdifferentiated (TD) cells was fully reversed upon TGFb withdrawal, together with partial re-induction of proliferation arrest and apoptosis. Co-injection of non-tumorigenic NMuMG cells with tumour-forming CHO cells oversecreting exogenous TGF beta 1 (CHO-TGF beta 1) allowed outgrowth of epithelioid cells in CHO-TGF beta 1 cell-induced tumours. These epithelial islands enhanced CHO-TGF beta 1 tumour cell proliferation, possibly due to chemokines (for example, JE/MCP-1) secreted by NMuMG/TD cells. We conclude that suppression of antiproliferative, proapoptotic TGF beta signalling in TD cells may permit TGF beta-dependent proliferation, survival and EMT-enhancing signalling pathways to act at low levels. Thus, TGF beta may modulate its own signalling to facilitate switching from tumour suppression to tumour progression.	[Gal, A.; Beug, H.] Res Inst Mol Pathol, A-1030 Vienna, Austria; [Gal, A.; Sjoeblom, T.; Moustakas, A.] Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; [Sjoeblom, T.; Fedorova, L.] Karolinska Inst, Microbiol & Tumor Biol Ctr, Stockholm, Sweden	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Ludwig Institute for Cancer Research; Karolinska Institutet	Beug, H (corresponding author), Inst Mol Pathol, Dr A Moustakas, A-1030 Vienna, Austria.	beug@imp.univie.ac.at; aris.moustakas@LICR.uu.se		Gal, Annamaria/0000-0001-8171-1389	Austrian Science Fund (FWF) [F 2802] Funding Source: researchfish	Austrian Science Fund (FWF)(Austrian Science Fund (FWF))		Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; DALAL BI, 1993, AM J PATHOL, V143, P381; Dooley S, 2001, FEBS LETT, V502, P4, DOI 10.1016/S0014-5793(01)02656-4; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Gotzmann J, 2002, J CELL SCI, V115, P1189; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Hui LJ, 2007, NAT GENET, V39, P741, DOI 10.1038/ng2033; IVANOVIC V, 1995, NAT MED, V1, P282, DOI 10.1038/nm0495-282; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Janda E, 2002, ONCOGENE, V21, P5148, DOI 10.1038/sj.onc.1205661; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; Piek E, 1999, J CELL SCI, V112, P4557; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Shim KS, 1999, CANCER-AM CANCER SOC, V85, P554, DOI 10.1002/(SICI)1097-0142(19990201)85:3<554::AID-CNCR6>3.0.CO;2-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Sjoblom T, 2001, CANCER RES, V61, P5778; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Waerner T, 2006, CANCER CELL, V10, P227, DOI 10.1016/j.ccr.2006.07.020	26	174	181	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1218	1230		10.1038/sj.onc.1210741	http://dx.doi.org/10.1038/sj.onc.1210741			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17724470				2022-12-17	WOS:000253407000004
J	Halkidou, K; Gnanapragasam, VJ; Mehta, PB; Logan, IR; Brady, ME; Cook, S; Leung, HY; Neal, DE; Robson, CN				Halkidou, K; Gnanapragasam, VJ; Mehta, PB; Logan, IR; Brady, ME; Cook, S; Leung, HY; Neal, DE; Robson, CN			Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development	ONCOGENE			English	Article						Tip60; co-activator; CWR22 xenograft; hormone refractory; prostate cancer	HORMONAL-REGULATION; BREAST-CANCER; CELL-LINE; PROTEIN; LNCAP; APOPTOSIS; ANTIGEN; ALPHA; TRANSCRIPTION; METHYLATION	Prostate cancer (CaP) is initially androgen sensitive and responsive to hormone ablation therapy. However, cancer growth recurs despite androgen deprivation in the majority of cases of advanced disease. The molecular basis of this progression still remains unknown. The significance of androgen receptor (AR) coactivator proteins in this androgen-dependent malignancy is only beginning to emerge. In the present study, we examined the role of Tat interactive protein, 60kDa (Tip60), an AR coactivator, in CaP progression. In hormone refractory CaP biopsies, we observed a nuclear accumulation of Tip60 expression in contrast to a more diffuse distribution pattern observed in benign prostate hyperplasia and primary CaP. Furthermore, in both the prostate xenograft model CWR22 and the LNCaP CaP cell line, we observed that androgen withdrawal promoted upregulation of Tip60 as well as nuclear accumulation. In contrast, androgen exposure resulted in decreased Tip60 expression that was more closely linked to a cytoplasmic presence. Chromatin immunoprecipitation analysis revealed Tip60's recruitment to the PSA gene promoter in both androgen dependent and -independent cell lines. Thus, in vitro and in vivo data support a possible role for Tip60 in the molecular pathway leading to the development of androgen-independent CaP following long-term androgen deprivation therapy.	Univ Newcastle Upon Tyne, Sch Surg & Reprod Sci, Prostate Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Cambridge, Addenbrookes Hosp, Ctr Oncol, Cambridge CB2 2QQ, England	Newcastle University - UK; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Robson, CN (corresponding author), Univ Newcastle Upon Tyne, Sch Surg & Reprod Sci, Prostate Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Neal, David/0000-0002-6033-5086; Leung, Hing Y./0000-0002-3933-3975				Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Brawer MK, 2000, SEMIN SURG ONCOL, V18, P3, DOI 10.1002/(SICI)1098-2388(200001/02)18:1<3::AID-SSU2>3.3.CO;2-9; Burkhart BA, 1999, EXP CELL RES, V247, P168, DOI 10.1006/excr.1998.4345; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; Chen SL, 2001, MOL ENDOCRINOL, V15, P783, DOI 10.1210/me.15.5.783; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; CRAWFORD ED, 1992, BRIT J UROL, V70, P33, DOI 10.1111/j.1464-410X.1992.tb15865.x; Cutress RI, 2001, J CLIN ONCOL, V19, P3706, DOI 10.1200/JCO.2001.19.16.3706; Gao M, 1999, J CELL PHYSIOL, V179, P336, DOI 10.1002/(SICI)1097-4652(199906)179:3<336::AID-JCP11>3.0.CO;2-Q; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Gaughan L, 2001, J BIOL CHEM, V276, P46841, DOI 10.1074/jbc.M103710200; Gnanapragasam VJ, 2002, ONCOGENE, V21, P5069, DOI 10.1038/sj.onc.1205663; Gregory CW, 2001, CANCER RES, V61, P4315; Horikawa I, 2001, J CELL BIOCHEM, V82, P415, DOI 10.1002/jcb.1169; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jaffe ES, 1996, J CELL PATHOL, V1, P125; Kinoshita H, 2000, CANCER RES, V60, P3623; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; Kurihara I, 2000, ENDOCR RES, V26, P1033, DOI 10.3109/07435800009048635; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; Lee HJ, 2001, J BIOL CHEM, V276, P16597, DOI 10.1074/jbc.C000909200; Majeed A, 2000, BJU INT, V85, P1058, DOI 10.1046/j.1464-410x.2000.00661.x; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Nagabhushan M, 1996, CANCER RES, V56, P3042; NORTON AJ, 1994, J PATHOL, V173, P371, DOI 10.1002/path.1711730413; Ran QT, 2000, GENE, V258, P141, DOI 10.1016/S0378-1119(00)00410-8; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Sheridan AM, 2001, MOL CELL BIOL, V21, P4470, DOI 10.1128/MCB.21.14.4470-4481.2001; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Sliva D, 1999, BIOCHEM BIOPH RES CO, V263, P149, DOI 10.1006/bbrc.1999.1083; Soto AM, 1995, ONCOL RES, V7, P545; Spector DL, 1993, CURR OPIN CELL BIOL, V5, P442, DOI 10.1016/0955-0674(93)90009-F; SWINNEN JV, 1994, MOL CELL ENDOCRINOL, V104, P153, DOI 10.1016/0303-7207(94)90118-X; Tekur S, 2001, MOL CARCINOGEN, V30, P1, DOI 10.1002/1098-2744(200101)30:1<1::AID-MC1008>3.0.CO;2-X; Thenot S, 1999, MOL CELL ENDOCRINOL, V156, P85, DOI 10.1016/S0303-7207(99)00139-2; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; YOUNG CYF, 1992, BIOCHEMISTRY-US, V31, P818, DOI 10.1021/bi00118a026; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401	46	174	183	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2466	2477		10.1038/sj.onc.1206342	http://dx.doi.org/10.1038/sj.onc.1206342			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717424				2022-12-17	WOS:000182383500010
J	Kato, K; Ogura, T; Kishimoto, A; Minegishi, Y; Nakajima, N; Miyazaki, M; Esumi, H				Kato, K; Ogura, T; Kishimoto, A; Minegishi, Y; Nakajima, N; Miyazaki, M; Esumi, H			Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation	ONCOGENE			English	Article						cancer; tolerance; glucose deprivation; AMP-activated protein kinase (AMPK)	SOLID TUMORS; ANGIOGENESIS; GLUCOSE; METABOLISM; EXPRESSION; GROWTH; GENE; INHIBITION; METASTASIS; THERAPY	As tumors grow and invade beyond their homeostatic limits, the tumor cells are subjected to insufficient nutrient and oxygen supplies because of excessive demand for nutrition and oxygen, and insufficient vascularization. We therefore hypothesized that tolerance to nutrient deprivation as well as angiogenesis may be critical in some malignancies, including pancreatic cancers, which are seen to be a hypovascular tumor. In this study, we assessed the effect of AMP-activated protein kinase (AMPK), which plays a major role in protecting cells from metabolic stresses, on tumor biology under nutrient-deprived condition. Whereas hepatic cancer cells had mostly died within 48 h during glucose deprivation, most pancreatic cancer cells survived more than 48 h. The tolerance to glucose deprivation tended to correlate with the cells level of expression of AMPK alpha1 and alpha2. The introduction of AMPK antisense RNA expression vectors into pancreas cancer cell lines, PANC-1 and AsPC-1, significantly diminished their tolerance to glucose deprivation, and the stable transfection of AMPK antisense into PANC-1 cells inhibited tumor growth in nude mice. These findings indicate that AMPK expression contributes to tolerance to nutrient starvation in cancer cells. We propose AMPK as a new target for therapeutic strategies to suppress tumor growth and invasion.	Natl Inst Canc Res, Invest Treatment Div, Chiba 2778577, Japan; Chiba Univ, Sch Med, Dept Surg 1, Chiba 2608677, Japan	National Cancer Center - Japan; Chiba University	Esumi, H (corresponding author), Natl Inst Canc Res, Invest Treatment Div, Chiba 2778577, Japan.	hesumi@east.nec.go.jp						AGUAN K, 1994, GENE, V149, P345, DOI 10.1016/0378-1119(94)90174-0; Barinaga M, 1997, SCIENCE, V275, P482, DOI 10.1126/science.275.5299.482; Brown JM, 1998, CANCER RES, V58, P1408; CARLING D, 1994, J BIOL CHEM, V269, P11442; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; Crute BE, 1998, J BIOL CHEM, V273, P35347, DOI 10.1074/jbc.273.52.35347; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Foretz M, 1998, J BIOL CHEM, V273, P14767, DOI 10.1074/jbc.273.24.14767; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hashimoto K, 2002, BIOCHEM BIOPH RES CO, V290, P263, DOI 10.1006/bbrc.2001.6193; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Heyer BS, 1997, MOL REPROD DEV, V47, P148, DOI 10.1002/(SICI)1098-2795(199706)47:2&lt;148::AID-MRD4&gt;3.0.CO;2-M; Hockel M, 1999, CANCER RES, V59, P4525; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Izuishi K, 2000, CANCER RES, V60, P6201; Koito K, 1997, AM J ROENTGENOL, V169, P1263, DOI 10.2214/ajr.169.5.9353439; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; Lefebvre DL, 2001, BIOCHEM J, V355, P297, DOI 10.1042/0264-6021:3550297; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; Rofstad EK, 1999, BRIT J CANCER, V80, P1697, DOI 10.1038/sj.bjc.6690586; Saaristo A, 2000, ONCOGENE, V19, P6122, DOI 10.1038/sj.onc.1203969; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; Tomida A, 1996, ONCOGENE, V13, P2699; Wartenberg M, 2001, FASEB J, V15, P995, DOI 10.1096/fj.00-0350com; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; Yu X, 2000, BIOCHEM BIOPH RES CO, V276, P564, DOI 10.1006/bbrc.2000.3508	33	174	180	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6082	6090		10.1038/sj.onc.1205737	http://dx.doi.org/10.1038/sj.onc.1205737			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203120				2022-12-17	WOS:000177671300011
J	Fiore, E; Fusco, C; Romero, P; Stamenkovic, I				Fiore, E; Fusco, C; Romero, P; Stamenkovic, I			Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity	ONCOGENE			English	Article						ICAM-1; MMP-9; tumor; proteases; cytotoxicity	INTERCELLULAR-ADHESION MOLECULE-1; EPIDERMAL GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; RAT EMBRYO CELLS; L-SELECTIN CD62L; SERUM LEVELS; METASTATIC PHENOTYPE; ENDOTHELIAL-CELLS; TISSUE INHIBITOR; IV COLLAGENASE	Shedding of intercellular adhesion molecule 1 (ICAM-1) is believed to play a role in tumor cell resistance to cell-mediated cytotoxicity. However, the mechanism whereby ICAM-1 is shed from the surface of tumor cells remains unclear. In this study, we have addressed the possibility that matrix metalloproteinases are implicated in ICAM-1 shedding. Our observations suggest a functional relationship between ICAM-1 and matrix metalloproteinase 9 (MMP-9) whereby ICAM-1 provides a cell surface docking mechanism for proMMP-9, which, upon activation, proteolytically cleaves the extracellular domain of ICAM-1 leading to its release from the cell surface. MMP-9-dependent shedding of ICAM-1 is found to augment tumor cell resistance to natural killer (NK) cell-mediated cytotoxicity. Taken together, our observations propose a mechanism for ICAM-1 shedding from the cell surface and provide support for MMP involvement in tumor cell evasion of immune surveillance.	Massachusetts Gen Hosp, Mol Pathol Unit, Boston, MA 02129 USA; Massachusetts Gen Hosp, MGH Canc Ctr, Boston, MA 02129 USA; Inst Univ Pathol, CH-1011 Lausanne, Switzerland; Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Ludwig Institute for Cancer Research	Stamenkovic, I (corresponding author), Massachusetts Gen Hosp, Mol Pathol Unit, Boston, MA 02129 USA.		Romero, Pedro/S-6015-2017	Romero, Pedro/0000-0002-9688-2882	NCI NIH HHS [CA55735] Funding Source: Medline; NIGMS NIH HHS [GM48614] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048614] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTOMONTE M, 1993, CANCER RES, V53, P3343; Aoudjit F, 1998, J IMMUNOL, V160, P2967; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Becker J C, 1995, Recent Results Cancer Res, V139, P205; BECKER JC, 1991, J IMMUNOL, V147, P4398; Bergers G, 2000, CURR OPIN GENET DEV, V10, P120, DOI 10.1016/S0959-437X(99)00043-X; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Fonsatti E, 1997, BRIT J CANCER, V76, P1255, DOI 10.1038/bjc.1997.545; GONG JH, 1994, LEUKEMIA, V8, P652; Grothey A, 1998, BRIT J CANCER, V77, P801, DOI 10.1038/bjc.1998.130; Gu B, 1998, BLOOD, V92, P946; Guo HM, 2000, CANCER RES, V60, P888; Hafezi-Moghadam A, 2001, J EXP MED, V193, P863, DOI 10.1084/jem.193.7.863; HARNING R, 1991, CANCER RES, V51, P5003; HERRON GS, 1986, J BIOL CHEM, V261, P2814; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Huang HY, 1998, J CLIN ENDOCR METAB, V83, P1721, DOI 10.1210/jc.83.5.1721; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Ismair MG, 1998, LEUKEMIA, V12, P1136, DOI 10.1038/sj.leu.2401042; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Kondapaka SB, 1997, INT J CANCER, V70, P722, DOI 10.1002/(SICI)1097-0215(19970317)70:6<722::AID-IJC15>3.3.CO;2-5; Kridel SJ, 2001, J BIOL CHEM, V276, P20572, DOI 10.1074/jbc.M100900200; Lyons PD, 1998, GLIA, V22, P103, DOI 10.1002/(SICI)1098-1136(199802)22:2<103::AID-GLIA1>3.0.CO;2-8; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; Mitsiades N, 2000, CANCER RES, V60, P4122; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; Olson MW, 1998, J BIOL CHEM, V273, P10672, DOI 10.1074/jbc.273.17.10672; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; PIZZOLO G, 1993, BRIT J HAEMATOL, V84, P161, DOI 10.1111/j.1365-2141.1993.tb03040.x; Sanchez-Rovira P, 1998, EUR J CANCER, V34, P394, DOI 10.1016/S0959-8049(97)10033-8; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; SPRINGER TA, 1990, ANNU REV CELL BIOL, V6, P359, DOI 10.1146/annurev.cellbio.6.1.359; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Tam YK, 1999, HUM GENE THER, V10, P1359, DOI 10.1089/10430349950018030; Toth M, 1997, CANCER RES, V57, P3159; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Yu Q, 2000, GENE DEV, V14, P163; Yu WH, 2000, J BIOL CHEM, V275, P4183, DOI 10.1074/jbc.275.6.4183; Zhao LC, 2001, J BIOL CHEM, V276, P30631, DOI 10.1074/jbc.M103748200	49	174	181	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2002	21	34					5213	5223		10.1038/sj.onc.1205684	http://dx.doi.org/10.1038/sj.onc.1205684			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149643				2022-12-17	WOS:000177193900003
J	Kuo, MT; Liu, ZS; Wei, YJ; Lin-Lee, YC; Tatebe, S; Mills, GB; Unate, H				Kuo, MT; Liu, ZS; Wei, YJ; Lin-Lee, YC; Tatebe, S; Mills, GB; Unate, H			Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappa B signaling	ONCOGENE			English	Article						2-acetylaminofluorene; MDR; P13 kinase; Akt; rac	TUMOR-SUPPRESSOR GENE; MULTIDRUG-RESISTANCE; PHOSPHATIDYLINOSITOL 3-KINASE; P-GLYCOPROTEIN; PROTEIN-KINASE; HEPATOCELLULAR-CARCINOMA; PROMOTER ACTIVITY; NADPH OXIDASE; RHO GTPASES; HEAT-SHOCK	The expression of P-glycoprotein encoded by the multidrug resistance (MDR1) gene is associated with the emergence of the NIDR phenotype in cancer cells. Human MDR1 and its rodent homolog mdr1a and mdr1b are frequently overexpressed in liver cancers. However, the underlying mechanisms are largely unknown. The hepatocarcinogen 2-acetylaminofluorene (2-AAF) efficiently activates rat mdr1b expression in cultured cells and in Fisher 344 rats. We recently reported that activation of rat mdr1b in cultured cells by 2-AAF involves a cis-activating element containing a NF-kappaB binding site located - 167 to - 158 of the rat mdr1b promoter. 2-AAF activates IkappaB kinase (IKK), resulting in degradation of IkappaBbeta and activation of NF-kappaB. In this study, we report that 2-AAF could also activate the human MDR1 gene in human hepatoma and embryonic fibroblast 293 cells. Induction of MDR1 by AAF was mediated by DNA sequence located at -6092 which contains a NF-kappaB binding site. Treating hepatoma cells with 2-AAF activated phosphoinositide 3-kinase (PI3K) and its downstream effectors Rac1, and NAD(P)H oxidase. Transient transfection assays demonstrated that constitutively activated PI3K and Rac1 enhanced the activation of the MDR1 promoter by 2-AAF. Treatment of hepatoma cells with 2-AAF also activated another PI3K downstream effector Akt. Transfection of recombinant encoding a dominant activated Akt also enhanced the activation of MDR1 promoter activation by 2-AAF. These results demonstrated that 2-AAF up-regulates MDR1 expression is mediated by the multiple effectors of the PI3K signaling pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kuo, MT (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Box 89,1515 Holcombe Blvd, Houston, TX 77030 USA.	tkuo@mail.mdanderson.org			NCI NIH HHS [CA16672, CA79085, CA72404] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072404, P30CA016672, R01CA079085] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Borst P, 1997, SEMIN CANCER BIOL, V8, P131, DOI 10.1006/scbi.1997.0072; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; CHIN KV, 1990, J BIOL CHEM, V265, P221; Cieslik K, 2001, J BIOL CHEM, V276, P1211, DOI 10.1074/jbc.M005305200; CORNWELL MM, 1993, J BIOL CHEM, V268, P15347; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Delhase M, 2000, NATURE, V406, P367, DOI 10.1038/35019154; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; Deng L, 2001, J BIOL CHEM, V276, P413, DOI 10.1074/jbc.M004551200; DENG LS, 2001, IN PRESS CLIN RELEVA; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; FAIRCHILD CR, 1987, P NATL ACAD SCI USA, V84, P7701, DOI 10.1073/pnas.84.21.7701; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fujiwara Y, 2000, JPN J CANCER RES, V91, P287, DOI 10.1111/j.1349-7006.2000.tb00943.x; Hopkin K, 1998, SCIENCE, V282, P1027, DOI 10.1126/science.282.5391.1027; Hu Z, 2000, J BIOL CHEM, V275, P2979, DOI 10.1074/jbc.275.4.2979; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Ling V, 1997, CANCER CHEMOTH PHARM, V40, pS3, DOI 10.1007/s002800051053; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MICKLEY LA, 1989, J BIOL CHEM, V264, P18031; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Ng IOL, 2000, AM J CLIN PATHOL, V113, P355, DOI 10.1309/AC1M-4TY4-U0TN-EN7T; Ogretmen B, 2000, BIOCHEMISTRY-US, V39, P194, DOI 10.1021/bi991943f; Ogretmen B, 1999, BIOCHEMISTRY-US, V38, P2189, DOI 10.1021/bi982236+; OZES MN, 2000, NATURE, V406, P307; Ozes ON, 1999, NATURE, V401, P82; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; POIRIER MC, 1991, CARCINOGENESIS, V12, P895, DOI 10.1093/carcin/12.5.895; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SHEN CJ, 1990, J BIOL CHEM, V265, P506; SILVERMAN JA, 1995, MOL CARCINOGEN, V13, P50, DOI 10.1002/mc.2940130109; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Soini Y, 1996, J CLIN PATHOL, V49, P470, DOI 10.1136/jcp.49.6.470; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sundseth R, 1997, MOL PHARMACOL, V51, P963, DOI 10.1124/mol.51.6.963; TEETER LD, 1993, MOL CARCINOGEN, V8, P67, DOI 10.1002/mc.2940080202; TEETER LD, 1993, INT J ONCOL, V2, P73; TEETER LD, 1990, MOL CELL BIOL, V10, P5728, DOI 10.1128/MCB.10.11.5728; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Verna L, 1996, PHARMACOL THERAPEUT, V71, P83, DOI 10.1016/0163-7258(96)00063-0; Vilaboa NE, 2000, J BIOL CHEM, V275, P24970, DOI 10.1074/jbc.M909136199; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Yao YJ, 1999, ONCOGENE, V18, P3181, DOI 10.1038/sj.onc.1202659; Yeh KT, 2000, CANCER INVEST, V18, P123, DOI 10.3109/07357900009038243; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174; Zhou G, 1996, CELL GROWTH DIFFER, V7, P1369	72	174	187	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					1945	1954		10.1038/sj.onc.1205117	http://dx.doi.org/10.1038/sj.onc.1205117			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960367				2022-12-17	WOS:000174827000001
J	Belzacq, AS; El Hamel, C; Vieira, HLA; Cohen, I; Haouzi, D; Metivier, D; Marchetti, P; Brenner, C; Kroemer, G				Belzacq, AS; El Hamel, C; Vieira, HLA; Cohen, I; Haouzi, D; Metivier, D; Marchetti, P; Brenner, C; Kroemer, G			Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437	ONCOGENE			English	Article						apoptosis; ATP; cell death; Bcl-2; vMIA; chemotherapy	PROGRAMMED CELL-DEATH; CYTOCHROME-C; TRANSITION PORE; NEUROBLASTOMA-CELLS; APOPTOSIS; BCL-2; BAX; NECROSIS; RELEASE; CHANNEL	An increasing number of experimental chemotherapeutic agents induce apoptosis by directly triggering mitochondrial membrane permeabilization (MMP). Here we examined MMP induced by lonidamine, arsenite, and the retinoid derivative CD437. Cells overexpressing the cytomegalovirus-encoded protein vMIA, a protein which interacts with the adenine nucleotide translocator, were strongly protected against the MMP-inducing and apoptogenic effects of lonidamine, arsenite, and CD437. In a cell-free system, lonidamine, arsenite, and CD437 induced the permeabilization of ANT proteoliposomes, yet had no effect on protein-free liposomes. The ANT-dependent membrane permeabilization was inhibited by the two ANT ligands ATP and ADP, as well as by recombinant Bcl-2 protein. Lonidamine, arsenite, and CD437, added to synthetic planar lipid bilayers containing ANT, elicited ANT channel activities with clearly distinct conductance levels of 20+/-7, 100+/-30, and 47+/-7 pS, respectively. Altering the ATP/ADP gradient built up on the inner mitochondrial membrane by inhibition of glycolysis and/or oxidative phosphorylation differentially modulated the cytocidal potential of lonidamine, arsenite, and CD437. Inhibition of F(0)F(1)ATPase without glycolysis inhibition sensitized to lonidamine-induced cell death. In contrast, only the combined inhibition of glycolysis plus F(0)F(1)ATPase sensitized to arsenite-induced cell death. No sensitization to cell death induction by CD437 was achieved by glucose depletion and/or oligomycin addition. These results indicate that ANT is a target of lonidamine, arsenite, and CD437 and unravel an unexpected heterogeneity in the mode of action of these three compounds.	Inst Gustave Roussy, CNRS, UMR 1599, F-94805 Villejuif, France; Univ Technol Compiegne, CNRS, UMR 6022, F-60205 Compiegne, France; INSERM, U459, F-59045 Lille, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Picardie Universites; Universite de Technologie de Compiegne; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 1599, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.		KROEMER, Guido/B-4263-2013; brenner, catherine/AAE-8632-2020; Vieira, Helena/AAZ-9562-2021; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; Vieira, Helena/0000-0001-9415-3742; MARCHETTI, Philippe/0000-0002-4663-6800				Aillet F, 1998, J VIROL, V72, P9698, DOI 10.1128/JVI.72.12.9698-9705.1998; Andre N, 2000, CANCER RES, V60, P5349; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Belzacq AS, 2001, CANCER RES, V61, P1260; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Colberg-Poley AM, 2000, J GEN VIROL, V81, P1779, DOI 10.1099/0022-1317-81-7-1779; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Genini D, 2000, BLOOD, V96, P3537; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; KLINGENBERG M, 1980, J MEMBRANE BIOL, V56, P97, DOI 10.1007/BF01875961; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 1999, JNCI-J NATL CANCER I, V91, P743, DOI 10.1093/jnci/91.9.743; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Marchetti P, 1999, CANCER RES, V59, P6257; Martin DS, 2000, CANCER RES, V60, P6776; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tinhofer I, 2001, FASEB J, V15, P1613, DOI 10.1096/fj.00-0675fje; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Watabe M, 2000, CANCER RES, V60, P5214; Xie ZH, 1998, BIOCHEMISTRY-US, V37, P6410, DOI 10.1021/bi973052i; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	52	174	180	0	13	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2001	20	52					7579	7587		10.1038/sj.onc.1204953	http://dx.doi.org/10.1038/sj.onc.1204953			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	491TC	11753636				2022-12-17	WOS:000172124100001
J	Handschuh, G; Candidus, S; Luber, B; Reich, U; Schott, C; Oswald, S; Becke, H; Hutzler, P; Birchmeier, W; Hofler, H; Becker, KF				Handschuh, G; Candidus, S; Luber, B; Reich, U; Schott, C; Oswald, S; Becke, H; Hutzler, P; Birchmeier, W; Hofler, H; Becker, KF			Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility	ONCOGENE			English	Article						E-cadherin; gastric carcinoma; cell adhesion; motility; morphology	TRANSCRIPTION FACTOR LEF-1; ALPHA-CATENIN EXPRESSION; HUMAN GASTRIC CARCINOMAS; BETA-CATENIN; GENE-MUTATIONS; FUNCTIONAL INTERACTION; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; EPITHELIAL-CELLS	A major function of the cell-to-cell adhesion molecule E-cadherin is the maintenance of cell adhesion and tissue integrity. E-cadherin deficiency in rumours leads to changes in cell morphology and motility, so that E-cadherin is considered to be a suppressor of invasion. In this study we investigated the functional consequences of three tumour-associated gene mutations that affect the extracellular portion of E-cadherin: in-frame deletions of exons 8 or 9 and a point mutation in exon 8, as they were found in human gastric carcinomas. Human MDA-MB-435S breast carcinoma cells and mouse L fibroblasts were stably transfected with the wild-type and mutant cDNAs, and the resulting changes in localization of E-cadherin, cell morphology, strength of calcium-dependent aggregation as well as cell motility and actin cytoskeleton organization were studied. We found that cells transfected with wild-ty pe E-cadherin showed an epitheloid morphology, while all cell lines expressing mutant E-cadherin exhibited more irregular cell shapes. Cells expressing E-cadherin mutated in exon 8 showed the most scattered appearance, whereas cells with deletion of exon 9 had an intermediate state, Mutant E-cadherins were localized to the lateral regions of cell-to-cell contact sites. Additionally, both exon 8-mutated E-cadherins showed apical and perinuclear localization, and actin filaments were drastically reduced. MDA-MB-435S cells with initial calcium-dependent cell aggregation exhibited decreased aggregation and, remarkably, increased cell motility, when mutant E-cadherin was expressed. Therefore, we conclude that these E-cadherin mutations may not simply affect cell adhesion but may act in a trans-dominant-active manner, i.e. lead to increased cell motility. Our study suggests that E-cadherin mutations affecting exons 8 or 9 are the cause of multiple morphological and functional disorders and could induce the scattered morphology and the invasive behaviour of diffuse type-gastric carcinomas.	GSF Forschungszentrum Umwelt & Gesundheit, Inst Pathol, D-85764 Neuherberg, Germany; Tech Univ Munich, Klinikum Rechts Isar, D-81675 Munich, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Becker, KF (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Ismaningerstr 22, D-81675 Munich, Germany.		Becker, Karl-Friedrich/D-3636-2015	Becker, Karl-Friedrich/0000-0002-6801-4498				Alattia JR, 1997, FEBS LETT, V417, P405, DOI 10.1016/S0014-5793(97)01333-1; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; Bailey T, 1998, AM J PATHOL, V152, P135; BECKER KF, 1993, HUM MOL GENET, V2, P803, DOI 10.1093/hmg/2.6.803; BECKER KF, 1994, CANCER RES, V54, P3845; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; BEHRENS J, 1991, EXP SUPPL, V59, P109; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BERX G, 1995, GENOMICS, V26, P281, DOI 10.1016/0888-7543(95)80212-5; Berx G, 1996, ONCOGENE, V13, P1919; BIRCHMEIER W, 1995, CANCER SURV, V24, P129; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BOYER B, 1989, J CELL BIOL, V109, P1495, DOI 10.1083/jcb.109.4.1495; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911; Candidus S, 1996, CANCER RES, V56, P49; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; Chen HY, 1997, J CELL SCI, V110, P345; Coman DR, 1944, CANCER RES, V4, P625; CUNNINGHAM BA, 1984, P NATL ACAD SCI-BIOL, V81, P5787, DOI 10.1073/pnas.81.18.5787; Dahl U, 1996, DEVELOPMENT, V122, P2895; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FUJIMORI T, 1993, MOL BIOL CELL, V4, P37, DOI 10.1091/mbc.4.1.37; Gabbert HE, 1996, INT J CANCER, V69, P184, DOI 10.1002/(SICI)1097-0215(19960621)69:3<184::AID-IJC6>3.0.CO;2-W; Gayther SA, 1998, CANCER RES, V58, P4086; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; Hay ED, 1995, ACTA ANAT, V154, P8; Hedrick Lora, 1993, Trends in Cell Biology, V3, P36, DOI 10.1016/0962-8924(93)90148-T; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Hertig CM, 1996, J CELL SCI, V109, P1; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huelsken Joerg, 1994, Journal of Cell Biology, V127, P2061; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; KANAI Y, 1994, JPN J CANCER RES, V85, P1035, DOI 10.1111/j.1349-7006.1994.tb02902.x; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Masuda A, 1996, ONCOGENE, V12, P2081; MATSUI S, 1994, VIRCHOWS ARCH, V424, P375; MAYER B, 1993, CANCER RES, V53, P1690; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MURRAY AB, 1991, BIOTECH HISTOCHEM, V66, P269, DOI 10.3109/10520299109109985; Muta H, 1996, JPN J CANCER RES, V87, P843, DOI 10.1111/j.1349-7006.1996.tb02109.x; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; OCHIAI A, 1994, JPN J CANCER RES, V85, P266, DOI 10.1111/j.1349-7006.1994.tb02092.x; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; OKA H, 1993, CANCER RES, V53, P1696; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; OZAWA M, 1990, J CELL BIOL, V111, P1645, DOI 10.1083/jcb.111.4.1645; PIGNATELLI M, 1994, J PATHOL, V174, P243, DOI 10.1002/path.1711740403; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; ROSAI J, 1989, ACKERMANNS SURG PATH, V1; ROSAI J, 1989, ACKERMANNS SURG PATH, V3; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Shibata T, 1996, CANCER LETT, V99, P147, DOI 10.1016/0304-3835(95)04047-1; SHIMOYAMA Y, 1991, CANCER RES, V51, P2185; SHINO Y, 1995, CANCER, V76, P2193, DOI 10.1002/1097-0142(19951201)76:11<2193::AID-CNCR2820761104>3.0.CO;2-2; SHORE EM, 1991, J BIOL CHEM, V266, P19672; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Streit M, 1996, J MOL MED-JMM, V74, P253, DOI 10.1007/s001090050027; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAHARA E, 1993, J CANCER RES CLIN, V119, P265, DOI 10.1007/BF01212724; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tamura G, 1996, JPN J CANCER RES, V87, P1153, DOI 10.1111/j.1349-7006.1996.tb03125.x; WOLLNER DA, 1992, J CELL BIOL, V116, P889, DOI 10.1083/jcb.116.4.889; Zhu AJ, 1996, J CELL SCI, V109, P3013; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	84	174	176	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 29	1999	18	30					4301	4312		10.1038/sj.onc.1202790	http://dx.doi.org/10.1038/sj.onc.1202790			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439038				2022-12-17	WOS:000081732700003
J	Unger, T; Sionov, RV; Moallem, E; Yee, CL; Howley, PM; Oren, M; Haupt, Y				Unger, T; Sionov, RV; Moallem, E; Yee, CL; Howley, PM; Oren, M; Haupt, Y			Mutations in serines 15 and 20 of human p53 impair its apoptotic activity	ONCOGENE			English	Article						serine; phosphorylation; p53; transactivation; apoptosis	CASEIN KINASE-II; CELL-CYCLE PROGRESSION; DNA-BINDING FUNCTION; PHOSPHORYLATION SITE; WILD-TYPE; TRANSACTIVATION DOMAIN; C-JUN; PROTEIN; GENE; MDM2	Phosphorylation of the p53 tumor suppressor protein is likely to play an important role in regulating its activity, To study the regulatory role of potential phosphorylation sites within the N-terminal transactivation domain of human p53 (hp53), a series of p53 serine mutants were evaluated for transcriptional transactivation and sequence specific DNA binding. The role of these mutations in regulating p53-mediated growth suppression and programmed cell death,vas examined. This mutational analysis comprised serine residues located at positions 6, 9, 15, 20, 33 and 37 of human p53. Substitution of serine for alanine, either at individual residues or at all sis residues together, did not affect the suppression of cell growth and cell transformation, or the ability to bind DNA specifically and to transactivate different promoters, nor did it alter p53 expression, However, the ability of p53 to induce apoptosis was impaired by specific serine substitutions. Mutations in all sis N-terminal serines together reduced the apoptotic activity of p53 in H1299 cells by 50%, Analysis of individual mutants revealed that mutations in serine 15 and 20 are primarily responsible for this impairment. Our results suggest that these serines play a role in the regulation of p53-mediated apoptosis.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel; NCI, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Weizmann Institute of Science; Hebrew University of Jerusalem; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School	Unger, T (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.			Oren, Moshe/0000-0003-4311-7172; Howley, Peter/0000-0002-8668-9579				ADDISON C, 1990, ONCOGENE, V5, P423; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; FISCELLA M, 1994, ONCOGENE, V9, P3249; FISCELLA M, 1993, ONCOGENE, V8, P1519; FUCHS B, 1995, ONCOGENE, V10, P789; Fuchs SY, 1996, ONCOGENE, V13, P1531; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Haupt Y, 1996, Behring Inst Mitt, P32; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Lohrum M, 1996, ONCOGENE, V13, P2527; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; MAYR GA, 1995, CANCER RES, V55, P2410; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MIETZ JA, 1997, EMBO J, V60, P1; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Momand J, 1997, J CELL BIOCHEM, V64, P343; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sionov RV, 1998, SPRINGER SEMIN IMMUN, V19, P345, DOI 10.1007/BF00787230; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Velculescu VE, 1996, CLIN CHEM, V42, P858; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Wyllie A, 1997, NATURE, V389, P237, DOI 10.1038/38405; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	58	174	176	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	1999	18	21					3205	3212		10.1038/sj.onc.1202656	http://dx.doi.org/10.1038/sj.onc.1202656			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359526				2022-12-17	WOS:000080523800003
J	CHEN, HM; RAYGALLET, D; ZHANG, P; HETHERINGTON, CJ; GONZALEZ, DA; ZHANG, DE; MOREAUGACHELIN, F; TENEN, DG				CHEN, HM; RAYGALLET, D; ZHANG, P; HETHERINGTON, CJ; GONZALEZ, DA; ZHANG, DE; MOREAUGACHELIN, F; TENEN, DG			PU.1 (SPI-1) AUTOREGULATES ITS EXPRESSION IN MYELOID CELLS	ONCOGENE			English	Article						PU.1 (SPI-1); SPI-B; PROMOTER; AUTOREGULATION; MYELOID CELL; IN VIVO FOOTPRINT	TRANSCRIPTION FACTOR GATA-1; MUSCLE-SPECIFIC ENHANCER; AUTO-REGULATION; CD11B PROMOTER; CHROMOSOMAL LOCALIZATION; FUNCTIONAL-ANALYSIS; PUTATIVE ONCOGENE; BINDING PROTEIN; ETS ONCOGENE; HEAVY-CHAIN	PU.1 (Spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid (granulocytes, monocytes and macrophages) and B cells. PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34(+) progenitors prior to this upregulation blocks myeloid colony formation. Since PU.1 expression appears to play a role in hematopoietic development, we characterized the PU.1 promoter. Here we report that the murine PU.1 promoter, as well as the human promoter, demonstrate tissue-specific reporter gene expression in myeloid cell lines but not in T cells and HeLa (non-hematopoietic cells) cells. Deletion analysis of the PU.1 promoter indicates that tissue-specific functional elements are encoded in the -61 to -39 bp and -7 to +34 bp regions. The first region contains a functional octamer (Oct) site at -54 bp and an Spl site at -39 bp. The second contains a binding site at +20 bp for both PU.1 itself and the related ets family member Spi-B. In vivo footprinting assays demonstrate that a hypersensitive band was detected at the PU.1 site in myeloid cells but not in HeLa. A mutation of the PU.1 site which abolished PU.1 binding caused a significant decrease in promoter activity., Mutation of the Oct and/or Spl site results in a lesser decrease of promoter activity in myeloid cells. Cotransfection of PU.1 or Spi-B in cells lacking PU.1 and Spi-B specifically transactivated a minimal promoter containing the PU.1 binding site, indicating that PU.1 can activate its own promoter elements in an autoregulatory loop. Positive autoregulation of the PU.1 promoter may play an important role in the function of PU.1 in myeloid cells.	HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02215 USA; FAC MED LARIBOISIERE, INSERM, U248, F-75010 PARIS, FRANCE	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Ray-Gallet, Dominique/A-9224-2019	Tenen, Daniel/0000-0002-6423-3888	NCI NIH HHS [CA59589, CA41456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA059589, R01CA041456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHNE B, 1994, J BIOL CHEM, V269, P17794; BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; BURN TC, 1992, BLOOD, V80, P3051; CARVALHO M, 1993, J VIROL, V67, P3885, DOI 10.1128/JVI.67.7.3885-3890.1993; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DELGADO MD, 1994, ONCOGENE, V9, P1723; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; FLEMING JC, 1993, J IMMUNOL, V150, P480; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GHOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117, DOI 10.1093/nar/21.13.3117; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HEHLGANS T, 1995, J IMMUNOL, V154, P5181; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; HROMAS R, 1993, BLOOD, V82, P2998; JOHANNSEN E, 1995, J VIROL, V69, P253, DOI 10.1128/JVI.69.1.253-262.1995; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P3283, DOI 10.1073/pnas.71.8.3283; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LAUX G, 1994, EMBO J, V13, P5624, DOI 10.1002/j.1460-2075.1994.tb06900.x; LEE ME, 1991, J BIOL CHEM, V266, P16188; MAURY W, 1994, J VIROL, V68, P6270, DOI 10.1128/JVI.68.10.6270-6279.1994; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; OKA T, 1991, ONCOGENE, V6, P2077; OMORI SA, 1993, P NATL ACAD SCI USA, V90, P11723, DOI 10.1073/pnas.90.24.11723; PAHL HL, 1992, BLOOD, V79, P865; PAHL HL, 1991, EXP HEMATOL, V19, P1038; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; RAY D, 1990, ONCOGENE, V5, P663; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; RAYGALLET D, 1995, ONCOGENE, V11, P303; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCHWARZENBACH H, 1995, J BIOL CHEM, V270, P898, DOI 10.1074/jbc.270.2.898; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; SMITH LT, 1994, BLOOD, V84, pA372; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; TOOTHAKER LE, 1991, BLOOD, V78, P1826; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; VOSO MT, 1994, P NATL ACAD SCI USA, V91, P7932, DOI 10.1073/pnas.91.17.7932; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	69	174	176	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1549	1560						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478579				2022-12-17	WOS:A1995TC53500013
J	Muller, DW; Bosserhoff, AK				Mueller, D. W.; Bosserhoff, A-K			Integrin beta(3) expression is regulated by let-7a miRNA in malignant melanoma	ONCOGENE			English	Article						microRNA; integrins; post-transcriptional silencing; melanoma progression	GENE-EXPRESSION; MICRORNA; PROGRESSION; ALPHA(V)BETA(3); MELANOCYTES; RAS; MIA	Although integrin beta(3) is known to play an important role in melanoma progression and invasion, regulation of integrin beta(3) expression in melanoma has not been analysed in detail until today. As transcriptional regulation of integrin beta(3) was ruled out by our analysis, we concentrated on the regulation by microRNAs (miRNAs). Comparing primary melanocytes and malignant melanoma cell lines, we found that one candidate miRNA, miR-let-7a, was lost in melanoma and sequence analysis suggested an interaction with the 3'-untranslated region (3'-UTR) of integrin beta(3) mRNA. Transfection of melanoma cells with let-7a pre-miR (TM) molecules resulted in the downregulation of integrin beta(3) mRNA and protein expression. In addition, we cloned the 3'-UTR of the integrin beta(3) mRNA containing the let-7a target sequence into a reporter plasmid and revealed that let-7a negatively regulates reporter gene expression. The repressed expression of integrin beta(3) accompanies with reduced invasive potential of melanoma cells transfected with synthetic let-7a molecules observed in Boyden chamber assays. On the other hand, the induction of integrin beta(3) expression was achieved in melanocytes by transfection with let-7 a anti-miRs, resulting in invasive behavior of transfected melanocytes. In summary, we determined miRNA let-7a to be an important regulator of integrin beta(3) expression and showed that the loss of let-7a expression is involved in development and progression of malignant melanoma.	[Mueller, D. W.; Bosserhoff, A-K] Univ Regensburg, Inst Pathol, D-93053 Regensburg, Germany	University of Regensburg	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X				ALBELDA SM, 1990, CANCER RES, V50, P6757; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; DANEN EHJ, 1995, INT J CANCER, V61, P491, DOI 10.1002/ijc.2910610411; DANEN EHJ, 1994, HISTOPATHOLOGY, V24, P249, DOI 10.1111/j.1365-2559.1994.tb00517.x; Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Haass NK, 2005, PIGM CELL RES, V18, P150, DOI 10.1111/j.1600-0749.2005.00235.x; Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023; Jin Y, 1998, BLOOD, V92, P2777, DOI 10.1182/blood.V92.8.2777.420k27_2777_2790; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kim VN, 2005, MOL CELLS, V19, P1; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Li XW, 1998, INVAS METAST, V18, P1, DOI 10.1159/000024494; Park SM, 2007, CELL CYCLE, V6, P2585, DOI 10.4161/cc.6.21.4845; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Poser I, 2004, ONCOGENE, V23, P6115, DOI 10.1038/sj.onc.1207797; Rothhammer T, 2005, CANCER RES, V65, P448; Tatzel J, 2005, PIGM CELL RES, V18, P92, DOI 10.1111/j.1600-0749.2005.00212.x; Van Belle PA, 1999, HUM PATHOL, V30, P562, DOI 10.1016/S0046-8177(99)90202-2; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Zhang HH, 2007, WORLD J GASTROENTERO, V13, P2883, DOI 10.3748/wjg.v13.i20.2883	23	173	184	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2008	27	52					6698	6706		10.1038/onc.2008.282	http://dx.doi.org/10.1038/onc.2008.282			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368QY	18679415				2022-12-17	WOS:000260638800008
J	El-Omar, EM; Ng, MT; Hold, GL				El-Omar, E. M.; Ng, M. T.; Hold, G. L.			Polymorphisms in Toll-like receptor genes and risk of cancer	ONCOGENE			English	Review						gastric cancer; Helicobacter pylori; genetic polymorphisms; single nucleotide polymorphisms; Toll-like receptors; prostate cancer	HELICOBACTER-PYLORI INFECTION; SINGLE-NUCLEOTIDE POLYMORPHISMS; STOP CODON POLYMORPHISM; DUODENAL-ULCER DISEASE; ALLELE-SPECIFIC PCR; SEQUENCE VARIANTS; INNATE IMMUNITY; GASTRIC-CANCER; ATROPHIC GASTRITIS; EPITHELIAL-CELLS	Host genetic factors are emerging as key determinants of disease risk for many cancers. Identifying candidate genes is a major challenge that has to stem from a profound understanding of the pathophysiology of the disease. The Toll-like receptors are important members of the host's innate immune response and their genes have been found to be polymorphic. This genetic variation allows for a more intricate repertoire that enables the host to withstand microbial challenges. While this may be advantageous on a population level, there may be less favourable outcomes for individuals that harbour certain genotypes associated with excessive immune activation and inflammatory drive. The damage is often collateral and is manifest in organs where this chronic inflammation alters normal physiology. A classic example of this paradigm is the Helicobacter pylori-induced gastric cancer model. Another emerging model is prostate cancer where Toll-like receptor polymorphisms have also been found to play a role. In this review, we discuss polymorphisms in Toll-like receptors and give an insight into how they may influence risk of cancer.	[El-Omar, E. M.; Ng, M. T.; Hold, G. L.] Univ Aberdeen, Dept Med & Therapeut, Inst Med Sci, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	El-Omar, EM (corresponding author), Univ Aberdeen, Dept Med & Therapeut, Inst Med Sci, Aberdeen AB25 2ZD, Scotland.	e.el-omar@abdn.ac.uk	El-Omar, Emad/AAT-7780-2021; Hold, Georgina Louise/AAG-9923-2020	Hold, Georgina Louise/0000-0001-7573-3397; El-Omar, Emad/0000-0002-0011-3924				Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Backhed F, 2003, J INFECT DIS, V187, P829; Berghofer B, 2005, CLIN EXP ALLERGY, V35, P1147, DOI 10.1111/j.1365-2222.2005.02325.x; Bochud PY, 2007, AIDS, V21, P441, DOI 10.1097/QAD.0b013e328012b8ac; Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626; De Marzo AM, 2003, UROLOGY, V62, P55, DOI 10.1016/j.urology.2003.09.053; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; El-Omar EM, 2003, GASTROENTEROLOGY, V124, P1193, DOI 10.1016/S0016-5085(03)00157-4; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; El-Omar EM, 2006, BEST PRACT RES CL GA, V20, P675, DOI 10.1016/j.bpg.2006.04.006; ElOmar EM, 1997, GASTROENTEROLOGY, V113, P15, DOI 10.1016/S0016-5085(97)70075-1; ELOMAR EM, 1995, GASTROENTEROLOGY, V109, P681, DOI 10.1016/0016-5085(95)90374-7; Franchimont D, 2004, GUT, V53, P987, DOI 10.1136/gut.2003.030205; Hamann L, 2005, J MOL MED, V83, P478, DOI 10.1007/s00109-005-0643-7; Hansson LE, 1996, NEW ENGL J MED, V335, P242, DOI 10.1056/NEJM199607253350404; Hawn TR, 2007, EUR J IMMUNOL, V37, P2280, DOI 10.1002/eji.200737034; Hawn TR, 2005, P NATL ACAD SCI USA, V102, P10593, DOI 10.1073/pnas.0501165102; Hawn TR, 2003, J EXP MED, V198, P1563, DOI 10.1084/jem.20031220; Higgins SC, 2003, J IMMUNOL, V171, P3119, DOI 10.4049/jimmunol.171.6.3119; Hold GL, 2007, GASTROENTEROLOGY, V132, P905, DOI 10.1053/j.gastro.2006.12.026; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jelavic TB, 2006, CLIN GENET, V70, P156, DOI 10.1111/j.1399-0004.2006.00651.x; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kang TJ, 2001, FEMS IMMUNOL MED MIC, V31, P53, DOI 10.1111/j.1574-695X.2001.tb01586.x; Kawahara T, 2001, J Med Invest, V48, P167; Kawahara T, 2001, INFECT IMMUN, V69, P4382, DOI 10.1128/IAI.69.7.4382-4389.2001; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Kutukculer N, 2007, BIOCHEM GENET, V45, P507, DOI 10.1007/s10528-007-9091-0; Lazarus R, 2004, AM J RESP CRIT CARE, V170, P594, DOI 10.1164/rccm.200404-491OC; Lazarus R, 2003, GENOMICS, V81, P85, DOI 10.1016/S0888-7543(02)00022-8; Lazarus R, 2002, IMMUNOL REV, V190, P9, DOI 10.1034/j.1600-065X.2002.19002.x; Lorenz E, 2002, ARCH INTERN MED, V162, P1028, DOI 10.1001/archinte.162.9.1028; Lorenz E, 2001, BIOTECHNIQUES, V31, P22, DOI 10.2144/01311bm01; Macarthur M, 2004, AM J PHYSIOL-GASTR L, V286, pG515, DOI 10.1152/ajpgi.00475.2003; Machado JC, 2003, GASTROENTEROLOGY, V125, P364, DOI 10.1016/S0016-5085(03)00899-0; Mandell L, 2004, INFECT IMMUN, V72, P6446, DOI 10.1128/IAI.72.11.6446-6454.2004; Mockenhaupt FP, 2006, P NATL ACAD SCI USA, V103, P177, DOI 10.1073/pnas.0506803102; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pasare C, 2005, ADV EXP MED BIOL, V560, P11; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Pierik M, 2006, INFLAMM BOWEL DIS, V12, P1, DOI 10.1097/01.MIB.0000195389.11645.ab; Pirie FJ, 2005, TISSUE ANTIGENS, V66, P125, DOI 10.1111/j.1399-0039.2005.00454.x; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; Sanduleanu S, 2001, ALIMENT PHARM THERAP, V15, P1163, DOI 10.1046/j.1365-2036.2001.01029.x; Schmausser B, 2004, CLIN EXP IMMUNOL, V136, P521, DOI 10.1111/j.1365-2249.2004.02464.x; Schroder NW, 2005, LANCET INFECT DIS, V5, P156, DOI 10.1016/S1473-3099(05)70023-2; Schroder NWJ, 2003, J MOL MED-JMM, V81, P368, DOI 10.1007/s00109-003-0443-x; Segal ED, 1997, P NATL ACAD SCI USA, V94, P7595, DOI 10.1073/pnas.94.14.7595; Smith MF, 2003, J BIOL CHEM, V278, P32552, DOI 10.1074/jbc.M305536200; Su B, 2003, INFECT IMMUN, V71, P3496, DOI 10.1128/IAI.71.6.3496-3502.2003; Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542; Sun JL, 2005, JNCI-J NATL CANCER I, V97, P525, DOI 10.1093/jnci/dji070; Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186; Tantisira K, 2004, GENES IMMUN, V5, P343, DOI 10.1038/sj.gene.6364096; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Yang IA, 2004, GENES IMMUN, V5, P41, DOI 10.1038/sj.gene.6364037; Zavros Y, 2002, GASTROENTEROLOGY, V122, P119, DOI 10.1053/gast.2002.30298; Zheng SL, 2004, CANCER RES, V64, P2918, DOI 10.1158/0008-5472.CAN-03-3280; Zhou XX, 2006, CANCER EPIDEM BIOMAR, V15, P862, DOI 10.1158/1055-9965.EPI-05-0874	61	173	185	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2008	27	2					244	252		10.1038/sj.onc.1210912	http://dx.doi.org/10.1038/sj.onc.1210912			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248OO	18176606				2022-12-17	WOS:000252163600011
J	Maxwell, PJ; Gallagher, R; Seaton, A; Wilson, C; Scullin, P; Pettigrew, J; Stratford, IJ; Williams, KJ; Johnston, PG; Waugh, DJJ				Maxwell, P. J.; Gallagher, R.; Seaton, A.; Wilson, C.; Scullin, P.; Pettigrew, J.; Stratford, I. J.; Williams, K. J.; Johnston, P. G.; Waugh, D. J. J.			HIF-1 and NF-kappa B-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells	ONCOGENE			English	Article						IL-8; hypoxia; CXCR1; CXCR2; HIF-1; NF-kappa B	ENDOTHELIAL GROWTH-FACTOR; CHEMOKINE RECEPTOR CXCR4; INTERLEUKIN-8 EXPRESSION; INDUCIBLE FACTOR; GENE-EXPRESSION; ACTIVATION; ANGIOGENESIS; TUMORIGENICITY; TRANSCRIPTION; METASTASIS	Hypoxic cancer cells are resistant to treatment, leading to the selection of cells with a more malignant phenotype. The expression of interleukin-8 (IL-8) plays an important role in the tumorigenesis and metastasis of solid tumors including prostate cancer. Recently, we detected elevated expression of IL-8 and IL-8 receptors in human prostate cancer tissue. The objective of the current study was to determine whether hypoxia increases IL-8 and IL-8 receptor expression in prostate cancer cells and whether this contributes to a survival advantage in hypoxic cells. IL-8, CXCR1 and CXCR2 messenger RNA (mRNA) expression in PC3 cells was upregulated in response to hypoxia in a time-dependent manner. Elevated IL-8 secretion following hypoxia was detected by enzyme-linked immunosorbent assay, while immunoblotting confirmed elevated receptor expression. Attenuation of hypoxia-inducible factor (HIF-1) and nuclear factor-kappa B (NF-kappa B) transcriptional activity using small interfering RNA (siRNA), a HIF-1 dominant-negative and pharmacological inhibitors, abrogated hypoxia-induced transcription of CXCR1 and CXCR2 in PC3 cells. Furthermore, chromatin-IP analysis demonstrated binding of HIF-1 and NF-kappa B to CXCR1. Finally, inhibition of IL-8 signaling potentiated etoposide-induced cell death in hypoxic PC3 cells. These results suggest that IL-8 signaling confers a survival advantage to hypoxic prostate cancer cells, and therefore, strategies to inhibit IL-8 signaling may sensitize hypoxic tumor cells to conventional treatments.	Queens Univ Belfast, Ctr Canc Res &Cell Biol, Belfast BT9 7AB, Antrim, North Ireland; Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester, Lancs, England	Queens University Belfast; University of Manchester	Waugh, DJJ (corresponding author), Queens Univ Belfast, Ctr Canc Res &Cell Biol, Univ Flr, Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.	d.waugh@qub.ac.uk		stratford, ian/0000-0002-5222-4765; WAUGH, DAVID/0000-0002-4022-3765	MRC [G0500366] Funding Source: UKRI; Medical Research Council [G0500366] Funding Source: Medline; Wellcome Trust [067104/Z/02/Z] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; Brown LM, 2006, MOL PHARMACOL, V69, P411, DOI 10.1124/mol.105.015743; Cairns RA, 2003, CURR MOL MED, V3, P659, DOI 10.2174/1566524033479447; Cairns RA, 2004, CANCER RES, V64, P2054, DOI 10.1158/0008-5472.CAN-03-3196; Carnell DM, 2006, INT J RADIAT ONCOL, V65, P91, DOI 10.1016/j.ijrobp.2005.11.044; Coffey RNT, 2005, CANCER-AM CANCER SOC, V103, P1363, DOI 10.1002/cncr.20918; Cvetkovic D, 2001, UROLOGY, V57, P821, DOI 10.1016/S0090-4295(00)01044-X; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; Fernandez A, 2001, J NATL CANCER I, V93, P208, DOI 10.1093/jnci/93.3.208; Ghafar MA, 2003, PROSTATE, V54, P58, DOI 10.1002/pros.10162; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Grutkoski PS, 1999, J LEUKOCYTE BIOL, V65, P171, DOI 10.1002/jlb.65.2.171; Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200; Hirota K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI 10.1016/j.critrevonc.2005.12.003; Inoue K, 2000, CANCER RES, V60, P2290; Inoue K, 2000, CLIN CANCER RES, V6, P2104; Kim KS, 2006, J IMMUNOL, V177, P7211, DOI 10.4049/jimmunol.177.10.7211; KOONG AC, 1994, CANCER RES, V54, P1425; Kunz M, 1999, AM J PATHOL, V155, P753, DOI 10.1016/S0002-9440(10)65174-7; Lee TH, 2002, J BIOL CHEM, V277, P10445, DOI 10.1074/jbc.M107348200; Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369; Li Aihua, 2005, Angiogenesis, V8, P63, DOI 10.1007/s10456-005-5208-4; MACMANUS CF, 2007, IN PRESS MOL CANC RE; Mizukami Y, 2005, NAT MED, V11, P992, DOI 10.1038/nm1294; Moldobaeva A, 2005, AM J PHYSIOL-LUNG C, V288, pL1117, DOI 10.1152/ajplung.00370.2004; Moore BB, 1999, AM J PATHOL, V154, P1503, DOI 10.1016/S0002-9440(10)65404-1; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Movsas B, 1999, UROLOGY, V53, P11, DOI 10.1016/S0090-4295(98)00500-7; MURPHY C, 2005, CLIN CANCER RES, V11, P4702; Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Shi Q, 2001, J INTERF CYTOK RES, V21, P553, DOI 10.1089/10799900152547812; Shi QA, 1999, J INTERF CYTOK RES, V19, P1363, DOI 10.1089/107999099312821; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; Sowter HM, 2003, CANCER RES, V63, P6130; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Subarsky P, 2003, CLIN EXP METASTAS, V20, P237, DOI 10.1023/A:1022939318102; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takami M, 2002, J IMMUNOL, V168, P4559, DOI 10.4049/jimmunol.168.9.4559; Trisciuoglio D, 2005, MOL BIOL CELL, V16, P4153, DOI 10.1091/mbc.e04-12-1087; Vaupel P, 2004, ONCOLOGIST, V9, P4, DOI 10.1634/theoncologist.9-90005-4; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Xu L, 1999, CANCER RES, V59, P5822; Xu L, 2004, CLIN CANCER RES, V10, P701, DOI 10.1158/1078-0432.CCR-0953-03; Yan SF, 1997, J BIOL CHEM, V272, P4287, DOI 10.1074/jbc.272.7.4287; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; Yoneda J, 1998, JNCI-J NATL CANCER I, V90, P447, DOI 10.1093/jnci/90.6.447	49	173	184	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2007	26	52					7333	7345		10.1038/sj.onc.1210536	http://dx.doi.org/10.1038/sj.onc.1210536			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17533374				2022-12-17	WOS:000250955700005
J	Reed, CC; Waterhouse, A; Kirby, S; Kay, P; Owens, RT; McQuillan, DJ; Iozzo, RV				Reed, CC; Waterhouse, A; Kirby, S; Kay, P; Owens, RT; McQuillan, DJ; Iozzo, RV			Decorin prevents metastatic spreading of breast cancer	ONCOGENE			English	Article						decorin proteoglycan; adenovirus gene therapy; breast carcinoma; doxycycline inducible promoter	LEUCINE-RICH PROTEOGLYCANS; GENE-EXPRESSION; EGF RECEPTOR; GROWTH SUPPRESSION; DOWN-REGULATION; CELLS; INHIBITION; CARCINOMA; MIGRATION	Metastases in breast cancer are a vital concern in treatment, with epidermal growth factor receptor and ErbB2 strongly implicated in mediating tumor invasion and spreading. In this study, we investigated the role of decorin in suppressing both primary breast carcinomas and pulmonary metastases. We show that decorin causes marked growth suppression both in vitro and in vivo using a metastatic breast cancer cell line and an orthotopic mammary carcinoma model. Treatment with decorin protein core reduced primary tumor growth by 70% and eliminated observed metastases. An adenoviral vector containing the decorin transgene caused primary tumor retardation of 70%, in addition to greatly reducing observed metastases. Moreover, we demonstrate that ErbB2 phosphorylation and total receptor protein levels are reduced in this model system upon de novo expression of decorin under the control of a doxycycline-inducible promoter. Primary tumor growth in vivo was reduced by up to 67% upon decorin induction, and pulmonary metastases were markedly hampered as well. These effects are likely occurring through decorin's long-term downregulation of the ErbB2 tyrosine kinase cascade. These results demonstrate a novel role for decorin in reduction or prevention of tumor metastases in this breast cancer model and could eventually lead to improved therapeutics for metastatic breast cancer.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, JAH, Philadelphia, PA 19107 USA; LifeCell Corp, Branchburg, NJ 08876 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Cellular Biol & Signaling Program, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, JAH, Room 249,1020 Locust St, Philadelphia, PA 19107 USA.	iozzo@mail.jci.tju.edu	Waterhouse, Anna/E-2464-2011; Waterhouse, Anna/M-1681-2018; Iozzo, Renato/AAS-1980-2020	Waterhouse, Anna/0000-0003-1498-9393; Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [R01 CA39481, R01 CA47282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047282, R01CA039481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADANY R, 1990, J BIOL CHEM, V265, P11389; Ahmed F, 2002, CANCER RES, V62, P7166; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Davies CD, 2001, MICROVASC RES, V62, P26, DOI 10.1006/mvre.2001.2311; Goldoni S, 2004, J BIOL CHEM, V279, P6606, DOI 10.1074/jbc.M310342200; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grant DS, 2002, ONCOGENE, V21, P4765, DOI 10.1038/sj.onc.1205595; Iozzo RV, 1999, P NATL ACAD SCI USA, V96, P3092, DOI 10.1073/pnas.96.6.3092; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Koninger J, 2004, CLIN CANCER RES, V10, P4776, DOI 10.1158/1078-0432.CCR-1190-03; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Nash MA, 2002, CLIN CANCER RES, V8, P1754; Nash MA, 1999, CANCER RES, V59, P6192; NERI A, 1982, J NATL CANCER I, V68, P507; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Reed CC, 2002, GLYCOCONJUGATE J, V19, P249, DOI 10.1023/A:1025383913444; Reed CC, 2002, ONCOGENE, V21, P3688, DOI 10.1038/sj.onc.1205470; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; Schonherr E, 2001, J BIOL CHEM, V276, P40687, DOI 10.1074/jbc.M105426200; Tralhao JG, 2003, FASEB J, V17, P464, DOI 10.1096/fj.02-0534fje; Troup S, 2003, CLIN CANCER RES, V9, P207; Verbeek BS, 1998, FEBS LETT, V425, P145, DOI 10.1016/S0014-5793(98)00224-5; Wang WG, 2002, CANCER RES, V62, P6278; Wyckoff JB, 2000, CANCER RES, V60, P2504; Xaus J, 2001, BLOOD, V98, P2124, DOI 10.1182/blood.V98.7.2124; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	33	173	184	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1104	1110		10.1038/sj.onc.1208329	http://dx.doi.org/10.1038/sj.onc.1208329			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15690056				2022-12-17	WOS:000226749200017
J	Keshamouni, VG; Reddy, RC; Arenberg, DA; Joel, B; Thannickal, VJ; Kalemkerian, GP; Standiford, TJ				Keshamouni, VG; Reddy, RC; Arenberg, DA; Joel, B; Thannickal, VJ; Kalemkerian, GP; Standiford, TJ			Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer	ONCOGENE			English	Article						PPAR-gamma; NSCLC; Erk1/2; differentiation	HUMAN BREAST-CANCER; PROTEASOME-DEPENDENT DEGRADATION; PPAR-GAMMA; ESTROGEN-RECEPTOR; RETINOIC ACID; MAP KINASE; MEDIATED PROTEOLYSIS; PROTEIN-KINASE; COLON-CANCER; OXIDIZED LDL	The peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is a member of the nuclear hormone receptor superfamily of ligand-activated transcription factors and a crucial regulator of cellular differentiation. Differentiation-inducing and antiproliferative effects of PPAR-gamma suggest that PPAR-gamma agonists might be useful as effective anticancer agents. Few studies have examined the efficacy of these agonists in animal models of tumorigenesis, and their mechanism(s) of action are still not clear. Our studies indicate higher PPAR-gamma expression in primary tumors from non-small-cell lung cancer (NSCLC) patients when compared to normal surrounding tissue. The expression of PPAR-gamma was also observed in several NSCLC lines. The treatment of lung adenocarcinoma cells (A549) with troglitazone (Tro), a PPAR-gamma ligand, enhanced PPAR-gamma transcriptional activity and induced a dose-dependent inhibition of A549 cell growth. The observed growth arrest was predominantly due to the inhibition of cell proliferation without significant induction of apoptosis. Cell cycle analysis of Tro-treated cells revealed a cell cycle arrest at G(0)/G(1) with concomitant downregulation of G(0)/G(1) cyclins D and E. In addition, Tro treatment stimulated sustained Erk1/2 activation in A549 cells, suggesting the activation of a differentiation-inducing pathway. Furthermore, treatment of A549 tumor-bearing SCID mice with Tro or Pio inhibited primary tumor growth by 66.7% and significantly inhibited the number of spontaneous lung metastatic lesions. Collectively, our data demonstrate that activation of PPAR-gamma impedes lung tumor progression and suggest that PPAR-gamma ligands may serve as potential therapeutic agents for NSCLC.	Univ Michigan, Med Ctr, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Standiford, TJ (corresponding author), Univ Michigan, Med Ctr, Div Pulm & Crit Care Med, 6301 MSRB III,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	tstandif@med.umich.edu	Arenberg, Douglas/P-7251-2014	Arenberg, Douglas/0000-0001-7707-5092; Keshamouni, Venkateshwar/0000-0003-1947-791X	NCI NIH HHS [R01 CA094121, R01 CA094121-02, R01 CA094121-01A1] Funding Source: Medline; NHLBI NIH HHS [P050 HL60289, HL57243, K08 HL070068] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094121] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057243, K08HL070068, P50HL060289] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; BLOCH A, 1984, CANCER TREAT REP, V68, P199; Chang TH, 2000, CANCER RES, V60, P1129; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9; El Khissiin A, 1999, FEBS LETT, V448, P160, DOI 10.1016/S0014-5793(99)00343-9; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Gurdon JB, 1998, CELL, V95, P159, DOI 10.1016/S0092-8674(00)81747-X; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; Heaney AP, 2002, NAT MED, V8, P1281, DOI 10.1038/nm784; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kassam A, 1998, MOL CELL ENDOCRINOL, V141, P153, DOI 10.1016/S0303-7207(98)00085-9; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; KRANENBURG O, 1995, ONCOGENE, V10, P87; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Kubota T, 1998, CANCER RES, V58, P3344; Lambe KG, 1996, EUR J BIOCHEM, V239, P1, DOI 10.1111/j.1432-1033.1996.0001u.x; Mandell JW, 1998, AM J PATHOL, V153, P1411, DOI 10.1016/S0002-9440(10)65728-8; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Panigrahy D, 2002, J CLIN INVEST, V110, P923, DOI 10.1172/JCI200215634; PIERCE GB, 1988, CANCER RES, V48, P1996; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shi YH, 2002, P NATL ACAD SCI USA, V99, P2613, DOI 10.1073/pnas.052707099; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Syvala H, 1998, LIFE SCI, V63, P1505, DOI 10.1016/S0024-3205(98)00417-2; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; Watkins PB, 1998, NEW ENGL J MED, V338, P916, DOI 10.1056/NEJM199803263381314; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807	45	173	181	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					100	108		10.1038/sj.onc.1206885	http://dx.doi.org/10.1038/sj.onc.1206885			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712215				2022-12-17	WOS:000187895300011
J	Lorimore, SA; Coates, PJ; Wright, EG				Lorimore, SA; Coates, PJ; Wright, EG			Radiation-induced genomic instability and bystander effects: inter-related nontargeted effects of exposure to ionizing radiation	ONCOGENE			English	Review						radiation; genetic instability; bystander effects; clastogenic factors; inflammation	INDUCED CHROMOSOMAL INSTABILITY; IRRADIATED MAMMALIAN-CELLS; TRANSFERABLE CLASTOGENIC ACTIVITY; INFLAMMATORY-TYPE RESPONSES; MURINE HEMATOPOIETIC-CELLS; SISTER-CHROMATID EXCHANGES; ALPHA-PARTICLE IRRADIATION; APOPTOSIS IN-VIVO; A-BOMB SURVIVORS; DNA-DAMAGE	The paradigm of genetic alterations being restricted to direct DNA damage after exposure to ionizing radiation has been challenged by observations in which cells that are not exposed to ionizing radiation exhibit responses typically associated with direct radiation exposure. These effects are demonstrated in cells that are the descendants of irradiated cells (radiation-induced genomic instability) or in cells that are in contact with irradiated cells or receive certain signals from irradiated cells (radiation-induced bystander effects). There is accumulating evidence that radiation-induced genomic instability may be a consequence of, and in some cell systems may also produce, bystander interactions involving intercellular signalling, production of cytokines and free-radical generation. These processes are also features of inflammatory responses that are known to have the potential for both bystander-mediated and persisting damage as well as for conferring a predisposition to malignancy. Thus, radiation-induced genomic instability and untargeted bystander effects may reflect inter-related aspects of inflammatory-type responses to radiation-induced stress and injury and contribute to the variety of pathological consequences of radiation exposures.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland	University of Dundee	Wright, EG (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.		Coates, Philip J/H-6854-2019	Coates, Philip J/0000-0003-1518-6306				AUCLAIR C, 1990, ARCH BIOCHEM BIOPHYS, V278, P238, DOI 10.1016/0003-9861(90)90253-U; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; BABIOR BM, 1984, BLOOD, V64, P959; Babior BM, 2000, AM J MED, V109, P33, DOI 10.1016/S0002-9343(00)00481-2; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Belyakov OV, 2003, BRIT J CANCER, V88, P767, DOI 10.1038/sj.bjc.6600804; Belyakov OV, 2002, RADIAT PROT DOSIM, V99, P249, DOI 10.1093/oxfordjournals.rpd.a006775; Belyakov OV, 1999, INT J RADIAT BIOL, V75, P985, DOI 10.1080/095530099139746; Belyakov OV, 2001, BRIT J CANCER, V84, P674, DOI 10.1054/bjoc.2000.1665; BIRNBOIM HC, 1982, SCIENCE, V215, P1247, DOI 10.1126/science.6276978; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Brenner DJ, 2002, RADIAT PROT DOSIM, V99, P283, DOI 10.1093/oxfordjournals.rpd.a006785; Brockhaus F, 1999, ONCOGENE, V18, P6403, DOI 10.1038/sj.onc.1203058; BROWN DC, 1994, INT J RADIAT BIOL, V66, P151, DOI 10.1080/09553009414551051; Brune B, 1996, BIOCHEM BIOPH RES CO, V229, P396, DOI 10.1006/bbrc.1996.1816; Burns TF, 2001, ONCOGENE, V20, P4601, DOI 10.1038/sj.onc.1204484; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHANG WSP, 1992, MUTAT RES, V270, P191, DOI 10.1016/0027-5107(92)90130-T; Chiba S, 2002, BONE MARROW TRANSPL, V29, P935, DOI 10.1038/sj.bmt.1703568; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; Clutton SM, 1996, CELL DEATH DIFFER, V3, P141; COATES PJ, 2003, IN PRESS J PATHOL; Coen N, 2001, J PATHOL, V195, P293; Darveau R, 1999, NAT BIOTECHNOL, V17, P19, DOI 10.1038/5188; Deshpande A, 1996, RADIAT RES, V145, P260, DOI 10.2307/3578980; DIZDAROGLU M, 1993, CANCER RES, V53, P1269; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; ELKIND MM, 1959, NATURE, V184, P1293, DOI 10.1038/1841293a0; EMERIT I, 1994, FREE RADICAL BIO MED, V16, P99, DOI 10.1016/0891-5849(94)90246-1; EMERIT I, 1991, FREE RADICAL BIO MED, V10, P371, DOI 10.1016/0891-5849(91)90045-5; EMERIT I, 1994, J CANCER RES CLIN, V120, P558, DOI 10.1007/BF01221035; EMERIT I, 1990, METHOD ENZYMOL, V186, P555; Emerit I, 1997, MUTAT RES-FUND MOL M, V377, P239, DOI 10.1016/S0027-5107(97)00080-8; EMERIT I, 1995, HUM GENET, V96, P14, DOI 10.1007/BF00214180; Fei PW, 2002, CANCER RES, V62, P7316; Futaki M, 2001, TRENDS MOL MED, V7, P560, DOI 10.1016/S1471-4914(01)02178-5; Giles KM, 2000, BRIT J HAEMATOL, V109, P1, DOI 10.1046/j.1365-2141.2000.01805.x; GOH KO, 1968, RADIAT RES, V35, P171, DOI 10.2307/3572443; GORGOJO L, 1989, INT J RADIAT BIOL, V55, P619, DOI 10.1080/09553008914550661; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gregory CD, 2000, CURR OPIN IMMUNOL, V12, P27, DOI 10.1016/S0952-7915(99)00047-3; Grosovsky AJ, 1996, MOL CELL BIOL, V16, P6252; Hall EJ, 2001, PHYS MEDICA, V17, P21; Harper K, 1997, EXP HEMATOL, V25, P263; Hayashi T, 2003, INT J RADIAT BIOL, V79, P129, DOI 10.1080/0955300021000038662; Hibner U, 1994, Cell Death Differ, V1, P33; HICKMAN AW, 1994, CANCER RES, V54, P5797; HOLLOWELL JG, 1967, J S C MED ASS, V63, P437; HOLMBERG K, 1995, INT J RADIAT BIOL, V68, P245, DOI 10.1080/09553009514551171; Holmberg K, 1998, INT J RADIAT BIOL, V73, P21, DOI 10.1080/095530098142671; Ishikawa Y, 2001, J Environ Pathol Toxicol Oncol, V20, P311; Iwamoto KS, 1999, CARCINOGENESIS, V20, P1283, DOI 10.1093/carcin/20.7.1283; Iyer R, 2000, CANCER RES, V60, P1290; Kadhim MA, 2001, RADIAT RES, V155, P122, DOI 10.1667/0033-7587(2001)155[0122:LTGIIH]2.0.CO;2; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; KADHIM MA, 1994, LANCET, V344, P987, DOI 10.1016/S0140-6736(94)91643-8; KADHIM MA, 2002, 49 ANN M RAD RES SOC, P84; Knudsen LE, 2001, MUTAT RES-FUND MOL M, V482, P83, DOI 10.1016/S0027-5107(01)00213-5; Lefevre SH, 2001, ONCOGENE, V20, P8092, DOI 10.1038/sj.onc.1205009; Lehnert BE, 1997, ENVIRON HEALTH PERSP, V105, P1095, DOI 10.2307/3433515; Lehnert BE, 1997, CANCER RES, V57, P2164; LI CY, 1994, MOL CELL BIOL, V14, P4373, DOI 10.1128/MCB.14.7.4373; LI CY, 1992, MOL CARCINOGEN, V5, P270, DOI 10.1002/mc.2940050407; Limoli CL, 1998, CANCER RES, V58, P3712; Limoli CL, 1997, CANCER RES, V57, P4048; Limoli CL, 1998, PHOTOCHEM PHOTOBIOL, V67, P233, DOI 10.1562/0031-8655(1998)067<0233:IOCAAD>2.3.CO;2; Limoli CL, 2001, FREE RADICAL BIO MED, V31, P10, DOI 10.1016/S0891-5849(01)00542-1; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; Little JB, 1998, INT J RADIAT BIOL, V74, P663, DOI 10.1080/095530098140925; Little JB, 1997, RADIAT RES, V148, P299, DOI 10.2307/3579514; LITTLE JB, 1990, INT J RADIAT ONCOL, V19, P1425, DOI 10.1016/0360-3016(90)90354-M; LITTLEFIELD LG, 1969, RADIOLOGY, V93, P879, DOI 10.1148/93.4.879; LLOYD DC, 1985, INT J RADIAT BIOL, V47, P433, DOI 10.1080/713860600; Lorimore SA, 1998, P NATL ACAD SCI USA, V95, P5730, DOI 10.1073/pnas.95.10.5730; Lorimore SA, 2003, INT J RADIAT BIOL, V79, P15, DOI 10.1080/0955300021000045664; Lorimore SA, 2001, ONCOGENE, V20, P7085, DOI 10.1038/sj.onc.1204903; Lyng FM, 2000, BRIT J CANCER, V83, P1223, DOI 10.1054/bjoc.2000.1433; Lyng FM, 2002, RADIAT RES, V157, P365, DOI 10.1667/0033-7587(2002)157[0365:IOAICE]2.0.CO;2; Maeda H, 1998, BIOCHEMISTRY-MOSCOW+, V63, P854; MARDER BA, 1993, MOL CELL BIOL, V13, P6667, DOI 10.1128/MCB.13.11.6667; Meyn MS, 1997, CURR TOP MICROBIOL, V221, P71; Mohrenweiser HW, 2000, RADIAT RES, V154, P722; Morgan WF, 2002, MUTAT RES-FUND MOL M, V504, P91, DOI 10.1016/S0027-5107(02)00083-0; Mothersill C, 2000, BRIT J CANCER, V82, P1740; Mothersill C, 1998, INT J RADIAT BIOL, V74, P673, DOI 10.1080/095530098140934; Mothersill C, 2000, INT J RADIAT BIOL, V76, P799, DOI 10.1080/09553000050028959; Mothersill C, 2000, Radiats Biol Radioecol, V40, P615; Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Mothersill C, 2001, CARCINOGENESIS, V22, P1465, DOI 10.1093/carcin/22.9.1465; Mothersill CE, 1999, CARCINOGENESIS, V20, P2273, DOI 10.1093/carcin/20.12.2273; Nagar S, 2003, CANCER RES, V63, P324; Nagasawa H, 1999, RADIAT RES, V152, P552, DOI 10.2307/3580153; NAGASAWA H, 1992, CANCER RES, V52, P6394; Narayanan PK, 1997, CANCER RES, V57, P3963; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Nebert DW, 2000, CLIN CHEM LAB MED, V38, P857, DOI 10.1515/CCLM.2000.124; Neriishi K, 2001, INT J RADIAT BIOL, V77, P475, DOI 10.1080/09553000010024911; PAMPFER S, 1989, INT J RADIAT BIOL, V55, P85, DOI 10.1080/09553008914550091; PANT GS, 1977, HIROSHIMA J MED SCI, V26, P149; PARCHMENT RE, 1992, CYTOTECHNOLOGY, V10, P93, DOI 10.1007/BF00570888; PARSONS WB, 1954, CANCER-AM CANCER SOC, V7, P179, DOI 10.1002/1097-0142(195401)7:1<179::AID-CNCR2820070120>3.0.CO;2-A; Pharoah PDP, 2002, NAT GENET, V31, P33, DOI 10.1038/ng853; Phillipson RP, 2002, FREE RADICAL BIO MED, V32, P474, DOI 10.1016/S0891-5849(01)00829-2; Ponnaiya B, 1997, RADIAT RES, V147, P121, DOI 10.2307/3579411; Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087; PUCK TT, 1956, J EXP MED, V103, P653, DOI 10.1084/jem.103.5.653; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; ROSIN MP, 1994, CANCER RES, V54, pS1929; SCOTT D, 1969, CELL TISSUE KINET, V2, P295, DOI 10.1111/j.1365-2184.1969.tb00239.x; SEYMOUR C, 1992, MUTAT RES, V267, P19, DOI 10.1016/0027-5107(92)90107-D; Seymour CB, 2000, RADIAT RES, V153, P508, DOI 10.1667/0033-7587(2000)153[0508:RCOBAT]2.0.CO;2; SEYMOUR CB, 1986, INT J RADIAT BIOL, V50, P167, DOI 10.1080/09553008614550541; SHACTER E, 1988, CARCINOGENESIS, V9, P2297, DOI 10.1093/carcin/9.12.2297; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Simons J. W. I. M., 1995, Critical Reviews in Oncogenesis, V6, P261; TAPPEL AL, 1973, FED PROC, V32, P1870; THOMPSON LH, 1969, INT J RADIAT BIOL RE, V15, P347, DOI 10.1080/09553006914550571; TROTT KR, 1970, INT J RADIAT BIOL RE, V17, P483, DOI 10.1080/09553007014550591; Uchimura E, 2000, J LEUKOCYTE BIOL, V67, P780, DOI 10.1002/jlb.67.6.780; Ullrich RL, 1998, INT J RADIAT BIOL, V74, P747, DOI 10.1080/095530098141023; Wallace M, 2001, ONCOGENE, V20, P3597, DOI 10.1038/sj.onc.1204496; Wang S, 2000, P NATL ACAD SCI USA, V97, P1584, DOI 10.1073/pnas.97.4.1584; Watson GE, 1997, INT J RADIAT BIOL, V71, P497, DOI 10.1080/095530097143824; Watson GE, 2000, CANCER RES, V60, P5608; Watson GE, 1996, INT J RADIAT BIOL, V69, P175, DOI 10.1080/095530096146002; Watson GE, 2001, INT J RADIAT BIOL, V77, P409, DOI 10.1080/09553000010028476; WEITBERG AB, 1983, NEW ENGL J MED, V308, P26, DOI 10.1056/NEJM198301063080107; WEITZMAN SA, 1981, SCIENCE, V212, P546, DOI 10.1126/science.6259738; WEITZMAN SA, 1990, BLOOD, V76, P655; Wright EG, 2002, INT CONGR SER, V1236, P271, DOI 10.1016/S0531-5131(01)00773-7; Wright EG, 1999, J PATHOL, V187, P19, DOI 10.1002/(SICI)1096-9896(199901)187:1<19::AID-PATH233>3.0.CO;2-1; Wu LJ, 1999, P NATL ACAD SCI USA, V96, P4959, DOI 10.1073/pnas.96.9.4959; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797; Zhou HN, 2001, P NATL ACAD SCI USA, V98, P14410, DOI 10.1073/pnas.251524798	138	173	189	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 13	2003	22	45					7058	7069		10.1038/sj.onc.1207044	http://dx.doi.org/10.1038/sj.onc.1207044			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557811				2022-12-17	WOS:000185903900011
J	Claus, R; Lubbert, M				Claus, R; Lubbert, M			Epigenetic targets in hematopoietic malignancies	ONCOGENE			English	Review						DNA methylation; chromatin; myeloid leukemia; myelodysplastic syndromes	DE-NOVO METHYLATION; RISK MYELODYSPLASTIC SYNDROME; ACUTE PROMYELOCYTIC LEUKEMIA; RECRUIT HISTONE DEACETYLASE; KINASE INHIBITOR P15(INK4B); ACUTE MYELOID-LEUKEMIA; DNA METHYLATION; CPG ISLAND; PROMOTER METHYLATION; HYPOMETHYLATING AGENT	Frequent genetic alterations in hematopoietic neoplasias ( chromosomal translocations, point mutations, etc.) have provided biologic targets for the development of effective novel therapies. A rapidly increasing body of knowledge provides evidence also for multiple epigenetic alterations in these disorders, which can complement or even precede genetic aberrations. Gene inactivation ('silencing') of tumor suppressor and growth inhibitory genes (e.g. the cyclin-dependent kinase inhibitors p16, p15, p21) is frequently mediated by DNA methylation of gene promoters. The acetylation state of histones ( functionally linked to the DNA methylation state by the methylcytosine binding protein 2, recruiting histone deacetylases) provides a second major epigenetic silencing mechanism. Therapeutic reversal strategies are being developed for acute leukemias, myelodysplastic syndromes and malignant lymphomas. Since the discovery of the DNA methyltransferase (Dnmt) inhibitory activity of two azanucleosides (5-azacytidine, 5-aza-2'-deoxycytidine/ decitabine) even at doses with minimal nonhematologic toxicity, both have been clinically studied in several myeloid neoplasias, particularly in elderly patients unable to tolerate aggressive treatment. Further development of agents counteracting aberrant methylation is directed at more targeted approaches, for example, antisense molecules against Dnmts. Histone deacetylases (HDACs) can be inhibited by numerous compounds ( sodium phenylbutyrate, valproic acid, novel compounds such as depsipeptide), which have entered the clinical arena in similar indications as Dnmt inhibitors. Impressive effects of HDAC inhibition in acute promyelocytic leukemia models (PML/RARA expression) translate the finding of HDAC recruitment by this chimeric transcription factor to its target genes. The recent discovery of recruitment by PML/RARA also of Dnmt activity to the retinoic acid receptor-beta promoter makes it an interesting candidate for Dnmt inhibitors. Studies combining a 're-expressor' strategy with inhibitors of Dnmts and HDACs are underway. Thus, resensitization to biological agents such as retinoids, colony-stimulating factors and other differentiation inducers may be envisioned.	Univ Freiburg, Med Ctr, Dept Internal Med 1, Div Hematol Oncol, D-79106 Freiburg, Germany	University of Freiburg	Lubbert, M (corresponding author), Univ Freiburg, Med Ctr, Dept Internal Med 1, Div Hematol Oncol, Hugstetter Str 55, D-79106 Freiburg, Germany.	Luebbert@mm11.ukl.uni-freiburg.de	Claus, Rainer/AAZ-5606-2020	Claus, Rainer/0000-0003-2617-8766				Aoki E, 2000, LEUKEMIA, V14, P586, DOI 10.1038/sj.leu.2401719; Au WY, 2003, BRIT J HAEMATOL, V120, P1062, DOI 10.1046/j.1365-2141.2003.04194.x; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; Batova A, 1997, CANCER RES, V57, P832; Baur AS, 1999, BLOOD, V94, P1773, DOI 10.1182/blood.V94.5.1773.417a12_1773_1781; BAYLIN SB, 1986, CANCER RES, V46, P2917; BAYLIN SB, 1987, BLOOD, V70, P412; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Camacho LH, 2001, BLOOD, V98, p460A; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chen H, 2002, CHINESE MED J-PEKING, V115, P987; Chim CS, 2002, HEMATOL ONCOL, V20, P167, DOI 10.1002/hon.694; Chim CS, 2001, J CLIN ONCOL, V19, P2033, DOI 10.1200/JCO.2001.19.7.2033; CLAUS R, 2003, UNPUB; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; Daskalakis M, 2002, BLOOD, V100, P2957, DOI 10.1182/blood.V100.8.2957; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Esteller M, 2001, CANCER RES, V61, P4689; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Fan Hongtao, 2000, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V8, P271; Garber K, 2002, J NATL CANCER I, V94, P874; Garcia MJ, 2002, AM J PATHOL, V161, P1007, DOI 10.1016/S0002-9440(10)64261-7; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gore SD, 2001, CLIN CANCER RES, V7, P2330; Goto T, 1998, MICROBIOL MOL BIOL R, V62, P362, DOI 10.1128/MMBR.62.2.362-378.1998; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446; He LZ, 2001, J CLIN INVEST, V108, P1321, DOI 10.1172/JCI200111537; Herman JG, 1997, CANCER RES, V57, P837; Hoshino K, 2002, BRIT J HAEMATOL, V117, P531, DOI 10.1046/j.1365-2141.2002.03451.x; Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0; Issa JP, 2001, BLOOD, V98, p594A; ISSA JP, 1997, LEUKEMIA S1, V11, P7; Issa JPJ, 1997, CANCER RES, V57, P1678; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; JAHANGEER S, 1982, BIOCHEM BIOPH RES CO, V108, P1434, DOI 10.1016/S0006-291X(82)80067-3; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134; Klisovic MI, 2003, LEUKEMIA, V17, P350, DOI 10.1038/sj.leu.2402776; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; KUNDGEN A, 2003, LEUK RES S1, V27, pS104; Leone G, 2002, HAEMATOLOGICA, V87, P1324; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lubbert M, 2002, BLOOD, V100, p268B; Lubbert M, 2001, BRIT J HAEMATOL, V114, P349, DOI 10.1046/j.1365-2141.2001.02933.x; Lubbert M, 2000, CURR TOP MICROBIOL, V249, P135; Lubbert M, 1996, BLOOD, V87, P447, DOI 10.1182/blood.V87.2.447.bloodjournal872447; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; Martinez-Delgado B, 1998, LEUKEMIA, V12, P937, DOI 10.1038/sj.leu.2401009; Melki JR, 1999, CANCER RES, V59, P3730; Miller CB, 2001, BLOOD, V98, p622A; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; Najfeld V, 2002, BLOOD, V100, p97A; Ng MHL, 1997, BLOOD, V89, P2500, DOI 10.1182/blood.V89.7.2500; Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465; Nguyen TT, 2000, BLOOD, V95, P2990, DOI 10.1182/blood.V95.9.2990.009k08_2990_2992; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; PFEIFER GP, 1988, CANCER LETT, V39, P185, DOI 10.1016/0304-3835(88)90103-6; PINTO A, 1984, LANCET, V2, P867; Preisler HD, 2001, LEUKEMIA, V15, P1589, DOI 10.1038/sj.leu.2402211; Quesnel B, 1998, BLOOD, V91, P2985, DOI 10.1182/blood.V91.8.2985.2985_2985_2990; RICHEL DJ, 1991, BRIT J CANCER, V64, P144, DOI 10.1038/bjc.1991.258; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Roman-Gomez J, 2002, BLOOD, V99, P2291, DOI 10.1182/blood.V99.7.2291; Rush LJ, 2001, BLOOD, V97, P3226, DOI 10.1182/blood.V97.10.3226; Sakashita K, 2001, J CLIN INVEST, V108, P1195, DOI 10.1172/JCI200113030; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Sato M, 2002, ONCOGENE, V21, P4822, DOI 10.1038/sj.onc.1205581; Shaker S, 2003, LEUKEMIA RES, V27, P437, DOI 10.1016/S0145-2126(02)00222-9; Shen LL, 2002, BLOOD, V100, P3432, DOI 10.1182/blood-2002-07-1990; Sigalotti L, 2003, BLOOD, V101, P4644, DOI 10.1182/blood-2002-11-3458; Silverman LR, 2002, J CLIN ONCOL, V20, P2429, DOI 10.1200/JCO.2002.04.117; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; Sun BD, 2001, CANCER RES, V61, P6931; Teofili L, 2001, BLOOD, V98, P495, DOI 10.1182/blood.V98.2.495; Teofili L, 2000, EXP HEMATOL, V28, P519, DOI 10.1016/S0301-472X(00)00139-9; Tien HF, 2001, BRIT J HAEMATOL, V112, P148, DOI 10.1046/j.1365-2141.2001.02496.x; Toyota M, 2001, BLOOD, V97, P2823, DOI 10.1182/blood.V97.9.2823; Toyota M, 1999, CANCER RES, V59, P4535; Uchida T, 1997, BLOOD, V90, P1403, DOI 10.1182/blood.V90.4.1403.1403_1403_1409; WAHLFORS J, 1992, BLOOD, V80, P2074; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956; Wijermans PW, 1997, LEUKEMIA, V11, P1, DOI 10.1038/sj.leu.2400526; Wong IHN, 2000, BLOOD, V95, P1942, DOI 10.1182/blood.V95.6.1942	92	173	183	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6489	6496		10.1038/sj.onc.1206814	http://dx.doi.org/10.1038/sj.onc.1206814			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528273				2022-12-17	WOS:000185700700005
J	Streit, M; Detmar, M				Streit, M; Detmar, M			Angiogenesis, lymphangiogenesis, and melanoma metastasis	ONCOGENE			English	Review						VEGF; FGF; LYVE-1; VEGF-C	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; INCREASES TUMOR-GROWTH; LYMPH-NODE METASTASIS; IN-SITU HYBRIDIZATION; MALIGNANT-MELANOMA; FACTOR EXPRESSION; FACTOR-C; TRANSFORMED PHENOTYPE; INHIBIT ANGIOGENESIS	The induction of angiogenesis is a critical point in the development of most human tumors - including melanomas. Some of the earliest studies in the field of tumor angiogenesis showed that transplantation of human melanoma fragments into the hamster cheek pouch stimulated blood vessel growth. Since then, numerous studies have demonstrated that human melanomas also induce angiogenesis. The prognostic importance of the degree of melanoma vascularization, however, has remained controversial. Elevated expression of several angiogenic factors, including vascular endothelial growth factor, basic fibroblast growth factor, and interleukin-8, has been detected in primary cutaneous melanomas, and the importance of these mediators in promoting melanoma angiogenesis and metastasis has been confirmed in tumor xenotransplant models. Based upon these findings, several clinical trials of angiogenesis inhibitors have been initiated in human melanoma patients and are currently underway. Recent experimental evidence indicates that tumor-associated lymphangiogenesis also plays an important role in mediating tumor spread to regional lymph nodes. These observations have important implications for prognosis and treatment of human melanomas.	Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Dept Dermatol, Charlestown, MA 02129 USA; Berlex Biosci, Richmond, CA 94804 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University	Detmar, M (corresponding author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA.	michael.detmar@cbrc2.mgh.harvard.edu			NCI NIH HHS [CA91861, CA86410, CA69184] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069184, R01CA086410, R01CA091861] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achen MG, 2001, J PATHOL, V193, P147, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH757>3.0.CO;2-G; Ahmed NU, 1997, MELANOMA RES, V7, P299, DOI 10.1097/00008390-199708000-00004; BARNHILL RL, 1993, AM J PATHOL, V143, P99; Barnhill RL, 1996, BRIT J DERMATOL, V135, P898, DOI 10.1046/j.1365-2133.1996.d01-1092.x; BARNHILL RL, 1992, LAB INVEST, V67, P331; Bayer-Garner IB, 1999, MODERN PATHOL, V12, P770; BECKER D, 1992, ONCOGENE, V7, P2303; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; Bhargava P, 1999, CLIN CANCER RES, V5, P1989; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Buerkle MA, 2002, BRIT J CANCER, V86, P788, DOI 10.1038/sj.bjc.6600141; BUSAM KJ, 1995, AM J PATHOL, V147, P1049; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CARNOCHAN P, 1991, BRIT J CANCER, V64, P102, DOI 10.1038/bjc.1991.250; Cascinelli N, 2000, EXP DERMATOL, V9, P439, DOI 10.1034/j.1600-0625.2000.009006439.x; Claffey KP, 1996, CANCER RES, V56, P172; DADRAS SS, 2003, IN PRESS AM J PATHOL; Detmar M, 1996, J INVEST DERMATOL, V106, P207, DOI 10.1111/1523-1747.ep12340457; Detmar M, 2002, J EXP MED, V196, P713, DOI 10.1084/jem.20021346; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; Dreau D, 2000, ONCOL RES, V12, P241; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Eisen T, 2000, BRIT J CANCER, V82, P812, DOI 10.1054/bjoc.1999.1004; Erhard H, 1997, MELANOMA RES, V7, pS19; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FOLKMAN J, 1975, ANN INTERN MED, V82, P96, DOI 10.7326/0003-4819-82-1-96; Folkman J, 2002, CANCER CELL, V1, P113, DOI 10.1016/S1535-6108(02)00038-7; FORSBERG K, 1993, P NATL ACAD SCI USA, V90, P393, DOI 10.1073/pnas.90.2.393; GITAYGOREN H, 1993, BIOCHEM BIOPH RES CO, V190, P702, DOI 10.1006/bbrc.1993.1106; Graeven U, 2001, CANCER RES, V61, P7282; Graeven U, 1999, J CANCER RES CLIN, V125, P621, DOI 10.1007/s004320050325; GRAHAM CH, 1994, AM J PATHOL, V145, P510; Grant SW, 1998, CANCER DETECT PREV, V22, P185, DOI 10.1046/j.1525-1500.1998.0oa18.x; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hartmann A, 1999, CANCER RES, V59, P1578; Hawighorst T, 2001, EMBO J, V20, P2631, DOI 10.1093/emboj/20.11.2631; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Hendrix MJC, 2002, CANCER RES, V62, P665; Huang SY, 1996, CLIN CANCER RES, V2, P1969; Huang SY, 2002, AM J PATHOL, V161, P125, DOI 10.1016/S0002-9440(10)64164-8; HUBLER WR, 1976, CANCER, V38, P187, DOI 10.1002/1097-0142(197607)38:1<187::AID-CNCR2820380129>3.0.CO;2-D; Hwu WJ, 2002, J CLIN ONCOL, V20, P2610, DOI 10.1200/JCO.2002.09.034; Hwu WJ, 2000, ONCOLOGY-NY, V14, P25; Ilmonen S, 1999, MELANOMA RES, V9, P273; Karpanen T, 2001, CANCER RES, V61, P1786; Kashani-Sabet M, 2002, J CLIN ONCOL, V20, P1826, DOI 10.1200/JCO.2002.07.082; Kumar CC, 2001, CANCER RES, V61, P2232; Kusters B, 2002, CANCER RES, V62, P341; Lacal PM, 2000, J INVEST DERMATOL, V115, P1000, DOI 10.1046/j.1523-1747.2000.00199.x; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; Li YW, 2002, J EXP MED, V195, P1575, DOI 10.1084/jem.20020072; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; Liu B, 1995, BIOCHEM BIOPH RES CO, V217, P721, DOI 10.1006/bbrc.1995.2832; Lode HN, 1999, P NATL ACAD SCI USA, V96, P1591, DOI 10.1073/pnas.96.4.1591; Luca M, 1997, AM J PATHOL, V151, P1105; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Marcoval J, 1997, J CUTAN PATHOL, V24, P212, DOI 10.1111/j.1600-0560.1997.tb01583.x; Miao WM, 2001, CANCER RES, V61, P7830; Mihm M C Jr, 1975, Semin Oncol, V2, P105; Min HY, 1996, CANCER RES, V56, P2428; Morin MJ, 2000, ONCOGENE, V19, P6574, DOI 10.1038/sj.onc.1204102; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Naglich JG, 2001, CANCER RES, V61, P8480; Nesbit M, 1999, ONCOGENE, V18, P6469, DOI 10.1038/sj.onc.1203066; Nurnberg W, 1999, J PATHOL, V189, P546, DOI 10.1002/(SICI)1096-9896(199912)189:4<546::AID-PATH487>3.0.CO;2-L; Oliver G, 2002, GENE DEV, V16, P773, DOI 10.1101/gad.975002; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Papoutsi M, 2000, HISTOCHEM CELL BIOL, V114, P373; Plum SM, 2000, VACCINE, V19, P1294, DOI 10.1016/S0264-410X(00)00210-3; Posey JA, 2001, CANCER BIOTHER RADIO, V16, P125, DOI 10.1089/108497801300189218; POTGENS AJG, 1995, AM J PATHOL, V146, P197; Prevo R, 2001, J BIOL CHEM, V276, P19420, DOI 10.1074/jbc.M011004200; Rak J, 2002, CANCER RES, V62, P1931; REED JA, 1994, AM J PATHOL, V144, P329; Reiher FK, 2002, INT J CANCER, V98, P682, DOI 10.1002/ijc.10247; Rofstad EK, 2000, CANCER RES, V60, P4932; Rofstad EK, 2002, BRIT J CANCER, V86, P301, DOI 10.1038/sj.bjc.6600052; Saeki H, 1999, J IMMUNOL, V162, P2472; Salven P, 1997, BRIT J CANCER, V76, P930, DOI 10.1038/bjc.1997.486; Salven P, 1998, AM J PATHOL, V153, P103, DOI 10.1016/S0002-9440(10)65550-2; Seftor REB, 2001, CANCER RES, V61, P6322; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Skobe M, 2001, AM J PATHOL, V159, P893, DOI 10.1016/S0002-9440(10)61765-8; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; SRIVASTAVA A, 1988, AM J PATHOL, V133, P419; SRIVASTAVA A, 1986, EUR J CANCER CLIN ON, V22, P1205, DOI 10.1016/0277-5379(86)90322-6; St Croix B, 2000, SCIENCE, V289, P1197; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Stacker SA, 2002, FASEB J, V16, P922, DOI 10.1096/fj.01-0945rev; STENZINGER W, 1983, EUR J CANCER CLIN ON, V19, P649, DOI 10.1016/0277-5379(83)90181-5; Straume O, 1999, INT J ONCOL, V15, P595; Straume O, 2002, AM J PATHOL, V160, P1009, DOI 10.1016/S0002-9440(10)64922-X; Straume O, 2001, AM J PATHOL, V159, P223, DOI 10.1016/S0002-9440(10)61688-4; Streit M, 2002, CANCER RES, V62, P2004; Ugurel S, 2001, J CLIN ONCOL, V19, P577, DOI 10.1200/JCO.2001.19.2.577; Vlaykova T, 1999, MELANOMA RES, V9, P59, DOI 10.1097/00008390-199902000-00008; WARREN BA, 1966, LAB INVEST, V15, P464; Weninger W, 1996, LAB INVEST, V75, P647; Wigle JT, 2002, EMBO J, V21, P1505, DOI 10.1093/emboj/21.7.1505; Wild R, 2000, BRIT J CANCER, V83, P1077, DOI 10.1054/bjoc.2000.1439; Wiley HE, 2001, J NATL CANCER I, V93, P1638, DOI 10.1093/jnci/93.21.1638; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159; Yu JL, 2002, CANCER RES, V62, P1838; Yu JL, 2001, AM J PATHOL, V158, P1325, DOI 10.1016/S0002-9440(10)64083-7; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765	110	173	279	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3172	3179		10.1038/sj.onc.1206457	http://dx.doi.org/10.1038/sj.onc.1206457			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789293				2022-12-17	WOS:000183096600019
J	Fedele, M; Battista, S; Kenyon, L; Baldassarre, G; Fidanza, V; Klein-Szanto, AJP; Parlow, AF; Visone, R; Pierantoni, GM; Outwater, E; Santoro, M; Croce, CM; Fusco, A				Fedele, M; Battista, S; Kenyon, L; Baldassarre, G; Fidanza, V; Klein-Szanto, AJP; Parlow, AF; Visone, R; Pierantoni, GM; Outwater, E; Santoro, M; Croce, CM; Fusco, A			Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas	ONCOGENE			English	Article						transgenic mice; HMGA2; pituitary adenomas; Pit-1; tumorigenesis	EXPRESS HIGH-LEVELS; GROUP PROTEIN GENE; NEOPLASTIC TRANSFORMATION; MESENCHYMAL TUMORS; HMGI(Y) PROTEINS; C GENE; CELLS; LIPOMAS; FAMILY; REARRANGEMENTS	Overexpression of the HMGA2 gene is a common feature of neoplastic cells both in experimental and human models. Intragenic and extragenic HMGA2 rearrangements responsible for HMGA2 gene overexpression have been frequently detected in human benign tumours of mesenchymal origin. To better understand the role of HMGA2 overexpression in human tumorigenesis, we have generated transgenic mice carrying the HMGA2 gene under the transcriptional control of the cytomegalovirus promoter. High expression of the transgene was demonstrated in all the mouse tissues analysed, whereas no expression of the endogenous HMGA2 gene was detected in the same tissues from wild-type mice. In this study, two indipendent lines of transgenic mice have been generated. By 6 months of age, 85% of female animals of both transgenic lines developed pituitary adenomas secreting prolactin and growth hormone. The transgenic males developed the same phenotype with a lower penetrance (40%) and a longer latency period (about 18 months). Therefore, these data demonstrate that the overexpression of HMGA2 leads to the onset of mixed growth hormone/prolactin cell pituitary adenomas. These transgenic mice may represent an important tool for the study of this kind of neoplasia.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Fac Med & Chirurg Napoli, Ctr Endocrinol & Oncol Sperimentale,CNR, I-80131 Naples, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Thomas Jefferson Univ Hosp, Dept Pathol, Philadelphia, PA 19107 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Harbor UCLA Med Ctr, Natl Hormone & Pituitary Program, Torrance, CA 90509 USA; Thomas Jefferson Univ, Jefferson Med Coll, Image Ctr, Philadelphia, PA 19107 USA; Univ Catanzaro, Dipartimento Med Sperimentale & Clin, Fac Med & Chirurg Catanzaro, Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Jefferson University; Jefferson University; Fox Chase Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Jefferson University; Magna Graecia University of Catanzaro	Fusco, A (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Fac Med & Chirurg Napoli, Ctr Endocrinol & Oncol Sperimentale,CNR, Via Pansini 5, I-80131 Naples, Italy.		Young, Richard A/F-6495-2012; Pierantoni, Giovanna Maria/O-7527-2015; Baldassarre, Gustavo/K-1350-2016; visone, rosa/K-7910-2016; Battista, Sabrina/AAY-2981-2020; Fedele, Monica/C-1417-2015	Young, Richard A/0000-0001-8855-8647; Pierantoni, Giovanna Maria/0000-0003-4078-8528; Baldassarre, Gustavo/0000-0002-9750-8825; Battista, Sabrina/0000-0001-5899-9759; Fedele, Monica/0000-0002-9171-1312; Fusco, Alfredo/0000-0003-3332-5197; Kenyon, Lawrence/0000-0002-3719-9565; VISONE, Rosa/0000-0002-4993-0220	NCI NIH HHS [P01 CA 76259, P30 CA 56036] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA056036, P01CA076259] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe N, 1999, CANCER RES, V59, P1169; Abe N, 2000, CANCER RES, V60, P3117; Anand A, 2000, NAT GENET, V24, P377, DOI 10.1038/74207; Arlotta P, 2000, J BIOL CHEM, V275, P14394, DOI 10.1074/jbc.M000564200; ASHAR HR, 1995, CELL, V82, P57; Bandiera A, 1998, CANCER RES, V58, P426; Battista S, 1999, CANCER RES, V59, P4793; BAUER K, 1990, ENDOCRINOLOGY, V127, P1224, DOI 10.1210/endo-127-3-1224; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Bol S, 1996, CANCER GENET CYTOGEN, V90, P88, DOI 10.1016/0165-4608(96)00062-3; Chiappetta G, 1998, CANCER RES, V58, P4193; Chiappetta G, 1996, ONCOGENE, V13, P2439; Chiappetta G, 2001, INT J CANCER, V91, P147, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1033>3.3.CO;2-M; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; Fedele M, 2001, CARCINOGENESIS, V22, P1583, DOI 10.1093/carcin/22.10.1583; Fedele M, 1996, CANCER RES, V56, P1896; Fejzo MS, 1996, GENE CHROMOSOME CANC, V17, P1, DOI 10.1002/(SICI)1098-2264(199609)17:1<1::AID-GCC1>3.0.CO;2-0; Finelli P, 2000, INT J CANCER, V86, P344, DOI 10.1002/(SICI)1097-0215(20000501)86:3<344::AID-IJC7>3.0.CO;2-8; FINELLI P, 2002, IN PRESS CANC RES; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; HOGAN B, 1983, NATURE, V306, P313, DOI 10.1038/306313a0; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; KAZMIERCZAK B, 1995, CANCER RES, V55, P2497; Nagpal S, 1999, J BIOL CHEM, V274, P22563, DOI 10.1074/jbc.274.32.22563; PellegriniBouiller I, 1997, HORM RES, V47, P251, DOI 10.1159/000185472; Rogalla P, 1996, AM J PATHOL, V149, P775; Rommel B, 1997, LEUKEMIA LYMPHOMA, V26, P603, DOI 10.3109/10428199709050896; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; Spady TJ, 1999, ENDOCRINE, V11, P217, DOI 10.1385/ENDO:11:3:217; Staats B, 1996, BREAST CANCER RES TR, V38, P299, DOI 10.1007/BF01806149; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; TSOKOS M, 1987, AM J PATHOL, V128, P484; Weil RJ, 1998, CANCER RES, V58, P4715; Wood LJ, 2000, CANCER RES, V60, P4256; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	36	173	178	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3190	3198		10.1038/sj.onc.1205428	http://dx.doi.org/10.1038/sj.onc.1205428			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082634				2022-12-17	WOS:000175373600010
J	Thyrell, L; Erickson, S; Zhivotovsky, B; Pokrovskaja, K; Sangfelt, O; Castro, J; Einhorn, S; Grander, D				Thyrell, L; Erickson, S; Zhivotovsky, B; Pokrovskaja, K; Sangfelt, O; Castro, J; Einhorn, S; Grander, D			Mechanisms of Interferon-alpha induced apoptosis in malignant cells	ONCOGENE			English	Article						interferon; apoptosis; caspase; mitochondria	CASPASE ACTIVATION; MULTIPLE-MYELOMA; PROTEIN-KINASE; UP-REGULATION; FAS LIGAND; IFN-GAMMA; B-CELLS; DEATH; INDUCTION; EXPRESSION	Interferon alpha (IFNalpha) has been used in the treatment of several types of cancer for almost 30 years, yet the mechanism(s) responsible for its anti-tumoral action remains unknown. A variety of cellular responses, including inhibition of cell growth and induction of apoptosis are induced by IFNs, and apoptotic induction by this cytokine has been proposed to be of importance for both its anti-tumoral in addition to its anti-viral responses. The aim of the present study was to delineate the pathways activated during IFNalpha-induced apoptosis in malignant cell lines. We found that apoptosis induced by IFNalpha was associated with activation of caspases-1, -2, -3, -8 and -9 and that this activation was a critical event. Caspase-3 activation was dependent on activity of caspases-8 and -9, moreover, activation of caspase-8 seems to be the upstream event in IFNalpha-induced caspase cascade. We also found loss of mitochondrial membrane potential as well as release of cytochrome c post IFN-treatment, clearly implicating the involvement of mitochondria in IFN-mediated apoptosis. Furthermore, IFNalpha-induced apoptosis was found to be independent on interactions between the Fas-receptor and its ligand. These studies form the basis for further investigations aiming to improve IFN therapy and the development of future strategies to overcome the IFN resistance observed in some malignancies.	Karolinska Hosp & Inst, Dept Pathol & Oncol, CCK, Res Lab Radiumhemmet, S-17176 Stockholm, Sweden; Karolinska Inst, Inst Environm Med, Dept Toxicol, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Grander, D (corresponding author), Karolinska Hosp & Inst, Dept Pathol & Oncol, CCK, Res Lab Radiumhemmet, S-17176 Stockholm, Sweden.		Zhivotovsky, Boris/A-4346-2014	Zhivotovsky, Boris/0000-0002-2238-3482; Pokrovskaja Tamm, Katja/0000-0001-6359-1256				Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bernassola F, 1999, CELL DEATH DIFFER, V6, P652, DOI 10.1038/sj.cdd.4400537; CASTRO J, 1993, CYTOMETRY, V14, P793, DOI 10.1002/cyto.990140712; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; Dai CH, 1999, BLOOD, V93, P3309, DOI 10.1182/blood.V93.10.3309.410k04_3309_3316; Dai CH, 1998, BLOOD, V91, P1235, DOI 10.1182/blood.V91.4.1235; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Gil J, 2000, ONCOGENE, V19, P3665, DOI 10.1038/sj.onc.1203710; GRANDER D, 1993, EUR J CANCER, V14, P1940; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Kaser A, 1999, CYTOKINE, V11, P736, DOI 10.1006/cyto.1998.0484; Kataoka T, 1998, J IMMUNOL, V161, P3936; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; Los M, 1997, BLOOD, V90, P3118, DOI 10.1182/blood.V90.8.3118; Luchetti F, 1998, HAEMATOLOGICA, V83, P974; MANABE A, 1993, LEUKEMIA, V7, P1990; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NIESVIZKY R, 1993, BLOOD REV, V7, P24, DOI 10.1016/0268-960X(93)90021-U; Raza A, 2000, LEUKEMIA RES, V24, P63, DOI 10.1016/S0145-2126(99)00152-6; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RHIM JS, 1989, ANTICANCER RES, V9, P1345; Roth W, 1998, J NEUROIMMUNOL, V87, P121, DOI 10.1016/S0165-5728(98)00079-4; Sangfelt O, 1997, CELL GROWTH DIFFER, V8, P343; Sarkar SN, 1999, J BIOL CHEM, V274, P25535, DOI 10.1074/jbc.274.36.25535; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sedger LM, 1999, J IMMUNOL, V163, P920; SILINS SL, 1995, INT J CANCER, V60, P65, DOI 10.1002/ijc.2910600110; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Spets H, 1998, BLOOD, V92, P2914, DOI 10.1182/blood.V92.8.2914.420k14_2914_2923; Stridh H, 1999, BIOCHEM BIOPH RES CO, V266, P460, DOI 10.1006/bbrc.1999.1821; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tan SL, 1999, J INTERF CYTOK RES, V19, P543, DOI 10.1089/107999099313677; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Wang YJ, 2000, MOL CELL BIOL, V20, P4505, DOI 10.1128/MCB.20.13.4505-4512.2000; Witzig TE, 2000, CLIN CANCER RES, V6, P681; Zeuner A, 1999, CELL DEATH DIFFER, V6, P1075, DOI 10.1038/sj.cdd.4400596	50	173	182	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2002	21	8					1251	1262		10.1038/sj.onc.1205179	http://dx.doi.org/10.1038/sj.onc.1205179			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850845				2022-12-17	WOS:000173729400013
J	Herdegen, T; Waetzig, V				Herdegen, T; Waetzig, V			AP-1 proteins in the adult brain: facts and fiction about effectors of neuroprotection and neurodegeneration	ONCOGENE			English	Review						Fos; JNK; JunD	N-TERMINAL KINASE; C-JUN EXPRESSION; SIGNAL-TRANSDUCTION PATHWAY; REPETITIVE ELECTROCONVULSIVE SEIZURES; CEREBELLAR GRANULE NEURONS; CEREBRAL-ARTERY OCCLUSION; RETINAL GANGLION-CELLS; IN-SITU HYBRIDIZATION; RAT-BRAIN; TRANSCRIPTION FACTORS	Jun and Fos proteins are induced and activated following most physiological and pathophysiological stimuli in the brain. Only few data allow conclusions about distinct functions of AP-1 proteins in neurodegeneration and neuroregeneration, and these functions mainly refer to c-Jun and its activation by JNKs, Apoptotic functions of activated c-Jun affect hippocampal, nigral and primary cultured neurons following excitotoxic stimulation and destruction of the neuron-target-axis including withdrawal of trophic molecules. The inhibition of JNKs might exert neuroprotection by subsequent omission of c-Jun activation. Besides endogenous neuronal functions, the c-Jun/AP-1 proteins can damage the nervous system by upregulation of harmful programs in non-neuronal cells (e,g, microglia) with release of neurodegenerative molecules. In contrast, the differentiation with neurite extension and maturation of neural cells in vitro indicate physiological and potentially neuroprotective functions of c-Jun and JNKs including sensoring for alterations in the cytoskeleton, This review summarizes the multiple molecular interfunctions which are involved in the shift from the physiological role to degenerative effects of the Jun/JNK-axis such as cell type-specific expression and intracellular localization of scaffold proteins and upstream activators, antagonistic phosphatases, interaction with other kinase systems, or the activation of transcription factors competing for binding to JNK proteins and AP-1 DNA elements.	Inst Pharmacol, D-24105 Kiel, Germany		Herdegen, T (corresponding author), Inst Pharmacol, Hosp Str 4, D-24105 Kiel, Germany.		herdegen, thomas/E-5135-2010					ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; Anguelova E, 2000, J NEUROSCI RES, V59, P209, DOI 10.1002/(SICI)1097-4547(20000115)59:2<209::AID-JNR7>3.0.CO;2-I; Arts J, 1996, EUR J BIOCHEM, V241, P393, DOI 10.1111/j.1432-1033.1996.00393.x; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Beer J, 1998, BRAIN RES, V794, P255, DOI 10.1016/S0006-8993(98)00233-9; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Boss V, 2001, J NEUROSCI, V21, P18, DOI 10.1523/JNEUROSCI.21-01-00018.2001; Brecht S, 1999, MOL BRAIN RES, V68, P101, DOI 10.1016/S0169-328X(99)00069-8; Carboni L, 1998, MOL BRAIN RES, V60, P57, DOI 10.1016/S0169-328X(98)00166-1; CARLETTI R, 1995, NEUROSCIENCE, V69, P1103, DOI 10.1016/0306-4522(95)00284-P; Chen JS, 1997, J NEUROSCI, V17, P4933; Chihab R, 1998, MOL BRAIN RES, V63, P105, DOI 10.1016/S0169-328X(98)00266-6; COFFER P, 1995, ONCOGENE, V10, P985; Coffey ET, 2000, J NEUROSCI, V20, P7602; Cruzalegui FH, 1999, EMBO J, V18, P1335, DOI 10.1093/emboj/18.5.1335; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Edelstein K, 2000, BRAIN RES, V870, P54, DOI 10.1016/S0006-8993(00)02401-X; Eilers A, 1998, J NEUROSCI, V18, P1713; Elliott RC, 2000, J NEUROSCI, V20, P2142; Falvo JV, 2000, MOL CELL BIOL, V20, P2239, DOI 10.1128/MCB.20.6.2239-2247.2000; Fernyhough P, 1999, DIABETES, V48, P881, DOI 10.2337/diabetes.48.4.881; FERRELL JE, 2000, SCI STKE, V52, P1; Ferrer I, 1997, NEUROSCIENCE, V80, P449, DOI 10.1016/S0306-4522(97)00126-7; GASS P, 1993, EUR J NEUROSCI, V5, P933, DOI 10.1111/j.1460-9568.1993.tb00944.x; Giasson BI, 1999, J NEUROCHEM, V72, P1081, DOI 10.1046/j.1471-4159.1999.0721081.x; Gingrich MB, 2000, TRENDS NEUROSCI, V23, P399, DOI 10.1016/S0166-2236(00)01617-9; Gonzalez MV, 2000, J CELL BIOL, V150, P1199, DOI 10.1083/jcb.150.5.1199; Grimm R, 1997, LEARN MEMORY, V3, P402, DOI 10.1101/lm.3.5.402; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Harada J, 1999, JPN J PHARMACOL, V79, P369, DOI 10.1254/jjp.79.369; Hata R, 2000, J CEREBR BLOOD F MET, V20, P306, DOI 10.1097/00004647-200002000-00012; Hayashi T, 2000, NEUROSCI LETT, V284, P195, DOI 10.1016/S0304-3940(00)01024-7; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Herzog KH, 1999, J NEUROSCI, V19, P4349; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Houle JD, 1999, NEUROSCIENCE, V94, P929, DOI 10.1016/S0306-4522(99)00359-0; Hsieh TF, 1998, EXP NEUROL, V149, P161, DOI 10.1006/exnr.1997.6686; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Ikeuchi T, 1998, Hum Cell, V11, P125; Ito M, 1999, MOL CELL BIOL, V19, P7539; JONES KJ, 1993, BRAIN RES BULL, V30, P491, DOI 10.1016/0361-9230(93)90283-H; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Kenney AM, 1998, J NEUROSCI, V18, P1318; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; Kim IJ, 1999, J NEUROCHEM, V72, P1335, DOI 10.1046/j.1471-4159.1999.721335.x; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Kita Y, 1998, J CELL SCI, V111, P907; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Kreutz MR, 1999, MOL BRAIN RES, V69, P232, DOI 10.1016/S0169-328X(99)00113-8; Kuboki Y, 2000, J BIOL CHEM, V275, P39815, DOI 10.1074/jbc.C000403200; Kurokawa T, 1999, INVEST OPHTH VIS SCI, V40, P3006; Lallemand D, 1998, EMBO J, V17, P5615, DOI 10.1093/emboj/17.19.5615; LEAH JD, 1991, BRAIN RES, V566, P198, DOI 10.1016/0006-8993(91)91699-2; LEE CY, 1970, NEW YORKS FOOD LIFE, V1, P1; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Levresse V, 2000, J NEUROSCI RES, V62, P799; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Liu YF, 2000, J BIOL CHEM, V275, P19035, DOI 10.1074/jbc.C000180200; Low W, 1999, ONCOGENE, V18, P3737, DOI 10.1038/sj.onc.1202702; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Maroney AC, 1998, J NEUROSCI, V18, P104; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; MartinezAnaya MA, 1996, FOOD SCI TECHNOL INT, V2, P35, DOI 10.1177/108201329600200105; Marushige K, 1999, ANTICANCER RES, V19, P3865; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Mielke K, 2000, MOL BRAIN RES, V75, P128, DOI 10.1016/S0169-328X(99)00308-3; Migheli A, 1997, J NEUROPATH EXP NEUR, V56, P1314, DOI 10.1097/00005072-199712000-00006; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Mulle C, 1998, NATURE, V392, P601, DOI 10.1038/33408; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Nakahara S, 1999, J NEUROPATH EXP NEUR, V58, P442, DOI 10.1097/00005072-199905000-00003; Namgung U, 2000, J NEUROSCI, V20, P6442, DOI 10.1523/JNEUROSCI.20-17-06442.2000; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Oo TF, 1999, J NEUROCHEM, V72, P557, DOI 10.1046/j.1471-4159.1999.0720557.x; Oren A, 1999, MOL CELL BIOL, V19, P1742; Ozawa H, 1999, NEUROSCI LETT, V262, P57, DOI 10.1016/S0304-3940(99)00034-8; Paratcha G, 2000, MOL BRAIN RES, V78, P120, DOI 10.1016/S0169-328X(00)00083-8; Pellet JB, 2000, EUR J NEUROSCI, V12, P621, DOI 10.1046/j.1460-9568.2000.00945.x; Pena E, 2000, EXP CELL RES, V256, P179, DOI 10.1006/excr.2000.4814; Pennypacker KR, 2000, NEUROSCI LETT, V289, P1, DOI 10.1016/S0304-3940(00)01250-7; Perez-Otano I, 1998, MOL BRAIN RES, V53, P41, DOI 10.1016/S0169-328X(97)00269-6; PURKISS RJ, 1993, EUR J NEUROSCI, V5, P1653, DOI 10.1111/j.1460-9568.1993.tb00233.x; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Rizzo MT, 1999, PROSTAG LEUKOTR ESS, V60, P187, DOI 10.1054/plef.1999.0024; ROBINSON GA, 1995, MOL BRAIN RES, V30, P61, DOI 10.1016/0169-328X(94)00277-L; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Sadot E, 1998, J NEUROCHEM, V70, P428; Salehi M, 1999, MECH AGEING DEV, V107, P61, DOI 10.1016/S0047-6374(98)00137-7; Saporito MS, 2000, J NEUROCHEM, V75, P1200, DOI 10.1046/j.1471-4159.2000.0751200.x; Schauwecker PE, 2000, BRAIN RES, V884, P116, DOI 10.1016/S0006-8993(00)02888-2; Sgambato V, 1998, J NEUROSCI, V18, P214; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Skinner M, 1997, MOL CELL BIOL, V17, P2372, DOI 10.1128/MCB.17.5.2372; Small DL, 1999, BRAIN RES, V842, P376, DOI 10.1016/S0006-8993(99)01852-1; SOMMER C, 1995, BRAIN PATHOL, V5, P135, DOI 10.1111/j.1750-3639.1995.tb00587.x; Standen CL, 2001, J NEUROCHEM, V76, P316, DOI 10.1046/j.1471-4159.2001.00102.x; Steward O, 1999, EXP NEUROL, V157, P19, DOI 10.1006/exnr.1999.7040; Sugino T, 2000, J NEUROSCI, V20, P4506, DOI 10.1523/JNEUROSCI.20-12-04506.2000; Telfeian AE, 2000, NEUROBIOL DIS, V7, P362, DOI 10.1006/nbdi.2000.0294; Timsit S, 1999, EUR J NEUROSCI, V11, P263, DOI 10.1046/j.1460-9568.1999.00434.x; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; Vaudano E, 1998, EUR J NEUROSCI, V10, P2644, DOI 10.1046/j.1460-9568.1998.t01-1-00282.x; Virdee K, 1997, J NEUROCHEM, V69, P550; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Watanabe Y, 1996, J NEUROSCI, V16, P3827; Winter C, 1998, BRAIN RES, V801, P198, DOI 10.1016/S0006-8993(98)00601-5; WOLLNIK F, 1995, EUR J NEUROSCI, V7, P388, DOI 10.1111/j.1460-9568.1995.tb00334.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu J, 2001, J NEUROSCI, V21, P92, DOI 10.1523/JNEUROSCI.21-01-00092.2001; Xu X, 1997, P NATL ACAD SCI USA, V94, P12655, DOI 10.1073/pnas.94.23.12655; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; Zhang Y, 1998, P NATL ACAD SCI USA, V95, P2586, DOI 10.1073/pnas.95.5.2586	129	173	178	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2001	20	19					2424	2437		10.1038/sj.onc.1204387	http://dx.doi.org/10.1038/sj.onc.1204387			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430HP	11402338				2022-12-17	WOS:000168568700009
J	Herrlich, P				Herrlich, P			Cross-talk between glucocorticoid receptor and AP-1	ONCOGENE			English	Review						immune response; NF-kappa B; tethering; CREB; GR D-loop mutation; genomic footprints	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; THYROID-HORMONE RECEPTOR; DNA-BINDING DOMAIN; RETINOIC ACID RECEPTORS; C-JUN; NUCLEAR FACTOR; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; MEDIATED REPRESSION	Cross-talk between different transcription factors, notably between the glucocorticoid receptor and AP-1, has been discovered more than 10 years ago: a bona fide transcription factor, without apparent need For its own direct DNA contact, influences the activity of another transcription factor. Recent experiments have added interesting aspects: in addition to major insights into the mechanism of cross-talk, it is now clear that the cross-talk ability of glucocorticoid receptor is essential for mouse development, while the activation of target promoters carrying a glucocorticoid response element (GRE), is surprisingly, dispensable for survival under animal house conditions. Interestingly, the cross-talk function is responsible for almost all regulatory actions of cortisol in the immune system. It is possible that the two functions of the glucocorticoid receptor can be activated separately by specific ligands, Future goals will be to define whether adverse effects of long-term corticosteroid treatment, e,g, osteoporosis, joint necroses, metabolic effects, can be ascribed to GRE-target gene activation and thus be dissociated from the desirable actions in the treatment e,g, of autoimmune disease.	Forschungszentrum Karlsruhe, Inst Toxicol & Genet, D-76021 Karlsruhe, Germany	Helmholtz Association; Karlsruhe Institute of Technology	Herrlich, P (corresponding author), Forschungszentrum Karlsruhe, Inst Toxicol & Genet, POB 3640, D-76021 Karlsruhe, Germany.							Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; Amiot F, 1997, MOL MED, V3, P864, DOI 10.1007/BF03401722; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baer M, 1999, COLD SPRING HARB SYM, V64, P437, DOI 10.1101/sqb.1999.64.437; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; Bauer A, 1999, GENE DEV, V13, P2996, DOI 10.1101/gad.13.22.2996; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; CATO ACB, 1992, J STEROID BIOCHEM, V43, P63, DOI 10.1016/0960-0760(92)90188-O; CHANG TJ, 1993, MOL ENDOCRINOL, V7, P528, DOI 10.1210/me.7.4.528; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; Cissel DS, 2000, J BIOL CHEM, V275, P7066, DOI 10.1074/jbc.275.10.7066; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; De Bosscher K, 2000, P NATL ACAD SCI USA, V97, P3919, DOI 10.1073/pnas.97.8.3919; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; DEBOSSCHER K, 2000, THESIS U GHENT; DEKLOET ER, 1993, CELL MOL NEUROBIOL, V13, P433, DOI 10.1007/BF00711582; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DiDomenico M, 1996, CANCER RES, V56, P4516; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; DROUIN J, 1993, EMBO J, V12, P145, DOI 10.1002/j.1460-2075.1993.tb05640.x; Dumont A, 1998, TRENDS BIOCHEM SCI, V23, P233, DOI 10.1016/S0968-0004(98)01212-2; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Fisher GJ, 1998, J CLIN INVEST, V101, P1432, DOI 10.1172/JCI2153; Frame S, 2000, CURR OPIN GENET DEV, V10, P106, DOI 10.1016/S0959-437X(99)00052-0; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GEISSE S, 1982, EMBO J, V1, P1613, DOI 10.1002/j.1460-2075.1982.tb01363.x; Gewert K, 2000, BIOCHEM PHARMACOL, V60, P545, DOI 10.1016/S0006-2952(00)00358-0; Godowski P.J., 1989, UCLA S MOL CELLULAR, P197; Gonzalez MV, 2000, J CELL BIOL, V150, P1199, DOI 10.1083/jcb.150.5.1199; Gonzalez MV, 1999, FEBS LETT, V459, P272, DOI 10.1016/S0014-5793(99)01257-0; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; GutierrezRamos JC, 1997, IMMUNOL TODAY, V18, P329, DOI 10.1016/S0167-5699(97)01085-2; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; Hirasawa N, 1998, J IMMUNOL, V161, P4939; Hoshino K, 1999, J IMMUNOL, V162, P3749; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; HYNES N, 1983, P NATL ACAD SCI-BIOL, V80, P3637, DOI 10.1073/pnas.80.12.3637; Ikeda M, 1996, J BIOL CHEM, V271, P23096, DOI 10.1074/jbc.271.38.23096; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JONAT C, 1990, THESIS U KARLSRUHE; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; Lee HY, 1999, MOL CELL BIOL, V19, P1973; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; LOPEZ G, 1993, MOL CELL BIOL, V13, P3042, DOI 10.1128/MCB.13.5.3042; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; MARODER M, 1993, MOL ENDOCRINOL, V7, P570, DOI 10.1210/me.7.4.570; Miller W.L., 1995, ADRENAL CORTEX, P555; Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Reichardt HM, 2000, MOL CELL BIOL, V20, P9009, DOI 10.1128/MCB.20.23.9009-9017.2000; REICHARDT HM, 2001, IN PRESS P NATL ACAD; REUL JMHM, 1985, ENDOCRINOLOGY, V117, P2505, DOI 10.1210/endo-117-6-2505; Rider LG, 1996, J IMMUNOL, V157, P2374; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SAXNE T, 1988, ARTHRITIS RHEUM, V31, P1041, DOI 10.1002/art.1780310816; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Tak PP, 1996, ARTHRITIS RHEUM, V39, P1077, DOI 10.1002/art.1780390702; TEURICH S, 1995, CHEM SENSES, V20, P251, DOI 10.1093/chemse/20.2.251; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; Tronche F, 1998, CURR OPIN GENET DEV, V8, P532, DOI 10.1016/S0959-437X(98)80007-5; Tuckermann JP, 1999, J CELL BIOL, V147, P1365, DOI 10.1083/jcb.147.7.1365; Tumlin JA, 1997, J CLIN INVEST, V99, P1217, DOI 10.1172/JCI119278; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; van Tilborg MAA, 2000, J MOL BIOL, V301, P947, DOI 10.1006/jmbi.2000.4001; Vanden Berghe W, 1999, MOL PHARMACOL, V56, P797; VANDESTOLPE A, 1993, AM J RESP CELL MOL, V8, P340, DOI 10.1165/ajrcmb/8.3.340; Vayssiere BM, 1997, MOL ENDOCRINOL, V11, P1245, DOI 10.1210/me.11.9.1245; Wang YS, 1997, J IMMUNOL, V159, P534; Widen C, 2000, J BIOL CHEM, V275, P39296, DOI 10.1074/jbc.M006943200; Wissink S, 1997, J BIOL CHEM, V272, P22278, DOI 10.1074/jbc.272.35.22278; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355; WONDISFORD FE, 1993, J BIOL CHEM, V268, P2749; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; ZHANG W, 1991, BIOTECHNIQUES, V11, P60	121	173	181	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2001	20	19					2465	2475		10.1038/sj.onc.1204388	http://dx.doi.org/10.1038/sj.onc.1204388			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430HP	11402341				2022-12-17	WOS:000168568700012
J	Higuchi, M; Honda, T; Proske, RJ; Yeh, ETH				Higuchi, M; Honda, T; Proske, RJ; Yeh, ETH			Regulation of reactive oxygen species-induced apoptosis and necrosis by caspase 3-like proteases	ONCOGENE			English	Article						reactive oxygen species; caspases; apoptosis; necrosis; cytochrome c	PROGRAMMED CELL-DEATH; MANGANOUS SUPEROXIDE-DISMUTASE; FAS-MEDIATED APOPTOSIS; NF-KAPPA-B; CYTOCHROME-C; U937 CELLS; THYMOCYTE APOPTOSIS; CYTO-TOXICITY; FACTOR-ALPHA; ACTIVATION	Reactive oxygen species (ROS) and caspases have been implicated as potential mediators of cell death. However, their mechanistic relationship remains to be elucidated, Here we investigated the roles of caspases in apoptosis and necrosis induced by ROS, generated by the mixture of xanthine and xanthine oxidase (X/XO), A low concentration of XO (0.025 U/ml) induced DNA fragmentation with little cellular membrane damage 3 h after treatment, suggesting the induction of apoptosis, The same treatment induced membrane blebbing, a morphological change typical of apoptosis, 15 min after treatment, A high concentration of XO (0.1 U/ml) damaged cell membranes with little concomitance of DNA fragmention, suggesting the induction of necrosis, ROS also activated caspase 3-like proteases and caspase 3 itself together with the release of cytochrome c which might be the cause of caspase activation. Apoptosis induced by low concentrations of XO and necrosis induced by high concentrations of XO was inhibited by z-DEVD-CH2F, an irreversible inhibitor of caspase 3. However, rapid induction of membrane blebbing was not inhibited by z-DEVD-CH2F. These results suggest that both apoptosis and necrosis could be induced by ROS through the activation of caspase 3-like protease; however, caspase 3 activation is not needed for ROS-induced membrane blebbing.	Univ Texas, Hlth Sci Ctr, Res Ctr Cardiovasc Dis, Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Div Mol Med, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Higuchi, M (corresponding author), Univ Texas, Hlth Sci Ctr, Res Ctr Cardiovasc Dis, Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA.							Barinaga M, 1996, SCIENCE, V273, P735, DOI 10.1126/science.273.5276.735; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; CHANG DJ, 1992, BIOCHEM BIOPH RES CO, V188, P538, DOI 10.1016/0006-291X(92)91089-9; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; COHEN JJ, 1984, J IMMUNOL, V132, P38; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; Eguchi Y, 1997, CANCER RES, V57, P1835; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; HIGUCHI M, 1995, J IMMUNOL METHODS, V178, P173, DOI 10.1016/0022-1759(94)00254-T; HIGUCHI M, 1992, J IMMUNOTHER, V12, P41, DOI 10.1097/00002371-199207000-00005; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; IKEBUCHI Y, 1991, J BIOL CHEM, V266, P13233; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KULL FC, 1981, CANCER RES, V41, P4885; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LYNCH RE, 1978, J BIOL CHEM, V253, P4697; MALORNI W, 1993, FEBS LETT, V327, P75, DOI 10.1016/0014-5793(93)81043-Y; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MATSUDA M, 1991, J IMMUNOL, V147, P3837; MATTHEWS N, 1987, IMMUNOLOGY, V62, P153; MAYER M, 1994, P NATL ACAD SCI USA, V91, P7496, DOI 10.1073/pnas.91.16.7496; MCCONKEY DJ, 1994, IMMUNOL REV, V142, P343, DOI 10.1111/j.1600-065X.1994.tb00896.x; McGowan AJ, 1996, FEBS LETT, V392, P299, DOI 10.1016/0014-5793(96)00838-1; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Palomba L, 1996, FEBS LETT, V390, P91, DOI 10.1016/0014-5793(96)00634-5; RUBIN R, 1984, ARCH BIOCHEM BIOPHYS, V228, P450, DOI 10.1016/0003-9861(84)90010-9; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Shimizu S, 1996, ONCOGENE, V12, P2045; Tsang SY, 1996, BIOCHEM J, V317, P13, DOI 10.1042/bj3170013; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; WONG GHW, 1995, BBA-MOL BASIS DIS, V1271, P205, DOI 10.1016/0925-4439(95)00029-4; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	42	173	174	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2753	2760		10.1038/sj.onc.1202211	http://dx.doi.org/10.1038/sj.onc.1202211			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840939				2022-12-17	WOS:000077146700008
J	YAMAMOTO, M; MARUI, N; SAKAI, T; MORII, N; KOZAKI, S; IKAI, K; IMAMURA, S; NARUMIYA, S				YAMAMOTO, M; MARUI, N; SAKAI, T; MORII, N; KOZAKI, S; IKAI, K; IMAMURA, S; NARUMIYA, S			ADP-RIBOSYLATION OF THE RHOA GENE-PRODUCT BY BOTULINUM C3 EXOENZYME CAUSES SWISS 3T3 CELLS TO ACCUMULATE IN THE G(1) PHASE OF THE CELL-CYCLE	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; IMMOBILIZED PH GRADIENTS; CLOSTRIDIUM-BOTULINUM; RIBOSYLTRANSFERASE; GROWTH; SEQUENCE; IDENTIFICATION; PURIFICATION; FIBROBLASTS; EXPRESSION	Using botulinum C3 exoenzyme, which specifically ADP-ribosylates the rho gene products (rho proteins), we examined the role of these proteins in cell cycle progression in Swiss 3T3 cells. Incubation of cell lysates with C3 exoenzyme revealed a single [P-32]ADP-ribosylated protein with an M(r) of 23K. This protein was identified as rhoA protein by isoelectric focusing and peptide mapping. When C3 exoenzyme was added to the culture, it ADP-ribosylated the substrate protein in the celts and reduced their growth rate and saturation density. The reduction was dependent on the amount of C3 exoenzyme and on the extent of ADP-ribosylation of the rho protein in the cells. Flow cytometric analysis of logarithmically growing cells showed that the enzyme treatment concentration-dependently accumulated the cells in the G1 phase of the cell cycle. When G1-enriched cells were treated with C3 exoenzyme and cell cycle progression initiated by the addition of serum was monitored, inhibition of G1-S transition was clearly observed. These results suggest that the rhoA gene product plays a critical role in G1-S progression in cultured Swiss 3T3 cells and that the ADP-ribosylation abolishes this activity and causes the cells to accumulate in G1 phase.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,FIS,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT DERMATOL,KYOTO 606,JAPAN; KYOTO PREFECTURAL UNIV MED,DEPT PREVENT MED,KAMIKYO KU,KYOTO 602,JAPAN; UNIV OSAKA PREFECTURE,COLL AGR,DEPT VET SCI,SAKAI,OSAKA 591,JAPAN	Kyoto University; Kyoto University; Kyoto Prefectural University of Medicine; Osaka Metropolitan University								AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; ALTLAND K, 1985, ELECTROPHORESIS, V6, P314, DOI 10.1002/elps.1150060704; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BENZEEV A, 1980, CELL, V21, P365, DOI 10.1016/0092-8674(80)90473-0; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DEAN PN, 1980, CELL TISSUE KINET, V13, P299, DOI 10.1111/j.1365-2184.1980.tb00468.x; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MATSUI Y, 1992, GENE, V114, P43, DOI 10.1016/0378-1119(92)90705-T; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; MORII N, 1991, J BIOL CHEM, V266, P7646; MORII N, 1992, J BIOL CHEM, V267, P20921; MORII N, 1990, J BIOCHEM-TOKYO, V107, P769, DOI 10.1093/oxfordjournals.jbchem.a123123; MORII N, 1988, J BIOL CHEM, V263, P12420; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; NEMOTO Y, 1992, J BIOL CHEM, V267, P20916; ONEILL C, 1990, J CELL SCI, V95, P577; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIMPILAINEN MA, 1985, ELECTROPHORESIS, V6, P419, DOI 10.1002/elps.1150060903; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; TOMINAGA T, 1993, IN PRESS J CELL BIOL; VINDELOV LL, 1977, VIRCHOWS ARCH B, V24, P227; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	40	173	175	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1449	1455						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502473				2022-12-17	WOS:A1993LE06400007
J	CAIRNS, P; PROCTOR, AJ; KNOWLES, MA				CAIRNS, P; PROCTOR, AJ; KNOWLES, MA			LOSS OF HETEROZYGOSITY AT THE RB-LOCUS IS FREQUENT AND CORRELATES WITH MUSCLE INVASION IN BLADDER-CARCINOMA	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; NON-OCULAR CANCER; HEREDITARY RETINOBLASTOMA; SOMATIC MUTATIONS; TUMORS; EXPRESSION; RELATIVES; SEQUENCE; IDENTIFICATION; CHROMOSOME-11	Studies of second, non-ocular tumours in surviving retinoblastoma patients and their families have reported a higher than expected incidence and lower age at diagnosis of bladder tumors. This suggests that RB mutations may predispose to bladder cancer. To determine whether this gene is involved in the development of sporadic bladder tumours we have examined 162 bladder tumours for evidence of structural alterations to the RB gene. Ninety-four patients were informative with one or more intragenic RB probes, and 28 of these (29%) showed loss of heterozygosity (LOH). Of these, two tumours showed homozygous deletions with the 5' intragenic probe p123M1.8. The probe p68RS2.0, which recognizes a variable number of tandem repeats site in intron 17 of the RB gene, detected new alleles in 5 of 162 tumours, one of which also showed LOH at another polymorphic site within the gene. The 28 tumours with RB LOH were screened with the RB cDNA probes pR3.8 and pR0.9, which revealed two homozygous deletions and one rearrangement. The tumours with RB LOH were also screened for loss of three markers which flank RB, D13S1 which maps proximal and D13S2 and D13S3 which map distal to RB on chromosome 13q. Two tumours showed retention of heterozygosity for flanking markers on one side of RB and another for markers on both sides. These results suggest that RB is the target gene on 13q in these bladder tumours. When RB loss was compared with tumour grade and stage, an association between high tumour grade and RB loss (0.005 > P > 0.001) and between muscle invasion and RB loss (P < 0.001) was found. Twenty-six of the 28 tumours with LOH were muscle-invasive. This represents 56% of invasive tumours. Only 2/48 (4%) superficial tumours showed RB allele loss, and one of these has progressed rapidly to invasive disease. These results show that LOH at the RB locus is a frequent genetic event in bladder tumours and may identify a subset of more aggressive tumours.			CAIRNS, P (corresponding author), MARIE SKLODOWSKA CURIE MEM INST,THE CHART,OXTED RH8 0TL,SURREY,ENGLAND.			Knowles, Margaret/0000-0002-9363-8657				AHERNE G, 1974, T OPHTHAL SOC UK, V94, P938; ARMOUR JAL, 1989, GENOMICS, V4, P328, DOI 10.1016/0888-7543(89)90338-8; CAVENEE W, 1984, AM J HUM GENET, V36, P10; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHAN H, 1977, J NATL CANCER I, V58, P205, DOI 10.1093/jnci/58.2.205; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CUTLER SJ, 1982, AUA MONOGRAPHS BLADD, V1, P35; DERKINDEREN DJ, 1988, INT J CANCER, V41, P499, DOI 10.1002/ijc.2910410405; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; KAYE KW, 1982, J UROLOGY, V128, P31, DOI 10.1016/S0022-5347(17)52738-X; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEPPERT M, 1986, AM J HUM GENET, V39, P425; LI SB, 1991, J NATL CANCER I, V83, P637, DOI 10.1093/jnci/83.9.637; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; PROCTOR AJ, 1991, ONCOGENE, V6, P789; SANDERS BM, 1989, BRIT J CANCER, V60, P358, DOI 10.1038/bjc.1989.285; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TARKKANEN A, 1984, OPHTHALMOLOGICA, V189, P143, DOI 10.1159/000309401; VARLEY JM, 1989, ONCOGENE, V4, P725; WADEY RB, 1990, ONCOGENE, V5, P901; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; YANDELL DW, 1991, CANCER RES, V32, P459; ZHU XP, 1989, NATURE, V340, P312, DOI 10.1038/340312a0; 1978, UNION INT CANCER	32	173	176	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2305	2309						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766677				2022-12-17	WOS:A1991GX73500019
J	SORRENTINO, V; GIORGI, M; GEREMIA, R; BESMER, P; ROSSI, P				SORRENTINO, V; GIORGI, M; GEREMIA, R; BESMER, P; ROSSI, P			EXPRESSION OF THE C-KIT PROTOONCOGENE IN THE MURINE MALE GERM-CELLS	ONCOGENE			English	Note							SPOTTING W LOCUS; SPERMATOGENIC CELLS; TYROSINE KINASE; V-KIT; MOUSE; PURIFICATION; TISSUES; PRODUCT; FAMILY; ACID	The proto-oncogene c-kit encodes a transmembrane protein tyrosine kinase receptor. The c-kit gene has recently been shown to be allelic with the W locus. Mutations at the white spotting locus (W) affect various aspects of hematopoiesis, melanogenesis and gametogenesis during development and in the adult animal. We have investigated the expression of the proto-oncogene c-kit in mouse testicular cell populations. The c-kit mRNA was found to be expressed at high levels in spermatogonia, and at lower levels in meiotic pachytene spermatocytes. Moreover, two novel testis-specific c-kit transcripts of 3.5 and 2.3 kb are present in postmeiotic haploid germ cells. These results suggest a role of c-kit not only during testis development in the embryo, but also throughout all stages of male germ cell development after birth.	MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; UNIV ROMA TOR VERGATA 2,DIPARTIMENTO SAN PUBBL & BIOL CELLULARE,ROME,ITALY	Memorial Sloan Kettering Cancer Center; University of Rome Tor Vergata	SORRENTINO, V (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY.		Sorrentino, Vincenzo/A-4793-2014; Rossi, Pellegrino/AAA-7072-2019	Sorrentino, Vincenzo/0000-0002-8573-8631; GEREMIA, Raffaele/0000-0001-9056-6603; GIORGI, Mauro/0000-0002-2923-4893; ROSSI, PELLEGRINO/0000-0003-4796-327X				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BESMER P, 1983, J VIROL, V46, P606, DOI 10.1128/JVI.46.2.606-613.1983; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BUCCI LR, 1986, BIOL REPROD, V34, P195, DOI 10.1095/biolreprod34.1.195; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLOUMBRE JL, 1954, J EXP ZOOL, V126, P277; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GEISSLER EN, 1981, GENETICS, V97, P337; GEREMIA R, 1976, Bollettino di Zoologia, V43, P139; GRIPPO P, 1978, CELL DIFFER DEV, V7, P237, DOI 10.1016/0045-6039(78)90025-8; HARRISON DE, 1976, TRANSPLANTATION, V22, P42, DOI 10.1097/00007890-197607000-00007; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; MCCULLOCH EA, 1964, SCIENCE, V144, P844, DOI 10.1126/science.144.3620.844; McLaren A, 1980, GERM CELLS SOMA NEW; MEISTRICH ML, 1981, BIOL REPROD, V25, P1065, DOI 10.1095/biolreprod25.5.1065; MEISTRICH ML, 1986, BIOL REPROD, V34, P17, DOI 10.1095/biolreprod34.1.17; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; NEBEL BR, 1961, SCIENCE, V134, P832, DOI 10.1126/science.134.3482.832; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; PONZETT C, 1987, MOL CELL BIOL, V5, P5301; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; RUSSELL ES, 1970, REGULATION HEMATOPOI, P649; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; Silvers W.K., 1979, COAT COLORS MICE, P206; SORRENTINO V, 1988, P NATL ACAD SCI USA, V85, P2191, DOI 10.1073/pnas.85.7.2191; STEFANINI M, 1984, BIOL FERTILIZATION, V2, P3; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; [No title captured]	41	173	178	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					149	151						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1704118				2022-12-17	WOS:A1991EY03900021
J	Choudhry, H; Albukhari, A; Morotti, M; Haider, S; Moralli, D; Smythies, J; Schodel, J; Green, CM; Camps, C; Buffa, F; Ratcliffe, P; Ragoussis, J; Harris, AL; Mole, DR				Choudhry, H.; Albukhari, A.; Morotti, M.; Haider, S.; Moralli, D.; Smythies, J.; Schoedel, J.; Green, C. M.; Camps, C.; Buffa, F.; Ratcliffe, P.; Ragoussis, J.; Harris, A. L.; Mole, D. R.			Tumor hypoxia induces nuclear paraspeckle formation through HIF-2 alpha dependent transcriptional activation of NEAT1 leading to cancer cell survival	ONCOGENE			English	Article							LONG NONCODING RNA; INDUCIBLE FACTOR-1; GENE-EXPRESSION; BINDING SITES; DNA-BINDING; HIF-1-ALPHA; HIF-1; RELOCATION; PROTEIN; BODIES	Activation of cellular transcriptional responses, mediated by hypoxia-inducible factor (HIF), is common in many types of cancer, and generally confers a poor prognosis. Known to induce many hundreds of protein-coding genes, HIF has also recently been shown to be a key regulator of the non-coding transcriptional response. Here, we show that NEAT1 long non-coding RNA (lncRNA) is a direct transcriptional target of HIF in many breast cancer cell lines and in solid tumors. Unlike previously described lncRNAs, NEAT1 is regulated principally by HIF-2 rather than by HIF-1. NEAT1 is a nuclear lncRNA that is an essential structural component of paraspeckles and the hypoxic induction of NEAT1 induces paraspeckle formation in a manner that is dependent upon both NEAT1 and on HIF-2. Paraspeckles are multifunction nuclear structures that sequester transcriptionally active proteins as well as RNA transcripts that have been subjected to adenosine-to-inosine (A-to-I) editing. We show that the nuclear retention of one such transcript, F11R (also known as junctional adhesion molecule 1, JAM1), in hypoxia is dependent upon the hypoxic increase in NEAT1, thereby conferring a novel mechanism of HIF-dependent gene regulation. Induction of NEAT1 in hypoxia also leads to accelerated cellular proliferation, improved clonogenic survival and reduced apoptosis, all of which are hallmarks of increased tumorigenesis. Furthermore, in patients with breast cancer, high tumor NEAT1 expression correlates with poor survival. Taken together, these results indicate a new role for HIF transcriptional pathways in the regulation of nuclear structure and that this contributes to the pro-tumorigenic hypoxia-phenotype in breast cancer.	[Choudhry, H.; Albukhari, A.] King Abdulaziz Univ, Fac Sci, Dept Biochem, Jeddah, Saudi Arabia; [Choudhry, H.; Moralli, D.; Green, C. M.; Camps, C.; Ragoussis, J.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, Oxon, England; [Albukhari, A.; Morotti, M.; Haider, S.; Harris, A. L.] Univ Oxford, Dept Oncol, Weatherall Inst Mol Med, Oxford OX3 7BN, Oxon, England; [Smythies, J.; Buffa, F.; Ratcliffe, P.; Mole, D. R.] Univ Oxford, Oxford OX3 7BN, Oxon, England; [Schoedel, J.] Univ Erlangen Nurnberg, Dept Nephrol & Hypertens, D-91054 Erlangen, Germany; [Ragoussis, J.] McGill Univ, Montreal, PQ, Canada; [Ragoussis, J.] Genome Quebec Innovat Ctr, Montreal, PQ, Canada; [Ragoussis, J.] BSRC Alexander Fleming, Athens, Greece	King Abdulaziz University; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; University of Oxford; University of Erlangen Nuremberg; McGill University; Alexander Fleming Biomedical Sciences Research Center	Mole, DR (corresponding author), Univ Oxford, Nuffield Dept Med, Henry Wellcome Bldg Mol Biol, Oxford OX3 7BN, Oxon, England.	drmole@well.ox.ac.uk	Albukhari, Ashwag/M-3690-2016; Harris, Adrian L/ABA-3343-2020; Ragoussis, Ioannis/AAD-9790-2022; Morotti, Matteo/AAE-8922-2020; Buffa, Francesca/D-2574-2013	Albukhari, Ashwag/0000-0003-3669-1184; Harris, Adrian L/0000-0003-1376-8409; Morotti, Matteo/0000-0002-1790-1185; Buffa, Francesca/0000-0003-0409-406X; Green, Catherine/0000-0002-7068-7106; Ratcliffe, Peter/0000-0002-2853-806X; Schodel, Johannes/0000-0002-3587-8839; Mole, David/0000-0002-0984-300X; Choudhry, Hani/0000-0003-0401-6619; Ragoussis, Ioannis/0000-0002-8515-0934	Wellcome Trust [088182/Z/09/Z, 078333/Z/05/Z, WT091857MA]; Higher Education Funding Council for England, Cancer Research UK [A16016]; Ludwig Institute for Cancer Research; Interdisciplinary Center of Clinical Research at the University of Erlangen-Nuremberg [TP J31]; Center of Innovation in Personalized Medicine, King Abdulaziz University, Ministry of High Education for Saudi Arabia; Cancer Research UK [18974, 11359, 16016] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); Higher Education Funding Council for England, Cancer Research UK; Ludwig Institute for Cancer Research; Interdisciplinary Center of Clinical Research at the University of Erlangen-Nuremberg; Center of Innovation in Personalized Medicine, King Abdulaziz University, Ministry of High Education for Saudi Arabia; Cancer Research UK(Cancer Research UK)	This work was funded by the Wellcome Trust (088182/Z/09/Z, 078333/Z/05/Z and WT091857MA), the Higher Education Funding Council for England, Cancer Research UK (A16016), the Ludwig Institute for Cancer Research, the Interdisciplinary Center of Clinical Research at the University of Erlangen-Nuremberg (TP J31) and Center of Innovation in Personalized Medicine, King Abdulaziz University, Ministry of High Education for Saudi Arabia.	Ben-Zvi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077702; Bond CS, 2009, J CELL BIOL, V186, P637, DOI 10.1083/jcb.200906113; Camps C, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-28; Chen LL, 2008, EMBO J, V27, P1694, DOI 10.1038/emboj.2008.94; Chen LL, 2009, MOL CELL, V35, P467, DOI 10.1016/j.molcel.2009.06.027; Choudhry H, 2014, EMBO REP, V15, P70, DOI 10.1002/embr.201337642; Clemson CM, 2009, MOL CELL, V33, P717, DOI 10.1016/j.molcel.2009.01.026; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200; Ferdin J, 2013, CELL DEATH DIFFER, V20, P1675, DOI 10.1038/cdd.2013.119; Fox AH, 2002, CURR BIOL, V12, P13, DOI 10.1016/S0960-9822(01)00632-7; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Guru SC, 1997, GENOME RES, V7, P725, DOI 10.1101/gr.7.7.725; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HEGGTVEIT HA, 1969, B WORLD HEALTH ORGAN, V41, P865; Hirose T, 2014, MOL BIOL CELL, V25, P169, DOI 10.1091/mbc.E13-09-0558; Hu CJ, 2007, MOL BIOL CELL, V18, P4528, DOI 10.1091/mbc.E06-05-0419; Imamura K, 2014, MOL CELL, V53, P393, DOI 10.1016/j.molcel.2014.01.009; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Koroleva OA, 2009, PLANT CELL, V21, P1592, DOI 10.1105/tpc.108.060434; Lau KW, 2007, BRIT J CANCER, V96, P1284, DOI 10.1038/sj.bjc.6603675; Li JL, 2007, CANCER RES, V67, P11244, DOI 10.1158/0008-5472.CAN-07-0969; Mao YTS, 2011, TRENDS GENET, V27, P295, DOI 10.1016/j.tig.2011.05.006; Matouk IJ, 2010, BBA-MOL CELL RES, V1803, P443, DOI 10.1016/j.bbamcr.2010.01.010; Milani M, 2008, EUR J CANCER, V44, P2766, DOI 10.1016/j.ejca.2008.09.025; Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1; Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200; Naganuma T, 2012, EMBO J, V31, P4020, DOI 10.1038/emboj.2012.251; Nakagawa S, 2011, J CELL BIOL, V193, P31, DOI 10.1083/jcb.201011110; Ortiz-Barahona A, 2010, NUCLEIC ACIDS RES, V38, P2332, DOI 10.1093/nar/gkp1205; Pollard PJ, 2008, BIOCHEM J, V416, P387, DOI 10.1042/BJ20081238; Prasanth KV, 2005, CELL, V123, P249, DOI 10.1016/j.cell.2005.08.033; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Risuleo G, 2003, MOL CELL BIOCHEM, V250, P73, DOI 10.1023/A:1024950317684; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Sasaki YTF, 2009, P NATL ACAD SCI USA, V106, P2525, DOI 10.1073/pnas.0807899106; Schodel J, 2012, NAT GENET, V44, P420, DOI 10.1038/ng.2204; Schodel J, 2011, BLOOD, V117, pE207, DOI 10.1182/blood-2010-10-314427; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Sunwoo H, 2009, GENOME RES, V19, P347, DOI 10.1101/gr.087775.108; Takahashi K, 2014, J CELL SCI, V127, P1585, DOI 10.1242/jcs.141069; Xue M, 2014, TUMOR BIOL, V35, P6901, DOI 10.1007/s13277-014-1925-x; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Yang F, 2013, MOL CELL, V49, P1083, DOI 10.1016/j.molcel.2013.01.010	47	172	178	3	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4482	4490		10.1038/onc.2014.378	http://dx.doi.org/10.1038/onc.2014.378			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25417700	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000360189200007
J	Robichaud, N; del Rincon, SV; Huor, B; Alain, T; Petruccelli, LA; Hearnden, J; Goncalves, C; Grotegut, S; Spruck, CH; Furic, L; Larsson, O; Muller, WJ; Miller, WH; Sonenberg, N				Robichaud, N.; del Rincon, S. V.; Huor, B.; Alain, T.; Petruccelli, L. A.; Hearnden, J.; Goncalves, C.; Grotegut, S.; Spruck, C. H.; Furic, L.; Larsson, O.; Muller, W. J.; Miller, W. H.; Sonenberg, N.			Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3	ONCOGENE			English	Article							INITIATION-FACTOR 4E; ACTIVATED PROTEIN-KINASE; HUMAN BREAST-CANCER; MESSENGER-RNA; STAGE-I; DIFFERENTIAL TRANSLATION; SIGNALING PATHWAY; PROSPECTIVE TRIAL; FACTOR EIF-4E; EXPRESSION	The progression of cancers from primary tumors to invasive and metastatic stages accounts for the overwhelming majority of cancer deaths. Understanding the molecular events which promote metastasis is thus critical in the clinic. Translational control is emerging as an important factor in tumorigenesis. The messenger RNA (mRNA) cap-binding protein eIF4E is an oncoprotein that has an important role in cancer initiation and progression. eIF4E must be phosphorylated to promote tumor development. However, the role of eIF4E phosphorylation in metastasis is not known. Here, we show that mice in which eukaryotic translation initiation factor 4E (eIF4E) cannot be phosphorylated are resistant to lung metastases in a mammary tumor model, and that cells isolated from these mice exhibit impaired invasion. We also demonstrate that transforming growth factor-beta (TGF beta) induces eIF4E phosphorylation to promote the translation of Snail and Mmp-3 mRNAs, and the induction of epithelial-to-mesenchymal transition (EMT). Furthermore, we describe a new model wherein EMT induced by TGF beta requires translational activation via the non-canonical TGF beta signaling branch acting through eIF4E phosphorylation.	[Robichaud, N.; Hearnden, J.; Muller, W. J.; Sonenberg, N.] McGill Univ, Dept Biochem, Montreal, PQ H3A 1A3, Canada; [Robichaud, N.; Hearnden, J.; Muller, W. J.; Sonenberg, N.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada; [del Rincon, S. V.; Huor, B.; Petruccelli, L. A.; Goncalves, C.; Miller, W. H.] McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Lady Davis Inst Med Res, Montreal, PQ H3A 1A3, Canada; [Alain, T.] Univ Ottawa, Childrens Hosp, Eastern Ontario Res Inst, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; [Grotegut, S.; Spruck, C. H.] Sanford Burnham Med Res Inst, Signal Transduct Program, La Jolla, CA USA; [Furic, L.] Monash Univ, Dept Anat & Dev Biol, Clayton, Vic, Australia; [Larsson, O.] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden	McGill University; McGill University; Lady Davis Institute; McGill University; University of Ottawa; Children's Hospital of Eastern Ontario; Sanford Burnham Prebys Medical Discovery Institute; Monash University; Karolinska Institutet	Miller, WH (corresponding author), McGill Univ, Goodman Canc Res Ctr, Dept Biochem, Canc Pavil,1160 Pine Ave West, Montreal, PQ H3A 1A3, Canada.	wmiller@ldi.jgh.mcgill.ca; nahum.sonenberg@mcgill.ca	Furic, Luc/F-4886-2012	Furic, Luc/0000-0002-1893-9812; Robichaud, Nathaniel/0000-0002-7653-0767; Larsson, Ola/0000-0003-1412-1308	Susan G. Komen Breast Cancer Foundation [IIR12224057]; Canadian Cancer Society [2010-700377]; Cancer Research Society [2012-17280]; PCFA [YI-0310]; Fonds de la Recherche en Sante du Quebec [20874]; Canadian Institutes of Health Research [220151]; Vanier Canada Graduate Scholarship [267839]; Swedish Research Council; Swedish Cancer Society; Wallenberg Academy	Susan G. Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); Canadian Cancer Society(Canadian Cancer Society (CCS)); Cancer Research Society; PCFA; Fonds de la Recherche en Sante du Quebec(Fonds de la Recherche en Sante du Quebec); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Vanier Canada Graduate Scholarship; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Wallenberg Academy	This work was by supported by The Susan G. Komen Breast Cancer Foundation (IIR12224057), and the Canadian Cancer Society (2010-700377) to NS. WHM was supported by the Cancer Research Society (2012-17280). LF was supported by PCFA#YI-0310. NS is a Howard Hughes Medical Institute Senior International Scholar. WHM is a Chercheur National of Fonds de la Recherche en Sante du Quebec (FRSQ). NR was supported by scholarships from the Fonds de la Recherche en Sante du Quebec (20874), the Canadian Institutes of Health Research (220151) and the Vanier Canada Graduate Scholarship (267839). OL is supported by the Swedish Research Council, the Swedish Cancer Society and the Wallenberg Academy Fellows Program. We thank I Topisirovic for advice; C Zakaria, A Sylvestre, S Perreault and C Lister for technical assistance, N Siddiqui for critical reading of the manuscript and S Ramon y Cajal (the Vall d'Hebron University Hospital, Barcelona, Spain) for his support and insights into tumor heterogeneity. We thank the Animal Facility and the Histology Facility at the Goodman Cancer Research Centre for mouse work and tissue processing.	Adesso L, 2013, ONCOGENE, V32, P2848, DOI 10.1038/onc.2012.306; Alain T, 2012, CANCER RES, V72, P6468, DOI 10.1158/0008-5472.CAN-12-2395; ALBINI A, 1987, CANCER RES, V47, P3239; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Astanehe A, 2012, ONCOGENE, V31, P4434, DOI 10.1038/onc.2011.617; Bakin AV, 2002, J CELL SCI, V115, P3193; Buxade M, 2005, IMMUNITY, V23, P177, DOI 10.1016/j.immuni.2005.06.009; BYERS HR, 1991, AM J PATHOL, V139, P423; Byrnes K, 2006, ANN SURG, V243, P684, DOI 10.1097/01.sla.0000216770.23642.d8; C.S.H. Laboratory, 2006, COLD SPRING HARBOR P, V2006; Chen CN, 2004, J SURG ONCOL, V86, P22, DOI 10.1002/jso.20037; Crew JP, 2000, BRIT J CANCER, V82, P161; DaSilva J, 2006, MOL CELL BIOL, V26, P1898, DOI 10.1128/MCB.26.5.1898-1907.2006; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Dilworth SM, 2002, NAT REV CANCER, V2, P951, DOI 10.1038/nrc946; DUNCAN R, 1987, J BIOL CHEM, V262, P380; Fan SQ, 2009, CANCER BIOL THER, V8, P1463, DOI 10.4161/cbt.8.15.8960; Ferrandiz-Pulido C, 2013, J UROLOGY, V190, P2288, DOI 10.1016/j.juro.2013.06.015; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; Franci C, 2006, ONCOGENE, V25, P5134, DOI 10.1038/sj.onc.1209519; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Graff JR, 2009, CANCER RES, V69, P3866, DOI 10.1158/0008-5472.CAN-08-3472; Grzmil M, 2011, CANCER RES, V71, P2392, DOI 10.1158/0008-5472.CAN-10-3112; Guil S, 2006, MOL CELL BIOL, V26, P5744, DOI 10.1128/MCB.00224-06; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Heppner KJ, 1996, AM J PATHOL, V149, P273; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; Holm N, 2008, ANN SURG ONCOL, V15, P3207, DOI 10.1245/s10434-008-0086-9; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Huang Da Wei, 2009, Curr Protoc Bioinformatics, VChapter 13, DOI 10.1002/0471250953.bi1311s27; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Imamura T, 2012, BREAST CANCER-TOKYO, V19, P118, DOI 10.1007/s12282-011-0321-2; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Jia Y, 2012, MED RES REV, V32, P786, DOI 10.1002/med.21260; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Konicek BW, 2011, CANCER RES, V71, P1849, DOI 10.1158/0008-5472.CAN-10-3298; Larsson O, 2011, BIOINFORMATICS, V27, P1440, DOI 10.1093/bioinformatics/btr146; Larsson O, 2010, P NATL ACAD SCI USA, V107, P21487, DOI 10.1073/pnas.1006821107; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lee T, 2012, FUTURE MED CHEM, V4, P19, DOI [10.4155/FMC.11.150, 10.4155/fmc.11.150]; Li BDL, 2002, ANN SURG, V235, P732, DOI 10.1097/00000658-200205000-00016; Li BDL, 1998, ANN SURG, V227, P756, DOI 10.1097/00000658-199805000-00016; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; Ling C, 2012, CANCER DISCOV, V2, P68, DOI 10.1158/2159-8290.CD-11-0189; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Malina A, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a012377; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; McClusky DR, 2005, ANN SURG, V242, P584, DOI 10.1097/01.sla.0000184224.55949.90; Nasr Z, 2013, ONCOGENE, V32, P861, DOI 10.1038/onc.2012.105; Nathan CA, 1997, ONCOGENE, V15, P1087, DOI 10.1038/sj.onc.1201272; Nathan CAO, 1999, J CLIN ONCOL, V17, P2909, DOI 10.1200/JCO.1999.17.9.2909; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Pettersson F, 2011, CLIN CANCER RES, V17, P2874, DOI 10.1158/1078-0432.CCR-10-2334; Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Ramon y Cajal, CLIN TRANSL IN PRESS; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Salehi Z, 2006, CLIN BIOCHEM, V39, P404, DOI 10.1016/j.clinbiochem.2005.11.007; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Scott PAE, 1998, BRIT J CANCER, V77, P2120, DOI 10.1038/bjc.1998.356; Seki N, 2002, CLIN CANCER RES, V8, P3046; Seki N, 2010, LUNG CANCER, V70, P329, DOI 10.1016/j.lungcan.2010.03.006; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Topisirovic I, 2004, CANCER RES, V64, P8639, DOI 10.1158/0008-5472.CAN-04-2677; Ueda T, 2010, P NATL ACAD SCI USA, V107, P13984, DOI 10.1073/pnas.1008136107; Wang XL, 2012, WORLD J GASTROENTERO, V18, P2540, DOI 10.3748/wjg.v18.i20.2540; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Wu MY, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0400-z; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yin B, 2006, LEUKEMIA, V20, P151, DOI 10.1038/sj.leu.2404033; Yoshizawa A, 2010, CLIN CANCER RES, V16, P240, DOI 10.1158/1078-0432.CCR-09-0986; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328; Zheng J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089220	82	172	175	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2032	2042		10.1038/onc.2014.146	http://dx.doi.org/10.1038/onc.2014.146			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909168	Green Accepted			2022-12-17	WOS:000353173400003
J	Chauvin, C; Koka, V; Nouschi, A; Mieulet, V; Hoareau-Aveilla, C; Dreazen, A; Cagnard, N; Carpentier, W; Kiss, T; Meyuhas, O; Pende, M				Chauvin, C.; Koka, V.; Nouschi, A.; Mieulet, V.; Hoareau-Aveilla, C.; Dreazen, A.; Cagnard, N.; Carpentier, W.; Kiss, T.; Meyuhas, O.; Pende, M.			Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program	ONCOGENE			English	Article						signal transduction; ribosome biogenesis; mTOR	MESSENGER-RNA TRANSLATION; CELL-SIZE; PHOSPHORYLATION; MTOR; REVEALS; TARGET; GROWTH; GENES; YEAST; IDENTIFICATION	S6 kinases (S6Ks) are mechanistic target of rapamycin substrates that participate in cell growth control. S6Ks phosphorylate ribosomal protein S6 (rpS6) and additional proteins involved in the translational machinery, although the functional roles of these modifications remain elusive. Here we analyze the S6K-dependent transcriptional and translational regulation of gene expression by comparing whole-genome microarray of total and polysomal mouse liver RNA after feeding. We show that tissue lacking S6Ks 1 and 2 (S6K1 and S6K2), displays a defect in the ribosome biogenesis (RiBi) transcriptional program after feeding. Over 75% of RiBi factors are controlled by S6K, including Nop56, Nop14, Gar1, Rrp9, Rrp15, Rrp12 and Pwp2 nucleolar proteins. Importantly, the reduced activity of RiBi transcriptional promoters in S6K1;S6K2(-/-) cells is also observed in rpS6 knock-in mutants that cannot be phosphorylated. As ribosomal protein synthesis is not affected by these mutations, our data reveal a distinct and specific aspect of RiBi under the control of rpS6 kinase activity, that is, the RiBi transcriptional program.	[Chauvin, C.; Koka, V.; Nouschi, A.; Mieulet, V.; Pende, M.] INSERM, U845, F-75015 Paris, France; [Chauvin, C.; Koka, V.; Nouschi, A.; Mieulet, V.; Cagnard, N.; Pende, M.] Univ Paris 05, Sorbonne Paris Cite, Fac Med, UMRS 845, Paris, France; [Hoareau-Aveilla, C.; Kiss, T.] Univ Toulouse UPS, Lab Biol Mol Eucaryote, Toulouse, France; [Hoareau-Aveilla, C.; Kiss, T.] CNRS, Toulouse, France; [Dreazen, A.; Meyuhas, O.] Hebrew Univ Jerusalem, Hadassah Med Sch, IMRIC, Dept Biochem & Mol Biol, IL-91010 Jerusalem, Israel; [Carpentier, W.] Univ Paris 06, Grp Hosp Pitie Salpetriere, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite Federale Toulouse Midi-Pyrenees (ComUE); Centre National de la Recherche Scientifique (CNRS); Hebrew University of Jerusalem; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Pende, M (corresponding author), INSERM, U845, 156 Rue Vaugirard, F-75015 Paris, France.	mario.pende@inserm.fr	Hoareau-Aveilla, Coralie/G-3787-2017; MIEULET, Virginie/F-1195-2017; Pende, Mario/AFR-1348-2022; Cagnard, Nicolas/K-2754-2014	Hoareau-Aveilla, Coralie/0000-0001-5506-4552; MIEULET, Virginie/0000-0001-5104-639X; Pende, Mario/0000-0002-7864-8937; Kiss, Tamas/0000-0003-0293-3093; Cagnard, Nicolas/0000-0002-9051-1896	European Research Council; Fondation de la Recherche Medicale; Fondation Schlumberger pour l'Education et la Recherche; ANR; US-Israel Binational Science Foundation [2009054]; Israel Cancer Research Fund; Ministry of Health; Coddim Ile de France	European Research Council(European Research Council (ERC)European Commission); Fondation de la Recherche Medicale(Fondation pour la Recherche Medicale); Fondation Schlumberger pour l'Education et la Recherche; ANR(French National Research Agency (ANR)); US-Israel Binational Science Foundation(US-Israel Binational Science Foundation); Israel Cancer Research Fund; Ministry of Health; Coddim Ile de France	We thank the Novartis Foundation and George Thomas laboratory for the use of S6K mutant mice. We are grateful to the members of INSERM-U845 for support, and to Stefano Fumagalli and Olivier Jean-Jean for helpful discussions and sharing reagents. We thank Sophie Berissi, Ana Diaz and Sylvie Fabrega for excellent technical support. We thank Pfizer for the generous gift of Temsirolimus. This work was supported by grants to MP from the European Research Council, from Fondation de la Recherche Medicale, from Fondation Schlumberger pour l'Education et la Recherche and from ANR and by grants to OM from the US-Israel Binational Science Foundation (2009054), Israel Cancer Research Fund and Ministry of Health. CC received a fellowship from the Coddim Ile de France.	Bernstein KA, 2006, MOL CELL BIOL, V26, P1195, DOI 10.1128/MCB.26.4.1195-1208.2006; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105; Dai MS, 2010, J BIOL CHEM, V285, P12587, DOI 10.1074/jbc.M109.056259; De Marchis ML, 2005, RNA, V11, P495, DOI 10.1261/rna.7200205; De S, 2010, BIOCHEM SOC T, V38, P1543, DOI 10.1042/BST0381543; De S, 2011, RNA, V17, P1713, DOI 10.1261/rna.2808411; Dibble CC, 2009, MOL CELL BIOL, V29, P5657, DOI 10.1128/MCB.00735-09; Dosil M, 2004, J BIOL CHEM, V279, P37385, DOI 10.1074/jbc.M404909200; Espeillac C, 2011, J CLIN INVEST, V121, P2821, DOI 10.1172/JCI44203; Gautier T, 1997, MOL CELL BIOL, V17, P7088, DOI 10.1128/MCB.17.12.7088; Ge JP, 2010, MOL CELL BIOL, V30, P413, DOI 10.1128/MCB.01128-09; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; Guertin DA, 2006, CURR BIOL, V16, P958, DOI 10.1016/j.cub.2006.03.084; Hannan KM, 2003, MOL CELL BIOL, V23, P8862, DOI 10.1128/MCB.23.23.8862-8877.2003; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Huber A, 2011, EMBO J, V30, P3052, DOI 10.1038/emboj.2011.221; Iadevaia V, 2012, NUCLEIC ACIDS RES, V40, P2527, DOI 10.1093/nar/gkr1040; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Jorgensen P, 2004, GENE DEV, V18, P2491, DOI 10.1101/gad.1228804; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; Kiss T, 2010, MOL CELL, V37, P597, DOI 10.1016/j.molcel.2010.01.032; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KRIEG J, 1988, J BIOL CHEM, V263, P11473; Laplante M, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011593; Lempiainen H, 2009, MOL CELL, V33, P704, DOI 10.1016/j.molcel.2009.01.034; Lempiainen H, 2009, CURR OPIN CELL BIOL, V21, P855, DOI 10.1016/j.ceb.2009.09.002; Liu PCC, 2001, MOL BIOL CELL, V12, P3644, DOI 10.1091/mbc.12.11.3644; Malygin AA, 2007, NUCLEIC ACIDS RES, V35, P6414, DOI 10.1093/nar/gkm701; Mariappan MM, 2011, AM J PHYSIOL-RENAL, V300, pF219, DOI 10.1152/ajprenal.00207.2010; Max X, 2008, CELL, V133, P303, DOI 10.1016/j.cell.2008.02.031; Mayer C, 2004, GENE DEV, V18, P423, DOI 10.1101/gad.285504; Mieulet V, 2007, AM J PHYSIOL-CELL PH, V293, pC712, DOI 10.1152/ajpcell.00499.2006; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Ohanna M, 2005, NAT CELL BIOL, V7, P286, DOI 10.1038/ncb1231; Patursky-Polischuk I, 2009, MOL CELL BIOL, V29, P640, DOI 10.1128/MCB.00980-08; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Powley IR, 2009, GENE DEV, V23, P1207, DOI 10.1101/gad.516509; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Shahbazian D, 2006, EMBO J, V25, P2781, DOI 10.1038/sj.emboj.7601166; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; THOMAS G, 1980, CELL, V19, P1015, DOI 10.1016/0092-8674(80)90092-6; Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Tremblay F, 2007, P NATL ACAD SCI USA, V104, P14056, DOI 10.1073/pnas.0706517104; Urban J, 2007, MOL CELL, V26, P663, DOI 10.1016/j.molcel.2007.04.020; Venema J, 2000, RNA, V6, P1660, DOI 10.1017/S1355838200001369; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Yoon A, 2006, SCIENCE, V312, P902, DOI 10.1126/science.1123835	52	172	179	4	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					474	483		10.1038/onc.2012.606	http://dx.doi.org/10.1038/onc.2012.606			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23318442				2022-12-17	WOS:000330214600008
J	Sanchez-Cespedes, M				Sanchez-Cespedes, M.			A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome	ONCOGENE			English	Review						LKB1; lung cancer; Peutz-Jeghers syndrome; tumor suppressor gene	TUMOR-SUPPRESSOR KINASE; SOMATIC MUTATIONS; LUNG-CANCER; LKB1/STK11 GENE; STK11/LKB1 GENE; KNOCKOUT MICE; GROWTH ARREST; EXPRESSION; STRAD; INDUCTION	Germline LKB1 mutations are responsible for Peutz Jeghers syndrome (PJS). Tumors at several locations frequently arise in these patients, confirming that LKB1 is linked to cancer predisposition and is therefore a bona. de tumor-suppressor gene. In humans, the LKB1 gene is located in the short arm of chromosome 19, which is frequently deleted in many tumors of sporadic origin. However, LKB1 alterations in tumors other than those of PJS are rarely reported. Notably, this is not the case for non-small-cell lung cancer, where nearly half of the tumors harbor somatic and homozygous inactivating mutations in LKB1. The present review considers the frequency and pattern of LKB1 gene mutations in sporadic cancers of various origins, and the role of the encoded protein in cancer development.	Spanish Natl Canc Ctr CNIO, Mol Pathol Programme, Madrid 28029, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO)	Sanchez-Cespedes, M (corresponding author), Spanish Natl Canc Ctr CNIO, Mol Pathol Programme, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	msanchez@cnio.es	Sanchez-Cespedes, Montse/H-8485-2012	Sanchez-Cespedes, Montse/0000-0002-6045-5627				Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H; Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Alhopuro P, 2005, BRIT J CANCER, V92, P1126, DOI 10.1038/sj.bjc.6602454; Avizienyte E, 1998, CANCER RES, V58, P2087; Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Bignell GR, 1998, CANCER RES, V58, P1384; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Buchet-Poyau K, 2002, CYTOGENET GENOME RES, V97, P171, DOI 10.1159/000066620; Carretero J, 2007, ONCOGENE, V26, P1616, DOI 10.1038/sj.onc.1209951; Carretero J, 2004, ONCOGENE, V23, P4037, DOI 10.1038/sj.onc.1207502; CONDE E, 2007, HUMAN PATHOL; Connolly DC, 2000, AM J PATHOL, V156, P339, DOI 10.1016/S0002-9440(10)64735-9; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Fernandez P, 2004, ONCOGENE, V23, P5084, DOI 10.1038/sj.onc.1207665; Ghaffar H, 2003, CLIN CANCER RES, V9, P2998; Giardiello FM, 2000, GASTROENTEROLOGY, V119, P1447, DOI 10.1053/gast.2000.20228; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Guldberg P, 1999, ONCOGENE, V18, P1777, DOI 10.1038/sj.onc.1202486; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hearle NCM, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.036830; Hearle N, 2006, CLIN CANCER RES, V12, P3209, DOI 10.1158/1078-0432.CCR-06-0083; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; JEGHERS H, 1949, NEW ENGL J MED, V241, P1031, DOI 10.1056/NEJM194912292412601; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jimenez AI, 2003, CANCER RES, V63, P1382; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Katajisto P, 2007, BBA-REV CANCER, V1775, P63, DOI 10.1016/j.bbcan.2006.08.003; Kim CJ, 2004, EUR J CANCER, V40, P136, DOI 10.1016/S0959-8049(03)00659-2; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kuragaki C, 2003, LAB INVEST, V83, P35, DOI 10.1097/01.LAB.0000049821.16698.D0; Launonen V, 2005, HUM MUTAT, V26, P291, DOI 10.1002/humu.20222; Lim W, 2004, GASTROENTEROLOGY, V126, P1788, DOI 10.1053/j.gastro.2004.03.014; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Luukko K, 1999, MECH DEVELOP, V83, P187, DOI 10.1016/S0925-4773(99)00050-7; Marignani PA, 2001, J BIOL CHEM, V276, P32415, DOI 10.1074/jbc.C100207200; Martone ME, 2003, NEUROINFORMATICS, V1, P379, DOI 10.1385/NI:1:4:379; MATSUMOTO S, 2007, ONCOGENE; Mehenni H, 1998, AM J HUM GENET, V63, P1641, DOI 10.1086/302159; Miyoshi H, 2002, CANCER RES, V62, P2261; Nakau M, 2002, CANCER RES, V62, P4549; NELLIST M, 1993, CELL, V75, P1305; Qiu W, 2006, ONCOGENE, V25, P2937, DOI 10.1038/sj.onc.1209325; Rossi DJ, 2002, P NATL ACAD SCI USA, V99, P12327, DOI 10.1073/pnas.192301399; Rowan A, 2000, J PATHOL, V192, P203; Rowan A, 1999, J INVEST DERMATOL, V112, P509, DOI 10.1046/j.1523-1747.1999.00551.x; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Spicer J, 2004, CURR BIOL, V14, pR383, DOI 10.1016/j.cub.2004.05.012; Su GH, 1999, AM J PATHOL, V154, P1835, DOI 10.1016/S0002-9440(10)65440-5; Thomas RK, 2006, NAT MED, V12, P852, DOI 10.1038/nm1437; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tiainen M, 2002, HUM MOL GENET, V11, P1497, DOI 10.1093/hmg/11.13.1497; Upadhyay S, 2006, CANCER RES, V66, P7870, DOI 10.1158/0008-5472.CAN-05-2902; Volikos E, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.039875; Wang ZJ, 1999, J MED GENET, V36, P365; Wang ZJ, 1999, BRIT J CANCER, V80, P70, DOI 10.1038/sj.bjc.6690323; Ylikorkala A, 1999, HUM MOL GENET, V8, P45, DOI 10.1093/hmg/8.1.45; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074	64	172	180	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2007	26	57					7825	7832		10.1038/sj.onc.1210594	http://dx.doi.org/10.1038/sj.onc.1210594			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599048				2022-12-17	WOS:000252163500001
J	Roman-Gomez, J; Jimenez-Velasco, A; Agirre, X; Cervantes, F; Sanchez, J; Garate, L; Barrios, M; Castillejo, JA; Navarro, G; Colomer, D; Prosper, F; Heiniger, A; Torres, A				Roman-Gomez, J; Jimenez-Velasco, A; Agirre, X; Cervantes, F; Sanchez, J; Garate, L; Barrios, M; Castillejo, JA; Navarro, G; Colomer, D; Prosper, F; Heiniger, A; Torres, A			RETRACTED: Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia (Retracted article. See vol. 32, pg. 804, 2013)	ONCOGENE			English	Article; Retracted Publication						CML; hypomethylation; retrotransposons; LINE-1; blast crisis	DNA HYPOMETHYLATION; C-MET; L1 RETROTRANSPOSONS; COLORECTAL-CANCER; IN-VITRO; METHYLATION; INSTABILITY; EXPRESSION; TRANSLOCATION; BREAKPOINT	Aberrant genome-wide hypomethylation is thought to be related to tumorigenesis by promoting genomic instability. Since DNA methylation is considered an important mechanism for the silencing of retroelements, hypomethylation in human tumors may lead to their reactivation. However, the role of DNA hypomethylation in chronic myeloid leukemia (CML) remains to be elucidated. In this study, the methylation status of the LINE-1 (L1) retrotransposon promoter was analysed in CML samples from the chronic-phase (CP, n = 140) and the blast crisis (BC, n = 47). L1 hypomethylation was significantly more frequent in BC (74.5%) than in CP (38%) (P < 0.0001). Furthermore, L1 hypomethylation led to activation of both ORF1 sense transcription (P < 0.0001) and c-MET gene antisense transcription (P < 0.0001), and was significantly associated with high levels of BCR-ABL (P = 0.02) and DNMT3b4 (P = 0.001) transcripts. Interestingly, in CP-CML, extensive L1 hypomethylation was associated with poorer prognosis in terms of cytogenetic response to interferon (P = 0.004) or imatinib (P = 0.034) and progression-free survival (P = 0.005). The above results strongly suggest that activation of both sense and antisense transcriptions by aberrant promoter hypomethylation of the L1 elements plays a role in the progression and clinical behavior of the CML.	Reina Sofia Hosp, Dept Hematol, Cordoba 14004, Spain; Carlos Haya Hosp, Dept Hematol, Malaga, Spain; Univ Navarra, Sch Med, Clin Univ, Hematol Dept,Cellular Therapy Area,Fdn Appl Med R, E-31080 Pamplona, Spain; Hosp Clin Barcelona, Dept Hematol, IDIBAPS, Barcelona, Spain	Hospital Universitario Reina Sofia - Cordoba; Hospital Carlos Haya; University of Navarra; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Roman-Gomez, J (corresponding author), Reina Sofia Hosp, Dept Hematol, Avda Menendez Pidal S-N, Cordoba 14004, Spain.	peperosa@teleline.es	COLOMER, DOLORS/ABG-6894-2020; Prosper, Felipe/H-6859-2017; Agirre, Xabier/ABE-4110-2020	Prosper, Felipe/0000-0001-6115-8790; COLOMER, DOLORS/0000-0001-7486-8484				Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BRATTHAUER GL, 1992, ONCOGENE, V7, P507; Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182/blood-2003-12-4111; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Christensen JG, 2003, CANCER RES, V63, P7345; Comoglio PM, 2001, NAT CELL BIOL, V3, pE161, DOI 10.1038/35083116; DANTE R, 1992, ANTICANCER RES, V12, P559; Deininger PL, 2002, GENOME RES, V12, P1455, DOI 10.1101/gr.282402; Deutsch E, 2001, BLOOD, V97, P2084, DOI 10.1182/blood.V97.7.2084; Deutsch E, 2003, BLOOD, V101, P4583, DOI 10.1182/blood-2002-10-3011; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Emig M, 1999, LEUKEMIA, V13, P1825, DOI 10.1038/sj.leu.2401566; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Florl AR, 1999, BRIT J CANCER, V80, P1312, DOI 10.1038/sj.bjc.6690524; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Hasford J, 1998, JNCI-J NATL CANCER I, V90, P850, DOI 10.1093/jnci/90.11.850; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HIGUMANN P, 2002, GENOMICS, V79, P628; Huntly BJP, 2003, BLOOD, V102, P1160, DOI 10.1182/blood-2003-01-0123; KANTARJIAN HM, 1990, AM J MED, V88, P1, DOI 10.1016/0002-9343(90)90119-X; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Lin CH, 2001, CANCER RES, V61, P4238; Liu J, 1997, GENE CHROMOSOME CANC, V18, P232, DOI 10.1002/(SICI)1098-2264(199703)18:3<232::AID-GCC10>3.0.CO;2-K; Ma PC, 2003, CANCER METAST REV, V22, P309, DOI 10.1023/A:1023768811842; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; Menendez L, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-12; MIKI Y, 1992, CANCER RES, V52, P643; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; NAGARAJAN L, 1990, BLOOD, V75, P82; Ovchinnikov I, 2002, P NATL ACAD SCI USA, V99, P10522, DOI 10.1073/pnas.152346799; POMYKALA HM, 1994, MOL CELL BIOL, V14, P7604, DOI 10.1128/MCB.14.11.7604; Prak ETL, 2000, NAT REV GENET, V1, P134; Rizwana R, 1999, J CELL SCI, V112, P4513; Saito Y, 2002, P NATL ACAD SCI USA, V99, P10060, DOI 10.1073/pnas.152121799; Santourlidis S, 1999, PROSTATE, V39, P166; Schulz WA, 2002, GENE CHROMOSOME CANC, V35, P58, DOI 10.1002/gcc.10092; Shet AS, 2002, LEUKEMIA, V16, P1402, DOI 10.1038/sj.leu.2402577; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; SOKAL JE, 1984, BLOOD, V63, P789, DOI 10.1182/blood.V63.4.789.789; Speek M, 2001, MOL CELL BIOL, V21, P1973, DOI 10.1128/MCB.21.6.1973-1985.2001; Suter CM, 2004, INT J COLORECTAL DIS, V19, P95, DOI 10.1007/s00384-003-0539-3; Takai D, 2000, JPN J CLIN ONCOL, V30, P306, DOI 10.1093/jjco/hyd079; Wong N, 2001, AM J PATHOL, V159, P465, DOI 10.1016/S0002-9440(10)61718-X; Woodcock DM, 1997, J BIOL CHEM, V272, P7810, DOI 10.1074/jbc.272.12.7810; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Yu F, 2001, NUCLEIC ACIDS RES, V29, P4493, DOI 10.1093/nar/29.21.4493	51	172	189	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7213	7223		10.1038/sj.onc.1208866	http://dx.doi.org/10.1038/sj.onc.1208866			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16170379	Green Published			2022-12-17	WOS:000232990100010
J	Simon, M; Grandage, VL; Linch, DC; Khwaja, A				Simon, M; Grandage, VL; Linch, DC; Khwaja, A			Constitutive activation of the Wnt/ss-catenin signalling pathway in acute myeloid leukaemia	ONCOGENE			English	Article						leukaemia; ss-catenin; CD34; differentiation	HEMATOPOIETIC STEM-CELLS; EFFICIENT GENE-TRANSFER; BETA-CATENIN; SELF-RENEWAL; TRANSLOCATION PRODUCTS; COLORECTAL-CANCER; FLT3 MUTATIONS; PROLIFERATION; LEUKEMOGENESIS; EXPRESSION	The beta-catenin protein is at the core of the canonical Wnt signalling pathway. Wnt stimulation leads to beta-catenin accumulation, nuclear translocation and interaction with T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription factors to regulate genes important for embryonic development and proliferation. Wnt/beta-catenin can promote stem cell self-renewal and is dysregulated in colon carcinoma. We have examined the role of the Wnt pathway in the development of acute myeloid leukaemia (AML) and find that the beta-catenin protein is: readily detected in primary AML samples. Using transfection of a TCF/LEF reporter construct into primary AML cells and normal human progenitors, we find increased reporter activity in 16/25 leukaemia samples. Retrovirally mediated expression of a mutant active beta-catenin in normal progenitors preserves CD34 expression and impairs myelomonocytic differentiation. Activation of TCF/LEF signalling decreases factor withdrawal-induced apoptosis of normal progenitors. A significant proportion of ANIL cases show aberrant expression of components of the Wnt pathway including Wnt-1, Wnt-2b and LEF-1. These results provide evidence for the involvement of the Wnt/beta-catenin pathway in the pathogenesis of AML.	UCL Royal Free & Univ Coll, Sch Med, Dept Haematol, London WC1E 6HX, England	University of London; University College London; UCL Medical School	Khwaja, A (corresponding author), UCL Royal Free & Univ Coll, Sch Med, Dept Haematol, 98 Chenies Mews, London WC1E 6HX, England.	a.khwaja@ucl.ac.uk	Khwaja, Asim/C-1509-2008					Abraham SC, 2002, AM J PATHOL, V160, P1361, DOI 10.1016/S0002-9440(10)62563-1; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Ardeshna KM, 2000, BLOOD, V96, P1039, DOI 10.1182/blood.V96.3.1039.015k04_1039_1046; Austin TW, 1997, BLOOD, V89, P3624, DOI 10.1182/blood.V89.10.3624.3624_3624_3635; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Chung EJ, 2002, BLOOD, V100, P982, DOI 10.1182/blood.V100.3.982; Cobas M, 2004, J EXP MED, V199, P221, DOI 10.1084/jem.20031615; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Kelly LM, 2002, ANNU REV GENOM HUM G, V3, P179, DOI 10.1146/annurev.genom.3.032802.115046; Kelly PF, 2000, BLOOD, V96, P1206, DOI 10.1182/blood.V96.4.1206.h8001206_1206_1214; Kikuchi A, 2003, CANCER SCI, V94, P225, DOI 10.1111/j.1349-7006.2003.tb01424.x; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kottaridis PD, 2002, BLOOD, V100, P2393, DOI 10.1182/blood-2002-02-0420; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; Lai W, 2003, J IMMUNOL METHODS, V282, P93, DOI 10.1016/j.jim.2003.07.015; Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535-6108(03)00268-X; McWhirter JR, 1999, P NATL ACAD SCI USA, V96, P11464, DOI 10.1073/pnas.96.20.11464; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Murdoch B, 2003, P NATL ACAD SCI USA, V100, P3422, DOI 10.1073/pnas.0130233100; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Quentmeier H, 2003, LEUKEMIA, V17, P120, DOI 10.1038/sj.leu.2402740; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Smalley MJ, 1999, CANCER METAST REV, V18, P215, DOI 10.1023/A:1006369223282; Stier S, 2002, BLOOD, V99, P2369, DOI 10.1182/blood.V99.7.2369; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Trompeter HI, 2003, J IMMUNOL METHODS, V274, P245, DOI 10.1016/S0022-1759(02)00431-3; Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817; Uematsu K, 2003, CANCER RES, V63, P4547; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Watts MJ, 2002, BRIT J HAEMATOL, V118, P117, DOI 10.1046/j.1365-2141.2002.03561.x; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Zheng XM, 2004, BLOOD, V103, P3535, DOI 10.1182/blood-2003-09-3335	44	172	184	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2410	2420		10.1038/sj.onc.1208431	http://dx.doi.org/10.1038/sj.onc.1208431			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735743				2022-12-17	WOS:000227877400013
J	Belguise, K; Kersual, N; Galtier, F; Chalbos, D				Belguise, K; Kersual, N; Galtier, F; Chalbos, D			FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells	ONCOGENE			English	Article						FRA-1; cell proliferation; in vitro invasion; gene expression; breast cancer cells	ENDOTHELIAL GROWTH-FACTOR; ACTIVATOR PROTEIN-1 ACTIVITY; FOS-RELATED ANTIGEN-1; TISSUE INHIBITOR; C-FOS; METALLOPROTEINASES-1 TIMP-1; MATRIX METALLOPROTEINASES; PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; BINDING-ACTIVITY	Breast cancer progression is likely a multistep process involving the activation and inactivation of a number of genes. Previously, we showed that the mRNA coding for Fra-1, a FOS family member and an AP-1 transcription factor component, was highly expressed in the more invasive estrogen receptor negative (ER-) breast cancer cell lines. We used a tet-off system to stably overexpress Fra-1 in MCF7 ER + cells and evaluate the impact of Fra-1 on this aggressive phenotype. Conversely, Fra-1 was silenced in highly invasive ER-MDA-MB231 cells using RNA interference. We report that in both systems the Fra-1 expression level was positively associated with cell proliferation, cell motility and invasiveness assessed in vitro. In addition, Fra-1 inhibition in fibroblastoid ER-cells, which formed colonies with large stellate projections in Matrigel, resulted in morphological changes. Cells acquired an epithelioid shape and had a spherical appearance in Matrigel. Fra-1 regulated several genes, implicated in invasion, angiogenesis and cell proliferation independently of beta1-integrin activation, and directly induced MMP-1 and MMP-9 promoter activity. These overall results show that high Fra-1 expression is associated with a more malignant cell phenotype and suggest that Fra-1 could have a pivotal role in breast cancer progression.	INSERM, U540, F-34090 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Chalbos, D (corresponding author), INSERM, U540, 60 Reu Navacelles, F-34090 Montpellier, France.	chalbos@u540.montp.inserm.fr		Belguise, Karine/0000-0003-3426-8040				Andersen H, 2002, ONCOGENE, V21, P4843, DOI 10.1038/sj.onc.1205590; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bamberger AM, 1999, INT J CANCER, V84, P533, DOI 10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J; Bamberger AM, 2000, HORM RES, V54, P32; BENBROOK DM, 1990, ONCOGENE, V5, P295; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brinckerhoff CE, 2000, CLIN CANCER RES, V6, P4823; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHALBOS D, 1982, J CLIN ENDOCR METAB, V55, P276, DOI 10.1210/jcem-55-2-276; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; CLARK GM, 1984, J CLIN ONCOL, V2, P1102, DOI 10.1200/JCO.1984.2.10.1102; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; Fisher E R, 1981, Breast Cancer Res Treat, V1, P37, DOI 10.1007/BF01807890; Gasparini G, 2000, Oncologist, V5 Suppl 1, P37; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRUDA MC, 1994, ONCOGENE, V9, P2537; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; Hua J, 1996, CANCER RES, V56, P5279; Hurd TW, 2002, BIOCHEM J, V368, P573, DOI 10.1042/BJ20020579; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Li GY, 1999, CANCER RES, V59, P6267; Luo YP, 2003, P NATL ACAD SCI USA, V100, P8850, DOI 10.1073/pnas.1033132100; MATSUI M, 1990, ONCOGENE, V5, P249; MCGUIRE WL, 1975, ANNU REV MED, V26, P353, DOI 10.1146/annurev.me.26.020175.002033; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Philips A, 1998, MOL ENDOCRINOL, V12, P973, DOI 10.1210/me.12.7.973; PHILIPS A, 1993, J BIOL CHEM, V268, P14103; Price DJ, 2001, CELL GROWTH DIFFER, V12, P129; Ramos-Nino ME, 2002, CANCER RES, V62, P6065; Schreiber M, 2000, DEVELOPMENT, V127, P4937; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TANG DG, 1995, J CELL PHYSIOL, V165, P291, DOI 10.1002/jcp.1041650210; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; Yoshiji H, 1998, INT J CANCER, V75, P81, DOI 10.1002/(SICI)1097-0215(19980105)75:1<81::AID-IJC13>3.3.CO;2-J; Yoshiji H, 1996, CANCER RES, V56, P2013; Yoshiji H, 1996, INT J CANCER, V69, P131, DOI 10.1002/(SICI)1097-0215(19960422)69:2<131::AID-IJC11>3.0.CO;2-C; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zajchowski DA, 2001, CANCER RES, V61, P5168	59	172	182	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1434	1444		10.1038/sj.onc.1208312	http://dx.doi.org/10.1038/sj.onc.1208312			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608675	Bronze			2022-12-17	WOS:000227092600013
J	Warner, JK; Wang, JCY; Hope, KJ; Jin, LQ; Dick, JE				Warner, JK; Wang, JCY; Hope, KJ; Jin, LQ; Dick, JE			Concepts of human leukemic development	ONCOGENE			English	Review						stem cell; NOD/SCID; leukemic stem cell; cancer stem cell; SCID-repopulating cell; SRC; SL-IC	ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; HEMATOPOIETIC STEM-CELLS; ABILITY IN-VITRO; INTERNAL TANDEM DUPLICATION; ACUTE MYELOBLASTIC-LEUKEMIA; MYOSIN HEAVY-CHAIN; BONE-MARROW-CELLS; PML-RAR-ALPHA; SELF-RENEWAL	Two fundamental problems in cancer research are identification of the normal cell within which cancer initiates and identification of the cell type capable of sustaining the growth of the neoplastic clone. There is overwhelming evidence that virtually all cancers are clonal and represent the progeny of a single cell. What is less clear for most cancers is which cells within the tumor clone possess tumorigenic or 'cancer stem cell' (CSC) properties and are capable of maintaining tumor growth. The concept that only a subpopulation of rare CSC is responsible for maintenance of the neoplasm emerged nearly 50 years ago. Testing of this hypothesis is most advanced for the hematopoietic system due to the establishment of functional in vitro and in vivo assays for stem and progenitor cells at all stages of development. This body of work led to conclusive proof for CSC with the identification and purification of leukemic stem cells capable of repopulating NOD/SCID mice. This review will focus on the historical development of the CSC hypothesis, the mechanisms necessary to subvert normal developmental programs, and the identification of the cell in which these leukemogenic events first occur.	Univ Toronto, Dept Mol Genet & Microbiol, Toronto, ON M5G 2C1, Canada; Univ Toronto, Div Cell & Mol Biol, Univ Hlth Network, Toronto, ON M5G 2C1, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Dick, JE (corresponding author), Univ Toronto, Toronto Gen Res Inst, Univ Hlth Network, Princess Margaret Hosp, Suite 7-700,620 Univ Ave, Toronto, ON M5G 2C1, Canada.	jdick@uhnres.utoronto.ca		Hope, Kristin/0000-0003-1449-4948; Dick, John/0000-0002-9527-8317; Wang, Jean/0000-0001-7543-3917				Abu-Duhier FM, 2001, BRIT J HAEMATOL, V113, P983, DOI 10.1046/j.1365-2141.2001.02850.x; Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; Ailles LE, 1999, BLOOD, V94, P1761, DOI 10.1182/blood.V94.5.1761.417k23_1761_1772; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Albitar M, 2002, BLOOD, V100, P791, DOI 10.1182/blood.V100.3.791; BECKER AJ, 1963, NATURE, V197, P452, DOI 10.1038/197452a0; Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; BENNETT JM, 1985, ANN INTERN MED, V103, P460, DOI 10.7326/0003-4819-103-3-460; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BERNSTEIN ID, 1992, BLOOD, V79, P1811, DOI 10.1182/blood.V79.7.1811.1811; Bhatia M, 1998, NAT MED, V4, P1038, DOI 10.1038/2023; BIRG F, 1992, BLOOD, V80, P2584; BLACKSTOCK AM, 1974, LANCET, V2, P1178; Blair A, 1997, BLOOD, V89, P3104, DOI 10.1182/blood.V89.9.3104; Blair A, 1998, BLOOD, V92, P4325, DOI 10.1182/blood.V92.11.4325; Blair A, 2000, EXP HEMATOL, V28, P660, DOI 10.1016/S0301-472X(00)00155-7; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Bonnet D, 2001, Rev Clin Exp Hematol, V5, P42, DOI 10.1046/j.1468-0734.2001.00028.x; BRADLEY TR, 1966, AUST J EXP BIOL MED, V44, P287, DOI 10.1038/icb.1966.28; Brendel C, 1999, LEUKEMIA, V13, P1770, DOI 10.1038/sj.leu.2401543; Britos-Bray M, 1998, BLOOD, V92, P4344, DOI 10.1182/blood.V92.11.4344.423a01_4344_4352; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; BRUCE WR, 1963, NATURE, V199, P79, DOI 10.1038/199079a0; BUDEL LM, 1989, BLOOD, V74, P565; BUICK RN, 1979, BLOOD, V54, P95; BUICK RN, 1981, BRIT J CANCER, V44, P349, DOI 10.1038/bjc.1981.191; BUICK RN, 1984, CANCER RES, V44, P4909; Busque L, 1996, BLOOD, V88, P59; CAMPOS L, 1993, BLOOD, V81, P3091; Carow CE, 1996, BLOOD, V87, P1089, DOI 10.1182/blood.V87.3.1089.bloodjournal8731089; Cashman J, 1997, BRIT J HAEMATOL, V98, P1026, DOI 10.1046/j.1365-2141.1997.3233140.x; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; CLARKSON B, 1970, CANCER, V25, P1237, DOI 10.1002/1097-0142(197006)25:6<1237::AID-CNCR2820250602>3.0.CO;2-7; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Dash A, 2001, BEST PRACT RES CL HA, V14, P49, DOI 10.1053/beha.2000.0115; Davis RE, 1998, LEUKEMIA RES, V22, P767, DOI 10.1016/S0145-2126(98)00051-4; Dehmel U, 1996, LEUKEMIA, V10, P261; Dick JE, 2003, P NATL ACAD SCI USA, V100, P3547, DOI 10.1073/pnas.0830967100; Dick JE, 2003, NATURE, V423, P231, DOI 10.1038/423231a; Drexler HG, 1999, LEUKEMIA LYMPHOMA, V33, P83, DOI 10.3109/10428199909093728; Edwards RH, 1999, AM J CLIN PATHOL, V112, P819; Engelhardt M, 1997, BLOOD, V90, P182; Enver T, 1998, CELL, V94, P9, DOI 10.1016/S0092-8674(00)81215-5; FERRARIS AM, 1985, BLOOD, V66, P342; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; FIALKOW PJ, 1981, BLOOD, V57, P1068; FIALKOW PJ, 1987, NEW ENGL J MED, V317, P468, DOI 10.1056/NEJM198708203170802; Gale RE, 1998, LEUKEMIA, V12, P117, DOI 10.1038/sj.leu.2400935; Gale RE, 1997, BRIT J HAEMATOL, V98, P512, DOI 10.1046/j.1365-2141.1997.2573078.x; Gari M, 1999, BRIT J HAEMATOL, V105, P894, DOI 10.1046/j.1365-2141.1999.01449.x; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gilliland DG, 2002, CANCER CELL, V1, P417, DOI 10.1016/S1535-6108(02)00081-8; GREAVES MF, 1986, BLOOD, V67, P1; GRIFFIN JD, 1986, BLOOD, V68, P1185; Grignani F, 2000, BLOOD, V96, P1531, DOI 10.1182/blood.V96.4.1531.h8001531_1531_1537; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grimwade D, 2002, CANCER RES, V62, P4730; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; Guan Y, 2000, LEUKEMIA, V14, P2135, DOI 10.1038/sj.leu.2401975; Guenechea G, 2000, MOL THER, V1, P566, DOI 10.1006/mthe.2000.0077; Guthridge MA, 2004, BLOOD, V103, P820, DOI 10.1182/blood-2003-06-1999; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; HAASE D, 1995, BLOOD, V86, P2906; HAMBURGER AW, 1977, SCIENCE, V197, P461, DOI 10.1126/science.560061; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris NL, 1999, J CLIN ONCOL, V17, P3835, DOI 10.1200/JCO.1999.17.12.3835; Haughn L, 2003, J BIOL CHEM, V278, P25158, DOI 10.1074/jbc.M212849200; Hayflick L, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1180; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; HEPPNER GH, 1984, CANCER RES, V44, P2259; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; HOPE K, 2004, NAT IMMUNOL     0530; ICHIKAWA Y, 1969, J CELL PHYSIOL, V73, P43, DOI 10.1002/jcp.1040730107; IKEDA H, 1991, BLOOD, V78, P2962; Jordan CT, 2000, LEUKEMIA, V14, P1777, DOI 10.1038/sj.leu.2401903; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KEINANEN M, 1988, NEW ENGL J MED, V318, P1153, DOI 10.1056/NEJM198805053181803; Kogan SC, 2001, J EXP MED, V193, P531, DOI 10.1084/jem.193.4.531; Konopleva M, 2000, BLOOD, V95, P3929; KORN A P, 1973, Experimental Hematology (Charlottesville), V1, P362; KRAEMER PM, 1986, J NATL CANCER I, V76, P703, DOI 10.1093/jnci/76.4.703; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lessard J, 1998, BLOOD, V91, P1216, DOI 10.1182/blood.V91.4.1216; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu Y, 2002, P NATL ACAD SCI USA, V99, P3597, DOI 10.1073/pnas.062549199; Lutterbach B, 1999, P NATL ACAD SCI USA, V96, P12822, DOI 10.1073/pnas.96.22.12822; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; MACKILLOP WJ, 1983, J NATL CANCER I, V70, P9; Matas D, 2004, CELL DEATH DIFFER, V11, P458, DOI 10.1038/sj.cdd.4401379; MCCULLOCH EA, 1979, BLOOD CELLS, V5, P261; MCCULLOCH EA, 1983, BLOOD, V62, P1; MEHROTRA B, 1995, BLOOD, V86, P1139; MENDELSOHN ML, 1962, SCIENCE, V135, P213, DOI 10.1126/science.135.3499.213; METCALF D, 1973, BRIT J CANCER, V27, P191, DOI 10.1038/bjc.1973.24; METCALF D, 1969, J NATL CANCER I, V43, P983; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Miller WH, 2002, ONCOGENE, V21, P3496, DOI 10.1038/sj/onc/1205328; MINDEN MD, 1979, BLOOD, V54, P186; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; Miyamoto T, 1996, BLOOD, V87, P4789, DOI 10.1182/blood.V87.11.4789.bloodjournal87114789; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; MOORE MAS, 1973, J NATL CANCER I, V50, P603, DOI 10.1093/jnci/50.3.603; Mulloy JC, 2003, BLOOD, V102, P4369, DOI 10.1182/blood-2003-05-1762; Nakao M, 1996, LEUKEMIA, V10, P1911; NARA N, 1985, BLOOD, V65, P1484, DOI 10.1182/blood.V65.6.1484.bloodjournal6561484; Ohyashiki JH, 2002, ONCOGENE, V21, P680, DOI 10.1038/sj.onc.1205075; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Pandolfi PP, 2001, ONCOGENE, V20, P3116, DOI 10.1038/sj.onc.1204299; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Park IK, 2002, BLOOD, V99, P488, DOI 10.1182/blood.V99.2.488; Pereira DS, 1998, P NATL ACAD SCI USA, V95, P8239, DOI 10.1073/pnas.95.14.8239; PLUZNIK DH, 1965, J CELL COMPAR PHYSL, V66, P319, DOI 10.1002/jcp.1030660309; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; RAYMAKERS R, 1995, LEUKEMIA, V9, P450; Reilly JT, 2003, BLOOD REV, V17, P241, DOI 10.1016/S0268-960X(03)00024-9; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rufer N, 1999, J EXP MED, V190, P157, DOI 10.1084/jem.190.2.157; Rufer N, 2001, BLOOD, V97, P575, DOI 10.1182/blood.V97.2.575; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Schnittger S, 2002, BLOOD, V100, P59, DOI 10.1182/blood.V100.1.59; Schwieger M, 2004, BLOOD, V103, P2744, DOI 10.1182/blood-2003-07-2280; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SINGH S, 2003, CANCER RES, V63, P5281; So CW, 2003, CANCER CELL, V3, P161, DOI 10.1016/S1535-6108(03)00019-9; SOUTHAM CM, 1961, CANCER, V14, P971, DOI 10.1002/1097-0142(196109/10)14:5<971::AID-CNCR2820140510>3.0.CO;2-O; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Sutherland HJ, 1996, BLOOD, V87, P4754, DOI 10.1182/blood.V87.11.4754.bloodjournal87114754; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Terpstra W, 1996, BLOOD, V88, P1944, DOI 10.1182/blood.V88.6.1944.bloodjournal8861944; Terpstra W, 1996, BLOOD, V87, P2187, DOI 10.1182/blood.V87.6.2187.bloodjournal8762187; Testa U, 1998, J CLIN INVEST, V101, P2278, DOI 10.1172/JCI1332; Testa U, 2004, LEUKEMIA, V18, P219, DOI 10.1038/sj.leu.2403224; Testa U, 2002, BLOOD, V100, P2980, DOI 10.1182/blood-2002-03-0852; Thiede C, 2002, BLOOD, V99, P4326, DOI 10.1182/blood.V99.12.4326; Thorsteinsdottir U, 1997, HEMATOL ONCOL CLIN N, V11, P1221, DOI 10.1016/S0889-8588(05)70491-3; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; TURHAN AG, 1995, BLOOD, V85, P2154, DOI 10.1182/blood.V85.8.2154.bloodjournal8582154; Wang JM, 2003, MOL CELL BIOL, V23, P1896, DOI 10.1128/MCB.23.6.1896-1909.2003; WANTZIN GL, 1977, EUR J CANCER, V13, P647, DOI 10.1016/0014-2964(77)90050-0; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Yokota S, 1997, LEUKEMIA, V11, P1605, DOI 10.1038/sj.leu.2400812; Yui J, 1998, BLOOD, V91, P3255, DOI 10.1182/blood.V91.9.3255.3255_3255_3262; Zanjani ED, 1998, EXP HEMATOL, V26, P353; Zheng R, 2004, BLOOD, V103, P267, DOI 10.1182/blood-2003-06-1969	153	172	176	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2004	23	43					7164	7177		10.1038/sj.onc.1207933	http://dx.doi.org/10.1038/sj.onc.1207933			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378077				2022-12-17	WOS:000223998800003
J	Fulda, S; Debatin, KM				Fulda, S; Debatin, KM			Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol	ONCOGENE			English	Article						apoptosis; resveratrol; anticancer drugs; cancer	CELL-CYCLE; NEUROBLASTOMA-CELLS; CD95 APO-1/FAS; CANCER; DEATH; CHEMOTHERAPY; SURVIVIN; DEGRADATION; INHIBITION; EXPRESSION	Current attempts to improve the survival of cancer patients largely depend on strategies to target tumor cell resistance. Naturally occurring dietary compounds such as resveratrol have gained considerable attention as cancer chemopreventive agents. Here, we report that resveratrol acts as potent sensitizer for anticancer drug-induced apoptosis by inducing cell cycle arrest, which in turn resulted in survivin depletion. Concomitant analysis of cell cycle and apoptosis revealed that pretreatment with resveratrol resulted in cell cycle arrest in S phase and apoptosis induction preferentially out of S phase upon subsequent drug treatment. Likewise, cell cycle arrest in S phase by cell cycle inhibitors enhanced drug-induced apoptosis. Resveratrol-mediated cell cycle arrest sensitized for apoptosis by downregulating survivin expression through transcriptional and post-transcriptional mechanisms. Similarly, downregulation of survivin expression using survivin antisense oligonucleotides sensitized for drug-induced apoptosis. Importantly, downregulation of survivin and enhanced drug-induced apoptosis by resveratrol occurred in various human tumor cell lines irrespective of p53 status. Thus, this combined sensitizer ( resveratrol)/inducer ( cytotoxic drugs) concept may be a novel strategy to enhance the efficacy of anticancer therapy in a variety of human cancers.	Univ Childrens Hosp, D-89075 Ulm, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Debatin, KM (corresponding author), Univ Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.	klaus-michael.debatin@medizin.uni-ulm.de	Debatin, Klaus-Michael/J-9704-2014; Fulda, Simone/D-5864-2011	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bernhard D, 2000, CELL DEATH DIFFER, V7, P834, DOI 10.1038/sj.cdd.4400719; Bierau J, 2003, INT J CANCER, V103, P387, DOI 10.1002/ijc.10858; Cal C., 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P77, DOI 10.2174/1568011033353443; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Fulda S, 2000, CANCER RES, V60, P3947; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Gusman J, 2001, CARCINOGENESIS, V22, P1111, DOI 10.1093/carcin/22.8.1111; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kim B, 2002, J BIOL CHEM, V277, P27393, DOI 10.1074/jbc.M201963200; Kong ANT, 2001, MUTAT RES-FUND MOL M, V480, P231, DOI 10.1016/S0027-5107(01)00182-8; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Mahotka C, 1999, CANCER RES, V59, P6097; Olie RA, 2000, CANCER RES, V60, P2805; Park EJ, 2002, CANCER METAST REV, V21, P231, DOI 10.1023/A:1021254725842; Pucci B, 2000, NEOPLASIA, V2, P291, DOI 10.1038/sj.neo.7900101; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sherr CJ, 2000, CANCER RES, V60, P3689; Smith DM, 2000, INT J MOL MED, V6, P503; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; Zhao J, 2000, J CELL SCI, V113, P4363	37	172	181	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6702	6711		10.1038/sj.onc.1207630	http://dx.doi.org/10.1038/sj.onc.1207630			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273734				2022-12-17	WOS:000223653600002
J	Lee, AY; He, B; You, L; Dadfarmay, S; Xu, ZD; Mazieres, J; Mikami, I; McCormick, F; Jablons, DM				Lee, AY; He, B; You, L; Dadfarmay, S; Xu, ZD; Mazieres, J; Mikami, I; McCormick, F; Jablons, DM			Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma	ONCOGENE			English	Article						SFRP; Wnt signaling; methylation; malignant pleural mesothelioma	DIFFERENTIAL EXPRESSION; BREAST-TUMORS; CANCER; INHIBITION; MECHANISMS; APOPTOSIS; PATTERNS; PATHWAY; BINDS; CELLS	Secreted frizzled-related proteins (sFRPs) comprise a family of five secreted glycoproteins that antagonize Wnt signaling. Aberrant activation and upregulation of the Wnt pathway is a key feature of many cancers. Thus, role of sFRP as a negative regulator of Wnt signaling may have important implications in tumorigenesis, and its downregulation has been correlated with human cancers. Recently, we reported Wnt signaling and dishevelled (Dvl) overexpression in malignant pleural mesothelioma (MM). Here, we report significant transcriptional downregulation of the SFRP gene family in MM primary tissues and cell lines as well as several other cancer cell lines ( breast, lung, glioma, and cervical) compared to normal cells. One or more SFRPs were downregulated in approximately 85% ( 18 of 21) of primary MM tumor specimens compared to normal pleural tissue. Eight of the nine cancer cell lines we examined showed silencing of the SFRP family. Methylation-specific PCR (MSP) analysis showed that SFRP1, SFRP4, and SFRP5 gene promoters are frequently methylated in MM primary tissue (>80%). Furthermore, transfection of the SFRP gene construct into MM cell lines lacking SFRP expression resulted in apoptosis and growth suppression. Our results suggest that methylation silencing of SFRPs may be one of the important mechanisms of aberrant Wnt signaling activation in MM.	Univ Calif San Francisco, Ctr Comprehens Canc, Dept Surg, Thorac Oncol Lab, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Jablons, DM (corresponding author), Ctr Canc, Dept Surg, 1600 Divisadero St,C322C,Box 1674, San Francisco, CA 94115 USA.	jablonsd@surgery.ucsf.edu	MAZIERES, JULIEN/M-3986-2014	MAZIERES, JULIEN/0000-0002-5921-7613	NATIONAL CANCER INSTITUTE [R01CA093708] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA093708-01A3, R01 CA093708] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abu-Jawdeh G, 1999, LAB INVEST, V79, P439; Abutaily AS, 2003, J PATHOL, V201, P355, DOI 10.1002/path.1458; Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Baylin SB, 2002, SEMIN CANCER BIOL, V12, P331, DOI 10.1016/S1044-579X(02)00053-6; Butchart E G, 1999, Oncologist, V4, P488; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Fukuhara K, 2002, J CLIN ENDOCR METAB, V87, P1729, DOI 10.1210/jc.87.4.1729; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hu ED, 1998, BIOCHEM BIOPH RES CO, V247, P287, DOI 10.1006/bbrc.1998.8784; Ijiri K, 2002, J RHEUMATOL, V29, P2266; Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136; Ko JS, 2002, EXP CELL RES, V280, P280, DOI 10.1006/excr.2002.5649; Lee Y C, 2000, Curr Opin Pulm Med, V6, P267, DOI 10.1097/00063198-200007000-00003; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Uematsu K, 2003, CANCER RES, V63, P4547; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wong SCC, 2002, J PATHOL, V196, P145, DOI 10.1002/path.1035; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4	23	172	192	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6672	6676		10.1038/sj.onc.1207881	http://dx.doi.org/10.1038/sj.onc.1207881			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15221014				2022-12-17	WOS:000223530800015
J	Sekiguchi, M; Tsuzuki, T				Sekiguchi, M; Tsuzuki, T			Oxidative nucleotide damage: consequences and prevention	ONCOGENE			English	Article						DNA replication fidelity; oxygen radicals; oxidized guanine base; mutagenesis; carcinogenesis; genomic stability	ESCHERICHIA-COLI MUTT; NUCLEOSIDE TRIPHOSPHATE PYROPHOSPHOHYDROLASE; GENERATES G.C->T.A TRANSVERSIONS; GENE ENCODING 8-OXO-DGTPASE; C-G TRANSVERSION; DNA-SYNTHESIS; MUTAGENIC SUBSTRATE; HUMAN-CELLS; MOLECULAR-CLONING; MTH1 GENE	8-Oxoguanine (8-oxo-7,8-dihydroguanine) is produced in DNA, as well as in nucleotide pools of cells, by reactive oxygen species normally formed during cellular metabolic processes. 8-Oxoguanine nucleotide can pair with cytosine and adenine nucleotides with an almost equal efficiency, then transversion mutation ensues. MutT protein of Escherichia coli and related mammalian protein MTH1 specifically degrade 8-oxo-dGTP to 8-oxo-dGMP, thereby preventing misincorporation of 8oxoguanine into DNA. The bacterial and mammalian enzymes are close in their size and share a highly conserved region consisting of 23 residues with 14 identical amino acids. Following saturation mutagenesis of this region, most of these residues proved to be essential to exert 8-oxo-dGTPase activity. Gene targeting was done to establish MTH1-deficient cell lines and mice for study. When examined 18 months after birth, a greater number of tumors were formed in the lungs, livers, and stomachs of MTHI-/- mice, as compared with findings in wild-type mice. These proteins protect genetic information from untoward effects of threats of endogenous oxygen.	Biomol Engn Res Inst, Suita, Osaka 5650874, Japan; Kyushu Univ, Fac Med Sci, Dept Med Biophys & Radiat Biol, Fukuoka 8128582, Japan	Kyushu University	Sekiguchi, M (corresponding author), Biomol Engn Res Inst, Suita, Osaka 5650874, Japan.							ABEYGUNAWARDANA C, 1995, BIOCHEMISTRY-US, V34, P14997, DOI 10.1021/bi00046a006; ABEYGUNAWARDANA C, 1993, BIOCHEMISTRY-US, V32, P13071, DOI 10.1021/bi00211a017; AKIYAMA M, 1987, MOL GEN GENET, V206, P9, DOI 10.1007/BF00326530; AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; BESSHO T, 1992, BIOCHEM BIOPH RES CO, V188, P372, DOI 10.1016/0006-291X(92)92395-E; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BESTWICK RK, 1982, J BIOL CHEM, V257, P9300; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; Boiteux S, 1999, BIOCHIMIE, V81, P59, DOI 10.1016/S0300-9084(99)80039-X; Brooks PJ, 2000, J BIOL CHEM, V275, P22355, DOI 10.1074/jbc.M002259200; BULLIONS LC, 1994, J BIOL CHEM, V269, P12339; CABRERA M, 1988, J BACTERIOL, V170, P5405, DOI 10.1128/jb.170.11.5405-5407.1988; CAI JP, 1995, CARCINOGENESIS, V16, P2343, DOI 10.1093/carcin/16.10.2343; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHUNG MH, 1991, MUTAT RES, V254, P1, DOI 10.1016/0921-8777(91)90035-N; Colussi C, 2002, CURR BIOL, V12, P912, DOI 10.1016/S0960-9822(02)00863-1; COX EC, 1967, P NATL ACAD SCI USA, V58, P1895, DOI 10.1073/pnas.58.5.1895; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; EGASHIRA A, 2002, DNA REPAIR, V75, P1; EVANS J, 1993, MUTAT RES, V299, P147, DOI 10.1016/0165-1218(93)90092-R; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; FRICK DN, 1995, BIOCHEMISTRY-US, V34, P5577, DOI 10.1021/bi00016a032; Fujii Y, 1999, J BIOL CHEM, V274, P38251, DOI 10.1074/jbc.274.53.38251; FURUICHI M, 1994, GENOMICS, V24, P485, DOI 10.1006/geno.1994.1657; GAJEWSKI E, 1990, BIOCHEMISTRY-US, V29, P7876, DOI 10.1021/bi00486a014; HAYAKAWA H, 1995, BIOCHEMISTRY-US, V34, P89, DOI 10.1021/bi00001a011; Hayakawa H, 1999, BIOCHEMISTRY-US, V38, P3610, DOI 10.1021/bi982361l; Henle ES, 1997, J BIOL CHEM, V272, P19095, DOI 10.1074/jbc.272.31.19095; Igarashi H, 1997, J BIOL CHEM, V272, P3766, DOI 10.1074/jbc.272.6.3766; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jackson AL, 1998, GENETICS, V148, P1483; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; KAMATH AV, 1993, GENE, V134, P99, DOI 10.1016/0378-1119(93)90180-B; KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Kobayashi M, 1998, J BIOL CHEM, V273, P26394, DOI 10.1074/jbc.273.41.26394; Kornberg A., 1992, DNA REPLICATION; Kuraoka I, 2000, P NATL ACAD SCI USA, V97, P3832, DOI 10.1073/pnas.070471597; Lin J, 1996, BIOCHEMISTRY-US, V35, P6715, DOI 10.1021/bi953071x; Lin J, 1997, BIOCHEMISTRY-US, V36, P1199, DOI 10.1021/bi962619c; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; MINNICK DT, 1994, NUCLEIC ACIDS RES, V22, P5658, DOI 10.1093/nar/22.25.5658; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; MO JY, 1991, J MOL BIOL, V222, P925, DOI 10.1016/0022-2836(91)90586-U; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; O'Handley SF, 1998, J BIOL CHEM, V273, P3192, DOI 10.1074/jbc.273.6.3192; Oda H, 1997, J BIOL CHEM, V272, P17843, DOI 10.1074/jbc.272.28.17843; Oda H, 1999, NUCLEIC ACIDS RES, V27, P4335, DOI 10.1093/nar/27.22.4335; OHandley SF, 1996, J BIOL CHEM, V271, P24649, DOI 10.1074/jbc.271.40.24649; Ohtsubo T, 1998, MOL GEN GENET, V259, P577, DOI 10.1007/s004380050851; PAVLOV YI, 1994, BIOCHEMISTRY-US, V33, P4695, DOI 10.1021/bi00181a029; Poole TM, 1996, CARCINOGENESIS, V17, P191, DOI 10.1093/carcin/17.2.191; Safrany ST, 1998, EMBO J, V17, P6599, DOI 10.1093/emboj/17.22.6599; Sakai Y, 2002, J BIOL CHEM, V277, P8579, DOI 10.1074/jbc.M110566200; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SCHAAPER RM, 1986, J MOL BIOL, V189, P273, DOI 10.1016/0022-2836(86)90509-7; Sheikh S, 1998, J BIOL CHEM, V273, P20924, DOI 10.1074/jbc.273.33.20924; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Shimokawa H, 2000, NUCLEIC ACIDS RES, V28, P3240, DOI 10.1093/nar/28.17.3240; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; SMITH KC, 1992, MUTAT RES, V277, P139, DOI 10.1016/0165-1110(92)90002-Q; Stoler DL, 1999, P NATL ACAD SCI USA, V96, P15121, DOI 10.1073/pnas.96.26.15121; Taddei F, 1997, SCIENCE, V278, P128, DOI 10.1126/science.278.5335.128; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; TREFFERS HP, 1954, P NATL ACAD SCI USA, V40, P1064, DOI 10.1073/pnas.40.11.1064; Tsuzuki T, 2001, P NATL ACAD SCI USA, V98, P11456, DOI 10.1073/pnas.191086798; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; WEBER DJ, 1993, BIOCHEMISTRY-US, V32, P13081, DOI 10.1021/bi00211a018; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274; YEH YC, 1991, J BIOL CHEM, V266, P6480	80	172	178	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	2002	21	58					8895	8904		10.1038/sj.onc.1206023	http://dx.doi.org/10.1038/sj.onc.1206023			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483507				2022-12-17	WOS:000179889500002
J	Hoffman, B; Amanullah, A; Shafarenko, M; Liebermann, DA				Hoffman, B; Amanullah, A; Shafarenko, M; Liebermann, DA			The proto-oncogene c-myc in hematopoietic development and leukemogenesis	ONCOGENE			English	Article						c-myc; hematopoiesis; differentiation; leukemogenesis	TRANSCRIPTION FACTOR EGR-1; CELL-CYCLE PROGRESSION; MYELOID-LEUKEMIA CELLS; DNA-BINDING; FAS LIGAND; MACROPHAGE DIFFERENTIATION; HISTONE DEACETYLASE; MOLECULAR CONTROL; ENHANCER-BINDING; ANTAGONIST MAD1	The proto-oncogene c-myc has been shown to play a pivotal role in cell cycle regulation, metabolism, apoptosis, differentiation, cell adhesion, and tumorigenesis, and participates in regulating hematopoietic homeostasis. It is a transcription regulator that is part of an extensive network of interacting factors. Most probably, different biological responses are elicited by different overlapping subsets of c-Myc target genes, both induced and suppressed. Results obtained from studies employing mouse models are consistent with the need for at least one, and possibly two, mutations in addition to deregulated c-myc for malignant tumor formation. Repression of c-myc is required for terminal differentiation of many cell types, including hematopoietic cells. It has been shown that deregulated expression of c-myc in both M1 myeloid leukemic cells and normal myeloid cells derived from murine bone marrow, not only blocked terminal differentiation and its associated growth arrest, but also induced apoptosis, which is dependent on the Fas/CD95 pathway. There is evidence to suggest that the CD95/Fas death receptor pathway is an integral part of the apoptotic response associated with the end of the normal terminal myeloid differentiation program, and that deregulated c-myc expression can activate this signaling pathway prematurely. The ability of egr-1 to promote terminal myeloid differentiation when co-expressed with c-myc, and of c-fos to partially abrogate the block imparted by deregulated c-myc on myeloid differentiation, make these two genes candidate tumor suppressors. Several different transcription factors have been implicated in the down-regulation of c-myc expression during differentiation, including C/EBPalpha, CTCF, BLIMP-1, and RFX1. Alterations in the expression and/or function of these transcription factors, or of the c-Myc and Max interacting proteins, such as MM-1 and Mxil, can influence the neoplastic process. Understanding how c-Myc controls cellular phenotypes, including the leukemic phenotype, should provide novel tools for designing drugs to promote differentiation and/ or apoptosis of leukemic cells.	Temple Univ, Sch Med, Dept Biochem, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Hoffman, B (corresponding author), Temple Univ, Sch Med, Dept Biochem, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	hoffman@unix.temple.edu			NCI NIH HHS [R01 CA81168] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081168] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1999, ONCOGENE, V18, P5268, DOI 10.1038/sj.onc.1202997; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Amanullah A, 2002, ONCOGENE, V21, P1600, DOI 10.1038/sj.onc.1205231; Amanullah A, 2000, ONCOGENE, V19, P2967, DOI 10.1038/sj.onc.1203638; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; Beckmann AM, 1997, NEUROCHEM INT, V31, P477, DOI 10.1016/S0197-0186(96)00136-2; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Bhatia K, 1995, Curr Top Microbiol Immunol, V194, P389; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Brunner T, 2000, J BIOL CHEM, V275, P9767, DOI 10.1074/jbc.275.13.9767; Cambier N, 1999, ONCOGENE, V18, P343, DOI 10.1038/sj.onc.1202302; Cameron ER, 2000, CELL DEATH DIFFER, V7, P80, DOI 10.1038/sj.cdd.4400630; Chang DH, 2000, NAT IMMUNOL, V1, P169, DOI 10.1038/77861; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; Chen L, 2000, J BIOL CHEM, V275, P32227, DOI 10.1074/jbc.M002645200; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Crossen PE, 1999, CANCER GENET CYTOGEN, V112, P144, DOI 10.1016/S0165-4608(98)00260-X; Cultraro CM, 1997, MOL CELL BIOL, V17, P2353, DOI 10.1128/MCB.17.5.2353; Dang CV, 1999, MOL CELL BIOL, V19, P1; Davies J, 1999, ONCOGENE, V18, P3643, DOI 10.1038/sj.onc.1202956; Delgado MD, 1999, FEBS LETT, V444, P5, DOI 10.1016/S0014-5793(99)00013-7; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Elliott K, 2000, ONCOGENE, V19, P4669, DOI 10.1038/sj.onc.1203681; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Fecho K, 1998, CELL IMMUNOL, V188, P19, DOI 10.1006/cimm.1998.1339; Feinberg AP, 2001, P NATL ACAD SCI USA, V98, P392, DOI 10.1073/pnas.98.2.392; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; Fujioka Y, 2001, J BIOL CHEM, V276, P45137, DOI 10.1074/jbc.M106127200; Genestier L, 1999, J EXP MED, V189, P231, DOI 10.1084/jem.189.2.231; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Harper SE, 1996, P NATL ACAD SCI USA, V93, P8536, DOI 10.1073/pnas.93.16.8536; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HAUPT Y, 1993, INT J CANCER, V55, P623, DOI 10.1002/ijc.2910550418; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; Hoffman B, 1996, CURR TOP MICROBIOL, V211, P17; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; Krishnaraju K, 1998, BLOOD, V92, P1957, DOI 10.1182/blood.V92.6.1957.418k24_1957_1966; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; Krishnaraju K, 2001, BLOOD, V97, P1298, DOI 10.1182/blood.V97.5.1298; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Liebermann DA, 1998, INT J ONCOL, V12, P685; LINDEMAN GJ, 1995, ONCOGENE, V10, P1013; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; McKenna SL, 1997, ADV CANCER RES, V71, P121, DOI 10.1016/S0065-230X(08)60098-6; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; McMahon SB, 1996, J LEUKOCYTE BIOL, V60, P159, DOI 10.1002/jlb.60.2.159; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Mori K, 1998, J BIOL CHEM, V273, P29794, DOI 10.1074/jbc.273.45.29794; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; O'Malley F, 1999, CANCER GENET CYTOGEN, V109, P123, DOI 10.1016/S0165-4608(98)00160-5; Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; QUESENBERRY PJ, 1990, HEMATOLOGY, P129; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Rao G, 1996, ONCOGENE, V12, P1165; Rasko JEJ, 2001, CANCER RES, V61, P6002; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Ryan KM, 1997, ONCOGENE, V14, P2835, DOI 10.1038/sj.onc.1201124; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; Wu SJ, 1996, ONCOGENE, V12, P621; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; ZORNIG M, 1995, ONCOGENE, V10, P2397	94	172	196	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3414	3421		10.1038/sj.onc.1205400	http://dx.doi.org/10.1038/sj.onc.1205400			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032779	Bronze			2022-12-17	WOS:000175633300014
J	Heasley, LE				Heasley, LE			Autocrine and paracrine signaling through neuropeptide receptors in human cancer	ONCOGENE			English	Review						neuropeptides; autocrine; paracrine; cancer cells; G proteins; receptors	CELL LUNG-CANCER; GASTRIN-RELEASING PEPTIDE; ELEVATES CYTOSOLIC CALCIUM; ACTIVATED PROTEIN-KINASE; GTPASE-DEFICIENT G-ALPHA(16); BOMBESIN-LIKE PEPTIDES; STRESS FIBER FORMATION; HUMAN PROSTATE-CANCER; PHOSPHOLIPASE C-BETA; MULTIPLE NEUROPEPTIDES	Autocrine and paracrine signaling leading to stimulation of tumor cell growth is a common theme in human cancers. In addition to polypeptide growth factors such as EGF family members which signal through receptor tyrosine kinases, accumulating evidence supports the autocrine and paracrine involvement of specific neuropeptides with defined physiologic actions as neurotransmitters and gut hormones in lung, gastric, colorectal, pancreatic and prostatic cancers. These neuropeptides, including gastrin-releasing peptide, neuromedin B, neurotensin, gastrin, cholecystokinin and arginine vasopressin bind seven transmembrane-spanning receptors that couple to heterotrimeric G proteins. Studies with human small cell lung cancer (SCLC) cells support a requirement for balanced signaling through G(q) and G(12/13) proteins leading to intracellular Ca2+ mobilization, PKC activation and regulation of the ERK and JNK MAP kinase pathways. While specific neuropeptide antagonists offer promise for interrupting the single neuropeptide autocrine systems operating in pancreatic and prostatic cancers, SCLC is exemplified by multiple, redundant neuropeptide autocrine systems such that tumor growth cannot be inhibited with a single specific antagonist. However, a novel class of neuropeptide derivatives based on the substance P sequence have been defined that exhibit broad specificity for neuropeptide receptors and induce apoptosis in SCLC by functioning as biased agonists that stimulate discordant signal transduction, Thus, interruption of autocrine and paracrine neuropeptide signaling with specific antagonists or broad-spectrum biased agonists offer promising new therapeutic approaches to the treatment of human cancers.	Univ Colorado, Hlth Sci Ctr, Dept Med, Div Renal Med, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Heasley, LE (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Renal Med, C-281,4200 E 9th Ave, Denver, CO 80262 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019928] Funding Source: NIH RePORTER; NCI NIH HHS [CA58157] Funding Source: Medline; NIDDK NIH HHS [DK19928] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aprikian AG, 1998, PROSTATE, P52; Aprikian AG, 1996, J MOL ENDOCRINOL, V16, P297, DOI 10.1677/jme.0.0160297; BALDWIN GS, 1995, J GASTROEN HEPATOL, V10, P215, DOI 10.1111/j.1440-1746.1995.tb01083.x; Baldwin GS, 1998, GUT, V42, P581, DOI 10.1136/gut.42.4.581; Barr AJ, 1997, J BIOL CHEM, V272, P2223; Bartholdi MF, 1998, INT J CANCER, V79, P82, DOI 10.1002/(SICI)1097-0215(19980220)79:1<82::AID-IJC16>3.0.CO;2-J; BATTEY J, 1991, TRENDS NEUROSCI, V14, P524, DOI 10.1016/0166-2236(91)90005-F; Beekman A, 1998, CANCER RES, V58, P910; BLACKMORE M, 1992, BRIT J CANCER, V66, P32, DOI 10.1038/bjc.1992.212; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; BUNN PA, 1992, CANCER RES, V52, P24; BURBACH JPH, 1992, EUR J PHARM-MOLEC PH, V227, P1, DOI 10.1016/0922-4106(92)90136-J; CARDONA C, 1991, CANCER RES, V51, P5205; Chatzistamou I, 2000, BRIT J CANCER, V83, P906, DOI 10.1054/bjoc.2000.1374; Chave HS, 2000, BRIT J CANCER, V82, P124; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; Coulson JM, 1999, BRIT J CANCER, V80, P1935, DOI 10.1038/sj.bjc.6690623; Coulson JM, 1999, CANCER RES, V59, P5123; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DAVIS TP, 1991, PEPTIDES, V12, P17, DOI 10.1016/0196-9781(91)90160-Q; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dockray GJ, 1999, J PHYSIOL-LONDON, V518, P315, DOI 10.1111/j.1469-7793.1999.0315p.x; EVERARD MJ, 1993, EUR J CANCER, V29A, P1450, DOI 10.1016/0959-8049(93)90019-C; FATHI Z, 1993, J BIOL CHEM, V268, P5979; Fruhwald MC, 1998, ANN NY ACAD SCI, V865, P420, DOI 10.1111/j.1749-6632.1998.tb11208.x; GEIJER T, 1990, FEBS LETT, V270, P30, DOI 10.1016/0014-5793(90)81227-F; Goetze JP, 2000, CANCER, V88, P2487, DOI 10.1002/1097-0142(20000601)88:11<2487::AID-CNCR9>3.0.CO;2-E; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; GORBULEV V, 1992, EUR J BIOCHEM, V208, P405, DOI 10.1111/j.1432-1033.1992.tb17201.x; GROSS AJ, 1993, CANCER RES, V53, P67; HAMILTON BP, 1972, J CLIN ENDOCR METAB, V35, P764, DOI 10.1210/jcem-35-5-764; Heasley LE, 1996, J BIOL CHEM, V271, P349, DOI 10.1074/jbc.271.1.349; Heasley LE, 1996, MOL CELL BIOL, V16, P648; Higashita R, 1997, J BIOL CHEM, V272, P25845, DOI 10.1074/jbc.272.41.25845; HONG M, 1991, PEPTIDES, V12, P1315, DOI 10.1016/0196-9781(91)90213-9; IVELL R, 1983, NEUROENDOCRINOLOGY, V37, P235, DOI 10.1159/000123549; Jarpe MB, 1998, J BIOL CHEM, V273, P3097, DOI 10.1074/jbc.273.5.3097; Jian XY, 1999, J BIOL CHEM, V274, P11573, DOI 10.1074/jbc.274.17.11573; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LANGDON S, 1992, CANCER RES, V52, P4554; Lawlor ER, 1998, CANCER RES, V58, P2469; Lobaugh LA, 1996, MOL PHARMACOL, V50, P493; MacKinnon AC, 1999, BRIT J CANCER, V80, P1026, DOI 10.1038/sj.bjc.6690458; MAHMOUD S, 1991, CANCER RES, V51, P1798; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; MARKOWITZ S, 1988, J CLIN INVEST, V82, P808, DOI 10.1172/JCI113683; Markwalder R, 1999, CANCER RES, V59, P1152; MILLER YE, 1989, AM REV RESPIR DIS, V140, P283, DOI 10.1164/ajrccm/140.2.283; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; MOODY TW, 1992, J PHARMACOL EXP THER, V263, P311; MOODY TW, 1981, SCIENCE, V214, P1246, DOI 10.1126/science.6272398; MOODY TW, 1985, LIFE SCI, V36, P1727, DOI 10.1016/0024-3205(85)90555-7; NAGALLA SR, 1994, CANCER RES, V54, P4461; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Nelson JB, 2000, CANCER INVEST, V18, P87, DOI 10.3109/07357900009023066; Nemenoff Raphael A., 1998, Frontiers in Bioscience, V3, pD194; North WG, 1998, CANCER RES, V58, P1866; NORTH WG, 1991, J CLIN ENDOCR METAB, V73, P1316, DOI 10.1210/jcem-73-6-1316; Nyeki O, 1998, J PEPT SCI, V4, P486, DOI 10.1002/(SICI)1099-1387(199812)4:8<486::AID-PSC168>3.3.CO;2-E; Ohki-Hamazaki H, 2000, PROG NEUROBIOL, V62, P297, DOI 10.1016/S0301-0082(00)00004-6; OhkiHamazaki H, 1997, NATURE, V390, P165, DOI 10.1038/36568; Paolucci L, 1999, CANCER RES, V59, P572; PICON A, 1995, J MOL ENDOCRINOL, V15, P187, DOI 10.1677/jme.0.0150187; Quick MW, 1996, J BIOL CHEM, V271, P32021, DOI 10.1074/jbc.271.50.32021; REEVE JG, 1994, BIOCHEM BIOPH RES CO, V199, P1313, DOI 10.1006/bbrc.1994.1374; Reubi JC, 1997, CANCER RES, V57, P1377; Rosati R, 1998, PEPTIDES, V19, P1519, DOI 10.1016/S0196-9781(98)00116-8; SAUSVILLE E, 1985, J BIOL CHEM, V260, P236; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Seckl MJ, 1997, CANCER RES, V57, P51; Seethalakshmi L, 1997, PROSTATE, V31, P183, DOI 10.1002/(SICI)1097-0045(19970515)31:3<183::AID-PROS7>3.0.CO;2-M; SEHGAL I, 1994, P NATL ACAD SCI USA, V91, P4673, DOI 10.1073/pnas.91.11.4673; SETHI T, 1991, CANCER RES, V51, P3621; SETHI T, 1992, CANCER RES, V52, pS2737; SETHI T, 1992, CANCER RES, V52, P6031; SETHI T, 1993, CANCER RES, V53, P5208; Seufferlein T, 1996, CANCER RES, V56, P5758; Smith JP, 1996, AM J PHYSIOL-REG I, V270, pR1078, DOI 10.1152/ajpregu.1996.270.5.R1078; SMITH JP, 1994, AM J PHYSIOL, V266, pR277, DOI 10.1152/ajpregu.1994.266.1.R277; STALEY J, 1989, BIOCHEM BIOPH RES CO, V163, P605, DOI 10.1016/0006-291X(89)92180-3; STALEY J, 1990, PEPTIDES, V11, P1033, DOI 10.1016/0196-9781(90)90029-5; Strassheim D, 2000, CANCER RES, V60, P2730; Sun BD, 2000, REGUL PEPTIDES, V90, P77, DOI 10.1016/S0167-0115(00)00114-2; Sun BD, 2000, PROSTATE, V42, P295; SUNDLER F, 1991, ACTA ONCOL, V30, P419, DOI 10.3109/02841869109092396; Thibonnier M, 1998, PROG BRAIN RES, V119, P147; ToiScott M, 1996, LUNG CANCER-J IASLC, V15, P341, DOI 10.1016/0169-5002(95)00597-8; VARAPRASAD MVV, 1995, J BIOL CHEM, V270, P18655; VERBEECK MAE, 1992, PATHOBIOLOGY, V60, P136, DOI 10.1159/000163712; Vincent JP, 1999, TRENDS PHARMACOL SCI, V20, P302, DOI 10.1016/S0165-6147(99)01357-7; Wadsworth SJ, 1997, J BIOL CHEM, V272, P28829, DOI 10.1074/jbc.272.46.28829; Wank SA, 1998, AM J PHYSIOL-GASTR L, V274, pG607, DOI 10.1152/ajpgi.1998.274.4.G607; WANK SA, 1995, AM J PHYSIOL-GASTR L, V269, pG628, DOI 10.1152/ajpgi.1995.269.5.G628; WATANAPA P, 1993, BRIT J CANCER, V67, P877, DOI 10.1038/bjc.1993.165; Weinberg DS, 1997, J CLIN INVEST, V100, P597, DOI 10.1172/JCI119570; Wittau N, 2000, ONCOGENE, V19, P4199, DOI 10.1038/sj.onc.1203777; WOLL PJ, 1989, BIOCHEM BIOPH RES CO, V164, P66, DOI 10.1016/0006-291X(89)91683-5; WOLL PJ, 1990, CANCER RES, V50, P3968; WOLL PJ, 1988, P NATL ACAD SCI USA, V85, P1859, DOI 10.1073/pnas.85.6.1859; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	101	172	181	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2001	20	13					1563	1569		10.1038/sj.onc.1204183	http://dx.doi.org/10.1038/sj.onc.1204183			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313903				2022-12-17	WOS:000168089800006
J	Crook, T; Nicholls, JM; Brooks, L; O'Nions, J; Allday, MJ				Crook, T; Nicholls, JM; Brooks, L; O'Nions, J; Allday, MJ			High level expression of Delta N-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)?	ONCOGENE			English	Article						p53; p63; p14(ARF); undifferentiated nasopharyngeal carcinoma; NPC	BARR-VIRUS INFECTION; TUMOR-SUPPRESSOR GENE; P16 GENE; POINT MUTATION; MDM2; PROTEIN; P63; LYMPHOMAGENESIS; OVEREXPRESSION; DEGRADATION	Undifferentiated nasopharyngeal carcinoma (NPC) is an epithelial malignancy that is consistently associated with Epstein-Barr virus (EBV) but which very rarely has p53 gene mutations in primary tumours, Since the tumour suppressor p53 is mutated in most human canters or the wild type protein is inactivated in a significant number of the remainder, here we have investigated cellular factors that could compromise p53 function in primary NPC, Twenty-five primary tumours were judged to carry only wild type p53 by SSCP analysis of all exons and sequence determination of exons 4-9, Only one tumour was found to express significant levels of hMdm2 and in 24/25 there were no detectable mutations or deletions in exons 1 beta and 2 of the p14(ARF) gene. However, immunohistochemistry consistently revealed that all the tumour cells express substantial amounts of the p53-related protein p63, Semi-quantitative RT- PCR analysis of mRNA from tumour biopsies showed that the dominant species expressed was invariably the truncated Delta N-isotype. Since this can block p53-mediated transactivation, it is potentially a dominant-negative isoform, In normal nasopharyngeal epithelium the distribution of p63 was restricted to the proliferating basal and suprabasal layers. We suggest that Delta N-p63 is a good candidate as a suppressor of wild type p53 function in these tumours and also that it may prove to be a valuable diagnostic marker for undifferentiated NPC.	Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Sect Virol & Cell Biol, London W2 1PG, England; Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England	Imperial College London; Ludwig Institute for Cancer Research; Imperial College London; University of Hong Kong; University of London; London School of Hygiene & Tropical Medicine	Allday, MJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, St Marys Campus,Norfolk Pl, London W2 1PG, England.		Nicholls, John Malcolm/C-4375-2009	Nicholls, John Malcolm/0000-0001-7217-7444				ALLDRED DC, 1993, J NATL CANCER I, V85, P200; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Gazzeri S, 1998, ONCOGENE, V16, P497, DOI 10.1038/sj.onc.1201559; Gulley ML, 1998, AM J PATHOL, V152, P865; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KLEIN G, 1979, EPSTEIN BARR VIRUS; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lo KW, 1996, CANCER RES, V56, P2721; LO KW, 1992, ANTICANCER RES, V12, P1957; LO KW, 1995, CANCER RES, V55, P2039; McGregor JM, 1997, ONCOGENE, V15, P1737, DOI 10.1038/sj.onc.1201339; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Murono S, 1999, HISTOPATHOLOGY, V34, P432; Niedobitek G, 1996, SEMIN CANCER BIOL, V7, P165, DOI 10.1006/scbi.1996.0023; NIEDOBITEK G, 1993, J PATHOL, V170, P457, DOI 10.1002/path.1711700409; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARSA R, 1999, J INVEST DERMATOL, V113; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1997, P NATL ACAD SCI USA, V94, P3436; Rickinson A. B., 1996, FIELDS VIROLOGY; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SHEU LF, 1995, HUM PATHOL, V26, P380, DOI 10.1016/0046-8177(95)90137-X; SPRUCK CH, 1992, CANCER RES, V52, P4787; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516; SUN Y, 1995, ONCOGENE, V10, P785; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	42	172	189	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 13	2000	19	30					3439	3444		10.1038/sj.onc.1203656	http://dx.doi.org/10.1038/sj.onc.1203656			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918601				2022-12-17	WOS:000088198100012
J	FISCELLA, M; ULLRICH, SJ; ZAMBRANO, N; SHIELDS, MT; LIN, D; LEESMILLER, SP; ANDERSON, CW; MERCER, WE; APPELLA, E				FISCELLA, M; ULLRICH, SJ; ZAMBRANO, N; SHIELDS, MT; LIN, D; LEESMILLER, SP; ANDERSON, CW; MERCER, WE; APPELLA, E			MUTATION OF THE SERINE 15 PHOSPHORYLATION SITE OF HUMAN P53 REDUCES THE ABILITY OF P53 TO INHIBIT CELL-CYCLE PROGRESSION	ONCOGENE			English	Article							CASEIN KINASE-II; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; PROTEIN-KINASE; GROWTH; GENE; SUPPRESSOR; INVITRO; P53-PROTEIN; EXPRESSION	Overexpression of wild-type p53 prevents cells from entering the S phase of the cell cycle. The amino-terminal transactivation region of p53 is phosphorylated by several protein kinases, including DNA-PK, a nuclear serine/threonine protein kinase that in vitro requires DNA for activity. DNA-PK was recently shown to phosphorylate serines 15 and 37 of human p53 (Lees-Miller et al, 1992. Mol. Cell. Biol., 12, 5041-5049). To prevent phosphorylation at these sites, mutants were constructed that changed the codons for serine 15 or serine 37 to alanine codons. Expression of p53-Ala-37 in stably transformed T98G cells blocked progression of the cells into S phase as well as did the expression of wild-type p53. In contrast, p53-Ala-15 was partially defective in blocking cell cycle progression. Several cell clones transformed with the mutant p53-Ala-15 gene expressed normal levels of p53 mRNA but accumulated little or no detectable p53 protein. However, by using a transient expression system driven by a strong cytomegalovirus promoter, we showed that the inability of p53-Ala-15 to fully block cell cycle progression was not due to inadequate levels of expression or to a failure of the mutant protein to accumulate in the nucleus. These results suggest that phosphorylation of Ser-15 may affect p53 function.	NIH,CELL BIOL LAB,BETHESDA,MD 20892; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	National Institutes of Health (NIH) - USA; Jefferson University; United States Department of Energy (DOE); Brookhaven National Laboratory			Zambrano, Nicola/B-9352-2014	Zambrano, Nicola/0000-0001-9395-3481; Lees-Miller, Susan/0000-0001-5809-2516	NCI NIH HHS [CA 42866] Funding Source: Medline; NCRR NIH HHS [BRSG S07 RR05417] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042866] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005417] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BASSIRI RM, 1972, ENDOCRINOLOGY, V90, P722, DOI 10.1210/endo-90-3-722; CHEN YR, 1991, J VIROL, V65, P5131, DOI 10.1128/JVI.65.10.5131-5140.1991; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JDONEHOWER LA, 1992, NATURE, V356, P215; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KLESSIG DF, 1975, J VIROL, V16, P1650, DOI 10.1128/JVI.16.6.1650-1668.1975; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEEK DW, 1990, J VIROL, V64, P1734, DOI 10.1128/JVI.64.4.1734-1744.1990; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER W E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P251; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MONTENARH M, 1992, ONCOGENE, V7, P1673; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RICHARDSON WD, 1984, J VIROL, V51, P559, DOI 10.1128/JVI.51.2.559-562.1984; RIGAUDY P, 1989, NUCLEIC ACIDS RES, V20, P8375; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SHEN YM, 1982, MOL CELL BIOL, V2, P1145, DOI 10.1128/MCB.2.9.1145; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SILVERMAN L, 1989, J VIROL, V63, P4376, DOI 10.1128/JVI.63.10.4376-4385.1989; SOUSSI T, 1990, ONCOGENE, V5, P945; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TACK LC, 1992, J VIROL, V66, P1312, DOI 10.1128/JVI.66.3.1312-1320.1992; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; UMPHRESS JL, 1992, EUR J BIOCHEM, V203, P239, DOI 10.1111/j.1432-1033.1992.tb19852.x; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	59	172	174	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1519	1528						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502477				2022-12-17	WOS:A1993LE06400015
J	KOVAR, H; DWORZAK, M; STREHL, S; SCHNELL, E; AMBROS, IM; AMBROS, PF; GADNER, H				KOVAR, H; DWORZAK, M; STREHL, S; SCHNELL, E; AMBROS, IM; AMBROS, PF; GADNER, H			OVEREXPRESSION OF THE PSEUDOAUTOSOMAL GENE MIC2 IN EWINGS-SARCOMA AND PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR	ONCOGENE			English	Note									UNIV VIENNA,INST PATHOL ANAT,VIENNA BONE TUMOR REGISTRY,A-1090 VIENNA,AUSTRIA	University of Vienna	KOVAR, H (corresponding author), ST ANNA CHILDRENS HOSP,CHILDRENS CANC RES INST,KINDERSPITALGASSE 6,A-1090 VIENNA,AUSTRIA.		Ambros, Peter/AAA-1266-2021	Ambros, Peter/0000-0002-5507-7211; Kovar, Heinrich/0000-0001-6873-9109; Strehl, Sabine/0000-0002-0179-0628				AMBROSSCHRATTER IM, 1988, 1ST P M EUR MUSC ONC, P56; AUBRIT F, 1989, EUR J IMMUNOL, V19, P1431, DOI 10.1002/eji.1830190813; BANTING GS, 1989, MOL IMMUNOL, V26, P181, DOI 10.1016/0161-5890(89)90100-4; BERNARD A, 1988, J IMMUNOL, V140, P1802; BROWN WRA, 1981, NATURE, V289, P456, DOI 10.1038/289456a0; DARLING SM, 1986, COLD SPRING HARB SYM, V51, P205, DOI 10.1101/SQB.1986.051.01.025; Ewing, 1921, P NEW YORK PATHOL S, V21, P17; FELLINGER EJ, 1989, INT S LIMB SALVAGE M, P219; GELIN C, 1989, EMBO J, V8, P3253, DOI 10.1002/j.1460-2075.1989.tb08485.x; GOODFELLOW P, 1983, DIFFERENTIATION S, V23, P35; GOODFELLOW PJ, 1986, SCIENCE, V234, P740, DOI 10.1126/science.2877492; HAMILTON G, 1988, CANCER RES, V48, P6127; LATRON F, 1987, BIOCHEM J, V247, P757, DOI 10.1042/bj2470757; LEVY R, 1979, P NATL ACAD SCI USA, V76, P6552, DOI 10.1073/pnas.76.12.6552; LIPINSKI M, 1987, CANCER RES, V47, P183; MCDERMID HE, 1989, GENOMICS, V5, P1, DOI 10.1016/0888-7543(89)90079-7; MILLER SC, 1977, J CELL BIOL, V72, P511, DOI 10.1083/jcb.72.3.511; MUJOO K, 1987, CANCER RES, V47, P1098; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; TRENT J M, 1988, Cytogenetics and Cell Genetics, V49, P236, DOI 10.1159/000132669; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3	23	172	173	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1990	5	7					1067	1070						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	1695726				2022-12-17	WOS:A1990DP41500018
J	ZEILLINGER, R; KURY, F; CZERWENKA, K; KUBISTA, E; SLIUTZ, G; KNOGLER, W; HUBER, J; ZIELINSKI, C; REINER, G; JAKESZ, R; STAFFEN, A; REINER, A; WRBA, F; SPONA, J				ZEILLINGER, R; KURY, F; CZERWENKA, K; KUBISTA, E; SLIUTZ, G; KNOGLER, W; HUBER, J; ZIELINSKI, C; REINER, G; JAKESZ, R; STAFFEN, A; REINER, A; WRBA, F; SPONA, J			HER-2 AMPLIFICATION, STEROID-RECEPTORS AND EPIDERMAL GROWTH-FACTOR RECEPTOR IN PRIMARY BREAST-CANCER	ONCOGENE			English	Article									VIENNA UNIV,DEPT OBSTET & GYNECOL 1,A-1090 VIENNA,AUSTRIA; VIENNA UNIV,DEPT SURG 2,A-1090 VIENNA,AUSTRIA; VIENNA UNIV,LUDWIG BOLTZMANN INST PRENATAL & EXPTL GENOME ANAL,A-1090 VIENNA,AUSTRIA; VIENNA UNIV,DEPT SURG 1,A-1090 VIENNA,AUSTRIA; VIENNA UNIV,DEPT PATHOL,A-1090 VIENNA,AUSTRIA; VIENNA UNIV,DEPT INTERNAL MED 2,A-1090 VIENNA,AUSTRIA	University of Vienna; University of Vienna; Ludwig Boltzmann Institute; University of Vienna; University of Vienna; University of Vienna; University of Vienna				Zeillinger, Robert/0000-0001-6771-4591				ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BERGER MS, 1988, CANCER RES, V48, P1238; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK GM, 1983, NEW ENGL J MED, V309, P1343, DOI 10.1056/NEJM198312013092240; CLINE MJ, 1987, J CLIN ONCOL, V5, P999, DOI 10.1200/JCO.1987.5.7.999; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIZIKES GJ, 1986, BIOCHEM BIOPH RES CO, V141, P53, DOI 10.1016/S0006-291X(86)80333-3; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; GRILL HJ, 1984, ONCOLOGY, V41, P25, DOI 10.1159/000225785; HAHNEL R, 1979, CANCER, V44, P671, DOI 10.1002/1097-0142(197908)44:2<671::AID-CNCR2820440238>3.0.CO;2-V; HILF R, 1980, CANCER-AM CANCER SOC, V45, P1993, DOI 10.1002/1097-0142(19800415)45:8<1993::AID-CNCR2820450802>3.0.CO;2-2; JAKESZ R, 1979, CANCER TREAT REP, V63, P1191; JAKESZ R, 1981, 17TH P ANN M AM SOC, V22, P150; KIANG DT, 1978, NEW ENGL J MED, V299, P1330, DOI 10.1056/NEJM197812142992403; KNIGHT WA, 1977, CANCER RES, V37, P4669; MCGUIRE WL, 1978, SEMIN ONCOL, V5, P428; REINER A, 1986, AM J PATHOL, V125, P443; REINER A, 1987, J CANCER RES CLIN, V113, P285, DOI 10.1007/BF00396387; REINER G, 1988, DEUT MED WOCHENSCHR, V113, P892, DOI 10.1055/s-2008-1067739; SAINSBURY JRC, 1987, LANCET, V1, P1398; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPONA J, 1983, CANCER DETECT PREV, V6, P227; STULLER I, 1987, ONKOLOGIE, V10, P302, DOI 10.1159/000216427; VARLEY JM, 1988, ONCOGENE, V3, P87; VIJVER M, 1987, MOL CELL BIOL, V7, P2019; VIJVER M, 1988, EUR J SURG ONCOL, V14, P111; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WRBA F, 1988, PATHOL RES PRACT, V183, P277, DOI 10.1016/S0344-0338(88)80122-5; YAMOMOTO T, 1986, NATURE, V319, P230; ZHOU DJ, 1988, ONCOGENE, V2, P279; ZIELINSKI CC, 1985, WIEN KLIN WOCHENSCHR, V97, P493; ZIELINSKI CC, 1986, LANCET, V1, P1164	41	172	174	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					109	114						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2915900				2022-12-17	WOS:A1989U567400017
J	Dodd, KM; Yang, J; Shen, MH; Sampson, JR; Tee, AR				Dodd, K. M.; Yang, J.; Shen, M. H.; Sampson, J. R.; Tee, A. R.			mTORC1 drives HIF-1 alpha and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3	ONCOGENE			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; MESSENGER-RNA TRANSLATION; ENDOTHELIAL GROWTH-FACTOR; TUBEROUS SCLEROSIS; MAMMALIAN TARGET; SERINE PHOSPHORYLATION; MAXIMAL ACTIVATION; CANCER-THERAPY; TUMOR-GROWTH; RAPAMYCIN	Recent clinical trials using rapalogues in tuberous sclerosis complex show regression in volume of typically vascularised tumours including angiomyolipomas and subependymal giant cell astrocytomas. By blocking mechanistic/mammalian target of rapamycin complex 1 (mTORC1) signalling, rapalogue efficacy is likely to occur, in part, through suppression of hypoxia-inducible factors (HIFs) and vascular endothelial growth factors (VEGFs). We show that rapamycin reduces HIF-1 alpha protein levels, and to a lesser extent VEGF-A levels, in renal cystadenoma cells in a Tsc2+/- mouse model. We established that mTORC1 drives HIF-1 alpha protein accumulation through enhanced transcription of HIF-1 alpha mRNA, a process that is blocked by either inhibition or knockdown of signal transducer and activation of transcription 3 (STAT3). Furthermore, we demonstrated that STAT3 is directly phosphorylated by mTORC1 on Ser727 during hypoxia, promoting HIF-1 alpha mRNA transcription. mTORC1 also regulates HIF-1 alpha synthesis on a translational level via co-operative regulation of both initiation factor 4E-binding protein 1 (4E-BP1) and ribosomal protein S6 kinase-1 (S6K1), whereas HIF-1 alpha degradation remains unaffected. We therefore proposed that mTORC1 drives HIF-1 alpha synthesis in a multifaceted manner through 4E-BP1/eIF4E, S6K1 and STAT3. Interestingly, we observed a disconnect between HIF-1 alpha protein levels and VEGF-A expression. Although both S6K1 and 4E-BP1 regulate HIF-1 alpha translation, VEGF-A is primarily under the control of 4E-BP1/eIF4E. S6K1 inhibition reduces HIF-1 alpha but not VEGF-A expression, suggesting that mTORC1 mediates VEGF-A expression via both HIF-1 alpha-dependent and -independent mechanisms. Our work has important implications for the treatment of vascularised tumours, where mTORC1 acts as a central mediator of STAT3, HIF-1 alpha, VEGF-A and angiogenesis via multiple signalling mechanisms.	[Dodd, K. M.; Yang, J.; Shen, M. H.; Sampson, J. R.; Tee, A. R.] Cardiff Univ, Inst Canc & Genet, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Tee, AR (corresponding author), Cardiff Univ, Inst Canc & Genet, Canc & Genet Bldg,Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	teea@cardiff.ac.uk		Tee, Andrew/0000-0002-5577-4631	Association for International Cancer Research Career Development Fellowship [06-914/915]; Tuberous Sclerosis Association [2013-F02]; Cancer Research UK development fund; Welsh Government's National Institute of Social Care and Health Research (NISCHR) through the Wales Gene Park; Tuberous Sclerosis Association; Worldwide Cancer Research [06-0914] Funding Source: researchfish	Association for International Cancer Research Career Development Fellowship; Tuberous Sclerosis Association; Cancer Research UK development fund; Welsh Government's National Institute of Social Care and Health Research (NISCHR) through the Wales Gene Park; Tuberous Sclerosis Association; Worldwide Cancer Research	This research was supported by the Association for International Cancer Research Career Development Fellowship (No. 06-914/915) (to AT), a Junior Fellowship from the Tuberous Sclerosis Association [Ref: 2013-F02: Investigating mTORC1 independent functions of TSC2] (to KD) and a Cancer Research UK development fund (to JS and AT). This work is further supported by the Welsh Government's National Institute of Social Care and Health Research (NISCHR) through the Wales Gene Park and by the Tuberous Sclerosis Association.	Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r; Arbiser JL, 2002, J AM ACAD DERMATOL, V46, P376, DOI 10.1067/mjd.2002.120530; Barbieri I, 2010, CANCER RES, V70, P2558, DOI 10.1158/0008-5472.CAN-09-2840; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Brugarolas J, 2004, CANCER CELL, V6, P7, DOI 10.1016/j.ccr.2004.06.020; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105; Choo AY, 2006, CANCER CELL, V9, P77, DOI 10.1016/j.ccr.2006.01.021; Davies DM, 2008, NEW ENGL J MED, V358, P200, DOI 10.1056/NEJMc072500; Dazert E, 2011, CURR OPIN CELL BIOL, V23, P744, DOI 10.1016/j.ceb.2011.09.003; Dempsey JM, 2010, ENZYMES, V28, P1, DOI 10.1016/S1874-6047(10)28001-0; Dibble CC, 2012, MOL CELL, V47, P535, DOI 10.1016/j.molcel.2012.06.009; Dodd KM, 2012, AM J PHYSIOL-ENDOC M, V302, pE1329, DOI 10.1152/ajpendo.00525.2011; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Dunlop EA, 2011, EUR J HUM GENET, V19, P789, DOI 10.1038/ejhg.2011.38; Dunlop EA, 2009, CELL SIGNAL, V21, P1073, DOI 10.1016/j.cellsig.2009.02.024; El-Hashemite N, 2005, AM J RESP CELL MOL, V33, P227, DOI 10.1165/rcmb.2005-0152RC; El-Hashemite N, 2004, CANCER RES, V64, P3436, DOI 10.1158/0008-5472.CAN-03-3609; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Garcia M, 2009, KU 0063794 IS SPECIF, V421; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Guo YA, 2013, MOL CANCER RES, V11, P467, DOI 10.1158/1541-7786.MCR-12-0605; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Kang SA, 2013, SCIENCE, V341, P364, DOI 10.1126/science.1236566; Koh MY, 2008, TRENDS BIOCHEM SCI, V33, P526, DOI 10.1016/j.tibs.2008.08.002; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Land SC, 2007, J BIOL CHEM, V282, P20534, DOI 10.1074/jbc.M611782200; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Li N, 2011, CANCER CELL, V19, P429, DOI 10.1016/j.ccr.2011.03.018; Lin L, 2010, CANCER RES, V70, P2445, DOI 10.1158/0008-5472.CAN-09-2468; Lu HS, 2002, J BIOL CHEM, V277, P23111, DOI 10.1074/jbc.M202487200; Lu X, 2010, CLIN CANCER RES, V16, P5928, DOI 10.1158/1078-0432.CCR-10-1360; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Marimpietri D, 2007, CLIN CANCER RES, V13, P3977, DOI 10.1158/1078-0432.CCR-06-2757; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Minet E, 1999, BIOCHEM BIOPH RES CO, V261, P534, DOI 10.1006/bbrc.1999.0995; Niu GL, 2008, MOL CANCER RES, V6, P1099, DOI 10.1158/1541-7786.MCR-07-2177; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Pearce LR, 2010, BIOCHEM J, V431, P245, DOI 10.1042/BJ20101024; Pfander D, 2003, J CELL SCI, V116, P1819, DOI 10.1242/jcs.00385; Phung TL, 2006, CANCER CELL, V10, P159, DOI 10.1016/j.ccr.2006.07.003; Pore N, 2006, CANCER RES, V66, P3197, DOI 10.1158/0008-5472.CAN-05-3090; Preston RS, 2011, ONCOGENE, V30, P1159, DOI 10.1038/onc.2010.497; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Rosser Tena, 2006, Semin Pediatr Neurol, V13, P27, DOI 10.1016/j.spen.2006.01.008; Schalm SS, 2005, J BIOL CHEM, V280, P11101, DOI 10.1074/jbc.M413995200; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Tandon P, 2011, P NATL ACAD SCI USA, V108, P2361, DOI 10.1073/pnas.1013629108; Tee AR, 2004, FEBS LETT, V564, P58, DOI 10.1016/S0014-5793(04)00313-8; Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337; Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Urano J, 2007, P NATL ACAD SCI USA, V104, P3514, DOI 10.1073/pnas.0608510104; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Weichhart T, 2008, IMMUNITY, V29, P565, DOI 10.1016/j.immuni.2008.08.012; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108; Woodrum C, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-14; Yang J, 2014, ONCOGENE; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7	70	171	180	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2239	2250		10.1038/onc.2014.164	http://dx.doi.org/10.1038/onc.2014.164			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	24931163	Green Accepted			2022-12-17	WOS:000353473000009
J	Garg, R; Benedetti, LG; Abera, MB; Wang, H; Abba, M; Kazanietz, MG				Garg, R.; Benedetti, L. G.; Abera, M. B.; Wang, H.; Abba, M.; Kazanietz, M. G.			Protein kinase C and cancer: what we know and what we do not	ONCOGENE			English	Review						protein kinase C (PKC); apoptosis; survival; tumorigenesis; metastasis; animal models	ESTER-INDUCED APOPTOSIS; DELTA PKC-DELTA; NF-KAPPA-B; DOMAIN-CONTAINING PROTEIN-1; BETA INHIBITOR ENZASTAURIN; AGGRESSIVE BREAST-CANCER; PHASE-II TRIAL; PROSTATE-CANCER; CELL-PROLIFERATION; GENE-EXPRESSION	Since their discovery in the late 1970s, protein kinase C (PKC) isozymes represent one of the most extensively studied signaling kinases. PKCs signal through multiple pathways and control the expression of genes relevant for cell cycle progression, tumorigenesis and metastatic dissemination. Despite the vast amount of information concerning the mechanisms that control PKC activation and function in cellular models, the relevance of individual PKC isozymes in the progression of human cancer is still a matter of controversy. Although the expression of PKC isozymes is altered in multiple cancer types, the causal relationship between such changes and the initiation and progression of the disease remains poorly defined. Animal models developed in the last years helped to better understand the involvement of individual PKCs in various cancer types and in the context of specific oncogenic alterations. Unraveling the enormous complexity in the mechanisms by which PKC isozymes have an impact on tumorigenesis and metastasis is key for reassessing their potential as pharmacological targets for cancer treatment.	[Garg, R.; Benedetti, L. G.; Abera, M. B.; Wang, H.; Kazanietz, M. G.] Univ Penn, Perelman Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; [Abba, M.] Univ Nacl La Plata, Fac Ciencias Med, Ctr Invest Inmunol Basicas & Aplicadas, La Plata, Buenos Aires, Argentina	University of Pennsylvania; Pennsylvania Medicine; National University of La Plata	Kazanietz, MG (corresponding author), Univ Penn, Perelman Sch Med, Dept Pharmacol, 1256 Biomed Res Bldg 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	marcelog@upenn.edu	Garg, Rachana/AAQ-9518-2020	Abba, Martin/0000-0002-9206-2369; Garg, Rachana/0000-0002-7808-1053	NIH [R01-CA89202, R01-CA139120]; Department of Defense [W81XWH-12-1-0009]; NATIONAL CANCER INSTITUTE [R01CA139120, R01CA089202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES013508] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Work in the laboratory of MGK is supported by grants R01-CA89202 and R01-CA139120 from NIH. RG is supported by a post-doctoral grant from the Department of Defense W81XWH-12-1-0009.	Advani R, 2004, CANCER-AM CANCER SOC, V100, P321, DOI 10.1002/cncr.11909; Akakura S, 2010, CELL CYCLE, V9, P4656, DOI 10.4161/cc.9.23.13974; Akita Y, 2002, J BIOCHEM, V132, P847, DOI 10.1093/oxfordjournals.jbchem.a003296; Akita Y, 2008, FEBS J, V275, P3995, DOI 10.1111/j.1742-4658.2008.06557.x; Allen-Petersen BL, 2014, ONCOGENE, V33, P1306, DOI 10.1038/onc.2013.59; Assender JW, 2007, J CLIN PATHOL, V60, P1216, DOI 10.1136/jcp.2006.041616; Atwood SX, 2013, NATURE, V494, P484, DOI 10.1038/nature11889; Aziz MH, 2007, CANCER RES, V67, P8828, DOI 10.1158/0008-5472.CAN-07-1604; Bae KM, 2007, CANCER RES, V67, P6053, DOI 10.1158/0008-5472.CAN-06-4037; Baldwin RM, 2008, ONCOGENE, V27, P3587, DOI 10.1038/sj.onc.1211027; BALTUCH GH, 1995, J NEURO-ONCOL, V24, P241, DOI 10.1007/BF01052840; Bao LW, 2009, CANCER RES, V69, P5829, DOI 10.1158/0008-5472.CAN-08-3465; Barry OP, 2001, CURR PHARM DESIGN, V7, P1725, DOI 10.2174/1381612013397041; Basso K, 2005, NAT GENET, V37, P382, DOI 10.1038/ng1532; Basu A, 2007, CELL SIGNAL, V19, P1633, DOI 10.1016/j.cellsig.2007.04.008; Basu A, 2010, THESCIENTIFICWORLDJO, V10, P2272, DOI 10.1100/tsw.2010.214; Benavides F, 2011, CELL CYCLE, V10, P268, DOI 10.4161/cc.10.2.14469; Besson A, 2001, ONCOGENE, V20, P7398, DOI 10.1038/sj.onc.1204899; Bezombes C, 2002, MOL PHARMACOL, V62, P1446, DOI 10.1124/mol.62.6.1446; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; Blackburn RV, 1998, CANCER, V82, P1137, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1137::AID-CNCR19>3.0.CO;2-7; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; Bredel M, 2005, CANCER RES, V65, P8679, DOI 10.1158/0008-5472.CAN-05-1204; Brenner W, 2003, ANTICANCER RES, V23, P4001; Buchholz M, 2005, ONCOGENE, V24, P6626, DOI 10.1038/sj.onc.1208804; Byers HR, 2010, MELANOMA RES, V20, P171, DOI 10.1097/CMR.0b013e32832f1581; CACACE AM, 1993, ONCOGENE, V8, P2095; Cacace AM, 1996, ONCOGENE, V13, P2517; Cacace AM, 1998, J CELL PHYSIOL, V175, P314, DOI 10.1002/(SICI)1097-4652(199806)175:3<314::AID-JCP9>3.0.CO;2-R; Cadoret A, 1998, ONCOGENE, V17, P877, DOI 10.1038/sj.onc.1202013; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Caino MC, 2012, ONCOGENE, V31, P2593, DOI 10.1038/onc.2011.428; Caino MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031714; Calcagno SR, 2008, INT J CANCER, V122, P2462, DOI 10.1002/ijc.23383; Cameron AJ, 2008, INT J CANCER, V123, P769, DOI 10.1002/ijc.23560; Cataldi A, 2003, J CELL BIOCHEM, V88, P144, DOI 10.1002/jcb.10305; Cesaro P, 2001, INT J CANCER, V93, P179, DOI 10.1002/ijc.1314; Chen CA, 2004, BBA-PROTEINS PROTEOM, V1697, P39, DOI 10.1016/j.bbapap.2003.11.012; Chisamore MJ, 2001, CLIN CANCER RES, V7, P3156; Civallero M, 2011, HEMATOL ONCOL, V29, P154, DOI 10.1002/hon.974; Civallero M, 2010, LEUKEMIA LYMPHOMA, V51, P671, DOI 10.3109/10428191003637290; Cornford P, 1999, AM J PATHOL, V154, P137, DOI 10.1016/S0002-9440(10)65260-1; CRAVEN PA, 1992, CANCER RES, V52, P2216; Dai CM, 2011, J HAZARD MATER, V198, P175, DOI 10.1016/j.jhazmat.2011.10.027; Dann SG, 2014, ONCOGENE, V33, P1385, DOI 10.1038/onc.2013.91; Dave SS, 2006, NEW ENGL J MED, V354, P2431, DOI 10.1056/NEJMoa055759; DAVIDSON D, 1994, MOL CELL BIOL, V14, P4554, DOI 10.1128/MCB.14.7.4554; Davidson LA, 1998, CARCINOGENESIS, V19, P253, DOI 10.1093/carcin/19.2.253; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Dhanasekaran SM, 2004, FASEB J, V18, P243, DOI 10.1096/fj.04-2415fje; Dupasquier S, 2009, J CELL SCI, V122, P2191, DOI 10.1242/jcs.036483; Dyrskjot L, 2004, CANCER RES, V64, P4040, DOI 10.1158/0008-5472.CAN-03-3620; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Espinosa I, 2006, ANN HEMATOL, V85, P597, DOI 10.1007/s00277-006-0144-y; Facchinetti MM, 2004, CANCER RES, V64, P3629, DOI 10.1158/0008-5472.CAN-03-3741; Felber M, 2007, PATHOL ONCOL RES, V13, P295, DOI 10.1007/BF02940308; Fikaris AJ, 2005, J BIOL CHEM, V280, P32107, DOI 10.1074/jbc.M504432200; Filomenko R, 2002, CANCER RES, V62, P1815; Fishman DD, 1998, INT J ONCOL, V12, P181; Frederick LA, 2008, ONCOGENE, V27, P4841, DOI 10.1038/onc.2008.119; French PJ, 2005, CANCER RES, V65, P11335, DOI 10.1158/0008-5472.CAN-05-1886; Frey MR, 2000, J CELL BIOL, V151, P763, DOI 10.1083/jcb.151.4.763; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Fukase N, 2011, ONCOL REP, V26, P1221, DOI 10.3892/or.2011.1415; Gallegos LL, 2006, J BIOL CHEM, V281, P30947, DOI 10.1074/jbc.M603741200; Gallegos LL, 2011, METHODS MOL BIOL, V756, P295, DOI 10.1007/978-1-61779-160-4_17; Galvez AS, 2009, MOL CELL BIOL, V29, P104, DOI 10.1128/MCB.01294-08; Garcia-Bermejo ML, 2002, J BIOL CHEM, V277, P645, DOI 10.1074/jbc.M107639200; Garg R, 2012, J BIOL CHEM, V287, P37570, DOI 10.1074/jbc.M112.398925; Gavrielides MV, 2004, CURR DRUG TARGETS, V5, P431, DOI 10.2174/1389450043345380; Gelardi T, 2008, BRIT J CANCER, V99, P473, DOI 10.1038/sj.bjc.6604493; Ghosh PM, 2002, CANCER RES, V62, P2630; Gokmen-Polar Y, 2010, BREAST CANCER RES TR, V124, P327, DOI 10.1007/s10549-010-0733-2; Gokmen-Polar Y, 1998, J BIOL CHEM, V273, P20261, DOI 10.1074/jbc.273.32.20261; GOLDSTEIN DR, 1995, CARCINOGENESIS, V16, P1121, DOI 10.1093/carcin/16.5.1121; Gonelli A, 2009, MINI-REV MED CHEM, V9, P498, DOI 10.2174/138955709787847967; Gonzalez-Guerrico AM, 2005, J BIOCHEM MOL BIOL, V38, P639; Gonzalez-Guerrico AM, 2005, J BIOL CHEM, V280, P38982, DOI 10.1074/jbc.M506767200; Gorin MA, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-9; Graff JR, 2005, CANCER RES, V65, P7462, DOI 10.1158/0008-5472.CAN-05-0071; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Grossman SA, 2005, NEURO-ONCOLOGY, V7, P32, DOI 10.1215/S1152851703000353; Grossoni VC, 2007, MOL CARCINOGEN, V46, P381, DOI 10.1002/mc.20287; Grossoni VC, 2009, BREAST CANCER RES TR, V118, P469, DOI 10.1007/s10549-008-0299-4; Guan LJ, 2007, J BIOL CHEM, V282, P14213, DOI 10.1074/jbc.M610513200; Gustafson WC, 2004, J BIOL CHEM, V279, P9400, DOI 10.1074/jbc.M312840200; Gwak J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046697; Gwak J, 2009, J CELL MOL MED, V13, P2171, DOI 10.1111/j.1582-4934.2009.00683.x; Hamilton M, 2001, J BIOL CHEM, V276, P29079, DOI 10.1074/jbc.M102001200; Hanauske AR, 2007, INVEST NEW DRUG, V25, P205, DOI 10.1007/s10637-007-9038-7; Hans CP, 2005, MODERN PATHOL, V18, P1377, DOI 10.1038/modpathol.3800434; Hao F, 2011, J BIOL CHEM, V286, P18104, DOI 10.1074/jbc.M110.208488; Hara T, 2012, ANTICANCER RES, V32, P3097; Haughian JM, 2009, INT J CANCER, V125, P2556, DOI 10.1002/ijc.24633; Hernandez RM, 2001, J CELL BIOCHEM, V83, P532, DOI 10.1002/jcb.1246; Hill KS, 2014, ONCOGENE, V33, P2134, DOI 10.1038/onc.2013.147; Hizli AA, 2006, J BIOL CHEM, V281, P14596, DOI 10.1074/jbc.M601959200; Huang B, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-88; Irie K, 2012, MED RES REV, V32, P518, DOI 10.1002/med.20220; Ishiguro H, 2009, P NATL ACAD SCI USA, V106, P16369, DOI 10.1073/pnas.0907044106; Jackson D, 2005, ONCOGENE, V24, P3067, DOI 10.1038/sj.onc.1208465; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Jamal MS, 2011, CANCER RES, V71, DOI 10.1158/1538-7445.AM2011-4204; Jansen AP, 2001, CANCER RES, V61, P808; Jasinski P, 2008, EUR J CANCER, V44, P1315, DOI 10.1016/j.ejca.2008.03.024; Justilien V, 2011, J BIOL CHEM, V286, P8149, DOI 10.1074/jbc.M110.196113; Kahana S, 2011, CELL SIGNAL, V23, P1348, DOI 10.1016/j.cellsig.2011.03.017; Kang GH, 2011, MODERN PATHOL, V24, P866, DOI 10.1038/modpathol.2011.11; KAZANIETZ MG, 1994, MOL PHARMACOL, V46, P374; Kharait S, 2006, BIOCHEM BIOPH RES CO, V343, P848, DOI 10.1016/j.bbrc.2006.03.044; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; Kiley SC, 1999, CANCER RES, V59, P3230; Kim J, 2011, ONCOGENE, V30, P323, DOI 10.1038/onc.2010.415; Kim JW, 2008, CANCER RES, V68, P6831, DOI 10.1158/0008-5472.CAN-07-6195; Kim J, 2011, PROSTATE, V71, P946, DOI 10.1002/pros.21310; Kim JY, 2013, P NATL ACAD SCI USA, V110, P6418, DOI 10.1073/pnas.1221799110; Kim KH, 2012, ANTICANCER RES, V32, P923; Kim S, 2012, J SURG RES, V176, pE21, DOI 10.1016/j.jss.2011.11.1041; Kong CZ, 2005, UROLOGY, V65, P1228, DOI 10.1016/j.urology.2005.01.007; Krasnitsky E, 2012, ANTICANCER RES, V32, P1507; Kreisl TN, 2010, NEURO-ONCOLOGY, V12, P181, DOI 10.1093/neuonc/nop042; Kruger JS, 2003, MOL CANCER RES, V1, P801; La Porta CAM, 2000, MELANOMA RES, V10, P527; La Porta CAM, 2000, MELANOMA RES, V10, P93, DOI 10.1097/00008390-200010020-00001; Lahn M, 2004, ONCOLOGY-BASEL, V67, P1, DOI 10.1159/000080279; LEACH KL, 1983, P NATL ACAD SCI-BIOL, V80, P4208, DOI 10.1073/pnas.80.14.4208; LEE HS, 1993, J BIOL CHEM, V268, P5255; Lee JM, 2010, MOL CELL, V37, P183, DOI 10.1016/j.molcel.2009.12.022; Lenburg ME, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-31; Li HY, 2006, CANCER RES, V66, P11399, DOI 10.1158/0008-5472.CAN-06-2386; Li N, 2013, ONCOGENE, V32, P4539, DOI 10.1038/onc.2012.466; Li SY, 2007, BIOL DIRECT, V2, DOI 10.1186/1745-6150-2-8; Lin CW, 2010, J CELL PHYSIOL, V225, P472, DOI 10.1002/jcp.22226; LIU B, 1994, J NATL CANCER I, V86, P1145, DOI 10.1093/jnci/86.15.1145; Liu SG, 2011, MOL CANCER RES, V9, P390, DOI 10.1158/1541-7786.MCR-10-0359; Lonne GK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-76; Lu DM, 2007, APOPTOSIS, V12, P1893, DOI 10.1007/s10495-007-0111-7; Lu DM, 2006, J BIOL CHEM, V281, P22799, DOI 10.1074/jbc.M603390200; Lu HC, 2010, PATHOL ONCOL RES, V16, P385, DOI 10.1007/s12253-009-9228-z; Lutzny G, 2013, CANCER CELL, V23, P77, DOI 10.1016/j.ccr.2012.12.003; Ma L, 2013, CELL, V152, P599, DOI 10.1016/j.cell.2012.12.028; Mahanivong C, 2008, ONCOGENE, V27, P1273, DOI 10.1038/sj.onc.1210746; Mandil R, 2001, CANCER RES, V61, P4612; Manni A, 1996, CELL GROWTH DIFFER, V7, P1187; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mauro LV, 2010, PANCREAS, V39, pE31, DOI 10.1097/MPA.0b013e3181bce796; McJilton MA, 2003, ONCOGENE, V22, P7958, DOI 10.1038/sj.onc.1206795; McKiernan E, 2008, BRIT J CANCER, V99, P1644, DOI 10.1038/sj.bjc.6604728; Meshki J, 2010, J BIOL CHEM, V285, P26033, DOI 10.1074/jbc.M110.128371; Metzger E, 2010, NATURE, V464, P792, DOI 10.1038/nature08839; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Miyazawa Y, 2010, CANCER RES, V70, P5136, DOI 10.1158/0008-5472.CAN-10-0220; Mochly-Rosen D, 2012, NAT REV DRUG DISCOV, V11, P937, DOI 10.1038/nrd3871; Motegi A, 2005, PATHOL INT, V55, P106, DOI 10.1111/j.1440-1827.2005.01806.x; Murray NR, 2011, J CELL PHYSIOL, V226, P879, DOI 10.1002/jcp.22463; Murray NR, 2004, J CELL BIOL, V164, P797, DOI 10.1083/jcb.200311011; Murray NR, 1999, J CELL BIOL, V145, P699, DOI 10.1083/jcb.145.4.699; Mustafi R, 2006, MOL CANCER RES, V4, P683, DOI 10.1158/1541-7786.MCR-06-0057; Mut M, 2010, TURK NEUROSURG, V20, P277, DOI 10.5137/1019-5149.JTN.3008-10.1; Nakagawa M, 2005, J BIOL CHEM, V280, P33926, DOI 10.1074/jbc.M505748200; Nakagawa S, 2003, MOL CARCINOGEN, V38, P106, DOI 10.1002/mc.10150; Nanjundan M, 2007, CANCER RES, V67, P3074, DOI 10.1158/0008-5472.CAN-06-2366; Nazarenko I, 2010, MOL CANCER RES, V8, P919, DOI 10.1158/1541-7786.MCR-09-0358; Okhrimenko H, 2005, CANCER RES, V65, P7301, DOI 10.1158/0008-5472.CAN-05-1064; Oliva JL, 2008, J BIOL CHEM, V283, P5466, DOI 10.1074/jbc.M707576200; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; Oster H, 2006, CANCER RES, V66, P6955, DOI 10.1158/0008-5472.CAN-06-0268; Pan Q, 2005, CANCER RES, V65, P8366, DOI 10.1158/0008-5472.CAN-05-0553; Pan Q, 2006, CANCER RES, V66, P9379, DOI 10.1158/0008-5472.CAN-06-2646; Paz-Ares L, 2006, J CLIN ONCOL, V24, P1428, DOI 10.1200/JCO.2005.04.3299; Perletti GP, 1998, ONCOGENE, V16, P3345, DOI 10.1038/sj.onc.1201871; Perletti GP, 1996, ONCOGENE, V12, P847; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; Pysz MA, 2009, EXP CELL RES, V315, P1415, DOI 10.1016/j.yexcr.2009.02.002; Querfeld C, 2006, J INVEST DERMATOL, V126, P1641, DOI 10.1038/sj.jid.5700322; Querfeld C, 2011, LEUKEMIA LYMPHOMA, V52, P1474, DOI 10.3109/10428194.2011.572265; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Reddig PJ, 1999, CANCER RES, V59, P5710; Regala RP, 2008, CANCER RES, V68, P5888, DOI 10.1158/0008-5472.CAN-08-0438; Regala RP, 2009, CANCER RES, V69, P7603, DOI 10.1158/0008-5472.CAN-09-2066; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Reno EM, 2008, HUM PATHOL, V39, P21, DOI 10.1016/j.humpath.2007.05.023; Rhodes DR, 2007, NEOPLASIA, V9, P443, DOI 10.1593/neo.07292; Rickman DS, 2001, CANCER RES, V61, P6885; Rimessi A, 2012, CELL CYCLE, V11, P1040, DOI 10.4161/cc.11.5.19520; Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375; Sand JM, 2010, J INVEST DERMATOL, V130, P270, DOI 10.1038/jid.2009.212; Sarkar S, 2010, CARCINOGENESIS, V31, P311, DOI 10.1093/carcin/bgp297; Sauma S, 1996, CELL GROWTH DIFFER, V7, P587; Schleifenbaum A, 2004, J AM CHEM SOC, V126, P11786, DOI 10.1021/ja0460155; Scotti ML, 2010, CANCER RES, V70, P2064, DOI 10.1158/0008-5472.CAN-09-2684; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Sengupta A, 2011, P NATL ACAD SCI USA, V108, P9957, DOI 10.1073/pnas.1103132108; SEYNAEVE CM, 1994, MOL PHARMACOL, V45, P1207; Shi MD, 2013, CELL BIOCHEM BIOPHYS, V66, P161, DOI 10.1007/s12013-012-9465-8; Spindler KLG, 2009, INT J COLORECTAL DIS, V24, P641, DOI 10.1007/s00384-009-0680-8; Stearman RS, 2005, AM J PATHOL, V167, P1763, DOI 10.1016/S0002-9440(10)61257-6; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Stewart JR, 2004, INVEST NEW DRUG, V22, P107, DOI 10.1023/B:DRUG.0000011787.75522.ec; Suga K, 1998, BIOCHEM MOL BIOL INT, V44, P523; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Symonds JM, 2011, CANCER RES, V71, P2087, DOI 10.1158/0008-5472.CAN-10-1511; Tachado SD, 2002, J CELL BIOCHEM, V85, P785, DOI 10.1002/jcb.10164; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Tam WL, 2013, CANCER CELL, V24, P347, DOI 10.1016/j.ccr.2013.08.005; Tan M, 2006, ONCOGENE, V25, P3286, DOI 10.1038/sj.onc.1209361; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; Teicher BA, 2001, CANCER CHEMOTH PHARM, V48, P473, DOI 10.1007/s002800100372; Teicher BA, 2002, INVEST NEW DRUG, V20, P241, DOI 10.1023/A:1016297611825; Teicher BA, 2001, CLIN CANCER RES, V7, P634; Tekle C, 2008, BRIT J CANCER, V99, P750, DOI 10.1038/sj.bjc.6604566; Tonetti DA, 2003, BRIT J CANCER, V88, P1400, DOI 10.1038/sj.bjc.6600923; Tonetti DA, 2000, BRIT J CANCER, V83, P782, DOI 10.1054/bjoc.2000.1326; Tonetti DA, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/740353; Truman JP, 2009, CANCER BIOL THER, V8, P54, DOI 10.4161/cbt.8.1.7119; Tsai JH, 2000, CANCER LETT, V161, P171, DOI 10.1016/S0304-3835(00)00597-8; Villar J, 2007, CANCER RES, V67, P10859, DOI 10.1158/0008-5472.CAN-07-2041; von Brandenstein M, 2012, AM J PATHOL, V180, P1787, DOI 10.1016/j.ajpath.2012.01.014; Wang HB, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M111.227991; Wang HB, 2010, MOL BIOL CELL, V21, P1398, DOI 10.1091/mbc.E09-08-0735; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Wheeler DL, 2005, AM J PATHOL, V166, P117, DOI 10.1016/S0002-9440(10)62237-7; Wheeler DL, 2004, CANCER RES, V64, P7756, DOI 10.1158/0008-5472.CAN-04-1881; Willey CD, 2010, INT J RADIAT ONCOL, V77, P1518, DOI 10.1016/j.ijrobp.2009.06.044; Win HY, 2008, CANCER LETT, V270, P302, DOI 10.1016/j.canlet.2008.05.023; Wu DQ, 2004, ONCOGENE, V23, P8659, DOI 10.1038/sj.onc.1207900; Wu DQ, 2002, CANCER RES, V62, P2423; Wu TT, 2008, J CELL BIOCHEM, V103, P9, DOI 10.1002/jcb.21378; Xiao LQ, 2008, METHOD ENZYMOL, V446, P123, DOI 10.1016/S0076-6879(08)01607-8; Xiao LQ, 2009, J BIOL CHEM, V284, P29365, DOI 10.1074/jbc.M109.007971; Xiao LQ, 2009, MOL CARCINOGEN, V48, P187, DOI 10.1002/mc.20476; Xin MG, 2007, J BIOL CHEM, V282, P21268, DOI 10.1074/jbc.M701613200; Yadav V, 2010, AM J PATHOL, V176, P1091, DOI 10.2353/ajpath.2010.090816; Yang MY, 2010, J AGR FOOD CHEM, V58, P5806, DOI 10.1021/jf100718b; Yonezawa Tomo, 2009, Recent Pat DNA Gene Seq, V3, P96; Yu LR, 2011, NEOPLASMA, V58, P491, DOI 10.4149/neo_2011_06_491; Yu WS, 2003, J BIOL CHEM, V278, P11167, DOI 10.1074/jbc.M211424200; Yun J, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.26; Zhang J, 2004, J BIOL CHEM, V279, P22118, DOI 10.1074/jbc.M400774200; Zhang L, 2006, CANCER RES, V66, P4627, DOI 10.1158/0008-5472.CAN-05-4527; Zhao M, 2012, ARCH IMMUNOL THER EX, V60, P361, DOI 10.1007/s00005-012-0188-8	244	171	179	1	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2014	33	45					5225	5237		10.1038/onc.2013.524	http://dx.doi.org/10.1038/onc.2013.524			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MD	24336328	Green Accepted, Green Published			2022-12-17	WOS:000345120400001
J	Uhlmann, S; Zhang, JD; Schwager, A; Mannsperger, H; Riazalhosseini, Y; Burmester, S; Ward, A; Korf, U; Wiemann, S; Sahin, O				Uhlmann, S.; Zhang, J. D.; Schwaeger, A.; Mannsperger, H.; Riazalhosseini, Y.; Burmester, S.; Ward, A.; Korf, U.; Wiemann, S.; Sahin, Oe			miR-200bc/429 cluster targets PLC gamma 1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer	ONCOGENE			English	Article						miR-200 family; PLC gamma 1; invasion; cell proliferation; tumor suppressor; breast cancer	MESENCHYMAL TRANSITION; GROWTH; MICRORNAS; CONTRIBUTES; SENSITIVITY; ACTIVATION; RESISTANCE; ARREST; FAMILY	The genes encoding microRNAs of the human miR-200 family map to fragile chromosomal regions and are frequently downregulated upon tumor progression. Although having been reported to regulate epithelial-to-mesenchymal transition and transforming growth factor-beta- driven cell invasion, the role of the miR-200 family in EGF-driven breast cancer cell invasion, viability, apoptosis and cell cycle progression is still unknown. In particular, there is no study comparing the roles of the two clusters of this miRNA family. In this study, we show for the first time that miR-200 family members differentially regulate EGF-driven invasion, viability, apoptosis and cell cycle progression of breast cancer cells. We showed that, all miR-200 family members regulate EGF-driven invasion, with the miR-200bc/429 cluster showing stronger effects than the miR-200a/141 cluster. Furthermore, expression of the miR-200a/141 cluster results in G1 arrest supported by increased p27/Kip1 and decreased cyclin dependent kinase 6 expression. In contrast, expression of the 200bc/429 cluster decreases G1 population and increases G2/M phase, in line with the observed reduction of p27/Kip1 and upregulation of the inhibitory phosphorylation of Cdc25C, respectively. To test the hypothesis that phenotypical differences observed between the two clusters are caused by differential targeting spectrums, we performed genome-wide microarray profiling in combination with gain-of-function studies. This identified phospholipase C gamma 1 (PLCG1), which was downregulated only by the miR-200bc/429 cluster, as a potential candidate contributing to these phenotypical differences. Luciferase reporter assays validated PLCG1 as a direct functional target of miR-200bc/429 cluster, but not of miR-200a/141 cluster. Finally, loss of PLCG1 in part mimicked the effect of miR-200bc/429 overexpression in viability, apoptosis and EGF-driven cell invasion of breast cancer cells. Our results suggest that the miR-200 family has a tumor-suppressor function by negatively regulating EGF-driven cell invasion, viability and cell cycle progression in breast cancer. Oncogene (2010) 29, 4297-4306; doi: 10.1038/onc.2010.201; published online 31 May 2010	[Uhlmann, S.; Zhang, J. D.; Schwaeger, A.; Mannsperger, H.; Burmester, S.; Ward, A.; Korf, U.; Wiemann, S.; Sahin, Oe] German Canc Res Ctr, Div Mol Genome Anal, D-6900 Heidelberg, Germany; [Riazalhosseini, Y.] German Canc Res Ctr, Div Funct Genome Anal, D-6900 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Sahin, O (corresponding author), German Canc Res Ctr, Div Mol Genome Anal, Neuenheimer Feld 580, D-69120 Heidelberg, Germany.	oe.sahin@dkfz-heidelberg.de	Sahin, Özgür/F-4403-2014; Korf, Ulrike/G-2795-2013; Wiemann, Stefan/E-4424-2013	Sahin, Özgür/0000-0002-8033-7089; Wiemann, Stefan/0000-0003-4683-3174; Ward Gahlawat, Aoife/0000-0001-7854-7207; Fullgrabe, Anja/0000-0002-8674-0039	National Genome Research Network of the Federal Ministry of Education and Research (BMBF) [01GS0864]; Wilhelm-Sander Stiftung [2009.051.1]; DKFZ International PhD Program	National Genome Research Network of the Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Wilhelm-Sander Stiftung; DKFZ International PhD Program	This work was supported in part by the National Genome Research Network (Contract No. 01GS0864) of the Federal Ministry of Education and Research (BMBF) and by Wilhelm-Sander Stiftung (Contract No. 2009.051.1). JDZ is supported by the DKFZ International PhD Program. We thank Moritz Kublbeck, Christian Schmidt and Ute Ernst for their excellent technical assistance.	Adam L, 2009, CLIN CANCER RES, V15, P5060, DOI 10.1158/1078-0432.CCR-08-2245; Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819; Baffa R, 2009, J PATHOL, V219, P214, DOI 10.1002/path.2586; Bagchi A, 2008, CANCER RES, V68, P2551, DOI 10.1158/0008-5472.CAN-07-2095; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Browaeys-Poly E, 2009, ANTICANCER RES, V29, P4965; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Cochrane DR, 2010, J ONCOL, V2010, DOI 10.1155/2010/821717; DiPaola RS, 2002, CLIN CANCER RES, V8, P3311; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Hyun S, 2009, CELL, V139, P1096, DOI 10.1016/j.cell.2009.11.020; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li SW, 2009, MOL ENDOCRINOL, V23, P901, DOI 10.1210/me.2008-0368; Liu Q, 2008, NUCLEIC ACIDS RES, V36, P5391, DOI 10.1093/nar/gkn522; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Markova B, 2010, ONCOGENE, V29, P739, DOI 10.1038/onc.2009.374; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Sahin O, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-1; Sahin O, 2007, P NATL ACAD SCI USA, V104, P6579, DOI 10.1073/pnas.0606827104; Sala G, 2008, CANCER RES, V68, P10187, DOI 10.1158/0008-5472.CAN-08-1181; Sato Y, 2001, LEUKEMIA, V15, P1193, DOI 10.1038/sj.leu.2402188; Saydam O, 2009, MOL CELL BIOL, V29, P5923, DOI 10.1128/MCB.00332-09; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Thomson S, 2005, CANCER RES, V65, P9455, DOI 10.1158/0008-5472.CAN-05-1058; Xia HP, 2010, BIOCHEM BIOPH RES CO, V391, P535, DOI 10.1016/j.bbrc.2009.11.093; Yauch RL, 2005, CLIN CANCER RES, V11, P8686, DOI 10.1158/1078-0432.CCR-05-1492	33	171	188	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2010	29	30					4297	4306		10.1038/onc.2010.201	http://dx.doi.org/10.1038/onc.2010.201			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20514023				2022-12-17	WOS:000280547900006
J	Molli, PR; Li, DQ; Murray, BW; Rayala, SK; Kumar, R				Molli, P. R.; Li, D. Q.; Murray, B. W.; Rayala, S. K.; Kumar, R.			PAK signaling in oncogenesis	ONCOGENE			English	Review						PAK; cancer; cytoskeleton; survival; mitosis; knockout mice	KINASE GAMMA-PAK; BREAST-CANCER CELLS; ANCHORAGE-INDEPENDENT GROWTH; P21-ACTIVATED KINASE-1-INTERACTING SUBSTRATE; NUCLEOTIDE EXCHANGE FACTOR; CASPASE-ACTIVATED PAK-2; FAMILY-MEMBER BIM; SERINE/THREONINE KINASE; MENTAL-RETARDATION; PROSTATE-CANCER	The p21-activated kinase (PAK) family of serine/threonine kinases is important in physiological processes including motility, survival, mitosis, transcription and translation. PAKs are evolutionally conserved and widely expressed in a variety of tissues and are often overexpressed in multiple cancer types. Depending on structural and functional similarities, the six members of PAK family are divided into two groups with three members in each group. Group I PAKs are activated by extracellular signals through GTPase-dependent and GTPase-independent mechanisms. In contrast, group II PAKs are constitutively active. Over the years, accumulating data from tissue culture models and human tumors has increased our understanding about the biology of PAK family members. In this review, we have summarized the complex regulation of PAK and its downstream diverse myriads of effectors, which in turn are responsible for the biological effects of PAK family of kinases in cancer cells. Oncogene (2009) 28, 2545-2555; doi: 10.1038/onc.2009.119; published online 25 May 2009	[Molli, P. R.; Li, D. Q.; Rayala, S. K.; Kumar, R.] George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20037 USA; [Murray, B. W.] La Jolla Labs, Pfizer Global Res & Dev, San Diego, CA USA	George Washington University; Pfizer	Kumar, R (corresponding author), George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, 2300 1 St NW,Suit 530, Washington, DC 20037 USA.	bcmrxk@gwumc.edu	Kumar, Rakesh/ABD-1065-2020	Kumar, Rakesh/0000-0001-7664-0803; murray, brion/0000-0003-1591-2566; Rayala, Suresh/0000-0003-4394-4450	NIH [CA90970, CA098823]; NATIONAL CANCER INSTITUTE [R01CA090970, R01CA098823] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Work in Professor Kumar's laboratory is supported by NIH grants CA90970 and CA098823.	Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Ahmed S, 1998, J BIOL CHEM, V273, P15693, DOI 10.1074/jbc.273.25.15693; Alahari SK, 2004, EMBO J, V23, P2777, DOI 10.1038/sj.emboj.7600291; Arias-Romero LE, 2008, BIOL CELL, V100, P97, DOI 10.1042/BC20070109; Bagheri-Yarmand R, 2006, INT J CANCER, V118, P2703, DOI 10.1002/ijc.21650; Banerjee M, 2002, CURR BIOL, V12, P1233, DOI 10.1016/S0960-9822(02)00956-9; Belletti B, 2008, MOL BIOL CELL, V19, P2003, DOI 10.1091/mbc.E07-09-0894; Bienvenu T, 2000, AM J MED GENET, V93, P294, DOI 10.1002/1096-8628(20000814)93:4<294::AID-AJMG8>3.0.CO;2-F; Block MR, 2008, EUR J CELL BIOL, V87, P491, DOI 10.1016/j.ejcb.2008.02.012; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Brecht M, 2005, INT J CANCER, V113, P533, DOI 10.1002/ijc.20626; Buday L, 2007, BBA-REV CANCER, V1775, P263, DOI 10.1016/j.bbcan.2006.12.002; Callow MG, 2005, J CELL SCI, V118, P1861, DOI 10.1242/jcs.02313; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Cammarano MS, 2005, MOL CELL BIOL, V25, P9532, DOI 10.1128/MCB.25.21.9532-9542.2005; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Chen S, 2003, J BIOL CHEM, V278, P20029, DOI 10.1074/jbc.M300818200; Chen SL, 2008, CANCER BIOL THER, V7, P1793, DOI 10.4161/cbt.7.11.6840; Chew TL, 1998, J MUSCLE RES CELL M, V19, P839, DOI 10.1023/A:1005417926585; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; Come C, 2004, J MAMMARY GLAND BIOL, V9, P183, DOI 10.1023/B:JOMG.0000037161.91969.de; Cotteret S, 2006, MOL CELL BIOL, V26, P3215, DOI 10.1128/MCB.26.8.3215-3230.2006; Cotteret S, 2003, MOL CELL BIOL, V23, P5526, DOI 10.1128/MCB.23.16.5526-5539.2003; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Dan C, 2001, J BIOL CHEM, V276, P32115, DOI 10.1074/jbc.M100871200; Davila M, 2003, J BIOL CHEM, V278, P36868, DOI 10.1074/jbc.M306196200; Deacon SW, 2008, CHEM BIOL, V15, P322, DOI 10.1016/j.chembiol.2008.03.005; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; Gedeon AK, 2003, AM J MED GENET A, V120A, P509, DOI 10.1002/ajmg.a.20131; Gnesutta N, 2003, MOL CELL BIOL, V23, P7838, DOI 10.1128/MCB.23.21.7838-7848.2003; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hashimoto S, 2001, J BIOL CHEM, V276, P6037, DOI 10.1074/jbc.M005854200; He H, 2004, CANCER BIOL THER, V3, P96, DOI 10.4161/cbt.3.1.643; Hirokawa Y, 2005, CANCER BIOL THER, V4, P956, DOI 10.4161/cbt.4.9.1911; Hoefen RJ, 2006, J CELL SCI, V119, P1469, DOI 10.1242/jcs.02925; Hofmann C, 2004, J CELL SCI, V117, P4343, DOI 10.1242/jcs.01392; Jakobi R, 2003, J BIOL CHEM, V278, P38675, DOI 10.1074/jbc.M306494200; Jakobi R, 2001, J BIOL CHEM, V276, P16624, DOI 10.1074/jbc.M007753200; Jung JH, 2005, J BIOL CHEM, V280, P40025, DOI 10.1074/jbc.M509075200; Kaur R, 2008, PROSTATE, V68, P1510, DOI 10.1002/pros.20787; Kimmelman AC, 2008, P NATL ACAD SCI USA, V105, P19372, DOI 10.1073/pnas.0809966105; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Koeppel MA, 2004, J BIOL CHEM, V279, P53653, DOI 10.1074/jbc.M410530200; Koh CG, 2002, CURR BIOL, V12, P317, DOI 10.1016/S0960-9822(02)00652-8; Kreis P, 2008, J NEUROCHEM, V106, P1184, DOI 10.1111/j.1471-4159.2008.05474.x; Krendel M, 2002, NAT CELL BIOL, V4, P294, DOI 10.1038/ncb773; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Lee SR, 2002, MOL ENDOCRINOL, V16, P85, DOI 10.1210/me.16.1.85; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Li XF, 2003, MOL CELL BIOL, V23, P7134, DOI 10.1128/MCB.23.20.7134-7142.2003; Ling J, 2005, EMBO J, V24, P4094, DOI 10.1038/sj.emboj.7600868; Lua BL, 2005, FEBS LETT, V579, P577, DOI 10.1016/j.febslet.2004.12.055; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Maroto B, 2008, ONCOGENE, V27, P4900, DOI 10.1038/onc.2008.131; Mazumdar A, 2003, FEBS LETT, V535, P6, DOI 10.1016/S0014-5793(02)03846-2; Meng JS, 2005, J NEUROSCI, V25, P6641, DOI 10.1523/JNEUROSCI.0028-05.2005; Meng Q, 2007, P NATL ACAD SCI USA, V104, P5866, DOI 10.1073/pnas.0701065104; Misra UK, 2005, J BIOL CHEM, V280, P26278, DOI 10.1074/jbc.M414467200; Morita T, 2007, J BIOL CHEM, V282, P8454, DOI 10.1074/jbc.M609983200; Nheu T, 2004, CELL CYCLE, V3, P71; Pandey A, 2002, ONCOGENE, V21, P3939, DOI 10.1038/sj.onc.1205478; Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a; Pirruccello M, 2006, J MOL BIOL, V361, P312, DOI 10.1016/j.jmb.2006.06.017; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Qu J, 2003, MOL CELL BIOL, V23, P7122, DOI 10.1128/MCB.23.20.7122-7133.2003; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; Rayala SK, 2006, CANCER RES, V66, P1694, DOI 10.1158/0008-5472.CAN-05-2922; Roig J, 1999, J BIOL CHEM, V274, P31119, DOI 10.1074/jbc.274.44.31119; Rousseau V, 2003, J BIOL CHEM, V278, P3912, DOI 10.1074/jbc.M207251200; Schatten H, 2008, HISTOCHEM CELL BIOL, V129, P667, DOI 10.1007/s00418-008-0427-6; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Settleman J, 2007, CELL, V128, P237, DOI 10.1016/j.cell.2007.01.002; Singh RR, 2005, J BIOL CHEM, V280, P18130, DOI 10.1074/jbc.M412607200; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Timm T, 2006, NEURODEGENER DIS, V3, P207, DOI 10.1159/000095258; Totsukawa G, 2004, J CELL BIOL, V164, P427, DOI 10.1083/jcb.200306172; Turner CE, 2000, J CELL SCI, V113, P4139; Vadlamudi RK, 2005, MOL CELL BIOL, V25, P3726, DOI 10.1128/MCB.25.9.3726-3736.2005; Vadlamudi RK, 2004, CANCER CELL, V5, P575, DOI 10.1016/j.ccr.2004.05.022; Vadlamudi RK, 2004, EMBO REP, V5, P154, DOI 10.1038/sj.embor.7400079; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; Wang RA, 2006, ONCOGENE, V25, P2931, DOI 10.1038/sj.onc.1209309; Wang RA, 2003, J CELL BIOL, V161, P583, DOI 10.1083/JCB.200212066; Webb BA, 2006, ARCH BIOCHEM BIOPHYS, V456, P183, DOI 10.1016/j.abb.2006.06.011; Weisz H. M., 2007, BIOCHEM J, V404, P487, DOI DOI 10.1042/BJ20061696; Wittmann T, 2004, J BIOL CHEM, V279, P6196, DOI 10.1074/jbc.M307261200; Wu XC, 2006, BIOCHEM BIOPH RES CO, V351, P328, DOI 10.1016/j.bbrc.2006.09.172; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Yang F, 2001, J BIOL CHEM, V276, P15345, DOI 10.1074/jbc.M010311200; Yang ZB, 2005, CANCER RES, V65, P3179, DOI 10.1158/0008-5472.CAN-04-3480; Yoshioka K, 2003, P NATL ACAD SCI USA, V100, P7247, DOI 10.1073/pnas.1232344100; Zhan Q, 2003, J IMMUNOL, V171, P3785, DOI 10.4049/jimmunol.171.7.3785; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035; Zhou GL, 2003, MOL CELL BIOL, V23, P8058, DOI 10.1128/MCB.23.22.8058-8069.2003	104	171	179	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2009	28	28					2545	2555		10.1038/onc.2009.119	http://dx.doi.org/10.1038/onc.2009.119			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	471LJ	19465939	Green Accepted			2022-12-17	WOS:000268058900001
J	Lee, Y; Kawagoe, R; Sasai, K; Li, Y; Russell, HR; Curran, T; McKinnon, PJ				Lee, Y.; Kawagoe, R.; Sasai, K.; Li, Y.; Russell, H. R.; Curran, T.; McKinnon, P. J.			Loss of suppressor-of-fused function promotes tumorigenesis	ONCOGENE			English	Article						suppressor of fused; sufu; patched1; medulloblastoma; hedgehog; HhAntag	MEDULLOBLASTOMA CELLS; SONIC HEDGEHOG; MICE; PATHWAY; GLI; SUFU; TRANSCRIPTION; DISRUPTION; REGULATOR; PROTEINS	The Sonic Hedgehog (SHH) signaling pathway is indispensable for development, and functions to activate a transcriptional program modulated by the GLI transcription factors. Here, we report that loss of a regulator of the SHH pathway, Suppressor of Fused (Sufu), resulted in early embryonic lethality in the mouse similar to inactivation of another SHH regulator, Patched1 (Ptch1). In contrast to Ptch(+/-) mice, Sufu(+/-) mice were not tumor prone. However, in conjunction with p53 loss, Sufu(+/-) animals developed tumors including medulloblastoma and rhabdomyosarcoma. Tumors present in Sufu(+/-) p53(-/-) animals resulted from Sufu loss of heterozygosity. Sufu(+/-) p53(-/-) medulloblastomas also expressed a signature gene expression pro. le typical of aberrant SHH signaling, including upregulation of N-myc, Sfrp1, Ptch2 and cyclin D1. Finally, the Smoothened inhibitor, hedgehog antagonist, did not block growth of tumors arising from Sufu inactivation. These data demonstrate that Sufu is essential for development and functions as a tumor suppressor.	St Jude Childrens Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA; St Jude Childrens Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	McKinnon, PJ (corresponding author), St Jude Childrens Hosp, Dept Genet & Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38105 USA.	peter.mckinnon@stjude.org	Curran, Tom/F-5234-2018; Curran, Tom/D-7515-2011; Curran, Tom/C-1164-2008; Curran, Thomas/AAE-7631-2019	Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Lee, Youngsoo/0000-0003-4773-6464	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS037956, R01NS037956] Funding Source: NIH RePORTER; NCI NIH HHS [CA-21765, P30-CA21765] Funding Source: Medline; NINDS NIH HHS [NS-37956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Callahan CA, 2004, GENE DEV, V18, P2724, DOI 10.1101/gad.1221804; Chen MH, 2005, MOL CELL BIOL, V25, P7042, DOI 10.1128/MCB.25.16.7042-7053.2005; Cheng SY, 2002, P NATL ACAD SCI USA, V99, P5442, DOI 10.1073/pnas.082096999; Cooper AF, 2005, DEVELOPMENT, V132, P4407, DOI 10.1242/dev.02021; Dellovade T, 2006, ANNU REV NEUROSCI, V29, P539, DOI 10.1146/annurev.neuro.29.051605.112858; Di Marcotullio L, 2004, P NATL ACAD SCI USA, V101, P10833, DOI 10.1073/pnas.0400690101; Dunaeva M, 2003, J BIOL CHEM, V278, P5116, DOI 10.1074/jbc.M209492200; Ferretti E, 2005, TRENDS MOL MED, V11, P537, DOI 10.1016/j.molmed.2005.10.005; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kimura H, 2005, ONCOGENE, V24, P4026, DOI 10.1038/sj.onc.1208567; Lawinger P, 2000, NAT MED, V6, P826, DOI 10.1038/77565; Lee Y, 2003, CANCER RES, V63, P5428; Lee Y, 2006, CANCER RES, V66, P6964, DOI 10.1158/0008-5472.CAN-06-0505; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Marino S, 2005, TRENDS MOL MED, V11, P17, DOI 10.1016/j.molmed.2004.11.008; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Paces-Fessy M, 2004, BIOCHEM J, V378, P353, DOI 10.1042/BJ20030786; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Sasai K, 2006, CANCER RES, V66, P4215, DOI 10.1158/0008-5472.CAN-05-4505; Svard J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Varjosalo M, 2006, DEV CELL, V10, P177, DOI 10.1016/j.devcel.2005.12.014; Weiner HL, 2002, CANCER RES, V62, P6385; Wetmore C, 2001, CANCER RES, V61, P513; Yan CT, 2006, P NATL ACAD SCI USA, V103, P7378, DOI 10.1073/pnas.0601938103	27	171	182	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2007	26	44					6442	6447		10.1038/sj.onc.1210467	http://dx.doi.org/10.1038/sj.onc.1210467			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17452975				2022-12-17	WOS:000249737600008
J	Erkan, M; Kleeff, J; Esposito, I; Giese, T; Ketterer, K; Buchler, MW; Giese, NA; Friess, H				Erkan, M; Kleeff, J; Esposito, I; Giese, T; Ketterer, K; Buchler, MW; Giese, NA; Friess, H			Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis	ONCOGENE			English	Article						hypoxia; apoptosis; PanIN; Bcl-2; chemoresistance; TGF-beta	HYPOXIC CELL-DEATH; PHASE-III TRIAL; PROTEIN BNIP3; CURATIVE RESECTION; BH3 DOMAIN; MITOCHONDRIAL; CARCINOMA; APOPTOSIS; BCL-2; 5-FLUOROURACIL	Altered expression of apoptosis-regulating genes plays an important role in the aggressive growth behavior and chemoresistance of pancreatic ductal adenocarcinoma. In the present study, the hypoxia-inducible proapoptotic gene, BNIP3, was analysed in terms of expression, effect on patient survival, and chemo-responsiveness in pancreatic cancer cell lines. cDNA microarray, real-time light cyclers quantitative polymerase chain reaction, laser-capture microdissection, and immunohistochemistry analyses were used to evaluate BNIP3 expression in normal and diseased pancreatic specimens. Modulation of BNIP3 expression was achieved using specific siRNA molecules. The effect of chemotherapeutic agents on pancreatic cancer cells was assessed utilizing 3-(4,5-methylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide assays. BNIP3 mRNA levels were 3.0- and 6.3-fold lower in chronic pancreatitis and pancreatic cancer compared to the normal pancreas, respectively. Microdissection analysis confirmed the reduction of BNIP3 expression in pancreatic cancer cells compared to normal duct cells. By immunohistochemistry, BNIP3 was predominantly expressed in the acinar cells of the normal and diseased pancreas. Interestingly, while BNIP3 was undetectable in the cancer cells of 59% of the cases, 75-100% of PanIN2/3 lesions displayed BNIP3 immunoreactivity. Loss of BNIP3 expression correlated with poorer survival of patients (8 vs 14 months for BNIP3 negative vs positive tumors). Hypoxia induced BNIP3 expression in four out of eight pancreatic cancer cell lines, while it was absent under normoxic and hypoxic conditions in the remaining four. Downregulation of BNIP3 resulted in increased resistance to 5-fluoro-uracil and gemcitabine. In conclusion, loss of BNIP3 expression occurs late in pancreatic cancer, con tributes to resistance to chemotherapy, and correlates with a worsened prognosis.	Heidelberg Univ, Dept Gen Surg, D-69120 Heidelberg, Germany; Heidelberg Univ, Inst Pathol, D-69120 Heidelberg, Germany; Heidelberg Univ, Inst Immunol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Friess, H (corresponding author), Heidelberg Univ, Dept Gen Surg, Im Neuenheimer Feld 110, D-69120 Heidelberg, Germany.	helmut_friess@med.uni-heidelberg.de	Kleeff, Jorg/B-2124-2009	Kleeff, Jorg/0000-0003-3432-6669				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bacon AL, 2004, ANN MED, V36, P530, DOI 10.1080/07853890410018231; Bani MR, 2004, MOL CANCER THER, V3, P111; Bold RJ, 1999, ANN SURG ONCOL, V6, P279, DOI 10.1007/s10434-999-0279-x; Brandt R, 2004, PANCREATOLOGY, V4, P587, DOI 10.1159/000082241; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Crnogorac-Jurcevic T, 2002, ONCOGENE, V21, P4587, DOI 10.1038/sj.onc.1205570; CROWN J, 1991, J CLIN ONCOL, V9, P1682, DOI 10.1200/JCO.1991.9.9.1682; CULLINAN S, 1990, CANCER, V65, P2207, DOI 10.1002/1097-0142(19900515)65:10<2207::AID-CNCR2820651007>3.0.CO;2-Y; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; De Angelis PM, 2004, INT J ONCOL, V24, P1279; Friess H, 1998, GASTROENTEROLOGY, V115, P1018, DOI 10.1016/S0016-5085(98)70278-1; Friess H, 2003, CELL MOL LIFE SCI, V60, P1180, DOI 10.1007/s00018-003-3036-5; Friess H, 1998, GUT, V43, P414, DOI 10.1136/gut.43.3.414; Giatromanolaki A, 2004, CLIN CANCER RES, V10, P5566, DOI 10.1158/1078-0432.CCR-04-0076; Graber HU, 1999, J GASTROINTEST SURG, V3, P74, DOI 10.1016/S1091-255X(99)80012-2; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Graham RA, 2004, J EXP BIOL, V207, P3189, DOI 10.1242/jeb.01109; Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032; Guo JC, 2004, ONCOGENE, V23, P71, DOI 10.1038/sj.onc.1206926; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Imazu T, 1999, ONCOGENE, V18, P4523, DOI 10.1038/sj.onc.1202722; Kennedy AS, 2000, INT J CANCER, V90, P175, DOI 10.1002/1097-0215(20000820)90:4<175::AID-IJC1>3.0.CO;2-W; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Ketterer K, 2003, CLIN CANCER RES, V9, P5127; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Kleeff J, 1999, BIOCHEM BIOPH RES CO, V255, P268, DOI 10.1006/bbrc.1999.0171; Kleeff J, 1999, DIGEST DIS SCI, V44, P1793, DOI 10.1023/A:1018882320500; Klinkenbijl JH, 1999, ANN SURG, V230, P776, DOI 10.1097/00000658-199912000-00006; Koong AC, 2000, INT J RADIAT ONCOL, V48, P919, DOI 10.1016/S0360-3016(00)00803-8; KORSMEYER SJ, 1992, BLOOD, V80, P879; Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666; Lamy L, 2003, J BIOL CHEM, V278, P23915, DOI 10.1074/jbc.M301869200; Monti P, 2004, VIRCHOWS ARCH, V445, P236, DOI 10.1007/s00428-004-1053-x; Moskaluk CA, 1997, CANCER RES, V57, P2140; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Reynolds TY, 1996, CANCER RES, V56, P5754; Richter A, 2003, WORLD J SURG, V27, P324, DOI 10.1007/s00268-002-6659-z; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Schmidt-Kastner R, 2004, BRAIN RES, V1001, P133, DOI 10.1016/j.brainres.2003.11.065; Shi X, 2002, ONCOLOGY-BASEL, V62, P354, DOI 10.1159/000065068; Sowter HM, 2003, J PATHOL, V201, P573, DOI 10.1002/path.1486; Sowter HM, 2001, CANCER RES, V61, P6669; Takaori K, 2004, PANCREAS, V28, P257, DOI 10.1097/00006676-200404000-00008; Tenedini E, 2004, BLOOD, V104, P3126, DOI 10.1182/blood-2003-07-2597; Tracey L, 2004, J INTERF CYTOK RES, V24, P185, DOI 10.1089/107999004322917034; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Wagner M, 2004, BRIT J SURG, V91, P586, DOI 10.1002/bjs.4484; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wilentz RE, 2000, CANCER RES, V60, P2002; Xu ZW, 2002, CANCER CHEMOTH PHARM, V49, P504, DOI 10.1007/s00280-002-0435-5; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yeo CJ, 1997, ANN SURG, V226, P248, DOI 10.1097/00000658-199709000-00004; Yook YH, 2004, BIOCHEM BIOPH RES CO, V321, P298, DOI 10.1016/j.bbrc.2004.06.144	61	171	181	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4421	4432		10.1038/sj.onc.1208642	http://dx.doi.org/10.1038/sj.onc.1208642			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15856026				2022-12-17	WOS:000229976900011
J	Clemens, MJ				Clemens, MJ			Targets and mechanisms for the regulation of translation in malignant transformation	ONCOGENE			English	Review						eIF2; eIF4E-binding proteins; oncogenic viruses; p53; PKR; TNF family	EPSTEIN-BARR-VIRUS; PROTEIN-KINASE PKR; INITIATION-FACTORS 4E; TUMOR-NECROSIS-FACTOR; CAP-BINDING PROTEIN; MYC-DEPENDENT APOPTOSIS; HEPATITIS-C VIRUS; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; DIFFERENTIAL REQUIREMENTS	There is increasing evidence that deregulation of gene expression at the level of mRNA translation can contribute to cell transformation and the malignant phenotype. Two steps in the pathway of polypeptide chain initiation, viz. the assembly of the 43S initiation complex catalysed by polypeptide chain initiation factor eIF2 and the binding of eIF4E to eIF4G during the recruitment of mRNA to the ribosome, have been shown to be likely targets for changes associated with tumorigenesis. The activity of eIF2 is controlled by changes in phosphorylation of the a subunit of this factor. The availability of eIF4E for binding to eIF4G is regulated by the phosphorylation of a small family of eIF4E-binding proteins (the 4E-BPs). The activities of the protein kinases and/or phosphatases responsible for the (de)phosphorylation of these substrates may in turn be controlled by cellular and viral oncogenes and tumour-suppressor genes. This review will describe recent aspects of the mechanisms involved, with particular emphasis on the regulation of the eIF2alpha kinase PKR and the control of 4E-BP phosphorylation by viral gene products, growth-inhibitory cytokines and the tumour-suppressor protein p53.	St George Hosp, Sch Med, Dept Basic Med Sci, Translat Control Grp, London SW17 0RE, England	St Georges University London	Clemens, MJ (corresponding author), St George Hosp, Sch Med, Dept Basic Med Sci, Translat Control Grp, Cranmer Terrace, London SW17 0RE, England.	m.clemens@sghms.ac.uk						Abraham N, 1998, EXP CELL RES, V244, P394, DOI 10.1006/excr.1998.4201; Appella E, 2001, EUR J BIOCHEM, V268, P2763, DOI 10.1046/j.1432-1327.2001.02224.x; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Balachandran S, 2000, J VIROL, V74, P1513, DOI 10.1128/JVI.74.3.1513-1523.2000; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; BARBER GN, 1995, J BIOL CHEM, V270, P17423, DOI 10.1074/jbc.270.29.17423; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bauer C, 2001, CANCER, V92, P822, DOI 10.1002/1097-0142(20010815)92:4<822::AID-CNCR1388>3.0.CO;2-A; Brass N, 1997, HUM MOL GENET, V6, P33, DOI 10.1093/hmg/6.1.33; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Carter PS, 1999, ONCOGENE, V18, P4326, DOI 10.1038/sj.onc.1202890; Chacko MS, 2002, ENDOCRINOLOGY, V143, P525, DOI 10.1210/en.143.2.525; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; CLEMENS M, 1992, NATURE, V360, P210, DOI 10.1038/360210a0; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Clemens MJ, 2001, PROG MOLEC, V27, P57; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Constantinou C, 2003, EUR J BIOCHEM, V270, P3122, DOI 10.1046/j.1432-1033.2003.03687.x; Deb A, 2001, EMBO J, V20, P2487, DOI 10.1093/emboj/20.10.2487; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Dilling MB, 2002, J BIOL CHEM, V277, P13907, DOI 10.1074/jbc.M110782200; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Ewen ME, 1996, BBA-REV CANCER, V1242, P181, DOI 10.1016/0304-419X(95)00010-D; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Galy B, 2001, ONCOGENE, V20, P4613, DOI 10.1038/sj.onc.1204630; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; Gao CF, 1999, JPN J CANCER RES, V90, P180, DOI 10.1111/j.1349-7006.1999.tb00731.x; Garcia MA, 2002, ONCOGENE, V21, P8379, DOI 10.1038/sj.onc.1206036; Gil J, 2000, ONCOGENE, V19, P3665, DOI 10.1038/sj.onc.1203710; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Graff JR, 1997, BIOCHEM BIOPH RES CO, V240, P15, DOI 10.1006/bbrc.1997.7592; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; Haines GK, 1996, TUMOR BIOL, V17, P5, DOI 10.1159/000217961; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Jeffrey IW, 2002, CANCER RES, V62, P2272; Jiang H, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-2; Kim SH, 2002, ONCOGENE, V21, P8741, DOI 10.1038/sj.onc.1205987; Kim SH, 2000, ONCOGENE, V19, P3086, DOI 10.1038/sj.onc.1203632; Kiyosawa K, 1998, CURR STUD HEMATOL BL, P161; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Komano J, 1999, J VIROL, V73, P9827, DOI 10.1128/JVI.73.12.9827-9831.1999; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Laing KG, 2002, VIROLOGY, V297, P253, DOI 10.1006/viro.2002.1354; Li S, 2003, J BIOL CHEM, V278, P3015, DOI 10.1074/jbc.M208821200; Li SN, 2002, MOL CELL BIOL, V22, P2853, DOI 10.1128/MCB.22.8.2853-2861.2002; Lobo MVT, 2000, HISTOCHEM J, V32, P139, DOI 10.1023/A:1004091122351; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; Meijer HA, 2002, BIOCHEM J, V367, P1, DOI 10.1042/BJ20011706; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; Morley SJ, 1998, FEBS LETT, V438, P41, DOI 10.1016/S0014-5793(98)01269-1; Morley SJ, 2000, FEBS LETT, V477, P229, DOI 10.1016/S0014-5793(00)01805-6; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Nanbo A, 2002, EMBO J, V21, P954, DOI 10.1093/emboj/21.5.954; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Nomura M, 2003, MOL CARCINOGEN, V38, P25, DOI 10.1002/mc.10140; Nussbaum JM, 2003, CANCER LETT, V196, P207, DOI 10.1016/S0304-3835(03)00276-3; Packham G, 1996, ONCOGENE, V13, P461; Parker LM, 2001, J BIOL CHEM, V276, P32522, DOI 10.1074/jbc.M104408200; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Polunovsky VA, 2000, J BIOL CHEM, V275, P24776, DOI 10.1074/jbc.M001938200; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Rau M, 1996, J BIOL CHEM, V271, P8983, DOI 10.1074/jbc.271.15.8983; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; Rosenwald IB, 1996, BIOESSAYS, V18, P243, DOI 10.1002/bies.950180312; Rosenwald IB, 2001, CANCER-AM CANCER SOC, V92, P2164, DOI 10.1002/1097-0142(20011015)92:8<2164::AID-CNCR1559>3.0.CO;2-A; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Ruf IK, 2000, J VIROL, V74, P10223, DOI 10.1128/JVI.74.21.10223-10228.2000; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Saelens X, 2001, J BIOL CHEM, V276, P41620, DOI 10.1074/jbc.M103674200; Salaun P, 2003, DEV BIOL, V255, P428, DOI 10.1016/S0012-1606(02)00099-4; Savinova O, 1999, INT J BIOCHEM CELL B, V31, P175, DOI 10.1016/S1357-2725(98)00140-X; SHARP TV, 1993, NUCLEIC ACIDS RES, V21, P4483, DOI 10.1093/nar/21.19.4483; SONENBERG N, 1994, BIOCHIMIE, V76, P839, DOI 10.1016/0300-9084(94)90185-6; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446; Taylor DR, 2000, MICROBES INFECT, V2, P1743, DOI 10.1016/S1286-4579(00)01329-0; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; von der Haar T, 2002, MOL MICROBIOL, V46, P531, DOI 10.1046/j.1365-2958.2002.03172.x; Vorburger SA, 2002, ONCOGENE, V21, P6278, DOI 10.1038/sj.onc.1205761; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vyas J, 2003, RNA, V9, P858, DOI 10.1261/rna.5330503; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang ST, 1999, AM J PATHOL, V155, P247, DOI 10.1016/S0002-9440(10)65118-8; Wang ST, 2001, THYROID, V11, P1101, DOI 10.1089/10507250152740939; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yamamoto N, 2000, FEBS LETT, V484, P153, DOI 10.1016/S0014-5793(00)02145-1; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556; Zamanian-Daryoush M, 1999, ONCOGENE, V18, P315, DOI 10.1038/sj.onc.1202293; Zimmer SG, 2000, ANTICANCER RES, V20, P1343	107	171	196	0	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2004	23	18					3180	3188		10.1038/sj.onc.1207544	http://dx.doi.org/10.1038/sj.onc.1207544			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094767				2022-12-17	WOS:000220879700006
J	Gemignani, F; Moreno, V; Landi, S; Moullan, N; Chabrier, A; Gutierrez-Enriquez, S; Hall, J; Guino, E; Peinado, MA; Capella, G; Canzian, F				Gemignani, F; Moreno, V; Landi, S; Moullan, N; Chabrier, A; Gutierrez-Enriquez, S; Hall, J; Guino, E; Peinado, MA; Capella, G; Canzian, F			A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA	ONCOGENE			English	Article						TP53; colorectal cancer; polymorphism; mRNA levels	BREAST-CANCER; COMMON POLYMORPHISMS; OVARIAN-CANCER; P53 GENE; SEQUENCE; INFORMATION; PREDICTION; MUTATIONS; VARIANTS	We undertook a case-control study to examine the possible associations of the TP53 variants Arg>Pro at codon 72 and p53PIN3, a 16 bp insertion/duplication in intron 3, with the risk of colorectal cancer (CRC). The p53PIN3 A2 allele (16 bp duplication) was associated with an increased risk (OR 1.55, 95% CI 1.10-2.18, P = 0.012), of the same order of magnitude as that observed in previous studies for other types of cancer. The Pro72 allele was weakly associated with CRC (OR = 1.34, 95% CI 0.98-1.84, P = 0.066). The possible functional role of p53PIN3 was investigated by examining the TP53 mRNA transcripts in 15 lymphoblastoid cell lines with different genotypes. The possibility that the insertion/deletion could lead to alternatively spliced mRNAs was excluded. However, we found reduced levels of TP53 mRNA associated with the A2 allele. In conclusion, the epidemiological study suggests a role for p53PIN3 in tumorigenesis, supported by the in vitro characterization of this variant.	Int Agcy Res Canc, Genome Anal Grp, F-69372 Lyon, France; Univ Pisa, Dipartimento Sci Uomo & Ambiente, I-56100 Pisa, Italy; Inst Catala Oncol, Barcelona, Spain; Inst Recerca Oncol, Barcelona, Spain	World Health Organization; International Agency for Research on Cancer (IARC); University of Pisa; Catalan Institute of Oncology	Canzian, F (corresponding author), Int Agcy Res Canc, Genome Anal Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	canzian@iarc.fr	Peinado, Miguel A./A-5591-2008; Canzian, Federico/I-2804-2014; Gutierrez, Sara/GXE-9832-2022; Moreno, Victor/A-1697-2010; Capella, Gabriel/I-1879-2015; hall, janet/G-1372-2013	Peinado, Miguel A./0000-0002-4090-793X; Moreno, Victor/0000-0002-2818-5487; Capella, Gabriel/0000-0002-4669-7320; hall, janet/0000-0002-4397-6295; GEMIGNANI, Federica/0000-0003-1297-0701; Canzian, Federico/0000-0002-4261-4583; Landi, Stefano/0000-0001-8364-6357; Gutierrez-Enriquez, Sara/0000-0002-1711-6101; Guino, Elisabet/0000-0003-0093-2652				BRUNAK S, 1991, J MOL BIOL, V220, P49, DOI 10.1016/0022-2836(91)90380-O; Cox DG, 2001, BIOINFORMATICS, V17, P738, DOI 10.1093/bioinformatics/17.8.738; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; Landi S, 2003, CANCER RES, V63, P3560; LAZAR V, 1993, ONCOGENE, V8, P1703; Powell BL, 2002, CARCINOGENESIS, V23, P311, DOI 10.1093/carcin/23.2.311; Rogan PK, 1998, HUM MUTAT, V12, P153, DOI 10.1002/(SICI)1098-1004(1998)12:3<153::AID-HUMU3>3.3.CO;2-O; RUNNEBAUM IB, 1995, LANCET, V345, P994, DOI 10.1016/S0140-6736(95)90745-9; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Tonisson N, 2002, P NATL ACAD SCI USA, V99, P5503, DOI 10.1073/pnas.082100599; Wang-Gohrke S, 2002, PHARMACOGENETICS, V12, P269, DOI 10.1097/00008571-200204000-00012; Wang-Gohrke S, 1999, BRIT J CANCER, V81, P179, DOI 10.1038/sj.bjc.6690669; Weston A, 1997, CANCER EPIDEM BIOMAR, V6, P105; Wu XF, 2002, JNCI-J NATL CANCER I, V94, P681	16	171	182	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1954	1956		10.1038/sj.onc.1207305	http://dx.doi.org/10.1038/sj.onc.1207305			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14647431				2022-12-17	WOS:000220129500018
J	Denison, SR; Wang, F; Becker, NA; Schule, B; Kock, N; Phillips, LA; Klein, C; Smith, DI				Denison, SR; Wang, F; Becker, NA; Schule, B; Kock, N; Phillips, LA; Klein, C; Smith, DI			Alterations in the common fragile site gene Parkin in ovarian and other cancers	ONCOGENE			English	Article						common fragile sites; Parkinson's disease; ovarian cancer	RECESSIVE JUVENILE PARKINSONISM; UBIQUITIN-PROTEIN LIGASE; FHIT GENE; MUTATIONS; DISEASE; FRA16D; INSTABILITY; SUPPRESSOR; REGION; WWOX	The cloning and characterization of the common fragile site (CFS) FRA6E (6q26) identified Parkin, the gene involved in the pathogenesis of many cases of juvenile, early-onset and, rarely, late-onset Parkinson's disease, as the third large gene to be localized within a large CFS. Initial analyses of Parkin indicated that in addition to playing a role in Parkinson's disease, it might also be involved in the development and/or progression of ovarian cancer. These analyses also indicated striking similarities among the large CFS-locus genes: fragile histidine triad gene (FHIT; 3p14.2), WW domain-containing oxidoreductase gene (WWOX; 16q23), and Parkin (6q26). Analyses of FHIT and WWOX in a variety of different cancer types have identified the presence of alternative transcripts with whole exon deletions. Interestingly, various whole exon duplications and deletions have been identified for Parkin in juvenile and early-onset Parkinson's patients. Therefore, we performed mutational/exon rearrangement analysis of Parkin in ovarian cancer cell lines and primary tumors. Four (66.7%) cell lines and four (18.2%) primary tumors were identified as being heterozygous for the duplication or deletion of a Parkin exon. Additionally, three of 23 (13.0%) nonovarian tumor-derived cell lines were also identified as having a duplication or deletion of one or more Parkin exons. Analysis of Parkin protein expression with antibodies revealed that most of the ovarian cancer cell lines and primary tumors had diminished or absent Parkin expression. While functional analyses have not yet been performed for Parkin, these data suggest that like FHIT and WWOX, Parkin may represent a tumor suppressor gene.	Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Div Expt Pathol, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Med Univ Lubeck, Dept Neurol, D-23538 Lubeck, Germany; Med Univ Lubeck, Dept Human Genet, D-23538 Lubeck, Germany	Mayo Clinic; University of Lubeck; University of Lubeck	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Div Expt Pathol, Dept Lab Med & Pathol, 200 1st St SW, Rochester, MN 55905 USA.	smith.david@mayo.edu		Schuele, Birgitt/0000-0002-9952-5776; Klein, Christine/0000-0003-2102-3431	NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arlt MF, 2002, GENE CHROMOSOME CANC, V33, P82, DOI 10.1002/gcc.10000; Becker NA, 2002, ONCOGENE, V21, P8713, DOI 10.1038/sj.onc.1205950; Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100; Corbin S, 2002, CANCER RES, V62, P3477; Darios F, 2003, HUM MOL GENET, V12, P517, DOI 10.1093/hmg/ddg044; Denison SR, 2003, GENE CHROMOSOME CANC, V38, P40, DOI 10.1002/gcc.10236; Druck T, 1997, CANCER RES, V57, P504; Druck T, 1998, ONCOL RES, V10, P341; Feany MB, 2003, NEURON, V38, P13, DOI 10.1016/S0896-6273(03)00201-0; GAMMA A, 1997, CANCER RES, V57, P1435; Hattori N, 1998, ANN NEUROL, V44, P935, DOI 10.1002/ana.410440612; Hedrich K, 2002, NEUROLOGY, V58, P1239, DOI 10.1212/WNL.58.8.1239; Hedrich K, 2001, HUM MOL GENET, V10, P1649, DOI 10.1093/hmg/10.16.1649; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Hoenicka J, 2002, ARCH NEUROL-CHICAGO, V59, P966, DOI 10.1001/archneur.59.6.966; Horowitz JM, 2001, J CHEM NEUROANAT, V21, P75, DOI 10.1016/S0891-0618(00)00111-3; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Huynh DP, 2000, ANN NEUROL, V48, P737, DOI 10.1002/1531-8249(200011)48:5<737::AID-ANA7>3.3.CO;2-4; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Ishii H, 2001, JAMA-J AM MED ASSOC, V286, P2441, DOI 10.1001/jama.286.19.2441; Kahns S, 2002, J BIOL CHEM, V277, P15303, DOI 10.1074/jbc.M111534200; Kann M, 2002, ANN NEUROL, V51, P621, DOI 10.1002/ana.10179; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; Krummel KA, 2002, GENE CHROMOSOME CANC, V34, P154, DOI 10.1002/gcc.10047; Le Beau MM, 1998, GENE CHROMOSOME CANC, V21, P281, DOI 10.1002/(SICI)1098-2264(199804)21:4<281::AID-GCC1>3.0.CO;2-V; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Mangelsdorf M, 2000, CANCER RES, V60, P1683; Nichols WC, 2002, J MED GENET, V39, P489, DOI 10.1136/jmg.39.7.489; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Paige AJW, 2000, CANCER RES, V60, P1690; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; Shiraishi T, 2001, P NATL ACAD SCI USA, V98, P5722, DOI 10.1073/pnas.091095898; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Smith DI, 1998, INT J ONCOL, V12, P187; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; Tanaka K, 2001, J MOL MED, V79, P482, DOI 10.1007/s001090100242; Verma RS., 1995, HUMAN CHROMOSOMES PR, V2; West A, 2002, AM J MED GENET, V114, P584, DOI 10.1002/ajmg.10525; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	45	171	174	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2003	22	51					8370	8378		10.1038/sj.onc.1207072	http://dx.doi.org/10.1038/sj.onc.1207072			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614460				2022-12-17	WOS:000186541500015
J	Freund, A; Chauveau, C; Brouillet, JP; Lucas, A; Lacroix, M; Licznar, A; Vignon, F; Lazennec, G				Freund, A; Chauveau, C; Brouillet, JP; Lucas, A; Lacroix, M; Licznar, A; Vignon, F; Lazennec, G			IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells	ONCOGENE			English	Article						estrogen receptor; breast; cancer; interleukin-8; invasion	AUTOCRINE GROWTH-FACTOR; HUMAN OVARIAN-CANCER; PROSTATE-CANCER; CARCINOMA-CELLS; ER-BETA; ENDOTHELIAL INTERLEUKIN-8; REDUCED TUMORIGENICITY; LEUKEMIC-CELLS; MESSENGER-RNA; NUDE-MICE	Estrogen-receptor (ER) status is an important parameter in breast cancer management as ER-positive breast cancers have a better prognosis than ER-negative tumors. This difference comes essentially from the lower aggressiveness and invasiveness of ER-positive tumors. Here, we demonstrate, that interleukin-8 (IL-8) was clearly over-expressed in most ER-negative breast, ovary cell lines and breast tumor samples tested, whereas no significant IL-8 level could be detected in ER-positive breast or ovarian cell tines. We have also cloned human IL-8 from ER-negative MDA-MB-231 cells, and we show that IL-8 produced by breast cancer cells is identical to monocyte-derived IL-8. Interestingly, the invasion potential of ER-negative breast cancer cells is associated at least in part with expression of IL-8, but not with IL-8 receptor levels. Moreover, IL-8 increases the invasiveness of ER-positive breast cancer cells by two fold, thus confirming the invasion-promoting role of IL-8. On the other hand, exogenous expression of estrogen receptors in ER-negative cells led to a decrease of IL-8 levels. In summary, our data show that IL-8 expression is negatively linked to ER status of breast and ovarian cancer cells. We also support the idea that IL-8 expression is associated with a higher invasiveness potential of cancer cells in vitro, which suggests that IL-8 could be a novel marker of tumor aggressiveness.	INSERM, U540, F-34090 Montpellier, France; Hop Arnaud de Villeneuve, Lab Biol Cellulaire & Hormonale, F-34295 Montpellier 5, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier	Lazennec, G (corresponding author), INSERM, U540, 60 Rue Navacelles, F-34090 Montpellier, France.		Lacroix, Matthieu/O-1928-2018	Lacroix, Matthieu/0000-0002-1268-9058; Lazennec, Gwendal/0000-0002-8522-1763				BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; Balbay MD, 1999, CLIN CANCER RES, V5, P783; BASOLO F, 1993, INT J CANCER, V55, P926, DOI 10.1002/ijc.2910550609; Brew R, 1997, BIOCHEM SOC T, V25, pS264, DOI 10.1042/bst025264s; Brouillet JP, 2001, INT J CANCER, V95, P205, DOI 10.1002/1097-0215(20010720)95:4<205::AID-IJC1035>3.0.CO;2-Y; De Larco JE, 2001, AM J PATHOL, V158, P639, DOI 10.1016/S0002-9440(10)64005-9; Fontanini G, 1999, BRIT J CANCER, V80, P579, DOI 10.1038/sj.bjc.6690394; GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538; Green AR, 1997, INT J CANCER, V72, P937; GREEN S, 1986, NATURE, V324, P615, DOI 10.1038/324615a0; Greene GF, 1997, AM J PATHOL, V150, P1571; Inoue K, 2000, CLIN CANCER RES, V6, P2104; Ivarsson K, 1998, GYNECOL ONCOL, V71, P420, DOI 10.1006/gyno.1998.5198; Lazennec G, 1997, MOL CELL BIOL, V17, P5053, DOI 10.1128/MCB.17.9.5053; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Lee LF, 2000, J IMMUNOL, V164, P2769, DOI 10.4049/jimmunol.164.5.2769; Luca M, 1997, AM J PATHOL, V151, P1105; MADSEN MW, 1990, EUR J CANCER, V26, P793, DOI 10.1016/0277-5379(90)90154-L; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MCGUIRE WL, 1975, CANCER, V36, P638; Merogi AJ, 1997, HUM PATHOL, V28, P321, DOI 10.1016/S0046-8177(97)90131-3; Miller LJ, 1998, ANTICANCER RES, V18, P77; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nakashima E, 1996, PHARMACEUT RES, V13, P1896, DOI 10.1023/A:1016057830271; Pisani Paola, 1992, Journal of Environmental Pathology Toxicology and Oncology, V11, P313; Platet Nadine, 1998, Invasion and Metastasis, V18, P198, DOI 10.1159/000024513; Pujol P, 1998, CANCER RES, V58, P5367; Roger P, 2001, CANCER RES, V61, P2537; SCHADENDORF D, 1993, J IMMUNOL, V151, P2667; SKOOG L, 1987, ACTA ONCOL, V26, P95, DOI 10.3109/02841868709091747; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Speirs V, 1996, INT J CANCER, V66, P551, DOI 10.1002/(SICI)1097-0215(19960516)66:4<551::AID-IJC21>3.0.CO;2-9; SPRENGER H, 1994, J IMMUNOL, V153, P2524; SPRENGER H, 1994, J BIOL CHEM, V269, P11065; Terui Y, 1998, BLOOD, V92, P2672, DOI 10.1182/blood.V92.8.2672.420k40_2672_2680; Terui Y, 1999, CANCER RES, V59, P5651; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Veltri RW, 1999, UROLOGY, V53, P139, DOI 10.1016/S0090-4295(98)00455-5; Xu L, 2000, ONCOL RES, V12, P97, DOI 10.3727/096504001108747567; Yoneda J, 1998, JNCI-J NATL CANCER I, V90, P447, DOI 10.1093/jnci/90.6.447; Youngs SJ, 1997, INT J CANCER, V71, P257, DOI 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D	42	171	185	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					256	265		10.1038/sj.onc.1206113	http://dx.doi.org/10.1038/sj.onc.1206113			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527894	Green Submitted, Green Accepted			2022-12-17	WOS:000180322400010
J	Windham, TC; Parikh, NU; Siwak, DR; Summy, JM; McConkey, DJ; Kraker, AJ; Gallick, GE				Windham, TC; Parikh, NU; Siwak, DR; Summy, JM; McConkey, DJ; Kraker, AJ; Gallick, GE			Src activation regulates anoikis in human colon tumor cell lines	ONCOGENE			English	Article						Src; protein tyrosine kinases; anoikis; colon cancer; Akt	FOCAL ADHESION KINASE; ENDOTHELIAL GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; DOWN-REGULATION; C-SRC; EXTRACELLULAR-MATRIX; INDUCED RESISTANCE; PP60C-SRC ACTIVITY; CODON 531; IN-SITU	Src is a non-receptor protein tyrosine kinase, the expression and activity of which is increased in >80% of human colon cancers with respect to normal colonic epithelium. Previous studies from this and other laboratories have demonstrated that Src activity contributes to tumorigenicity of established colon adenocarcinoma cell lines. Src participates in the regulation of many signal transduction pathways, among which are those leading to cellular survival. In this study, we addressed the potential role of Src activation to a specific aspect of tumor cell survival, resistance to detachment-induced apoptosis (anoikis). Using five colon tumor cell lines with different biologic properties and genetic alterations, we demonstrate that expression and activity of Src corresponds with resistance to anoikis. Enforced expression of activated Src in subclones of SW480 cells (of low intrinsic Src expression and activity) increases resistance to anoikis; whereas decreased Src expression in HT29 cells (of high Src expression and activity) by transfection with anti-sense Src expression vectors increases susceptibility to anoikis. In contrast, increasing or decreasing Src expression had no effect on susceptibility to staurosporine-induced apoptosis in attached cells. PD173955, a Src family-specific tyrosine kinase inhibitor, increases the susceptibility of HT29 cells to anoikis in a dose- and time-dependent manner. Increasing Src expression and activity led to increased phosphorylation of Akt, a mediator of cellular survival pathways, whereas decreasing Src activity led to decreased Akt phosphorylation. In colon tumor cells with high Src activity, the PI3 kinase inhibitor LY 294002 sensitized cells to anoikis. These results suggest that Src activation may contribute to colon tumor progression and metastasis in part by activating Akt-mediated survival pathways that decrease sensitivity of detached cells to anoikis.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Pfizer Global Res & Dev, Dept Canc Res, Ann Arbor, MI 48105 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Pfizer	Gallick, GE (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ggallick@mdanderson.org			NCI NIH HHS [T32CA09599, CA53617, CA65527] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009599, U19CA053617, R01CA065527, U01CA053617] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allgayer H, 2002, CANCER, V94, P344, DOI 10.1002/cncr.10221; Allgayer H, 1999, J BIOL CHEM, V274, P18428, DOI 10.1074/jbc.274.26.18428; Barvian M. R., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P176; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Coll ML, 2002, ONCOGENE, V21, P2908, DOI 10.1038/sj.onc.1205388; Daigo Y, 1999, CANCER RES, V59, P4222; DEFILIPPI P, 1994, CELL ADHES COMMUN, V2, P75, DOI 10.3109/15419069409014203; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Ellis LM, 1998, J BIOL CHEM, V273, P1052, DOI 10.1074/jbc.273.2.1052; Fincham VJ, 2000, MOL CELL BIOL, V20, P6518, DOI 10.1128/MCB.20.17.6518-6536.2000; Fleming RYD, 1997, SURGERY, V122, P501, DOI 10.1016/S0039-6060(97)90044-1; FOSS FM, 1989, ONCOGENE RES, V5, P13; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; GARCIA R, 1991, ONCOGENE, V6, P1983; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Grossmann J, 2001, CELL GROWTH DIFFER, V12, P147; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HALL PA, 1994, J CELL SCI, V107, P3569; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; Irby R, 1997, CELL GROWTH DIFFER, V8, P1287; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; JESSUP JM, 1992, CURR PROB CANCER, V16, P265; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Moasser MM, 1999, CANCER RES, V59, P6145; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Paul R, 2001, NAT MED, V7, P222, DOI 10.1038/84675; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Schmidt R, 1998, INT J CANCER, V76, P91, DOI 10.1002/(SICI)1097-0215(19980330)76:1<91::AID-IJC15>3.0.CO;2-J; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; STRATER J, 1995, GUT, V37, P819, DOI 10.1136/gut.37.6.819; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Wang NM, 2000, CANCER LETT, V150, P201, DOI 10.1016/S0304-3835(99)00398-5; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; Weng ZG, 2002, J BIOL CHEM, V277, P18677, DOI 10.1074/jbc.M105331200; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Xing LP, 2001, GENE DEV, V15, P241, DOI 10.1101/gad.840301; Zhong MH, 2002, ONCOGENE, V21, P1071, DOI 10.1038/sj/onc/1205165	58	171	175	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2002	21	51					7797	7807		10.1038/sj.onc.1205989	http://dx.doi.org/10.1038/sj.onc.1205989			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420216				2022-12-17	WOS:000178946000004
J	Turker, MS				Turker, MS			Gene silencing in mammalian cells and the spread of DNA methylation	ONCOGENE			English	Article						DNA methylation; methylation spreading; silencing	DE-NOVO METHYLATION; CPG-ISLAND METHYLATION; DENOVO METHYLATION; APRT GENE; PREIMPLANTATION DEVELOPMENT; DROSOPHILA-MELANOGASTER; CYTOSINE METHYLATION; CARCINOMA-CELLS; HISTONE CODE; IN-VIVO	Aberrant gene silencing in mammalian cells is associated with promoter region methylation, but the sequence of these two events is not clear. This review will consider the possibility that gene silencing is not a single event, but instead a series of events that begins with a dramatic drop in transcription potential and ends with its complete cessation. This transition will be portrayed as a chaotic process that ensues when transcription levels drop and DNA methylation begins spreading haltingly towards the diminished promoter. According to this view, silencing is stabilized when the promoter region is 'captured' by the spread of DNA methylation near or into its transcription factor binding sites.	Oregon Hlth Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Turker, MS (corresponding author), Oregon Hlth Sci Univ, Ctr Res Occupat & Environm Toxicol, L606,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NCI NIH HHS [R01 CA92114] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092114] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahuja N, 2000, HISTOL HISTOPATHOL, V15, P835, DOI 10.14670/HH-15.835; Arnaud P, 2000, MOL CELL BIOL, V20, P3434, DOI 10.1128/MCB.20.10.3434-3441.2000; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; CHANDLER LA, 1987, CELL, V50, P711, DOI 10.1016/0092-8674(87)90329-1; Cherry SR, 2000, MOL CELL BIOL, V20, P7419, DOI 10.1128/MCB.20.20.7419-7426.2000; COOPER GE, 1993, SOMAT CELL MOLEC GEN, V19, P221, DOI 10.1007/BF01233070; Dodge JE, 1998, INT J CANCER, V78, P561, DOI 10.1002/(SICI)1097-0215(19981123)78:5<561::AID-IJC6>3.0.CO;2-R; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; GAUTSCH JW, 1983, NATURE, V301, P32, DOI 10.1038/301032a0; Gerasimova TI, 2001, ANNU REV GENET, V35, P193, DOI 10.1146/annurev.genet.35.102401.090349; Gowher H, 2000, EMBO J, V19, P6918, DOI 10.1093/emboj/19.24.6918; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Hanel ML, 2001, MOL CELL BIOL, V21, P2384, DOI 10.1128/MCB.21.7.2384-2392.2001; Hansen RS, 2000, HUM MOL GENET, V9, P2575, DOI 10.1093/hmg/9.18.2575; HASSE A, 1994, J BIOL CHEM, V269, P1821; Hejnar J, 2001, P NATL ACAD SCI USA, V98, P565, DOI 10.1073/pnas.98.2.565; HOWLETT SK, 1991, DEVELOPMENT, V113, P119; Issa JP, 2000, CURR TOP MICROBIOL, V249, P101; JAHNER D, 1985, NATURE, V315, P594, DOI 10.1038/315594a0; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002; Liang GN, 2000, CANCER RES, V60, P4907; Lorincz MC, 2000, MOL CELL BIOL, V20, P842, DOI 10.1128/MCB.20.3.842-850.2000; Lyko F, 2000, NATURE, V408, P538, DOI 10.1038/35046205; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MAGEWU AN, 1994, MOL CELL BIOL, V14, P4225, DOI 10.1128/MCB.14.6.4225; Melki JR, 2000, BLOOD, V95, P3208; MICHAUD EJ, 1994, GENE DEV, V8, P1463, DOI 10.1101/gad.8.12.1463; Millar DS, 2000, J BIOL CHEM, V275, P24893, DOI 10.1074/jbc.M906538199; MONK M, 1987, DEVELOPMENT, V99, P371; MUMMANENI P, 1993, J BIOL CHEM, V268, P552; MUMMANENI P, 1995, J BIOL CHEM, V270, P788, DOI 10.1074/jbc.270.2.788; Mummaneni P, 1998, NUCLEIC ACIDS RES, V26, P5163, DOI 10.1093/nar/26.22.5163; Nosaka K, 2000, CANCER RES, V60, P1043; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pannell D, 2000, EMBO J, V19, P5884, DOI 10.1093/emboj/19.21.5884; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Rougier N, 1998, GENE DEV, V12, P2108, DOI 10.1101/gad.12.14.2108; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; SILVA AJ, 1988, CELL, V54, P145, DOI 10.1016/0092-8674(88)90546-6; SILVA AJ, 1993, DEV BIOL, V156, P391, DOI 10.1006/dbio.1993.1086; Song SH, 2001, CANCER RES, V61, P4628; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; Turker MS, 1998, SEMIN CANCER BIOL, V8, P407, DOI 10.1006/scbi.1998.0112; Turker MS, 1999, SEMIN CANCER BIOL, V9, P329, DOI 10.1006/scbi.1999.0133; TURKER MS, 1989, J BIOL CHEM, V264, P11632; Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008; Wakimoto BT, 1998, CELL, V93, P321, DOI 10.1016/S0092-8674(00)81159-9; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; Wong DJ, 1999, MOL CELL BIOL, V19, P5642; Yates PA, 1999, J BIOL CHEM, V274, P36357, DOI 10.1074/jbc.274.51.36357; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	66	171	179	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	2002	21	35					5388	5393		10.1038/sj.onc.1205599	http://dx.doi.org/10.1038/sj.onc.1205599			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC	12154401				2022-12-17	WOS:000177197700005
J	Lan, KH; Sheu, ML; Hwang, SJ; Yen, SH; Chen, SY; Wu, JC; Wang, YJ; Kato, N; Omata, M; Chang, FY; Lee, SD				Lan, KH; Sheu, ML; Hwang, SJ; Yen, SH; Chen, SY; Wu, JC; Wang, YJ; Kato, N; Omata, M; Chang, FY; Lee, SD			HCVNS5A interacts with p53 and inhibits p53-mediated apoptosis	ONCOGENE			English	Article						HCVNS5A; p53; apoptosis	HEPATITIS-C VIRUS; NONSTRUCTURAL PROTEIN 5A; HUMAN CELL-LINES; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVATION; X PROTEIN; NUCLEAR-LOCALIZATION; DNA-BINDING; WILD-TYPE; IN-VITRO	Hepatitis C virus (HCV) causes a persistent infection, chronic hepatitis and hepatocellular carcinoma. HCV NS5A, one of non-structural proteins of HCV, was suggested to play a role in oncogenic transformation. Since the tumor suppressor p53 is important for preventing neoplastic transformation, we investigated the functional effects of HCV NS5A on p53. In vitro and in vivo coimmunoprecipitation and confocal microscopy were used to determine the interaction of NS5A and p53. HCV NS5A binds directly to p53 and colocalizes p53 in the perinuclear region. NS5A inhibits transcriptional transactivation by p53 in a dose-dependent manner by use of a reporter assay. Down regulation of endogenous p21/waf1 expression, which is activated by p53 in Hep3B cells, by NS5A was demonstrated by using FLAG- and FLAG-NS5A Hep3B stable cell lines. The effect of NS5A on p53-mediated apoptosis was determined by flow cytometry in both NS5A permanently and transiently transfected Hep3B cells with exogenous p53. The p53-induced apoptosis was abrogated by NS5A and the inhibition effect correlates well with the binding ability of NS5A to p53. In addition, HCV NS5A protein interacts with and colocalizes hTAF(II)32, a component of TFIID and an essential coactivator of p53, in vivo. These results suggest that HCV NS5A interacts with and partially sequestrates p53 and hTAF(II)32 in the cytoplasm and suppresses p53-mediated transcriptional transactivation and apoptosis during HCV infection, which may contribute to the hepatocarcinogenesis of HCV infection.	Taipei Vet Gen Hosp, Dept Med, Div Gastroenterol, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Med, Taipei 11217, Taiwan; Taipei Vet Gen Hosp, Dept Family Med, Taipei 11217, Taiwan; Natl Yang Ming Univ, Sch Med, Taipei 11217, Taiwan; Taipei Vet Gen Hosp, Ctr Canc, Taipei 11217, Taiwan; Natl Yang Ming Univ, Sch Med, Taipei 11217, Taiwan; Taipei Vet Gen Hosp, Dept & Inst Pharmacol, Taipei 11217, Taiwan; Taipei Vet Gen Hosp, Inst Biochem, Taipei 11217, Taiwan; Univ Tokyo, Dept Gastroenterol, Fac Med, Bunkyo Ku, Tokyo 1138655, Japan	Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; Taipei Veterans General Hospital; University of Tokyo	Lee, SD (corresponding author), Taipei Vet Gen Hosp, Dept Med, Div Gastroenterol, 201 Shih Pai Rd,Sec 2, Taipei 112, Taiwan.	sdlee@vghtpe.gov.tw	Sheu, Meei-Ling/AAT-3401-2020	Sheu, Meei-Ling/0000-0002-0431-1282				Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Chung KM, 1997, MOL CELLS, V7, P661; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Fukuma T, 1998, HEPATOLOGY, V28, P1147, DOI 10.1002/hep.510280433; Gale M, 1999, J VIROL, V73, P6506, DOI 10.1128/JVI.73.8.6506-6516.1999; Ghosh AK, 1999, J GEN VIROL, V80, P1179, DOI 10.1099/0022-1317-80-5-1179; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; HOUGHTON M, 1996, FIELDS VIROLOGY, P1035; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Ide Y, 1996, GENE, V182, P203, DOI 10.1016/S0378-1119(96)00555-0; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KANEKO T, 1994, BIOCHEM BIOPH RES CO, V205, P320, DOI 10.1006/bbrc.1994.2667; Kato N, 1997, J VIROL, V71, P8856, DOI 10.1128/JVI.71.11.8856-8859.1997; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lu W, 1999, VIROLOGY, V264, P134, DOI 10.1006/viro.1999.9979; Majumder M, 2001, J VIROL, V75, P1401, DOI 10.1128/JVI.75.3.1401-1407.2001; Moradpour D, 1998, HEPATOLOGY, V28, P192, DOI 10.1002/hep.510280125; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Muralidhar S, 1996, J VIROL, V70, P8691, DOI 10.1128/JVI.70.12.8691-8700.1996; Neil JC, 1997, TRENDS MICROBIOL, V5, P115, DOI 10.1016/S0966-842X(96)10083-4; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ohashi M, 1999, GUT, V44, P366, DOI 10.1136/gut.44.3.366; Otsuka M, 2000, J BIOL CHEM, V275, P34122, DOI 10.1074/jbc.M000578200; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Polyak SJ, 1999, HEPATOLOGY, V29, P1262, DOI 10.1002/hep.510290438; Prost S, 1998, J BIOL CHEM, V273, P33327, DOI 10.1074/jbc.273.50.33327; Ray RB, 1997, J BIOL CHEM, V272, P10983; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Satoh S, 2000, VIROLOGY, V270, P476, DOI 10.1006/viro.2000.0287; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SHAULSKY G, 1991, ONCOGENE, V6, P2055; Sheppard HM, 1999, MOL CELL BIOL, V19, P2746; SHIEH YSC, 1993, INT J CANCER, V54, P558; SHIRATORI Y, 1995, HEPATOLOGY, V22, P1027, DOI 10.1002/hep.1840220403; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Takada S, 1997, ONCOGENE, V15, P1895, DOI 10.1038/sj.onc.1201369; Tanimoto A, 1997, BIOCHEM BIOPH RES CO, V236, P360, DOI 10.1006/bbrc.1997.6967; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Uchida T, 1996, INT J CANCER, V67, P892; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	66	171	181	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2002	21	31					4801	4811		10.1038/sj.onc.1205589	http://dx.doi.org/10.1038/sj.onc.1205589			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101418				2022-12-17	WOS:000176716300009
J	Crnogorac-Jurcevic, T; Efthimiou, E; Nielsen, T; Loader, J; Terris, B; Stamp, G; Baron, A; Scarpa, A; Lemoine, NR				Crnogorac-Jurcevic, T; Efthimiou, E; Nielsen, T; Loader, J; Terris, B; Stamp, G; Baron, A; Scarpa, A; Lemoine, NR			Expression profiling of microdissected pancreatic adenocarcinomas	ONCOGENE			English	Article						pancreatic adenocareinoma; laser capture microdissection; cDNA arrays; tissue arrays	SUPEROXIDE-DISMUTASE; CANCER; GENE; AMPULLARY; DUCTS; CD59; ARG	Pancreatic ductal adenocarcinoma is characterized by a paucity of neoplastic cells embedded in a densely desmoplastic stroma. Therefore, laser capture microdissection was performed to obtain homogeneous populations of normal and neoplastic ductal cells. These were subjected to a comparative study of gene expression utilizing human cDNA arrays. A variety of dysregulated genes were identified, comprising cell cycle and growth regulators, invasion regulators, signalling and developmental molecules. In addition to genes already found to be overexpressed in pancreatic cancer, such as TIMP1, MMP7, CD59, rhoC and NDKA, we present evidence to implicate genes which have not previously been reported in this tumour type. These include the overexpressed genes ABL2, Notch4 and SOD1, as well as XRCC1, a DNA repair gene whose transcript was found downregulated. Quantitative real-time RT-PCR (QRT-PCR) was employed to confirm differential expression of ABL2, Notch4 and SOD1 and immunohistochemical analysis was used to verify decreased protein expression of XRCC1 using a custom-built pancreatic tissue array. Combining microarray-derived gene expression profiles of pure pancreatic cell populations, QRT-PCR and pancreas-specific tissue arrays therefore proved to be highly informative in elucidating the molecular pathology of this highly malignant tumour type.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Mol Oncol Unit, Canc Res UK,Dept Canc Med, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Histopathol, London W12 0NN, England; Oxford Glycosci Proteome Discovery, Abingdon, Oxon, England; Univ Verona, Dept Pathol, I-37100 Verona, Italy	Cancer Research UK; Imperial College London; Imperial College London; University of Verona	Lemoine, NR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Mol Oncol Unit, Canc Res UK,Dept Canc Med, Hammersmith Campus, London W12 0NN, England.	nick.lemoine@cancer.org.uk	Terris, Benoit/P-1497-2017; scarpa, aldo/K-6832-2016	scarpa, aldo/0000-0003-1678-739X				Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Audic S, 1997, GENOME RES, V7, P986, DOI 10.1101/gr.7.10.986; BANKSON DD, 1993, CLIN LAB MED, V13, P463, DOI 10.1016/S0272-2712(18)30449-9; Baskaran R, 1997, J BIOL CHEM, V272, P18905, DOI 10.1074/jbc.272.30.18905; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; Bramhall SR, 1997, J PATHOL, V182, P347, DOI 10.1002/(SICI)1096-9896(199707)182:3<347::AID-PATH848>3.0.CO;2-J; Bramhall SR, 1996, BRIT J CANCER, V73, P972, DOI 10.1038/bjc.1996.190; Cazzaniga G, 1999, BLOOD, V94, P4370, DOI 10.1182/blood.V94.12.4370.424k34_4370_4373; Crnogorac-Jurcevic T, 2001, ONCOGENE, V20, P7437, DOI 10.1038/sj.onc.1204935; CRNOGORACJURCEV.T, 2002, METHODS MOL BIOL RT; Fitzgerald K, 2000, ONCOGENE, V19, P4191, DOI 10.1038/sj.onc.1203766; Furukawa T, 1996, AM J PATHOL, V148, P1763; GOLD EB, 1995, SURG CLIN N AM, V75, P819, DOI 10.1016/S0039-6109(16)46730-7; GRESS TM, 1995, INT J CANCER, V62, P407, DOI 10.1002/ijc.2910620409; Hruban RH, 2000, AM J PATHOL, V156, P1821, DOI 10.1016/S0002-9440(10)65054-7; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Kallioniemi OP, 2001, HUM MOL GENET, V10, P657, DOI 10.1093/hmg/10.7.657; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Maio M, 1998, INT J ONCOL, V13, P305; Moore PS, 2001, BRIT J CANCER, V84, P253, DOI 10.1054/bjoc.2000.1567; OBERLEY LW, 1979, CANCER RES, V39, P1141; Rice PA, 1999, NAT STRUCT BIOL, V6, P805, DOI 10.1038/12257; Schmitt CA, 1999, EUR J CANCER, V35, P117, DOI 10.1016/S0959-8049(98)00290-1; Sirivatanauksorn V, 2001, INT J CANCER, V91, P350, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.3.CO;2-3; Sirivatanauksorn Y, 1999, J PATHOL, V189, P150, DOI 10.1002/(SICI)1096-9896(199910)189:2<150::AID-PATH451>3.0.CO;2-G; WESTMAN NG, 1981, CANCER RES, V41, P2962; Whitehouse CJ, 2001, CELL, V104, P107, DOI 10.1016/S0092-8674(01)00195-7; Zhou W, 1998, CANCER EPIDEM BIOMAR, V7, P109	31	171	184	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2002	21	29					4587	4594		10.1038/sj.onc.1205570	http://dx.doi.org/10.1038/sj.onc.1205570			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085237				2022-12-17	WOS:000176476700013
J	Yao, J; Xiong, SB; Klos, K; Nguyen, N; Grijalva, R; Li, P; Yu, D				Yao, J; Xiong, SB; Klos, K; Nguyen, N; Grijalva, R; Li, P; Yu, D			Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta 1 in human breast cancer cells	ONCOGENE			English	Article						MMP-9; heregulin-beta 1; signaling; breast cancer; invasion	EPIDERMAL GROWTH-FACTOR; GA-BINDING-PROTEIN; IV COLLAGENASE; GENE-EXPRESSION; MAMMARY ADENOCARCINOMA; DIFFERENTIATION FACTOR; REGULATED KINASE; TUMOR-CELLS; IN-VITRO; GELATINASE	Matrix metalloproteinase-9 (MMP-9) plays important roles in tumor,invasion and angiogenesis. Secretion of MMP-9 has been reported in various cancer types including lung cancer, colon cancer, and breast cancer. In our investigation of MMP-9 regulation by growth factors, MMP-9 was activated by heregulin-beta1 as shown by zymography in both SKBr3 and MCF-7 breast cancer cell lines. Increase in MMP-9 activity was due to increased MMP-9 protein and mRNA levels, which mainly results from transcriptional upregulation of MMP-9 by heregulin-beta1. Heregulin-beta1. activates multiple signaling pathways in breast cancer cells, including Erk, p38 kinase, PKC, and PI3-K pathways. We examined the pathways involved in heregulin-beta1-mediated MMP-9 activation using chemical inhibitors that specifically inhibit each of these heregulin-beta1-activated pathways. The PKC inhibitor RO318220 and p38 kinase inhibitor SB203580 completely blocked heregulin-beta1-mediated activation of MMP-9. MEK-1 inhibitor PD098059 partially blocked MMP-9 activation, whereas PI3-K inhibitor wortmannin had no effect on heregulin-beta1-mediated MMP-9 activation. Therefore, at least three signaling pathways are involved in the activation of MMP-9 by heregulin-beta1. Since MMP-9 is tightly associated with invasion/metastasis and angiogenesis, our studies suggest that blocking heregulin-beta1-mediated activation of MMP-9 by inhibiting the related signaling pathways may provide new strategies for inhibition of cancer metastasis and angiogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Yu, D (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd,Box 107, Houston, TX 77030 USA.		Xiong, Shunbin/AAR-5823-2021	Yu, Dihua/0000-0001-6231-9381	NCI NIH HHS [2R01-CA60448, P30-CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; DAVIES B, 1993, CANCER RES, V53, P5365; DAVIES B, 1993, CANCER RES, V53, P2087; GARBISA S, 1987, CANCER RES, V47, P1523; Gramolini AO, 1999, P NATL ACAD SCI USA, V96, P3223, DOI 10.1073/pnas.96.6.3223; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; HUJANEN ES, 1994, INT J CANCER, V58, P582, DOI 10.1002/ijc.2910580422; Jones JL, 1999, J PATHOL, V189, P161, DOI 10.1002/(SICI)1096-9896(199910)189:2<161::AID-PATH406>3.0.CO;2-2; Khurana TS, 1999, MOL BIOL CELL, V10, P2075, DOI 10.1091/mbc.10.6.2075; Kondapaka SB, 1997, INT J CANCER, V70, P722, DOI 10.1002/(SICI)1097-0215(19970317)70:6<722::AID-IJC15>3.3.CO;2-5; Kozawa O, 2000, CELL SIGNAL, V12, P375, DOI 10.1016/S0898-6568(00)00061-9; Lozonschi L, 1999, CANCER RES, V59, P1252; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MOLL UM, 1990, CANCER RES, V50, P6162; NAKAJIMA M, 1993, CANCER RES, V53, P5802; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; PARKS WC, MATRIX METALLOPROTEI; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; RAO JS, 1993, CANCER RES, V53, P2208; SAMUEL SK, 1992, EMBO J, V11, P1599, DOI 10.1002/j.1460-2075.1992.tb05205.x; SATO H, 1993, J BIOL CHEM, V268, P23460; Segain JP, 1996, CANCER RES, V56, P5506; Sehgal I, 1996, CANCER RES, V56, P3359; SHIMA I, 1993, BRIT J CANCER, V67, P721, DOI 10.1038/bjc.1993.132; Simon C, 1998, CANCER RES, V58, P1135; Simon C, 1999, BRIT J CANCER, V80, P1412, DOI 10.1038/sj.bjc.6690537; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Tan M, 1999, CANCER RES, V59, P1620; Tan M, 1997, CANCER RES, V57, P1199; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Williger BT, 1999, J BIOL CHEM, V274, P735, DOI 10.1074/jbc.274.2.735; Xiong SB, 2001, CANCER RES, V61, P1727; Yu Q, 2000, GENE DEV, V14, P163	42	171	188	0	12	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2001	20	56					8066	8074		10.1038/sj.onc.1204944	http://dx.doi.org/10.1038/sj.onc.1204944			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781819				2022-12-17	WOS:000172396800003
J	Kamei, T; Matozaki, T; Sakisaka, T; Kodama, A; Yokoyama, S; Peng, YF; Nakano, K; Takaishi, K; Takai, Y				Kamei, T; Matozaki, T; Sakisaka, T; Kodama, A; Yokoyama, S; Peng, YF; Nakano, K; Takaishi, K; Takai, Y			Coendocytosis of cadherin and c-Met coupled to disruption of cell-cell adhesion in MDCK cells - regulation by Rho, Rac and Rab small G proteins	ONCOGENE			English	Article						c-Met; E-cadherin; endocytosis; small G proteins	EPIDERMAL GROWTH-FACTOR; CANINE KIDNEY-CELLS; FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; ENDOCYTIC PATHWAY; KINASE; ACTIVATION; TRANSPORT; SITES; MORPHOGENESIS	Both E-cadherin, a cell-cell adhesion molecule, and c-Met, the hepatocyte growth factor (HGF)/scatter factor (SF) receptor, were colocalized at cell-cell adhesion sites of MDCK cells. HGF/SF or a phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA), induced disruption of cell-cell adhesion, which was accompanied by endocytosis of both E-cadherin and c-Met. Reduction of medium Ca2+ to a micromolar range showed the same effects. Re-increase in medium Ca2+ to a millimolar range formed cell-cell adhesion, which was accompanied by exocytosis of E-cadherin and c-Met, followed by their re-colocalization at the cell-cell adhesion sites. These results suggest that E-cadherin and c-Met are colocalized at cell-cell adhesion sites and undergo co-endo-exocytosis. We have previously shown that TPA does not induce disruption of cell-cell adhesion and subsequent scattering of MDCK cells stably expressing a dominant active mutant of RhoA or Rac1 small G protein or a dominant negative mutant of Rab5 small G protein. In these cell lines, the HGF- or TPA-induced coendocytosis of E-cadherin and c-Met was inhibited, but the coendocytosis of E-cadherin and c-Met in response to reduction of medium Ca2+ was not affected. Wortmannin, an inhibitor of phosphoinositide (PI) 3-kinase, inhibited the HGF-induced disruption of cell-cell junction and endocytosis of E-cadherin and c-Met, but not the TPA-induced ones. These results suggest that disruption of cell-cell adhesion is involved in the HGF- or TPA-induced coendocytosis of E-cadherin and c-Met in MDCK cells, and that the Rho and Rab family members indirectly regulate this coendocytosis. In addition, coendocytosis of E-cadherin and c-Met in response to HGF is partly mediated by PI 3-kinase. The cross-talk between cell-cell and cell-matrix adherens junctions is discussed.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Imamura H, 1998, MOL BIOL CELL, V9, P2561, DOI 10.1091/mbc.9.9.2561; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; MARATOSFLIER E, 1987, J CELL BIOL, V105, P1595, DOI 10.1083/jcb.105.4.1595; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Seaman MNJ, 1996, CURR OPIN CELL BIOL, V8, P549, DOI 10.1016/S0955-0674(96)80034-2; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O	37	171	178	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6776	6784		10.1038/sj.onc.1203114	http://dx.doi.org/10.1038/sj.onc.1203114			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597286				2022-12-17	WOS:000083792000020
J	Cuddihy, AR; Wong, AHT; Tam, NWN; Li, SY; Koromilas, AE				Cuddihy, AR; Wong, AHT; Tam, NWN; Li, SY; Koromilas, AE			The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro	ONCOGENE			English	Article						tumor suppressor; protein kinase; protein-protein interactions; phosphorylation	C-TERMINAL DOMAIN; NF-KAPPA-B; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; MALIGNANT TRANSFORMATION; INDUCED APOPTOSIS; NUCLEIC-ACIDS; IN-VITRO; INTERFERON; REPRESSION	The tumor suppressor p53 is a multifunctional protein that plays a critical role in modulating cellular responses upon DNA damage or other stresses, These functions of p53 are regulated both by protein-protein interactions and phosphorylation, The double-stranded RNA activated protein kinase PKR is a serine/threonine kinase that modulates protein synthesis through the phosphorylation of translation initiation factor eIF-2 alpha. PKR is an interferon (IFN)-inducible protein that is thought to mediate the anti-viral and anti-proliferative effects of IFN via its capacity to inhibit protein synthesis, Here we report that PKR physically associates with p53. The interaction of PKR with p53 is enhanced by IFNs and upon conditions that p53 acquires a wild type conformation. PKR/p53 complex formation in vitro requires the N-terminal regulatory domain of PKR and the last 30 amino acids of the C-terminus of human p53. In addition, p53 may function as a substrate of PKR since phosphorylation of human p53 on serine(392) is induced by activated PKR in vitro. These novel findings raise the possibility of a functional interaction between PKR and p53 in vivo, which may account, at least in part, for the ability of each protein to regulate gene expression at both the transcriptional and the translational levels.	McGill Univ, Dept Oncol, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ, Canada	McGill University; McGill University; McGill University; McGill University	Koromilas, AE (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, 3755 Cote St Catharine Rd,Room 528-1, Montreal, PQ H3T 1E2, Canada.			Cuddihy, Andrew/0000-0002-9898-0443				Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BALKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413; BALKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362; BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAIN R, 1994, ONCOGENE, V9, P1775; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ewen ME, 1996, BBA-REV CANCER, V1242, P181, DOI 10.1016/0304-419X(95)00010-D; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; Fontoura BMA, 1997, MOL CELL BIOL, V17, P3146, DOI 10.1128/MCB.17.6.3146; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARPER JW, 1993, CELL, V75, P805; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HOWE JG, 1984, CELL, V37, P85; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1995, ONCOGENE, V10, P1485; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LEE C, 1994, J OBJECT-ORIENT PROG, V7, P49; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SB, 1997, VIROLOGY, V231, P81, DOI 10.1006/viro.1997.8494; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Milne DM, 1996, ONCOGENE, V13, P205; Min W, 1996, MOL CELL BIOL, V16, P359; MIYASHITA T, 1995, CELL, V80, P293; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; Pfeifer GP, 1997, BBA-REV CANCER, V1333, pM1, DOI 10.1016/S0304-419X(97)00004-8; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; RendeFournier R, 1997, VIROLOGY, V238, P410, DOI 10.1006/viro.1997.8824; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Takizawa T, 1996, J VIROL, V70, P8128, DOI 10.1128/JVI.70.11.8128-8132.1996; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; Zhu SH, 1996, J BIOL CHEM, V271, P24989, DOI 10.1074/jbc.271.40.24989	68	171	176	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	1999	18	17					2690	2702		10.1038/sj.onc.1202620	http://dx.doi.org/10.1038/sj.onc.1202620			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348343				2022-12-17	WOS:000080124900004
J	Rao, S; Lowe, M; Herliczek, TW; Keyomarsi, K				Rao, S; Lowe, M; Herliczek, TW; Keyomarsi, K			Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53	ONCOGENE			English	Article						lovastatin; cell cycle; cyclins; CKIs; CDKs; adaptor molecule	DEPENDENT KINASE INHIBITOR; MAMMARY EPITHELIAL-CELLS; GROWTH-FACTOR-BETA; CYCLE ARREST; RETINOBLASTOMA PROTEIN; CANCER CELLS; POTENTIAL MEDIATOR; MEVALONATE PATHWAY; RESTRICTION POINT; ACTIVATING KINASE	Previously, we reported that lovastatin, a potent inhibitor of the enzyme HMG CoA reductase also acts as an antimitogenic agent by arresting cells in the G1 phase of the cell cycle resulting in cell cycle-independent alteration of cyclin dependent kinase inhibitors (CKIs), In the present study we have investigated the nature of the CKIs (p21 and p27) alterations resulting in G1 arrest in both normal and tumor breast cell lines by lovastatin, We show that even though lovastatin treatment causes G1 arrest in a wide variety of normal and tumor breast cells irrespective of their p53 or pRb status, the p21 and p27 protein levels are not increased in all cell lines treated suggesting that the increase in p21 and p27 protein expression per se is not necessary for lovastatin mediated G1 arrest. However, the binding of p21 and p27 to CDK2 increases significantly following treatment of cells with lovastatin leading to inhibition of CDK2 activity and a subsequent arrest of cells in G1, The increased CKI binding to CDK2 is achieved by the redistribution of both p21 and p27 from CDK4 to CDK2 complexes subsequent to decreases in CDK4 and cyclin D3 expression following lovastatin treatment, Lastly, we show that lovastatin treatment of 76N-E6 breast cell line with an altered p53 pathway also results in G1 arrest and similar redistribution of CKIs from CDK4 to CDK2 as observed in other breast cell lines examined, These observations suggest that lovastatin induced G1 arrest of breast cell lines is through a p53 independent pathway and is mediated by decreased CDK2 activity through redistribution of CKIs from CDK4 to CDK2.	Wadsworth Ctr, Div Mol Med, Lab Diagnost Oncol, Albany, NY 12201 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12222 USA	Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Keyomarsi, K (corresponding author), Wadsworth Ctr, Div Mol Med, Lab Diagnost Oncol, Albany, NY 12201 USA.		Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849	NCI NIH HHS [R29-CA666062] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; BERNSTEIN L, 1993, EPIDEMIOL REV, V15, P48, DOI 10.1093/oxfordjournals.epirev.a036116; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DAVIGNON J, 1993, ARCH INTERN MED, V153, P1079; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fang XJ, 1998, ONCOGENE, V16, P1, DOI 10.1038/sj.onc.1201525; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GrayBablin J, 1997, CANCER RES, V57, P604; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Harper JW, 1998, GENE DEV, V12, P285, DOI 10.1101/gad.12.3.285; Harper JW, 1997, CANCER SURV, V29, P91; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HESSLING JJ, 1980, J IMMUNOL METHODS, V38, P315, DOI 10.1016/0022-1759(80)90280-X; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Jakus J, 1996, ONCOGENE, V12, P2369; JANI JP, 1993, INVAS METAST, V13, P314; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KEYOMARSI K, 1995, ONCOGENE, V11, P941; Keyomarsi Khandan, 1996, Methods in Cell Science, V18, P109, DOI 10.1007/BF00122161; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MICHIELI P, 1994, CANCER RES, V54, P3391; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Retterstol K, 1996, AM J CARDIOL, V78, P1369, DOI 10.1016/S0002-9149(96)00649-2; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOULE HD, 1990, CANCER RES, V50, P6075; TAM SW, 1994, ONCOGENE, V9, P2663; Thibault A, 1996, CLIN CANCER RES, V2, P483; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, NATURE, V366, P710; Zhu WY, 1997, EXP CELL RES, V234, P293, DOI 10.1006/excr.1997.3589	69	171	176	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2393	2402		10.1038/sj.onc.1202322	http://dx.doi.org/10.1038/sj.onc.1202322			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811471				2022-12-17	WOS:000076723300014
J	Kato, M; Takahashi, M; Akhand, AA; Liu, W; Dai, Y; Shimizu, S; Iwamoto, T; Suzuki, H; Nakashima, I				Kato, M; Takahashi, M; Akhand, AA; Liu, W; Dai, Y; Shimizu, S; Iwamoto, T; Suzuki, H; Nakashima, I			Transgenic mouse model for skin malignant melanoma	ONCOGENE			English	Article						malignant melanoma; Ret; transgenic mouse	METASTATIC CELL-LINES; MATRIX METALLOPROTEINASES; TUMOR PROGRESSION; RET; EXPRESSION; MICE; GENE; ESTABLISHMENT; ACTIVATION; MECHANISM	We report here on a novel metallothionein-I (MT)/ret transgenic mouse line in which skin melanosis, benign melanocytic tumor and malignant melanoma metastasizing to distant organs develop stepwise. The process of tumor development and its malignant transformation in this line may resemble that of the human giant congenital melanocytic nevus that is present at birth and that frequently gives rise to malignant melanoma during aging. We observed an increase in the expression level and activity of the ret transgene during the disease progression. That increase in transgene expression accompanied an activation of mitogen-activated protein kinases (MAPKs) and c-Jun as well as matrix metalloproteinases. These results suggest that progressive dysregulation of the expression level of the ret transgene might play a crucial role in the malignant transformation of melanocytic tumors developed in the MT/ret transgenic mouse line.	Nagoya Univ, Sch Med, Dept Immunol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Aichi Canc Ctr, Res Inst, Pathophysiol Unit, Chikusa Ku, Nagoya, Aichi 4640021, Japan	Nagoya University; Nagoya University; Aichi Cancer Center	Nakashima, I (corresponding author), Nagoya Univ, Sch Med, Dept Immunol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		TAKAHASHI, Masahide/I-7244-2014; Takahashi, Masahide/AAN-4770-2020; KATO, Masashi/I-7250-2014	Takahashi, Masahide/0000-0002-2803-2683; 				BALCH CM, 1989, PRINCIPLES PRACTICE, P1519; BRADL M, 1991, P NATL ACAD SCI USA, V88, P164, DOI 10.1073/pnas.88.1.164; Chen S, 1996, J INVEST DERMATOL, V106, P1145, DOI 10.1111/1523-1747.ep12340194; CRAWFORD HC, 1994, INVAS METAST, V14, P234; DAVIES B, 1993, CANCER RES, V53, P5365; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; Iwata H, 1996, JPN J CANCER RES, V87, P602, DOI 10.1111/j.1349-7006.1996.tb00266.x; KATO M, 1994, CELL IMMUNOL, V159, P15, DOI 10.1006/cimm.1994.1291; KOH HK, 1992, TUMORS SKIN DERMATOL, P1753; MONTGOMERY AMP, 1994, CANCER RES, V54, P5467; OHMIYA N, 1995, CLIN EXP IMMUNOL, V100, P151; Pu MY, 1996, ONCOGENE, V13, P2615; Sakata K, 1996, JPN J CANCER RES, V87, P78, DOI 10.1111/j.1349-7006.1996.tb00203.x; SATO H, 1993, J BIOL CHEM, V268, P23460; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TANIGUCHI M, 1992, ONCOGENE, V7, P1491; YAMAGATA S, 1988, BIOCHEM BIOPH RES CO, V151, P158, DOI 10.1016/0006-291X(88)90573-6; YAMAMOTO K, 1989, CHEM RES TOXICOL, V2, P234, DOI 10.1021/tx00010a004	20	171	172	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1885	1888		10.1038/sj.onc.1202077	http://dx.doi.org/10.1038/sj.onc.1202077			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778055				2022-12-17	WOS:000076303300015
J	Bartkova, J; Lukas, J; Strauss, M; Bartek, J				Bartkova, J; Lukas, J; Strauss, M; Bartek, J			Cyclin D3: requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation	ONCOGENE			English	Article						cell cycle; cyclin D3; cell and tissue differentiation; G1/S transition	CELL-CYCLE; RETINOBLASTOMA-PROTEIN; DEPENDENT KINASES; D1 PROTEIN; PHASE PROGRESSION; EXPRESSION; G(1); GENE; FIBROBLASTS; LINES	The mammalian D-type cyclins DI, D2, and D3 activate the cyclin-dependent kinases CDK4 and CDK6 in G1 and thereby promote the cell's commitment to enter S phase. To elucidate the extent of functional overlap among the D-type cyclins, we have examined several aspects of the least characterized member of this subfamily of G1 cyclin proteins, cyclin D3. Microinjection of cyclin D3-neutralizing antibody inhibited G1/S transition in human (IMR-90) and rat (R12) diploid fibroblasts, indicating that analogous to cyclins D1 and D2, cyclin D3 is essential for timely progression through Gf. In contrast to cyclins D1 and D2, cyclin D3 was (i) ubiquitously expressed among a panel of 70 human cultured cell types; (ii) strongly upregulated upon induction of HL-60 leukaemia cells to differentiate; and (iii) accumulated to high levels in a wide range of quiescent cell types in mouse and human differentiated tissues. Complementary analyses of human biopsies and mouse tissues at different stages of foetal and postnatal development revealed lineage-dependent transient or long-term accumulation of the cyclin D3 protein, correlating with initiation/establishment or maintenance of the mature phenotypes, respectively. Our data support the notion that the biological roles of the individual D-type cyclins are not fully redundant, and suggest a possible dual role for cyclin D3 in cell proliferation and induction and/or maintenance of terminal differentiation.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen O, Denmark; Humboldt Univ, Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Danish Cancer Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen O, Denmark.		Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X				ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; COLLINS SJ, 1987, BLOOD, V70, P1233; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HERBER B, 1994, ONCOGENE, V9, P1295; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JAHN L, 1994, EXP CELL RES, V212, P297, DOI 10.1006/excr.1994.1147; KERKHOFF E, 1995, EMBO J, V14, P1892, DOI 10.1002/j.1460-2075.1995.tb07181.x; KIESS M, 1995, ONCOGENE, V10, P159; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LOVEC H, 1994, ONCOGENE, V9, P322; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1995, ONCOGENE, V10, P2125; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MURAO S, 1994, CELL BIOL LAB HDB, P207; PALMERO I, 1993, ONCOGENE, V8, P1049; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; Pokrovskaja K, 1996, CELL GROWTH DIFFER, V7, P1723; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Savatier P, 1996, ONCOGENE, V12, P309; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Sun W, 1996, MOL REPROD DEV, V43, P414, DOI 10.1002/(SICI)1098-2795(199604)43:4<414::AID-MRD2>3.0.CO;2-S; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; TAM SW, 1994, ONCOGENE, V9, P2663; Wang ZY, 1996, GENOMICS, V35, P156, DOI 10.1006/geno.1996.0334; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; Zimmet JM, 1997, MOL CELL BIOL, V17, P7248, DOI 10.1128/MCB.17.12.7248	50	171	174	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					1027	1037		10.1038/sj.onc.1202016	http://dx.doi.org/10.1038/sj.onc.1202016			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747882				2022-12-17	WOS:000075560900011
J	Mao, WG; Irby, R; Coppola, D; Fu, L; Wloch, M; Turner, J; Yu, H; Garcia, R; Jove, R; Yeatman, TJ				Mao, WG; Irby, R; Coppola, D; Fu, L; Wloch, M; Turner, J; Yu, H; Garcia, R; Jove, R; Yeatman, TJ			Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential	ONCOGENE			English	Article						EGFR; Src; colon cancer	EPIDERMAL-GROWTH-FACTOR; HUMAN COLORECTAL CARCINOMAS; HUMAN BREAST-CANCER; NUDE-MICE; PP60C-SRC ACTIVITY; IN-VIVO; FAMILY KINASES; TRANSFORMATION; LINES; EXPRESSION	Recent data suggest that signal transduction may have a critical role in the development and regulation of the metastatic phenotype. Here, we investigated the role of c-Src activation in the process of human colon cancer metastasis to the Liver, Our data, derived from two different sets of human colon cancer cell line metastatic variants, suggest that not only do highly-metastatic cells display constitutively elevated c-Src protein kinase activity when compared to poorly metastatic cells, but also that receptor tyrosine kinases participate in the ligand-activation of c-Src above basal levels. Specifically, the epidermal growth factor receptor (EGFR), p185HER2/Neu and the hepatocyte growth factor receptor (c-Met) appear to be Linked to the process because they preferentially activate c-Src in highly-metastatic cells, EGFR was found to associate with c-Src in colon cancer cells and specific inhibitors of the EGFR resulted in a reduction of c-Src activity to basal levels. In addition, c-Src transfectants displayed partially-activated EGFRs, suggesting a feedback role for c-Src in the regulation of the EGFR. p185HER2/Neu was also identified in immunocomplexes of c-Src following Ligand activation of the EGFR, but only in highly-metastatic cells, Collectively, these observations suggest a paradigm whereby c-Src interacts with multiple cell-surface growth factors in a catalytic fashion for the development of tumor cells with metastatic potential.	Univ S Florida, H Lee Moffitt Canc Ctr, Dept Surg, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Dept Med Microbiol & Immunol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Yeatman, TJ (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr, Dept Surg, Tampa, FL 33612 USA.			YU, Hua/0000-0003-0931-1000				ANTCZAK M, 1990, J VIROL, V64, P1451, DOI 10.1128/JVI.64.4.1451-1458.1990; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Brunton VG, 1997, ONCOGENE, V14, P283, DOI 10.1038/sj.onc.1200827; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHAKRABARTY S, 1995, CLIN EXP METASTAS, V13, P191, DOI 10.1007/BF00132207; COFFEY RJ, 1987, CANCER RES, V47, P4590; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; GARCIA R, 1991, ONCOGENE, V6, P1983; GREENBERG AH, 1989, INVAS METAST, V9, P360; HAMAGUCHI M, 1995, ONCOGENE, V10, P1037; JESSUP JM, 1989, CANCER RES, V49, P6906; JESSUP JM, 1988, CANCER RES, V48, P1689; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Mahvi DM, 1996, HUM GENE THER, V7, P1535, DOI 10.1089/hum.1996.7.13-1535; Mayer K, 1996, ANTICANCER RES, V16, P1733; MORIKAWA K, 1988, CANCER RES, V48, P1943; MORIKAWA K, 1988, CANCER RES, V48, P6863; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; MUTHUSWAMY SK, 1994, ADV CANCER RES, V64, P111, DOI 10.1016/S0065-230X(08)60836-2; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PENA SV, 1995, GASTROENTEROLOGY, V108, P117, DOI 10.1016/0016-5085(95)90015-2; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; RADINSKY R, 1993, CANCER METAST REV, V12, P345, DOI 10.1007/BF00665962; Rewcastle GW, 1996, J MED CHEM, V39, P1823, DOI 10.1021/jm9508651; Shah V, 1994, In Vivo, V8, P321; TALAMONTI MA, 1991, J CLIN INVEST, V91, P53; TATSUKA PM, 1996, MOL CARCINOG, V15, P300; TERMUHLEN PM, 1993, J SURG RES, V54, P54; WANG P, 1991, BRIT J CANCER, V64, P531, DOI 10.1038/bjc.1991.344; WEBER TK, 1992, J CLIN INVEST, V90, P815, DOI 10.1172/JCI115956; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; WEERNINK PAO, 1994, FEBS LETT, V352, P296, DOI 10.1016/0014-5793(94)00977-5; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; WITTY JP, 1994, CANCER RES, V54, P4805; YEATMAN TJ, 1993, SEMIN SURG ONCOL, V9, P256; Yeatman TJ, 1996, CLIN EXP METASTAS, V14, P246; ZIRVI KA, 1993, CANCER LETT, V72, P39, DOI 10.1016/0304-3835(93)90008-W	53	171	184	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3083	3090		10.1038/sj.onc.1201496	http://dx.doi.org/10.1038/sj.onc.1201496			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444956				2022-12-17	WOS:000070968000008
J	Carbone, M; Rizzo, P; Pass, HI				Carbone, M; Rizzo, P; Pass, HI			Simian virus 40, poliovaccines and human tumors: a review of recent developments	ONCOGENE			English	Review						SV40; poliovaccines; human tumors	LARGE-T-ANTIGEN; HUMAN-BRAIN-TUMORS; HUMAN PLEURAL MESOTHELIOMA; SIMIAN-VIRUS-40 LARGE-T; DELETION MUTANTS; HUMAN FIBROBLASTS; MONKEY CELLS; SV40; DNA; TRANSFORMATION	Recently, wild-type SV40 and/or DNA sequences indistinguishable from SV40 have been detected in specific types of human tumors: ependymoma and choroid plexus tumors, mesothelioma, osteosarcoma and sarcoma. The same tumor types will develop in hamsters after injection with SV40. These findings are interesting in themselves for they could shed light on the pathogenesis of these tumors. These findings also have public health implications. SV40 was found to have contaminated the poliovaccines and the adenovaccines from 1955 until 1963, therefore resulting in the inadvertent injection of millions of people with this tumor virus. Moreover, our society pays a high cost for asbestos causality, a carcinogen associated with the development of mesothelioma. In addition to asbestos, the potential impact of finding another possible cause for mesothelioma (i.e., SV40), as well as the possible pathogenic role of the contaminated poliovaccines, has generated considerable public interest and concern. To discuss these recent findings, the NM (National Institutes of Health) and the FDA (Food and Drug Administration), organized an International Conference at the NM, Bethesda, MD, January 27-28, 1997. The association of SV40 with human mesothelioma was also discussed in a special session at the IV International Mesothelioma Conference that was held at the University of Pennsylvania, Philadelphia, PA, May 13-16, 1997. The purpose of this review is to summarize data, from the discovery of the contaminated poliovaccines, to the most recent findings presented at the meetings in Bethesda and Philadelphia, to discuss technical and other problems associated with this research, and the potential for using these findings to develop new diagnostic and therapeutic approaches for SV40-associated malignancies.	WAYNE STATE UNIV, KARMANOS CANC INST, DETROIT, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Carbone, M (corresponding author), LOYOLA UNIV, DEPT PATHOL, CANC IMMUNOL PROGRAM, CARDINAL BERNARDIN CANC CTR, MAYWOOD, IL 60153 USA.			Pass, Harvey/0000-0003-3222-3471; rizzo, paola/0000-0001-7174-9674	NCI NIH HHS [CA-74283-01] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPEL JD, 1988, P NATL ACAD SCI USA, V85, P7670, DOI 10.1073/pnas.85.20.7670; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; BELL DW, 1997, P 4 INT MES C U PENN, P27; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; BRIGHT RK, 1994, CLIN EXP IMMUNOL, V96, P491; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1996, ONCOGENE, V13, P527; CARBONE M, 1989, CANCER RES, V49, P1565; CARBONE M, 1991, MOL BASIS HUMAN CANC, P191; CARBONE M, IN PRESS NATURE MED; CICALA C, 1994, J VIROL, V68, P3138, DOI 10.1128/JVI.68.5.3138-3144.1994; CICALA C, 1993, AM J PATHOL, V142, P1524; CICALA C, 1992, VIROLOGY, V190, P475, DOI 10.1016/0042-6822(92)91237-O; COLE NC, 1996, VIROLOGY, V2, P1997; *COMM DIS CTR, 1961, 248 COMM DIS CTR; Cristaudo A., 1995, Journal of Environmental Pathology Toxicology and Oncology, V14, P29; DELUCA A, IN PRESS NATURE MED; DEVILLERS E, 1997, SV40 POSS HUM POL WO, V1, P176; DIAMANDOPOULOS GT, 1972, SCIENCE, V176, P173, DOI 10.1126/science.176.4031.173; DIXON K, 1982, NATURE, V296, P672, DOI 10.1038/296672a0; Dubes G. R., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P185; EDDY BE, 1961, P SOC EXP BIOL MED, V107, P191; EDDY BE, 1962, VIROLOGY, V17, P65, DOI 10.1016/0042-6822(62)90082-X; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FRAUMENI JF, 1963, JAMA-J AM MED ASSOC, V185, P713, DOI 10.1001/jama.1963.03060090045016; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; GALATEAUSALLE F, 1997, SV40 POSS HUM POL WO, V1, P186; GEISSLER E, 1990, PROG MED VIROL, V37, P211; GRIFFITHS D, 1997, SV40 POSS HUM POLL W, V1, P171; ILYINSKII PO, 1992, J VIROL, V66, P6353, DOI 10.1128/JVI.66.11.6353-6360.1992; JENSEN F, 1964, J NATL CANCER I, V32, P917; KIRSCHSTEIN RL, 1962, NATURE, V195, P299, DOI 10.1038/195299b0; KRIEG P, 1981, P NATL ACAD SCI-BIOL, V78, P6446, DOI 10.1073/pnas.78.10.6446; LABELLA F, 1985, VIRUS RES, V2, P329, DOI 10.1016/0168-1702(85)90029-2; LEDNICKY JA, 1995, VIROLOGY, V212, P710, DOI 10.1006/viro.1995.1529; LEDNICKY JA, 1995, VIRUS RES, V35, P143, DOI 10.1016/0168-1702(94)00093-R; LEDNICKY JA, IN PRESS INT J CANC; LEWIS AM, 1979, P NATL ACAD SCI USA, V76, P4299, DOI 10.1073/pnas.76.9.4299; LEWIS AM, 1973, BIOHAZARDS BIOL RES, P96; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; LINNAINMAA K, 1997, P 4 INT MES C U PENN, P30; MARK EJ, 1991, ANN NY ACAD SCI, V643, P196, DOI 10.1111/j.1749-6632.1991.tb24463.x; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; MARSELLA JM, IN PRESS ENV HLTH PE; MARSHALL J, 1991, ONCOGENE, V6, P1673; Martini F, 1996, CANCER RES, V56, P4820; MELNICK JL, 1962, P SOC EXP BIOL MED, V109, P965, DOI 10.3181/00379727-109-27392; MELNICK JL, 1996, VIROLOGY, V1, P655; MONINI P, 1995, DNA TUMOR VIRUSES ON, P51; Moorwood K, 1996, EXP CELL RES, V223, P308, DOI 10.1006/excr.1996.0086; MORRIS JA, 1961, P SOC EXP BIOL MED, V108, P56, DOI 10.3181/00379727-108-26843; MORTIMER EA, 1981, NEW ENGL J MED, V305, P1517, DOI 10.1056/NEJM198112173052507; OLIN P, 1997, SV40 POSS HUM POL WO, V1, P315; Ozer HL, 1996, EXP GERONTOL, V31, P303, DOI 10.1016/0531-5565(95)00024-0; Pass Harvey I., 1996, P89; PASS HI, 1997, SV40 POSS HUM POL WO, V1, P180; Pepper C, 1996, THORAX, V51, P1074, DOI 10.1136/thx.51.11.1074; PETO J, 1995, LANCET, V345, P535, DOI 10.1016/S0140-6736(95)90462-X; Price B, 1997, AM J EPIDEMIOL, V145, P211, DOI 10.1093/oxfordjournals.aje.a009093; RABSON AS, 1962, J NATL CANCER I, V29, P765; RAY AR, 1994, J NEUROONCOLOGY, V20, P55; Ray F.A., 1995, DNA TUMOR VIRUSES ON, P15; REDDEL RR, 1989, J NATL CANCER I, V81, P945, DOI 10.1093/jnci/81.12.945; RHIM JS, 1986, SCIENCE, V232, P385, DOI 10.1126/science.2421406; ROGGLI VL, 1992, PATHOLOGY ASBESTOS A, P383; RULEY EH, 1996, IMPORTANT ADV ONCOLO, P89; SHAH KV, 1971, AM J EPIDEMIOL, V93, P291, DOI 10.1093/oxfordjournals.aje.a121260; SHEIN HM, 1962, P NATL ACAD SCI USA, V48, P1164, DOI 10.1073/pnas.48.7.1164; SIMMONS DT, 1995, DNA TUMOR VIRUSES ON, P27; SORIANO F, 1974, NATURE, V249, P421, DOI 10.1038/249421a0; STOIAN M, 1984, REV ROUM MED VIROL, V35, P127; Strickler HD, 1996, CANCER EPIDEM BIOMAR, V5, P473; STRICKLER HD, 1997, SV40 POSS HUM POL WO, V1, P323; SWEET BH, 1960, P SOC EXP BIOL MED, V105, P420, DOI 10.3181/00379727-105-26128; TEVETHIA SS, 1990, MOL BIOL MED, V7, P83; TIEMANN F, 1995, J VIROL, V69, P6115, DOI 10.1128/JVI.69.10.6115-6121.1995; VONDERWETH A, 1992, VIROLOGY, V189, P334, DOI 10.1016/0042-6822(92)90711-W; WALSH JW, 1982, NEUROSURGERY, V10, P643, DOI 10.1227/00006123-198205000-00018; WEINER LP, 1972, NEW ENGL J MED, V305, P1517; WEISS AF, 1975, P NATL ACAD SCI USA, V72, P609, DOI 10.1073/pnas.72.2.609	83	171	174	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	1997	15	16					1877	1888		10.1038/sj.onc.1201375	http://dx.doi.org/10.1038/sj.onc.1201375			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365233				2022-12-17	WOS:A1997YA87200001
J	IWABUCHI, K; LI, B; BARTEL, P; FIELDS, S				IWABUCHI, K; LI, B; BARTEL, P; FIELDS, S			USE OF THE 2-HYBRID SYSTEM TO IDENTIFY THE DOMAIN OF P53 INVOLVED IN OLIGOMERIZATION	ONCOGENE			English	Note							WILD-TYPE P53; T-ANTIGEN; MUTANT P53; SV40-TRANSFORMED CELLS; PROTEINS BIND; SEQUENCE; TRANSFORMATION; IDENTIFICATION; MUTATIONS; ONCOGENE	We used a yeast-based genetic assay, the two-hybrid system, to characterize the domain of the tumor-suppressor p53 involved in oligomerization. This assay relies on the reconstitution of the function of a transcriptional activator, the yeast GAL4 protein, via the interaction of a protein fused to the DNA-binding domain of GAL4 with a protein fused to the transcriptional activation domain of GAL4. We show by a reconstruction experiment that this approach could detect the interaction of p53 deleted for its N-terminal activation domain with SV40 large T antigen. We then searched a library of human proteins present as activation domain hybrids for proteins that can interact with the hybrid of p53 with the DNA-binding domain. This search identified 36 plasmids containing the p53 gene, representing 10 different classes. These results provide an additional in viro demonstration of p53 oligomerization. The smallest p53 fragment identified from screening the library contained only amino acids 331-393, indicating that this small C-terminal fragment is sufficient to mediate oligomerization. In addition, a mutant p53 protein could bind to the wild-type protein in this assay, providing support for the idea that mutant forms of p53 act in a dominant-negative manner through C-terminal oligomerization with the wild type.	SUNY,DEPT MICROBIOL,STONY BROOK,NY 11794; SUNY,GRAD PROGRAM MOLEC & CELL BIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College					NCI NIH HHS [CA54699] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054699] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Miller J.H., 1972, EXPT MOL GENETICS; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8	32	171	200	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1693	1696						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502489				2022-12-17	WOS:A1993LE06400035
J	Luker, KE; Steele, JM; Mihalko, LA; Ray, P; Luker, GD				Luker, K. E.; Steele, J. M.; Mihalko, L. A.; Ray, P.; Luker, G. D.			Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands	ONCOGENE			English	Article						breast cancer; chemokines; chemokine receptors; bioluminescence imaging; luciferase; protein fragment complementation	TUMOR-GROWTH; RECEPTOR; PROTEIN; MIGRATION; CXCL12; DIMERIZATION; CHEMOTAXIS; INHIBITION; EXPRESSION; SURFACE	CXCR7 is a receptor for chemokines including CXCL12 (stromal-derived factor-1), a molecule that promotes tumor growth and metastasis in breast cancer and other malignancies. Building on the recent observation that CXCR7 sequesters CXCL12, we investigated mechanisms for CXCR7-dependent uptake of chemokines. Breast cancer cells expressing CXCR7 accumulated chemokines CXCL12 and CXC11 present at concentrations < 1ng/ml, unlike cells expressing CXCR4. CXCR7-dependent accumulation of chemokines was reduced by inhibitors of clathrin-mediated endocytosis. After CXCR7-mediated internalization, CXCL12 trafficked to lysosomes and was degraded, although levels of CXCR7 remained stable. CXCR7 reduced CXCL12 in the extracellular space, limiting the amounts of chemokine available to acutely stimulate signaling through CXCR4. CXCR7 constitutively internalized and recycled to the cell membrane even in the absence of ligand, and addition of chemokines did not significantly enhance receptor internalization. Chemokines at concentrations less than the Kd values for ligand-receptor binding did not alter levels of CXCR7 at the cell surface. Higher concentrations of chemokine ligands reduced the total cell surface expression of CXCR7 without affecting receptor internalization, indicating that receptor recycling was inhibited. CXCR7dependent uptake of chemokines and receptor trafficking were regulated by beta-arrestin 2. These studies establish mechanisms through which CXCR7 regulates the availability of chemokine ligands in the extracellular space. Oncogene (2010) 29, 4599-4610; doi: 10.1038/onc.2010.212; published online 7 June 2010	[Luker, G. D.] Univ Michigan, Dept Microbiol & Immunol, Sch Med, Ctr Mol Imaging, Ann Arbor, MI 48109 USA; [Luker, K. E.; Steele, J. M.; Mihalko, L. A.; Ray, P.; Luker, G. D.] Ctr Mol Imaging, Dept Radiol, Ann Arbor, MI USA	University of Michigan System; University of Michigan	Luker, GD (corresponding author), Univ Michigan, Dept Microbiol & Immunol, Sch Med, Ctr Mol Imaging, 109 Zina Pitcher Pl,A526 BSRB, Ann Arbor, MI 48109 USA.	gluker@umich.edu		luker, gary/0000-0001-6832-2581	NIH [R01CA136553, R01CA136829, P50CA093990]; NATIONAL CANCER INSTITUTE [R01CA136829, P50CA093990, R01CA136553] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research was supported by NIH grants R01CA136553, R01CA136829 and P50CA093990. We thank ChemoCentryx for mAb 11G8 and CCX733.	Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Atanackovic D, 2008, TUMOR BIOL, V29, P93, DOI 10.1159/000135689; Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Boldajipour B, 2008, CELL, V132, P463, DOI 10.1016/j.cell.2007.12.034; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; Cox JH, 2008, J BIOL CHEM, V283, P19389, DOI 10.1074/jbc.M800266200; Dar A, 2005, NAT IMMUNOL, V6, P1038, DOI 10.1038/ni1251; Fermas S, 2008, GLYCOBIOLOGY, V18, P1054, DOI 10.1093/glycob/cwn088; Furuya M, 2007, HUM PATHOL, V38, P1676, DOI 10.1016/j.humpath.2007.03.023; Galliera E, 2004, J BIOL CHEM, V279, P25590, DOI 10.1074/jbc.M400363200; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; Hansell CAH, 2006, BIOCHEM SOC T, V34, P1009, DOI 10.1042/BST0341009; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Kalatskaya I, 2009, MOL PHARMACOL, V75, P1240, DOI 10.1124/mol.108.053389; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; KELLY K, 2006, MOL IMAGING BIOL, V8, P1536; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kollmar O, 2007, NEOPLASIA, V9, P862, DOI 10.1593/neo.07559; Laguri C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001110; Levoye A, 2009, BLOOD, V113, P6085, DOI 10.1182/blood-2008-12-196618; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Luker GD, 2003, NAT MED, V9, P969, DOI 10.1038/nm894; Luker KE, 2008, ANAL CHEM, V80, P5565, DOI 10.1021/ac8005457; Luker KE, 2006, CANCER LETT, V238, P30, DOI 10.1016/j.canlet.2005.06.021; Luker KE, 2009, NEOPLASIA, V11, P1022, DOI 10.1593/neo.09724; Luker KE, 2009, BIOTECHNIQUES, V47, P625, DOI 10.2144/000113126; Luker KE, 2009, FASEB J, V23, P823, DOI 10.1096/fj.08-116749; Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Miao Z, 2007, P NATL ACAD SCI USA, V104, P15735, DOI 10.1073/pnas.0610444104; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Naumann U, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009175; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Proost P, 2001, BLOOD, V98, P3554, DOI 10.1182/blood.V98.13.3554; Pruenster M, 2009, NAT IMMUNOL, V10, P101, DOI 10.1038/ni.1675; Raggo C, 2005, CANCER RES, V65, P5084, DOI 10.1158/0008-5472.CAN-04-2822; Sadir R, 2004, J BIOL CHEM, V279, P43854, DOI 10.1074/jbc.M405392200; Sharma V, 1996, J MED CHEM, V39, P3483, DOI 10.1021/jm950823c; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; Sierro F, 2007, P NATL ACAD SCI USA, V104, P14759, DOI 10.1073/pnas.0702229104; Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844; Strieter RM, 2006, EUR J CANCER, V42, P768, DOI 10.1016/j.ejca.2006.01.006; van Weert AWM, 2000, EUR J CELL BIOL, V79, P394, DOI 10.1078/0171-9335-00062; Vandercappellen J, 2008, CANCER LETT, V267, P226, DOI 10.1016/j.canlet.2008.04.050; Wang JH, 2008, J BIOL CHEM, V283, P4283, DOI 10.1074/jbc.M707465200; Weber M, 2004, MOL BIOL CELL, V15, P2492, DOI 10.1091/mbc.E03-09-0634; Wu FY, 2008, MOL CANCER RES, V6, P1276, DOI 10.1158/1541-7786.MCR-07-2108; Yang XL, 2006, VACCINE, V24, P2966, DOI 10.1016/j.vaccine.2005.12.004; Zabel BA, 2009, J IMMUNOL, V183, P3204, DOI 10.4049/jimmunol.0900269; Zhang GB, 2007, CHINA COMMUN, V4, P46; Zhao M, 2008, BREAST CANCER RES TR, V110, P211, DOI 10.1007/s10549-007-9712-7	53	170	170	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2010	29	32					4599	4610		10.1038/onc.2010.212	http://dx.doi.org/10.1038/onc.2010.212			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	638AQ	20531309	Green Accepted			2022-12-17	WOS:000280862300010
J	Yin, G; Chen, R; Alvero, AB; Fu, HH; Holmberg, J; Glackin, C; Rutherford, T; Mor, G				Yin, G.; Chen, R.; Alvero, A. B.; Fu, H-H; Holmberg, J.; Glackin, C.; Rutherford, T.; Mor, G.			TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214	ONCOGENE			English	Article						ovarian CSCs; Twist1; miR-199a/214 cluster; IKK beta	KAPPA-B ACTIVITY; SURFACE EPITHELIUM; IN-VIVO; DIFFERENTIATION; MICRORNAS; ONCOGENESIS; ACTIVATION; EXPRESSION; RESISTANCE; SURVIVAL	Cancer stem cells are responsible for sustaining the tumor and giving rise to proliferating and progressively differentiating cells. However, the molecular mechanisms regulating the process of cancer stem cell (CSC) differentiation is not clearly understood. Recently, we reported the isolation of the epithelial ovarian cancer (EOC) stem cells (type I/CD44+). In this study, we show that type I/CD44+ cells are characterized by low levels of both miR-199a and miR-214, whereas mature EOC cells (type II/CD44-) have higher levels of miR-199a and miR-214. Moreover, these two micro RNAs (miRNAs) are regulated as a cluster on pri-miR-199a2 within the human Dnm3os gene (GenBank FJ623959). This study identify Twist1 as a regulator of this unique miRNA cluster responsible for the regulation of the IKK beta/NF-kappa beta and PTEN/AKT pathways and its association of ovarian CSC differentiation. Our data suggest that Twist1 may be an important regulator of 'stemness' in EOC cells. The regulation of MIR199A2/214 expression may be used as a potential therapeutic approach in EOC patients. Oncogene (2010) 29, 3545-3553; doi:10.1038/onc.2010.111; published online 19 April 2010	[Mor, G.] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, Reprod Immunol Unit, New Haven, CT 06520 USA; [Glackin, C.] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA USA	Yale University; City of Hope; Beckman Research Institute of City of Hope	Mor, G (corresponding author), Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, Reprod Immunol Unit, 333 Cedar St,LSOG 305A, New Haven, CT 06520 USA.	gil.mor@yale.edu	Yin, Gang/H-3289-2011	Holmberg, Jennie/0000-0002-1106-4718; Alvero, Ayesha/0000-0002-6593-3595	NCI/NIH [RO1CA127913, RO1CA118678]; Janet Burros Memorial Foundation; Sands Family Foundation; Discovery To Cure Research Program; NATIONAL CANCER INSTITUTE [R01CA118678, R01CA127913] Funding Source: NIH RePORTER	NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Janet Burros Memorial Foundation; Sands Family Foundation; Discovery To Cure Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported in part by grants from NCI/NIH RO1CA127913, RO1CA118678, the Janet Burros Memorial Foundation, the Sands Family Foundation and the Discovery To Cure Research Program.	Ahmed N, 2007, J CELL PHYSIOL, V213, P581, DOI 10.1002/jcp.21240; Alison MR, 2008, CELL TISSUE RES, V331, P109, DOI 10.1007/s00441-007-0510-7; Alvarez-Garcia I, 2005, DEVELOPMENT, V132, P4653, DOI 10.1242/dev.02073; Alvero AB, 2009, STEM CELLS, V27, P2405, DOI 10.1002/stem.191; Alvero AB, 2009, CELL CYCLE, V8, P158, DOI 10.4161/cc.8.1.7533; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Baylies MK, 1996, SCIENCE, V272, P1481, DOI 10.1126/science.272.5267.1481; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Chen R, 2008, ONCOGENE, V27, P4712, DOI 10.1038/onc.2008.112; Chen R, 2007, AM J REPROD IMMUNOL, V57, P93, DOI 10.1111/j.1600-0897.2006.00441.x; Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200; Cheng GZ, 2008, CURR CANCER DRUG TAR, V8, P2; Cheng GZ, 2008, CANCER RES, V68, P957, DOI 10.1158/0008-5472.CAN-07-5067; Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Clarke-Pearson DL, 2009, NEW ENGL J MED, V361, P170, DOI 10.1056/NEJMcp0901926; Entz-Werle N, 2005, INT J CANCER, V117, P349, DOI 10.1002/ijc.21068; Espey DK, 2007, CANCER-AM CANCER SOC, V110, P2119, DOI 10.1002/cncr.23044; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kamsteeg M, 2003, ONCOGENE, V22, P2611, DOI 10.1038/sj.onc.1206422; Koga K, 2009, AM J REPROD IMMUNOL, V61, P196, DOI 10.1111/j.1600-0897.2008.00682.x; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; Lee MS, 1999, J CELL BIOCHEM, V75, P566, DOI 10.1002/(SICI)1097-4644(19991215)75:4<566::AID-JCB3>3.0.CO;2-0; Lee MS, 2000, BONE, V27, P591, DOI 10.1016/S8756-3282(00)00380-X; Lee YB, 2009, NUCLEIC ACIDS RES, V37, P123, DOI 10.1093/nar/gkn920; Liu JD, 2005, NAT CELL BIOL, V7, P719, DOI 10.1038/ncb1274; Loebel DAF, 2002, GENESIS, V33, P103, DOI 10.1002/gene.10091; Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008-5472.CAN-05-0712; Miska EA, 2005, CURR OPIN GENET DEV, V15, P563, DOI 10.1016/j.gde.2005.08.005; ODWYER PJ, 1994, CANCER RES, V54, P724; Ota MS, 2004, DEV DYNAM, V230, P216, DOI 10.1002/dvdy.20047; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Papagiannakopoulos T, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-15; Salamanca CM, 2004, J SOC GYNECOL INVEST, V11, P241, DOI 10.1016/j.jsgi.2003.10.010; Schwartz Peter E, 2002, Cancer Treat Res, V107, P99; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; Taylor DD, 2008, GYNECOL ONCOL, V110, P13, DOI 10.1016/j.ygyno.2008.04.033; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; WOOLAS RP, 1993, JNCI-J NATL CANCER I, V85, P1748, DOI 10.1093/jnci/85.21.1748; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	42	170	186	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2010	29	24					3545	3553		10.1038/onc.2010.111	http://dx.doi.org/10.1038/onc.2010.111			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20400975	Green Accepted			2022-12-17	WOS:000278835400009
J	Karagianni, P; Wong, J				Karagianni, P.; Wong, J.			HDAC3: taking the SMRT-N-CoRrect road to repression	ONCOGENE			English	Review						HDAC3; SMRT; N-CoR; corepressor complex; histone deacetylation; repression and cancer	NUCLEAR RECEPTOR-COREPRESSOR; THYROID-HORMONE RECEPTOR; ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID RECEPTOR; HUMAN HISTONE DEACETYLASE; PML-RAR-ALPHA; CO-REPRESSOR; TRANSCRIPTIONAL REPRESSION; KAPPA-B; FUSION PROTEIN	Known histone deacetylases ( HDACs) are divided into different classes, and HDAC3 belongs to Class I. Through forming multiprotein complexes with the corepressors SMRT and N-CoR, HDAC3 regulates the transcription of a plethora of genes. A growing list of nonhistone substrates extends the role of HDAC3 beyond transcriptional repression. Here, we review data on the composition, regulation and mechanism of action of the SMRT/N-CoR-HDAC3 complexes and provide several examples of nontranscriptional functions, to illustrate the wide variety of physiological processes affected by this deacetylase. Furthermore, we discuss the implication of HDAC3 in cancer, focusing on leukemia. We conclude with some thoughts about the potential therapeutic efficacies of HDAC3 activity modulation.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Wong, J (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	jmweng@bio.ecnu.edu.cn		Wong, Jiemin/0000-0002-5311-842X	NIDDK NIH HHS [DK58679] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058679] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alenghat T, 2006, EMBO J, V25, P3966, DOI 10.1038/sj.emboj.7601280; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Atsumi A, 2006, BIOCHEM BIOPH RES CO, V345, P1471, DOI 10.1016/j.bbrc.2006.05.047; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bartling B, 2005, LUNG CANCER-J IASLC, V49, P145, DOI 10.1016/j.lungcan.2005.02.006; Breiding DE, 1997, MOL CELL BIOL, V17, P7208, DOI 10.1128/MCB.17.12.7208; Buggy JJ, 2000, BIOCHEM J, V350, P199, DOI 10.1042/0264-6021:3500199; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Cho YS, 2005, GENOMICS, V86, P606, DOI 10.1016/j.ygeno.2005.07.007; Chuang HC, 2006, NUCLEIC ACIDS RES, V34, P1459, DOI 10.1093/nar/gkl048; Codina A, 2005, P NATL ACAD SCI USA, V102, P6009, DOI 10.1073/pnas.0500299102; Cowger JJM, 2006, BIOCHEMISTRY-US, V45, P13150, DOI 10.1021/bi060562g; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; Dangond F, 1998, BIOCHEM BIOPH RES CO, V242, P648, DOI 10.1006/bbrc.1997.8033; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; ERICKSON P, 1992, BLOOD, V80, P1825; Escaffit F, 2007, MOL CELL BIOL, V27, P554, DOI 10.1128/MCB.00869-06; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Fischle W, 2005, NATURE, V438, P1116, DOI 10.1038/nature04219; Foglietti C, 2006, J BIOL CHEM, V281, P17968, DOI 10.1074/jbc.M511945200; Frank R, 1995, ONCOGENE, V11, P2667; Fu JHJ, 2007, MOL CELL BIOL, V27, P4641, DOI 10.1128/MCB.00857-06; Fu MF, 2005, J BIOL CHEM, V280, P16934, DOI 10.1074/jbc.M500403200; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Gao ZG, 2006, J BIOL CHEM, V281, P4540, DOI 10.1074/jbc.M507784200; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Glaser KB, 2003, BIOCHEM BIOPH RES CO, V310, P529, DOI 10.1016/j.bbrc.2003.09.043; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gregoire S, 2007, MOL CELL BIOL, V27, P1280, DOI 10.1128/MCB.00882-06; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guenther MG, 2000, GENE DEV, V14, P1048; Guenther MG, 2002, GENE DEV, V16, P3130, DOI 10.1101/gad.1037502; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; Guidez F, 2000, BLOOD, V96, P2557; Hartman HB, 2005, EMBO REP, V6, P445, DOI 10.1038/sj.embor.7400391; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hirota T, 2005, NATURE, V438, P1176, DOI 10.1038/nature04254; Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hoogeveen AT, 2002, ONCOGENE, V21, P6703, DOI 10.1038/sj.onc.1205882; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Huang EY, 2000, GENE DEV, V14, P45; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Huang Y, 2006, SCIENCE, V312, P748, DOI 10.1126/science.1125162; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Jepsen K, 2002, J CELL SCI, V115, P689; Jeyakumar M, 2007, J BIOL CHEM, V282, P9312, DOI 10.1074/jbc.M609009200; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Jin X.-Q., 2002, CO COMP SCI, V2; Johnson CA, 2002, J BIOL CHEM, V277, P9590, DOI 10.1074/jbc.M107942200; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kao HY, 2000, GENE DEV, V14, P55; Karagiannis TC, 2007, LEUKEMIA, V21, P61, DOI 10.1038/sj.leu.2404464; Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Li D, 2005, J BIOL CHEM, V280, P26941, DOI 10.1074/jbc.M500463200; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Li JW, 2002, GENE DEV, V16, P687, DOI 10.1101/gad.962502; Li Y, 2006, GENE DEV, V20, P2566, DOI 10.1101/gad.1455006; Liby P, 2006, FOLIA BIOL-PRAGUE, V52, P21; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin HM, 2002, J BIOL CHEM, V277, P28733, DOI 10.1074/jbc.M203380200; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu XF, 2004, J BIOL CHEM, V279, P15050, DOI 10.1074/jbc.M311932200; Longworth MS, 2006, ONCOGENE, V25, P4495, DOI 10.1038/sj.onc.1209473; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Monte M, 2006, P NATL ACAD SCI USA, V103, P11160, DOI 10.1073/pnas.0510834103; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Narita N, 2005, ONCOGENE, V24, P7346, DOI 10.1038/sj.onc.1208879; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; Park EJ, 1999, P NATL ACAD SCI USA, V96, P3519, DOI 10.1073/pnas.96.7.3519; Peng YC, 2001, MOL CELL BIOL, V21, P5913, DOI 10.1128/MCB.21.17.5913-5924.2001; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Pijnappel WWMP, 2001, GENE DEV, V15, P2991, DOI 10.1101/gad.207401; Racanicchi S, 2005, EMBO J, V24, P1232, DOI 10.1038/sj.emboj.7600593; RIGGS MG, 1977, NATURE, V268, P462, DOI 10.1038/268462a0; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Rowley J D, 1982, Natl Cancer Inst Monogr, V60, P17; Schroeder TM, 2004, J BIOL CHEM, V279, P41998, DOI 10.1074/jbc.M403702200; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Smith WL, 1997, ACAD RADIOL, V4, P657, DOI 10.1016/S1076-6332(05)80273-9; Spain BH, 1996, MOL CELL BIOL, V16, P6698; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takami Y, 2000, J BIOL CHEM, V275, P16191, DOI 10.1074/jbc.M908066199; Tanaka Tomoyuki, 1997, Leukemia (Basingstoke), V11, P299; Thevenet L, 2004, EMBO J, V23, P3336, DOI 10.1038/sj.emboj.7600352; Uchida H, 1997, J IMMUNOL, V158, P2251; Vermeulen M, 2004, MOL CELL BIOL, V24, P2364, DOI 10.1128/MCB.24.6.2364-2372.2004; Vermeulen M, 2006, MOL CELL BIOL, V26, P5226, DOI 10.1128/MCB.00440-06; VIDALI G, 1978, P NATL ACAD SCI USA, V75, P2239, DOI 10.1073/pnas.75.5.2239; Villa R, 2006, P NATL ACAD SCI USA, V103, P1400, DOI 10.1073/pnas.0509343103; Wang L, 1998, EUR T ELECTR POWER, V8, P21, DOI 10.1002/etep.4450080105; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200; Xia Y, 2007, MOL CELL, V25, P219, DOI 10.1016/j.molcel.2007.01.005; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yang WM, 2002, J BIOL CHEM, V277, P9447, DOI 10.1074/jbc.M105993200; Yin L, 2005, MOL ENDOCRINOL, V19, P1452, DOI 10.1210/me.2005-0057; Yoon HG, 2005, MOL CELL BIOL, V25, P324, DOI 10.1128/MCB.25.1.324-335.2005; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Yu JJ, 2003, EMBO J, V22, P3403, DOI 10.1093/emboj/cdg326; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9; Zeng LF, 2006, J CELL BIOL, V174, P1059, DOI 10.1083/jcb.200605113; Zhang DZ, 2005, MOL CELL BIOL, V25, P6404, DOI 10.1128/MCB.25.15.6404-6414.2005; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9; Zhang XH, 2005, GENE DEV, V19, P827, DOI 10.1101/gad.1286005; Zhang XH, 2004, MOL CELL BIOL, V24, P5106, DOI 10.1128/MCB.24.12.5106-5118.2004	125	170	177	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5439	5449		10.1038/sj.onc.1210612	http://dx.doi.org/10.1038/sj.onc.1210612			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694085				2022-12-17	WOS:000248674300012
J	Herbert, BS; Gellert, GC; Hochreiter, A; Pongracz, K; Wright, WE; Zielinska, D; Chin, AC; Harley, CB; Shay, JW; Gryaznov, SM				Herbert, BS; Gellert, GC; Hochreiter, A; Pongracz, K; Wright, WE; Zielinska, D; Chin, AC; Harley, CB; Shay, JW; Gryaznov, SM			Lipid modification of GRN163, an N3 ' -> P5 ' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition	ONCOGENE			English	Article						telomerase inhibitors; oligonucleotide; thio-phosphoramidates; lipid conjugates	CHOLESTERYL-CONJUGATED OLIGONUCLEOTIDES; HUMAN IMMUNODEFICIENCY VIRUS; AMPLIFICATION PROTOCOL TRAP; ANTISENSE OLIGONUCLEOTIDES; TEMPLATE ANTAGONIST; MULTIPLE-MYELOMA; IN-VITRO; CELLS; CANCER; OLIGODEOXYNUCLEOTIDES	The vast majority of human cancers express telomerase activity, while most human somatic cells do not have detectable telomerase activity. Since telomerase plays a critical role in cell immortality, it is an attractive target for a selective cancer therapy. Oligonucleotides complementary to the RNA template region of human telomerase (hTR) have been shown to be effective inhibitors of telomerase and, subsequently, cancer cell growth in vitro. We show here that a lipid-modified N3'-> P5' thio-phosphoramidate oligonucleotide (GRN163L) inhibits telomerase more potently than its parental nonconjugated thio-phosphoramidate sequence (GRN163). Cells were treated with both the first- (GRN163) and second-generation (GRN163L) oligonucleotides, including a mismatch control, with or without a transfection enhancer reagent. GRN163L inhibited telomerase activity effectively in a dose-dependent manner, even without the use of a transfection reagent. The IC50 values for GRN163 in various cell lines were on average sevenfold higher than for GRN163L. GRN163L inhibition of telomerase activity resulted in a more rapid loss of telomeres and cell growth than GRN163. This report is the first to show that lipid modi. cation enhanced the potency of the novel GRN163 telomerase inhibitor. These results suggest that the lipid-conjugated thio-phosphoramidates could be important for improved pharmacodynamics of telomerase inhibitors in cancer therapy.	Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Indiana Univ, Ctr Canc, Indianapolis, IN 46202 USA; Geron Corp, Menlo Pk, CA 94025 USA	Indiana University System; Indiana University-Purdue University Indianapolis; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Indiana University System; Indiana University-Purdue University Indianapolis; Geron Corporation	Herbert, BS (corresponding author), Indiana Univ, Sch Med, Dept Med & Mol Genet, 975 W Walnut St,IB242, Indianapolis, IN 46202 USA.	brherber@iupui.edu	Shay, Jerry W/F-7878-2011		NCPDCID CDC HHS [NCI CA85363, NCI CA70907] Funding Source: Medline	NCPDCID CDC HHS		AGRAWAL S, 1988, P NATL ACAD SCI USA, V85, P7079, DOI 10.1073/pnas.85.19.7079; Akiyama M, 2003, CANCER RES, V63, P6187; Asai A, 2003, CANCER RES, V63, P3931; BOUTORIN AS, 1989, FEBS LETT, V254, P129, DOI 10.1016/0014-5793(89)81023-3; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; FAROOQUI F, 1991, BIOCONJUGATE CHEM, V2, P422, DOI 10.1021/bc00012a007; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Holt Shawn E., 1996, Methods in Cell Science, V18, P237, DOI 10.1007/BF00132889; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; LETSINGER RL, 1989, P NATL ACAD SCI USA, V86, P6553, DOI 10.1073/pnas.86.17.6553; MACKELLAR C, 1992, NUCLEIC ACIDS RES, V20, P3411, DOI 10.1093/nar/20.13.3411; MISHRA RK, 1995, BBA-GENE STRUCT EXPR, V1264, P229, DOI 10.1016/0167-4781(95)00145-7; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; OBERHAUSER B, 1992, NUCLEIC ACIDS RES, V20, P533, DOI 10.1093/nar/20.3.533; Ouellette MM, 1999, BIOCHEM BIOPH RES CO, V254, P795, DOI 10.1006/bbrc.1998.0114; Ozawa T, 2004, NEURO-ONCOLOGY, V6, P218, DOI 10.1215/S1152851704000055; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; POLUSHIN NN, 1994, NUCLEIC ACIDS RES, V22, P5492, DOI 10.1093/nar/22.24.5492; REED MW, 1991, BIOCONJUGATE CHEM, V2, P217, DOI 10.1021/bc00010a005; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SHEA RG, 1990, NUCLEIC ACIDS RES, V18, P3777, DOI 10.1093/nar/18.13.3777; Shea-Herbert B, 2002, ONCOGENE, V21, P638, DOI 10.1038/sj.onc.1205064; STEIN CA, 1991, BIOCHEMISTRY-US, V30, P2439, DOI 10.1021/bi00223a020; Wang ES, 2004, BLOOD, V103, P258, DOI 10.1182/blood-2003-02-0546; White LK, 2001, TRENDS BIOTECHNOL, V19, P114, DOI 10.1016/S0167-7799(00)01541-9; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Yi XM, 2000, NEOPLASIA, V2, P433, DOI 10.1038/sj.neo.7900113; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	31	170	209	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5262	5268		10.1038/sj.onc.1208760	http://dx.doi.org/10.1038/sj.onc.1208760			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15940257				2022-12-17	WOS:000230964600014
J	Luttrell, DK; Luttrell, LM				Luttrell, DK; Luttrell, LM			Not so strange bedfellows: G-protein-coupled receptors and Src family kinases	ONCOGENE			English	Review						G-protein-coupled receptor; focal adhesion kinase; epidermal growth factor; mitogen-activated protein kinase; receptor crosstalk	GROWTH-FACTOR RECEPTOR; SMOOTH-MUSCLE-CELLS; FOCAL ADHESION KINASE; DEPENDENT TYROSINE KINASE; C-SRC; EGF RECEPTOR; ANGIOTENSIN-II; MAP KINASE; BETA-ARRESTIN; LYSOPHOSPHATIDIC ACID	Src family nonreceptor tyrosine kinases are an integral component of the signal transduction apparatus employed by growth factor receptor tyrosine kinases. As such, their role in cellular growth control and malignant transformation has been the subject of intensive investigation. In contrast, classical G-protein-coupled receptor ( GPCR) signaling involves activation of second messenger-regulated serine/threonine kinases or ion channels, and is primarily involved in neurotransmission and the short-term regulation of intermediary metabolism. Over the past decade, this strictly dichotomous model of transmembrane signaling has been challenged by the discovery that GPCRs also exert control over cellular growth, proliferation, and differentiation, and do so by stimulating tyrosine phosphorylation cascades. Several mechanisms, from the direct association of Src family kinases with GPCRs or receptor-associated proteins, to the transactivation of receptor tyrosine kinases and focal adhesion complexes by G-protein-mediated signals, permit GPCRs to activate Src family kinases. Conversely, Src activity plays a central role in controlling GPCR trafficking and effects on cell proliferation and cytoskeletal rearrangement. It is now clear that GPCRs and Src family kinases do not belong to separate, exclusive clubs. Rather, these strange bedfellows are intimately involved in multilayered forms of crosstalk that influence a host of cellular processes.	Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Mol Biol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Luttrell, LM (corresponding author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, 96 Jonathan Lucas St,816 CSB,POB 250624, Charleston, SC 29425 USA.	luttrell@musc.edu		Luttrell, Louis/0000-0003-2805-6949	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK055524, R01DK055524, R01DK058283, R01DK064353] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55524, DK64353, DK58283] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Baron V, 1998, ENDOCRINOLOGY, V139, P3034, DOI 10.1210/en.139.6.3034; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; BUSHMAN WA, 1990, P NATL ACAD SCI USA, V87, P7462, DOI 10.1073/pnas.87.19.7462; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHEN YH, 1994, J BIOL CHEM, V269, P27372; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Dong JY, 2000, J BIOL CHEM, V275, P557, DOI 10.1074/jbc.275.1.557; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Elorza A, 2000, MOL PHARMACOL, V57, P778, DOI 10.1124/mol.57.4.778; Fan GF, 2001, J BIOL CHEM, V276, P13240, DOI 10.1074/jbc.M011578200; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Goldkorn T, 1997, BBA-MOL CELL RES, V1358, P289, DOI 10.1016/S0167-4889(97)00063-3; Gschwind A, 2002, CANCER RES, V62, P6329; Haskell MD, 2001, CHEM REV, V101, P2425, DOI 10.1021/cr0002341; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; Imamura T, 2001, J BIOL CHEM, V276, P43663, DOI 10.1074/jbc.M105364200; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1998, J BIOL CHEM, V273, P9361, DOI 10.1074/jbc.273.16.9361; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Liu J, 2004, J BIOL CHEM, V279, P8212, DOI 10.1074/jbc.M312230200; Liu WW, 1996, P NATL ACAD SCI USA, V93, P8258, DOI 10.1073/pnas.93.16.8258; LUTTRELL DK, 1992, CELL SIGNAL, V4, P531, DOI 10.1016/0898-6568(92)90022-Z; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; MOYERS JS, 1995, BIOCHEM J, V305, P411, DOI 10.1042/bj3050411; MOYERS JS, 1993, MOL CELL BIOL, V13, P2391, DOI 10.1128/MCB.13.4.2391; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; Penela P, 2003, CELL SIGNAL, V15, P973, DOI 10.1016/S0898-6568(03)00099-8; Penela P, 2001, EMBO J, V20, P5129, DOI 10.1093/emboj/20.18.5129; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; Rodriguez-Fernandez JL, 1998, J BIOL CHEM, V273, P19321, DOI 10.1074/jbc.273.30.19321; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Roelle S, 2003, J BIOL CHEM, V278, P47307, DOI 10.1074/jbc.M304377200; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Sarnago S, 1999, J BIOL CHEM, V274, P34411, DOI 10.1074/jbc.274.48.34411; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; Shalloway D, 1997, TRENDS CELL BIOL, V7, P215; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Slack BE, 1998, P NATL ACAD SCI USA, V95, P7281, DOI 10.1073/pnas.95.13.7281; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; Thuringer D, 2002, J BIOL CHEM, V277, P2028, DOI 10.1074/jbc.M109493200; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; VAN BT, 1995, NATURE, V376, P781; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Werbonat Y, 2000, J BIOL CHEM, V275, P21969, DOI 10.1074/jbc.M001736200; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	103	170	174	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2004	23	48					7969	7978		10.1038/sj.onc.1208162	http://dx.doi.org/10.1038/sj.onc.1208162			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863JR	15489914				2022-12-17	WOS:000224558300007
J	Schmidt-Hansen, B; Ornas, D; Grigorian, M; Klingelhofer, J; Tulchinsky, E; Lukanidin, E; Ambartsumian, N				Schmidt-Hansen, B; Ornas, D; Grigorian, M; Klingelhofer, J; Tulchinsky, E; Lukanidin, E; Ambartsumian, N			Extracellular S100A4(mts1) stimulates invasive growth of mouse endothelial cells and modulates MMP-13 matrix metalloproteinase activity	ONCOGENE			English	Article						metastasis-promoting; S100A4; extracellular; activity; MMP-13 induction; angiogenesis	METASTASIS-ASSOCIATED PROTEIN; FACTOR-KAPPA-B; TUMOR-CELLS; IN-VITRO; DIFFERENTIAL REGULATION; PLASMINOGEN-ACTIVATOR; COLLAGENASE-3 MMP-13; PROGNOSTIC MARKERS; SIGNALING PATHWAYS; OSTEOSARCOMA CELLS	S100A4(mts1) protein expression has been strongly associated with metastatic tumor progression. It has been suggested as a prognostic marker for a number of human cancers. It is proposed that extracellular S100A4 accelerates cancer progression by stimulating the motility of endothelial cells, thereby promoting angiogenesis. Here we show that in 3D culture mouse endothelial cells (SVEC 4-10) respond to recombinant S100A4 by stimulating invasive growth of capillary-like structures. The outgrowth is not dependent on the stimulation of cell proliferation, but rather correlates with the transcriptional modulation of genes involved in the proteolytic degradation of extracellular matrix (ECM). Treatment of SVEC 4-10 with the S100A4 protein leads to the transcriptional activation of collagenase 3 (MMP-13) mRNA followed by subsequent release of the protein from the cells. beta-Casein zymography demonstrates enhancement of proteolytic activity associated with MMP-13. This observation indicates that extracellular S100A4 stimulates the production of ECM degrading enzymes from endothelial cells, thereby stimulating the remodeling of ECM. This could explain the angiogenic and metastasis-stimulating activity of S100A4(mts1).	Danish Canc Soc, Dept Mol Canc Biol, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Univ Leicester, Dept Canc Studies & Mol Med, Leicester LE 7LX, Leics, England	Danish Cancer Society; University of Leicester	Ambartsumian, N (corresponding author), Danish Canc Soc, Dept Mol Canc Biol, Inst Canc Biol, Strand Blvd 49, DK-2100 Copenhagen, Denmark.	na@cancer.dk	Klingelhöfer, Jörg/C-1676-2013; Tulchinsky, Eugene/ABD-7070-2021					Airola K, 1997, J INVEST DERMATOL, V109, P225, DOI 10.1111/1523-1747.ep12319441; Ambartsumian N, 2001, ONCOGENE, V20, P4685, DOI 10.1038/sj.onc.1204636; AMBARTSUMIAN N, IN PRESS CELL BIOL L; Ambartsumian NS, 1996, ONCOGENE, V13, P1621; Andersen K, 1998, ANTICANCER RES, V18, P3299; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Belot N, 2002, BBA-PROTEINS PROTEOM, V1600, P74, DOI 10.1016/S1570-9639(02)00447-8; Bjornland K, 2001, J PEDIATR SURG, V36, P1040, DOI 10.1053/jpsu.2001.24735; Bjornland K, 1999, CANCER RES, V59, P4702; Bond M, 2001, CARDIOVASC RES, V50, P556, DOI 10.1016/S0008-6363(01)00220-6; BRAUNHUT SJ, 1994, J BIOL CHEM, V269, P13472; Cazorla M, 1998, J PATHOL, V186, P144, DOI 10.1002/(SICI)1096-9896(1998100)186:2<144::AID-PATH147>3.0.CO;2-#; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Davies BR, 2002, J PATHOL, V196, P292, DOI 10.1002/path.1051; Davies MPA, 1996, ONCOGENE, V13, P1631; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Duarte WR, 2003, J BONE MINER RES, V18, P493, DOI 10.1359/jbmr.2003.18.3.493; Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; Endo H, 2002, J BIOL CHEM, V277, P26396, DOI 10.1074/jbc.M202244200; FERNANDEZRESA P, 1995, ANAL BIOCHEM, V224, P434, DOI 10.1006/abio.1995.1063; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FORD HL, 1995, ONCOGENE, V10, P1597; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Grigorian M, 1996, INT J CANCER, V67, P831, DOI 10.1002/(SICI)1097-0215(19960917)67:6<831::AID-IJC13>3.0.CO;2-4; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hattori Y, 2003, EXP MOL PATHOL, V74, P230, DOI 10.1016/S0014-4800(03)00014-5; Heikkila P, 2002, ANTI-CANCER DRUG, V13, P245, DOI 10.1097/00001813-200203000-00006; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Johansson N, 1999, AM J PATHOL, V154, P469, DOI 10.1016/S0002-9440(10)65293-5; Johansson N, 1997, AM J PATHOL, V151, P499; Kim HG, 2000, BIOCHEM BIOPH RES CO, V269, P401; Kriajevska M, 1998, J BIOL CHEM, V273, P9852, DOI 10.1074/jbc.273.16.9852; Kriajevska M, 2002, J BIOL CHEM, V277, P5229, DOI 10.1074/jbc.M110976200; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Lemaitre V, 1997, BIOCHEM BIOPH RES CO, V230, P202, DOI 10.1006/bbrc.1996.5924; Lloyd BH, 1998, ONCOGENE, V17, P465, DOI 10.1038/sj.onc.1201948; Maelandsmo GM, 1996, CANCER RES, V56, P5490; Mengshol JA, 2000, ARTHRITIS RHEUM, V43, P801, DOI 10.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4; Mikkelsen SE, 2001, J NEUROCHEM, V79, P767, DOI 10.1046/j.1471-4159.2001.00605.x; Novitskaya V, 2000, J BIOL CHEM, V275, P41278, DOI 10.1074/jbc.M007058200; OCONNELL KA, 1990, J IMMUNOL, V144, P521; Peeters-Joris C, 1998, BBA-MOL CELL RES, V1405, P14, DOI 10.1016/S0167-4889(98)00094-9; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; Philip S, 2003, J BIOL CHEM, V278, P14487, DOI 10.1074/jbc.M207309200; Platt-Higgins AM, 2000, INT J CANCER, V89, P198, DOI 10.1002/(SICI)1097-0215(20000320)89:2<198::AID-IJC16>3.0.CO;2-L; Qian XH, 1997, EXP CELL RES, V235, P403, DOI 10.1006/excr.1997.3681; Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Takenaga K, 1997, ONCOGENE, V14, P331, DOI 10.1038/sj.onc.1200820; Tulchinsky E, 1997, J BIOL CHEM, V272, P4828, DOI 10.1074/jbc.272.8.4828; Uozumi M, 2000, CANCER LETT, V149, P135, DOI 10.1016/S0304-3835(99)00352-3; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; Vincenti MP, 2002, ARTHRITIS RES, V4, P157, DOI 10.1186/ar401; Wang H, 2000, BIOCHEM BIOPH RES CO, V272, P900, DOI 10.1006/bbrc.2000.2852; Wilasrusmee C, 2002, J SURG RES, V104, P131, DOI 10.1006/jsre.2002.6429; Yeow KM, 2002, MATRIX BIOL, V21, P75, DOI 10.1016/S0945-053X(01)00180-9; Yonemura Y, 2000, CLIN CANCER RES, V6, P4234; Yu WH, 2001, ANAL BIOCHEM, V293, P38, DOI 10.1006/abio.2001.5099; Zaragoza C, 2002, KIDNEY INT, V61, P804, DOI 10.1046/j.1523-1755.2002.00224.x; Zaragoza C, 2002, MOL PHARMACOL, V62, P927, DOI 10.1124/mol.62.4.927	66	170	180	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5487	5495		10.1038/sj.onc.1207720	http://dx.doi.org/10.1038/sj.onc.1207720			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15122322				2022-12-17	WOS:000222588400008
J	Little, JB				Little, JB			Genomic instability and bystander effects: a historical perspective	ONCOGENE			English	Review						genomic instability; bystander effect; ionizing radiation; clastogenic factors; oxidative stress; gap junction intercellular communication	INDUCED CHROMOSOMAL INSTABILITY; DELAYED REPRODUCTIVE DEATH; SISTER-CHROMATID EXCHANGES; VERY-LOW FLUENCES; X-RAY INDUCTION; IN-VIVO; ALPHA-PARTICLES; INTERCELLULAR COMMUNICATION; HIGH-LET; MICROSATELLITE INSTABILITY	Data have been emerging over the past two decades concerning two phenomena in which important biological effects of ionizing radiation arise in cells that in themselves receive no radiation exposure. In the first, radiation-induced genomic instability, biological effects occur in the progeny of the irradiated cell after many generations of cell division. In the second, radiation-induced bystander effects, they arise in cells that receive no radiation exposure as a consequence of damage signals transmitted from neighboring irradiated cells; transmission may be mediated either by direct intercellular communication through gap junctions, or by factors released into the surrounding medium. In both phenomena, the biological effects appear to be associated with an upregulation of oxidative metabolism. The present paper is designed to review the historical background leading to our current knowledge of these two phenomena, and to indicate some future directions for research that will allow us to assess better their importance in the health effects of exposure to ionizing radiation.	Harvard Univ, Sch Med, Radiobiol Lab, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Little, JB (corresponding author), Harvard Univ, Sch Med, Radiobiol Lab, 665 Huntington Ave, Boston, MA 02115 USA.	jlittle@hsph.harvard.edu						Azzam EI, 2002, CANCER RES, V62, P5436; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; BACQ EM, 1961, FUNDAMENTALS RADIOBI; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Baverstock K, 2000, MUTAT RES-FUND MOL M, V454, P89, DOI 10.1016/S0027-5107(00)00100-7; Belyakov OV, 1999, INT J RADIAT BIOL, V75, P985, DOI 10.1080/095530099139746; Belyakov OV, 2001, BRIT J CANCER, V84, P674, DOI 10.1054/bjoc.2000.1665; Bishayee A, 1999, RADIAT RES, V152, P88, DOI 10.2307/3580054; Bouffler SD, 2001, RADIAT RES, V155, P345, DOI 10.1667/0033-7587(2001)155[0345:LODTCI]2.0.CO;2; Bouffler SD, 2001, INT J RADIAT BIOL, V77, P995, DOI 10.1080/09553000110069326; Boulton E, 2001, INT J RADIAT BIOL, V77, P21, DOI 10.1080/0955300010001880; BOYCE RP, 1964, P NATL ACAD SCI USA, V51, P293, DOI 10.1073/pnas.51.2.293; CHANG WP, 1991, INT J RADIAT BIOL, V60, P483, DOI 10.1080/09553009114552331; CHANG WSP, 1992, MUTAT RES, V270, P191, DOI 10.1016/0027-5107(92)90130-T; CHENG KC, 1993, ADV CANCER RES, V60, P121; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; DEMEREC M, 1946, COLD SPRING HARB SYM, V11, P38; Deshpande A., 1996, RADIAT RES, V152, P552; di Fagagna FD, 2001, CURR BIOL, V11, P1192, DOI 10.1016/S0960-9822(01)00328-1; Dugan LC, 2003, RADIAT RES, V159, P301, DOI 10.1667/0033-7587(2003)159[0301:ACIIBE]2.0.CO;2; DUTRILLAUX B, 1997, RADIOPROTECTION, V32, pC431; Emerit I, 1997, MUTAT RES-FUND MOL M, V373, P47, DOI 10.1016/S0027-5107(96)00187-X; Emerit I, 1998, NATO ADV SCI I A-LIF, V296, P375; Evans HH, 2001, RADIAT RES, V156, P259, DOI 10.1667/0033-7587(2001)156[0259:DDEIHL]2.0.CO;2; Fabre F., 1983, CELLULAR RESPONSE DN, P379; FAGUET GB, 1984, CANCER GENET CYTOGEN, V12, P73, DOI 10.1016/0165-4608(84)90010-4; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; Fouladi B, 2000, NEOPLASIA, V2, P540, DOI 10.1038/sj.neo.7900107; FRANK JP, 1982, SCIENCE, V216, P307, DOI 10.1126/science.7063888; FREEMAN SM, 1993, CANCER RES, V53, P5274; Gilley D, 2001, P NATL ACAD SCI USA, V98, P15084, DOI 10.1073/pnas.261574698; GOH KO, 1968, RADIAT RES, V35, P171, DOI 10.2307/3572443; GORGOJO L, 1989, INT J RADIAT BIOL, V55, P619, DOI 10.1080/09553008914550661; Grosovsky AJ, 1996, MOL CELL BIOL, V16, P6252; HANAWALT PC, 1977, DNA REPAIR PROCESS, P1; HOLLOWELL JG, 1968, P SOC EXP BIOL MED, V129, P240; HOLMBERG K, 1993, MUTAT RES, V286, P321, DOI 10.1016/0027-5107(93)90197-N; Howell RW, 2002, MICRON, V33, P127, DOI 10.1016/S0968-4328(01)00007-5; Huo LH, 2001, RADIAT RES, V156, P521, DOI 10.1667/0033-7587(2001)156[0521:HMIIBC]2.0.CO;2; Iyer R, 2000, CANCER RES, V60, P1290; Iyer R, 2002, RADIAT RES, V157, P3, DOI 10.1667/0033-7587(2002)157[0003:APIIIT]2.0.CO;2; Jamali M, 1996, INT J RADIAT BIOL, V70, P705, DOI 10.1080/095530096144590; JOHNSON PR, 1976, BRIT J CANCER, V33, P370, DOI 10.1038/bjc.1976.61; Kadhim MA, 2001, RADIAT RES, V155, P122, DOI 10.1667/0033-7587(2001)155[0122:LTGIIH]2.0.CO;2; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; KADHIM MA, 1995, INT J RADIAT BIOL, V67, P287, DOI 10.1080/09553009514550341; Kato Kyozo, 1994, Neurologia Medico-Chirurgica, V34, P339, DOI 10.2176/nmc.34.339; KENNEDY AR, 1984, NATURE, V307, P85, DOI 10.1038/307085a0; KENNEDY AR, 1980, CARCINOGENESIS, V1, P1039, DOI 10.1093/carcin/1.12.1039; KENNEDY AR, 1980, P NATL ACAD SCI-BIOL, V77, P7262, DOI 10.1073/pnas.77.12.7262; KETTMAN J, 1974, EUR J IMMUNOL, V4, P641, DOI 10.1002/eji.1830041002; Lehnert BE, 1997, CANCER RES, V57, P2164; LI CY, 1992, MOL CARCINOGEN, V5, P270, DOI 10.1002/mc.2940050407; LIBER HL, 1983, MUTAT RES, V111, P387, DOI 10.1016/0027-5107(83)90035-0; Limoli CL, 1998, CANCER RES, V58, P3712; Limoli CL, 2000, ADV SPACE RES, V25, P2107, DOI 10.1016/S0273-1177(99)01062-5; Limoli CL, 2001, FREE RADICAL BIO MED, V31, P10, DOI 10.1016/S0891-5849(01)00542-1; Little JB, 2003, RADIAT RES, V159, P262, DOI 10.1667/0033-7587(2003)159[0262:IOTNEJ]2.0.CO;2; LITTLE JB, 1971, INT J RADIAT BIOL RE, V20, P87, DOI 10.1080/09553007114550921; Little JB, 1998, INT J RADIAT BIOL, V74, P663, DOI 10.1080/095530098140925; Little JB, 1997, RADIAT RES, V148, P299, DOI 10.2307/3579514; LITTLE JB, 1990, INT J RADIAT ONCOL, V19, P1425, DOI 10.1016/0360-3016(90)90354-M; Loeb LA, 2001, CANCER RES, V61, P3230; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Lyng FM, 2002, RADIAT RES, V157, P365, DOI 10.1667/0033-7587(2002)157[0365:IOAICE]2.0.CO;2; Lyng FM, 2001, BIOCHEM SOC T, V29, P350; MacDonald D, 2001, INT J RADIAT BIOL, V77, P1023, DOI 10.1080/09553000110073411; MARDER BA, 1993, MOL CELL BIOL, V13, P6667, DOI 10.1128/MCB.13.11.6667; MARTIN RF, 1981, SCIENCE, V213, P896, DOI 10.1126/science.7256283; Matsumoto H, 2001, RADIAT RES, V155, P387, DOI 10.1667/0033-7587(2001)155[0387:IORBAN]2.0.CO;2; MENDONCA MS, 1989, RADIAT RES, V119, P387, DOI 10.2307/3577629; Mesnil M, 2000, CANCER RES, V60, P3989; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Morgan WF, 1996, RADIAT RES, V146, P247, DOI 10.2307/3579454; Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Mothersill C, 2001, RADIAT RES, V155, P759, DOI 10.1667/0033-7587(2001)155[0759:RIBEPH]2.0.CO;2; Nagar S, 2003, CANCER RES, V63, P324; Nagasawa H, 1999, RADIAT RES, V152, P552, DOI 10.2307/3580153; Nagasawa H, 2003, INT J RADIAT BIOL, V79, P35, DOI 10.1080/0955300021000019230; Nagasawa H, 2002, CANCER RES, V62, P2531; NAGASAWA H, 1992, CANCER RES, V52, P6394; Nakanishi M, 2001, INT J RADIAT BIOL, V77, P687, DOI 10.1080/095530000110047537; Narayanan PK, 1997, CANCER RES, V57, P3963; NIAS AHW, 1965, INT J RADIAT BIOL RE, V9, P275, DOI 10.1080/09553006514550331; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Okayasu R, 2000, CANCER RES, V60, P4342; PAMPFER S, 1989, INT J RADIAT BIOL, V55, P85, DOI 10.1080/09553008914550091; PAQUETTE B, 1994, CANCER RES, V54, P3173; Ponnaiya B, 1997, RADIAT RES, V147, P121, DOI 10.2307/3579411; Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087; RAJEWSKY K, 1972, EUR J IMMUNOL, V2, P592, DOI 10.1002/eji.1830020622; Redpath JL, 2001, INT J RADIAT BIOL, V77, P1081, DOI 10.1080/09553000110065807; Romney CA, 2001, MOL CARCINOGEN, V32, P118, DOI 10.1002/mc.1071; Romney CA, 2001, MUTAT RES-FUND MOL M, V478, P97, DOI 10.1016/S0027-5107(01)00126-9; SABATIER L, 1992, NATURE, V357, P548, DOI 10.1038/357548a0; Sankaranarayanan K, 2001, RADIAT RES, V156, P648, DOI 10.1667/0033-7587(2001)156[0648:IOCPAR]2.0.CO;2; Sawant SG, 2002, RADIAT RES, V157, P361, DOI 10.1667/0033-7587(2002)157[0361:TRIBEF]2.0.CO;2; Sawant SG, 2001, RADIAT RES, V155, P397, DOI 10.1667/0033-7587(2001)155[0397:TBEIRO]2.0.CO;2; SCOTT D, 1969, CELL TISSUE KINET, V2, P295, DOI 10.1111/j.1365-2184.1969.tb00239.x; SELVANAYAGAM CS, 1995, CANCER RES, V55, P3310; SETLOW RB, 1964, P NATL ACAD SCI USA, V51, P226, DOI 10.1073/pnas.51.2.226; SEYMOUR CB, 1986, INT J RADIAT BIOL, V50, P167, DOI 10.1080/09553008614550541; Shao C, 2002, INT J RADIAT BIOL, V78, P837, DOI 10.1080/09553000210149786; SINCLAIR WK, 1964, RADIAT RES, V21, P584, DOI 10.2307/3571653; SMYTHE WR, 1994, CANCER RES, V54, P2055; STAMATO T, 1987, SOMAT CELL MOLEC GEN, V13, P57, DOI 10.1007/BF02422299; Suzuki K, 2003, CANCER RES, V63, P936; Syljuasen RG, 2001, RADIAT RES, V155, P215, DOI 10.1667/0033-7587(2001)155[0215:MEIRT]2.0.CO;2; TERZAGHI M, 1976, CANCER RES, V36, P1367; Touraine RL, 1998, GENE THER, V5, P1705, DOI 10.1038/sj.gt.3300784; Trosko James E., 1998, Frontiers in Bioscience, V3, pD208; Trosko JE, 2001, MUTAT RES-FUND MOL M, V480, P219, DOI 10.1016/S0027-5107(01)00181-6; Ullrich RL, 1999, RADIAT RES, V152, P170, DOI 10.2307/3580090; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Watson GE, 1997, INT J RADIAT BIOL, V71, P497, DOI 10.1080/095530097143824; Watson GE, 2000, CANCER RES, V60, P5608; Watson GE, 1996, INT J RADIAT BIOL, V69, P175, DOI 10.1080/095530096146002; Watson GE, 2001, INT J RADIAT BIOL, V77, P409, DOI 10.1080/09553000010028476; Whitehouse CA, 2001, RADIAT RES, V156, P467, DOI 10.1667/0033-7587(2001)156[0467:NEFCII]2.0.CO;2; WU JK, 1994, NEUROSURGERY, V35, P1094, DOI 10.1227/00006123-199412000-00012; Wu LJ, 1999, P NATL ACAD SCI USA, V96, P4959, DOI 10.1073/pnas.96.9.4959; Wygoda MR, 1997, CANCER RES, V57, P1699; Xue LY, 2002, P NATL ACAD SCI USA, V99, P13765, DOI 10.1073/pnas.182209699; YAMASAKI H, 1990, PROG CLIN BIOL RES, V340, P153; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797; Zhou HN, 2002, MUTAT RES-FUND MOL M, V499, P135, DOI 10.1016/S0027-5107(01)00285-8; Zhou HN, 2001, P NATL ACAD SCI USA, V98, P14410, DOI 10.1073/pnas.251524798; ZIRKLE RE, 1953, SCIENCE, V117, P487, DOI 10.1126/science.117.3045.487	131	170	190	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2003	22	45					6978	6987		10.1038/sj.onc.1206988	http://dx.doi.org/10.1038/sj.onc.1206988			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557801				2022-12-17	WOS:000185903900001
J	Morgan, WF				Morgan, WF			Is there a common mechanism underlying genomic instability, bystander effects and other nontargeted effects of exposure to ionizing radiation?	ONCOGENE			English	Article						genomic instability; bystander effects; death inducing effect; transgenerational effects	INDUCED CHROMOSOMAL INSTABILITY; INFLAMMATORY-TYPE RESPONSES; ALPHA-PARTICLE IRRADIATION; IN-VIVO; UNIRRADIATED CELLS; DOSE-RESPONSE; OXIDATIVE STRESS; APOPTOSIS; INDUCTION; TRANSMISSION	A number of nontargeted and delayed effects associated with radiation exposure have now been described. These include radiation-induced genomic instability, death-inducing and bystander effects, clastogenic factors and transgenerational effects. It is unlikely that these nontargeted effects are directly induced by cellular irradiation. Instead, it is proposed that some as yet to be identified secreted factor can be produced by irradiated cells that can stimulate effects in nonirradiated cells (death-inducing and bystander effects, clastogenic factors) and perpetuate genomic instability in the clonally expanded progeny of an irradiated cell. The proposed factor must be soluble and capable of being transported between cells by cell-to-cell gap junction communication channels. Furthermore, it must have the potential to stimulate cellular cytokines and/or reactive oxygen species. While it is difficult to imagine a role for such a secreted factor in contributing to transgenerational effects, the other nontargeted effects of radiation may all share a common mechanism.	Univ Maryland, Radiat Oncol Res Lab, Baltimore, MD 21201 USA; Univ Maryland, Greenebaum Canc Ctr, Dept Radiat Oncol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Morgan, WF (corresponding author), Univ Maryland, Radiat Oncol Res Lab, 655 W Baltimore St,BRB 7-011, Baltimore, MD 21201 USA.				NATIONAL CANCER INSTITUTE [R01CA073924, R01CA083872] Funding Source: NIH RePORTER; NCI NIH HHS [CA73924, CA 83872] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; Dubrova YE, 2000, MUTAT RES-FUND MOL M, V453, P17, DOI 10.1016/S0027-5107(00)00068-3; Dubrova YE, 1998, INT J RADIAT BIOL, V74, P689, DOI 10.1080/095530098140952; Dubrova YE, 1998, P NATL ACAD SCI USA, V95, P6251, DOI 10.1073/pnas.95.11.6251; Dubrova YE, 2000, NATURE, V405, P37, DOI 10.1038/35011135; Folkard M, 1997, INT J RADIAT BIOL, V72, P375, DOI 10.1080/095530097143158; HUANG L, 2003, IN PRESS ONCOGENE RE; Iyer R, 2000, CANCER RES, V60, P1290; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; Limoli CL, 1998, CANCER RES, V58, P3712; Limoli CL, 1997, CANCER RES, V57, P5557; Limoli CL, 1999, RADIAT RES, V151, P677, DOI 10.2307/3580206; Limoli CL, 2001, FREE RADICAL BIO MED, V31, P10, DOI 10.1016/S0891-5849(01)00542-1; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; Little JB, 2002, RADIAT PROT DOSIM, V99, P159, DOI 10.1093/oxfordjournals.rpd.a006751; Lorimore SA, 1998, P NATL ACAD SCI USA, V95, P5730, DOI 10.1073/pnas.95.10.5730; Lorimore SA, 2003, INT J RADIAT BIOL, V79, P15, DOI 10.1080/0955300021000045664; Lorimore SA, 2001, ONCOGENE, V20, P7085, DOI 10.1038/sj.onc.1204903; Lyng FM, 2000, BRIT J CANCER, V83, P1223, DOI 10.1054/bjoc.2000.1433; Lyng FM, 2002, RADIAT RES, V157, P365, DOI 10.1667/0033-7587(2002)157[0365:IOAICE]2.0.CO;2; MARDER BA, 1993, MOL CELL BIOL, V13, P6667, DOI 10.1128/MCB.13.11.6667; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Morgan WF, 2002, MUTAT RES-FUND MOL M, V504, P91, DOI 10.1016/S0027-5107(02)00083-0; Morgan WF, 1996, RADIAT RES, V146, P247, DOI 10.2307/3579454; Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030; Nagar S, 2003, CANCER RES, V63, P324; Ponnaiya B, 1997, RADIAT RES, V147, P121, DOI 10.2307/3579411; Randers-Pehrson G, 2001, RADIAT RES, V156, P210, DOI 10.1667/0033-7587(2001)156[0210:TCUSIM]2.0.CO;2; Rugo RE, 2002, RADIAT RES, V158, P210, DOI 10.1667/0033-7587(2002)158[0210:XRCAPI]2.0.CO;2; Seymour CB, 2000, RADIAT RES, V153, P508, DOI 10.1667/0033-7587(2000)153[0508:RCOBAT]2.0.CO;2; Smith LE, 2003, HEALTH PHYS, V85, P23, DOI 10.1097/00004032-200307000-00006; Watson GE, 1997, INT J RADIAT BIOL, V71, P497, DOI 10.1080/095530097143824; Watson GE, 2000, CANCER RES, V60, P5608; Wright EG, 1998, INT J RADIAT BIOL, V74, P681, DOI 10.1080/095530098140943; Xue LY, 2002, P NATL ACAD SCI USA, V99, P13765, DOI 10.1073/pnas.182209699	37	170	183	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 13	2003	22	45					7094	7099		10.1038/sj.onc.1206992	http://dx.doi.org/10.1038/sj.onc.1206992			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557815				2022-12-17	WOS:000185903900015
J	Jhappan, C; Noonan, FP; Merlino, G				Jhappan, C; Noonan, FP; Merlino, G			Ultraviolet radiation and cutaneous malignant melanoma	ONCOGENE			English	Review						cell cycle arrest; DNA damage response; DNA repair; melanoma; transgenic mice; UV radiation	NORMAL HUMAN MELANOCYTES; COMPARATIVE GENOMIC HYBRIDIZATION; MELANOCORTIN-1 RECEPTOR VARIANTS; CYCLOBUTANE PYRIMIDINE DIMERS; INDUCED SIGNAL-TRANSDUCTION; HUMAN-SKIN FIBROBLASTS; FACTOR SCATTER FACTOR; CELL-CYCLE ARREST; STIMULATING HORMONE; DNA-REPAIR	Recent years have seen a steady rise in the incidence of cutaneous malignant melanoma worldwide. Although it is now appreciated that the key to understanding the process by which melanocytes are transformed into malignant melanoma lies in the interplay between genetic factors and the ultraviolet (UV) spectrum of sunlight, the nature of this relation has remained obscure. Recently, prospects for elucidating the molecular mechanisms underlying such gene-environment interactions have brightened considerably through the development of UV-responsive experimental animal models of melanoma. Genetically engineered mice and human skin xenografts constitute novel platforms upon which to build studies designed to elucidate the pathogenesis of UV-induced melanomagenesis. The future refinement of these in vivo models should provide a wealth of information on the cellular and genetic targets of UV, the pathways responsible for the repair of UV-induced DNA damage, and the molecular interactions between melanocytes and other skin cells in response to UV. It is anticipated that exploitation of these model systems will contribute significantly toward the development of effective approaches to the prevention and treatment of melanoma.	NCI, Mol Biol Lab, Mol Genet Sect, Bethesda, MD 20892 USA; George Washington Univ, Sch Med, Sch Publ Hlth & Hlth Serv, Dept Environm & Occupat Hlth,Lab Photobil & Photo, Washington, DC 20037 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); George Washington University	Merlino, G (corresponding author), NCI, Mol Biol Lab, Mol Genet Sect, Bethesda, MD 20892 USA.	gmerlino@helix.nih.gov		Noonan, Frances/0000-0002-3302-7280				Abdel-Malek Z, 1999, ANN NY ACAD SCI, V885, P117; ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; ADIMOOLAM S, 2002, P NATL ACAD SCI USA, V19, P19; ALBINO AP, 1992, PIGM CELL RES, P199; AMSTAD P, 1994, MOL CARCINOGEN, V10, P181, DOI 10.1002/mc.2940100402; Amundson SA, 2000, RADIAT RES, V154, P342, DOI 10.1667/0033-7587(2000)154[0342:IOPMBI]2.0.CO;2; Amundson SA, 2002, CANCER BIOL THER, V1, P145, DOI 10.4161/cbt.59; ANDERS F, 1984, ADV CANCER RES, V42, P191, DOI 10.1016/S0065-230X(08)60459-5; Ao Y, 1998, EXP CELL RES, V244, P117, DOI 10.1006/excr.1998.4086; APPLEGATE LA, 1987, PHOTOCHEM PHOTOBIOL, V45, P241, DOI 10.1111/j.1751-1097.1987.tb05371.x; ARCHAMBAULT M, 1995, J INVEST DERMATOL, V104, P859, DOI 10.1111/1523-1747.ep12607034; Armstrong B K, 1997, Australas J Dermatol, V38 Suppl 1, pS1; ARMSTRONG BK, 1988, J DERMATOL SURG ONC, V14, P835, DOI 10.1111/j.1524-4725.1988.tb03588.x; ARMSTRONG BK, 1995, DERMATOL CLIN, V13, P583, DOI 10.1016/S0733-8635(18)30064-0; ARMSTRONG BK, 1994, CANCER SURV, V20, P219; Atillasoy ES, 1998, AM J PATHOL, V152, P1179; Autier P, 1998, INT J CANCER, V77, P533, DOI 10.1002/(SICI)1097-0215(19980812)77:4<533::AID-IJC10>3.0.CO;2-7; Bardeesy N, 2000, ADV CANCER RES, V79, P123, DOI 10.1016/S0065-230X(00)79004-X; BARNHILL RL, 1993, SEMIN DIAGN PATHOL, V10, P47; Bastian BC, 1998, CANCER RES, V58, P2170; BENNETT JP, 1994, ANN ROY COLL SURG, V76, P373; Berking C, 2002, CARCINOGENESIS, V23, P181, DOI 10.1093/carcin/23.1.181; Berking C, 2001, HISTOL HISTOPATHOL, V16, P669, DOI 10.14670/HH-16.669; Bishop DT, 2002, J NATL CANCER I, V94, P894, DOI 10.1093/jnci/94.12.894; Black HS, 1997, J PHOTOCH PHOTOBIO B, V40, P29, DOI 10.1016/S1011-1344(97)00021-3; BOLOGNIA J, 1989, J INVEST DERMATOL, V92, P651, DOI 10.1111/1523-1747.ep12696836; Box NF, 1997, HUM MOL GENET, V6, P1891, DOI 10.1093/hmg/6.11.1891; BRULS WAG, 1984, PHOTOCHEM PHOTOBIOL, V39, P63, DOI 10.1111/j.1751-1097.1984.tb03405.x; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; Cadet J, 1997, BIOL CHEM, V378, P1275; CAMPBELL C, 1993, BRIT J DERMATOL, V129, P235, DOI 10.1111/j.1365-2133.1993.tb11840.x; Carrier F, 1999, MOL CELL BIOL, V19, P1673; CHAKRABORTY A, 1995, J INVEST DERMATOL, V105, P655, DOI 10.1111/1523-1747.ep12324134; Chakraborty AK, 1999, ANN NY ACAD SCI, V885, P100; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; Chin L, 1998, GENE DEV, V12, P3467, DOI 10.1101/gad.12.22.3467; Cleaver JE, 2002, FRONT BIOSCI-LANDMRK, V7, pD1024, DOI 10.2741/cleaver; Comoglio PM, 2001, SEMIN CANCER BIOL, V11, P153, DOI 10.1006/scbi.2000.0366; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; de Gruijl FR, 1999, EUR J CANCER, V35, P2003, DOI 10.1016/S0959-8049(99)00283-X; Decraene D, 2001, J PHOTOCH PHOTOBIO B, V63, P78, DOI 10.1016/S1011-1344(01)00204-4; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ELDER DE, 1987, PATHOBIOLOGY MALIGNA; Elwood JM, 1997, INT J CANCER, V73, P198, DOI 10.1002/(SICI)1097-0215(19971009)73:2<198::AID-IJC6>3.0.CO;2-R; EPSTEIN JH, 1967, J NATL CANCER I, V38, P19; EVANS RD, 1988, J DERMATOL SURG ONC, V14, P393, DOI 10.1111/j.1524-4725.1988.tb03373.x; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Funasaka Y, 1998, BRIT J DERMATOL, V139, P216; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; GARBE C, 1994, J INVEST DERMATOL, V102, P695, DOI 10.1111/1523-1747.ep12374280; Gause PR, 1997, MOL CARCINOGEN, V20, P78, DOI 10.1002/(SICI)1098-2744(199709)20:1<78::AID-MC9>3.0.CO;2-E; Gilchrest BA, 1999, J INVEST DERM SYMP P, V4, P35, DOI 10.1038/sj.jidsp.5640178; Gilchrest BA, 1999, NEW ENGL J MED, V340, P1341, DOI 10.1056/NEJM199904293401707; Goldstein AM, 2001, ARCH DERMATOL, V137, P1493; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; Halaban R, 1996, SEMIN ONCOL, V23, P673; Haluska FG, 1998, J CLIN ONCOL, V16, P670, DOI 10.1200/JCO.1998.16.2.670; Healy E, 2000, LANCET, V355, P1072, DOI 10.1016/S0140-6736(00)02042-0; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; Hearing VJ, 1999, J INVEST DERM SYMP P, V4, P24, DOI 10.1038/sj.jidsp.5640176; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Hersey P, 2001, NAT REV CANCER, V1, P142, DOI 10.1038/35101078; HERZINGER T, 1995, ONCOGENE, V11, P2151; HIROBE T, 1984, ANAT REC, V208, P589, DOI 10.1002/ar.1092080414; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; Hollander MC, 2001, CANCER RES, V61, P2487; HOLMAN CDJ, 1983, JNCI-J NATL CANCER I, V71, P651; Howe HL, 2001, J NATL CANCER I, V93, P824, DOI 10.1093/jnci/93.11.824; HUNT G, 1995, J INVEST DERMATOL, V104, P83, DOI 10.1111/1523-1747.ep12613565; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Insinga R P, 2001, WMJ, V100, P27; IRWIN C, 1993, PHOTOCHEM PHOTOBIOL, V57, P504, DOI 10.1111/j.1751-1097.1993.tb02326.x; ISLAS AL, 1995, CANCER RES, V55, P336; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jemal A, 2001, JNCI-J NATL CANCER I, V93, P678, DOI 10.1093/jnci/93.9.678; Jiang WD, 2001, P NATL ACAD SCI USA, V98, P9790, DOI 10.1073/pnas.171066498; Jiang WD, 1999, ONCOGENE, V18, P4247, DOI 10.1038/sj.onc.1202789; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Jung E G, 1986, Curr Probl Dermatol, V15, P117; KAIDBEY KH, 1979, J INVEST DERMATOL, V72, P253, DOI 10.1111/1523-1747.ep12531710; KAMADA S, 1995, CANCER RES, V55, P354; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kaskel P, 2001, BRIT J DERMATOL, V145, P602, DOI 10.1046/j.1365-2133.2001.04432.x; Kato M, 1998, ONCOGENE, V17, P1885, DOI 10.1038/sj.onc.1202077; Kato M, 2000, J INVEST DERMATOL, V115, P1157, DOI 10.1046/j.1523-1747.2000.0202a-2.x; Kawada Akira, 1994, Journal of Dermatology (Tokyo), V21, P571; Kazianis S, 1998, GENE CHROMOSOME CANC, V22, P210, DOI 10.1002/(SICI)1098-2264(199807)22:3<210::AID-GCC6>3.3.CO;2-E; Kelsall SR, 1998, CANCER RES, V58, P4061; Kennedy C, 2001, J INVEST DERMATOL, V117, P294, DOI 10.1046/j.0022-202x.2001.01421.x; Khlgatian MK, 2002, J INVEST DERMATOL, V118, P126, DOI 10.1046/j.0022-202x.2001.01667.x; KLEINPARKER HA, 1994, J CUTAN PATHOL, V21, P297, DOI 10.1111/j.1600-0560.1994.tb00703.x; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KRAEMER KH, 1994, JPN J CANC RES, V85; Kulms D, 2002, J DERMATOL, V29, P189, DOI 10.1111/j.1346-8138.2002.tb00248.x; Kusewitt DF, 1996, CANCER SURV, V26, P35; Landi MT, 2002, JNCI-J NATL CANCER I, V94, P94, DOI 10.1093/jnci/94.2.94; Langley RGB, 1997, CANCER INVEST, V15, P561, DOI 10.3109/07357909709047598; LARUE L, 1992, P NATL ACAD SCI USA, V89, P9534, DOI 10.1073/pnas.89.20.9534; LERNER AB, 1986, J INVEST DERMATOL, V87, P299, DOI 10.1111/1523-1747.ep12524353; LEY RD, 1987, PHOTODERMATOLOGY, V4, P173; Ley RD, 2002, FRONT BIOSCI, V7, pD1531, DOI 10.2741/ley; LEY RD, 1988, MUTAT RES, V194, P49, DOI 10.1016/0167-8817(88)90055-7; Ley RD, 2001, PHOTOCHEM PHOTOBIOL, V73, P20, DOI 10.1562/0031-8655(2001)073<0020:DRFURA>2.0.CO;2; Li G, 1998, BRIT J DERMATOL, V139, P3; LIBOW LF, 1988, PIGM CELL RES, V1, P397, DOI 10.1111/j.1600-0749.1988.tb00142.x; Linge C, 1996, CANCER SURV, V26, P71; LIU SCC, 1982, J INVEST DERMATOL, V79, P330, DOI 10.1111/1523-1747.ep12500087; MacKie RM, 1998, EUR J CANCER, V34, pS3; MALITSCHEK B, 1995, BIOESSAYS, V17, P1017, DOI 10.1002/bies.950171205; Marks R, 2000, CLIN EXP DERMATOL, V25, P459, DOI 10.1046/j.1365-2230.2000.00693.x; Matsumura Y, 2002, FRONT BIOSCI-LANDMRK, V7, pD765, DOI 10.2741/matsumur; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; McGOVERN V J, 1952, Med J Aust, V1, P139; MCLANE JA, 1988, BIOCHEMISTRY-US, V27, P3743, DOI 10.1021/bi00410a033; MEDRANO EE, 1995, CANCER RES, V55, P4047; Mildner M, 1999, J INVEST DERMATOL, V113, P1136, DOI 10.1046/j.1523-1747.1999.00815.x; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Nairn RS, 1996, P NATL ACAD SCI USA, V93, P13042, DOI 10.1073/pnas.93.23.13042; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; NATARAJ AJ, 1995, PHOTOCHEM PHOTOBIOL, V62, P218, DOI 10.1111/j.1751-1097.1995.tb05262.x; Noonan FP, 2000, CANCER RES, V60, P3738; Noonan FP, 2001, NATURE, V413, P271, DOI 10.1038/35095108; Norris W, 1857, 8 CASES MELANOSIS PA; Nylander K, 2000, J PATHOL, V190, P39, DOI 10.1002/(SICI)1096-9896(200001)190:1<39::AID-PATH492>3.0.CO;2-V; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ortonne JP, 2002, BRIT J DERMATOL, V146, P7, DOI 10.1046/j.1365-2133.146.s61.3.x; Otsuka T, 1998, CANCER RES, V58, P5157; Palmer JS, 2000, AM J HUM GENET, V66, P176, DOI 10.1086/302711; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Pavey S, 2002, CANCER RES, V62, P875; Pavey S, 2001, ONCOGENE, V20, P6103, DOI 10.1038/sj.onc.1204707; PLETTENBERG A, 1995, AM J PATHOL, V146, P651; Powell MB, 1999, CARCINOGENESIS, V20, P1747, DOI 10.1093/carcin/20.9.1747; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Recio JA, 2002, CANCER RES, V62, P6724; Reedy MV, 1998, DEV DYNAM, V213, P476, DOI 10.1002/(SICI)1097-0177(199812)213:4<476::AID-AJA12>3.0.CO;2-R; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; Rigel DS, 2000, CA-CANCER J CLIN, V50, P215, DOI 10.3322/canjclin.50.4.215; Romerdahl C A, 1989, Cancer Commun, V1, P209; ROSENSTEIN BS, 1987, PHOTOCHEM PHOTOBIOL, V45, P775, DOI 10.1111/j.1751-1097.1987.tb07881.x; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; RUNGER TM, 1995, J INVEST DERMATOL, V104, P68, DOI 10.1111/1523-1747.ep12613504; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Schaffer JV, 2001, ARCH DERMATOL, V137, P1477; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; SCHARTL A, 1995, CANCER RES, V55, P159; SCOTT G, 1991, J INVEST DERMATOL, V96, P318, DOI 10.1111/1523-1747.ep12465203; Scott MC, 2002, J CELL SCI, V115, P2349; SETLOW RB, 1994, MUTAT RES, V307, P365, DOI 10.1016/0027-5107(94)90310-7; SETLOW RB, 1989, P NATL ACAD SCI USA, V86, P8922, DOI 10.1073/pnas.86.22.8922; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shih Ie-Ming, 1994, In Vivo (Attiki), V8, P113; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Smith ML, 2002, MUTAGENESIS, V17, P149, DOI 10.1093/mutage/17.2.149; Smith R, 1998, J INVEST DERMATOL, V111, P119, DOI 10.1046/j.1523-1747.1998.00252.x; Suzuki I, 1999, J INVEST DERM SYMP P, V4, P29, DOI 10.1038/sj.jidsp.5640177; Tada A, 1998, CELL GROWTH DIFFER, V9, P575; Takahashi S, 2001, CANCER RES, V61, P1187; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Takimoto R, 2002, CANCER BIOL THER, V1, P177, DOI 10.4161/cbt.65; Taylor SC, 2002, J AM ACAD DERMATOL, V46, pS41, DOI 10.1067/mjd.2002.120790; Thody AJ, 1998, PIGM CELL RES, V11, P265, DOI 10.1111/j.1600-0749.1998.tb00735.x; Thody AJ, 1999, ANN NY ACAD SCI, V885, P217, DOI 10.1111/j.1749-6632.1999.tb08679.x; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tornaletti S, 1996, BIOESSAYS, V18, P221, DOI 10.1002/bies.950180309; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; TUCKER MA, 1983, J PEDIATR-US, V103, P65, DOI 10.1016/S0022-3476(83)80777-X; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Valverde P, 1996, HUM MOL GENET, V5, P1663, DOI 10.1093/hmg/5.10.1663; Van Dyke T, 2002, CELL, V108, P135, DOI 10.1016/S0092-8674(02)00621-9; VANDENOORD JJ, 1994, AM J PATHOL, V145, P294; Wan YS, 2001, INT J ONCOL, V18, P461; Wang SQ, 2001, J AM ACAD DERMATOL, V44, P767, DOI 10.1067/mjd.2001.112384; Wang SQ, 2001, J AM ACAD DERMATOL, V44, P837, DOI 10.1067/mjd.2001.114594; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Whiteman DC, 2001, CANCER CAUSE CONTROL, V12, P69, DOI 10.1023/A:1008980919928; WILTSHIRE RN, 1995, CANCER RES, V55, P3954; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; WONG G, 1974, NATURE, V248, P351, DOI 10.1038/248351a0; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Yaar M, 2001, CLIN EXP DERMATOL, V26, P583, DOI 10.1046/j.1365-2230.2001.00895.x; Yamamura K, 1996, CANCER RES, V56, P3546; Yang Q, 2000, J BIOL CHEM, V275, P36892, DOI 10.1074/jbc.M005319200; You YH, 2001, J BIOL CHEM, V276, P44688, DOI 10.1074/jbc.M107696200; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	196	170	176	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3099	3112		10.1038/sj.onc.1206450	http://dx.doi.org/10.1038/sj.onc.1206450			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789287				2022-12-17	WOS:000183096600012
J	Krutovskikh, VA; Piccoli, C; Yamasaki, H				Krutovskikh, VA; Piccoli, C; Yamasaki, H			Gap junction intercellular communication propagates cell death in cancerous cells	ONCOGENE			English	Article						gap junctions; apoptosis; Connexin43	CONNEXIN GENES; CALCIUM; GROWTH; TUMORIGENICITY; LOCALIZATION; HEMICHANNELS; SUPPRESSION; INHIBITION; EXPRESSION; TUMORS	Gap junction intercellular communication (GJIC) or cell coupling has an important function in maintaining tissue homeostasis and is thus a critical factor in the life and death balance of cells. While the role of GJIC in cell growth regulation has been much studied, its involvement in apoptosis remains unclear. In this study we elucidated the possibility that cell death is propagated via gap junctions, employing the rat bladder carcinoma cell line BC31. BC31 cells proliferate quickly, are tumorigenic, and are well-coupled via gap junctions that contain the gap junction protein Connexin43 (Cx43). In addition, these cells are predisposed to spontaneous death by apoptosis, particularly upon achieving confluency. We found that many dying BC31 cells express Cx43 just as their non-apoptotic counterparts do. Furthermore, Cx43 in apoptotic cells could be functionally competent, supporting coupling of these cells with their non-apoptotic neighbors, and as a result, clusters of coordinately dying cells were observed. The role of Cx43 and GJIC in propagating cell death was shown by analysing clones of BC31 cells expressing a mutant of Cx43 that is a dominant negative inhibitor of GJIC, and by using beta-glycyrrhetinic acid to inhibit intrinsic cell coupling in BC31 cells: in both cases the formation of clusters of dying cells was abrogated, and the intensity of cell death was considerably decreased. These results suggest that GJIC spreads cell-killing signals initially generated by a single cell that spontaneously initiates apoptosis, into healthy surrounding cells, thus increasing the level of cell death. Treatment of BC31 cells with the sleep-inducing lipid Oleamide, which selectively restricts gap junction permeability to Ca2+ ions, did not abrogate coordinated cell death by clusters, indicating that Ca2+ ions are the most probable cell-killing signals spread through gap junctions.	Int Agcy Res Canc, Unit Gene Environm Interact, F-69372 Lyon, France; Kwansei Gakuin Univ, Nishinomiya, Hyogo 6628501, Japan	World Health Organization; International Agency for Research on Cancer (IARC); Kwansei Gakuin University	Krutovskikh, VA (corresponding author), Int Agcy Res Canc, Unit Gene Environm Interact, 150 Cours Albert Thomas, F-69372 Lyon, France.	krutovskikh@iarc.fr						ASAMOTO M, 1994, CARCINOGENESIS, V15, P2163, DOI 10.1093/carcin/15.10.2163; Blanc EM, 1998, J NEUROCHEM, V70, P958; Budd SL, 1998, NAT NEUROSCI, V1, P431, DOI 10.1038/2147; CHIPMAN TK, 1995, HUM EXP TOXICOL, V14, P539; CORTINA ML, 1998, J NEUROSCI, V18, P2520; DAVIDSON JS, 1986, BIOCHEM BIOPH RES CO, V134, P29, DOI 10.1016/0006-291X(86)90522-X; DuflotDancer A, 1997, ONCOGENE, V15, P2151, DOI 10.1038/sj.onc.1201393; Estin D, 1999, NEUROSURGERY, V44, P361, DOI 10.1097/00006123-199902000-00068; FITZGERALD DJ, 1983, CANCER RES, V43, P3614; Guan XJ, 1997, J CELL BIOL, V139, P1785, DOI 10.1083/jcb.139.7.1785; Guan XJ, 1996, MOL CARCINOGEN, V16, P157; John SA, 1999, J BIOL CHEM, V274, P236, DOI 10.1074/jbc.274.1.236; Jorgensen NR, 1997, J CELL BIOL, V139, P497, DOI 10.1083/jcb.139.2.497; Krutovskikh V, 1997, HISTOL HISTOPATHOL, V12, P761; Krutovskikh VA, 1998, MOL CARCINOGEN, V23, P254, DOI 10.1002/(SICI)1098-2744(199812)23:4<254::AID-MC9>3.0.CO;2-4; Krutovskikh VA, 2000, ONCOGENE, V19, P505, DOI 10.1038/sj.onc.1203340; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; LOEWENSTEIN WR, 1992, SEMIN CELL BIOL, V2, P59; MARTIKAINEN P, 1990, PROSTATE, V17, P175, DOI 10.1002/pros.2990170302; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; MCDONNELL TJ, 1993, MOL CARCINOGEN, V8, P209, DOI 10.1002/mc.2940080402; Mehta P, 1999, DEV GENET, V24, P91, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<91::AID-DVG10>3.0.CO;2-#; Mesnil M, 1996, P NATL ACAD SCI USA, V93, P1831, DOI 10.1073/pnas.93.5.1831; Pfahnl A, 1999, PFLUG ARCH EUR J PHY, V437, P345, DOI 10.1007/s004240050788; Rawanduzy A, 1997, J NEUROSURG, V87, P916, DOI 10.3171/jns.1997.87.6.0916; Reznikov K, 2000, FASEB J, V14, P1754, DOI 10.1096/fj.99-0890com; WOLSZON LR, 1994, J NEUROSCI, V14, P3437; YAMASAKI H, 1990, CARCINOGENESIS, V11, P1051, DOI 10.1093/carcin/11.7.1051; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; Zhang ZQ, 1998, CARCINOGENESIS, V19, P1889, DOI 10.1093/carcin/19.11.1889	31	170	183	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					1989	1999		10.1038/sj.onc.1205187	http://dx.doi.org/10.1038/sj.onc.1205187			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960371				2022-12-17	WOS:000174827000005
J	Jiang, XH; Wong, BCY; Lin, MCM; Zhu, GH; Kung, HF; Jiang, SH; Yang, D; Lam, SK				Jiang, XH; Wong, BCY; Lin, MCM; Zhu, GH; Kung, HF; Jiang, SH; Yang, D; Lam, SK			Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappa B activation in gastric cancer cells	ONCOGENE			English	Article						apoptosis; NF-kappa B; AP-1; p53 status; gastric cancer	WILD-TYPE P53; TRIPTERYGIUM-WILFORDII HOOK; NECROSIS-FACTOR-ALPHA; TRANSCRIPTION; INDUCTION; ARREST; PHOSPHORYLATION; CHEMOTHERAPY; EXPRESSION; INHIBITORS	Triptolide, a major component in the extract of Chinese herbal plant Tripterygium wilfordii Hook f (TWHf), has potential anti-neoplastic effect. In the present study we investigated the potential therapeutic effects and mechanisms of triptolide against human gastric cancer cells. Four gastric cancer cell lines with different p53 status, AGS and MKN-45 (wild type p53); MKN-28 and SGC-7901 (mutant p53) were observed as to cell growth inhibition and induction of apoptosis in response to triptolide treatment. We showed that triptolide inhibited cell growth, induced apoptosis and suppressed NK-kappaB and AP-1 transactivation in AGS cells with wild-type p53. Triptolide induced apoptosis by stimulating the expressions of p53, p21(waf1/cip1), bax protein, and increased the activity of caspases. In addition, it caused cell cycle arrest in the G(0)/G(1) phase. To examine the role of p53 in these functions, we showed that suppression of p53 level with antisense oligonucleotide abrogated triptolide-induced apoptosis and over-expression of dominant negative p53 abolished the inhibitory effect on NF-kappa dB activation. Furthermore, we demonstrated that triptolide had differential effects on gastric cancer cells with different p53 status. We showed that triptolide also inhibited cell growth and induced apoptosis in MKN-45 with wild-type p53, whereas it had no significant growth-inhibition and apoptosis induction effects on the MKN-28 and SGC-7901 cells with mutant p53. Our data suggest that triptolide exhibits anti-tumor and anti-inflammatory effects by inhibiting cell proliferation, inducing apoptosis and inhibiting NF-kappaB and AP-1 transcriptional activity. However, a functional p53 is required for these proapoptotic, anti-inflammatory and anti-tumor effects.	Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China; Rui Jin Hosp, Dept Gastroenterol, Shanghai, Peoples R China; Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Chem, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Wong, BCY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China.	bcywong@hku.hk	Wong, Benjamin Chun Yu/ABB-1962-2020; Yang, Dan/D-3151-2009; jiang, cynthia xiaohua/F-7580-2017	jiang, cynthia xiaohua/0000-0002-7372-4961				Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; CALVERT AH, 1999, SEMIN ONCOL, V16, pS90; Chang WT, 2001, J BIOL CHEM, V276, P2221, DOI 10.1074/jbc.M009713200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; GRANT S, 1992, CANCER RES, V52, P6270; JIANG XY, 1994, PEDIATR NEPHROL, V8, P343, DOI 10.1007/BF00866356; Kobayashi T, 1995, ONCOGENE, V11, P2311; KUPCHAN SM, 1972, J AM CHEM SOC, V94, P7194, DOI 10.1021/ja00775a078; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE JM, 1995, CANCER METAST REV, V14, P149, DOI 10.1007/BF00665797; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Li JJ, 1997, CANCER RES, V57, P3569; Linke SP, 1997, CANCER RES, V57, P1171; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MIYASHITA T, 1995, CELL, V80, P293; Mueller H, 1996, ANTICANCER RES, V16, P3845; NISHIZAKI M, 2000, ONCOGENE, V19, P726; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Penninger JM, 1998, ADV IMMUNOL, V68, P51, DOI 10.1016/S0065-2776(08)60558-1; PU LX, 1990, ACTA PHARM SINIC, V11, P76; QIN WZ, 1981, CHINESE MED J-PEKING, V94, P827; Qiu DM, 1999, J BIOL CHEM, V274, P13443, DOI 10.1074/jbc.274.19.13443; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; TAO XL, 1989, CHINESE MED J-PEKING, V102, P327; Tetu B, 1998, MODERN PATHOL, V11, P823; Vasey PA, 1996, MOL PHARMACOL, V50, P1536; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Webster GA, 1999, MOL CELL BIOL, V19, P3485; WEI YS, 1991, ACTA PHARM SINIC, V12, P406; Weller M, 1998, CELL TISSUE RES, V292, P435, DOI 10.1007/s004410051072; YANG SX, 1992, INT J IMMUNOPHARMACO, V14, P963; Yang YL, 1998, IMMUNOPHARMACOLOGY, V40, P139, DOI 10.1016/S0162-3109(98)00036-8; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zhan QM, 1996, ONCOGENE, V13, P2287; ZHANG L X, 1990, Yaoxue Xuebao, V25, P573; Zhao GH, 2000, AM J PHYSIOL-LUNG C, V279, pL958, DOI 10.1152/ajplung.2000.279.5.L958; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhu GH, 2000, GASTROENTEROLOGY, V118, P507, DOI 10.1016/S0016-5085(00)70256-3; Zhu GH, 1999, DIGEST DIS SCI, V44, P2020, DOI 10.1023/A:1026670301787	45	170	193	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2001	20	55					8009	8018		10.1038/sj.onc.1204981	http://dx.doi.org/10.1038/sj.onc.1204981			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753684				2022-12-17	WOS:000172288700010
J	Bustelo, XR				Bustelo, XR			Vav proteins, adaptors and cell signaling	ONCOGENE			English	Article						Vav; exchange factors; Rho/Rac proteins; tyrosine kinase; adaptor proteins; Ca2+	TYROSINE KINASE ACTIVATION; EXCHANGE FACTOR VAV; T-CELL; RHO-FAMILY; SYNERGISTIC ACTIVATION; B-LYMPHOCYTES; HIV-1 NEF; RECEPTOR; SLP-76; PHOSPHORYLATION	The Vav family is a group of signal transduction molecules with oncogenic potential that play important roles in development and cell signaling. Members of this family are distributed in all animal metazoans but not in unicellular organisms. Recent genomic studies suggest that the function of Vav proteins co-evolved with tyrosine kinase pathways, probably to assure the optimal conversion of extracellular signals into biological responses coupled to the cytoskeleton and gene transcription. To date, the best-known function of Vav proteins is their role as GDP/GTP exchange factors for Rho/Rac molecules, a function strictly controlled by tyrosine phosphorylation. Recent publications indicate that this function is highly dependent on the interaction of adaptor proteins that aid in the proper phosphorylation of Vav proteins, their interaction with other signaling molecules, and in modulating the strength of their signal outputs. In addition to the function of Vav proteins as exchange factors, there is increasing evidence suggesting that Vav proteins can mediate other cellular functions independently of their exchange activities, probably by working themselves as adaptor molecules. In this review, we will give a summary of the recent advances in this field, placing special emphasis on the non-catalytic roles of Vav and its interaction with other adaptor molecules.	Univ Salamanca, Ctr Invest Canc, E-37007 Salamanca, Spain; Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Bustelo, XR (corresponding author), Univ Salamanca, Ctr Invest Canc, Campus Unamuno, E-37007 Salamanca, Spain.	xbustelo@usal.es	Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072	NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER; NCI NIH HHS [CA7373501] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Arudchandran R, 2000, J EXP MED, V191, P47, DOI 10.1084/jem.191.1.47; Billadeau DD, 2000, J IMMUNOL, V164, P3971, DOI 10.4049/jimmunol.164.8.3971; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Doody GM, 2000, EMBO J, V19, P6173, DOI 10.1093/emboj/19.22.6173; DOODY GM, 2001, NAT IMMUNOL, V6, P482; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Fackler OT, 2000, MOL CELL BIOL, V20, P2619, DOI 10.1128/MCB.20.7.2619-2627.2000; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Fang N, 1999, J BIOL CHEM, V274, P16206, DOI 10.1074/jbc.274.23.16206; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Fujimoto M, 1999, J IMMUNOL, V162, P7088; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kim HH, 1998, J BIOL CHEM, V273, P296, DOI 10.1074/jbc.273.1.296; Ku GM, 2001, EMBO J, V20, P457, DOI 10.1093/emboj/20.3.457; Kuhne MR, 2000, J BIOL CHEM, V275, P2185, DOI 10.1074/jbc.275.3.2185; Li XL, 1997, J IMMUNOL, V158, P5649; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Lorenzo PS, 2000, MOL PHARMACOL, V57, P840; Manninen A, 2000, J BIOL CHEM, V275, P16513, DOI 10.1074/jbc.M910032199; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Musci MA, 1997, J IMMUNOL, V159, P1639; O'Rourke LM, 1998, IMMUNITY, V8, P635, DOI 10.1016/S1074-7613(00)80568-3; Okumura K, 1997, ONCOGENE, V14, P713, DOI 10.1038/sj.onc.1200878; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; Renkema GH, 2000, FRONT BIOSCI-LANDMRK, V5, pD268, DOI 10.2741/Renkema; Roshal M, 2001, APOPTOSIS, V6, P103, DOI 10.1023/A:1009636530839; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Serfling E, 2000, BBA-MOL CELL RES, V1498, P1, DOI 10.1016/S0167-4889(00)00082-3; Skowronski J, 1999, COLD SPRING HARB SYM, V64, P453, DOI 10.1101/sqb.1999.64.453; Swigut T, 2001, EMBO J, V20, P1593, DOI 10.1093/emboj/20.7.1593; Trenkle T, 2000, GENE, V245, P139, DOI 10.1016/S0378-1119(00)00026-3; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; WENG WK, 1994, J BIOL CHEM, V269, P32514; WU J, 1995, MOL CELL BIOL, V15, P4337; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhu J, 2000, CELL MOL LIFE SCI, V57, P411, DOI 10.1007/PL00000703	55	170	173	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	2001	20	44					6372	6381		10.1038/sj.onc.1204780	http://dx.doi.org/10.1038/sj.onc.1204780			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607839				2022-12-17	WOS:000171640600012
J	Coldwell, MJ; Mitchell, SA; Stoneley, M; MacFarlane, M; Willis, AE				Coldwell, MJ; Mitchell, SA; Stoneley, M; MacFarlane, M; Willis, AE			Initiation of Apaf-1 translation by internal ribosome entry	ONCOGENE			English	Article						cap-dependent translation; Apaf-1; apoptosis; IRES; 5 ' UTR; Ced-4	CAP-INDEPENDENT TRANSLATION; PROGRAMMED CELL-DEATH; FACTOR MESSENGER-RNA; FACTOR 4G EIF4G; BCL-X-L; PROTEIN-SYNTHESIS; C-MYC; ALTERNATIVE TRANSLATION; BINDING-PROTEIN; CYTOCHROME-C	The apoptotic protease activating factor (Apaf-1) plays a central role in apoptosis: interaction of this protein with procaspase-9 leads to cleavage and activation of this initiator caspase, In common with other mRNAs whose protein products have a major regulatory function, the 5' untranslated region (UTR) of Apaf-1 is long, G-C rich and has the potential to form secondary structure. We have shown that the 5' UTR of Apaf-1 contains an internal ribosome entry segment, located in a 233 nucleotide region towards the 3' end of the leader, and that the translation initiation of this mRNA occurs only by internal ribosome entry. The Apaf-1 IRES is active in almost all human cell types tested, including Human cervical carcinoma (HeLa), Human liver carcinoma (HepG2), Human breast carcinoma (MCF7), Human embryonic kidney (HK293), African Green Monkey kidney (COS7) and Human lung (MRCS), The Apaf-1 IRES initiates translation as efficiently as the HRV IRES, but is less active than the c-myc IRES, We propose that the Apaf-1 IRES ensures that a constant cellular level of Apaf-1 protein is maintained even under conditions where cap-dependent translation is compromised.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester; University of Leicester	Willis, AE (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.			Willis, Anne/0000-0002-1470-8531				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bernstein J, 1997, J BIOL CHEM, V272, P9356; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; Burgess DH, 1999, CELL DEATH DIFFER, V6, P256, DOI 10.1038/sj.cdd.4400489; Cardozo TJ, 1998, J MOL MODEL, V4, P83, DOI 10.1007/s008940050134; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Clemens MJ, 1998, ONCOGENE, V17, P2921, DOI 10.1038/sj.onc.1202227; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Jackson RJ, 1995, CURR TOP MICROBIOL, V203, P1; JACKSON RJ, 1994, MOL BIOL REP, V19, P147, DOI 10.1007/BF00986957; Jackson RJ, 1995, RNA, V1, P985; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kevil C, 1995, ONCOGENE, V11, P2339; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; Miller DL, 1998, FEBS LETT, V434, P417, DOI 10.1016/S0014-5793(98)01025-4; Morley SJ, 1998, FEBS LETT, V438, P41, DOI 10.1016/S0014-5793(98)01269-1; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; PANNIERS R, 1994, BIOCHIMIE, V76, P737, DOI 10.1016/0300-9084(94)90078-7; Perkins C, 1998, CANCER RES, V58, P4561; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Rhoads RE, 1995, CURR TOP MICROBIOL, V203, P131; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; STONELEY M, 1998, THESIS U LEICESTER; STONELEY M, 2000, IN PRESS MOL CELL BI, V20; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; West MJ, 1995, ONCOGENE, V11, P2515; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; ZAMORA AJ, 1995, EUR J APPL PHYSIOL O, V71, P505, DOI 10.1007/BF00238552; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	51	170	175	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2000	19	7					899	905		10.1038/sj.onc.1203407	http://dx.doi.org/10.1038/sj.onc.1203407			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702798				2022-12-17	WOS:000085567700007
J	Lennartsson, J; Blume-Jensen, P; Hermanson, M; Ponten, E; Carlberg, M; Ronnstrand, L				Lennartsson, J; Blume-Jensen, P; Hermanson, M; Ponten, E; Carlberg, M; Ronnstrand, L			Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction	ONCOGENE			English	Article						c-kit; Src; Ras; MAP kinase; Shc; mitogenicity	TERNARY COMPLEX-FORMATION; PROTEIN-TYROSINE KINASES; PDGF BETA-RECEPTOR; GROWTH-FACTOR; HEMATOPOIETIC-CELLS; ENDOTHELIAL-CELLS; ALPHA-RECEPTOR; IDENTIFICATION; ASSOCIATION; PRODUCT	In this report we show that Tyr568 and Tyr570 are phosphorylated in vivo in the Kit/stem cell factor receptor (Kit/SCFR) following ligand-stimulation, By mutation of Tyr568 and Tyr570 to phenylalanine residues and expression of the mutated receptors in porcine aortic endothelial (PAE) cells, we could demonstrate a loss of activation of members of the Src family of tyrosine kinases when Tyr568 was mutated, while mutation of Tyr570 only led to a minor decrease in activation of Src family members. Mutation of both tyrosine residues led to a complete loss of Src family kinase activation, Phosphorylation of the adapter protein Shc by growth factor receptors provides association sites for Grb2-Sos, thereby activating the Ras/MAP kinase pathway. A much lowered degree of Shc phosphorylation, Ras and Erk2 activation and c-fas induction was seen in the Y568F mutant, while in the Y570F mutant these responses mere less affected, In contrast, the mitogenic response was only slightly reduced, In a mutant receptor with both Tyr568 and Tyr570 mutated to phenylalanine residues, no phosphorylation of Shc and no activation of Ras and Erk2 was seen in response to stem cell factor stimulation, very weak induction of c-fas was seen and the mitogenic response was severely depressed, These data show that Ras/MAP kinase activation and c-fos induction by Kit/SCFR are mediated by members of the Src family kinases, However, the mitogenic response is only to a minor extent dependent on Src kinase activity.	Ludwig Inst Canc Res, Ctr Biomed, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Lennartsson, J (corresponding author), Ludwig Inst Canc Res, Ctr Biomed, Box 595, S-75124 Uppsala, Sweden.		Ronnstrand, Lars/A-2429-2011	Ronnstrand, Lars/0000-0003-1275-5809				ALAI M, 1992, J BIOL CHEM, V267, P18021; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; BLUMEJENSEN P, 1994, J BIOL CHEM, V269, P21793; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; FLEISCHMAN RA, 1993, TRENDS GENET, V9, P285, DOI 10.1016/0168-9525(93)90015-A; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Gelderloos JA, 1998, J BIOL CHEM, V273, P5908, DOI 10.1074/jbc.273.10.5908; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; HERBST R, 1995, ONCOGENE, V10, P369; HERBST R, 1991, J BIOL CHEM, V266, P19908; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hooshmand-Rad R, 1998, J CELL SCI, V111, P607; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; Linnekin D, 1997, J BIOL CHEM, V272, P27450, DOI 10.1074/jbc.272.43.27450; MIYAZONO K, 1985, BIOCHEM BIOPH RES CO, V126, P83, DOI 10.1016/0006-291X(85)90574-1; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Price DJ, 1997, J BIOL CHEM, V272, P5915, DOI 10.1074/jbc.272.9.5915; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	42	170	172	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	1999	18	40					5546	5553		10.1038/sj.onc.1202929	http://dx.doi.org/10.1038/sj.onc.1202929			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523831	Green Published			2022-12-17	WOS:000082894700007
J	Mancini, DN; Rodenhiser, DI; Ainsworth, PJ; O'Malley, FP; Singh, SM; Xing, WR; Archer, TK				Mancini, DN; Rodenhiser, DI; Ainsworth, PJ; O'Malley, FP; Singh, SM; Xing, WR; Archer, TK			CPG methylation within the 5 ' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site	ONCOGENE			English	Article						BRCA1; methylation; CpG dinucleotides; CREB	CANCER SUSCEPTIBILITY GENE; ESTROGEN-RECEPTOR GENE; DNA METHYLATION; BREAST-CANCER; OVARIAN-CANCER; SUPPRESSOR GENE; TRANSCRIPTION; EXPRESSION; MUTATIONS; ISLAND	Breast cancer is a genetic disease arising from a series of germ-line and/or somatic DNA changes in a variety of genes, including BRCA1 and BRCA2, DNA modifications have been shown to occur by a number of mechanisms that include DNA methylation, In some cases, the aberrant methylation of CpGs within 5' regulatory regions has led to suppression of gene activity. In this report we describe a variation in the pattern of DNA methylation within the regulatory region of the BRCA1 gene, We found no evidence of methylation at CpGs within the BRCA1 promoter in a variety of normal human tissues, However, screening of a series of randomly sampled breast carcinomas revealed the presence of CpG methylation adjacent to the BRCA1 transcription start site. One such methylated CpG occurs at a putative CREB (cAMP-responsive element binding) transcription factor binding site in the BRCA1 promoter, Gelshift assays with methylated and unmethylated BRCA1/CREB binding site oligonucleotides demonstrate that this site is sensitive to site-specific CpG methylation, These data suggest that aberrant DNA methylation at regulatory sequences in the BRCA1 locus may play a role in the transcriptional inactivation of the BRCA1 gene within subclones of breast tumors, This study represents the first evidence suggesting a role for DNA methylation in the transcriptional inactivation of the BRCA1 in human breast cancer.	London Hlth Sci Ctr, CHRI, SW Ontario Med Genet Program, London, ON N6C 2V5, Canada; Univ Western Ontario, London Reg Canc Ctr, London, ON, Canada; Univ Western Ontario, Dept Biochem, London, ON, Canada; Univ Western Ontario, Dept Obstet & Gynecol, London, ON, Canada; Univ Western Ontario, Dept Oncol, London, ON, Canada; Univ Western Ontario, Dept Pathol, London, ON, Canada; Univ Western Ontario, Dept Paediat, London, ON, Canada; Univ Western Ontario, Dept Zool, London, ON, Canada	London Health Sciences Centre; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Rodenhiser, DI (corresponding author), London Hlth Sci Ctr, CHRI, SW Ontario Med Genet Program, A4WT,800 Commiss Rd E, London, ON N6C 2V5, Canada.		Archer, Trevor K/E-5191-2019	Archer, Trevor K/0000-0001-7651-3644				Andrews JD, 1996, HUM MOL GENET, V5, P503, DOI 10.1093/hmg/5.4.503; ARCHER TK, 1990, P NATL ACAD SCI USA, V87, P7560, DOI 10.1073/pnas.87.19.7560; BENHATTAR J, 1989, NUCLEIC ACIDS RES, V17, P10179, DOI 10.1093/nar/17.24.10179; Brown MA, 1996, ONCOGENE, V12, P2507; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2290; CLAUS EB, 1991, AM J HUM GENET, V48, P232; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; FERGUSON AT, 1995, CANCER RES, V55, P2279; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Huang THM, 1997, CANCER RES, V57, P1030; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; Issa JPJ, 1996, CANCER RES, V56, P973; Issa JPJ, 1996, CANCER RES, V56, P3655; JOHNSON CA, 1995, BIOCHEM J, V305, P791, DOI 10.1042/bj3050791; Jones PA, 1996, CANCER RES, V56, P2463; Kuukasjarvi T, 1997, CANCER RES, V57, P1597; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; Maesawa C, 1996, CANCER RES, V56, P3875; Mancini D, 1997, AM J HUM GENET, V61, P80, DOI 10.1086/513898; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P1; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; PALVIMO JJ, 1991, NUCLEIC ACIDS RES, V19, P3921, DOI 10.1093/nar/19.14.3921; Rodenhiser D, 1996, ONCOGENE, V12, P2623; Rodenhiser DI, 1997, MUTAT RES-FUND MOL M, V373, P185, DOI 10.1016/S0027-5107(96)00171-6; Sambrook J, 1989, MOL CLONING LAB MANU; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; TASHEVA ES, 1993, SOMAT CELL MOLEC GEN, V19, P275, DOI 10.1007/BF01233075; TORNALETTI S, 1995, ONCOGENE, V10, P1493; Wang F, 1997, BIOCHEMISTRY-US, V36, P7793, DOI 10.1021/bi963100j; WEIH F, 1991, EMBO J, V10, P2559, DOI 10.1002/j.1460-2075.1991.tb07796.x; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259	41	170	193	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 5	1998	16	9					1161	1169		10.1038/sj.onc.1201630	http://dx.doi.org/10.1038/sj.onc.1201630			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528858				2022-12-17	WOS:000072336000007
J	Volpert, OV; Dameron, KM; Bouck, N				Volpert, OV; Dameron, KM; Bouck, N			Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity	ONCOGENE			English	Article						neovascularization; fibrosarcoma; VEGF; thrombospondin; tumor progression	ENDOTHELIAL GROWTH-FACTOR; SOFT-TISSUE SARCOMAS; WILD-TYPE P53; N-RAS; MALIGNANT PROGRESSION; EXPRESSION; THROMBOSPONDIN; ABNORMALITIES; INHIBITOR; CELLS	As normal cells progress to malignancy they must acquire an angiogenic phenotype that will enable them to attract the blood vessels necessary to support their progressive growth. Here we define the mechanism by which human fibroblasts cultured from Li Fraumeni patients and progressing to tumorigenicity in vitro become angiogenic. Initially cells were anti-angiogenic due to the secretion of high levels of inhibitory thrombospondin that overrode the modest amounts of the major inducer, vascular endothelial cell growth factor (VEGF), that were also produced. Cells became fully angiogenic in two steps, the first dependent on the loss of both alleles of wild-type p53 which caused a drop of at least 20-fold in secreted thrombospondin and a fourfold increase in secreted VEGF. Angiogenic activity increased again upon transformation by activated ras due to a further twofold increase in VEGF. Changes in relative levels of VEGF mRNA were sufficient to account for changes in secreted protein levels and in overall angiogenic activity. These studies demonstrate that an angiogenic phenotype able to support tumorigenicity can arise in a step-wise fashion in response to both oncogene activation and tumor suppressor gene loss and involve both a decrease in the secretion of inhibitors and the sequential ratcheting up of the secretion of inducers of angiogenesis.	NORTHWESTERN UNIV, SCH MED, DEPT MICROBIOL IMMUNOL, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, RH LURIE CANC CTR, CHICAGO, IL 60611 USA	Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center					NCI NIH HHS [CA52750, CA64239] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064239] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDEOL Y, 1988, INT J CANCER, V41, P732, DOI 10.1002/ijc.2910410516; ANDREASSEN A, 1993, CANCER RES, V53, P468; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF FZ, 1991, ONCOGENE, V6, P138; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; CHRISTOFORI G, 1994, SEMIN CANCER BIOL, V5, P3; CORDONCARDO C, 1994, CANCER RES, V54, P794; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DAMERON KM, 1994, COLD SPRING HARB SYM, V59, P483, DOI 10.1101/SQB.1994.059.01.053; DROBNJAK M, 1994, J NATL CANCER I, V86, P549, DOI 10.1093/jnci/86.7.549; Folkman J., 1995, MOL BASIS CANC, P206; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; LEACH FS, 1993, CANCER RES, V53, P2231; MAILLET MW, 1992, MODERN PATHOL, V5, P410; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PATERSON H, 1987, CELL, V51, P803, DOI 10.1016/0092-8674(87)90103-6; POLLOCK RE, 1994, SEMIN SURG ONCOL, V10, P315, DOI 10.1002/ssu.2980100503; POLVERINI PJ, 1991, METHOD ENZYMOL, V198, P440; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; RAK J, 1995, CANCER RES, V55, P4575; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SEIMEISTER G, 1996, CANCER RES, V56, P2299; STRATTON MR, 1989, CANCER RES, V49, P6324; SUGIHARA T, 1994, BBA-MOL CELL RES, V1224, P365, DOI 10.1016/0167-4889(94)90269-0; TANAKA T, 1986, CANCER RES, V46, P1465; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209	32	170	187	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	1997	14	12					1495	1502		10.1038/sj.onc.1200977	http://dx.doi.org/10.1038/sj.onc.1200977			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136993				2022-12-17	WOS:A1997WT58400012
J	LARSSON, LG; PETTERSSON, M; OBERG, F; NILSSON, K; LUSCHER, B				LARSSON, LG; PETTERSSON, M; OBERG, F; NILSSON, K; LUSCHER, B			EXPRESSION OF MAD, MXI1, MAX AND C-MYC DURING INDUCED-DIFFERENTIATION OF HEMATOPOIETIC-CELLS - OPPOSITE REGULATION OF MAD AND C-MYC	ONCOGENE			English	Note							DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; MESSENGER-RNA; ONCOGENE; PROTEIN; FOS; COTRANSFORMATION; ONCOPROTEIN; INTERFERON; DOMAINS	The Myc proto-oncoprotein family is considered to play an important role in the control of cell growth and differentiation. It appears that the interaction of Myc with its heterodimeric partner Max is essential for Myc function. Recently two other partners of Max, called Mad and Mxi1, have been identified. In an effort to gain insight into the network of these four proteins we have started to analyse the expression of the c-myc, max, mad and mxi1 genes at the mRNA level during hematopoietic cell growth and differentation. In the human myeloid cell lines U-937, HL-60 and ML-1 c-myc expression was down-regulated as shown previously after induction of differentiation, whereas the expression of max was only slightly affected. In contrast to these two genes the expression of mad was induced upon differentiation in the three cell lines by TPA, retinoic acid, vitamin D3, dimethyl sulfoxide, and interferon-gamma and remained elevated for at least 3 days. A kinetic analysis showed that the induction of mad in U-937 in response to TPA was rapid (15 min) and at least in part transcriptional, reminiscent of immediate early genes. The expression of mxi1 was induced in U-937 by some inducers but not in HL-60 or ML-1. Its induction occurred slowly, peaking around 48 h. These analysis thus suggest that the expression of mad and c-myc is inversely regulated during induced hematopoietic differentiation.	UNIV UPPSALA,UNIV HOSP,DEPT PATHOL,S-75185 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital	LARSSON, LG (corresponding author), HANNOVER MED SCH,INST MOLEK BIOL,KONSTANTY GUTSCHOW STR 8,D-30623 HANNOVER,GERMANY.		Larsson, Lars-Gunnar/D-9747-2012; Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMATI B, 1993, CELL, V72, P235; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KREZNER L, 1992, NATURE, V359, P426; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LARSSON LG, 1991, LEUKEMIA LYMPHOMA, V4, P193, DOI 10.3109/10428199109068065; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MILLER LJ, 1986, J IMMUNOL, V137, P2891; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; Nilsson K., 1980, INT S NEW TRENDS HUM, P271; OBERG F, 1991, P NATL ACAD SCI USA, V88, P5567, DOI 10.1073/pnas.88.13.5567; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; REDDY CD, 1992, ONCOGENE, V7, P2085; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; TODD RF, 1981, J IMMUNOL, V126, P1435; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; WATT SM, 1991, BLOOD, V78, P63; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	40	170	171	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1247	1252						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134128				2022-12-17	WOS:A1994NC04800030
J	PROCTOR, AJ; COOMBS, LM; CAIRNS, JP; KNOWLES, MA				PROCTOR, AJ; COOMBS, LM; CAIRNS, JP; KNOWLES, MA			AMPLIFICATION AT CHROMOSOME 11Q13 IN TRANSITIONAL CELL TUMORS OF THE BLADDER	ONCOGENE			English	Article							HUMAN ESOPHAGEAL CARCINOMAS; HUMAN-BREAST TUMORS; PROTO-ONCOGENE; URINARY-BLADDER; HUMAN-MELANOMA; GROWTH-FACTOR; KINASE GENE; INT-2 GENES; CANCER; DNA	Amplification of several markers which map to chromosome 11q13 was detected by Southern blotting in transitional cell tumours of the urinary bladder. The oncogenes INT2 and HST and the BCL1 locus were co-amplified in 20/97 (20.6%) tumours and the locus-specific minisatellite probe pMS51 (D11S97) detected amplification in 17/97 (17.5%) tumours. The high frequency of heterozygosity (> 70%) detected by this latter probe on HaeIII-digested DNAs provided a sensitive means to measure low levels of gene amplification (2-fold) by comparing signals obtained from each allele. A number of probes which map to 11q were used in an attempt to map the region of amplification more precisely. PGA, PGR, STMY, D11Z1 and D11S149 were not amplified in any tumours studied. SEA was amplified in 1/59 tumours and D11S146 in 12/89 tumours. A comparison of the patterns of co-amplification of individual markers in this series of tumours revealed that of the 23 tumours with amplification at this site, 11 had co-amplification of D11S97, D11S146, BCL1, INT2 and HST, 3 had co-amplification of D11S97, BCL1, INT2 and HST, 6 had co-amplification of BCL1, INT2 and HST, 1 had co-amplification of D11S97 and D11S146 and 2 had amplification of D11S97 alone. Based on available linkage data for these markers, this suggests that a putative target gene within this amplicon lies centromeric to BCL1. Amplification at 11q13 showed no correlation with tumour grade or with HER2 amplification.	MARIE SKLODOWSKA CURIE MEM INST,EPITHELIAL CARCINOGENESIS LAB,OXTED RH8 0TL,SURREY,ENGLAND		KNOWLES, MA (corresponding author), MARIE SKLODOWSKA CURIE MEM INST,EPITHELIAL CARCINOGENESIS LAB,OXTED RH8 0TL,SURREY,ENGLAND.			Knowles, Margaret/0000-0002-9363-8657				ADELAIDE J, 1988, ONCOGENE, V2, P413; ADNANE J, 1989, ONCOGENE, V4, P1389; ALI IU, 1989, ONCOGENE, V4, P89; ATKIN NB, 1985, CANCER GENET CYTOGEN, V15, P253, DOI 10.1016/0165-4608(85)90169-4; BABU VR, 1987, CANCER RES, V47, P6800; BERENSON JR, 1990, ONCOGENE, V5, P1343; BERGER CS, 1986, CANCER GENET CYTOGEN, V23, P1, DOI 10.1016/0165-4608(86)90145-7; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHODAK GW, 1988, CANCER RES, V48, P2083; COOMBS LM, 1991, IN PRESS BR J CANCER; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIBAS Z, 1984, CANCER RES, V44, P1257; GIBAS Z, 1986, CANCER GENET CYTOGEN, V19, P229, DOI 10.1016/0165-4608(86)90051-8; GUSTAFSON H, 1982, SCAND J UROL NEPHROL, V16, P141, DOI 10.3109/00365598209179743; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; HOLM T, 1988, NUCLEIC ACIDS RES, V16, P4746, DOI 10.1093/nar/16.10.4746; JEFFREYS AJ, 1988, NUCLEIC ACIDS RES, V16, P10953, DOI 10.1093/nar/16.23.10953; JULIER C, 1990, GENOMICS, V7, P335, DOI 10.1016/0888-7543(90)90167-S; LAU YF, 1984, P NATL ACAD SCI-BIOL, V81, P414, DOI 10.1073/pnas.81.2.414; LAW ML, 1987, P NATL ACAD SCI USA, V84, P2877, DOI 10.1073/pnas.84.9.2877; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LIMAS C, 1979, CANCER, V44, P2099, DOI 10.1002/1097-0142(197912)44:6<2099::AID-CNCR2820440621>3.0.CO;2-I; LISCIA DS, 1989, ONCOGENE, V4, P1219; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P376, DOI 10.1093/nar/16.1.376; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NGUYEN C, 1988, ONCOGENE, V3, P703; PADUA RA, 1985, MOL CELL BIOL, V5, P582, DOI 10.1128/MCB.5.3.582; RABBITTS PH, 1988, ONCOGENE, V3, P99; RAGHAVAN D, 1990, NEW ENGL J MED, V322, P1129, DOI 10.1056/NEJM199004193221607; RAMAEKERS F, 1985, LAB INVEST, V52, P31; ROYLE NJ, 1987, CYTOGENET CELL GENET, V46, P685; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; SOMERS KD, 1990, ONCOGENE, V5, P915; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; TAGGART RT, 1985, P NATL ACAD SCI USA, V82, P6240, DOI 10.1073/pnas.82.18.6240; THEILLET C, 1990, ONCOGENE, V5, P147; THEILLET C, 1989, ONCOGENE, V4, P915; TSAI YC, 1990, CANCER RES, V50, P44; TSUDA T, 1989, JPN J CLIN ONCOL, V19, P26; TSUDA T, 1988, JPN J CANCER RES, V79, P584, DOI 10.1111/j.1349-7006.1988.tb00026.x; TSUDA T, 1989, CANCER RES, V49, P5505; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; TSUTSUMI M, 1988, JPN J CANCER RES, V79, P428, DOI 10.1111/j.1349-7006.1988.tb01609.x; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VANNI R, 1988, CANCER GENET CYTOGEN, V30, P35, DOI 10.1016/0165-4608(88)90090-8; VARLEY JM, 1988, ONCOGENE, V3, P87; WADA A, 1988, BIOCHEM BIOPH RES CO, V157, P828, DOI 10.1016/S0006-291X(88)80324-3; WAYE JS, 1987, HUM GENET, V77, P151, DOI 10.1007/BF00272383; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILLIAMS BP, 1987, CYTOGENET CELL GENET, V46, P717; YOSHIDA MC, 1988, P NATL ACAD SCI USA, V85, P4861, DOI 10.1073/pnas.85.13.4861; YOSHIDA T, 1987, BIOCHEM BIOPH RES CO, V142, P1019, DOI 10.1016/0006-291X(87)91516-6; ZHOU DJ, 1988, ONCOGENE, V2, P279; 1978, UNION INT CONTRE CAN	65	170	171	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					789	795						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	2052357				2022-12-17	WOS:A1991GT82500015
J	RUTHER, U; KOMITOWSKI, D; SCHUBERT, FR; WAGNER, EF				RUTHER, U; KOMITOWSKI, D; SCHUBERT, FR; WAGNER, EF			C-FOS EXPRESSION INDUCES BONE-TUMORS IN TRANSGENIC MICE	ONCOGENE			English	Article									GERMAN CANC RES CTR,INST EXPTL PATHOL,D-6900 HEIDELBERG,FED REP GER	Helmholtz Association; German Cancer Research Center (DKFZ)	RUTHER, U (corresponding author), EUROPEAN MOLEC BIOL LAB,POSTFACH 102209,MEYERHOFSTR 1,D-6900 HEIDELBERG,FED REP GER.		Schubert, Frank/C-1658-2010	Schubert, Frank/0000-0001-7567-8471; Wagner, Erwin F/0000-0001-7872-0196				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Dahlin DC., 1986, BONE TUMORS; Finkel M. P., 1973, COLSTON PAP, V24, P353; FINKEL MP, 1966, SCIENCE, V151, P698, DOI 10.1126/science.151.3711.698; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HOGAN B, 1986, MANIPULATION MOUSE E; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MILLER AD, 1984, CELL, V36, P51; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PRICE CHG, 1972, BRIT J CANCER, V26, P2; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; RUTHER U, 1988, CELL, V53, P847, DOI 10.1016/S0092-8674(88)90289-9; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TEITELMAN G, 1988, CELL, V52, P97, DOI 10.1016/0092-8674(88)90534-X; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; VERMA IM, 1986, TRENDS GENET, V2, P93, DOI 10.1016/0168-9525(86)90191-5; WARD JM, 1976, CANCER RES, V36, P3985; WHITE MP, 1982, AM J MED, V72, P193	27	170	176	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					861	865						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2547184				2022-12-17	WOS:A1989AE58400007
J	SHIBANUMA, M; KUROKI, T; NOSE, K				SHIBANUMA, M; KUROKI, T; NOSE, K			INDUCTION OF DNA-REPLICATION AND EXPRESSION OF PROTO-ONCOGENE CIS-MYC AND CIS-FOS IN QUIESCENT BALB/3T3 CELLS BY XANTHINE XANTHINE-OXIDASE	ONCOGENE			English	Article									UNIV TOKYO,INST MED SCI,DEPT CANC CELL RES,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN	University of Tokyo			Kuroki, Toshio/A-9500-2011	Kuroki, Toshio/0000-0001-6369-4351				BESTERMAN JM, 1984, J CELL BIOL, V99, P340, DOI 10.1083/jcb.99.1.340; CASSEL D, 1983, P NATL ACAD SCI-BIOL, V80, P6224, DOI 10.1073/pnas.80.20.6224; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHIDA K, 1986, CANCER RES, V46, P1055; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; FISCHER SM, 1985, CANCER RES, V45, P3130; FISCHER SM, 1986, CARCINOGENESIS, V7, P915, DOI 10.1093/carcin/7.6.915; FISCHER SM, 1988, IN PRESS TUMOR PROMO; FRIEDMAN J, 1983, CARCINOGENESIS, V4, P1425, DOI 10.1093/carcin/4.11.1425; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HESKETH TR, 1985, NATURE, V313, P481, DOI 10.1038/313481a0; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KENSLER TW, 1983, SCIENCE, V221, P75, DOI 10.1126/science.6857269; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LALLEMAIN G, 1984, J BIOL CHEM, V259, P5809; MANIATIS T, 1982, LABORATORY MANUAL; MILLS GB, 1985, J BIOL CHEM, V260, P2500; MIZUKI K, 1985, BIOCHEM BIOPH RES CO, V128, P1037, DOI 10.1016/0006-291X(85)90152-4; MOOLENAAR WH, 1984, NATURE, V312, P371, DOI 10.1038/312371a0; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; RODRIGUEZPENA A, 1985, EMBO J, V4, P71, DOI 10.1002/j.1460-2075.1985.tb02319.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SCHULDINER S, 1982, P NATL ACAD SCI-BIOL, V79, P7778, DOI 10.1073/pnas.79.24.7778; SHAAFI RI, 1986, BIOCHEM BIOPH RES CO, V137, P50, DOI 10.1016/0006-291X(86)91174-5; SHIBANUMA M, 1987, EUR J BIOCHEM, V164, P15, DOI 10.1111/j.1432-1033.1987.tb10985.x; SHIBANUMA M, 1987, BIOCHEM BIOPH RES CO, V144, P1317, DOI 10.1016/0006-291X(87)91454-9; SHIBANUMA M, 1988, IN PRESS J CELL PHYS; Sies H., 1985, OXIDATIVE STRESS; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; ZIMMERMAN R, 1984, P NATL ACAD SCI US, V81, P2084; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	36	170	171	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1988	3	1					17	21						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	P0354					2022-12-17	WOS:A1988P035400003
J	Yuan, XT; Larsson, C; Xu, DW				Yuan, Xiaotian; Larsson, Catharina; Xu, Dawei			Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players	ONCOGENE			English	Review							CATALYTIC SUBUNIT HTERT; PROMOTER MUTATIONS; INSERTIONAL MUTAGENESIS; BLADDER-CANCER; MESSENGER-RNA; GENE PROMOTER; LIFE-SPAN; EXPRESSION; REARRANGEMENTS; MAINTENANCE	Long-lived species Homo sapiens have evolved robust protection mechanisms against cancer by repressing telomerase and maintaining short telomeres, thereby delaying the onset of the majority of cancer types until post-reproductive age. Indeed, telomerase is silent in most differentiated human cells, predominantly due to the transcriptional repression of its catalytic component telomerase reverse transcriptase (TERT) gene. The lack of telomerase/TERT expression leads to progressive telomere erosion in dividing human cells, whereas critically shortened telomere length induces a permanent growth arrest stage named replicative senescence. TERT/telomerase activation has been experimentally shown to be essential to cellular immortalization and malignant transformation by stabilizing telomere length and erasing the senescence barrier. Consistently, TERT expression/telomerase activity is detectable in up to 90% of human primary cancers. Compelling evidence has also accumulated that TERT contributes to cancer development and progression via multiple activities beyond its canonical telomere-lengthening function. Given these key roles of telomerase and TERT in oncogenesis, great efforts have been made to decipher mechanisms underlying telomerase activation and TERT induction. In the last two decades since the TERT gene and promoter were cloned, the derepression of the TERT gene has been shown to be achieved typically at a transcriptional level through dysregulation of oncogenic factors or signaling, post-transcriptional/translational regulation and genomic amplification. However, advances in high-throughput next-generation sequencing technologies have prompted a revolution in cancer genomics, which leads to the recent discovery that genomic alterations take center stage in activating the TERT gene. In this review article, we summarize critical mechanisms activating TERT transcription, with special emphases on the contribution of TERT promoter mutations and structural alterations at the TERT locus, and briefly discuss the underlying implications of these genomic events-driven TERT hyperactivity in cancer initiation/progression and potential clinical applications as well.	[Yuan, Xiaotian] Shandong Univ, Sch Med, Jinan 250012, Shandong, Peoples R China; [Yuan, Xiaotian; Xu, Dawei] Karolinska Inst, CMM, Dept Med, S-17164 Solna, Sweden; [Yuan, Xiaotian; Larsson, Catharina; Xu, Dawei] Karolinska Inst, Bioclinicum, S-17164 Solna, Sweden; [Yuan, Xiaotian; Larsson, Catharina; Xu, Dawei] Karolinska Univ Hosp Solna, S-17164 Solna, Sweden; [Larsson, Catharina] Karolinska Inst, Dept Oncol Pathol, S-17164 Solna, Sweden	Shandong University; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Yuan, XT (corresponding author), Shandong Univ, Sch Med, Jinan 250012, Shandong, Peoples R China.; Yuan, XT; Xu, DW (corresponding author), Karolinska Inst, CMM, Dept Med, S-17164 Solna, Sweden.; Yuan, XT; Xu, DW (corresponding author), Karolinska Inst, Bioclinicum, S-17164 Solna, Sweden.; Yuan, XT; Xu, DW (corresponding author), Karolinska Univ Hosp Solna, S-17164 Solna, Sweden.	Xiaotian.Yan@ki.se; Dawei.Xu@ki.se		Xu, Dawei/0000-0003-3141-4524	China Postdoctoral Science Foundation [2019M652404]; Swedish Cancer Society; Swedish Research Council; Cancer Society in Stockholm; Karolinska Institutet Foundation; Swedish Foundation for International Cooperation in Research and Higher Education (STINT); Nanna Svartz Foundation; Ruth and Richard Julin Foundation	China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Cancer Society in Stockholm; Karolinska Institutet Foundation(Karolinska Institutet); Swedish Foundation for International Cooperation in Research and Higher Education (STINT); Nanna Svartz Foundation; Ruth and Richard Julin Foundation	This work was supported by grants from China Postdoctoral Science Foundation Grant (2019M652404), the Swedish Cancer Society, Swedish Research Council, the Cancer Society in Stockholm, Karolinska Institutet Foundation, Swedish Foundation for International Cooperation in Research and Higher Education (STINT), Ruth and Richard Julin Foundation and Nanna Svartz Foundation.	Ackermann S, 2018, SCIENCE, V362, P1165, DOI 10.1126/science.aat6768; Barthel FP, 2017, NAT GENET, V49, P349, DOI 10.1038/ng.3781; Bayard Q, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07552-9; Bell RJA, 2016, MOL CANCER RES, V14, P315, DOI 10.1158/1541-7786.MCR-16-0003; Bell RJA, 2015, SCIENCE, V348, P1036, DOI 10.1126/science.aab0015; Bellon M, 2008, JNCI-J NATL CANCER I, V100, P98, DOI 10.1093/jnci/djm269; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bougel S, 2013, CLIN CANCER RES, V19, P2216, DOI 10.1158/1078-0432.CCR-12-1246; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Casillas MA, 2003, GENE, V316, P57, DOI 10.1016/S0378-1119(03)00739-X; Cassar L, 2008, CANCER RES, V68, P9157, DOI 10.1158/0008-5472.CAN-08-1323; Castelo-Branco P, 2013, LANCET ONCOL, V14, P534, DOI 10.1016/S1470-2045(13)70110-4; Chang KP, 2017, HEAD NECK-J SCI SPEC, V39, P1131, DOI 10.1002/hed.24728; Chen X, 2019, GENOME RES, V29, P819, DOI 10.1101/gr.242529.118; Chiba K, 2017, SCIENCE, V357, P1416, DOI 10.1126/science.aao0535; Chiba K, 2015, ELIFE, V4, DOI 10.7554/eLife.07918; Chou WC, 2001, J CLIN INVEST, V108, P1541, DOI 10.1172/JCI200114064; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Dahlstrom J, 2016, ANN HEMATOL, V95, P1825, DOI 10.1007/s00277-016-2787-7; Davis CF, 2014, CANCER CELL, V26, P319, DOI 10.1016/j.ccr.2014.07.014; Ding DQ, 2013, FASEB J, V27, P4375, DOI 10.1096/fj.13-230904; Diplas BH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04448-6; Drevytska TI, 2014, CELL BIOCHEM FUNCT, V32, P565, DOI 10.1002/cbf.3051; Dwight T, 2018, ENDOCR-RELAT CANCER, V25, P1, DOI 10.1530/ERC-17-0306; Fan YD, 2005, CLIN CANCER RES, V11, P4331, DOI 10.1158/1078-0432.CCR-05-0099; Ge Z, 2006, MOL CELL BIOL, V26, P230, DOI 10.1128/MCB.26.1.230-237.2006; Gewin L, 2004, GENE DEV, V18, P2269, DOI 10.1101/gad.1214704; Gomes NMV, 2011, AGING CELL, V10, P761, DOI 10.1111/j.1474-9726.2011.00718.x; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; Horikawa I, 2001, J NATL CANCER I, V93, P1171, DOI 10.1093/jnci/93.15.1171; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Hu CJ, 2017, GUT, V66, P31, DOI 10.1136/gutjnl-2015-309322; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Hurst CD, 2014, EUR UROL, V65, P367, DOI 10.1016/j.eururo.2013.08.057; Im E, 2017, J CELL PHYSIOL, V232, P2083, DOI 10.1002/jcp.25607; Juratli TA, 2018, ACTA NEUROPATHOL, V136, P779, DOI 10.1007/s00401-018-1899-7; Juratli TA, 2018, CLIN CANCER RES, V24, P5282, DOI 10.1158/1078-0432.CCR-17-3717; Kim W, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.2000016; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Labgaa I, 2018, ONCOGENE, V37, P3740, DOI 10.1038/s41388-018-0206-3; Lassmann T, 2015, INT J MOL SCI, V16, P1192, DOI 10.3390/ijms16011192; Lee DD, 2019, J CLIN INVEST, V129, P223, DOI 10.1172/JCI121303; Levine M, 2014, CELL, V157, P13, DOI 10.1016/j.cell.2014.02.009; Li C, 2015, ONCOTARGET, V6, P19542, DOI 10.18632/oncotarget.4295; Li WJ, 2008, CANCER LETT, V260, P28, DOI 10.1016/j.canlet.2007.10.018; Li YY, 2010, FASEB J, V24, P1442, DOI 10.1096/fj.09-149328; Lin YB, 2018, J CLIN PATHOL, V71, P832, DOI 10.1136/jclinpath-2018-205132; Liu C, 2007, CANCER RES, V67, P2626, DOI 10.1158/0008-5472.CAN-06-4126; Liu L, 2017, ONCOLOGIST, V22, P1178, DOI 10.1634/theoncologist.2017-0064; Liu N, 2016, NUCLEIC ACIDS RES, V44, P8693, DOI 10.1093/nar/gkw549; Liu T, 2014, ONCOGENE, V33, P4978, DOI 10.1038/onc.2013.446; Liu TT, 2016, GENES-BASEL, V7, DOI 10.3390/genes7070038; Liu Z, 2013, ONCOGENE, V32, P4203, DOI 10.1038/onc.2012.441; Ma RZ, 2019, UROL ONCOL-SEMIN ORI, V37, DOI 10.1016/j.urolonc.2019.01.014; Maida Y, 2015, CANCER SCI, V106, P1486, DOI 10.1111/cas.12806; Mancini A, 2018, CANCER CELL, V34, P513, DOI 10.1016/j.ccell.2018.08.003; Maryoung L, 2017, J CLIN INVEST, V127, P982, DOI 10.1172/JCI91161; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; Mitchell TJ, 2018, CELL, V173, P611, DOI 10.1016/j.cell.2018.02.020; Nault JC, 2015, NAT GENET, V47, P1187, DOI 10.1038/ng.3389; Park JI, 2009, NATURE, V460, P66, DOI 10.1038/nature08137; Paterlini-Brechot P, 2003, ONCOGENE, V22, P3911, DOI 10.1038/sj.onc.1206492; Peifer M, 2015, NATURE, V526, P700, DOI 10.1038/nature14980; Sahm F, 2015, JNCI-J NATL CANCER I, V108, P108, DOI 10.1093/jnci/djv1377; Saretzki G, 2014, CURR PHARM DESIGN, V20, P6386, DOI 10.2174/1381612820666140630095606; Schilling G, 2013, LEUKEMIA RES, V37, P280, DOI 10.1016/j.leukres.2012.10.009; Seluanov A, 2018, NAT REV CANCER, V18, P433, DOI 10.1038/s41568-018-0004-9; Shay JW, 2019, NAT REV GENET, V20, P299, DOI 10.1038/s41576-019-0099-1; Sizemore GM, 2017, NAT REV CANCER, V17, P337, DOI 10.1038/nrc.2017.20; Stern JL, 2015, GENE DEV, V29, P2219, DOI 10.1101/gad.269498.115; Straat K, 2009, JNCI-J NATL CANCER I, V101, P488, DOI 10.1093/jnci/djp031; Sung WK, 2012, NAT GENET, V44, P765, DOI 10.1038/ng.2295; Svahn F, 2018, CLIN ENDOCRINOL, V88, P343, DOI 10.1111/cen.13513; Takakura M, 1999, CANCER RES, V59, P551; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; Valentijn LJ, 2015, NAT GENET, V47, P1411, DOI 10.1038/ng.3438; Vogelstein B, 2015, NEW ENGL J MED, V373, P1895, DOI 10.1056/NEJMp1508811; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wang K, 2015, ONCOLOGIST, V20, P263, DOI 10.1634/theoncologist.2014-0391; Wang N, 2014, J CLIN ENDOCR METAB, V99, pE1571, DOI 10.1210/jc.2014-1158; Wang XG, 2016, MOL NEUROBIOL, V53, P2726, DOI 10.1007/s12035-015-9400-2; Wong MS, 2014, TRENDS GENET, V30, P430, DOI 10.1016/j.tig.2014.07.006; Xie H, 2014, ONCOTARGET, V5, P10048, DOI 10.18632/oncotarget.2491; Xing MZ, 2014, J CLIN ONCOL, V32, P2718, DOI 10.1200/JCO.2014.55.5094; Xu DK, 2008, J BIOL CHEM, V283, P23567, DOI 10.1074/jbc.M800790200; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yu JY, 2018, CANCER LETT, V434, P33, DOI 10.1016/j.canlet.2018.07.013; Yuan XT, 2019, ONCOGENE, V38, P965, DOI 10.1038/s41388-018-0483-x; Yuan XT, 2017, ONCOTARGET, V8, P23120, DOI 10.18632/oncotarget.15498; Zeng JP, 2009, J PATHOL, V218, P419, DOI 10.1002/path.2530; Zhang AJ, 2000, CANCER RES, V60, P6230; Zhang AJ, 2003, AM J HUM GENET, V72, P940, DOI 10.1086/374565; Zhang K, 2017, CANCER RES, V77, P2534, DOI 10.1158/0008-5472.CAN-16-1887; Zhao JQ, 2000, NEOPLASIA, V2, P531, DOI 10.1038/sj.neo.7900114; Zhao YJ, 2009, GENE CHROMOSOME CANC, V48, P963, DOI 10.1002/gcc.20698; Zhou JZ, 2014, AGING CELL, V13, P197, DOI 10.1111/acel.12161	98	169	170	12	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2019	38	34					6172	6183		10.1038/s41388-019-0872-9	http://dx.doi.org/10.1038/s41388-019-0872-9			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IS5RM	31285550	Green Published, hybrid			2022-12-17	WOS:000482210100002
J	Chen, D; Fan, Z; Rauh, M; Buchfelder, M; Eyupoglu, IY; Savaskan, N				Chen, D.; Fan, Z.; Rauh, M.; Buchfelder, M.; Eyupoglu, I. Y.; Savaskan, N.			ATF4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xCT-dependent manner	ONCOGENE			English	Article							ACTIVATING TRANSCRIPTION FACTOR-4; ENDOPLASMIC-RETICULUM STRESS; TUMOR ANGIOGENESIS; ER-STRESS; MALIGNANT GLIOMAS; CANCER-THERAPY; GROWTH; BRAIN; PATHWAY; RESISTANCE	Activating transcription factor 4 (ATF4) is a critical mediator of metabolic and oxidative homeostasis and cell survival. ATF4 is elevated in response to diverse microenvironmental stresses, including starvation, ER stress damages and exposure to toxic factors. Here we show that ATF4 expression fosters the malignancy of primary brain tumors (WHO grade III and IV gliomas) and increases proliferation and tumor angiogenesis. Hence, ATF4 expression promotes cell migration and anchorage-independent cell growth, whereas siRNA-mediated knockdown of ATF4 attenuates these features of malignancy in human gliomas. Further experiments revealed that ATF4-dependent tumor promoting effects are mediated by transcriptional targeting the glutamate antiporter xCT/SCL7A11 (also known as system Xc(-)). Thus, xCT is elevated as a consequence of ATF4 activation. We further found evidence that ATF4-induced proliferation can be attenuated by pharmacological or genetic xCT inhibition and ferroptosis inducers such as sorafenib, erastin and GPx4 inhibitor RSL3. Further, fostered xCT expression promotes cell survival and growth in ATF4 knockdown cells. Moreover, increased xCT levels ameliorate sorafenib and erastin-induced ferroptosis. Conversely, ATF4 knockdown renders cells susceptible for erastin, sorafenib and RSL3-induced ferroptosis. We further identified that ATF4 promotes tumor-mediated neuronal cell death which can be alleviated by xCT inhibition. Moreover, elevated ATF4 expression in gliomas promotes tumor angiogenesis. Noteworthy, ATF4-induced angiogenesis could be diminished by ferroptosis inducers erastin and by GPx4 inhibitor RSL3. Our data provide proof-of-principle evidence that ATF4 fosters proliferation and induces a toxic microenvironmental niche. Furthermore, ATF4 increases tumor angiogenesis and shapes the vascular architecture in a xCT-dependent manner. Thus, inhibition of ATF4 is a valid target for diminishing tumor growth and vasculature via sensitizing tumor cells for ferroptosis.	[Chen, D.; Fan, Z.; Eyupoglu, I. Y.; Savaskan, N.] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klinikum Erlangen UKER, Translat Cell Biol & Neurooncol Lab, Schwabachanlage 6, D-91054 Erlangen, Germany; [Chen, D.] Chinese Peoples Liberat Army Gen Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China; [Fan, Z.] ETHZ Zurich, ETH Zurich, Lab Exercise & Hlth, Dept Hlth Sci & Technol, Zurich, Switzerland; [Rauh, M.] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klinikum Erlangen UKER, Dept Pediat & Adolescent Med, Erlangen, Germany; [Buchfelder, M.; Eyupoglu, I. Y.; Savaskan, N.] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klinikum Erlangen UKER, Dept Neurosurg, Erlangen, Germany; [Savaskan, N.] BiMECON Ent, Berlin, Germany	University of Erlangen Nuremberg; Chinese People's Liberation Army General Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Erlangen Nuremberg; University of Erlangen Nuremberg	Savaskan, N (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klinikum Erlangen UKER, Translat Cell Biol & Neurooncol Lab, Schwabachanlage 6, D-91054 Erlangen, Germany.; Savaskan, N (corresponding author), BiMECON, Schwabachanlage 6, D-91054 Erlangen, Germany.	savaskan@gmx.net	Savaskan, Nicolai/D-2923-2018	Savaskan, Nicolai/0000-0003-1348-094X	China Scholarship Council (CSC) [201308110471]; Verein zur Forderung des Tumorzentrums der Universitat Erlangen-Nurnberg e.V.	China Scholarship Council (CSC)(China Scholarship Council); Verein zur Forderung des Tumorzentrums der Universitat Erlangen-Nurnberg e.V.	We thank all members of the Translational Neurooncology laboratory for valuable comments on this study and helpful suggestions. Christiane Muhle (Department of Psychiatry, Erlangen, Germany) is gratefully acknowledged for providing assistance with the digital qRT-PCR procedure. Christoph J. Wruck (from the RWTH Aachen, Germany) as well as Jana Wrosch and Marc Dahlmanns (from the Department of Psychiatry, Erlangen, Germany, and Molecular Medicine program at the Universitatsklinikum Erlangen) are acknowledged for sharing imaging technics and constructs exchange. DC holds a grant from the China Scholarship Council (CSC: 201308110471). This study was funded by the Verein zur Forderung des Tumorzentrums der Universitat Erlangen-Nurnberg e.V. to NES.	Angeli JPF, 2014, NAT CELL BIOL, V16, P1180, DOI 10.1038/ncb3064; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Broggini T, 2016, AGING-US, V8, P2463, DOI 10.18632/aging.101066; Castranova D, 2016, ARTERIOSCL THROM VAS, V36, P655, DOI 10.1161/ATVBAHA.115.307087; Chakraborty G, 2008, CANCER RES, V68, P152, DOI 10.1158/0008-5472.CAN-07-2126; Chevet E, 2015, CANCER DISCOV, V5, P586, DOI 10.1158/2159-8290.CD-14-1490; Conrad M, 2016, NAT REV DRUG DISCOV, V15, P348, DOI 10.1038/nrd.2015.6; Dey S, 2015, J CLIN INVEST, V125, P2592, DOI 10.1172/JCI78031; Dixon SJ, 2014, NAT CHEM BIOL, V10, P9, DOI 10.1038/nchembio.1416; Eyupoglu IY, 2013, NAT REV NEUROL, V9, P141, DOI 10.1038/nrneurol.2012.279; Fan Z, 2016, ONCOTARGET, V7, P26692, DOI 10.18632/oncotarget.8592; Fan Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093264; Fels DR, 2006, CANCER BIOL THER, V5, P723, DOI 10.4161/cbt.5.7.2967; Ghoochani A, 2016, ONCOGENE, V35, P6246, DOI 10.1038/onc.2016.160; Ghoochani A, 2016, ONCOTARGET, V7, P38306, DOI 10.18632/oncotarget.9439; Ghoochani A, 2016, ONCOTARGET, V7, P1838, DOI 10.18632/oncotarget.6550; Han J, 2013, NAT CELL BIOL, V15, P481, DOI 10.1038/ncb2738; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Igarashi T, 2007, ONCOGENE, V26, P4749, DOI 10.1038/sj.onc.1210289; Iurlaro R, 2016, FEBS J, V283, P2640, DOI 10.1111/febs.13598; Kilberg MS, 2009, TRENDS ENDOCRIN MET, V20, P436, DOI 10.1016/j.tem.2009.05.008; Mao XY, 2016, ONCOTARGET, V7, P33451, DOI 10.18632/oncotarget.7962; McConkey DJ, 2017, BIOCHEM BIOPH RES CO, V482, P450, DOI 10.1016/j.bbrc.2016.11.047; Pakos-Zebrucka K, 2016, EMBO REP, V17, P1374, DOI 10.15252/embr.201642195; Pereira ER, 2014, J BIOL CHEM, V289, P3352, DOI 10.1074/jbc.M113.507194; Robert SM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8103; Savaskan NE, 2011, ONCOGENE, V30, P43, DOI 10.1038/onc.2010.391; Savaskan NE, 2010, ANN ANAT, V192, P309, DOI 10.1016/j.aanat.2010.07.003; Savaskan NE, 2008, NAT MED, V14, P629, DOI 10.1038/nm1772; Savaskan NE, 2015, CURR NEUROPHARMACOL, V13, P258, DOI 10.2174/1570159X13666150122224158; Sehm T, 2016, ONCOTARGET, V7, P74630, DOI 10.18632/oncotarget.11858; Sehm T, 2016, ONCOTARGET, V7, P36021, DOI 10.18632/oncotarget.8651; Singleton DC, 2012, EXPERT OPIN THER TAR, V16, P1189, DOI 10.1517/14728222.2012.728207; Takeuchi S, 2013, NEUROSURGERY, V72, P33, DOI 10.1227/NEU.0b013e318276b2de; Tanabe M, 2003, CANCER RES, V63, P8592; Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020; Wang YG, 2013, NEOPLASIA, V15, P989, DOI 10.1593/neo.13262; Xu TF, 2016, SCI REP-UK, V6, DOI 10.1038/srep19799; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Zeng H, 2016, ONCOTARGET, V7, P7329, DOI 10.18632/oncotarget.6940; Zhao EH, 2016, CELL REP, V14, P506, DOI 10.1016/j.celrep.2015.12.053	42	169	175	8	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2017	36	40					5593	5608		10.1038/onc.2017.146	http://dx.doi.org/10.1038/onc.2017.146			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI8ZW	28553953	Green Published, hybrid			2022-12-17	WOS:000412293600004
J	Zou, Z; Huang, B; Wu, X; Zhang, H; Qi, J; Bradner, J; Nair, S; Chen, LF				Zou, Z.; Huang, B.; Wu, X.; Zhang, H.; Qi, J.; Bradner, J.; Nair, S.; Chen, L-F			Brd4 maintains constitutively active NF-kappa B in cancer cells by binding to acetylated RelA	ONCOGENE			English	Article						Brd4; cancer; degradation; JQ; NF-kappa B; ubiquitination	POSTTRANSLATIONAL MODIFICATIONS; DOWN-REGULATION; PROTEINS; TARGET; INFLAMMATION; INHIBITOR	Acetylation of the RelA subunit of NF-kappa B at lysine-310 regulates the transcriptional activation of NF-kappa B target genes and contributes to maintaining constitutively active NF-kappa B in tumors. Bromodomain-containing factor Brd4 has been shown to bind to acetylated lysine-310 (AcLys310) and to regulate the transcriptional activity of NF-kappa B, but the role of this binding in maintaining constitutively active NF-kappa B in tumors remains elusive. In this study, we demonstrate the structural basis for the binding of bromodomains (BDs) of bromodomain-containing protein 4 ( Brd4) to AcLys310 and identify the BD inhibitor JQ1 as an effective small molecule to block this interaction. JQ1 suppresses TNF-alpha-mediated NF-kappa B activation and NF-kappa B-dependent target gene expression. In addition, JQ1 inhibits the proliferation and transformation potential of A549 lung cancer cells and suppresses the tumorigenicity of A549 cells in severe combined immunodeficiency mice. Furthermore, we demonstrate that depletion of Brd4 or treatment of cells with JQ1 induces the ubiquitination and degradation of the constitutively active nuclear form of RelA. Our results identify a novel function of Brd4 in maintaining the persistently active form of NF-kappa B found in tumors, and they suggest that interference with the interaction between acetylated RelA and Brd4 could be a potential therapeutic approach for the treatment of NF-kappa B-driven cancer.	[Zou, Z.; Huang, B.; Wu, X.; Zhang, H.; Nair, S.; Chen, L-F] Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA; [Qi, J.; Bradner, J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Chen, L-F] Univ Illinois, Coll Med, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; Harvard University; Dana-Farber Cancer Institute; University of Illinois System; University of Illinois Urbana-Champaign	Chen, LF (corresponding author), Univ Illinois, Coll Med, Dept Biochem, MC-714, Urbana, IL 61801 USA.	lfchen@life.illinois.edu	Nair, Satish/AAY-2510-2021; 高, 雨莉/HGU-8187-2022	Zou, Zhenhua/0000-0003-0296-6231	UIUC; NIH [DK-085158]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK093865, R01DK085158] Funding Source: NIH RePORTER	UIUC; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank members in the Chen lab for discussion and A Lamb for assistance in the preparation of the manuscript. This work is supported in part by funds provided by UIUC (to LFC) and NIH grants DK-085158 (to LFC).	Adcock IM, 2007, CURR OPIN IMMUNOL, V19, P694, DOI 10.1016/j.coi.2007.07.016; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Belkina AC, 2012, NAT REV CANCER, V12, P465, DOI 10.1038/nrc3256; Chaturvedi MM, 2011, ONCOGENE, V30, P1615, DOI 10.1038/onc.2010.566; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chen LF, 2005, MOL CELL BIOL, V25, P7966, DOI 10.1128/MCB.25.18.7966-7975.2005; Chiarella C, 2009, ROUTL INT STUD MONEY, P1; Choi KC, 2009, MOL CANCER RES, V7, P2011, DOI 10.1158/1541-7786.MCR-09-0239; Chung CW, 2012, PROGR MED CHEM, V51, P1, DOI 10.1016/B978-0-12-396493-9.00001-7; Dai Y, 2005, MOL CELL BIOL, V25, P5429, DOI 10.1128/MCB.25.13.5429-5444.2005; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; French CA, 2012, ANNU REV PATHOL-MECH, V7, P247, DOI 10.1146/annurev-pathol-011811-132438; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gupta SC, 2010, BBA-GENE REGUL MECH, V1799, P775, DOI 10.1016/j.bbagrm.2010.05.004; Huang B, 2012, ONCOGENE, V31, P527, DOI 10.1038/onc.2011.252; Huang B, 2010, CELL SIGNAL, V22, P1282, DOI 10.1016/j.cellsig.2010.03.017; Huang B, 2009, MOL CELL BIOL, V29, P1375, DOI 10.1128/MCB.01365-08; Ishinaga H, 2007, EMBO J, V26, P1150, DOI 10.1038/sj.emboj.7601546; Jang MK, 2009, J VIROL, V83, P2592, DOI 10.1128/JVI.02275-08; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Lee AY, 2009, J BIOL CHEM, V284, P2778, DOI 10.1074/jbc.M805835200; Lee H, 2009, CANCER CELL, V15, P283, DOI 10.1016/j.ccr.2009.02.015; Maruyama T, 2002, MOL CELL BIOL, V22, P6509, DOI 10.1128/MCB.22.18.6509-6520.2002; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Oliver SS, 2011, ANGEW CHEM INT EDIT, V50, P5801, DOI 10.1002/anie.201101414; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Saccani S, 2004, J EXP MED, V200, P107, DOI 10.1084/jem.20040196; Sen R, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000257; Sims RJ, 2008, NAT REV MOL CELL BIO, V9, P815, DOI 10.1038/nrm2502; Wu SY, 2007, J BIOL CHEM, V282, P13141, DOI 10.1074/jbc.R700001200; Yang XD, 2010, MOL CELL BIOL, V30, P2170, DOI 10.1128/MCB.01343-09; Yang XD, 2009, EMBO J, V28, P1055, DOI 10.1038/emboj.2009.55; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; You J, 2004, CELL, V117, P349, DOI 10.1016/S0092-8674(04)00402-7; Zhang GT, 2012, J BIOL CHEM, V287, P28840, DOI 10.1074/jbc.M112.359505; Zheng G, 2009, J VIROL, V83, P8683, DOI 10.1128/JVI.00674-09; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	51	169	177	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2395	2404		10.1038/onc.2013.179	http://dx.doi.org/10.1038/onc.2013.179			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23686307	Green Accepted			2022-12-17	WOS:000335451800012
J	Tagscherer, KE; Fassl, A; Campos, B; Farhadi, M; Kraemer, A; Bock, BC; Macher-Goeppinger, S; Radlwimmer, B; Wiestler, OD; Herold-Mende, C; Roth, W				Tagscherer, K. E.; Fassl, A.; Campos, B.; Farhadi, M.; Kraemer, A.; Boeck, B. C.; Macher-Goeppinger, S.; Radlwimmer, B.; Wiestler, O. D.; Herold-Mende, C.; Roth, W.			Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins	ONCOGENE			English	Article						apoptosis; brain tumors; glioma; ABT-737; Bcl-2 inhibitor	HUMAN-MALIGNANT GLIOMA; BH3 MIMETIC ABT-737; ACUTE LYMPHOBLASTIC-LEUKEMIA; GROWTH-FACTOR-RECEPTOR; CELL LUNG-CANCER; IN-VIVO; STEM-CELLS; IMMUNOHISTOCHEMICAL ANALYSIS; CHEMOTHERAPEUTIC-AGENTS; DOWN-REGULATION	Defects in the apoptotic signaling cascades contribute to the poor therapeutic response of malignant gliomas. As glioblastomas are characterized by high expression levels of anti-apoptotic Bcl-2 family proteins, we studied the effects of the novel Bcl-2 inhibitor, ABT-737, on malignant glioma cells. ABT-737 treatment released the pro-apoptotic Bax protein from its binding partner Bcl-2 and potently induced apoptotic cell death in glioblastoma cells in vitro and in vivo. The local administration of ABT-737 prolonged the survival in an intracranial glioma xenograft model. Downregulation of Mcl-1 and overexpression of Bcl-2 sensitized the cells to ABT-737mediated apoptosis. Moreover, ABT-737 potentiated the cytotoxicity of the chemotherapeutic drugs vincristine and etoposide, and of the death ligand TRAIL. As glioma stem cells may play a crucial role for the tumor progression and the resistance to treatment in glioblastomas, we investigated the effects of ABT-737 on the subpopulation of glioma cells exhibiting stem cell characteristics. Inhibition of proliferation and induction of apoptosis by ABT-737 were less efficient in glioma stem cells than in non-stem cell-like glioma cells. As the resistance of glioma stem cells was associated with high Mcl-1 expression levels, ABT-737 treatment combined with downregulation of Mcl-1 could represent a promising novel approach in glioblastoma treatment.	[Roth, W.] German Canc Res Ctr, DKFZ, D-69120 Heidelberg, Germany; [Campos, B.; Farhadi, M.; Herold-Mende, C.] Heidelberg Univ, Dept Neurosurg, Div Neurosurg Res, Heidelberg, Germany; [Macher-Goeppinger, S.; Roth, W.] Heidelberg Univ, Inst Pathol, Heidelberg, Germany; [Radlwimmer, B.] German Canc Res Ctr, Div Mol Genet, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Roth, W (corresponding author), German Canc Res Ctr, DKFZ, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	W.Roth@dkfz.de	Radlwimmer, Bernhard F/I-3229-2013; Fassl, Anne/AAA-5249-2022; Tagscherer, Katrin/AAS-3809-2021	Radlwimmer, Bernhard F/0000-0002-4553-7800; Tagscherer, Katrin/0000-0002-0657-6399	Deutsche Krebshilfe	Deutsche Krebshilfe(Deutsche Krebshilfe)	This work was supported by a grant from the Deutsche Krebshilfe to WR (German Cancer Aid, Max Eder Program). We thank Ilona Demir, Monika Frank-Stohr and Sarah MeBnard for expert technical assistance. We thank Manfred Jugold (Molecular Imaging, German Cancer Research Center) for performing magnetic resonance imaging of animals.	Adams JM, 2005, COLD SH Q B, V70, P469, DOI 10.1101/sqb.2005.70.009; Ahmadi R, 2006, FREE RADICAL BIO MED, V40, P763, DOI 10.1016/j.freeradbiomed.2005.09.031; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; CAMPOS B, 2008, DIFFERENTIATIO UNPUB; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chauhan D, 2007, ONCOGENE, V26, P2374, DOI 10.1038/sj.onc.1210028; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Chen S, 2007, CANCER RES, V67, P782, DOI 10.1158/0008-5472.CAN-06-3964; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; Del Bufalo D, 2001, J CELL BIOCHEM, V83, P473, DOI 10.1002/jcb.1245; Deng J, 2007, CANCER RES, V67, P11867, DOI 10.1158/0008-5472.CAN-07-1961; Deng J, 2007, CANCER CELL, V12, P171, DOI 10.1016/j.ccr.2007.07.001; Dictus C, 2007, J NEUROSCI METH, V161, P250, DOI 10.1016/j.jneumeth.2006.11.012; Eramo A, 2006, CELL DEATH DIFFER, V13, P1238, DOI 10.1038/sj.cdd.4401872; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; Glaser T, 1999, ONCOGENE, V18, P5044, DOI 10.1038/sj.onc.1202882; Gong YX, 2007, PLOS MED, V4, P1655, DOI 10.1371/journal.pmed.0040294; Green DR, 2006, CANCER CELL, V9, P328, DOI 10.1016/j.ccr.2006.05.004; Hann CL, 2008, CANCER RES, V68, P2321, DOI 10.1158/0008-5472.CAN-07-5031; Huang SB, 2008, CANCER RES, V68, P2944, DOI 10.1158/0008-5472.CAN-07-2508; Kajiwara Y, 2003, CANCER-AM CANCER SOC, V97, P1077, DOI 10.1002/cncr.11122; Kang MH, 2008, JNCI-J NATL CANCER I, V100, P580, DOI 10.1093/jnci/djn076; Kang MH, 2007, BLOOD, V110, P2057, DOI 10.1182/blood-2007-03-080325; Karcher S, 2006, INT J CANCER, V118, P2182, DOI 10.1002/ijc.21648; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Krajewski S, 1997, AM J PATHOL, V150, P805; KRAJEWSKI S, 1995, AM J PATHOL, V146, P1309; Kraus JA, 2001, J NEURO-ONCOL, V52, P263, DOI 10.1023/A:1010684203704; Letai A, 2006, CANCER CELL, V10, P343, DOI 10.1016/j.ccr.2006.10.014; Lin X, 2007, ONCOGENE, V26, P3972, DOI 10.1038/sj.onc.1210166; Moore VD, 2008, BLOOD, V111, P2300, DOI 10.1182/blood-2007-06-098012; Moore VD, 2007, J CLIN INVEST, V117, P112, DOI 10.1172/JCI28281; Nagane M, 2000, CANCER RES, V60, P847; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; Olejniczak ET, 2007, MOL CANCER RES, V5, P331, DOI 10.1158/1541-7786.MCR-06-0367; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Pollack IF, 2001, CLIN CANCER RES, V7, P1362; Reed JC, 2006, NAT CLIN PRACT ONCOL, V3, P388, DOI 10.1038/ncponc0538; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Riemenschneider MJ, 2006, CANCER RES, V66, P5618, DOI 10.1158/0008-5472.CAN-06-0364; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Sinicrope FA, 2004, CLIN CANCER RES, V10, P8284, DOI 10.1158/1078-0432.CCR-04-1289; Stupp R, 2007, NAT BIOTECHNOL, V25, P193, DOI 10.1038/nbt0207-193; Tahir SK, 2007, CANCER RES, V67, P1176, DOI 10.1158/0008-5472.CAN-06-2203; Trudel S, 2007, CLIN CANCER RES, V13, P621, DOI 10.1158/1078-0432.CCR-06-1526; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Wagenknecht B, 1999, CELL DEATH DIFFER, V6, P370, DOI 10.1038/sj.cdd.4400503; Webb JL, 1963, ENZYMES METABOL INH, V1, P487; Weiler M, 2006, CELL DEATH DIFFER, V13, P1156, DOI 10.1038/sj.cdd.4401786; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Zangemeister-Wittke U, 2003, ANN NY ACAD SCI, V1002, P90, DOI 10.1196/annals.1281.019	55	169	171	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2008	27	52					6646	6656		10.1038/onc.2008.259	http://dx.doi.org/10.1038/onc.2008.259			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368QY	18663354				2022-12-17	WOS:000260638800003
J	Leslie, NR; Batty, IH; Maccario, H; Davidson, L; Downes, CP				Leslie, N. R.; Batty, I. H.; Maccario, H.; Davidson, L.; Downes, C. P.			Understanding PTEN regulation: PIP2, polarity and protein stability	ONCOGENE			English	Review						phosphatase; phosphoinositide; cell polarity; Akt; SHIP	TUMOR-SUPPRESSOR PTEN; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE ACCUMULATION; PHOSPHOLIPASE C-GAMMA; TENSIN-HOMOLOG; NEURONAL POLARITY; REDOX REGULATION; CELL POLARITY; LEADING-EDGE; PHOSPHATASE-ACTIVITY; LIPID PHOSPHATASES	The PTEN tumour suppressor is a lipid and protein phosphatase that inhibits phosphoinositide 3-kinase (PI3K)-dependent signalling by dephosphorylating phosphatidylinositol 3,4,5-trisphosphate (PtdInsP(3)). Here, we discuss the concept of PTEN as an 'interfacial enzyme', which exists in a high activity state when bound transiently at membrane surfaces containing its substrate and other acidic lipids, such as PtdIns(4,5)P-2 and phosphatidylserine (PtdSer). This mechanism ensures that PTEN functions in a spatially restricted manner, and may explain its involvement in forming the gradients of PtdInsP(3), which are necessary for generating and/or sustaining cell polarity during motility, in developing neurons and in epithelial tissues. Coordinating PTEN activity with alternative mechanisms of PtdInsP(3) metabolism, by the tightly regulated SHIP 5-phoshatases, synthesizing the independent second messenger PtdIns(3,4)P-2, may also be important for cellular polarization in some cell types. Superimposed on this interfacial mechanism are additional post-translational regulatory processes, which generally act to reduce PTEN activity. Oxidation of the active site cysteine residue by reactive oxygen species and phosphorylation of serine/threonine residues at sites in the C-terminus of the protein inhibit PTEN. These phosphorylation sites also appear to play a role in regulating both stability and localization of PTEN, as does ubiquitination of PTEN. Because genetic studies in mice show that the level of expression of PTEN in an organism profoundly influences tumour susceptibility, factors that regulate PTEN, localization, activity and turnover should be important in understanding its biological functions as a tumour suppressor.	[Leslie, N. R.; Batty, I. H.; Maccario, H.; Davidson, L.; Downes, C. P.] Univ Dundee, Div Mol Physiol, Coll Life Sci, James Black Ctr, Dundee DD1 5EH, Scotland	University of Dundee	Leslie, NR (corresponding author), Univ Dundee, Div Mol Physiol, Coll Life Sci, James Black Ctr, Dow St, Dundee DD1 5EH, Scotland.	n.r.leslie@dundee.ac.uk; c.p.downes@dundee.ac.uk	Leslie, Nicholas/D-2699-2009	LESLIE, Nicholas/0000-0001-5131-0541	Medical Research Council; Association for International Cancer Research; consortium of pharmaceutical companies comprising Astra Zeneca; Boehringer Ingelheim; GlaxoSmithKline; Merck and Co; Merck KGaA; Pfizer; Medical Research Council [G9403619] Funding Source: researchfish; MRC [G9403619] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Association for International Cancer Research; consortium of pharmaceutical companies comprising Astra Zeneca(AstraZeneca); Boehringer Ingelheim(Boehringer Ingelheim); GlaxoSmithKline(GlaxoSmithKline); Merck and Co(Merck & Company); Merck KGaA; Pfizer(Pfizer); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Research in the Inositol Lipid Signalling laboratory is funded by the Medical Research Council, the Association for International Cancer Research and a consortium of pharmaceutical companies comprising Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck and Co., Merck KGaA and Pfizer.	Adler CE, 2006, NAT NEUROSCI, V9, P511, DOI 10.1038/nn1666; Ahn Y, 2008, BIOCHEM J, V412, P331, DOI 10.1042/BJ20071403; Al-Khouri AM, 2005, J BIOL CHEM, V280, P35195, DOI 10.1074/jbc.M503045200; Aoki K, 2005, MOL BIOL CELL, V16, P2207, DOI 10.1091/mbc.e04-10-0904; Arevalo MA, 2006, MOL BIOL CELL, V17, P3369, DOI 10.1091/mbc.E05-12-1144; Arimura N, 2007, NAT REV NEUROSCI, V8, P194, DOI 10.1038/nrn2056; Backers K, 2003, ADV ENZYME REGUL, V43, P15, DOI 10.1016/S0065-2571(02)00043-2; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Baker SJ, 2007, CELL, V128, P25, DOI 10.1016/j.cell.2006.12.023; Batty IH, 1996, BIOCHEM J, V317, P347, DOI 10.1042/bj3170347; BATTY IH, 2001, BIOCHEM J, V379, P641; BATTY IH, 2002, BIOCHEM J, V407, P255; Blero D, 2001, BIOCHEM BIOPH RES CO, V282, P839, DOI 10.1006/bbrc.2001.4639; Cai ZQ, 2005, CIRC RES, V97, P1351, DOI 10.1161/01.RES.0000195656.52760.30; Campbell RB, 2003, J BIOL CHEM, V278, P33617, DOI 10.1074/jbc.C300296200; Chadborn NH, 2006, J CELL SCI, V119, P951, DOI 10.1242/jcs.02801; Charest PG, 2006, CURR OPIN GENET DEV, V16, P339, DOI 10.1016/j.gde.2006.06.016; Choi YC, 2004, FUND CLIN PHARMACOL, V18, P547, DOI 10.1111/j.1472-8206.2004.00284.x; Costello PS, 2002, NAT IMMUNOL, V3, P1082, DOI 10.1038/ni848; Covey TM, 2007, ONCOGENE, V26, P5784, DOI 10.1038/sj.onc.1210391; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Dey N, 2008, CANCER RES, V68, P1862, DOI 10.1158/0008-5472.CAN-07-1182; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; Downes CP, 2007, BIOCHEM SOC T, V35, P188, DOI 10.1042/BST0350188; Downes CP, 2007, BIOCHEM SOC SYMP, V74, P69, DOI 10.1042/BSS2007c07; Dyson JM, 2005, INT J BIOCHEM CELL B, V37, P2260, DOI 10.1016/j.biocel.2005.05.003; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Franca-Koh J, 2007, NAT CELL BIOL, V9, P15, DOI 10.1038/ncb0107-15; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Gil A, 2006, MOL BIOL CELL, V17, P4002, DOI 10.1091/mbc.E06-05-0380; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Giuriato S, 1997, J BIOL CHEM, V272, P26857, DOI 10.1074/jbc.272.43.26857; Giuriato S, 2002, BIOCHEM BIOPH RES CO, V296, P106, DOI 10.1016/S0006-291X(02)00787-8; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; Harriague J, 2002, NAT IMMUNOL, V3, P1090, DOI 10.1038/ni847; Harris SJ, 2008, J BIOL CHEM, V283, P2465, DOI 10.1074/jbc.R700044200; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; Hoshino Y, 2007, J CELL BIOCHEM, V100, P515, DOI 10.1002/jcb.21085; Hui STY, 2008, P NATL ACAD SCI USA, V105, P3921, DOI 10.1073/pnas.0800293105; Iglesias PA, 2008, CURR OPIN CELL BIOL, V20, P35, DOI 10.1016/j.ceb.2007.11.011; Iijima M, 2004, J BIOL CHEM, V279, P16606, DOI 10.1074/jbc.M312098200; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Iijima M, 2002, DEV CELL, V3, P469, DOI 10.1016/S1534-5807(02)00292-7; Ijuin T, 2000, J BIOL CHEM, V275, P10870, DOI 10.1074/jbc.275.15.10870; Insall R, 2007, CURR OPIN MICROBIOL, V10, P578, DOI 10.1016/j.mib.2007.10.004; Janetopoulos C, 2006, J CELL BIOL, V174, P485, DOI 10.1083/jcb.200603156; Jiang H, 2005, CELL, V120, P123, DOI 10.1016/j.cell.2004.12.033; Keizer-Gunnink I, 2007, J CELL BIOL, V177, P579, DOI 10.1083/jcb.200611046; Kim KY, 2004, EUR J PHARMACOL, V497, P267, DOI 10.1016/j.ejphar.2004.06.058; Kortholt A, 2007, MOL BIOL CELL, V18, P4772, DOI 10.1091/mbc.E07-05-0407; Kotelevets L, 2004, FASEB J, V18, P115, DOI 10.1096/fj.04-1942fje; Koul D, 2002, ONCOGENE, V21, P2357, DOI 10.1038/sj/onc/1205296; Krause M, 2004, DEV CELL, V7, P571, DOI 10.1016/j.devcel.2004.07.024; Krugmann S, 2006, METHOD ENZYMOL, V406, P91, DOI 10.1016/S0076-6879(06)06008-3; Krugmann S, 2004, CURR BIOL, V14, P1380, DOI 10.1016/j.cub.2004.07.058; Krystal G, 1999, INT J BIOCHEM CELL B, V31, P1007, DOI 10.1016/S1357-2725(99)00072-2; Kwon J, 2004, P NATL ACAD SCI USA, V101, P16419, DOI 10.1073/pnas.0407396101; Lacalle RA, 2004, J CELL SCI, V117, P6207, DOI 10.1242/jcs.01545; Lazar DF, 2006, NAT REV DRUG DISCOV, V5, P333, DOI 10.1038/nrd2007; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Leslie NR, 2007, CURR BIOL, V17, P115, DOI 10.1016/j.cub.2006.12.026; Leslie NR, 2006, ANTIOXID REDOX SIGN, V8, P1765, DOI 10.1089/ars.2006.8.1765; Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Leslie NR, 2001, BIOCHEM J, V357, P427, DOI 10.1042/0264-6021:3570427; Li DM, 1997, CANCER RES, V57, P2124; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Lindsay Y, 2006, J CELL SCI, V119, P5160, DOI 10.1242/jcs.000133; Liu FH, 2005, J CELL BIOCHEM, V96, P221, DOI 10.1002/jcb.20525; Liu H, 2004, J CELL BIOL, V164, P603, DOI 10.1083/jcb.200306090; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; Maccario H, 2007, BIOCHEM J, V405, P439, DOI 10.1042/BJ20061837; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; McConnachie G, 2003, BIOCHEM J, V371, P947, DOI 10.1042/BJ20021848; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Miller SJ, 2002, FEBS LETT, V528, P145, DOI 10.1016/S0014-5793(02)03274-X; Mochizuki Y, 1999, J BIOL CHEM, V274, P36790, DOI 10.1074/jbc.274.51.36790; Ning K, 2006, EMBO J, V25, P2377, DOI 10.1038/sj.emboj.7601118; Nishio M, 2007, NAT CELL BIOL, V9, P36, DOI 10.1038/ncb1515; NORRIS FA, 1995, J BIOL CHEM, V270, P16128, DOI 10.1074/jbc.270.27.16128; Norris FA, 1997, J BIOL CHEM, V272, P23859, DOI 10.1074/jbc.272.38.23859; Nystuen A, 2001, NEURON, V32, P203, DOI 10.1016/S0896-6273(01)00468-8; Odriozola L, 2007, J BIOL CHEM, V282, P23306, DOI 10.1074/jbc.M611240200; Okahara F, 2004, J BIOL CHEM, V279, P45300, DOI 10.1074/jbc.C400377200; Okamura A, 2006, LIFE SCI, V78, P1624, DOI 10.1016/j.lfs.2005.07.041; Okumura K, 2005, P NATL ACAD SCI USA, V102, P2703, DOI 10.1073/pnas.0409370102; Okumura K, 2006, J BIOL CHEM, V281, P26562, DOI 10.1074/jbc.M605391200; Ong CJ, 2007, BLOOD, V110, P1942, DOI 10.1182/blood-2007-03-079699; Pallares J, 2005, MODERN PATHOL, V18, P719, DOI 10.1038/modpathol.3800347; Papakonstanti EA, 2007, EMBO J, V26, P3050, DOI 10.1038/sj.emboj.7601763; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Perren A, 2000, AM J PATHOL, V157, P1097, DOI 10.1016/S0002-9440(10)64624-X; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Pinal N, 2006, CURR BIOL, V16, P140, DOI 10.1016/j.cub.2005.11.068; Rafiq K, 2006, J BIOL CHEM, V281, P19781, DOI 10.1074/jbc.M513040200; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Redfern RE, 2008, BIOCHEMISTRY-US, V47, P2162, DOI 10.1021/bi702114w; Rhee SG, 2005, CURR OPIN CELL BIOL, V17, P183, DOI 10.1016/j.ceb.2005.02.004; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Rohrschneider LR, 2000, GENE DEV, V14, P505; Sanchez T, 2005, P NATL ACAD SCI USA, V102, P4312, DOI 10.1073/pnas.0409784102; Seo JH, 2005, MOL BIOL CELL, V16, P348, DOI 10.1091/mbc.E04-05-0369; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Shin HW, 2005, J CELL BIOL, V170, P607, DOI 10.1083/jcb.200505128; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Sleeman MW, 2005, NAT MED, V11, P199, DOI 10.1038/nm1178; Song P, 2007, CIRCULATION, V116, P1585, DOI 10.1161/CIRCULATIONAHA.107.716498; Subauste MC, 2005, J BIOL CHEM, V280, P5676, DOI 10.1074/jbc.M405561200; Suzuki A, 2003, J EXP MED, V197, P657, DOI 10.1084/jem.20021101; Suzuki A, 2008, CANCER SCI, V99, P209, DOI 10.1111/j.1349-7006.2007.00670.x; Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979; Taylor V, 2000, MOL CELL BIOL, V20, P6860, DOI 10.1128/MCB.20.18.6860-6871.2000; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2003, J BIOL CHEM, V278, P30652, DOI 10.1074/jbc.M212610200; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Valiente M, 2005, J BIOL CHEM, V280, P28936, DOI 10.1074/jbc.M504761200; Van der Kaay J, 1999, J BIOL CHEM, V274, P35963, DOI 10.1074/jbc.274.50.35963; Van Keymeulen A, 2006, J CELL BIOL, V174, P437, DOI 10.1083/jcb.200604113; Vazquez F, 2006, P NATL ACAD SCI USA, V103, P3633, DOI 10.1073/pnas.0510570103; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; von Stein W, 2005, DEVELOPMENT, V132, P1675, DOI 10.1242/dev.01720; Vyas P, 2000, P NATL ACAD SCI USA, V97, P13696, DOI 10.1073/pnas.250476397; Walker SM, 2004, BIOCHEM J, V379, P301, DOI 10.1042/BJ20031839; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Weiner OD, 2002, CURR OPIN CELL BIOL, V14, P196, DOI 10.1016/S0955-0674(02)00310-1; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; Wu H, 2007, MOL CELL, V28, P886, DOI 10.1016/j.molcel.2007.10.028; Wu WD, 2003, J BIOL CHEM, V278, P28258, DOI 10.1074/jbc.M303318200; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; Yeung T, 2008, SCIENCE, V319, P210, DOI 10.1126/science.1152066; Yeung T, 2007, IMMUNOL REV, V219, P17, DOI 10.1111/j.1600-065X.2007.00546.x; Yeung T, 2006, SCIENCE, V313, P347, DOI 10.1126/science.1129551; Yu CX, 2005, MOL PHARMACOL, V68, P847, DOI 10.1124/mol.104.010504	145	169	174	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2008	27	41					5464	5476		10.1038/onc.2008.243	http://dx.doi.org/10.1038/onc.2008.243			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KW	18794881				2022-12-17	WOS:000259280700008
J	Osipo, C; Patel, P; Rizzo, P; Clementz, AG; Hao, L; Golde, TE; Miele, L				Osipo, C.; Patel, P.; Rizzo, P.; Clementz, A. G.; Hao, L.; Golde, T. E.; Miele, L.			ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor	ONCOGENE			English	Article						ErbB-2; trastuzumab; Notch-1; GSI; breast cancer	PHASE-II TRIAL; TRASTUZUMAB RESISTANCE; TAMOXIFEN RESISTANCE; MONOCLONAL-ANTIBODY; WEEKLY VINORELBINE; 1ST-LINE THERAPY; RECEPTOR; GROWTH; HER2; CHEMOTHERAPY	ErbB-2 overexpression in breast tumors is associated with poor survival. Expression of Notch-1 and its ligand, Jagged-1, is associated with the poorest survival, including ErbB-2-positive tumors. Trastuzumab plus chemotherapy is the standard of care for ErbB-2-positive breast cancer. A proportion of tumors are initially resistant to trastuzumab and acquired resistance to trastuzumab occurs in metastatic breast cancer and is associated with poor prognosis. Thus, we investigated whether Notch-1 contributes to trastuzumab resistance. ErbB-2-positive cells have low Notch transcriptional activity compared to non-overexpressing cells. Trastuzumab or a dual epidermal growth factor receptor (EGFR)/ErbB-2 tyrosine kinase inhibitor (TKI) increased Notch activity by 2- to 6-fold in SKBr3, BT474 and MCF-7/HER2-18 cells. The increase in activity was abrogated by a Notch inhibitor, gamma-secretase inhibitor (GSI) or Notch-1 small-interfering RNA ( siRNA). Trastuzumab decreased Notch-1 (TM) precursor, increased amount and nuclear accumulation of active Notch-1(IC) and increased expression of targets, Hey1 and Deltex1 mRNAs, and Hes5, Hey1, Hes1 proteins. Importantly, trastuzumab-resistant BT474 cells treated with trastuzumab for 6 months expressed twofold higher Notch-1, twofold higher Hey1, ninefold higher Deltex1 mRNAs and threefold higher Notch-1 and Hes5 proteins, compared to trastuzumab-sensitive BT474 cells. The increase in Hey1 and Deltex1 mRNAs in resistant cells was abrogated by a Notch-1 siRNA. Cell proliferation was inhibited more effectively by trastuzumab or TKI plus a GSI than either agent alone. Decreased Notch-1 by siRNA increased efficacy of trastuzumab in BT474 sensitive cells and restored sensitivity in resistant cells. Trastuzumab plus a GSI increased apoptosis in sensitive cells by 20-30%. A GSI alone was sufficient to increase apoptosis in trastuzumab-resistant BT474 cells by 20%, which increased to 30% with trastuzumab. Notch-1 siRNA alone decreased cell growth by 30% in sensitive and more than 50% in resistant BT474 cells. Furthermore, growth of both trastuzumab sensitive and resistant cells was completely inhibited by combining trastuzumab plus Notch-1 siRNA. More importantly, Notch-1 siRNA or a GSI resensitized trastuzumab-resistant BT474 cells to trastuzumab. These results demonstrate that ErbB-2 overexpression suppresses Notch-1 activity, which can be reversed by trastuzumab or TKI. These results suggest that Notch-1 might play a novel role in resistance to trastuzumab, which could be prevented or reversed by inhibiting Notch-1.	[Osipo, C.; Rizzo, P.; Hao, L.; Miele, L.] Loyola Univ, Inst Oncol, Med Ctr, Cardinal Bernardin Canc Ctr,Dept Pathol, Maywood, IL 60153 USA; [Osipo, C.; Patel, P.; Clementz, A. G.] Loyola Univ, Cardinal Bernardin Canc Ctr, Med Ctr, Mol & Cellular Biochem Program, Maywood, IL 60153 USA; [Hao, L.; Miele, L.] Loyola Univ, Cardinal Bernardin Canc Ctr, Med Ctr, Program Mol Biol, Maywood, IL 60153 USA; [Golde, T. E.] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA; [Miele, L.] Loyola Univ, Dept Pharmacol & Mol Therapeut, Cardinal Bernardin Canc Ctr, Med Ctr, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; Mayo Clinic; Loyola University Chicago	Osipo, C (corresponding author), Loyola Univ, Inst Oncol, Med Ctr, Cardinal Bernardin Canc Ctr,Dept Pathol, 2160 S 1st Ave, Maywood, IL 60153 USA.	cosipo@lumc.edu		Miele, Lucio/0000-0002-5853-7287; rizzo, paola/0000-0001-7174-9674				Amar S, 2008, BREAST CANCER RES TR, V109, P1, DOI 10.1007/s10549-007-9636-2; Arpino G, 2005, JNCI-J NATL CANCER I, V97, P1254, DOI 10.1093/jnci/dji249; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Baonza A, 2005, DEV CELL, V8, P529, DOI 10.1016/j.devcel.2005.01.019; Baselga J, 2001, SEMIN ONCOL, V28, P4, DOI 10.1053/sonc.2001.28544; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Burstein HJ, 2003, J CLIN ONCOL, V21, P2889, DOI 10.1200/JCO.2003.02.018; Burstein HJ, 2001, J CLIN ONCOL, V19, P2722, DOI 10.1200/JCO.2001.19.10.2722; Calzavara E, 2008, J CELL BIOCHEM, V103, P1405, DOI 10.1002/jcb.21527; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Dickson BC, 2007, MODERN PATHOL, V20, P685, DOI 10.1038/modpathol.3800785; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Efstratiadis A, 2007, CELL CYCLE, V6, P418, DOI 10.4161/cc.6.4.3838; Farnie G, 2007, JNCI-J NATL CANCER I, V99, P616, DOI 10.1093/jnci/djk133; Florena AM, 2007, PATHOBIOLOGY, V74, P317, DOI 10.1159/000110024; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; Jahanzeb M, 2002, ONCOLOGIST, V7, P410, DOI 10.1634/theoncologist.7-5-410; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Lu YH, 2004, INT J CANCER, V108, P334, DOI 10.1002/ijc.11445; Menendez JA, 2006, J CLIN ONCOL, V24, P3735, DOI 10.1200/JCO.2005.04.3489; Miele L, 2006, CLIN CANCER RES, V12, P1074, DOI 10.1158/1078-0432.CCR-05-2570; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Miele L, 2006, CURR MOL MED, V6, P905, DOI 10.2174/156652406779010830; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; Nabholtz JM, 2001, SEMIN ONCOL, V28, P1; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2006, CANCER LETT, V232, P123, DOI 10.1016/j.canlet.2005.01.041; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; O'Neill CF, 2007, AM J PATHOL, V171, P1023, DOI 10.2353/ajpath.2007.061029; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Osipo C, 2003, J NATL CANCER I, V95, P1597, DOI 10.1093/jnci/djg079; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Papaldo P, 2006, ANN ONCOL, V17, P630, DOI 10.1093/annonc/mdj110; Parks AL, 2000, DEVELOPMENT, V127, P1373; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Politi K, 2004, SEMIN CANCER BIOL, V14, P341, DOI 10.1016/j.semcancer.2004.04.013; Price-Schiavi SA, 2002, INT J CANCER, V99, P783, DOI 10.1002/ijc.10410; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; REEDIJK M, 2007, BREAST CANC RES TREA; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seidman AD, 2001, J CLIN ONCOL, V19, P2587, DOI 10.1200/JCO.2001.19.10.2587; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Vooijs M, 2004, J BIOL CHEM, V279, P50864, DOI 10.1074/jbc.M409430200; Weber U, 2003, DEV CELL, V5, P559, DOI 10.1016/S1534-5807(03)00273-9; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Xia W, 2006, P NATL ACAD SCI USA, V103, P7795, DOI 10.1073/pnas.0602468103; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396; Yokoyama Goro, 2005, Int J Clin Oncol, V10, P139	67	169	181	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2008	27	37					5019	5032		10.1038/onc.2008.149	http://dx.doi.org/10.1038/onc.2008.149			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18469855				2022-12-17	WOS:000258914800005
J	Gotzmann, J; Fischer, ANM; Zojer, M; Mikula, M; Proell, V; Huber, H; Jechlinger, M; Waerner, T; Weith, A; Beug, H; Mikulits, W				Gotzmann, J.; Fischer, A. N. M.; Zojer, M.; Mikula, M.; Proell, V.; Huber, H.; Jechlinger, M.; Waerner, T.; Weith, A.; Beug, H.; Mikulits, W.			A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes	ONCOGENE			English	Review						hepatocytes; epithelial to mesenchymal transition; expression profiling; PDGF	GROWTH-FACTOR-BETA; EPITHELIAL-MESENCHYMAL TRANSITIONS; E-CADHERIN EXPRESSION; HUMAN HEPATOCELLULAR-CARCINOMA; TRANSCRIPTION FACTOR SNAIL; JUN NH2-TERMINAL KINASE-1; HEPATIC STELLATE CELLS; BREAST-CANCER; GENE-EXPRESSION; TUMOR-CELLS	Polarized hepatocytes expressing hyperactive Ha-Ras adopt an invasive and metastatic phenotype in cooperation with transforming growth factor (TGF)-beta. This dramatic increase in malignancy is displayed by an epithelial to mesenchymal transition (EMT), which mimics the TGF-beta-mediated progression of human hepatocellular carcinomas. In culture, hepatocellular EMT occurs highly synchronously, facilitating the analysis of molecular events underlying the various stages of this process. Here, we show that in response to TGF-beta, phosphorylated Smads rapidly translocated into the nucleus and activated transcription of target genes such as E-cadherin repressors of the Snail superfamily, causing loss of cell adhesion. Within the TGF-beta superfamily of cytokines, TGF-beta 1, -beta 2 and -beta 3 were specific for the induction of hepatocellular EMT. Expression pro. ling of EMT kinetics revealed 78 up- and 235 downregulated genes, which preferentially modulate metabolic activities, extracellular matrix composition, transcriptional activities and cell survival. Independent of the genetic background, platelet-derived growth factor (PDGF)- A ligand and both PDGF receptor subunits were highly elevated, together with autocrine secretion of bioactive PDGF. Interference with PDGF signalling by employing hepatocytes expressing the dominant-negative PDGF-alpha receptor revealed decreased TGF-beta-induced migration in vitro and efficient suppression of tumour growth in vivo. In conclusion, these results provide evidence for a crucial role of PDGF in TGF-beta-mediated tumour progression of hepatocytes and suggest PDGF as a target for therapeutic intervention in liver cancer.	Med Univ Vienna, Dept Med 1, Div Inst Canc Res, A-1090 Vienna, Austria; Boehringer Ingelheim KG, Genom Grp, Biberach, Germany; Res Inst Mol Pharmacol, Vienna, Austria	Medical University of Vienna; Boehringer Ingelheim	Mikulits, W (corresponding author), Med Univ Vienna, Dept Med 1, Div Inst Canc Res, Borschke Gasse 8A, A-1090 Vienna, Austria.	wolfgang.mikulits@meduniwien.ac.at	Jechlinger, Martin/AAC-9442-2020; Mikulits, Wolfgang/AAH-4043-2021	Jechlinger, Martin/0000-0002-3710-4466; Mikula, Mario/0000-0001-5782-0681; Gotzmann, Josef/0000-0001-6392-2115; Mikulits, Wolfgang/0000-0003-4612-7106				Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; Bates RC, 2003, CURR BIOL, V13, P1721, DOI 10.1016/j.cub.2003.09.002; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917; Behrens J, 1992, Semin Cell Biol, V3, P169; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Cai J, 1998, INT J MOL MED, V1, P273; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carloni V, 2001, HEPATOLOGY, V34, P42, DOI 10.1053/jhep.2001.25224; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Coyle B, 2003, J BIOL CHEM, V278, P5920, DOI 10.1074/jbc.M211300200; Croom KF, 2003, DRUGS, V63, P513, DOI 10.2165/00003495-200363050-00005; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Deininger MWN, 2004, J CANCER RES CLIN, V130, P59, DOI 10.1007/s00432-003-0502-2; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dubois CM, 2001, AM J PATHOL, V158, P305, DOI 10.1016/S0002-9440(10)63970-3; Dumont N, 2000, BREAST CANCER RES, V2, P125, DOI 10.1186/bcr44; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; EHRMANN RL, 1956, J NATL CANCER I, V16, P1375; Fischer ANM, 2005, CARCINOGENESIS, V26, P931, DOI 10.1093/carcin/bgi043; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; George D, 2001, SEMIN ONCOL, V28, P27, DOI 10.1053/sonc.2001.29185; Germain S, 2000, GENE DEV, V14, P435; Gotzmann J, 2004, MUTAT RES-REV MUTAT, V566, P9, DOI 10.1016/S1383-5742(03)00033-4; Gotzmann J, 2002, J CELL SCI, V115, P1189; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Hajra KM, 2002, CANCER RES, V62, P1613; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hawley TS, 2001, BIOTECHNIQUES, V30, P1028, DOI 10.2144/01305rr01; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; HELDIN P, 1991, EXP CELL RES, V193, P364, DOI 10.1016/0014-4827(91)90108-7; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; ITO N, 1991, CANCER RES, V51, P4080; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jechlinger M, 2003, ONCOGENE, V22, P7155, DOI 10.1038/sj.onc.1206887; JIANG WG, 1995, CANCER RES, V55, P5043; Joensuu H, 2002, MED KLIN, V97, P28; Joensuu H, 2001, ANN MED, V33, P451, DOI 10.3109/07853890109002093; Kilic T, 2000, CANCER RES, V60, P5143; Kim SJ, 2004, CANCER RES, V64, P4201, DOI 10.1158/0008-5472.CAN-03-3763; Knittel T, 1999, GASTROENTEROLOGY, V117, P1205, DOI 10.1016/S0016-5085(99)70407-5; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; Mahadevappa M, 1999, NAT BIOTECHNOL, V17, P1134, DOI 10.1038/15124; Matsuzaki K, 2000, CANCER RES, V60, P1394; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Mikula M, 2004, HEPATOLOGY, V39, P628, DOI 10.1002/hep.20084; Mikula M, 2003, ONCOGENE, V22, P6725, DOI 10.1038/sj.onc.1206781; Mikulits W, 2000, FASEB J, V14, P1641, DOI 10.1096/fj.14.11.1641; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Newton Herbert B, 2003, Expert Rev Anticancer Ther, V3, P595, DOI 10.1586/14737140.3.5.595; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Ostman A, 2001, ADV CANCER RES, V80, P1, DOI 10.1016/S0065-230X(01)80010-5; Paulsson Y, 1988, GROWTH FACTORS, V1, P19, DOI 10.3109/08977198809000243; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; PINZANI M, 1994, HEPATOLOGY, V19, P701, DOI 10.1002/hep.1840190323; Pinzani M, 1996, AM J PATHOL, V148, P785; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Pradet-Balade B, 2001, TRENDS BIOCHEM SCI, V26, P225, DOI 10.1016/S0968-0004(00)01776-X; Proell V, 2005, BBA-MOL CELL RES, V1744, P76, DOI 10.1016/j.bbamcr.2004.12.009; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; Risau W, 1992, GROWTH FACTORS, V7, P261, DOI 10.3109/08977199209046408; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rossmanith W, 2001, MICROSC RES TECHNIQ, V52, P430, DOI 10.1002/1097-0029(20010215)52:4<430::AID-JEMT1028>3.0.CO;2-3; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; SHIRAI Y, 1994, CANCER, V73, P2275, DOI 10.1002/1097-0142(19940501)73:9<2275::AID-CNCR2820730907>3.0.CO;2-T; SOMA Y, 1989, J CELL PHYSIOL, V140, P246, DOI 10.1002/jcp.1041400209; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsou AP, 1998, GENOMICS, V50, P331, DOI 10.1006/geno.1998.5338; Tsuda T, 2001, DEV DYNAM, V222, P89, DOI 10.1002/dvdy.1172; Uehara H, 2003, J NATL CANCER I, V95, P458, DOI 10.1093/jnci/95.6.458; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; VONRUDEN T, 1988, EMBO J, V7, P2749, DOI 10.1002/j.1460-2075.1988.tb03129.x; Witz IP, 2000, J CELL BIOCHEM, P61; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; XU JM, 1995, J BIOL CHEM, V270, P6308, DOI 10.1074/jbc.270.11.6308; Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yu JH, 2000, J BIOL CHEM, V275, P19076, DOI 10.1074/jbc.M910329199; Yu JH, 2003, J BIOL CHEM, V278, P49582, DOI 10.1074/jbc.M309986200; Yue JB, 2000, J BIOL CHEM, V275, P35656; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069	107	169	174	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3170	3185		10.1038/sj.onc.1209083	http://dx.doi.org/10.1038/sj.onc.1209083			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16607286				2022-12-17	WOS:000237951000008
J	Rosell, R; Scagliotti, G; Danenberg, KD; Lord, RVN; Bepler, G; Novello, S; Cooc, J; Crino, L; Sanchez, JJ; Taron, M; Boni, C; De Marinis, F; Tonato, M; Marangolo, M; Gozzelino, F; Di Costanzo, F; Rinaldi, M; Salonga, D; Stephens, C				Rosell, R; Scagliotti, G; Danenberg, KD; Lord, RVN; Bepler, G; Novello, S; Cooc, J; Crino, L; Sanchez, JJ; Taron, M; Boni, C; De Marinis, F; Tonato, M; Marangolo, M; Gozzelino, F; Di Costanzo, F; Rinaldi, M; Salonga, D; Stephens, C			Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer	ONCOGENE			English	Article						NSCLC; gene expression; beta-tubulin III; RRM1; stathmin	BETA-TUBULIN GENE; CHROMOSOME SEGMENT 11P15.5; PHASE-III; RIBONUCLEOTIDE REDUCTASE; CARCINOMA-CELLS; PLUS CISPLATIN; ONCOLOGY-GROUP; PACLITAXEL; EXPRESSION; GEMCITABINE	Non-small-cell lung cancer patients with locally advanced or metastatic disease at the time of diagnosis show marginal response to chemotherapy in terms of tumor shrinkage, time to progression and median survival. The identification and implementation of predictive genetic markers of response-specific cytotoxic drugs is a priority of current research and future trials. In this study, we have used quantitative PCR to analyse expression of beta-tubulin III, stathmin, RRM1, COX-2 and GSTP1 in mRNA isolated from paraffin-embedded tumor biopsies of 75 nonsmall-cell lung cancer patients treated as part of a large randomized trial. In total, 22 patients were treated with gemcitabine/cisplatin, 25 with vinorelbine/cisplatin and 28 with paclitaxel/carboplatin. There were no differences in clinical characteristics and transcript levels in the pretreatment biopsies according to treatment arm. Patients with low beta-tubulin III levels had better response in the paclitaxel/carboplatin arm (P = 0.05), and those with low RRM1 levels showed a tendency to better response in the gemcitabine/cisplatin arm. Time to progression was influenced by beta-tubulin III (P = 0.03) and stathmin (P = 0.05) levels in the vinorelbine/cisplatin arm, and there was a tendency toward correlation between beta-tubulin III levels and time to progression in the paclitaxel/carboplatin arm. RRM1 levels influenced time to progression (P = 0.05) and even more so, survival (P = 0.0028) in the gemcitabine/cisplatin arm. The predictive value of beta-tubulin III, stathmin and RRM1 should be tested in prospective customized chemotherapy trials, the results of which will help tailor chemotherapy to improve patient survival.	Hosp Germans Trias & Pujol, Dept Oncol, Med Oncol Serv, Barcelona 08916, Spain; Univ Turin, Dept Clin & Biol Sci, Turin, Italy; Response Genet, Los Angeles, CA 90033 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Program, Tampa, FL 33612 USA; Bellaria Hosp, Dept Oncol, Bologna, Italy; Autonomous Univ Madrid, E-28049 Madrid, Spain; Santa Maria Nuova Hosp, Dept Oncol, Reggio Emilia, Italy; Forlanini Hosp, Dept Oncol, Rome, Italy; Policlin Hosp, Perugia, Italy; Santa Maria delle Croci Hosp, Ravenna, Italy; Infermi Hosp, Biella, Italy; S Maria Hosp Terni, Terni, Italy; Regina Elena Inst Canc Res, Dept Oncol, I-00161 Rome, Italy	Hospital Germans Trias i Pujol; University of Turin; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; AUSL di Bologna; Autonomous University of Madrid; IRCCS Arcispedale S. Maria Nuova; Azienda Ospedaliera San Camillo-Forlanini; Hospital of Rimini; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Rosell, R (corresponding author), Hosp Germans Trias & Pujol, Dept Oncol, Med Oncol Serv, Ctra Canyet S-N, Barcelona 08916, Spain.		de Marinis, Filippo/AAR-2826-2020; novello, silvia/K-6335-2016	Lord, Reginald V N/0000-0001-7475-492X				Amayed P, 2002, J BIOL CHEM, V277, P22718, DOI 10.1074/jbc.M111605200; Bepler G, 2002, J CLIN ONCOL, V20, P1353, DOI 10.1200/JCO.20.5.1353; Bepler G, 1999, GENOMICS, V55, P164, DOI 10.1006/geno.1998.5659; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Bol DK, 2002, CANCER RES, V62, P2516; Bonomi P, 2000, J CLIN ONCOL, V18, P623, DOI 10.1200/JCO.2000.18.3.623; Brattsand G, 2000, BRIT J CANCER, V83, P311, DOI 10.1054/bjoc.2000.1264; Cardenal F, 1999, J CLIN ONCOL, V17, P12, DOI 10.1200/JCO.1999.17.1.12; Crino L, 1999, J CLIN ONCOL, V17, P3522, DOI 10.1200/JCO.1999.17.11.3522; Crino L, 1997, J CLIN ONCOL, V15, P297, DOI 10.1200/JCO.1997.15.1.297; Giannakakou P, 2000, P NATL ACAD SCI USA, V97, P2904, DOI 10.1073/pnas.040546297; Giannakakou P, 2000, ONCOGENE, V19, P3078, DOI 10.1038/sj.onc.1203642; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Goan YG, 1999, CANCER RES, V59, P4204; GOTO S, 1995, CANCER RES, V55, P4297; HARBOTTLE A, 2002, CANC HDB, P1347; He LF, 2001, MOL CANCER THER, V1, P3; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Iancu C, 2000, CANCER RES, V60, P3537; Iwata T, 2002, MOL BRAIN RES, V102, P105, DOI 10.1016/S0169-328X(02)00187-0; Kavallaris M, 1999, BRIT J CANCER, V80, P1020, DOI 10.1038/sj.bjc.6690507; Kavallaris M, 1997, J CLIN INVEST, V100, P1282, DOI 10.1172/JCI119642; Kelley MJ, 2001, J NATL CANCER I, V93, P1886, DOI 10.1093/jnci/93.24.1886; LECHEVALIER T, 1994, J CLIN ONCOL, V12, P360, DOI 10.1200/JCO.1994.12.2.360; Li M, 2001, INT J CANCER, V93, P218, DOI 10.1002/ijc.1322; Lord RVN, 2000, J GASTROINTEST SURG, V4, P135, DOI 10.1016/S1091-255X(00)80049-9; Lord RVN, 2002, CLIN CANCER RES, V8, P2286; Monzo M, 1999, J CLIN ONCOL, V17, P1786, DOI 10.1200/JCO.1999.17.6.1786; MONZO M, 2002, J NATL CANCER I, V94, P61; Nicoletti MI, 2001, CLIN CANCER RES, V7, P2912; Nishio K, 2001, CANCER, V91, P1494, DOI 10.1002/1097-0142(20010415)91:8<1494::AID-CNCR1157>3.0.CO;2-7; Pitterle DM, 1999, MAMM GENOME, V10, P916, DOI 10.1007/s003359901114; Ramsey SD, 2002, J NATL CANCER I, V94, P291, DOI 10.1093/jnci/94.4.291; Ranganathan S, 1998, BRIT J CANCER, V77, P562, DOI 10.1038/bjc.1998.91; Sale S, 2002, MOL CANCER THER, V1, P215; Sandler AB, 2000, J CLIN ONCOL, V18, P122, DOI 10.1200/JCO.2000.18.1.122; SCAGLIOTTI GV, 2001, P AN M AM SOC CLIN, V20, pA308; Song SM, 2001, BIOCHEM BIOPH RES CO, V281, P872, DOI 10.1006/bbrc.2001.4433; Tsurutani J, 2002, LUNG CANCER-J IASLC, V35, P11, DOI 10.1016/S0169-5002(01)00291-4; Wozniak AJ, 1998, J CLIN ONCOL, V16, P2459, DOI 10.1200/JCO.1998.16.7.2459; Zhao BH, 2001, ONCOGENE, V20, P8154, DOI 10.1038/sj.onc.1205027	42	169	194	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3548	3553		10.1038/sj.onc.1206419	http://dx.doi.org/10.1038/sj.onc.1206419			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789263				2022-12-17	WOS:000183399200005
J	Bingle, L; Singleton, V; Bingle, CD				Bingle, L; Singleton, V; Bingle, CD			The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms	ONCOGENE			English	Article						WAP domain; 4-disulphide core; gene expression; alternative splicing; chromosome 20; elafin	EPITHELIAL-CELLS; FAMILY; ELAFIN; CARCINOMAS; HYBRIDIZATION; EPIDIDYMIS; DISCOVERY	The whey acidic protein (WAP) domain is a conserved motif, containing eight cysteines found in a characteristic 4-disulphide core arrangement, that is present in a number of otherwise unrelated proteins. WAP motifs are present in SLPI and elafin, two antiproteinases located on chromosome 20q12-13, in a locus rich in poorly characterized WAP domain proteins. One of these proteins, which contains two WAP domains, is HE4 (also known as WFDC2), originally described as an epididymis specific protein but more recently suggested to be a putative serum tumour marker for ovarian cancer. We have shown that HE4 is expressed in a number of normal human tissues outside of the mate reproductive system, including regions of the respiratory tract and nasopharynx, as well as in a subset of lung tumour cell lines. Comparison of multiple HE4 cDNAs and RT-PCR products with genomic sequence allowed the elucidation of the genomic organization. These studies revealed that HE4 can undergo a complex series of alternative splicing events that can potentially yield five distinct WAP domain containing protein isoforms. These results cast doubt on the potential role of HE4 as a serum tumour marker specific for ovarian cancer and open the door to understanding the function of multiple WAP domain containing protein isoforms arising from a single gene.	Univ Sheffield, Sch Med, Resp Cell & Mol Biol Lab,Royal Hallamshire Hosp, Resp Med Unit,Div Genom Med, Sheffield S10 2RX, S Yorkshire, England	University of Sheffield	Bingle, CD (corresponding author), Univ Sheffield, Sch Med, Resp Cell & Mol Biol Lab,Royal Hallamshire Hosp, Resp Med Unit,Div Genom Med, M128,Glossop Rd, Sheffield S10 2RX, S Yorkshire, England.	c.d.bingle@sheffield.ac.uk		Bingle, Colin/0000-0002-5405-6988				Bingle CD, 2000, BBA-GENE STRUCT EXPR, V1493, P363, DOI 10.1016/S0167-4781(00)00196-2; Bingle L, 2001, AM J RESP CELL MOL, V25, P84, DOI 10.1165/ajrcmb.25.1.4341; ELLERBROCK K, 1994, INT J ANDROL, V17, P314, DOI 10.1111/j.1365-2605.1994.tb01262.x; Hough CD, 2000, CANCER RES, V60, P6281; Imai FL, 2001, INT J MOL MED, V7, P43; Jia HP, 2001, GENE, V263, P211; Kirchhoff C, 1998, ANDROLOGIA, V30, P225; Kirchhoff C, 1998, REV REPROD, V3, P86; KIRCHHOFF C, 1991, BIOL REPROD, V45, P350, DOI 10.1095/biolreprod45.2.350; Larramendy ML, 2000, CANCER GENET CYTOGEN, V119, P132, DOI 10.1016/S0165-4608(99)00226-5; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Perry ACF, 1999, BIOL REPROD, V61, P965, DOI 10.1095/biolreprod61.4.965; Ranganathan S, 1999, J MOL GRAPH MODEL, V17, P106, DOI 10.1016/S1093-3263(99)00023-6; Richardson RT, 2001, GENE, V270, P93, DOI 10.1016/S0378-1119(01)00462-0; Robinson PA, 1996, J ORAL PATHOL MED, V25, P135, DOI 10.1111/j.1600-0714.1996.tb00208.x; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; SALLENAVE JM, 1994, AM J RESP CELL MOL, V11, P733, DOI 10.1165/ajrcmb.11.6.7946401; Schalkwijk J, 1999, BIOCHEM J, V340, P569, DOI 10.1042/0264-6021:3400569; Schummer M, 1999, GENE, V238, P375, DOI 10.1016/S0378-1119(99)00342-X; Simpson KJ, 2000, J BIOL CHEM, V275, P23074, DOI 10.1074/jbc.M002161200; Tanner MM, 2000, CLIN CANCER RES, V6, P1833; Trexler M, 2001, P NATL ACAD SCI USA, V98, P3705, DOI 10.1073/pnas.061028398; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9; Xu WD, 1996, ARCH ANDROLOGY, V37, P135, DOI 10.3109/01485019608988514; Yamamoto S, 1997, BRIT J CANCER, V76, P1081, DOI 10.1038/bjc.1997.511; Zhang M, 1997, CANCER RES, V57, P4631; ZHANG M, 1995, CANCER RES, V55, P2537	27	169	192	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2768	2773		10.1038/sj.onc.1205363	http://dx.doi.org/10.1038/sj.onc.1205363			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965550				2022-12-17	WOS:000174996500017
J	Lee, JH; Takahashi, T; Yasuhara, N; Inazawa, J; Kamada, S; Tsujimoto, Y				Lee, JH; Takahashi, T; Yasuhara, N; Inazawa, J; Kamada, S; Tsujimoto, Y			Bis, a Bcl-2-binding protein that synergizes with Bcl-2 in preventing cell death	ONCOGENE			English	Article						apoptosis; Bcl-2; Bis	SPINAL MUSCULAR-ATROPHY; CYTOCHROME-C; MITOCHONDRIAL-MEMBRANES; ENDOPLASMIC-RETICULUM; KINASE RAF-1; ION-CHANNEL; APOPTOSIS; ACTIVATION; EXPRESSION; BAX	Bcl-2 is the best characterized inhibitor of apoptosis, although the molecular basis of this action is not fully understood. Using a protein interaction cloning procedure, we identified a human gene designated as bis (mapped to chromosome 10q25) that encoded a novel Bcl-2-interacting protein. Eis protein showed no significant homology with Bcl-2 family proteins and had no prominent functional motif. Co-immunoprecipitation analysis confirmed that Eis interacted with Bcl-2 in vivo. DNA transfection experiments indicated that Eis itself exerted only weak anti-apoptotic activity, but was synergistic with Bcl-2 in preventing flax-induced and Fas-mediated apoptosis. These results suggest that Bis is a novel modulator of cellular anti-apoptotic activity that functions through its interaction with Bcl-2.	Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Med Genet, Osaka, Japan; Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan; Tokyo Med & Dent Univ, Med Res Inst, Div Genet, Dept Mol Cytogenet,Bunkyo Ku, Tokyo 1138519, Japan	Osaka University; Japan Science & Technology Agency (JST); Tokyo Medical & Dental University (TMDU)	Tsujimoto, Y (corresponding author), Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Med Genet, Osaka, Japan.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AKAO Y, 1994, CANCER RES, V54, P2468; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Boulakia CA, 1996, ONCOGENE, V12, P529; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OLTAVI ZN, 1993, CELL, V74, P609; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RaasRothschild A, 1996, J MED GENET, V33, P996, DOI 10.1136/jmg.33.12.996; REED JC, 1992, ANAL BIOCHEM, V205, P70, DOI 10.1016/0003-2697(92)90580-Z; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Sambrook J, 1989, MOL CLONING LAB MANU; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 1996, ONCOGENE, V12, P2251; Shimizu S, 1996, ONCOGENE, V12, P2045; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Verge CF, 1998, J CLIN INVEST, V102, P1569, DOI 10.1172/JCI3379; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yasuhara N, 1997, ONCOGENE, V15, P1921, DOI 10.1038/sj.onc.1201370; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	52	169	176	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6183	6190		10.1038/sj.onc.1203043	http://dx.doi.org/10.1038/sj.onc.1203043			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597216				2022-12-17	WOS:000083934100001
J	Albrecht, JH; Poon, RYC; Ahonen, CL; Rieland, BM; Deng, CX; Crary, GS				Albrecht, JH; Poon, RYC; Ahonen, CL; Rieland, BM; Deng, CX; Crary, GS			Involvement of p21 and p27 in the regulation of CDK activity and cell cycle progression in the regenerating liver	ONCOGENE			English	Article						cyclins; cyclin-dependent kinases; liver regeneration; G1 phase	GROWTH-FACTOR-BETA; KINASE INHIBITOR P21; DEPENDENT KINASES; MICE LACKING; RESTRICTION POINT; GENE-EXPRESSION; MESSENGER-RNA; DNA-SYNTHESIS; TGF-BETA; P27(KIP1)	In tissue culture systems, p21 and p27 inhibit cyclin-dependent kinase (CDK) activity and cell cycle progression in response to numerous stimuli, but little is known about their involvement in cell growth in vivo. We examined the modulation of CDK activity by these proteins after 70% partial hepatectomy (PH), an in vivo model of synchronous hepatocyte cell cycle progression, After PH In BALB/c mice, p21 was induced during the prereplicative (G1) phase and was maximally expressed after peak hepatocyte DNA synthesis. p27 was present in quiescent liver and was minimally induced after PH. p21 and p27 immunoprecipitated with CDK2, CDK4, and cyclin D1 in the regenerating liver. The activity of CDK2-, CDK4- and cyclin D1-associated kinases was upregulated after PH, and maximal activity of these enzyme complexes corresponded to peak DNA synthesis. Immunodepletion experiments suggested that p27 plays a role in downregulating CDK2 activity before and after peak DNA synthesis. Compared to cogenic wild-type mice, p21-/-mice demonstrated evidence of markedly accelerated hepatocyte progression through G1 phase after PH: DNA synthesis, upregulation of cyclin A and PCNA, induction of cyclin D1- and CDK2-associated kinase activity, and appearance of a phosphorylated retinoblastoma protein (Rh) species occurred earlier in the p21-/-mice. These results suggest that p21 and p27 modulate CDK activity in the regenerating liver, and that p21 regulates the rate of progression through G1 phase of the cell cycle in vivo.	Hennepin Cty Med Ctr, Dept Med 865B, Minneapolis, MN 55415 USA; Hennepin Cty Med Ctr, Dept Pathol, Minneapolis, MN 55415 USA; Minneapolis Med Res Fdn, Minneapolis, MN 55404 USA; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong; NIDDKD, Biochem & Metab Lab, NIH, Bethesda, MD 20892 USA	Hennepin County Medical Center; Hennepin County Medical Center; Minneapolis Medical Research Foundation; Hong Kong University of Science & Technology; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Albrecht, JH (corresponding author), Hennepin Cty Med Ctr, Dept Med 865B, 701 Park Ave, Minneapolis, MN 55415 USA.		deng, chuxia/N-6713-2016	Poon, Randy/0000-0001-5571-6231				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; ALBRECHT JH, 1994, FEBS LETT, V347, P157, DOI 10.1016/0014-5793(94)00527-3; ALBRECHT JH, 1995, BIOCHEM BIOPH RES CO, V209, P648, DOI 10.1006/bbrc.1995.1548; Albrecht JH, 1997, HEPATOLOGY, V25, P557, DOI 10.1002/hep.510250311; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; BUCHER NLR, 1963, INT REV CYTOL, V15, P245, DOI 10.1016/S0074-7696(08)61119-5; CASTRO A, 1994, BIOCHEM BIOPH RES CO, V201, P1072, DOI 10.1006/bbrc.1994.1814; Chen Y, 1996, J BIOL CHEM, V271, P19637, DOI 10.1074/jbc.271.33.19637; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; CORNELL RP, 1990, HEPATOLOGY, V11, P916, DOI 10.1002/hep.1840110603; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GRANA X, 1995, ONCOGENE, V11, P211; GREENBAUM LE, 1995, J CLIN INVEST, V96, P1351, DOI 10.1172/JCI118170; GRISHAM JW, 1962, CANCER RES, V22, P842; GUO K, 1995, MOL CELL BIOL, V15, P3823; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Kren BT, 1996, FASEB J, V10, P559, DOI 10.1096/fasebj.10.5.8621056; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Lin Bryan T. Y., 1992, V170, P227; LORUP C, 1977, CELL TISSUE KINET, V10, P477, DOI 10.1111/j.1365-2184.1977.tb00866.x; LOYER P, 1994, J BIOL CHEM, V269, P2491; Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484; LU XP, 1992, J BIOL CHEM, V267, P2841; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARX J, 1995, SCIENCE, V267, P963, DOI 10.1126/science.7863339; MEAD JE, 1990, CANCER RES, V50, P7023; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Paulsen J E, 1990, In Vivo, V4, P235; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; POON RYC, 1994, J CELL SCI, V107, P2789; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sclafani RA, 1996, CURR OPIN CELL BIOL, V8, P788, DOI 10.1016/S0955-0674(96)80079-2; Serfas MS, 1997, CELL GROWTH DIFFER, V8, P951; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; STEER CJ, 1995, FASEB J, V9, P1396, DOI 10.1096/fasebj.9.14.7589980; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	65	169	174	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2141	2150		10.1038/sj.onc.1201728	http://dx.doi.org/10.1038/sj.onc.1201728			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572495				2022-12-17	WOS:000073177200012
J	KERPPOLA, TK; CURRAN, T				KERPPOLA, TK; CURRAN, T			MAF AND NRL CAN BIND TO AP-1 SITES AND FORM HETERODIMERS WITH FOS AND JUN	ONCOGENE			English	Article							DNA-BINDING; LEUCINE ZIPPER; TRANSCRIPTION FACTORS; YEAST GCN4; GENE; INVITRO; PROTEINS; TRANSFORMATION; ONCOGENE; ENCODES	The c-maf proto-oncogene and the neural retina specific gene nrl encode members of a new bZIP protein subfamily. We have examined the dimerization and DNA binding properties of this new protein family using polypeptides encompassing the leucine zipper and basic regions. Purified polypeptides bound specifically to the AP-1 and CRE sites as well as to variants of the AP-1 site. Maf and Nrl were also able to form heterodimers with Fos and Jun in vitro. All pairwise combinations of Maf, Nrl, Fos and Jun could be co-immunoprecipitated by antisera directed against either subunit. Heterodimers among these proteins bound to the AP-1 site, although with different affinities. Mutations in the leucine zipper dimerization interface or in the basic DNA contact region inhibited heterodimer formation and binding to the AP-1 site. These results indicate that Maf and Nrl together with Fos and Jun family proteins form a bZIP protein superfamily whose members can form an array of heterodimers that have overlapping DNA binding specificities.			KERPPOLA, TK (corresponding author), ROCHE INST MOLEC BIOL,NUTLEY,NJ 07110, USA.		Curran, Tom/C-1164-2008; Curran, Tom/F-5234-2018; Kerppola, Tom/AFK-6155-2022; Kerppola, Tom/AAG-4457-2022; Curran, Thomas/AAE-7631-2019; Curran, Tom/D-7515-2011	Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Kerppola, Tom/0000-0002-0611-9446; Kerppola, Tom/0000-0002-0611-9446; Curran, Thomas/0000-0003-1444-7551; 				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COHEN DR, 1990, ONCOGENE, V5, P929; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1987, ONCOGENE, V2, P79; EARNEST DJ, 1990, EXP NEUROL, V109, P353, DOI 10.1016/S0014-4886(05)80027-5; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HIPSKIND RA, 1991, J BIOL CHEM, V266, P19583; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; OKUNO H, 1991, ONCOGENE, V6, P1491; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PU WT, 1991, MOL CELL BIOL, V11, P4918, DOI 10.1128/MCB.11.10.4918; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1991, ONCOGENE, V6, P533; SAGAR SM, 1990, MOL BRAIN RES, V7, P17, DOI 10.1016/0169-328X(90)90068-O; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	37	169	172	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					675	684						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108109				2022-12-17	WOS:A1994MW55100001
J	CUADRADO, A; CARNERO, A; DOLFI, F; JIMENEZ, B; LACAL, JC				CUADRADO, A; CARNERO, A; DOLFI, F; JIMENEZ, B; LACAL, JC			PHOSPHORYLCHOLINE - A NOVEL 2ND MESSENGER ESSENTIAL FOR MITOGENIC ACTIVITY OF GROWTH-FACTORS	ONCOGENE			English	Article							CHOLINE KINASE-ACTIVITY; PHOSPHATIDYLCHOLINE BREAKDOWN; PHOSPHOLIPASE-D; TYROSINE PHOSPHORYLATION; GUANINE-NUCLEOTIDE; PDGF RECEPTOR; RAS ONCOGENE; 3T3 CELLS; ACTIVATION; PROTEIN	Growth factor stimulation of quiescent cells induces a series of intracellular early and late events that ultimately lead to DNA synthesis and cell division. We describe here that production of phosphorylcholine is an essential component of the late events involved in the induction of DNA synthesis by platelet-derived growth factor (PDGF-BB), a prototype mitogen for fibroblasts. Moreover, phosphorylcholine itself is mitogenic when added exogenously to NIH3T3 cells, further indicating its role as a crucial intracellular messenger for DNA synthesis. Choline kinase, the first step in the route of phosphatidylcholine synthesis appears to be the critical regulatory enzyme in phosphorylcholine production, indicating that regulation of choline kinase represents a key step during mitogenic stimulation. We also describe that several growth factors (PDGF-AA, basic FGF, EGF and phorbol esters) rely on their ability to generate phosphorylcholine for their proliferating activity. In contrast, DNA synthesis induced by serum did not require phosphorylcholine. Moreover, the requirement for phosphorylcholine production in PDGF-stimulated cells can be over-ruled by addition of insulin. Thus, cell proliferation in NIH3T3 cells can be triggered off by alternative pathways and one of them involves generation of phosphorylcholine.	INST INVEST BIOMED,ARTURO DUPERIER 4,E-28029 MADRID,SPAIN; UNIV AUTONOMA MADRID,FAC MED,DEPT BIOQUIM,E-28029 MADRID,SPAIN	Autonomous University of Madrid			Cuenca, Benilde Jimenez/K-9959-2014; IBIS, CANCER/P-3323-2015; Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	Lacal, Juan Carlos/0000-0002-1908-2777; Carnero, Amancio/0000-0003-4357-3979; Cuadrado, Antonio/0000-0002-4039-7140; Jimenez Cuenca, Benilde/0000-0002-1806-6636; Cuadrado, Antonio/0000-0002-3444-9012				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ANTHES JC, 1991, BIOCHEM BIOPH RES CO, V175, P236, DOI 10.1016/S0006-291X(05)81225-2; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; CANNON JG, 1988, PHARMACEUT RES, V5, P359, DOI 10.1023/A:1015955527100; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO CK, 1988, BIOCHEM J, V254, P33, DOI 10.1042/bj2540033; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COOK SJ, 1992, BIOCHEM J, V285, P247, DOI 10.1042/bj2850247; CUADRADO A, 1993, UNPUB; DALY PF, 1987, J BIOL CHEM, V262, P14875; DOOPLER W, 1987, GENE, V54, P147; EXTON JH, 1990, J BIOL CHEM, V265, P1; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; GUYENET P, 1973, MOL PHARMACOL, V9, P630; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1990, J CELL SCI, V96, P193; JIMENEZ B, 1992, INT J CANCER, V49, P417; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LACAL JC, 1988, ONCOGENE HDB, P255; LEACH KL, 1991, J BIOL CHEM, V266, P3215; MACARA IG, 1985, AM J PHYSIOL, V248, pC3, DOI 10.1152/ajpcell.1985.248.1.C3; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MURRAY JJ, 1990, BIOCHEM J, V270, P63, DOI 10.1042/bj2700063; OHTSUKA T, 1990, BIOCHEM BIOPH RES CO, V170, P328, DOI 10.1016/0006-291X(90)91278-Z; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; PORTER TJ, 1990, J BIOL CHEM, V265, P414; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; TAMARU M, 1989, NEUROCHEM RES, V14, P607, DOI 10.1007/BF00964868; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; TSHOPP J, 1989, NATURE, V337, P272; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; WARDEN CH, 1985, J BIOL CHEM, V260, P6006	45	169	173	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2959	2968						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414498				2022-12-17	WOS:A1993MC09300009
J	Arlt, A; Bauer, I; Schafmayer, C; Tepel, J; Muerkoster, SS; Brosch, M; Roder, C; Kalthoff, H; Hampe, J; Moyer, MP; Folsch, UR; Schafer, H				Arlt, A.; Bauer, I.; Schafmayer, C.; Tepel, J.; Mueerkoester, S. Sebens; Brosch, M.; Roeder, C.; Kalthoff, H.; Hampe, J.; Moyer, M. P.; Foelsch, U. R.; Schaefer, H.			Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2)	ONCOGENE			English	Article						regulated proteolysis; ubiquitination; gene transcription; oxidative stress; tumorigenesis	NF-KAPPA-B; ANTIOXIDANT RESPONSE ELEMENT; GENE-EXPRESSION; 26S PROTEASOME; BREAST-CANCER; NRF2-DEFICIENT MICE; UBIQUITIN RECEPTORS; ADAPTIVE RESPONSE; 20S PROTEASOME; EMERGING ROLES	An elevated proteasome activity contributes to tumorigenesis, particularly by providing cancer cells with antiapoptotic protection and efficient clearance from irregular proteins. Still, the underlying mechanisms are poorly known. In this study, we report that in colon cancer patients, higher proteasome activity was detected in tumoral tissue compared with surrounding normal tissue, and also that increased levels of proteasomal subunit proteins, such as S5a/PSMD4 and alpha-5/PSMA5, could be detected. Colon tumors showed higher nuclear levels of nuclear factor E2-related factor 2 (Nrf2), a transcription factor supposed to be involved in the control of proteasomal subunit protein expression. The induction or overexpression of Nrf2 led to stronger S5a and alpha-5 expression in the human colon cancer cell lines, Colo320 and Lovo, as well as in NCM460 colonocytes along with higher proteasome activity. The small interfering RNA (siRNA)-mediated Nrf2 knockdown decreased S5a and alpha-5 expression and reduced proteasome activity. Additionally, Nrf2-dependent S5a and alpha-5 expression conferred protection from tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, an effect preceded by an increased nuclear factor (NF)-kappa B activation and higher expression of antiapoptotic NF-kappa B target genes. These findings point to an important role of Nrf2 in the gain of proteasome activity, thereby contributing to colorectal carcinogenesis. Nrf2 may therefore serve as a potential target in anticancer therapy. Oncogene (2009) 28, 3983-3996; doi:10.1038/onc.2009.264; published online 7 September 2009	[Arlt, A.; Bauer, I.; Mueerkoester, S. Sebens; Brosch, M.; Hampe, J.; Foelsch, U. R.; Schaefer, H.] Univ Hosp Schleswig Holstein UKSH, Dept Internal Med, D-24105 Kiel, Germany; [Schafmayer, C.; Tepel, J.; Roeder, C.; Kalthoff, H.] UKSH, Dept Gen & Thorac Surg, Kiel, Germany; [Moyer, M. P.] INCELL Corp LLC, San Antonio, TX USA	University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital	Schafer, H (corresponding author), Univ Hosp Schleswig Holstein UKSH, Dept Internal Med, Campus Kiel,Schittenhelmstr 12, D-24105 Kiel, Germany.	hschaef@1med.uni-kiel.de	Hampe, Jochen/A-2555-2010; Schäfer, Heiner/C-1055-2011; Sebens, Susanne/C-1222-2010; Arlt, Alexander/G-7308-2019; 高, 雨莉/HGU-8187-2022; Kalthoff, Holger/B-1618-2010; Roeder, Christian/F-1068-2010	Hampe, Jochen/0000-0002-2421-6127; Arlt, Alexander/0000-0002-6160-1059; Roeder, Christian/0000-0001-7881-9110; Brosch, Mario/0000-0001-8983-6557	German Research Society [DFG/SFB415-A13]; German Cluster of Excellence 'Inflammation at Interfaces'	German Research Society(German Research Foundation (DFG)); German Cluster of Excellence 'Inflammation at Interfaces'	The authors thank Maike Grossmann and Dagmar Leisner for technical support, and the German Research Society (DFG/SFB415-A13) and the German Cluster of Excellence 'Inflammation at Interfaces' for funding.	Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; Almond JB, 2002, LEUKEMIA, V16, P433, DOI 10.1038/sj.leu.2402417; Arlt A, 2003, ONCOGENE, V22, P3343, DOI 10.1038/sj.onc.1206524; Arlt A, 2007, BIOCHEM J, V402, P367, DOI 10.1042/BJ20061072; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Chen L, 2005, CANCER RES, V65, P5599, DOI 10.1158/0008-5472.CAN-05-0201; Chen W, 2009, ONCOL REP, V21, P531, DOI 10.3892/or_00000254; Cho HY, 2005, FREE RADICAL BIO MED, V38, P325, DOI 10.1016/j.freeradbiomed.2004.10.013; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dahlmann B, 2007, BMC BIOCHEM, V8, DOI 10.1186/1471-2091-8-S1-S3; Devoy A, 2005, ESSAYS BIOCHEM, V41, P187, DOI 10.1042/EB0410187; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Elsasser S, 2004, J BIOL CHEM, V279, P26817, DOI 10.1074/jbc.M404020200; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goldberg AL, 2007, BIOCHEM SOC T, V35, P12, DOI 10.1042/BST0350012; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Goy A, 2003, BLOOD, V102, p180A; Gudmundsdottir K, 2007, ONCOGENE, V26, P7601, DOI 10.1038/sj.onc.1210579; Hayes JD, 2009, TRENDS BIOCHEM SCI, V34, P176, DOI 10.1016/j.tibs.2008.12.008; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hu R, 2006, CANCER LETT, V243, P170, DOI 10.1016/j.canlet.2005.11.050; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Kang Y, 2007, J MOL BIOL, V369, P168, DOI 10.1016/j.jmb.2007.03.008; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kepa JK, 2003, BIOCHEM BIOPH RES CO, V311, P446, DOI 10.1016/j.bbrc.2003.10.021; Khor TO, 2006, CANCER RES, V66, P11580, DOI 10.1158/0008-5472.CAN-06-3562; Kwak MK, 2006, BIOCHEM BIOPH RES CO, V345, P1350, DOI 10.1016/j.bbrc.2006.05.043; Kwak MK, 2003, MOL CELL BIOL, V23, P8786, DOI 10.1128/MCB.23.23.8786-8794.2003; Lau A, 2008, PHARMACOL RES, V58, P262, DOI 10.1016/j.phrs.2008.09.003; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Liu CW, 2006, MOL CELL, V24, P39, DOI 10.1016/j.molcel.2006.08.025; Liu GH, 2008, BBA-MOL CELL RES, V1783, P713, DOI 10.1016/j.bbamcr.2008.01.002; London MK, 2004, FEBS LETT, V567, P259, DOI 10.1016/j.febslet.2004.04.078; Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081; McBride WH, 2003, ONCOGENE, V22, P5755, DOI 10.1038/sj.onc.1206676; Moyer MP, 1996, IN VITRO CELL DEV-AN, V32, P315; Muerkoster SS, 2008, ONCOGENE, V27, P1122, DOI 10.1038/sj.onc.1210728; Murata S, 2009, NAT REV MOL CELL BIO, V10, P104, DOI 10.1038/nrm2630; Nair S, 2008, BRIT J CANCER, V99, P2070, DOI 10.1038/sj.bjc.6604703; Nioi P, 2007, BIOCHEM BIOPH RES CO, V362, P816, DOI 10.1016/j.bbrc.2007.08.051; Orlowski RZ, 2003, BREAST CANCER RES, V5, P1, DOI 10.1186/bcr460; Osburn WO, 2008, MUTAT RES-REV MUTAT, V659, P31, DOI 10.1016/j.mrrev.2007.11.006; Osburn WO, 2007, INT J CANCER, V121, P1883, DOI 10.1002/ijc.22943; Pitts TM, 2009, MOL CANCER THER, V8, P342, DOI 10.1158/1535-7163.MCT-08-0534; Ren SR, 2000, ONCOGENE, V19, P1419, DOI 10.1038/sj.onc.1203462; Rho JH, 2008, J PROTEOME RES, V7, P2959, DOI 10.1021/pr8000892; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Shibata T, 2008, GASTROENTEROLOGY, V135, P1358, DOI 10.1053/j.gastro.2008.06.082; Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Smith DM, 2005, MOL CELL, V20, P687, DOI 10.1016/j.molcel.2005.10.019; Sobin, 2009, UICC TNM CLASSIFICAT; Song MY, 2009, TOXICOL APPL PHARM, V235, P57, DOI 10.1016/j.taap.2008.11.007; Sun XM, 2004, MOL CELL, V14, P81, DOI 10.1016/S1097-2765(04)00156-X; Sun Y, 2006, NEOPLASIA, V8, P645, DOI 10.1593/neo.06376; Trauzold A, 2001, ONCOGENE, V20, P4258, DOI 10.1038/sj.onc.1204559; van Tijn P, 2008, PROG NEUROBIOL, V85, P176, DOI 10.1016/j.pneurobio.2008.03.001; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wyke SM, 2004, BRIT J CANCER, V91, P1742, DOI 10.1038/sj.bjc.6602165; Xie YM, 2001, P NATL ACAD SCI USA, V98, P3056, DOI 10.1073/pnas.071022298; Yamamoto T, 2008, MOL CELL BIOL, V28, P2758, DOI 10.1128/MCB.01704-07; Yi JJ, 2007, PHARMACOL REV, V59, P14, DOI 10.1124/pr.59.1.4; Zhang HG, 2004, ONCOGENE, V23, P2009, DOI 10.1038/sj.onc.1207373	68	168	179	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2009	28	45					3983	3996		10.1038/onc.2009.264	http://dx.doi.org/10.1038/onc.2009.264			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AC	19734940				2022-12-17	WOS:000272560300004
J	Wang, S				Wang, S.			The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway	ONCOGENE			English	Review						tumor necrosis factor-related apoptosis-inducing ligand; TNF receptor superfamily; DR4; KILLER/DR5; apoptosis; cancer therapy	RADIATION-INDUCED APOPTOSIS; CARCINOMA CELL-LINES; NF-KAPPA-B; DEATH-RECEPTOR; IN-VIVO; MEDIATED APOPTOSIS; TUMOR-CELL; CASPASE-9 INHIBITOR; MONOCLONAL-ANTIBODY; FUNCTIONAL-ANALYSIS	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily and has been shown to induce apoptosis in cancer cells but not normal cells. TRAIL triggers apoptosis through binding to its receptors DR4 and KILLER/DR5. Chemo or radiotherapy induces apoptosis through activation of p53 in response to cellular damage, whereas TRAIL induces apoptosis independent of p53. Mutations or deletions of p53 occurred in more than half of human tumors confer resistance to chemo-radiotherapy. Treatment of TRAIL-resistant tumors with agents targeting death receptors, intrinsic Bcl-2 family members, inhibitor of apoptosis proteins or PI3K/Akt pathway restores the sensitivity to TRAIL-induced apoptosis. Combination of rhTRAIL or the agonist antibody for TRAIL receptor with conventional chemotherapeutic agents results in enhanced efficacy in preventing tumor progression and metastasis. Therefore, the rational design of TRAIL-based therapy combining with other modality that either synergizes to apoptosis induction or overcomes the resistance represents a challenging strategy to achieve the systemic tumor targeting and augment the antitumor activity of cancer therapeutics.	Fudan Univ, Sch Life Sci, Inst Genet, State Key Lab Genet Engn, Shanghai 200433, Peoples R China	Fudan University	Wang, S (corresponding author), Fudan Univ, Sch Life Sci, Inst Genet, State Key Lab Genet Engn, Shanghai 200433, Peoples R China.	shulinwang@fudan.edu.cn						Adams C, 2008, CELL DEATH DIFFER, V15, P751, DOI 10.1038/sj.cdd.4402306; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Ashkenazi A, 2008, J CLIN INVEST, V118, P1979, DOI 10.1172/JCI34359; Blankenstein T, 2005, CURR OPIN IMMUNOL, V17, P180, DOI 10.1016/j.coi.2005.01.008; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Burns TF, 2001, J BIOL CHEM, V276, P37879; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Clohessy JG, 2006, J BIOL CHEM, V281, P5750, DOI 10.1074/jbc.M505688200; Corazza N, 2006, J CLIN INVEST, V116, P2493, DOI 10.1172/JCI27726; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Diehl GE, 2004, IMMUNITY, V21, P877, DOI 10.1016/j.immuni.2004.11.008; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Finnberg N, 2005, MOL CELL BIOL, V25, P2000, DOI 10.1128/MCB.25.5.2000-2013.2005; Finnberg N, 2008, J CLIN INVEST, V118, P111, DOI 10.1172/JCI29900; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Georgakis GV, 2006, CLIN CANCER RES, V12, P584, DOI 10.1158/1078-0432.CCR-05-1194; Gliniak B, 1999, CANCER RES, V59, P6153; Grosse-Wilde A, 2008, J CLIN INVEST, V118, P100, DOI 10.1172/JCI33061; Hall MA, 2007, CANCER CELL, V12, P4, DOI 10.1016/j.ccr.2007.06.011; Hersey P, 2001, NAT REV CANCER, V1, P142, DOI 10.1038/35101078; Hopkins-Donaldson S, 2003, CELL DEATH DIFFER, V10, P356, DOI 10.1038/sj.cdd.4401157; Hotte SJ, 2008, CLIN CANCER RES, V14, P3450, DOI 10.1158/1078-0432.CCR-07-1416; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; Jin XH, 2007, J UROLOGY, V177, P1894, DOI 10.1016/j.juro.2007.01.018; Kaelin WG, 2007, METHOD ENZYMOL, V435, P371, DOI 10.1016/S0076-6879(07)35019-2; Kataoka T, 2005, CRIT REV IMMUNOL, V25, P31, DOI 10.1615/CritRevImmunol.v25.i1.30; Khanbolooki S, 2006, MOL CANCER THER, V5, P2251, DOI 10.1158/1535-7163.MCT-06-0075; Kim M, 2004, CANCER RES, V64, P4078, DOI 10.1158/0008-5472.CAN-04-0284; Kim M, 2008, CANCER RES, V68, P3440, DOI 10.1158/0008-5472.CAN-08-0014; Kim SH, 2008, CANCER RES, V68, P2062, DOI 10.1158/0008-5472.CAN-07-6278; Kim SH, 2004, J BIOL CHEM, V279, P40044, DOI 10.1074/jbc.M404541200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Laguinge LM, 2008, CANCER RES, V68, P909, DOI 10.1158/0008-5472.CAN-06-1806; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Liu SX, 2001, J IMMUNOL, V166, P5407, DOI 10.4049/jimmunol.166.9.5407; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lub-de Hooge MN, 2005, ANN RHEUM DIS, V64, P854, DOI 10.1136/ard.2004.029058; Mace TA, 2006, IMMUNOL INVEST, V35, P279, DOI 10.1080/08820130600745463; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Marini P, 2006, ONCOGENE, V25, P5145, DOI 10.1038/sj.onc.1209516; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Meng XW, 2007, J BIOL CHEM, V282, P29831, DOI 10.1074/jbc.M706110200; Merino D, 2006, MOL CELL BIOL, V26, P7046, DOI 10.1128/MCB.00520-06; Mongkolsapaya J, 1999, NAT STRUCT BIOL, V6, P1048; Ozoren N, 2000, CANCER RES, V60, P6259; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; Pai SI, 1998, CANCER RES, V58, P3513; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Panner A, 2005, MOL CELL BIOL, V25, P8809, DOI 10.1128/MCB.25.20.8809-8823.2005; Pespeni MH, 2007, CANCER RES, V67, P2865, DOI 10.1158/0008-5472.CAN-06-3871; Ravi R, 2002, CURR OPIN ONCOL, V14, P490, DOI 10.1097/00001622-200209000-00004; Ray S, 2005, APOPTOSIS, V10, P1411, DOI 10.1007/s10495-005-2490-y; Ricci MS, 2007, CANCER CELL, V12, P66, DOI 10.1016/j.ccr.2007.05.006; Ricci MS, 2004, MOL CELL BIOL, V24, P8541, DOI 10.1128/MCB.24.19.8541-8555.2004; Romagnoli M, 2007, CLIN CANCER RES, V13, P6010, DOI 10.1158/1078-0432.CCR-07-0140; Rosato RR, 2007, CANCER RES, V67, P9490, DOI 10.1158/0008-5472.CAN-07-0598; Schneider P, 2003, J BIOL CHEM, V278, P5444, DOI 10.1074/jbc.M210783200; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shrader M, 2007, CANCER RES, V67, P1430, DOI 10.1158/0008-5472.CAN-06-1224; Singh TR, 2005, ONCOGENE, V24, P4609, DOI 10.1038/sj.onc.1208585; Sinicrope FA, 2004, CLIN CANCER RES, V10, P8284, DOI 10.1158/1078-0432.CCR-04-1289; Smyth MJ, 2003, IMMUNITY, V18, P1, DOI 10.1016/S1074-7613(02)00502-2; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Trauzold A, 2006, ONCOGENE, V25, P7434, DOI 10.1038/sj.onc.1209719; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wandinger KP, 2003, LANCET, V361, P2036, DOI 10.1016/S0140-6736(03)13641-0; Wang SL, 2003, P NATL ACAD SCI USA, V100, P15095, DOI 10.1073/pnas.2435285100; Wang SL, 2004, CANCER RES, V64, P6666, DOI 10.1158/0008-5472.CAN-04-1734; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wang Y, 2004, CANCER CELL, V5, P501, DOI 10.1016/S1535-6108(04)00113-8; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1999, CANCER RES, V59, P2770; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Younes M, 2006, EUR J CANCER, V42, P542, DOI 10.1016/j.ejca.2005.11.013; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	92	168	183	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	48					6207	6215		10.1038/onc.2008.298	http://dx.doi.org/10.1038/onc.2008.298			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	361YB	18931688				2022-12-17	WOS:000260162800003
J	Tajeddine, N; Galluzzi, L; Kepp, O; Hangen, E; Morselli, E; Senovilla, L; Araujo, N; Pinna, G; Larochette, N; Zamzami, N; Modjtahedi, N; Harel-Bellan, A; Kroemer, G				Tajeddine, N.; Galluzzi, L.; Kepp, O.; Hangen, E.; Morselli, E.; Senovilla, L.; Araujo, N.; Pinna, G.; Larochette, N.; Zamzami, N.; Modjtahedi, N.; Harel-Bellan, A.; Kroemer, G.			Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death	ONCOGENE			English	Article						apoptosis; Bcl-2 family; caspases; mitochondria; non-small cell lung cancer (NSCLC); reactive oxygen species (ROS)	DEPENDENT ANION CHANNEL; MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; ADENINE-NUCLEOTIDE TRANSLOCATOR; TRANSITION PORE; CYTOCHROME-C; LUNG-CANCER; APOPTOSIS; PROTEINS; DAMAGE; BCL-2	Following the screening of a battery of distinct small-interfering RNAs that target various components of the apoptotic machinery, we found that knockdown of the voltage-dependent anion channel 1 (VDAC1) was particularly efficient in preventing cell death induced by cisplatin (CDDP) in non-small cell lung cancer cells. Both the downregulation of VDAC1 and its chemical inhibition with 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid reduced the apoptosis-associated modi. cations induced by CDDP, including mitochondrial transmembrane potential dissipation and plasma membrane permeabilization. VDAC1 inhibition strongly reduced the CDDP-induced conformational activation of Bax, yet had no discernible effect on the activation of Bak, suggesting that VDAC1 acts downstream of Bak and upstream of Bax. Accordingly, knockdown of Bak abolished the activation of Bax, whereas Bax downregulation had no effect on Bak activation. In VDAC1-depleted cells, the failure of CDDP to activate Bax could be reversed by means of the Bcl-2/Bcl-XL antagonist ABT-737, which concomitantly restored CDDP cytotoxicity. Altogether, these results delineate a novel pathway for the induction of mitochondrial membrane permeabilization (MMP) in the course of CDDP-induced cell death that involves a hierarchical contribution of Bak, VDAC1 and Bax. Moreover, our data suggest that VDAC1 may act as a facultative regulator/effector of MMP, depending on the initial cytotoxic event.	[Tajeddine, N.; Galluzzi, L.; Kepp, O.; Hangen, E.; Morselli, E.; Senovilla, L.; Zamzami, N.; Modjtahedi, N.; Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; [Tajeddine, N.; Galluzzi, L.; Kepp, O.; Hangen, E.; Morselli, E.; Senovilla, L.; Araujo, N.; Pinna, G.; Zamzami, N.; Modjtahedi, N.; Harel-Bellan, A.; Kroemer, G.] Univ Paris 11, Villejuif, France; [Araujo, N.; Pinna, G.; Harel-Bellan, A.] Inst Andre Lwoff, Lab Epigenet & Canc, CNRS, FRE 2944, Villejuif, France; [Larochette, N.] Inst Biol Physicochim, Lab Biol Cellulaire & Mol Secret, CNRS, UPR1929, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, PR1,Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Harel-Bellan, Annick/M-9795-2015; Galluzzi, Lorenzo/AAH-3286-2021; LAROCHETTE, Nathanael/R-4298-2017; Galluzzi, Lorenzo/AAG-6432-2019; Senovilla, Laura/AAX-5599-2021; Galluzzi, Lorenzo/AAG-6294-2019; Kepp, Oliver/N-2763-2017; Kroemer, Guido/AAY-9859-2020; Kepp, Oliver/GPX-8627-2022; Galluzzi, Lorenzo/K-2709-2012; MODJTAHEDI, Nazanine/D-4377-2017; KROEMER, Guido/B-4263-2013	LAROCHETTE, Nathanael/0000-0002-7936-678X; Kepp, Oliver/0000-0002-6081-9558; Galluzzi, Lorenzo/0000-0003-2257-8500; KROEMER, Guido/0000-0002-9334-4405; Senovilla, Laura/0000-0001-6887-2436; Harel-Bellan, Annick/0000-0002-2339-153X; MODJTAHEDI, NAZANINE/0000-0002-1832-0710; PINNA, Guillaume/0000-0001-7841-7250				Baines CP, 2007, NAT CELL BIOL, V9, P550, DOI 10.1038/ncb1575; Bartz SR, 2006, MOL CELL BIOL, V26, P9377, DOI 10.1128/MCB.01229-06; Belzacq AS, 2002, BIOCHIMIE, V84, P167, DOI 10.1016/S0300-9084(02)01366-4; Berndtsson M, 2007, INT J CANCER, V120, P175, DOI 10.1002/ijc.22132; Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Castedo M, 2003, ANN NY ACAD SCI, V1010, P19, DOI 10.1196/annals.1299.004; Chandra D, 2005, J BIOL CHEM, V280, P19051, DOI 10.1074/jbc.M501391200; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Cosaert J, 2002, BRIT J CANCER, V87, P825, DOI 10.1038/sj.bjc.6600540; Criollo A, 2007, APOPTOSIS, V12, P3, DOI 10.1007/s10495-006-0328-x; Galluzzi L, 2007, NAT CELL BIOL, V9, P487, DOI 10.1038/ncb0507-487; Galluzzi L, 2007, APOPTOSIS, V12, P803, DOI 10.1007/s10495-007-0720-1; Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Grimm S, 2007, APOPTOSIS, V12, P841, DOI 10.1007/s10495-007-0747-3; Kepp O, 2007, EMBO J, V26, P825, DOI 10.1038/sj.emboj.7601533; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Lalier L, 2007, APOPTOSIS, V12, P887, DOI 10.1007/s10495-007-0749-1; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Modjtahedi N, 2006, TRENDS CELL BIOL, V16, P264, DOI 10.1016/j.tcb.2006.03.008; Olaussen KA, 2006, NEW ENGL J MED, V355, P983, DOI 10.1056/NEJMoa060570; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Perfettini JL, 2004, NAT CELL BIOL, V6, P386, DOI 10.1038/ncb0504-386; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; Rouge TD, 2007, CANCER RES, V67, P6253, DOI 10.1158/0008-5472.CAN-07-0538; Rudin CM, 2003, CANCER RES, V63, P312; Seve Pascal, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P73, DOI 10.2174/1568011053352604; Shafir I, 1998, J BIOENERG BIOMEMBR, V30, P499, DOI 10.1023/A:1020598315287; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, ONCOGENE, V19, P4309, DOI 10.1038/sj.onc.1203788; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; ShoshanBarmatz V, 1996, FEBS LETT, V386, P205, DOI 10.1016/0014-5793(96)00442-5; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Tarze A, 2007, ONCOGENE, V26, P2606, DOI 10.1038/sj.onc.1210074; THINNES FP, 1990, BIOL CHEM H-S, V371, P1047, DOI 10.1515/bchm3.1990.371.2.1047; Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200; Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 2005, BIOCHEM BIOPH RES CO, V331, P685, DOI 10.1016/j.bbrc.2005.04.013; ZAMZAMI N, 2003, METH MOL B, V282, P103; Zermati Y, 2007, MOL CELL, V28, P624, DOI 10.1016/j.molcel.2007.09.030; Zhang K, 2001, MOL PHARMACOL, V59, P837, DOI 10.1124/mol.59.4.837	47	168	176	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2008	27	30					4221	4232		10.1038/onc.2008.63	http://dx.doi.org/10.1038/onc.2008.63			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18362892				2022-12-17	WOS:000257496800009
J	Siddiqui, IA; Malik, A; Adhami, VM; Asim, M; Hafeez, BB; Sarfaraz, S; Mukhtar, H				Siddiqui, I. A.; Malik, A.; Adhami, V. M.; Asim, M.; Hafeez, B. B.; Sarfaraz, S.; Mukhtar, H.			Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis	ONCOGENE			English	Article						EGCG; TRAIL; intrinsic pathway; extrinsic pathway; angiogenesis; metastasis	CANCER CELLS; PROTEASOME INHIBITOR; DEATH RECEPTOR-5; IN-VIVO; EXPRESSION; PATHWAY; GROWTH; (-)-EPIGALLOCATECHIN-3-GALLATE; CHEMOPREVENTION; MODULATION	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL/Apo2L) is a promising candidate for cancer therapy, however, emergence of drug resistance limits its potential use. Here, we report for the first time that epigallocatechin-3-gallate (EGCG), the major polyphenolic constituent of green tea, sensitizes TRAIL-resistant LNCaP cells to TRAIL-mediated apoptosis through modulation of intrinsic and extrinsic apoptotic pathways. When combined with EGCG, Apo2L/TRAIL exhibited enhanced apoptotic activity in LNCaP cells characterized by three major molecular events. First, apoptosis induction was accompanied by the upregulation of poly (ADP-ribose) polymerase cleavage and modulation of pro-and antiapoptotic Bcl2 family of proteins. A synergistic inhibition of inhibitors of apoptosis with concomitant increase in caspase cleavage was observed. Second, pretreatment of cells with EGCG resulted in modulation of death-inducing signaling cascade complex involving DR4/TRAIL R1, Fas-associated death domain and FLICE-inhibitory protein proteins. Last, we observed a synergistic inhibition in the invasion and migration of LNCaP cells. This effect was observed to be mediated through inhibition in the protein expression of vascular endothelial growth factor, uPA and angiopoietin 1 and 2. Further, the activity and protein expression of MMP-2, -3 and -9 and upregulation of TIMP1 in cells treated with a combination of EGCG and TRAIL was observed. These data might have implications for developing new strategies aimed at eliminating prostate cancer cells resistant to TRAIL.	[Siddiqui, I. A.; Malik, A.; Adhami, V. M.; Asim, M.; Hafeez, B. B.; Sarfaraz, S.; Mukhtar, H.] Univ Wisconsin, Med Sci Ctr B 25, Dept Dermatol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Mukhtar, H (corresponding author), Univ Wisconsin, Med Sci Ctr B 25, Dept Dermatol, 1300 Univ Ave, Madison, WI 53706 USA.	hmukhtar@wisc.edu	Siddiqui, Imtiaz/B-6587-2009; Adhami, Vaqar/AAY-2837-2020	Adhami, Vaqar/0000-0002-2048-4570	NATIONAL CANCER INSTITUTE [R01CA120451, R01CA101039, R01CA078809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK065303] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 101039, R01 CA 120451, R01 CA 78809] Funding Source: Medline; NIDDK NIH HHS [P50 DK065303-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adhami VM, 2007, CLIN CANCER RES, V13, P1611, DOI 10.1158/1078-0432.CCR-06-2269; Adhami VM, 2004, CANCER RES, V64, P8715, DOI 10.1158/0008-5472.CAN-04-2840; Bettuzzi S, 2006, CANCER RES, V66, P1234, DOI 10.1158/0008-5472.CAN-05-1145; Bigelow RLH, 2006, ONCOGENE, V25, P1922, DOI 10.1038/sj.onc.1209227; Cantarella G, 2006, BRIT J CANCER, V94, P1428, DOI 10.1038/sj.bjc.6603092; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; de Bock CE, 2004, MED RES REV, V24, P13, DOI 10.1002/med.10054; Deeb D, 2004, MOL CANCER THER, V3, P803; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Gao S, 2005, MOL ENDOCRINOL, V19, P1792, DOI 10.1210/me.2004-0445; He Q, 2004, ONCOGENE, V23, P2554, DOI 10.1038/sj.onc.1207351; He Q, 2002, ONCOGENE, V21, P2623, DOI 10.1038/sj.onc.1205345; Hu HB, 2006, MOL CANCER THER, V5, P1873, DOI 10.1158/1535-7163.MCT-06-0063; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jian L, 2004, INT J CANCER, V108, P130, DOI 10.1002/ijc.11550; Koshida K, 2004, INT J UROL, V11, P1114, DOI 10.1111/j.1442-2042.2004.00961.x; Lakshmikanthan V, 2006, INT J CANCER, V119, P221, DOI 10.1002/ijc.21824; Lam WH, 2004, BIOORGAN MED CHEM, V12, P5587, DOI 10.1016/j.bmc.2004.08.002; Landis-Piwowar KR, 2005, INT J MOL MED, V15, P735; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Munshi A, 2002, CANCER CHEMOTH PHARM, V50, P46, DOI 10.1007/s00280-002-0465-z; Nencioni A, 2005, CLIN CANCER RES, V11, P4259, DOI 10.1158/1078-0432.CCR-04-2496; Ozawa F, 2001, CANCER LETT, V163, P71, DOI 10.1016/S0304-3835(00)00660-1; Qin J, 2007, BIOCHEM BIOPH RES CO, V354, P852, DOI 10.1016/j.bbrc.2007.01.003; Saleem M, 2006, P NATL ACAD SCI USA, V103, P14825, DOI 10.1073/pnas.0606747103; Schimmer AD, 2004, CANCER RES, V64, P7183, DOI 10.1158/0008-5472.CAN-04-1918; Siddiqui IA, 2006, MOL NUTR FOOD RES, V50, P130, DOI 10.1002/mnfr.200500113; Siddiqui IA, 2004, J CELL BIOCHEM, V91, P232, DOI 10.1002/jcb.10737; Siddiqui IA, 2007, ACTA PHARMACOL SIN, V28, P1392, DOI 10.1111/j.1745-7254.2007.00693.x; Stresemann C, 2006, CANCER RES, V66, P2794, DOI 10.1158/0008-5472.CAN-05-2821; Thurston G, 2003, CELL TISSUE RES, V314, P61, DOI 10.1007/s00441-003-0749-6; Yamaguchi K, 2005, ONCOGENE, V24, P5868, DOI 10.1038/sj.onc.1208742; Zhang XD, 2000, FEBS LETT, V482, P193, DOI 10.1016/S0014-5793(00)02042-1	33	168	170	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 27	2008	27	14					2055	2063		10.1038/sj.onc.1210840	http://dx.doi.org/10.1038/sj.onc.1210840			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17998943				2022-12-17	WOS:000254359100010
J	Coiffier, B				Coiffier, B.			Rituximab therapy in malignant lymphoma	ONCOGENE			English	Review						rituximab; R-CHOP; follicular lymphoma; diffuse large B-cell lymphoma; monoclonal antibodies	B-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMA; ANTI-CD20 MONOCLONAL-ANTIBODY; CHRONIC LYMPHOCYTIC-LEUKEMIA; PHASE-II TRIAL; CHEMOTHERAPY PLUS RITUXIMAB; SOLID-ORGAN TRANSPLANTATION; FOLLICULAR LYMPHOMA; R-CHOP; MAINTENANCE RITUXIMAB	Rituximab is the first monoclonal antibody to have been registered for the treatment of B-cell lymphomas. Randomized studies haves demonstrated its activity in follicular lymphoma ( FL), mantle cell lymphoma and diffuse large B-cell lymphoma (DLBCL) in untreated or relapsing patients. Non-comparative studies have shown an activity in all other lymphomas. Because of its high activity and low toxicity ratio, rituximab has transformed the outcome of patients with B-cell lymphoma. A combination of rituximab plus chemotherapy, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone (R-CHOP), has the highest efficacy ever described with any chemotherapy in DLBCL and FL. Some patients are refractory to rituximab but the precise mechanisms of this refractoriness are not understood.	CH Lyon Sud, Dept Hematol, F-69495 Pierre Benite, France; Univ Lyon 1, Pierre Benite, France	CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Coiffier, B (corresponding author), CH Lyon Sud, Dept Hematol, F-69495 Pierre Benite, France.	bertrand.coiffier@chu-lyon.fr						Alas S, 2000, ANTICANCER RES, V20, P2961; Alas S, 2001, CANCER RES, V61, P5137; Ardeshna KM, 2003, LANCET, V362, P516, DOI 10.1016/S0140-6736(03)14110-4; Belhadj K, 2004, ANN ONCOL, V15, P504, DOI 10.1093/annonc/mdh090; Berinstein NL, 1998, ANN ONCOL, V9, P995, DOI 10.1023/A:1008416911099; Bienvenu J, 2001, Hematol J, V2, P378, DOI 10.1038/sj.thj.6200133; Blaes AH, 2005, CANCER-AM CANCER SOC, V104, P1661, DOI 10.1002/cncr.21391; Boettcher S, 2004, BLOOD, V104, p170A, DOI 10.1182/blood.V104.11.590.590; Bohen SP, 2003, P NATL ACAD SCI USA, V100, P1926, DOI 10.1073/pnas.0437875100; Boue F, 2006, J CLIN ONCOL, V24, P4123, DOI 10.1200/JCO.2005.05.4684; Brugger W, 2004, SEMIN ONCOL, V31, P33, DOI 10.1053/j.seminoncol.2003.12.008; Byrd JC, 2003, BLOOD, V101, P6, DOI 10.1182/blood-2002-04-1258; Byrd JC, 2005, BLOOD, V105, P49, DOI 10.1182/blood-2004-03-0796; Byrd JC, 2001, J CLIN ONCOL, V19, P2153, DOI 10.1200/JCO.2001.19.8.2153; Cartron G, 2004, BLOOD, V104, P2635, DOI 10.1182/blood-2004-03-1110; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Coiffier B, 2005, J CLIN ONCOL, V23, P6387, DOI 10.1200/JCO.2005.05.015; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; COIFFIER B, 2005, ONCOLOGY, V18, P7; COIFFIER B, 2005, IN PRESS CURR OP HEM, V12; Coiffier B, 2006, SEMIN HEMATOL, V43, P213, DOI 10.1053/j.seminhematol.2006.07.004; Coiffier Bertrand, 2005, Clin Adv Hematol Oncol, V3, P484; Colombat P, 2001, BLOOD, V97, P101, DOI 10.1182/blood.V97.1.101; Conconi A, 2003, BLOOD, V102, P2741, DOI 10.1182/blood-2002-11-3496; Czuczman MS, 2004, J CLIN ONCOL, V22, P4711, DOI 10.1200/JCO.2004.04.020; Davis TA, 2000, CLIN CANCER RES, V6, P2644; Davis TA, 2000, J CLIN ONCOL, V18, P3135, DOI 10.1200/JCO.2000.18.17.3135; Demidem A, 1997, CANCER BIOTHER RADIO, V12, P177, DOI 10.1089/cbr.1997.12.177; Eisenbeis CF, 2004, CLIN CANCER RES, V10, P6101, DOI 10.1158/1078-0432.CCR-04-0525; Ekstrand BC, 2003, BLOOD, V101, P4285, DOI 10.1182/blood-2002-08-2644; Farinha P, 2006, BLOOD, V108, p245A; Feugier P, 2005, J CLIN ONCOL, V23, P4117, DOI 10.1200/JCO.2005.09.131; Foran JM, 2000, J CLIN ONCOL, V18, P317, DOI 10.1200/JCO.2000.18.2.317; Forstpointner R, 2004, BLOOD, V104, P3064, DOI 10.1182/blood-2004-04-1323; Forstpointner R, 2006, BLOOD, V108, P4003, DOI 10.1182/blood-2006-04-016725; Foussard C, 2006, J CLIN ONCOL, V24, p424S; Ghetie MA, 2001, BLOOD, V97, P1392, DOI 10.1182/blood.V97.5.1392; Ghetie MA, 2006, J IMMUNOTHER, V29, P536, DOI 10.1097/01.cji.0000211307.05869.6c; Ghielmini M, 2004, BLOOD, V103, P4416, DOI 10.1182/blood-2003-10-3411; Gianni AM, 2003, BLOOD, V102, P749, DOI 10.1182/blood-2002-08-2476; Gordan LN, 2005, J CLIN ONCOL, V23, P1096, DOI 10.1200/JCO.2005.12.171; Grillo-Lopez AJ, 2002, SEMIN ONCOL, V29, P105, DOI 10.1053/sonc.2002.30145; Habermann TM, 2006, J CLIN ONCOL, V24, P3121, DOI 10.1200/JCO.2005.05.1003; Habermann TM, 2003, BLOOD, V102, p6A; HAGBERG H, 2006, ANN ONCOL S4, V17; Hainsworth JD, 2003, J CLIN ONCOL, V21, P1746, DOI 10.1200/JCO.2003.09.027; Hainsworth JD, 2004, SEMIN ONCOL, V31, P17, DOI 10.1053/j.seminoncol.2003.12.005; Hainsworth JD, 2005, J CLIN ONCOL, V23, P1088, DOI 10.1200/JCO.2005.12.191; Hainsworth JD, 2002, J CLIN ONCOL, V20, P4261, DOI 10.1200/JCO.2002.08.674; Herold M, 2004, BLOOD, V104, p169A, DOI 10.1182/blood.V104.11.584.584; Hiddemann W, 2003, BLOOD, V102, p104A; Hiddemann W, 2005, BLOOD, V106, P3725, DOI 10.1182/blood-2005-01-0016; HOCHSTER HS, 2004, P ASCO NEW ORLEANS; Horwitz Steven M, 2004, Curr Hematol Rep, V3, P227; Jain AB, 2005, TRANSPLANTATION, V80, P1692, DOI 10.1097/01.tp.0000185570.41571.df; Janas E, 2005, CLIN EXP IMMUNOL, V139, P439, DOI 10.1111/j.1365-2249.2005.02720.x; Kahl BS, 2006, CLIN LYMPHOMA MYELOM, V6, P423, DOI 10.3816/CLM.2006.n.024; KAPLAN LD, 2004, P AM SOC CLIN ONCOL; Keating MJ, 2005, J CLIN ONCOL, V23, P4079, DOI 10.1200/JCO.2005.12.051; Kennedy AD, 2004, J IMMUNOL, V172, P3280, DOI 10.4049/jimmunol.172.5.3280; Kim DH, 2006, BLOOD, V108, P2720, DOI 10.1182/blood-2006-01-009480; Kimby E, 2005, CANCER TREAT REV, V31, P456, DOI 10.1016/j.ctrv.2005.05.007; Kimby E, 2002, SEMIN ONCOL, V29, P7, DOI 10.1053/sonc.2002.32747; Lemieux B, 2004, HEMATOL J, V5, P467, DOI 10.1038/sj.thj.6200559; Lemieux B, 2004, BONE MARROW TRANSPL, V33, P921, DOI 10.1038/sj.bmt.1704467; Lim SH, 2004, BLOOD, V104, p395A; Lim SH, 2005, BONE MARROW TRANSPL, V35, P207, DOI 10.1038/sj.bmt.1704742; Maloney DG, 1999, SEMIN ONCOL, V26, P74; Marcus R, 2005, BLOOD, V105, P1417, DOI 10.1182/blood-2004-08-3175; MARCUS R, 2006, BLOOD, V108; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; Milpied N, 2000, ANN ONCOL, V11, P113, DOI 10.1023/A:1008372814223; Mounier N, 2006, HAEMATOLOGICA, V91, P715; Neumann F, 2006, ANN HEMATOL, V85, P530, DOI 10.1007/s00277-006-0113-5; O'Brien SM, 2001, J CLIN ONCOL, V19, P2165, DOI 10.1200/JCO.2001.19.8.2165; Paydas S, 2003, LEUKEMIA LYMPHOMA, V44, P2165, DOI 10.1080/1042819031000123555; PFREUNDSCHUH MG, 2004, P ASCO NEW ORLEANS; Pfreundschuh M, 2006, LANCET ONCOL, V7, P379, DOI 10.1016/S1470-2045(06)70664-7; Portlock CS, 2006, LEUKEMIA LYMPHOMA, V47, P1260, DOI 10.1080/10428190600565354; Rehwald U, 2003, BLOOD, V101, P420, DOI 10.1182/blood.V101.2.420; Salles GA, 2004, BLOOD, V104, p49A; Sehn LH, 2007, BLOOD, V109, P1857, DOI 10.1182/blood-2006-08-038257; Sehn LH, 2005, J CLIN ONCOL, V23, P5027, DOI 10.1200/JCO.2005.09.137; Smith MR, 2003, ONCOGENE, V22, P7359, DOI 10.1038/sj.onc.1206939; SOLALCELIGNY P, 2004, BLOOD, V104; Thomas DA, 2006, CANCER-AM CANCER SOC, V106, P1569, DOI 10.1002/cncr.21776; Traulle Catherine, 2005, Future Oncol, V1, P297; van der Kolk LE, 2002, LEUKEMIA, V16, P693, DOI 10.1038/sj.leu.2402424; van Oers MHJ, 2006, BLOOD, V108, P3295, DOI 10.1182/blood-2006-05-021113; Vega MI, 2004, ONCOGENE, V23, P3530, DOI 10.1038/sj.onc.1207336; Weng WK, 2001, BLOOD, V98, P1352, DOI 10.1182/blood.V98.5.1352; Weng WK, 2003, J CLIN ONCOL, V21, P3940, DOI 10.1200/JCO.2003.05.013; Wierda W, 2005, J CLIN ONCOL, V23, P4070, DOI 10.1200/JCO.2005.12.516; Winkler U, 1999, BLOOD, V94, P2217, DOI 10.1182/blood.V94.7.2217.419k02_2217_2224; Winter JN, 2006, BLOOD, V107, P4207, DOI 10.1182/blood-2005-10-4222; Younes A, 2003, CANCER, V98, P310, DOI 10.1002/cncr.11511	96	168	187	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3603	3613		10.1038/sj.onc.1210376	http://dx.doi.org/10.1038/sj.onc.1210376			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530014				2022-12-17	WOS:000246816100003
J	Huang, H; Wang, H; Sinz, M; Zoeckler, M; Staudinger, J; Redinbo, MR; Teotico, DG; Locker, J; Kalpana, GV; Mani, S				Huang, H.; Wang, H.; Sinz, M.; Zoeckler, M.; Staudinger, J.; Redinbo, M. R.; Teotico, D. G.; Locker, J.; Kalpana, G. V.; Mani, S.			Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole	ONCOGENE			English	Article						drug metabolism; transcriptional regulation; orphan nuclear receptors	PREGNANE-X-RECEPTOR; CYP3A4 GENE-EXPRESSION; XENOBIOTIC RECEPTOR; TRANSCRIPTIONAL REGULATION; COACTIVATOR PGC-1-ALPHA; CLINICAL-RELEVANCE; ACID SENSOR; BINDING; AGENTS; LIGAND	Individual variation in drug metabolism is a major cause of unpredictable side effects during therapy. Drug metabolism is controlled by a class of orphan nuclear receptors (NRs), which regulate expression of genes such as CYP (cytochrome) 3A4 and MDR-1 (multi-drug resistance-1), that are involved in this process. We have found that xenobiotic-mediated induction of CYP3A4 and MDR-1 gene transcription was inhibited by ketoconazole, a commonly used antifungal drug. Ketoconazole mediated its effect by inhibiting the activation of NRs, human pregnenolone X receptor and constitutive androstene receptor, involved in regulation of CYP3A4 and MDR-1. The effect of ketoconazole was specific to the group of NRs that control xenobiotic metabolism. Ketoconazole disrupted the interaction of the xenobiotic receptor PXR with the co-activator steroid receptor co-activator-1. Ketoconazole treatment resulted in delayed metabolism of tribromoethanol anesthetic in mice, which was correlated to the inhibition of PXR activation and downmodulation of cyp3a11 and mdr-1 genes and proteins. These studies demonstrate for the first time that ketoconazole represses the coordinated activation of genes involved in drug metabolism, by blocking activation of a specific subset of NRs. Our results suggest that ketoconazole can be used as a pan-antagonist of NRs involved in xenobiotic metabolism in vivo, which may lead to novel strategies that improve drug effect and tolerance.	Yeshiva Univ Albert Einstein Coll Med, Dept Oncol, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Bristol Myers Squibb Co, Wallingford, CT 06492 USA; Univ Kansas, Dept Toxicol, Lawrence, KS 66045 USA; Univ N Carolina, Dept Chem, Chapel Hill, NC USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Bristol-Myers Squibb; University of Kansas; University of North Carolina; University of North Carolina Chapel Hill; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Mani, S (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Oncol, Albert Einstein Canc Ctr, 1300 Morris Pk Ave,Chanin 302D-1, Bronx, NY 10461 USA.	smani@montefiore.org		Kalpana, Ganjam/0000-0003-4111-0604				Albers M, 2005, MOL CELL PROTEOMICS, V4, P205, DOI 10.1074/mcp.M400169-MCP200; BEETENS JR, 1986, BIOCHEM PHARMACOL, V35, P883, DOI 10.1016/0006-2952(86)90072-9; Berthold DR, 2005, J CLIN ONCOL, V23, P8247, DOI 10.1200/JCO.2005.03.1435; Bhalla S, 2004, J BIOL CHEM, V279, P45139, DOI 10.1074/jbc.M405423200; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Bourdoncle A, 2005, J MOL BIOL, V347, P921, DOI 10.1016/j.jmb.2005.01.048; Ding XS, 2005, J PHARMACOL EXP THER, V312, P849, DOI 10.1124/jpet.104.076331; Dresser GK, 2000, CLIN PHARMACOKINET, V38, P41, DOI 10.2165/00003088-200038010-00003; Dussault I, 2003, P NATL ACAD SCI USA, V100, P833, DOI 10.1073/pnas.0336235100; ELLSWORTH JL, 1994, BBA-LIPID LIPID MET, V1210, P321, DOI 10.1016/0005-2760(94)90236-4; Eloranta JJ, 2005, METHOD ENZYMOL, V400, P511, DOI 10.1016/S0076-6879(05)00028-5; Evans RM, 2005, MOL ENDOCRINOL, V19, P1429, DOI 10.1210/me.2005-0046; Fujino T, 2003, J STEROID BIOCHEM, V87, P247, DOI 10.1016/j.jsbmb.2003.09.008; Gnerre C, 2004, PHARMACOGENETICS, V14, P635, DOI 10.1097/00008571-200410000-00001; Hamaguchi Taizo, 2002, Nihon Ishinkin Gakkai Zasshi, V43, P95, DOI 10.3314/jjmm.43.95; Handschin C, 2005, ARCH BIOCHEM BIOPHYS, V433, P387, DOI 10.1016/j.abb.2004.08.030; Johnson DR, 2006, MOL PHARMACOL, V69, P99, DOI 10.1124/mol.105.013375; Kanda N, 2002, J INVEST DERMATOL, V119, P590, DOI 10.1046/j.1523-1747.2002.01864.x; Kanda N, 2002, J INVEST DERMATOL, V119, P174, DOI 10.1046/j.1523-1747.2002.01804.x; KIM SG, 1992, MOL PHARMACOL, V42, P273; Kliewer SA, 2002, ENDOCR REV, V23, P687, DOI 10.1210/er.2001-0038; Lee HS, 2002, J BIOCHEM, V131, P399, DOI 10.1093/oxfordjournals.jbchem.a003115; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Li TG, 2005, AM J PHYSIOL-GASTR L, V288, pG74, DOI 10.1152/ajpgi.00258.2004; LOOSE DS, 1983, J CLIN INVEST, V71, P1495, DOI 10.1172/JCI110903; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Mani S, 2005, CLIN CANCER RES, V11, P6359, DOI 10.1158/1078-0432.CCR-05-0252; Matheny CJ, 2004, DRUG METAB DISPOS, V32, P1008; Miquel M, 1999, PHARMACOL BIOCHEM BE, V64, P89, DOI 10.1016/S0091-3057(99)00070-2; Pascussi JM, 2001, EUR J BIOCHEM, V268, P6346, DOI 10.1046/j.0014-2956.2001.02540.x; SELYE H, 1971, J PHARM SCI, V60, P1, DOI 10.1002/jps.2600600102; Sohn YC, 2003, MOL ENDOCRINOL, V17, P366, DOI 10.1210/me.2002-0150; Sonoda J, 2003, CURR DRUG METAB, V4, P59, DOI 10.2174/1389200033336739; STALLA GK, 1988, ENDOCRINOLOGY, V122, P618; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912; Tabb MM, 2004, ENVIRON HEALTH PERSP, V112, P163, DOI 10.1289/ehp.6560; TAKAGI K, 1989, J BIOL CHEM, V264, P12352; Takeshita A, 2002, J BIOL CHEM, V277, P32453, DOI 10.1074/jbc.M111245200; Tzanakakis GN, 2002, J GASTROINTEST CANC, V32, P23, DOI 10.1385/IJGC:32:1:23; Undevia SD, 2005, NAT REV CANCER, V5, P447, DOI 10.1038/nrc1629; Venkatakrishnan K, 2000, CLIN PHARMACOKINET, V38, P111, DOI 10.2165/00003088-200038020-00002; Wei P., 2002, Pharmacogenomics Journal, V2, P117, DOI 10.1038/sj.tpj.6500087; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Xie W, 2003, P NATL ACAD SCI USA, V100, P4150, DOI 10.1073/pnas.0438010100; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Yamamoto A, 2000, J Dermatol, V27, P598; Yong WP, 2005, CLIN CANCER RES, V11, P6699, DOI 10.1158/1078-0432.CCR-05-0703; Zhu ZR, 2004, J BIOMOL SCREEN, V9, P533, DOI 10.1177/1087057104264902	50	168	180	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	2					258	268		10.1038/sj.onc.1209788	http://dx.doi.org/10.1038/sj.onc.1209788			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819505				2022-12-17	WOS:000243398300009
J	Wu, Y; Fan, Y; Xue, B; Luo, L; Shen, J; Zhang, S; Jiang, Y; Yin, Z				Wu, Y.; Fan, Y.; Xue, B.; Luo, L.; Shen, J.; Zhang, S.; Jiang, Y.; Yin, Z.			Human glutathione S-transferase P1-1 interacts with TRAF2 and regulates TRAF2-ASK1 signals	ONCOGENE			English	Article						glutathione S-transferase P1-1; TNF-alpha; TRAF2; ASK1; apoptosis	NF-KAPPA-B; INDUCED CELL-DEATH; TNF RECEPTOR 1; PROTEIN-KINASE; TERMINAL KINASE; INDUCED ACTIVATION; STRUCTURAL BASIS; HEAT-SHOCK; APOPTOSIS; ASK1	Human glutathione S-transferase P1-1 (GSTP1-1) is an ubiquitously expressed protein that plays an important role in the detoxification and xenobiotics metabolism. It has been shown that GSTP1-1 interacts with c-Jun NH2-terminal kinase (JNK) and suppresses its activity. Here, we report a novel function of GSTP1-1 in regulating tumor necrosis factor-alpha (TNF-alpha)-triggered signaling. The present experiments showed that GSTP1-1 physically associated with tumor necrosis factor receptor-associated factor 2(TRAF2) in vivo and in vitro. Overexpression of GSTP1-1 inhibited TRAF2-induced activation of both JNK and p38 but not of nuclear factor-KB (NF-KB). Glutathione S-transferase P1-1 also attenuated TRAF2-enhanced apoptosis signal-regulating kinase 1 (ASK1) autophosphorylation and inhibited TRAF2-ASK1-induced cell apoptosis by suppressing the interaction of TRAF2 and ASK1. Conversely, silencing of GSTP1-1 expression through RNA interference (RNAi) resulted in increase of TNF-alpha-dependent TRAF2-ASK1 association followed by hyper-activation of ASK1 and JNK. A mutant GSTP1-1 lacking TRAF domain-binding motif exhibited a significant decline of capacity to bind TRAF2 and block TRAF2-ASK1 signaling compared with the wild type of GSTP1-1. Moreover, the glutathione-conjugating activity of GSTP1-1 was not involved in the regulation of TRAF2 signaling. These findings indicate that GSTP1-1 plays an important regulatory role in TNF-alpha-induced signaling by forming ligand-binding interactions with TRAF2, which provides a new insight for analysing the protective effects of GSTP1-1 in tumor cells.	Nanjing Normal Univ, Coll Life Sci, Jiangsu Prov Key Lab Mol & Med Biotechnol, Nanjing 210097, JiangSu, Peoples R China; Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210008, Peoples R China; So Med Univ, Dept Pathophysiol, Key Lab Funct Proteom Guangdong Prov, Guangzhou, Peoples R China	Nanjing Normal University; Nanjing University; Southern Medical University - China	Yin, Z (corresponding author), Nanjing Normal Univ, Coll Life Sci, Jiangsu Prov Key Lab Mol & Med Biotechnol, 122 Ninghai Rd, Nanjing 210097, JiangSu, Peoples R China.	yinzhimin@njnu.edu.cn		Xue, Bin/0000-0002-5472-1300				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Arch RH, 1999, ANNU REV CELL DEV BI, V15, P113, DOI 10.1146/annurev.cellbio.15.1.113; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; Chung JY, 2002, J CELL SCI, V115, P679; Cumming RC, 2001, NAT MED, V7, P814, DOI 10.1038/89937; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dorion S, 2002, J BIOL CHEM, V277, P30792, DOI 10.1074/jbc.M203642200; Fan YM, 2005, CELL BIOL INT, V29, P695, DOI 10.1016/j.cellbi.2005.04.006; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Fessler MB, 2002, J BIOL CHEM, V277, P31291, DOI 10.1074/jbc.M200755200; Gate Laurent, 2001, Expert Opin Ther Targets, V5, P477; Gilot D, 2002, J BIOL CHEM, V277, P49220, DOI 10.1074/jbc.M207325200; Gotoh Y, 2004, BIOCHEM BIOPH RES CO, V314, P688, DOI 10.1016/j.bbrc.2003.12.148; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Hoeflich KP, 1999, ONCOGENE, V18, P5814, DOI 10.1038/sj.onc.1202975; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; KONG KH, 1992, BIOCHEM BIOPH RES CO, V182, P1122, DOI 10.1016/0006-291X(92)91848-K; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Lo HW, 2004, CANCER RES, V64, P9131, DOI 10.1158/0008-5472.CAN-04-0283; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lu M, 2004, ONCOGENE, V23, P3945, DOI 10.1038/sj.onc.1207500; Matsuzawa A, 2005, NAT IMMUNOL, V6, P587, DOI 10.1038/ni1200; MOSCOW JA, 1989, CANCER RES, V49, P1422; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Noguchi T, 2005, J BIOL CHEM, V280, P37033, DOI 10.1074/jbc.M506771200; Park HS, 2002, MOL CELL BIOL, V22, P7721, DOI 10.1128/MCB.22.22.7721-7730.2002; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; PINKUS R, 1995, BIOCHEMISTRY-US, V34, P81, DOI 10.1021/bi00001a010; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Ryoo K, 2004, J BIOL CHEM, V279, P43589, DOI 10.1074/jbc.M404359200; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SHEA TC, 1988, CANCER RES, V48, P527; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TEW KD, 1994, CANCER RES, V54, P4313; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Townsend Danyelle, 2003, Am J Pharmacogenomics, V3, P157, DOI 10.2165/00129785-200303030-00002; Townsend DM, 2003, ONCOGENE, V22, P7369, DOI 10.1038/sj.onc.1206940; Townsend DM, 2002, MOL CANCER THER, V1, P1089; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; XIA ZP, 2005, SCI STKE, V272, pPE7; Xu LG, 2004, J BIOL CHEM, V279, P17278, DOI 10.1074/jbc.C400063200; Xue B, 2005, FEBS LETT, V579, P4081, DOI 10.1016/j.febslet.2005.06.034; Ye H, 2000, P NATL ACAD SCI USA, V97, P8961, DOI 10.1073/pnas.160241997; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yin ZM, 2000, CANCER RES, V60, P4053; Yin ZM, 2001, ACTA BIOCH BIOPH SIN, V33, P185; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhang R, 2005, ONCOGENE, V24, P3954, DOI 10.1038/sj.onc.1208548; Zhou L, 2005, BLOOD, V105, P1198, DOI 10.1182/blood-2003-12-4299	71	168	174	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5787	5800		10.1038/sj.onc.1209576	http://dx.doi.org/10.1038/sj.onc.1209576			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16636664				2022-12-17	WOS:000240765800009
J	Bossi, G; Lapi, E; Strano, S; Rinaldo, C; Blandino, G; Sacchi, A				Bossi, G; Lapi, E; Strano, S; Rinaldo, C; Blandino, G; Sacchi, A			Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression	ONCOGENE			English	Article						mutant p53; gain of function; human cancer cells; RNA interference	GENE-EXPRESSION; WILD-TYPE; MUTATIONS; DOXORUBICIN; RESISTANCE; SUPPRESSOR; REQUIRES	Mutations in the TP53 tumor suppressor gene are the most frequent genetic alteration in human cancers. These alterations are mostly missense point mutations that cluster in the DNA binding domain. There is growing evidence that many of these mutations generate mutant p53 proteins that have acquired new biochemical and biological properties. Through this gain of function activity, mutant p53 is believed to contribute to tumor malignancy. The purpose of our study was to explore mutant p53 as a target for novel anticancer treatments. To this aim, we inhibited mutant p53 expression by RNA interference in three different cancer cell lines endogenously expressing mutant p53 proteins, and evaluated the effects on the biological activities through which mutant p53 exerts gain of function. We found that depletion of mutant p53 reduces cell proliferation, in vitro and in vivo tumorigenicity, and resistance to anticancer drugs. Our results demonstrate that mutant p53 knocking down weakens the aggressiveness of human cancer cells, and provides further insight into the comprehension of mutant p53 gain of function activity in human tumor.	Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, I-00158 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Sacchi, A (corresponding author), Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, Via Messi Oro 156, I-00158 Rome, Italy.	bossi@ifo.it; sacchi@ifo.it	Lapi, Eleonora/ABF-9748-2021; strano, sabrina/B-6743-2013; Bossi, Gianluca/ABH-6846-2020; Strano, Sabrina/K-9654-2016; Bossi, Gianluca/G-8375-2016; Blandino, Giovanni/B-1137-2013; Bossi, Gianluca/B-9394-2017; Rinaldo, Cinzia/A-4252-2015	Lapi, Eleonora/0000-0003-4052-0361; strano, sabrina/0000-0002-6341-4230; Bossi, Gianluca/0000-0002-2947-1063; Bossi, Gianluca/0000-0002-2947-1063; Blandino, Giovanni/0000-0002-6970-2241; Bossi, Gianluca/0000-0002-2947-1063; Rinaldo, Cinzia/0000-0001-6124-762X				Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Care A, 2001, CANCER RES, V61, P6532; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; Scian MJ, 2004, ONCOGENE, V23, P4430, DOI 10.1038/sj.onc.1207553; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1991, CANCER RES, V51, P5232; Sigal A, 2000, CANCER RES, V60, P6788; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Tsang WP, 2005, INT J CANCER, V114, P331, DOI 10.1002/ijc.20818; Vousden KH, 2005, CELL, V120, P7, DOI 10.1016/j.cell.2004.12.027; Wang LH, 1998, ANTICANCER RES, V18, P321; Weisz L, 2004, CANCER RES, V64, P8318, DOI 10.1158/0008-5472.CAN-04-1145; Zalcenstein A, 2003, ONCOGENE, V22, P5667, DOI 10.1038/sj.onc.1206724	24	168	173	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					304	309		10.1038/sj.onc.1209026	http://dx.doi.org/10.1038/sj.onc.1209026			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170357				2022-12-17	WOS:000234583600015
J	Gupta, S; Hastak, K; Afaq, F; Ahmad, N; Mukhtar, H				Gupta, S; Hastak, K; Afaq, F; Ahmad, N; Mukhtar, H			Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor kappaB and induction of apoptosis	ONCOGENE			English	Article						green tea; epigallocatechin-3-gallate; caspases; apoptosis; nuclear factor-kappa B	TEA CONSTITUENT (-)-EPIGALLOCATECHIN-3-GALLATE; PROSTATE CARCINOMA-CELLS; EPIGALLOCATECHIN GALLATE; CANCER-THERAPY; CYCLE ARREST; DEATH; PROTEASE; GROWTH; PATHWAYS; ACTIVATION	Green tea constituent (-) epigallocatechin-3-gallate (EGCG) has shown remarkable cancer-preventive and some cancer-therapeutic effects. This is partially because of its ability to induce apoptosis in cancer cells without affecting normal cells. Previous studies from our laboratory have shown the involvement of NF-kappaB pathway in EGCG-mediated cell-cycle deregulation and apoptosis of human epidermoid carcinoma A431 cells. Here we show the essential role of caspases in EGCG-mediated inhibition of NF-kappaB and its subsequent apoptosis. Treatment of A431 cells with EGCG (10-40 mug/ml) resulted in dose-dependent inhibition of NF-kappaB/p65, induction of DNA breaks, cleavage of poly(ADP-ribose) polymerase (PARP) and morphological changes consistent with apoptosis. EGCG treatment of cells also resulted in significant activation of caspases, as shown by the dose- and time-dependent increase in DEVDase activity, and protein expression of caspase-3, -8 and -9. EGCG-mediated caspase activation induces proteolytic cleavage of NF-kappaB/p65 subunit, leading to the loss of transactivation domains, and driving the cells towards apoptosis. EGCG-mediated induction of apoptosis was significantly blocked by the caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (Z-VAD-FMK), and moderately blocked by the specific caspase-3 inhibitor Z-DEVD-FMK. Further, pretreatment of cells with Z-VAD-FMK was found to suppress the cleavage of NF-kappaB/p65 subunit, thereby increasing nuclear translocation, DNA binding and transcriptional activity, thus protecting the cells from EGCG-induced apoptosis. Taken together, these studies for the first time demonstrate that EGCG-mediated activation of caspases is critical, at least in part, for inhibition of NF-kappaB and subsequent apoptosis.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Madison, WI 53706 USA; Case Western Reserve Univ, Dept Urol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Environm Hlth Sci, Cleveland, OH 44106 USA	University of Wisconsin System; University of Wisconsin Madison; Case Western Reserve University; Case Western Reserve University	Mukhtar, H (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, 1300 Univ Ave, Madison, WI 53706 USA.	hmukhtar@wisc.edu		Gupta, Sanjay/0000-0002-9492-3249	NCI NIH HHS [R01 CA 78809] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078809] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2000, BIOCHEM PHARMACOL, V60, P1033, DOI 10.1016/S0006-2952(00)00393-2; Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; Chen ZP, 1998, CANCER LETT, V129, P173, DOI 10.1016/S0304-3835(98)00108-6; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chung JH, 2003, FASEB J, V17, P1913, DOI 10.1096/fj.02-0914fje; Chung LY, 2001, LIFE SCI, V68, P1207, DOI 10.1016/S0024-3205(00)01020-1; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Clement MV, 1998, BLOOD, V92, P996; Ferreira CG, 2002, CLIN CANCER RES, V8, P2024; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Grutter MG, 2000, CURR OPIN STRUC BIOL, V10, P649, DOI 10.1016/S0959-440X(00)00146-9; Gupta S, 2000, TOXICOL APPL PHARM, V164, P82, DOI 10.1006/taap.1999.8885; Gupta S, 2003, ARCH BIOCHEM BIOPHYS, V410, P177, DOI 10.1016/S0003-9861(02)00668-9; Hastak K, 2003, ONCOGENE, V22, P4851, DOI 10.1038/sj.onc.1206708; Hayakawa S, 2001, BIOCHEM BIOPH RES CO, V285, P1102, DOI 10.1006/bbrc.2001.5293; Islam S, 2000, BIOCHEM BIOPH RES CO, V270, P793, DOI 10.1006/bbrc.2000.2536; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kim PKM, 2001, DRUG RESIST UPDATE, V4, P293, DOI 10.1054/drup.2001.0223; Kong ANT, 2001, MUTAT RES-FUND MOL M, V480, P231, DOI 10.1016/S0027-5107(01)00182-8; Kuo PL, 2003, J BIOMED SCI, V10, P219, DOI 10.1159/000068711; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Masuda M, 2001, CLIN CANCER RES, V7, P4220; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Ravi R, 1998, CANCER RES, V58, P882; Schwartz SA, 1999, SURG ONCOL, V8, P143, DOI 10.1016/S0960-7404(00)00012-8; Singh AK, 2002, ARCH BIOCHEM BIOPHYS, V401, P29, DOI 10.1016/S0003-9861(02)00013-9; Stennicke HR, 2000, BBA-PROTEIN STRUCT M, V1477, P299, DOI 10.1016/S0167-4838(99)00281-2; Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611; Yu R, 1998, CANCER RES, V58, P402; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	41	168	182	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2507	2522		10.1038/sj.onc.1207353	http://dx.doi.org/10.1038/sj.onc.1207353			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14676829				2022-12-17	WOS:000220558000008
J	Takahashi, M; Yang, XMJ; Sugimura, J; Backdahl, J; Tretiakova, M; Qian, CN; Gray, SG; Knapp, R; Anema, J; Kahnoski, R; Nicol, D; Vogelzang, NJ; Furge, KA; Kanyama, H; Kagawa, S; Teh, BT				Takahashi, M; Yang, XMJ; Sugimura, J; Backdahl, J; Tretiakova, M; Qian, CN; Gray, SG; Knapp, R; Anema, J; Kahnoski, R; Nicol, D; Vogelzang, NJ; Furge, KA; Kanyama, H; Kagawa, S; Teh, BT			Molecular subclassification of kidney tumors and the discovery of new diagnostic markers	ONCOGENE			English	Article						kidney tumor; microarray; gene expression profiling; molecular classification; diagnosis	RENAL-CELL CARCINOMA; DIFFERENTIALLY EXPRESSED GENES; II-DEFICIENT MICE; PROSTATE-CANCER; CDNA MICROARRAY; IDENTIFICATION; CLASSIFICATION; CARCINOGENESIS; RACEMASE; SURVIVAL	We analysed the expression profiles of 70 kidney tumors of different histological subtypes to determine if these subgroups can be distinguished by their gene expression profiles, and to gain insights into the molecular mechanisms underlying each subtype. In all, 39 clear cell renal cell carcinomas (RCC), seven primary and one metastatic papillary RCC, six granular RCC from old classification, five chromophobe RCC, five sarcomatoid RCC, two oncocytomas, three transitional cell carcinomas (TCC) of the renal pelvis and five Wilms' tumors were compared with noncancerous kidney tissues using microarrays containing 19 968 cDNAs. Based on global gene clustering of 3560 selected cDNAs, we found distinct molecular signatures in clear cell, papillary, chromophobe RCC/ oncocytoma, TCC and Wilms' subtypes. The close clustering in each of these subtypes points to different tumorigenic pathways as reflected by their histological characteristics. In the clear cell RCC clustering, two subgroups emerged that correlated with clinical outcomes, confirming the potential use of gene expression signatures as a predictor of survival. In the so-called granular cell RCC ( terminology for a subtype that is no longer preferred), none of the six cases clusters together, supporting the current view that they do not represent a single entity. Blinded histological re-evaluation of four cases of 'granular RCC' led to their reassignment to other existing histological subtypes, each compatible with our molecular classification. Finally, we found gene sets specific to each subtype. In order to establish the use of some of these genes as novel subtype markers, we selected four genes and performed immunohistochemical analysis on 40 cases of primary kidney tumors. The results were consistent with the gene expression microarray data: glutathione S-transferase alpha was highly expressed in clear cell RCC, a methylacyl racemase in papillary RCC, carbonic anhydrase II in chromophobe RCC and K19 in TCC. In conclusion, we demonstrated that molecular profiles of kidney cancers closely correlated with their histological subtypes. We have also identified in these subtypes differentially expressed genes that could have important diagnostic and therapeutic implications.	Van Andel Res Inst, Canc Genet Lab, Grand Rapids, MI 49503 USA; Univ Tokushima, Sch Med, Dept Urol, Tokushima 7708503, Japan; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Urol Surg, Chicago, IL 60637 USA; Spectrum Hlth Hosp, Dept Pathol, Grand Rapids, MI 49503 USA; Spectrum Hlth Hosp, Div Urol, Grand Rapids, MI 49503 USA; Princess Alexandra Hosp, Dept Urol, Brisbane, Qld 4102, Australia; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Van Andel Res Inst, Bioinforamt Program, Grand Rapids, MI 49503 USA; Univ Tokushima, Sch Med, Dept Urol, Tokushima 7708503, Japan; Iwate Med Univ, Sch Med, Dept Urol, Morioka, Iwate 0208505, Japan	Van Andel Institute; Tokushima University; University of Chicago; University of Chicago; University of Chicago; Van Andel Institute; Tokushima University; Iwate Medical University	Teh, BT (corresponding author), Van Andel Res Inst, Canc Genet Lab, 333 Bostwick NE, Grand Rapids, MI 49503 USA.		Tretiakova, Maria/U-3320-2019; Gray, Steven G./I-3081-2019; Nicol, David L/M-6809-2016	Gray, Steven G./0000-0002-5850-6392; Nicol, David L/0000-0002-5623-7467; Teh, Bin Tean/0000-0003-1514-1124; Sugimura, Jun/0000-0003-3587-5395; Nicol, David/0000-0003-0107-6990				Boer JM, 2001, GENOME RES, V11, P1861, DOI 10.1101/gr.184501; BRECHUE WF, 1991, BIOCHIM BIOPHYS ACTA, V1066, P201, DOI 10.1016/0005-2736(91)90187-D; Bugert P, 1996, AM J PATHOL, V149, P2081; Chow WH, 1999, JAMA-J AM MED ASSOC, V281, P1628, DOI 10.1001/jama.281.17.1628; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; GRIGNON DJ, 1994, MODERN PATHOL, V7, P186; HADDAD R, 2002, APPL GENOM PROTEOM, V1, P51; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Jiang Z, 2001, AM J SURG PATHOL, V25, P1397, DOI 10.1097/00000478-200111000-00007; Lai LW, 1998, J CLIN INVEST, V101, P1320, DOI 10.1172/JCI1694; LEWIS SE, 1988, P NATL ACAD SCI USA, V85, P1962, DOI 10.1073/pnas.85.6.1962; Luo J, 2002, CANCER RES, V62, P2220; MOSTFI FK, 1998, WHO INT HISTOLOGICAL; Motzer RJ, 2002, J CLIN ONCOL, V20, P2376, DOI 10.1200/JCO.2002.11.123; Okabe H, 2001, CANCER RES, V61, P2129; Ono K, 2000, CANCER RES, V60, P5007; Presti JC, 1996, GENE CHROMOSOME CANC, V17, P199, DOI 10.1002/(SICI)1098-2264(199612)17:4<199::AID-GCC1>3.0.CO;2-Z; Rhodes DR, 2002, BIOINFORMATICS, V18, P205, DOI 10.1093/bioinformatics/18.1.205; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Rubin MA, 2002, JAMA-J AM MED ASSOC, V287, P1662, DOI 10.1001/jama.287.13.1662; Sobin, 2009, UICC TNM CLASSIFICAT; Storkel S, 1997, CANCER, V80, P987, DOI 10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R; Takahashi M, 2001, P NATL ACAD SCI USA, V98, P9754, DOI 10.1073/pnas.171209998; VANMUIJEN GNP, 1987, EXP CELL RES, V171, P331, DOI 10.1016/0014-4827(87)90166-2; Xu JC, 2000, CANCER RES, V60, P1677; Young AN, 2001, AM J PATHOL, V158, P1639, DOI 10.1016/S0002-9440(10)64120-X	29	168	177	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 2	2003	22	43					6810	6818		10.1038/sj.onc.1206869	http://dx.doi.org/10.1038/sj.onc.1206869			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555994				2022-12-17	WOS:000185799300016
J	Li, YQ; Liu, D; Chen, DS; Kharbanda, S; Kufe, D				Li, YQ; Liu, D; Chen, DS; Kharbanda, S; Kufe, D			Human DF3/MUC1 carcinoma-associated protein functions as an oncogene	ONCOGENE			English	Article						DF3/MUC1; 3Y1 cells; anchorage-independent growth; cellular transformation	BETA-CATENIN; CELL-ADHESION; C-SRC; ANTIGEN; CANCER; DF3	The human DF3/MUC1 mucin-like glycoprotein is aberrantly overexpressed by most carcinomas of the breast and other epithelia. The contribution of MUC1 overexpression to the malignant phenotype is, however, not known. In the present studies, we have stably expressed MUC1 in rat 3Y1 fibroblasts. MUC1-positive cells were selected from independent transfections. The results demonstrate that, as found in human carcinomas, MUC1 is expressed on the cell surface and as a complex with P-catenin in the nucleus of the transfectants. Colony formation in soft agar demonstrates that cells expressing MUC1, but not the empty vector, exhibit anchorage-independent growth. The results also show that MUC1 expression confers tumor formation in nude mice. These findings provide the first evidence that MUC1 induces cellular transformation.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; ILEX Prod Inc, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			NCI NIH HHS [R01 CA097098, CA97098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; GENDLER S, 1988, J BIOL CHEM, V263, P12820; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; Kondo K, 1998, CANCER RES, V58, P2014; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIGHTENBERG M, 1992, CANCER RES, V52, P223; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; VLERNINCKX K, 1991, CELL, V66, P107; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492	17	168	186	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6107	6110		10.1038/sj.onc.1206732	http://dx.doi.org/10.1038/sj.onc.1206732			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955090	Green Accepted			2022-12-17	WOS:000185137800020
J	Kothari, S; Cizeau, J; McMillan-Ward, E; Israels, SJ; Bailes, M; Ens, K; Kirshenbaum, LA; Gibson, SB				Kothari, S; Cizeau, J; McMillan-Ward, E; Israels, SJ; Bailes, M; Ens, K; Kirshenbaum, LA; Gibson, SB			BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF	ONCOGENE			English	Article						hypoxia; cell death; tumor; BNIP3; EGF; IGF	MITOCHONDRIAL PERMEABILITY TRANSITION; ADVANCED BREAST-CANCER; TUMOR ANGIOGENESIS; INDUCED APOPTOSIS; PROTEIN BNIP3; BH3 DOMAIN; FACTOR-I; EXPRESSION; NIP3; HERCEPTIN	Hypoxic regions within solid tumors are often resistant to chemotherapy and radiation. BNIP3 (Bcl-2/E1B 19 kDa interacting protein) is a proapoptotic member of the Bcl-2 family that is expressed in hypoxic regions of tumors. During hypoxia, BNIP3 expression is increased in many cell types and upon forced overexpression BNIP3 induces cell death. Herein, we have demonstrated that blockage of hypoxia-induced BNIP3 expression using antisense oligonucleotides against BNIP3 or blockage of BNIP3 function through expression of a mutant form of BNIP3 inhibits hypoxia-induced cell death in human embryonic kidney 293 cells. We have also determined that hypoxia-mediated BNIP3 expression is regulated by the transcription factor, hypoxia-inducible factor-1alpha (HIF-1alpha) in human epithelial cell lines. Furthermore, HIF-1alpha directly binds to a consensus HIF-1alpha-responsive element (HRE) in the human BNIP3 promoter that upon mutation of this HRE site eliminates the hypoxic responsiveness of the promoter. Since BNIP3 is expressed in hypoxic regions of tumors but fails to induce cell death, we determined whether growth factors block BNIP3-induced cell death. Treatment of the breast cancer cell line MCF-7 cells with epidermal growth factor (EGF) or insulin-like growth factor effectively protected these cells from BNIP3-induced cell death. Furthermore, inhibiting EGF receptor signaling using antibodies against ErbB2 (Herceptin) resulted in increased hypoxia-induced cell death in MCF-7 cells. Taken together, BNIP3 plays a role in hypoxia-induced cell death in human epithelial cells that could be circumvented by growth factor signaling.	Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB, Canada; St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, Winnipeg, MB R2H 2A6, Canada; Univ Manitoba, Fac Med, Dept Physiol, Winnipeg, MB, Canada; Univ Manitoba, Fac Med, Dept Biochem & Med Genet, Winnipeg, MB, Canada	University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; University of Manitoba	Gibson, SB (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB, Canada.		Kirshenbaum, Lorrie A./F-5742-2014; Israels, Sara/ABC-3684-2021	Israels, Sara/0000-0002-1849-4825; Ryplanski, Kairee/0000-0002-3737-7181; Gibson, Spencer/0000-0003-0119-732X				Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Burris HA, 2000, SEMIN ONCOL, V27, P19; Caro J, 2001, HIGH ALT MED BIOL, V2, P145, DOI 10.1089/152702901750265251; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Cizeau J, 2000, ONCOGENE, V19, P5453, DOI 10.1038/sj.onc.1203929; Clawson TF, 1999, BIOL SIGNAL RECEPT, V8, P281; Farooq M, 2001, EXP MOL MED, V33, P169, DOI 10.1038/emm.2001.29; Furstenberger G, 2002, LANCET ONCOL, V3, P298, DOI 10.1016/S1470-2045(02)00731-3; Giatromanolaki A, 2001, ANTICANCER RES, V21, P4317; Gibson EM, 2002, CANCER RES, V62, P488; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Goonewardene TI, 2002, MICROSC RES TECHNIQ, V59, P41, DOI 10.1002/jemt.10175; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hellermann JP, 2002, AM J MED, V113, P324, DOI 10.1016/S0002-9343(02)01185-3; Hochachka PW, 2002, BIOESSAYS, V24, P749, DOI 10.1002/bies.10131; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Hung MC, 1999, SEMIN ONCOL, V26, P51; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kim JY, 2002, ARCH BIOCHEM BIOPHYS, V398, P147, DOI 10.1006/abbi.2001.2673; Knowles HJ, 2001, BREAST CANCER RES, V3, P318, DOI 10.1186/bcr314; Koukourakis MI, 2001, ANTICANCER RES, V21, P4285; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Leek RD, 2002, CANCER RES, V62, P1326; Miura M, 2000, METHOD ENZYMOL, V322, P480; Mizutani A, 2002, J BIOL CHEM, V277, P15851, DOI 10.1074/jbc.M111431200; Mrsic M, 2001, ANN ONCOL, V12, P95, DOI 10.1023/A:1011116224931; Piret JP, 2002, BIOCHEM PHARMACOL, V64, P889, DOI 10.1016/S0006-2952(02)01155-3; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Regula KM, 2002, CIRC RES, V91, P226, DOI 10.1161/01.RES.0000029232.42227.16; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Seigel G, 2000, MOL VIS, V6, P157; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Sowter HM, 2001, CANCER RES, V61, P6669; Stebbing J, 2000, CANCER TREAT REV, V26, P287, DOI 10.1053/ctrv.2000.0182; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327	45	168	179	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4734	4744		10.1038/sj.onc.1206666	http://dx.doi.org/10.1038/sj.onc.1206666			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879018				2022-12-17	WOS:000184157000014
J	Graves, PR; Lovly, CM; Uy, GL; Piwnica-Worms, H				Graves, PR; Lovly, CM; Uy, GL; Piwnica-Worms, H			Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding	ONCOGENE			English	Article						cell cycle; Cdc25C; 14-3-3; nuclear import; nuclear export	CELL-CYCLE REGULATION; XENOPUS EGG EXTRACTS; TYROSINE KINASE; DNA-DAMAGE; HUMAN WEE1; 7-HYDROXYSTAUROSPORINE UCN-01; PHOSPHORYLATION SITES; MOLECULAR-CLONING; DEPENDENT KINASES; G(2) CHECKPOINT	Entry into mitosis requires activation of the Cdc2 protein kinase by the Cdc25C protein phosphatase, The interactions between Cdc2 and Cdc25C are negatively regulated throughout interphase and in response to G2 checkpoint activation. This is accomplished in part by maintaining the Cdc25 phosphatase in a phosphorylated form that binds 14-3-3 proteins. Here we report that 14-3-3 binding regulates the intracellular trafficking of Cdc25C, Although primarily cytoplasmic, Cdc25C accumulated in the nuclei of leptomycin B (LMB)-treated cells, indicating that Cdc25C is actively exported out of the nucleus. A mutant of Cdc25C that is unable to bind 14-3-3 was partially nuclear in the absence of LMB and its nuclear accumulation was greatly enhanced by LMB-treatment, A nuclear export signal (NES) was identified within the amino terminus of Cdc25C, Although mutation of the NES did not effect 14-3-3 binding, it did cause nuclear accumulation of Cdc25C, These results demonstrate that 14-3-3 binding is dispensable for the nuclear export of Cdc25C, However, complete nuclear accumulation of Cdc25C required loss of both NES function and 14-3-3 binding and this was accomplished both pharmacologically and by mutation. These findings suggest that the nuclear export of Cdc25C is mediated by an intrinsic NES and that 14-3-3 binding negatively regulates nuclear import.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Piwnica-Worms, H (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.		Piwnica-Worms, Helen/C-5214-2012; Uy, Geoffrey/A-2058-2010; Uy, Geoffrey/AAD-9815-2021	Uy, Geoffrey/0000-0002-7809-0996; Lovly, Christine/0000-0002-3641-6361				Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Busby EC, 2000, CANCER RES, V60, P2108; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Davezac N, 2000, ONCOGENE, V19, P2179, DOI 10.1038/sj.onc.1203545; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HONDA R, 1992, BIOCHEM BIOPH RES CO, V186, P1333, DOI 10.1016/S0006-291X(05)81552-9; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUANG J, 1994, MOL BIOL CELL, V5, P135, DOI 10.1091/mbc.5.2.135; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LI JK, 1995, MOL BIOL CELL, V6, P1111, DOI 10.1091/mbc.6.9.1111; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NISHI K, 1994, J BIOL CHEM, V269, P6320; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; OGG S, 1994, J BIOL CHEM, V269, P30461; OUYANG B, 1997, J BIOL CHEM, P28646; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang J, 1999, TRENDS CELL BIOL, V9, P207, DOI 10.1016/S0962-8924(99)01577-9; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zeng Y, 1999, MOL CELL BIOL, V19, P7410	71	168	175	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2001	20	15					1839	1851		10.1038/sj.onc.1204259	http://dx.doi.org/10.1038/sj.onc.1204259			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313932				2022-12-17	WOS:000167908400005
J	Clarke, PA; Hostein, I; Banerji, U; Di Stefano, F; Maloney, A; Walton, M; Judson, I; Workman, P				Clarke, PA; Hostein, I; Banerji, U; Di Stefano, F; Maloney, A; Walton, M; Judson, I; Workman, P			Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of hsp90 molecular chaperone	ONCOGENE			English	Article						gene array; cancer therapy; hsp90 chaperone; 17-allylamino-17-demethoxygeldanamycin	ROUS-SARCOMA VIRUS; RAT-KIDNEY CELLS; IN-VIVO; HEAT-SHOCK; GLUCOCORTICOID RECEPTOR; CDNA MICROARRAY; DT-DIAPHORASE; GELDANAMYCIN; KINASE; PROTEIN	A number of molecular therapeutic agents, derived from exploiting our knowledge of the oncogenic pathways that are frequently deregulated in cancer, are now entering clinical trials. One of these is the novel agent 17-allylamino-17-demethoxygeldanamycin that acts to inhibit the hsp90 molecular chaperone. Treatment of four human colon cancer cell lines with iso-effective concentrations of this agent resulted in depletion of c-raf-1 and akt and inhibition of signal transduction. We have used gene expression array analysis to identify genes responsive to treatment with this drug. The expression of hsp90 client protein genes was not affected, but hsc hsp70, hsp90 beta, keratin 8, keratin 18 and caveolin-1 were deregulated following treatment. These observations were consistent with inhibition of signal transduction and suggested a possible mechanism of resistance or recovery from 17-allylamino-17-demethoxygeldanamycin treatment. The results shed light on the molecular mode of action of the hsp90 inhibitors, and suggest possible molecular markers of drug action for use in hypothesis testing clinical trials.	Inst Canc Res, Canc Res Campaign, Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England	University of London; Institute of Cancer Research - UK	Workman, P (corresponding author), Inst Canc Res, Canc Res Campaign, Ctr Canc Therapeut, E Block,15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.			Clarke, Paul/0000-0001-9342-1290; Banerji, Udai/0000-0003-1503-3123				Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Brunton VG, 1998, CANCER CHEMOTH PHARM, V41, P417, DOI 10.1007/s002800050760; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Byrd CA, 1999, P NATL ACAD SCI USA, V96, P5645, DOI 10.1073/pnas.96.10.5645; Chavany C, 1996, J BIOL CHEM, V271, P4974; DeRisi J, 1996, NAT GENET, V14, P457; Egorin MJ, 1998, CANCER RES, V58, P2385; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; Garrett MD, 1999, EUR J CANCER, V35, P2010, DOI 10.1016/S0959-8049(99)00280-4; Gelmon KA, 1999, J NATL CANCER I, V91, P1281, DOI 10.1093/jnci/91.15.1281; GIBBS JB, 1994, CELL, V79, P193, DOI 10.1016/0092-8674(94)90189-9; HANSEN LK, 1991, EXP CELL RES, V192, P587, DOI 10.1016/0014-4827(91)90080-E; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Hilsenbeck SG, 1999, J NATL CANCER I, V91, P453, DOI 10.1093/jnci/91.5.453; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Kelland LR, 1999, J NATL CANCER I, V91, P1940, DOI 10.1093/jnci/91.22.1940; Khan J, 1998, CANCER RES, V58, P5009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Martin S, 1998, EUR PHYS J D, V4, P1, DOI 10.1007/s100530050178; MILLER P, 1994, CANCER RES, V54, P2724; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; MURAKAMI Y, 1991, EXP CELL RES, V195, P338, DOI 10.1016/0014-4827(91)90382-5; MURAKAMI Y, 1991, BIOCHEM J, V301, P63; Oshima RG, 1996, CANCER METAST REV, V15, P445, DOI 10.1007/BF00054012; Pawson T, 1999, CELL, V97, P675, DOI 10.1016/S0092-8674(00)80779-5; Price MA, 1996, PHILOS T ROY SOC B, V351, P551, DOI 10.1098/rstb.1996.0054; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; SCHNUR RC, 1995, J MED CHEM, V38, P3806, DOI 10.1021/jm00019a010; Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; Sgroi DC, 1999, CANCER RES, V59, P5656; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Strawn L M, 1998, Expert Opin Investig Drugs, V7, P553, DOI 10.1517/13543784.7.4.553; SUPKO JG, 1995, CANCER CHEMOTH PHARM, V36, P305, DOI 10.1007/BF00689048; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; Vasilevskaya IA, 1999, CANCER RES, V59, P3935; Vlahos Chris J., 1995, Drugs of the Future, V20, P165; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; ZOU J, 1996, CELL, V94, P471	51	168	176	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2000	19	36					4125	4133		10.1038/sj.onc.1203753	http://dx.doi.org/10.1038/sj.onc.1203753			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962573				2022-12-17	WOS:000088955100006
J	Kotenko, SV; Pestka, S				Kotenko, SV; Pestka, S			Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes	ONCOGENE			English	Review						cytokines; interleukin-10; interferons; receptors; IFN-8; IFN-alpha	INTERFERON-GAMMA RECEPTOR; HUMAN-TISSUE FACTOR; PROTEIN-TYROSINE KINASE; COAGULATION-FACTOR VIIA; ALPHA-BETA RECEPTOR; CRYSTAL-STRUCTURE; IFN-GAMMA; ERYTHROPOIETIN RECEPTOR; GROWTH-HORMONE; INTRACELLULAR DOMAIN	Cells of the immune system communicate with each other to initiate, establish and maintain immune responses. The communication occurs through cell-to-cell contact or through a variety of intercellular mediators that include cytokines, chemokines, growth factors and hormones. In the case of cytokines, the signal is transmitted from the outside to the inside of a cell through cell surface receptors specific for each cytokine, At this step the signal is also decoded and amplified: ligand binding causes recruitment and/or activation of numerous cytoplasmic proteins. One cytokine can activate number of signal transduction pathways leading to regulation of a wide array of biological activities, One of these pathways, the Jak-Stat pathway, is briefly reviewed here with respect to the class II cytokine receptors, Signal transduction through receptors for interferons Type I (IFN-alpha, IFN-beta, IFN-omega) and Type II (IFN-gamma), and interleukin 10 (IL-10) is described in detail. In addition, a complex between tissue factor (TF) and coagulation factor VIIa, and two new receptors related to the class II cytokine receptor family are discussed.	Canc Inst New Jersey, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center	Pestka, S (corresponding author), Canc Inst New Jersey, 195 Little Albany St, New Brunswick, NJ 08901 USA.				NATIONAL CANCER INSTITUTE [P30CA072720, R01CA046465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036450] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA46465, 1P30-CA72720] Funding Source: Medline; NIAID NIH HHS [R01 AI36450] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adler K, 1996, FEBS LETT, V395, P286, DOI 10.1016/0014-5793(96)01053-8; AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; Araki T, 1998, EMBO J, V17, P4018, DOI 10.1093/emboj/17.14.4018; Arduini RM, 1999, PROTEIN SCI, V8, P1867, DOI 10.1110/ps.8.9.1867; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BACH EA, 1995, SCIENCE, V270, P1215, DOI 10.1126/science.270.5239.1215; Bach EA, 1996, MOL CELL BIOL, V16, P3214; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; BROMBERG ME, 1995, P NATL ACAD SCI USA, V92, P8205, DOI 10.1073/pnas.92.18.8205; Caldenhoven E, 1999, J LEUKOCYTE BIOL, V65, P391, DOI 10.1002/jlb.65.3.391; Camerer E, 1999, J BIOL CHEM, V274, P32225, DOI 10.1074/jbc.274.45.32225; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Carmeliet P, 1998, INT J BIOCHEM CELL B, V30, P661, DOI 10.1016/S1357-2725(97)00121-0; CARSON SD, 1985, SCIENCE, V229, P991, DOI 10.1126/science.4023720; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; Cunningham MA, 1999, BLOOD, V94, P3413, DOI 10.1182/blood.V94.10.3413.422k24_3413_3420; Cutrone EC, 1997, FEBS LETT, V404, P197, DOI 10.1016/S0014-5793(97)00129-4; DASILVA L, 1994, J BIOL CHEM, V269, P18267; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Domanski P, 1997, J BIOL CHEM, V272, P26388, DOI 10.1074/jbc.272.42.26388; Domanski Paul, 1996, Cytokine and Growth Factor Reviews, V7, P143, DOI 10.1016/1359-6101(96)00017-2; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; FISHER KL, 1987, THROMB RES, V48, P89, DOI 10.1016/0049-3848(87)90349-5; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; Gall JG, 1999, MOL BIOL CELL, V10, P4385, DOI 10.1091/mbc.10.12.4385; Gibbs VC, 1996, J BIOL CHEM, V271, P28710, DOI 10.1074/jbc.271.45.28710; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GuilletDeniau I, 1997, J BIOL CHEM, V272, P14825, DOI 10.1074/jbc.272.23.14825; Halle JP, 1996, TRENDS GENET, V12, P161, DOI 10.1016/0168-9525(96)30035-8; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; JUNG V, 1988, SOMAT CELL MOLEC GEN, V14, P583, DOI 10.1007/BF01535312; JUNG V, 1990, J BIOL CHEM, V265, P1827; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; KEMPNER ES, 1986, METHOD ENZYMOL, V119, P255; Kirchhofer D, 1996, CURR OPIN BIOTECH, V7, P386, DOI 10.1016/S0958-1669(96)80112-1; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kotenko SV, 1996, J BIOL CHEM, V271, P17174, DOI 10.1074/jbc.271.29.17174; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; Kotenko SV, 1999, P NATL ACAD SCI USA, V96, P5007, DOI 10.1073/pnas.96.9.5007; Kotenko SV, 2000, P NATL ACAD SCI USA, V97, P1695, DOI 10.1073/pnas.97.4.1695; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; LANGER JA, 1990, SOMAT CELL MOLEC GEN, V16, P231, DOI 10.1007/BF01233359; LIU Y, 1994, J IMMUNOL, V152, P1821; LOK S, 1999, Patent No. 5965704; LOK S, 1999, Patent No. 5945511; LUTFALLA G, 1990, J INTERFERON RES, V10, P515, DOI 10.1089/jir.1990.10.515; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; LUTFALLA G, 1993, GENOMICS, V16, P366, DOI 10.1006/geno.1993.1199; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Mogensen KE, 1999, J INTERF CYTOK RES, V19, P1069, DOI 10.1089/107999099313019; MOORE D, 1993, ADDICT RES, V1, P11; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Muthukumaran G, 1997, J BIOL CHEM, V272, P4993, DOI 10.1074/jbc.272.8.4993; Nadeau OW, 1999, J BIOL CHEM, V274, P4045, DOI 10.1074/jbc.274.7.4045; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Novelli F, 1996, J IMMUNOL, V157, P1935; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Ollivier V, 1998, BLOOD, V91, P2698, DOI 10.1182/blood.V91.8.2698.2698_2698_2703; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Pendurthi UR, 1997, P NATL ACAD SCI USA, V94, P12598, DOI 10.1073/pnas.94.23.12598; PERNIS A, 1995, SCIENCE, V269, P245, DOI 10.1126/science.7618088; PESTKA S, 1983, J BIOL CHEM, V258, P9706; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.bi.56.070187.003455; Pestka Sidney, 1997, Cytokine and Growth Factor Reviews, V8, P189, DOI 10.1016/S1359-6101(97)00009-9; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; POLLACK BP, 2000, UNPUB; Poulsen LK, 1998, J BIOL CHEM, V273, P6228, DOI 10.1074/jbc.273.11.6228; RASHIDBAIGI A, 1986, P NATL ACAD SCI USA, V83, P384, DOI 10.1073/pnas.83.2.384; Reboul J, 1999, GENOME RES, V9, P242; RUI H, 1994, J BIOL CHEM, V269, P5364; Sakatsume M, 1996, J IMMUNOL, V156, P4160; Sato T, 1997, BLOOD, V90, P4749, DOI 10.1182/blood.V90.12.4749.4749_4749_4758; SCARPATI EM, 1987, BIOCHEMISTRY-US, V26, P5234, DOI 10.1021/bi00391a004; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SKRENTA H, 1996, EUR CYTOKINE NETW, V7, P622; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SOH JM, 1994, J BIOL CHEM, V269, P18102; SPICER EK, 1987, P NATL ACAD SCI USA, V84, P5148, DOI 10.1073/pnas.84.15.5148; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TANIYAMA T, 1995, HUM GENET, V95, P99; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; USACHEVA A, 2000, UNPUB; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WALTER MR, 1995, BIOCHEMISTRY-US, V34, P12118, DOI 10.1021/bi00038a004; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; Wehinger J, 1996, FEBS LETT, V394, P365, DOI 10.1016/0014-5793(96)00990-8; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; ZDANOV A, 1995, STRUCTURE, V3, P591, DOI 10.1016/S0969-2126(01)00193-9; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang XK, 1999, MOL CELL BIOL, V19, P7138	112	168	194	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2557	2565		10.1038/sj.onc.1203524	http://dx.doi.org/10.1038/sj.onc.1203524			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851054				2022-12-17	WOS:000087459400011
J	Serebriiskii, I; Estojak, J; Sonoda, G; Testa, JR; Golemis, EA				Serebriiskii, I; Estojak, J; Sonoda, G; Testa, JR; Golemis, EA			Association of Krev-1/rapla with Krit1, a novel ankyrin repeat-containing protein encoded by a gene mapping to 7q21-22	ONCOGENE			English	Article						Krit1; Krev-1/Rapla; 7q21-22; ankyrin repeat; interaction	BUD-SITE-SELECTION; GTP-BINDING PROTEINS; RAS-RELATED GENE; SACCHAROMYCES-CEREVISIAE; CHILDHOOD MONOSOMY-7; SUPPRESSOR ACTIVITY; ACTIVATING PROTEIN; HUMAN-NEUTROPHILS; TUMOR-SUPPRESSOR; SIGNAL PATHWAY	Krev-1/rap1A is an evolutionarily conserved Ras-family GTPase whose cellular function remains unclear, hut which has been proposed to function as a tumor suppressor gene, and may act as a Ras antagonist, To elucidate Krev-1 activity, we have used LexA-Krev-1 in a two-hybrid screen of a HeLa cell cDNA library, Of the two cDNA classes isolated, one contained a single isolate encoding the known Krev-1 interactor Raf, while the second contained multiple isolates coding for a previously undescribed protein which we have designated Krit1 (for Krev Interaction Trapped 1), The full length Krit1 cDNA encodes a protein of 529 amino acids, with an amino-terminal ankyrin repeat domain and a novel carboxy-terminal domain required for association with Krit1, Krit1 interacted strongly with Krev-1 but only weakly with Ras, suggesting it might specifically regulate Krev-1 activities, Krit1 mRNA and protein are expressed endogenously at low levels, with tissue specific variation, Intriguingly, the Krit cDNA has been mapped by FISH to chromosome 7q21-22, a region known to be frequently deleted or amplified in multiple forms of cancer.	FOX CHASE CANC CTR,DIV BASIC SCI,PHILADELPHIA,PA 19111; FOX CHASE CANC CTR,DIV MED SCI,PHILADELPHIA,PA 19111	Fox Chase Cancer Center; Fox Chase Cancer Center				Golemis, Erica/0000-0003-3618-3673	NATIONAL CANCER INSTITUTE [R29CA063366, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927, R29 CA63366] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BELL DW, 1995, CYTOGENET CELL GENET, V70, P263, DOI 10.1159/000134048; BENDER A, 1993, P NATL ACAD SCI USA, V90, P9926, DOI 10.1073/pnas.90.21.9926; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BOKOCH GM, 1994, CURR OPIN IMMUNOL, V6, P98, DOI 10.1016/0952-7915(94)90040-X; BOKOCH GM, 1995, TRENDS CELL BIOL, V5, P109, DOI 10.1016/S0962-8924(00)88960-6; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; *CONS I GEN RES, 1995, NATURE, V377, P3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GOLEMIS EA, 1996, CURRENT PROTOCOLS MO; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JELINEK MA, 1992, ONCOGENE, V7, P1687; KERE J, 1987, BLOOD, V70, P1349; KHAZAK V, 1995, MOL BIOL CELL, V6, P759, DOI 10.1091/mbc.6.7.759; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Law SF, 1996, MOL CELL BIOL, V16, P3327; LUNAFINEMAN S, 1995, BLOOD, V85, P1985, DOI 10.1182/blood.V85.8.1985.bloodjournal8581985; MALY FE, 1994, J BIOL CHEM, V269, P18743; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; Moult J, 1996, CURR OPIN BIOTECH, V7, P422, DOI 10.1016/S0958-1669(96)80118-2; NASSAR N, 1995, NATURE, V375, P554; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; PEDERSENBJERGAARD J, 1982, BLOOD, V60, P172; PIZON V, 1988, ONCOGENE, V3, P201; PIZON V, 1994, J CELL SCI, V107, P1661; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; QUINN MT, 1992, BLOOD, V79, P1563; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; RUGGIERI R, 1992, MOL CELL BIOL, V12, P758, DOI 10.1128/MCB.12.2.758; SAKODA T, 1992, ONCOGENE, V7, P1705; SARGENT MS, 1994, CANCER GENET CYTOGEN, V77, P65, DOI 10.1016/0165-4608(94)90151-1; SATO KY, 1994, CANCER RES, V54, P552; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; WEISS K, 1987, LEUKEMIA, V1, P97; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; WOJTASZEK PA, 1993, ONCOGENE, V8, P755; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YAMADA T, 1990, GENE CHROMOSOME CANC, V2, P88, DOI 10.1002/gcc.2870020203; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626; [No title captured]	62	168	175	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1043	1049		10.1038/sj.onc.1201268	http://dx.doi.org/10.1038/sj.onc.1201268			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285558				2022-12-17	WOS:A1997XT16100005
J	Watters, D; Khanna, KK; Beamish, H; Birrell, G; Spring, K; Kedar, P; Gatei, M; Stenzel, D; Hobson, K; Kozlov, S; Zhang, N; Farrell, A; Ramsay, J; Gatti, R; Lavin, M				Watters, D; Khanna, KK; Beamish, H; Birrell, G; Spring, K; Kedar, P; Gatei, M; Stenzel, D; Hobson, K; Kozlov, S; Zhang, N; Farrell, A; Ramsay, J; Gatti, R; Lavin, M			Cellular localisation of the ataxia-telangiectasia (ATM) gene product and discrimination between mutated and normal forms	ONCOGENE			English	Article						ataxia-telangiectasia; cellular localisation; mutations; radiation; p53	CYCLE CHECKPOINT PATHWAY; FLOW CYTOMETRIC ANALYSIS; IONIZING-RADIATION; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; SACCHAROMYCES-CEREVISIAE; MAMMALIAN PROTEIN; CELLS; PROGRESSION; RAPAMYCIN	The recently cloned gene (ATM) mutated in the human genetic disorder ataxia-telangiectasia (A-T) is involved in DNA damage response at different cell cycle checkpoints and also appears to have a wider role in signal transduction. Antibodies prepared against peptides from the predicted protein sequence detected a similar to 350 kDa protein corresponding to the open reading frame, which was absent in 13/23 A-T homozygotes. Subcellular fractionation, immunoelectronmicroscopy and immunofluorescence showed that the ATM protein is present in the nucleus and cytoplasmic vesicles. This distribution did not change after irradiation, We also provide evidence that ATM protein binds to p53 and this association is defective in A-T cells compatible with the defective p53 response in these cells. These results provide further support for a role for the ATM protein as a sensor of DNA damage and in a more general role in cell signalling, compatible with the broader phenotype of the syndrome.	PO ROYAL BRISBANE HOSP, QUEENSLAND CANC FUND RES UNIT, QUEENSLAND INST MED RES, HERSTON, QLD 4029, AUSTRALIA; QUEENSLAND UNIV TECHNOL, ANALYT ELECTRON MICROSCOPE FACIL, BRISBANE, QLD 4000, AUSTRALIA; ROYAL BRISBANE HOSP, QUEENSLAND RADIUM INST, BRISBANE, QLD 4029, AUSTRALIA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PATHOL, CTR HLTH SCI, LOS ANGELES, CA USA; UNIV QUEENSLAND, ROYAL BRISBANE HOSP, DEPT SURG, BRISBANE, QLD 4029, AUSTRALIA	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Queensland University of Technology (QUT); Royal Brisbane & Women's Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Royal Brisbane & Women's Hospital; University of Queensland			Lavin, Martin F/F-5961-2014; Watters, Dianne J/E-6007-2010; Hobson, Keith/Q-9306-2019; Kozlov, Sergei/T-9779-2019; Kozlov, Sergei/M-2067-2014; Ramsay, Jonathan/F-7009-2013; Khanna, Kum Kum/I-1747-2013	Lavin, Martin F/0000-0002-5940-4769; Watters, Dianne J/0000-0002-2555-5825; Kozlov, Sergei/0000-0001-6183-7339; Khanna, Kum Kum/0000-0001-8650-5381; Spring, Kevin/0000-0003-0601-924X; Birrell, Geoff/0000-0002-6593-1514				ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; Beamish H, 1996, ONCOGENE, V13, P963; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; CANMAN CE, 1994, CANCER RES, V54, P5054; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Finnie NJ, 1996, PHILOS T ROY SOC B, V351, P173, DOI 10.1098/rstb.1996.0014; FORD MD, 1984, MUTAT RES, V125, P115, DOI 10.1016/0027-5107(84)90038-1; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HARNDEN DG, 1994, INT J RADIAT BIOL, V66, pS13, DOI 10.1080/09553009414551811; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; IMRAY FP, 1983, MUTAT RES, V112, P369; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; KONDO N, 1993, SCAND J IMMUNOL, V38, P45, DOI 10.1111/j.1365-3083.1993.tb01692.x; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LAVIN MF, 1995, TRENDS BIOCHEM SCI, V20, P382, DOI 10.1016/S0968-0004(00)89083-0; LAVIN MF, 1994, INT J RADIAT BIOL, V66, pS151; LAVIN MF, 1997, IN PRESS ANN REV IMM; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MEYN MS, 1995, CANCER RES, V55, P5991; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; OCONNOR RD, 1980, CLIN IMMUNOL IMMUNOP, V15, P66, DOI 10.1016/0090-1229(80)90021-5; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAULES RS, 1995, CANCER RES, V55, P1763; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; ROEST PAM, 1993, HUM MOL GENET, V2, P1719, DOI 10.1093/hmg/2.10.1719; ROTMAN G, 1996, J CLIN IMMUNOL, V16, P254; RUDOLPH NS, 1989, MUTAT RES, V211, P19, DOI 10.1016/0027-5107(89)90103-6; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SCHNITT S, 1996, SCIENCE, V272, P123; SCOTT D, 1982, INT J RADIAT BIOL, V42, P679, DOI 10.1080/09553008214551661; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SHAFMAN TD, 1995, CANCER RES, V55, P3242; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; SiddooAtwal C, 1996, CANCER RES, V56, P443; SINGH SP, 1990, MOL CELL BIOL, V10, P5279, DOI 10.1128/MCB.10.10.5279; STOLZENBACH F, 1966, METHOD ENZYMOL, V9, P278; TEALE B, 1992, J BIOL CHEM, V267, P10295; TEALE B, 1993, J BIOL CHEM, V268, P22450; Telatar M, 1996, AM J HUM GENET, V59, P40; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; Uziel T, 1996, GENOMICS, V33, P317, DOI 10.1006/geno.1996.0201; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; XU Y, 1996, GENE DEV, V10, P2389; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	64	168	171	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	1997	14	16					1911	1921		10.1038/sj.onc.1201037	http://dx.doi.org/10.1038/sj.onc.1201037			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150358				2022-12-17	WOS:A1997WV80400004
J	GUILLOUF, C; ROSSELLI, F; KRISHNARAJU, K; MOUSTACCHI, E; HOFFMAN, B; LIEBERMANN, DA				GUILLOUF, C; ROSSELLI, F; KRISHNARAJU, K; MOUSTACCHI, E; HOFFMAN, B; LIEBERMANN, DA			P53 INVOLVEMENT IN CONTROL OF G2 EXIT OF THE CELL-CYCLE - ROLE IN DNA DAMAGE-INDUCED APOPTOSIS	ONCOGENE			English	Article						P53; DNA DAMAGING AGENTS; APOPTOSIS; G2 CHECKPOINT	WILD-TYPE P53; ATAXIA-TELANGIECTASIA; ERYTHROLEUKEMIA-CELLS; INDUCTION; AGENTS; RADIATION; CAFFEINE; PROTEIN; GROWTH; LINE	DNA damage in proliferating mammalian cells induces a complex cellular response comprising perturbation of the cell cycle and programmed cell death. The relationship between p53-dependent and p53-independent apoptotic cell death, as well as the cell cycle checkpoints induced by DNA damaging agents were explored in hematopoietic cells, using M1 myeloblastic leukemia cells, which are null for p53 expression, genetically engineered M1 variants, expressing p53(ts) and bcl-2 transgenes, as well as myeloblast enriched bone-marrow cells obtained from wild type p53 (wt p53) and p53-deficient mice. It is shown that gamma-irradiation of M1p53(ts) cells activated a function of the temperature sensitive mutant transgene p53 (p53(ts)), promoting increased apoptosis relative to parental, null p53 M1 cells. It is also shown that the kinetics of apoptotic cell death induced by gamma-irradiation correlated with the rapidity of exit from gamma-ray-induced G2 arrest for all the different hematopoietic cell types indicated above. Finally, data has been obtained to demonstrate that, in addition to a role in apoptosis and G1 arrest, wild-type p53 positively modulated the exit from the gamma-ray-induced G2 checkpoint. Taken together, these findings indicate that this new function for p53 is a component of the physiological pathway by which p53 exerts its role in apoptosis.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; INST CURIE,CNRS,UA 1292,F-75231 PARIS 05,FRANCE	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Filippo, Rosselli/AAO-6393-2020	Filippo, Rosselli/0000-0003-1080-5745	NCI NIH HHS [1RO1CA51162, 1RO1CA43618] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043618, R01CA051162] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUSSE PM, 1977, RADIAT RES, V71, P666, DOI 10.2307/3574634; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; FRITSCHE M, 1993, ONCOGENE, V8, P307; GUILLOUF C, 1995, IN PRESS BLOOD; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IMAMURA J, 1994, BLOOD, V8, P2412; IMRAY FP, 1983, MUTAT RES, V112, P369; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; NATARAJAN AT, 1980, HUM GENET, V54, P183, DOI 10.1007/BF00278969; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P203, DOI 10.1080/09553009414550241; RADFORD IR, 1994, INT J RADIAT BIOL, V66, P557, DOI 10.1080/09553009414551621; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P217, DOI 10.1080/09553009414550251; RAMQVIST T, 1993, ONCOGENE, V8, P1495; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SELVAKUMARAN M, 1994, MOL CELL BIOL, V4, P2352; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STEWART N, 1995, ONCOGENE, V10, P109; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; THACKER J, 1990, MUTAT RES, V235, P49, DOI 10.1016/0921-8777(90)90057-C; WALDREN CA, 1978, RADIAT RES, V73, P95, DOI 10.2307/3574576; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, ONCOGENE, V9, P3743	40	168	168	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2263	2270						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784074				2022-12-17	WOS:A1995RB70300025
J	OHNO, T; OUCHIDA, M; LEE, L; GATALICA, Z; RAO, VN; REDDY, ESP				OHNO, T; OUCHIDA, M; LEE, L; GATALICA, Z; RAO, VN; REDDY, ESP			THE EWS GENE, INVOLVED IN EWING FAMILY OF TUMORS, MALIGNANT-MELANOMA OF SOFT PARTS AND DESMOPLASTIC SMALL ROUND-CELL TUMORS, CODES FOR AN RNA-BINDING PROTEIN WITH NOVEL REGULATORY DOMAINS	ONCOGENE			English	Article							ETS-RELATED PROTEIN; TRANSCRIPTIONAL ACTIVATION DOMAINS; PUTATIVE ONCOGENE SPI-1; SERUM RESPONSE FACTOR; LONG TERMINAL REPEAT; DNA-BINDING; C-FOS; C-ETS-1 PROTOONCOGENE; LEUKEMIA-VIRUS; FLI-1 GENE	The EWS gene, which maps to band q12 of human chromosome 22, is involved in a wide variety of human solid tumors including Ewing sarcoma, related primitive neuroectodermal tumors, malignant melanoma of soft parts and desmoplastic small round cell tumors. In these tumors, the EWS is fused to genes encoding transcriptional activators/repressors, like Fli-1 or erg or ATF 1 or wt1. To better understand the function of the EWS protein, we cloned the EWS cDNA. Sequence analysis of this cDNA revealed differential splicing invoving two exons encoding 72 amino acids. Both alternatively spliced transcripts, EWS and EWS-b, are expressed in a variety of cells. Because EWS proteins contain putative conserved RNA binding motifs, we studied the RNA binding properties of the EWS protein. The EWS-b protein binds to RNA in vitro and, specifically, to poly G and poly U. The RNA binding activity was localized to the carboxy terminal 86 amino acids, which constitute RGG box. Thus the amino terminal domain of EWS (NTD-EWS), which is involved in chromosome translocation may regulate the specificity of RNA binding activity of EWS. An EWS-erg chimeric protein, which is found in Ewing's sarcoma cells, functions as a transcriptional activator. Mutational analysis of EWS-erg chimeric protein revealed that NTD-EWS functions as a regulatory domain for the transcriptional activation properties of EWS-erg chimeric protein.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; PROGRAM RESOURCES INC,FREDERICK,MD 21702; THOMAS JEFFERSON UNIV,DEPT PATHOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University					NATIONAL CANCER INSTITUTE [R01CA058642, R01CA057157, P01CA051083] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58642, CA 51083, CA 57157] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BHATTACHARYA G, 1993, ONCOGENE, V8, P3459; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; COQUILLAND M, 1988, ONCOGENE RES, V2, P335; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAYNES SR, 1992, NEW BIOL, V4, P421; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; ICHIKAWAH, 1994, CANCER RES, V54, P2865; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KLEMSZ M, 1994, GENOMICS, V20, P291, DOI 10.1006/geno.1994.1169; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LADANYI M, 1994, CANCER RES, V54, P2837; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MONTE D, 1994, ONCOGENE, V9, P1397; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; OHNO T, 1993, CANCER RES, V53, P5859; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; PRASAD DDK, 1994, ONCOGENE, V9, P669; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRIBYL LJ, 1991, ONCOGENE, V6, P1175; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; REDDY ESP, 1990, CANCER RES, V50, P5013; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; [No title captured]	66	168	173	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3087	3097						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084618				2022-12-17	WOS:A1994PG82200042
J	FAGIOLI, M; ALCALAY, M; PANDOLFI, PP; VENTURINI, L; MENCARELLI, A; SIMEONE, A; ACAMPORA, D; GRIGNANI, F; PELICCI, PG				FAGIOLI, M; ALCALAY, M; PANDOLFI, PP; VENTURINI, L; MENCARELLI, A; SIMEONE, A; ACAMPORA, D; GRIGNANI, F; PELICCI, PG			ALTERNATIVE SPLICING OF PML TRANSCRIPTS PREDICTS COEXPRESSION OF SEVERAL CARBOXY-TERMINALLY DIFFERENT PROTEIN ISOFORMS	ONCOGENE			English	Article							RETINOIC ACID RECEPTOR; GLYCOGEN-SYNTHASE; MYELOID-LEUKEMIA; ALPHA GENE; TRANSLOCATION; CHROMOSOME-17; MECHANISM; ONCOGENE; KINASE; RNA	The acute promyelocytic leukaemia (APL)-specific chromosome 15;17 translocation leads to the fusion of a newly identified putative transcription factor, PML, and the retinoic acid receptor alpha. We have characterized the structure of the PML genomic locus and preliminarily characterized its expression pattern. The PML locus spans a minimum of 35 kb and is subdivided into nine exons. The putative PML DNA binding site is encoded by exons 2 and 3. We isolated a large number of alternatively spliced PML transcripts that encode numerous PML isoforms. Two groups of isoforms were identified that differed either in their C-terminal region or in the length of their central region, but retained the putative DNA-binding and dimerization domains. RNAase protection experiments revealed that the different PML isoforms are equally expressed in established cell lines of different histological origin.	UNIV PERUGIA,MONTELUCE POLICLIN,IST CLIN MED 1,I-06100 PERUGIA,ITALY; CNR,IST GENET & BIOFIS,I-80125 NAPLES,ITALY	University of Perugia; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)			Alcalay, Myriam/B-3182-2016; Alcalay, Myriam/AAB-4300-2019; Simeone, Antonio/ABG-5269-2020; Grignani, Francesco/AAC-2565-2022; Acampora, Dario/C-2156-2013; Pelicci, Pier Giuseppe/AAL-6572-2020	Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Simeone, Antonio/0000-0003-2693-9836; 				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BERG JM, 1990, J BIOL CHEM, V265, P6513; BIONDI A, 1991, BLOOD, V77, P1418; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; CANAANI E, 1984, LANCET, V1, P593; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GIGUERE V, 1987, NATURE, V330, P324; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LONGO L, 1990, ONCOGENE, V5, P1557; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MITELMAN F, 1988, CATALOG CHROMOSOME A; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PANDOLFI PP, 1992, IN PRESS EMBO J; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; Sambrook J., 1989, MOL CLONING LAB MANU; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SHEORAIN VS, 1984, J BIOL CHEM, V259, P7024; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	31	168	172	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1083	1091						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594241				2022-12-17	WOS:A1992HU64200005
J	KARN, J; WATSON, JV; LOWE, AD; GREEN, SM; VEDECKIS, W				KARN, J; WATSON, JV; LOWE, AD; GREEN, SM; VEDECKIS, W			REGULATION OF CELL-CYCLE DURATION BY C-MYC LEVELS	ONCOGENE			English	Article									MRC, CLIN ONCOL UNIT, CAMBRIDGE CB2 2QH, ENGLAND		KARN, J (corresponding author), MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND.							ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BRAUMBACH WR, 1986, J VIROL, V59, P276; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; CAMPISI J, 1984, EXP CELL RES, V152, P459, DOI 10.1016/0014-4827(84)90647-5; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; EISENMAN RN, 1985, MOL CELL BIOL, V5, P114, DOI 10.1128/MCB.5.1.114; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIERS W, 1978, NATURE, V273, P113, DOI 10.1038/273113a0; GAUTCHI W, 1964, APPLIED MATH SERIES, V55, P297; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; GREEN SM, 1989, ONCOGENE, V4, P737; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; GUTIERREZ C, 1987, MOL CELL BIOL, V7, P4594, DOI 10.1128/MCB.7.12.4594; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KELEKAR A, 1987, MOL CELL BIOL, V7, P3899, DOI 10.1128/MCB.7.11.3899; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KENTER AL, 1987, J IMMUNOL METHODS, V97, P111, DOI 10.1016/0022-1759(87)90112-8; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MILLER AD, 1985, MOL CELL BIOL, V5, P431, DOI 10.1128/MCB.5.3.431; MILLER AD, 1984, J VIROL, V49, P214, DOI 10.1128/JVI.49.1.214-222.1984; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MORSE HC, 1986, P NATL ACAD SCI USA, V83, P6868, DOI 10.1073/pnas.83.18.6868; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PIECHACZYK M, 1987, TRENDS GENET, V3, P47, DOI 10.1016/0168-9525(87)90166-1; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SORRENTINO V, 1987, P NATL ACAD SCI USA, V84, P4131, DOI 10.1073/pnas.84.12.4131; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; SULLIVAN NF, 1986, COLD SPRING HARB SYM, V51, P943, DOI 10.1101/SQB.1986.051.01.107; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WATSON JV, 1988, J IMMUNOL METHODS, V113, P205, DOI 10.1016/0022-1759(88)90333-X; WATSON JV, 1985, J IMMUNOL METHODS, V83, P179, DOI 10.1016/0022-1759(85)90071-7; WATSON JV, 1987, NATURE, V325, P741, DOI 10.1038/325741a0; WATSON JV, 1985, BRIT J CANCER, V51, P433, DOI 10.1038/bjc.1985.60; WATSON JV, 1981, CYTOMETRY, V2, P14, DOI 10.1002/cyto.990020103; WATSON JV, 1980, CYTOMETRY, V1, P143, DOI 10.1002/cyto.990010209; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; WHITE JG, 1987, J CELL BIOL, V105, P41, DOI 10.1083/jcb.105.1.41; WILTSHIRE CR, 1978, BRIT J CANCER, V37, P286; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	75	168	171	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1989	4	6					773	787						15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2660073				2022-12-17	WOS:A1989AA66000014
J	Liu, T; Wang, N; Cao, J; Sofiadis, A; Dinets, A; Zedenius, J; Larsson, C; Xu, D				Liu, T.; Wang, N.; Cao, J.; Sofiadis, A.; Dinets, A.; Zedenius, J.; Larsson, C.; Xu, D.			The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas	ONCOGENE			English	Article						TERT promoter mutation; telomere shortening; telomerase; thyroid cancer	REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT; GENE-EXPRESSION; DIAGNOSIS; SURVIVAL; SAMPLES; LENGTH; TUMORS; PCR	Telomerase activation through induction of its catalytic component telomerase reverse transcriptase (TERT) expression is essential for malignant transformation. TERT promoter mutations namely C228T and C250T that stimulate TERT transcription and telomerase activation have recently been identified in many human malignancies. We thus determined these mutations and their biological and clinical implications in thyroid carcinomas in the present study. The TERT promoter was sequenced in 10 thyroid cancer cell lines and 144 tumors from 20 patients with anaplastic thyroid carcinoma (ATC), 51 with papillary thyroid carcinoma (PTC), 36 with follicular thyroid carcinoma (FTC), and 37 with medullary thyroid carcinoma (MTC). We identified C228T or C250T mutation in 6/8 of ATC cell lines, as well as in tumor tissue from 10/20, 13/51, 8/36 and 0/37 patients with ATC, PTC, FTC and MTC, respectively. In PTC patients, these mutations were exclusively present in the group with age 445 years (P<0.0001), and highly correlated shorter telomeres (P<0.0001) and distant metastasis (P = 0.028). The previous radioactivity exposure did not induce the mutation. The presence of C228T or C250T was an independent predictor associated with shorter disease-related survival (DRS) in the entire cohort (P<0.0001), as well as among patients 445 years (P = 0.021). ATC patients carrying the mutation survived shorter than those without mutations, although not statistically significant (P = 0.129). The TERT promoter mutation was associated with overall survival (P = 0.038) and DRS (P = 0.058) of FTC patients. Taken together, age-and shorter telomere-dependent TERT promoter mutations occur frequently in follicular cell-derived thyroid carcinoma (ATC, PTC and FTC) but not in parafollicular cell-originated MTC, and may serve as a marker for aggressive disease and poor outcome.	[Liu, T.; Xu, D.] Karolinska Inst, Dept Med, Div Hematol, S-17176 Stockholm, Sweden; [Liu, T.; Xu, D.] Karolinska Inst, Dept Med, Ctr Mol Med, S-17176 Stockholm, Sweden; [Liu, T.; Wang, N.; Cao, J.; Sofiadis, A.; Dinets, A.; Zedenius, J.; Larsson, C.; Xu, D.] Karolinska Univ Hosp Solna, Stockholm, Sweden; [Wang, N.; Sofiadis, A.; Larsson, C.] Karolinska Inst, Dept Oncol Pathol, S-17176 Stockholm, Sweden; [Wang, N.; Sofiadis, A.; Larsson, C.] Karolinska Inst, Canc Ctr Karolinska, S-17176 Stockholm, Sweden; [Cao, J.] Karolinska Inst, Dept Womens & Childrens Hlth, S-17176 Stockholm, Sweden; [Cao, J.] Karolinska Inst, Ctr Mol Med, S-17176 Stockholm, Sweden; [Dinets, A.; Zedenius, J.] Karolinska Inst, Dept Mol Med & Surg, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet	Larsson, C (corresponding author), Karolinska Inst, Dept Oncol Pathol, S-17176 Stockholm, Sweden.	catharina.larsson@ki.se; Dawei.Xu@ki.se	Dinets, Andrii/AAA-3494-2019	Dinets, Andrii/0000-0001-9680-7519; Sofiadis, Anastasios/0000-0003-4057-7739; Xu, Dawei/0000-0003-3141-4524	Swedish Cancer Society, the Swedish Research Council; Cancer Society in Stockholm, the Stockholm County Council; Karolinska Institutet	Swedish Cancer Society, the Swedish Research Council(Swedish Research CouncilSwedish Cancer Society); Cancer Society in Stockholm, the Stockholm County Council; Karolinska Institutet(Karolinska Institutet)	We thank Drs N-E Heldin (Uppsala University, Sweden), and BG Robinson and Mr. E Wennerberg (University of Sydney, Australia) for cell lines. The study was funded by grants from the Swedish Cancer Society, the Swedish Research Council, Cancer Society in Stockholm, the Stockholm County Council and Karolinska Institutet. Dr M Hulchiy (Kyiv CIty Teaching Endocrinological Center, Ukraine) for help with retrieval of Ukraine PTC tissue samples.	Aogi K, 1998, CLIN CANCER RES, V4, P1965; Asaad Nancy Y, 2006, J Egypt Natl Canc Inst, V18, P8; Blackburn EH, 2006, NAT MED, V12, P1133, DOI 10.1038/nm1006-1133; Bornstein-Quevedo L, 2003, ENDOCR PATHOL, V14, P213, DOI 10.1007/s12022-003-0013-3; Brousset P, 1997, J CLIN ENDOCR METAB, V82, P4214, DOI 10.1210/jc.82.12.4214; Cao Y, 2002, ONCOGENE, V21, P3130, DOI 10.1038/sj.onc.1205419; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Cheng AJ, 1998, BRIT J CANCER, V77, P2177, DOI 10.1038/bjc.1998.363; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; Daniel M, 2012, GENE, V498, P135, DOI 10.1016/j.gene.2012.01.095; Dinets A, 2012, EUR J ENDOCRINOL, V166, P1049, DOI 10.1530/EJE-12-0144; Domomt J, 2005, J CLIN ONCOL, V23, P3086, DOI 10.1200/JCO.2005.06.944; Foukakis T, 2007, ENDOCR-RELAT CANCER, V14, P381, DOI 10.1677/ERC-06-0023; Gertler R, 2004, J CLIN ONCOL, V22, P1807, DOI 10.1200/JCO.2004.09.160; Guerra LN, 2006, CLIN CHIM ACTA, V370, P180, DOI 10.1016/j.cca.2006.02.009; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoang-Vu C, 2002, INT J ONCOL, V21, P265; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Kammori M, 2003, INT J ONCOL, V22, P985; Killela PJ, 2013, P NATL ACAD SCI USA, V110, P6021, DOI 10.1073/pnas.1303607110; Lerma E, 2005, CANCER CYTOPATHOL, V105, P492, DOI 10.1002/cncr.21380; Liu XL, 2013, ENDOCR-RELAT CANCER, V20, P603, DOI 10.1530/ERC-13-0210; Liu Z, 2013, ONCOGENE, V32, P4203, DOI 10.1038/onc.2012.441; Park JI, 2009, NATURE, V460, P66, DOI 10.1038/nature08137; Saji M, 1999, CLIN CANCER RES, V5, P1483; Sanders RP, 2004, J CLIN ONCOL, V22, P3790, DOI 10.1200/JCO.2004.03.043; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Sputova Klara, 2013, Genome Integr, V4, P4, DOI 10.1186/2041-9414-4-4; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Straight AM, 2002, J ENDOCRINOL INVEST, V25, P302, DOI 10.1007/BF03344009; Tallet A, 2014, ONCOGENE, V33, P3748, DOI 10.1038/onc.2013.351; Umbricht CB, 1997, CANCER RES, V57, P2144; Wang YC, 2008, THYROID, V18, P1055, DOI 10.1089/thy.2008.0101; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431	35	167	173	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2014	33	42					4978	4984		10.1038/onc.2013.446	http://dx.doi.org/10.1038/onc.2013.446			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OB	24141777				2022-12-17	WOS:000343768000002
J	John, T; Liu, G; Tsao, MS				John, T.; Liu, G.; Tsao, M-S			Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors	ONCOGENE			English	Review						erlotinib; gefitinib; polymerase chain reaction; biomarker; survival	GROWTH-FACTOR-RECEPTOR; IN-SITU HYBRIDIZATION; DINUCLEOTIDE REPEAT POLYMORPHISM; RESOLUTION MELTING ANALYSIS; GEFITINIB SENSITIVITY; ACTIVATING MUTATIONS; ACQUIRED-RESISTANCE; MESSENGER-RNA; PROGNOSTIC INDICATORS; JAPANESE PATIENTS	Most patients with non-small-cell lung cancer (NSCLC) present with advanced disease. Current treatment paradigms are shifting from cytotoxic chemotherapies alone to single-agent and combination biological and targeted therapies. As patient responses to these therapies vary, predictive biomarkers will be an important facet of a patient's diagnostic workup in personalized medicine, as there is accumulating evidence that they may enable the prognostication and prediction of therapeutic response. Potential biomarkers for the selection of patients with NSCLC most likely to benefit from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, include mutations, gene copy number increase and single-nucleotide polymorphisms of the EGFR gene, EGFR protein expression and oncogenic mutation on the KRAS gene. Many techniques are available to assay for these biomarkers. In this review, we present the current weight of evidence for using these methods as biomarkers for anti-EGFR therapy in patients with NSCLC. Oncogene (2009) 28, S14-S23; doi:10.1038/onc.2009.197	[John, T.; Liu, G.; Tsao, M-S] Univ Toronto, Ontario Canc Inst, Univ Hlth Network, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Tsao, MS (corresponding author), Room 7-611,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	ming.tsao@uhn.on.ca	Tsao, Ming-Sound/M-3503-2017; Tsao, Ming Sound/AFQ-7332-2022	Tsao, Ming Sound/0000-0002-9160-5405; John, Thomas/0000-0003-3399-5342; Liu, Geoffrey/0000-0002-2603-7296	Boehringer Ingelheim Pharmaceuticals Inc.	Boehringer Ingelheim Pharmaceuticals Inc.(Boehringer Ingelheim)	This article was funded by Boehringer Ingelheim Pharmaceuticals Inc. Dr John is an International Association for Study of Lung Cancer (IASLC) Translational Fellow in Lung Cancer Research. Dr Liu is the Alan B Brown Chair in Molecular Genomics, and Dr Tsao is the M Qasim Choksi Chair in Lung Cancer Translational Research.	Atkins D, 2004, J HISTOCHEM CYTOCHEM, V52, P893, DOI 10.1369/jhc.3A6195.2004; Aviel-Ronen S, 2006, CLIN LUNG CANCER, V8, P30, DOI 10.3816/CLC.2006.n.030; Bell DW, 2005, J CLIN ONCOL, V23, P8081, DOI 10.1200/JCO.2005.02.7078; Bhargava R, 2006, CANCER-AM CANCER SOC, V106, P1857, DOI 10.1002/cncr.21782; Buckley AF, 2007, APPL IMMUNOHISTO M M, V15, P305, DOI 10.1097/01.pai.0000213141.47277.bf; Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023; Cappuzzo F, 2005, JNCI-J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112; Chang JWC, 2008, LUNG CANCER, V61, P328, DOI 10.1016/j.lungcan.2008.01.009; Chen YR, 2006, ONCOGENE, V25, P1205, DOI 10.1038/sj.onc.1209159; Cheng TL, 2005, CHEST, V128, P1453, DOI 10.1378/chest.128.3.1453; Chou TY, 2005, CLIN CANCER RES, V11, P3750, DOI 10.1158/1078-0432.CCR-04-1981; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Cortes-Funes H, 2005, ANN ONCOL, V16, P1081, DOI 10.1093/annonc/mdi221; Cusatis G, 2006, J NATL CANCER I, V98, P1739, DOI 10.1093/jnci/djj469; Daniele L, 2007, MOL CANCER THER, V6, P1223, DOI 10.1158/1535-7163.MCT-06-0719; Dei Tos AP, 2005, EUR J CANCER, V41, P1383, DOI 10.1016/j.ejca.2005.03.018; Dubey S, 2006, J THORAC ONCOL, V1, P406, DOI 10.1097/01243894-200606000-00005; Dziadziuszko R, 2007, ANN ONCOL, V18, P447, DOI 10.1093/annonc/mdl407; Dziadziuszko R, 2006, CLIN CANCER RES, V12, P3078, DOI 10.1158/1078-0432.CCR-06-0106; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Eberhard DA, 2008, J CLIN ONCOL, V26, P983, DOI 10.1200/JCO.2007.12.9858; Elkind NB, 2005, CANCER RES, V65, P1770, DOI 10.1158/0008-5472.CAN-04-3303; Engelman JA, 2008, CLIN CANCER RES, V14, P2895, DOI 10.1158/1078-0432.CCR-07-2248; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Engelman JA, 2006, J CLIN INVEST, V116, P2695, DOI 10.1172/JCI28656; Etienne-Grimaldi MC, 2005, ANN ONCOL, V16, P934, DOI 10.1093/annonc/mdi189; Fontanini G, 1998, CLIN CANCER RES, V4, P241; Fukui T, 2008, CLIN CANCER RES, V14, P4751, DOI 10.1158/1078-0432.CCR-07-5207; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; GARDAR AF, 2009, ONCOGENE S1, V28, pS24; Gebhardt F, 1999, J BIOL CHEM, V274, P13176, DOI 10.1074/jbc.274.19.13176; Gregorc V, 2008, CLIN PHARMACOL THER, V83, P477, DOI 10.1038/sj.clpt.6100320; HALEY JD, 1991, J BIOL CHEM, V266, P1746; Han SW, 2007, PHARMACOGENET GENOM, V17, P313, DOI 10.1097/FPC.0b013e328011abc0; Han SW, 2005, J CLIN ONCOL, V23, P2493, DOI 10.1200/JCO.2005.01.388; Hirsch FR, 2009, ONCOGENE, V28, pS32, DOI 10.1038/onc.2009.199; Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069; Hirsch FR, 2008, J CLIN ONCOL, V26, P3351, DOI 10.1200/JCO.2007.14.0111; Hirsch FR, 2008, CANCER-AM CANCER SOC, V112, P1114, DOI 10.1002/cncr.23282; Hirsch FR, 2006, J CLIN ONCOL, V24, P5034, DOI 10.1200/JCO.2006.06.3958; Hsieh ETK, 2000, LUNG CANCER, V29, P151, DOI 10.1016/S0169-5002(00)00116-1; Huang SF, 2004, CLIN CANCER RES, V10, P8195, DOI 10.1158/1078-0432.CCR-04-1245; Ichihara S, 2007, INT J CANCER, V120, P1239, DOI 10.1002/ijc.22513; Janne PA, 2006, CLIN CANCER RES, V12, P751, DOI 10.1158/1078-0432.CCR-05-2047; Kim KS, 2005, CLIN CANCER RES, V11, P2244, DOI 10.1158/1078-0432.CCR-04-2081; Kimura H, 2007, BRIT J CANCER, V97, P778, DOI 10.1038/sj.bjc.6603949; Kimura H, 2006, CLIN CANCER RES, V12, P3915, DOI 10.1158/1078-0432.CCR-05-2324; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kondo M, 2005, LUNG CANCER, V50, P385, DOI 10.1016/j.lungcan.2005.06.008; Kosaka T, 2007, J CLIN ONCOL, V25; Kosaka T, 2004, CANCER RES, V64, P8919, DOI 10.1158/0008-5472.CAN-04-2818; Kosaka T, 2006, CLIN CANCER RES, V12, P5764, DOI 10.1158/1078-0432.CCR-06-0714; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Li AR, 2008, J MOL DIAGN, V10, P242, DOI 10.2353/jmoldx.2008.070178; Li J, 2007, CANCER BIOL THER, V6, P432, DOI 10.4161/cbt.6.3.3763; Liu G, 2008, PHARMACOGENOMICS J, V8, P129, DOI 10.1038/sj.tpj.6500444; Liu WQ, 2005, CANCER RES, V65, P46; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Ma PC, 2005, CANCER RES, V65, P1479, DOI 10.1158/0008-5472.CAN-04-2650; MAEKAWA T, 1989, J BIOL CHEM, V264, P5488; Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668; Marchetti A, 2005, J CLIN ONCOL, V23, P857, DOI 10.1200/JCO.2005.08.043; Massarelli E, 2007, CLIN CANCER RES, V13, P2890, DOI 10.1158/1078-0432.CCR-06-3043; Miller VA, 2004, J CLIN ONCOL, V22, P1103, DOI 10.1200/JCO.2004.08.158; Miller VA, 2008, J CLIN ONCOL, V26, P1472, DOI 10.1200/JCO.2007.13.0062; Mitsudomi T, 2005, J CLIN ONCOL, V23, P2513, DOI 10.1200/JCO.2005.00.992; Mok T, 2008, ANN ONCOL, V19, P1; Molina JR, 2006, J THORAC ONCOL, V1, P7, DOI 10.1097/01243894-200601000-00004; Mu XL, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-51; Nagai Y, 2005, CANCER RES, V65, P7276, DOI 10.1158/0008-5472.CAN-05-0331; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; Nie Q, 2007, EUR J PHARMACOL, V570, P175, DOI 10.1016/j.ejphar.2007.05.015; Nomoto K, 2006, AM J CLIN PATHOL, V126, P608, DOI 10.1309/N5PQNGW2QKMX09X7; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Penault-Llorca F, 2006, ONCOL REP, V16, P1173; Riely GJ, 2006, CLIN CANCER RES, V12, P7232, DOI 10.1158/1078-0432.CCR-06-0658; Rossi G, 2005, J CLIN ONCOL, V23, P8774, DOI 10.1200/JCO.2005.02.8233; Rudin CM, 2008, J CLIN ONCOL, V26, P1119, DOI 10.1200/JCO.2007.13.1128; Ruiz MIG, 2007, HISTOPATHOLOGY, V51, P631, DOI 10.1111/j.1365-2559.2007.02854.x; Rusch V, 1997, CLIN CANCER RES, V3, P515; Sakurada A, 2006, CLIN LUNG CANCER, V7, pS138, DOI 10.3816/CLC.2006.s.005; Sasaki H, 2006, INT J CANCER, V118, P180, DOI 10.1002/ijc.21301; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shepherd FA, 2006, J CLIN ONCOL, V24, P1219, DOI 10.1200/JCO.2005.04.4420; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Shih JY, 2006, INT J CANCER, V118, P963, DOI 10.1002/ijc.21458; Sholl LM, 2007, MODERN PATHOL, V20, P1028, DOI 10.1038/modpathol.3800946; Sone T, 2007, CANCER-AM CANCER SOC, V109, P1836, DOI 10.1002/cncr.22593; Takano T, 2005, J CLIN ONCOL, V23, P6829, DOI 10.1200/JCO.2005.01.0793; Taron M, 2005, CLIN CANCER RES, V11, P5878, DOI 10.1158/1078-0432.CCR-04-2618; Tokumo M, 2005, CLIN CANCER RES, V11, P1167; Tomizawa Y, 2005, CLIN CANCER RES, V11, P6816, DOI 10.1158/1078-0432.CCR-05-0441; TRASK B, 1985, SCIENCE, V230, P1401, DOI 10.1126/science.2416058; Tsao MS, 1998, LUNG CANCER, V20, P1, DOI 10.1016/S0169-5002(98)00007-5; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736; Uramoto H, 2006, LUNG CANCER, V51, P71, DOI 10.1016/j.lungcan.2005.08.006; Varella-Garcia M, 2006, DIAGN PATHOL, V1, DOI 10.1186/1746-1596-1-19; Whitcombe D, 1999, NAT BIOTECHNOL, V17, P804, DOI 10.1038/11751; Willmore-Payne C, 2006, HUM PATHOL, V37, P755, DOI 10.1016/j.humpath.2006.02.004; Yoshida K, 2007, J THORAC ONCOL, V2, P22, DOI 10.1097/01243894-200701000-00006; Zhang XT, 2005, ANN ONCOL, V16, P1334, DOI 10.1093/annonc/mdi340; Zhou QY, 2006, CANCER BIOL THER, V5, P1445, DOI 10.4161/cbt.5.11.3457; Zhu CQ, 2008, J CLIN ONCOL, V26, P4268, DOI 10.1200/JCO.2007.14.8924	107	167	173	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28			1			S14	S23		10.1038/onc.2009.197	http://dx.doi.org/10.1038/onc.2009.197			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QF	19680292				2022-12-17	WOS:000269515400003
J	Jiang, M; Wei, Q; Wang, J; Du, Q; Yu, J; Zhang, L; Dong, Z				Jiang, M.; Wei, Q.; Wang, J.; Du, Q.; Yu, J.; Zhang, L.; Dong, Z.			Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis	ONCOGENE			English	Article						p53; PUMA; mitochondria; cisplatin; apoptosis; nephrotoxicity	BCL-X-L; COLORECTAL-CANCER CELLS; PROXIMAL TUBULE CELLS; MITOCHONDRIAL DYSFUNCTION; INDUCED NEPHROTOXICITY; DEATH; BAX; PATHWAYS; EXPRESSION; GENE	Nephrotoxicity is a major side effect of cisplatin, a widely used cancer therapy drug. Depending on its concentration, cisplatin induces necrosis or apoptosis of tubular cells in the kidneys, whereas the underlying injury mechanism is unclear. Our recent work has suggested a critical role for p53 in cisplatin-induced tubular cell apoptosis; nevertheless, the apoptotic events triggered by p53 remain elusive. The current study has examined Bcl-2 family proteins, critical regulators of apoptosis that may be subjected to p53 regulation. Following cisplatin treatment, the expression of Bcl-xL, an antiapoptotic molecule, was suppressed, while the expression of Bak, a proapoptotic molecule, increased slightly. Of interest, PUMA-alpha, a newly identified p53-responsive proapoptotic Bcl-2 family protein, was drastically induced by cisplatin. PUMA-alpha induction preceded or paralleled the development of apoptosis. Induced PUMA-alpha was localized in mitochondria and appeared to antagonize Bcl-xL via molecular interaction. PUMA-alpha induction during cisplatin treatment was attenuated by pifithrin-alpha, a pharmacological inhibitor of p53, which was accompanied by the amelioration of Bax activation, cytochrome c release and apoptosis. Moreover, PUMA-alpha induction was suppressed by dominant-negative p53. Importantly, cisplatin-induced apoptosis was ameliorated in PUMA-alpha knockout cells. In vivo, cisplatin induced PUMA-alpha in the kidneys, and the inductive response was abrogated in p53-deficient animals. Together, this study has demonstrated the first compelling evidence for the involvement of PUMA-alpha in p53-mediated renal cell apoptosis during cisplatin nephrotoxicity.	Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA; Univ Pittsburgh, Inst Canc, Dept Pathol, Pittsburgh, PA USA; Univ Pittsburgh, Inst Canc, Dept Pharmacol, Pittsburgh, PA USA; Dept Vet Affairs Med Ctr, Med Res Serv, Augusta, GA USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Dong, Z (corresponding author), Med Coll Georgia, Dept Cellular Biol & Anat, 1459 Laney Walker Blvd,CB2917, Augusta, GA 30912 USA.	zdong@mail.mcg.edu	Yu, Jian/A-8301-2009; Zhang, Lin/A-7389-2009	Yu, Jian/0000-0002-4021-1000; Zhang, Lin/0000-0003-0018-3903; Livingston, Man/0000-0001-8638-0902; Du, Quansheng/0000-0003-4079-8662				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Akeshima R, 2001, BRIT J CANCER, V84, P1551, DOI 10.1054/bjoc.2001.1812; Arany I, 2003, SEMIN NEPHROL, V23, P460, DOI 10.1016/S0270-9295(03)00089-5; Arany I, 2004, AM J PHYSIOL-RENAL, V287, pF543, DOI 10.1152/ajprenal.00112.2004; Baliga R, 1998, KIDNEY INT, V53, P394, DOI 10.1046/j.1523-1755.1998.00767.x; Chang JS, 2005, LIFE SCI, V76, P1883, DOI 10.1016/j.lfs.2004.11.003; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Cummings BS, 2002, J PHARMACOL EXP THER, V302, P8, DOI 10.1124/jpet.302.1.8; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dong Z, 2004, J BIOL CHEM, V279, P9215, DOI 10.1074/jbc.M312225200; Dong Z, 2003, AM J PATHOL, V163, P663, DOI 10.1016/S0002-9440(10)63693-0; Fuertes MA, 2003, CURR MED CHEM, V10, P257, DOI 10.2174/0929867033368484; Gottlieb RA, 2002, METHODS, V26, P341, DOI 10.1016/S1046-2023(02)00040-3; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gudkov AV, 2005, BIOCHEM BIOPH RES CO, V331, P726, DOI 10.1016/j.bbrc.2005.03.153; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jiang M, 2004, AM J PHYSIOL-RENAL, V287, pF1140, DOI 10.1152/ajprenal.00262.2004; Kaushal GP, 2001, KIDNEY INT, V60, P1726, DOI 10.1046/j.1523-1755.2001.00026.x; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Li SY, 2004, AM J PHYSIOL-RENAL, V287, pF990, DOI 10.1152/ajprenal.00206.2004; Liu H, 2003, KIDNEY INT, V63, P1687, DOI 10.1046/j.1523-1755.2003.00908.x; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Megyesi J, 1998, J CLIN INVEST, V101, P777, DOI 10.1172/JCI1497; MIYASHITA T, 1995, CELL, V80, P293; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Niedner H, 2001, MOL PHARMACOL, V60, P1153, DOI 10.1124/mol.60.6.1153; Nowak G, 2002, J BIOL CHEM, V277, P43377, DOI 10.1074/jbc.M206373200; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Park MS, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134858; Ramesh G, 2002, J CLIN INVEST, V110, P835, DOI 10.1172/JCI200215606; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Sheikh-Hamad D, 2004, ARCH TOXICOL, V78, P147, DOI 10.1007/s00204-003-0521-4; Shen ZN, 2005, BIOCHEM BIOPH RES CO, V328, P375, DOI 10.1016/j.bbrc.2004.12.186; Shiraishi F, 2000, AM J PHYSIOL-RENAL, V278, pF726, DOI 10.1152/ajprenal.2000.278.5.F726; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Tomasoni S, 2004, CURR GENE THER, V4, P115, DOI 10.2174/1566523044578013; Tomita N, 2004, CURR DRUG TARGETS, V5, P717, DOI 10.2174/1389450043345146; Tsuruya K, 2003, KIDNEY INT, V63, P72, DOI 10.1046/j.1523-1755.2003.00709.x; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang JZ, 2004, J BIOL CHEM, V279, P19948, DOI 10.1074/jbc.M313629200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei QQ, 2005, AM J NEPHROL, V25, P491, DOI 10.1159/000088171; Woost PG, 1996, KIDNEY INT, V50, P125, DOI 10.1038/ki.1996.295; Yi XL, 2003, J BIOL CHEM, V278, P16992, DOI 10.1074/jbc.M300039200; Yu F, 2005, AM J PHYSIOL-RENAL, V289, pF514, DOI 10.1152/ajprenal.00101.2005; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	52	167	174	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2006	25	29					4056	4066		10.1038/sj.onc.1209440	http://dx.doi.org/10.1038/sj.onc.1209440			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16491117				2022-12-17	WOS:000238802400006
J	Bouton, AH; Riggins, RB; Bruce-Staskal, PJ				Bouton, AH; Riggins, RB; Bruce-Staskal, PJ			Functions of the adapter protein Cas: signal convergence and the determination of cellular responses	ONCOGENE			English	Review						Cas; Src; Crk; Rac1; migration; adapter	FOCAL ADHESION KINASE; CRK-ASSOCIATED SUBSTRATE; DEPENDENT TYROSINE PHOSPHORYLATION; HOMOLOGY 3 DOMAIN; GROWTH-FACTOR; C-SRC; V-CRK; DOCKING PROTEIN; BREAST-CANCER; STABLE ASSOCIATION	Since Cas was first identified as a highly phosphorylated 130 kilodalton protein that associated with the v-Src and v-Crk-oncoproteins, considerable effort has been made to determine its function. Its predicted role as a scaffolding molecule based on its domain structure has been largely confirmed. Through its ability to undergo rapid changes in phosphorylation, subcellular localization and association with heterologous proteins, Cas may spatially and temporally regulate the function of its binding partners. Numerous proteins have been identified that bind to Cas in vitro and/or in vivo, but in only a few cases is there an understanding of how Cas may function in these protein complexes. To date, Cas-Crk and Cas-Src complexes have been most frequently implicated in Cas function, particularly in regards to processes involving regulation of the actin cytoskeleton and proliferation. These and other Cas protein complexes contribute to the critical role of Cas in cell adhesion, migration, proliferation and survival of normal cycling cells. However, under conditions in which these processes are deregulated, Cas appears to play a role in oncogenic transformation and perhaps metastasis. Therefore, in its capacity as an adapter protein, Cas serves as a point of convergence for many distinct signaling inputs, ultimately contributing to the generation of specific cellular responses.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia	Bouton, AH (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Box 800734, Charlottesville, VA 22908 USA.	ahb8y@virginia.edu	Riggins, Rebecca/GQH-4466-2022	Riggins, Rebecca/0000-0002-1555-4431				Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Andersson K, 1996, MOL MICROBIOL, V20, P1057, DOI 10.1111/j.1365-2958.1996.tb02546.x; Aplin AE, 1999, J CELL SCI, V112, P695; Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Astier A, 1997, LEUKEMIA LYMPHOMA, V28, P65, DOI 10.3109/10428199709058332; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; Bannerman DD, 1998, J BIOL CHEM, V273, P35371, DOI 10.1074/jbc.273.52.35371; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; Black DS, 1998, MOL MICROBIOL, V29, P1263, DOI 10.1046/j.1365-2958.1998.01014.x; Brinkman A, 2000, JNCI-J NATL CANCER I, V92, P112, DOI 10.1093/jnci/92.2.112; Bruce-Staskal PJ, 2001, EXP CELL RES, V264, P296, DOI 10.1006/excr.2000.5137; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Burnham MR, 1999, MOL CARCINOGEN, V26, P20, DOI 10.1002/(SICI)1098-2744(199909)26:1<20::AID-MC3>3.0.CO;2-M; Burnham MR, 1996, ONCOGENE, V12, P2467; Cai DP, 1999, J IMMUNOL, V163, P2104; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Casamassima A, 1998, J BIOL CHEM, V273, P26149, DOI 10.1074/jbc.273.40.26149; Casamassima A, 1997, J BIOL CHEM, V272, P9363; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; Chan YR, 1998, J BIOL CHEM, V273, P28978, DOI 10.1074/jbc.273.44.28978; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; de Jong R, 1997, J BIOL CHEM, V272, P32649, DOI 10.1074/jbc.272.51.32649; Dersch P, 2000, INFECT IMMUN, V68, P2930, DOI 10.1128/IAI.68.5.2930-2938.2000; Dodelet VC, 1999, J BIOL CHEM, V274, P31941, DOI 10.1074/jbc.274.45.31941; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Donaldson JC, 2000, EXP CELL RES, V256, P168, DOI 10.1006/excr.2000.4822; Eisenmann KM, 1999, NAT CELL BIOL, V1, P507, DOI 10.1038/70302; Ferris HA, 1999, BIOCHEMISTRY-US, V38, P1497, DOI 10.1021/bi981903w; FOEKENS JA, 1994, J CLIN ONCOL, V12, P1648, DOI 10.1200/JCO.1994.12.8.1648; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Frishknecht F, 2001, TRENDS CELL BIOL, V11, P30, DOI 10.1016/S0962-8924(00)01871-7; Garcia-Guzman M, 1999, J BIOL CHEM, V274, P5762, DOI 10.1074/jbc.274.9.5762; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Gotoh T, 2000, J BIOL CHEM, V275, P30118, DOI 10.1074/jbc.M003074200; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Harrington EO, 2001, AM J PHYSIOL-LUNG C, V280, pL342, DOI 10.1152/ajplung.2001.280.2.L342; Harte MT, 2000, BBA-MOL CELL RES, V1499, P34, DOI 10.1016/S0167-4889(00)00104-X; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; ILLC D, 1995, NATURE, V377, P539; Isberg RR, 2000, MICROBES INFECT, V2, P793, DOI 10.1016/S1286-4579(00)90364-2; Ishino M, 1995, ONCOGENE, V11, P2331; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; Khwaja A, 1996, ONCOGENE, V12, P2491; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; Kirsch KH, 1998, J BIOL CHEM, V273, P25673, DOI 10.1074/jbc.273.40.25673; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kook S, 2000, MOL BIOL CELL, V11, P929, DOI 10.1091/mbc.11.3.929; Kook S, 2000, CELL BIOCHEM FUNCT, V18, P1; KOSTER A, 1991, ANTICANCER RES, V11, P193; Lakkakorpi PT, 1999, J BIOL CHEM, V274, P4900, DOI 10.1074/jbc.274.8.4900; Lamorte L, 2000, ONCOGENE, V19, P5973, DOI 10.1038/sj.onc.1203977; Larsson H, 1999, J BIOL CHEM, V274, P25726, DOI 10.1074/jbc.274.36.25726; Law SF, 1998, MOL CELL BIOL, V18, P3540, DOI 10.1128/MCB.18.6.3540; Law SF, 1999, EXP CELL RES, V252, P224, DOI 10.1006/excr.1999.4609; Law SF, 1996, MOL CELL BIOL, V16, P3327; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Li EG, 2000, J BIOL CHEM, V275, P14729, DOI 10.1074/jbc.275.19.14729; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Lu YM, 1999, J BIOL CHEM, V274, P10047, DOI 10.1074/jbc.274.15.10047; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1988, COLD SPRING HARB SYM, V53, P907, DOI 10.1101/SQB.1988.053.01.104; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; Meijne AML, 1997, EXP CELL RES, V234, P477, DOI 10.1006/excr.1997.3637; Mielenz D, 2001, J BIOL CHEM, V276, P13417, DOI 10.1074/jbc.M011481200; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; Murakami H, 1999, ONCOGENE, V18, P1975, DOI 10.1038/sj.onc.1202514; Nakamoto T, 2000, MOL CELL BIOL, V20, P1649, DOI 10.1128/MCB.20.5.1649-1658.2000; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nakamura I, 1998, J BIOL CHEM, V273, P11144, DOI 10.1074/jbc.273.18.11144; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Owen JD, 1999, MOL CELL BIOL, V19, P4806; PATCH LA, 1995, J CELL SCI, V108, P1371; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Prasad N, 2001, MOL CELL BIOL, V21, P1416, DOI 10.1128/MCB.21.4.1416-1428.2001; Reiske HR, 2000, FEBS LETT, V486, P275, DOI 10.1016/S0014-5793(00)02295-X; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sakakibara A, 2000, J BIOL CHEM, V275, P6404, DOI 10.1074/jbc.275.9.6404; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHRAW W, 1995, BIOCHEMISTRY-US, V34, P13760, DOI 10.1021/bi00042a006; Sorokin A, 1998, BIOCHEM J, V334, P595, DOI 10.1042/bj3340595; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Takahashi T, 1998, AM J PHYSIOL-HEART C, V274, pH1059, DOI 10.1152/ajpheart.1998.274.4.H1059; Tamura M, 1999, CANCER RES, V59, P442; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Ueki K, 1998, FEBS LETT, V432, P197, DOI 10.1016/S0014-5793(98)00862-X; van Agthoven T, 1998, EMBO J, V17, P2799, DOI 10.1093/emboj/17.10.2799; van der Flier S, 2000, INT J CANCER, V89, P465, DOI 10.1002/1097-0215(20000920)89:5<465::AID-IJC11>3.0.CO;2-O; van der Flier S, 2000, JNCI-J NATL CANCER I, V92, P120, DOI 10.1093/jnci/92.2.120; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wang X, 2000, ONCOGENE, V19, P2346, DOI 10.1038/sj.onc.1203558; Weidow CL, 2000, CELL MICROBIOL, V2, P549, DOI 10.1046/j.1462-5822.2000.00079.x; Weng LP, 1999, GENES CELLS, V4, P185, DOI 10.1046/j.1365-2443.1999.00251.x; WILSON LK, 1990, ONCOGENE, V5, P1471; Xing LZ, 2000, MOL CELL BIOL, V20, P7363, DOI 10.1128/MCB.20.19.7363-7377.2000; Yamakita Y, 1999, J CELL BIOL, V144, P315, DOI 10.1083/jcb.144.2.315; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; Zhou SY, 1998, METH MOL B, V87, P87; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zhou SY, 2001, METHOD ENZYMOL, V332, P171; Zhu T, 1998, J BIOL CHEM, V273, P10682, DOI 10.1074/jbc.273.17.10682	136	167	167	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2001	20	44					6448	6458		10.1038/sj.onc.1204785	http://dx.doi.org/10.1038/sj.onc.1204785			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607844	Bronze			2022-12-17	WOS:000171640600017
J	Troussard, AA; Costello, P; Yoganathan, TN; Kumagai, S; Roskelley, CD; Dedhar, S				Troussard, AA; Costello, P; Yoganathan, TN; Kumagai, S; Roskelley, CD; Dedhar, S			The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9)	ONCOGENE			English	Article						tumor invasion; matrix metalloproteinases; integrins; signal transduction; AP-1 transcription factor	ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; IV COLLAGENASE; GROWTH-FACTOR; E-CADHERIN; IN-VITRO; CELL-ADHESION; EXPRESSION; GELATINASE; INHIBITORS	Overexpression of Integrin Linked Kinase (ILK) in intestinal and mammary epithelial cells results in a highly invasive phenotype, associated with increased levels of expression of the matrix metalloproteinase MMP-9. This increase was at the transcriptional level as determined by MMP-9 promoter-CAT reporter assays. Mutations in the two AP-1 binding sites within the MMP-9 promoter completely inhibited the reporter activity. We have previously shown that ILK inhibits glycogen synthase kinase-3 (GSK-3) activity, Transient transfection of wild-type GSK-3 beta in ILK-overexpressing cells decreased MMP-9 promoter activity and AP-I activity, indicating that ILK can stimulate MMP-9 expression via GSK-3 beta and AP-1 transcription factor, A small molecule inhibitor of the ILK kinase reduced the in vitro invasiveness of ILK-overexpressing cells as well as the invasiveness of several human brain tumor cell lines. Furthermore, both MMP-9 promoter and AP-1 activities mere inhibited by the ILK inhibitor. Invasiveness of ILK-overexpressing cells was also reduced by inhibition of MMP-9. These data demonstrate that ILK can induce an invasive phenotype via AP-1-dependent upregulation of MMP-9.	British Columbia Canc Agcy, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Vancouver Hosp, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Kinetek Pharmaceut Inc, Vancouver, BC V6P 6P2, Canada; Kanazawa Univ, Sch Med, Kanazawa, Ishikawa 920, Japan; Univ British Columbia, Dept Anat, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	British Columbia Cancer Agency; University of British Columbia; University of British Columbia; Kanazawa University; University of British Columbia; University of British Columbia	Dedhar, S (corresponding author), British Columbia Canc Agcy, Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.		Roskelley, Calvin D/F-4630-2011	Dedhar, Shoukat/0000-0003-4355-1657				Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Janji B, 1999, INT J CANCER, V83, P255, DOI 10.1002/(SICI)1097-0215(19991008)83:2<255::AID-IJC18>3.3.CO;2-O; Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6; Kolkhorst V, 1998, J CANCER RES CLIN, V124, P598, DOI 10.1007/s004320050221; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; Llorens A, 1998, LAB INVEST, V78, P1131; Luo J, 1999, CANCER RES, V59, P3552; Mira E, 1999, ENDOCRINOLOGY, V140, P1657, DOI 10.1210/en.140.4.1657; Morimoto AM, 2000, ONCOGENE, V19, P200, DOI 10.1038/sj.onc.1203288; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Ozes ON, 1999, NATURE, V401, P82; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; RAO JS, 1994, J NEURO-ONCOL, V18, P129, DOI 10.1007/BF01050419; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sato F, 1999, BRIT J CANCER, V80, P1366, DOI 10.1038/sj.bjc.6690530; SATO H, 1993, ONCOGENE, V8, P395; Simon C, 1998, CANCER RES, V58, P1135; Tamaki M, 1997, J NEUROSURG, V87, P602, DOI 10.3171/jns.1997.87.4.0602; Tonn JC, 1999, INT J CANCER, V80, P764, DOI 10.1002/(SICI)1097-0215(19990301)80:5<764::AID-IJC22>3.0.CO;2-J; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528	31	167	176	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5444	5452		10.1038/sj.onc.1203928	http://dx.doi.org/10.1038/sj.onc.1203928			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114721				2022-12-17	WOS:000165396100004
J	Maacke, H; Jost, K; Opitz, S; Miska, S; Yuan, Y; Hasselbach, L; Luttges, J; Kalthoff, H; Sturzbecher, HW				Maacke, H; Jost, K; Opitz, S; Miska, S; Yuan, Y; Hasselbach, L; Luttges, J; Kalthoff, H; Sturzbecher, HW			DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma	ONCOGENE			English	Article						carcinogenesis; drug resistance; p53; genetic instability; SOS-repair	HOMOLOGOUS RECOMBINATION; BREAK REPAIR; PROTEIN; CELLS; RESISTANCE; RADIATION; SPHEROIDS; GENES; P53	Molecular processes that could contribute to differences in chemo- and radioresistance include variations in DNA repair mechanisms. In mammalian cells, the product of the rad51 gene mediates DNA repair via homologous recombination. We describe that in contrast to conventional monolayer cell systems Rad51 protein accumulates to high-levels in three-dimensional cell culture models as well as in orthotopic xeno-transplants of human pancreatic cancer cells. Strikingly, over-expression of wild-type Rad51 was also found in 66% of human pancreatic adenocarcinoma tissue specimens. Functional analysis revealed that Rad51 over-expression enhances survival of cells after induction of DNA double strand breaks. These data suggest that perturbations of Rad51 expression contribute to the malignant phenotype of pancreatic cancer.	Med Univ Lubeck, Univ Clin Lubeck, Inst Human Genet, D-23538 Lubeck, Germany; Univ Kiel, Inst Pathol, Clin Gen & Thorac Surg, D-24105 Kiel, Germany	University of Lubeck; University of Kiel	Sturzbecher, HW (corresponding author), Med Univ Lubeck, Univ Clin Lubeck, Inst Human Genet, Ratzeburger Allee 160, D-23538 Lubeck, Germany.		Kalthoff, Holger/B-1618-2010					Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Buchhop S, 1996, HYBRIDOMA, V15, P205, DOI 10.1089/hyb.1996.15.205; Chen FQ, 1997, MUTAT RES-DNA REPAIR, V384, P205, DOI 10.1016/S0921-8777(97)00020-7; Desoize B, 1998, ANTICANCER RES, V18, P4147; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Israel L, 1996, J THEOR BIOL, V178, P375, DOI 10.1006/jtbi.1996.0033; KALTHOFF H, 1993, ONCOGENE, V8, P289; Kloppel GES, 1996, HISTOLOGICAL TYPING; Loeb LA, 1998, ADV CANCER RES, V72, P25, DOI 10.1016/S0065-230X(08)60699-5; MuellerKlieser W, 1997, AM J PHYSIOL-CELL PH, V273, pC1109, DOI 10.1152/ajpcell.1997.273.4.C1109; Ohnishi T, 1998, BIOCHEM BIOPH RES CO, V245, P319, DOI 10.1006/bbrc.1998.8440; OLIVE PL, 1994, CANCER METAST REV, V13, P121, DOI 10.1007/BF00689632; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Strauss BS, 1998, GENETICS, V148, P1619; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; Xia SJJ, 1997, MOL CELL BIOL, V17, P7151, DOI 10.1128/MCB.17.12.7151; Yamamoto A, 1996, MOL GEN GENET, V251, P1; Yanagisawa T, 1998, ORAL ONCOL, V34, P524, DOI 10.1016/S1368-8375(98)00045-1	20	167	175	0	12	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 25	2000	19	23					2791	2795		10.1038/sj.onc.1203578	http://dx.doi.org/10.1038/sj.onc.1203578			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851081				2022-12-17	WOS:000087318500009
J	Behrens, A; Jochum, W; Sibilia, M; Wagner, EF				Behrens, A; Jochum, W; Sibilia, M; Wagner, EF			Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation	ONCOGENE			English	Article						C-Jun N-terminal phosphorylation; tumorigenesis; Ras; Fos; Src	CELL-CYCLE PROGRESSION; NUCLEOTIDE EXCHANGE FACTOR; EMBRYONAL CARCINOMA-CELLS; TRANSGENIC MICE; HA-RAS; ACTIVATION DOMAIN; PROTEIN; MOUSE; AP-1; EXPRESSION	The nuclear phosphoprotein c-Jun is a major component of the AP-1 transcription factor, whose activity is augmented by many oncogenes, An important mechanism to stimulate AP-1 function is N-terminal phosphorylation of c-Jun at the serine residues 63 and 73 by the c-Jun N-terminal kinases (JNKs), Mice and cells harboring a mutant allele of c-jun, which has the JNK phosphoacceptor serines changed to alanines (junAA), were used to determine the function of c-Jun N-terminal phosphorylation (JNP) during oncogenic transformation in vitro and ill ripe. JunAA immortalized fibroblasts expressing v-ras and v-fos showed reduced tumorigenicity in nude mice, but the efficiency of v-src transformation was unaffected by the lack of JNP. To assess the significance of JNP in tumour development in vivo, two transgenic mouse tumour models were employed. Skin tumour development caused by constitutive activation of the ras pathway by KS-SOS-P expression and c-fos-induced osteosarcoma formation were impaired in mice lacking JNP. Inhibition of JNP may, therefore, be a novel therapeutic strategy to inhibit tumour growth in vivo.	Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Wagner, EF (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.			Sibilia, Maria/0000-0001-6129-5613; Behrens, Axel/0000-0002-1557-1143; Wagner, Erwin F/0000-0001-7872-0196				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Bannister AJ, 1995, ONCOGENE, V11, P2509; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOULTER CA, 1988, ONCOGENE, V2, P207; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Pompetti F, 1996, J CELL BIOCHEM, V63, P37; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; REDMOND SMS, 1988, ONCOGENE, V2, P259; Rutberg SE, 1996, ONCOGENE, V13, P167; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SIBILIA M, 2000, UNPUB; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; TODARO GJ, 1965, J CELL COMPAR PHYSL, V66, P325, DOI 10.1002/jcp.1030660310; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VOGT PK, 1992, CANCER, V69, P2610, DOI 10.1002/1097-0142(19920515)69:10<2610::AID-CNCR2820691035>3.0.CO;2-J; WAGNER EF, 1985, EMBO J, V4, P663, DOI 10.1002/j.1460-2075.1985.tb03680.x; WANG ZQ, 1995, CANCER RES, V55, P6244; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6	40	167	173	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 18	2000	19	22					2657	2663		10.1038/sj.onc.1203603	http://dx.doi.org/10.1038/sj.onc.1203603			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851065				2022-12-17	WOS:000087193000001
J	Kuo, TH; Kim, HRC; Zhu, LP; Yu, YJ; Lin, HM; Tsang, W				Kuo, TH; Kim, HRC; Zhu, LP; Yu, YJ; Lin, HM; Tsang, W			Modulation of endoplasmic reticulum calcium pump by Bcl-2	ONCOGENE			English	Article						Bcl-2; endoplasmic reticulum calcium pump; gene expression	INTRACELLULAR CALCIUM; GENE-EXPRESSION; CELL-GROWTH; APOPTOSIS; CA2+; HOMEOSTASIS; RECEPTOR; CHANNEL; PROTEIN; THAPSIGARGIN	Members of the bcl-2 gene family encode proteins that function either to promote or to inhibit apoptosis. Despite numerous efforts, the mechanism of action of Bcl-2, an anti-apoptotic protein, is still not clear. In particular, the relation between Bcl-2 and the endoplasmic reticulum (ER) calcium store is not well-understood. In the present work, we examined the effect of Bcl-2 on the ER store. We demonstrate that overexpression of Bcl-2 in breast epithelial cells modulates ER store by upregulating calcium pump (SERCA) expression,without affecting the release channel (IP3R). The steady state levels of SERCA2 mRNA and protein were both increased in Bcl-2 expression clones. The increase in SERCA2 protein leads to accelerated calcium uptake and enhanced Ca2+ loading. In addition, we also show the detection of intracellular interaction between Bcl-2 and SERCA molecules by co-immunoprecipitation. Since high lumenal Ca2+ concentration of ER is essential for normal cell functions, the results suggest that Bcl-2 preserves the ER Ca2+ store by upregulating SERCA gene expression as well as by a possible interaction with the pump.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Wayne State University	Kuo, TH (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA.				NCI NIH HHS [CA-64139] Funding Source: Medline; NHLBI NIH HHS [HL-39481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064139, R01CA064139] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; CALPHAM DE, 1995, CELL, V80, P259; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; Cheng GM, 1996, ARCH BIOCHEM BIOPHYS, V329, P65, DOI 10.1006/abbi.1996.0192; Distelhorst CW, 1996, ONCOGENE, V12, P2051; DOWD DR, 1992, MOL ENDOCRINOL, V6, P1843, DOI 10.1210/me.6.11.1843; FURUYA Y, 1994, CANCER RES, V54, P6167; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kuo TH, 1997, CELL CALCIUM, V21, P399, DOI 10.1016/S0143-4160(97)90051-8; KUO TH, 1992, BIOCHIM BIOPHYS ACTA, V1138, P343, DOI 10.1016/0925-4439(92)90013-D; LIU CM, 1978, J BIOL CHEM, V253, P5892; LODISH HF, 1992, J BIOL CHEM, V267, P12753; Marin MC, 1996, ONCOGENE, V12, P2259; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Preston GA, 1997, CANCER RES, V57, P537; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; UPADHYAY S, 1995, CANCER RES, V55, P4520; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; WALDRON RT, 1994, J BIOL CHEM, V269, P11927; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZHAO H, 1990, J BIOL CHEM, V265, P21419; ZHU WH, 1995, LIFE SCI, V57, P2091, DOI 10.1016/0024-3205(95)02202-T; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	36	167	168	0	19	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1903	1910		10.1038/sj.onc.1202110	http://dx.doi.org/10.1038/sj.onc.1202110			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788433				2022-12-17	WOS:000076423500003
J	Feilotter, HE; Nagai, MA; Boag, AH; Eng, C; Mulligan, LM				Feilotter, HE; Nagai, MA; Boag, AH; Eng, C; Mulligan, LM			Analysis of PTEN and the 10q23 region in primary prostate carcinomas	ONCOGENE			English	Article						prostate carcinoma; 10q23; PTEN; loss of heterozygosity	ALLELIC LOSS; DELETION; CHROMOSOME-10; ADENOCARCINOMA; GLIOMAS; CANCER; GENES; MAP	Deletions involving chromosome 10q23 occur frequently in prostatic carcinomas. Recently, a novel tumour suppressor gene, PTEN, mapping to this interval, has been identified, Mutation or deletion of PTEN has been observed in a proportion of prostate cancer cell lines; however, primary prostate carcinomas have not been studied, We have investigated the involvement of PTEN in primary prostatic adenocarcinomas using a panel of 51 matched normal and prostate tumour DNAs, Wie first determined the proportion of tumours with allele loss at loci in 10q23 which span the region containing the PTEN gene. Our results show that LOH involving 10q23 is common in primary prostate carcinomas. Twenty-five of 51 (49%) tumours showed loss of heterozygosity (LOH) over the region spanning the PTEN locus, We next directly analysed the PTEN gene for mutations of the coding region using single strand conformation polymorphism (SSCP) and sequence analyses, Of those tumours with LOH, only a single tumour nas found to carry a missense mutation in PTEN, No mutations in PTEN were identified in tumours without LOH. Our results suggest either that mutation of PTEN is a late event in prostate tumorigenesis, or that another tumour suppressor gene important in prostate cancer mag Lie close to PTEN in 10q23.	Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; USP, Fac Med, Dept Radiol, Disciplina Oncol, BR-09500900 Sao Paulo, Brazil; Harvard Univ, Sch Med, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Human Canc Genet Unit, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med,Program Populat Sci, Boston, MA 02115 USA	Queens University - Canada; Universidade de Sao Paulo; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Mulligan, LM (corresponding author), Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada.		Nagai, Maria A/C-6162-2012	Nagai, Maria A/0000-0002-0728-4937; Eng, Charis/0000-0002-3693-5145				Albarosa R, 1996, AM J HUM GENET, V58, P1260; Brothman AR, 1997, CANCER GENET CYTOGEN, V95, P116, DOI 10.1016/S0165-4608(96)00302-0; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; CHUMAKOV IM, 1995, NATURE, V377, P175; Cunningham JM, 1996, CANCER RES, V56, P4475; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; FUJIMORI M, 1991, CANCER RES, V51, P89; Gray IC, 1997, GENOMICS, V43, P85, DOI 10.1006/geno.1997.4809; GRAY IC, 1995, CANCER RES, V55, P4800; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HERBST RA, 1994, CANCER RES, V54, P3111; Ittmann M, 1996, CANCER RES, V56, P2143; KERANGUEVEN F, 1996, ONCOGENE, V13, P339; Lalani EN, 1997, CANCER METAST REV, V16, P29, DOI 10.1023/A:1005792206377; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Marsh DJ, 1997, CANCER RES, V57, P500; MATHEW CGP, 1987, NATURE, V328, P524, DOI 10.1038/328524a0; MORITA R, 1991, CANCER RES, V51, P5817; Moschonas N. K., 1996, Cytogenetics and Cell Genetics, V72, P99, DOI 10.1159/000134172; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PEIFFER SL, 1995, CANCER RES, V55, P1922; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Trybus TM, 1996, CANCER RES, V56, P2263; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153	28	167	174	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1743	1748		10.1038/sj.onc.1200205	http://dx.doi.org/10.1038/sj.onc.1200205			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582022				2022-12-17	WOS:000072807600012
J	TAMAGNONE, L; LAHTINEN, I; MUSTONEN, T; VIRTANEVA, K; FRANCIS, F; MUSCATELLI, F; ALITALO, R; SMITH, CIE; LARSSON, C; ALITALO, K				TAMAGNONE, L; LAHTINEN, I; MUSTONEN, T; VIRTANEVA, K; FRANCIS, F; MUSCATELLI, F; ALITALO, R; SMITH, CIE; LARSSON, C; ALITALO, K			BMX, A NOVEL NONRECEPTOR TYROSINE KINASE GENE OF THE BTK/ITK/TEC/TXK FAMILY LOCATED IN CHROMOSOME XP22.2	ONCOGENE			English	Note							X-LINKED AGAMMAGLOBULINEMIA; SRC FAMILY; SIGNAL TRANSDUCTION; HEMATOPOIETIC-CELLS; MESSENGER-RNAS; EXPRESSION; RECEPTOR; IDENTIFICATION; PP60C-SRC; SEQUENCE	The Bmx sequence was identified and cloned during our search for novel tyrosine kinase genes expressed in human bone marrow cells. Bmx cDNA comprises a long open reading frame of 675 amino acids, containing one SH3, one SH2 and one tyrosine kinase domain, which are about 70% identical with Btk, Itk and Tec and somewhat less with Txk tyrosine kinase sequences. The amino terminal sequences of these four tyrosine kinases are about 40% identical and each contains a so-called pleckstrin homology domain. The 2.7 kb Bmx mRNA was expressed in endothelial cells and several human tissues by Northern blotting and an 80 kD Bmx polypeptide was detected in human endothelial cells. Immunoprecipitates of COS cells transfected with a Bmx expression vector and NIH3T3 cells expressing a Bmx retrovirus contained a tyrosyl phosphorylated Bmx polypeptide of similar molecular weight. The BMX gene was located in chromosomal band Xp22.2 between the DXS197 and DXS207 loci. Interestingly, chromosome X also contains the closest relative of BMX, the BTK gene, implicated in X-linked agammaglobulinemia. The BMX gene thus encodes a novel nonreceptor tyrosine kinase, which may play a role;in the growth and differentiation of hematopoietic cells.	UNIV HELSINKI,TRANSPLANTAT LAB,SF-00014 HELSINKI,FINLAND; UNIV HELSINKI,DEPT GENET,MOLEC CANC BIOL LAB,SF-00014 HELSINKI,FINLAND; IMPERIAL CANC RES FUND,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND,OXFORD OX3 9DU,ENGLAND; KAROLINSKA INST,NOVUM,CTR BIOTECHNOL,S-14157 HUDDINGE,SWEDEN; KAROLINSKA HOSP,DEPT CLIN GENET,S-17176 STOCKHOLM,SWEDEN	University of Helsinki; University of Helsinki; Cancer Research UK; University of Oxford; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital			Francis, Fiona/B-5854-2016; Muscatelli, Françoise/P-4650-2016; Alitalo, Kari K/J-5013-2014; Tamagnone, Luca/J-8948-2018	Muscatelli, Françoise/0000-0003-4001-6528; Alitalo, Kari K/0000-0002-7331-0902; Tamagnone, Luca/0000-0002-2884-7946; Francis, Fiona/0000-0001-8542-7537; Mustonen, Tuija/0000-0002-2429-5064; SMITH, C. I. Edvard/0000-0003-1907-3392				BOLEN JB, 1993, ONCOGENE, V8, P2025; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GIBSON S, 1993, BLOOD, V82, P1561; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MANO H, 1993, ONCOGENE, V8, P417; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MORGENSTERN JP, 1990, NUC ACIDS RES, V12, P6460; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; MUSTELIN T, 1994, SRC FAMILY TYROSINE; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; SAFFRAN DC, 1994, NEW ENGL J MED, V330, P1488, DOI 10.1056/NEJM199405263302104; SICILIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194; SMITH CIE, 1994, IMMUNOL REV, V138, P159, DOI 10.1111/j.1600-065X.1994.tb00851.x; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404; ZHU QL, 1994, J EXP MED, V180, P461, DOI 10.1084/jem.180.2.461	39	167	178	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3683	3688						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970727				2022-12-17	WOS:A1994PT39200032
J	DATI, C; ANTONIOTTI, S; TAVERNA, D; PERROTEAU, I; DEBORTOLI, M				DATI, C; ANTONIOTTI, S; TAVERNA, D; PERROTEAU, I; DEBORTOLI, M			INHIBITION OF C-ERBB-2 ONCOGENE EXPRESSION BY ESTROGENS IN HUMAN BREAST-CANCER CELLS	ONCOGENE			English	Article									UNIV TURIN,DEPT ANIM BIOL,MOLEC CELL BIOL LAB,VIA ACC ALBERTINA 17,I-10123 TURIN,ITALY	University of Turin			taverna, daniela/J-8358-2016; De Bortoli, Michele/B-5418-2013	taverna, daniela/0000-0002-6365-527X; De Bortoli, Michele/0000-0002-6666-9052; Perroteau, Isabelle/0000-0001-9797-2276				ADNANE J, 1989, ONCOGENE, V4, P1389; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ARMELIN HA, 1973, P NATL ACAD SCI USA, V70, P2702, DOI 10.1073/pnas.70.9.2702; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERGER MS, 1988, CANCER RES, V48, P1238; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; COWLEY BD, 1989, J BIOL CHEM, V264, P8389; DEBORTOLI M, 1986, ENDOCRINOLOGY MALIGN, P104; DEBORTOLI ME, 1985, BIOCHEM BIOPH RES CO, V127, P699, DOI 10.1016/S0006-291X(85)80218-7; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GUERIN M, 1988, ONCOGENE RES, V3, P21; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; HISSOM JR, 1989, ENDOCRINOLOGY, V125, P418, DOI 10.1210/endo-125-1-418; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LACROIX H, 1989, ONCOGENE, V4, P145; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MURPHY LJ, 1986, CANCER RES, V46, P728; NISHIKURA K, 1983, P NATL ACAD SCI-BIOL, V80, P4822, DOI 10.1073/pnas.80.15.4822; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SHIU RPC, 1984, CANCER RES, V44, P1178; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; THOMAS DB, 1984, CANCER-AM CANCER SOC, V53, P595, DOI 10.1002/1097-0142(19840201)53:3+<595::AID-CNCR2820531304>3.0.CO;2-Y; THOMPSON NL, 1986, CANCER RES, V46, P3111; TSUDA H, 1989, CANCER RES, V49, P3104; VANDERBURG B, 1989, MOL CELL ENDOCRINOL, V64, P223, DOI 10.1016/0303-7207(89)90149-4; VARLEY JM, 1987, ONCOGENE, V1, P423; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; Vonderhaar B, 1984, CONTROL CELL GROWTH, P11; Vonderhaar B. K., 1985, Biological Responses in Cancer, V4, P125; WRIGHT C, 1989, CANCER RES, V49, P2087; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	41	167	190	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1990	5	7					1001	1006						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	1973827				2022-12-17	WOS:A1990DP41500007
J	Strub, T; Giuliano, S; Ye, T; Bonet, C; Keime, C; Kobi, D; Le Gras, S; Cormont, M; Ballotti, R; Bertolotto, C; Davidson, I				Strub, T.; Giuliano, S.; Ye, T.; Bonet, C.; Keime, C.; Kobi, D.; Le Gras, S.; Cormont, M.; Ballotti, R.; Bertolotto, C.; Davidson, I.			Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma	ONCOGENE			English	Article						senescence; DNA repair; cancer; metastasis	CELL-DIVISION; MALIGNANT-MELANOMA; LINEAGE SURVIVAL; GENE-EXPRESSION; DAMAGE RESPONSE; GROWTH-FACTOR; NEURAL CREST; HUMAN CANCER; MITF; APOPTOSIS	Malignant melanoma is an aggressive cancer known for its notorious resistance to most current therapies. The basic helix-loop-helix microphthalmia transcription factor (MITF) is the master regulator determining the identity and properties of the melanocyte lineage, and is regarded as a lineage-specific 'oncogene' that has a critical role in the pathogenesis of melanoma. MITF promotes melanoma cell proliferation, whereas sustained supression of MITF expression leads to senescence. By combining chromatin immunoprecipitation coupled to high throughput sequencing (ChIP-seq) and RNA sequencing analyses, we show that MITF directly regulates a set of genes required for DNA replication, repair and mitosis. Our results reveal how loss of MITF regulates mitotic fidelity, and through defective replication and repair induces DNA damage, ultimately ending in cellular senescence. These findings reveal a lineage-specific control of DNA replication and mitosis by MITF, providing new avenues for therapeutic intervention in melanoma. The identification of MITF-binding sites and gene-regulatory networks establish a framework for understanding oncogenic basic helix-loop-helix factors such as N-myc or TFE3 in other cancers. Oncogene (2011) 30, 2319-2332; doi: 10.1038/onc.2010.612; published online 24 January 2011	[Giuliano, S.; Bonet, C.; Ballotti, R.; Bertolotto, C.] CHU Nice, INSERM, U895, Team 1, Nice, France; [Giuliano, S.; Bonet, C.; Ballotti, R.; Bertolotto, C.] CHU Nice, Dept Dermatol, Nice, France; [Strub, T.; Ye, T.; Keime, C.; Kobi, D.; Le Gras, S.; Davidson, I.] Univ Strasbourg, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; [Cormont, M.] Fac Med Nice, INSERM, U895, Team 7, F-06034 Nice, France	CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Nice; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Bertolotto, C (corresponding author), CHU Nice, INSERM, U895, Team 1, Nice, France.	corine.bertolotto@unice.fr; irwin@igbmc.fr	Giuliano, Sandy/U-2498-2019; Bertolotto, Corine/AAF-6634-2021; BALLOTTI, Robert/F-8825-2013; Strub, Thomas/AAH-3573-2019; Ye, Tao/D-8026-2011; Bertolotto-Ballotti, Corine/O-2155-2016	Bertolotto, Corine/0000-0001-6971-7753; Strub, Thomas/0000-0001-6252-0181; Davidson, Irwin/0000-0001-5533-1171; BALLOTTI, Robert/0000-0002-7322-4908; KEIME, Celine/0000-0001-7604-3814; Le Gras, Stephanie/0000-0001-6293-6507; CORMONT, Mireille/0000-0001-6918-2410	CNRS; INSERM; Association pour la Recherche contre le Cancer [4985, 7823]; Ligue Nationale contre le Cancer; Institut national du Cancer [R08009AP]; ANR; Conseil Regional de la Region Provence-Alpes-Cote d'Azur; Nice University Hospital; Conseil General des Alpes Maritimes	CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Institut national du Cancer(Institut National du Cancer (INCA) France); ANR(French National Research Agency (ANR)); Conseil Regional de la Region Provence-Alpes-Cote d'Azur(Region Provence-Alpes-Cote d'Azur); Nice University Hospital; Conseil General des Alpes Maritimes(Region Provence-Alpes-Cote d'Azur)	We thank B Jost for Illumina sequencing, A Hamiche and E Soutoglou for antibodies. This work was supported by grants from the CNRS, the INSERM, the Association pour la Recherche contre le Cancer grant 4985 and 7823, the Ligue Nationale contre le Cancer, the Institut national du Cancer grant R08009AP and the ANR Regulome project grant. We thank the Conseil Regional de la Region Provence-Alpes-Cote d'Azur, the Nice University Hospital and the Conseil General des Alpes Maritimes for funding of the C3M MiCa Cell Imaging Facility. ID and CB are 'equipes labellisees' of the Ligue Nationale contre le Cancer.	Abraham J, 2003, EMBO J, V22, P6137, DOI 10.1093/emboj/cdg580; Artandi SE, 2000, NAT MED, V6, P852, DOI 10.1038/78595; Artandi SE, 2010, CARCINOGENESIS, V31, P9, DOI 10.1093/carcin/bgp268; Bentley DJ, 2002, J CELL SCI, V115, P1551; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; Beuret L, 2007, J BIOL CHEM, V282, P14140, DOI 10.1074/jbc.M611563200; Busca R, 2005, J CELL BIOL, V170, P49, DOI 10.1083/jcb.200501067; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Carroll CW, 2009, NAT CELL BIOL, V11, P896, DOI 10.1038/ncb1899; Cheeseman IM, 2006, CELL, V127, P983, DOI 10.1016/j.cell.2006.09.039; Chiaverini C, 2008, J BIOL CHEM, V283, P12635, DOI 10.1074/jbc.M800130200; Delacroix L, 2010, MOL CELL BIOL, V30, P231, DOI 10.1128/MCB.00756-09; Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014; Dynek JN, 2008, CANCER RES, V68, P3124, DOI 10.1158/0008-5472.CAN-07-6622; Fagiani E, 2007, CANCER RES, V67, P3064, DOI 10.1158/0008-5472.CAN-06-2301; Foltz DR, 2006, NAT CELL BIOL, V8, P458, DOI 10.1038/ncb1397; Garraway LA, 2005, COLD SH Q B, V70, P25, DOI 10.1101/sqb.2005.70.016; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Giuliano S, 2010, CANCER RES, V70, P3813, DOI 10.1158/0008-5472.CAN-09-2913; Goding C R, 2000, Forum (Genova), V10, P176; Goding CR, 2000, GENE DEV, V14, P1712; Gomez-Baldo L, 2010, CELL CYCLE, V9, P1143, DOI 10.4161/cc.9.6.11018; Goodall J, 2008, CANCER RES, V68, P7788, DOI 10.1158/0008-5472.CAN-08-1053; Hoek KS, 2008, PIGM CELL MELANOMA R, V21, P665, DOI 10.1111/j.1755-148X.2008.00505.x; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Hou L, 2008, CELL RES, V18, P1163, DOI 10.1038/cr.2008.303; Kim DS, 2004, INT J BIOCHEM CELL B, V36, P1482, DOI 10.1016/j.biocel.2003.10.023; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kobi D, 2010, PIGM CELL MELANOMA R, V23, P404, DOI 10.1111/j.1755-148X.2010.00697.x; Koyanagi K, 2006, CLIN CANCER RES, V12, P1137, DOI 10.1158/1078-0432.CCR-05-1847; Krebs A, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-533; Larribere L, 2005, GENE DEV, V19, P1980, DOI 10.1101/gad.335905; Levy C, 2010, CELL, V141, P994, DOI 10.1016/j.cell.2010.05.004; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Moore R, 2004, ONCOGENE, V23, P6726, DOI 10.1038/sj.onc.1207675; Neumann B, 2010, NATURE, V464, P721, DOI 10.1038/nature08869; Nishimura EK, 2010, CELL STEM CELL, V6, P130, DOI 10.1016/j.stem.2009.12.010; Ouhtit A, 2009, BBA-REV CANCER, V1795, P130, DOI 10.1016/j.bbcan.2009.01.002; Pinner S, 2009, CANCER RES, V69, P7969, DOI 10.1158/0008-5472.CAN-09-0781; Rothhammer T, 2005, CANCER RES, V65, P448; Ruchaud S, 2007, NAT REV MOL CELL BIO, V8, P798, DOI 10.1038/nrm2257; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Schmit TL, 2009, J INVEST DERMATOL, V129, P2843, DOI 10.1038/jid.2009.172; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Steingrimsson E, 2008, PIGM CELL MELANOMA R, V21, P412, DOI 10.1111/j.1755-148X.2008.00473.x; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159; Wu GK, 2008, MOL CELL BIOL, V28, P3652, DOI 10.1128/MCB.01923-07; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	52	166	172	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	20					2319	2332		10.1038/onc.2010.612	http://dx.doi.org/10.1038/onc.2010.612			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	766NF	21258399				2022-12-17	WOS:000290789200004
J	Hezel, AF; Bardeesy, N				Hezel, A. F.; Bardeesy, N.			LKB1; linking cell structure and tumor suppression	ONCOGENE			English	Review						polarity; mouse models; Peutz-Jeghers; cancer; hamartoma; STK11	PEUTZ-JEGHERS-SYNDROME; ACTIVATED PROTEIN-KINASE; SOMATIC MUTATIONS; GLUCOSE-HOMEOSTASIS; LKB1-AMPK PATHWAY; SPORADIC BREAST; DROSOPHILA LKB1; LUMEN POLARITY; C-ZETA; CANCER	Germ line mutations in the LKB1 tumor suppressor gene are associated with the Peutz-Jeghers polyposis and cancer syndrome. Somatic mutations in Lkb1 are observed in sporadic pulmonary, pancreatic and biliary cancers and melanomas. The LKB1 serine-threonine kinase functionally and biochemically links control of cellular structure and energy utilization through activation of the AMPK family of kinases. Lkb1 regulates cell polarity through downstream kinases including AMPKs, MARKs and BRSKs, and nutrient utilization and cellular metabolism through the AMPK-mTOR pathway. LKB1 has been shown to affect normal chromosomal segregation, TGF-beta signaling in the mesenchyme and WNT and p53 activity. Although each of the LKB1-dependent processes and downstream pathways have been individually delineated through work across a range of experimental systems, how they relate to Lkb1's role as a tumor suppressor remains to be fully explored and elucidated. The recent development of mouse cancer models harboring engineered mutations in Lkb1 have offered insights into how LKB1 may be functioning to restrain tumorigenesis and how its role as a master regulator of polarity and metabolism could contribute to its tumor suppressor function.	[Hezel, A. F.; Bardeesy, N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc,Dept Med, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Bardeesy, N (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc,Dept Med, Boston, MA 02114 USA.	Bardeesy.Nabeel@MGH.Harvard.edu						Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Amin RMS, 2008, PATHOL INT, V58, P84, DOI 10.1111/j.1440-1827.2007.02194.x; Aretz S, 2005, HUM MUTAT, V26, P513, DOI 10.1002/humu.20253; Asada N, 2007, J NEUROSCI, V27, P11769, DOI 10.1523/JNEUROSCI.1938-07.2007; Avizienyte E, 1998, CANCER RES, V58, P2087; Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Baas AF, 2004, TRENDS CELL BIOL, V14, P312, DOI 10.1016/j.tcb.2004.04.001; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Barnes AP, 2007, CELL, V129, P549, DOI 10.1016/j.cell.2007.03.025; Bettencourt-Dias M, 2004, NATURE, V432, P980, DOI 10.1038/nature03160; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bignell GR, 1998, CANCER RES, V58, P1384; Blumer JB, 2003, J BIOL CHEM, V278, P23217, DOI 10.1074/jbc.C200686200; Bonaccorsi S, 2007, DEVELOPMENT, V134, P2183, DOI 10.1242/dev.02848; Boudeau J, 2004, J CELL SCI, V117, P6365, DOI 10.1242/jcs.01571; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Carretero J, 2007, ONCOGENE, V26, P1616, DOI 10.1038/sj.onc.1209951; Cohen D, 2004, J CELL BIOL, V164, P717, DOI 10.1083/jcb.200308104; Cohen D, 2007, MOL BIOL CELL, V18, P2203, DOI 10.1091/mbc.E07-02-0095; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; Contreras CM, 2008, CANCER RES, V68, P759, DOI 10.1158/0008-5472.CAN-07-5014; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; de Leng WWJ, 2003, CLIN CANCER RES, V9, P3065; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Dunlop MG, 2002, GUT, V51, pV21, DOI 10.1136/gut.51.suppl_5.v21; Elbert M, 2006, MOL BIOL CELL, V17, P3345, DOI 10.1091/mbc.E06-03-0193; Entius MM, 2001, J CLIN PATHOL, V54, P126, DOI 10.1136/jcp.54.2.126; Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Forcet C, 2005, HUM MOL GENET, V14, P1283, DOI 10.1093/hmg/ddi139; FORCET C, 2007, SCI STKE, pPE51; Forster LF, 2000, J CLIN PATHOL, V53, P791, DOI 10.1136/jcp.53.10.791; Giardiello FM, 2006, CLIN GASTROENTEROL H, V4, P408, DOI 10.1016/j.cgh.2005.11.005; Giardiello FM, 2000, GASTROENTEROLOGY, V119, P1447, DOI 10.1053/gast.2000.20228; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Gruber SB, 1998, CANCER RES, V58, P5267; Guldberg P, 1999, ONCOGENE, V18, P1777, DOI 10.1038/sj.onc.1202486; Gurumurthy S, 2008, CANCER RES, V68, P55, DOI 10.1158/0008-5472.CAN-07-3225; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Hatakeyama M, 2008, ONCOGENE, V27, P7047, DOI 10.1038/onc.2008.353; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hearle N, 2006, CLIN CANCER RES, V12, P3209, DOI 10.1158/1078-0432.CCR-06-0083; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hemminki A, 1997, NAT GENET, V15, P87, DOI 10.1038/ng0197-87; Hezel AF, 2008, MOL CELL BIOL, V28, P2414, DOI 10.1128/MCB.01621-07; Horman S, 2008, J BIOL CHEM, V283, P18505, DOI 10.1074/jbc.M802053200; Huang X, 2008, BIOCHEM J, V412, P211, DOI 10.1042/BJ20080557; Hurov J, 2007, CELL CYCLE, V6, P1966, DOI 10.4161/cc.6.16.4576; Hurov JB, 2007, P NATL ACAD SCI USA, V104, P5680, DOI 10.1073/pnas.0701179104; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Jansen M, 2006, GUT, V55, P1, DOI 10.1136/gut.2005.069062; JEGHERS H, 1949, NEW ENGL J MED, V241, P1031, DOI 10.1056/NEJM194912292412601; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Jimenez AI, 2003, CANCER RES, V63, P1382; Jishage K, 2002, P NATL ACAD SCI USA, V99, P8903, DOI 10.1073/pnas.122254599; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Katajisto P, 2008, NAT GENET, V40, P455, DOI 10.1038/ng.98; Katajisto P, 2007, BBA-REV CANCER, V1775, P63, DOI 10.1016/j.bbcan.2006.08.003; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kim BG, 2006, NATURE, V441, P1015, DOI 10.1038/nature04846; Koh HJ, 2006, MOL CELL BIOL, V26, P8217, DOI 10.1128/MCB.00979-06; Koivunen JP, 2008, BRIT J CANCER, V99, P245, DOI 10.1038/sj.bjc.6604469; Lee JH, 2007, NATURE, V447, P1017, DOI 10.1038/nature05828; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Lim W, 2004, GASTROENTEROLOGY, V126, P1788, DOI 10.1053/j.gastro.2004.03.014; Lin-Marq N, 2005, MOL GENET GENOMICS, V273, P184, DOI 10.1007/s00438-005-1124-y; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Mehenni H, 2005, HUM MOL GENET, V14, P2209, DOI 10.1093/hmg/ddi225; Memmott RM, 2008, CANCER RES, V68, P580, DOI 10.1158/0008-5472.CAN-07-3091; Mirouse V, 2007, J CELL BIOL, V177, P387, DOI 10.1083/jcb.200702053; Miyaki M, 2000, CANCER RES, V60, P6311; Miyoshi H, 2002, CANCER RES, V62, P2261; Nakau M, 2002, CANCER RES, V62, P4549; Narbonne P, 2006, DEVELOPMENT, V133, P611, DOI 10.1242/dev.02232; Olschwang S, 2001, J MED GENET, V38, P356, DOI 10.1136/jmg.38.6.356; Ossipova O, 2003, NAT CELL BIOL, V5, P889, DOI 10.1038/ncb1048; Partanen JI, 2007, P NATL ACAD SCI USA, V104, P14694, DOI 10.1073/pnas.0704677104; Pearson HB, 2008, CANCER RES, V68, P2223, DOI 10.1158/0008-5472.CAN-07-5169; PEUTZ J, 1921, NED MAANDSCHR GENEES; PODCZASKI E, 1991, GYNECOL ONCOL, V42, P74, DOI 10.1016/0090-8258(91)90234-V; Rossi DJ, 2002, P NATL ACAD SCI USA, V99, P12327, DOI 10.1073/pnas.192301399; Rowan A, 1999, J INVEST DERMATOL, V112, P509, DOI 10.1046/j.1523-1747.1999.00551.x; Sahin F, 2003, MODERN PATHOL, V16, P686, DOI 10.1097/01.MP.0000075645.97329.86; Sakamoto K, 2005, EMBO J, V24, P1810, DOI 10.1038/sj.emboj.7600667; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sapkota GP, 2002, BIOCHEM J, V368, P507, DOI 10.1042/BJ20021284; Sapkota GP, 2002, BIOCHEM J, V362, P481, DOI 10.1042/0264-6021:3620481; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Sato N, 2001, AM J PATHOL, V159, P2017, DOI 10.1016/S0002-9440(10)63053-2; Schneider MB, 2001, GASTROENTEROLOGY, V120, P1263, DOI 10.1053/gast.2001.23258; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; Shaw RJ, 2006, CURR OPIN CELL BIOL, V18, P598, DOI 10.1016/j.ceb.2006.10.005; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Shelly M, 2007, CELL, V129, P565, DOI 10.1016/j.cell.2007.04.012; Song P, 2008, J BIOL CHEM, V283, P12446, DOI 10.1074/jbc.M708208200; Song P, 2007, CIRCULATION, V116, P1585, DOI 10.1161/CIRCULATIONAHA.107.716498; Spicer J, 2003, ONCOGENE, V22, P4752, DOI 10.1038/sj.onc.1206669; SPIGELMAN AD, 1989, GUT, V30, P1588, DOI 10.1136/gut.30.11.1588; Su GH, 1999, AM J PATHOL, V154, P1835, DOI 10.1016/S0002-9440(10)65440-5; Takeda H, 2006, ONCOGENE, V25, P1816, DOI 10.1038/sj.onc.1209207; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tiainen M, 2002, HUM MOL GENET, V11, P1497, DOI 10.1093/hmg/11.13.1497; Tomlinson IPM, 1997, J MED GENET, V34, P1007, DOI 10.1136/jmg.34.12.1007; Udd L, 2004, GASTROENTEROLOGY, V127, P1030, DOI 10.1053/j.gastro.2004.07.059; Volikos E, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.039875; Wang ZJ, 1999, J PATHOL, V188, P9, DOI 10.1002/(SICI)1096-9896(199905)188:1<9::AID-PATH326>3.0.CO;2-E; Wang ZJ, 1998, AM J PATHOL, V153, P363, DOI 10.1016/S0002-9440(10)65579-4; Watts JL, 2000, DEVELOPMENT, V127, P1467; Wei C, 2008, CLIN CANCER RES, V14, P1167, DOI 10.1158/1078-0432.CCR-07-4007; Wei CJ, 2005, CANCER RES, V65, P11297, DOI 10.1158/0008-5472.CAN-05-0716; Westerman AM, 1999, LANCET, V353, P1211, DOI 10.1016/S0140-6736(98)08018-0; Williams T, 2008, TRENDS CELL BIOL, V18, P193, DOI 10.1016/j.tcb.2008.01.008; Xie ZL, 2006, J BIOL CHEM, V281, P6366, DOI 10.1074/jbc.M511178200; Yee NS, 2003, CANCER BIOL THER, V2, P38; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074; YOUNG S, 1995, AM J SURG PATHOL, V19, P50, DOI 10.1097/00000478-199501000-00007; Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500; Zhang L, 2006, P NATL ACAD SCI USA, V103, P17272, DOI 10.1073/pnas.0608531103; Zhang SM, 2008, CANCER RES, V68, P740, DOI 10.1158/0008-5472.CAN-07-2989; Zheng B, 2007, P NATL ACAD SCI USA, V104, P819, DOI 10.1073/pnas.0610157104	127	166	177	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2008	27	55					6908	6919		10.1038/onc.2008.342	http://dx.doi.org/10.1038/onc.2008.342			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029933				2022-12-17	WOS:000261108200004
J	Delmas, D; Rebe, C; Micheau, O; Athias, A; Gambert, P; Grazide, S; Laurent, G; Latruffe, N; Solary, E				Delmas, D; Rebe, C; Micheau, O; Athias, A; Gambert, P; Grazide, S; Laurent, G; Latruffe, N; Solary, E			Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells	ONCOGENE			English	Article						apoptosis; death receptors; lipid rafts; resveratrol	INDUCED APOPTOSIS; MEDIATED APOPTOSIS; GROWTH-INHIBITION; CANCER-CELLS; LIPID RAFTS; ACTIVATION; CASPASE-8; SENSITIZATION; COMPOUND; PATHWAY	The natural phytoalexin resveratrol (3,5,4'-trihydroxystilbene) exhibits both chemopreventive and antitumor activities through a variety of mechanisms. We have shown previously that resveratrol-induced apoptosis of a human colon cancer cell line involved the redistribution of CD95 (Fas/Apo-1) into lipid rafts. Here, we show that, in colon cancer cells that resist to resveratrol-induced apoptosis, the polyphenol also induces a redistribution of death receptors into lipid rafts. This effect sensitizes these tumor cells to death receptor-mediated apoptosis. In resveratrol-treated cells, tumor necrosis factor (TNF), anti-CD95 antibodies and TNF-related apoptosis-inducing ligand (TRAIL) activate a caspase-dependent death pathway that escapes Bcl-2-mediated inhibition. Resveratrol does not enhance the number of death receptors at the surface of tumor cells but induces their redistribution into lipid rafts and facilitates the caspase cascade activation in response to death receptor stimulation. The cholesterol sequestering agent nystatin prevents resveratrol-induced death receptor redistribution and cell sensitization to death receptor stimulation. Thus, whatever its ability to induce apoptosis in a tumor cell, resveratrol induces redistribution of death receptors into lipid rafts. This redistribution sensitizes the cells to death receptor stimulation. Such a sensitizing effect may be of therapeutic interest if TRAIL agonists are introduced in clinics.	INSERM, U517, IFR100, Fac Med, F-21000 Dijon, France; Univ Burgundy, Mol & Cellular Biol Lab, GDR CNRS 2583, IFR92, F-21000 Dijon, France; CHU Bocage, INSERM, U498, IFR100, F-21034 Dijon, France; Inst Claudius Regaud, INSERM E9910, F-31052 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Centre National de la Recherche Scientifique (CNRS); Universite de Bourgogne; CHU Dijon Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud	Solary, E (corresponding author), INSERM, U517, IFR100, Fac Med, 7 Blvd Jeanne Arc, F-21000 Dijon, France.	esolary@u-bourgogne.fr	REBE, Cédric/AAD-4316-2019; Delmas, Dominique/AAD-9749-2019; micheau, olivier/C-3574-2011	REBE, Cédric/0000-0001-8831-145X; Delmas, Dominique/0000-0003-3576-0248; micheau, olivier/0000-0001-8499-7984; Solary, Eric/0000-0002-8629-1341; Delmas, Dominique/0000-0002-8911-8499				Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Bernhard D, 2000, CELL DEATH DIFFER, V7, P834, DOI 10.1038/sj.cdd.4400719; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Brakenhielm E, 2001, FASEB J, V15, P1798, DOI 10.1096/fj.01-0028fje; Chan SW, 2000, CIRC RES, V86, P1038, DOI 10.1161/01.RES.86.10.1038; Clement MV, 1998, BLOOD, V92, P996; Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Dorrie J, 2001, CANCER RES, V61, P4731; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Garofalo T, 2002, J BIOL CHEM, V277, P11233, DOI 10.1074/jbc.M109601200; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; Hueber AO, 2003, CELL DEATH DIFFER, V10, P7, DOI 10.1038/sj.cdd.4401155; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Joe AK, 2002, CLIN CANCER RES, V8, P893; Keane MM, 1999, CANCER RES, V59, P734; Kubota T, 2003, ANTICANCER RES, V23, P4039; Lacour S, 2003, ONCOGENE, V22, P1807, DOI 10.1038/sj.onc.1206127; Lacour S, 2004, CANCER RES, V64, P3593, DOI 10.1158/0008-5472.CAN-03-2787; Lacour S, 2001, CANCER RES, V61, P1645; Lozupone F, 2004, J BIOL CHEM, V279, P9199, DOI 10.1074/jbc.M305561200; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Micheau O, 1997, J NATL CANCER I, V89, P783, DOI 10.1093/jnci/89.11.783; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Muppidi JR, 2004, NAT IMMUNOL, V5, P182, DOI 10.1038/ni1024; Opipari AW, 2004, CANCER RES, V64, P696, DOI 10.1158/0008-5472.CAN-03-2404; Pervaiz S, 2003, FASEB J, V17, P1975, DOI 10.1096/fj.03-0168rev; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scarlatti F, 2003, FASEB J, V17, P2339, DOI 10.1096/fj.03-0292fje; Scheel-Toellner D, 2002, BIOCHEM BIOPH RES CO, V297, P876, DOI 10.1016/S0006-291X(02)02311-2; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Sun ZJ, 2002, WORLD J GASTROENTERO, V8, P79, DOI 10.3748/wjg.v8.i1.79; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Tinhofer I, 2001, FASEB J, V15, P1613, DOI 10.1096/fj.00-0675fje; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Zoberi I, 2002, CANCER LETT, V175, P165, DOI 10.1016/S0304-3835(01)00719-4	41	166	168	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8979	8986		10.1038/sj.onc.1208086	http://dx.doi.org/10.1038/sj.onc.1208086			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15480430				2022-12-17	WOS:000225354600013
J	Lamalice, L; Houle, F; Jourdan, G; Huot, J				Lamalice, L; Houle, F; Jourdan, G; Huot, J			Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38	ONCOGENE			English	Article						VEGF; VEGFR2; SAPK2/p38; Cdc42	ENDOTHELIAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASE PATHWAYS; FOCAL ADHESION KINASE; ACTIN-BASED MOTILITY; CELL-MIGRATION; DNA-SYNTHESIS; PAF SYNTHESIS; P38 MAPK; RECEPTOR	Activation of the tyrosine kinase receptor vascular endothelial growth factor receptor 2 (VEGFR2) by VEGF leads to the activation of stress-activated protein kinase (SAPK)2/p38 and then to actin polymerization and reorganization into stress fibers in endothelial cells. In turn, this triggers endothelial cell migration. Yet, nothing is known about the molecular mechanisms that couple VEGFR2 to SAPK2/p38. Here, we found that VEGF increased by twofold the activity of the small GTPase Cdc42 and that the expression of two different constitutively active forms of Cdc42 (Cdc42 V12 and Cdc42 L61) led to a marked increase in the formation of stress fibers that was sensitive to SAPK/p38 inhibition by SB203580. Moreover, the expression of a dominant-negative form of Cdc42 (Cdc42 N17) inhibited the activation of SAPK2/p38 and of its direct target MAP kinase-activated protein kinase 2. These results indicate that Cdc42 is upstream of SAPK2/p38 in response to the activation of VEGFR2 by VEGF. In contrast, we found that neither RhoA nor Rac was involved in the SAPK2/p38-mediated actin reorganization induced by VEGF. Using a site-specific mutant of the major autophosphorylation site Y1214 on VEGFR2, we found that the mutant Y1214F inhibited the activation of both Cdc42 and SAPK2/p38 in response to VEGF. We conclude that phosphorylation of Y1214 on VEGFR2 is required to trigger the sequential activation of Cdc42 and SAPK2/p38 and to drive the SAPK2/p38-mediated actin remodeling in stress fibers in endothelial cells exposed to VEGF.	Univ Laval, Hotel Dieu Quebec, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada	Laval University	Huot, J (corresponding author), Univ Laval, Hotel Dieu Quebec, Ctr Rech Cancerol, 9 Rue McMahon, Quebec City, PQ G1R 2J6, Canada.	Jacques.Huot@phc.ulaval.ca						Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Barleon B, 1997, CANCER RES, V57, P5421; BARRY ST, 1994, J CELL SCI, V107, P2033; Bernatchez PN, 2002, J CELL BIOCHEM, V85, P629, DOI 10.1002/jcb.10155; Bernatchez PN, 2001, BRIT J PHARMACOL, V134, P1253, DOI 10.1038/sj.bjp.0704367; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Clerk A, 2001, MOL CELL BIOL, V21, P1173, DOI 10.1128/MCB.21.4.1173-1184.2001; Dechert MA, 2001, AM J PHYSIOL-CELL PH, V281, pC123, DOI 10.1152/ajpcell.2001.281.1.C123; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Fan WT, 1998, CURR BIOL, V8, P935, DOI 10.1016/S0960-9822(07)00376-4; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Ferrara N, 1996, Curr Opin Nephrol Hypertens, V5, P35, DOI 10.1097/00041552-199601000-00008; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Javerzat S, 2002, TRENDS MOL MED, V8, P483, DOI 10.1016/S1471-4914(02)02394-8; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Kroll J, 2000, Z KARDIOL, V89, P206, DOI 10.1007/s003920050472; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Li XD, 2002, J BIOL CHEM, V277, P15207, DOI 10.1074/jbc.M109913200; Masson-Gadais B, 2003, CELL STRESS CHAPERON, V8, P37, DOI 10.1379/1466-1268(2003)8<37:IVRFVA>2.0.CO;2; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Mudgett JS, 2000, P NATL ACAD SCI USA, V97, P10454, DOI 10.1073/pnas.180316397; Nakamura M, 2002, PATHOL INT, V52, P331, DOI 10.1046/j.1440-1827.2002.01367.x; Pai KS, 2002, J NEUROCHEM, V80, P715, DOI 10.1046/j.0022-3042.2001.00761.x; Pai KS, 2001, J BIOL CHEM, V276, P32642, DOI 10.1074/jbc.M104212200; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; Polverini Peter J, 2002, J Dent Educ, V66, P962; Ratcliffe KE, 2002, ONCOGENE, V21, P6307, DOI 10.1038/sj.onc.1205781; Renkema GH, 2002, MOL CELL BIOL, V22, P6719, DOI 10.1128/MCB.22.19.6719-6725.2002; Ridley A, 2000, J CELL BIOL, V150, pF107, DOI 10.1083/jcb.150.4.F107; Ridley AJ, 1999, NAT CELL BIOL, V1, pE64, DOI 10.1038/11034; Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Rousseau S, 2000, TRENDS CARDIOVAS MED, V10, P321, DOI 10.1016/S1050-1738(01)00072-X; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; Sato Y, 2000, ANN NY ACAD SCI, V902, P201; SEETHARAM L, 1995, ONCOGENE, V10, P135; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Van Trappen PO, 2002, BRIT J CANCER, V87, P537, DOI 10.1038/sj.bjc.6600471; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; ZENG H, 2002, J BIOL CHEM, V19, P19; Zeng HY, 2002, J BIOL CHEM, V277, P4003, DOI 10.1074/jbc.M110842200; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	53	166	171	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					434	445		10.1038/sj.onc.1207034	http://dx.doi.org/10.1038/sj.onc.1207034			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724572				2022-12-17	WOS:000188098300014
J	Huang, L; Snyder, AR; Morgan, WF				Huang, L; Snyder, AR; Morgan, WF			Radiation-induced genomic instability and its implications for radiation carcinogenesis	ONCOGENE			English	Article						ionizing radiation; chromosome instability; chromosome breakage syndromes; epigenetic factors	STRAND BREAK REPAIR; DELAYED CHROMOSOMAL INSTABILITY; IONIZING-RADIATION; DNA-REPAIR; IN-VIVO; CLASTOGENIC FACTORS; INTERCELLULAR COMMUNICATION; OXIDATIVE STRESS; BRCA2; CELLS	Radiation-induced genomic instability is characterized by an increased rate of genetic alterations including cytogenetic rearrangements, mutations, gene amplifications, transformation and cell death in the progeny of irradiated cells multiple generations after the initial insult. Chromosomal rearrangements are the best-characterized end point of radiation-induced genomic instability, and many of the rearrangements described are similar to those found in human cancers. Chromosome breakage syndromes are defined by chromosome instability, and individuals with these diseases are cancer prone. Consequently, chromosomal instability as a phenotype may underlie some fraction of those changes leading to cancer. Here we attempt to relate current knowledge regarding radiation-induced chromosome instability with the emerging molecular information on the chromosome breakage syndromes. The goal is to understand how genetic and epigenetic factors might influence the onset of chromosome instability and the role of chromosomal instability in carcinogenesis.	Univ Maryland, Grad Program Human Genet, Baltimore, MD 21201 USA; Univ Maryland, Radiat Oncol Res Lab, Baltimore, MD 21201 USA; Univ Maryland, Mol & Cell Biol Grad Program, Baltimore, MD 21201 USA; Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Huang, L (corresponding author), Univ Maryland, Grad Program Human Genet, 655 W Baltimore St, Baltimore, MD 21201 USA.	lhuan001@umaryland.edu			NATIONAL CANCER INSTITUTE [R01CA073924, R01CA083872] Funding Source: NIH RePORTER; NCI NIH HHS [CA 83872, CA73924] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; Bagby GC, 2003, CURR OPIN HEMATOL, V10, P68, DOI 10.1097/00062752-200301000-00011; Barcellos-Hoff MH, 2001, RADIAT RES, V156, P618, DOI 10.1667/0033-7587(2001)156[0618:ESTTMA]2.0.CO;2; Baverstock K, 2000, MUTAT RES-FUND MOL M, V454, P89, DOI 10.1016/S0027-5107(00)00100-7; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; Coleman WB, 1999, ANTICANCER RES, V19, P4645; Cui X, 1999, MUTAT RES-DNA REPAIR, V434, P75, DOI 10.1016/S0921-8777(99)00010-5; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Day JP, 1998, CARCINOGENESIS, V19, P259, DOI 10.1093/carcin/19.2.259; Duker NJ, 2002, AM J MED GENET, V115, P125, DOI 10.1002/ajmg.10688; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EMERIT I, 1994, FREE RADICAL BIO MED, V16, P99, DOI 10.1016/0891-5849(94)90246-1; EMERIT I, 1982, HUM GENET, V61, P65, DOI 10.1007/BF00291336; EMERIT I, 1990, METHOD ENZYMOL, V186, P555; EMERIT I, 1995, HUM GENET, V96, P14, DOI 10.1007/BF00214180; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Griffin CS, 2000, INT J RADIAT BIOL, V76, P963, DOI 10.1080/09553000050050972; Hickson ID, 2001, BIOCHEM SOC T, V29, P201, DOI 10.1042/0300-5127:0290201; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Hollander MC, 2002, ONCOGENE, V21, P6228, DOI 10.1038/sj.onc.1205774; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Imamura O, 2002, ONCOGENE, V21, P954, DOI 10.1038/sj.onc.1205143; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; Kadhim MA, 1996, INT J RADIAT BIOL, V69, P167, DOI 10.1080/095530096145995; Kaplan MI, 1998, RADIAT RES, V150, P382, DOI 10.2307/3579656; Karanjawala ZE, 2002, CURR BIOL, V12, P397, DOI 10.1016/S0960-9822(02)00684-X; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kramer A, 2002, LEUKEMIA, V16, P767, DOI 10.1038/sj.leu.2402454; Larminat F, 2002, ONCOGENE, V21, P5188, DOI 10.1038/sj.onc.1205659; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Limoli CL, 1998, CANCER RES, V58, P3712; Limoli CL, 1997, CANCER RES, V57, P4048; Limoli CL, 1997, CANCER RES, V57, P5557; Limoli CL, 2000, INT J RADIAT BIOL, V76, P1599, DOI 10.1080/09553000050201082; Limoli CL, 1999, RADIAT RES, V151, P677, DOI 10.2307/3580206; Limoli CL, 2001, FREE RADICAL BIO MED, V31, P10, DOI 10.1016/S0891-5849(01)00542-1; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; Lorimore SA, 1998, P NATL ACAD SCI USA, V95, P5730, DOI 10.1073/pnas.95.10.5730; Lorimore SA, 2001, ONCOGENE, V20, P7085, DOI 10.1038/sj.onc.1204903; MARDER BA, 1993, MOL CELL BIOL, V13, P6667, DOI 10.1128/MCB.13.11.6667; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; Mitelman F, 1997, CANCER GENET CYTOGEN, V95, P1, DOI 10.1016/S0165-4608(96)00252-X; Mitelman F, 2000, MUTAT RES-REV MUTAT, V462, P247, DOI 10.1016/S1383-5742(00)00006-5; MORGAN WF, 1988, MOL CELL BIOL, V8, P4204, DOI 10.1128/MCB.8.10.4204; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Morgan WF, 2002, MUTAT RES-FUND MOL M, V504, P91, DOI 10.1016/S0027-5107(02)00083-0; Morgan WF, 1996, RADIAT RES, V146, P247, DOI 10.2307/3579454; Morgan WF, 1998, MUTAT RES-FUND MOL M, V404, P125, DOI 10.1016/S0027-5107(98)00104-3; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Nagar S, 2003, CANCER RES, V63, P324; Nakayama H, 2002, ONCOGENE, V21, P9008, DOI 10.1038/sj.onc.1205959; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Okayasu R, 2000, CANCER RES, V60, P4342; PAQUETTE B, 1994, CANCER RES, V54, P3173; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Ponnaiya B, 1997, RADIAT RES, V147, P121, DOI 10.2307/3579411; Seymour C B, 1997, Radiat Oncol Investig, V5, P106, DOI 10.1002/(SICI)1520-6823(1997)5:3<106::AID-ROI4>3.0.CO;2-1; SHAHAM M, 1980, CYTOGENET CELL GENET, V27, P155, DOI 10.1159/000131476; Stewart G, 2002, MOL CELL, V10, P2, DOI 10.1016/S1097-2765(02)00580-4; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Taylor AMR, 2001, BEST PRACT RES CL HA, V14, P631, DOI 10.1053/beha.2001.0158; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/s0079-6603(08)60611-x; Watson GE, 1997, INT J RADIAT BIOL, V71, P497, DOI 10.1080/095530097143824; Watson GE, 2000, CANCER RES, V60, P5608; Wojcik A, 1996, RADIAT RES, V145, P119, DOI 10.2307/3579165; Wright EG, 1998, INT J RADIAT BIOL, V74, P681, DOI 10.1080/095530098140943; Wright EG, 1999, J PATHOL, V187, P19, DOI 10.1002/(SICI)1096-9896(199901)187:1<19::AID-PATH233>3.0.CO;2-1; Yu YJ, 2001, CANCER RES, V61, P1820	81	166	177	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5848	5854		10.1038/sj.onc.1206697	http://dx.doi.org/10.1038/sj.onc.1206697			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947391				2022-12-17	WOS:000185086100011
J	MacFarlane, M; Harper, N; Snowden, RT; Dyer, MJS; Barnett, GA; Pringle, JH; Cohen, GM				MacFarlane, M; Harper, N; Snowden, RT; Dyer, MJS; Barnett, GA; Pringle, JH; Cohen, GM			Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia	ONCOGENE			English	Article						caspases; CD95; c-FLIP; IAPs; DISC	FLICE-INHIBITORY PROTEIN; FAS-MEDIATED APOPTOSIS; SIGNALING COMPLEX; CANCER-CELLS; CD95-MEDIATED APOPTOSIS; CASPASE-8 ACTIVATION; LEUKEMIA CELLS; DEATH DOMAIN; APO-2 LIGAND; RECEPTOR	Primary B cells from B cell chronic lymphocytic leukaemia (B-CLL) were resistant to the novel selective cytotoxic agent, TNF-related apoptosis-inducing ligand (TRAIL). Low levels of the death-inducing TRAIL receptors, TRAIL-R1 and TRAIL-R2 but not the putative 'decoy' receptors, TRAIL-R3 and TRAIL-R4, were expressed on the surface of B-CLL cells. Resistance to TRAIL was upstream of caspase-8 activation, as little or no caspase-8 was processed in TRAIL-treated B-CLL cells. Low levels of a TRAIL death-inducing signalling complex (DISC) were formed in these cells, accompanied by the recruitment of endogenous FADD, caspase-8 and c-FLIPL but not c-FLIPS. Both caspase-8 and c-FLIPL were cleaved to form two stable intermediates of similar to43 kDa, which remained associated with the DISC. Caspase-8 was not further processed to its active heterotetramer. Thus the resistance of B-CLL cells to TRAIL may be due partly to low surface expression of the death receptors resulting in low levels of DISC formation and also to the high ratio of c-FLIPL to caspase-8 within the DISC, which would prevent further activation of caspase-8. Our results highlight the possibility of sensitising B-CLL cells to TRAIL by modulation of c-FLIP levels or by upregulation of surface expression of death receptors.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Univ Leicester, Dept Pathol, Leicester Royal Infirm, Leicester LE2 7LX, Leics, England; Univ Leicester, Dept Hematol, Leicester Royal Infirm, Leicester LE2 7LX, Leics, England	University of Leicester; University of Leicester; University of Leicester	Cohen, GM (corresponding author), Univ Leicester, MRC, Toxicol Unit, Hodgkin Bldg,POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England.		Cohen, Gerald M/A-1687-2008; Dyer, Martin/F-2691-2014	Dyer, Martin/0000-0002-5033-2236				Ahmad M, 2000, ONCOGENE, V19, P3363, DOI 10.1038/sj.onc.1203679; Almond JB, 2001, LEUKEMIA, V15, P1388, DOI 10.1038/sj.leu.2402201; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Fulda S, 2000, CANCER RES, V60, P3947; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1999, J IMMUNOL, V162, P2597; Harper N, 2001, J BIOL CHEM, V276, P34743, DOI 10.1074/jbc.M105693200; Hennino A, 2000, J IMMUNOL, V165, P3023, DOI 10.4049/jimmunol.165.6.3023; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Keane MM, 1999, CANCER RES, V59, P734; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim KH, 2000, CLIN CANCER RES, V6, P335; King D, 1998, LEUKEMIA, V12, P1553, DOI 10.1038/sj.leu.2401153; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769; Leverkus M, 2000, CANCER RES, V60, P553; MacFarlane M, 2000, J CELL BIOL, V148, P1239, DOI 10.1083/jcb.148.6.1239; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Mori S, 1999, J IMMUNOL, V162, P5616; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nesterov A, 2002, ONCOGENE, V21, P1135, DOI 10.1038/sj.onc.1205151; OBRIEN KAF, 1987, TOXICOL IN VITRO, V1, P85, DOI 10.1016/0887-2333(87)90005-1; Pai SI, 1998, CANCER RES, V58, P3513; Plumas J, 1998, BLOOD, V91, P2875, DOI 10.1182/blood.V91.8.2875.2875_2875_2885; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; ROZMAN C, 1995, NEW ENGL J MED, V333, P1052, DOI 10.1056/NEJM199510193331606; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Snell V, 1997, BRIT J HAEMATOL, V99, P618, DOI 10.1046/j.1365-2141.1997.4393250.x; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tepper CG, 1999, BLOOD, V94, P1727, DOI 10.1182/blood.V94.5.1727.417k03_1727_1737; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang DK, 1997, BRIT J HAEMATOL, V97, P409, DOI 10.1046/j.1365-2141.1997.422688.x; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Willems F, 2000, BLOOD, V95, P3478, DOI 10.1182/blood.V95.11.3478.011k10_3478_3482; Xerri L, 1998, BRIT J CANCER, V78, P225, DOI 10.1038/bjc.1998.469; Xerri L, 1997, LEUKEMIA, V11, P1868, DOI 10.1038/sj.leu.2400815; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang J, 1996, MOL CELL BIOL, V16, P2756; Zhou T, 1999, NAT MED, V5, P42, DOI 10.1038/4723	56	166	170	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6809	6818		10.1038/sj.onc.1205853	http://dx.doi.org/10.1038/sj.onc.1205853			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360407				2022-12-17	WOS:000178315800011
J	Rhee, CS; Sen, M; Lu, DS; Wu, C; Leoni, L; Rubin, J; Corr, M; Carson, DA				Rhee, CS; Sen, M; Lu, DS; Wu, C; Leoni, L; Rubin, J; Corr, M; Carson, DA			Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas	ONCOGENE			English	Article						head and neck squamous cell carcinomas; frizzled; beta-catenin; apoptosis	BETA-CATENIN; EXPRESSION; PATTERN; ESTABLISHMENT; GENES; LMX1	The diverse receptor-ligand pairs of the Wnt and frizzled (Fz) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. Hence, we investigated the expression and function of five Writ (Wnt-1, 5a, 7a, 10b, 13) and two Fz (Fz-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC). In comparison to normal bronchial or oral epithelial cells, all the HNSCC had markedly increased mRNA levels of Wnt-1, 7a, 10b, and 13, as well as Fz-2. Moreover, the levels of Wnt-1, 10b, and Fz-2 proteins were also markedly increased in HNSCC, relative to normal epithelial cells. Treatment of one HNSCC cell line (SNU 1076) with anti-Wnt-1 antibodies reduced the activity of the Wnt/Fz dependent transcription factor LEF/TCF, and diminished the expression of cyclin D1 and beta-catenin proteins. Blocking Wnt-1 signaling also inhibited proliferation and induced apoptosis in these cells. These results show that HNSCC cell lines often overexpress one or more Wnt and Fz genes, and suggest that the growth and survival of a subset of HNSCC may depend on the Wnt/Fz pathway. Hence, the Writ and Fz receptors may be possible targets for immunotherapy therapy of this common cancer.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, La Jolla, CA 92093 USA; NCI, Bethesda, MD 20892 USA; Seoul Natl Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Seoul, South Korea	University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Seoul National University (SNU)	Carson, DA (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	dcarson@ucsd.edu	Lu, desheng/E-4822-2013; Rhee, Chae-Seo/D-5904-2012	Lu, desheng/0000-0002-3616-6657; Lu, Desheng/0000-0002-0314-5649	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023200] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Kim SY, 1997, ACTA OTO-LARYNGOL, V117, P775, DOI 10.3109/00016489709113477; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Ku JL, 1999, LARYNGOSCOPE, V109, P976, DOI 10.1097/00005537-199906000-00025; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Ng JK, 1999, CURR TOP DEV BIOL, V41, P37; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33; PARR BA, 1993, DEVELOPMENT, V119, P247; Ramsdell AF, 1998, TRENDS GENET, V14, P459, DOI 10.1016/S0168-9525(98)01599-6; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; Sagara N, 1998, BIOCHEM BIOPH RES CO, V252, P117, DOI 10.1006/bbrc.1998.9607; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; VOGEL A, 1995, NATURE, V378, P716, DOI 10.1038/378716a0; Whiteside TL, 1998, CLIN CANCER RES, V4, P1135; YASUMURA S, 1993, CANCER RES, V53, P1461; Yoganathan TN, 2000, BIOCHEM PHARMACOL, V60, P1115, DOI 10.1016/S0006-2952(00)00444-5	22	166	192	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2002	21	43					6598	6605		10.1038/sj.onc.1205920	http://dx.doi.org/10.1038/sj.onc.1205920			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242657				2022-12-17	WOS:000178202300005
J	Ashcroft, M; Ludwig, RL; Woods, DB; Copeland, TD; Weber, HO; MacRae, EJ; Vousden, KH				Ashcroft, M; Ludwig, RL; Woods, DB; Copeland, TD; Weber, HO; MacRae, EJ; Vousden, KH			Phosphorylation of HDM2 by Akt	ONCOGENE			English	Article						HDM2; Akt; P53; phosphorylation	ATM-DEPENDENT PHOSPHORYLATION; NUCLEOLAR-LOCALIZATION; MDM2; P53; PROTEIN; IDENTIFICATION; ACTIVATION; INDUCTION; UBIQUITINATION; PREVENTS	The HDM2 protein is a key regulator of the tumour suppressor, p53. Control of HDM2 function is critical for normal cell proliferation and stress responses, and it is becoming evident that multiple modifications of HDM2 can regulate its function within cells. In this study we show that HDM2 associated with the serinethreonine kinase, Akt, in response to growth factor stimulation of human primary cells. This association was concurrent with phosphorylation of Akt (at Ser 473), and resulted in elevated expression of HDM2 and enhanced nuclear localization. However, analysis of HDM2 proteins mutated at the consensus Akt recognition sites at serines 166 and 186 indicated that modification at these residues was not sufficient for the increased expression of the protein, which was blocked by the PI3 kinase inhibitor LY294002. Tryptic peptide and mutational analyses revealed evidence for an Akt phosphorylation site in HDM2 additional to the two consensus sites.	NCI, FCRDC, Regulat Cell Growth Lab, Frederick, MD 21702 USA; Inst Canc Res, CRC, Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of London; Institute of Cancer Research - UK	Vousden, KH (corresponding author), NCI, FCRDC, Regulat Cell Growth Lab, Frederick, MD 21702 USA.	ashcroft@icr.ac.uk						Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 1999, ONCOGENE, V18, P4586, DOI 10.1038/sj.onc.1202814; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHENG ADY, 1995, GRAVITATION COSMOLOG, V1, P1; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Gotz C, 1999, EUR J BIOCHEM, V266, P493, DOI 10.1046/j.1432-1327.1999.00882.x; Guerra B, 1997, ONCOGENE, V14, P2683, DOI 10.1038/sj.onc.1201112; Hay TJ, 2000, FEBS LETT, V478, P183, DOI 10.1016/S0014-5793(00)01850-0; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Leri A, 1999, AM J PATHOL, V154, P567, DOI 10.1016/S0002-9440(10)65302-3; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mayo LD, 1997, CANCER RES, V57, P5013; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Zhang TT, 2001, J BIOL CHEM, V276, P29702, DOI 10.1074/jbc.M011326200; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	37	166	169	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					1955	1962		10.1038/sj.onc.1205276	http://dx.doi.org/10.1038/sj.onc.1205276			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960368				2022-12-17	WOS:000174827000002
J	Nahum, A; Hirsch, K; Danilenko, M; Watts, CKW; Prall, OWJ; Levy, J; Sharoni, Y				Nahum, A; Hirsch, K; Danilenko, M; Watts, CKW; Prall, OWJ; Levy, J; Sharoni, Y			Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes	ONCOGENE			English	Article						lycopene; breast cancer; endometrial cancer; cell cycle; cyclin D1; retinoblastoma; p27(kip1)	1,25-DIHYDROXYVITAMIN D-3; ALPHA-CAROTENE; EXPRESSION; GROWTH; DIFFERENTIATION; RETINOIDS; RISK; P21; KINASES; GENE	Numerous studies have demonstrated the anticancer activity of the tomato carotenoid, lycopene. However, the molecular mechanism of this action remains unknown. Lycopene inhibition of human breast and endometrial cancer cell growth is associated with inhibition of cell cycle progression at the G(1) phase. In this study we determined the lycopene-mediated changes in the cell cycle machinery. Cells synchronized in the G1 phase by serum deprivation were treated with lycopene or vehicle and restimulated with 5% serum. Lycopene treatment decreased serum-induced phosphorylation of the retinoblastoma protein and related pocket proteins. This effect was associated with reduced cyclin-dependent kinase (cdk4 and cdk2) activities with no alterations in CDK protein levels. Lycopene caused a decrease in cyclin D1 and D3 levels whereas cyclin E levels did not change. The CDK inhibitor p21(Cip1/Waf1) abundance was reduced while p27(Kip1) levels were unaltered in comparison to control cells. Serum stimulation of control cells resulted in reduction in the p27 content in the cyclin E-cdk2 complex and its accumulation in the cyclin D1-cdk4 complex. This change in distribution was largely prevented by lycopene treatment. These results suggest that lycopene inhibits cell cycle progression via reduction of the cyclin D level and retention of p27 in cyclin E-cdk2, thus leading to inhibition of G(1) CDK activities.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem, IL-84105 Beer Sheva, Israel; Soroka Med Ctr Kupat Holim, Beer Sheva, Israel; St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia	Ben Gurion University; Ben Gurion University; Soroka Medical Center; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Sharoni, Y (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem, POB 653, IL-84105 Beer Sheva, Israel.		SHARONI, YOAV/F-1223-2012; Danilenko, Michael/F-2283-2012	Danilenko, Michael/0000-0001-9466-6169				Amir H, 1999, NUTR CANCER, V33, P105, DOI 10.1080/01635589909514756; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; COUNTRYMAN C, 1991, Clinical Chemistry, V37, P1056; Giovannucci E, 1999, JNCI-J NATL CANCER I, V91, P317, DOI 10.1093/jnci/91.4.317; GIOVANNUCCI E, 1995, J NATL CANCER I, V87, P1767, DOI 10.1093/jnci/87.23.1767; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; JEOUNG DI, 1995, J BIOL CHEM, V270, P18367, DOI 10.1074/jbc.270.31.18367; Karas M, 2000, NUTR CANCER, V36, P101, DOI 10.1207/S15327914NC3601_14; Kim DJ, 1997, CANCER LETT, V120, P15, DOI 10.1016/S0304-3835(97)00281-4; Kobayashi T, 1996, ANTI-CANCER DRUG, V7, P195, DOI 10.1097/00001813-199602000-00008; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEVY J, 1995, NUTR CANCER, V24, P257, DOI 10.1080/01635589509514415; Liu Y, 1996, CANCER RES, V56, P31; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mantzoros CS, 1997, BRIT J CANCER, V76, P1115, DOI 10.1038/bjc.1997.520; MAZARS P, 1995, FEBS LETT, V362, P295, DOI 10.1016/0014-5793(95)00247-7; Michaud DS, 2000, AM J CLIN NUTR, V72, P990; Musgrove EA, 1998, MOL CELL BIOL, V18, P1812, DOI 10.1128/MCB.18.4.1812; NAGASAWA H, 1995, ANTICANCER RES, V15, P1173; Narisawa T, 1996, CANCER LETT, V107, P137, DOI 10.1016/0304-3835(96)04354-6; Sharoni Y, 1997, CANCER DETECT PREV, V21, P118; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SILVA MDP, 1997, MOL CELL BIOL, V17, P4059; Sweeney K J, 1996, Cancer Treat Res, V83, P141; TABIBZADEH S, 1990, IN VITRO CELL DEV B, V26, P1173; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; WANG C-J, 1989, Proceedings of the National Science Council Republic of China Part B Life Sciences, V13, P176; WANG CJ, 1989, CANCER LETT, V48, P135, DOI 10.1016/0304-3835(89)90050-5; Wang QM, 1996, CANCER RES, V56, P264; WATTS CKW, 1994, BREAST CANCER RES TR, V31, P95, DOI 10.1007/BF00689680; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhang SM, 1997, AM J CLIN NUTR, V66, P626, DOI 10.1093/ajcn/66.3.626; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142	40	166	171	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2001	20	26					3428	3436		10.1038/sj.onc.1204452	http://dx.doi.org/10.1038/sj.onc.1204452			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423993				2022-12-17	WOS:000169248800013
J	Muchardt, C; Yaniv, M				Muchardt, C; Yaniv, M			When the SWI/SNF complex remodels ... the cell cycle	ONCOGENE			English	Review						N-CoR; HDAC; cyclin A; cyclin E; G0	SWI-SNF COMPLEX; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; C-MYC; TRANSCRIPTIONAL ACTIVATION; RETINOBLASTOMA PROTEIN; DROSOPHILA-BRAHMA; GCN5 BROMODOMAIN; HIV-1 INTEGRASE; GROWTH ARREST	Mammalian cells contain several chromatin-remodeling complexes associated with the Brm and Brg1 helicase-like proteins. These complexes likely represent the functional homologs of the SWI/SNF and RSC complexes found in Saccharomyces cerevisiae. The mammalian chromatin-remodeling complexes are involved in both activation and repression of a variety of genes. Several lines of evidence also indicate that they play a specific role in the regulation of cell growth. Brm is down-regulated by ras signaling and its forced reexpression suppresses transformation by this oncogene, Besides, the Brg1 gene is silenced or mutated in several tumors cell lines and a Brg1-associated complex was recently found to co-purify with BRCA1, involved in breast and ovarian cancers, Finally, the gene encoding SNF5/Ini1, a subunit common to all mammalian SWI/SNF complexes, is inactivated in rhabdoid sarcomas, a very aggressive form of pediatric cancer, The current review will address observations made upon inactivation of Brm, Brg1 and SNF5/Ini1 by homologous recombination in the mouse, as well as the possible implication of these factors in the regulation of the Retinoblastoma pRb-mediated repression of the transcription factor E2F.	Inst Pasteur, Dept Biotechnol, CNRS, URA1644,Unite Virus Oncogenes, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite	Muchardt, C (corresponding author), Inst Pasteur, Dept Biotechnol, CNRS, URA1644,Unite Virus Oncogenes, 25 Rue Docteur Roux, F-75724 Paris 15, France.							Adler HT, 1999, MOL CELL BIOL, V19, P7050; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Cairns BR, 1999, MOL CELL, V4, P715, DOI 10.1016/S1097-2765(00)80382-2; Callebaut I, 1999, FEBS LETT, V446, P189, DOI 10.1016/S0014-5793(99)00132-5; Cao YX, 1997, MOL CELL BIOL, V17, P3323, DOI 10.1128/MCB.17.6.3323; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; DENOOIJ JC, 1995, SCIENCE, V270, P983, DOI 10.1126/science.270.5238.983; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; DINGWALL AK, 1995, MOL BIOL CELL, V6, P777, DOI 10.1091/mbc.6.7.777; Du J, 1998, GENETICS, V150, P987; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Hudson BP, 2000, J MOL BIOL, V304, P355, DOI 10.1006/jmbi.2000.4207; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kal AJ, 2000, GENE DEV, V14, P1058; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; LeGouy E, 1998, DEV DYNAM, V212, P38, DOI 10.1002/(SICI)1097-0177(199805)212:1<38::AID-AJA4>3.0.CO;2-3; Logie C, 1999, BIOCHEMISTRY-US, V38, P2514, DOI 10.1021/bi982109d; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Monteiro ANA, 2000, TRENDS BIOCHEM SCI, V25, P469, DOI 10.1016/S0968-0004(00)01632-7; Moreira JMA, 1999, EMBO J, V18, P2836, DOI 10.1093/emboj/18.10.2836; Morozov A, 1998, P NATL ACAD SCI USA, V95, P1120, DOI 10.1073/pnas.95.3.1120; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; O'Neill DW, 2000, MOL CELL BIOL, V20, P7572, DOI 10.1128/MCB.20.20.7572-7582.2000; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Papoulas O, 1998, DEVELOPMENT, V125, P3955; Parissi V, 2000, GENE, V247, P129, DOI 10.1016/S0378-1119(00)00108-6; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Staehling-Hampton K, 1999, GENETICS, V153, P275; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; SumiIchinose C, 1997, MOL CELL BIOL, V17, P5976, DOI 10.1128/MCB.17.10.5976; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Takayama M, 2000, GENES CELLS, V5, P481, DOI 10.1046/j.1365-2443.2000.00338.x; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Tsuchiya E, 1998, NUCLEIC ACIDS RES, V26, P3286, DOI 10.1093/nar/26.13.3286; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wong AKC, 2000, CANCER RES, V60, P6171; Xue YT, 2000, P NATL ACAD SCI USA, V97, P13015, DOI 10.1073/pnas.240208597; Yukawa M, 1999, GENES CELLS, V4, P99, DOI 10.1046/j.1365-2443.1999.00242.x; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	79	166	169	1	12	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3067	3075		10.1038/sj.onc.1204331	http://dx.doi.org/10.1038/sj.onc.1204331			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420722				2022-12-17	WOS:000169308500010
J	Fukuhara, S; Chikumi, H; Gutkind, JS				Fukuhara, S; Chikumi, H; Gutkind, JS			RGS-containing RhoGEFs: the missing link between transforming G proteins and Rho?	ONCOGENE			English	Article						Rho; G proteins; Ras; signal transduction; G protein-coupled receptors	GUANINE-NUCLEOTIDE EXCHANGE; VAV PROTOONCOGENE PRODUCT; HETEROTRIMERIC G-PROTEINS; CONSTITUTIVELY ACTIVATING MUTATION; SERUM RESPONSE ELEMENT; CELL-SHAPE CHANGES; COUPLED RECEPTORS; TYROSINE PHOSPHORYLATION; ALPHA-SUBUNIT; LYSOPHOSPHATIDIC ACID		Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; EN X, 2000, J CELL SCI, V113, P3673; Flower DR, 1999, BBA-REV BIOMEMBRANES, V1422, P207, DOI 10.1016/S0304-4157(99)00006-4; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Gutkind JS, 1998, CONT ENDOCRINOL, V6, P101; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hacker U, 1998, GENE DEV, V12, P274, DOI 10.1101/gad.12.2.274; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HEASLEY LE, 2001, IN PRESS ONCOGENE; Hellmich MR, 2000, J BIOL CHEM, V275, P32122, DOI 10.1074/jbc.M005754200; Hoff Ana O., 1999, Neoplasia (New York), V1, P485; Ilic D, 1996, EXP CELL RES, V222, P298, DOI 10.1006/excr.1996.0038; ILLC D, 1995, NATURE, V377, P539; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kotlar TJ, 1997, J CLIN ENDOCR METAB, V82, P1020, DOI 10.1210/jc.82.4.1020; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; LANGDON S, 1992, CANCER RES, V52, P4554; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; NICHOLAS J, 1992, NATURE, V355, P362, DOI 10.1038/355362a0; Offermanns S, 1999, N-S ARCH PHARMACOL, V360, P5, DOI 10.1007/s002109900030; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSENKILDE MM, 2001, IN PRESS ONCOGENE; SETHI T, 1992, CANCER RES, V52, pS2737; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Sodhi A, 2000, CANCER RES, V60, P4873; Spiegel AM, 1996, J CLIN ENDOCR METAB, V81, P2434, DOI 10.1210/jc.81.7.2434; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Teramoto H, 1997, J BIOL CHEM, V272, P10751; THOMAS F, 1992, CANCER RES, V52, P4872; UEDA T, 1990, J BIOL CHEM, V265, P9373; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; WILKBLASZCZAK MA, 1994, NEURON, V13, P1215, DOI 10.1016/0896-6273(94)90059-0; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; Zohn IE, 2000, ONCOGENE, V19, P3866, DOI 10.1038/sj.onc.1203731	80	166	169	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2001	20	13					1661	1668		10.1038/sj.onc.1204182	http://dx.doi.org/10.1038/sj.onc.1204182			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313914				2022-12-17	WOS:000168089800017
J	Lin, RT; Genin, P; Mamane, Y; Sgarbanti, M; Battistini, A; Harrington, WJ; Barber, GN; Hiscott, J				Lin, RT; Genin, P; Mamane, Y; Sgarbanti, M; Battistini, A; Harrington, WJ; Barber, GN; Hiscott, J			HHV-8 encoded vIRF-1 represses the interferon antiviral response by blocking IRF-3 recruitment of the CBP/p300 coactivators	ONCOGENE			English	Article						interferon; chemokines; herpes; vIRF-1; IRF-3; CBP/P300; transcription	SARCOMA-ASSOCIATED HERPESVIRUS; REGULATORY FACTOR-3; TRANSCRIPTION FACTORS; FUNCTIONAL-ANALYSIS; POSITIVE FEEDBACK; VIRUS-INFECTION; DNA-SEQUENCES; KAPPA-B; ACTIVATION; PROTEIN	Human herpes virus 8 (HHV-8) has developed unique mechanisms for altering cellular proliferative and apoptotic control pathways by incorporating viral homologs to several cellular regulatory genes into its genome. One of the, important pirated genes encoded by the ORF K9 reading frame is a viral homolog of the interferon regulatory factors (TRF), a family of cellular transcription proteins that regulates expression of genes involved in pathogen response, immune modulation and cell proliferation, vIRF-1 has been shown to downregulate the interferon- and IRF-mediated transcriptional activation of ISG and murine IFNA4 gene promoters. In this study we demonstrate that vIRF-1 efficiently inhibited virus-induced expression of endogenous interferon B, CC chemokine RANTES and CXC chemokine IP-10 genes, Go-expression analysis revealed that vIRF-1 selectively blocked IRF-3 but not IRF-7-mediated transactivation. vIRF-1 was able to bind to both IRF-3 and IRF-7 in vivo as detected by coimmunoprecipitation analysis, but did not affect IRF-3 dimerization, nuclear translocation and DNA binding activity, Rather, vIRF-1 interacted with the CBP/p300 coactivators and efficiently inhibited the formation of transcriptionally competent IRF-3-CBP/p300 complexes, These results illustrate that vIRF-1 is able to block the early stages of the IFN response to virus infection by interfering with the activation of IRF-3 responsive, immediate early IFN genes.	McGill Univ, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Immunol & Microbiol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; Ist Super Sanita, I-00161 Rome, Italy	Lady Davis Institute; McGill University; McGill University; McGill University; University of Miami; Istituto Superiore di Sanita (ISS)	Lin, RT (corresponding author), McGill Univ, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada.		BATTISTINI, ANGELA/C-2944-2016; SGARBANTI, MARCO/C-2962-2016; Lin, Rongtuan/A-1442-2008	SGARBANTI, MARCO/0000-0002-0433-5110; Lin, Rongtuan/0000-0002-2238-3503; Genin, Pierre/0000-0002-7502-3851				Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; Burysek L, 1999, J VIROL, V73, P7334; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Genin P, 2000, J IMMUNOL, V164, P5352, DOI 10.4049/jimmunol.164.10.5352; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; Jayachandra S, 1999, P NATL ACAD SCI USA, V96, P11566, DOI 10.1073/pnas.96.20.11566; Kung AL, 2000, GENE DEV, V14, P272; Li M, 2000, MOL CELL BIOL, V20, P8254, DOI 10.1128/MCB.20.21.8254-8263.2000; Li MT, 1998, J VIROL, V72, P5433, DOI 10.1128/JVI.72.7.5433-5440.1998; LIN RT, 1994, J BIOL CHEM, V269, P17542; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 2000, MOL CELL BIOL, V20, P6342, DOI 10.1128/MCB.20.17.6342-6353.2000; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Maldonado E, 1999, CELL, V99, P455, DOI 10.1016/S0092-8674(00)81533-0; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; NGUYEN H, 1995, ONCOGENE, V11, P537; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Oike Y, 1999, BLOOD, V93, P2771; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Sarid R, 1999, ADV VIRUS RES, V52, P139, DOI 10.1016/S0065-3527(08)60299-7; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Senger K, 2000, MOL CELL, V6, P931, DOI 10.1016/S1097-2765(05)00081-X; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; Vescio RA, 1999, CURR TOP MICROBIOL, V246, P403; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Zimring JC, 1998, J VIROL, V72, P701, DOI 10.1128/JVI.72.1.701-707.1998	38	166	177	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2001	20	7					800	811		10.1038/sj.onc.1204163	http://dx.doi.org/10.1038/sj.onc.1204163			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314014				2022-12-17	WOS:000166924400003
J	Forgacs, E; Biesterveld, EJ; Sekido, Y; Fong, K; Muneer, S; Wistuba, II; Milchgrub, S; Brezinschek, R; Virmani, A; Gazdar, AF; Minna, JD				Forgacs, E; Biesterveld, EJ; Sekido, Y; Fong, K; Muneer, S; Wistuba, II; Milchgrub, S; Brezinschek, R; Virmani, A; Gazdar, AF; Minna, JD			Mutation analysis of the PTEN/MMAC1 gene in lung cancer	ONCOGENE			English	Article						homozygous deletion; loss of heterozygosity; chromosome 10q23	TUMOR-SUPPRESSOR GENE; COWDEN-DISEASE; PROSTATE-CANCER; PTEN; CARCINOMAS; PHOSPHATASE; DELETIONS; FREQUENT; BREAST; IDENTIFICATION	We studied PTEN/MMAC1, a newly discovered candidate tumor suppressor gene at 10q23.3, for mutations in lung cancer. One hundred and thirty-six lung cancer cell line DNAs (66 small cell lung cancers, SCLC, 61 non-small cell lung cancers, NSCLC, four mesotheliomas, five extrapulmonary small cell cancers) were analysed for PTEN/MMAC1 homozygous deletions and five (8%) SCLC lines showed homozygous deletions interrupting the PTEN/MMAC1 gene. Using single stranded conformation polymorphism (SSCP) analysis, we screened the PTEN/MMAC1 open reading frame of 53 lung cancer cell line cDNAs for point mutations and found that 3/35 SCLCs and 3/18 NSCLCs contained homozygous amino acid sequence altering mutations. Northern blot analysis revealed that expression of the PTEN/MMAC1 gene was considerably lower in all the tumor cell lines with point mutations while no expression was detected for cell lines with PTEN/MMAC1 homozygous deletions. Mutation analysis of 22 uncultured, microdissected, primary SCLC tumors and metastases showed two silent mutations, and two apparent homozygous deletions. We also discovered a processed pseudogene (PTEN2) which has 98.5% nt identity to PTEN/MMAC1, that needs to be accounted for in cDNA mutation analysis, Our findings suggest that genetic abnormalities of the PTEN/MMAC1 gene are only involved in a relatively small subset of lung cancers.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Minna, JD (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Sekido, Yoshitaka/P-9756-2015; Muneer, Sowbiya/S-5382-2019; Fong, Kwun M/G-6369-2010	Sekido, Yoshitaka/0000-0002-2428-3848; Fong, Kwun/0000-0002-6507-1403	NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arch EM, 1997, AM J MED GENET, V71, P489, DOI 10.1002/(SICI)1096-8628(19970905)71:4<489::AID-AJMG24>3.0.CO;2-B; Bostrom J, 1998, CANCER RES, V58, P29; Dahia PLM, 1997, CANCER RES, V57, P4710; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; Frayling IM, 1997, CANCER GENET CYTOGEN, V97, P64, DOI 10.1016/S0165-4608(97)00011-3; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Guldberg P, 1997, CANCER RES, V57, P3660; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; Kawamata N, 1996, PROSTATE, V29, P191, DOI 10.1002/1097-0045(199609)29:3<191::AID-PROS2990290305>3.0.CO;2-1; LEVIN NA, 1994, CANCER RES, V54, P5086; Li DM, 1997, ENG FRACT MECH, V57, P1, DOI 10.1016/S0013-7944(97)00023-4; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Marsh DJ, 1997, CANCER RES, V57, P500; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; Rhei E, 1997, CANCER RES, V57, P3657; RIED T, 1994, CANCER RES, V54, P1801; RIED T, 1997, BRIT J CANCER, V75, P79; Sambrook J., 1982, MOL CLONING; Schwendel A, 1997, INT J CANCER, V74, P86, DOI 10.1002/(SICI)1097-0215(19970220)74:1<86::AID-IJC15>3.0.CO;2-G; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tashiro H, 1997, CANCER RES, V57, P3935; Teng DHF, 1997, CANCER RES, V57, P5221; VIRMANI A, 1998, IN PRESS GENES CHROM; Wechsler DS, 1996, GENOMICS, V32, P466, DOI 10.1006/geno.1996.0144	29	166	175	7	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1557	1565		10.1038/sj.onc.1202070	http://dx.doi.org/10.1038/sj.onc.1202070			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794233				2022-12-17	WOS:000076089900008
J	Ambartsumian, NS; Grigorian, MS; Larsen, IF; Karlstrom, O; Sidenius, N; Rygaard, J; Georgiev, G; Lukanidin, E				Ambartsumian, NS; Grigorian, MS; Larsen, IF; Karlstrom, O; Sidenius, N; Rygaard, J; Georgiev, G; Lukanidin, E			Metastasis of mammary carcinomas in GRS/A hybrid mice transgenic for the mts1 gene	ONCOGENE			English	Article						transgenic mice; mts1 gene; MMTV induced mammary carcinomas; metastasis	CALCIUM-BINDING PROTEIN; TUMOR VIRUS; NONMUSCLE MYOSIN; EXPRESSION; ONCOGENE; INDUCTION; ACTIVATION; INVASION; TISSUES; DISEASE	Transgenic mice, carrying the mts1 gene, one of the genes involved in the acquisition of the metastatic phenotype, were generated, The mts1 gene was placed under the control of the mouse mammary tumor virus (MMTV) long terminal repeat (LTR) promoter leading to overexpression in the lactating mammary gland of transgenic animals, Animals bearing the transgene appear phenotypically normal, Animals of two transgenic lines (Tg463 and Tg507) were crossed with the GRS/A mice, The GRS/A strain is characterized by high incidence of mammary tumors which rarely metastasize, 40% of the tumor bearing hybrid GRS/A mts1 females mere found to develop secondary tumors in the lungs, The Mts1 protein was detected in the transgene primary tumor cells as well as in the corresponding metastases, Nontransgenic littermates expressed the Mts1 protein only in the stromal cells surrounding the tumor but not in the tumor cells by itself, Taken together these observations indicate that overexpression of the mts1 gene in the mouse mammary carcinoma cells gives rise to more aggressive tumors which are able to metastasize.	ARMENIAN ACAD SCI, INST MOL BIOL, YEREVAN 44, ARMENIA; UNIV COPENHAGEN, DEPT MOL CELL BIOL, DK-1353 COPENHAGEN K, DENMARK; KOMMUNE HOSP COPENHAGEN, BARTHOLIN INST, DK-1399 COPENHAGEN K, DENMARK; RUSSIAN ACAD SCI, INST GENE BIOL, MOSCOW, RUSSIA	National Academy of Sciences of Armenia; Institute of Molecular Biology - NAS RA; University of Copenhagen; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences	Ambartsumian, NS (corresponding author), DANISH CANC SOC, DEPT MOL CANC BIOL, STRANDBLVD 49, DK-2100 COPENHAGEN O, DENMARK.		Sidenius, Nicolai/M-9643-2015	Sidenius, Nicolai/0000-0002-7825-7629				CARDIFF RD, 1993, CANCER SURV, V16, P97; CHOI YW, 1987, J VIROL, V61, P3013, DOI 10.1128/JVI.61.10.3013-3019.1987; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAVIES BR, 1993, ONCOGENE, V8, P999; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; FORD HL, 1995, ONCOGENE, V10, P1597; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GRIGORIAN M, 1996, IN PRESS INT J CANC; GRIGORIAN MS, 1993, GENE, V135, P229, DOI 10.1016/0378-1119(93)90070-J; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HALTER SA, 1992, AM J PATHOL, V140, P1131; Hogan B., 1986, MANIPULATING MOUSE E; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Lukanidin EM, 1996, CURR TOP MICROBIOL, V213, P171; MACDONALD NJ, 1993, CANCER SURV, V16, P175; MESTER J, 1987, J VIROL, V61, P1073, DOI 10.1128/JVI.61.4.1073-1078.1987; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NICOLSON GL, 1994, FRONT RADIAT THER ON, V28, P11; NIGAM AK, 1994, GUT, V35, P996, DOI 10.1136/gut.35.7.996; Nusse R, 1991, Curr Top Microbiol Immunol, V171, P43; ROELINK H, 1992, ONCOGENE, V7, P487; ROLLINI P, 1992, J VIROL, V66, P4580, DOI 10.1128/JVI.66.7.4580-4586.1992; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHUURING E, 1990, ONCOGENE, V5, P459; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAMP G, 1992, CELL GROWTH DIFFER, V3, P929; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; TAKENAGA K, 1994, JPN J CANCER RES, V85, P831, DOI 10.1111/j.1349-7006.1994.tb02955.x; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; VANDERVALK MA, 1981, MAMMARY TUMORS MOUSE, P46; VANNIE R, 1971, J NATL CANCER I, V46, P885; VANNIE R, 1981, MAMMARY TUMORS MOUSE, P202; VINEY JL, 1995, CANCER METAST REV, V14, P77, DOI 10.1007/BF00665792; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	38	166	168	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1621	1630						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895507				2022-12-17	WOS:A1996VM88700006
J	Matsuda, S; KawamuraTsuzuku, J; Ohsugi, M; Yoshida, M; Emi, M; Nakamura, Y; Onda, M; Yoshida, Y; Nishiyama, A; Yamamoto, T				Matsuda, S; KawamuraTsuzuku, J; Ohsugi, M; Yoshida, M; Emi, M; Nakamura, Y; Onda, M; Yoshida, Y; Nishiyama, A; Yamamoto, T			Tob, a novel protein that interacts with p185(erbB2), is associated with antiproliferative activity	ONCOGENE			English	Article						c-erbB-2; receptor tyrosine kinase; BTG1; growth suppression; chromosome 17q21	EPIDERMAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; NEU ONCOGENE; C-ERBB-2; DOMAIN; PROTOONCOGENE; PRODUCTS; CLONING; ERBB-2; BREAST	We have molecularly cloned a cDNA for a novel protein termed Tob (Transducer of ErbB-2) that interacts with the c-erbB-2 gene product p185(erbB2). Nucleotide sequencing reveals that the Tob protein is a 45 kDa protein that does not contain either SH2 (Src Homology 2) or SH3 domain but is homologous to the previously characterized anti-proliferative gene product BTG-1 at its amino-terminal half. The carboxyl-terminal half of Tob is characterized by the presence of a sequence rich in proline and glutamine and shows no homology to known proteins. Like BTG-1, exogenously expressed Tob is able to suppress growth of NIH3T3 cells, but the growth suppression is hampered by the presence of kinase-active p185(erbB2). By using the GST-Tob protein that contains either full length or amino-terminal half of Tob, we show that the carboxyl-terminal half of Tob is relevant to its interaction with p185(erbB2). Furthermore, we could co-immunoprecipitate the Tob protein with anti-ErbB-2 antibody, and reciprocally the p185(erbB2). With anti-Tob antibodies. These data suggest that p185(erbB2) negatively regulates the Tob-mediated anti-proliferative pathway through its interaction with Tob, resulting possibly in growth stimulation by p185(erbB2). Finally, expression of the Tob mRNA is observed in various cell types and is not correlated with expression of c-erbB-2, suggesting that other receptor-type protein-tyrosine kinases are also involved in the Tob-mediated regulation of cell growth.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN; UNIV TOKYO,INST MED SCI,MOLEC MED LAB,MINATO KU,TOKYO 108,JAPAN; 2ND HOSP,NIPPON MED SCH,NAKAHARA KU,KAWASAKI,KANAGAWA 211,JAPAN; HOKKAIDO UNIV,FAC SCI,SAPPORO,HOKKAIDO 060,JAPAN	University of Tokyo; University of Tokyo; Nippon Medical School; Hokkaido University				Ohsugi, Miho/0000-0003-0288-3428				AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FUJIMOTO A, 1991, BIOCHEM BIOPH RES CO, V17, P724; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTER P, 1990, SCIENCE, V247, P63; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASUKO T, 1989, JPN J CANCER RES, V80, P10, DOI 10.1111/j.1349-7006.1989.tb02237.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1993, ONCOGENE, V8, P2105; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YAMAMOTO T, 1986, NATURE, V45, P649; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YOKOTA J, 1986, LANCET, V1, P765	35	166	180	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					705	713						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632892				2022-12-17	WOS:A1996TW68600001
J	PRIGENT, SA; LEMOINE, NR; HUGHES, CM; PLOWMAN, GD; SELDEN, C; GULLICK, WJ				PRIGENT, SA; LEMOINE, NR; HUGHES, CM; PLOWMAN, GD; SELDEN, C; GULLICK, WJ			EXPRESSION OF THE C-ERBB-3 PROTEIN IN NORMAL HUMAN ADULT AND FETAL TISSUES	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; ANTIBODIES; LOCALIZATION; CELLS	c-erbB-3 is a member of the type I family of growth factor receptors which includes the epidermal growth factor (EGF) receptor and c-erhB-2. Whereas for EGF receptor and c-erbB-2 the expression patterns in normal tissues are well documented, there is currently little information available about the sites of c-erhB-3 expression. In order to examine the normal tissue distribution of c-erbB-3, polyclonal antibodies were raised against eight synthetic peptides corresponding to distinct sites on the intracellular domain of c-erbB-3. Of these, three produced antibodies which reacted with a 160-kDa protein on immunoblots of human embryonal cells (293 cells) transfected with the cDNA encoding c-erbB-3, and two of the three antibodies immunoprecipitated a protein of similar size from the same cells. These antibodies were used for immunochemical staining of a wide variety of normal human adult and fetal tissues employing formalin-fixed, paraffin-embedded material. The c-erbB-3 protein was identified in cells of the gastrointestinal, reproductive, respiratory and urinary tracts as well as the skin, endocrine and nervous system in a distribution distinctly different from that observed for EGF receptor and c-erbB-2. The level of expression of the mRNA for c-erbB-3 was also examined in extracts of a selection of fetal tissues. In general the sites of mRNA and protein expression were concordant.	HAMMERSMITH HOSP,MOLEC PATHOL LAB,ICRF,ONCOL GRP,LONDON W12 0HS,ENGLAND; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA; HAMMERSMITH HOSP,RPMS,GASTROENTEROL UNIT,LONDON W12 0HS,ENGLAND	Imperial College London; Bristol-Myers Squibb; Imperial College London	PRIGENT, SA (corresponding author), HAMMERSMITH HOSP,MOLEC ONCOL LAB,DU CANE RD,LONDON W12 0HS,ENGLAND.		PLOWMAN, Greg D/E-2012-2011	Selden, Angela/0000-0003-2648-443X				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAMJANOV I, 1986, LAB INVEST, V55, P588; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; GULLICK WJ, 1986, CANCER RES, V46, P285; GULLICK WJ, 1986, EUR J BIOCHEM, V158, P245, DOI 10.1111/j.1432-1033.1986.tb09744.x; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; GULLICK WJ, 1989, MOL BIOL CANCER, P38; GUSTERSON B, 1984, CELL BIOL INT REP, V8, P649, DOI 10.1016/0309-1651(84)90045-6; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; LEMOINE NR, 1991, BRIT J CANCER, V64, P79, DOI 10.1038/bjc.1991.243; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRESS MF, 1990, ONCOGENE, V5, P953; QUIRKE P, 1989, BRIT J CANCER, V60, P64, DOI 10.1038/bjc.1989.221; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207	21	166	176	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1273	1278						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1377811				2022-12-17	WOS:A1992HZ97100004
J	ADDISON, C; JENKINS, JR; STURZBECHER, HW				ADDISON, C; JENKINS, JR; STURZBECHER, HW			THE P53 NUCLEAR-LOCALIZATION SIGNAL IS STRUCTURALLY LINKED TO A P34CDC2 KINASE MOTIF	ONCOGENE			English	Note									MARIE CURIE CANC RES INST,CELL PROLIFERAT LAB,THE CHART,OXTED RH8 0TL,SURREY,ENGLAND									BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JENKINS JR, 1989, CANCER CELLS MOL DIA, P127; JENKINS JR, 1988, ONCOGENE HDB, P403; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; NELSON M, 1989, MOL CELL BIOL, V9, P384, DOI 10.1128/MCB.9.2.384; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RIGAUDY P, 1989, NUCLEIC ACIDS RES, V17, P8375, DOI 10.1093/nar/17.20.8375; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; ROVINSKI B, 1988, ONCOGENE, V2, P445; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; STURZBECHER HW, 1988, ONCOGENE, V3, P405; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6	30	166	167	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					423	426						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	2156209				2022-12-17	WOS:A1990CW41500022
J	Zhao, D; Pan, C; Sun, J; Gilbert, C; Drews-Elger, K; Azzam, DJ; Picon-Ruiz, M; Kim, M; Ullmer, W; El-Ashry, D; Creighton, CJ; Slingerland, JM				Zhao, D.; Pan, C.; Sun, J.; Gilbert, C.; Drews-Elger, K.; Azzam, D. J.; Picon-Ruiz, M.; Kim, M.; Ullmer, W.; El-Ashry, D.; Creighton, C. J.; Slingerland, J. M.			VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2	ONCOGENE			English	Article							ENDOTHELIAL-GROWTH-FACTOR; BREAST-CANCER; TUMOR-GROWTH; LUNG; SURVIVAL; PATHWAY; ANGIOGENESIS; METASTASIS; EXPRESSION; CAPACITY	Vascular endothelial growth factor-A (VEGF), a potent angiogenic factor, is also implicated in self-renewal in several normal tissue types. VEGF has been shown to drive malignant stem cells but mechanisms thereof and tumor types affected are not fully characterized. Here, we show VEGF promotes breast and lung cancer stem cell (CSC) self-renewal via VEGF receptor-2 (VEGFR-2)/STAT3-mediated upregulation of Myc and Sox2. VEGF increased tumor spheres and aldehyde dehydrogenase activity, both proxies for stem cell function in vitro, in triple-negative breast cancer (TNBC) lines and dissociated primary cancers, and in lung cancer lines. VEGF exposure before injection increased breast cancer-initiating cell abundance in vivo yielding increased orthotopic tumors, and increased metastasis from orthotopic primaries and following tail vein injection without further VEGF treatment. VEGF rapidly stimulated VEGFR-2/JAK2/STAT3 binding and activated STAT3 to bind MYC and SOX2 promoters and induce their expression. VEGFR-2 knockdown or inhibition abrogated VEGF-mediated STAT3 activation, MYC and SOX2 induction and sphere formation. Notably, knockdown of either STAT3, MYC or SOX2 impaired VEGF-upregulation of pSTAT3, MYC and SOX2 expression and sphere formation. Each transcription factor, once upregulated, appears to promote sustained activation of the others, creating a feed-forward loop to drive self-renewal. Thus, in addition to angiogenic effects, VEGF promotes tumor-initiating cell self-renewal through VEGFR-2/STAT3 signaling. Analysis of primary breast and lung cancers (>1300 each) showed high VEGF expression, was prognostic of poor outcome and strongly associated with STAT3 and MYC expression, supporting the link between VEGF and CSC self-renewal. High-VEGF tumors may be most likely to escape anti-angiogenics by upregulating VEGF, driving CSC self-renewal to re-populate post-treatment. Our work highlights the need to better define VEGF-driven cancer subsets and supports further investigation of combined therapeutic blockade of VEGF or VEGFR-2 and JAK2/STAT3.	[Zhao, D.; Pan, C.; Sun, J.; Gilbert, C.; Drews-Elger, K.; Azzam, D. J.; Picon-Ruiz, M.; Kim, M.; Ullmer, W.; El-Ashry, D.; Slingerland, J. M.] Univ Miami, Miller Sch Med, Braman Family Breast Canc Inst, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; [Zhao, D.; El-Ashry, D.; Slingerland, J. M.] Univ Miami, Miller Sch Med, Sheila & David Fuente Grad Program Canc Biol, Miami, FL 33136 USA; [Azzam, D. J.; Kim, M.; Slingerland, J. M.] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA; [El-Ashry, D.; Slingerland, J. M.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA; [Creighton, C. J.] Baylor Coll Med, Div Biostat, Duncan Canc Ctr, Houston, TX 77030 USA	University of Miami; University of Miami; University of Miami; University of Miami; Baylor College of Medicine	Slingerland, JM (corresponding author), Univ Miami, Miller Sch Med, Braman Family Breast Canc Inst, Sylvester Comprehens Canc Ctr, 1501 NW 10th Ave,BRB708, Miami, FL 33136 USA.	jslingerland@med.miami.edu	Ruiz, Manuel Picón/I-3624-2015; Zhao, Dekuang/H-5671-2015; Azzam, Diana/ABB-8342-2021	Ruiz, Manuel Picón/0000-0002-9427-0946; Zhao, Dekuang/0000-0002-7251-2481; Azzam, Diana/0000-0002-2605-8855; Drews-Elger, Katherine/0000-0001-9540-0610	Breast Cancer Research Foundation;  [P30 CA125123]; NATIONAL CANCER INSTITUTE [P30CA125123] Funding Source: NIH RePORTER	Breast Cancer Research Foundation; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Breast Cancer Research Foundation (JMS) and P30 CA125123 (CJC). We thank Fengju Chen for technical assistance. We also thank Dr Brekken (UT southwestern Medical Center) for providing VEGFR-2 blocking antibody 2C3.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Annovazzi L, 2011, CANCER GENOM PROTEOM, V8, P139; Assou S, 2007, STEM CELLS, V25, P961, DOI 10.1634/stemcells.2006-0352; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Bayliss J, 2007, CLIN CANCER RES, V13, P7029, DOI 10.1158/1078-0432.CCR-07-0587; Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525; Boere IA, 2010, CANCER SCI, V101, P7, DOI 10.1111/j.1349-7006.2009.01369.x; Brekken RA, 2000, CANCER RES, V60, P5117; Bromberg J, 2009, CANCER CELL, V15, P79, DOI 10.1016/j.ccr.2009.01.009; Brusselmans K, 2005, J BIOL CHEM, V280, P3493, DOI 10.1074/jbc.M406613200; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Calvo CF, 2011, GENE DEV, V25, P831, DOI 10.1101/gad.615311; Cao X, 2012, ONCOGENE, V31, P104, DOI 10.1038/onc.2011.219; Cao Y, 2007, J CLIN INVEST, V117, P2362, DOI 10.1172/JCI32239; Chatterjee S, 2013, J CLIN INVEST, V123, P1732, DOI 10.1172/JCI65385; Chung AS, 2010, NAT REV CANCER, V10, P505, DOI 10.1038/nrc2868; Conley SJ, 2012, P NATL ACAD SCI USA, V109, P2784, DOI 10.1073/pnas.1018866109; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Deasy BM, 2009, MOL THER, V17, P1788, DOI 10.1038/mt.2009.136; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Drews-Elger K, 2014, BREAST CANCER RES TR, V144, P503, DOI 10.1007/s10549-014-2887-9; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403; Feng XH, 2010, NAT REV MOL CELL BIO, V11, P466, DOI 10.1038/nrm2923; Folkins C, 2009, CANCER RES, V69, P7243, DOI 10.1158/0008-5472.CAN-09-0167; Foshay KM, 2008, STEM CELLS DEV, V17, P269, DOI 10.1089/scd.2007.0098; Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821; Gilbertson RJ, 2007, NAT REV CANCER, V7, P733, DOI 10.1038/nrc2246; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Goel HL, 2013, EMBO MOL MED, V5, P488, DOI 10.1002/emmm.201202078; Guo SC, 2010, BBA-REV CANCER, V1806, P108, DOI 10.1016/j.bbcan.2010.04.004; Hamerlik P, 2012, J EXP MED, V209, P507, DOI 10.1084/jem.20111424; Han H, 2001, ANN SURG ONCOL, V8, P72, DOI 10.1245/aso.2001.8.1.72; Heath VL, 2009, NAT REV CLIN ONCOL, V6, P395, DOI 10.1038/nrclinonc.2009.52; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Ivy SP, 2009, NAT REV CLIN ONCOL, V6, P569, DOI 10.1038/nrclinonc.2009.130; Jeter CR, 2011, ONCOGENE, V30, P3833, DOI 10.1038/onc.2011.114; Kane NM, 2011, PHARMACOL THERAPEUT, V129, P29, DOI 10.1016/j.pharmthera.2010.10.004; Kessler JD, 2012, SCIENCE, V335, P348, DOI 10.1126/science.1212728; Kidder BL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003932; Lee TH, 2003, J BIOL CHEM, V278, P5277, DOI 10.1074/jbc.M210063200; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Li LH, 2006, CANCER RES, V66, P4553, DOI 10.1158/0008-5472.CAN-05-3986; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Lichtenberger BM, 2010, CELL, V140, P268, DOI 10.1016/j.cell.2009.12.046; Liu SL, 2005, BREAST CANCER RES, V7, P86, DOI 10.1186/bcr1021; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Miller Kathy D, 2003, Clin Breast Cancer, V3, P421, DOI 10.3816/CBC.2003.n.007; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Mishra DK, 2014, INT J CANCER, V134, P789, DOI 10.1002/ijc.28428; Montero AJ, 2012, CURR ONCOL REP, V14, P1, DOI 10.1007/s11912-011-0202-z; Montero AJ, 2012, NEW ENGL J MED, V366, P374, DOI 10.1056/NEJMe1113368; Nair R, 2014, ONCOGENE, V33, P3992, DOI 10.1038/onc.2013.368; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Nourse MB, 2010, ARTERIOSCL THROM VAS, V30, P80, DOI 10.1161/ATVBAHA.109.194233; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007; Ryden L, 2005, BREAST CANCER RES TR, V89, P135, DOI 10.1007/s10549-004-1655-7; Sakariassen PO, 2006, P NATL ACAD SCI USA, V103, P16466, DOI 10.1073/pnas.0607668103; Shibuya M, 2008, BMB REP, V41, P278, DOI 10.5483/BMBRep.2008.41.4.278; Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196; Tang JM, 2011, CARDIOVASC RES, V91, P402, DOI 10.1093/cvr/cvr053; Tanno S, 2004, LUNG CANCER, V46, P11, DOI 10.1016/j.lungcan.2004.03.006; Verseijden F, 2009, TISSUE ENG PT A, V15, P445, DOI 10.1089/ten.tea.2007.0429; Xiang R, 2011, BRIT J CANCER, V104, P1410, DOI 10.1038/bjc.2011.94; Yang F, 2011, CANCER RES, V71, P5512, DOI 10.1158/0008-5472.CAN-10-2614; Yu F, 2011, ONCOGENE, V30, P2161, DOI 10.1038/onc.2010.591	73	165	179	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3107	3119		10.1038/onc.2014.257	http://dx.doi.org/10.1038/onc.2014.257			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25151964				2022-12-17	WOS:000356101100003
J	Wang, P; Chen, L; Zhang, J; Chen, H; Fan, J; Wang, K; Luo, J; Chen, Z; Meng, Z; Liu, L				Wang, P.; Chen, L.; Zhang, J.; Chen, H.; Fan, J.; Wang, K.; Luo, J.; Chen, Z.; Meng, Z.; Liu, L.			Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1	ONCOGENE			English	Article						miR-124; pancreatic cancer; methylation; prognosis; Rac1	HEPATOCELLULAR-CARCINOMA; TUMOR-SUPPRESSOR; DNA METHYLATION; MICRORNA; EXPRESSION; ADENOCARCINOMA; PATTERNS; SURVIVAL; GTPASES	Previous studies have demonstrated that microRNA (miRNA) expression is altered in human cancer. However, the molecular mechanism underlying these changes in miRNA expression remains unclear. In this study, we investigated the epigenetic modification of miR-124 genes and the potential function of miR-124 in pancreatic cancer. Using pyrosequencing analysis, we found that miR-124 genes (including miR-124-1, miR-124-2 and miR-124-3) are highly methylated in pancreatic cancer tissues compared with in non-cancerous tissues. Hypermethylation mediated the silencing of miR-124, which was a frequent event in pancreatic duct adenocarcinoma (PDAC). Furthermore, miR-124 downregulation was significantly associated with worse survival of PDAC patients. Functional studies showed that miR-124 inhibited cell proliferation, invasion and metastasis. Furthermore, we characterized Rac1 as a direct target of miR-124, and miR-124 interacted with the 3'-untranslated region of Rac1, which we showed to be a putative tumor promoter in pancreatic cancer. Thus, the miR-124-mediated downregulation of Rac1 led to the inactivation of the MKK4-JNK-c-Jun pathway. Therefore, our study demonstrates that miR-124 is a tumor suppressor miRNA that is epigenetically silenced in pancreatic cancer. Our findings suggest a previously unidentified molecular mechanism involved in the progression and metastasis of pancreatic cancer.	[Wang, P.; Chen, L.; Zhang, J.; Chen, H.; Wang, K.; Chen, Z.; Meng, Z.; Liu, L.] Fudan Univ, Shanghai Canc Ctr, Dept Integrat Oncol, Shanghai 200032, Peoples R China; [Wang, P.; Chen, L.; Zhang, J.; Chen, H.; Wang, K.; Chen, Z.; Meng, Z.; Liu, L.] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Fan, J.] Fudan Univ, Huashan Hosp, Dept Pathol, Shanghai 200032, Peoples R China; [Luo, J.] Fudan Univ, Shanghai Canc Ctr, Cent Lab, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University	Chen, Z (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Integrat Oncol, 270 Dong An Rd, Shanghai 200032, Peoples R China.	cz.chenzhen@gmail.com; mengzhq@sh163.net; llm1010@yahoo.com.cn	Meng, Zhiqiang/ABE-7747-2021	Chen, Zhen/0000-0002-4502-0801	Science Fundation of China [81001061]; Shanghai Nature Science Fund, Shanghai, China [09ZR1406800]; Doctoral Programs Foundation of Ministry of Education of China [20090071120076]; Shanghai Science and Technology Committee Rising-Star Program [11QA1401300]; Medical Talents Training Program of Health Bureau of Shanghai [XYQ2011008]; 985 research grants	Science Fundation of China; Shanghai Nature Science Fund, Shanghai, China; Doctoral Programs Foundation of Ministry of Education of China(Ministry of Education, China); Shanghai Science and Technology Committee Rising-Star Program; Medical Talents Training Program of Health Bureau of Shanghai; 985 research grants	The authors would like to thank Professor Zude Xu from Department of Pathology, Huashan Hospital, Fudan University, Shanghai for providing human pancreatic cancer samples. This study was supported by National Science Fundation of China (81001061); Shanghai Nature Science Fund, Shanghai, China (09ZR1406800); Doctoral Programs Foundation of Ministry of Education of China (20090071120076); Shanghai Science and Technology Committee Rising-Star Program (11QA1401300); and Medical Talents Training Program of Health Bureau of Shanghai (XYQ2011008) and 985 research grants.	Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219; Azuma H, 2005, JNCI-J NATL CANCER I, V97, P1734, DOI 10.1093/jnci/dji399; Bloomston M, 2007, JAMA-J AM MED ASSOC, V297, P1901, DOI 10.1001/jama.297.17.1901; Chan AY, 2005, ONCOGENE, V24, P7821, DOI 10.1038/sj.onc.1208909; Chen LL, 2010, J CLIN INVEST, V120, P1178, DOI 10.1172/JCI40665; Deprez RHL, 2002, ANAL BIOCHEM, V307, P63, DOI 10.1016/S0003-2697(02)00021-0; Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250; Greither T, 2010, INT J CANCER, V126, P73, DOI 10.1002/ijc.24687; GRIFFIN JF, 1990, CANCER, V66, P56, DOI 10.1002/1097-0142(19900701)66:1<56::AID-CNCR2820660112>3.0.CO;2-6; Grijelmo C, 2007, CELL SIGNAL, V19, P1722, DOI 10.1016/j.cellsig.2007.03.008; Hanoun N, 2010, CLIN CHEM, V56, P1107, DOI 10.1373/clinchem.2010.144709; Heid I, 2011, GASTROENTEROLOGY, V141, P719, DOI 10.1053/j.gastro.2011.04.043; Hummel R, 2010, EUR J CANCER, V46, P298, DOI 10.1016/j.ejca.2009.10.027; Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317; Jamieson NB, 2012, CLIN CANCER RES, V18, P534, DOI 10.1158/1078-0432.CCR-11-0679; Kanwal R, 2012, J APPL PHYSIOL, V109, P598; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632; Kong KL, 2012, GUT, V61, P33, DOI 10.1136/gutjnl-2011-300178; Kubo T, 2011, CLIN CANCER RES, V17, P4965, DOI 10.1158/1078-0432.CCR-10-3040; Lee KH, 2009, PANCREATOLOGY, V9, P293, DOI 10.1159/000186051; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Li XH, 2010, GUT, V59, P579, DOI 10.1136/gut.2008.175497; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Mardin W, 2009, ANN SURG ONCOL, V16, P3183, DOI 10.1245/s10434-009-0623-1; Medina PP, 2009, NAT METHODS, V6, P37, DOI 10.1038/nmeth0109-37; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Murphy JD, 2007, INT J RADIAT ONCOL, V68, P801, DOI 10.1016/j.ijrobp.2006.12.053; Nuovo GJ, 2009, NAT PROTOC, V4, P107, DOI 10.1038/nprot.2008.215; Ouyang HQ, 2011, PANCREAS, V40, P120, DOI 10.1097/MPA.0b013e3181e6e398; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Rathinam R, 2011, FRONT BIOSCI-LANDMRK, V16, P2561, DOI 10.2741/3872; Shi WD, 2009, CANCER LETT, V283, P84, DOI 10.1016/j.canlet.2009.03.030; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Su H, 2009, CANCER RES, V69, P1135, DOI 10.1158/0008-5472.CAN-08-2886; Szafranska AE, 2007, ONCOGENE, V26, P4442, DOI 10.1038/sj.onc.1210228; Takai Daiya, 2003, In Silico Biology, V3, P235; Wang P, 2009, CARCINOGENESIS, V30, P1497, DOI 10.1093/carcin/bgp154; Wilting SM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-167; Yu SL, 2008, CANCER CELL, V13, P48, DOI 10.1016/j.ccr.2007.12.008; Zhang SY, 2011, CARCINOGENESIS, V32, P1183, DOI 10.1093/carcin/bgr105; Zhang Y, 2011, CANCER RES, V71, P3552, DOI 10.1158/0008-5472.CAN-10-2435; Zhao WG, 2010, CARCINOGENESIS, V31, P1726, DOI 10.1093/carcin/bgq160; Zheng F, 2012, GUT, V61, P278, DOI 10.1136/gut.2011.239145	47	165	182	3	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					514	524		10.1038/onc.2012.598	http://dx.doi.org/10.1038/onc.2012.598			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23334332				2022-12-17	WOS:000330214600012
J	Xiang, Y; Ma, N; Wang, D; Zhang, Y; Zhou, J; Wu, G; Zhao, R; Huang, H; Wang, X; Qiao, Y; Li, F; Han, D; Wang, L; Zhang, G; Gao, X				Xiang, Y.; Ma, N.; Wang, D.; Zhang, Y.; Zhou, J.; Wu, G.; Zhao, R.; Huang, H.; Wang, X.; Qiao, Y.; Li, F.; Han, D.; Wang, L.; Zhang, G.; Gao, X.			MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine	ONCOGENE			English	Article						cisplatin resistance; microRNA; DNMT1; decitabine; ovarian cancer	DNA METHYLTRANSFERASE 1; GENE-EXPRESSION; IN-VITRO; HEPATOCELLULAR-CARCINOMA; ENDOMETRIAL CANCER; PLATINUM-RESISTANT; DRUG-RESISTANCE; BREAST-CANCER; LINES; METHYLATION	Epithelial ovarian cancer (EOC) is a highly lethal gynaecological malignancy. Cisplatin is the basal chemotherapeutic agent used to treat EOC, but resistance to cisplatin leads to chemotherapy failure. MicroRNAs are a novel class of regulators that function by controlling gene expression at the post-transcriptional level. Several recent reports have identified some microRNAs that are related to chemotherapy sensitivity. In this study, we found two microRNAs miR-152 and miR-185 that were significantly downregulated in the cisplatin-resistant ovarian cell lines SKOV3/DDP and A2780/DDP, compared with their sensitive parent line SKOV3 and A2780, respectively. Subsequently, the roles of miR-152 and miR-185 were evaluated in vitro and in vivo. The overexpression of miR-152 or miR-185 increased cisplatin sensitivity of SKOV3/DDP and A2780/DDP cells by inhibiting proliferation and promoting apoptosis, then we further confirmed that these miRNAs functioned through suppressing DNA methyltransferase 1 (DNMT1) directly. Concordantly, CD-1/CD-1 nude mice that were injected intraperitoneally with SKOV3/DDP cells transfected with miR-152 mimics exhibited upregulated cisplatin sensitivity in vivo. Interestingly, we found that there were no significant changes in the expression of these two microRNAs after treatment with decitabine (DAC), a traditional epigenetic therapeutic agent, suggesting these miRNAs represented two new regulators independent of DAC. Finally, the survival assay in A549 and HepG2 cells revealed that the two microRNAs involved in cisplatin sensitivity were related to cell types. Our results indicated that miR-152 and miR-185 were involved in ovarian cancer cisplatin resistance in vitro and in vivo by targeting DNMT1 directly. These molecules may serve as potential epigenetic therapeutic targets in other cancers.	[Xiang, Y.; Ma, N.; Wang, D.; Zhou, J.; Wu, G.; Zhao, R.; Huang, H.; Wang, X.; Qiao, Y.; Li, F.; Han, D.; Wang, L.; Gao, X.] Harbin Med Univ, Dept Biochem & Mol Biol, Harbin 150086, Peoples R China; [Zhang, Y.] Harbin Med Univ, Dept Lab Diag, Affiliated Hosp 1, Harbin 150086, Peoples R China; [Zhang, G.] Harbin Med Univ, Dept Obstet & Gynecol, Affiliated Hosp 1, Harbin 150086, Peoples R China; [Gao, X.] Minist Educ, Key Lab Cardiovasc Med Res, Harbin, Peoples R China; [Gao, X.] Harbin Med Univ, State Prov Key Labs Biomed Pharmaceut China, Harbin 150086, Peoples R China	Harbin Medical University; Harbin Medical University; Harbin Medical University; Harbin Medical University	Zhang, G (corresponding author), Harbin Med Univ, Dept Obstet & Gynecol, Affiliated Hosp 1, Harbin 150086, Peoples R China.	zhangguangmei@126.com; gaoxu_671227@yahoo.com.cn	gao, xu/U-4765-2019	Xiang, Ying/0000-0002-4879-2751	Natural Science Foundation of Heilongjiang Province for youth and for outstanding youth [QC2010002, JC201110]; Natural Science Foundation of China [81101373, 81270511, 81001033]; Science Foundation of Health Department of Heilongjiang Province [2012-525]; Science Foundation of the First Affiliated Hospital of Harbin Medical University [2009Y24]	Natural Science Foundation of Heilongjiang Province for youth and for outstanding youth; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science Foundation of Health Department of Heilongjiang Province; Science Foundation of the First Affiliated Hospital of Harbin Medical University	This work was supported by the Natural Science Foundation of Heilongjiang Province for youth (QC2010002) and for outstanding youth (JC201110), the Natural Science Foundation of China (81101373/81270511/81001033), the Science Foundation of Health Department of Heilongjiang Province(2012-525) and the Science Foundation of the First Affiliated Hospital of Harbin Medical University (2009Y24).	Akcakaya P, 2011, INT J ONCOL, V39, P311, DOI 10.3892/ijo.2011.1043; Barabas K, 2008, VET COMP ONCOL, V6, P1, DOI 10.1111/j.1476-5829.2007.00142.x; Basu A., 2010, J NUCL ACIDS, V2010; Blum KA, 2010, BRIT J HAEMATOL, V150, P189, DOI 10.1111/j.1365-2141.2010.08213.x; Blum W, 2012, BLOOD, V119, P6025, DOI 10.1182/blood-2012-03-413898; Chan TA, 2008, PLOS MED, V5, P823, DOI 10.1371/journal.pmed.0050114; Chen Huaping, 2011, Frontiers in Genetics, V2, P67, DOI 10.3389/fgene.2011.00067; Chen Y, 2010, J GASTROINTEST SURG, V14, P1170, DOI 10.1007/s11605-010-1202-2; Cho KR, 2009, ANNU REV PATHOL-MECH, V4, P287, DOI 10.1146/annurev.pathol.4.110807.092246; Fan H, 2009, WORLD J GASTROENTERO, V15, P2020, DOI 10.3748/wjg.15.2020; Fang F, 2010, CANCER-AM CANCER SOC, V116, P4043, DOI 10.1002/cncr.25204; Fu X, 2012, FEBS LETT, V586, P1279, DOI 10.1016/j.febslet.2012.03.006; Fung-Kee-Fung M, 2007, Curr Oncol, V14, P195; Glasspool RM, 2006, BRIT J CANCER, V94, P1087, DOI 10.1038/sj.bjc.6603024; Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342; Hendrickson DG, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000238; Holleman A, 2011, ONCOGENE, V30, P4386, DOI 10.1038/onc.2011.148; Huang JF, 2010, HEPATOLOGY, V52, P60, DOI 10.1002/hep.23660; Imam JS, 2010, ONCOGENE, V29, P4971, DOI 10.1038/onc.2010.233; Ishida S, 2002, P NATL ACAD SCI USA, V99, P14298, DOI 10.1073/pnas.162491399; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kantarjian HM, 2005, SEMIN HEMATOL, V42, pS17, DOI 10.1053/j.seminhematol.2005.05.006; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Kovalchuk O, 2008, MOL CANCER THER, V7, P2152, DOI 10.1158/1535-7163.MCT-08-0021; Kwon MJ, 2011, INT J MOL SCI, V12, P983, DOI 10.3390/ijms12020983; LENZI R, 1994, ANTICANCER RES, V14, P247; Li M, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-34; Liao JM, 2011, J BIOL CHEM, V286, P33901, DOI 10.1074/jbc.M111.262030; Lu JA, 2011, CANCER RES, V71, P225, DOI 10.1158/0008-5472.CAN-10-1850; Luszczek W, 2010, MOL CANCER THER, V9, P2309, DOI 10.1158/1535-7163.MCT-10-0309; Malizia AP, 2011, WIRES SYST BIOL MED, V3, P183, DOI 10.1002/wsbm.111; Matei D, 2012, CANCER RES, V72, P2197, DOI 10.1158/0008-5472.CAN-11-3909; Matei DE, 2010, GYNECOL ONCOL, V116, P195, DOI 10.1016/j.ygyno.2009.09.043; Myatt SS, 2010, CANCER RES, V70, P367, DOI 10.1158/0008-5472.CAN-09-1891; OZOLS RF, 1991, SEMIN ONCOL, V18, P222; Plumb JA, 2000, CANCER RES, V60, P6039; Qin TC, 2009, BLOOD, V113, P659, DOI 10.1182/blood-2008-02-140038; Saito Y, 2009, BIOCHEM BIOPH RES CO, V379, P726, DOI 10.1016/j.bbrc.2008.12.098; Sangodkar J, 2012, J CLIN INVEST, V122, P2637, DOI 10.1172/JCI62058; Selvakumaran M, 2003, CANCER RES, V63, P1311; Selvakumaran M, 2001, CANCER RES, V61, P1291; Singh RK, 2008, GYNECOL ONCOL, V109, P240, DOI 10.1016/j.ygyno.2008.01.042; Takahashi Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006677; Tang MQ, 2009, CURR GENOMICS, V10, P336, DOI 10.2174/138920209788920994; Tohyama K, 2012, CURR PHARM DESIGN, V18, P3190, DOI 10.2174/1381612811209023190; Tsai KW, 2011, INT J CANCER, V129, P2600, DOI 10.1002/ijc.25919; Tsuruta T, 2011, CANCER RES, V71, P6450, DOI 10.1158/0008-5472.CAN-11-0364; Yang DF, 2012, J IMMUNOL, V188, P4441, DOI 10.4049/jimmunol.1103035; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yang N, 2008, CANCER RES, V68, P10307, DOI 10.1158/0008-5472.CAN-08-1954; Yi TZ, 2012, CHEMOTHERAPY, V58, P19, DOI 10.1159/000333077; Zhang JQ, 2012, GASTROENTEROLOGY, V143, P246, DOI 10.1053/j.gastro.2012.03.045; Zhang ZP, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-124; Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200; Zhao ZW, 2012, BIOCHEM J, V444, P291, DOI 10.1042/BJ20111855; Zhou X, 2012, ONCOL REP, V27, P447, DOI 10.3892/or.2011.1482	56	165	177	1	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					378	386		10.1038/onc.2012.575	http://dx.doi.org/10.1038/onc.2012.575			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318422				2022-12-17	WOS:000330214000012
J	Zhang, Y; Wang, Z; Li, X; Magnuson, NS				Zhang, Y.; Wang, Z.; Li, X.; Magnuson, N. S.			Pim kinase-dependent inhibition of c-Myc degradation	ONCOGENE			English	Article						c-Myc; phosphorylation; Pim-1/Pim-2; stabilization	TRANSGENIC MICE; TRANSCRIPTIONAL ACTIVATION; LYMPHOID TUMORS; N-MYC; PROTOONCOGENE; PHOSPHORYLATION; LYMPHOMAGENESIS; CANCER; IDENTIFICATION; GROWTH	Pim kinases are found to be highly expressed in leukemia, lymphoma, prostate and pancreatic cancer. Bitransgenic mice overexpressing either Pim-1 or Pim-2 and c-Myc succumb to pre-B-cell lymphoma at a strikingly accelerated speed. Despite that Pim-1/Pim-2 has long been recognized as a strong synergistic partner with c-Myc in tumorigenesis, the mechanism underlying the synergism is still not well understood. Overexpression of Pim-1/Pim-2 kinase dramatically stabilizes c-Myc in vivo, and the stabilization is partially mediated by phosphorylation of c-Myc by Pim kinase on a novel site, Ser329. We provide evidence that Pim-2 is more efficient in directly phosphorylating c-Myc Ser329 to stabilize c-Myc. In contrast, we find that Pim-1 is more effective in mediating a decrease in c-Myc Thr58 phosphorylation and an increase in c-Myc Ser62 phosphorylation than in phosphorylating Ser329. In either case, through stabilizing c-Myc, Pim-1/Pim-2 kinases enhance the transcriptional activity of c-Myc. Also knocking down either Pim-1 or Pim-2 dramatically decreases the endogenous levels of c-Myc and thus, its transcriptional activity. Finally, coexpression of the Pim kinases and c-Myc enhances the transforming activity of c-Myc as does the phosphomimic mutant of c-Myc on Ser329. We conclude that these findings appear to explain at least in part the mechanism underlying the synergism between the Pim kinases and c-Myc in tumorigenesis.	[Zhang, Y.; Wang, Z.; Magnuson, N. S.] Washington State Univ, Sch Mol Biosci, Pullman, WA 99163 USA; [Li, X.] Univ Idaho, Dept Microbiol Mol Biol & Biochem, Moscow, ID 83843 USA	Washington State University; Idaho; University of Idaho	Magnuson, NS (corresponding author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99163 USA.	magnuson@wsu.edu	Zhang, Yandong/AAE-2231-2019	Zhang, Yandong/0000-0002-1900-7224	NATIONAL CANCER INSTITUTE [R01CA104470] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA104470] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen JD, 1997, ONCOGENE, V15, P1133, DOI 10.1038/sj.onc.1201288; Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; BREUER M, 1991, CANCER RES, V51, P958; Bubman D, 2007, ONCOGENE, V26, P4979, DOI 10.1038/sj.onc.1210299; Chen WW, 2005, MOL CANCER RES, V3, P443, DOI 10.1158/1541-7786.MCR-05-0007; Cowling VH, 2006, SEMIN CANCER BIOL, V16, P242, DOI 10.1016/j.semcancer.2006.08.001; CUYPERS HT, 1984, CELL, V37, P141; Dang CV, 2005, CANCER CELL, V8, P177, DOI 10.1016/j.ccr.2005.08.005; DEBOTH NJ, 1989, LEUKEMIA RES, V13, P53, DOI 10.1016/0145-2126(89)90031-3; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; FRIEDMANN M, 1992, ARCH BIOCHEM BIOPHYS, V298, P594, DOI 10.1016/0003-9861(92)90454-5; HOOVER D, 1991, J BIOL CHEM, V266, P14018; Hurlin PJ, 2006, SEMIN CANCER BIOL, V16, P265, DOI 10.1016/j.semcancer.2006.07.009; Li YY, 2006, CANCER RES, V66, P6741, DOI 10.1158/0008-5472.CAN-05-4272; Liu JY, 2007, J VIROL, V81, P10451, DOI 10.1128/JVI.00804-07; Macdonald A, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-1; Malempati S, 2006, LEUKEMIA, V20, P1572, DOI 10.1038/sj.leu.2404317; Mikkers H, 2004, MOL CELL BIOL, V24, P6104, DOI 10.1128/MCB.24.13.6104-6115.2004; MOROY T, 1991, ONCOGENE, V6, P1941; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Peng C, 2007, J BIOCHEM, V141, P353, DOI 10.1093/jb/mvm040; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Zhang YD, 2007, MOL CANCER RES, V5, P909, DOI 10.1158/1541-7786.MCR-06-0388; Zippo A, 2007, NAT CELL BIOL, V9, P932, DOI 10.1038/ncb1618	33	165	174	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2008	27	35					4809	4819		10.1038/onc.2008.123	http://dx.doi.org/10.1038/onc.2008.123			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18438430				2022-12-17	WOS:000258445100006
J	Regl, G; Neill, GW; Eichberger, T; Kasper, M; Ikram, MS; Koller, J; Hintner, H; Quinn, AG; Frischauf, AM; Aberger, F				Regl, G; Neill, GW; Eichberger, T; Kasper, M; Ikram, MS; Koller, J; Hintner, H; Quinn, AG; Frischauf, AM; Aberger, F			Human GLI2 and GLI1 are part of a positive feedback mechanism in Basal Cell Carcinoma	ONCOGENE			English	Article						Basal Cell Carcinoma; hedgehog signalling; GLI genes; cell proliferation	EXPRESSING SONIC HEDGEHOG; PATCHED SIGNALING PATHWAY; TRANSCRIPTION FACTOR; FLOOR PLATE; HUMAN HOMOLOG; HUMAN SKIN; GENE; MICE; INDUCTION; ACTIVATION	Transgenic mouse models have provided evidence that activation of the zinc-finger transcription factor GLI1 by Hedgehog (Hh)-signalling is a key step in the initiation of the tumorigenic programme leading to Basal Cell Carcinoma (BCC). However, the downstream events underlying Hh/GLI-induced BCC development are still obscure. Using in vitro model systems to analyse the effect of Hh/GLI-signalling in human keratinocytes, we identified a positive feedback mechanism involving the zinc finger transcription factors GLI1 and GLI2. Expression of GLI1 in human keratinocytes induced the transcriptional activator isoforms GL12alpha and GL12beta. Both isoforms were also shown to be expressed at elevated levels in 21 BCCs compared to normal skin. Detailed time course experiments monitoring the transcriptional response of keratinocytes either to GLI1 or to GLI2 suggest that GLI1 is a direct target of GLI2, while activation of GLI2 by GLI1 is likely to be indirect. Furthermore, expression of either GLI2 or GLI1 led to an increase in DNA-synthesis in confluent human keratinocytes. Taken together, these results suggest an important role of the positive GLI1-GLI2 feedback loop in Hh-mediated epidermal cell proliferation.	Salzburg Univ, Inst Genet, A-5020 Salzburg, Austria; Univ London Queen Mary Coll, St Bartholomews & Royal London Sch Med & Dent, Ctr Cutaneous Res, London, England; St Johann Hosp, Dept Dermatol, A-5020 Salzburg, Austria	Salzburg University; University of London; Queen Mary University London	Aberger, F (corresponding author), Salzburg Univ, Inst Genet, Hellbrunner Str 34, A-5020 Salzburg, Austria.		Neill, Graham/C-9008-2012; Aberger, Fritz/B-6357-2012; Kasper, Maria/Q-6318-2016	Aberger, Fritz/0000-0003-2009-6305; Kasper, Maria/0000-0002-6117-2717				Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Altaba ARI, 1999, TRENDS GENET, V15, P418, DOI 10.1016/S0168-9525(99)01840-5; Altaba ARI, 1998, DEVELOPMENT, V125, P2203; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Aza-Blanc P, 2000, DEVELOPMENT, V127, P4293; Bai CYB, 2001, DEVELOPMENT, V128, P5161; Bonifas JM, 2001, J INVEST DERMATOL, V116, P739, DOI 10.1046/j.1523-1747.2001.01315.x; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Dahmane N, 2001, DEVELOPMENT, V128, P5201; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Deng H, 1997, NAT BIOTECHNOL, V15, P1388, DOI 10.1038/nbt1297-1388; Ding Q, 1998, DEVELOPMENT, V125, P2533; Fan HR, 1999, J CELL BIOL, V147, P71, DOI 10.1083/jcb.147.1.71; Fan HR, 1997, NAT MED, V3, P788, DOI 10.1038/nm0797-788; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Ghali L, 1999, J INVEST DERMATOL, V113, P595, DOI 10.1046/j.1523-1747.1999.00729.x; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Green J, 1998, BRIT J DERMATOL, V139, P911; Hahn H, 1999, J MOL MED-JMM, V77, P459, DOI 10.1007/s001099900018; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Hardcastle Z, 1998, DEVELOPMENT, V125, P2803; Hynes M, 1997, NEURON, V19, P15, DOI 10.1016/S0896-6273(00)80344-X; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kinto N, 1997, FEBS LETT, V404, P319, DOI 10.1016/S0014-5793(97)00014-8; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Liu CZ, 1998, GENE, V209, P1, DOI 10.1016/S0378-1119(97)00668-9; Martin KJ, 2001, P NATL ACAD SCI USA, V98, P2646, DOI 10.1073/pnas.041622398; Matise MP, 1999, ONCOGENE, V18, P7852, DOI 10.1038/sj.onc.1203243; Matise MP, 1998, DEVELOPMENT, V125, P2759; Mo R, 1997, DEVELOPMENT, V124, P113; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; Mullor JL, 2001, CURR BIOL, V11, P769, DOI 10.1016/S0960-9822(01)00229-9; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Park HL, 2000, DEVELOPMENT, V127, P1593; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Shin SH, 1999, P NATL ACAD SCI USA, V96, P2880, DOI 10.1073/pnas.96.6.2880; Tanimura A, 1998, J VIROL, V72, P3958, DOI 10.1128/JVI.72.5.3958-3964.1998; Toftgard R, 2000, CELL MOL LIFE SCI, V57, P1720, DOI 10.1007/PL00000654; Villavicencio EH, 2000, AM J HUM GENET, V67, P1047, DOI 10.1016/S0002-9297(07)62934-6; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	48	165	171	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	2002	21	36					5529	5539		10.1038/sj.onc.1205748	http://dx.doi.org/10.1038/sj.onc.1205748			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165851				2022-12-17	WOS:000177442000002
J	Harada, K; Toyooka, S; Maitra, A; Maruyama, R; Toyooka, KO; Timmons, CF; Tomlinson, GE; Mastrangelo, D; Hay, RJ; Minna, JD; Gazdar, AF				Harada, K; Toyooka, S; Maitra, A; Maruyama, R; Toyooka, KO; Timmons, CF; Tomlinson, GE; Mastrangelo, D; Hay, RJ; Minna, JD; Gazdar, AF			Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines	ONCOGENE			English	Article						epigenetic; tumor suppressor gene; pediatric tumor	LUNG-CANCER PATIENTS; CPG ISLAND; EPIGENETIC INACTIVATION; SUPPRESSOR GENE; HUMAN NEOPLASIA; BREAST CANCERS; HYPERMETHYLATION; 3P21.3; DNA; EXPRESSION	Aberrant promoter methylation of tumor suppressor genes has not been fully investigated in pediatric tumors. Therefore, we examined the methylation status of nine genes (p16(Ink4a), MGMT, GSTP1, RASSF1A, APC, DAPK, RARbeta, CDH1 and CDH13) in 175 primary pediatric tumors and 23 tumor cell lines using methylation-specific PCR. We studied the major forms of pediatric tumors - Wilms' tumor, neuroblastoma, hepatoblastoma, medulloblastoma, rhabdomyosarcoma, osteosarcoma, Ewing's sarcoma, retinoblastoma and acute leukemia. The most frequently methylated gene in both primary tumors and cell lines was RASSF1A (40, 86%, respectively). However, the rates of RASSF1A methylation in individual tumor types varied from 0 to 88%. RASSF1A methylation was tumor specific and was absent in adjacent non-malignant tissues. Methylation of the other genes was relatively rare in tumors and nonmalignant tissues (less than 5%). Neuroblastoma patients with methylation of RASSF1A were significantly older than patients without methylation (P=0.008). There was no relationship between methylation status and other clinico-pathologic parameters. We treated six cell lines lacking RASSF1A mRNA with 5-aza-2'deoxycytidine to examine the relationship between methylation and transcriptional silencing. In five of six cell lines, restoration of RASSF1A mRNA was confirmed by RT-PCR. Our findings indicate that aberrant promoter methylation of RASSF1A may contribute to the pathogenesis of many different forms of pediatric tumors.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Childrens Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Amer Type Culture Collect, Manassas, VA 20110 USA; Univ Siena, Dept Ophthalmol, I-53100 Siena, Italy	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Siena	Gazdar, AF (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd,NB8-206, Dallas, TX 75390 USA.		Tomlinson, Gail/AAR-9776-2020		NATIONAL CANCER INSTITUTE [U01CA084971] Funding Source: NIH RePORTER; NCI NIH HHS [U01CA8497102] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Baylin SB, 1998, ADV CANCER RES, V72, P141; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Chen B, 1998, AM J PATHOL, V152, P1071; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Davidoff A M, 2001, Semin Pediatr Surg, V10, P106, DOI 10.1053/spsu.2001.24700; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 1998, CANCER RES, V58, P4515; Esteller M, 2001, CANCER RES, V61, P3225; Fruhwald MC, 2001, GENE CHROMOSOME CANC, V30, P38; Fruhwald MC, 2001, ONCOGENE, V20, P5033, DOI 10.1038/sj.onc.1204613; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Loeb LA, 2001, CANCER RES, V61, P3230; Mares J, 2001, CANCER LETT, V166, P165, DOI 10.1016/S0304-3835(01)00402-5; Maruyama R, 2001, CANCER RES, V61, P8659; Maruyama R, 2002, CLIN CANCER RES, V8, P514; Mollerup S, 1999, CANCER RES, V59, P3317; Morrissey C, 2001, CANCER RES, V61, P7277; Nakamura M, 1999, LEUKEMIA, V13, P884, DOI 10.1038/sj.leu.2401437; OhtaniFujita N, 1997, CANCER GENET CYTOGEN, V98, P43, DOI 10.1016/S0165-4608(96)00395-0; Sato M, 1998, HUM GENET, V103, P96, DOI 10.1007/s004390050790; Takita J, 2000, MED PEDIATR ONCOL, V35, P541, DOI 10.1002/1096-911X(20001201)35:6<541::AID-MPO9>3.0.CO;2-T; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Toyooka KO, 2001, CANCER RES, V61, P4556; Toyooka S, 2001, CANCER RES, V61, P5727; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Wong IHN, 2000, BLOOD, V95, P1942, DOI 10.1182/blood.V95.6.1942; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466	33	165	177	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4345	4349		10.1038/sj.onc.1205446	http://dx.doi.org/10.1038/sj.onc.1205446			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082624				2022-12-17	WOS:000176174200019
J	Hasegawa, M; Nelson, HH; Peters, E; Ringstrom, E; Posner, M; Kelsey, KT				Hasegawa, M; Nelson, HH; Peters, E; Ringstrom, E; Posner, M; Kelsey, KT			Patterns of gene promoter methylation in squamous cell cancer of the head and neck	ONCOGENE			English	Article						p16(INK4a); DAP-kinase; RASSF1A; E-Cadherin; hypermethylation; oral cancer; head and neck cancer	TUMOR-SUPPRESSOR GENE; E-CADHERIN EXPRESSION; CPG ISLAND; EPIGENETIC INACTIVATION; LUNG-CANCER; DNA HYPERMETHYLATION; BREAST CANCERS; HIGH-FREQUENCY; CARCINOMAS; RASSF1A	Promoter methylation is an important pathway in transcriptional silencing of known and candidate tumor suppressor genes in Head and Neck Squamous Cell Carcinoma (HNSCC). In order to study the association of tumor suppressor gene promoter methylation in HNSCC with patient clinical characteristics, especially alcohol consumption and tobacco smoking, we examined promoter methylation of the p16(INK4a), DAP-kinase, E-Cadherin, and RASSF1A genes using methylation-specific PCR (MSP) in 80 patients. The prevalence of p16(INK4a), DAP-kinase, E-Cadherin, and RASSF1A promoter methylation was 26/80 (32.5%), 19/80 (23.8%), 29/80 (36.3%), 6/80 (7.5%) respectively. In 48 cases (60%), at least one of these promoters was methylated. There was a significant association of methylation of any of these genes and ever smoking (P=0.006). p16(INK4a), gene promoter methylation was associated with a younger age of smoking initiation (P<0.03); E-Cadherin promoter methylation was associated with an increased number of pack years smoked (P<0.03). We also found an association of methylation of any gene and T status (OR=2.7, P<0.05). Tumors with p16(INK4a) methylation were significantly less likely to show lymph node metastasis (P<0.001). DAP-kinase promoter methylation was significantly associated with lymph node metastasis and this relationship was dependent upon p16(INK4a) promoter methylation status. Our results suggest that, in HNSCC, promoter methylation of these four genes accumulates with increasing tumor size. This may reflect distinct pathways of somatic inactivation leading to cancer; additional larger studies are needed to further investigate this possibility. Tobacco smoking may play an important role in both the occurrence of promoter methylation as well as delineating the precise pathway that eventually results in a tumorigenic phenotype.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Environm Epidemiol Program, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Dent & Oral Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Adult Oncol, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute	Kelsey, KT (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA.		Peters, Edward S/H-1077-2015; Kelsey, Karl T/I-1252-2014	Peters, Edward S/0000-0003-4928-6532; Nelson, Heather/0000-0003-1901-9513	NCI NIH HHS [CA78609] Funding Source: Medline; NIDCR NIH HHS [1P01-DE12467-05] Funding Source: Medline; NIEHS NIH HHS [ES08357, ES00002] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078609] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002, R01ES008357] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Baylin SB, 1998, ADV CANCER RES, V72, P141; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Belinsky SA, 1995, TOXICOL LETT, V82-3, P335, DOI 10.1016/0378-4274(95)03486-2; BLOT WJ, 1988, CANCER RES, V48, P3282; BRANDEIS M, 1993, BIOESSAYS, V15, P709, DOI 10.1002/bies.950151103; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Califano J, 1996, CANCER RES, V56, P2488; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Eguchi K, 1997, CANCER RES, V57, P4913; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 2001, CANCER RES, V61, P3225; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; GRAFF JR, 1995, CANCER RES, V55, P5195; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; JOST JP, 1993, P NATL ACAD SCI USA, V90, P4684, DOI 10.1073/pnas.90.10.4684; Kim DH, 2001, CANCER RES, V61, P3419; Kim DH, 2001, ONCOGENE, V20, P1765, DOI 10.1038/sj.onc.1204302; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lo KW, 2001, CANCER RES, V61, P3877; MAESTRO R, 1993, CANCER RES, V53, P5775; Morrissey C, 2001, CANCER RES, V61, P7277; Nagai MA, 1999, BRAZ J MED BIOL RES, V32, P897, DOI 10.1590/S0100-879X1999000700015; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Reed AL, 1996, CANCER RES, V56, P3630; Riese U, 1999, INT J MOL MED, V4, P61; Rosas SLB, 2001, CANCER RES, V61, P939; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; SARACCI R, 1987, EPIDEMIOL REV, V9, P175, DOI 10.1093/oxfordjournals.epirev.a036301; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPITZ MR, 1999, HEAD NECK CANC MULTI, P11; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; YARBROUGH WG, 1994, LARYNGOSCOPE, V104, P1337; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	41	165	173	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4231	4236		10.1038/sj.onc.1205528	http://dx.doi.org/10.1038/sj.onc.1205528			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082610				2022-12-17	WOS:000176174200005
J	Mitsuuchi, Y; Johnson, SW; Sonoda, G; Tanno, S; Golemis, EA; Testa, JR				Mitsuuchi, Y; Johnson, SW; Sonoda, G; Tanno, S; Golemis, EA; Testa, JR			Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase AKT2	ONCOGENE			English	Article						AKT2; serine-threonine kinase; APPL; protein interaction	PROTEIN-KINASE; CENP-E; INSULIN; ONCOGENE; CELLS; CLONING; DOMAINS; PHOSPHORYLATION; ACTIVATION; BINDING	AKT2 is a serine/threonine kinase implicated in human ovarian and pancreatic cancers, AKT2 is activated by a variety of growth factors and insulin via phosphatidylinositol 3-kinase (PI3K), However, its normal cellular role is not well understood, To gain insight into the function of AKT2, we performed yeast two-hybrid system to screen for interacting proteins. Using this technique, we identified a novel interactor, designated APPL, which contains a pleckstrin homology (PH) domain, a phosphotyrosine binding (PTB) domain and a leucine zipper, classes of motifs defined in signaling molecules as functional interaction domains with specific targets. The PH domain of APPL shows similarity to those found in GTPase-activating proteins such as oligophrenin-1 and Craf, whereas its PTB domain exhibits homology with CED-6, an adaptor protein that promotes engulfment of apoptotic cells, and IB1, a transactivator of the GLUT2 gene. APPL is highly expressed in skeletal muscle, heart, ovary and pancreas, tissues in which AKT2 mRNA is abundant. APPL interacts with the inactive form of AKT2; moreover, APPL binds to the PI3K catalytic subunit, p110 alpha. These data suggest that APPL is an adaptor that may tether inactive AKT2 to p110 alpha in the cytoplasm and thereby may expedite recruitment of AKT2 and p110 alpha to the cell membrane upon mitogenic stimulation. Furthermore, the APPL gene was mapped to human chromosome 3p14.3-p21.1, where deletions and other rearrangements have often been reported in a variety of tumor types, The identification of APPL may facilitate further analysis of the physiological and oncogenic activities of AKT2.	Fox Chase Canc Ctr, Mol Oncol Program, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Testa, JR (corresponding author), Fox Chase Canc Ctr, Mol Oncol Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.			Golemis, Erica/0000-0003-3618-3673	NATIONAL CANCER INSTITUTE [R01CA077429, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA77429, CA06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altomare DA, 1998, ONCOGENE, V16, P2407, DOI 10.1038/sj.onc.1201750; ALTOMARE DA, 1995, ONCOGENE, V11, P1055; BELL DW, 1995, CYTOGENET CELL GENET, V70, P263, DOI 10.1159/000134048; Billuart P, 1998, NATURE, V392, P923, DOI 10.1038/31940; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; BULLARD B, 1988, J MOL BIOL, V204, P621, DOI 10.1016/0022-2836(88)90360-9; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; delPeso L, 1997, SCIENCE, V278, P687; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANKES WT, 1993, BIOCHIM BIOPHYS ACTA, V1216, P479, DOI 10.1016/0167-4781(93)90018-9; Liu AX, 1998, CANCER RES, V58, P2973; Liu QA, 1998, CELL, V93, P961, DOI 10.1016/S0092-8674(00)81202-7; Mitsuuchi Y, 1998, J CELL BIOCHEM, V70, P433, DOI 10.1002/(SICI)1097-4644(19980915)70:4<433::AID-JCB1>3.0.CO;2-K; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; THROWER DA, 1995, EMBO J, V14, P918, DOI 10.1002/j.1460-2075.1995.tb07073.x; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	37	165	179	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	1999	18	35					4891	4898		10.1038/sj.onc.1203080	http://dx.doi.org/10.1038/sj.onc.1203080			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490823				2022-12-17	WOS:000082321700001
J	Villanueva, A; Garcia, C; Paules, AB; Vicente, M; Megias, M; Reyes, G; de Villalonga, P; Agell, N; Lluis, F; Bachs, O; Capella, G				Villanueva, A; Garcia, C; Paules, AB; Vicente, M; Megias, M; Reyes, G; de Villalonga, P; Agell, N; Lluis, F; Bachs, O; Capella, G			Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells	ONCOGENE			English	Article						pancreatic cancer; p15; Smad4; Smad2; TGF beta-RII; CDC25A	TUMOR-SUPPRESSOR GENE; MAD-RELATED PROTEIN; DPC4 GENE; TRANSFORMING GROWTH-FACTOR-BETA-1; RECEPTOR; ADENOCARCINOMA; MUTATIONS; CARCINOMA; DELETION; PHOSPHATASES	Resistance to TGF-beta 1 occurred in pancreatic cancer cells suggesting that inactivation of TGF-beta inhibitory signaling pathways may play an important role in human pancreatic cancer. The aim of our study was to determine the presence of alterations in the main putative components of the TGF-beta inhibitory signaling pathways (p15, Smad4, Smad2, TGF beta-RII, CDC25A). A panel of human carcinomas of the exocrine pancreas orthotopically implanted and perpetuated in nude mice and pancreatic cancer cell lines were studied. p15 gene alterations, mainly homozygous deletions that involved exons 1 and/or 2, were found in the 62.5% (5 of 8) of pancreatic xenografts whereas Smad4 gene aberrations were found in one of eight xenografts and in two of seven cell lines, Additional aberrations in these genes were acquired during in vivo perpetuation and distal dissemination. Paradoxically, TGF beta-RII overexpression and a decrease in CDC25A protein levels were found in all tumors and cell lines. In one cell line, resistance to TGF-beta 1 occurred in the absence of alterations in the genes analysed so far. We conclude that all human pancreatic tumor cells analysed herein have non-functional TGF-beta pathways. The majority of cells harbor alterations in at least one of the putative components of TGF-beta pathways, mainly in p15 and Smad4 genes. These results suggest that inactivation of TGF-beta signaling pathways plays an important role in human pancreatic tumorigenesis.	Hosp de la Santa Creu & Sant Pau, Inst Recerca, Lab Invest Gastrointestinal, Barcelona, Spain; Univ Barcelona, Fac Med, Dept Cellular Biol, Barcelona, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); University of Barcelona	Capella, G (corresponding author), Hosp de la Santa Creu & Sant Pau, Inst Recerca, Lab Invest Gastrointestinal, Barcelona, Spain.		Capella, Gabriel/I-1879-2015; Agell, Neus/E-9640-2016; Villalonga, Priam/K-4350-2014	Capella, Gabriel/0000-0002-4669-7320; Agell, Neus/0000-0002-1205-6074; Villalonga, Priam/0000-0002-7190-6884; Lluis, Felix/0000-0002-4770-0923				Akiyama Y, 1997, GASTROENTEROLOGY, V112, P33, DOI 10.1016/S0016-5085(97)70216-6; BALDWIN RL, 1993, GROWTH FACTORS, V8, P23, DOI 10.3109/08977199309029131; Barrett MT, 1996, CANCER RES, V56, P4351; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FRIESS H, 1993, CANCER RES, V53, P2704; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1996, CANCER RES, V56, P490; HAHN SA, 1995, CANCER RES, V55, P4670; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Huang LY, 1996, CANCER RES, V56, P1137; IVARAONE A, 1997, NATURE, V87, P417; JEN J, 1994, CANCER RES, V54, P6353; Kim IY, 1996, CANCER RES, V56, P44; Kim SK, 1996, CANCER RES, V56, P2519; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MATO E, 1993, J PINEAL RES, V15, P43, DOI 10.1111/j.1600-079X.1993.tb00508.x; Nagatake M, 1996, CANCER RES, V56, P2718; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; Naumann M, 1996, GASTROENTEROLOGY, V110, P1215, DOI 10.1053/gast.1996.v110.pm8613012; Reyes G, 1996, CANCER RES, V56, P5713; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Riggins GJ, 1997, CANCER RES, V57, P2578; SCARPA A, 1994, INT J CANCER, V57, P167; Schutte M, 1996, CANCER RES, V56, P2527; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Souza RF, 1997, GASTROENTEROLOGY, V112, P40, DOI 10.1016/S0016-5085(97)70217-8; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Tsubari M, 1997, CANCER RES, V57, P2966; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	41	165	173	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1969	1978		10.1038/sj.onc.1202118	http://dx.doi.org/10.1038/sj.onc.1202118			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788440				2022-12-17	WOS:000076423500010
J	Park, SH; Weinberg, RA				Park, SH; Weinberg, RA			A putative effector of Ral has homology to Rho/Rac GTPase activating proteins	ONCOGENE			English	Article						Ral; Rho GTPase activating protein; protein interactions	PLATELET GN-PROTEINS; BINDING PROTEINS; GENE-PRODUCTS; IDENTIFICATION; EXPRESSION; RHO	We report here the cloning of a gene encoding a novel Pal interacting protein (RIP1) from a cDNA expression library using radiolabeled Pal as probe, RIP1 binds to Pal in a GTP-dependent manner, The 4.1 kb transcript of the RIP1 gene is present in all tissues analysed and encodes for a protein product of 648 residues, RIP1 shares sequence similarity with GAP proteins that are capable of activating the GTPase activity of members of the Rho/Rac family of GTPases, When tested, RIP1 could activate the GTPase activity of CDC42 and, to a lesser extent, Rad but not RhoA, Pas, or Pal. Activated Pal had no direct effect on the GTPase-activating ability of RIP1, in vitro.	MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)					NCI NIH HHS [CA39826-11] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BHULLAR RP, 1990, FEBS LETT, V260, P48, DOI 10.1016/0014-5793(90)80063-O; BHULLAR RP, 1992, FEBS LETT, V298, P61, DOI 10.1016/0014-5793(92)80022-9; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; EMKEY R, 1991, J BIOL CHEM, V266, P9703; HATEBOER G, 1995, EMBO J, V14, P3159, DOI 10.1002/j.1460-2075.1995.tb07318.x; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLOFSSON B, 1988, ONCOGENE, V3, P231; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; WILDEY GM, 1993, BIOCHEM BIOPH RES CO, V194, P552, DOI 10.1006/bbrc.1993.1855	24	165	168	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2349	2355						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570186				2022-12-17	WOS:A1995TK70200019
J	CHEN, JY; FUNK, WD; WRIGHT, WE; SHAY, JW; MINNA, JD				CHEN, JY; FUNK, WD; WRIGHT, WE; SHAY, JW; MINNA, JD			HETEROGENEITY OF TRANSCRIPTIONAL ACTIVITY OF MUTANT P53 PROTEINS AND P53 DNA TARGET SEQUENCES	ONCOGENE			English	Article							WILD-TYPE P53; CELL LUNG-CANCER; TUMOR SUPPRESSOR GENE; BINDING PROTEIN; T-ANTIGEN; MUTATIONS; EXPRESSION; CYCLE; INVITRO; GROWTH	Transcriptional activity of p53 was monitored by co-transfection of pCMV expression vectors containing wild-type and mutant p53 cDNAs into the p53-null H1299 lung cancer cells along with luciferase reporter plasmids containing different p53 target sequences in the 5' regulatory region: fragment A of the ribosomal gene cluster (RGC); p53 consensus sequence (p53CON); or a tandemly linked RGC+p53CON sequence. Our results show: (1) wild-type p53 stimulates the transcription of reporter genes with p53CON and RGC in their 5' region while most p53 mutants occurring in human cancers have lost this activity; (2) the R273H mutant retains transcriptional activity for the p53CON sequence but not RGC; (3) some mutants are temperature-sensitive for the transcriptional activity with the p53CON but not the RGC sequence; (4) p53 mutants vary in their ability to inhibit wild-type p53 transactivation but there is no difference between p53CON and RGC sequences; (5) lung cancer cells with endogenous mutant p53 proteins (M246I in H23 cells and R248L in H322 cells) retain transcriptional activity for the p53CON but not the RGC sequence. We conclude that p53 DNA target sequences vary in their response to mutant p53 proteins, and that p53 mutants vary in several transactivation related functions.	UNIV TEXAS,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas	CHEN, JY (corresponding author), UNIV TEXAS,SIMMONS CANC CTR,DALLAS,TX 75235, USA.		Chen, Joanne Jeou-Yuan/S-7022-2018; Shay, Jerry W/F-7878-2011					AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BODNER SM, 1992, ONCOGENE, V7, P743; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BROWER M, 1986, CANCER RES, V46, P798; CARON DFC, 1992, GENE CHROMOSOME CANC, V4, P1; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIBA I, 1990, ONCOGENE, V5, P1603; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DAMICO D, 1992, ONCOGENE, V7, P339; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GILLESPIE PG, 1991, P NATL ACAD SCI USA, V88, P2563, DOI 10.1073/pnas.88.6.2563; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEDCALF EA, 1992, ONCOGENE, V7, P71; MERCER WE, 1990, ONCOGENE, V5, P973; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, ONCOGENE, V5, P1683; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSNER J, 1992, ONCOGENE, V7, P661; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; OROURKE RW, 1990, ONCOGENE, V5, P1829; QUINLAN DC, 1992, CANCER RES, V52, P4828; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1992, P NATL ACAD SCI USA, V89, P3952, DOI 10.1073/pnas.89.9.3952	70	165	168	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2159	2166						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336941				2022-12-17	WOS:A1993LP17100016
J	RUSSELL, SEH; HICKEY, GI; LOWRY, WS; WHITE, P; ATKINSON, RJ				RUSSELL, SEH; HICKEY, GI; LOWRY, WS; WHITE, P; ATKINSON, RJ			ALLELE LOSS FROM CHROMOSOME-17 IN OVARIAN-CANCER	ONCOGENE			English	Note									QUEENS UNIV BELFAST,SCH BIOL & BIOCHEM,BELFAST BT7 1NN,ANTRIM,NORTH IRELAND	Queens University Belfast	RUSSELL, SEH (corresponding author), QUEENS UNIV BELFAST,DEPT ONCOL,WHITLA MED BLDG,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND.							ATKIN NB, 1981, CANCER GENET CYTOGEN, V3, P275, DOI 10.1016/0165-4608(81)90095-9; BOLTZ EM, 1989, INT J CANCER, V43, P428, DOI 10.1002/ijc.2910430314; EHLEN T, 1990, ONCOGENE, V5, P219; FILMUS JE, 1985, CANCER RES, V45, P4468; LEE JH, 1989, CANCER RES, V49, P1220; LYNCH HT, 1989, OVARIAN CANCER BIOL, P7; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; VOGELSTEIN B, 1989, SCIENCE, V244, P206; WAKE N, 1980, CANCER RES, V40, P4512; WHANGPENG J, 1984, CANCER GENET CYTOGEN, V11, P91, DOI 10.1016/0165-4608(84)90102-X; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; ZHOU DJ, 1988, CANCER, V62, P1573, DOI 10.1002/1097-0142(19881015)62:8<1573::AID-CNCR2820620819>3.0.CO;2-M	13	165	166	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1990	5	10					1581	1583						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	2250914				2022-12-17	WOS:A1990EK50200019
J	Astle, MV; Hannan, KM; Ng, PY; Lee, RS; George, AJ; Hsu, AK; Haupt, Y; Hannan, RD; Pearson, RB				Astle, M. V.; Hannan, K. M.; Ng, P. Y.; Lee, R. S.; George, A. J.; Hsu, A. K.; Haupt, Y.; Hannan, R. D.; Pearson, R. B.			AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy	ONCOGENE			English	Article						PI3K; AKT; stress; senescence; p53; mTOR	ONCOGENE-INDUCED SENESCENCE; HUMAN-DIPLOID FIBROBLASTS; HEMATOPOIETIC STEM-CELLS; RAS-INDUCED SENESCENCE; RIBOSOMAL-PROTEIN L11; CELLULAR SENESCENCE; HUMAN CANCER; PREMATURE SENESCENCE; TRANSLATIONAL CONTROL; SIGNALING PATHWAY	The phosphatidylinositol 3-kinase (PI3K)/AKT and RAS oncogenic signalling modules are frequently mutated in sporadic human cancer. Although each of these pathways has been shown to play critical roles in driving tumour growth and proliferation, their activation in normal human cells can also promote cell senescence. Although the mechanisms mediating RAS-induced senescence have been well characterised, those controlling PI3K/AKT-induced senescence are poorly understood. Here we show that PI3K/AKT pathway activation in response to phosphatase and tensin homolog (PTEN) knockdown, mutant PI3K, catalytic, alpha polypeptide (PIK3CA) or activated AKT expression, promotes accumulation of p53 and p21, increases cell size and induces senescence-associated beta-galactosidase activity. We demonstrate that AKT-induced senescence is p53-dependent and is characterised by mTORC1-dependent regulation of p53 translation and stabilisation of p53 protein following nucleolar localisation and inactivation of MDM2. The underlying mechanisms of RAS and AKT-induced senescence appear to be distinct, demonstrating that different mediators of senescence may be deregulated during transformation by specific oncogenes. Unlike RAS, AKT promotes rapid proliferative arrest in the absence of a hyperproliferative phase or DNA damage, indicating that inactivation of the senescence response is critical at the early stages of PI3K/AKT-driven tumourigenesis. Furthermore, our data imply that chronic activation of AKT signalling provides selective pressure for the loss of p53 function, consistent with observations that PTEN or PIK3CA mutations are significantly associated with p53 mutation in a number of human tumour types. Importantly, the demonstration that mTORC1 is an essential mediator of AKT-induced senescence raises the possibility that targeting mTORC1 in tumours with activated PI3K/AKT signalling may exert unexpected detrimental effects due to inactivation of a senescence brake on potential cancer-initiating cells. Oncogene (2012) 31, 1949-1962; doi:10.1038/onc.2011.394; published online 12 September 2011	[Pearson, R. B.] Peter MacCallum Canc Ctr, Prot Chem Lab, Growth Control & Differentiat Program, Trescowthick Res Labs, Melbourne, Vic 8006, Australia; [George, A. J.] Univ Queensland, Sch Biomed Sci, Brisbane, Qld, Australia; [George, A. J.; Haupt, Y.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia; [Hsu, A. K.] Peter MacCallum Canc Ctr, Hematol Immunol Translat Res Lab, Trescowthick Res Labs, Melbourne, Vic 8006, Australia; [Hannan, R. D.; Pearson, R. B.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia; [Haupt, Y.; Hannan, R. D.; Pearson, R. B.] Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic, Australia	Peter Maccallum Cancer Center; University of Queensland; University of Melbourne; Peter Maccallum Cancer Center; Monash University; University of Melbourne	Pearson, RB (corresponding author), Peter MacCallum Canc Ctr, Prot Chem Lab, Growth Control & Differentiat Program, Trescowthick Res Labs, Locked Bag 1,ABeckett St, Melbourne, Vic 8006, Australia.	rick.pearson@petermac.org	Pearson, Richard Bruce/I-1451-2013	Pearson, Richard Bruce/0000-0001-5919-5090; Hannan, Katherine/0000-0003-4186-8167; George, Amee/0000-0002-0265-4476; Hannan, Ross/0000-0002-2166-4493; Haupt, Ygal/0000-0001-5925-0096	National Health and Medical Research Council (NHMRC) of Australia [166908, 251688, 509087, 400116]; Cancer Council Victoria	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria)	We acknowledge the Victorian Centre for Functional Genomics for the use of equipment and advice. This work was supported by grants from the National Health and Medical Research Council (NHMRC) of Australia to RDH (NHMRC Nos. 166908 and 251688) and to RBP (NHMRC Nos. 509087 and 400116) and from Cancer Council Victoria to RBP. RDH and RBP are NHMRC Senior Research Fellows. We thank Professor Stephen Jane and Loretta Cerruti for assistance with retrovirus production.	Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; Alimonti A, 2010, J CLIN INVEST, V120, P681, DOI 10.1172/JCI40535; Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Andjelkovic T, 2011, TRANSL RES, V157, P19, DOI 10.1016/j.trsl.2010.09.004; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Bellodi C, 2010, EMBO J, V29, P1865, DOI 10.1038/emboj.2010.83; Benanti JA, 2004, MOL CELL BIOL, V24, P2842, DOI 10.1128/MCB.24.7.2842-2852.2004; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Bhatt AP, 2010, BLOOD, V115, P4455, DOI 10.1182/blood-2009-10-251082; Brachmann S, 2009, CURR OPIN CELL BIOL, V21, P194, DOI 10.1016/j.ceb.2008.12.011; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Catasus L, 2009, MODERN PATHOL, V22, P522, DOI 10.1038/modpathol.2009.5; Chan JC, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001754; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Cristiano BE, 2006, CANCER RES, V66, P11718, DOI 10.1158/0008-5472.CAN-06-1968; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dowling RJO, 2010, BBA-PROTEINS PROTEOM, V1804, P433, DOI 10.1016/j.bbapap.2009.12.001; Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Ferbeyre G, 2000, GENE DEV, V14, P2015; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; Freund A, 2010, TRENDS MOL MED, V16, P238, DOI 10.1016/j.molmed.2010.03.003; Gewirtz DA, 2008, BIOCHEM PHARMACOL, V76, P947, DOI 10.1016/j.bcp.2008.06.024; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Gorgoulis VG, 2010, CURR OPIN CELL BIOL, V22, P816, DOI 10.1016/j.ceb.2010.07.013; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hannan KM, 2011, IUBMB LIFE, V63, P79, DOI 10.1002/iub.428; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021; Huot TJ, 2002, MOL CELL BIOL, V22, P8135, DOI 10.1128/MCB.22.23.8135-8143.2002; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Kim JS, 2007, MOL CELL BIOL, V27, P662, DOI 10.1128/MCB.00537-06; Korotchkina LG, 2010, AGING-US, V2, P344, DOI 10.18632/aging.100160; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Lee CH, 2007, EMBO J, V26, P4812, DOI 10.1038/sj.emboj.7601900; Leontieva OV, 2010, AGING, V31, P31; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Mavrakis KJ, 2008, GENE DEV, V22, P2178, DOI 10.1101/gad.1690808; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meek DW, 2003, MOL CANCER RES, V1, P1017; Miyauchi H, 2004, EMBO J, V23, P212, DOI 10.1038/sj.emboj.7600045; Moral M, 2009, CANCER RES, V69, P1099, DOI 10.1158/0008-5472.CAN-08-3240; Nardella C, 2011, NAT REV CANCER, V11, P503, DOI 10.1038/nrc3057; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Narita M, 2011, SCIENCE, V332, P966, DOI 10.1126/science.1205407; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Nosho K, 2008, NEOPLASIA, V10, P534, DOI 10.1593/neo.08336; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Oki E, 2005, CANCER LETT, V227, P33, DOI 10.1016/j.canlet.2004.12.006; Orjalo AV, 2009, P NATL ACAD SCI USA, V106, P17031, DOI 10.1073/pnas.0905299106; Ouellette MM, 1999, BIOCHEM BIOPH RES CO, V254, P795, DOI 10.1006/bbrc.1998.0114; Proud CG, 2007, BIOCHEM J, V403, P217, DOI 10.1042/BJ20070024; Puzio-Kuter AM, 2009, GENE DEV, V23, P675, DOI 10.1101/gad.1772909; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Solomon B, 2009, J THORAC ONCOL, V4, P787, DOI 10.1097/JTO.0b013e3181a74dba; Tremain R, 2000, ONCOGENE, V19, P1698, DOI 10.1038/sj.onc.1203471; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wolyniec K, 2009, ONCOGENE, V28, P2502, DOI 10.1038/onc.2009.101; Xu Z, 2011, J BIOL CHEM, V286, P21401, DOI 10.1074/jbc.M110.198630; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	95	164	171	3	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	15					1949	1962		10.1038/onc.2011.394	http://dx.doi.org/10.1038/onc.2011.394			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	926CW	21909130	Green Published, hybrid			2022-12-17	WOS:000302809900007
J	Zhu, QS; Rosenblatt, K; Huang, KL; Lahat, G; Brobey, R; Bolshakov, S; Nguyen, T; Ding, Z; Belousov, R; Bill, K; Luo, X; Lazar, A; Dicker, A; Mills, GB; Hung, MC; Lev, D				Zhu, Q-S; Rosenblatt, K.; Huang, K-L; Lahat, G.; Brobey, R.; Bolshakov, S.; Nguyen, T.; Ding, Z.; Belousov, R.; Bill, K.; Luo, X.; Lazar, A.; Dicker, A.; Mills, G. B.; Hung, M-C; Lev, D.			Vimentin is a novel AKT1 target mediating motility and invasion	ONCOGENE			English	Article						soft-tissue sarcoma; AKT1; vimentin; phosphorylation; migration/invasion	EPITHELIAL-MESENCHYMAL TRANSITION; INTERMEDIATE FILAMENT PROTEINS; SOFT-TISSUE SARCOMA; CANCER CELLS; UP-REGULATION; HUMAN BREAST; EXPRESSION; KINASE; PHOSPHORYLATION; CARCINOMA	The PI3K/AKT signaling pathway is aberrant in a wide variety of cancers. Downstream effectors of AKT are involved in survival, growth and metabolic-related pathways. In contrast, contradictory data relating to AKT effects on cell motility and invasion, crucial prometastatic processes, have been reported pointing to a potential cell type and isoform type-specific AKT-driven function. By implication, study of AKT signaling should optimally be conducted in an appropriate intracellular environment. Prognosis in soft-tissue sarcoma (STS), the aggressive malignancies of mesenchymal origin, is poor, reflecting our modest ability to control metastasis, an effort hampered by lack of insight into molecular mechanisms driving STS progression and dissemination. We examined the impact of the cancer progression-relevant AKT pathway on the mesenchymal tumor cell internal milieu. We demonstrate that AKT1 activation induces STS cell motility and invasiveness at least partially through a novel interaction with the intermediate filament vimentin (Vim). The binding of AKT (tail region) to Vim (head region) results in Vim Ser39 phosphorylation enhancing the ability of Vim to induce motility and invasion while protecting Vim from caspase-induced proteolysis. Moreover, vimentin phosphorylation was shown to enhance tumor and metastasis growth in vivo. Insights into this mesenchymal-related molecular mechanism may facilitate the development of critically lacking therapeutic options for these devastating malignancies. Oncogene (2011) 30, 457-470; doi: 10.1038/onc.2010.421; published online 20 September 2010	[Lev, D.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Zhu, Q-S; Huang, K-L; Lahat, G.; Bolshakov, S.; Nguyen, T.; Belousov, R.; Bill, K.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Ding, Z.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Luo, X.] Univ Texas Med Branch, Mass Spectrometry Core Lab, Galveston, TX USA; [Lazar, A.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Dicker, A.] Thomas Jefferson Univ, Dept Radiat Oncol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Hung, M-C] China Med Univ & Hosp, Ctr Mol Med, Taichung, Taiwan; [Hung, M-C] China Med Univ & Hosp, Grad Inst Canc Biol, Taichung, Taiwan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; UTMD Anderson Cancer Center; Jefferson University; University of Texas System; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan	Lev, D (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, 8515 Fannin,Unit 1104, Houston, TX 77030 USA.	dlev@mdanderson.org	Lazar, Alexander J/A-3416-2008; Hung, Mien-Chie/ABD-5911-2021	Lazar, Alexander J/0000-0002-6395-4499; Hung, Mien-Chie/0000-0003-4317-4740; Huang, Kai-Lieh/0000-0001-5407-648X; Dicker, Adam/0000-0003-0733-3337	NIH/NHLBI [NO1-HV-28184]; NIH [CA138345]; RTOG; Welch Foundation Endowment [L-AU-0002]; NCI Cancer Center [16672]; NIH/NCI [CA138345]; DIVISION OF HEART AND VASCULAR DISEASES [N01HV028184] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA138345] Funding Source: NIH RePORTER	NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); RTOG; Welch Foundation Endowment; NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Giranda (Abbot Laboratories, Abbott Park, IL) for providing A674563 (A563), Dr Cryns (Division of Endocrinology, Northwestern University, Chicago, IL) for providing human Vim cDNA and Dr Fletcher (Brigham and Women's Hospital, Boston, MA) for the MPNST724 cell line. We thank the UTMB NHLBI Proteomic Center for assistance with mass spectrometry experiments. (The work was supported by the NIH/NHLBI proteomics Initiative NO1-HV-28184 (to KPR).) Vu is thanked for aid in figure preparation and Lo for her assistance with scientific editing. This paper was supported in part by NIH RO1 Grant CA138345 and a RTOG seed grant (to DL). Dr Rosenblatt is a recipient of a Welch Foundation Endowment in Chemistry and Related Science Fellowship award (Grant # L-AU-0002). All experiments conducted at UT-MDACC Core Facilities were further supported by an NCI Cancer Center Support Grant (CA#16672).; This paper was supported by NIH/NCI RO1 Grant CA138345 and an RTOG seed grant (to DL), and by NIH/NHLBI proteomics Initiative grant NO1-HV-28184 (to KPR).	Ackah E, 2005, J CLIN INVEST, V115, P2119, DOI 10.1172/JCI24726; Arboleda MJ, 2003, CANCER RES, V63, P196; Bhattacharya R, 2009, J CELL SCI, V122, P1390, DOI 10.1242/jcs.043042; Bodenstine TM, 2008, CANCER MICROENVIRON, V1, P1, DOI 10.1007/s12307-008-0001-8; BROERS JLV, 1989, DIFFERENTIATION, V40, P119, DOI 10.1111/j.1432-0436.1989.tb00821.x; Byun Y, 2001, CELL DEATH DIFFER, V8, P443, DOI 10.1038/sj.cdd.4400840; Clark MA, 2005, NEW ENGL J MED, V353, P701, DOI 10.1056/NEJMra041866; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; Eckes B, 1998, J CELL SCI, V111, P1897; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Grille SJ, 2003, CANCER RES, V63, P2172; Gu YM, 2006, FEBS LETT, V580, P305, DOI 10.1016/j.febslet.2005.12.024; Hendrix MJC, 1997, AM J PATHOL, V150, P483; Hernando E, 2007, NAT MED, V13, P748, DOI 10.1038/nm1560; Hutchinson JN, 2004, CANCER RES, V64, P3171, DOI 10.1158/0008-5472.CAN-03-3465; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Ivaska J, 2005, EMBO J, V24, P3834, DOI 10.1038/sj.emboj.7600847; Ju XM, 2007, P NATL ACAD SCI USA, V104, P7438, DOI 10.1073/pnas.0605874104; Kanda S, 2004, J BIOL CHEM, V279, P4007, DOI 10.1074/jbc.M307569200; Kim MA, 2009, HISTOPATHOLOGY, V54, P442, DOI 10.1111/j.1365-2559.2009.03247.x; Liu H, 2006, P NATL ACAD SCI USA, V103, P4134, DOI 10.1073/pnas.0511342103; Luo ML, 2007, ENDOCRINOLOGY, V148, P4895, DOI 10.1210/en.2007-0049; Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782; McInroy L, 2007, BIOCHEM BIOPH RES CO, V360, P109, DOI 10.1016/j.bbrc.2007.06.036; Menet V, 2001, J NEUROSCI, V21, P6147; Miyazaki T, 2007, AM J PHYSIOL-CELL PH, V293, pC1216, DOI 10.1152/ajpcell.00083.2007; Morishima N, 1999, GENES CELLS, V4, P401, DOI 10.1046/j.1365-2443.1999.00270.x; NELSON WJ, 1983, MOL CELL BIOL, V3, P1146, DOI 10.1128/MCB.3.6.1146; Phung TL, 2006, CANCER CELL, V10, P159, DOI 10.1016/j.ccr.2006.07.003; Pittenger JT, 2008, BIOCHEMISTRY-US, V47, P10863, DOI 10.1021/bi801137m; Qi XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200; Sin WC, 1998, MOL CELL BIOL, V18, P6325, DOI 10.1128/MCB.18.11.6325; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Sumitani S, 2002, ENDOCRINOLOGY, V143, P820, DOI 10.1210/en.143.3.820; Tanno S, 2001, CANCER RES, V61, P589; Tomita Y, 2006, CLIN CANCER RES, V12, P3070, DOI 10.1158/1078-0432.CCR-05-1732; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Zhu QS, 2008, CANCER RES, V68, P2895, DOI 10.1158/0008-5472.CAN-07-6268	40	164	173	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	4					457	470		10.1038/onc.2010.421	http://dx.doi.org/10.1038/onc.2010.421			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711WH	20856200	Green Submitted, Green Accepted			2022-12-17	WOS:000286621600008
J	Lee, KH; Chen, YL; Yeh, SD; Hsiao, M; Lin, JT; Goan, YG; Lu, PJ				Lee, K-H; Chen, Y-L; Yeh, S-D; Hsiao, M.; Lin, J-T; Goan, Y-G; Lu, P-J			MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation	ONCOGENE			English	Article						miR-330; E2F1; Akt; apoptosis; prostate cancer	GASTRIC-CANCER; EXPRESSION; SURVIVAL; PATHWAY; E2F1; GENE; AGGRESSIVENESS; TRANSCRIPTION; SENSITIVITY; CARCINOMA	MicroRNAs (miRNAs) make up a novel class of gene regulators; they function as oncogenes or tumor suppressors by targeting tumor-suppressor genes or oncogenes. A recent study that analysed a large number of human cancer cell lines showed that miR-330 is a potential tumor-suppressor gene. However, the function and molecular mechanism of miR-330 in determining the aggressiveness of human prostate cancer has not been studied. Here, we show that miR-330 is significantly lower expressed in human prostate cancer cell lines than in nontumorigenic prostate epithelial cells. Bioinformatics analyses reveal a conserved target site for miR-330 in the 3'-untranslated region (UTR) of E2F1 at nucleotides 1018-1024. MiR-330 significantly suppressed the activity of a luciferase reporter containing the E2F1-3'-UTR in the cells. This activity could be abolished with the transfection of anti-miR-330 or mutated E2F1-3'-UTR. In addition, the expression level of miR-330 and E2F1 was inversely correlated in cell lines and prostate cancer specimens. After overexpressing of miR-330 in PC-3 cells, cell growth was suppressed by reducing E2F1-mediated Akt phosphorylation and thereby inducing apoptosis. Collectively, this is the first study to show that E2F1 is negatively regulated by miR-330 and also show that miR-330 induces apoptosis in prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene (2009) 28, 3360-3370; doi: 10.1038/onc.2009.192; published online 13 July 2009	[Lu, P-J] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan 704, Taiwan; [Lee, K-H] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan; [Chen, Y-L] Natl Cheng Kung Univ, Coll Med, Inst Oral Med, Tainan 70101, Taiwan; [Yeh, S-D] Taipei Med Univ, Dept Urol, Taipei, Taiwan; [Hsiao, M.] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Lin, J-T] Kaohsiung Vet Gen Hosp, Dept Surg, Div Urol Surg, Kaohsiung, Taiwan; [Goan, Y-G] Natl Yang Ming Univ, Dept Surg, Taipei 112, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Taipei Medical University; Academia Sinica - Taiwan; Kaohsiung Veterans General Hospital; National Yang Ming Chiao Tung University	Lu, PJ (corresponding author), Natl Cheng Kung Univ, Inst Clin Med, Coll Med, 138,Sheng Li Rd, Tainan 704, Taiwan.	pjlu2190@mail.ncku.edu.tw	Hsiao, Michael/U-6238-2019; Jackson, Benjamin L/C-4297-2012; Chen, Yuh-Ling/AAS-7957-2021	Hsiao, Michael/0000-0001-8529-9213; 	National Cheng Kung University Hospital [NCKUH-9701004]; National Science Council [NSC 97-2311-B-006-003-MY3, NSC-98-3112-B-006-012]	National Cheng Kung University Hospital; National Science Council(Ministry of Science and Technology, Taiwan)	We thank the grant support from National Cheng Kung University Hospital Grant (NCKUH-9701004 to P-J Lu), National Science Council (NSC 97-2311-B-006-003-MY3 to P-J Lu and NSC-98-3112-B-006-012 to Y-L Chen). We also thank Dr Chen in the Department Urology College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, for his generous gifts of Akt plasmid DNA.	ALTMAN DG, 1994, BRIT MED J, V308, P1552, DOI 10.1136/bmj.308.6943.1552; Ambros V, 2007, DEVELOPMENT, V134, P1635, DOI 10.1242/dev.002006; Ayala G, 2004, CLIN CANCER RES, V10, P6572, DOI 10.1158/1078-0432.CCR-04-0477; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Chaussepied M, 2004, MOL CELL, V16, P831, DOI 10.1016/j.molcel.2004.11.003; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davis JN, 2006, CANCER RES, V66, P11897, DOI 10.1158/0008-5472.CAN-06-2497; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698; Guo XM, 2007, CIRC RES, V101, P1113, DOI 10.1161/CIRCRESAHA.107.157644; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnson DG, 2006, CURR MOL MED, V6, P731; Jovanovic M, 2006, ONCOGENE, V25, P6176, DOI 10.1038/sj.onc.1209912; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kent OA, 2006, ONCOGENE, V25, P6188, DOI 10.1038/sj.onc.1209913; Kim R, 1999, ANTICANCER RES, V19, P1779; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Leung KW, 2009, ONCOL REP, V21, P1097, DOI 10.3892/or_00000329; Liu K, 2006, EMBO J, V25, P4795, DOI 10.1038/sj.emboj.7601355; Matos P, 2008, GASTROENTEROLOGY, V135, P899, DOI 10.1053/j.gastro.2008.05.052; Neville PJ, 2003, GENE CHROMOSOME CANC, V36, P332, DOI 10.1002/gcc.10165; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Pal P, 2007, HUM GENET, V122, P251, DOI 10.1007/s00439-007-0394-3; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Ruike Y, 2008, J HUM GENET, V53, P515, DOI 10.1007/s10038-008-0279-x; Shiau CW, 2005, CANCER RES, V65, P1561, DOI 10.1158/0008-5472.CAN-04-1677; Slager SL, 2003, AM J HUM GENET, V72, P759, DOI 10.1086/368230; Stanelle J, 2006, TRENDS MOL MED, V12, P177, DOI 10.1016/j.molmed.2006.02.002; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Thomas GV, 2004, CLIN CANCER RES, V10, P8351, DOI 10.1158/1078-0432.CCR-04-0130; Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200; Tyagi A, 2003, ONCOGENE, V22, P1302, DOI 10.1038/sj.onc.1206265; Uney JB, 2006, P NATL ACAD SCI USA, V103, P15278, DOI 10.1073/pnas.0607655103; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	43	164	178	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2009	28	38					3360	3370		10.1038/onc.2009.192	http://dx.doi.org/10.1038/onc.2009.192			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	497ZD	19597470				2022-12-17	WOS:000270103300003
J	Smalley, KSM; Xiao, M; Villanueva, J; Nguyen, TK; Flaherty, KT; Letrero, R; Van Belle, P; Elder, DE; Wang, Y; Nathanson, KL; Herlyn, M				Smalley, K. S. M.; Xiao, M.; Villanueva, J.; Nguyen, T. K.; Flaherty, K. T.; Letrero, R.; Van Belle, P.; Elder, D. E.; Wang, Y.; Nathanson, K. L.; Herlyn, M.			CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations	ONCOGENE			English	Article						melanoma; BRAF; CRAF; targeted therapy; sorafenib	MALIGNANT-MELANOMA; KINASE-KINASE; B-RAF; ERK; SURVIVAL; PROTEIN; PHOSPHORYLATION; SUPPRESSION; EXPRESSION; SORAFENIB	Here, we identify a panel of melanoma lines with non-V600E mutations in BRAF. These G469E- and D594G-mutated melanomas were found to exhibit constitutive levels of phospho-extracellular signal-regulated kinase (pERK) and low levels of phospho-mitogen-activated protein kinase/ERKkinase (pMEK) and were resistant to MEK inhibition. Upon treatment with the CRAF inhibitor sorafenib, these lines underwent apoptosis and associated with mitochondrial depolarization and relocalization of apoptosis-inducing factor, whereas the BRAF-V600-Emutated melanomas did not. Studies have shown low-activity mutants of BRAF (G469E/D594G) instead signal through CRAF. Unlike BRAF, CRAF directly regulates apoptosis through mitochondrial localization where it binds to Bcl-2 and phosphorylates BAD. The CRAF inhibitor sorafenib was found to induce a time-dependent reduction in both BAD phosphorylation and Bcl-2 expression in the D594G/G469E lines only. Knockdown of CRAF using a lentiviral shRNA suppressed both Bcl-2 expression and induced apoptosis in the D594G melanoma line but not in a V600E-mutated line. Finally, we showed in a series of xenograft studies that sorafenib was more potent at reducing the growth of tumors with the D594G mutation than those with the V600E mutation. In summary, we have identified a group of melanomas with low-activity BRAF mutations that are reliant upon CRAF-mediated survival activity.	[Smalley, K. S. M.; Xiao, M.; Villanueva, J.; Nguyen, T. K.; Herlyn, M.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; [Flaherty, K. T.] Univ Penn, Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; [Letrero, R.; Nathanson, K. L.] Univ Penn, Sch Med, Div Med Genet, Philadelphia, PA 19104 USA; [Van Belle, P.; Elder, D. E.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Wang, Y.] Univ Penn, Sch Med, Dept Otorhinolaryngol, Philadelphia, PA 19104 USA; [Flaherty, K. T.; Nathanson, K. L.] Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Smalley, KSM (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	k.smalley@mac.com; herlynm@wistar.org	Smalley, Keiran S/A-1320-2007	Smalley, Keiran S/0000-0002-4121-8335; Nathanson, Katherine/0000-0002-6740-0901; Smalley, Keiran/0000-0003-1089-9307	Bayer Corporation [BAY 43-9006]; NATIONAL CANCER INSTITUTE [R01CA080999, R01CA047159, R01CA076674, P01CA114046, P50CA093372, P01CA025874] Funding Source: NIH RePORTER	Bayer Corporation(Bayer AG); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Bayer Corporation for providing the BAY 43-9006 (sorafenib).	Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhomen N, 2007, CURR OPIN GENET DEV, V17, P31, DOI 10.1016/j.gde.2006.12.005; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Eisen T, 2006, BRIT J CANCER, V95, P581, DOI 10.1038/sj.bjc.6603291; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Haass NK, 2008, CLIN CANCER RES, V14, P230, DOI 10.1158/1078-0432.CCR-07-1440; Houben R, 2008, J INVEST DERMATOL, V128, P2003, DOI 10.1038/jid.2008.30; Jin SH, 2005, J BIOL CHEM, V280, P24698, DOI 10.1074/jbc.M413374200; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; O'Neill E, 2004, SCIENCE, V306, P2267, DOI 10.1126/science.1103233; Panka DJ, 2006, CANCER RES, V66, P1611, DOI 10.1158/0008-5472.CAN-05-0808; Rapp UR, 2004, BBA-MOL CELL RES, V1644, P149, DOI 10.1016/j.bbamcr.2003.10.015; Smalley KM, 2007, BRIT J CANCER, V96, P445, DOI 10.1038/sj.bjc.6603596; Smalley KSM, 2007, CANCER RES, V67, P209, DOI 10.1158/0008-5472.CAN-06-1538; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Smalley KSM, 2006, MOL CANCER THER, V5, P1136, DOI 10.1158/1535-7163.MCT-06-0084; Smalley KSM, 2005, AM J PATHOL, V166, P1541, DOI 10.1016/S0002-9440(10)62370-X; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Spittle C, 2007, J MOL DIAGN, V9, P464, DOI 10.2353/jmoldx.2007.060191; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	27	164	173	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2009	28	1					85	94		10.1038/onc.2008.362	http://dx.doi.org/10.1038/onc.2008.362			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18794803	Green Accepted			2022-12-17	WOS:000262294100009
J	Obsil, T; Obsilova, V				Obsil, T.; Obsilova, V.			Structure/function relationships underlying regulation of FOXO transcription factors	ONCOGENE			English	Review						FOXO; forkhead transcription factors; 14-3-3 protein; phosphorylation; acetylation; ubiquitination	PROTEIN-KINASE-B; WINGED HELIX PROTEINS; DNA-BINDING DOMAIN; INSULIN-RESPONSE SEQUENCE; FORKHEAD GENE FAMILY; EXTENDS LIFE-SPAN; FACTOR AFX FOXO4; CRYSTAL-STRUCTURE; CAENORHABDITIS-ELEGANS; NUCLEAR-LOCALIZATION	The FOXO subgroup of forkhead transcription factors plays a central role in cell-cycle control, differentiation, metabolism control, stress response and apoptosis. Therefore, the function of these important molecules is tightly controlled by a wide range of protein-protein interactions and posttranslational modifications including phosphorylation, acetylation and ubiquitination. The mechanisms by which these processes regulate FOXO activity are mostly elusive. This review focuses on recent advances in structural studies of forkhead transcription factors and the insights they provide into the mechanism of DNA recognition. On the basis of these data, we discuss structural aspects of protein-protein interactions and posttranslational modi. cations that target the forkhead domain and the nuclear localization signal of FOXO proteins.	[Obsil, T.] Charles Univ Prague, Fac Sci, Dept Phys & Macromol Chem, Prague 12843, Czech Republic; [Obsil, T.; Obsilova, V.] Acad Sci Czech Republ, Inst Physiol, Prague, Czech Republic	Charles University Prague; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences	Obsil, T (corresponding author), Charles Univ Prague, Fac Sci, Dept Phys & Macromol Chem, Prague 12843, Czech Republic.	obsil@natur.cuni.cz	Obsil, Tomas/B-7142-2012; Obsilova, Veronika/B-7116-2012	Obsil, Tomas/0000-0003-4602-1272; Obsilova, Veronika/0000-0003-4887-0323				AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; Aitken A, 2006, SEMIN CANCER BIOL, V16, P162, DOI 10.1016/j.semcancer.2006.03.005; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Asada S, 2007, CELL SIGNAL, V19, P519, DOI 10.1016/j.cellsig.2006.08.015; Berdichevsky A, 2006, CELL, V125, P1165, DOI 10.1016/j.cell.2006.04.036; Biggs WH, 2001, MAMM GENOME, V12, P416, DOI 10.1007/s003350020002; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Bois PRJ, 2005, MOL CELL BIOL, V25, P7645, DOI 10.1128/MCB.25.17.7645-7656.2005; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Boura E, 2007, J BIOL CHEM, V282, P8265, DOI 10.1074/jbc.M605682200; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; DAVIS RJ, 1994, CANCER RES, V54, P2869; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Frescas D, 2005, J BIOL CHEM, V280, P20589, DOI 10.1074/jbc.M412357200; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fukuoka M, 2003, INT J MOL MED, V12, P503; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Huang HJ, 2006, SCIENCE, V314, P294, DOI 10.1126/science.1130512; Jin CW, 1999, J MOL BIOL, V292, P641, DOI 10.1006/jmbi.1999.3106; Kaestner KH, 2000, GENE DEV, V14, P142; KAUFMANN E, 1995, J MOL BIOL, V248, P239, DOI 10.1006/jmbi.1995.0218; Kobayashi Y, 2005, INT J MOL MED, V16, P237; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; Lehmann OJ, 2003, TRENDS GENET, V19, P339, DOI 10.1016/S0168-9525(03)00111-2; Lehtinen MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu PP, 2002, PROTEINS, V49, P543, DOI 10.1002/prot.10227; Marsden I, 1998, J MOL BIOL, V278, P293, DOI 10.1006/jmbi.1998.1703; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102; Mazet F, 2003, GENE, V316, P79, DOI 10.1016/S0378-1119(03)00741-8; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Obsil T, 2003, BIOCHEMISTRY-US, V42, P15264, DOI 10.1021/bi0352724; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Obsilova V, 2005, BIOCHEMISTRY-US, V44, P11608, DOI 10.1021/bi050618r; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Oh SW, 2005, P NATL ACAD SCI USA, V102, P4494, DOI 10.1073/pnas.0500749102; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Seimiya H, 2000, EMBO J, V19, P2652, DOI 10.1093/emboj/19.11.2652; Sheng WY, 2002, BIOCHEMISTRY-US, V41, P3286, DOI 10.1021/bi011908k; Shiyanova T, 1999, ARCH BIOCHEM BIOPHYS, V362, P356, DOI 10.1006/abbi.1998.1040; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; Stroud JC, 2006, STRUCTURE, V14, P159, DOI 10.1016/j.str.2005.10.005; Sunayama J, 2005, J CELL BIOL, V170, P295, DOI 10.1083/jcb.200409117; Sutton J, 1996, J BIOL CHEM, V271, P23126, DOI 10.1074/jbc.271.38.23126; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tran Hien, 2003, Sci STKE, V2003, pRE5, DOI 10.1126/stke.2003.172.re5; Tsai KL, 2007, NUCLEIC ACIDS RES, V35, P6984, DOI 10.1093/nar/gkm703; Tsai KL, 2006, J BIOL CHEM, V281, P17400, DOI 10.1074/jbc.M600478200; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Van der Heide LP, 2005, BIOCHEM J, V391, P623, DOI 10.1042/BJ20050525; van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167; Van der Hoeven PCJ, 2000, BIOCHEM J, V345, P297, DOI 10.1042/0264-6021:3450297; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469; van Dongen MJP, 2000, J MOL BIOL, V296, P351, DOI 10.1006/jmbi.1999.3476; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Vogt PK, 2005, CELL CYCLE, V4, P908, DOI 10.4161/cc.4.7.1796; Wang MC, 2005, CELL, V121, P115, DOI 10.1016/j.cell.2005.02.030; Wang Y, 2006, MECH AGEING DEV, V127, P741, DOI 10.1016/j.mad.2006.05.005; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; Weigelt J, 2001, BIOCHEMISTRY-US, V40, P5861, DOI 10.1021/bi001663w; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhang SS, 1999, J BIOL CHEM, V274, P24865, DOI 10.1074/jbc.274.35.24865; Zhang XH, 2002, J BIOL CHEM, V277, P45276, DOI 10.1074/jbc.M208063200; Zhao XS, 2004, BIOCHEM J, V378, P839, DOI 10.1042/BJ20031450; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	109	164	175	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2008	27	16					2263	2275		10.1038/onc.2008.20	http://dx.doi.org/10.1038/onc.2008.20			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	285NE	18391969	Bronze			2022-12-17	WOS:000254782700002
J	Jackson-Bernitsas, DG; Ichikawa, H; Takada, Y; Myers, JN; Lin, XL; Darnay, BG; Chaturvedi, MM; Aggarwal, BB				Jackson-Bernitsas, D. G.; Ichikawa, H.; Takada, Y.; Myers, J. N.; Lin, X. L.; Darnay, B. G.; Chaturvedi, M. M.; Aggarwal, B. B.			Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappa B activation and proliferation in human head and neck squamous cell carcinoma	ONCOGENE			English	Article						head and neck squamous cell carcinoma; nuclear factor-kappa B; tumor necrosis factor; proliferation	TUMOR-NECROSIS-FACTOR; GENE-EXPRESSION; FACTOR-RECEPTOR; GROWTH-FACTOR; ALPHA; TNF; APOPTOSIS; REQUIRES; CURCUMIN; SURVIVAL	Constitutively activated nuclear factor-kappa B (NF-kappa B) has been associated with a variety of aggressive tumor types, including head and neck squamous cell carcinoma (HNSCC); however, the mechanism of its activation is not fully understood. Therefore, we investigated the molecular pathway that mediates constitutive activation of NF-kappa B in a series of HNSCC cell lines. We confirmed that NF-kappa B was constitutively active in all HNSCC cell lines (FaDu, LICR-LON-HN5 and SCC4) examined as indicated by DNA binding, immunocytochemical localization of p65, by NF-kappa B-dependent reporter gene expression and its inhibition by dominant-negative (DN)-inhibitory subunit of NF-kappa B (I kappa B alpha), the natural inhibitor of NF-kappa B. Constitutive NF-kappa B activation in HNSCC was found to be due to constitutive activation of IjBa kinase (IKK); and this correlated with constitutive expression of phosphorylated forms of I kappa B alpha and p65 proteins. All HNSCC showed the expression of p50, p52, p100 and receptor-interacting protein; all linked with NF-kappa B activation. The expression of constitutively active NF-kappa B in HNSCC is mediated through the tumor necrosis factor (TNF) signaling pathway, as NF-kappa B reporter activity was inhibited by DN-TNF receptor-associated death domain ( TRADD), DN-TNF receptor-associated factor ( TRAF) 2, DN-receptor-interacting protein ( RIP), DN-transforming growth factor-beta-activated kinase 1 (TAK1), DN-kappa-Ras, DN-AKT and DN-IKK but not by DN-TRAF5 or DN-TRAF6. Constitutive NF-kappa B activation was also associated with the autocrine expression of TNF, TNF receptors and receptor-activator of NF-kappa B and its ligand in HNSCC cells but not interleukin (IL)-1 beta. All HNSCC cell lines expressed IL-6, a NF-kappa B-regulated gene product. Furthermore, treatment of HNSCC cells with anti-TNF antibody downregulated constitutively active NF-kappa B, and this was associated with inhibition of IL-6 expression and cell proliferation. Our results clearly demonstrate that constitutive activation of NF-kappa B is mediated through the TRADD-TRAF2-RIP-TAK1-IKK pathway, making TNF a novel target in the treatment of head and neck cancer.	Univ Texas, MD Anderson Canc Ctr, Cytokine Res Lab, Dept Expt Therapeut,Unit 143, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Cytokine Res Lab, Dept Expt Therapeut,Unit 143, 1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013		NCI NIH HHS [P01CA91844] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA091844] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 1996, CANCER RES, V56, P5156; Aggarwal BB, 2006, E SCHERING RES FDN W, V56, P161; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Aggarwal S, 2004, INT J CANCER, V111, P679, DOI 10.1002/ijc.20333; Bancroft CC, 2002, INT J CANCER, V99, P538, DOI 10.1002/ijc.10398; Blonska M, 2005, J BIOL CHEM, V280, P43056, DOI 10.1074/jbc.M507807200; Buchholz TA, 2005, CLIN CANCER RES, V11, P8398, DOI 10.1158/1078-0432.CCR-05-0885; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Dong G, 2001, CANCER RES, V61, P4797; Duffey DC, 1999, CANCER RES, V59, P3468; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; ESTROV Z, 1993, J EXP MED, V177, P763, DOI 10.1084/jem.177.3.763; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Izzo JG, 2006, J CLIN ONCOL, V24, P748, DOI 10.1200/JCO.2005.03.8810; Li HX, 2006, J BIOL CHEM, V281, P13636, DOI 10.1074/jbc.M600620200; Li QT, 2000, GENE DEV, V14, P1729; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Loercher A, 2004, CANCER RES, V64, P6511, DOI 10.1158/0008-5472.CAN-04-0852; LoTempio MM, 2005, CLIN CANCER RES, V11, P6994, DOI 10.1158/1078-0432.CCR-05-0301; Majumdar S, 2002, J IMMUNOL, V168, P2644, DOI 10.4049/jimmunol.168.6.2644; Manna SK, 2000, J IMMUNOL, V165, P4927, DOI 10.4049/jimmunol.165.9.4927; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Ondrey FG, 1999, MOL CARCINOGEN, V26, P119, DOI 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N; Ozes ON, 1999, NATURE, V401, P82; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Shishodia S, 2004, BIOCHEM PHARMACOL, V68, P1071, DOI 10.1016/j.bcp.2004.04.026; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Thomas GR, 2004, CANCER IMMUNOL IMMUN, V53, P33, DOI 10.1007/s00262-003-0433-4; Wang YF, 2002, HEAD NECK-J SCI SPEC, V24, P850, DOI 10.1002/hed.10145; Wolf JS, 2001, CLIN CANCER RES, V7, P1812; Woods KV, 1998, CANCER RES, V58, P3142	39	164	171	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1385	1397		10.1038/sj.onc.1209945	http://dx.doi.org/10.1038/sj.onc.1209945			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16953224				2022-12-17	WOS:000244558800003
J	Koturbash, I; Rugo, RE; Hendricks, CA; Loree, J; Thibault, B; Kutanzi, K; Pogribny, I; Yanch, JC; Engelward, BP; Kovalchuk, O				Koturbash, I.; Rugo, R. E.; Hendricks, C. A.; Loree, J.; Thibault, B.; Kutanzi, K.; Pogribny, I.; Yanch, J. C.; Engelward, B. P.; Kovalchuk, O.			Irradiation induces DNA damage and modulates epigenetic effectors in distant bystander tissue in vivo	ONCOGENE			English	Article						radiation; bystander effect; DNA damage; epigenetics	INDUCED GENOMIC INSTABILITY; DOUBLE-STRAND BREAKS; HUMAN RAD51 PROTEIN; IONIZING-RADIATION; MAMMALIAN-CELLS; ALPHA-PARTICLES; HOMOLOGOUS RECOMBINATION; HUMAN FIBROBLASTS; HISTONE H2AX; GLOBAL DNA	Irradiated cells induce chromosomal instability in unirradiated bystander cells in vitro. Although bystander effects are thought to be linked to radiation-induced secondary cancers, almost no studies have evaluated bystander effects in vivo. Furthermore, it has been proposed that epigenetic changes mediate bystander effects, but few studies have evaluated epigenetic factors in bystander tissues in vivo. Here, we describe studies in which mice were unilaterally exposed to X-irradiation and the levels of DNA damage, DNA methylation and protein expression were evaluated in irradiated and bystander cutaneous tissue. The data show that X-ray exposure to one side of the animal body induces DNA strand breaks and causes an increase in the levels of Rad51 in unexposed bystander tissue. In terms of epigenetic changes, unilateral radiation suppresses global methylation in directly irradiated tissue, but not in bystander tissue at given time-points studied. Intriguingly, however, we observed a significant reduction in the levels of the de novo DNA methyltransferases DNMT3a and 3b and a concurrent increase in the levels of the maintenance DNA methyltransferase DNMT1 in bystander tissues. Further more, the levels of two methyl-binding proteins known to be involved in transcriptional silencing, MeCP2 and MBD2, were also increased in bystander tissue. Together, these results show that irradiation induces DNA damage in bystander tissue more than a centimeter away from directly irradiated tissues, and suggests that epigenetic transcriptional regulation may be involved in the etiology of radiation-induced bystander effects.	Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada; MIT, Div Biol Engn, Cambridge, MA 02139 USA; Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA; MIT, Dept Nucl Sci & Engn, Cambridge, MA 02139 USA	University of Lethbridge; Massachusetts Institute of Technology (MIT); US Food & Drug Administration (FDA); Massachusetts Institute of Technology (MIT)	Kovalchuk, O (corresponding author), Univ Lethbridge, Dept Biol Sci, 4401 Univ Dr,HH127, Lethbridge, AB T1K 3M4, Canada.	olga.kovalchuk@uleth.ca		Loree, Jonathan/0000-0001-8189-2132	NCI NIH HHS [R01CA79827, P01-CA26731, R01 CA079827, R21 CA084740] Funding Source: Medline; NIEHS NIH HHS [P30 ES001209-26A1, P30-ES02109, P30 ES002109] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079827, R21CA084740, P01CA026731] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		[Anonymous], 2003, MCNP GEN MONT CARL N; Balmain A, 2000, CARCINOGENESIS, V21, P371, DOI 10.1093/carcin/21.3.371; Basnakian AG, 1996, DNA CELL BIOL, V15, P255, DOI 10.1089/dna.1996.15.255; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bowen NJ, 2004, CELL MOL LIFE SCI, V61, P2163, DOI 10.1007/s00018-004-4177-x; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Goldberg Z, 2003, ONCOGENE, V22, P7011, DOI 10.1038/sj.onc.1206990; Goldberg Z, 2002, INT J ONCOL, V21, P337; Gonzalgo ML, 1997, MUTAT RES-REV MUTAT, V386, P107, DOI 10.1016/S1383-5742(96)00047-6; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hall EJ, 2003, HEALTH PHYS, V85, P31, DOI 10.1097/00004032-200307000-00008; Helleday T, 2003, MUTAT RES-FUND MOL M, V532, P103, DOI 10.1016/j.mrfmmm.2003.08.013; Hendrich B, 2003, TRENDS GENET, V19, P269, DOI 10.1016/S0168-9525(03)00080-5; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Huang L, 2003, ONCOGENE, V22, P5848, DOI 10.1038/sj.onc.1206697; Huo LH, 2001, RADIAT RES, V156, P521, DOI 10.1667/0033-7587(2001)156[0521:HMIIBC]2.0.CO;2; Ichijima Y, 2005, BIOCHEM BIOPH RES CO, V336, P807, DOI 10.1016/j.bbrc.2005.08.164; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; KALINICH JF, 1989, RADIAT RES, V117, P185, DOI 10.2307/3577319; Kashino G, 2004, MUTAT RES-FUND MOL M, V556, P209, DOI 10.1016/j.mrfmmm.2004.08.009; Koturbash I, 2005, BIOCHEM BIOPH RES CO, V337, P526, DOI 10.1016/j.bbrc.2005.09.084; Kovalchuk O, 2004, MOL CANCER RES, V2, P567; Little JB, 1999, CR ACAD SCI III-VIE, V322, P127, DOI 10.1016/S0764-4469(99)80034-1; Little JB, 1998, INT J RADIAT BIOL, V74, P663, DOI 10.1080/095530098140925; Lundin C, 2003, J MOL BIOL, V328, P521, DOI 10.1016/S0022-2836(03)00313-9; Maguire P, 2005, RADIAT RES, V163, P384, DOI 10.1667/RR3325; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; Minamoto T, 1999, CARCINOGENESIS, V20, P519, DOI 10.1093/carcin/20.4.519; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Morgan WF, 2002, MUTAT RES-FUND MOL M, V504, P91, DOI 10.1016/S0027-5107(02)00083-0; Mothersill C, 2005, RADIAT RES, V163, P391, DOI 10.1667/RR3320; Mothersill C, 2004, NAT REV CANCER, V4, P158, DOI 10.1038/nrc1277; Mothersill C, 2002, RADIAT RES, V158, P626, DOI 10.1667/0033-7587(2002)158[0626:BADEAF]2.0.CO;2; Mothersill CE, 2004, INT J RADIAT ONCOL, V58, P575, DOI 10.1016/j.ijrobp.2003.09.038; Nagar S, 2003, CANCER RES, V63, P324; NAGASAWA H, 1992, CANCER RES, V52, P6394; Panayiotidis MI, 2004, ANTIOXID REDOX SIGN, V6, P129, DOI 10.1089/152308604771978435; Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187; Pogribny I, 2004, BIOCHEM BIOPH RES CO, V320, P1253, DOI 10.1016/j.bbrc.2004.06.081; Pogrlbny I, 2005, MOL CANCER RES, V3, P553, DOI 10.1158/1541-7786.MCR-05-0074; Ponnaiya B, 2004, MUTAT RES-FUND MOL M, V568, P41, DOI 10.1016/j.mrfmmm.2004.06.045; Raiche J, 2004, BIOCHEM BIOPH RES CO, V325, P39, DOI 10.1016/j.bbrc.2004.10.002; Richardson C, 2004, ONCOGENE, V23, P546, DOI 10.1038/sj.onc.1207098; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Rothkamm K, 2002, INT J ONCOL, V21, P433; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Rugo RE, 2005, ONCOGENE, V24, P5016, DOI 10.1038/sj.onc.1208690; Sawant SG, 2001, RADIAT RES, V155, P397, DOI 10.1667/0033-7587(2001)155[0397:TBEIRO]2.0.CO;2; Sigurdson AJ, 2003, ONCOGENE, V22, P7018, DOI 10.1038/sj.onc.1206989; Sokolov MV, 2005, ONCOGENE, V24, P7257, DOI 10.1038/sj.onc.1208886; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Tawa R, 1998, J RADIAT RES, V39, P271, DOI 10.1269/jrr.39.271; TURK PW, 1995, CARCINOGENESIS, V16, P1253, DOI 10.1093/carcin/16.5.1253; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Ward JF, 2002, MUTAT RES-FUND MOL M, V499, P151, DOI 10.1016/S0027-5107(01)00286-X; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Xue LY, 2002, P NATL ACAD SCI USA, V99, P13765, DOI 10.1073/pnas.182209699; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797; Zhou HN, 2002, MUTAT RES-FUND MOL M, V499, P135, DOI 10.1016/S0027-5107(01)00285-8	68	164	184	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2006	25	31					4267	4275		10.1038/sj.onc.1209467	http://dx.doi.org/10.1038/sj.onc.1209467			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16532033				2022-12-17	WOS:000239240100002
J	Shinohara, ET; Cao, C; Niermann, K; Mu, Y; Zeng, FH; Hallahan, DE; Lu, B				Shinohara, ET; Cao, C; Niermann, K; Mu, Y; Zeng, FH; Hallahan, DE; Lu, B			Enhanced radiation damage of tumor vasculature by mTOR inhibitors	ONCOGENE			English	Article						mTOR; radiation; rapamycin; blood supply; neoplasms; angiogenesis; glioma; VEGF	ENDOTHELIAL GROWTH-FACTOR; PROTEIN-KINASE-B; GLIOBLASTOMA-MULTIFORME; MALIGNANT GLIOMA; FACTOR RECEPTOR; ANAPLASTIC ASTROCYTOMA; RHABDOMYOSARCOMA CELLS; MAMMALIAN TARGET; BRAIN-TUMORS; RAPAMYCIN	It is known that radiation activates the phosphoinositol-3 kinase (PI3K)/Akt pathway and that inhibition of PI3K or Akt sensitizes tumor vasculature to radiotherapy. Mammalian target of rapamycin (mTOR) is a downstream target of Akt, and we hypothesized that irradiation activates mTOR signaling in both glioma and endothelial cells (ECs) and that radiosensitization results from inhibiting mTOR signaling. mTOR inhibitors, rapamycin and RAD001 (everolimus) were found to radiosensitize vascular ECs, but failed to sensitize glioma cells as determined by clonogenic assay. Therefore, we investigated the anti-angiogenic effects of mTOR inhibitors. Increased phospho-mTOR protein was detected in irradiated human umbilical vein endothelial cells (HUVEC), but not in GL261 glioma cells. Phospho-S6, a biomarker for mTOR signaling, was also found to be induced following irradiation in HUVEC and this effect was inhibited by PI3K or mTOR inhibitors. Significant increase in cleaved caspase 3 was detected when Rad001 was combined with radiation. Endothelial tube formation was significantly diminished following treatment with rapamycin and 3 Gy of radiation. Histological sections of GL261 tumors from mice showed a greatly reduced vascular density when treated with RAD001 and radiation. Power Weighted Doppler of glioma xenografts in mice showed a significant reduction in vasculature and blood flow compared with mice treated with 3 Gy or RAD001 alone. We conclude that irradiation activates mTOR signaling in vascular endothetium and that rapamycin and RAD001 increased apoptosis of ECs in response to radiation. To the authors' best knowledge this is the first study which demonstrates that mTOR inhibitors may be a way to target the vasculature by radiosensitizing the vascular endothelium resulting in better tumor control as seen in experiments demonstrating increased tumor growth delay in mice treated with rapamycin with radiation compared with mice treat with either treatment alone. We conclude that mTOR inhibitors have increased efficacy as antiangiogenics when combined with radiation.	Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Vanderbilt Ingram Canc Ctr,Vanderbilt Clin B902, Nashville, TN 37232 USA	Vanderbilt University	Lu, B (corresponding author), Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Vanderbilt Ingram Canc Ctr,Vanderbilt Clin B902, 1301 22nd Ave S, Nashville, TN 37232 USA.	bo.lu@vanderbilt.edu	lu, bo/G-4573-2010		NCI NIH HHS [T-32 CA93240] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA093240] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beamish H, 1996, ONCOGENE, V13, P963; Boulay A, 2004, CANCER RES, V64, P252, DOI 10.1158/0008-5472.CAN-3554-2; Chakravarti A, 2002, CANCER RES, V62, P4307; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; Cheyney IW, 1999, CANCER RES, V59, P2318; CURRAN WJ, 1993, J NATL CANCER I, V85, P704, DOI 10.1093/jnci/85.9.704; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Dilling MB, 2002, J BIOL CHEM, V277, P13907, DOI 10.1074/jbc.M110782200; DILLING MB, 1994, CANCER RES, V54, P903; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; DUMONT FJ, 1995, CELL IMMUNOL, V163, P70, DOI 10.1006/cimm.1995.1100; Edwards E, 2002, CANCER RES, V62, P4671; Ermoian RP, 2002, CLIN CANCER RES, V8, P1100; Eshleman JS, 2002, CANCER RES, V62, P7291; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Geng L, 2001, CANCER RES, V61, P2413; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; HOCHBERG FH, 1980, NEUROLOGY, V30, P907, DOI 10.1212/WNL.30.9.907; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Hosoi H, 1999, CANCER RES, V59, P886; Huang S, 2001, DRUG RESIST UPDATE, V4, P378, DOI 10.1054/drup.2002.0227; Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7; Huang SL, 2001, CANCER RES, V61, P3373; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; Leon SP, 1996, CANCER-AM CANCER SOC, V77, P362, DOI 10.1002/(SICI)1097-0142(19960115)77:2<362::AID-CNCR20>3.0.CO;2-Z; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Munafo DB, 2001, J CELL SCI, V114, P3619; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; NEWCOMB EW, 1993, BRAIN PATHOL, V3, P229, DOI 10.1111/j.1750-3639.1993.tb00749.x; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; SALAZAR OM, 1976, INT J RADIAT ONCOL, V1, P627, DOI 10.1016/0360-3016(76)90144-9; Sonoda Y, 2001, CANCER RES, V61, P6674; Tan JH, 2003, CANCER RES, V63, P7663; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; WALLNER KE, 1989, INT J RADIAT ONCOL, V16, P1405, DOI 10.1016/0360-3016(89)90941-3; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Wesseling P, 1997, J NEURO-ONCOL, V32, P253, DOI 10.1023/A:1005746320099; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J	43	164	183	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5414	5422		10.1038/sj.onc.1208715	http://dx.doi.org/10.1038/sj.onc.1208715			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15940265				2022-12-17	WOS:000231222300002
J	Andrews, PD				Andrews, PD			Aurora kinases: shining lights on the therapeutic horizon?	ONCOGENE			English	Review						aurora kinase; microtubule; spindle checkpoint; centrosome; kinetochore; therapy	INNER CENTROMERE PROTEIN; SPINDLE ASSEMBLY CHECKPOINT; KINETOCHORE-MICROTUBULE ATTACHMENT; CHROMOSOMAL PASSENGER PROTEIN; MITOTIC SPINDLE; BUDDING YEAST; CENTROSOME AMPLIFICATION; A OVEREXPRESSION; CELL-DIVISION; IN-VIVO	The Aurora kinases have been implicated in tumorigenesis and are important regulators of diverse cell cycle events, ranging from the entry into mitosis, centrosome function, mitotic spindle formation, chromosome biorientation and segregation, and cytokinesis. The recent identification of novel binding partners and key downstream effectors, together with new small-molecule inhibitors that display efficacy against tumours, heralds an upsurge of interest in these critical kinases. This review details new developments in the field and analyses the potential of Aurora kinases as anticancer targets.	Univ Dundee, Div Gene Regulat & Express, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland	University of Dundee	Andrews, PD (corresponding author), Univ Dundee, Div Gene Regulat & Express, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland.	p.d.andrews@dundee.ac.uk		Andrews, Paul/0000-0001-7699-5604	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altieri DC, 2003, ADV CANCER RES, V88, P31, DOI 10.1016/S0065-230X(03)88303-3; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Andrews PD, 2003, CURR OPIN CELL BIOL, V15, P672, DOI 10.1016/j.ceb.2003.10.013; Andrews PD, 2004, DEV CELL, V6, P253, DOI 10.1016/S1534-5807(04)00025-5; Bar-Shira A, 2002, CANCER RES, V62, P6803; Bayliss R, 2003, MOL CELL, V12, P851, DOI 10.1016/S1097-2765(03)00392-7; Bellanger JM, 2003, CURR BIOL, V13, P1488, DOI 10.1016/S0960-9822(03)00582-7; Biggins S, 2001, GENE DEV, V15, P3118, DOI 10.1101/gad.934801; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Brown JR, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-39; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Chen JS, 2004, CANCER GENE THER, V11, P740, DOI 10.1038/sj.cgt.7700752; Conte N, 2003, ONCOGENE, V22, P8102, DOI 10.1038/sj.onc.1206972; Crane R, 2004, J CELL SCI, V117, P5975, DOI 10.1242/jcs.01418; Dancey J, 2003, NAT REV DRUG DISCOV, V2, P296, DOI 10.1038/nrd1066; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Draviam VM, 2004, CURR OPIN GENET DEV, V14, P120, DOI 10.1016/j.gde.2004.02.007; Dutertre S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108; EARNSHAW WC, 1991, J CELL SCI, V98, P443; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Eyers PA, 2003, CURR BIOL, V13, P691, DOI 10.1016/S0960-9822(03)00166-0; Eyers PA, 2004, J BIOL CHEM, V279, P9008, DOI 10.1074/jbc.M312424200; Farruggio DC, 1999, P NATL ACAD SCI USA, V96, P7306, DOI 10.1073/pnas.96.13.7306; Fraizer GC, 2004, INT J ONCOL, V25, P1631; Gadea BB, 2005, MOL BIOL CELL, V16, P1305, DOI 10.1091/mbc.E04-10-0891; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; Goepfert TM, 2002, CANCER RES, V62, P4115; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; Gruss OJ, 2004, J CELL BIOL, V166, P949, DOI 10.1083/jcb.200312112; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; He XW, 2001, CELL, V106, P195, DOI 10.1016/S0092-8674(01)00438-X; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Jeng YM, 2004, CLIN CANCER RES, V10, P2065, DOI 10.1158/1078-0432.CCR-1057-03; Jiang Y, 2003, ONCOGENE, V22, P8293, DOI 10.1038/sj.onc.1206873; Kamada K, 2004, ONCOL REP, V12, P593; Kang JS, 2001, J CELL BIOL, V155, P763, DOI 10.1083/jcb.200105029; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Kunitoku N, 2003, DEV CELL, V5, P853, DOI 10.1016/S1534-5807(03)00364-2; Lampson MA, 2004, NAT CELL BIOL, V6, P232, DOI 10.1038/ncb1102; Lan WJ, 2004, CURR BIOL, V14, P273, DOI 10.1016/j.cub.2004.01.055; Lengauer C, 2004, NAT GENET, V36, P1144, DOI 10.1038/ng1104-1144; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Li JJ, 2004, P NATL ACAD SCI USA, V101, P18123, DOI 10.1073/pnas.0408273101; Li XY, 2004, J BIOL CHEM, V279, P47201, DOI 10.1074/jbc.M403029200; Liu Q, 2004, J BIOL CHEM, V279, P18210, DOI 10.1074/jbc.M400678200; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Mollinedo F, 2003, APOPTOSIS, V8, P413, DOI 10.1023/A:1025513106330; Moore A, 2004, TRENDS CELL BIOL, V14, P537, DOI 10.1016/j.tcb.2004.09.001; Moreno-Bueno G, 2003, CANCER RES, V63, P5697; Murata-Hori M, 2002, CURR BIOL, V12, P894, DOI 10.1016/S0960-9822(02)00848-5; Murnion ME, 2001, J BIOL CHEM, V276, P26656, DOI 10.1074/jbc.M102288200; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Ning S, 2004, INT J ONCOL, V25, P1065; Nowak MA, 2002, P NATL ACAD SCI USA, V99, P16226, DOI 10.1073/pnas.202617399; Ohi R, 2003, DEV CELL, V5, P309, DOI 10.1016/S1534-5807(03)00229-6; Ohi R, 2004, MOL BIOL CELL, V15, P2895, DOI 10.1091/mbc.E04-02-0082; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Okada H, 2004, J EXP MED, V199, P399, DOI 10.1084/jem.20032092; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Ovechkina Y, 2003, TRAFFIC, V4, P367, DOI 10.1034/j.1600-0854.2003.00099.x; Pagliaro L, 2004, CURR OPIN CHEM BIOL, V8, P442, DOI 10.1016/j.cbpa.2004.06.006; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Petersen J, 2003, CURR BIOL, V13, P590, DOI 10.1016/S0960-9822(03)00205-7; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; RAJAGOPALAN H, 2004, NAT CANC REV, V3, P659; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Romano A, 2003, J CELL BIOL, V161, P229, DOI 10.1083/jcb.200207117; Sager JA, 2003, CANCER BIOL THER, V2, P452, DOI 10.4161/cbt.2.4.448; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Sampath SC, 2004, CELL, V118, P187, DOI 10.1016/j.cell.2004.06.026; Sasai K, 2004, CELL MOTIL CYTOSKEL, V59, P249, DOI 10.1002/cm.20039; Sausville EA, 2004, NAT MED, V10, P234, DOI 10.1038/nm0304-234; Shang C, 2003, MOL BIOL CELL, V14, P3342, DOI 10.1091/mbc.E02-11-0765; Song ZY, 2004, MOL BIOL CELL, V15, P1287, DOI 10.1091/mbc.E03-07-0512; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; Sun T, 2004, CARCINOGENESIS, V25, P2225, DOI 10.1093/carcin/bgh244; Tanaka T, 1999, CANCER RES, V59, P2041; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; Toji S, 2004, GENES CELLS, V9, P383, DOI 10.1111/j.1356-9597.2004.00732.x; Tong T, 2004, CLIN CANCER RES, V10, P7304, DOI 10.1158/1078-0432.CCR-04-0806; Trinkle-Mulcahy L, 2003, MOL BIOL CELL, V14, P107, DOI 10.1091/mbc.E02-07-0376; Tsai MY, 2003, NAT CELL BIOL, V5, P242, DOI 10.1038/ncb936; Tu SP, 2005, GASTROENTEROLOGY, V128, P361, DOI 10.1053/j.gastro.2004.11.058; Uchida H, 2004, MOL THER, V10, P162, DOI 10.1016/j.ymthe.2004.05.006; Vagnarelli P, 2004, CHROMOSOMA, V113, P211, DOI 10.1007/s00412-004-0307-3; Westermann S, 2003, J CELL BIOL, V163, P215, DOI 10.1083/jcb.200305100; Wheatley SP, 2004, J BIOL CHEM, V279, P5655, DOI 10.1074/jbc.M311299200; Xing Z, 2004, J EXP MED, V199, P69, DOI 10.1084/jem.20031588; Yang D, 2004, P NATL ACAD SCI USA, V101, P15100, DOI 10.1073/pnas.0406665101; Yang H, 2004, CANCER RES, V64, P463, DOI 10.1158/0008-5472.CAN-03-2907; Zhang DW, 2004, ONCOGENE, V23, P8720, DOI 10.1038/sj.onc.1208153	100	164	175	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5005	5015		10.1038/sj.onc.1208752	http://dx.doi.org/10.1038/sj.onc.1208752			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	16049526				2022-12-17	WOS:000230816900001
J	Park, JI; Lee, MG; Cho, KC; Park, BJ; Chae, KS; Byun, DS; Ryu, BK; Park, YK; Chi, SG				Park, JI; Lee, MG; Cho, KC; Park, BJ; Chae, KS; Byun, DS; Ryu, BK; Park, YK; Chi, SG			Transforming growth factor-beta 1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappa B, JNK, and Ras signaling pathways	ONCOGENE			English	Article						IL-6; TGF-beta 1; Smad; nuclear factor-kappa B; c-Jun; prostate cancer	GROWTH-FACTOR-BETA; MESSENGER-RNA STABILITY; NF-KAPPA-B; PROTEIN-KINASE PATHWAY; TGF-BETA; GENE-EXPRESSION; TERMINAL KINASE; NEUROENDOCRINE DIFFERENTIATION; IL-6 FUNCTIONS; RICH ELEMENTS	Transforming growth factor (TGF)-beta1 acts as a potent growth inhibitor of prostate epithelial cells, and aberrant function of its receptor type I and II correlates with tumor aggressiveness. However, intracellular and serum TGF-beta1 levels are elevated in prostate cancer patients and further increased in patients with metastatic carcinoma, suggesting the oncogenic switch of TGF-beta1 role in prostate tumorigenesis. Recently, we reported the mitogenic conversion of TGF-beta1 effect by oncogenic Ha-Ras in prostate cancer cells. Here, we show that TGF-beta1 activates interleukin (IL)-6, which has been implicated in the malignant progression of prostate cancers, via multiple signaling pathways including Smad2, nuclear factor-kappaB (NF-kappaB), JNK, and Ras. TGF-beta1-induced IL-6 gene expression was strongly inhibited by DN-Smad2 but not by DN-Smad3 while it was further activated by wild-type Smad2 transfection. IL-6 activation by TGF-beta1 was accompanied by nuclear translocation of NF-kappaB, which was blocked by the p38 inhibitors SB202190 and SB203580 or by IkappaBalphaDeltaN transfection, indicating the crucial role for the p38-NF-kappaB signaling in TGF-beta1 induction of IL-6. TGF-beta1 activated c-Jun phosphorylation, and IL-6 induction by TGF-beta1 was severely impeded by DN-c-Jun and DN-JNK or AP-1 inhibitor curcumin, showing that the JNK-c-Jun-AP-1 signaling plays a pivotal role in TGF-beta1 stimulation of IL-6. It was also found that the Ras-Raf-MEK1 cascade is activated by TGF-beta1 and participates in the TGF-beta1 induction of IL-6 in an AP-1-dependent manner. Cotransfection assays demonstrated that TGF-beta1 stimulation of IL-6 results from the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK-c-Jun-AP-1, or Ras-Raf-MEK1 cascades. In addition, a time course IL-6 decay revealed that mRNA stability of IL-6 is modestly increased by TGF-beta1, indicating that TGF-beta1 also regulates IL-6 at the post-transcriptional level. Intriguingly, IL-6 inactivation restored the sensitivity to TGF-beta1-mediated growth arrest and apoptosis, suggesting that elevated IL-6 in advanced prostate tumors might act as a resistance factor against TGF-beta1. Collectively, our data demonstrate that IL-6 expression is stimulated by tumor-producing TGF-beta1 in human prostate cancer cells through multiple signaling pathways including Smad2, p38, JNK, and Ras, and enhanced expression of IL-6 could contribute to the oncogenic switch of TGF-beta1 role for prostate tumorigenesis, in part by counteracting its growth suppression function.	Kyung Hee Univ, Dept Pathol, Coll Med, Seoul 130701, South Korea; Korea Univ, Grad Sch Life Sci & Biotechnol, Seoul 136701, South Korea	Kyung Hee University; Korea University	Chi, SG (corresponding author), Kyung Hee Univ, Dept Pathol, Coll Med, Seoul 130701, South Korea.	sgchi@khu.ac.kr	park, jaeil/AAS-5894-2021	PARK, JAE-IL/0000-0002-0737-2654				Adler HL, 1999, J UROLOGY, V161, P182, DOI 10.1016/S0022-5347(01)62092-5; Akira S, 1992, Semin Cancer Biol, V3, P17; Asschert JGW, 1999, INT J CANCER, V82, P244, DOI 10.1002/(SICI)1097-0215(19990719)82:2<244::AID-IJC15>3.0.CO;2-N; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Barrack ER, 1997, PROSTATE, V31, P61; BORSELLINO N, 1995, CANCER RES, V55, P4633; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN PH, 1994, ONCOGENE, V9, P791; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chi SG, 1997, CLIN CANCER RES, V3, P1889; Chung TDK, 2000, PROSTATE, V42, P1; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Deeble PD, 2001, MOL CELL BIOL, V21, P8471, DOI 10.1128/MCB.21.24.8471-8482.2001; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI12973; Drachenberg DE, 1999, PROSTATE, V41, P127, DOI 10.1002/(SICI)1097-0045(19991001)41:2<127::AID-PROS7>3.0.CO;2-H; EASTHAM JA, 1995, LAB INVEST, V73, P628; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; EUSTACE D, 1993, GYNECOL ONCOL, V50, P15, DOI 10.1006/gyno.1993.1156; Franchimont N, 1999, J BIOL CHEM, V274, P6783, DOI 10.1074/jbc.274.10.6783; Franchimont N, 2000, BONE, V26, P249, DOI 10.1016/S8756-3282(99)00275-6; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Junn E, 2000, J IMMUNOL, V165, P2190, DOI 10.4049/jimmunol.165.4.2190; Kim IY, 1998, CLIN CANCER RES, V4, P1625; Kim IY, 1996, CANCER RES, V56, P44; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; Kossakowska AE, 1999, BLOOD, V94, P2080, DOI 10.1182/blood.V94.6.2080.418k30_2080_2089; Krause A, 1998, J BIOL CHEM, V273, P23681, DOI 10.1074/jbc.273.37.23681; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Lou W, 2000, PROSTATE, V42, P239, DOI 10.1002/(SICI)1097-0045(20000215)42:3<239::AID-PROS10>3.0.CO;2-G; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Mazzarelli P, 1998, J NEUROIMMUNOL, V87, P185, DOI 10.1016/S0165-5728(98)00110-6; MIKI S, 1989, FEBS LETT, V250, P607, DOI 10.1016/0014-5793(89)80805-1; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; Montero L, 1999, CANCER RES, V59, P5286; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Nabors LB, 2001, CANCER RES, V61, P2154; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Oka M, 1996, CANCER RES, V56, P2776; Okamoto M, 1997, CANCER RES, V57, P141; Okamoto M, 1998, PROSTATE, V35, P255, DOI 10.1002/(SICI)1097-0045(19980601)35:4<255::AID-PROS4>3.0.CO;2-F; Park BJ, 2000, CANCER RES, V60, P3031; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Riggins GJ, 1997, CANCER RES, V57, P2578; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SCHWARZ LC, 1988, CANCER RES, V48, P6999; Sehgal I, 1999, MOL BIOL CELL, V10, P407, DOI 10.1091/mbc.10.2.407; Sehgal I, 1996, CANCER RES, V56, P3359; Seymour JF, 1997, AM J MED, V102, P21; SIEGALL CB, 1990, CANCER RES, V50, P7786; SIEGSMUND MJ, 1994, J UROLOGY, V151, P1396, DOI 10.1016/S0022-5347(17)35267-9; St-Arnaud Rene, 1998, Frontiers in Bioscience, V3, pD838; Stearns ME, 1999, CLIN CANCER RES, V5, P711; Troppmair J, 1998, ONCOGENE, V17, P685, DOI 10.1038/sj.onc.1201981; TRUONG LD, 1993, HUM PATHOL, V24, P4, DOI 10.1016/0046-8177(93)90055-L; TWILLIE DA, 1995, UROLOGY, V45, P542, DOI 10.1016/S0090-4295(99)80034-X; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Wery-Zennaro S, 2000, ONCOGENE, V19, P1596, DOI 10.1038/sj.onc.1203458; Williams RH, 1996, CLIN CANCER RES, V2, P635; Wong C, 1999, MOL CELL BIOL, V19, P1821; Yakymovych I, 2002, BIOCHEMISTRY-US, V41, P11000, DOI 10.1021/bi025936u; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhao Y, 1996, J BIOL CHEM, V271, P2369, DOI 10.1074/jbc.271.5.2369; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	83	164	171	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4314	4332		10.1038/sj.onc.1206478	http://dx.doi.org/10.1038/sj.onc.1206478			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853969				2022-12-17	WOS:000183978900002
J	Fry, AM				Fry, AM			The Nek2 protein kinase: a novel regulator of centrosome structure	ONCOGENE			English	Review						Nek2; centrosome; mitosis; NIMA; Fin1; protein kinase	NIMA-RELATED KINASE; CELL-CYCLE REGULATORS; ASPERGILLUS-NIDULANS; SACCHAROMYCES-CEREVISIAE; CHROMATIN CONDENSATION; EXPRESSION PATTERN; MITOTIC REGULATOR; VERTEBRATE CELLS; IN-VIVO; PHOSPHORYLATION	Regulation of the centrosome, the major microtubule organizing centre in an animal cell, is in large part controlled by cell cycle-dependent protein phosphorylation. Along with cyclin dependent kinases, polo kinases and Aurora kinases, NIMA-related kinases are emerging as critical regulators of centrosome structure and function. Nek2 is the most closely related vertebrate protein by sequence to the essential mitotic regulator NIMA of Aspergillus nidulans. Nek2 is highly enriched at the centrosome and functional studies in human and Xenopus systems support a role for Nek2 in both maintenance and modulation of centrosome architecture. In particular, current evidence supports a model in which one function of Nek2 kinase activity is to promote the splitting of duplicated centrosomes at the onset of mitosis through phosphorylation of core centriolar proteins. Recent studies in lower organisms have raised the possibility that kinases related to Nek2 may have conserved functions in MTOC organization, as well as in other aspects of mitotic progression.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Fry, AM (corresponding author), Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England.	amf5@le.ac.uk		Fry, Andrew/0000-0003-4417-7329				Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; Arama E, 1998, ONCOGENE, V16, P1813, DOI 10.1038/sj.onc.1201710; BARTON AB, 1992, GENE, V117, P137, DOI 10.1016/0378-1119(92)90502-G; Belham C, 2001, CURR BIOL, V11, P1155, DOI 10.1016/S0960-9822(01)00369-4; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; Chen Y, 1997, J BIOL CHEM, V272, P24081, DOI 10.1074/jbc.272.38.24081; Chen YM, 1997, MOL CELL BIOL, V17, P6049, DOI 10.1128/MCB.17.10.6049; Cohen PTW, 2002, J CELL SCI, V115, P241; De Souza CPC, 2000, CELL, V102, P293, DOI 10.1016/S0092-8674(00)00035-0; Di Agostino S, 2002, DEVELOPMENT, V129, P1715; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Francis SE, 2000, CURR TOP DEV BIOL, V49, P105; Fry AM, 1999, J BIOL CHEM, V274, P16304, DOI 10.1074/jbc.274.23.16304; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; FRY AM, 1995, CURR BIOL, V5, P1122, DOI 10.1016/S0960-9822(95)00227-2; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Fry AM, 2001, METHOD CELL BIOL, V67, P305; Fry AM, 2000, J CELL SCI, V113, P1973; Fry AM, 2000, CURR TOP DEV BIOL, V49, P291; Fujioka T, 2000, BIOCHEM BIOPH RES CO, V279, P799, DOI 10.1006/bbrc.2000.4021; Graf R, 2002, J CELL SCI, V115, P1919; Graf R, 2000, CURR TOP DEV BIOL, V49, P161; GRALLERT A, 2002, IN PRESS EMBO J; Hagan IM, 2000, CURR TOP DEV BIOL, V49, P133; Hames RS, 2001, EMBO J, V20, P7117, DOI 10.1093/emboj/20.24.7117; Hames RS, 2002, BIOCHEM J, V361, P77, DOI 10.1042/0264-6021:3610077; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Holland PM, 2002, J BIOL CHEM, V277, P16229, DOI 10.1074/jbc.M108662200; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jean C, 1999, EUR J CELL BIOL, V78, P549, DOI 10.1016/S0171-9335(99)80020-X; JONES DGL, 1990, GENE, V90, P87, DOI 10.1016/0378-1119(90)90442-T; Kandli M, 2000, GENOMICS, V68, P187, DOI 10.1006/geno.2000.6293; Kim YH, 2002, BIOCHEM BIOPH RES CO, V290, P730, DOI 10.1006/bbrc.2001.6212; Krien MJE, 1998, J CELL SCI, V111, P967; Krien MJE, 2002, EMBO J, V21, P1713, DOI 10.1093/emboj/21.7.1713; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; LEVEDAKOU EN, 1994, ONCOGENE, V9, P1977; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; Lutz W, 2001, J BIOL CHEM, V276, P20774, DOI 10.1074/jbc.M101324200; Mack GJ, 1998, ARTHRITIS RHEUM, V41, P551; Mahjoub MR, 2002, J CELL SCI, V115, P1759; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; Mayor T, 2000, J CELL BIOL, V151, P837, DOI 10.1083/jcb.151.4.837; Mayor T, 1999, FEBS LETT, V452, P92, DOI 10.1016/S0014-5793(99)00534-7; Meraldi P, 2001, J CELL SCI, V114, P3749; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; Osmani SA, 1996, BIOCHEM J, V317, P633, DOI 10.1042/bj3170633; PAINTRAND M, 1992, J STRUCT BIOL, V108, P107, DOI 10.1016/1047-8477(92)90011-X; Pfleger CM, 2000, GENE DEV, V14, P655; Piel M, 2000, J CELL BIOL, V149, P317, DOI 10.1083/jcb.149.2.317; PU RT, 1995, J BIOL CHEM, V270, P18110, DOI 10.1074/jbc.270.30.18110; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rhee K, 1997, DEVELOPMENT, V124, P2167; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P625; SCHWEITZER B, 1992, MOL GEN GENET, V234, P164, DOI 10.1007/BF00272358; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Takahashi Y, 2000, GENE DEV, V14, P804; Tanaka K, 1999, J BIOL CHEM, V274, P13491, DOI 10.1074/jbc.274.19.13491; Tanaka K, 1997, EXP CELL RES, V237, P264, DOI 10.1006/excr.1997.3788; Upadhya P, 2000, P NATL ACAD SCI USA, V97, P217, DOI 10.1073/pnas.97.1.217; Uto K, 1999, DEV BIOL, V208, P456, DOI 10.1006/dbio.1999.9231; Uto K, 2000, EMBO J, V19, P1816, DOI 10.1093/emboj/19.8.1816; Wai DH, 2002, INT J ONCOL, V20, P441; Whitehead CM, 1999, J CELL BIOCHEM, P192; Wu L, 1998, J CELL BIOL, V141, P1575, DOI 10.1083/jcb.141.7.1575; Ye XS, 1998, MOL BIOL CELL, V9, P3019, DOI 10.1091/mbc.9.11.3019; Ye XS, 1996, EMBO J, V15, P3599, DOI 10.1002/j.1460-2075.1996.tb00729.x; Zimmerman W, 2000, TRAFFIC, V1, P927, DOI 10.1034/j.1600-0854.2000.011202.x	77	164	176	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2002	21	40					6184	6194		10.1038/sj.onc.1205711	http://dx.doi.org/10.1038/sj.onc.1205711			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214248				2022-12-17	WOS:000177840500007
J	Ferrigno, O; Lallemand, F; Verrecchia, F; L'Hoste, S; Camonis, J; Atfi, A; Mauviel, A				Ferrigno, O; Lallemand, F; Verrecchia, F; L'Hoste, S; Camonis, J; Atfi, A; Mauviel, A			Yes-associated protein (YAP65) interacts with Smad7 and potentiates its inhibitory activity against TGF-beta/Smad signaling	ONCOGENE			English	Article						TGF-beta; Smad signaling; Src/Yes; Smad7; gene expression and regulation	GROWTH-FACTOR-BETA; SH3 DOMAIN; APOPTOSIS; RECEPTOR; IDENTIFICATION; DEGRADATION; STRAP; BINDS; CELLS	Members of the TGF-beta family of growth factors signal from the cell surface through serine/threonine kinase receptors. Intracellular propagation of the signal occurs by phosphorylation of intracellular proteins of the Smad family. Smad7 belongs to the subclass of inhibitory Smads that function as antagonists of TGF-beta signaling. A yeast two-hybrid screen of a human placental cDNA expression library using full-length mouse Smad7 as bait identified Yes-Associated Protein (YAP65) as a novel Smad7-interacting protein. The association of Smad7 with YAP65 was confirmed using co-expressed tagged proteins in COS-7 cells. Deletion of the PY motif of Smad7 reduced but did not abolish YAP65-Smad7 association, suggesting the existence of several interacting domains. We demonstrate that YAP65 potentiates the inhibitory activity of Smad7 against TGF-beta-induced, Smad3/4-dependent, gene transactivation. Furthermore, YAP65 augments the association of Smad7 to activated TGF-beta receptor type I (TbetaRI), whereas YAP65(1-301), which exerts a dominant-negative effect against Smad7-driven inhibition of TGF-beta signaling, reduces these interactions. Together, these data provide the first evidence that YAP65 is a Smad7 partner that facilitates the recruitment of the latter to activated TbetaRI, and enhances the inhibitory activity of Smad7 against TGF-beta signaling.	Hop St Louis, INSERM, U532, Inst Rech Peau, F-75475 Paris 10, France; Hop St Antoine, INSERM, U482, F-75571 Paris, France; Inst Curie, INSERM, U528, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Mauviel, A (corresponding author), Hop St Louis, INSERM, U532, Inst Rech Peau, Pavillon Bazin,1 Ave Claude Vellefaux, F-75475 Paris 10, France.		Verrecchia, Franck/G-5535-2018; ferrigno, olivier/GSN-8581-2022; MAUVIEL, Alain/F-6251-2013	Verrecchia, Franck/0000-0003-4920-2554; ferrigno, olivier/0000-0001-7544-4384; Mauviel, Alain/0000-0002-0438-2793				Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286-4579(99)00250-6; Datta PK, 2000, MOL CELL BIOL, V20, P3157, DOI 10.1128/MCB.20.9.3157-3167.2000; Datta PK, 1998, J BIOL CHEM, V273, P34671, DOI 10.1074/jbc.273.52.34671; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Lallemand F, 2001, ONCOGENE, V20, P879, DOI 10.1038/sj.onc.1204167; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mazars A, 2001, J BIOL CHEM, V276, P36797, DOI 10.1074/jbc.M101672200; MUSACCHIO A, 1994, PROG BIOPHYS MOL BIO, V61, P283, DOI 10.1016/0079-6107(94)90003-5; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Rotin D, 1998, CURR TOP MICROBIOL, V228, P115; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SUDOL M, 1994, ONCOGENE, V9, P2145; Sudol M, 2001, FEBS LETT, V490, P190, DOI 10.1016/S0014-5793(01)02122-6; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551	23	164	171	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4879	4884		10.1038/sj.onc.1205623	http://dx.doi.org/10.1038/sj.onc.1205623			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118366	Green Submitted			2022-12-17	WOS:000176874800002
J	Xiang, YY; Ladeda, V; Filmus, J				Xiang, YY; Ladeda, V; Filmus, J			Glypican-3 expression is silenced in human breast cancer	ONCOGENE			English	Article						glypicans; breast cancer; DNA methylation	GOLABI-BEHMEL-SYNDROME; OVERGROWTH SYNDROME; GENE; GPC3; DYSPLASIA	Glypican-3 (GPC3) is, a membrane-bound heparan sulfate proteoglycan that is mutated in the Simpson-Golabi-Behmel syndrome. This is an X-linked condition characterized by overgrowth, and various visceral and skeletal dysmorphisms. The phenotype of the Simpson-Golabi-Behmel, syndrome patients and GM-deficient mice, as well as gene transfection experiments indicate that GPC3 can act as an inhibitor of cell proliferation and survival. It has been previously shown that GPC3 expression is downregulated in mesotheliomas and ovarian cancer. Here we report that GPC3 expression is also silenced in human. breast cancer, and that this silencing is due, at least in part, to hypermethylation of the GPC3 promoter. Ectopic expression of GPC3 inhibited growth in eight out of 10 breast cancer cell lines. Collectively, these data suggest that GPC3 can act as a negative regulator of breast cancer growth.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Mol & Cell Biol Res Program, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Filmus, J (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Mol & Cell Biol Res Program, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	filmus@sten.sunnybrook.utoronto.ca						BEHMEL A, 1984, HUM GENET, V67, P409, DOI 10.1007/BF00291401; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Cano-Gauci DF, 1999, J CELL BIOL, V146, P255; Duenas-Gonzalez A, 1998, J CELL BIOL, V141, P1407, DOI 10.1083/jcb.141.6.1407; Filmus J, 2001, GLYCOBIOLOGY, V11, p19R, DOI 10.1093/glycob/11.3.19R; FILMUS J, 2000, PROTEOGLYCANS, P161; GARGANTA CL, 1992, AM J MED GENET, V44, P129, DOI 10.1002/ajmg.1320440202; GOLABI M, 1984, AM J MED GENET, V17, P345, DOI 10.1002/ajmg.1320170128; Grisaru S, 2001, DEV BIOL, V231, P31, DOI 10.1006/dbio.2000.0127; Huber R, 1999, P NATL ACAD SCI USA, V96, P616, DOI 10.1073/pnas.96.2.616; HUGHESBENZIE RM, 1992, AM J MED GENET, V43, P428, DOI 10.1002/ajmg.1320430165; HughesBenzie RM, 1996, AM J MED GENET, V66, P227, DOI 10.1002/(SICI)1096-8628(19961211)66:2<227::AID-AJMG20>3.0.CO;2-U; Lin HC, 1999, CANCER RES, V59, P807; Murthy SS, 2000, ONCOGENE, V19, P410, DOI 10.1038/sj.onc.1203322; Neri G, 1998, AM J MED GENET, V79, P279, DOI 10.1002/(SICI)1096-8628(19981002)79:4<279::AID-AJMG9>3.0.CO;2-H; Paine-Saunders S, 2000, DEV BIOL, V225, P179, DOI 10.1006/dbio.2000.9831; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; XIANG YY, 1994, CANCER RES, V54, P3034	18	164	180	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7408	7412		10.1038/sj.onc.1204925	http://dx.doi.org/10.1038/sj.onc.1204925			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704870				2022-12-17	WOS:000171894200013
J	Minucci, S; Nervi, C; Lo Coco, F; Pelicci, PG				Minucci, S; Nervi, C; Lo Coco, F; Pelicci, PG			Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?	ONCOGENE			English	Review						histone deacetylases; acute myeloid leukemias; PML-RAR; differentiation therapy	ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID RECEPTOR; PLZF-RAR-ALPHA; TRANSCRIPTIONAL ACTIVATION; CELL-DIFFERENTIATION; FUSION PROTEIN; EXPRESSION; ETO; PML; OLIGOMERIZATION	Recent discoveries have identified key molecular events in the pathogenesis of acute promyelocytic leukemia (APL), caused by chromosomal rearrangements of the transcription factor RAR (resulting in a fusion protein with the product of other cellular genes, such as PML), Oligomerization of RAR, through a self-association domain present in PML, imposes an altered interaction with transcriptional co-regulators (NCoR/SMRT). NCoR/SMRT are responsible for recruitment of histone deacetylases (HDACs), which is required for transcriptional repression of PML-RAR target genes, and for the transforming potential of the fusion protein, Oligomerization and altered recruitment of HDACs are also responsible for transformation by the fusion protein AML1-ETO, extending these mechanisms to other forms of acute myeloid leukemias (AMLs) and suggesting that HDAC is a common target for myeloid leukemias, Strikingly, AML1-ETO expression blocks retinoic acid (RA) signaling in hematopoietic cells, suggesting that interference with the RA pathway (genetically altered in APL) by HDAC recruitment may be a common theme in AMLs. Treatment of APLs with RA, and of other AMLs with RA plus HDAC inhibitors (HDACi), results in myeloid differentiation. Thus, activation of the RA signaling pathway and inhibition of HDAC activity might represent a general strategy for the differentiation treatment of myeloid leukemias.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Vita Salute, Dept Gen Pathol, I-20100 Milan, Italy; Univ La Sapienza, Dept Histol & Med Embryol, I-00161 Rome, Italy; Univ La Sapienza, Dept Cellular Biotechnol & Hematol, I-00161 Rome, Italy	IRCCS European Institute of Oncology (IEO); Vita-Salute San Raffaele University; Sapienza University Rome; Sapienza University Rome	Minucci, S (corresponding author), European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy.		Pelicci, Pier Giuseppe/AAL-6572-2020; Minucci, Saverio/J-9669-2012	NERVI, Clara/0000-0001-9341-0188				Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; Deininger M W, 1998, Curr Opin Hematol, V5, P302; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; FERRARA F, 2001, IN PRESS CANC RES; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Glass CK, 2000, GENE DEV, V14, P121; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guenther MG, 2000, GENE DEV, V14, P1048; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hiebert SW, 1996, CURR TOP MICROBIOL, V211, P253; Huang EY, 2000, GENE DEV, V14, P45; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KASTNER P, 2001, IN PRESS BLOOD; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Lo Coco F, 1999, BLOOD, V94, P12, DOI 10.1182/blood.V94.1.12.413a44_12_22; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Minucci S, 1999, SEMIN CELL DEV BIOL, V10, P215, DOI 10.1006/scdb.1999.0303; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Uchida H, 1999, ONCOGENE, V18, P1015, DOI 10.1038/sj.onc.1202383; VanLint C, 1996, GENE EXPRESSION, V5, P245; Wang JX, 1999, CANCER RES, V59, P2766; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; Westervelt P, 1999, BLOOD, V93, P2143, DOI 10.1182/blood.V93.7.2143.407a32_2143_2148; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zeng YX, 1996, ONCOGENE, V12, P1557; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	47	164	183	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3110	3115		10.1038/sj.onc.1204336	http://dx.doi.org/10.1038/sj.onc.1204336			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420727				2022-12-17	WOS:000169308500015
J	Zamzami, N; El Hamel, C; Maisse, C; Brenner, C; Munoz-Pinedo, C; Belzacq, AS; Costantini, P; Vieira, H; Loeffler, M; Molle, G; Kroemer, G				Zamzami, N; El Hamel, C; Maisse, C; Brenner, C; Munoz-Pinedo, C; Belzacq, AS; Costantini, P; Vieira, H; Loeffler, M; Molle, G; Kroemer, G			Bid acts on the permeability transition pore complex to induce apoptosis	ONCOGENE			English	Article						apoptosis; Bcl-2; mitochondria; permeability transition; t-Bid	DEPENDENT ANION CHANNEL; CYTOCHROME-C RELEASE; MITOCHONDRIAL CONTROL; BAX; BCL-2; MEMBRANES; PROTEINS; YEAST; PURIFICATION	Similar to most if not all pro-apoptotic members of the Bcl-2 family, Bid land its truncated product t-Bid) triggers cell death via mitochondrial membrane permeabilization (MMP). This effect can be monitored in intact cells, upon microinjection of recombinant Bid protein into the cytoplasm, as well as in purified mitochondria, upon addition of Bid protein. Here we show that Bid-induced MMP can be inhibited, both in cells and in the cell-free system, by three pharmacological inhibitors of the permeability transiton pore complex (PTPC), namely cyclosporin A, N-methyl-4-Val-cyclosporin A, and bongkrekic acid (a ligand of the adenine nucleotide translocase, ANT, one of the PTPC components). Bid effects on synthetic membranes were studied either in proteoliposomes or in synthetic bilayers subjected to electrophysiological measurements. Full length Bid preferentially permeabilizes membranes and induces the formation of large conductance channels at neutral pH, when added to liposomes or bilayers containing both purified ANT and Bax, yet has no or little effect combined with ANT or Bax alone. t-Bid acts on membranes containing ANT alone with the same efficiency as on those containing both ANT and Bax. These results suggest that the proapoptotic effects of Bid are mediated, at least in part, by its functional interaction with ANT, one of the major components of PTPC.	Inst Gustave Roussy, CNRS, UMR 1599, F-94805 Villejuif, France; Univ Technol Compiegne, UMR 6022, CNRS, F-60205 Compiegne, France; Fac Sci, IFRMP23, UMR 6522, CNRS, F-76821 Mont St Aignan, France; CSIC, Inst Parasitol & Biomed, Granada 18001, Spain	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Picardie Universites; Universite de Technologie de Compiegne; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 1599, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		KROEMER, Guido/B-4263-2013; brenner, catherine/AAE-8632-2020; Munoz-Pinedo, Cristina/B-6118-2008; Vieira, Helena/AAZ-9562-2021; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; Munoz-Pinedo, Cristina/0000-0002-9120-664X; Vieira, Helena/0000-0001-9415-3742; Maisse, Carine/0000-0003-2848-1638				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; Brenner C, 2000, METHOD ENZYMOL, V322, P243; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Feldmann G, 2000, HEPATOLOGY, V31, P674, DOI 10.1002/hep.510310318; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; Harris MH, 2000, MOL CELL BIOL, V20, P3590, DOI 10.1128/MCB.20.10.3590-3596.2000; Hatano E, 2000, J BIOL CHEM, V275, P11814, DOI 10.1074/jbc.275.16.11814; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Priault M, 1999, FEBS LETT, V456, P232, DOI 10.1016/S0014-5793(99)00957-6; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, CURR OPIN IMMUNOL, V11, P277, DOI 10.1016/S0952-7915(99)80045-4; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Susin SA, 2000, METHOD ENZYMOL, V322, P205; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	51	164	169	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2000	19	54					6342	6350		10.1038/sj.onc.1204030	http://dx.doi.org/10.1038/sj.onc.1204030			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175349				2022-12-17	WOS:000166210500018
J	Bouvard, V; Zaitchouk, T; Vacher, M; Duthu, A; Canivet, M; Choisy-Rossi, C; Nieruchalski, M; May, E				Bouvard, V; Zaitchouk, T; Vacher, M; Duthu, A; Canivet, M; Choisy-Rossi, C; Nieruchalski, M; May, E			Tissue and cell-specific expression of the p53-target genes: bax, fas, mdm2 and waf1/p21, before and following ionising irradiation in mice	ONCOGENE			English	Article						p53-target genes; tissue and cell-specific expression; gamma irradiation	WILD-TYPE P53; IN-VIVO; INDUCED APOPTOSIS; DNA-DAMAGE; TRANSGENIC MICE; BINDING-SITE; MUTANT P53; PROTEIN; ACTIVATION; RADIATION	The mechanisms by which the p53 tumour suppressor protein would, in vivo, co-ordinate the adaptive response to genotoxic stress is poorly understood. p53 has been shown to transactivate several genes that could be involved in two main cellular responses, growth arrest and apoptosis. To get further insight into the tissue-specific regulation of p53 transcriptional activity, we performed an extensive study looking at the expression of four well characterized p53-responsive genes, before and after gamma-irradiation in p53 wild-type (p53 +/+) and p53-deficient (p53 -/-) mice. The waf1, bax, fas and mdm2 genes were chosen for their different potential roles in the cellular response to stress. Our data demonstrate the strict p53-dependence of mRNA up-regulation for bax, fas and mdm2 in irradiated tissues and confirm such findings for wafl. They further highlight complex levels of regulatory mechanisms that could lead, in vivo, to selective transcriptional activation of genes by p53. In addition, our results provide arguments for the involvement of p53 in the basal mRNA expression of the four genes in some organs. Finally, in situ expression of Bax and p21Waf-1 protein suggests, at least in lymphoid organs, a direct correlation between selective p53-target gene expression and particular response of a cell to ionising radiation.	CEA, Ctr Etud Nucl, DSV,DRR,Lab Cancerogenese Mol, CNRS,UMR 217, F-92265 Fontenay Aux Roses, France	CEA; Centre National de la Recherche Scientifique (CNRS)	May, E (corresponding author), CEA, Ctr Etud Nucl, DSV,DRR,Lab Cancerogenese Mol, CNRS,UMR 217, F-92265 Fontenay Aux Roses, France.							Akashi M, 1999, BIOCHEM J, V337, P607, DOI 10.1042/0264-6021:3370607; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; JACKSON P, 1993, ONCOGENE, V8, P589; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kitada S, 1996, ONCOGENE, V12, P187; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobayashi T, 1998, CELL DEATH DIFFER, V5, P584, DOI 10.1038/sj.cdd.4400382; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUNA RMD, 1995, NATURE, V378, P203; MacCallum DE, 1996, ONCOGENE, V13, P2575; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mayo LD, 1997, CANCER RES, V57, P5013; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; MUNSCH D, 2000, IN PRESS J BIOL CHEM, V275; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Prives C, 1999, J PATHOL, V187, P112; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Reinke V, 1997, ONCOGENE, V15, P1527, DOI 10.1038/sj.onc.1201316; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SHICH SY, 1997, CELL, V91, P325; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; TAMURA T, 1995, ONCOGENE, V11, P1939; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; vanParijs L, 1996, CURR OPIN IMMUNOL, V8, P355, DOI 10.1016/S0952-7915(96)80125-7; WALDMAN T, 1995, CANCER RES, V55, P5187; Walker PR, 1997, J IMMUNOL, V158, P4521; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	74	164	170	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 3	2000	19	5					649	660		10.1038/sj.onc.1203366	http://dx.doi.org/10.1038/sj.onc.1203366			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698510				2022-12-17	WOS:000085192000007
J	Snouwaert, JN; Gowen, LC; Latour, AM; Mohn, AR; Xiao, A; DiBiase, L; Koller, BH				Snouwaert, JN; Gowen, LC; Latour, AM; Mohn, AR; Xiao, A; DiBiase, L; Koller, BH			BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a Brca1 transgene	ONCOGENE			English	Article						BRCA1 proteins; homologous recombination; ES cells; DNA repair; non-homologous recombination	DOUBLE-STRAND BREAK; MURINE BRCA1; TRANSCRIPTIONAL ACTIVATION; NUCLEAR PHOSPHOPROTEIN; OVARIAN-CANCER; MEIOTIC CELLS; DNA-DAMAGE; GENE BRCA1; MOUSE; REPAIR	BRCA1 is a nuclear phosphoprotein that has been classified as a tumor suppressor based on the fact that women carrying a mutated copy of the BRCA1 gene are at increased risk of developing breast and ovarian cancer. The association of BRCA1 with RAD51 has led to the hypothesis that BRCA1 is involved in DNA repair. We describe here the generation and analysis of murine embryonic stem (ES) cell lines in which both copies of the murine homologue of the human BRCA1 gene have been disrupted by gene targeting. We show that exogenous DNA introduced into these BRCA1 deficient cells by electroporation is randomly integrated into the genome at a significantly higher rate than in wild type ES cells. In contrast, integration of exogenous DNA by homologous recombination occurs in BRCA1 deficient cells at a significantly lower rate than in wild type controls. When BRCA1 expression is re-established at 5-10% of normal levels by introduction of a Brca1 transgene into BRCA1 deficient ES cells, the frequency of random integration is reduced to wild type levels, although the frequency of homologous recombination is not significantly improved. These results suggest that BRCA1 plays a role in determining the response of cells to double stranded DNA breaks.	Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Koller, BH (corresponding author), Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.			Ramsey, Amy/0000-0002-2717-5279; Morton, Lori/0000-0002-5214-5784	NATIONAL CANCER INSTITUTE [R01CA082423] Funding Source: NIH RePORTER; NCI NIH HHS [CA82423] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chambers JA, 1996, GENOMICS, V38, P305, DOI 10.1006/geno.1996.0633; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen YM, 1996, CANCER RES, V56, P3168; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1; EASTON DF, 1993, AM J HUM GENET, V52, P678; Game J., 1983, YEAST GENETICS FUNDA, P109; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Larson JS, 1997, CANCER RES, V57, P3351; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOHN A, 1995, DNA CLONING, V4, P143; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1997, P NATL ACAD SCI USA, V94, P8988, DOI 10.1073/pnas.94.17.8988; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; REID LH, 1990, P NATL ACAD SCI USA, V87, P4299, DOI 10.1073/pnas.87.11.4299; REID LH, 1991, MOL CELL BIOL, V11, P2769, DOI 10.1128/MCB.11.5.2769; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SHARAN SK, 1995, HUM MOL GENET, V4, P2275, DOI 10.1093/hmg/4.12.2275; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Snouwaert JN, 1998, CURRENT TOPICS ON BRCA1, P33, DOI 10.3233/BD-1998-101-206; Templeton NS, 1997, GENE THER, V4, P700, DOI 10.1038/sj.gt.3300457; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; WARD JF, 1995, RADIAT RES, V142, P362, DOI 10.2307/3579145; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zabludoff SD, 1996, ONCOGENE, V13, P649; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	49	164	165	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 20	1999	18	55					7900	7907		10.1038/sj.onc.1203334	http://dx.doi.org/10.1038/sj.onc.1203334			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	268GL	10630642				2022-12-17	WOS:000084405900006
J	Mashima, T; Naito, M; Tsuruo, T				Mashima, T; Naito, M; Tsuruo, T			Caspase-mediated cleavage of cytoskeletal actin plays a positive role in the process of morphological apoptosis	ONCOGENE			English	Article						caspase; actin; etoposide; morphology; apoptosis	INTERLEUKIN 1-BETA-CONVERTING ENZYME; AGENT-INDUCED APOPTOSIS; ICE-LIKE PROTEASES; INTERLEUKIN-1-BETA-CONVERTING ENZYME; CELL-DEATH; CYTOCHROME-C; PHOSPHATIDYLSERINE EXTERNALIZATION; DNA FRAGMENTATION; ACTIVATION; GELSOLIN	Tumors result from the imbalance between cell growth and apoptosis. One of the characteristic changes in cancers is the abnormality in cytoskeleton, which suggests some roles of cytoskeletal proteins in tumorigenesis or the maintenance of tumor cells. Previously we showed that cytoskeletal actin is the substrate of caspases, the proteases responsible for apoptosis, while the role of actin cleavage in apoptosis remained unknown. To examine the cleavage of actin in vivo, we extensively performed immunoblot analysis using actin fragment-specific antibody. Here, we showed that, in some solid tumor cells, induction of apoptosis was accompanied by caspase-dependent actin-cleavage to 15 and 31 kDa fragments in vivo. To elucidate the role of actin-cleavage further, we introduced actin cleaved-fragments. We found that ectopic expression of an actin 15 kDa fragment induces morphological changes resembling those of apoptotic cells, The expression of the actin fragment induced a dramatic change of cellular actin localization, as visualized by enhanced green fluorescent protein (EGFP)-tagged actin, while the actin fragment expression did not cause caspase activation nor the cleavage of a marker substrate protein, poly (ADP-ribose) polymerase. These results indicate that actin cleavage could play a positive role in the morphological changes of apoptosis downstream of caspase activation.	Univ Tokyo, Inst Mol & Cellular Biosci, Biomed Res Lab, Bunkyo Ku, Tokyo 113, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 170, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Biomed Res Lab, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 113, Japan.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Asch HL, 1996, CANCER RES, V56, P4841; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; CHAPONNIER C, 1989, AM J PATHOL, V134, P597; Chen ZH, 1996, CANCER RES, V56, P5224; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; COTTER TG, 1992, CANCER RES, V52, P997; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Naito M, 1997, BLOOD, V89, P2060, DOI 10.1182/blood.V89.6.2060; NEAMATI N, 1995, J IMMUNOL, V154, P3788; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Shiratsuchi A, 1997, J BIOL CHEM, V272, P2354, DOI 10.1074/jbc.272.4.2354; TANAKA M, 1995, CANCER RES, V55, P3228; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VANDEKERCKHOVE J, 1980, CELL, V22, P893, DOI 10.1016/0092-8674(80)90566-8; Westphal M, 1997, CURR BIOL, V7, P176, DOI 10.1016/S0960-9822(97)70088-5; Wong WW, 1998, AGENT ACTION SUPPL, V49, P5; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	46	164	171	1	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2423	2430		10.1038/sj.onc.1202558	http://dx.doi.org/10.1038/sj.onc.1202558			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229193				2022-12-17	WOS:000079703300002
J	Walker, DR; Bond, JP; Tarone, RE; Harris, CC; Makalowski, W; Boguski, MS; Greenblatt, MS				Walker, DR; Bond, JP; Tarone, RE; Harris, CC; Makalowski, W; Boguski, MS; Greenblatt, MS			Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features	ONCOGENE			English	Article						molecular evolution; missense mutation; crystal structure; DNA binding; domain	TUMOR-SUPPRESSOR; CRYSTAL-STRUCTURE; CELL-LINES; GENE; DOMAIN; SUBSTITUTIONS; APOPTOSIS; CANCER	Missense mutations in p53 frequently occur at 'hotspot' amino acids which are highly conserved and represent regions of structural or functional importance. Using the p53 mutation database and the p53 DNA sequences for 11 species, we more precisely defined the relationships among conservation, mutation frequency and protein structure. We aligned the p53 sequences codon-by-codon and determined the degree of substitution among them. As a whole, p53 is evolving at an average rate for a mammalian protein-coding gene. As expected, the DNA binding domain is evolving more slowly than the carboxy and amino termini, A detailed map of evolutionary conservation shows that within the DNA binding domain there are repeating peaks and valleys of higher and lower evolutionary constraint, Mutation hotspots were identified by comparing the observed distribution of mutations to the pattern expected from a random multinomial distribution, Seventy-three hotspots were identified; these 19% of codons account for 88% of all reported p53 mutations. Both high evolutionary constraint and mutation hotspots are noted at amino acids close to the protein-DNA interface and at others more distant from DNA, often buried within the core of the folded protein but sometimes on its surface. The results indicate that targeting highly conserved regions for mutational and functional analysis may be efficient strategies for the study of cancer-related genes.	NCI, Natl Ctr Biotechnol Informat, Natl Lib Med, NIH, Bethesda, MD 20894 USA; NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA; NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH National Library of Medicine (NLM); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University	Greenblatt, MS (corresponding author), Univ Vermont, Coll Med, Dept Med, Hematol Oncol Unit, Patrick 534,MCHV Campus, Burlington, VT 05401 USA.		Makalowski, Wojciech/I-2843-2016	Makalowski, Wojciech/0000-0003-2303-9541	DIVISION OF BASIC SCIENCES - NCI [Z01BC005794] Funding Source: NIH RePORTER; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [Z01CP010130] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; INA Y, 1995, J MOL EVOL, V40, P190, DOI 10.1007/BF00167113; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KYTE J, 1995, MECH PROTEIN CHEM; Li W.H., 1997, MOL EVOLUTION; LI WH, 1991, FUNDAMENTALS MOL EVO, P69; MAKALOWSKI W, 1998, IN PRESS P NATL ACAD; Miller R. G., 1981, SIMULTANEOUS STAT IN, P6; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Rodin SN, 1998, INT J MOL MED, V1, P191; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SOUSSI T, 1990, ONCOGENE, V5, P945; SVED J, 1990, P NATL ACAD SCI USA, V87, P4692, DOI 10.1073/pnas.87.12.4692; TICHER A, 1989, J MOL EVOL, V28, P286, DOI 10.1007/BF02103424; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; WALKER DR, 1997, INTELL SYST MOL BIOL, V5, P333; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219	27	164	169	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					211	218		10.1038/sj.onc.1202298	http://dx.doi.org/10.1038/sj.onc.1202298			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926936				2022-12-17	WOS:000078166000023
J	Jain, N; Zhang, T; Fong, SL; Lim, CP; Cao, XM				Jain, N; Zhang, T; Fong, SL; Lim, CP; Cao, XM			Repression of Stat3 activity by activation of mitogen-activated protein kinase (MAPK)	ONCOGENE			English	Article						repression; Stat3 transactivation; ERK2; phosphorylation; association	EPIDERMAL GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; C-FOS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; SIGNAL-TRANSDUCTION; CYTOKINE RECEPTORS; INTERFERON-ALPHA; GENE-EXPRESSION	STAT proteins are activated by phosphorylation at specific tyrosine residue at the carboxy-terminus which is required for dimer-formation, nuclear translocation, DNA binding and transcriptional activity in cells treated with cytokines and growth factors. Recent studies have indicated that STATs are also phosphorylated by MAPK, or extracellular signal-regulated kinase (ERK) on serine, We investigated the role of ERK on the regulation of STAT activity. Here, we report that ERK2 activated by its upstream kinase, MEK1, represses Stat3 transcriptional activity induced by Src or Jak-2, To unravel the mechanism of repression, we further showed that Stat3 DNA binding activity and its tyrosine phosphorylation are also inhibited under the same conditions. ERK2 phosphorylates Stat3 on three serine-containing peptides and decreases its tyrosine phosphorylation induced by EGF treatment. We also detected an association of ERK2 and Stall in vivo which is modulated positively by activation of ERK2, but negatively by Jak2, We propose that MAP kinase cascade may negatively regulate Stat3 activities by decreasing its tyrosine phosphorylation and also possibly by association.	Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Cao, XM (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117609, Singapore.							AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAO XM, 1993, J BIOL CHEM, V268, P16949; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HELM MH, 1995, SCIENCE, V267, P1347; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jain N, 1996, J BIOL CHEM, V271, P13530, DOI 10.1074/jbc.271.23.13530; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	45	164	176	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	1998	17	24					3157	3167		10.1038/sj.onc.1202238	http://dx.doi.org/10.1038/sj.onc.1202238			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872331				2022-12-17	WOS:000077517400009
J	Lanoix, J; DAgati, V; Szabolcs, M; Trudel, M				Lanoix, J; DAgati, V; Szabolcs, M; Trudel, M			Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD)	ONCOGENE			English	Article						ADPKD; proliferation; apoptosis	C-MYC; TRANSGENIC MICE; PROTOONCOGENE EXPRESSION; EPITHELIAL HYPERPLASIA; B-CELLS; DEATH; BCL-2; GENE; PROTEIN; P53	The proto-oncogene c-myc has been implicated in both cellular proliferation and apoptosis, and we have shown that overexpression of c-myc can induce polycystic kidney disease in transgenic mice, To elucidate the molecular and cellular defects underlying cystogenesis, we have investigated the potential roles of cell proliferation and apoptosis as they relate to c-myc and modulators of c-myc function in human autosomal dominant polycystic kidney disease (ADPKD), Renal c-myc expression was consistently elevated, up to 15-fold, in ADPKD, High levels of c-myc expression correlated with 10- to 100-fold increased proliferation index in cystic epithelium, Interestingly, steady-state levels of bcl-2 mRNA were also increased up to 20-fold and Bcl-2 protein was markedly elevated. In contrast, the expression of bax and p53 was virtually unchanged. However, apoptosis was consistently and significantly increased in ADPKD kidneys, unchecked by high levels of Bcl-2, Together with proliferation, apoptosis may thus represent a general mechanism for cyst growth and tissue remodeling. We conclude that both epithelial cell proliferation and apoptosis required for normal kidney homeostasis are deregulated in ADPKD, regulating the renal developmental program. Furthermore, abnormal expression of proto-oncogenes regulating these processes is an important mediator of cystogenesis in human ADPKD.	UNIV MONTREAL,FAC MED,INST RECH CLIN MONTREAL,MONTREAL,PQ,CANADA; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Columbia University					NIDDK NIH HHS [DK 44864] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044864] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1994, CELL, V77, P881; [Anonymous], 1995, CELL, V81, P289; AVNER ED, 1992, P NATL ACAD SCI USA, V89, P7447, DOI 10.1073/pnas.89.16.7447; BARISONI L, 1995, AM J PATHOL, V147, P1728; BERNSTEIN J, 1987, AM J PATHOL, V129, P92; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BURN TC, 1995, HUM MOL GENET, V4, P575, DOI 10.1093/hmg/4.4.575; CHEN IT, 1986, P NATL ACAD SCI USA, V83, P6907, DOI 10.1073/pnas.83.18.6907; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COWLEY BD, 1987, P NATL ACAD SCI USA, V84, P8394, DOI 10.1073/pnas.84.23.8394; COWLEY BD, 1991, J AM SOC NEPHROL, V1, P1048; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; Daoust Martin C., 1994, Clinical and Investigative Medicine, V17, pB97; EVAN AP, 1979, KIDNEY INT, V16, P743, DOI 10.1038/ki.1979.191; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GRANTHAM JJ, 1990, AM J KIDNEY DIS, V15, P110, DOI 10.1016/S0272-6386(12)80507-5; GRANTHAM JJ, 1987, KIDNEY INT, V31, P1145, DOI 10.1038/ki.1987.121; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KOSEKI C, 1992, J CELL BIOL, V119, P1327, DOI 10.1083/jcb.119.5.1327; MICHAUD J, 1994, AM J MED GENET, V51, P240, DOI 10.1002/ajmg.1320510314; MIYASHITA T, 1995, CELL, V80, P293; MUGRAUER G, 1991, J CELL BIOL, V112, P13, DOI 10.1083/jcb.112.1.13; NADASDY T, 1995, J AM SOC NEPHROL, V5, P1462; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PULENDRAN B, 1995, NATURE, V375, P331, DOI 10.1038/375331a0; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; SCHMID P, 1989, SCIENCE, V243, P226, DOI 10.1126/science.2911736; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; Szabolcs Matthias J., 1993, Journal of the American Society of Nephrology, V4, P690; TRUDEL M, 1991, KIDNEY INT, V39, P665, DOI 10.1038/ki.1991.80; TRUDEL M, 1994, MAMM GENOME, V5, P149, DOI 10.1007/BF00352345; VANADELSBERG JS, 1995, NAT MED, V1, P359, DOI 10.1038/nm0495-359; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WILSON PD, 1991, KIDNEY INT, V39, P450, DOI 10.1038/ki.1991.56; WILSON PD, 1986, KIDNEY INT, V30, P371, DOI 10.1038/ki.1986.194; WOO D, 1995, NEW ENGL J MED, V333, P18, DOI 10.1056/NEJM199507063330104; Yin DX, 1996, P NATL ACAD SCI USA, V93, P3394, DOI 10.1073/pnas.93.8.3394	50	164	171	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1153	1160						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808689				2022-12-17	WOS:A1996VJ20200006
J	BUTZ, K; SHAHABEDDIN, L; GEISEN, C; SPITKOVSKY, D; ULLMANN, A; HOPPESEYLER, F				BUTZ, K; SHAHABEDDIN, L; GEISEN, C; SPITKOVSKY, D; ULLMANN, A; HOPPESEYLER, F			FUNCTIONAL P53 PROTEIN IN HUMAN PAPILLOMAVIRUS-POSITIVE CANCER-CELLS	ONCOGENE			English	Article						TUMOR VIRUS; TUMOR SUPPRESSOR GENES; P21; P53; HPV	WILD-TYPE P53; DNA-DAMAGE; ONCOGENE EXPRESSION; IONIZING-RADIATION; CELLULAR-RESPONSE; MUTANT P53; TRANSCRIPTION; BINDING; E6; SEQUENCES	There is accumulating evidence that the p53 protein contributes to tumor suppression by stimulating the transcription of specific cellular genes, such as the cell cycle control gene WAF1/ClP1. p53-mediated transcriptional activation is inhibited in cotransfection assays by overexpressed E6 protein from cancer-associated human papillomavirus (HPV) types, pointing at a possible molecular mechanism by which these viruses contribute to malignant cell, transformation. Here we analysed the transcriptional transactivation function of endogenous p53 protein in a series of cervical cancer cell lines, which express the E6 gene from integrated viral sequences. Transient and stable transfection analyses employing p53-responsive reporter constructs indicated that HPV-positive cervical cancer cells contained transactivating p53 protein, Treatment of HPV-positive cells with genotoxic agents, such as mitomycin C, cisplatin, or u.v. irradiation, resulted in an increase of nuclear p53 protein levels and enhanced binding of p53 to a p53-recognition site. These effects were accompanied by an increase of WAF1/ClP1 mRNA levels. In several HPV-positive cell lines, these molecular events were linked to a cell cycle arrest in G(1). In contrast, cancer cells containing mutant p53 genes did not contain transactivating endogenous p53 protein and lacked the p53-mediated response to DNA damaging agents. These results indicate that the tumorigenic phenotype of HPV-positive cancer cell lines does not necessarily correlate with a lack of basal or DNA damage induced p53 activities and that therefore the presence of high risk HPV sequences is not functionally equivalent to the loss of p53 function through somatic mutations of the p53 gene.	DEUTSCH KREBSFORSCHUNGSZENTRUM, PROJEKTGRP ANGEW TUMORVIROL, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)				Hoppe-Seyler, Felix/0000-0002-1864-300X				ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BOHM S, 1993, INT J CANCER, V55, P791, DOI 10.1002/ijc.2910550517; BUTZ K, 1993, J VIROL, V67, P6476, DOI 10.1128/JVI.67.11.6476-6486.1993; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1994, ONCOGENE, V9, P1225; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUJITA M, 1992, CANCER RES, V52, P5323; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GU ZM, 1994, ONCOGENE, V9, P629; HARPER JW, 1993, CELL, V75, P805; HAUSEN HZ, 1989, CANCER RES, V49, P4677; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HOPPESEYLER F, 1991, J VIROL, V65, P5613, DOI 10.1128/JVI.65.10.5613-5618.1991; HOPPESEYLER F, 1991, NUCLEIC ACIDS RES, V19, P5080, DOI 10.1093/nar/19.18.5080; HOPPESEYLER F, 1992, NUCLEIC ACIDS RES, V20, P6701, DOI 10.1093/nar/20.24.6701; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MITSUDOMI T, 1992, ONCOGENE, V7, P171; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PARK DJ, 1994, ONCOGENE, V9, P205; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; PIM D, 1994, ONCOGENE, V9, P1869; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REUTER S, 1991, J VIROL, V65, P5564, DOI 10.1128/JVI.65.10.5564-5568.1991; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VONKNEBELDOEBERITZ M, 1994, J VIROL, V68, P2811, DOI 10.1128/JVI.68.5.2811-2821.1994; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YEE C, 1985, AM J PATHOL, V119, P361; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	65	164	166	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	1995	10	5					927	936						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898934				2022-12-17	WOS:A1995QL03800014
J	CHAZIN, VR; KALEKO, M; MILLER, AD; SLAMON, DJ				CHAZIN, VR; KALEKO, M; MILLER, AD; SLAMON, DJ			TRANSFORMATION MEDIATED BY THE HUMAN HER-2 GENE INDEPENDENT OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR	ONCOGENE			English	Article							TYROSINE KINASE-ACTIVITY; HUMAN-BREAST-CANCER; NEU ONCOGENE; EGF RECEPTOR; MONOCLONAL-ANTIBODIES; C-ERBB-2 PROTEIN; POINT MUTATION; OVARIAN-CANCER; CELL-GROWTH; 3T3 CELLS	Amplification of the HER-2 (c-erbB-2) gene and overexpression of the p185HER-2 gene product is found in approximately one-third of primary human breast and ovarian cancers and is associated with a poor clinical outcome of early relapse and death. The HER-2 gene encodes a cell-surface growth factor receptor with intrinsic tyrosine kinase activity. Wild-type human HER-2 has been shown to act as a potent oncogene when overexpressed in mouse fibroblasts. Recent data suggest that the mechanism by which HER-2 mediates transformation requires the interaction of the epidermal growth factor (EGF) receptor. To test whether overexpression of normal human HER-2 can transform cells independently of the EGF receptor, we have introduced multiple copies of HER-2 into the EGF receptor-negative cell line, NR6, and have performed assays for both transformation and tumorigenicity. Engineered NR6 cells that overexpress the HER-2 gene product display a highly transformed and tumorigenic phenotype as compared with control cells. Additionally, a monoclonal antibody to the extracellular domain of the HER-2 receptor is able to inhibit the proliferation of the overexpressing cells in vitro as well as tumor growth in vivo. This study provides clear evidence that HER-2-mediated transformation can be achieved independently of the EGF receptor.	UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; FRED HUTCHINSON CANC RES CTR,DEPT MOLEC MED,SEATTLE,WA 98104	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Fred Hutchinson Cancer Center				Miller, Dusty/0000-0002-3736-3660	NATIONAL CANCER INSTITUTE [R01CA036827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36827] Funding Source: Medline; NIGMS NIH HHS [GM-07185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERCHUCK A, 1990, CANCER RES, V50, P4087; Chen E, 1986, Biochem Soc Symp, V52, P65; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KUMAR R, 1991, MOL CELL BIOL, V11, P976; LEMOINE NR, 1990, ONCOGENE, V5, P237; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; OREILLY SM, 1991, BRIT J CANCER, V63, P444, DOI 10.1038/bjc.1991.102; OSBORNE WRA, 1988, P NATL ACAD SCI USA, V85, P6851, DOI 10.1073/pnas.85.18.6851; PRESS MF, 1984, LAB INVEST, V50, P480; PRESS MF, 1988, ENDOCRINOLOGY, V122, P1165, DOI 10.1210/endo-122-3-1165; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; SARUP JC, 1991, GROWTH REGULAT, V1, P72; SAYA H, 1990, MOL CARCINOGEN, V3, P198, DOI 10.1002/mc.2940030406; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1989, CANCER CEL, V7, P371; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179	47	164	179	2	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1859	1866						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1354348				2022-12-17	WOS:A1992JJ37600023
J	MILNE, DM; PALMER, RH; CAMPBELL, DG; MEEK, DW				MILNE, DM; PALMER, RH; CAMPBELL, DG; MEEK, DW			PHOSPHORYLATION OF THE P53 TUMOR-SUPPRESSOR PROTEIN AT 3 N-TERMINAL SITES BY A NOVEL CASEIN KINASE I-LIKE ENZYME	ONCOGENE			English	Article							LARGE T-ANTIGEN; GLYCOGEN-SYNTHASE; DNA-REPLICATION; MOUSE P53; WILD-TYPE; SV40-TRANSFORMED CELLS; 3T3 CELLS; ONCOGENE; TRANSFORMATION; IDENTIFICATION	Wild-type mouse p53, expressed in Escherichia coli, was phosphorylated by highly purified casein kinase I (CKI) from rabbit muscle. The major site of phosphorylation in the p53 was identified as serine 6, which is known to be phosphorylated in vivo. Serines 4 and 9 were also phosphorylated. To determine whether CKI is likely to be a physiological p53 kinase, SV3T3 cell lysates were fractionated on a Mono Q column and assayed for p53 kinase and casein kinase activities. Four p53 kinase activities were detected, one of which co-purified with CKI activity. This p53 kinase (designated PK270) further co-purified with CKI on sucrose gradients and had a native molecular weight, like CKI, in the range of 35000-45000. However, PK270 was separated from the bulk of CKI activity on a phosvitin-Sepharose affinity column, and was therefore likely to be a CKI-related kinase. In support of these conclusions, phosphorylation of p53, by both CKI and PK270, was inhibited by a peptide corresponding to a consensus CKI target sequence, but not by a non-specific peptide. Moreover, phosphopeptide analyses of p53 phosphorylated by CKI or by PK270 gave similar results, indicating that these two kinases phosphorylate the same sites in p53.	UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND	University of Dundee			Campbell, David G/K-1874-2015	Campbell, David G/0000-0003-2278-2149				ADDISON C, 1990, ONCOGENE, V5, P423; AGOSTINIS P, 1989, FEBS LETT, V259, P75, DOI 10.1016/0014-5793(89)81498-X; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GRAESSER FA, 1988, VIROLOGY, V165, P13; GREEN MR, 1989, CELL, V51, P1; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HERRMANN CPE, 1991, ONCOGENE, V6, P877; KURET J, 1985, EUR J BIOCHEM, V151, P39, DOI 10.1111/j.1432-1033.1985.tb09066.x; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MEEK DW, 1990, J VIROL, V64, P1734, DOI 10.1128/JVI.64.4.1734-1744.1990; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1990, ONCOGENE, V5, P973; MUNDAY MR, 1988, EUR J BIOCHEM, V175, P331, DOI 10.1111/j.1432-1033.1988.tb14201.x; NAKIELNY S, 1991, EUR J BIOCHEM, V199, P713, DOI 10.1111/j.1432-1033.1991.tb16175.x; OROURKE RW, 1990, ONCOGENE, V5, P1829; PATCHINSKY T, 1990, ONCOGENE, V5, P1071; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; POTTER V, 1980, J VIROL, V36, P547; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; SAMAD A, 1991, MOL CELL BIOL, V11, P1598, DOI 10.1128/MCB.11.3.1598; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1988, ONCOGENE, V3, P405; STURZBECHER HW, 1987, VIROLOGY, V160, P445; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG YH, 1986, J BIOL CHEM, V261, P6909; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	57	164	165	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1361	1369						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620549				2022-12-17	WOS:A1992HZ97100015
J	Fong, WN; Li, Q; Yu, J				Fong, Winnie; Li, Qing; Yu, Jun			Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer	ONCOGENE			English	Review							LACTOBACILLUS-RHAMNOSUS GG; LACTIC-ACID BACTERIA; COLON-CANCER; PROBIOTIC LACTOBACILLUS; INTESTINAL MICROBIOTA; DOUBLE-BLIND; ACIDOPHILUS DEFICIENT; ESCHERICHIA-COLI; BARRIER FUNCTION; POTENTIAL ROLE	Research about the role of gut microbiome in colorectal cancer (CRC) is a newly emerging field of study. Gut microbiota modulation, with the aim to reverse established microbial dysbiosis, is a novel strategy for prevention and treatment of CRC. Different strategies including probiotics, prebiotics, postbiotics, antibiotics, and fecal microbiota transplantation (FMT) have been employed. Although these strategies show promising results, mechanistically by correcting microbiota composition, modulating innate immune system, enhancing gut barrier function, preventing pathogen colonization and exerting selective cytotoxicity against tumor cells, it should be noted that they are accompanied by risks and controversies that can potentially introduce clinical complications. During bench-to-bedside translation, evaluation of risk-and-benefit ratio, as well as patient selection, should be carefully performed. In view of the individualized host response to gut microbiome intervention, developing personalized microbiome therapy may be the key to successful clinical treatment.	[Fong, Winnie; Li, Qing; Yu, Jun] Chinese Univ Hong Kong, Inst Digest Dis & Dept Med & Therapeut, State Key Lab Digest Dis,Li Ka Shing Inst Hlth Sc, CUHK Shenzhen Res Inst, Hong Kong, Peoples R China; [Fong, Winnie] Chinese Univ Hong Kong, Sch Pharm, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis & Dept Med & Therapeut, State Key Lab Digest Dis,Li Ka Shing Inst Hlth Sc, CUHK Shenzhen Res Inst, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Li, Qing/ABC-4649-2020; Jun, Yu/D-8569-2015	Li, Qing/0000-0002-0169-8098; Jun, Yu/0000-0001-5008-2153	National Natural Science Foundation of China (National Science Foundation of China) [81972576] Funding Source: Medline	National Natural Science Foundation of China (National Science Foundation of China)(National Natural Science Foundation of China (NSFC))		Ahmad R, 2017, ONCOGENE, V36, P6592, DOI 10.1038/onc.2017.259; Alang N, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv004; Alvarez CS, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01981; Ambalam P, 2016, BEST PRACT RES CL GA, V30, P119, DOI 10.1016/j.bpg.2016.02.009; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Azcarate-Peril MA, 2017, P NATL ACAD SCI USA, V114, pE367, DOI 10.1073/pnas.1606722113; Belcheva A, 2014, CELL, V158, P288, DOI 10.1016/j.cell.2014.04.051; Bermudez-Brito M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059370; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bullman S, 2017, SCIENCE, V358, P1443, DOI 10.1126/science.aal5240; Bultman SJ, 2014, CELL HOST MICROBE, V16, P143, DOI 10.1016/j.chom.2014.07.011; Campana R, 2017, GUT PATHOG, V9, DOI 10.1186/s13099-017-0162-4; Canani RB, 2011, WORLD J GASTROENTERO, V17, P1519, DOI [10.3748/wjg.v17.i12.1519, 10.3748/wjg.v17.i12. 1519]; Cannon JP, 2005, EUR J CLIN MICROBIOL, V24, P31, DOI 10.1007/s10096-004-1253-y; Cao HL, 2017, INT J CANCER, V140, P2545, DOI 10.1002/ijc.30643; Cao Y, 2018, GUT, V67, P672, DOI 10.1136/gutjnl-2016-313413; Chang CW, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00983; Chen CC, 2012, BRIT J NUTR, V107, P1623, DOI 10.1017/S0007114511004934; Chen LL, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/909514; Chen ZF, 2015, FUTURE MICROBIOL, V10, P1433, DOI 10.2217/fmb.15.66; Chen ZY, 2017, MOLECULES, V22, DOI 10.3390/molecules22010107; Chung L, 2018, CELL HOST MICROBE, V23, P421, DOI 10.1016/j.chom.2018.02.004; Crook N, 2019, CELL HOST MICROBE, V25, P499, DOI 10.1016/j.chom.2019.02.005; Cui M, 2017, EMBO MOL MED, V9, P448, DOI 10.15252/emmm.201606932; Dai ZW, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0451-2; Daillere R, 2016, IMMUNITY, V45, P931, DOI 10.1016/j.immuni.2016.09.009; De Marco S, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/1756308; Delia P, 2007, WORLD J GASTROENTERO, V13, P912, DOI 10.3748/wjg.v13.i6.912; Demers M, 2014, CLIN NUTR, V33, P761, DOI 10.1016/j.clnu.2013.10.015; Derosa L, 2018, ANN ONCOL, V29, P1437, DOI 10.1093/annonc/mdy103; Dewulf EM, 2013, GUT, V62, P1112, DOI 10.1136/gutjnl-2012-303304; Dik VK, 2016, DIGEST DIS SCI, V61, P255, DOI 10.1007/s10620-015-3828-0; Doron S, 2015, CLIN INFECT DIS, V60, pS129, DOI 10.1093/cid/civ085; Escamilla J, 2012, NUTR CANCER, V64, P871, DOI 10.1080/01635581.2012.700758; Fayol-Messaoudi D, 2005, APPL ENVIRON MICROB, V71, P6008, DOI 10.1128/AEM.71.10.6008-6013.2005; Feng Q, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7528; Food and Drug Administration, 2019, IMP SAF AL REG US FE; Forchielli ML, 2005, BRIT J NUTR, V93, pS41, DOI 10.1079/BJN20041356; Fukuda S, 2011, NATURE, V469, P543, DOI 10.1038/nature09646; Gamallat Y, 2016, BIOMED PHARMACOTHER, V83, P536, DOI 10.1016/j.biopha.2016.07.001; Gao J, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00477; Geier MS, 2006, CANCER BIOL THER, V5, P1265, DOI 10.4161/cbt.5.10.3296; Geller LT, 2017, SCIENCE, V357, P1156, DOI 10.1126/science.aah5043; Ghadimi D, 2012, J LEUKOCYTE BIOL, V92, P895, DOI 10.1189/jlb.0611286; Gibson GR, 2017, NAT REV GASTRO HEPAT, V14, P491, DOI 10.1038/nrgastro.2017.75; Gibson GR, 2000, J NUTR, V130, p391S, DOI 10.1093/jn/130.2.391S; GIBSON GR, 1995, J NUTR, V125, P1401, DOI 10.1093/jn/125.6.1401; Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234; Gillor O, 2008, APPL MICROBIOL BIOT, V81, P591, DOI 10.1007/s00253-008-1726-5; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Gregory JC, 2015, J BIOL CHEM, V290, P5647, DOI 10.1074/jbc.M114.618249; Gueimonde M, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00202; Hassan H, 2018, SUPPORT CARE CANCER, V26, P2503, DOI 10.1007/s00520-018-4216-z; Hattori N, 2019, CANCER SCI, V110, P147, DOI 10.1111/cas.13880; Hohmann EL, 2014, NEW ENGL J MED, V371, P668, DOI 10.1056/NEJMcpc1400842; Hu YF, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3151; Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527; Ijssennagger N, 2015, P NATL ACAD SCI USA, V112, P10038, DOI 10.1073/pnas.1507645112; Ishikawa H, 2005, INT J CANCER, V116, P762, DOI 10.1002/ijc.21115; Ito H, 2011, J AGR FOOD CHEM, V59, P5771, DOI 10.1021/jf200859z; Jacobsen L, 2007, FEMS MICROBIOL ECOL, V59, P158, DOI 10.1111/j.1574-6941.2006.00212.x; Jacouton E, 2019, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03281; Jeon Seong Gyu, 2012, PLoS Pathog, V8, pe1002714, DOI 10.1371/journal.ppat.1002714; Kamada N, 2012, SCIENCE, V336, P1325, DOI 10.1126/science.1222195; Khazaie K, 2012, P NATL ACAD SCI USA, V109, P10462, DOI 10.1073/pnas.1207230109; Kilkkinen A, 2008, INT J CANCER, V123, P2152, DOI 10.1002/ijc.23622; Klaenhammer TR, 2012, NAT REV IMMUNOL, V12, P728, DOI 10.1038/nri3312; Konieczna P, 2012, GUT, V61, P354, DOI 10.1136/gutjnl-2011-300936; Konishi H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12365; Konstantinov SR, 2013, NAT REV GASTRO HEPAT, V10, P741, DOI 10.1038/nrgastro.2013.178; Kotzampassi K, 2015, WORLD J SURG, V39, P2776, DOI 10.1007/s00268-015-3071-z; Kroemer G, 2018, NAT REV IMMUNOL, V18, P87, DOI 10.1038/nri.2018.4; Kumar M, 2017, AM J PHYSIOL-GASTR L, V312, pG34, DOI 10.1152/ajpgi.00298.2016; Kuugbee ED, 2016, DIGEST DIS SCI, V61, P2908, DOI 10.1007/s10620-016-4238-7; Kyriacou DN, 2016, JAMA-J AM MED ASSOC, V316, P1818, DOI 10.1001/jama.2016.16435; Lenoir M, 2016, J GASTROENTEROL, V51, P862, DOI 10.1007/s00535-015-1158-9; Li HL, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00455; Lin XXB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083644; Lindsay JO, 2006, GUT, V55, P348, DOI 10.1136/gut.2005.074971; Liu C, 2009, BIOMED ENVIRON SCI, V22, P401, DOI 10.1016/S0895-3988(10)60018-9; Liu Z, 2011, ALIMENT PHARM THER, V33, P50, DOI 10.1111/j.1365-2036.2010.04492.x; Liu ZH, 2013, AM J CLIN NUTR, V97, P117, DOI 10.3945/ajcn.112.040949; Long XH, 2019, NAT MICROBIOL, V4, P2319, DOI 10.1038/s41564-019-0541-3; Mackowiak Philip A, 2013, Front Public Health, V1, P52, DOI 10.3389/fpubh.2013.00052; Maier TV, 2017, MBIO, V8, DOI [10.1128/mbio.01343-17, 10.1128/mBio.01343-17]; Martin R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41738-5; Mego M, 2015, COMPLEMENT THER MED, V23, P356, DOI 10.1016/j.ctim.2015.03.008; Mi H, 2017, CELL PHYSIOL BIOCHEM, V42, P2330, DOI 10.1159/000480005; Miller LE, 2017, NUTRIENTS, V9, DOI 10.3390/nu9030191; Mills JP, 2018, CURR OPIN GASTROEN, V34, P3, DOI 10.1097/MOG.0000000000000410; Mima K, 2016, GUT, V65, P1973, DOI 10.1136/gutjnl-2015-310101; Mohamadzadeh M, 2011, P NATL ACAD SCI USA, V108, P4623, DOI 10.1073/pnas.1005066107; Monteagudo-Mera A, 2019, APPL MICROBIOL BIOT, V103, P6463, DOI 10.1007/s00253-019-09978-7; Osterlund P, 2007, BRIT J CANCER, V97, P1028, DOI 10.1038/sj.bjc.6603990; Parkin DM, 2011, BRIT J CANCER, V105, pS77, DOI 10.1038/bjc.2011.489; Piewngam P, 2018, NATURE, V562, P532, DOI 10.1038/s41586-018-0616-y; Puppa MJ, 2011, BBA-MOL BASIS DIS, V1812, P1601, DOI 10.1016/j.bbadis.2011.08.010; Quera R, 2014, J CROHNS COLITIS, V8, P252, DOI 10.1016/j.crohns.2013.10.002; Rafter J, 2007, AM J CLIN NUTR, V85, P488, DOI 10.1093/ajcn/85.2.488; Ridaura VK, 2013, SCIENCE, V341, P1079, DOI 10.1126/science.1241214; Rocha-Ramirez LM, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/4607491; Rosshart SP, 2017, CELL, V171, P1015, DOI 10.1016/j.cell.2017.09.016; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Rubinstein MR, 2013, CELL HOST MICROBE, V14, P195, DOI 10.1016/j.chom.2013.07.012; Salva S, 2014, INT IMMUNOPHARMACOL, V22, P209, DOI 10.1016/j.intimp.2014.06.017; Sanders ME, 2018, CURR OPIN BIOTECH, V49, P207, DOI 10.1016/j.copbio.2017.09.007; Sanders ME, 2010, GUT MICROBES, V1, P164, DOI 10.4161/gmic.1.3.12127; Sangild PT, 2018, AM J PHYSIOL-GASTR L, V314, pG231, DOI 10.1152/ajpgi.00204.2017; Schwartz M, 2013, AM J GASTROENTEROL, V108, P1367, DOI 10.1038/ajg.2013.164; Scott AJ, 2019, GUT, V68, P1624, DOI 10.1136/gutjnl-2019-318556; Sekirov I, 2010, PHYSIOL REV, V90, P859, DOI 10.1152/physrev.00045.2009; Sethi V, 2018, GASTROENTEROLOGY, V155, P33, DOI 10.1053/j.gastro.2018.04.001; Shields CED, 2016, J INFECT DIS, V214, P122, DOI 10.1093/infdis/jiw069; Shin W, 2018, P NATL ACAD SCI USA, V115, pE10539, DOI 10.1073/pnas.1810819115; Shoaf K, 2006, INFECT IMMUN, V74, P6920, DOI 10.1128/IAI.01030-06; Sichetti M, 2018, NUTRITION, V53, P95, DOI 10.1016/j.nut.2018.02.005; Singh V, 2018, CELL, V175, P679, DOI 10.1016/j.cell.2018.09.004; Sitaraman R, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0551-z; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Skye SM, 2018, CIRC RES, V123, P1164, DOI 10.1161/CIRCRESAHA.118.313142; Smits LP, 2013, GASTROENTEROLOGY, V145, P946, DOI 10.1053/j.gastro.2013.08.058; Soler AP, 1999, CARCINOGENESIS, V20, P1425, DOI 10.1093/carcin/20.8.1425; Southcott E, 2008, DIGEST DIS SCI, V53, P1837, DOI 10.1007/s10620-008-0275-1; Taper HS, 2005, IN VIVO, V19, P201; Tong LC, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00253; Toomey N, 2009, FOODBORNE PATHOG DIS, V6, P925, DOI 10.1089/fpd.2009.0278; Triner D, 2019, GASTROENTEROLOGY, V156, P1467, DOI 10.1053/j.gastro.2018.12.003; Tuomola EM, 1999, FEMS IMMUNOL MED MIC, V26, P137, DOI 10.1111/j.1574-695X.1999.tb01381.x; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537; Wang F, 2018, P NATL ACAD SCI USA, V115, P157, DOI 10.1073/pnas.1712901115; Wang LH, 2014, J BIOL CHEM, V289, P20234, DOI 10.1074/jbc.M114.553800; Wang Y, 2017, MUCOSAL IMMUNOL, V10, P373, DOI 10.1038/mi.2016.57; Wang ZK, 2014, WORLD J GASTROENTERO, V20, P14805, DOI 10.3748/wjg.v20.i40.14805; Weingarden AR, 2017, GUT MICROBES, V8, P238, DOI 10.1080/19490976.2017.1290757; Willing BP, 2011, NAT REV MICROBIOL, V9, P233, DOI 10.1038/nrmicro2536; Wong JMW, 2006, J CLIN GASTROENTEROL, V40, P235, DOI 10.1097/00004836-200603000-00015; Yan F, 2012, GUT MICROBES, V3, P25, DOI 10.4161/gmic.19245; Yang YZ, 2017, GASTROENTEROLOGY, V152, P851, DOI 10.1053/j.gastro.2016.11.018; Yang YZ, 2016, ONCOTARGET, V7, P8432, DOI 10.18632/oncotarget.7045; Yeung CY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138746; Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008; Zackular JP, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00001-15; Zackular JP, 2013, MBIO, V4, DOI 10.1128/mBio.00692-13; Zaharuddin L, 2019, BMC GASTROENTEROL, V19, DOI 10.1186/s12876-019-1047-4; Zhao S, 2019, LUNG CANCER, V130, P10, DOI 10.1016/j.lungcan.2019.01.017; Zyrek AA, 2007, CELL MICROBIOL, V9, P804, DOI 10.1111/j.1462-5822.2006.00836.x	147	163	164	23	97	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 25	2020	39	26					4925	4943		10.1038/s41388-020-1341-1	http://dx.doi.org/10.1038/s41388-020-1341-1		JUN 2020	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MQ2YO	32514151	Green Published, hybrid			2022-12-17	WOS:000538969800002
J	Xu, Y; Zhao, F; Wang, Z; Song, Y; Luo, Y; Zhang, X; Jiang, L; Sun, Z; Miao, Z; Xu, H				Xu, Y.; Zhao, F.; Wang, Z.; Song, Y.; Luo, Y.; Zhang, X.; Jiang, L.; Sun, Z.; Miao, Z.; Xu, H.			MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1	ONCOGENE			English	Article						MicroRNA; gastric cancer; miR-335; SP1; Bcl-w	TRANSCRIPTION FACTOR SP1; SINGLE NUCLEOTIDE POLYMORPHISM; DOWN-REGULATION; TUMOR-SUPPRESSOR; EXPRESSION; GENE; FAMILY; RISK; PROLIFERATION; APOPTOSIS	Aberrant expression of miR-335 has been frequently reported in cancer studies, suggesting that there is a close correlation between miR-335 and cancer during its development, progression, metastasis and prognosis. The expression of miR-335 in gastric cancer and its effects are not known. Relative expression of miR-335 in 4 gastric cancer cell lines and in 70 gastric cancer tissues was confirmed by real-time quantitative reverse transcriptase-PCR compared with controls. Transwell cell migration and Matrigel invasion assay in vitro and metastasis formation assay in vivo were used to examine the effects of miR-335 expression on gastric cancer cell invasion and metastasis. The effect of miR-335 expression on gastric cancer cell proliferation was estimated by the 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay. Luciferase reporter assay and western blot were used to examine the potential target genes and related pathways. Gene silencing with small-interfering RNA was used to examine the effects of target genes on gastric cancer cell invasion. miR-335 was dramatically down-regulated in gastric cancer cell lines than in the normal gastric cell line GES-1. Low expression of miR-335 was significantly associated with lymph-node metastasis, poor pT stage, poor pN stage and invasion of lymphatic vessels. Overexpression of miR-335 suppressed gastric cancer cell invasion and metastasis in vitro and in vivo, but has no significant effects on cell proliferation. Furthermore, miR-335 might suppress gastric cancer invasion and metastasis by targeting Bcl-w and specificity protein 1 (SP1). Taken together, our results provide evidence that miR-335 might function as a metastasis suppressor in gastric cancer by targeting SP1 directly and indirectly through the Bcl-w-induced phosphoinositide 3-kinase-Akt-Sp1 pathway. miR-335 showing altered expression at different stages of gastric cancer could be a target for gastric cancer therapies and could be further developed as a potential prognostic factor. Oncogene (2012) 31, 1398-1407; doi:10.1038/onc.2011.340; published online 8 August 2011	[Xu, Y.; Zhao, F.; Wang, Z.; Song, Y.; Sun, Z.; Miao, Z.; Xu, H.] China Med Univ, Dept Surg Oncol & Gen Surg, Hosp 1, Shenyang 110001, Peoples R China; [Xu, Y.] China Med Univ, Dept Breast Surg, Hosp 1, Shenyang 110001, Peoples R China; [Luo, Y.; Zhang, X.; Jiang, L.] China Med Univ, Res Ctr Med Genom, Shenyang 110001, Peoples R China; [Luo, Y.; Zhang, X.; Jiang, L.] China Med Univ, MOH Key Lab Cell Biol, Shenyang 110001, Peoples R China	China Medical University; China Medical University; China Medical University; China Medical University	Xu, H (corresponding author), China Med Univ, Dept Surg Oncol & Gen Surg, Hosp 1, 155 N Nanjing St, Shenyang 110001, Peoples R China.	huimianxu@yahoo.cn	wang, zhen ning/E-1878-2011; Gao, Peng/B-8031-2013; Xu, Yingying/E-3884-2018	wang, zhen ning/0000-0003-0557-3097; Xu, Yingying/0000-0003-4924-9379	National Science Foundation of China [81000943, 30873043]; Scientific Research Foundation for Doctors of Liaoning Province [20101146]; Key Laboratory Programme of Education Department of Liaoning Province [LS2010165]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Scientific Research Foundation for Doctors of Liaoning Province; Key Laboratory Programme of Education Department of Liaoning Province	We thank the Department of Surgical Oncology of the First Hospital of China Medical University for providing human gastric tissue samples. We also thank the College of China Medical University for technical assistance in experiments. This work was supported by the National Science Foundation of China (no. 81000943 and no. 30873043), the Scientific Research Foundation for Doctors of Liaoning Province (no. 20101146) and the Key Laboratory Programme of Education Department of Liaoning Province (LS2010165).	Antonsson B, 2001, CELL TISSUE RES, V306, P347, DOI 10.1007/s00441-001-0472-0; Bae IH, 2006, CANCER RES, V66, P4991, DOI 10.1158/0008-5472.CAN-05-4254; Bae IH, 2009, CANCER LETT, V277, P22, DOI 10.1016/j.canlet.2008.11.022; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bertuccio P, 2009, INT J CANCER, V125, P666, DOI 10.1002/ijc.24290; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chen Y, 2010, J GASTROINTEST SURG, V14, P1170, DOI 10.1007/s11605-010-1202-2; Chiang YP, 2011, J GASTROINTEST SURG, V15, P63, DOI 10.1007/s11605-010-1367-8; Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103; Du Y, 2009, J GASTROENTEROL, V44, P556, DOI 10.1007/s00535-009-0037-7; Gironella M, 2007, P NATL ACAD SCI USA, V104, P16170, DOI 10.1073/pnas.0703942104; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Jiang CG, 2010, J SURG ONCOL, V102, P737, DOI 10.1002/jso.21678; Kanai M, 2006, CLIN CANCER RES, V12, P6395, DOI 10.1158/1078-0432.CCR-06-1034; Kim YK, 2009, NUCLEIC ACIDS RES, V37, P1672, DOI 10.1093/nar/gkp002; Kuo LY, 2006, J CELL PHYSIOL, V207, P729, DOI 10.1002/jcp.20616; Lee HW, 2003, CANCER RES, V63, P1093; Liu T, 2009, CANCER LETT, V273, P233, DOI 10.1016/j.canlet.2008.08.003; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lou Z, 2005, CANCER RES, V65, P1007; Marcucci G, 2008, J CLIN ONCOL, V26, P5078, DOI 10.1200/JCO.2008.17.5554; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Ronchetti D, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-37; Song YX, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-1; Soon PSH, 2009, CLIN CANCER RES, V15, P7684, DOI 10.1158/1078-0432.CCR-09-1587; Sorrentino A, 2008, GYNECOL ONCOL, V111, P478, DOI 10.1016/j.ygyno.2008.08.017; Sun Z, 2010, ANN SURG ONCOL, V17, P1278, DOI 10.1245/s10434-009-0890-x; Sun Z, 2009, ANN SURG ONCOL, V16, P3028, DOI 10.1245/s10434-009-0624-0; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Uren RT, 2007, J CELL BIOL, V177, P277, DOI 10.1083/jcb.200606065; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wada R, 2010, INT J CANCER, V127, P1106, DOI 10.1002/ijc.25126; Wang FJ, 2010, GYNECOL ONCOL, V119, P586, DOI 10.1016/j.ygyno.2010.07.021; Wang LW, 2003, CLIN CANCER RES, V9, P6371; Wang LW, 2005, CLIN EXP METASTAS, V22, P205, DOI 10.1007/s10585-005-5684-3; Wang YX, 2010, J DIGEST DIS, V11, P50, DOI 10.1111/j.1751-2980.2009.00413.x; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103; Wu Q, 2010, BIOCHEM BIOPH RES CO, V392, P340, DOI 10.1016/j.bbrc.2009.12.182; Xu YY, 2007, WORLD J GASTROENTERO, V13, P5133, DOI 10.3748/wjg.v13.i38.5133; Yao JC, 2004, CLIN CANCER RES, V10, P4109, DOI 10.1158/1078-0432.CCR-03-0628; Yao MZ, 2005, J NEUROSCI, V25, P1149, DOI 10.1523/JNEUROSCI.4736-04.2005; Yu CY, 2002, CANCER RES, V62, P6430; Zhang H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007826	49	163	175	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	11					1398	1407		10.1038/onc.2011.340	http://dx.doi.org/10.1038/onc.2011.340			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL	21822301	Green Published, hybrid			2022-12-17	WOS:000301780000007
J	Pineiro, R; Maffucci, T; Falasca, M				Pineiro, R.; Maffucci, T.; Falasca, M.			The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation	ONCOGENE			English	Article						G-protein-coupled receptor; lysophosphatidylinositol; GPR55; prostate cancer; ABC transporters; phospholipase A2	PROTEIN-COUPLED RECEPTOR; L-ALPHA-LYSOPHOSPHATIDYLINOSITOL; HUMAN PROSTATE-CANCER; DRUG-RESISTANCE; LYSOPHOSPHOLIPIDS; IDENTIFICATION; ACTIVATION; EXPRESSION; MIGRATION	Recently, the orphan receptor G protein-coupled receptor 55 (GPR55) has been proposed as a potential cannabinoid receptor, although controversy remains on its physiological roles. Current evidence suggests a role for GPR55 as a receptor for the lysophospholipid lysophosphatidylinositol (LPI). In this study, we show that GPR55 is expressed in several prostate and ovarian cancer cell lines, both at the mRNA and at the protein level, and that it has a critical role in regulating proliferation and anchorage-independent growth. We further show that GPR55 mediates the effects of LPI in prostate and ovarian cancer cells. Indeed we demonstrate that LPI is able to induce calcium mobilization and activation of Akt and extracellular signal-regulated kinase (ERK)1/2 in these cells and that both pharmacological blockade of GPR55 and its downregulation using specific small interfering RNA strongly inhibits these processes. We further identify an autocrine loop by which LPI is synthesized by cytosolic phospholipase A2, pumped out of the cell by the ATP-binding cassette transporter ABCC1/MRP1, and is then able to initialize cascades downstream of GPR55. All together, these data demonstrate a role of LPI and its receptor GPR55 in cancer cells in activating an autocrine loop that regulates cell proliferation. These findings may have important implications for LPI as a novel cancer biomarker and for its receptor GPR55 as a potential therapeutic target. Oncogene (2011) 30, 142-152; doi:10.1038/onc.2010.417; published online 13 September 2010	[Pineiro, R.; Maffucci, T.; Falasca, M.] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst Cell & Mol Sci, Ctr Diabet,Inositide Signalling Grp, London E1 2AT, England	University of London; Queen Mary University London	Falasca, M (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst Cell & Mol Sci, Ctr Diabet,Inositide Signalling Grp, 4 Newark St, London E1 2AT, England.	m.falasca@qmul.ac.uk	Piñeiro, Roberto/AAN-5561-2020; Falasca, Marco/S-4020-2016	Piñeiro, Roberto/0000-0001-9479-139X; Falasca, Marco/0000-0002-9801-7235	British Heart Foundation [PG/06/022/204348]	British Heart Foundation(British Heart Foundation)	We thank Prof D Baker (Queen Mary University of London), Prof WH Moolenaar (The Netherlands Cancer Institute), Dr N Divecha (The Paterson Institute for Cancer Research, Manchester) and Dr R Sabatini (LPath Inc) for critical reading of the paper. We also thank the National Institute of Drug Abuse, Bethesda, MD, USA for providing SR141716A. RP was supported by the British Heart Foundation (grant PG/06/022/204348 to MF).	Davies MA, 1999, CANCER RES, V59, P2551; Falasca M, 1998, ONCOGENE, V16, P2357, DOI 10.1038/sj.onc.1201758; FALASCA M, 1995, ONCOGENE, V10, P2113; FALASCA M, 1994, EUR J BIOCHEM, V221, P383, DOI 10.1111/j.1432-1033.1994.tb18750.x; Ford LA, 2010, BRIT J PHARMACOL, V160, P762, DOI 10.1111/j.1476-5381.2010.00743.x; Henstridge CM, 2009, FASEB J, V23, P183, DOI 10.1096/fj.08-108670; Hoffmann U, 2004, DRUG METAB REV, V36, P669, DOI 10.1081/DMR-200033473; Kapur A, 2009, J BIOL CHEM, V284, P29817, DOI 10.1074/jbc.M109.050187; Kreitzer FR, 2009, PHARMACOL THERAPEUT, V122, P83, DOI 10.1016/j.pharmthera.2009.01.005; Lauckner JE, 2008, P NATL ACAD SCI USA, V105, P2699, DOI 10.1073/pnas.0711278105; Mitra P, 2006, P NATL ACAD SCI USA, V103, P16394, DOI 10.1073/pnas.0603734103; Monet M, 2009, BBA-MOL CELL RES, V1793, P528, DOI 10.1016/j.bbamcr.2009.01.003; Nevalainen T, 2010, CURR TOP MED CHEM, V10, P799, DOI 10.2174/156802610791164229; Oka S, 2007, BIOCHEM BIOPH RES CO, V362, P928, DOI 10.1016/j.bbrc.2007.08.078; Oka S, 2010, J BIOCHEM, V147, P671, DOI 10.1093/jb/mvp208; Patel MI, 2008, CLIN CANCER RES, V14, P8070, DOI 10.1158/1078-0432.CCR-08-0566; Pettus BJ, 2004, J BIOL CHEM, V279, P11320, DOI 10.1074/jbc.M309262200; Ross RA, 2009, TRENDS PHARMACOL SCI, V30, P156, DOI 10.1016/j.tips.2008.12.004; Ryberg E, 2007, BRIT J PHARMACOL, V152, P1092, DOI 10.1038/sj.bjp.0707460; Sawzdargo M, 1999, MOL BRAIN RES, V64, P193, DOI 10.1016/S0169-328X(98)00277-0; Sharir H, 2010, PHARMACOL THERAPEUT, V126, P301, DOI 10.1016/j.pharmthera.2010.02.004; Soga T, 2005, BIOCHEM BIOPH RES CO, V326, P744, DOI 10.1016/j.bbrc.2004.11.120; Staton PC, 2008, PAIN, V139, P225, DOI 10.1016/j.pain.2008.04.006; Sullivan GF, 2000, J CLIN INVEST, V105, P1261, DOI 10.1172/JCI9290; Sullivan GF, 1998, CLIN CANCER RES, V4, P1393; Sutphen R, 2004, CANCER EPIDEM BIOMAR, V13, P1185; Waldeck-Weiermair M, 2008, J CELL SCI, V121, P1704, DOI 10.1242/jcs.020958; Whyte LS, 2009, P NATL ACAD SCI USA, V106, P16511, DOI 10.1073/pnas.0902743106; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; Xiao YJ, 2000, ANN NY ACAD SCI, V905, P242; Yin H, 2009, J BIOL CHEM, V284, P12328, DOI 10.1074/jbc.M806516200	31	163	170	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	2					142	152		10.1038/onc.2010.417	http://dx.doi.org/10.1038/onc.2010.417			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709LG	20838378				2022-12-17	WOS:000286438900003
J	Fridman, AL; Tainsky, MA				Fridman, A. L.; Tainsky, M. A.			Critical pathways in cellular senescence and immortalization revealed by gene expression profiling	ONCOGENE			English	Review						immortalization; senescence; cell cycle; interferon; cytoskeletal; IGF-related genes	MAMMARY EPITHELIAL-CELLS; PLASMINOGEN-ACTIVATOR INHIBITOR-1; FACTOR-BINDING PROTEIN-5; ONE COMPLEMENTATION GROUP; REPLICATIVE LIFE-SPAN; HUMAN FIBROBLASTS; IN-VITRO; DNA METHYLATION; GROWTH ARREST; TRANSCRIPTION FACTOR	Bypassing cellular senescence and becoming immortal is a prerequisite step in the tumorigenic transformation of a cell. It has long been known that loss of a key tumor suppressor gene, such as p53, is necessary, but not sufficient, for spontaneous cellular immortalization. Therefore, there must be additional mutations and/or epigenetic alterations required for immortalization to occur. Early work on these processes included somatic cell genetic studies to estimate the number of senescence genes, and microcell-mediated transfer of chromosomes into immortalized cells to identify putative senescence-inducing genetic loci. These principal studies laid the foundation for the field of senescence/immortalization, but were labor intensive and the results were somewhat limited. The advent of gene expression pro. ling and bioinformatics analysis greatly facilitated the identification of genes and pathways that regulate cellular senescence/ immortalization. In this review, we present the findings of several gene expression pro. ling studies and supporting functional data, where available. We identified universal genes regulating senescence/ immortalization and found that the key regulator genes represented six pathways: the cell cycle pRB/p53, cytoskeletal, interferon-related, insulin growth factor-related, MAP kinase and oxidative stress pathway. The identification of the genes and pathways regulating senescence/ immortalization could provide novel molecular targets for the treatment and/or prevention of cancer.	[Tainsky, M. A.] Wayne State Univ, Sch Med, Program Mol Biol & Genet, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pathol, Ctr Mol Med & Genet, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University	Tainsky, MA (corresponding author), Wayne State Univ, Sch Med, Program Mol Biol & Genet, Barbara Ann Karmanos Canc Inst, 110 E Warren Ave, Detroit, MI 48201 USA.	tainskym@karmanos.org		Tainsky, Michael/0000-0002-0261-831X	Barbara Ann Karmanos Cancer Institute; State of Michigan Life Sciences Corridor; Wayne State University; Michigan Center for Genomic Technologies Applied Genomics Technology Center [MEDC 085P10009816]; Genomics and Biostatistics Cores of the Barbara Ann Karmanos Cancer Institute [P30CA022453]; NATIONAL CANCER INSTITUTE [P30CA022453] Funding Source: NIH RePORTER	Barbara Ann Karmanos Cancer Institute; State of Michigan Life Sciences Corridor; Wayne State University; Michigan Center for Genomic Technologies Applied Genomics Technology Center; Genomics and Biostatistics Cores of the Barbara Ann Karmanos Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the Barbara and Fred Erb Endowed Chair in Cancer Genetics (to MAT), and by funds from the Barbara Ann Karmanos Cancer Institute, the State of Michigan Life Sciences Corridor, Wayne State University and Michigan Center for Genomic Technologies Applied Genomics Technology Center (MEDC 085P10009816), and the Genomics and Biostatistics Cores of the Barbara Ann Karmanos Cancer Institute (P30CA022453). We thank the numerous members of the Tainsky lab who over the past 20 years have contributed to the studies of the immortalization of Li-Fraumeni cells, including Sun Yim, Farideh Bischoff, Tian-Ai Wu, Eliayhu Kraus, Sylvia Dryden, Olga Kulaeva, Lin Tang, Rita Rosati, Janice Kraniak and Qunfang Li. We acknowledge Louise C Strong whose insight into human cancer genetics led to the establishment of cell lines from Li-Fraumeni patients. We thank Dr Janice Kraniak for critical reading of the manuscript.	Bachinski LL, 2005, CANCER RES, V65, P427; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Benvenuti S, 2002, ONCOGENE, V21, P4403, DOI 10.1038/sj.onc.1205525; Benvenuti S, 2002, MOL CELL PROTEOMICS, V1, P280, DOI 10.1074/mcp.M100028-MCP200; BERRY IJ, 1994, MOL CARCINOGEN, V9, P134, DOI 10.1002/mc.2940090305; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Berube NG, 1998, AM J HUM GENET, V62, P1015, DOI 10.1086/301848; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Boulet G, 2007, INT J BIOCHEM CELL B, V39, P2006, DOI 10.1016/j.biocel.2007.07.004; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Campisi J, 2001, EXP GERONTOL, V36, P1619, DOI 10.1016/S0531-5565(01)00160-7; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chuaqui RF, 2002, NAT GENET, V32, P509, DOI 10.1038/ng1034; Coates PJ, 2002, J PATHOL, V196, P371, DOI 10.1002/path.1073; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; CRISTOFALO VJ, 1993, PHYSIOL REV, V73, P617, DOI 10.1152/physrev.1993.73.3.617; d'Adda di Fagagna F, 2003, NATURE, V426, P194, DOI [10.1038/nature02118, DOI 10.1038/NATURE02118]; Dairkee SH, 2007, ONCOGENE, V26, P6269, DOI 10.1038/sj.onc.1210452; Di Bacco A, 2003, ONCOGENE, V22, P5436, DOI 10.1038/sj.onc.1206670; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Drayton S, 2002, CURR OPIN GENET DEV, V12, P98, DOI 10.1016/S0959-437X(01)00271-4; DUNCAN EL, 1993, EXP CELL RES, V205, P337, DOI 10.1006/excr.1993.1095; Esteller M, 2001, CANCER RES, V61, P3225; Feinberg AP, 2002, SEMIN CANCER BIOL, V12, P389, DOI 10.1016/S1044-579X(02)00059-7; Forsyth NR, 2004, NEOPLASIA, V6, P258, DOI 10.1593/neo.04103; Fridman AL, 2007, BIOCHEM BIOPH RES CO, V357, P785, DOI 10.1016/j.bbrc.2007.04.019; Fridman AL, 2006, J GERONTOL A-BIOL, V61, P879, DOI 10.1093/gerona/61.9.879; Garbe J, 1999, ONCOGENE, V18, P2169, DOI 10.1038/sj.onc.1202523; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Goeman F, 2005, MOL CELL BIOL, V25, P422, DOI 10.1128/MCB.25.1.422-431.2005; GOLDSTEIN S, 1991, P NATL ACAD SCI USA, V88, P9680, DOI 10.1073/pnas.88.21.9680; Gollahon LS, 1998, ONCOGENE, V17, P709, DOI 10.1038/sj.onc.1201987; Gonzalez L, 2006, ONCOGENE, V25, P5173, DOI 10.1038/sj.onc.1209526; HAAF T, 1995, PHARMACOL THERAPEUT, V65, P19, DOI 10.1016/0163-7258(94)00053-6; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; Haq R, 2002, CANCER RES, V62, P5076; Harley CB, 2002, ONCOGENE, V21, P494, DOI 10.1038/sj.onc.1205076; HARVEY M, 1993, ONCOGENE, V8, P2457; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Hayflick L, 1985, Clin Geriatr Med, V1, P15; Itahana K, 2004, BIOGERONTOLOGY, V5, P1, DOI 10.1023/B:BGEN.0000017682.96395.10; Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003; Jha KK, 1998, EXP CELL RES, V245, P1, DOI 10.1006/excr.1998.4272; Kanai Y, 2001, J CANCER RES CLIN, V127, P697; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; KANEKO S, 1995, CELL STRUCT FUNCT, V20, P107, DOI 10.1247/csf.20.107; Kang MK, 2003, EXP CELL RES, V287, P272, DOI 10.1016/S0014-4827(03)00061-2; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Kim KS, 2007, MOL BIOL CELL, V18, P4543, DOI 10.1091/mbc.E07-03-0280; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kortlever RM, 2006, CELL CYCLE, V5, P2697, DOI 10.4161/cc.5.23.3510; Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448; Kraniak JM, 2006, MOL CARCINOGEN, V45, P141, DOI 10.1002/mc.20145; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594; LeckaCzernik B, 1996, EXP GERONTOL, V31, P159, DOI 10.1016/0531-5565(95)02014-4; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lee CC, 2002, BIOCHEM BIOPH RES CO, V291, P185, DOI 10.1006/bbrc.2002.6415; Leung KM, 2002, CANCER RES, V62, P4890; Li QF, 2008, MOL CANCER RES, V6, P770, DOI 10.1158/1541-7786.MCR-07-0114; Li YZ, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-7; Liang G, 2002, CANCER RES, V62, P961; LINSKENS MHK, 1995, NUCLEIC ACIDS RES, V23, P3244, DOI 10.1093/nar/23.16.3244; Lopatina N, 2002, J CELL BIOCHEM, V84, P324, DOI 10.1002/jcb.10015; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; Morelli C, 2000, GENE, V252, P217, DOI 10.1016/S0378-1119(00)00231-6; Morelli C, 2002, ONCOGENE, V21, P7266, DOI 10.1038/sj.onc.1205573; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; Nam TJ, 1997, ENDOCRINOLOGY, V138, P2972, DOI 10.1210/en.138.7.2972; Neumeister P, 2002, INT J BIOCHEM CELL B, V34, P1475, DOI 10.1016/S1357-2725(02)00079-1; Ozawa S, 2006, BIOCHEM BIOPH RES CO, V348, P406, DOI 10.1016/j.bbrc.2006.07.070; Paz MF, 2003, CANCER RES, V63, P1114; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Quackenbush J, 2003, SCIENCE, V302, P240, DOI 10.1126/science.1090887; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Roninson IB, 2003, CANCER RES, V63, P2705; Rubin H, 2002, NAT BIOTECHNOL, V20, P675, DOI 10.1038/nbt0702-675; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; Salomonis N, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-217; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; SASAKI M, 1994, CANCER RES, V54, P6090; SATOH Y, 1994, MUTAT RES, V316, P25, DOI 10.1016/0921-8734(94)90005-1; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Schwarze SR, 2002, J BIOL CHEM, V277, P14877, DOI 10.1074/jbc.M200373200; Sekaric P, 2007, ONCOGENE, V26, P6261, DOI 10.1038/sj.onc.1210462; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Sommer M, 2006, CELL CYCLE, V5, P2005, DOI 10.4161/cc.5.17.3194; Sorrell AM, 2006, J BIOL CHEM, V281, P10883, DOI 10.1074/jbc.M508505200; Stampfer MR, 2003, CANCER LETT, V194, P199, DOI 10.1016/S0304-3835(02)00707-3; Stratford FLL, 2006, FEBS LETT, V580, P3989, DOI 10.1016/j.febslet.2006.06.029; Suzuki T, 2001, EXP GERONTOL, V36, P465, DOI 10.1016/S0531-5565(00)00223-0; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; Takaoka A, 2006, CELL MICROBIOL, V8, P907, DOI 10.1111/j.1462-5822.2006.00716.x; Takebayashi S, 2001, BIOCHEM BIOPH RES CO, V288, P921, DOI 10.1006/bbrc.2001.5863; Tandle AT, 2005, CYTOKINE, V30, P347, DOI 10.1016/j.cyto.2005.01.020; Tominaga K, 2002, MECH AGEING DEV, V123, P927, DOI 10.1016/S0047-6374(02)00030-1; TSUTSUI T, 1995, CARCINOGENESIS, V16, P25, DOI 10.1093/carcin/16.1.25; Tsutsui T, 1997, MOL CARCINOGEN, V18, P7, DOI 10.1002/(SICI)1098-2744(199701)18:1<7::AID-MC2>3.0.CO;2-F; Untergasser G, 2002, CANCER RES, V62, P6255; Varley JM, 1997, CANCER RES, V57, P3245; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; Vojta PJ, 1996, GENE CHROMOSOME CANC, V16, P55; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wilson HMP, 2002, CELL GROWTH DIFFER, V13, P205; Yaswen P, 2002, INT J BIOCHEM CELL B, V34, P1382, DOI 10.1016/S1357-2725(02)00047-X; Yoon IK, 2004, EXP GERONTOL, V39, P1369, DOI 10.1016/j.exger.2004.07.002; Zhang H, 2004, GENE DEV, V18, P3028, DOI 10.1101/gad.1253004; Zhang H, 2004, ONCOGENE, V23, P6193, DOI 10.1038/sj.onc.1207834; Zhang H, 2003, P NATL ACAD SCI USA, V100, P3251, DOI 10.1073/pnas.2627983100	129	163	170	0	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2008	27	46					5975	5987		10.1038/onc.2008.213	http://dx.doi.org/10.1038/onc.2008.213			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	358BO	18711403	Green Accepted			2022-12-17	WOS:000259891600001
J	Hsieh, SH; Ying, NW; Wu, MH; Chiang, WF; Hsu, CL; Wong, TY; Jin, YT; Hong, TM; Chen, YL				Hsieh, S. H.; Ying, N. W.; Wu, M. H.; Chiang, W. F.; Hsu, C. L.; Wong, T. Y.; Jin, Y. T.; Hong, T. M.; Chen, Y. L.			Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells	ONCOGENE			English	Article						galectin-1; neuropilin-1; endothelial cells; oral cancer	BREAST-CANCER; GROWTH-FACTOR; EXPRESSION; RECEPTORS; FIBRONECTIN; DIFFERENTIATION; SUSCEPTIBILITY; GLYCOSYLATION; ANGIOGENESIS; PROGRESSION	Galectin-1 (Gal-1), a homodimeric prototype of the galectins with a single carbohydrate-recognition domain, was recently identified as being overexpressed in tumor-associated capillary endothelial cells. The role of Gal-1 in endothelial cellular functions and the mechanism of action of Gal-1 remain unknown. Neuropilin-1 (NRP1) is a neuronal receptor that mediates repulsive growth cone guidance, and NRP1 functions in endothelial cells as a coreceptor (with vascular endothelial growth factor receptors (VEGFRs)) for VEGF(165). In this study, we found that Gal-1 was overexpressed in the tumor-associated endothelial cells of oral squamous cell carcinomas (P<0.001). Gal-1 increased the proliferation and adhesion of endothelial cells, and enhanced cell migration in combination with VEGF165. Surprisingly, Gal-1 selectively bound NRP1 via the carbohydrate-recognition domain, but did not bind VEGFR-1, VEGFR-2 or VEGFR-3. The Gal-1-NRP1 interaction mediated the migration and adhesion of endothelial cells. The binding of Gal-1 to NRP1 enhanced VEGFR-2 phosphorylation and stimulated the activation of the mitogen activated protein (MAP) kinases SAPK1/JNK (stress activated protein kinase-1/c-Jun NH2-terminal kinase). These findings show, for the first time, that Gal-1 can directly bind to NRP1 on endothelial cells, and can promote the NRP1/VEGFR-2-mediated signaling pathway as well as NRP1-mediated biological activities.	[Hsieh, S. H.; Ying, N. W.; Wong, T. Y.; Jin, Y. T.; Chen, Y. L.] Natl Cheng Kung Univ, Coll Med, Inst Oral Med, Tainan 70101, Taiwan; [Wu, M. H.; Chen, Y. L.] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan; [Chiang, W. F.] Chi Mei Med Ctr, Oral Maxillofacial Sect, Tainan, Taiwan; [Hsu, C. L.] Chang Gung Mem Hosp, Dept Internal Med, Div Hematol Oncol, Taipei 10591, Taiwan; [Wong, T. Y.] Natl Taiwan Univ, Coll Med, NTU Ctr Gen Med, Taipei 10764, Taiwan	National Cheng Kung University; National Cheng Kung University; Chi Mei Hospital; Chang Gung Memorial Hospital; National Taiwan University	Chen, YL (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Oral Med, 1 Univ Rd, Tainan 70101, Taiwan.	htm@gate.sinica.edu.tw; yuhling@mail.ncku.edu.tw	Chiang, Wei-Fan/L-6537-2019; Chen, Yuh-Ling/AAS-7957-2021	Chiang, Wei-Fan/0000-0002-9240-1404; 				Camby I, 2006, GLYCOBIOLOGY, V16, p137R, DOI 10.1093/glycob/cwl025; Castro-Rivera E, 2004, P NATL ACAD SCI USA, V101, P11432, DOI 10.1073/pnas.0403969101; CHIANG WF, 2007, ORAL ONCOL IN PRESS; Clausse N, 1999, Angiogenesis, V3, P317, DOI 10.1023/A:1026584523789; Elola MT, 2005, J BIOMED SCI, V12, P13, DOI 10.1007/s11373-004-8169-5; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fischer C, 2005, J BIOL CHEM, V280, P37266, DOI 10.1074/jbc.M411580200; Fons P, 2004, J CELL PHYSIOL, V200, P351, DOI 10.1002/jcp.20076; Gaudet AD, 2005, CURR DRUG TARGETS, V6, P419, DOI 10.2174/1389450054021864; Glinsky VV, 2000, CANCER RES, V60, P2584; GU MJ, 1994, J CELL SCI, V107, P175; He J, 2006, LAB INVEST, V86, P578, DOI 10.1038/labinvest.3700420; Hong TM, 2007, CLIN CANCER RES, V13, P4759, DOI 10.1158/1078-0432.CCR-07-0001; Hu B, 2007, ONCOGENE, V26, P5577, DOI 10.1038/sj.onc.1210348; Jung EJ, 2007, INT J CANCER, V120, P2331, DOI 10.1002/ijc.22434; Kadri T, 2005, STEM CELLS DEV, V14, P204, DOI 10.1089/scd.2005.14.204; Konigsberg W, 2001, THROMB HAEMOSTASIS, V86, P757, DOI 10.1055/s-0037-1616129; Murga M, 2005, BLOOD, V105, P1992, DOI 10.1182/blood-2004-07-2598; Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2; OZEKI Y, 1995, GLYCOBIOLOGY, V5, P255, DOI 10.1093/glycob/5.2.255; Parsons-Wingerter P, 2005, AM J PATHOL, V167, P193, DOI 10.1016/S0002-9440(10)62965-3; QUN Z, 1993, ARCH BIOCHEM BIOPHYS, V300, P6, DOI 10.1006/abbi.1993.1002; Rabinovich GA, 2005, BRIT J CANCER, V92, P1188, DOI 10.1038/sj.bjc.6602493; Rorive S, 2001, GLIA, V33, P241, DOI 10.1002/1098-1136(200103)33:3<241::AID-GLIA1023>3.0.CO;2-1; Shintani Y, 2006, EMBO J, V25, P3045, DOI 10.1038/sj.emboj.7601188; Thijssen VLJL, 2006, P NATL ACAD SCI USA, V103, P15975, DOI 10.1073/pnas.0603883103; Toscano MA, 2007, NAT IMMUNOL, V8, P825, DOI 10.1038/ni1482; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; Valenzuela HF, 2007, CANCER RES, V67, P6155, DOI 10.1158/0008-5472.CAN-05-4431; van den Brule FA, 2001, J PATHOL, V193, P80, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH730>3.0.CO;2-2	30	163	170	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3746	3753		10.1038/sj.onc.1211029	http://dx.doi.org/10.1038/sj.onc.1211029			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18223683				2022-12-17	WOS:000256659300012
J	Chen, R; Alvero, AB; Silasi, DA; Steffensen, KD; Mor, G				Chen, R.; Alvero, A. B.; Silasi, D-A; Steffensen, K. D.; Mor, G.			Cancers take their Toll - the function and regulation of Toll-like receptors in cancer cells	ONCOGENE			English	Review						ovarian cancer; Toll-like receptors; MyD88; inflammation; tissue repair; chemoresistance	NF-KAPPA-B; INFLAMMATION-ASSOCIATED CANCER; PROMOTES TUMOR-GROWTH; OVARIAN-CANCER; PROTEINS FAS; MURINE MODEL; APOPTOSIS; ACTIVATION; MACROPHAGES; CARCINOMA	Cancer could be deemed as an abnormal and uncontrolled tissue repair process. Therefore, it would not be surprising that factors that function in the tissue repair process, such as cytokines, chemokines, growth factors and Toll-like receptor (TLR) ligands, as well as growth signals for compensatory proliferation, would also be key factors in regulating and enhancing cancer progression. The TLR pathways, which play a critical role in tissue repair, are also key regulators in cancer progression as well as chemoresistance. TLRs serve as cell surface sensors that can initiate pathways leading to proliferation and chemoresistance; as well as mediators that are able to regulate the infiltrating immune cells to provide further support for cancer progression.	[Alvero, A. B.; Silasi, D-A; Mor, G.] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, Reprod Immunol Unit, New Haven, CT 06520 USA; [Chen, R.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT USA; [Steffensen, K. D.] Vejle Hosp, Dept Oncol, Vejle, Denmark	Yale University; Yale University; University of Southern Denmark; Lillebaelt Hospital	Mor, G (corresponding author), Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, Reprod Immunol Unit, 333 Cedar St,FMB 301, New Haven, CT 06520 USA.	gil.mor@yale.edu		Dahl Steffensen, Karina/0000-0002-9217-3907; Alvero, Ayesha/0000-0002-6593-3595				Akira S, 2003, BIOCHEM SOC T, V31, P637, DOI 10.1042/BST0310637; Alvero AB, 2006, CANCER-AM CANCER SOC, V106, P599, DOI 10.1002/cncr.21633; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Balkwill F, 2004, NATURE, V431, P405, DOI 10.1038/431405a; Barton GM, 2004, NAT IMMUNOL, V5, P472, DOI 10.1038/ni0504-472; Beachy PA, 2004, NATURE, V431, P402, DOI 10.1038/431402a; Ben-Hur H, 2000, EUR J GYNAECOL ONCOL, V21, P53; Ben-Hur H, 2000, EUR J GYNAECOL ONCOL, V21, P141; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen CJ, 2007, NAT MED, V13, P851, DOI 10.1038/nm1603; CHEN R, 2007, UNPUB J CLIN INVEST; Chen R, 2007, AM J REPROD IMMUNOL, V57, P93, DOI 10.1111/j.1600-0897.2006.00441.x; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Covert MW, 2005, SCIENCE, V309, P1854, DOI 10.1126/science.1112304; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Ernst PB, 2001, DIGEST DIS, V19, P104, DOI 10.1159/000050663; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fukata M, 2005, AM J PHYSIOL-GASTR L, V288, pG1055, DOI 10.1152/ajpgi.00328.2004; Gannot G, 2002, BRIT J CANCER, V86, P1444, DOI 10.1038/sj.bjc.6600282; Girling JE, 2007, IMMUNOL CELL BIOL, V85, P481, DOI 10.1038/sj.icb.7100086; Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5; Gorden KB, 2005, J IMMUNOL, V174, P1259, DOI 10.4049/jimmunol.174.3.1259; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Harmey JH, 2002, INT J CANCER, V101, P415, DOI 10.1002/ijc.10632; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; He WG, 2007, MOL IMMUNOL, V44, P2850, DOI 10.1016/j.molimm.2007.01.022; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Huang B, 2005, CANCER RES, V65, P5009, DOI 10.1158/0008-5472.CAN-05-0784; Huang B, 2007, CANCER RES, V67, P4346, DOI 10.1158/0008-5472.CAN-06-4067; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Kamsteeg M, 2003, ONCOGENE, V22, P2611, DOI 10.1038/sj.onc.1206422; Kelly MG, 2006, CANCER RES, V66, P3859, DOI 10.1158/0008-5472.CAN-05-3948; Koff JL, 2006, J IMMUNOL, V177, P8693, DOI 10.4049/jimmunol.177.12.8693; Kreuz S, 2004, J CELL BIOL, V166, P369, DOI 10.1083/jcb.200401036; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Li QT, 2005, TRENDS IMMUNOL, V26, P318, DOI 10.1016/j.it.2005.04.003; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; McDermott EP, 2002, J BIOL CHEM, V277, P7808, DOI 10.1074/jbc.M108133200; Menard S, 1997, CLIN CANCER RES, V3, P817; Mor G, 1998, J STEROID BIOCHEM, V67, P403, DOI 10.1016/S0960-0760(98)00143-5; Mor G, 2002, BIOCHEM PHARMACOL, V64, P1305, DOI 10.1016/S0006-2952(02)01267-4; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; Philip M, 2004, SEMIN CANCER BIOL, V14, P433, DOI 10.1016/j.semcancer.2004.06.006; Pidgeon GP, 1999, BRIT J CANCER, V81, P1311, DOI 10.1038/sj.bjc.6694369; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Pull SL, 2005, P NATL ACAD SCI USA, V102, P99, DOI 10.1073/pnas.0405979102; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rana TM, 2007, NAT REV MOL CELL BIO, V8, P23, DOI 10.1038/nrm2085; Riman T, 2004, ACTA OBSTET GYN SCAN, V83, P783, DOI 10.1111/j.0001-6349.2004.00550.x; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Ruvkun G, 2001, SCIENCE, V294, P797, DOI 10.1126/science.1066315; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Schwartz Peter E, 2002, Cancer Treat Res, V107, P99; Sekizawa Akihiko, 2004, Medical Electron Microscopy, V37, P97; Shishodia S, 2002, J BIOCHEM MOL BIOL, V35, P28; Silasi Dan-Arin, 2006, Yale J Biol Med, V79, P153; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tam W, 1997, MOL CELL BIOL, V17, P1490, DOI 10.1128/MCB.17.3.1490; Tsan MF, 2006, SEMIN CANCER BIOL, V16, P32, DOI 10.1016/j.semcancer.2005.07.004; Virchow R., 1863, KRANKHAFTEN GESCHWUL, P57; VIRSCHOW R, 1858, ARCH PATHOL ANAT KLI, V14, P1; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Werner SL, 2005, SCIENCE, V309, P1857, DOI 10.1126/science.1113319; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wiemer EAC, 2007, EUR J CANCER, V43, P1529, DOI 10.1016/j.ejca.2007.04.002; Yarovinsky F, 2005, SCIENCE, V308, P1626, DOI 10.1126/science.1109893; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	76	163	184	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2008	27	2					225	233		10.1038/sj.onc.1210907	http://dx.doi.org/10.1038/sj.onc.1210907			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248OO	18176604				2022-12-17	WOS:000252163600009
J	Longley, DB; Wilson, TR; McEwan, M; Allen, WL; McDermott, U; Galligan, L; Johnston, PG				Longley, DB; Wilson, TR; McEwan, M; Allen, WL; McDermott, U; Galligan, L; Johnston, PG			c-FLIP inhibits chemotherapy-induced colorectal cancer cell death	ONCOGENE			English	Article						c-FLIP; 5-fluorouracil; oxaliplatin; irinotecan; apoptosis	LIGAND-INDEPENDENT ACTIVATION; MULTICENTER RANDOMIZED-TRIAL; RECEPTOR-INDUCED APOPTOSIS; UP-REGULATION; 1ST-LINE TREATMENT; CARCINOMA-CELLS; FAS; 5-FLUOROURACIL; FLUOROURACIL; RESISTANCE	FLIP inhibits caspase 8 activation and apoptosis mediated by death receptors such as Fas and DR5. We studied the effect of c-FLIP on the apoptotic response to chemotherapies used in colorectal cancer (CRC) (5-fluorouracil, oxaliplatin and irinotecan). Simultaneous downregulation of both c-FLIP splice forms c-FLIPL and c-FLIPS with siRNA synergistically enhanced chemotherapy-induced apoptosis in p53 wild-type (HCT116p53(+/+), RKO), null (HCT116p53(-/-)) and mutant (H630) CRC cell lines. Furthermore, overexpression of c-FLIPL, but not c-FLIPS, potently inhibited apoptosis induced by chemotherapy in HCT116p53(-/-) cells, suggesting that c-FLIPL was the more important splice form in mediating chemoresistance. In support of this, siRNA specifically targeted against c-FLIPL synergistically enhanced chemotherapy-induced apoptosis in a manner similar to the siRNA targeted against both splice forms. Inhibition of caspase 8 blocked the enhanced apoptosis induced by c-FLIP-targeted (FT) siRNA and chemotherapy. Furthermore, we found that downregulating cell surface DR5, but not Fas, also inhibited apoptosis induced by FT siRNA and chemotherapy. Interestingly, these effects were not dependent on activation of DR5 by its ligand TRAIL. These results indicate that c-FLIP inhibits TRAIL-independent, DR5- and caspase 8-dependent apoptosis in response to chemotherapy in CRC cells. Moreover, targeting c-FLIP in combination with existing chemotherapies may have therapeutic potential for the treatment of CRC.	Queens Univ Belfast, Ctr Canc Res & Cell Biol, Drug Resistance Grp, Belfast BT9 7AB, Antrim, North Ireland	Queens University Belfast	Longley, DB (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, Drug Resistance Grp, Univ Floor,Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.	d.longley@qub.ac.uk	Wilson, Timothy R/F-8210-2012; McEwan, Miranda V/A-6900-2012	McDermott, Ultan/0000-0001-9032-4700	Medical Research Council [G0400302] Funding Source: Medline; MRC [G0400302] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; CHINNAIYAN AM, 1995, CELL, V81, P512; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Conticello C, 2004, J IMMUNOL, V172, P5467, DOI 10.4049/jimmunol.172.9.5467; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Fulda S, 2000, CANCER RES, V60, P3947; Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136; Gniadecki R, 2004, BIOCHEM BIOPH RES CO, V320, P165, DOI 10.1016/j.bbrc.2004.05.145; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Iordanov MS, 2005, APOPTOSIS, V10, P167, DOI 10.1007/s10495-005-6071-x; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jin TG, 2004, J BIOL CHEM, V279, P55594, DOI 10.1074/jbc.M401056200; Kamarajan P, 2003, BIOCHEM J, V376, P253, DOI 10.1042/BJ20030659; Kataoka T, 2004, MOL CELL BIOL, V24, P2627, DOI 10.1128/MCB.24.7.2627-2636.2004; Kataoka T, 1998, J IMMUNOL, V161, P3936; Kim SG, 2004, MOL BIOL CELL, V15, P420, DOI 10.1091/mbc.E03-04-0201; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Longley DB, 2002, CANCER RES, V62, P2644; Mathas S, 2004, J EXP MED, V199, P1041, DOI 10.1084/jem.20031080; Matta H, 2002, CANCER BIOL THER, V1, P652, DOI 10.4161/cbt.315; Maxwell PJ, 2003, CANCER RES, V63, P4602; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Nam SY, 2003, CANCER SCI, V94, P1066, DOI 10.1111/j.1349-7006.2003.tb01402.x; Park SJ, 2001, BIOCHEM BIOPH RES CO, V289, P1205, DOI 10.1006/bbrc.2001.6086; Poulaki V, 2002, AM J PATHOL, V161, P643, DOI 10.1016/S0002-9440(10)64220-4; Ryu BK, 2001, J PATHOL, V194, P15, DOI 10.1002/path.835; Santiago B, 2004, J IMMUNOL, V172, P560, DOI 10.4049/jimmunol.172.1.560; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Wang SL, 2004, CANCER RES, V64, P6666, DOI 10.1158/0008-5472.CAN-04-1734; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Zhou XD, 2004, CLIN SCI, V106, P397, DOI 10.1042/CS20030238	39	163	173	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2006	25	6					838	848		10.1038/sj.onc.1209122	http://dx.doi.org/10.1038/sj.onc.1209122			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16247474				2022-12-17	WOS:000235212700003
J	Meinhold-Heerlein, I; Bauerschlag, D; Hilpert, F; Dimitrov, P; Sapinoso, LM; Orlowska-Volk, M; Bauknecht, T; Park, TW; Jonat, W; Jacobsen, A; Sehouli, J; Luttges, J; Krajewski, M; Krajewski, S; Reed, JC; Arnold, N; Hampton, GM				Meinhold-Heerlein, I; Bauerschlag, D; Hilpert, F; Dimitrov, P; Sapinoso, LM; Orlowska-Volk, M; Bauknecht, T; Park, TW; Jonat, W; Jacobsen, A; Sehouli, J; Luttges, J; Krajewski, M; Krajewski, S; Reed, JC; Arnold, N; Hampton, GM			Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential	ONCOGENE			English	Article						microarray; cluster; cell cycle	FATTY-ACID SYNTHASE; GENE-EXPRESSION PROFILES; POLO-LIKE KINASE; BREAST-CANCER; CELL-PROLIFERATION; PROSTATE-CANCER; CDNA MICROARRAY; TUMORS; BORDERLINE; P53	Profiles of gene transcription have begun to delineate the molecular basis of ovarian cancer, including distinctions between carcinomas of differing histology, tumor progression and patient outcome. However, the similarities and differences among the most commonly diagnosed noninvasive borderline ( low malignant potential, LMP) lesions and invasive serous carcinomas of varying grade (G1, G2 and G3) have not yet been explored. Here, we used oligonucleotide arrays to pro. le the expression of 12 500 genes in a series of 57 predominantly stage III serous ovarian adenocarcinomas from 52 patients, eight with borderline tumors and 44 with adenocarcinomas of varying grade. Unsupervised and supervised analyses showed that LMP lesions were distinct from high-grade serous adenocarcinomas, as might be expected; however, well-differentiated ( G1) invasive adenocarcinomas showed a strikingly similar pro. le to LMP tumors as compared to cancers with moderate ( G2) or poor ( G3) cellular differentiation, which were also highly similar. Comparative genomic hybridization of an independent cohort of five LMP and 63 invasive carcinomas of varying grade demonstrated LMP and G1 were again similar, exhibiting significantly less chromosomal aberration than G2/G3 carcinomas. A majority of LMP and G1 tumors were characterized by high levels of p21/WAF1, with concomitant expression of cell growth suppressors, gadd34 and BTG-2. In contrast, G2/G3 cancers were characterized by the expression of genes associated with the cell cycle and by STAT-1-, STAT-3/JAK-1/2-induced gene expression. The distinction between the LMP-G1 and G2 G3 groups of tumors was highly correlated to patient outcome ( v 2 for equivalence of death rates = 7.681189; P = 0.0056, log-rank test). Our results are consistent with the recent demonstration of a poor differentiation molecular 'meta-signature' in human cancer, and underscore a number of cell-cycle- and STAT-associated targets that may prove useful as points of therapeutic intervention for those patients with aggressive disease.	Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; Univ Hosp Schleswig Holstein, Dept Gynecol & Obstet, Kiel, Germany; Univ Freiburg, Dept Pathol, D-7800 Freiburg, Germany; Lilly Deutschland, Bad Homburg, Germany; Univ Bonn, Dept Gynecol & Obstet, D-5300 Bonn, Germany; Univ Hosp Charite, Dept Gynecol & Obstet, Berlin, Germany; Univ Kiel, Dept Pathol, D-24098 Kiel, Germany; Burnham Inst, La Jolla, CA 92037 USA	Novartis; University of Kiel; Schleswig Holstein University Hospital; University of Freiburg; Eli Lilly; Lilly Deutschland GmbH; University of Bonn; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Kiel; Sanford Burnham Prebys Medical Discovery Institute	Hampton, GM (corresponding author), Novartis Res Fdn, Genom Inst, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA.	hampton@gnf.org	Jonat, Walter/E-3024-2010; Meinhold-Heerlein, Ivo/AAK-1240-2021; Bauerschlag, Dirk/H-9393-2015; Bauerschlag, Dirk/B-1958-2013; Arnold, Norbert/E-3012-2010; Meinhold-Heerlein, Dr. Ivo/A-8970-2015	Arnold, Norbert/0000-0003-4523-8808; Bauerschlag, Dirk O./0000-0001-8157-6121; Meinhold-Heerlein, Dr. Ivo/0000-0002-0331-8781				Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; Anttila MA, 1999, BRIT J CANCER, V79, P1870, DOI 10.1038/sj.bjc.6690298; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Arnold N, 1996, GENE CHROMOSOME CANC, V16, P46, DOI 10.1002/(SICI)1098-2264(199605)16:1<46::AID-GCC7>3.0.CO;2-3; Auersperg N, 2002, INT J GYNECOL CANCER, V12, P691, DOI 10.1046/j.1525-1438.2002.01152.x; BEREK JS, 2000, CANC MED, P1687; Broggini M, 2000, ANTICANCER RES, V20, P4835; Caduff RF, 1999, AM J SURG PATHOL, V23, P323, DOI 10.1097/00000478-199903000-00012; Capranico G, 1999, Cancer Chemother Biol Response Modif, V18, P125; Chan WY, 2000, AM J PATHOL, V156, P409, DOI 10.1016/S0002-9440(10)64744-X; Collins Y, 2004, INT J MOL MED, V14, P43; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Gansler TS, 1997, HUM PATHOL, V28, P686, DOI 10.1016/S0046-8177(97)90177-5; Gemignani ML, 2003, GYNECOL ONCOL, V90, P378, DOI 10.1016/S0090-8258(03)00264-6; Gershenson DM, 2002, BEST PRACT RES CL OB, V16, P513, DOI 10.1053/beog.2002.0308; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; HAMILTON SR, 1992, J CELL BIOCHEM, P41; HAMPTON GM, 2003, EXPRESSION PROFILING, P277; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hellstrom I, 2003, CANCER RES, V63, P3695; HENRIKSEN R, 1994, ANTICANCER RES, V14, P603; Hollander MC, 2003, ONCOGENE, V22, P3827, DOI 10.1038/sj.onc.1206567; IWABUCHI H, 1995, CANCER RES, V55, P6172; Jazaeri AA, 2003, MOL CARCINOGEN, V36, P53, DOI 10.1002/mc.10098; Kiechle M, 2001, CANCER, V91, P534, DOI 10.1002/1097-0142(20010201)91:3<534::AID-CNCR1031>3.0.CO;2-T; Kim JH, 2002, JAMA-J AM MED ASSOC, V287, P1671, DOI 10.1001/jama.287.13.1671; Kim JH, 2003, CLIN CANCER RES, V9, P4782; Korkolopoulou P, 2002, GYNECOL ONCOL, V85, P404, DOI 10.1006/gyno.2002.6627; Krajewski S, 1999, ENDOCR-RELAT CANCER, V6, P29, DOI 10.1677/erc.0.0060029; KRAJEWSKI S, 1994, AM J PATHOL, V145, P515; KREIPE H, 1993, AM J PATHOL, V142, P1689; Kuo ML, 2003, CANCER RES, V63, P1046; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Luo C, 2004, DRUG DISCOV TODAY, V9, P268, DOI 10.1016/S1359-6446(03)03014-9; Marx D, 1997, ANTICANCER RES, V17, P775; Matei D, 2002, ONCOGENE, V21, P6289, DOI 10.1038/sj.onc.1205785; Meinhold-Heerlein I, 2001, AM J PATHOL, V158, P1335, DOI 10.1016/S0002-9440(10)64084-9; Morice P, 2003, ANN ONCOL, V14, P592, DOI 10.1093/annonc/mdg173; Muggia Franco, 2003, Expert Opin Emerg Drugs, V8, P203, DOI 10.1517/eoed.8.1.203.21032; Nijjar T, 1999, CANCER RES, V59, P5112; Okamoto Y, 2003, CANCER RES, V63, P4167; Ortiz BH, 2001, CANCER RES, V61, P7264; Palazzo JP, 2000, HUM PATHOL, V31, P698, DOI 10.1053/hupa.2000.7641; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 1998, CANCER-AM CANCER SOC, V83, P528, DOI 10.1002/(SICI)1097-0142(19980801)83:3<528::AID-CNCR22>3.0.CO;2-X; Pizer ES, 1996, CANCER RES, V56, P2745; Pizer ES, 1998, CANCER RES, V58, P4611; RENTROP M, 1986, HISTOCHEM J, V18, P271, DOI 10.1007/BF01676237; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Santin AD, 2004, INT J CANCER, V112, P14, DOI 10.1002/ijc.20408; Schummer M, 1999, GENE, V238, P375, DOI 10.1016/S0378-1119(99)00342-X; Schwartz DR, 2002, CANCER RES, V62, P4722; Seidman JD, 2003, HEMATOL ONCOL CLIN N, V17, P909, DOI 10.1016/S0889-8588(03)00061-3; Seidman JD, 2002, BEST PRACT RES CL OB, V16, P499, DOI 10.1053/beog.2002.0300; Shih IM, 2004, AM J PATHOL, V164, P1511, DOI 10.1016/S0002-9440(10)63708-X; Shurbaji MS, 1996, HUM PATHOL, V27, P917, DOI 10.1016/S0046-8177(96)90218-X; Singer G, 2002, AM J PATHOL, V160, P1223, DOI 10.1016/S0002-9440(10)62549-7; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Su AI, 2001, CANCER RES, V61, P7388; Takai N, 2001, CANCER LETT, V164, P41, DOI 10.1016/S0304-3835(00)00703-5; Terlikowski S, 1999, ARCH GYNECOL OBSTET, V263, P29, DOI 10.1007/s004040050257; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vassilopoulos I, 2003, HISTOL HISTOPATHOL, V18, P761, DOI 10.14670/HH-18.761; Wagner KW, 2004, ONCOGENE, V23, P6621, DOI 10.1038/sj.onc.1207861; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9; Wang Y, 2001, CANCER LETT, V167, P99, DOI 10.1016/S0304-3835(01)00464-5; Wang Y, 2001, CLIN CHIM ACTA, V304, P107, DOI 10.1016/S0009-8981(00)00404-6; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; Weichert W, 2004, BRIT J CANCER, V90, P815, DOI 10.1038/sj.bjc.6601610; Welsh JB, 2001, CANCER RES, V61, P5974; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Yagi A, 2003, J CELL BIOCHEM, V90, P1242, DOI 10.1002/jcb.10711	76	163	171	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1053	1065		10.1038/sj.onc.1208298	http://dx.doi.org/10.1038/sj.onc.1208298			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15558012				2022-12-17	WOS:000226749200011
J	Yuan, JP; Yan, RL; Kramer, A; Eckerdt, F; Roller, M; Kaufmann, M; Strebhardt, K				Yuan, JP; Yan, RL; Kramer, A; Eckerdt, F; Roller, M; Kaufmann, M; Strebhardt, K			Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells	ONCOGENE			English	Article						small interfering RNAs; cyclin B1; G2/M arrest; proliferation; apoptosis	B1 OVEREXPRESSION; CANCER-CELLS; CARCINOMA; LOCALIZATION; ACTIVATION; PLK1	Cyclin B1 is the regulatory subunit of M-phase promoting factor, and proper regulation of cyclin B1 is essential for the initiation of mitosis. Increasing evidence indicates that the deregulation of cyclin B1 is involved in neoplastic transformation, suggesting the suppression of cyclin B1 could be an attractive strategy for antiproliferative therapy. In the present work, we analysed the impact of small interfering RNAs (siRNAs) targeted to cyclin B1 on different human tumor cell lines. Cyclin B1 siRNAs reduced the protein level of cyclin B1 in HeLa, MCF-7, BT-474 and MDA-MB-435 tumor cells and efficiently reduced the kinase activity of Cdc2/cyclin B1 in HeLa cells. siRNA-treated cells were arrested in G2/M phase in all tumor cell lines tested. Proliferation of tumor cells from different origins was suppressed by 50-80% 48 h after transfection and apoptosis was increased from 5 to 40-50%. Furthermore, tumor cells showed less colony-forming ability after siRNA treatment. In contrast, primary human umbilical vein endothelial cells exhibited only a slight change in cell cycle, and neither apoptosis nor clear inhibition of proliferation was observed after cyclin B1 siRNA treatment for 48 h. These results indicate that siRNAs against cyclin B1 could become a powerful antiproliferative tool in future antitumor therapy.	Univ Frankfurt, Dept Obstet & Gynaecol, Sch Med, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Strebhardt, K (corresponding author), Univ Frankfurt, Dept Obstet & Gynaecol, Sch Med, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	strebhardt@em.uni-frankfurt.de	Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Davies TG, 2002, NAT STRUCT BIOL, V9, P745, DOI 10.1038/nsb842; Dong YY, 2002, CANCER LETT, V177, P13, DOI 10.1016/S0304-3835(01)00770-4; Hassan KA, 2002, CANCER RES, V62, P6414; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Knockaert M, 2002, ONCOGENE, V21, P6413, DOI 10.1038/sj.onc.1205908; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Li JQ, 2003, INT J ONCOL, V22, P1101; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Park M, 2000, CANCER RES, V60, P542; Santana C, 2002, MUTAT RES-FUND MOL M, V508, P49, DOI 10.1016/S0027-5107(02)00172-0; Sarafan-Vasseur N, 2002, ONCOGENE, V21, P2051, DOI 10.1038/sj.onc.1205257; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Takeno S, 2002, CANCER, V94, P2874, DOI 10.1002/cncr.10542; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; Yin XY, 2001, CANCER RES, V61, P6487; Yuan JP, 2002, CANCER RES, V62, P4186; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011	20	163	180	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5843	5852		10.1038/sj.onc.1207757	http://dx.doi.org/10.1038/sj.onc.1207757			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15208674				2022-12-17	WOS:000222629800014
J	Lockshin, RA; Zakeri, Z				Lockshin, RA; Zakeri, Z			Caspase-independent cell death?	ONCOGENE			English	Review						caspase; caspase-independent; apoptosis; programmed cell death; lysosome; autophagocytosis; protease	MITOCHONDRIAL PERMEABILITY TRANSITION; NEMATODE CAENORHABDITIS-ELEGANS; HUMAN EPIDERMAL-KERATINOCYTES; LENS FIBER DIFFERENTIATION; TERMINAL DIFFERENTIATION; DROSOPHILA CASPASE; CYTOCHROME-C; MEMBRANE PERMEABILIZATION; MORPHOLOGICAL-CHANGES; NUCLEAR DEGENERATION	Many cells die with apoptotic morphology and with documented activation of an effector caspase, but there are also many exceptions. Cells frequently display activation of other proteases, including granzymes, lysosomal cathepsins, matrix metalloproteinases, and proteasomal proteases, and others display morphologies that are not fully consistent with classical apoptosis. In some experimental situations, evidence of caspase-dependent death is indirect, demonstrating that the cell can activate caspases rather than that it does. In other situations, such as involution of mammary or prostate tissue, many cells display autophagic or other morphology different from apoptosis, and there is considerable evidence for the activation of a lysosomal system. Prior to total collapse and necrosis, cells that are in trouble can activate numerous physiological pathways toward self-destruction. Intrinsic or extrinsic routes to effector caspase activation are frequently the most rapid and efficient. If neither of these routes is immediately available, owing to mutation, genetic manipulation, inhibitor, or the biology of the cell, other routes may be followed, leading to variant forms of cell death that may display one or more characteristics of apoptosis. Experimental and therapeutic procedures must account for this possibility.	CUNY Queens Coll, Dept Biol, Flushing, NY 11367 USA; CUNY, Grad Ctr, Flushing, NY 11367 USA; St Johns Univ, Dept Biol Sci, Jamaica, NY 11439 USA	City University of New York (CUNY) System; Queens College NY (CUNY); City University of New York (CUNY) System; Saint John's University	Lockshin, RA (corresponding author), CUNY Queens Coll, Dept Biol, 65-30 Kissena Blvd, Flushing, NY 11367 USA.	lockshin@stjohns.edu						Allombert-Blaise C, 2003, CELL DEATH DIFFER, V10, P850, DOI 10.1038/sj.cdd.4401245; Andersson M, 2003, EXP EYE RES, V76, P175, DOI 10.1016/S0014-4835(02)00283-X; Arama E, 2003, DEV CELL, V4, P687, DOI 10.1016/S1534-5807(03)00120-5; Baehrecke EH, 2003, DEV CELL, V4, P608, DOI 10.1016/S1534-5807(03)00134-5; Bauvy C, 2001, EXP CELL RES, V268, P139, DOI 10.1006/excr.2001.5285; Berg CP, 2001, CELL DEATH DIFFER, V8, P1197, DOI 10.1038/sj.cdd.4400905; BOLOGNIA JL, 1995, AM J MED, V98, pS99, DOI 10.1016/S0002-9343(99)80066-7; BOWEN ID, 1993, CELL BIOL INT, V17, P13, DOI 10.1006/cbir.1993.1002; Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952; Bratosin D, 2001, CELL DEATH DIFFER, V8, P1143, DOI 10.1038/sj.cdd.4400946; Cakouros D, 2002, J CELL BIOL, V157, P985, DOI 10.1083/jcb.200201034; Cerri PS, 2003, J PERIODONTAL RES, V38, P223, DOI 10.1034/j.1600-0765.2003.02006.x; Chua CC, 2003, BBA-MOL CELL RES, V1642, P79, DOI 10.1016/S0167-4889(03)00100-9; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Clarke PGH, 1996, ANAT EMBRYOL, V193, P81; COTMAN CW, 1998, CELLS DIE COMPREHENS, P385; Counis MF, 1998, CELL DEATH DIFFER, V5, P251, DOI 10.1038/sj.cdd.4400351; Dahm R, 2002, OPHTHALMIC RES, V34, P288, DOI 10.1159/000065605; Dahm R, 1997, BIOCHEM SOC T, V25, pS584, DOI 10.1042/bst025s584; Dahm R, 1999, OPHTHALMIC RES, V31, P163, DOI 10.1159/000055530; Daugas E, 2001, CELL DEATH DIFFER, V8, P1131, DOI 10.1038/sj.cdd.4400953; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Dorstyn L, 1999, J BIOL CHEM, V274, P30778, DOI 10.1074/jbc.274.43.30778; Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje; Fromm L, 1997, DEV GENET, V20, P276, DOI 10.1002/(SICI)1520-6408(1997)20:3<276::AID-DVG10>3.0.CO;2-6; Gandarillas A, 1999, EXP DERMATOL, V8, P71, DOI 10.1111/j.1600-0625.1999.tb00350.x; Gao CY, 1997, DEV GENET, V20, P267; Gniadecki R, 2001, EXP DERMATOL, V10, P71, DOI 10.1034/j.1600-0625.2001.010002071.x; Gorski SM, 2003, CURR BIOL, V13, P358, DOI 10.1016/S0960-9822(03)00082-4; HAAS AL, 1995, J BIOL CHEM, V270, P9407, DOI 10.1074/jbc.270.16.9407; HALABY R, 1994, BIOCHEM CELL BIOL, V72, P597, DOI 10.1139/o94-079; Harvey NL, 2001, J BIOL CHEM, V276, P25342, DOI 10.1074/jbc.M009444200; HELMINEN HJ, 1968, J ULTRA MOL STRUCT R, V25, P240, DOI 10.1016/S0022-5320(68)80072-3; Hensey C, 1999, ANN NY ACAD SCI, V887, P105, DOI 10.1111/j.1749-6632.1999.tb07926.x; Hikim APS, 2003, J STEROID BIOCHEM, V85, P175, DOI 10.1016/S0960-0760(03)00193-6; HORVITZ HR, 1983, COLD SPRING HARB SYM, V48, P453, DOI 10.1101/SQB.1983.048.01.050; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Jellinger KA, 2001, J ALZHEIMERS DIS, V3, P31, DOI 10.3233/JAD-2001-3106; Jochova J, 1997, CELL DEATH DIFFER, V4, P140, DOI 10.1038/sj.cdd.4400216; Jochova J, 1997, DEV GENET, V21, P249, DOI 10.1002/(SICI)1520-6408(1997)21:4<249::AID-DVG2>3.0.CO;2-7; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KERR JFR, 1974, J CELL SCI, V14, P571; Kierszenbaum AL, 2001, MOL REPROD DEV, V58, P1, DOI 10.1002/1098-2795(200101)58:1&lt;1::AID-MRD1&gt;3.0.CO;2-0; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lambert E, 2003, BIOCHEM J, V372, P767, DOI 10.1042/BJ20030187; LANG F, 2003, PFLUGERS ARCH, V121, P919; Lang KS, 2004, CELL DEATH DIFFER, V11, P231, DOI 10.1038/sj.cdd.4401311; Lang KS, 2003, CELL DEATH DIFFER, V10, P249, DOI 10.1038/sj.cdd.4401144; Lee CY, 2000, CELL RES, V10, P193, DOI 10.1038/sj.cr.7290048; Lee CY, 2003, CURR BIOL, V13, P350, DOI 10.1016/S0960-9822(03)00085-X; Lemasters JJ, 2002, ANTIOXID REDOX SIGN, V4, P769, DOI 10.1089/152308602760598918; Lemasters JJ, 1998, BIOFACTORS, V8, P283, DOI 10.1002/biof.5520080316; Lippens S, 2000, CELL DEATH DIFFER, V7, P1218, DOI 10.1038/sj.cdd.4400785; Lockshin RA, 2001, NAT REV MOL CELL BIO, V2, P545, DOI 10.1038/35080097; LOCKSHIN RA, 1969, LYSOSOM BIOL PATHOL, P363; Macho A, 1997, J IMMUNOL, V158, P4612; Mammone T, 1998, SKIN PHARMACOL APPL, V11, P152, DOI 10.1159/000029821; Mammone T, 2000, CELL BIOL TOXICOL, V16, P293, DOI 10.1023/A:1026746330146; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Mogi M, 2003, J BIOL CHEM, V278, P47477, DOI 10.1074/jbc.M307055200; Mori M, 2003, J CELL PHYSIOL, V195, P290, DOI 10.1002/jcp.10245; NORSGAARD H, 1994, ARCH GERONTOL GERIAT, P185, DOI 10.1016/S0167-4943(05)80064-0; Oppenheim RW, 2001, J NEUROSCI, V21, P4752, DOI 10.1523/JNEUROSCI.21-13-04752.2001; Perfettini JL, 2003, NAT IMMUNOL, V4, P308, DOI 10.1038/ni0403-308; POLAKOWSKA RR, 1994, DEV DYNAM, V199, P176, DOI 10.1002/aja.1001990303; Print CG, 2000, BIOESSAYS, V22, P423, DOI 10.1002/(SICI)1521-1878(200005)22:5&lt;423::AID-BIES4&gt;3.0.CO;2-0; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; SANCHEZPRIETO R, 1995, ONCOGENE, V11, P675; Sanders EJ, 2003, DIFFERENTIATION, V71, P425, DOI 10.1046/j.1432-0436.2003.7107005.x; Sanders EJ, 2002, J ANAT, V201, P121, DOI 10.1046/j.1469-7580.2002.00081.x; SASAKI K, 1993, J ANAT, V183, P113; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306; SMITH FF, 1992, MOL REPROD DEV, V33, P363, DOI 10.1002/mrd.1080330402; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Sun JS, 2003, J BIOMED MATER RES A, V64A, P616, DOI 10.1002/jbm.a.10439; TAMADA Y, 1994, BRIT J DERMATOL, V131, P521; Tolkovsky AM, 2002, BIOCHIMIE, V84, P233, DOI 10.1016/S0300-9084(02)01371-8; Torriglia A, 2001, EXP EYE RES, V72, P443, DOI 10.1006/exer.2000.0969; Vaux DL, 1996, MICROSC RES TECHNIQ, V34, P259, DOI 10.1002/(SICI)1097-0029(19960615)34:3<259::AID-JEMT8>3.0.CO;2-K; WEBER R, 1969, LYSOSOM BIOL PATHOL, V1, P437; Weil M, 1999, CURR BIOL, V9, P361, DOI 10.1016/S0960-9822(99)80162-6; WEINBERG WC, 1995, ONCOGENE, V10, P2271; Weisfelner Michelle Emily, 2003, J Drugs Dermatol, V2, P385; Wride MA, 1999, DEV BIOL, V213, P142, DOI 10.1006/dbio.1999.9375; Wride MA, 2000, APOPTOSIS, V5, P203, DOI 10.1023/A:1009653326511; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Xue L, 2001, CURR BIOL, V11, P361, DOI 10.1016/S0960-9822(01)00100-2; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; Yao K, 2003, CHINESE MED J-PEKING, V116, P1034; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; ZAKERI Z, 1992, MOL REPROD DEV, V33, P373, DOI 10.1002/mrd.1080330403; ZAKERI Z, 1990, J CELL BIOL, V111, P337; ZAKERI ZF, 1993, FASEB J, V7, P470, DOI 10.1096/fasebj.7.5.8462789; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572; Zhuang SG, 2003, ONCOGENE, V22, P4413, DOI 10.1038/sj.onc.1206604	104	163	175	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2766	2773		10.1038/sj.onc.1207514	http://dx.doi.org/10.1038/sj.onc.1207514			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077140				2022-12-17	WOS:000220799600004
J	Horie, R; Watanabe, T; Morishita, Y; Ito, K; Ishida, T; Kanegae, Y; Saito, I; Higashihara, M; Mori, S; Kadin, ME; Watanabe, T				Horie, R; Watanabe, T; Morishita, Y; Ito, K; Ishida, T; Kanegae, Y; Saito, I; Higashihara, M; Mori, S; Kadin, ME; Watanabe, T			Ligand-independent signaling by overexpressed CD30 drives NF-kappa B activation in Hodgkin-Reed-Sternberg cells	ONCOGENE			English	Article						Hodgkin-Reed-Sternberg cells; CD30; TRAF proteins; NF-kappa B; adenovirus vector	TNF RECEPTOR SUPERFAMILY; IMMUNOGLOBULIN GENE REARRANGEMENTS; CYTOPLASMIC DOMAIN; BINDING-SITES; TUMOR-CELLS; DISEASE; DEATH; EXPRESSION; PROTEINS; FAMILY	Overexpression of CD30 and constitutive NF-kappaB activation characterizes tumor cells of Hodgkin's disease (HD), Hodgkin and Reed-Sternberg (H-RS) cells. We report that in H-RS cells overexpression of CD30 leads to self-aggregation, recruitment of TRAF2 and TRAF5, and NF-kappaB activation, independent of CD30 ligand. CD30 and TRAF proteins co-localized in H-RS cell lines and in lymph nodes of HD. An adenovirus-vector carrying a decoy CD30 lacking the cytoplasmic region or a dominant negative IkappaBalpha mutant blocks NF-kappaB activation, down regulates IL-13 expression and induces apoptosis. Thus, in H-RS cells, ligand-independent activation of CD30 signaling drives NF-kappaB activation and this leads to constitutive cytokine expression, which provides a molecular basis for HD. Inhibition of NF-kappaB activation by adenovirus vector-mediated gene transfer may provide a novel strategy of cell- and target molecule-specific therapy for patients with HD.	Univ Tokyo, Inst Med Sci, Div Pathol, Minato Ku, Tokyo 1088639, Japan; Kitasato Univ, Fac Med, Dept Hematol, Kanagawa, Japan; Univ Tokyo, Inst Med Sci, Mol Genet Lab, Minato Ku, Tokyo 1088639, Japan; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	University of Tokyo; Kitasato University; University of Tokyo; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Watanabe, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Pathol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tnabe@ims.u-tokyo.ac.jp						ADAM D, 1995, J BIOL CHEM, V270, P17482; Aizawa S, 1997, J BIOL CHEM, V272, P2042; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boucher LM, 1997, BIOCHEM BIOPH RES CO, V233, P592, DOI 10.1006/bbrc.1997.6509; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Cantwell MJ, 1996, BLOOD, V88, P4676, DOI 10.1182/blood.V88.12.4676.bloodjournal88124676; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Cossman J, 1999, BLOOD, V94, P411, DOI 10.1182/blood.V94.2.411; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; FALINI B, 1995, BLOOD, V85, P1; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; Gruss HJ, 1996, BAILLIERE CLIN HAEM, V9, P417, DOI 10.1016/S0950-3536(96)80019-9; GRUSS HJ, 1994, BLOOD, V83, P2045; Harris NL, 1999, SEMIN HEMATOL, V36, P220; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Horie R, 1998, INT IMMUNOL, V10, P203, DOI 10.1093/intimm/10.2.203; Horie R, 1998, SEMIN IMMUNOL, V10, P457, DOI 10.1006/smim.1998.0156; Horie R, 1996, BLOOD, V88, P2422, DOI 10.1182/blood.V88.7.2422.bloodjournal8872422; Hsu PL, 2000, LAB INVEST, V80, P1111, DOI 10.1038/labinvest.3780117; JOSIMOVICALASEVIC O, 1989, EUR J IMMUNOL, V19, P157, DOI 10.1002/eji.1830190125; Kadin ME, 1999, HODGKIN'S DISEASE, P139; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; Kanzler H, 1996, J EXP MED, V184, P1495, DOI 10.1084/jem.184.4.1495; Kapp U, 1999, J EXP MED, V189, P1939, DOI 10.1084/jem.189.12.1939; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; KUPPERS R, 1994, P NATL ACAD SCI USA, V91, P10962, DOI 10.1073/pnas.91.23.10962; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; Marafioti T, 2000, BLOOD, V95, P1443, DOI 10.1182/blood.V95.4.1443.004k55_1443_1450; Medina DJ, 1999, BLOOD, V94, P3499; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Papoff G, 1999, J BIOL CHEM, V274, P38241, DOI 10.1074/jbc.274.53.38241; Pinto A, 1996, BLOOD, V88, P3299, DOI 10.1182/blood.V88.9.3299.bloodjournal8893299; Prince HM, 1998, EXP HEMATOL, V26, P27; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1994, J BIOL CHEM, V269, P22492; Teoh G, 1998, BLOOD, V92, P4591, DOI 10.1182/blood.V92.12.4591.424k08_4591_4601; Vandevoorde V, 1997, J CELL BIOL, V137, P1627, DOI 10.1083/jcb.137.7.1627; von Wasielewski R, 2000, BLOOD, V95, P1207, DOI 10.1182/blood.V95.4.1207.004k34_1207_1213; Wood KM, 1998, ONCOGENE, V16, P2131, DOI 10.1038/sj.onc.1201735; Wu MY, 1999, J BIOL CHEM, V274, P11868, DOI 10.1074/jbc.274.17.11868	53	163	171	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2493	2503		10.1038/sj.onc.1205337	http://dx.doi.org/10.1038/sj.onc.1205337			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971184				2022-12-17	WOS:000174918400006
J	Hiyama, E; Hiyama, K				Hiyama, E; Hiyama, K			Clinical utility of telomerase in cancer	ONCOGENE			English	Article						telomerase; telomerase reverse transcriptase (hTERT); cytology; diagnosis; prognosis; immunohistochemistry	HTERT MESSENGER-RNA; CELL LUNG-CANCER; PROGNOSTIC INDICATOR; COLORECTAL-CANCER; BLADDER-CANCER; HEPATOCELLULAR-CARCINOMA; PANCREATIC-CANCER; GASTRIC-CANCER; BREAST-LESIONS; EXPRESSION	This review will focus on the clinical utilities of telomerase for human cancer diagnosis. Much attention has been focused on detection of telomerase activity and its essential components (hTR and hTERT) in cancer and noncancerous tissues. Expression of hTR and hTERT is upregulated in almost all human malignant tumors but not in benign or normal tissues with the exception of germline cells, proliferative stem cells, activated lymphocytes, and certain benign tumors. Thus, telomerase is a useful marker for cancer diagnosis and in some instance as a prognostic indicator of outcome. Telomerase detection in cells derived from breast fine needle aspirates, bronchial washes, and pancreatic juices show high sensitivity and specificity for cancer detection. In tissue samples, the level of telomerase activity is a useful prognostic indicator in certain adult cancers such as gastric and colon cancers and in neuroblastomas. Immunohistochemical detection of hTERT will facilitate exact diagnosis of the telomerase positive cells and expand the application of telomerase in cancer diagnosis.	Hiroshima Univ, Sch Med, Fac Med, Dept Gen Med,Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Sch Med, Fac Med, Dept Internal Med 2,Minami Ku, Hiroshima 7348551, Japan	Hiroshima University; Hiroshima University	Hiyama, E (corresponding author), Hiroshima Univ, Sch Med, Fac Med, Dept Gen Med,Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.		Hiyama, Eiso/A-2013-2019	Hiyama, Eiso/0000-0001-9179-5037				Ahn MJ, 1997, EUR J CANCER, V33, P1309, DOI 10.1016/S0959-8049(97)00113-5; Bonatz G, 2001, HUM PATHOL, V32, P605, DOI 10.1053/hupa.2001.25002; BRENTNALL TA, 1995, CANCER RES, V55, P4264; Carey LA, 1999, J CLIN ONCOL, V17, P3075, DOI 10.1200/JCO.1999.17.10.3075; CHADENEAU C, 1995, CANCER RES, V55, P2533; Clark GM, 1997, J NATL CANCER I, V89, P1874, DOI 10.1093/jnci/89.24.1874; Dhaene K, 2000, VIRCHOWS ARCH, V437, P1, DOI 10.1007/s004280000189; Dome JS, 1999, CANCER RES, V59, P4301; Falchetti ML, 1999, J CLIN PATHOL, V52, P234, DOI 10.1136/jcp.52.3.234; Fang DC, 1999, J GASTROEN HEPATOL, V14, P328, DOI 10.1046/j.1440-1746.1999.01862.x; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Heine B, 1998, J PATHOL, V184, P71; Hirashima T, 2000, ANTICANCER RES, V20, P2181; Hiyama E, 1997, EUR J CANCER, V33, P1932, DOI 10.1016/S0959-8049(97)00226-8; Hiyama E, 1996, INT J ONCOL, V9, P453; Hiyama E, 1997, CANCER RES, V57, P326; Hiyama E, 1996, J NATL CANCER I, V88, P116, DOI 10.1093/jnci/88.2.116; HIYAMA E, 1995, CANCER RES, V55, P3258; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; Hiyama E, 2001, NEOPLASIA, V3, P17, DOI 10.1038/sj.neo.7900134; Hiyama E, 2000, CANCER CYTOPATHOL, V90, P235, DOI 10.1002/1097-0142(20000825)90:4<235::AID-CNCR6>3.3.CO;2-Q; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; Hiyama K, 1998, INT J MOL MED, V1, P545; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Hou M, 2001, CLIN CHEM, V47, P519; Huang F, 1999, J NEURO-ONCOL, V43, P137, DOI 10.1023/A:1006258817785; Inoue H, 2001, CANCER, V91, P35, DOI 10.1002/1097-0142(20010101)91:1<35::AID-CNCR5>3.0.CO;2-A; Iwao T, 1997, J NATL CANCER I, V89, P1621, DOI 10.1093/jnci/89.21.1621; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, EUR J CANCER, V33, P781, DOI 10.1016/S0959-8049(97)00057-9; Kinoshita H, 1997, J NATL CANCER I, V89, P724, DOI 10.1093/jnci/89.10.724; Koyanagi K, 2000, CANCER, V88, P1524, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1524::AID-CNCR4>3.0.CO;2-6; Koyanagi Y, 2000, ANTICANCER RES, V20, P773; Lancelin F, 2000, BJU INT, V85, P526, DOI 10.1046/j.1464-410x.2000.00466.x; Langford LA, 1997, HUM PATHOL, V28, P416, DOI 10.1016/S0046-8177(97)90029-0; Leris C, 2000, J SURG ONCOL, V75, P72, DOI 10.1002/1096-9098(200009)75:1<72::AID-JSO14>3.0.CO;2-Z; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; Marchetti A, 1999, CLIN CANCER RES, V5, P2077; Matthews P, 2001, J PATHOL, V194, P183, DOI 10.1002/path.848; Mokbel K, 1999, J CLIN ONCOL, V17, P3856; Morales CP, 1998, GASTROINTEST ENDOSC, V48, P402, DOI 10.1016/S0016-5107(98)70011-2; Muller M, 1996, INT J ONCOL, V9, P1169; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakashio R, 1997, INT J CANCER, V74, P141, DOI 10.1002/(SICI)1097-0215(19970422)74:2<141::AID-IJC1>3.0.CO;2-Z; Nakatani K, 1997, CANCER, V80, P471, DOI 10.1002/(SICI)1097-0142(19970801)80:3<471::AID-CNCR15>3.0.CO;2-U; Ohta K, 1997, J GASTROENTEROL, V32, P791, DOI 10.1007/BF02936956; Ohyashiki JH, 1997, CLIN CANCER RES, V3, P619; Okayasu I, 1997, JPN J CANCER RES, V88, P965, DOI 10.1111/j.1349-7006.1997.tb00316.x; Orlando C, 2001, J UROLOGY, V166, P666, DOI 10.1016/S0022-5347(05)66040-5; Parris CN, 1999, BRIT J CANCER, V79, P47, DOI 10.1038/sj.bjc.6690010; Pearson AS, 2000, INT J ONCOL, V17, P381; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; Poremba C, 1999, J CLIN ONCOL, V17, P2020, DOI 10.1200/JCO.1999.17.7.2020; Poremba C, 1999, ANN ONCOL, V10, P715, DOI 10.1023/A:1008333500733; Rahat MA, 1999, CANCER, V85, P919; Reddy VG, 2001, INT J GYNECOL CANCER, V11, P100; Reynolds CP, 1997, EUR J CANCER, V33, P1929, DOI 10.1016/S0959-8049(97)00287-6; Sangiorgi L, 2001, INT J CANCER, V95, P156, DOI 10.1002/1097-0215(20010520)95:3<156::AID-IJC1027>3.0.CO;2-L; Schneider-Stock R, 2000, INT J CANCER, V89, P63, DOI 10.1002/(SICI)1097-0215(20000120)89:1<63::AID-IJC10>3.0.CO;2-V; Sen S, 2001, LUNG CANCER, V33, P41, DOI 10.1016/S0169-5002(01)00193-3; Shay J W, 1997, Ciba Found Symp, V211, P148; Shay JW, 1996, LEUKEMIA, V10, P1255; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Streutker CJ, 2001, PEDIATR DEVEL PATHOL, V4, P62, DOI 10.1007/s100240010108; Suehara N, 1997, CLIN CANCER RES, V3, P2479; Tahara H, 1995, CLIN CANCER RES, V1, P1245; Tang RP, 1998, CANCER RES, V58, P4052; Tatsumoto N, 2000, CLIN CANCER RES, V6, P2696; TAYLOR RS, 1996, J INVEST DERMATOL, V106, P756; Ulaner GA, 1998, CANCER RES, V58, P4168; Wisman GBA, 2001, INT J CANCER, V91, P658, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1099>3.0.CO;2-7; Wright WE, 1996, DEV GENET, V18, P173; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Yahata N, 1998, J NATL CANCER I, V90, P684, DOI 10.1093/jnci/90.9.684; Yoshida K, 1997, BRIT J CANCER, V75, P548, DOI 10.1038/bjc.1997.96; Zheng PS, 2000, GYNECOL ONCOL, V77, P394, DOI 10.1006/gyno.2000.5779	76	163	189	3	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					643	649		10.1038/sj.onc.1205070	http://dx.doi.org/10.1038/sj.onc.1205070			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850791				2022-12-17	WOS:000173390500018
J	Wajant, H; Moosmayer, D; Wuest, T; Bartke, T; Gerlach, E; Schonherr, U; Peters, N; Scheurich, P; Pfizenmaier, K				Wajant, H; Moosmayer, D; Wuest, T; Bartke, T; Gerlach, E; Schonherr, U; Peters, N; Scheurich, P; Pfizenmaier, K			Differential activation of TRAIL-R1 and-2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative	ONCOGENE			English	Article						antibody-mediated; targeting; apoptosis; tumor; TNF ligand family	APOPTOSIS-INDUCING LIGAND; TUMORICIDAL ACTIVITY; T-CELLS; EXPRESSION	TNF-related apoptosis-inducing ligand (TRAIL) is a typical member of the tumor necrosis factor (TNF) ligand family that is expressed as a type Il membrane protein (memTRAIL) and signals apoptosis via the death domain-containing receptors TRAIL-R1 and -2, Soluble recombinant derivatives of TRAIL (sTRAIL) are considered as novel tumors therapeutics because of their selective apoptosis inducing activity in a variety of human tumors but not in normal cells. Using antagonistic antigen-binding fragment (Fab) preparations of TRAIL-R1- and TRAIL-R2-specific antibodies, we demonstrate in this study that TRAIL-R1 becomes activated by both the soluble and the membrane-bound form of the ligand, whereas TRAIL-R2 becomes only activated by memTRAIL or soluble TRAIL secondarily cross-linked by antibodies. Furthermore, we show that the restricted signal capacity of sTRAIL can be readily converted into a fully signal competent memTRAIL-like molecule, i.e. a TRAIL-R2 stimulating ligand, by genetic fusion to an antibody derivative that allows antigen-dependent 'immobilization' of the fusion protein to cell surfaces. We conclude that antibody targeting-dependent activation can be used to design selective therapeutics derived of those ligands of the TNF family that are biologically inactive in their soluble form.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany	University of Stuttgart	Wajant, H (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.		Wajant, Harald/A-3020-2017	Wajant, Harald/0000-0002-2005-3949				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Mariani SM, 1998, EUR J IMMUNOL, V28, P973, DOI 10.1002/(SICI)1521-4141(199803)28:03<973::AID-IMMU973>3.3.CO;2-K; Mariani SM, 1998, EUR J IMMUNOL, V28, P1492, DOI 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X; Muhlenbeck F, 2000, J BIOL CHEM, V275, P32208, DOI 10.1074/jbc.M000482200; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; Rippmann JF, 2000, BIOCHEM J, V349, P805, DOI 10.1042/bj3490805; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Schneider P, 2000, Pharm Acta Helv, V74, P281, DOI 10.1016/S0031-6865(99)00038-2; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517	15	163	176	2	12	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 5	2001	20	30					4101	4106		10.1038/sj.onc.1204558	http://dx.doi.org/10.1038/sj.onc.1204558			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494138				2022-12-17	WOS:000169681500018
J	Yang, HS; Jansen, AP; Nair, R; Shibahara, K; Verma, AK; Cmarik, JL; Colburn, NH				Yang, HS; Jansen, AP; Nair, R; Shibahara, K; Verma, AK; Cmarik, JL; Colburn, NH			A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-kappa B or ODC transactivation	ONCOGENE			English	Article						pdcd4; AP-1; NF-kappa B; transformation	MOUSE EPIDERMAL-CELLS; NEOPLASTIC TRANSFORMATION; TUMOR PROMOTION; JB6 CELLS; TRANSCRIPTIONAL REGULATION; ANCHORAGE INDEPENDENCE; HUMAN KERATINOCYTES; TRANSGENIC MICE; EXPRESSION; ACTIVATION	Pdcd4 is a novel transformation suppressor that is highly expressed in promotion-resistant (P-) mouse epidermal JB6 cells but not in susceptible (P+) cells. Overexpression of pdcd4 cDNA in stably transfected P+ cells rendered cells resistant to tumor promoter-induced transformation, indicating that elevated expression of Pdcd4 protein is sufficient to suppress neoplastic transformation. To determine whether Pdcd4 suppresses neoplastic transformation through inhibiting known transformation required events, se examined the possibility that pdcd4 inhibited the activation of AP-1 or NF-kappaB dependent transcription or of ornithine decarboxylase (ODC) activity. Activation of AP-1-dependent transcriptional activity mas inhibited bai pdcd4 expression in a concentration dependent manner. In contrast, Pdcd4 slightly increased NF-kappaB-dependent transcription and did not alter ODC enzymatic activity. Previous studies suggested that activation of AP-1 was required for P+ cell transformation as well as for tumor promotion in vivo. These results indicate that Pdcd4 functions as a transformation suppressor, possibly through inhibiting AP-1 activation in combination with other factors such as enhancing NF-kappaB activation. Pdcd4 may thus constitute a useful molecular target for cancer prevention.	NCI, Basic Res Lab, Gene Regulat Sect, Frederick, MD 21702 USA; Univ Wisconsin, Sch Med, Dept Human Oncol, Madison, WI 53792 USA; Kyoto Univ, Sakyo Ku, Kyoto 606, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Wisconsin System; University of Wisconsin Madison; Kyoto University	Yang, HS (corresponding author), NCI, Basic Res Lab, Gene Regulat Sect, Frederick, MD 21702 USA.		Yang, Hsin-Sheng/A-6419-2008; Yang, Hsin-Sheng/AAF-6793-2020	Yang, Hsin-Sheng/0000-0002-0566-3036; Yang, Hsin-Sheng/0000-0002-0566-3036				AMSTAD P, 1994, J BIOL CHEM, V269, P1606; Amstad PA, 1997, CARCINOGENESIS, V18, P479, DOI 10.1093/carcin/18.3.479; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Azzoni L, 1998, J IMMUNOL, V161, P3493; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; Bernstein LR, 1999, BBA-GENE STRUCT EXPR, V1489, P263, DOI 10.1016/S0167-4781(99)00191-8; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chang PL, 2000, J CELL BIOCHEM, V78, P8, DOI 10.1002/(SICI)1097-4644(20000701)78:1<8::AID-JCB2>3.3.CO;2-J; Cmarik J.L., 1997, FOOD FACTORS CANC PR, P67, DOI [10.1007/978-4-431-67017-9_13, DOI 10.1007/978-4-431-67017-9_13]; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; COLBURN NH, 1980, CARCINOGENESIS, V1, P951, DOI 10.1093/carcin/1.11.951; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; DEBENEDETTI F, 1990, PROG LEUC B, V10, P275; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Foo SY, 1999, TRENDS GENET, V15, P229; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; Hsu TC, 2000, FREE RADICAL BIO MED, V28, P1338, DOI 10.1016/S0891-5849(00)00220-3; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; Jansen AP, 1999, ONCOGENE, V18, P5806, DOI 10.1038/sj.onc.1202965; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Li JJ, 1997, CANCER RES, V57, P3569; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; Matsuhashi Sachiko, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P109; OBrien TG, 1997, CANCER RES, V57, P2630; Onishi Y, 1996, BIOCHEM BIOPH RES CO, V228, P7, DOI 10.1006/bbrc.1996.1609; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; TAKAHASHI K, 1986, CANCER RES, V46, P5923; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Yoshinaga H, 1999, PATHOL INT, V49, P1067, DOI 10.1046/j.1440-1827.1999.00995.x; Yoshinaga Hidetoshi, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P121; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	41	163	169	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2001	20	6					669	676		10.1038/sj.onc.1204137	http://dx.doi.org/10.1038/sj.onc.1204137			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314000				2022-12-17	WOS:000166806000002
J	Dihlmann, S; Siermann, A; Doeberitz, MV				Dihlmann, S; Siermann, A; Doeberitz, MV			The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling	ONCOGENE			English	Article						WNT; NSAID; colorectal cancer; transcriptional regulation; tumor prevention	NF-KAPPA-B; BETA-CATENIN; CYCLOOXYGENASE-2 INHIBITORS; COLORECTAL-CANCER; SULINDAC SULFIDE; COLON-CANCER; CYCLIN D1; APC; TARGET; CELLS	Increasing epidemiological and experimental evidence implicates non-steroidal anti-inflanmatory drugs (NSAIDs) as anti-tumorigenic agents. The precise mechanisms whereby NSAIDs exert their anti-neoplastic effects remain poorly understood. Studies from hereditary and sporadic colorectal cancer (CRC) patients suggest that NSAIDs may interfere with initiating steps of carcinogenesis, i.e. disturbances,within the beta -catenin signaling pathway. We therefore investigated beta -catenin/ TCF signaling in response to aspirin or indomethacin, respectively, in four CRC cell lines (SW948, SW480, HCT116, LoVo). Both, aspirin and indomethacin inhibited transcription of a beta -catenin/TCF-responsive reporter gene In a dose dependent manner, In addition, the beta -catenin/TCF transcriptional target cyclin D1 was downregulated by both drugs, Endogenous beta -catenin levels remained unaffected by either drug. Moreover, indirect immunofluorescence studies revealed no significant changes of subcellular beta -catenin localization in either cell line after NSAID treatment, Likewise, binding of the beta -catenin/TCF complex to its specific DNA-binding sites was not altered, as demonstrated by electrophoretic mobility shift assay (EMSA) of nuclear extracts derived from NSAID treated cells, These results strongly suggest that aspirin and indomethacin attenuate the transcription of beta -catenin/TCF-responsive gents, by modulating TCF activity without disrupting beta -catenin/ TCF complex formation.	Heidelberg Univ, Dept Surg, Div Mol Diagnost & Therapy, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Doeberitz, MV (corresponding author), Heidelberg Univ, Dept Surg, Div Mol Diagnost & Therapy, D-69120 Heidelberg, Germany.			Dihlmann, Susanne/0000-0002-3737-7755				AHNEN DJ, 1988, EUR J SURG S, V582, P111; Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bordonaro M, 1999, CELL GROWTH DIFFER, V10, P713; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Dihlmann S, 1999, CANCER RES, V59, P1857; DuBois RN, 1996, J GASTROENTEROL, V31, P898, DOI 10.1007/BF02358623; Goodman L. S., 1996, PHARM BASIS THERAPEU; Goppelt-Struebe M, 2000, N-S ARCH PHARMACOL, V361, P636, DOI 10.1007/s002100000231; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Herrmann C, 1998, ONCOGENE, V17, P1769, DOI 10.1038/sj.onc.1202085; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Ilyas M, 1999, EUR J CANCER, V35, P335, DOI 10.1016/S0959-8049(98)00431-6; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; Mahmoud NN, 1997, CANCER RES, V57, P5045; Mahmoud NN, 1998, SURGERY, V124, P225, DOI 10.1016/S0039-6060(98)70124-2; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; McEntee MF, 1999, CARCINOGENESIS, V20, P635, DOI 10.1093/carcin/20.4.635; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Patten EJ, 1999, CANCER LETT, V147, P95, DOI 10.1016/S0304-3835(99)00282-7; Pennisi E, 1998, SCIENCE, V281, P1438, DOI 10.1126/science.281.5382.1438; Polakis P, 1999, ADV EXP MED BIOL, V470, P23; Prescott SM, 2000, BBA-REV CANCER, V1470, pM69, DOI 10.1016/S0304-419X(00)00006-8; Ricchi P, 1997, INT J CANCER, V73, P880; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Ruschoff J, 1998, P NATL ACAD SCI USA, V95, P11301, DOI 10.1073/pnas.95.19.11301; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; Stevenson MA, 1999, J IMMUNOL, V163, P5608; Subbegowda R, 1998, CANCER RES, V58, P2772; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; Taketo MM, 1998, J NATL CANCER I, V90, P1529, DOI 10.1093/jnci/90.20.1529; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Webb SJ, 1999, FASEB J, V13, P339, DOI 10.1096/fasebj.13.2.339; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	45	163	172	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2001	20	5					645	653		10.1038/sj.onc.1204123	http://dx.doi.org/10.1038/sj.onc.1204123			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313997				2022-12-17	WOS:000166755000012
J	Suzuki, A; Hayashida, M; Ito, T; Kawano, H; Nakano, T; Miura, M; Akahane, K; Shiraki, K				Suzuki, A; Hayashida, M; Ito, T; Kawano, H; Nakano, T; Miura, M; Akahane, K; Shiraki, K			Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/Cyclin E complex activation	ONCOGENE			English	Article						Survivin; Cdk; INK4a; p27; cell cycle progression	ANTI-APOPTOSIS GENE; DEPENDENT KINASE INHIBITOR; FAS-MEDIATED APOPTOSIS; TUMOR NECROSIS FACTOR; DEATH FACTOR; RETINOBLASTOMA PROTEIN; IAP GENE; CANCER; P21; EXPRESSION	Survivin is observed uniquely in tumor cells and developmental cells, which undergo either inappropriate or programmed cell growth, In the current study, we investigated the influence of Survivin on cell cycle, Overexpression of Survivin resulted in accelerated S phase shift, resistance to G1 arrest, and activated Cdk2/Cyclin E complex leading Rb phosphorylation, In addition, nuclear translocation of Survivin followed by an interaction with Cdk4 was detected. Interestingly, Survivin nuclear translocation coincided with S phase shift, and prevention of nuclear transport suppressed Survivin nuclear translocation and S phase shift. Further, we also observed that Survivin competitively interacted with the Cdk4/p16(INK4n) complex in a cell free system and in vivo. These results suggest that Survivin initiates the cell cycle entry as a result of nuclear translocation followed by an interaction with Cdk4.	Daiichi Pharmaceut Co Ltd, Basic Technol Res Lab, Project Cell Death Res, Tokyo R&D Ctr,Edogawa Ku, Tokyo 1348630, Japan; Mie Univ, Dept Internal Med 1, Sch Med, Tsu, Mie 5148507, Japan; Osaka Univ, Sch Med, Biomed Res Ctr, Dept Neuroanat, Suita, Osaka 565, Japan; Daiichi Pharmaceut Co Ltd, New Prod Res Labs 4, Tokyo R&D Ctr, Edogawa Ku, Tokyo 1348630, Japan	Daiichi Sankyo Company Limited; Mie University; Osaka University; Daiichi Sankyo Company Limited	Suzuki, A (corresponding author), Daiichi Pharmaceut Co Ltd, Basic Technol Res Lab, Project Cell Death Res, Tokyo R&D Ctr,Edogawa Ku, Kitakasai 1-16-13, Tokyo 1348630, Japan.							Adida C, 1998, LANCET, V351, P882, DOI 10.1016/S0140-6736(05)70294-4; Adida C, 1998, AM J PATHOL, V152, P43; Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HARPER JW, 1993, CELL, V75, P805; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Ito T, 2000, HEPATOLOGY, V31, P1080, DOI 10.1053/he.2000.6496; Kawasaki H, 1998, CANCER RES, V58, P5071; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li FZ, 1999, CANCER RES, V59, P3143; LI Y, 1994, ONCOGENE, V9, P2261; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; Lu CD, 1998, CANCER RES, V58, P1808; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1994, PHILOS T ROY SOC B, V345, P281, DOI 10.1098/rstb.1994.0107; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Parry D, 1999, MOL CELL BIOL, V19, P1775; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Sugimoto M, 1999, GENE DEV, V13, P3027, DOI 10.1101/gad.13.22.3027; Suzuki A, 1996, EMBO J, V15, P211, DOI 10.1002/j.1460-2075.1996.tb00351.x; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; Swana HS, 1999, NEW ENGL J MED, V341, P452, DOI 10.1056/NEJM199908053410614; Tamm I, 1998, CANCER RES, V58, P5315; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	48	163	231	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2000	19	29					3225	3234		10.1038/sj.onc.1203665	http://dx.doi.org/10.1038/sj.onc.1203665			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918579				2022-12-17	WOS:000088019300001
J	Sun, SC; Ballard, DW				Sun, SC; Ballard, DW			Persistent activation of NF-kappa B by the Tax transforming protein of HTLV-1: hijacking cellular I kappa B kinases	ONCOGENE			English	Review						HTLV-1; Tax; NF-kappa B; I kappa B; IKK; viral oncogenesis; leukemia	VIRUS TYPE-I; HUMAN T-CELLS; SITE-SPECIFIC PHOSPHORYLATION; UBIQUITIN-PROTEASOME PATHWAY; PRIMARY HUMAN-LYMPHOCYTES; RECEPTOR GENE-EXPRESSION; NECROSIS-FACTOR-ALPHA; LEUKEMIA-VIRUS; TRANSCRIPTIONAL ACTIVATOR; TRANSACTIVATOR TAX	Biochemical coupling of transcription factor NF-kappa B to antigen and co-stimulatory receptors is required for the temporal control of T-cell proliferation. In contrast to its transitory activation during normal growth-signal transduction, NF-kappa B is Constitutively deployed in T-cells transformed by the type 1 human T-cell leukemia virus (HTLV-1). This viral/host interaction is mediated by the HTLV-1-encoded Tax protein, which has potent oncogenic properties. As reviewed here, Tax activates NF-kappa B primarily via a pathway leading to the chronic phosphorylation and degradation of I kappa B alpha, a cytoplasmic inhibitor of NF-kappa B. To access this pathway, Tax associates stably with a cytokine-inducible I kappa B kinase (IKK), which contains both catalytic (IKK alpha and IKK beta) and noncatalytic (IKK gamma) subunits. Unlike their transiently induced counterparts in cytokine-treated cells, Tax-associated forms of IKK alpha and IKK beta are persistently activated in HTLV-1-infected T cells. Acquisition of the deregulated IKK phenotype is contingent on the presence of IKK gamma, which functions as a molecular adaptor in the assembly of pathologic Tax/I kappa B kinase complexes. These findings highlight a key mechanistic role for Wt in the Tax/NF-kappa B signaling axis and define new intracellular targets for the therapeutic control HTLV-1-associated disease.	Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Vanderbilt University	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, 500 Univ Dr, Hershey, PA 17033 USA.				NATIONAL CANCER INSTITUTE [R01CA082556, R01CA068471] Funding Source: NIH RePORTER; NCI NIH HHS [CA82556, CA68471] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; ALEXANDRE C, 1991, ONCOGENE, V6, P543; ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; Attar RM, 1998, MOL CELL BIOL, V18, P477, DOI 10.1128/MCB.18.1.477; Azimi N, 1998, P NATL ACAD SCI USA, V95, P2452, DOI 10.1073/pnas.95.5.2452; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BEIMLING P, 1989, ONCOGENE, V4, P511; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; BERAUD C, 1991, EMBO J, V10, P3795, DOI 10.1002/j.1460-2075.1991.tb04949.x; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; Beraud C, 1996, J ACQ IMMUN DEF SYND, V13, pS76, DOI 10.1097/00042560-199600001-00014; Bohnlein E, 1989, Haematol Blood Transfus, V32, P393; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Cann A.J., 1996, FIELDS VIROLOGY, P1849; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHEN L, 1998, NATURE, V17, P292; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; Cowan EP, 1997, J VIROL, V71, P6982, DOI 10.1128/JVI.71.9.6982-6989.1997; CRENON I, 1993, ONCOGENE, V8, P867; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Doi TS, 1997, J EXP MED, V185, P953, DOI 10.1084/jem.185.5.953; DONALD R, 1995, J BIOL CHEM, V270, P9, DOI 10.1074/jbc.270.1.9; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; Esslinger CW, 1997, J IMMUNOL, V158, P5075; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; FELBER BK, 1985, SCIENCE, V229, P54; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; Fujimoto T, 1999, CANCER GENET CYTOGEN, V109, P1, DOI 10.1016/S0165-4608(98)00141-1; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Good L, 1997, J BIOL CHEM, V272, P1425, DOI 10.1074/jbc.272.3.1425; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; GRILLI M, 1993, INT REV CYTOL, V143, P1; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Harhaj EW, 1999, ONCOGENE, V18, P1341, DOI 10.1038/sj.onc.1202405; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Higashimura N, 1996, JPN J CANCER RES, V87, P227, DOI 10.1111/j.1349-7006.1996.tb00210.x; HIMES SR, 1993, ONCOGENE, V8, P3198; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HIRAI H, 1992, ONCOGENE, V7, P1737; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; KANNO T, 1994, MOL CELL BIOL, V14, P6443, DOI 10.1128/MCB.14.10.6443; KANNO T, 1995, J BIOL CHEM, V270, P11745, DOI 10.1074/jbc.270.20.11745; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LAHERTY CD, 1993, J BIOL CHEM, V268, P5032; LANOIX J, 1994, ONCOGENE, V9, P841; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LI CCH, 1993, J VIROL, V67, P4205, DOI 10.1128/JVI.67.7.4205-4213.1993; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; LILIENBAUM A, 1993, J BIOL CHEM, V268, P2180; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; LINDHOLM PF, 1992, J VIROL, V66, P1294, DOI 10.1128/JVI.66.3.1294-1302.1992; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; MAGGIRWAR SB, 1995, ONCOGENE, V11, P993; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; MOCH H, 1992, J VIROL, V66, P7346, DOI 10.1128/JVI.66.12.7346-7354.1992; Mori N, 1998, CANCER RES, V58, P3993; Mori N, 1996, BLOOD, V87, P3410, DOI 10.1182/blood.V87.8.3410.bloodjournal8783410; MORI N, 1994, BLOOD, V84, P2904; MURAKAMI T, 1995, VIROLOGY, V206, P1066, DOI 10.1006/viro.1995.1029; MURAOKA O, 1993, IMMUNOL LETT, V37, P159, DOI 10.1016/0165-2478(93)90026-X; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Ohtani K, 1998, J BIOL CHEM, V273, P14119, DOI 10.1074/jbc.273.23.14119; Orian A, 1999, MOL CELL BIOL, V19, P3664; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAUL NL, 1993, CYTOKINE, V5, P372, DOI 10.1016/1043-4666(93)90070-L; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Petropoulos L, 1996, VIROLOGY, V225, P52, DOI 10.1006/viro.1996.0574; Petropoulos L, 1998, VIROLOGY, V252, P189, DOI 10.1006/viro.1998.9430; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Ressler S, 1996, FEMS MICROBIOL LETT, V140, P99, DOI 10.1016/0378-1097(96)00166-8; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Ross TM, 1996, J VIROL, V70, P5194, DOI 10.1128/JVI.70.8.5194-5202.1996; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; SANADA I, 1986, LEUKEMIA RES, V10, P1377, DOI 10.1016/0145-2126(86)90003-2; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SHIRAISHI Y, 1985, CANCER GENET CYTOGEN, V15, P65, DOI 10.1016/0165-4608(85)90131-1; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; SUZUKI T, 1994, ONCOGENE, V9, P3099; SUZUKI T, 1995, ONCOGENE, V10, P1199; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tanaka Y, 1996, J VIROL, V70, P8508, DOI 10.1128/JVI.70.12.8508-8517.1996; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Trejo SR, 1996, J BIOL CHEM, V271, P14584, DOI 10.1074/jbc.271.24.14584; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; UITTENBOGAARD MN, 1994, J BIOL CHEM, V269, P22466; WACHSMAN W, 1985, SCIENCE, V228, P1534, DOI 10.1126/science.2990032; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WATANABE M, 1993, ONCOGENE, V8, P2949; Weil R, 1999, J VIROL, V73, P3709, DOI 10.1128/JVI.73.5.3709-3717.1999; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zandi E, 1999, MOL CELL BIOL, V19, P4547; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	187	163	170	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	1999	18	49					6948	6958		10.1038/sj.onc.1203220	http://dx.doi.org/10.1038/sj.onc.1203220			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259LZ	10602469				2022-12-17	WOS:000083896500011
J	Togawa, A; Miyoshi, J; Ishizaki, H; Tanaka, M; Takakura, A; Nishioka, H; Yoshida, H; Doi, T; Mizoguchi, A; Matsuura, N; Niho, Y; Nishimune, Y; Nishikawa, S; Takai, Y				Togawa, A; Miyoshi, J; Ishizaki, H; Tanaka, M; Takakura, A; Nishioka, H; Yoshida, H; Doi, T; Mizoguchi, A; Matsuura, N; Niho, Y; Nishimune, Y; Nishikawa, S; Takai, Y			Progressive impairment of kidneys and reproductive organs in mice lacking Rho GDI alpha	ONCOGENE			English	Article						gene targeting; small G protein; Rho; Rho GDI alpha; nephrotic syndrome; infertility	GTP-BINDING PROTEINS; DISSOCIATION INHIBITOR GDI; CELL-CYCLE PROGRESSION; SMALL GTPASES RAC; REGULATORY PROTEIN; MDCK CELLS; CA2+-DEPENDENT EXOCYTOSIS; STRESS FIBERS; CDC42 GTPASES; MAST-CELLS	The Rho small G protein family members regulate various actin cytoskeleton-dependent cell functions. The Rho GDI (GDP dissociation inhibitor) family, consisting of Rho GDI alpha, -beta, and -gamma, is a regulator that keeps the Rho family members in the cytosol as the GDP-bound inactive form and translocates the GDP-bound form from the membranes to the cytosol after the GTP-bound form accomplishes their functions. Rho GDI alpha is ubiquitously expressed in mouse tissues and shows GDI activity on all the Rho family members in vitro. We have generated mice lacking Rho GDI alpha by homologous recombination to clarify its in vivo function. Rho GDI alpha -/- mice showed several abnormal phenotypes, Firstly, Rho GDI alpha -/- mice were initially viable but developed massive proteinuria mimicking nephrotic syndrome, leading to death due to renal failure within a year. Histologically, degeneration of tubular epithelial cells and dilatation of distal and collecting tubules were readily detected in the kidneys. Secondly, Rho GDI alpha -/- male mice were infertile and showed impaired spermatogenesis with vacuolar degeneration of seminiferous tubules in their testes. Thirdly, Rho GDI alpha -/- embryos derived from Rho GDI alpha -/- female mice were defective in the postimplantation development, In addition, these morphological and functional abnormalities showed age-dependent progression. These results suggest that the signaling pathways of the Rho family members regulated by Rho GDI alpha play important roles in maintaining the structure and physiological function of at least kidneys and reproductive systems in adult mice.	JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan; Kyoto Univ, Fac Med, Dept Mol Genet, Kyoto 6068507, Japan; Kyoto Univ Hosp, Div Artificial Kidneys, Kyoto 6068507, Japan; Kyoto Univ, Fac Med, Dept Anat, Kyoto 6068507, Japan; Osaka Univ, Sch Allied Hlth Sci, Dept Pathol, Osaka 5650871, Japan; Kyushu Univ, Fac Med, Dept Internal Med 4, Fukuoka 81282, Japan; Osaka Univ, Microbial Dis Res Inst, Div Mol Embryol, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Mol Biol & Biochem, ERATO,Takai Biotimer Project, Osaka 5650871, Japan	Japan Science & Technology Agency (JST); Kyoto University; Kyoto University; Kyoto University; Osaka University; Kyushu University; Osaka University; Japan Science & Technology Agency (JST); Osaka University	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, ERATO,Takai Biotimer Project, Osaka 5650871, Japan.			Tanaka-Okamoto, Miki/0000-0002-6429-7662				Adra CN, 1997, P NATL ACAD SCI USA, V94, P4279, DOI 10.1073/pnas.94.9.4279; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; Hogan B., 1994, MANIPULATING MOUSE E, P296; Imamura H, 1998, MOL BIOL CELL, V9, P2561, DOI 10.1091/mbc.9.9.2561; ISOMURA M, 1991, ONCOGENE, V6, P119; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; Kotani H, 1997, ONCOGENE, V14, P1705, DOI 10.1038/sj.onc.1200998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; LEONARD D, 1992, J BIOL CHEM, V267, P22860; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Mariot P, 1996, EMBO J, V15, P6476, DOI 10.1002/j.1460-2075.1996.tb01038.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIURA Y, 1993, J BIOL CHEM, V268, P510; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PLATKO JV, 1995, P NATL ACAD SCI USA, V92, P2974, DOI 10.1073/pnas.92.7.2974; PRICE LS, 1995, CURR BIOL, V5, P68, DOI 10.1016/S0960-9822(95)00018-2; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; Roberts R G, 1987, Biomed Chromatogr, V2, P71, DOI 10.1002/bmc.1130020207; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; UEDA T, 1990, J BIOL CHEM, V265, P9373; Zalcman G, 1996, J BIOL CHEM, V271, P30366, DOI 10.1074/jbc.271.48.30366	42	163	166	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5373	5380		10.1038/sj.onc.1202921	http://dx.doi.org/10.1038/sj.onc.1202921			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498891				2022-12-17	WOS:000082718600002
J	Dragovich, T; Rudin, CM; Thompson, CB				Dragovich, T; Rudin, CM; Thompson, CB			Signal transduction pathways that regulate cell survival and cell death	ONCOGENE			English	Article						signal transduction; bcl-2 proteins; caspases; death receptors	NF-KAPPA-B; TRAF-INTERACTING PROTEIN; CYTOCHROME-C; DNA-DAMAGE; GENE CED-3; APOPTOSIS; BCL-2; BCL-X(L); BAX; ACTIVATION	Apoptosis or programmed cell death (PCD) is a physiological process critical for organ development, tissue homeostasis and elimination of defective or potentially dangerous cells in complex organisms. Apoptosis permits cell death without a concomitant inflammatory response in the surrounding tissues. The process of apoptosis depends on the reception of multiple extracellular and intracellular signals, integration and amplification of these signals by second messengers and finally, activation of the death effector proteases, Defects in control of apoptotic pathways may contribute to a variety of diseases including cancer, autoimmune and neurodegenerative conditions and AIDS, While many components of the regulatory network controlling apoptosis have been defined, the mechanisms of action and patterns of interaction of these factors remain controversial. This article summarizes some of the known aspects of signaling pathways involved in apoptosis.	Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago; Howard Hughes Medical Institute; University of Chicago; University of Chicago	Thompson, CB (corresponding author), Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA.		Rudin, Charles/R-2530-2019	Rudin, Charles/0000-0001-5204-3465; Dragovich, Tomislav/0000-0002-1569-2172				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Aplin AE, 1998, PHARMACOL REV, V50, P197; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Casiano CA, 1996, J EXP MED, V184, P765, DOI 10.1084/jem.184.2.765; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; KASTAN MB, 1997, NEW ENGL J MED, V333, P662; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1993, BLOOD, V81, P151; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RATHMEL JC, 1998, IN PRESS ANN REV IMM; Rathmell JC, 1996, CELL, V87, P319, DOI 10.1016/S0092-8674(00)81349-5; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wyllie A, 1997, NATURE, V389, P237, DOI 10.1038/38405; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	62	163	171	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 24	1998	17	25					3207	3213		10.1038/sj.onc.1202587	http://dx.doi.org/10.1038/sj.onc.1202587			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916983				2022-12-17	WOS:000078048200002
J	Dominguez, A; Ramos-Morales, F; Romero, F; Rios, RM; Dreyfus, F; Tortolero, M; Pintor-Toro, JA				Dominguez, A; Ramos-Morales, F; Romero, F; Rios, RM; Dreyfus, F; Tortolero, M; Pintor-Toro, JA			hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG	ONCOGENE			English	Article						PTTG; oncogene; transcription; tumorigenesis	SECONDARY-STRUCTURE; IMMUNE PRIVILEGE; PROTEINS; YEAST; GENE; DOMAINS; LIGAND; BRCA1	We have isolated a human cDNA clone encoding a novel protein of 22 kDa that is a human counterpart of the rat oncoprotein PTTG. We show that the corresponding gene (hpttg) is overexpressed in Jurkat cells (a human T lymphoma cell line) and in samples from patients with different kinds of hematopoietic malignancies. Analysis of the sequence showed that hPTTG has an aminoterminal basic domain and a carboxyl-terminal! acidic domain, and that it is a proline-rich protein with several putative SH3-binding sites, Subcellular fractionation studies show that, although hPTTG is mainly a cytosolic protein, it is partially localized in the nucleus. In addition we demonstrate that the acidic carboxyl-terminal region of hPTTG acts as a transactivation domain when fused to a heterologous DNA binding domain, both in yeast and in mammalian cells.	CSIC, Inst Recursos Nat & Agrobiol, E-41080 Seville, Spain; Univ Sevilla, Fac Biol, Dept Microbiol, E-41080 Seville, Spain; Hop Cochin, Hematol Serv, F-75015 Paris, France	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS); University of Sevilla; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Pintor-Toro, JA (corresponding author), CSIC, Inst Recursos Nat & Agrobiol, Apdo 1052, E-41080 Seville, Spain.		Tortolero, Maria/K-5744-2014; rios, rosa m/G-5742-2015; Ramos-Morales, Francisco/C-5734-2008; Romero, Francisco/K-2101-2014	Tortolero, Maria/0000-0003-1797-9940; rios, rosa m/0000-0001-5778-6946; Ramos-Morales, Francisco/0000-0002-1151-4547; Romero, Francisco/0000-0002-9588-6881				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bartel PL, 1993, CELLULAR INTERACTION, P153; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HWANG LY, 1995, CURR OPIN IMMUNOL, V7, P659, DOI 10.1016/0952-7915(95)80074-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RamosMorales F, 1997, BIOCHEM BIOPH RES CO, V237, P735, DOI 10.1006/bbrc.1997.7221; Remacle JE, 1997, EMBO J, V16, P5722, DOI 10.1093/emboj/16.18.5722; RIOS RM, 1994, J CELL BIOL, V125, P997, DOI 10.1083/jcb.125.5.997; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SANZ L, 1995, MOL CELL BIOL, V15, P3164; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SETH A, 1992, J BIOL CHEM, V267, P24796; Sherman F., 1986, METHODS YEAST GENETI; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; STREILEIN JW, 1993, CURR OPIN IMMUNOL, V5, P428, DOI 10.1016/0952-7915(93)90064-Y; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z	39	163	185	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2187	2193		10.1038/sj.onc.1202140	http://dx.doi.org/10.1038/sj.onc.1202140			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811450				2022-12-17	WOS:000076698200005
J	Fuchs, SY; Dolan, L; Davis, RJ; Ronai, Z				Fuchs, SY; Dolan, L; Davis, RJ; Ronai, Z			Phosphorylation-dependent targeting of c-jun ubiquitination by Jun N-kinase	ONCOGENE			English	Article						c-jun; c-jun N-kinase; ubiquitination; phosphorylation	SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASE; DELTA-DOMAIN; PROTEASOME PATHWAY; ACTIVATION DOMAIN; HA-RAS; V-JUN; TRANSCRIPTION; CELLS; TRANSFORMATION	Ubiquitination of key cellular regulatory proteins marks them for efficient degradation via the proteasome pathway. The delta domain of c-jun is essential for its ubiquitination and also for the activating phosphorylation of neighboring serines by the stress activated jun-N-terminal kinases (JNK). Using an in vitro model system we demonstrate that JNK is among the hydrophobic binding proteins that target c-jun for efficient ubiquitination. Immunodepletion of JNK markedly inhibits c-jun ubiquitination. Conversely, c-jun ubiquitination is increased by adding purified JNK2 or extracts prepared from cells transfected with JNK2. Although c-jun ubiquitination is enhanced by JNK, the phosphorylation of c-jun on Ser(73) by JNK protects c-jun from ubiquitination and prolongs its half-life. The dual activity of JNK in targeting c-jun for ubiquitination or in protecting c-jun from entering this pathway via phosphorylation points to the role of JNK in the control of c-jun stability in cells exposed to environmental stress or inflammatory cytokines.	AMER HLTH FDN,MOL CARCINOGENESIS PROGRAM,VALHALLA,NY 10595; UNIV MASSACHUSETTS,MED CTR,HOWARD HUGHES MED INST,WORCESTER,MA	American Health Foundation; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester				RONAI, ZEEV/0000-0002-3859-0400; Reinhart, Lisa/0000-0001-6266-3342	NCI NIH HHS [CA59908, CA58396] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059908, R01CA058396] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1994, J BIOL CHEM, V269, P11186; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FORNACE AJ, 1989, NUCLEIC ACIDS RES, V17, P1215, DOI 10.1093/nar/17.3.1215; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MAMROUDKIDRON E, 1994, FEBS LETT, V337, P239, DOI 10.1016/0014-5793(94)80199-1; MORGAN IM, 1993, ONCOGENE, V8, P1135; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106	29	163	167	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1531	1535						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875991				2022-12-17	WOS:A1996VL38400018
J	FUJIWARA, KT; KATAOKA, K; NISHIZAWA, M				FUJIWARA, KT; KATAOKA, K; NISHIZAWA, M			2 NEW MEMBERS OF THE MAF ONCOGENE FAMILY, MAFK AND MAFF, ENCODE NUCLEAR B-ZIP PROTEINS LACKING PUTATIVE TRANSACTIVATOR DOMAIN	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; DNA-BINDING PROTEIN; LEUCINE ZIPPER; C-JUN; FOS PROTEINS; V-JUN; GENE; C/EBP; TRANSFORMATION; RETROVIRUS	The v-maf oncogene of the avian musculoaponeurotic fibrosarcoma virus, AS42, encodes a nuclear protein which contains a characteristic b-Zip domain. By screening a chicken embryo fibroblast (CEF) cDNA library under moderately stringent hybridization conditions, we picked up a series of cDNA clones for a novel maf-related gene which we named mafK. We also identified another maf-related gene named mafF by screening a chicken genomic library using a mafK probe. Structural analyses suggested that the mafK and mafF genes consist of three exons. The exon-intron structures of the two genes resemble each other, but differ from that of the chicken c-maf gene. As compared to the c-Maf protein, the proteins encoded by the mafK and the mafF genes are rather small in size and lack the regions corresponding to the amino terminal acidic domain present in the c-Maf protein. On the other hand, the structures of the b-Zip domain are well conserved among these Maf-related proteins. When overexpressed by using an avian retroviral vector, the two maf-related genes did not induce morphological transformation of CEF cells but induced colony formation in soft agar with very low efficiencies. With a specific antibody, the MafK protein was detected predominantly in the nuclei of the cells infected with the virus which carries the mafK gene. Tissue distributions of these three maf-family genes are different from one another, probably reflecting their different functions in vivo.	JAPANESE FDN CANC RES,INST CANC,DEPT VIRAL ONCOL,1-37-1 KAMI IKEBUKURO,TOSHIMA KU,TOKYO 170,JAPAN	Japanese Foundation for Cancer Research								BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CURRAN T, 1984, CELL, V36, P259; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; HARLOW E, 1988, ANTIBODIES LABORATOR; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KAWAI S, 1992, VIROLOGY, V188, P778, DOI 10.1016/0042-6822(92)90532-T; KAWAI S, 1972, VIROLOGY, V48, P126, DOI 10.1016/0042-6822(72)90120-1; KAWAI S, 1970, JPN J EXP MED, V40, P243; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Marston F. A. O., 1987, DNA CLONING, P59; MITCHELL P, 1989, SCIENCE, V289, P371; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SEMBA K, 1990, MOL CELL BIOL, V10, P3095, DOI 10.1128/MCB.10.6.3095; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; TABATA T, 1991, EMBO J, V10, P1459, DOI 10.1002/j.1460-2075.1991.tb07666.x; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; VOGT PK, 1964, NATL CANCER I MONOGR, V17, P527; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	39	163	171	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2371	2380						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361754				2022-12-17	WOS:A1993LT36800007
J	SETH, A; PAPAS, TS				SETH, A; PAPAS, TS			THE C-ETS-1 PROTOONCOGENE HAS ONCOGENIC ACTIVITY AND IS POSITIVELY AUTOREGULATED	ONCOGENE			English	Article							AUTO-REGULATION; ETS GENES; MYC; EXPRESSION; ENHANCER; DAUGHTERLESS; SEQUENCE; PROTEINS; COMPLEX; BINDING	The proto-oncogene ets-1 is a member of the ets family of genes that share homology with the viral oncogene, v-ets, of the avian leukemia virus E26. By using expression vectors, we demonstrate that the ets-1 gene transforms NIH3T3 cells and the ets-1 transfected cells from colonies in soft agar and induce tumors in nude mice. We have also determined that the ets-1 protein contains homology with the helix-loop-helix motif of the HLH family proteins, but lacks the basic domain upstream of helix I. Transfection of the NIH3T3 cells with ets-1 vectors results in the activation of the endogenous ets-1 gene. Using hybridization probes that can distinguish between transcripts from endogenous and exogenous templates, we show that the endogenous ets-1 gene is activated by the expression of the transfected exogenous ets-1. In contrast, the expression of transfected ets-2 has no effect on the endogenous ets-1 gene expression. The results indicate that the ets-1 proto-oncogene is positively autoregulated by its product.			SETH, A (corresponding author), NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702, USA.							ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BHAT NK, 1989, J IMMUNOL, V142, P672; BLAIR DG, 1980, P NATL ACAD SCI-BIOL, V77, P3504, DOI 10.1073/pnas.77.6.3504; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P773; FISHER RJ, 1990, ONCOGENESIS, P249; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; KARPINSKI BA, 1989, MOL CELL BIOL, V9, P2588, DOI 10.1128/MCB.9.6.2588; KATZAV S, 1989, ONCOGENE, V4, P1129; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; KOIZUMI S, 1990, ONCOGENE, V5, P675; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; Maniatis T., 1982, MOL CLONING; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PAVLAKIS GN, 1987, GENE TRANSFER VECTOR, P29; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; POGNONEC P, 1990, ONCOGENE, V5, P603; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SERFLING E, 1989, TRENDS GENET, V5, P131, DOI 10.1016/0168-9525(89)90049-8; SETH A, 1989, ONCOGENE RES, V5, P61; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1989, ADV GENE TECHNOLOGY, P155; SETH A, 1990, ONCOGENESIS, P297; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1988, VIROLOGY, V164, P99, DOI 10.1016/0042-6822(88)90624-1; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1990, ONCOGENESIS, P221; YUAN CC, 1989, J VIROL, V63, P205, DOI 10.1128/JVI.63.1.205-215.1989; ZHAN X, 1987, ONCOGENE, V1, P369	38	163	165	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1990	5	12					1761	1767						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET436	2284095				2022-12-17	WOS:A1990ET43600004
J	Du, WW; Yang, WN; Li, XM; Awan, FM; Yang, ZG; Fang, L; Lyu, JJ; Li, FY; Peng, C; Krylov, SN; Xie, YZ; Zhang, Y; He, CY; Wu, N; Zhang, C; Sdiri, M; Dong, J; Ma, J; Gao, CQ; Hibberd, S; Yang, BB				Du, William W.; Yang, Weining; Li, Xiangmin; Awan, Faryal Mehwish; Yang, Zhenguo; Fang, Ling; Lyu, Juanjuan; Li, Feiya; Peng, Chun; Krylov, Sergey N.; Xie, Yizhen; Zhang, Yaou; He, Chengyan; Wu, Nan; Zhang, Chao; Sdiri, Mouna; Dong, Jun; Ma, Jian; Gao, Chunqi; Hibberd, Steven; Yang, Burton B.			A circular RNA circ-DNMT1 enhances breast cancer progression by activating autophagy	ONCOGENE			English	Article							MATURE MIR-17-5P; SEQUENCING DATA; BINDING DOMAIN; NONCODING RNAS; FOXO3 ACTIVITY; GROWTH-FACTOR; TUMOR-GROWTH; HNRNP D0; P53; INHIBITION	Circular RNAs are a large group of noncoding RNAs that are widely expressed in mammalian cells. Genome-wide analyses have revealed abundant and evolutionarily conserved circular RNAs across species, which suggest specific physiological roles of these species. Using a microarray approach, we detected increased expression of a circular RNA circ-Dnmt1 in eight breast cancer cell lines and in patients with breast carcinoma. Silencing circ-Dnmt1 inhibited cell proliferation and survival. Ectopic circ-Dnmt1 increased the proliferative and survival capacities of breast cancer cells by stimulating cellular autophagy. We found that circ-Dnmt1-mediated autophagy was essential in inhibiting cellular senescence and increasing tumor xenograft growth. We further found that ectopically expressed circ-Dnmt1 could interact with both p53 and AUF1, promoting the nuclear translocation of both proteins. Nuclear translocation of p53 induced cellular autophagy while AUF1 nuclear translocation reduced Dnmt1 mRNA instability, resulting in increased Dnmt1 translation. From here, functional Dnmt1 could then translocate into the nucleus, inhibiting p53 transcription. Computational algorithms revealed that both p53 and AUF1 could bind to different regions of circ-Dnmt1 RNA. Our results showed that the highly expressed circular RNA circ-Dnmt1 could bind to and regulate oncogenic proteins in breast cancer cells. Thus circ-Dnmt1 appears to be an oncogenic circular RNA with potential for further preclinical research.	[Du, William W.; Yang, Weining; Li, Xiangmin; Awan, Faryal Mehwish; Yang, Zhenguo; Fang, Ling; Lyu, Juanjuan; Li, Feiya; Wu, Nan; Zhang, Chao; Sdiri, Mouna; Dong, Jun; Ma, Jian; Gao, Chunqi; Hibberd, Steven; Yang, Burton B.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON, Canada; [Li, Xiangmin; Xie, Yizhen] Guangdong Inst Microbiol, State Key Lab Appl Microbiol Southern China, Guangdong Prov Key Lab Microbial Culture Collect, Guangzhou 510070, Guangdong, Peoples R China; [Awan, Faryal Mehwish] NUST, ASAB, H-12, Islamabad, Pakistan; [Fang, Ling; He, Chengyan] Jilin Univ, China Japan Union Hosp, Jilin, Jilin, Peoples R China; [Peng, Chun] York Univ, Dept Biol, Toronto, ON, Canada; [Krylov, Sergey N.] York Univ, Dept Chem, 4700 Keele St, Toronto, ON M3J 1P3, Canada; [Krylov, Sergey N.] York Univ, Ctr Res Biomol Interact, 4700 Keele St, Toronto, ON M3J 1P3, Canada; [Xie, Yizhen] Yuewei Edible Fungi Technol Co Ltd, Guangzhou, Guangdong, Peoples R China; [Zhang, Yaou] Tsinghua Univ, Div Life Sci, Key Lab Hlth Sci & Technol, Grad Sch Shenzhen, Shenzhen 518055, Peoples R China; [Yang, Burton B.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Guangdong Academy of Sciences; Institute of Microbiology, Guangdong Academy of Sciences; National University of Sciences & Technology - Pakistan; Jilin University; York University - Canada; York University - Canada; York University - Canada; Tsinghua University; University Town of Shenzhen; Tsinghua Shenzhen International Graduate School; University of Toronto	Yang, BB (corresponding author), Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON, Canada.; Yang, BB (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.	byang@sri.utoronto.ca	ma, jian/AAV-9930-2021; Gao, Chun/AAP-2262-2020	Awan, Faryal Mehwish/0000-0002-8146-8929; Yang, Burton B/0000-0002-2892-7209	Canadian Institutes of Health Research [PJT-153105]; National Natural Science Foundation of Guangdong [2017A030310088]; Innovation and Entrepreneurship Leading Talent of Guangzhou Development Zone [2017-L181]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Natural Science Foundation of Guangdong(National Natural Science Foundation of Guangdong Province); Innovation and Entrepreneurship Leading Talent of Guangzhou Development Zone	This work was supported by grants from Canadian Institutes of Health Research (PJT-153105), National Natural Science Foundation of Guangdong (2017A030310088), and Innovation and Entrepreneurship Leading Talent of Guangzhou Development Zone (2017-L181).	Bachmayr-Heyda A, 2015, SCI REP-UK, V5, DOI 10.1038/srep08057; Bai Y, 2018, J NEUROSCI, V38, P32, DOI 10.1523/JNEUROSCI.1348-17.2017; Burd CE, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001233; CAPEL B, 1993, CELL, V73, P1019, DOI 10.1016/0092-8674(93)90279-Y; Chen JM, 2013, PROTEIN SCI, V22, P510, DOI 10.1002/pro.2230; Dempsey LA, 1998, GENOMICS, V49, P378, DOI 10.1006/geno.1998.5237; Du WW, 2017, EUR HEART J, V38, P1402, DOI 10.1093/eurheartj/ehw001; Du WW, 2017, CELL DEATH DIFFER, V24, P357, DOI 10.1038/cdd.2016.133; Du WW, 2016, NUCLEIC ACIDS RES, V44, P2846, DOI 10.1093/nar/gkw027; Du WW, 2015, MOL THER, V23, P1222, DOI 10.1038/mt.2015.64; Enuka Y, 2016, NUCLEIC ACIDS RES, V44, P1370, DOI 10.1093/nar/gkv1367; Georgia S, 2013, GENE DEV, V27, P372, DOI 10.1101/gad.207001.112; Gratacos FM, 2010, WIRES RNA, V1, P457, DOI 10.1002/wrna.26; Hansen TB, 2013, CANCER RES, V73, P5609, DOI 10.1158/0008-5472.CAN-13-1568; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hsiao KY, 2017, CANCER RES, V77, P2339, DOI 10.1158/0008-5472.CAN-16-1883; Huang RR, 2017, AUTOPHAGY, V13, P1722, DOI 10.1080/15548627.2017.1356975; Jeck WR, 2014, NAT BIOTECHNOL, V32, P453, DOI 10.1038/nbt.2890; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Kastritis PL, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2012.0835; Katahira M, 2001, J MOL BIOL, V311, P973, DOI 10.1006/jmbi.2001.4862; Klein CJ, 2011, NAT GENET, V43, P595, DOI 10.1038/ng.830; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Liu YC, 2016, NUCLEIC ACIDS RES, V44, pD209, DOI 10.1093/nar/gkv940; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; Nagata T, 1999, J MOL BIOL, V287, P221, DOI 10.1006/jmbi.1999.2616; Panda AC, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkx297; Pietal MJ, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-333; Rutnam ZJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3914; Salzman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030733; Shan SW, 2013, J CELL SCI, V126, P1517, DOI 10.1242/jcs.122895; Shan SW, 2009, NAT CELL BIOL, V11, P1031, DOI 10.1038/ncb1917; Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Torrisani J, 2007, MOL CELL BIOL, V27, P395, DOI 10.1128/MCB.01236-06; Tuszynska I, 2015, NUCLEIC ACIDS RES, V43, pW425, DOI 10.1093/nar/gkv493; Washietl S, 2012, WIRES RNA, V3, P759, DOI 10.1002/wrna.1134; Yang BL, 2000, J BIOL CHEM, V275, P21255, DOI 10.1074/jbc.M001443200; Yang Q, 2017, CELL DEATH DIFFER, V24, P1609, DOI 10.1038/cdd.2017.86; Yang W, 2016, ONCOGENE, V35, P3919, DOI 10.1038/onc.2015.460; Yang XL, 2013, NUCLEIC ACIDS RES, V41, P9688, DOI 10.1093/nar/gkt680; Yang YB, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx166; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287; Yoshida Y, 2004, ONCOGENE, V23, P4371, DOI 10.1038/sj.onc.1207583; Zeng Y, 2017, THERANOSTICS, V7, P3842, DOI 10.7150/thno.19764; Zhang Y, 2013, MOL CELL, V51, P792, DOI 10.1016/j.molcel.2013.08.017; Zheng LL, 2016, NUCLEIC ACIDS RES, V44, pD196, DOI 10.1093/nar/gkv1273	48	162	170	2	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2018	37	44					5829	5842		10.1038/s41388-018-0369-y	http://dx.doi.org/10.1038/s41388-018-0369-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY9EX	29973691				2022-12-17	WOS:000448943100002
J	Colombo, E; Alcalay, M; Pelicci, PG				Colombo, E.; Alcalay, M.; Pelicci, P. G.			Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases	ONCOGENE			English	Review						nucleophosmin; leukemia; cancer	ACUTE-MYELOID-LEUKEMIA; ARF TUMOR-SUPPRESSOR; ACUTE MYELOGENOUS LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; NUCLEOLAR PROTEIN B23; NF-KAPPA-B; ONCOGENE-INDUCED SENESCENCE; SUMO-SPECIFIC PROTEASE; TRANS-RETINOIC ACID; NUCLEAR EXPORT	Nucleophosmin (NPM, also known as B23, numatrin or NO38) is a ubiquitously expressed phosphoprotein belonging to the nucleoplasmin family of chaperones. NPM is mainly localized in the nucleolus where it exerts many of its functions, but a proportion of the protein continuously shuttles between the nucleus and the cytoplasm. A growing number of cellular proteins have been described as physical interactors of NPM, and consequently, NPM is thought to have a relevant role in diverse cellular functions, including ribosome biogenesis, centrosome duplication, DNA repair and response to stress. NPM has been implicated in the pathogenesis of several human malignancies and intriguingly, it has been described both as an activating oncogene and a tumor suppressor, depending on cell type and protein levels. In fact, increased NPM expression is associated with different types of solid tumors whereas an impairment of NPM function is characteristic of a subgroup of hematolologic malignancies. A large body of experimental evidence links the deregulation of specific NPM functions to cellular transformation, yet the molecular mechanisms through which NPM contributes to tumorigenesis remain elusive. In this review, we have summarized current knowledge concerning NPM functions, and attempted to interpret its multifaceted and sometimes apparently contradictory activities in the context of both normal cellular homeostasis and neoplastic transformation. Oncogene (2011) 30, 2595-2609; doi:10.1038/onc.2010.646; published online 31 January 2011	[Colombo, E.; Alcalay, M.; Pelicci, P. G.] Ist Europeo Oncol, Dept Expt Oncol, I-20139 Milan, Italy; [Colombo, E.; Alcalay, M.; Pelicci, P. G.] Univ Milan, Dipartimento Med Chirurg & Odontoiatria, Milan, Italy	IRCCS European Institute of Oncology (IEO); University of Milan	Colombo, E (corresponding author), Ist Europeo Oncol, Dept Expt Oncol, Via Adamello 16, I-20139 Milan, Italy.	emanuela.colombo@ifom-ieo-campus.it; piergiuseppe.pelicci@ifom-ieo-campus.it	Alcalay, Myriam/AAB-4300-2019; Alcalay, Myriam/B-3182-2016; Colombo, Emanuela/AAO-8113-2020; Pelicci, Pier Giuseppe/AAL-6572-2020	Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Colombo, Emanuela/0000-0003-2079-7398; 	AIRC; EC; Ministero della Salute	AIRC(Fondazione AIRC per la ricerca sul cancro); EC(European CommissionEuropean Commission Joint Research Centre); Ministero della Salute(Ministry of Health, Italy)	This work was supported by grants from AIRC, EC and Ministero della Salute to PGP, EC and MA.	Adon AM, 2010, MOL CELL BIOL, V30, P694, DOI 10.1128/MCB.00253-09; Ahn JY, 2005, MOL CELL, V18, P435, DOI 10.1016/j.molcel.2005.04.010; Albiero E, 2007, LEUKEMIA, V21, P1099, DOI 10.1038/sj.leu.2404597; Alcalay M, 2005, BLOOD, V106, P899, DOI 10.1182/blood-2005-02-0560; Amin HM, 2007, BLOOD, V110, P2259, DOI 10.1182/blood-2007-04-060715; Amin MA, 2008, FEBS LETT, V582, P3839, DOI 10.1016/j.febslet.2008.10.023; Andersen MT, 2008, LEUKEMIA, V22, P951, DOI 10.1038/leu.2008.17; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Berger R, 2006, LEUKEMIA, V20, P319, DOI 10.1038/sj.leu.2404063; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Bolli N, 2009, LEUKEMIA, V23, P501, DOI 10.1038/leu.2008.326; Bolli N, 2007, CANCER RES, V67, P6230, DOI 10.1158/0008-5472.CAN-07-0273; Bolli N, 2010, BLOOD, V115, P3329, DOI 10.1182/blood-2009-02-207225; Bonetti P, 2008, J CELL BIOL, V182, P19, DOI 10.1083/jcb.200711040; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Borggrefe T, 1998, J BIOL CHEM, V273, P17025, DOI 10.1074/jbc.273.27.17025; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004; Brown P, 2007, BLOOD, V110, P979, DOI 10.1182/blood-2007-02-076604; Burnett AK, 2010, BLOOD, V115, P948, DOI 10.1182/blood-2009-08-236588; Caudill JSC, 2006, BRIT J HAEMATOL, V133, P638, DOI 10.1111/j.1365-2141.2006.06081.x; Cazzaniga G, 2005, BLOOD, V106, P1419, DOI 10.1182/blood-2005-03-0899; Chang JH, 1998, BIOCHEM J, V329, P539; Cheng K, 2007, ONCOGENE, V26, P7391, DOI 10.1038/sj.onc.1210549; Cheng K, 2010, BLOOD, V115, P3341, DOI 10.1182/blood-2009-03-208587; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Chou CC, 2007, LIFE SCI, V80, P2051, DOI 10.1016/j.lfs.2007.03.004; Cilloni D, 2008, LEUKEMIA, V22, P1234, DOI 10.1038/leu.2008.68; Colombo E, 2006, CANCER RES, V66, P3044, DOI 10.1158/0008-5472.CAN-05-2378; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Dalenc F, 2002, INT J CANCER, V100, P662, DOI 10.1002/ijc.10558; Del Poeta G, 2010, BRIT J HAEMATOL, V149, P383, DOI 10.1111/j.1365-2141.2010.08098.x; den Besten W, 2005, CELL CYCLE, V4, P1593; Dhar SK, 2009, J BIOL CHEM, V284, P16409, DOI 10.1074/jbc.M109.005736; Dhar SK, 2004, J BIOL CHEM, V279, P28209, DOI 10.1074/jbc.M403553200; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dohner K, 2005, BLOOD, V106, P3740, DOI 10.1182/blood-2005-05-2164; Du W, 2010, CARCINOGENESIS, V31, P302, DOI 10.1093/carcin/bgp270; Eitoku M, 2008, CELL MOL LIFE SCI, V65, P414, DOI 10.1007/s00018-007-7305-6; Endo A, 2009, J BIOL CHEM, V284, P27918, DOI 10.1074/jbc.M109.037218; Endo A, 2009, J CELL SCI, V122, P678, DOI 10.1242/jcs.044461; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Falini B, 2008, LEUKEMIA, V22, P891, DOI 10.1038/leu.2008.44; Falini B, 2008, HAEMATOLOGICA, V93, P439, DOI 10.3324/haematol.12153; Falini B, 2007, HAEMATOLOGICA, V92, P519, DOI 10.3324/haematol.11007; Falini B, 2006, BLOOD, V108, P1999, DOI 10.1182/blood-2006-03-007013; Falini B, 2006, BLOOD, V107, P4514, DOI 10.1182/blood-2005-11-4745; Foltz DR, 2009, CELL, V137, P472, DOI 10.1016/j.cell.2009.02.039; Foltz DR, 2006, NAT CELL BIOL, V8, P458, DOI 10.1038/ncb1397; Frehlick LJ, 2007, BIOESSAYS, V29, P49, DOI 10.1002/bies.20512; Frelin C, 2005, BLOOD, V105, P804, DOI 10.1182/blood-2004-04-1463; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gao H, 2005, J BIOL CHEM, V280, P10988, DOI 10.1074/jbc.M412720200; Garzon R, 2008, P NATL ACAD SCI USA, V105, P3945, DOI 10.1073/pnas.0800135105; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grummitt Charles G, 2008, J Biol Chem, V283, P23326, DOI 10.1074/jbc.M801706200; Gruszka AM, 2010, BLOOD, V116, P2096, DOI 10.1182/blood-2010-01-266908; Gurumurthy M, 2008, J MOL BIOL, V378, P302, DOI 10.1016/j.jmb.2008.02.055; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Haferlach C, 2009, BLOOD, V114, P3024, DOI 10.1182/blood-2009-01-197871; Haindl M, 2008, EMBO REP, V9, P273, DOI 10.1038/embor.2008.3; HERRERA JE, 1995, NUCLEIC ACIDS RES, V23, P3974, DOI 10.1093/nar/23.19.3974; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Hsu CY, 2000, INT J CANCER, V88, P392, DOI 10.1002/1097-0215(20001101)88:3<392::AID-IJC11>3.0.CO;2-7; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Jian Y, 2009, ONCOGENE, V28, P4201, DOI 10.1038/onc.2009.275; Jongen-Lavrencic M, 2008, BLOOD, V111, P5078, DOI 10.1182/blood-2008-01-133355; Joukov V, 2006, CELL, V127, P539, DOI 10.1016/j.cell.2006.08.053; Kau TR, 2003, CANCER CELL, V4, P463, DOI 10.1016/S1535-6108(03)00303-9; Kau TR, 2003, DRUG DISCOV TODAY, V8, P78, DOI 10.1016/S1359-6446(02)02562-X; Kerr LE, 2007, ONCOGENE, V26, P2554, DOI 10.1038/sj.onc.1210044; Koike A, 2010, CANCER RES, V70, P6746, DOI 10.1158/0008-5472.CAN-10-0382; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Kraus WL, 2008, CURR OPIN CELL BIOL, V20, P294, DOI 10.1016/j.ceb.2008.03.006; Krause A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009849; Kuo ML, 2008, CELL CYCLE, V7, P3378, DOI 10.4161/cc.7.21.6930; Kuo ML, 2004, GENE DEV, V18, P1862, DOI 10.1101/gad.1213904; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Lee SB, 2008, P NATL ACAD SCI USA, V105, P16584, DOI 10.1073/pnas.0807668105; Leotoing L, 2008, ONCOGENE, V27, P2858, DOI 10.1038/sj.onc.1210942; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; Li J, 2005, LEUKEMIA RES, V29, P1415, DOI 10.1016/j.leukres.2005.05.005; Li J, 2004, J BIOL CHEM, V279, P41275, DOI 10.1074/jbc.C400297200; Li J, 2007, CARCINOGENESIS, V28, P1163, DOI 10.1093/carcin/bgm025; Li J, 2006, J BIOL CHEM, V281, P16536, DOI 10.1074/jbc.M601386200; Li ZL, 2008, P NATL ACAD SCI USA, V105, P18794, DOI 10.1073/pnas.0806879105; Liu H, 2007, EMBO REP, V8, P394, DOI 10.1038/sj.embor.7400909; Liu H, 2008, J EXP MED, V205, P1843, DOI 10.1084/jem.20072102; Liu X, 2007, P NATL ACAD SCI USA, V104, P9679, DOI 10.1073/pnas.0701806104; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Maggi LB, 2008, MOL CELL BIOL, V28, P7050, DOI 10.1128/MCB.01548-07; Maiguel DA, 2004, MOL CELL BIOL, V24, P3703, DOI 10.1128/MCB.24.9.3703-3711.2004; Mariano AR, 2006, ONCOGENE, V25, P4376, DOI 10.1038/sj.onc.1209453; Martelli MP, 2010, BLOOD, V116, P3907, DOI 10.1182/blood-2009-08-238899; Meder VS, 2005, J CELL SCI, V118, P211, DOI 10.1242/jcs.01606; MELONI G, 2008, HAEMATOLOGICA, V94, P298; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Mrozek K, 2007, CURR OPIN HEMATOL, V14, P106, DOI 10.1097/MOH.0b013e32801684c7; Mukudai Y, 2008, MOL CELL BIOL, V28, P6134, DOI 10.1128/MCB.00495-08; Murano K, 2008, MOL CELL BIOL, V28, P3114, DOI 10.1128/MCB.02078-07; Mutka SC, 2009, CANCER RES, V69, P510, DOI 10.1158/0008-5472.CAN-08-0858; Naoe T, 2006, CANCER SCI, V97, P963, DOI 10.1111/j.1349-7006.2006.00270.x; Negi SS, 2006, J CELL SCI, V119, P3676, DOI 10.1242/jcs.03090; Nishida T, 2008, BIOCHEM BIOPH RES CO, V374, P382, DOI 10.1016/j.bbrc.2008.07.047; Nousiainen M, 2006, P NATL ACAD SCI USA, V103, P5391, DOI 10.1073/pnas.0507066103; Okada M, 2007, J BIOL CHEM, V282, P36744, DOI 10.1074/jbc.M706169200; Okazuka K, 2007, INT J HEMATOL, V86, P246, DOI 10.1007/BF03006928; Oki Y, 2006, HAEMATOLOGICA, V91, P1147; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Okuwaki M, 2002, MOL BIOL CELL, V13, P2016, DOI 10.1091/mbc.02-03-0036; Okuwaki M, 2001, J MOL BIOL, V311, P41, DOI 10.1006/jmbi.2001.4812; Okuwaki M, 2001, FEBS LETT, V506, P272, DOI 10.1016/S0014-5793(01)02939-8; Palaniswamy V, 2006, NAT STRUCT MOL BIOL, V13, P429, DOI 10.1038/nsmb1080; Pang QS, 2003, J BIOL CHEM, V278, P41709, DOI 10.1074/jbc.M301392200; Pasqualucci L, 2006, BLOOD, V108, P4146, DOI 10.1182/blood-2006-06-026716; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; RAMSAMOOJ P, 1995, RADIAT RES, V143, P158, DOI 10.2307/3579152; Redner RL, 2000, BLOOD, V95, P2683; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Rodway H, 2004, ONCOGENE, V23, P6186, DOI 10.1038/sj.onc.1207854; ROUSSEL P, 1994, EXP CELL RES, V214, P465, DOI 10.1006/excr.1994.1283; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; Sato K, 2004, J BIOL CHEM, V279, P30919, DOI 10.1074/jbc.C400169200; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; Schlenk RF, 2008, NEW ENGL J MED, V358, P1909, DOI 10.1056/NEJMoa074306; Schlenk RF, 2009, HAEMATOL-HEMATOL J, V94, P54, DOI 10.3324/haematol.13378; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schnittger S, 2005, BLOOD, V106, P3733, DOI 10.1182/blood-2005-06-2248; Schnittger S, 2009, BLOOD, V114, P2220, DOI 10.1182/blood-2009-03-213389; Shandilya J, 2009, MOL CELL BIOL, V29, P5115, DOI 10.1128/MCB.01969-08; Sportoletti P, 2008, BLOOD, V111, P3859, DOI 10.1182/blood-2007-06-098251; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Suzuki T, 2005, BLOOD, V106, P2854, DOI 10.1182/blood-2005-04-1733; Swaminathan V, 2005, MOL CELL BIOL, V25, P7534, DOI 10.1128/MCB.25.17.7534-7545.2005; Szebeni A, 1997, BIOCHEMISTRY-US, V36, P3941, DOI 10.1021/bi9627931; Szebeni A, 1999, PROTEIN SCI, V8, P905; Szebeni A, 2003, J BIOL CHEM, V278, P9107, DOI 10.1074/jbc.M204411200; Tago K, 2005, P NATL ACAD SCI USA, V102, P7689, DOI 10.1073/pnas.0502978102; Takemura M, 1999, J BIOCHEM-TOKYO, V125, P904, DOI 10.1093/oxfordjournals.jbchem.a022367; Tarapore P, 2006, FEBS LETT, V580, P399, DOI 10.1016/j.febslet.2005.12.022; Taussig DC, 2010, BLOOD, V115, P1976, DOI 10.1182/blood-2009-02-206565; Thiede C, 2006, BLOOD, V107, P4011, DOI 10.1182/blood-2005-08-3167; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Verhaak RGW, 2005, BLOOD, V106, P3747, DOI 10.1182/blood-2005-05-2168; WANG DR, 1993, CELL MOL BIOL RES, V39, P33; Wang GX, 2010, BIOCHEMISTRY-US, V49, P3842, DOI 10.1021/bi9021928; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Wanzel M, 2008, NAT CELL BIOL, V10, P1051, DOI 10.1038/ncb1764; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wilson CS, 2006, BLOOD, V108, P685, DOI 10.1182/blood-2004-12-4633; Wu MH, 2002, INT J CANCER, V97, P297, DOI 10.1002/ijc.1606; Wu MH, 2002, CARCINOGENESIS, V23, P93, DOI 10.1093/carcin/23.1.93; Xiao JY, 2009, CELL CYCLE, V8, P889, DOI 10.4161/cc.8.6.7898; Yao JH, 2004, FEBS LETT, V575, P112, DOI 10.1016/j.febslet.2004.08.047; Yao Z, 2010, ONCOGENE, V29, P1821, DOI 10.1038/onc.2009.473; Yoneda-Kato N, 2005, EMBO J, V24, P1739, DOI 10.1038/sj.emboj.7600656; Yoneda-Kato N, 2008, MOL CELL BIOL, V28, P422, DOI 10.1128/MCB.02335-06; YonedaKato N, 1996, ONCOGENE, V12, P265; Yu Y, 2006, MOL CELL BIOL, V26, P3798, DOI 10.1128/MCB.26.10.3798-3809.2006; Yun CW, 2008, J CELL BIOL, V183, P589, DOI 10.1083/jcb.200807185; Yung Benjamin Yat Ming, 2007, Chang Gung Med J, V30, P285; Yusufzai TM, 2004, MOL CELL, V13, P291, DOI 10.1016/S1097-2765(04)00029-2; Zhang H, 2004, J BIOL CHEM, V279, P35726, DOI 10.1074/jbc.M403264200; Zhang Y, 2007, LEUKEMIA RES, V31, P109, DOI 10.1016/j.leukres.2006.03.013; Zhou Y, 2008, BLOOD, V112, P2474, DOI 10.1182/blood-2007-12-130211; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	173	162	168	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	23					2595	2609		10.1038/onc.2010.646	http://dx.doi.org/10.1038/onc.2010.646			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778CV	21278791				2022-12-17	WOS:000291677800001
J	Xu, MZ; Chan, SW; Liu, AM; Wong, KF; Fan, ST; Chen, J; Poon, RT; Zender, L; Lowe, SW; Hong, W; Luk, JM				Xu, M. Z.; Chan, S. W.; Liu, A. M.; Wong, K. F.; Fan, S. T.; Chen, J.; Poon, R. T.; Zender, L.; Lowe, S. W.; Hong, W.; Luk, J. M.			AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma	ONCOGENE			English	Article						cancer signaling; Hippo pathway; YAP1 oncogene; AXL receptor kinase; HCC; hepatocellular carcinoma	HIPPO SIGNALING PATHWAY; CELL CONTACT INHIBITION; YES-ASSOCIATED PROTEIN; ORGAN SIZE CONTROL; NF-KAPPA-B; LIVER-CANCER; TYROSINE KINASES; GROWTH-CONTROL; TUMOR-GROWTH; EXPRESSION	Yes-associated protein (YAP) is a downstream effector of the Hippo signaling pathway, which controls organ expansion and tissue development. We have recently defined the tumorigenic potential and clinical significance of the YAP1 oncogene in human hepatocellular carcinoma (HCC). The present study aims to define the tumorigenic properties of YAP in HCC and elucidate the related downstream signaling mechanism. In a gain-of-function study, we demonstrated that ectopic increased expression of YAP in the immortalized non-tumorigenic hepatocyte cell line MIHA confers tumorigenic and metastatic potentials, as evidenced by (1) enhanced aptitudes in cell viability, anchorage-independent growth, migration and invasion; (2) tumor formation in a xenograft mouse model; and (3) induction of HCC biomarker alpha-fetoprotein and activation of mitogen-activated protein kinase. Furthermore, we have identified AXL, a receptor tyrosine kinase, as a key downstream target that drives YAP-dependent oncogenic functions. RNAi-mediated knockdown of AXL expression decreased the ability of YAP-expressing MIHA cells and of the primary HCC cell line to proliferate and invade. These results indicate that AXL is a mediator of YAP-dependent oncogenic activities and implicates it as a potential therapeutic target for HCC. Oncogene (2011) 30, 1229-1240; doi: 10.1038/onc.2010.504; published online 15 November 2010	[Xu, M. Z.; Chen, J.; Luk, J. M.] Nanjing Med Univ, Dept Oncol, Affiliated Nanjing Hosp 1, Nanjing, Peoples R China; [Xu, M. Z.; Liu, A. M.; Wong, K. F.; Fan, S. T.; Poon, R. T.; Luk, J. M.] Univ Hong Kong, Dept Surg, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China; [Chan, S. W.; Hong, W.] ASTAR, Canc & Dev Cell Biol Div, Inst Mol & Cell Biol, Singapore, Singapore; [Liu, A. M.; Wong, K. F.; Luk, J. M.] Natl Univ Singapore, Canc Sci Inst, Singapore 117597, Singapore; [Zender, L.] Helmholtz Ctr Infect Res, Dept Cell Biol, Braunschweig, Germany; [Lowe, S. W.] Cold Spring Harbor Lab, Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA; [Lowe, S. W.] Cold Spring Harbor Lab, CSHL Canc Ctr, Cold Spring Harbor, NY 11724 USA	Nanjing Medical University; University of Hong Kong; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Helmholtz Association; Helmholtz-Center for Infection Research; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; Cold Spring Harbor Laboratory	Luk, JM (corresponding author), Natl Univ Singapore, Dept Pharmacol, Clin Res Ctr MD11 05 30B, Dept Surg, 10 Med Dr, Singapore 117597, Singapore.	jmluk@nus.edu.sg	HONG, Wanjin/E-9927-2010; Luk, John/A-4085-2008	Luk, John/0000-0002-6323-7940	Biomedical Research Grants Council of Singapore; National University Cancer Institute (NCIS) Centre; National Natural Science Foundation of China [81000880]; National Cancer Institute of NIH [CA13106]; A*STAR; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER	Biomedical Research Grants Council of Singapore; National University Cancer Institute (NCIS) Centre; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Cancer Institute of NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); A*STAR(Agency for Science Technology & Research (A*STAR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Sources of support: The work was supported by grants to JML from the Biomedical Research Grants Council of Singapore and by the National University Cancer Institute (NCIS) Centre Grant; WH was supported by the A*STAR and MX by the National Natural Science Foundation of China (Grant No. 81000880). SWL is an investigator in the Howard Hughes Medical Institute and Dr Lowe's work is supported by a program grant (CA13106) from the National Cancer Institute of NIH.	Bandura JL, 2008, DEV CELL, V14, P315, DOI 10.1016/j.devcel.2008.02.010; Berclaz G, 2001, ANN ONCOL, V12, P819, DOI 10.1023/A:1011126330233; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Bueno L, 2008, EUR J CANCER, V44, P142, DOI 10.1016/j.ejca.2007.10.008; Buttitta LA, 2007, NAT CELL BIOL, V9, P1225, DOI 10.1038/ncb1107-1225; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Cao XW, 2008, GENE DEV, V22, P3320, DOI 10.1101/gad.1726608; Chan SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; Demarchi F, 2001, J BIOL CHEM, V276, P31738, DOI 10.1074/jbc.M104457200; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Edgar BA, 2006, CELL, V124, P267, DOI 10.1016/j.cell.2006.01.005; Goruppi S, 1996, ONCOGENE, V12, P471; Hafizi S, 2006, CYTOKINE GROWTH F R, V17, P295, DOI 10.1016/j.cytogfr.2006.04.004; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Hasanbasic I, 2004, AM J PHYSIOL-HEART C, V287, pH1207, DOI 10.1152/ajpheart.00020.2004; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Lay JD, 2007, CANCER RES, V67, P3878, DOI 10.1158/0008-5472.CAN-06-3191; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Liu AM, 2010, EXPERT OPIN THER TAR, V14, P855, DOI 10.1517/14728222.2010.499361; Liu LX, 2009, HEPATOLOGY, V50, P1453, DOI 10.1002/hep.23143; Luk JM, 2005, J IMMUNOL METHODS, V305, P39, DOI 10.1016/j.jim.2005.07.006; Oh H, 2010, TRENDS CELL BIOL, V20, P410, DOI 10.1016/j.tcb.2010.04.005; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007; Peeper D, 2006, CELL, V125, P1230, DOI 10.1016/j.cell.2006.06.018; Sainaghi PP, 2005, J CELL PHYSIOL, V204, P36, DOI 10.1002/jcp.20265; Sawabu T, 2007, MOL CARCINOGEN, V46, P155, DOI 10.1002/mc.20211; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Tai KY, 2008, ONCOGENE, V27, P4044, DOI 10.1038/onc.2008.57; Thompson BJ, 2006, CELL, V126, P767, DOI 10.1016/j.cell.2006.07.013; Tsou AP, 1998, GENOMICS, V50, P331, DOI 10.1006/geno.1998.5338; Wong BW, 2003, BIOCHEM BIOPH RES CO, V311, P618, DOI 10.1016/j.bbrc.2003.10.032; Wu S, 2008, DEV CELL, V14, P388, DOI 10.1016/j.devcel.2008.01.007; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; YIN F, 2007, SCI STKE, pPE12, DOI DOI 10.1126/STKE.3802007PE12; Zender L, 2008, CURR OPIN ONCOL, V20, P72, DOI 10.1097/CCO.0b013e3282f31d5d; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zender L, 2008, CELL, V135, P852, DOI 10.1016/j.cell.2008.09.061; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhang YX, 2008, CANCER RES, V68, P1905, DOI 10.1158/0008-5472.CAN-07-2661; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhao B, 2008, CURR OPIN CELL BIOL, V20, P638, DOI 10.1016/j.ceb.2008.10.001	46	162	166	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	10					1229	1240		10.1038/onc.2010.504	http://dx.doi.org/10.1038/onc.2010.504			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732QD	21076472	Green Accepted			2022-12-17	WOS:000288202400009
J	Liao, YL; Sun, YM; Chau, GY; Chau, YP; Lai, TC; Wang, JL; Horng, JT; Hsiao, M; Tsou, AP				Liao, Y-L; Sun, Y-M; Chau, G-Y; Chau, Y-P; Lai, T-C; Wang, J-L; Horng, J-T; Hsiao, M.; Tsou, A-P			Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma	ONCOGENE			English	Article						SOX4; HCC metastasis; synexpression; target prediction	BREAST-CANCER METASTASIS; TRANSCRIPTIONAL REGULATION; MOUSE GENOME; CELLS; MICE; GUIDANCE; FAMILY; SYNEXPRESSION; NEOPLASMS; PROTEINS	A comprehensive microarray analysis of hepatocellular carcinoma (HCC) revealed distinct synexpression patterns during intrahepatic metastasis. Recent evidence has demonstrated that synexpression group member genes are likely to be regulated by master control gene(s). Here we investigate the functions and gene regulation of the transcription factor SOX4 in intrahepatic metastatic HCC. SOX4 is important in tumor metastasis as RNAi knockdown reduces tumor cell migration, invasion, in vivo tumorigenesis and metastasis. A multifaceted approach integrating gene pro. ling, binding site computation and empirical veri. cation by chromatin immunoprecipitation and gene ablation refined the consensus SOX4 binding motif and identified 32 binding loci in 31 genes with high confidence. RNAi knockdown of two SOX4 target genes, neuropilin 1 and semaphorin 3C, drastically reduced cell migration activity in HCC cell lines suggesting that SOX4 exerts some of its action via regulation of these two downstream targets. The discovery of 31 previously unidentified targets expands our knowledge of how SOX4 modulates HCC progression and implies a range of novel SOX4 functions. This integrated approach sets a paradigm whereby a subset of member genes from a synexpression group can be regulated by one master control gene and this is exemplified by SOX4 and advanced HCC.	[Liao, Y-L; Tsou, A-P] Natl Yang Ming Univ, Dept Biotechnol & Lab Sci Med, Taipei 112, Taiwan; [Sun, Y-M; Horng, J-T] Natl Cent Univ, Inst Comp Sci & Informat Engn, Chungli 32054, Taiwan; [Chau, G-Y] Taipei Vet Gen Hosp, Dept Surg, Taipei, Taiwan; [Chau, Y-P] Natl Yang Ming Univ, Inst Anat & Cell Biol, Taipei 112, Taiwan; [Lai, T-C; Wang, J-L; Hsiao, M.] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan	National Yang Ming Chiao Tung University; National Central University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Tsou, AP (corresponding author), Natl Yang Ming Univ, Dept Biotechnol & Lab Sci Med, Taipei 112, Taiwan.	horng@db.csie.ncu.edu.tw; mhsiao@gate.sinica.edu.tw; aptsou@ym.edu.tw	Hsiao, Michael/U-6238-2019; Lai, Tsung-Ching/AAQ-9967-2021	Hsiao, Michael/0000-0001-8529-9213; 	National Research Program for Genomic Medicine (NRPGM); National Science Council; National Research Program for Genomic Medicine [NSC 94-3112-B-001-003, NSC 94-3112-B-001-018-Y]; National Science Council [NSC 95-2752-B-010-002-PAE]; Ministry of Education	National Research Program for Genomic Medicine (NRPGM)(Ministry of Science and Technology, Taiwan); National Science Council(Ministry of Science and Technology, Taiwan); National Research Program for Genomic Medicine(Ministry of Science and Technology, Taiwan); National Science Council(Ministry of Science and Technology, Taiwan); Ministry of Education	We acknowledge the technical supports provided by the Microarray & Gene Expression Analysis Core Facility of the VGH National Yang-Ming University Genome Research Center (VYMGC). The Gene Expression Analysis Core Facility is supported by National Research Program for Genomic Medicine (NRPGM), National Science Council. RNAi reagents were obtained from the National RNAi Core Facility located at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica (supported by the National Research Program for Genomic Medicine Grants of NSC (NSC 94-3112-B-001-003 and NSC 94-3112-B-001-018-Y). We thank Dr Hua-Chien Chen for providing the PCR primers for the RT-qPCR assays. This work was supported in part by grant (NSC 95-2752-B-010-002-PAE) from National Science Council (Program for Promoting Academic Excellence of Universities Phase II) and a grant from the Ministry of Education, Aim for the Top University Plan to APT and YPC.	Aaboe M, 2006, CANCER RES, V66, P3434, DOI 10.1158/0008-5472.CAN-05-3456; ATTIA MAM, 1966, CANCER RES, V26, P1787; Bielenberg DR, 2006, EXP CELL RES, V312, P584, DOI 10.1016/j.yexcr.2005.11.024; Bowles J, 2000, DEV BIOL, V227, P239, DOI 10.1006/dbio.2000.9883; Chau GY, 2007, HISTOPATHOLOGY, V51, P204, DOI 10.1111/j.1365-2559.2007.02738.x; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Cheung M, 2000, MOL BRAIN RES, V79, P180, DOI 10.1016/S0169-328X(00)00109-1; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Fickett JW, 2000, CURR OPIN BIOTECH, V11, P19, DOI 10.1016/S0958-1669(99)00049-X; Geijsen N, 2001, SCIENCE, V293, P1136, DOI 10.1126/science.1059157; Gonthier B, 2007, CEREB CORTEX, V17, P1712, DOI 10.1093/cercor/bhl082; Grizzi F, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-3; Guan KL, 2003, NAT REV NEUROSCI, V4, P941, DOI 10.1038/nrn1254; Hardison RC, 1997, GENOME RES, V7, P959, DOI 10.1101/gr.7.10.959; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Herman JG, 2007, INT J ONCOL, V30, P1231; Hong TM, 2007, CLIN CANCER RES, V13, P4759, DOI 10.1158/1078-0432.CCR-07-0001; Hunt SMN, 1999, BIOL REPROD, V61, P476, DOI 10.1095/biolreprod61.2.476; Hur EH, 2004, BIOCHEM BIOPH RES CO, V325, P59, DOI 10.1016/j.bbrc.2004.09.215; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Karaulanov E, 2004, EMBO J, V23, P844, DOI 10.1038/sj.emboj.7600101; Kim Y, 2005, TOXICOL PATHOL, V33, P175, DOI 10.1080/01926230590522130; Lee YC, 2003, J BIOL CHEM, V278, P39615, DOI 10.1074/jbc.M304095200; Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055; Lu YS, 2007, HEPATOLOGY, V46, P1119, DOI 10.1002/hep.21804; Maes T, 2002, GENOMICS, V80, P21, DOI 10.1006/geno.2002.6799; McCracken S, 1997, ONCOGENE, V15, P2929, DOI 10.1038/sj.onc.1201474; Mertin S, 1999, NUCLEIC ACIDS RES, V27, P1359, DOI 10.1093/nar/27.5.1359; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Nelson JD, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj004; Niehrs C, 1999, NATURE, V402, P483, DOI 10.1038/990025; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; Pramoonjago P, 2006, ONCOGENE, V25, P5626, DOI 10.1038/sj.onc.1209566; Remenyi A, 2004, NAT STRUCT MOL BIOL, V11, P812, DOI 10.1038/nsmb820; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; SHOUVAL D, 1988, VIRCHOWS ARCH A, V412, P595, DOI 10.1007/BF00844296; Tang ZY, 2004, J CANCER RES CLIN, V130, P187, DOI 10.1007/s00432-003-0511-1; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; Wasserman WW, 2000, NAT GENET, V26, P225, DOI 10.1038/79965; Wilson M, 2002, CURR OPIN GENET DEV, V12, P441, DOI 10.1016/S0959-437X(02)00323-4; WOTTON D, 1995, J BIOL CHEM, V270, P7515, DOI 10.1074/jbc.270.13.7515; Ya J, 1998, CIRC RES, V83, P986, DOI 10.1161/01.RES.83.10.986; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843	45	162	171	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2008	27	42					5578	5589		10.1038/onc.2008.168	http://dx.doi.org/10.1038/onc.2008.168			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KX	18504433				2022-12-17	WOS:000259280800004
J	van der Vos, KE; Coffer, PJ				van der Vos, K. E.; Coffer, P. J.			FOXO-binding partners: it takes two to tango	ONCOGENE			English	Review						FOXO; transcription; co-factor; DNA-binding; PKB; PI3K	FORKHEAD TRANSCRIPTION FACTOR; PROSTATE-CANCER CELLS; ACTIVATED RECEPTOR-GAMMA; SMOOTH-MUSCLE-CELLS; ANDROGEN RECEPTOR; CAENORHABDITIS-ELEGANS; GENE-EXPRESSION; SKELETAL-MUSCLE; INSULIN ACTION; FACTOR FKHR	Modulation FOXO transcription factor activities can lead to a variety of cellular outputs resulting in changes in proliferation, apoptosis, differentiation and metabolic responses. Although FOXO proteins all contain an identical DNA-binding domain their cellular functions appear to be distinct, as exemplified by differences in the phenotype of Foxo1, Foxo3 and Foxo4 null mutant mice. While some of these differences may be attributable to the differential expression patterns of these transcription factors, many cells and tissues express several FOXO isoforms. Recently it has become clear that FOXO proteins can regulate transcriptional responses independently of direct DNA-binding. It has been demonstrated that FOXOs can associate with a variety of unrelated transcription factors, regulating activation or repression of diverse target genes. The complement of transcription factors expressed in a particular cell type is thus critical in determining the functional end point of FOXO activity. These interactions greatly expand the possibilities for FOXO-mediated regulation of transcriptional programmes. This review details currently described FOXO-binding partners and examines the role of these interactions in regulating cell fate decisions.	[van der Vos, K. E.; Coffer, P. J.] Univ Med Ctr, Wilhelmina Childrens Hosp, Dept Immunol, Mol Immunol Lab, NL-3584 EA Utrecht, Netherlands; [Coffer, P. J.] Univ Med Ctr, Wilhelmina Childrens Hosp, Dept Pediat Immunol, NL-3584 EA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis	Coffer, PJ (corresponding author), Univ Med Ctr, Wilhelmina Childrens Hosp, Dept Immunol, Mol Immunol Lab, Lundlaan 6, NL-3584 EA Utrecht, Netherlands.	p.j.coffer@umcutrecht.nl	Coffer, Paul J/A-5769-2009; Coffer, Paul/AAF-7970-2020					Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200; Arce L, 2006, ONCOGENE, V25, P7492, DOI 10.1038/sj.onc.1210056; Armoni M, 2003, J BIOL CHEM, V278, P30614, DOI 10.1074/jbc.M304654200; Armoni M, 2007, TRENDS ENDOCRIN MET, V18, P100, DOI 10.1016/j.tem.2007.02.001; Armoni M, 2006, J BIOL CHEM, V281, P19881, DOI 10.1074/jbc.M600320200; Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599; Barthel A, 2005, TRENDS ENDOCRIN MET, V16, P183, DOI 10.1016/j.tem.2005.03.010; Benson GV, 1996, DEVELOPMENT, V122, P2687; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Biggins JB, 2007, CURR OPIN CHEM BIOL, V11, P99, DOI 10.1016/j.cbpa.2006.10.042; Birkenkamp KU, 2003, J IMMUNOL, V171, P1623, DOI 10.4049/jimmunol.171.4.1623; Bocchinfuso WP, 1997, J MAMMARY GLAND BIOL, V2, P323, DOI 10.1023/A:1026339111278; Brar AK, 1997, ENDOCRINE, V6, P301, DOI 10.1007/BF02820507; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Buzzio OL, 2006, ENDOCRINOLOGY, V147, P3870, DOI 10.1210/en.2006-0167; Christian M, 2002, J BIOL CHEM, V277, P20825, DOI 10.1074/jbc.M201018200; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Dong XY, 2006, CANCER RES, V66, P6998, DOI 10.1158/0008-5472.CAN-06-0411; Dowell P, 2003, J BIOL CHEM, V278, P45485, DOI 10.1074/jbc.M309069200; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Fan WQ, 2007, J BIOL CHEM, V282, P7329, DOI 10.1074/jbc.M610447200; Fievet C, 2006, CURR OPIN PHARMACOL, V6, P606, DOI 10.1016/j.coph.2006.06.009; Finck BN, 2006, J CLIN INVEST, V116, P615, DOI 10.1172/JCI27794; Foucher I, 2002, DEVELOPMENT, V129, P4065; Gao WQ, 2005, CHEM REV, V105, P3352, DOI 10.1021/cr020456u; GIUDICE LC, 1993, J CLIN ENDOCR METAB, V76, P1115, DOI 10.1210/jc.76.5.1115; Glass DA, 2007, ENDOCRINOLOGY, V148, P2630, DOI 10.1210/en.2006-1372; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Gomis RR, 2006, P NATL ACAD SCI USA, V103, P12747, DOI 10.1073/pnas.0605333103; GOTTLIEB S, 1994, GENETICS, V137, P107; Grinius L, 2006, J ENDOCRINOL, V189, P179, DOI 10.1677/joe.1.06451; Hanashima C, 2004, SCIENCE, V303, P56, DOI 10.1126/science.1090674; Hayashi K, 1999, J CELL BIOL, V145, P727, DOI 10.1083/jcb.145.4.727; Hirota K, 2003, J BIOL CHEM, V278, P13056, DOI 10.1074/jbc.C200553200; Hosaka T, 2004, P NATL ACAD SCI USA, V101, P2975, DOI 10.1073/pnas.0400093101; Huang HJ, 2004, J BIOL CHEM, V279, P13866, DOI 10.1074/jbc.M314143200; Kamei Y, 2003, FEBS LETT, V536, P232, DOI 10.1016/S0014-5793(03)00062-0; Kim JJ, 2005, BIOL REPROD, V73, P833, DOI 10.1095/biolreprod.105.043182; Kim JJ, 2003, BIOL REPROD, V68, P24, DOI 10.1095/biolreprod.102.009316; Kitamura T, 2007, J CLIN INVEST, V117, P2477, DOI 10.1172/JCI32054; Kodama S, 2004, MOL CELL BIOL, V24, P7931, DOI 10.1128/MCB.24.18.7931-7940.2004; Kortylewski M, 2003, J BIOL CHEM, V278, P5242, DOI 10.1074/jbc.M205403200; Krebs LT, 2000, GENE DEV, V14, P1343; LARSEN PL, 1995, GENETICS, V139, P1567; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Li PF, 2001, J BIOL CHEM, V276, P20444, DOI 10.1074/jbc.M010226200; Li YW, 2007, J BIOL CHEM, V282, P21542, DOI 10.1074/jbc.M701978200; Liu ZP, 2005, DEV CELL, V9, P261, DOI 10.1016/j.devcel.2005.05.017; Luo D, 2005, SEMIN CELL DEV BIOL, V16, P612, DOI 10.1016/j.semcdb.2005.07.002; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nechamen CA, 2007, MOL CELL ENDOCRINOL, V260, P93, DOI 10.1016/j.mce.2006.08.014; Nerlov C, 2007, TRENDS CELL BIOL, V17, P318, DOI 10.1016/j.tcb.2007.07.004; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Pardee Keith, 2004, Sci Aging Knowledge Environ, V2004, pre8, DOI 10.1126/sageke.2004.47.re8; Park KW, 2005, ARTERIOSCL THROM VAS, V25, P742, DOI 10.1161/01.ATV.0000156288.70849.26; Patterson GI, 1997, GENE DEV, V11, P2679, DOI 10.1101/gad.11.20.2679; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Pilch PF, 2006, MOL PHARMACOL, V70, P779, DOI 10.1124/mol.106.026104; Plevin MJ, 2005, TRENDS BIOCHEM SCI, V30, P66, DOI 10.1016/j.tibs.2004.12.001; Pohnke Y, 1999, J BIOL CHEM, V274, P24808, DOI 10.1074/jbc.274.35.24808; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Qiao LP, 2006, J BIOL CHEM, V281, P39915, DOI 10.1074/jbc.M607215200; Qu S, 2007, AM J PHYSIOL-ENDOC M, V292, pE421, DOI 10.1152/ajpendo.00157.2006; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Ren PF, 1996, SCIENCE, V274, P1389, DOI 10.1126/science.274.5291.1389; Rudd MD, 2007, J MOL ENDOCRINOL, V38, P673, DOI 10.1677/JME-07-0017; Samuel VT, 2006, DIABETES, V55, P2042, DOI 10.2337/db05-0705; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Sandri M, 2006, P NATL ACAD SCI USA, V103, P16260, DOI 10.1073/pnas.0607795103; Schilling MM, 2006, NATURE, V443, pE10, DOI 10.1038/nature05288; Schuur ER, 2001, J BIOL CHEM, V276, P33554, DOI 10.1074/jbc.M105555200; Sekine K, 2007, EMBO J, V26, P3607, DOI 10.1038/sj.emboj.7601784; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; So CW, 2003, BLOOD, V101, P633, DOI 10.1182/blood-2002-06-1785; van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang ZG, 2004, NATURE, V428, P185, DOI 10.1038/nature02382; Yamamura Y, 2006, J BIOL CHEM, V281, P5267, DOI 10.1074/jbc.M512151200; Zhao HH, 2001, J BIOL CHEM, V276, P27907, DOI 10.1074/jbc.M104278200	86	162	164	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2008	27	16					2289	2299		10.1038/onc.2008.22	http://dx.doi.org/10.1038/onc.2008.22			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	285NE	18391971	Green Published			2022-12-17	WOS:000254782700004
J	Martin, D; Galisteo, R; Ji, Y; Montaner, S; Gutkind, JS				Martin, D.; Galisteo, R.; Ji, Y.; Montaner, S.; Gutkind, J. S.			An NF-kappa B gene expression signature contributes to Kaposi's sarcoma virus vGPCR-induced direct and paracrine neoplasia	ONCOGENE			English	Article						G proteins; signal transduction; G protein coupled receptors; angiosarcoma; endothelial cell; angiogenesis	PROTEIN-COUPLED-RECEPTOR; HERPESVIRUS; KSHV; CELL; CANCER; ANGIOGENESIS; SURVIVAL; PROMOTE	Kaposi's sarcoma (KS) is the most frequent AIDS-associated malignancy, etiologically linked to the infection with the human herpesvirus 8 (HHV-8/KSHV). This member of the gamma-herpesviridae family encodes 81 open reading frames, several bearing oncogenic potential. A constitutively active virally encoded G protein-coupled receptor (vGPCR) readily induces KS-like lesions when expressed in endothelial cells in vivo, and unmasks the oncogenic potential of other HHV-8 genes in a paracrine fashion. How vGPCR causes endothelial cell transformation is still not fully understood. Using full-genome microarray analysis we show here that the expression of nuclear factor-kappa B (NF-kappa B)regulated genes is a prominent feature triggered by vGPCR in cells expressing this viral oncogene and in cells exposed to vGPCR-induced secretions, thus mimicking its paracrine effect. Indeed, vGPCR activates the NF-kappa B pathway potently, and NF-kappa B activation is a hallmark of both human and experimental KS. Of interest, whereas constitutive NF-kappa B signaling is not sufficient to promote endothelial cells transformation, NF-kappa B function is strictly required for vGPCR-induced direct and paracrine neoplasia. Taken together, these results strongly support the role of NF-kappa B regulated genes in KS pathogenesis, thus providing the rationale for the development of novel mechanism-based therapies for this angioproliferative disease.	[Martin, D.; Galisteo, R.; Gutkind, J. S.] Natl Inst Dent & Craniofacial Res, NIH, Oral & Pharyngeal Canc Branch, Bethesda, MD 20892 USA; [Ji, Y.; Montaner, S.] Univ Maryland, Dept Diagnost Sci & Pathol, Baltimore, MD 21201 USA; [Ji, Y.; Montaner, S.] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, NIH, Oral & Pharyngeal Canc Branch, 30 Convent Dr,Bldg 30,Room 211, Bethesda, MD 20892 USA.	sg39v@nih.gov	Abrams, William R/A-5782-2008; Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482; Martin Izquierdo, Daniel/0000-0002-8880-9087	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Asou H, 1998, BLOOD, V91, P2475, DOI 10.1182/blood.V91.7.2475.2475_2475_2481; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Basile JR, 2004, CANCER RES, V64, P5212, DOI 10.1158/0008-5472.CAN-04-0126; Bower M, 2006, CURR OPIN INFECT DIS, V19, P14, DOI 10.1097/01.qco.0000200295.30285.13; Cesarman E, 2007, CURR TOP MICROBIOL, V312, P263; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Hamilton TA, 2002, IMMUNOL RES, V25, P229, DOI 10.1385/IR:25:3:229; Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200; Hiscott J, 2006, ONCOGENE, V25, P6844, DOI 10.1038/sj.onc.1209941; Kanegane H, 1997, J INFECT DIS, V176, P254, DOI 10.1086/517260; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Montaner S, 2006, CANCER RES, V66, P168, DOI 10.1158/0008-5472.CAN-05-1026; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Montaner S, 2001, CANCER RES, V61, P2641; Morris K, 2003, LANCET ONCOL, V4, P5, DOI 10.1016/S1470-2045(03)00969-0; Mutlu AD, 2007, CANCER CELL, V11, P245, DOI 10.1016/j.ccr.2007.01.015; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Rezza G, 1999, J NATL CANCER I, V91, P1468, DOI 10.1093/jnci/91.17.1468; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; SCIACCA FL, 1994, J IMMUNOL, V153, P4816; Sodhi A, 2004, NAT REV MOL CELL BIO, V5, P998, DOI 10.1038/nrm1529; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445	27	162	167	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1844	1852		10.1038/sj.onc.1210817	http://dx.doi.org/10.1038/sj.onc.1210817			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17934524				2022-12-17	WOS:000254150600004
J	Shao, C; Folkard, M; Prise, KM				Shao, C.; Folkard, M.; Prise, K. M.			Role of TGF-beta 1 and nitric oxide in the bystander response of irradiated glioma cells	ONCOGENE			English	Article						targeted irradiation; bystander signaling; TGF-beta 1; nitric oxide; glioma	CHARGED-PARTICLE MICROBEAM; MEDIATED INTERCELLULAR COMMUNICATION; INDUCED GENOMIC INSTABILITY; GROWTH-FACTOR BETA-1; IONIZING-RADIATION; ALPHA-PARTICLES; HUMAN FIBROBLASTS; TGF-BETA; COUNTED PARTICLES; EPITHELIAL-CELLS	The radiation-induced bystander effect (RIBE) increases the probability of cellular response and therefore has important implications for cancer risk assessment following low-dose irradiation and for the likelihood of secondary cancers after radiotherapy. However, our knowledge of bystander signaling factors, especially those having long half-lives, is still limited. The present study found that, when a fraction of cells within a glioblastoma population were individually irradiated with helium ions from a particle microbeam, the yield of micronuclei (MN) in the nontargeted cells was increased, but these bystander MN were eliminated by treating the cells with either aminoguanidine (an inhibitor of inducible nitric oxide (NO) synthase) or anti-transforming growth factor beta 1 (anti-TGF-beta 1), indicating that NO and TGF-beta 1 are involved in the RIBE. Intracellular NO was detected in the bystander cells, and additional TGF-b1 was detected in the medium from irradiated T98G cells, but it was diminished by aminoguanidine. Consistent with this, an NO donor, diethylamine nitric oxide (DEANO), induced TGF-beta 1 generation in T98G cells. Conversely, treatment of cells with recombinant TGF-beta 1 could also induce NO and MN in T98G cells. Treatment of T98G cells with anti-TGF-beta 1 inhibited the NO production when only 1% of cells were targeted, but not when 100% of cells were targeted. Our results indicate that, downstream of radiation-induced NO, TGF-beta 1 can be released from targeted T98G cells and plays a key role as a signaling factor in the RIBE by further inducing free radicals and DNA damage in the nontargeted bystander cells.	[Prise, K. M.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland; [Shao, C.; Folkard, M.; Prise, K. M.] Mt Vernon Hosp, Gray Canc Inst, Northwood HA6 2RN, Middx, England; [Shao, C.] Fudan Univ, Inst Radiat Med, Shanghai 200433, Peoples R China	Queens University Belfast; University of Oxford; Fudan University	Prise, KM (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	k.prise@qub.ac.uk	Prise, Kevin/N-7872-2015	Prise, Kevin/0000-0001-6134-7946; Shao, Chunlin/0000-0001-9336-9912	Cancer Research UK [A7047] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Albertini RJ, 2000, MUTAT RES-REV MUTAT, V463, P111, DOI 10.1016/S1383-5742(00)00049-1; Arnold SF, 1999, RADIAT RES, V152, P487, DOI 10.2307/3580144; Ayache N, 2002, OSTEOARTHR CARTILAGE, V10, P344, DOI 10.1053/joca.2001.0499; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; Barcellos-Hoff MH, 2005, SEMIN CANCER BIOL, V15, P138, DOI 10.1016/j.semcancer.2004.08.010; Bishayee A, 1999, RADIAT RES, V152, P88, DOI 10.2307/3580054; BLANCO FJ, 1995, J IMMUNOL, V154, P4018; Boerma M, 2002, INT J RADIAT BIOL, V78, P219, DOI 10.1080/09553000110094797; Burdak-Rothkamm S, 2007, ONCOGENE, V26, P993, DOI 10.1038/sj.onc.1209863; CHESROWN SE, 1994, BIOCHEM BIOPH RES CO, V200, P126, DOI 10.1006/bbrc.1994.1424; Dedon PC, 2004, ARCH BIOCHEM BIOPHYS, V423, P12, DOI 10.1016/j.abb.2003.12.017; Deshpande A, 1996, RADIAT RES, V145, P260, DOI 10.2307/3578980; Folkard M, 1997, INT J RADIAT BIOL, V72, P375, DOI 10.1080/095530097143158; Folkard M, 1997, INT J RADIAT BIOL, V72, P387, DOI 10.1080/095530097143167; Gizatullina ZZ, 2003, BIOCHEM BIOPH RES CO, V304, P643, DOI 10.1016/S0006-291X(03)00654-5; Hamby ME, 2006, GLIA, V54, P566, DOI 10.1002/glia.20411; Han JX, 2006, RADIAT RES, V165, P283, DOI 10.1667/RR3516.1; Iyer R, 2000, CANCER RES, V60, P1290; Jobling ME, 2006, RADIAT RES, V166, P839, DOI 10.1667/RR0695.1; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; Lewis DA, 2001, RADIAT RES, V156, P251, DOI 10.1667/0033-7587(2001)156[0251:PODDAN]2.0.CO;2; Limoli CL, 2000, ADV SPACE RES, V25, P2107, DOI 10.1016/S0273-1177(99)01062-5; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; Lyng FM, 2006, RADIAT RES, V165, P400, DOI 10.1667/RR3527.1; Matsumoto H, 2001, RADIAT RES, V155, P387, DOI 10.1667/0033-7587(2001)155[0387:IORBAN]2.0.CO;2; Matsumoto H, 2000, INT J RADIAT BIOL, V76, P1649; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Nagasawa H, 1999, RADIAT RES, V152, P552, DOI 10.2307/3580153; NAGASAWA H, 1992, CANCER RES, V52, P6394; Narayanan PK, 1997, CANCER RES, V57, P3963; Nesti LJ, 2007, J CELL BIOCHEM, V101, P348, DOI 10.1002/jcb.21180; Newman E, 2004, J BIOL CHEM, V279, P33547, DOI 10.1074/jbc.M403892200; Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087; Sawant SG, 2001, RADIAT RES, V155, P397, DOI 10.1667/0033-7587(2001)155[0397:TBEIRO]2.0.CO;2; Schmidt A, 2003, CARDIOVASC RES, V58, P671, DOI 10.1016/S0008-6363(03)00322-5; Seymour C B, 1997, Radiat Oncol Investig, V5, P106, DOI 10.1002/(SICI)1520-6823(1997)5:3<106::AID-ROI4>3.0.CO;2-1; Shao C, 2005, INT J CANCER, V116, P45, DOI 10.1002/ijc.21003; Shao C, 2003, CANCER RES, V63, P8437; Shao CL, 2006, RADIAT RES, V166, P479, DOI 10.1667/RR3600.1; Shao CL, 2004, P NATL ACAD SCI USA, V101, P13495, DOI 10.1073/pnas.0404930101; Shao CL, 2004, J RADIAT RES, V45, P97, DOI 10.1269/jrr.45.97; Shao CL, 2003, RADIAT ENVIRON BIOPH, V42, P183, DOI 10.1007/s00411-003-0202-y; Sokolov MV, 2005, ONCOGENE, V24, P7257, DOI 10.1038/sj.onc.1208886; Tartier L, 2007, CANCER RES, V67, P5872, DOI 10.1158/0008-5472.CAN-07-0188; Vodovotz Y, 1999, CANCER RES, V59, P2142; Yang HY, 2005, ONCOGENE, V24, P2096, DOI 10.1038/sj.onc.1208439; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797	51	162	168	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					434	440		10.1038/sj.onc.1210653	http://dx.doi.org/10.1038/sj.onc.1210653			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17621264	Green Accepted			2022-12-17	WOS:000252426100003
J	Mori, S; Matsuzaki, K; Yoshida, K; Furukawa, F; Tahashi, Y; Yamagata, H; Sekimoto, G; Seki, T; Matsui, H; Nishizawa, M; Fujisawa, JI; Okazaki, K				Mori, S; Matsuzaki, K; Yoshida, K; Furukawa, F; Tahashi, Y; Yamagata, H; Sekimoto, G; Seki, T; Matsui, H; Nishizawa, M; Fujisawa, JI; Okazaki, K			TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions	ONCOGENE			English	Article						TGF-beta; HGF; JNK; MAPK; Smad; PAI-1	TRANSFORMING-GROWTH-FACTOR; PLASMINOGEN-ACTIVATOR; FUNCTIONAL-CHARACTERIZATION; IDENTIFICATION; INHIBITOR; RECEPTOR; P15(INK4B); MECHANISM; PATHWAYS; PROMOTER	Although hepatocyte growth factor (HGF) can act synergistically or antagonistically with transforming growth factor-beta (TGF-beta) signaling, molecular mechanism of their crosstalk remains unknown. Using antibodies which selectively distinguished receptor-regulated Smads (R-Smads) phosphorylated at linker regions from those at C-terminal regions, we herein showed that either HGF or TGF-beta treatment of normal stomach-origin cells activated the JNK pathway, thereafter inducing endogenous R-Smads phosphorylation at linker regions. However, the phosphorylation at their C-terminal regions was not induced by HGF treatment. The activated JNK could directly phosphorylate R-Smads in vitro at the same sites that were phosphorylated in response to TGF-beta or HGF in vivo. Thus, the linker regions of R-Smads were the common phosphorylation sites for HGF and TGF-beta signaling pathways. The phosphorylation induced by simultaneous treatment with HGF and TGF-beta allowed R-Smads to associate with Smad4 and to translocate into the nucleus. JNK pathway involved HGF and TGF-beta-mediated infiltration potency since a JNK inhibitor SP600125 caused the reduction of invasive capacity induced by HGF and TGF-beta signals. Moreover, a combined treatment with HGF and TGF-beta led to a potent increase in plasminogen activator inhibitor type 1 transcriptional activity through Smad3 phosphorylation at the linker region. In contrast, HGF treatment reduced TGF-beta-dependent activation of p15(INK4B) promoter, in which Smad3 phosphorylation at the C-terminal region was involved. In conclusion, HGF and TGF-beta transmit the signals through JNK-mediated R-Smads phosphorylation at linker regions.	Kansai Med Univ, Dept Internal Med 3, Osaka 5708507, Japan; Univ Tsukuba, Inst Clin Med, Div Gastroenterol, Tsukuba, Ibaraki 3058576, Japan; Inst Chem & Phys RIKEN, RIKEN Cell Bank, Tsukuba, Ibaraki 3050074, Japan; Kansai Med Univ, Dept Med Chem, Osaka 5708507, Japan; Kansai Med Univ, Dept Microbiol, Osaka 5708507, Japan	Kansai Medical University; University of Tsukuba; RIKEN; Kansai Medical University; Kansai Medical University	Matsuzaki, K (corresponding author), Kansai Med Univ, Dept Internal Med 3, 10-15 Fumizonocho, Osaka 5708507, Japan.	matsuzak@takii.kmu.ac.jp						Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Furukawa F, 2003, HEPATOLOGY, V38, P879, DOI 10.1053/jhep.2003.50384; Gutierrez LS, 2000, CANCER RES, V60, P5839; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hirashima Y, 2003, J BIOL CHEM, V278, P26793, DOI 10.1074/jbc.M212187200; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; Kobayashi I, 1996, IN VITRO CELL DEV-AN, V32, P259; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuzaki K, 2000, CANCER RES, V60, P1394; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; WRANA JL, 2000, SCI STKE, pRE1; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	37	162	174	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7416	7429		10.1038/sj.onc.1207981	http://dx.doi.org/10.1038/sj.onc.1207981			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15326485				2022-12-17	WOS:000224021400012
J	Chakravarti, D; Mailander, PC; Li, KM; Higginbotham, S; Zhang, HL; Gross, ML; Meza, JL; Cavalieri, EL; Rogan, EG				Chakravarti, D; Mailander, PC; Li, KM; Higginbotham, S; Zhang, HL; Gross, ML; Meza, JL; Cavalieri, EL; Rogan, EG			Evidence that a burst of DNA depurination in SENCAR mouse skin induces error-prone repair and forms mutations in the H-ras gene	ONCOGENE			English	Article						estradiol-3,4-quinone; depurinating adducts; abasic sites; DNA repair; mismatched heteroduplex; H-ras mutation in SENCAR mouse skin	BASE EXCISION-REPAIR; HAMSTER OVARY CELLS; DEOXYRIBONUCLEIC ACID; TUMOR INITIATION; IN-VITRO; ADDUCTS; GLYCOSYLASE; SITES; OVEREXPRESSION; IDENTIFICATION	Treatment of SENCAR mouse skin with dibenzo[a,l]pyrene results in abundant formation of abasic sites that undergo error-prone excision repair, forming oncogenic H-ras mutations in the early preneoplastic period. To examine whether the abundance of abasic sites causes repair infidelity, we treated SENCAR mouse skin with estradiol-3,4-quinone (E-2-3,4-Q) and determined adduct levels I h after treatment, as well as mutation spectra in the H-ras gene between 6 h and 3 days after treatment. E-2-3,4-Q formed predominantly (greater than or equal to 99%) the rapidly-depurinating 4-hydroxy estradiol (4-OHE2)-1-N3Ade adduct and the slower-depurinating 4-OHE2-1-N7Gua adduct. Between 6 h and 3 days, E-2-3,4-Q induced abundant A to G mutations in H-ras DNA, frequently in the context of a 3'-G residue. Using a T.G-DNA glycosylase (TDG)-PCR assay, we determined that the early A to G mutations (6 and 12 h) were in the form of G.T heteroduplexes, suggesting misrepair at A-specific depurination sites. Since G-specific mutations were infrequent in the spectra, it appears that the slow rate of depurination of the N7Gua adducts during active repair may not generate a threshold level of G-specific abasic sites to affect repair fidelity. These results also suggest that E-2-3,4-Q, a suspected endogenous carcinogen, is a genotoxic compound and could cause mutations.	Univ Nebraska, Med Ctr 986805, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr 986805, Dept Prevent & Societal Med, Omaha, NE 68198 USA; Washington Univ, Dept Chem, St Louis, MO 63130 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Washington University (WUSTL)	Chakravarti, D (corresponding author), Univ Nebraska, Med Ctr 986805, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.				NCI NIH HHS [P01 CA49210, CA 36727] Funding Source: Medline; NCRR NIH HHS [P41 RR 00954] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049210, P30CA036727] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Atamna H, 2000, P NATL ACAD SCI USA, V97, P686, DOI 10.1073/pnas.97.2.686; Berdal KG, 1998, EMBO J, V17, P363, DOI 10.1093/emboj/17.2.363; BOWDEN GT, 1974, CHEM-BIOL INTERACT, V8, P379, DOI 10.1016/0009-2797(74)90044-1; Braithwaite E, 1998, CARCINOGENESIS, V19, P1239, DOI 10.1093/carcin/19.7.1239; Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937; CAVALIERI EL, 1998, HDB ENV CHEM PAHS J, V3, P81; CHAKRAVARTI D, 1995, P NATL ACAD SCI USA, V92, P10422, DOI 10.1073/pnas.92.22.10422; Chakravarti D, 1998, ONCOGENE, V16, P3203, DOI 10.1038/sj.onc.1201853; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P15710; Chakravarti D, 2000, MUTAT RES-FUND MOL M, V456, P17, DOI 10.1016/S0027-5107(00)00102-0; Chakravarti D, 1998, DNA CELL BIOL, V17, P529, DOI 10.1089/dna.1998.17.529; Chen L, 1996, CHEM RES TOXICOL, V9, P897, DOI 10.1021/tx960004a; Choi DJ, 1996, J MOL BIOL, V264, P213, DOI 10.1006/jmbi.1996.0635; COQUERELLE T, 1995, MUTAT RES-DNA REPAIR, V336, P9, DOI 10.1016/0921-8777(94)00035-5; Dean SW, 1998, MUTAGENESIS, V13, P515, DOI 10.1093/mutage/13.5.515; DWIVEDY I, 1992, CHEM RES TOXICOL, V5, P828, DOI 10.1021/tx00030a016; GILL RD, 1991, ENVIRON MOL MUTAGEN, V18, P200, DOI 10.1002/em.2850180307; Glassner BJ, 1998, P NATL ACAD SCI USA, V95, P9997, DOI 10.1073/pnas.95.17.9997; GORELICK NJ, 1995, MOL CARCINOGEN, V14, P53, DOI 10.1002/mc.2940140110; IBEANU G, 1992, CARCINOGENESIS, V13, P1989, DOI 10.1093/carcin/13.11.1989; Jankowiak R, 1998, CHEM RES TOXICOL, V11, P1339, DOI 10.1021/tx980119+; Jankowiak R, 1998, CHEM RES TOXICOL, V11, P674, DOI 10.1021/tx970232k; KAUFMANN WK, 1995, CANCER METAST REV, V14, P31, DOI 10.1007/BF00690209; KLUGLAND A, 1992, EMBO J, V11, P4439; Kong LY, 2000, INT J ONCOL, V17, P1141; Lau AY, 2000, P NATL ACAD SCI USA, V97, P13573, DOI 10.1073/pnas.97.25.13573; Li K.-M., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P636; Li K.-M., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P46; Lindahl T, 2000, MUTAT RES-REV MUTAT, V462, P129, DOI 10.1016/S1383-5742(00)00024-7; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1973, BIOCHEMISTRY-US, V12, P5151, DOI 10.1021/bi00749a020; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; MAHER VM, 1987, MECH CELLULAR TRANSF, P135; Moriya M, 1996, BIOCHEMISTRY-US, V35, P16646, DOI 10.1021/bi9608875; Nakamura J, 1999, CANCER RES, V59, P2522; Nakamura J, 1998, CANCER RES, V58, P222; *NIH, 1981, NIH GUID LAB US CHEM; PAULES RS, 1988, P NATL ACAD SCI USA, V85, P2176, DOI 10.1073/pnas.85.7.2176; Robertson KA, 2001, CANCER RES, V61, P2220; ROGAN EG, 1993, CHEM RES TOXICOL, V6, P356, DOI 10.1021/tx00033a017; ROMENTY B, 2000, NUCLEIC ACIDS RES, V28, pE50; SAWYER TW, 1988, CARCINOGENESIS, V9, P1197, DOI 10.1093/carcin/9.7.1197; Skopek TR, 1996, ENVIRON MOL MUTAGEN, V28, P376; SLAGA TJ, 1974, CANCER RES, V34, P771; SLAGA TJ, 1973, CANCER RES, V33, P769; Stack D E, 1998, Adv Pharmacol, V42, P833; Terashima I, 2001, BIOCHEMISTRY-US, V40, P166, DOI 10.1021/bi002273c; Tsutsui T, 2000, INT J CANCER, V86, P8, DOI 10.1002/(SICI)1097-0215(20000401)86:1<8::AID-IJC2>3.0.CO;2-V; WATANABE M, 1985, MUTAT RES, V146, P285, DOI 10.1016/0167-8817(85)90070-7	49	162	167	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2001	20	55					7945	7953		10.1038/sj.onc.1204969	http://dx.doi.org/10.1038/sj.onc.1204969			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753677				2022-12-17	WOS:000172288700003
J	Bren, GD; Solan, NJ; Miyoshi, H; Pennington, KN; Pobst, LJ; Paya, CV				Bren, GD; Solan, NJ; Miyoshi, H; Pennington, KN; Pobst, LJ; Paya, CV			Transcription of the RelB gene is regulated by NF-kappa B	ONCOGENE			English	Article						RelA; RelB; promoter; NF-kappa B; p21WAF1	HUMAN-IMMUNODEFICIENCY-VIRUS; DENDRITIC CELLS; DIFFERENTIAL EXPRESSION; MULTIORGAN INFLAMMATION; B/REL FAMILY; C-MYB; ALPHA; INDUCTION; ACTIVATION; APOPTOSIS	ReA and RelB are two members of the NF-kappaB family that differ structurally and functionally. While RelA is regulated through its cytosolic localization by inhibitor proteins or I kappaB and not through transcriptional mechanisms, the regulation of RelB is poorly understood. In this study we demonstrate that stimuli (TNF or LPS) lead within minutes to the nuclear translocation of RelA, but require hours to result in the nuclear translocation of RelB. The delayed nuclear translocation of RelB correlates with increases in its protein synthesis which are secondary to increases in RelB gene transcription. RelA is alone sufficient to induce RelB gene transcription and to mediate the stimuli-driven increase in RelB transcription. Cloning and characterization of the RelB 5 ' untranslated gene region indicates that RelB transcription is dependent on a TATA-less promoter containing two NF-kappaB binding sites. One of the NF-kappaB sites is primarily involved in the binding of p50 while the other one in the binding and transactivation by RelA and also RelB. Lastly, it is observed that p21, a protein involved in cell cycle control and oncogenesis known to be regulated by NF-kappaB, is upregulated at the transcriptional level by RelB. Thus, RelB is regulated at least at the level of transcription in a RelA and RelB dependent manner and may exert an important role in p21 regulation.	Mayo Clin, Dept Expt Pathol & Lab Med, Rochester, MN 55905 USA; Mayo Clin, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin, Div Infect Dis, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Paya, CV (corresponding author), Mayo Clin, Dept Expt Pathol & Lab Med, 200 1st St SW GU501, Rochester, MN 55905 USA.			MacIver, Nancie/0000-0003-3676-9391	NIAID NIH HHS [R01 AI36076] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036076] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ammon C, 2000, BIOCHEM BIOPH RES CO, V268, P99, DOI 10.1006/bbrc.1999.2083; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Asin S, 1999, J VIROL, V73, P3893, DOI 10.1128/JVI.73.5.3893-3903.1999; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; Ferreira V, 1998, J BIOL CHEM, V273, P592, DOI 10.1074/jbc.273.1.592; Francis DA, 1998, INT IMMUNOL, V10, P285, DOI 10.1093/intimm/10.3.285; HANNINK M, 1990, ONCOGENE, V5, P1843; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Jiang YL, 1998, BIOCHEM BIOPH RES CO, V245, P691, DOI 10.1006/bbrc.1998.8390; Kistler B, 1998, J IMMUNOL, V160, P2308; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LERNBECHER T, 1994, EMBO J, V13, P4060, DOI 10.1002/j.1460-2075.1994.tb06723.x; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; MCELHINNY JA, 1995, J VIROL, V69, P1500, DOI 10.1128/JVI.69.3.1500-1509.1995; Menetski JP, 2000, J BIOL CHEM, V275, P7619, DOI 10.1074/jbc.275.11.7619; Neumann M, 1996, J IMMUNOL, V157, P4862; Neumann M, 2000, BLOOD, V95, P277; Olashaw NE, 1996, J BIOL CHEM, V271, P30307; Pennington KN, 2001, MOL CELL BIOL, V21, P1930, DOI 10.1128/MCB.21.6.1930-1941.2001; Pettit AR, 1997, J IMMUNOL, V159, P3681; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Suhasini M, 1997, ONCOGENE, V15, P1859, DOI 10.1038/sj.onc.1201530; Suhasini M, 1999, ONCOGENE, V18, P7360, DOI 10.1038/sj.onc.1203158; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Weih F, 1996, J IMMUNOL, V157, P3974; WEIH F, 1994, ONCOGENE, V9, P3289; Weih F, 1996, ONCOGENE, V12, P445; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6	40	162	167	1	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2001	20	53					7722	7733		10.1038/sj.onc.1204868	http://dx.doi.org/10.1038/sj.onc.1204868			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753650				2022-12-17	WOS:000172161700003
J	Zelent, A; Guidez, F; Melnick, A; Waxman, S; Licht, JD				Zelent, A; Guidez, F; Melnick, A; Waxman, S; Licht, JD			Translocations of the RAR alpha gene in acute promyelocytic leukemia	ONCOGENE			English	Review						PLZF; NuMA; NPM; STAT; differentiation; retinoic acid	ACID RECEPTOR-ALPHA; MITOTIC APPARATUS PROTEIN; PML-RETINOIC ACID; POLYMERASE-CHAIN-REACTION; ZINC-FINGER GENE; MINIMAL RESIDUAL DISEASE; NUCLEAR-MATRIX PROTEINS; FUSION PROTEIN; DNA-BINDING; TRANSCRIPTIONAL REPRESSION	Acute promyelocytic leukemia (APL) has been recognized as a distinct clinical entity for over 40 years. Although relatively rare among hematopoietic malignancies (approximately 10% of AML cases), this disease has attracted a particularly good share of attention by becoming the first human cancer in which all-trans-retinoic acid (ATRA), a physiologically active derivative of vitamin A, was able to induce complete remission (CR). ATRA induced remission is not associated with rapid cell death, as in the case of conventional chemotherapy, but with a restoration of the 'normal' granulocytic differentiation pathway. With this remarkable medical success story APL has overnight become a paradigm for the differentiation therapy of cancer. A few years later, excitement with APL was further enhanced by the discovery that a cytogenetic marker for this disease, the t(15:17) reciprocal chromosomal translocation, involves a fusion between the retinoic acid receptor alpha (RAR alpha) gene and a previously unknown locus named promyelocytic leukemia (PML). Consequence of this gene rearrangement is expression of the PML-RAR alpha chimeric oncoprotein, which is responsible for the cellular transformation as well as ATRA response that is observed in APL. Since this initial discovery, a number of different translocation partner genes of RAR alpha have been reported in rarer cases of APL, strongly suggesting that disruption of RAR alpha underlies its pathogenesis. This article reviews various rearrangements of the RAR alpha gene that have so far been described in literature, functions of the proteins encoded by the different RAR alpha partner loci, and implications that these may have for the molecular pathogenesis of APL.	Inst Canc Res, Leukaemia Res Fund Ctr, Chester Beatty Labs, London SW3 6JB, England; Mt Sinai Med Ctr, Dept Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Mt Sinai Med Ctr, Dept Med, Div Med Oncol, New York, NY 10029 USA	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Zelent, A (corresponding author), Inst Canc Res, Leukaemia Res Fund Ctr, Chester Beatty Labs, 237 Fulham Rd, London SW3 6JB, England.	a.zelent@icr.ac.uk	Melnick, Ari/AAA-5763-2020; Licht, Jonathan/AAL-9184-2020; Guidez, Fabien/B-3750-2009; Licht, Jonathan/L-4239-2019; Guidez, Fabien/P-4220-2019; Zelent, Arthur/B-3532-2009	Licht, Jonathan/0000-0002-3942-1369; Guidez, Fabien/0000-0003-1380-4473; Zelent, Arthur/0000-0002-7968-9888	NATIONAL CANCER INSTITUTE [R01CA059936, K08CA073762] Funding Source: NIH RePORTER; NCI NIH HHS [KO8 CA73762, CA59936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Al-Omar H. M., 1997, Blood, V90, p207B; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Ball HJ, 1999, NUCLEIC ACIDS RES, V27, P4106, DOI 10.1093/nar/27.20.4106; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Benoit G, 1999, EMBO J, V18, P7011, DOI 10.1093/emboj/18.24.7011; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BORROW J, 1994, GENE CHROMOSOME CANC, V9, P234, DOI 10.1002/gcc.2870090403; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRAND NJ, 1990, NUCLEIC ACIDS RES, V18, P6799, DOI 10.1093/nar/18.23.6799; Casiano CA, 1996, J EXP MED, V184, P765, DOI 10.1084/jem.184.2.765; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chan PK, 1997, NUCLEIC ACIDS RES, V25, P1225, DOI 10.1093/nar/25.6.1225; CHAN PK, 1995, BBA-GENE STRUCT EXPR, V1262, P37, DOI 10.1016/0167-4781(95)00044-H; Chan PK, 1999, BIOCHEM PHARMACOL, V57, P1265, DOI 10.1016/S0006-2952(99)00043-X; CHAN PK, 1986, J BIOL CHEM, V261, P14335; CHAN PK, 1987, CANCER RES, V47, P3798; CHAN PK, 1986, J BIOL CHEM, V261, P1868; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHEN A, 1994, BLOOD, V84, P2122, DOI 10.1182/blood.V84.7.2122.bloodjournal8472122; CHEN SJ, 1992, ONCOGENE, V7, P1223; CHEN SJ, 1991, BLOOD, V78, P2696; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Cheng GX, 1999, P NATL ACAD SCI USA, V96, P6318, DOI 10.1073/pnas.96.11.6318; Chou CC, 2001, MOL PHARMACOL, V59, P38, DOI 10.1124/mol.59.1.38; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; COMPTON DA, 1993, J CELL BIOL, V120, P947, DOI 10.1083/jcb.120.4.947; COMPTON DA, 1994, CURR OPIN CELL BIOL, V6, P343, DOI 10.1016/0955-0674(94)90024-8; COMPTON DA, 1992, J CELL BIOL, V116, P1395, DOI 10.1083/jcb.116.6.1395; Constantino S, 2001, ONCOGENE, V20, P2080, DOI 10.1038/sj.onc.1204308; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; COREY SJ, 1994, LEUKEMIA, V8, P1350; Culligan DJ, 1998, BRIT J HAEMATOL, V100, P328, DOI 10.1046/j.1365-2141.1998.00575.x; DANIEL MT, 1993, BLOOD, V82, P1858; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; DERENZINI M, 1995, LAB INVEST, V73, P497; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; Dionne MA, 1999, CELL MOTIL CYTOSKEL, V42, P189, DOI 10.1002/(SICI)1097-0169(1999)42:3<189::AID-CM3>3.0.CO;2-X; DIVERIO D, 1992, BLOOD, V79, P3331; Diverio D, 1998, BLOOD, V92, P784; Dong F, 1998, J IMMUNOL, V161, P6503; Dong S, 2000, BLOOD, V96, p457A; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Du CC, 1999, BLOOD, V94, P793, DOI 10.1182/blood.V94.2.793.414k43_793_802; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Fenaux Pierre, 1996, Current Opinion in Oncology, V8, P3, DOI 10.1097/00001622-199601000-00002; Ferbeyre G, 2000, GENE DEV, V14, P2015; FEUERSTEIN N, 1988, J BIOL CHEM, V263, P10608; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; FUKUTANI H, 1995, LEUKEMIA, V9, P1478; GALLAGHER RE, 1995, BLOOD, V86, P1540, DOI 10.1182/blood.V86.4.1540.bloodjournal8641540; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; Glass CK, 2000, GENE DEV, V14, P121; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gordon MB, 2001, J CELL BIOL, V152, P425, DOI 10.1083/jcb.152.3.425; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grimwade D, 2000, BLOOD, V96, P1297; Grimwade D, 1997, BLOOD, V90, P4876; GuethHallonet C, 1997, EXP CELL RES, V233, P21, DOI 10.1006/excr.1997.3557; GUIDEZ F, 1994, LEUKEMIA, V8, P312; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Harborth J, 2000, J BIOL CHEM, V275, P31979, DOI 10.1074/jbc.M000994200; Harborth J, 1999, EMBO J, V18, P1689, DOI 10.1093/emboj/18.6.1689; HARBORTH J, 1995, EMBO J, V14, P2447, DOI 10.1002/j.1460-2075.1995.tb07242.x; Hauksdottir H, 2001, CELL GROWTH DIFFER, V12, P85; He D, 1995, INT REV CYTOL, V162B, P1; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; HERNANDEZVERDUN D, 1982, CHROMOSOMA, V85, P461, DOI 10.1007/BF00327343; HIORNS LR, 1994, BLOOD, V83, P2946, DOI 10.1182/blood.V83.10.2946.2946; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hsu CY, 1998, ONCOGENE, V16, P915, DOI 10.1038/sj.onc.1201615; Hsu CY, 2000, INT J CANCER, V88, P392, DOI 10.1002/1097-0215(20001101)88:3<392::AID-IJC11>3.0.CO;2-7; Hsu HL, 1996, J CELL SCI, V109, P277; HUANG W, 1993, BLOOD, V82, P1264, DOI 10.1182/blood.V82.4.1264.bloodjournal8241264; Hummel JL, 1999, ONCOGENE, V18, P633, DOI 10.1038/sj.onc.1202357; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; Ivins S, 1998, BLOOD, V92, p308A; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Jansen JH, 1999, BLOOD, V94, P39, DOI 10.1182/blood.V94.1.39.413a26_39_45; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; Jiang PS, 1999, BIOCHEM BIOPH RES CO, V257, P865, DOI 10.1006/bbrc.1999.0551; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kane JR, 1996, LEUKEMIA, V10, P1296; Kazansky AV, 2001, CELL GROWTH DIFFER, V12, P1; KEMPF T, 1994, FEBS LETT, V354, P307, DOI 10.1016/0014-5793(94)01151-6; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kieslinger M, 2000, GENE DEV, V14, P232; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Lee JH, 1997, INT J CANCER, V71, P1035, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1035::AID-IJC20>3.3.CO;2-T; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Li XM, 1999, CANCER RES, V59, P5275; Li YP, 1996, EUR J BIOCHEM, V237, P153, DOI 10.1111/j.1432-1033.1996.0153n.x; Li YP, 1997, BLOOD, V90, P306; Licht JD, 1996, ONCOGENE, V12, P323; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Lin JX, 2000, ONCOGENE, V19, P2566, DOI 10.1038/sj.onc.1203523; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Liu WH, 1999, INT J CANCER, V83, P765, DOI 10.1002/(SICI)1097-0215(19991210)83:6<765::AID-IJC12>3.0.CO;2-J; Long JJ, 1998, MOL CELL BIOL, V18, P1467, DOI 10.1128/MCB.18.3.1467; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LUDERUS MEE, 1994, MOL CELL BIOL, V14, P6297, DOI 10.1128/MCB.14.9.6297; LYDERSEN BK, 1980, CELL, V22, P489, DOI 10.1016/0092-8674(80)90359-1; MAEKAWA T, 1993, J CELL SCI, V105, P589; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Matikainen S, 1996, BLOOD, V88, P114; Matikainen S, 1999, BLOOD, V93, P1980, DOI 10.1182/blood.V93.6.1980.406k20_1980_1991; McConnell MJ, 2000, BLOOD, V96, p457A; Melnick A, 2000, BLOOD, V96, P3939, DOI 10.1182/blood.V96.12.3939.h8003939_3939_3947; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; Miaw SC, 2000, IMMUNITY, V12, P323, DOI 10.1016/S1074-7613(00)80185-5; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MILLER WH, 1993, BLOOD, V82, P1689; MILLER WH, 1990, J NATL CANCER I, V82, P1932, DOI 10.1093/jnci/82.24.1932; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NAKAMAKI T, 1994, ANTICANCER RES, V14, P817; Neves H, 1999, BLOOD, V93, P1197, DOI 10.1182/blood.V93.4.1197.404k33_1197_1207; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; OLSON MOJ, 1974, J BIOL CHEM, V249, P2823; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; Pollock JL, 1999, P NATL ACAD SCI USA, V96, P15103, DOI 10.1073/pnas.96.26.15103; RAFF JW, 1994, EMBO J, V13, P5977, DOI 10.1002/j.1460-2075.1994.tb06943.x; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; REDNER R, 1996, BLOOD, V10, pA551; Redner RL, 2000, BLOOD, V95, P2683; Redner RL, 1997, LEUKEMIA, V11, P1014, DOI 10.1038/sj.leu.2400661; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; ROWLEY JD, 1977, LANCET, V1, P549; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Ruthardt M, 1998, ONCOGENE, V16, P1945, DOI 10.1038/sj.onc.1201722; Sainty D, 2000, BLOOD, V96, P1287; Saredi A, 1997, J CELL SCI, V110, P1287; Saredi A, 1996, J CELL SCI, V109, P619; SCOTT AA, 1994, BLOOD, V84, P244; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; SHIOTA M, 1995, BLOOD, V86, P1954, DOI 10.1182/blood.V86.5.1954.bloodjournal8651954; Sirri V, 1997, CYTOMETRY, V28, P147, DOI 10.1002/(SICI)1097-0320(19970601)28:2<147::AID-CYTO8>3.3.CO;2-G; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; Slack JL, 1997, J CLIN ONCOL, V15, P1786, DOI 10.1200/JCO.1997.15.5.1786; SMETANA K, 1984, EXP CELL RES, V152, P195, DOI 10.1016/0014-4827(84)90244-1; So CW, 2000, LEUKEMIA, V14, P77, DOI 10.1038/sj.leu.2401643; SPARKS CA, 1993, GENOMICS, V17, P222, DOI 10.1006/geno.1993.1307; Stadler M, 1995, ONCOGENE, V11, P2565; Szebeni A, 1997, BIOCHEMISTRY-US, V36, P3941, DOI 10.1021/bi9627931; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TAKEMURA M, 1994, BIOCHEM BIOPH RES CO, V199, P46, DOI 10.1006/bbrc.1994.1191; TANG TK, 1994, J CELL SCI, V107, P1389; TANG TK, 1993, J CELL SCI, V104, P249; TASHIRO S, 1994, ONCOGENE, V9, P1939; TAWFIC S, 1995, J BIOL CHEM, V270, P21009, DOI 10.1074/jbc.270.36.21009; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; TERRIS B, 1995, CANCER RES, V55, P1590; TSUTSUI K, 1993, J BIOL CHEM, V268, P12886; VAHDAT L, 1994, BLOOD, V84, P3843, DOI 10.1182/blood.V84.11.3843.bloodjournal84113843; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; Waxman S, 1999, BLOOD, V94, p61A; WAXMAN S, 1978, LEUKEMIA CELL, P169; Wells RA, 1996, LEUKEMIA, V10, P735; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; YANG CH, 1992, J CELL BIOL, V116, P1303, DOI 10.1083/jcb.116.6.1303; YANG CH, 1992, MOL BIOL CELL, V3, P1259, DOI 10.1091/mbc.3.11.1259; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; YonedaKato N, 1996, ONCOGENE, V12, P265; YOSHIDA H, 1995, GENE CHROMOSOME CANC, V12, P37, DOI 10.1002/gcc.2870120107; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8; YUNG BYM, 1985, BIOCHEM PHARMACOL, V34, P4059, DOI 10.1016/0006-2952(85)90387-9; Zatsepina OV, 1999, J CELL SCI, V112, P455; Zelent A, 2001, NAT MED, V7, P662, DOI 10.1038/89031; ZENG CQ, 1994, CELL MOTIL CYTOSKEL, V29, P167, DOI 10.1002/cm.970290208; ZHU J, 2001, IN PRESS BLOOD; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4; Zweyer M, 1997, EXP CELL RES, V230, P325, DOI 10.1006/excr.1996.3415	211	162	168	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7186	7203		10.1038/sj.onc.1204766	http://dx.doi.org/10.1038/sj.onc.1204766			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704847				2022-12-17	WOS:000171891900007
J	Date, K; Matsumoto, K; Kuba, K; Shimura, H; Tanaka, M; Nakamura, T				Date, K; Matsumoto, K; Kuba, K; Shimura, H; Tanaka, M; Nakamura, T			Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor	ONCOGENE			English	Article						c-Met; hepatocyte growth factor; HGF-antagonist; tumor invasion; tumor-stromal interactions	SCATTER FACTOR EXPRESSION; HUMAN PANCREATIC-CANCER; C-MET; TYROSINE PHOSPHORYLATION; FACTOR/SCATTER FACTOR; RECEPTOR EXPRESSION; MOLECULAR-CLONING; EPITHELIAL-CELLS; CARCINOMA-CELLS; BREAST-CANCER	Invasion of various carcinoma cells follows their interaction with stromal cells. Hepatocyte growth factor (HGF), four-kringle-containing growth factor, is a mesenchymal or stromal-derived mediator which affects the growth and the invasiveness of carcinoma cells. We now have evidence that a four-kringle-containing antagonist for HGF, HGF/NK4 inhibits invasion of tumors in vivo, as well as in vitro. HGF/NK4 competitively inhibited the binding of HGF to Met/HGF receptors on GB-d1 human gallbladder carcinoma cells. HGF induced invasion of the cells through Matrigel basement membrane components and into collagen gels, but HGF-induced invasion was inhibited by HGF/NK4. Invasion of GB-d1 cells was induced by co-cultivation with stromal fibroblasts, which mimics tumor-stromal interaction, but it was almost completely suppressed by HGF/NK4. Likewise, invasive growth induced by HGF in collagen gels in GB-d1 cells, HuCC-T1 human cholangiocarcinoma cells, and ME-180 human uterus cervical carcinoma cells was also strongly inhibited by HGF/NK4. When GB-d1 cells were implanted subcutaneously into nude mouse, tumor cells invaded muscular tissue, but the infusion of HGF/NK4 inhibited this invasion. Furthermore, HGF/NK4 increased apoptotic cell death of GB-d1 cells and inhibited tumor growth in vivo. These results indicate that HGF/NK4 may inhibit growth and invasion of carcinoma cells, as mediated by HGF during tumor-stromal interactions. We propose that there is a unique therapeutic potential for HGF/NK4 to prevent tumor invasion and perhaps even metastasis.	Osaka Univ, Sch Med, Biomed Res Ctr, Dept Oncol,Div Biochem, Osaka 5650871, Japan; Kyushu Univ, Fac Med, Dept Surg 1, Fukuoka 8120054, Japan	Osaka University; Kyushu University	Nakamura, T (corresponding author), Osaka Univ, Sch Med, Biomed Res Ctr, Dept Oncol,Div Biochem, Osaka 5650871, Japan.		MATSUMOTO, Kunio/D-8441-2015	MATSUMOTO, Kunio/0000-0002-6532-4482				BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; Date K, 1997, FEBS LETT, V420, P1, DOI 10.1016/S0014-5793(97)01475-0; DIRENZO MF, 1995, CANCER RES, V55, P1129; EBERT M, 1994, CANCER RES, V54, P5775; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GREY AM, 1989, P NATL ACAD SCI USA, V86, P2438, DOI 10.1073/pnas.86.7.2438; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HUMPHREY PA, 1995, AM J PATHOL, V147, P386; Inoue T, 1997, JPN J CANCER RES, V88, P152, DOI 10.1111/j.1349-7006.1997.tb00360.x; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; JIANG WG, 1993, CLIN EXP METASTAS, V11, P235, DOI 10.1007/BF00121166; JIANG WG, 1993, BRIT J SURG, V80, P1368, DOI 10.1002/bjs.1800801104; Lamszus K, 1997, LAB INVEST, V76, P339; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LOKKER NA, 1993, J BIOL CHEM, V268, P17145; Matsumoto K, 1996, CANCER CHEMOTH PHARM, V38, pS42, DOI 10.1007/s002800051037; Matsumoto K, 1996, JPN J CANCER RES, V87, P702, DOI 10.1111/j.1349-7006.1996.tb00281.x; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; Matsumoto K, 1997, BIOCHEM BIOPH RES CO, V239, P639, DOI 10.1006/bbrc.1997.7517; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; Nagy J, 1996, SURG ONCOL, V5, P15, DOI 10.1016/S0960-7404(96)80017-X; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nakamura T, 1997, CANCER RES, V57, P3305; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; Natali PG, 1996, INT J CANCER, V69, P212, DOI 10.1002/(SICI)1097-0215(19960621)69:3<212::AID-IJC11>3.0.CO;2-9; OKIGAKI M, 1992, BIOCHEMISTRY-US, V31, P9555, DOI 10.1021/bi00155a007; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROSEN EM, 1994, J CELL BIOL, V127, P225, DOI 10.1083/jcb.127.1.225; Rosen EM, 1996, INT J CANCER, V67, P248, DOI 10.1002/(SICI)1097-0215(19960717)67:2<248::AID-IJC16>3.0.CO;2-7; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; SEKI T, 1990, BIOCHEM BIOPH RES CO, V172, P321, DOI 10.1016/S0006-291X(05)80212-8; SESLAR SP, 1993, CANCER RES, V53, P1233; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SHIMURA H, 1995, JPN J CANCER RES, V86, P662, DOI 10.1111/j.1349-7006.1995.tb02450.x; SILVAGNO F, 1995, ARTERIOSCL THROM VAS, V15, P1857, DOI 10.1161/01.ATV.15.11.1857; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; TAKAISHI K, 1994, ONCOGENE, V9, P273; VANDENHOOFF A, 1988, ADV CANCER RES, V50, P159, DOI 10.1016/S0065-230X(08)60437-6; VASSALLI JD, 1984, J EXP MED, V159, P1653, DOI 10.1084/jem.159.6.1653; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Yamamoto S, 1997, JPN J CANCER RES, V88, P564, DOI 10.1111/j.1349-7006.1997.tb00420.x; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; [No title captured]	52	162	185	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	1998	17	23					3045	3054		10.1038/sj.onc.1202231	http://dx.doi.org/10.1038/sj.onc.1202231			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881707				2022-12-17	WOS:000077427800012
J	Rousset, R; Fabre, S; Desbois, C; Bantignies, F; Jalinot, P				Rousset, R; Fabre, S; Desbois, C; Bantignies, F; Jalinot, P			The C-terminus of the HTLV-1 Tax oncoprotein mediates interaction with the PDZ domain of cellular proteins	ONCOGENE			English	Article						HTLV-1; Tax; PDZY; two-hybrid	VIRUS TYPE-I; COMPLETE NUCLEOTIDE-SEQUENCE; NMDA RECEPTOR SUBUNITS; NF-KAPPA-B; LEUKEMIA-VIRUS; TRANSGENIC MICE; TRANSCRIPTION FACTORS; TRANSACTIVATOR TAX; GUANYLATE KINASES; GENE	Infection by HTLV-1 has been correlated with the appearance of various proliferative or degenerative diseases. Some of these disorders have been observed in transgenic mice expressing the Tax protein, which is known to transactivate various viral and cellular promoters through interactions with several transcription factors. In this study we show that the C-terminus of this viral oncoprotein represents a motif permitting binding of Tax to the PDZ domains of several cellular proteins. A two-hybrid screen with Tax as bait indeed yielded complementary DNAs coding for six proteins including PDZ domains. Two of them correspond to truncated forms of the PSD-95 and beta 1-syntrophin proteins, another clone codes for a protein homologous to the product of the C. elegans gene lin-7. The other three clones code for new human members of the PDZ family of cellular proteins. The interaction of Tax with the products of these clones was confirmed by immunoprecipitation assays in mammalian cells, and analysis of various mutants of Tax established the importance of the C-terminal amino acids for several of these interactions. These data suggest that Tax could perturb the normal function of targeted cellular proteins by strongly interacting with their PDZ domains.	Ecole Normale Super Lyon, Lab Biol Mol & Cellulaire, CNRS, UMR 49, F-69364 Lyon 07, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet	Jalinot, P (corresponding author), Ecole Normale Super Lyon, Lab Biol Mol & Cellulaire, CNRS, UMR 49, 46 Allee Italie, F-69364 Lyon 07, France.		Fabre, Stéphane/ABC-1483-2020; Morris, Christelle/M-8168-2014; Rousset, Raphael/E-5908-2017; FABRE, Stéphane/AAQ-8400-2020	Morris, Christelle/0000-0003-1575-4609; Rousset, Raphael/0000-0002-4999-403X; FABRE, Stéphane/0000-0001-7350-9500				AHN AH, 1994, P NATL ACAD SCI USA, V91, P4446, DOI 10.1073/pnas.91.10.4446; Ahn AH, 1996, J BIOL CHEM, V271, P2724, DOI 10.1074/jbc.271.5.2724; AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Bantignies F, 1996, MOL CELL BIOL, V16, P2174; BENVENISTY N, 1992, ONCOGENE, V7, P2399; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CRENON I, 1993, ONCOGENE, V8, P867; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FURUTA Y, 1989, J VIROL, V63, P3185, DOI 10.1128/JVI.63.7.3185-3189.1989; GESSAIN A, 1993, J VIROL, V67, P1015, DOI 10.1128/JVI.67.2.1015-1023.1993; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; Harlow E., 1988, ANTIBODIES LAB MANUA, P447; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; IWAKURA Y, 1991, SCIENCE, V253, P1026, DOI 10.1126/science.1887217; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISTNER U, 1995, FEBS LETT, V359, P159, DOI 10.1016/0014-5793(95)00030-D; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LAURANCE ME, 1997, J BIOL CHEM, V272, P24646; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MALIK KTA, 1988, J GEN VIROL, V69, P1695, DOI 10.1099/0022-1317-69-7-1695; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; Miller J.H., 1972, EXPT MOL GENETICS; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NERENBERG MI, 1989, AM J PATHOL, V135, P1025; Niethammer M, 1996, J NEUROSCI, V16, P2157; Ozden S, 1996, J ACQ IMMUN DEF SYND, V13, pS154, DOI 10.1097/00042560-199600001-00024; PERRIMON N, 1987, DEV BIOL, V119, P587, DOI 10.1016/0012-1606(87)90061-3; PFEFFER U, 1995, BIOTECHNIQUES, V18, P204; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RUBEN S M, 1989, New Biologist, V1, P275; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; TSUJIMOTO A, 1988, MOL BIOL MED, V5, P29; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yoshida M, 1996, J ACQ IMMUN DEF SYND, V13, pS63, DOI 10.1097/00042560-199600001-00012	63	162	175	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					643	654		10.1038/sj.onc.1201567	http://dx.doi.org/10.1038/sj.onc.1201567			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482110				2022-12-17	WOS:000071816600009
J	JUNG, JM; BRUNER, JM; RUAN, SB; LANGFORD, LA; KYRITSIS, AP; KOBAYASHI, T; LEVIN, VA; ZHANG, W				JUNG, JM; BRUNER, JM; RUAN, SB; LANGFORD, LA; KYRITSIS, AP; KOBAYASHI, T; LEVIN, VA; ZHANG, W			INCREASED LEVELS OF P21(WAF1/CIP1) IN HUMAN BRAIN-TUMORS	ONCOGENE			English	Article						GLIOMA; P21(WAF1/CIP1); CELL CYCLE; IMMUNOHISTOCHEMISTRY	HUMAN GLIOMAS; AMPLIFICATION; GENE; EXPRESSION; RECEPTORS	The cdk inhibitor p21(WAF1/Cip1) (p21), which can be transcriptionally activated by p53, functions to block cell cycle progression. In this study, we analysed the expression of p21 in normal and reactive brain and in gliomas of various malignancy grades. Southern blotting showed no p21 gene deletion. Western blotting and immunohistochemical assay showed that the levels of p21 protein in normal and reactive brain tissue were very low; however, p21 was elevated in a majority of gliomas tested, regardless of their malignancy grades. In glioblastoma multiforme, marked elevation of p21 was observed in samples harboring either wild-type or mutant p53. But, in anaplastic astrocytomas, the level of p21 was not elevated in samples harboring mutant-type p53. Immunohistochemical staining of paraffin-embedded astrocytomas and glioblastomas showed that tumor cells and not contaminating normal cells were positive for p21. Therefore, overexpression of p21 appears to be an early event in the development of glial neoplasms and p53-dependent p21 expression appears to be tumor grade specific.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROONCOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [P01CA055261] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 55261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLO MJ, 1994, GENE CHROMOSOME CANC, V9, P33; CHOZICK BS, 1994, CANCER, V73, P406, DOI 10.1002/1097-0142(19940115)73:2<406::AID-CNCR2820730228>3.0.CO;2-S; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FLEMING TP, 1992, CANCER RES, V52, P4550; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; JEN J, 1994, CANCER RES, V54, P6353; JUNG JM, 1995, CELL GROWTH DIFFER, V6, P909; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KORNBLAU SM, 1994, BLOOD, V84, P256; KUN LE, 1994, MOSS RAD ONCOLOGY RA, P737; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; LI YJ, 1995, ONCOGENE, V10, P599; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LOUIS DN, 1994, J NEUROPATH EXP NEUR, V53, P11, DOI 10.1097/00005072-199401000-00002; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MICHIELI P, 1994, CANCER RES, V54, P3391; MORRISON RS, 1990, CANCER RES, V50, P2524; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PATCHELL RA, 1992, CHEMOTHERAPY SOURCE, P908; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; Russell D., 1989, PATHOLOGY TUMORS NER; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; VAN MEIR EG, 1994, CANCER RES, V54, P649; VANMEYEL DJ, 1994, JNCI-J NATL CANCER I, V86, P1011, DOI 10.1093/jnci/86.13.1011; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WRANN M, 1987, EMBO J, V6, P1633, DOI 10.1002/j.1460-2075.1987.tb02411.x; YUNG WKA, 1990, CANCER COMMUN, V2, P201, DOI 10.3727/095535490820874416; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG W, 1995, LEUKEMIA LYMPHOMA, V16, P191, DOI 10.3109/10428199509049757; Zhang W, 1995, CLIN CANCER RES, V1, P1051; ZHANG W, 1995, CANCER RES, V55, P668	41	162	166	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2021	2028						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478521				2022-12-17	WOS:A1995TF29700012
J	MARQUARDT, B; FRITH, D; STABEL, S				MARQUARDT, B; FRITH, D; STABEL, S			SIGNALING FROM TPA TO MAP KINASE REQUIRES PROTEIN-KINASE-C, RAF AND MEK - RECONSTITUTION OF THE SIGNALING PATHWAY IN-VITRO	ONCOGENE			English	Article							PHORBOL ESTER; GROWTH-FACTORS; ONCOGENIC P21(RAS); RAT-1 FIBROBLASTS; THREONINE KINASE; IN-VITRO; ACTIVATION; PHOSPHORYLATION; CELLS; TYROSINE	The phorbol ester PMA/TPA (phorbol 12-myristate 13-acetate) is a potent tumor promoter which mimicks distinct intracellular signalling events triggered by activated growth factor receptors, e.g. the activation of MAP kinases. The largest known family of TPA-binding proteins comprise members of the protein kinase C (PKC) family although other TPA-binding proteins outside the PKC family have recently been identified. In this report we addressed the mechanism and the pathway by which TPA induces the activation Of MAPkinases. Using recombinant proteins and in vitro phosphorylation reactions we identified the components in the signal transduction pathway from TPA to MAPkinase and we show that the activation of MAPkinase by TPA requires the presence of protein kinase C, c-raf and the MAPkinase activator MEK. We also find that the activation of raf autophosphorylation in vitro correlates with the ability of Raf to signal to MAPkinase. Thus the activation of Raf by PKC apparently can trigger the same signalling pathway as oncogenic Raf or Raf activation by vas in combination with tyrosine phosphorylation.	MAX PLANCK GESELL,MAX DELBRUCK LAB,D-50829 COLOGNE,GERMANY; UNIV LONDON IMPERIAL COLL SCI & TECHNOL,LONDON SW7 2AY,ENGLAND	Max Planck Society; Imperial College London								ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; ADEREM A, 1992, PROTEIN KINASE C CUR, P255; AHMED S, 1993, J BIOL CHEM, V268, P10709; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BLUMBERG PM, 1981, CRC CR REV TOXICOL, V8, P199, DOI 10.3109/10408448109109658; BLUMER KJ, 1994, P NATL ACAD SCI USA, V91, P4925, DOI 10.1073/pnas.91.11.4925; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CHUNG DL, 1992, P NATL ACAD SCI USA, V89, P1993, DOI 10.1073/pnas.89.5.1993; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; GAUSE KC, 1993, J BIOL CHEM, V268, P16124; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HARLOW E, 1988, ANTIBODIES LABORATOR; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARQUARDT B, 1992, GENE, V120, P297, DOI 10.1016/0378-1119(92)90109-3; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOOLENAAR WH, 1984, NATURE, V312, P371, DOI 10.1038/312371a0; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PFEIFER AMA, 1989, P NATL ACAD SCI USA, V86, P10075, DOI 10.1073/pnas.86.24.10075; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SOZERI O, 1992, ONCOGENE, V7, P2259; Stabel S., 1993, INTRACELLULAR MESSEN, P167; STABEL S, 1993, METH NEUROSCI, V18, P154; STITH BJ, 1987, EXP CELL RES, V169, P514, DOI 10.1016/0014-4827(87)90211-4; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUMMERS MD, 1987, TEXAS EXP STATION B, V1555; TOBE K, 1991, J BIOL CHEM, V266, P24793; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARNER LC, 1993, ONCOGENE, V8, P3249; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	56	162	162	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3213	3218						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936644				2022-12-17	WOS:A1994PM65800013
J	Sia, D; Tovar, V; Moeini, A; Llovet, JM				Sia, D.; Tovar, V.; Moeini, A.; Llovet, J. M.			Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies	ONCOGENE			English	Review						cholangiocarcinoma; molecular pathogenesis; targeted therapies	GROWTH-FACTOR-RECEPTOR; BILIARY-TRACT CANCER; PRIMARY LIVER CANCERS; GENOME-WIDE ANALYSIS; C VIRUS-INFECTION; PHASE-II; HEPATOCELLULAR-CARCINOMA; GENE-EXPRESSION; UNITED-STATES; BILE-DUCT	Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy with very poor prognosis. Genome-wide, high-throughput technologies have made major advances in understanding the molecular basis of this disease, although important mechanisms are still unclear. Recent data have revealed specific genetic mutations (for example, KRAS, IDH1 and IDH2), epigenetic silencing, aberrant signaling pathway activation (for example, interleukin (IL)-6/signal transducer and activator of transcription 3 (STAT3), tyrosine kinase receptor-related pathways) and molecular subclasses with unique alterations (for example, proliferation and inflammation subclasses). In addition, some ICCs share common genomic traits with hepatocellular carcinoma. All this information provides the basis to explore novel targeted therapies. Currently, surgery at early stage is the only effective therapy. At more advanced stages, chemotherapy regimens are emerging (that is, cisplatin plus gemcitabine), along with molecular targeted agents tested in several ongoing clinical trials. Nonetheless, a first-line conclusive treatment remains an unmet need. Similarly, there are no studies assessing tumor response related with genetic alterations. This review explores the recent advancements in the knowledge of the molecular alterations underlying ICC and the future prospects in terms of therapeutic strategies leading towards a more personalized treatment of this neoplasm.	[Sia, D.; Tovar, V.; Moeini, A.; Llovet, J. M.] Hosp Clin Barcelona, Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona Clin Liver Canc Grp, HCC Translat Res Lab,Liver Unit, E-08036 Barcelona, Catalonia, Spain; [Sia, D.] Natl Canc Inst, Gastrointestinal Surg & Liver Transplantat Unit, I-20133 Milan, Italy; [Llovet, J. M.] Mt Sinai Sch Med, Tisch Canc Inst, Dept Med, Div Liver Dis,Mt Sinai Liver Canc Program, New York, NY USA; [Llovet, J. M.] Inst Catalana Recerca & Estudis Avancats, Barcelona, Catalonia, Spain; [Llovet, J. M.] Univ Barcelona, Barcelona, Catalonia, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Fondazione IRCCS Istituto Nazionale Tumori Milan; Icahn School of Medicine at Mount Sinai; ICREA; University of Barcelona	Llovet, JM (corresponding author), Hosp Clin Barcelona, Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona Clin Liver Canc Grp, HCC Translat Res Lab,Liver Unit, Villarroel 170, E-08036 Barcelona, Catalonia, Spain.	jmllovet@clinic.ub.es	Llovet, Josep M/D-4340-2014; Llovet, Josep M/ABB-6264-2021	Llovet, Josep M/0000-0003-0547-2667; Llovet, Josep M/0000-0003-0547-2667; Sia, Daniela/0000-0002-9000-611X	US National Institutes of Diabetes and Digestive and Kidney Diseases [1R01DK076986]; European Commission [259744]; Asociacion Espanola Contra el Cancer; Spanish National Health Institute [SAF-2010-16055]; Samuel Waxman Cancer Research Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076986] Funding Source: NIH RePORTER; ICREA Funding Source: Custom	US National Institutes of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); European Commission(European CommissionEuropean Commission Joint Research Centre); Asociacion Espanola Contra el Cancer; Spanish National Health Institute(Spanish Government); Samuel Waxman Cancer Research Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); ICREA(ICREA)	Josep M Llovet is supported by grants from the US National Institutes of Diabetes and Digestive and Kidney Diseases (1R01DK076986), the European Commission's Framework Programme 7 (HEPTROMIC; 259744), the Asociacion Espanola Contra el Cancer, the Spanish National Health Institute (SAF-2010-16055) and the Samuel Waxman Cancer Research Foundation.	Aishima S, 2007, AM J SURG PATHOL, V31, P1059, DOI 10.1097/PAS.0b013e31802b34b6; Andersen JB, 2012, GASTROENTEROLOGY, V142, P1021, DOI 10.1053/j.gastro.2011.12.005; Bekaii-Saab T, 2011, J CLIN ONCOL, V29, P2357, DOI 10.1200/JCO.2010.33.9473; Bengala C, 2010, BRIT J CANCER, V102, P68, DOI 10.1038/sj.bjc.6605458; Berthiaume EP, 2004, SEMIN LIVER DIS, V24, P127, DOI 10.1055/s-2004-828890; Blechacz B, 2008, HEPATOLOGY, V48, P308, DOI 10.1002/hep.22310; Borbath C, 6 ILCA ANN C 2012; Borger DR, 2012, ONCOLOGIST, V17, P72, DOI 10.1634/theoncologist.2011-0386; Bragazzi MC., 2012, TRANSL GASTROINTEST, V1, P21, DOI [10.3978/j.issn.2224-4778.2011.11.04, DOI 10.3978/J.ISSN.2224-4778.2011.11.04]; Chen L, 2009, J HEPATOL, V50, P358, DOI 10.1016/j.jhep.2008.09.015; Chen TC, 2012, ANN SURG ONCOL, V19, pS675, DOI [10.1245/s10434-012-2224-7, 10.1245/s10434-012-2451-y]; Chiang DY, 2008, CANCER RES, V68, P6779, DOI 10.1158/0008-5472.CAN-08-0742; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Dachrut S, 2009, ASIAN PAC J CANCER P, V10, P575; de Jong MC, 2011, J CLIN ONCOL, V29, P3140, DOI 10.1200/JCO.2011.35.6519; Deshpande V, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-60; Edge S., 2010, AJCC CANC STAGING MA, V7th; El-Khoueiry AB, 2012, INVEST NEW DRUG, V30, P1646, DOI 10.1007/s10637-011-9719-0; El-Serag HB, 2009, HEPATOLOGY, V49, P116, DOI 10.1002/hep.22606; Endo K, 2002, HEPATOLOGY, V36, P439, DOI 10.1053/jhep.2002.34435; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Farazi PA, 2006, CANCER RES, V66, P6622, DOI 10.1158/0008-5472.CAN-05-4609; Fingas CD, 2011, HEPATOLOGY, V54, P2076, DOI 10.1002/hep.24588; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Furubo S, 1999, HISTOPATHOLOGY, V35, P230; Gruenberger B, 2010, LANCET ONCOL, V11, P1142, DOI 10.1016/S1470-2045(10)70247-3; Guedj N, 2009, J HEPATOL, V51, P93, DOI 10.1016/j.jhep.2009.03.017; Hammill CW, 2008, J AM COLL SURGEONS, V207, P594, DOI 10.1016/j.jamcollsurg.2008.04.031; Han C, 2004, CANCER RES, V64, P1369, DOI 10.1158/0008-5472.CAN-03-1086; Hasita H, 2010, CANCER SCI, V101, P1913, DOI 10.1111/j.1349-7006.2010.01614.x; Hedvat M, 2009, CANCER CELL, V16, P487, DOI 10.1016/j.ccr.2009.10.015; Hezel AF, 2010, J CLIN ONCOL, V28, P3531, DOI 10.1200/JCO.2009.27.4787; Hodge DR, 2001, J BIOL CHEM, V276, P39508, DOI 10.1074/jbc.C100343200; Homayounfar K, 2009, HUM PATHOL, V40, P834, DOI 10.1016/j.humpath.2008.11.005; Hoshida Y, 2009, CANCER RES, V69, P7385, DOI 10.1158/0008-5472.CAN-09-1089; Isa T, 2002, HEPATO-GASTROENTEROL, V49, P604; Isomoto H, 2007, GASTROENTEROLOGY, V132, P384, DOI 10.1053/j.gastro.2006.10.037; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jensen LH, 2012, ANN ONCOL, V23, P2341, DOI 10.1093/annonc/mds008; Jimeno A, 2005, CANCER RES, V65, P3003, DOI 10.1158/0008-5472.CAN-04-3586; Jinawath N, 2006, HEPATOLOGY, V44, P1025, DOI 10.1002/hep.21330; Karamitopoulou E, 2008, AM J CLIN PATHOL, V130, P780, DOI 10.1309/AJCP35FDCAVANWMM; Khan SA, 2005, LANCET, V366, P1303, DOI 10.1016/S0140-6736(05)67530-7; Kiguchi K, 2001, CANCER RES, V61, P6971; Kipp BR, 2012, HUM PATHOL, V43, P1552, DOI 10.1016/j.humpath.2011.12.007; Kobayashi M, 2000, CANCER, V88, P2471, DOI 10.1002/1097-0142(20000601)88:11<2471::AID-CNCR7>3.0.CO;2-T; Kobayashi S, 2005, GASTROENTEROLOGY, V128, P2054, DOI 10.1053/j.gastro.2005.03.010; Koo SH, 2001, CANCER GENET CYTOGEN, V130, P22, DOI 10.1016/S0165-4608(01)00460-5; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Lee J, 2012, LANCET ONCOL, V13, P181, DOI 10.1016/S1470-2045(11)70301-1; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Lee S, 2002, AM J PATHOL, V161, P1015, DOI 10.1016/S0002-9440(10)64262-9; Leelawat K, 2006, J SURG RES, V136, P78, DOI 10.1016/j.jss.2006.05.031; Leelawat K, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-30; Leone F, 2006, CLIN CANCER RES, V12, P1680, DOI 10.1158/1078-0432.CCR-05-1692; Li B, 2012, FEBS J, V279, P2393, DOI 10.1111/j.1742-4658.2012.08618.x; Li H, 2012, LIVER INT, V32, P38, DOI 10.1111/j.1478-3231.2011.02646.x; Lubner SJ, 2010, J CLIN ONCOL, V28, P3491, DOI 10.1200/JCO.2010.28.4075; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Malhi H, 2006, J HEPATOL, V45, P856, DOI 10.1016/j.jhep.2006.09.001; Meng F, 2008, ONCOGENE, V27, P378, DOI 10.1038/sj.onc.1210648; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Meng F, 2006, J HEPATOL, V44, P1055, DOI 10.1016/j.jhep.2005.10.030; Mesa RA, 2012, NAT REV DRUG DISCOV, V11, P103, DOI 10.1038/nrd3652; Miller G, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-62; Miyamoto M, 2011, BRIT J CANCER, V105, P131, DOI 10.1038/bjc.2011.199; Momoi H, 2001, J HEPATOL, V35, P235, DOI 10.1016/S0168-8278(01)00106-4; Nakazawa K, 2005, J PATHOL, V206, P356, DOI 10.1002/path.1779; Nathan H, 2010, CURR OPIN GASTROEN, V26, P269, DOI 10.1097/MOG.0b013e328337c899; O'Dell MR, 2012, CANCER RES, V72, P1557, DOI 10.1158/0008-5472.CAN-11-3596; Obama K, 2005, HEPATOLOGY, V41, P1339, DOI 10.1002/hep.20718; Oishi N, 2012, HEPATOLOGY, V56, P1792, DOI 10.1002/hep.25890; Okabe H, 2009, ANN SURG ONCOL, V16, P2555, DOI 10.1245/s10434-009-0568-4; Okuda K, 2002, J GASTROEN HEPATOL, V17, P1049, DOI 10.1046/j.1440-1746.2002.02781.x; Ong CK, 2012, NAT GENET, V44, P690, DOI 10.1038/ng.2273; Palmer WC, 2012, J HEPATOL, V57, P69, DOI 10.1016/j.jhep.2012.02.022; Pardanani A, 2011, J CLIN ONCOL, V29, P789, DOI 10.1200/JCO.2010.32.8021; Park BK, 2006, AM J CLIN ONCOL-CANC, V29, P138, DOI 10.1097/01.coc.0000204402.29830.08; Park J, 1999, HEPATOLOGY, V30, P1128, DOI 10.1002/hep.510300522; Parkin DM, 2002, CANC INCIDENCE 5 CON, VVIII; Pascher Andreas, 2003, J Hepatobiliary Pancreat Surg, V10, P282, DOI 10.1007/s00534-002-0731-9; Patel T, 2001, HEPATOLOGY, V33, P1353, DOI 10.1053/jhep.2001.25087; Philip PA, 2006, J CLIN ONCOL, V24, P3069, DOI 10.1200/JCO.2005.05.3579; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Radaeva S, 1999, HEPATOLOGY, V29, P1453, DOI 10.1002/hep.510290524; Ramanathan RK, 2009, CANCER CHEMOTH PHARM, V64, P777, DOI 10.1007/s00280-009-0927-7; Roskams T, 2006, ONCOGENE, V25, P3818, DOI 10.1038/sj.onc.1209558; Sandhu DS, 2008, LIVER INT, V28, P12, DOI 10.1111/j.1478-3231.2007.01624.x; Selaru FM, 2009, HEPATOLOGY, V49, P1595, DOI 10.1002/hep.22838; Sempoux C, 2011, SEMIN LIVER DIS, V31, P49, DOI 10.1055/s-0031-1272839; Settakorn J, 2005, J CLIN PATHOL, V58, P1249, DOI 10.1136/jcp.2005.026575; Shaib Y, 2004, SEMIN LIVER DIS, V24, P115, DOI 10.1055/s-2004-828889; Shaib YH, 2005, GASTROENTEROLOGY, V128, P620, DOI 10.1053/j.gastro.2004.12.048; Shaib YH, 2004, J HEPATOL, V40, P472, DOI 10.1016/j.jhep.2003.11.030; Shibahara H, 2004, HEPATOLOGY, V39, P220, DOI 10.1002/hep.20031; Shin HR, 2010, CANCER SCI, V101, P579, DOI 10.1111/j.1349-7006.2009.01458.x; Sia D, 2013, GASTROENTER IN PRESS; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; Sirica AE, 2002, SEMIN LIVER DIS, V22, P303, DOI 10.1055/s-2002-34507; Sirica AE, 2008, HEPATOLOGY, V47, P1178, DOI 10.1002/hep.22088; Sirica AE, 2012, NAT REV GASTRO HEPAT, V9, P44, DOI 10.1038/nrgastro.2011.222; Sirica AE, 2011, CURR OPIN GASTROEN, V27, P276, DOI 10.1097/MOG.0b013e32834405c3; Sirica AE, 2009, CLIN GASTROENTEROL H, V7, pS68, DOI 10.1016/j.cgh.2009.08.023; Sirica AE, 2008, WORLD J GASTROENTERO, V14, P7033, DOI 10.3748/wjg.14.7033; Sirica AE, 2008, HEPATOLOGY, V48, P2040, DOI 10.1002/hep.22623; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sugimachi K, 2001, MODERN PATHOL, V14, P900, DOI 10.1038/modpathol.3880409; Sugiyama H, 2011, J GASTROENTEROL, V46, P779, DOI 10.1007/s00535-011-0380-3; Tabernero J, 2007, MOL CANCER RES, V5, P203, DOI 10.1158/1541-7786.MCR-06-0404; Tannapfel A, 2000, DIGEST DIS SCI, V45, P317, DOI 10.1023/A:1005412626515; Tannapfel A, 2000, GUT, V47, P721, DOI 10.1136/gut.47.5.721; Tannapfel A, 2003, GUT, V52, P706, DOI 10.1136/gut.52.5.706; Tannapfel A, 2002, J PATHOL, V197, P624, DOI 10.1002/path.1139; Terada T, 1998, HUM PATHOL, V29, P175, DOI 10.1016/S0046-8177(98)90229-5; Tischoff I, 2005, INT J CANCER, V115, P684, DOI 10.1002/ijc.20944; Tokumoto N, 2005, INT J ONCOL, V27, P973; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736; Uhm KO, 2005, CANCER GENET CYTOGEN, V157, P37, DOI 10.1016/j.cancergencyto.2004.05.007; Valle Juan, 2010, N Engl J Med, V362, P1273, DOI 10.1056/NEJMoa0908721; Verstovsek S, 2010, NEW ENGL J MED, V363, P1117, DOI 10.1056/NEJMoa1002028; Wang P, 2012, CANC RES; Wehbe H, 2006, CANCER RES, V66, P10517, DOI 10.1158/0008-5472.CAN-06-2130; Welzel TM, 2011, HEPATOLOGY, V54, P463, DOI 10.1002/hep.24397; Wong N, 2002, J HEPATOL, V37, P633, DOI 10.1016/S0168-8278(02)00269-6; Woo HG, 2010, CANCER RES, V70, P3034, DOI 10.1158/0008-5472.CAN-09-2823; Wu GS, 2003, WORLD J GASTROENTERO, V9, P1302, DOI 10.3748/wjg.v9.i6.1302; Wu T, 2004, MOL CANCER THER, V3, P299; Xin H, 2011, CANCER RES, V71, P6601, DOI 10.1158/0008-5472.CAN-11-1217; Yamagiwa Y, 2006, LIFE SCI, V78, P2494, DOI 10.1016/j.lfs.2005.10.015; Yamamoto S, 2004, CANCER SCI, V95, P592, DOI 10.1111/j.1349-7006.2004.tb02492.x; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; Yang B, 2005, MODERN PATHOL, V18, P412, DOI 10.1038/modpathol.3800287; Yi JH, 2012, EUR J CANCER, V48, P196, DOI 10.1016/j.ejca.2011.11.017; Yoon JH, 2004, J HEPATOL, V41, P808, DOI 10.1016/j.jhep.2004.07.016; Yoshikawa D, 2008, BRIT J CANCER, V98, P418, DOI 10.1038/sj.bjc.6604129; Yoshikawa D, 2009, BRIT J CANCER, V100, P1257, DOI 10.1038/sj.bjc.6604988; Zhang ZC, 2010, HEPATOLOGY, V52, P975, DOI 10.1002/hep.23773; Zhu AX, 2011, HEPATOLOGY, V53, P695, DOI 10.1002/hep.24145; Zhu AX, 2010, LANCET ONCOL, V11, P48, DOI 10.1016/S1470-2045(09)70333-X	139	161	171	0	28	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4861	4870		10.1038/onc.2012.617	http://dx.doi.org/10.1038/onc.2012.617			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23318457	Green Accepted			2022-12-17	WOS:000325717800001
J	Cheli, Y; Guiliano, S; Botton, T; Rocchi, S; Hofman, V; Hofman, P; Bahadoran, P; Bertolotto, C; Ballotti, R				Cheli, Y.; Guiliano, S.; Botton, T.; Rocchi, S.; Hofman, V.; Hofman, P.; Bahadoran, P.; Bertolotto, C.; Ballotti, R.			Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny	ONCOGENE			English	Article						Mitf; p27; melanoma; cancer-initiating-cells; tumorigenicity	CANCER STEM-CELLS; TRANSCRIPTION FACTOR; DISTINCT SUBPOPULATION; GROWTH; POPULATIONS; MELANOCYTES; PHENOTYPE; APOPTOSIS; DILUTION; PATHWAY	In melanoma, as well as in other solid tumors, the cells within a given tumor exhibit strong morphological, functional and molecular heterogeneity that might reflect the existence of different cancer cell populations, among which are melanoma-initiating cells (MICs) with 'stemness' properties and their differentiated, fast-growing progeny. The existence of a slow-growing population might explain the resistance of melanoma to classical chemotherapies that target fast growing cells. Therefore, elucidating the biologic properties of MICs and, more importantly, the molecular mechanisms that drive the transition between MICs and their proliferating progeny needs to be addressed to develop an efficient melanoma therapy. Using B16 mouse melanoma cells and syngeneic mice, we show that the inhibition of microphthalmia-associated transcription factor (Mitf), the master regulator of melanocyte differentiation, increases the tumorigenic potential of melanoma cells and upregulates the stem cell markers Oct4 and Nanog. Notably, p27, the CDK inhibitor, is increased in Mitf-depleted cells and is required for exacerbation of the tumorigenic properties of melanoma cells. Further, a slow-growing population with low-Mitf level and high tumorigenic potential exists spontaneously in melanoma. Ablation of this population dramatically decreases tumor formation. Importantly, these data were confirmed using human melanoma cell lines and freshly isolated human melanoma cell from lymph node and skin melanoma metastasis. Taken together our data, identified Mitf and p27 as the key molecular switches that control the transition between MICs and their differentiated progeny. Eradication of low-Mitf cells might be an appealing strategy to cure melanoma. Oncogene (2011) 30, 2307-2318; doi: 10.1038/onc.2010.598; published online 31 January 2011	[Cheli, Y.; Guiliano, S.; Botton, T.; Rocchi, S.; Bahadoran, P.; Bertolotto, C.; Ballotti, R.] Ctr Mediterraneen Med Mol C3M, INSERM, U895, Equipe Biol Pathol Melanocytes 1,Equipe Labellise, F-06204 Nice 3, France; [Cheli, Y.; Guiliano, S.; Botton, T.; Rocchi, S.; Hofman, P.; Bahadoran, P.; Bertolotto, C.; Ballotti, R.] Univ Nice Sophia Antipolis, UFR Med, Nice, France; [Hofman, V.; Hofman, P.] ERI21 EA 4319 & Human Biobank, Nice, France; [Bahadoran, P.; Bertolotto, C.; Ballotti, R.] CHU Nice, Dept Dermatol, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice	Ballotti, R (corresponding author), Ctr Mediterraneen Med Mol C3M, INSERM, U895, Equipe Biol Pathol Melanocytes 1,Equipe Labellise, 151 Route St Antoine Ginestiere, F-06204 Nice 3, France.	ballotti@unice.fr	Hofman, Paul/P-7654-2018; Bertolotto, Corine/AAF-6634-2021; Rocchi, Stephane/O-4152-2016; Cheli, Yann/O-5783-2016; Botton, Thomas/AAA-9258-2020; BALLOTTI, Robert/F-8825-2013	Hofman, Paul/0000-0003-0431-9353; Bertolotto, Corine/0000-0001-6971-7753; Rocchi, Stephane/0000-0002-0943-1304; Cheli, Yann/0000-0001-9839-4332; Botton, Thomas/0000-0001-9079-7014; Bahadoran, Philippe/0000-0002-2481-0556; veronique, HOFMAN/0000-0003-0943-1627; BALLOTTI, Robert/0000-0002-7322-4908	Association pour la Recherche contre le Cancer [ARC 4985]; ARC	Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); ARC(Australian Research Council)	We wish to thank Genevieve Gozzerino, Agnes Loubat and Karine Bille for their help. This work was supported by the 'Association pour la Recherche contre le Cancer' (grant ARC 4985) and YC and TB have been supported by ARC's fellowships.	Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Botton T, 2009, J INVEST DERMATOL, V129, P1208, DOI 10.1038/jid.2008.346; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755-148X.2009.00653.x; Dalerba P, 2007, CELL STEM CELL, V1, P241, DOI 10.1016/j.stem.2007.08.012; Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Goodall J, 2008, CANCER RES, V68, P7788, DOI 10.1158/0008-5472.CAN-08-1053; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Larribere L, 2005, GENE DEV, V19, P1980, DOI 10.1101/gad.335905; Larribere L, 2004, CELL DEATH DIFFER, V11, P1084, DOI 10.1038/sj.cdd.4401475; Larue L, 2006, FRONT BIOSCI-LANDMRK, V11, P733, DOI 10.2741/1831; Lyons AB, 2001, METHOD CELL BIOL, V63, P375; Nishimura EK, 2010, CELL STEM CELL, V6, P130, DOI 10.1016/j.stem.2009.12.010; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Pinner S, 2009, CANCER RES, V69, P7969, DOI 10.1158/0008-5472.CAN-09-0781; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Schouwey K, 2008, HISTOL HISTOPATHOL, V23, P609, DOI 10.14670/HH-23.609; Spira AI, 2003, CURR OPIN PHARMACOL, V3, P338, DOI 10.1016/S1471-4892(03)00081-X; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Strizzi L, 2008, CELL CYCLE, V7, P1931, DOI 10.4161/cc.7.13.6236; Yang G, 2008, MOL CELL, V32, P554, DOI 10.1016/j.molcel.2008.11.002	28	161	165	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	20					2307	2318		10.1038/onc.2010.598	http://dx.doi.org/10.1038/onc.2010.598			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	766NF	21278797				2022-12-17	WOS:000290789200003
J	Bonavida, B				Bonavida, B.			'Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions'	ONCOGENE			English	Review						rituximab; CD20 signaling; rituximab resistance; rituximab-induced chemoimmunosensitization	NON-HODGKINS-LYMPHOMA; NF-KAPPA-B; TRAIL-MEDIATED APOPTOSIS; MONOCLONAL-ANTIBODY; DOWN-REGULATION; SIGNALING PATHWAY; STAT3 ACTIVITY; UP-REGULATION; NITRIC-OXIDE; PIVOTAL ROLE	Rituximab (chimeric anti-CD20 monoclonal antibody) is the first Food and Drug Administration approved antitumor antibody and is used in the treatment of B-non-Hodgkin's lymphoma (B-NHL). It is used as single monotherapy or in combination with chemotherapy and has improved the treatment outcome of patients with B-NHL. The in vivo mechanisms of rituximab-mediated antitumor effects include antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cell cytotoxicity (CDC), growth-inhibition and apoptosis. A subset of patients does not initially respond to rituximab and several responsive patients develop resistance to further rituximab treatment. The mechanism of rituximab unresponsiveness is not known. Besides the above-postulated mechanisms, rituximab has been shown to trigger the cells via CD20. Studies performed with B-NHL cell lines as model systems revealed several novel mechanisms of rituximab-mediated effects that are involved in chemo/immunosensitization and the development of resistance to rituximab. Rituximab has been shown to inhibit the p38 mitogen-activated protein kinase, nuclear factor-kappa B (NF-kappa B), extracellular signal-regulated kinase 1/2 (ERK 1/2) and AKT antiapoptotic survival pathways, all of which result in upregulation of phosphatase and tensin homolog deleted on chromosome ten and Raf kinase inhibitor protein and in the downregulation of antiapoptotic gene products (particularly Bcl-2, Bcl-(xL) and Mcl-1), and resulting in chemo/immunosensitization. Further, rituximab treatment inhibits the overexpressed transcription repressor Yin Yang 1 (YY1), which negatively regulates Fas and DR5 expression and its inhibition leads to sensitization to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Rituximab-resistant clones were generated as model to examine the mechanism of in vivo rituximab unresponsiveness. These clones showed reduced expression of CD20 and hyperactivation of the above antiapoptotic signaling pathways and failure of rituximab to trigger the cells leading to inhibition of ADCC, CDC and chemo/immunosensitization. Interference with the hyperactivated pathways with various pharmacological and proteasome inhibitors reversed resistance. Furthermore, the above findings have identified several gene products that can serve as new prognostic/diagnostic biomarkers as well as targets for therapeutic intervention in B-NHL.	Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Bonavida, B (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA.	BBonavida@mednet.ucla.edu						Alas S, 2003, CLIN CANCER RES, V9, P316; Alas S, 2001, CANCER RES, V61, P5137; Alas S, 2001, CLIN CANCER RES, V7, P709; Baritaki S, 2007, MOL CANCER THER, V6, P1387, DOI 10.1158/1535-7163.MCT-06-0521; Bezombes C, 2004, BLOOD, V104, P1166, DOI 10.1182/blood-2004-01-0277; BLAY JY, 1993, EUR J IMMUNOL, V23, P768; Coiffier Bertrand, 2005, Clin Adv Hematol Oncol, V3, P484; Cragg Mark S., 2005, V8, P140; DEANS JP, 1995, J BIOL CHEM, V270, P22632, DOI 10.1074/jbc.270.38.22632; DEANS JP, 1993, J IMMUNOL, V151, P4494; Deans JP, 1998, J BIOL CHEM, V273, P344, DOI 10.1074/jbc.273.1.344; Deans JP, 2002, IMMUNOLOGY, V107, P176, DOI 10.1046/j.1365-2567.2002.01495.x; Demidem A, 1997, CANCER BIOTHER RADIO, V12, P177, DOI 10.1089/cbr.1997.12.177; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; FREEDMAN AS, 1991, HEMATOL ONCOL CLIN N, V5, P871, DOI 10.1016/S0889-8588(18)30390-3; Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Golay J, 2001, BLOOD, V98, P3383, DOI 10.1182/blood.V98.12.3383; Haidar JH, 2003, EUR J HAEMATOL, V70, P330, DOI 10.1034/j.1600-0609.2003.00007.x; Hainsworth JD, 2004, SEMIN ONCOL, V31, P17, DOI 10.1053/j.seminoncol.2003.12.005; Huerta-Yepez S, 2004, ONCOGENE, V23, P4993, DOI 10.1038/sj.onc.1207655; Janas E, 2005, CLIN EXP IMMUNOL, V139, P439, DOI 10.1111/j.1365-2249.2005.02720.x; Jazirehi AR, 2007, CANCER RES, V67, P1270, DOI 10.1158/0008-5472.CAN-06-2184; Jazirehi AR, 2004, BLOOD, V104, p930A, DOI 10.1182/blood.V104.11.3410.3410; Jazirehi AR, 2005, ONCOGENE, V24, P2121, DOI 10.1038/sj.onc.1208349; Jazirehi AR, 2004, CANCER RES, V64, P7117, DOI 10.1158/0008-5472.CAN-03-3500; Jazirehi AR, 2003, MOL CANCER THER, V2, P1183; Jazirehi AR, 2005, CANCER RES, V65, P264; JAZIREHI AR, 2006, P AM ASS CANC RES, V47; Kennedy AD, 2003, BLOOD, V101, P1071, DOI 10.1182/blood-2002-03-0876; Kennedy AD, 2004, J IMMUNOL, V172, P3280, DOI 10.4049/jimmunol.172.5.3280; MANSHOURI T, 2003, LEUKEMIA LYMPHOMA, V44, pS15; REFF ME, 1994, BLOOD, V83, P435; Semac I, 2003, CANCER RES, V63, P534; Shan DM, 2000, CANCER IMMUNOL IMMUN, V48, P673, DOI 10.1007/s002620050016; SUZUKI E, 2007, IN PRESS ONCOGENE; Vega MI, 2005, ONCOGENE, V24, P8114, DOI 10.1038/sj.onc.1208954; Vega MI, 2005, J IMMUNOL, V175, P2174, DOI 10.4049/jimmunol.175.4.2174; Vega MI, 2004, ONCOGENE, V23, P3530, DOI 10.1038/sj.onc.1207336; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Xerri L, 1996, BRIT J HAEMATOL, V92, P900, DOI 10.1046/j.1365-2141.1996.423958.x; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001	45	161	166	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3629	3636		10.1038/sj.onc.1210365	http://dx.doi.org/10.1038/sj.onc.1210365			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530016				2022-12-17	WOS:000246816100005
J	Takeda, K; Stagg, J; Yagita, H; Okumura, K; Smyth, MJ				Takeda, K.; Stagg, J.; Yagita, H.; Okumura, K.; Smyth, M. J.			Targeting death-inducing receptors in cancer therapy	ONCOGENE			English	Review						TNF superfamily; TRAIL; DR5; DR4; apoptosis; anti-tumor immune response	TUMOR-NECROSIS-FACTOR; TRAIL-INDUCED APOPTOSIS; ANTI-DR5 ANTIBODY THERAPY; FLICE-INHIBITORY PROTEIN; ACTIVATING FC-RECEPTORS; I CLINICAL-TRIAL; T-CELL RESPONSES; MONOCLONAL-ANTIBODIES; DENDRITIC CELLS; LIGAND TRAIL	Deregulated cell death pathways may lead to the development of cancer, and induction of tumor cell apoptosis is the basis of many cancer therapies. Knowledge accumulated concerning the molecular mechanisms of apoptotic cell death has aided the development of new therapeutic strategies to treat cancer. Signals through death receptors of the tumor necrosis factor (TNF) superfamily have been well elucidated, and death receptors are now one of the most attractive therapeutic targets in cancer. In particular, DR5 and DR4, death receptors of TNF-related apoptosis-inducing ligand (TRAIL or Apo2L), are interesting targets of antibody-based therapy, since TRAIL may also bind decoy receptors that may prevent TRAIL-mediated apoptosis, whereas TRAIL ligand itself selectively induces apoptosis in cancer cells. Here, we review the potential therapeutic utility of agonistic antibodies against DR5 and DR4 and discuss the possible extension of this single-antibody-based strategy when combined with additional modalities that either synergizes to cause enhanced apoptosis or further engage the cellular immune response. Rational design of antibody-based therapies combining the induction of tumor cell apoptosis and activation of tumor-specific adaptive immunity enables promotion of distinct steps of the antitumor immune response, thereby enhancing tumor-specific lymphocytes that can eradicate TRAIL/DR5-resistant mutating, large established and heterogeneous tumors in a manner that does not require the definition of individual tumor-specific antigens.	Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan; Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic, Australia	Juntendo University; Peter Maccallum Cancer Center	Takeda, K (corresponding author), Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan.	ktakeda@med.juntendo.ac.jp	Smyth, Mark J/H-8709-2014	Smyth, Mark J/0000-0001-7098-7240				Akiyama K, 2003, J IMMUNOL, V170, P1641, DOI 10.4049/jimmunol.170.4.1641; Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; An JB, 2003, CLIN CANCER RES, V9, P4537; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; BASOMBRIO MA, 1970, CANCER RES, V30, P2458; Bianco R, 2005, CURR DRUG TARGETS, V6, P275, DOI 10.2174/1389450053765842; Buchsbaum DJ, 2003, CLIN CANCER RES, V9, P3731; Bucur O, 2006, FRONT BIOSCI-LANDMRK, V11, P1549, DOI 10.2741/1903; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Chawla-Sarkar M, 2002, J IMMUNOL, V169, P847, DOI 10.4049/jimmunol.169.2.847; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Chuntharapai A, 2001, J IMMUNOL, V166, P4891, DOI 10.4049/jimmunol.166.8.4891; Clancy L, 2005, P NATL ACAD SCI USA, V102, P18099, DOI 10.1073/pnas.0507329102; Clarke N, 2004, EMBO J, V23, P3051, DOI 10.1038/sj.emboj.7600302; Clynes R, 1998, P NATL ACAD SCI USA, V95, P652, DOI 10.1073/pnas.95.2.652; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cragg MS, 1999, CURR OPIN IMMUNOL, V11, P541, DOI 10.1016/S0952-7915(99)00010-2; CREAGAN ET, 1988, CANCER, V62, P2467, DOI 10.1002/1097-0142(19881215)62:12<2467::AID-CNCR2820621202>3.0.CO;2-5; CREAVEN PJ, 1987, CANCER CHEMOTH PHARM, V20, P137; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Croft M, 2003, CYTOKINE GROWTH F R, V14, P265, DOI 10.1016/S1359-6101(03)00025-X; Croft M, 2003, NAT REV IMMUNOL, V3, P609, DOI 10.1038/nri1148; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Daniels RA, 2005, CELL RES, V15, P430, DOI 10.1038/sj.cr.7290311; de Bono JS, 2002, BRIT MED BULL, V64, P227, DOI 10.1093/bmb/64.1.227; Degli-Esposti M, 1999, J LEUKOCYTE BIOL, V65, P535, DOI 10.1002/jlb.65.5.535; Dhodapkar KM, 2002, J EXP MED, V195, P125, DOI 10.1084/jem.20011097; Diehl GE, 2004, IMMUNITY, V21, P877, DOI 10.1016/j.immuni.2004.11.008; Diehl L, 1999, NAT MED, V5, P774, DOI 10.1038/10495; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Egen JG, 2002, NAT IMMUNOL, V3, P611, DOI 10.1038/ni0702-611; French RR, 1999, NAT MED, V5, P548, DOI 10.1038/8426; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Futagawa T, 2002, INT IMMUNOL, V14, P275, DOI 10.1093/intimm/14.3.275; Gallop JR, 1995, CERN REPORT, V95, P1; Ganten TM, 2005, HEPATOLOGY, V42, P588, DOI 10.1002/hep.20807; Gelderman KA, 2004, TRENDS IMMUNOL, V25, P158, DOI 10.1016/j.it.2004.01.008; Georgakis GV, 2005, BRIT J HAEMATOL, V130, P501, DOI 10.1111/j.1365-2141.2005.05656.x; Gliniak B, 1999, CANCER RES, V59, P6153; Griffith TS, 1999, J IMMUNOL, V162, P2597; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hao CH, 2004, CANCER RES, V64, P8502, DOI 10.1158/0008-5472.CAN-04-2599; Hayakawa Y, 2004, J IMMUNOL, V172, P123, DOI 10.4049/jimmunol.172.1.123; HERSH EM, 1991, J IMMUNOTHER, V10, P426, DOI 10.1097/00002371-199112000-00006; Higuchi H, 2002, J PHARMACOL EXP THER, V303, P461, DOI 10.1124/jpet.102.040030; Hinoda Y, 2004, CANCER SCI, V95, P621, DOI 10.1111/j.1349-7006.2004.tb03319.x; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; ITOH N, 1993, J BIOL CHEM, V268, P10932; Janssen HLA, 2003, J HEPATOL, V39, P414, DOI 10.1016/S0168-8278(03)00265-4; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kaufmann SH, 2005, LEUKEMIA, V19, P2195, DOI 10.1038/sj.leu.2403946; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kircheis R, 2002, GENE THER, V9, P731, DOI 10.1038/sj.gt.3301748; Kurbanov BM, 2005, J INVEST DERMATOL, V125, P1010, DOI 10.1111/j.0022-202X.2005.23900.x; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lee SJ, 2004, J IMMUNOL, V173, P3002, DOI 10.4049/jimmunol.173.5.3002; Leverkus M, 2000, BLOOD, V96, P2628; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Marini P, 2006, ONCOGENE, V25, P5145, DOI 10.1038/sj.onc.1209516; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Melero I, 1998, CELL IMMUNOL, V190, P167, DOI 10.1006/cimm.1998.1396; Merchant MS, 2004, CANCER RES, V64, P8349, DOI 10.1158/0008-5472.CAN-04-1705; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Mori E, 2004, CELL DEATH DIFFER, V11, P203, DOI 10.1038/sj.cdd.4401331; Motoki K, 2005, CLIN CANCER RES, V11, P3126, DOI 10.1158/1078-0432.CCR-04-1867; Mundt B, 2005, GUT, V54, P1590, DOI 10.1136/gut.2004.056929; Mundt B, 2002, FASEB J, V16, P94, DOI 10.1096/fj.02-0537fje; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; O'Kane HF, 2006, J UROLOGY, V175, P432, DOI 10.1016/S0022-5347(05)00160-6; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Ohtsuka T, 2003, ONCOGENE, V22, P2034, DOI 10.1038/sj.onc.1206290; Papageorgiou A, 2004, CANCER RES, V64, P8973, DOI 10.1158/0008-5472.CAN-04-1909; Pardoll D, 2004, NAT MED, V10, P887, DOI 10.1038/nm0904-887; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; POLLOK KE, 1993, J IMMUNOL, V150, P771; Pukac L, 2005, BRIT J CANCER, V92, P1430, DOI 10.1038/sj.bjc.6602487; Pulendran B, 2001, TRENDS IMMUNOL, V22, P41, DOI 10.1016/S1471-4906(00)01794-4; Qin JZ, 2001, NAT MED, V7, P385, DOI 10.1038/86401; Rafiq K, 2002, J CLIN INVEST, V110, P71, DOI 10.1172/JCI200215640; Reed JC, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.30155; Rowinsky EK, 2005, J CLIN ONCOL, V23, P9394, DOI 10.1200/JCO.2005.02.2889; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sayers TJ, 2006, CANCER IMMUNOL IMMUN, V55, P76, DOI 10.1007/s00262-005-0676-3; Schmitz I, 2000, INT J BIOCHEM CELL B, V32, P1123, DOI 10.1016/S1357-2725(00)00048-0; Schneider P, 2003, J BIOL CHEM, V278, P5444, DOI 10.1074/jbc.M210783200; Selenko N, 2001, LEUKEMIA, V15, P1619, DOI 10.1038/sj.leu.2402226; Shankar S, 2004, DRUG RESIST UPDATE, V7, P139, DOI 10.1016/j.drup.2004.03.002; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shuford WW, 1997, J EXP MED, V186, P47, DOI 10.1084/jem.186.1.47; Smith MR, 2003, ONCOGENE, V22, P7359, DOI 10.1038/sj.onc.1206939; Smyth MJ, 2006, J IMMUNOL, V176, P6347, DOI 10.4049/jimmunol.176.10.6347; Smyth MJ, 2003, IMMUNITY, V18, P1, DOI 10.1016/S1074-7613(02)00502-2; Sotomayor EM, 1999, NAT MED, V5, P780, DOI 10.1038/10503; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Takahashi C, 1999, J IMMUNOL, V162, P5037; Takeda K, 2004, J EXP MED, V199, P437, DOI 10.1084/jem.20031457; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Timmer T, 2002, J PATHOL, V196, P125, DOI 10.1002/path.1028; Trcka J, 2002, IMMUNITY, V16, P861, DOI 10.1016/S1074-7613(02)00327-8; Truneh A, 2000, J BIOL CHEM, V275, P23319, DOI 10.1074/jbc.M910438199; Uno T, 2006, NAT MED, V12, P693, DOI 10.1038/nm1405; van Geelen CMM, 2003, BRIT J CANCER, V89, P363, DOI 10.1038/sj.bjc.6601065; Varela N, 2001, J BIOL CHEM, V276, P17779, DOI 10.1074/jbc.M100815200; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Voelkel-Johnson C, 2003, CANCER BIOL THER, V2, P283, DOI 10.4161/cbt.2.3.398; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Wilcox RA, 2002, J CLIN INVEST, V109, P651, DOI 10.1172/JCI200214184; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yagita H, 2004, CANCER SCI, V95, P777, DOI 10.1111/j.1349-7006.2004.tb02181.x; Zeng Y, 2006, INT J ONCOL, V28, P421; Zhang ML, 2004, CANCER RES, V64, P5825, DOI 10.1158/0008-5472.CAN-04-1088; Zhang XD, 1999, CANCER RES, V59, P2747; zum Buschenfelde CM, 2002, CANCER RES, V62, P2244	131	161	171	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3745	3757		10.1038/sj.onc.1210374	http://dx.doi.org/10.1038/sj.onc.1210374			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530027				2022-12-17	WOS:000246816100016
J	Singh, TR; Shankar, S; Srivastava, RK				Singh, TR; Shankar, S; Srivastava, RK			HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma	ONCOGENE			English	Article						TRAIL/Apo-2L; apoptosis; histone deacetylase inhibitor; breast cancer; death receptors	NF-KAPPA-B; HISTONE-DEACETYLASE INHIBITORS; LIGAND-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; FAMILY-MEMBER BIM; CANCER IN-VITRO; IONIZING-RADIATION; MEDIATED APOPTOSIS; NUCLEAR-FACTOR; CELL-DEATH	Histone deacetylase ( HDAC) inhibitors induce differentiation and/or apoptosis in a variety of cell types by activating transcription of target genes. Activation of the death receptor (DR) pathway by tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL) induces apoptosis preferentially in cancer cells. Here, we investigated the intracellular mechanisms by which HDAC inhibitors ( suberoylanilide hydroxamic acid, m-carboxycinnamic acid bis-hydroxamide, MS-275 and trichostatin A) enhance the apoptosis-inducing potential of TRAIL in breast cancer cells in vitro. A synergism in apoptosis was observed in both TRAIL-sensitive and -resistant cells upon sequential treatments with HDAC inhibitors followed by TRAIL. HDAC inhibitors synergized with TRAIL by inducing DRs DR4/TRAIL-R1 and DR5/TRAIL-R2 through NF kappa B activation and some of the proapoptotic members of the Bcl-2 family, and engaging the mitochondrial pathway. The ability of HDAC inhibitors to sensitize TRAIL-resistant cells suggests that HDAC inhibitors may induce fundamental alterations in cell signaling pathways. Thus, the sequential treatments with HDAC inhibitors followed by TRAIL may be used as a new therapeutic approach for the treatment of human cancers.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Mol & Cellular Biol Program,Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Srivastava, RK (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Mol & Cellular Biol Program,Greenebaum Canc Ctr, Pharm Hall,20 N Pine St, Baltimore, MD 21201 USA.	rsrivast@rx.umaryland.edu		singh, thiyam/0000-0002-0441-6818				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bernhard D, 1999, CELL DEATH DIFFER, V6, P609, DOI 10.1038/sj.cdd.4400531; Bernhard D, 2001, CELL DEATH DIFFER, V8, P1014, DOI 10.1038/sj.cdd.4400914; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Burgess AJ, 2001, MOL PHARMACOL, V60, P828; Butler LM, 2000, CANCER RES, V60, P5165; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Chen XF, 2003, CANCER RES, V63, P1059; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Cohen LA, 1999, ANTICANCER RES, V19, P4999; Degenhardt K, 2002, CANCER CELL, V2, P193, DOI 10.1016/S1535-6108(02)00126-5; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Gessner PK, 1995, TOXICOLOGY, V105, P161, DOI 10.1016/0300-483X(95)03210-7; Gil J, 2001, J GEN VIROL, V82, P3027, DOI 10.1099/0022-1317-82-12-3027; Glass CK, 2000, GENE DEV, V14, P121; Glick RD, 1999, CANCER RES, V59, P4392; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hernandez A, 2001, J GASTROINTEST SURG, V5, P56, DOI 10.1016/S1091-255X(01)80014-7; Herrera B, 2002, FEBS LETT, V520, P93, DOI 10.1016/S0014-5793(02)02774-6; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kandasamy K, 2003, CANCER RES, V63, P1712; Kandasamy K, 2002, CANCER RES, V62, P4929; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Keane MM, 1999, CANCER RES, V59, P734; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564; Kim YH, 2004, CARCINOGENESIS, V25, P1813, DOI 10.1093/carcin/bgh188; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Maier JKX, 2002, J NEUROSCI, V22, P2035, DOI 10.1523/JNEUROSCI.22-06-02035.2002; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Nagane M, 2000, CANCER RES, V60, P847; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Neuzil H, 2004, BIOCHEM BIOPH RES CO, V314, P186, DOI 10.1016/j.bbrc.2003.12.074; NEWMARK HL, 1994, CANCER LETT, V78, P1, DOI 10.1016/0304-3835(94)90023-X; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; Rosato RR, 2003, CANCER RES, V63, P3637; Rosato RR, 2003, CANCER BIOL THER, V2, P30; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; Salvesen GS, 1999, APMIS, V107, P73, DOI 10.1111/j.1699-0463.1999.tb01528.x; Shankar S, 2004, DRUG RESIST UPDATE, V7, P139, DOI 10.1016/j.drup.2004.03.002; Shankar S, 2004, PROSTATE, V61, P35, DOI 10.1002/pros.20069; Shankar S, 2004, INT J ONCOL, V24, P1133; Shankar S, 2005, PROSTATE, V62, P165, DOI 10.1002/pros.20126; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Singh TR, 2003, CANCER RES, V63, P5390; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Srivastava Rakesh K., 2000, Molecular Cell Biology Research Communications, V4, P67, DOI 10.1006/mcbr.2001.0265; Srivastava RK, 2001, NEOPLASIA, V3, P535, DOI 10.1038/sj.neo.7900203; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Tallarida RJ, 2002, PAIN, V98, P163, DOI 10.1016/S0304-3959(02)00041-6; Thomas WD, 2000, J IMMUNOL, V165, P5612, DOI 10.4049/jimmunol.165.10.5612; VanLint C, 1996, GENE EXPRESSION, V5, P245; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; YOSHIZAWA H, 1994, J ADHES SCI TECHNOL, V8, P1; Zhang XD, 2003, BIOCHEM PHARMACOL, V66, P1537, DOI 10.1016/S0006-2952(03)00509-4	99	161	166	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4609	4623		10.1038/sj.onc.1208585	http://dx.doi.org/10.1038/sj.onc.1208585			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15897906				2022-12-17	WOS:000230304500001
J	Johnson, TR; Stone, K; Nikrad, M; Yeh, T; Zong, WX; Thompson, CB; Nesterov, A; Kraft, AS				Johnson, TR; Stone, K; Nikrad, M; Yeh, T; Zong, WX; Thompson, CB; Nesterov, A; Kraft, AS			The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells	ONCOGENE			English	Article						PS-341; TRAIL; Bax; Bcl-2; apoptosis	CYTOCHROME-C RELEASE; FACTOR-KAPPA-B; INDUCED APOPTOSIS; MULTIPLE-MYELOMA; TUMOR-CELLS; DRUG-RESISTANCE; LIGAND TRAIL; DEATH; ACTIVATION; RECEPTOR	We demonstrate that PS-341, a small molecule inhibitor of the proteasome, markedly sensitizes resistant prostate, colon, and bladder cancer cells to TNF-like apoptosis-inducing ligand (TRAIL)-induced apoptosis irrespective of Bcl-xL overexpression. PS-341 treatment by itself does not affect the levels of Bax, Bak, caspases 3 and 8, c-Flip or FADD, but elevates levels of TRAIL receptors DR4 and DR5. This increase in receptor protein levels is associated with the ubiquitination of the DR5 protein. When PS-341 is combined with TRAIL, the levels of activated caspase 8 and cleaved Bid are substantially increased. In Bax-negative TRAIL-resistant HC-4 colon cancer cells, the combination of PS-341 and TRAIL overcomes the block to activation of the mitochondrial pathway and causes SMAC and cytochrome c release followed by apoptosis. Similarly, murine embryonic fibroblasts lacking Bax undergo apoptosis when exposed to the combination of PS-341 and TRAIL; however, fibroblasts lacking Bak are significantly resistant. Taken together, these findings indicate that PS-341 enhances TRAIL-induced apoptosis by increasing the cleavage of caspase 8, causing Bak-dependent release of mitochondrial proapoptotic proteins.	Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA; Univ Penn, Dept Med Canc Biol & Pathol & Lab Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Pennsylvania; Pennsylvania Medicine	Kraft, AS (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Med Oncol, 4200 E 9th Ave, Denver, CO 80262 USA.	Andrew.Kraft@UCHSC.edu	高, 雨莉/HGU-8187-2022					Adams J, 1999, CANCER RES, V59, P2615; An WG, 2000, LEUKEMIA, V14, P1276, DOI 10.1038/sj.leu.2401812; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHOU TC, 1983, TRENDS PHARMACOL SCI, V4, P450, DOI 10.1016/0165-6147(83)90490-X; Cusack JC, 2001, CANCER RES, V61, P3535; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Drabkin H, 2002, LEUKEMIA, V16, P186, DOI 10.1038/sj.leu.2402354; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hao CH, 2001, CANCER RES, V61, P1162; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; Hideshima T, 2001, CANCER RES, V61, P3071; Hietakangas V, 2003, MOL CELL BIOL, V23, P1278, DOI 10.1128/MCB.23.4.1278-1291.2003; Higuchi H, 2003, J BIOL CHEM, V278, P454, DOI 10.1074/jbc.M209387200; Kelly MM, 2002, CANCER BIOL THER, V1, P520, DOI 10.4161/cbt.1.5.169; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Lacour S, 2001, CANCER RES, V61, P1645; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Mandic A, 2001, MOL CELL BIOL, V21, P3684, DOI 10.1128/MCB.21.11.3684-3691.2001; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Nagane M, 2000, CANCER RES, V60, P847; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Pawlowski JE, 2000, ANTICANCER RES, V20, P4243; Racke MM, 2002, J NEUROCHEM, V80, P1039, DOI 10.1046/j.0022-3042.2002.00787.x; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sunwoo JB, 2001, CLIN CANCER RES, V7, P1419; Teicher BA, 1999, CLIN CANCER RES, V5, P2638; van Bokhoven A, 2001, CANCER RES, V61, P6340; van Kerkhof P, 2002, ENDOCRINOLOGY, V143, P1243, DOI 10.1210/en.143.4.1243; van Kerkhof P, 2001, MOL BIOL CELL, V12, P2556, DOI 10.1091/mbc.12.8.2556; van Kerkhof P, 2001, BIOCHEM SOC T, V29, P488, DOI 10.1042/BST0290488; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Zhang XD, 2000, J IMMUNOL, V164, P3961, DOI 10.4049/jimmunol.164.8.3961; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	56	161	165	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					4953	4963		10.1038/sj.onc.1206656	http://dx.doi.org/10.1038/sj.onc.1206656			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902978				2022-12-17	WOS:000184578900003
J	Li, YF; Pei, J; Xia, H; Ke, HN; Wang, HY; Tao, WF				Li, YF; Pei, J; Xia, H; Ke, HN; Wang, HY; Tao, WF			Lats2, a putative tumor suppressor, inhibits G1/S transition	ONCOGENE			English	Article						Lats2; tumor suppressor; G1/S transition; cell cycle	PROTEIN-KINASE; HUMAN HOMOLOG; DNA-DAMAGE; CHECKPOINT PATHWAY; DEPENDENT KINASES; MITOTIC APPARATUS; DROSOPHILA LATS; CDK REGULATION; GENE; CANCER	Lats2 is a new member of the Lats tumor suppressor family. The human LATS2 gene is located at chromosome 13q11-12, which has been shown to be a hot spot (67%) for LOH in nonsmall cell lung cancer. In order to understand the function of LATS2 in the control of tumor development, we ectopically expressed mouse Lats2 via retroviral infection in NIH3T3/v-ras cells to examine whether Lats2 plays a role in suppressing tumor development and regulating cell proliferation. We have found that ectopic expression of Lats2 in NIH3T3/nu-ras cells suppresses development of tumors in athymic nude mice and inhibits proliferation of NIH3T3/nu-ras cells in an in vitro assay. Cell cycle profile analysis demonstrated that ectopic expression of Lats2 inhibited the G1/S transition. Further mechanistic studies revealed that cyclin E/CDK2 kinase activity was downregulated in Lats2-transduced NIH3T3/nu-ras cells, while other cell cycle regulators controlling the G1/S transition were not affected. We have also shown that LATS2 kinase activity and two LATS conserved domains (LCDs) are required for Lats2 to suppress tumorigenicity and to inhibit cell growth. In addition, the LATS2 protein is cytoplasmic during interphase in NIH3T3 cells, while it becomes localized to the mitotic apparatus during mitosis. Finally, we propose a model in which a combination of mammalian Lats2 and Lats1 control cell proliferation by negatively regulating different cell cycle check points.	Univ Minnesota, Sch Med, Stem Cell Inst, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Tao, WF (corresponding author), Univ Minnesota, Sch Med, Stem Cell Inst, Div Hematol Oncol & Transplantat, MMC716,420 Delaware St SE, Minneapolis, MN 55455 USA.							Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Blow JJ, 2001, EMBO J, V20, P3293, DOI 10.1093/emboj/20.13.3293; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Girard L, 2000, CANCER RES, V60, P4894; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hori T, 2000, ONCOGENE, V19, P3101, DOI 10.1038/sj.onc.1203659; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morinaga N, 2000, INT J ONCOL, V17, P1125; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Xia H, 2002, ONCOGENE, V21, P1233, DOI 10.1038/sj.onc.1205174; XU TA, 1995, DEVELOPMENT, V121, P1053; Yabuta N, 2000, GENOMICS, V63, P263, DOI 10.1006/geno.1999.6065; Yang XL, 2001, ONCOGENE, V20, P6516, DOI 10.1038/sj.onc.1204817	29	161	173	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 10	2003	22	28					4398	4405		10.1038/sj.onc.1206603	http://dx.doi.org/10.1038/sj.onc.1206603			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853976				2022-12-17	WOS:000183978900009
J	Jirmanova, L; Afanassieff, M; Gobert-Gosse, S; Markossian, S; Savatier, P				Jirmanova, L; Afanassieff, M; Gobert-Gosse, S; Markossian, S; Savatier, P			Differential contributions of ERK and PI3-kinase to the regulation of cyclin D1 expression and to the control of the G1/S transition in mouse embryonic stem cells	ONCOGENE			English	Article						embryonic stem cell; cell cycle; cyclin D1; extracellular regulated kinase; phosphatidylinositol 3-kinase	PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3; AIRWAY SMOOTH-MUSCLE; PHOSPHATIDYLINOSITOL 3-KINASE; CANCER CELLS; SIGNAL-TRANSDUCTION; DNA-SYNTHESIS; G(1) PHASE; PHOSPHORYLATION; ACTIVATION	Mouse embryonic stem (ES) cells are known to express D-type cyclins at very low levels and these levels increase dramatically during in vitro and in vivo differentiation. Here, we investigate some of the signalling pathways regulating expression of cyclin D1 and progression to S phase, the Ras/Extracellular signal-regulated protein kinase (ERK) pathway and the phosphatidylinositol 3-kinase (P13-kinase) pathway. We demonstrate that ERK phosphorylation is fully dispensable for the regulation of cyclin D1 level and for the progression from G1 to S phase in ES cells. By contrast, P13-kinase activity is required for both. Differentiation induced by retinoic acid results in the gain of ERK-dependent control of cyclin D1 expression and of S phase progression. Differentiation is also paralleled by an increase in P13-kinase activity. This leads (a) to an increase in the p70 S6 kinase-dependent regulation of the steady-state level of cyclin D1, and (b) to a concomitant decrease in the GSK3beta-dependent rate of cyclin D1 degradation. Altogether, these multiple pathways account for the dramatic increase in the level of cyclin D1 protein which parallels ES cell differentiation. Our studies suggest that P13-kinase is an important regulator of the ES cell cycle and that its activity is not regulated by mitogen stimulation.	Ecole Normale Super Lyon, INRA, CNRS, UMR 5665,LA913,Lab Biol Mol & Cellulaire, F-69364 Lyon 07, France; Univ Lyon 1, CNRS, Ctr Genet Mol & Cellulaire, CNRS UMR 5534, F-69622 Villeurbanne, France	INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Savatier, P (corresponding author), Ecole Normale Super Lyon, INRA, CNRS, UMR 5665,LA913,Lab Biol Mol & Cellulaire, 46 Allee Italie, F-69364 Lyon 07, France.		SAVATIER, Pierre/J-4663-2014; AFANASSIEFF, Marielle/M-6570-2014; stephanie, gobert/AAC-4061-2020	AFANASSIEFF, Marielle/0000-0002-6353-6617; Markossian, Suzy/0000-0003-3545-569X				Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Badache A, 2001, CANCER RES, V61, P383; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Brennan P, 2002, ONCOGENE, V21, P1263, DOI 10.1038/sj.onc.1205182; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dani C, 1998, DEV BIOL, V203, P149, DOI 10.1006/dbio.1998.9026; DEL PL, 1997, SCIENCE, V278, P687; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Grewe M, 1999, CANCER RES, V59, P3581; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; HERBER B, 1994, ONCOGENE, V9, P1295; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Negoro S, 2001, CIRCULATION, V103, P555, DOI 10.1161/01.CIR.103.4.555; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Ramakrishnan M, 1998, AM J RESP CELL MOL, V18, P736, DOI 10.1165/ajrcmb.18.6.3152; Ravenhall C, 2000, BRIT J PHARMACOL, V131, P17, DOI 10.1038/sj.bjp.0703454; Savatier P, 1996, ONCOGENE, V12, P309; Savatier P, 2002, Methods Mol Biol, V185, P27; SAVATIER P, 1994, ONCOGENE, V9, P809; Schiemann WP, 1997, J BIOL CHEM, V272, P16631, DOI 10.1074/jbc.272.26.16631; Schratt G, 2001, MOL CELL BIOL, V21, P2933, DOI 10.1128/MCB.21.8.2933-2943.2001; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Stewart AG, 1999, MOL PHARMACOL, V56, P1079, DOI 10.1124/mol.56.5.1079; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Treinies I, 1999, MOL CELL BIOL, V19, P321; vanEngeland M, 1996, CYTOMETRY, V24, P131, DOI 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3	57	161	167	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	2002	21	36					5515	5528		10.1038/sj.onc.1205728	http://dx.doi.org/10.1038/sj.onc.1205728			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165850				2022-12-17	WOS:000177442000001
J	Schwindinger, WF; Robishaw, JD				Schwindinger, WF; Robishaw, JD			Heterotrimeric G-protein beta gamma-dimers in growth and differentiation	ONCOGENE			English	Article						MAPK; PI3K	COUPLED RECEPTORS; PHOSPHOINOSITIDE 3-KINASE; MAP KINASE; TYROSINE KINASE; FARNESYLTRANSFERASE INHIBITORS; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; ALPHA-SUBUNIT; ACTIVATION; RAS	Heterotrimeric C-proteins are components of the signal transduction pathways for the soluble and cell-contact signals that regulate normal growth and differentiation. There is now a greater appreciation of the role of the G beta gamma -dimer in the regulation of a variety of intracellular effecters, including ion channels, adenylyl cyclase, and phospholipase C beta, In many cases, G beta gamma -dimers are required for the activation of mitogen activated protein kinase (MAPK) pathways that promote cellular proliferation, although the underlying mechanisms have yet to be fully elucidated, Activation of phosphotidylinositol-3-kinase (PI3K) is a critical step in the intracellular transduction of survival signals. G beta gamma -dimers directly activate PI3K gamma as well as the more widely distributed PI3K beta. The activation of PI3K gamma by G beta gamma -dimers likely involves direct binding of specific G beta gamma -dimers to both subunits of PI3K gamma. Thus, G beta gamma -dimers transmit signals from numerous receptors to a variety of intracellular effecters in distinct cellular contexts. Five distinct G beta -subunits and 12 distinct G gamma -subunits have been identified. New experimental approaches are needed to elucidate the specific roles of individual G beta gamma -dimers in the pathways that transduce signals for proliferation and survival.	Geisinger Med Clin, Weis Ctr Res, Danville, PA 17822 USA	Geisinger Medical Center	Robishaw, JD (corresponding author), Geisinger Med Clin, Weis Ctr Res, 100 N Acad Ave, Danville, PA 17822 USA.							Abrams CS, 1996, J BIOL CHEM, V271, P25192, DOI 10.1074/jbc.271.41.25192; Balcueva EA, 2000, EXP CELL RES, V257, P310, DOI 10.1006/excr.2000.4893; Bell B, 1999, J BIOL CHEM, V274, P7982, DOI 10.1074/jbc.274.12.7982; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Cacace AM, 1999, MOL CELL BIOL, V19, P229; CHOI KY, 1994, CELL, V78, P499; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Cook LA, 1998, BIOCHEMISTRY-US, V37, P12280, DOI 10.1021/bi980230e; Coso OA, 1996, J BIOL CHEM, V271, P3963; Craft CM, 1998, BIOCHEMISTRY-US, V37, P15758, DOI 10.1021/bi980921a; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; DOWNWARD J, 1995, CELL, V83, P831, DOI 10.1016/0092-8674(95)90198-1; FAURE M, 1994, J BIOL CHEM, V269, P7851; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Ghahremani MH, 2000, MOL CELL BIOL, V20, P1497, DOI 10.1128/MCB.20.5.1497-1506.2000; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gutkind J.S, 2000, SCI STKE; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Huang LQ, 1999, NAT NEUROSCI, V2, P1055, DOI 10.1038/15981; Hurowitz EH, 2000, DNA RES, V7, P111, DOI 10.1093/dnares/7.2.111; Iaccarino G, 1999, P NATL ACAD SCI USA, V96, P3945, DOI 10.1073/pnas.96.7.3945; ITO A, 1995, FEBS LETT, V368, P183, DOI 10.1016/0014-5793(95)00643-N; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; Klein S, 2000, P NATL ACAD SCI USA, V97, P3219, DOI 10.1073/pnas.050015797; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Krugmann S, 1999, J BIOL CHEM, V274, P17152, DOI 10.1074/jbc.274.24.17152; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Maier U, 2000, J BIOL CHEM, V275, P13746, DOI 10.1074/jbc.275.18.13746; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; Morishita R, 1999, J NEUROCHEM, V73, P2369, DOI 10.1046/j.1471-4159.1999.0732369.x; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Murga C, 1999, TRENDS ENDOCRIN MET, V10, P122, DOI 10.1016/S1043-2760(98)00131-3; Myung CS, 1999, J BIOL CHEM, V274, P16595, DOI 10.1074/jbc.274.23.16595; Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5; Park JG, 1999, EMBO J, V18, P4004, DOI 10.1093/emboj/18.14.4004; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Prasad SVN, 2000, J BIOL CHEM, V275, P4693, DOI 10.1074/jbc.275.7.4693; Prendergast GC, 2000, CURR OPIN CELL BIOL, V12, P166, DOI 10.1016/S0955-0674(99)00072-1; Rebois RV, 1997, CELL SIGNAL, V9, P141, DOI 10.1016/S0898-6568(96)00133-7; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Rubio I, 1997, BIOCHEM J, V326, P891, DOI 10.1042/bj3260891; Sasaki T, 2000, NATURE, V406, P897, DOI 10.1038/35022585; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Shibata K, 1999, CANCER RES, V59, P1096; Shibata K, 1998, BIOCHEM BIOPH RES CO, V246, P205, DOI 10.1006/bbrc.1998.8581; Simonds WF, 1999, TRENDS PHARMACOL SCI, V20, P66, DOI 10.1016/S0165-6147(99)01307-3; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Stoyanova S, 1997, BIOCHEM J, V324, P489, DOI 10.1042/bj3240489; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; YI F, 1991, J BIOL CHEM, V266, P3900	65	161	163	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	2001	20	13					1653	1660		10.1038/sj.onc.1204181	http://dx.doi.org/10.1038/sj.onc.1204181			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313913				2022-12-17	WOS:000168089800016
J	Jimenez, GS; Khan, SH; Stommel, JM; Wahl, GM				Jimenez, GS; Khan, SH; Stommel, JM; Wahl, GM			p53 regulation by post-translational modification and nuclear retention in response to diverse stresses	ONCOGENE			English	Review						p53; DNA damage; nuclear export signal; microtubule depolymerization; post translational modification	DEPENDENT PROTEIN-KINASE; WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; CELL-CYCLE ARREST; NORMAL HUMAN FIBROBLASTS; DNA-BINDING FUNCTION; VIRUS-X PROTEIN; TETRAMERIZATION DOMAIN; TRANSCRIPTION FACTOR; CYTOPLASMIC SEQUESTRATION	p53 activation by diverse stresses involves post-translational modifications that alter its structure and result in its nuclear accumulation. We will discuss several unresolved topics regarding p53 regulation which are currently under investigation. DNA damage is perhaps the best-studied stress which activates p53, and recent data implicate phosphorylation at N-terminal serine residues as critical in this process. We discuss recent data regarding the potential kinases which modify p53 and the possible role of the resulting phosphorylation events. By contrast, much less is understood about agents which disrupt the mitotic spindle, The cell cycle phase, induction signal, and biochemical mechanism of the reversible arrest induced by microtubule disruption are currently under investigation. Finally, a key event in response to any genotoxic stress is the accumulation of p53 in the nucleus. The factors which determine the steady state level of p53 are starting to be elucidated, but the mechanisms responsible for nuclear accumulation and nuclear export remain controversial. We discuss new studies revealing a mechanism for nuclear retention of p53, and the potential contributions of MDM2 to this process.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92037 USA	Salk Institute; University of California System; University of California San Diego	Wahl, GM (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Stommel, Jayne M/M-3439-2017					Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOSARI S, 1995, AM J PATHOL, V147, P790; Briggs LJ, 1998, J BIOL CHEM, V273, P22745, DOI 10.1074/jbc.273.35.22745; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; Crook T, 1998, ONCOGENE, V16, P1429, DOI 10.1038/sj.onc.1201699; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Danska JS, 1996, MOL CELL BIOL, V16, P5507; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Di Leonardo A, 1997, CANCER RES, V57, P1013; Drier EA, 1999, GENE DEV, V13, P556, DOI 10.1101/gad.13.5.556; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elkeles A, 1999, MOL CELL BIOL, V19, P2594; ELKIND NB, 1995, ONCOGENE, V11, P841; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Farr KA, 1998, MOL CELL BIOL, V18, P2738, DOI 10.1128/MCB.18.5.2738; FEITELSON MA, 1993, ONCOGENE, V8, P1109; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; FISCELLA M, 1993, ONCOGENE, V8, P1519; Fontoura BMA, 1997, MOL CELL BIOL, V17, P3146, DOI 10.1128/MCB.17.6.3146; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUCHS B, 1995, ONCOGENE, V10, P789; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; GANNON JV, 1991, NATURE, V349, P802; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Gurley KE, 1996, CARCINOGENESIS, V17, P2537, DOI 10.1093/carcin/17.12.2537; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1994, ONCOGENE, V9, P299; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Heist EK, 1998, J BIOL CHEM, V273, P19763, DOI 10.1074/jbc.273.31.19763; HENNEKES H, 1993, J CELL BIOL, V120, P1293, DOI 10.1083/jcb.120.6.1293; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Huang LC, 1996, CANCER RES, V56, P2940; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Isaacs JS, 1999, MOL CARCINOGEN, V24, P70, DOI 10.1002/(SICI)1098-2744(199901)24:1<70::AID-MC10>3.0.CO;2-5; ISHIOKA C, 1995, ONCOGENE, V10, P1485; JANS DA, 1995, J BIOL CHEM, V270, P17064, DOI 10.1074/jbc.270.29.17064; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; KAHN SH, 1998, CANCER RES, V58, P396; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Klotzsche O, 1998, ONCOGENE, V16, P3423, DOI 10.1038/sj.onc.1202155; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Komarova EA, 1997, CANCER RES, V57, P5217; Konig C, 1999, J VIROL, V73, P2253; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; LAVIN MF, 1994, INT J RADIAT BIOL, V66, pS151; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lomax ME, 1998, ONCOGENE, V17, P643, DOI 10.1038/sj.onc.1201974; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; Mayo LD, 1997, CANCER RES, V57, P5013; MAYR GA, 1995, CANCER RES, V55, P2410; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Metcalfe S, 1999, ONCOGENE, V18, P2351, DOI 10.1038/sj.onc.1202559; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Middeler G, 1997, ONCOGENE, V14, P1407, DOI 10.1038/sj.onc.1200949; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rathmell WK, 1997, CANCER RES, V57, P68; RIEDER CL, 1992, J CELL SCI, V102, P387; ROBERTS BT, 1994, MOL CELL BIOL, V14, P8282, DOI 10.1128/MCB.14.12.8282; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Schlamp CL, 1997, J NATL CANCER I, V89, P1530, DOI 10.1093/jnci/89.20.1530; Scolnick DM, 1997, CANCER RES, V57, P3693; Sepehrnia B, 1996, J BIOL CHEM, V271, P15084, DOI 10.1074/jbc.271.25.15084; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; STENMARKASKMALM M, 1994, EUR J CANCER, V30A, P175, DOI 10.1016/0959-8049(94)90082-5; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; SUGANO T, 1995, JPN J CANCER RES, V86, P415, DOI 10.1111/j.1349-7006.1995.tb03072.x; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; TAKAHASHI K, 1994, ONCOGENE, V9, P183; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Tarunina M, 1996, ONCOGENE, V13, P589; Thomas M, 1996, ONCOGENE, V13, P265; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Varley JM, 1996, ONCOGENE, V12, P2437; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAJDEL MEB, 1988, ONCOGENE, V2, P579; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	162	161	166	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	1999	18	53					7656	7665		10.1038/sj.onc.1203013	http://dx.doi.org/10.1038/sj.onc.1203013			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DD	10618705				2022-12-17	WOS:000084634500004
J	Cortez, D; Reuther, G; Pendergast, AM				Cortez, D; Reuther, G; Pendergast, AM			The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells	ONCOGENE			English	Article						Bcr-Abl; tyrosine kinase; cell cycle; mitogenesis	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC GRANULOCYTIC LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; PHILADELPHIA-CHROMOSOME; POSITIVE LEUKEMIAS; MAMMALIAN-CELLS; MAP KINASES; TRANSFORMATION; APOPTOSIS	Bcr-Abl is a constitutively active tyrosine kinase that is expressed in Philadelphia chromosome (Ph-1)-positive human leukemias. Bcr-Abl has been shown to inhibit apoptosis and cause anchorage independent growth. However, its ability to activate mitogenic signaling pathways is controversial. Here we show that Bcr-Abl signaling prevents down-regulation of cyclin-dependent kinase activity and cell cycle arrest after growth factor deprivation of hematopoietic progenitor cells, Using an inducible system to regulate Bcr-Abl expression, we also demonstrate that Bcr-Abl expression is sufficient to induce G1-to-S phase transition, DNA synthesis, and activation of cyclin-dependent kinases in cells that were arrested in G(0) by growth factor deprivation, Furthermore, Bcr-Abl activates Pas, Erk, and Jnk pathways as a primary consequence of expression. These data show that Bcr-Abl is one of a select group of oncogenes that is capable of both inhibiting apoptosis and deregulating cell proliferation. The combination of these activities is likely to be important for the progression of CML.	DUKE UNIV, MED CTR, DEPT PHARMACOL & CANC BIOL, DURHAM, NC 27710 USA	Duke University			Reuther, Gary/AFR-2892-2022	Pendergast, Ann Marie/0000-0002-1250-6880	NCI NIH HHS [CA61033] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061033] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMOS TAS, 1995, BRIT J HAEMATOL, V91, P387, DOI 10.1111/j.1365-2141.1995.tb05308.x; ATHENS JW, 1965, J CLIN INVEST, V44, P765, DOI 10.1172/JCI105189; BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; CARLESSO N, 1994, ONCOGENE, V9, P149; CHERVENICK PA, 1968, SER HAEMATOL, V1, P24; CLARK SS, 1989, ANNU REV MED, V40, P113; CLARKSON B, 1993, LEUKEMIA, V7, P1683; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; Cortez D, 1996, ONCOGENE, V13, P2589; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; GALBRAITH PR, 1972, BRIT J HAEMATOL, V22, P135, DOI 10.1111/j.1365-2141.1972.tb08795.x; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; GOTO T, 1982, BLOOD, V59, P793; GROFFEN J, 1993, LEUKEMIA LYMPHOMA, V11, P19, DOI 10.3109/10428199309047857; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; Kortenjann M, 1995, CRIT REV ONCOGENESIS, V6, P99; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LANEUVILLE P, 1994, CANCER RES, V54, P1360; MANDANAS RA, 1993, BLOOD, V82, P1838; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; OGAWA M, 1970, CANCER-AM CANCER SOC, V25, P1031, DOI 10.1002/1097-0142(197005)25:5<1031::AID-CNCR2820250507>3.0.CO;2-N; Pane F, 1996, BLOOD, V88, P2410, DOI 10.1182/blood.V88.7.2410.bloodjournal8872410; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; RIBEIRO RC, 1987, BLOOD, V70, P948; Roger R, 1996, BLOOD, V87, P1113, DOI 10.1182/blood.V87.3.1113.bloodjournal8731113; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCOTT JL, 1971, BLOOD-J HEMATOL, V38, P162, DOI 10.1182/blood.V38.2.162.162; SMETSERS TFCM, 1994, LEUKEMIA, V8, P129; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRIFE A, 1988, SEMIN HEMATOL, V25, P1; STRYCKMANS PA, 1977, CLIN HAEMATOL, V6, P21; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TSAI LH, 1993, ONCOGENE, V8, P1593; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; VONCKEN JW, 1992, CANCER RES, V52, P4534; WADA H, 1995, CANCER RES, V55, P3192; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079	65	161	167	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	1997	15	19					2333	2342		10.1038/sj.onc.1201400	http://dx.doi.org/10.1038/sj.onc.1201400			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393877				2022-12-17	WOS:A1997YE15700007
J	Vairo, G; Innes, KM; Adams, JM				Vairo, G; Innes, KM; Adams, JM			Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival	ONCOGENE			English	Article						bcl-2; differentiation; cell cycle; G(0); haemopoiesis; apoptosis	C-MYC; GROWTH-FACTORS; PROTOONCOGENE EXPRESSION; LEUKEMIA-CELLS; HL-60 CELLS; DIFFERENTIATION; APOPTOSIS; PROTEIN; DEATH; INDUCTION	Myeloid maturation appears to require exit from the cell cycle and leads to activation of apoptosis in the differentiated cells. The level of Bcl-2, which is known to promote cell survival, is shown here to influence both these critical steps. Bcl-2 function during myelomonocytic differentiation was investigated by introducing a deregulated bcl-2 gene into HL60 promyelocytic luekaemia cells, which can be induced to exit the cell cycle and differentiate into granulocytes or monocytes. Deregulated Bcl-2 expression did not itself promote differentiation but extended the lifespan of mature cells elicited by granulocytic or monocytic inducers. Unexpectedly, in response to induction, Bcl-2 overexpression markedly potentiated and hastened cell cycle withdrawal into G(0). Enhanced survival cannot account for the elevated numbers of G(0) cells, because they arose under induction conditions that did not kill control cells. Since the cell cycle status and growth of uninduced cells was not affected by Bcl-2-overexpression, its cell cycle inhibitory activity must require an induction signal. While cell cycle withdrawal may be necessary for maturation, it was not sufficient, implicating a requirement for specific differentiative signals. These results identify, for the first time, a function for the bcl-2 proto-oncogene that is separable from its enhancement of cell survival.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute			Adams, Jerry M/E-1199-2013	Adams, Jerry/0000-0002-4360-8628	NCI NIH HHS [CA12421] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1991, ONCOGENE, V6, P1915; BENITO A, 1995, AM J PATHOL, V146, P481; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BREITMAN TR, 1990, METHOD ENZYMOL, V190, P118; Cochrane C. G., 1968, Advances in Immunology, V9, P97, DOI 10.1016/S0065-2776(08)60442-3; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; COLLINS MKL, 1994, BIOESSAYS, V16, P133, DOI 10.1002/bies.950160210; COLLINS SJ, 1987, BLOOD, V70, P1233; CORY S, 1994, COLD SPRING HARB SYM, V59, P365, DOI 10.1101/SQB.1994.059.01.041; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Crissman H A, 1990, Methods Cell Biol, V33, P305; DANDREA AD, 1994, CURR OPIN CELL BIOL, V6, P804, DOI 10.1016/0955-0674(94)90048-5; DARZYNKIEWICZ Z, 1990, FLOW CYTOMETRY SORTI, P469; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; DURO D, 1995, ONCOGENE, V11, P21; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; Guy CT, 1996, MOL CELL BIOL, V16, P685; HENSON PM, 1987, J CLIN INVEST, V79, P669, DOI 10.1172/JCI112869; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JIANG HP, 1994, ONCOGENE, V9, P3397; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LONDON L, 1987, J EXP MED, V166, P1419, DOI 10.1084/jem.166.5.1419; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; MARVEL J, 1994, ONCOGENE, V9, P1117; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAUMOVSKI L, 1994, BLOOD, V83, P2261; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARK JR, 1994, BLOOD, V84, P440; PEZZELLA F, 1990, AM J PATHOL, V137, P225; PIETENPOL JA, 1994, CANCER RES, V54, P3714; PILZ RB, 1987, J CLIN INVEST, V79, P1006, DOI 10.1172/JCI112867; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; STRASSER A, 1996, IN PRESS EMBO J; TERUI Y, 1995, J CELL PHYSIOL, V164, P74, DOI 10.1002/jcp.1041640110; Uhlmann EJ, 1996, CANCER RES, V56, P2506; VAIRO G, 1991, IMMUNOL TODAY, V12, P362, DOI 10.1016/0167-5699(91)90067-4; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; ZUCKER RM, 1983, CYTOMETRY, V3, P414, DOI 10.1002/cyto.990030605	60	161	171	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1511	1519						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875989				2022-12-17	WOS:A1996VL38400016
J	HENRIKSSON, M; BAKARDJIEV, A; KLEIN, G; LUSCHER, B				HENRIKSSON, M; BAKARDJIEV, A; KLEIN, G; LUSCHER, B			PHOSPHORYLATION SITES MAPPING IN THE N-TERMINAL DOMAIN OF C-MYC MODULATE ITS TRANSFORMING POTENTIAL	ONCOGENE			English	Article							CASEIN KINASE-II; GLYCOGEN-SYNTHASE KINASE-3; HIERARCHICAL PROTEIN-PHOSPHORYLATION; NUCLEOTIDE-SEQUENCE ANALYSIS; MYELOCYTOMATOSIS VIRUS MC29; E-MU-MYC; V-MYC; TRANSGENIC MICE; CELL-LINES; NEOPLASTIC TRANSFORMATION	The nuclear proto-oncoprotein c-Myc is involved in the regulation of cell growth and differentiation. c-Myc is phosphorylated at multiple sites in vivo, two of which we have identified near the amino terminus. In chicken Thr-61/Ser-65 are phosphorylated, as are the comparable positions, Thr-58/Ser-62 in human c-Myc. These residues are located within a domain that is implicated in transactivation and is important for the transforming potential of the protein. Furthermore, these phosphorylation sites or nearby amino acids are frequently mutated in v-myc and in several c-myc genes from Burkitt's lymphoma cells. In vitro these two phosphorylation sites can be modified by glycogen synthase kinase 3 and mitogen activated protein kinase. To address their biological importance we mutated these amino terminal phosphorylation sites separately and together. Stably transfected Rat1A cells expressing the mutated proteins have an increased growth potential in soft agar Compared to wt-c-myc transfectants. These altered transformation characteristics indicate that Myc function may be negatively regulated by the amino terminal phosphorylation.	HANNOVER MED SCH, INST MOLEC BIOL, D-30623 HANNOVER, GERMANY; KAROLINSKA INST, DEPT TUMOR BIOL, S-10401 STOCKHOLM, SWEDEN	Hannover Medical School; Karolinska Institutet			Henriksson, Marie Arsenian/F-5010-2015; Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67; ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BIEGALKE BJ, 1987, J VIROL, V61, P2138, DOI 10.1128/JVI.61.7.2138-2142.1987; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DENT P, 1989, FEBS LETT, V248, P67, DOI 10.1016/0014-5793(89)80433-8; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; FIRZLAFF J M, 1989, New Biologist, V1, P44; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; FRYKBERG L, 1987, ONCOGENE, V1, P415; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HAYASHI K, 1987, NUCLEIC ACIDS RES, V15, P6419, DOI 10.1093/nar/15.16.6419; HAYFLICK J, 1985, P NATL ACAD SCI USA, V82, P2718, DOI 10.1073/pnas.82.9.2718; HEANEY ML, 1986, J VIROL, V60, P167, DOI 10.1128/JVI.60.1.167-176.1986; HIHARA H, 1974, NATL I ANIM HEALTH Q, V14, P163; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lenoir GM, 1987, ADV VIRAL ONCOL, V7, P173; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; OVERELL RW, 1989, ONCOGENE, V4, P1425; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SAKSELA K, 1992, ONCOGENE, V7, P347; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SETH A, 1991, J BIOL CHEM, V266, P23521; SETH A, 1992, J BIOL CHEM, V267, P24796; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; STREET AJ, 1990, CURR TOP MICROBIOL, V166, P251; SYMONDS G, 1989, ONCOGENE, V4, P285; VANBENEDEN RJ, 1986, P NATL ACAD SCI USA, V83, P3698; VENNSTROM B, 1982, J VIROL, V42, P773, DOI 10.1128/JVI.42.3.773-779.1982; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WALKER CW, 1992, ONCOGENE, V7, P2007; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P3642, DOI 10.1073/pnas.80.12.3642; WESTAWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P843, DOI 10.1073/pnas.81.3.843; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3	74	161	162	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3199	3209						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247524				2022-12-17	WOS:A1993MG78200002
J	MANO, H; MANO, K; TANG, B; KOEHLER, M; YI, T; GILBERT, DJ; JENKINS, NA; COPELAND, NG; IHLE, JN				MANO, H; MANO, K; TANG, B; KOEHLER, M; YI, T; GILBERT, DJ; JENKINS, NA; COPELAND, NG; IHLE, JN			EXPRESSION OF A NOVEL FORM OF TEC KINASE IN HEMATOPOIETIC-CELLS AND MAPPING OF THE GENE TO CHROMOSOME-5 NEAR KIT	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; AMINO-TERMINAL DOMAIN; SENSITIVE V-ABL; SIGNAL TRANSDUCTION; C-ABL; DEVELOPMENTAL EXPRESSION; CYTOPLASMIC DOMAINS; ANTIGEN RECEPTOR; MESSENGER-RNA; MYELOID CELLS	The Tec kinase was initially identified as a novel cytoplasmic protein tyrosine kinase that is preferentially expressed in the liver and is highly homologous to the Drosophila Dsrc28C src-related tyrosine kinase. In screening of interleukin 3 (IL-3)-dependent myeloid leukemia cells for protein tyrosine kinases, we observed that all cell lines examined expressed high levels of Tec transcripts. However, characterization of Tec cDNAs indicated that they differed significantly from the published sequence. Most strikingly, an insertion of 41 bp in the 5' region affects the initiation codon and results in replacing the published 13 amino acid amino-terminal sequences with 94 amino acids. Using polymerase chain reaction (PCR) analysis, only the form containing the insertion was detected in hematopoietic cells. In addition, we found an in-frame insertion of 66 bp that introduces an additional 22 amino acids into the SH3 domain. This insertion restores conserved SH3 sequences that are found in the src gene family and in the Dsrc28C gene. By PCR analysis, approximately equal levels of Tec transcripts containing the intact SH3 domain and containing the 22 amino acid deletion were found in hematopoietic cells. Lastly, by interspecies backcross analysis, we show that the Tec gene is tightly linked to the c-Kit gene on mouse chromosome 5.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, 332 N LAUDERDALE, MEMPHIS, TN 38105 USA; NCI, FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM, MAMMALIAN GENET LAB, FREDERICK, MD 21702 USA	St Jude Children's Research Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [N01-CO-74101, P30 CA21765] Funding Source: Medline; NIDDK NIH HHS [DK42932] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BERNARDS A, 1988, ONCOGENE, V2, P297; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DEGIORGI L, 1981, NATURE, V292, P545, DOI 10.1038/292545a0; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Green EL, 1981, GENETICS PROBABILITY, P77; Green MC., 1989, GENETIC VARIANTS STR, P12; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; IHLE JN, 1989, INT J CELL CLONING, V7, P68, DOI 10.1002/stem.5530070202; IHLE JN, 1992, CHEM IMMUNOL, V51, P65; IHLE JN, 1990, PEPTIDE GROWTH FACTO; ISFORT R, 1988, J BIOL CHEM, V263, P19203; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KANAKURA Y, 1990, BLOOD, V76, P706; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; MANO H, 1990, ONCOGENE, V5, P1781; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; QUELLE FW, 1991, J BIOL CHEM, V266, P609; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VINCENT WS, 1989, GENE DEV, V3, P334, DOI 10.1101/gad.3.3.334; WADSWORTH SC, 1990, DEV BIOL, V138, P296, DOI 10.1016/0012-1606(90)90198-R; WILKS AF, 1988, ONCOGENE, V3, P289; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391	63	161	168	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					417	424						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	7678927				2022-12-17	WOS:A1993KN00600021
J	LEMOINE, NR; STADDON, S; DICKSON, C; BARNES, DM; GULLICK, WJ				LEMOINE, NR; STADDON, S; DICKSON, C; BARNES, DM; GULLICK, WJ			ABSENCE OF ACTIVATING TRANSMEMBRANE MUTATIONS IN THE C-ERBB-2 PROTOONCOGENE IN HUMAN BREAST-CANCER	ONCOGENE			English	Note									GUYS & ST THOMAS HOSP,IMPERIAL CANC RES FUND,CLIN ONCOL UNIT,LONDON SE1 9RT,ENGLAND; IMPERIAL CANC RES FUND,VIRAL CARCINOGENESIS LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; Cancer Research UK	LEMOINE, NR (corresponding author), HAMMERSMITH HOSP,MRC,IMPERIAL CANC RES FUND,MOLEC ONCOL GRP,CYCLOTRON BLDG,DUCANE RD,LONDON W12 0HS,ENGLAND.							BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; KUMAR R, 1988, ONCOGENE, V3, P647; KUMAR R, 1989, ONCOGENE RES, V1, P235; PROSPERI MT, 1987, ONCOGENE RES, V1, P121; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	15	161	162	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1990	5	2					237	239						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU029	2181382				2022-12-17	WOS:A1990CU02900011
J	ZHOU, DJ; AHUJA, H; CLINE, MJ				ZHOU, DJ; AHUJA, H; CLINE, MJ			PROTO-ONCOGENE ABNORMALITIES IN HUMAN-BREAST CANCER - C-ERBB-2 AMPLIFICATION DOES NOT CORRELATE WITH RECURRENCE OF DISEASE	ONCOGENE			English	Article									UNIV CALIF LOS ANGELES,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NCI NIH HHS [CA 15619] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA015619] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1988, SCIENCE, V240, P1795, DOI 10.1126/science.3289120; BERGER MS, 1988, CANCER RES, V48, P1238; BONADONNA G, 1987, NEOPLASMS BREAST MED, P959; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CLINE MJ, 1987, J CLIN ONCOL, V5, P999, DOI 10.1200/JCO.1987.5.7.999; Cutler S J, 1974, Semin Oncol, V1, P91; DIXON WJ, 1983, BMDP STATISTICAL SOF; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MASUDA H, 1987, MOL BIOL MED, V4, P213; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STENKVIST B, 1982, CANCER-AM CANCER SOC, V50, P2884, DOI 10.1002/1097-0142(19821215)50:12<2884::AID-CNCR2820501231>3.0.CO;2-K; THEILLET C, 1986, CANCER RES, V46, P4776; VARLEY JM, 1987, ONCOGENE, V1, P423; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; YOKOTA J, 1986, LANCET, V1, P765; ZHOU DJ, 1987, CANCER RES, V47, P6123	22	161	163	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					105	108						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2915899				2022-12-17	WOS:A1989U567400016
J	ZAHM, P; HOFSCHNEIDER, PH; KOSHY, R				ZAHM, P; HOFSCHNEIDER, PH; KOSHY, R			THE HBV X-ORF ENCODES A TRANSACTIVATOR - A POTENTIAL FACTOR IN VIRAL HEPATOCARCINOGENESIS	ONCOGENE			English	Article									MAX PLANCK INST BIOCHEM,D-8033 MARTINSRIED,FED REP GER	Max Planck Society								BEASLEY RP, 1982, HEPATOLOGY S, V2, P21; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOHNLEIN E, 1985, NUCLEIC ACIDS RES, V13, P4789, DOI 10.1093/nar/13.13.4789; BROOME S, 1985, CELL, V40, P537, DOI 10.1016/0092-8674(85)90202-8; BRUCK C, 1987, CONTR ONCOL, V24, P166; CATTANEO R, 1983, EMBO J, V2, P511, DOI 10.1002/j.1460-2075.1983.tb01455.x; CHANG HK, 1987, NUCLEIC ACIDS RES, V15, P2261, DOI 10.1093/nar/15.5.2261; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; ELFASSI E, 1986, P NATL ACAD SCI USA, V83, P2219, DOI 10.1073/pnas.83.7.2219; ELKAREH A, 1985, P NATL ACAD SCI USA, V82, P1002, DOI 10.1073/pnas.82.4.1002; FASEL N, 1982, EMBO J, V11, P3; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GORMAN CM, 1982, MOL CELL BIOL, V2, P1046; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HESS JL, 1985, SCIENCE, V229, P482, DOI 10.1126/science.2990051; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KAY A, 1985, EMBO J, V4, P1287, DOI 10.1002/j.1460-2075.1985.tb03774.x; KODAMA K, 1985, J VIROL, V56, P978, DOI 10.1128/JVI.56.3.978-986.1985; KOSHY R, 1987, CONTRIB ONCOL, V24, P97; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUSKY M, 1985, J VIROL, V53, P955, DOI 10.1128/JVI.53.3.955-965.1985; LUSKY M, 1981, NATURE, V293, P79, DOI 10.1038/293079a0; MEYERS ML, 1986, J VIROL, V57, P101, DOI 10.1128/JVI.57.1.101-109.1986; MILLER RH, 1986, P NATL ACAD SCI USA, V83, P2531, DOI 10.1073/pnas.83.8.2531; MIYAKI M, 1986, J GEN VIROL, V67, P1449, DOI 10.1099/0022-1317-67-7-1449; MORIARTY AM, 1985, SCIENCE, V227, P429, DOI 10.1126/science.2981434; NAGAYA T, 1987, GENE DEV, V1, P773, DOI 10.1101/gad.1.8.773; PERSING DH, 1986, J VIROL, V60, P177, DOI 10.1128/JVI.60.1.177-184.1986; ROOSSINCK MJ, 1986, MOL CELL BIOL, V6, P1393, DOI 10.1128/MCB.6.5.1393; ROSEN CA, 1985, SCIENCE, V227, P320, DOI 10.1126/science.2981432; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SASSONECORSI P, 1985, NATURE, V313, P458, DOI 10.1038/313458a0; SHAUL Y, 1985, EMBO J, V4, P427, DOI 10.1002/j.1460-2075.1985.tb03646.x; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SPANDAU FD, 1988, J VIROL, V62, P427; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TOGNONI A, 1985, NUCLEIC ACIDS RES, V13, P7457, DOI 10.1093/nar/13.20.7457; TREININ M, 1987, MOL CELL BIOL, V7, P545, DOI 10.1128/MCB.7.1.545; ULFENDAHL PJ, 1987, EMBO J, V6, P2037, DOI 10.1002/j.1460-2075.1987.tb02468.x; VONLORINGHOVEN AF, 1985, EMBO J, V4, P249, DOI 10.1002/j.1460-2075.1985.tb02343.x; WONGSTAAL F, 1985, NATURE, V317, P395, DOI 10.1038/317395a0; YAGINUMA K, 1987, P NATL ACAD SCI USA, V84, P2678, DOI 10.1073/pnas.84.9.2678	49	161	163	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					169	177						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	2457861				2022-12-17	WOS:A1988Q053400007
J	Semenza, GL				Semenza, G. L.			Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis	ONCOGENE			English	Review						breast cancer; extravasation; intravasation; lung metastasis; lymph node; lymphatic metastasis; metastatic niche formation	ENDOTHELIAL-GROWTH-FACTOR; ANGIOPOIETIN-LIKE 4; BREAST-CANCER; FACTOR-I; LYMPHATIC METASTASIS; TUMOR HYPOXIA; FACTOR EXPRESSION; MALIGNANT PROGRESSION; HIF-1-ALPHA SYNTHESIS; BONE METASTASES	Interactions between cancer cells and stromal cells, including blood vessel endothelial cells (BECs), lymphatic vessel endothelial cells (LECs), bone marrow-derived angiogenic cells (BMDACs) and other bone marrow-derived cells (BMDCs) play important roles in cancer progression. Intratumoral hypoxia, which affects both cancer and stromal cells, is associated with a significantly increased risk of metastasis and mortality in many human cancers. Recent studies have begun to delineate the molecular mechanisms underlying the effect of intratumoral hypoxia on cancer progression. Reduced O-2 availability induces the activity of hypoxia-inducible factors (HIFs), which activate the transcription of target genes encoding proteins that play important roles in many critical aspects of cancer biology. Included among these are secreted factors, including angiopoietin 2, angiopoietin-like 4, placental growth factor, platelet-derived growth factor B, stem cell factor (kit ligand), stromal-derived factor 1, and vascular endothelial growth factor. These factors are produced by hypoxic cancer cells and directly mediate functional interactions with BECs, LECs, BMDACs and other BMDCs that promote angiogenesis, lymphangiogenesis, and metastasis. In addition, lysyl oxidase (LOX) and LOX-like proteins, which are secreted by hypoxic breast cancer cells, remodel extracellular matrix in the lungs, which leads to BMDC recruitment and metastatic niche formation.	[Semenza, G. L.] Johns Hopkins Univ, Sch Med, Vasc Program, Inst Cell Engn, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Semenza, GL (corresponding author), Johns Hopkins Univ, Sch Med, Vasc Program, Inst Cell Engn, 733 N Broadway,Suite 671, Baltimore, MD 21205 USA.	gsemenza@jhmi.edu			American Cancer Society; National Cancer Institute [U54-CA143868]; Susan G. Komen Breast Cancer Foundation; Johns Hopkins Institute for Cell Engineering; NATIONAL CANCER INSTITUTE [U54CA143868] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G. Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); Johns Hopkins Institute for Cell Engineering; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Cancer research in the author's laboratory is supported by grants from the American Cancer Society, National Cancer Institute (U54-CA143868; Johns Hopkins Physical Sciences-Oncology Center), Susan G. Komen Breast Cancer Foundation, and the Johns Hopkins Institute for Cell Engineering. G. L. S. is the C. Michael Armstrong Professor at the Johns Hopkins University School of Medicine and an American Cancer Society Research Professor.	Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328; Bos R, 2003, CANCER, V97, P1573, DOI 10.1002/cncr.11246; Bos R, 2005, HISTOPATHOLOGY, V46, P31, DOI 10.1111/j.1365-2559.2005.02045.x; Bosch-Marce M, 2007, CIRC RES, V101, P1310, DOI 10.1161/CIRCRESAHA.107.153346; Branco-Price C, 2012, CANCER CELL, V21, P52, DOI 10.1016/j.ccr.2011.11.017; Brizel DM, 1996, CANCER RES, V56, P941; Cao RH, 2004, CANCER CELL, V6, P333, DOI 10.1016/j.ccr.2004.08.034; Cao YH, 2005, NAT REV CANCER, V5, P735, DOI 10.1038/nrc1693; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chintala S, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-293; Conley SJ, 2012, P NATL ACAD SCI USA, V109, P2784, DOI 10.1073/pnas.1018866109; Dales JP, 2005, INT J CANCER, V116, P734, DOI 10.1002/ijc.20984; Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034; Dunn LK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006896; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Ebos JML, 2011, NAT REV CLIN ONCOL, V8, P210, DOI 10.1038/nrclinonc.2011.21; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Falcon BL, 2009, AM J PATHOL, V175, P2159, DOI 10.2353/ajpath.2009.090391; Ferrara N, 2010, CYTOKINE GROWTH F R, V21, P21, DOI 10.1016/j.cytogfr.2009.11.003; Fidler IJ, 1999, CANCER CHEMOTH PHARM, V43, pS3, DOI 10.1007/s002800051091; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hiraga T, 2007, CANCER RES, V67, P4157, DOI 10.1158/0008-5472.CAN-06-2355; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hockel M, 1996, CANCER RES, V56, P4509; Imamura T, 2009, INT J CANCER, V124, P763, DOI 10.1002/ijc.24032; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Kallergi G, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2452; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B; Kim YN, 2012, INT J CELL BIOL, V2012, DOI DOI 10.1155/2012/306879; Kodama M, 2010, CANCER SCI, V101, P1984, DOI 10.1111/j.1349-7006.2010.01639.x; Koyama Yu, 2003, Clin Breast Cancer, V4, P354, DOI 10.3816/CBC.2003.n.041; Krishnamachary B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044078; Kummar S, 2011, CLIN CANCER RES, V17, P5123, DOI 10.1158/1078-0432.CCR-11-0682; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lee K, 2009, P NATL ACAD SCI USA, V106, P17910, DOI 10.1073/pnas.0909353106; Lee K, 2009, P NATL ACAD SCI USA, V106, P2353, DOI 10.1073/pnas.0812801106; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Li H, 2011, HEPATOLOGY, V54, P910, DOI 10.1002/hep.24479; Liu M, 2005, CANCER RES, V65, P5325, DOI 10.1158/0008-5472.CAN-04-4589; Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001; Lofstedt T, 2007, CELL CYCLE, V6, P919, DOI 10.4161/cc.6.8.4133; Luwor RB, 2005, ONCOGENE, V24, P4433, DOI 10.1038/sj.onc.1208625; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Pal SK, 2011, BREAST CANCER RES TR, V125, P627, DOI 10.1007/s10549-010-1293-1; Polyak K, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003244; Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039; Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-05-4598; Ran S, 2010, PATHOPHYSIOLOGY, V17, P229, DOI DOI 10.1016/J.PATH0PHYS.2009.11.003; Rapisarda A, 2002, CANCER RES, V62, P4316; Schito L, 2012, P NATL ACAD SCI USA, V109, pE2707, DOI 10.1073/pnas.1214019109; Schoppmann SF, 2006, BREAST CANCER RES TR, V99, P135, DOI 10.1007/s10549-006-9190-3; Schwartz GF, 2012, CANCER-AM CANCER SOC, V118, P2031, DOI 10.1002/cncr.27431; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Simon MP, 2008, J CELL PHYSIOL, V217, P809, DOI 10.1002/jcp.21558; Takano S, 2010, J NEURO-ONCOL, V99, P177, DOI 10.1007/s11060-010-0118-8; Takeda N, 2010, GENE DEV, V24, P491, DOI 10.1101/gad.1881410; Tammela T, 2010, CELL, V140, P460, DOI 10.1016/j.cell.2010.01.045; Tan MJ, 2012, MOL CANCER RES, V10, P677, DOI 10.1158/1541-7786.MCR-11-0519; Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337; Thomas S, 2012, CANCER RES, V72, P5600, DOI 10.1158/0008-5472.CAN-11-3666; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Vaupel P, 2004, METHOD ENZYMOL, V381, P335; Vergis R, 2008, LANCET ONCOL, V9, P342, DOI 10.1016/S1470-2045(08)70076-7; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wong CCL, 2012, J MOL MED, V90, P803, DOI 10.1007/s00109-011-0855-y; Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Zhang H, 2012, ONCOGENE, V31, P1757, DOI 10.1038/onc.2011.365; Zhang HF, 2008, P NATL ACAD SCI USA, V105, P19579, DOI 10.1073/pnas.0809763105; Zhu PC, 2011, CANCER CELL, V19, P401, DOI 10.1016/j.ccr.2011.01.018	83	160	168	0	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2013	32	35					4057	4063		10.1038/onc.2012.578	http://dx.doi.org/10.1038/onc.2012.578			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	23222717	Green Accepted, Bronze			2022-12-17	WOS:000323748500001
J	Acunzo, M; Visone, R; Romano, G; Veronese, A; Lovat, F; Palmieri, D; Bottoni, A; Garofalo, M; Gasparini, P; Condorelli, G; Chiariello, M; Croce, CM				Acunzo, M.; Visone, R.; Romano, G.; Veronese, A.; Lovat, F.; Palmieri, D.; Bottoni, A.; Garofalo, M.; Gasparini, P.; Condorelli, G.; Chiariello, M.; Croce, C. M.			miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222	ONCOGENE			English	Article						MET; miR-130a; NSCLC; TRAIL	CELL LUNG-CANCER; SIGNALING PATHWAY; OVARIAN-CANCER; RESISTANCE; APOPTOSIS	Non-small cell lung cancer (NSCLC) accounts for similar to 80% of all lung cancers. Although some advances in lung cancer therapy have been made, patient survival is still quite poor. Two microRNAs, miR-221 and miR-222, upregulated by the MET proto-oncogene, have been already described to enhance cell survival and to induce TNF-related apoptosis-inducing ligand (TRAIL) resistance in NSCLC cell lines, through the downregulation of p27(kip1), PTEN and TIMP3. Here, we further investigated this pathway and showed that miR-130a, expressed at low level in lung cancer cell lines, by targeting MET was able to reduce TRAIL resistance in NSCLC cells through the c-Jun-mediated downregulation of miR-221 and miR-222. Moreover, we found that miR-130a reduced migratory capacity of NSCLC. A better understanding of MET-miR-221 and 222 axis regulation in drug resistance is the key in developing new strategies in NSCLC therapy. Oncogene (2012) 31, 634-642; doi:10.1038/onc.2011.260; published online 27 June 2011	[Acunzo, M.; Visone, R.; Veronese, A.; Lovat, F.; Palmieri, D.; Bottoni, A.; Garofalo, M.; Gasparini, P.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Romano, G.] Fdn IRCCS SDN, Naples, Italy; [Palmieri, D.; Condorelli, G.] Univ Naples Federico II, Fac Biotechnol Sci, Consiglio Nazl Ric, Dept Cellular & Mol Biol & Pathol,Ist Endocrinol, Naples, Italy; [Chiariello, M.] Consiglio Nazl Ric IFC CNR, ITT, Siena, Italy; [Chiariello, M.] Consiglio Nazl Ric IFC CNR, Ist Fisiol Clin, Siena, Italy	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; IRCCS Istituto di Ricerca Diagnostica e Nucleare (SDN); Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR)	Croce, CM (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.	carlo.croce@osumc.edu	visone, rosa/K-7910-2016; Chiariello, Mario/O-3642-2014; Young, Richard A/F-6495-2012; Condorelli, Gerolama/AAC-3472-2022; Acunzo, Mario/ABE-1739-2020; Gasparini, Pierluigi/ABA-2811-2021; Veronese, Angelo/I-4292-2019	Chiariello, Mario/0000-0001-8434-5177; Young, Richard A/0000-0001-8855-8647; Condorelli, Gerolama/0000-0003-0177-8829; Gasparini, Pierluigi/0000-0001-8311-8845; Veronese, Angelo/0000-0002-1451-1392; Palmieri, Dario/0000-0002-0797-4268; Acunzo, Mario/0000-0002-3942-9061; VISONE, Rosa/0000-0002-4993-0220	NCI; Associazione Italiana Ricerca sul Cancro, AIRC; NATIONAL CANCER INSTITUTE [P01CA129242, U01CA152758] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Associazione Italiana Ricerca sul Cancro, AIRC(Fondazione AIRC per la ricerca sul cancro); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the NCI grants to (CMC) and Associazione Italiana Ricerca sul Cancro, AIRC grant to GC. We thank Veronica Balatti, Giampiero di Leva, Claudia Piovan, Hansjuerg Alder and Paolo Fadda for the helpful discussions about this manuscript.	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Cecchi F, 2010, EUR J CANCER, V46, P1260, DOI 10.1016/j.ejca.2010.02.028; Cimmino A, 2006, P NATL ACAD SCI USA, V103, P2464, DOI 10.1073/pnas.0510793103; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Fan S, 2004, MOL CELL BIOL, V21, P4968; Gao W, 2010, BIOMED PHARMACOTHER, V64, P399, DOI 10.1016/j.biopha.2010.01.018; Garofalo M, 2008, ONCOGENE, V27, P3845, DOI 10.1038/onc.2008.6; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Hummel R, 2010, EUR J CANCER, V46, P298, DOI 10.1016/j.ejca.2009.10.027; Incoronato M, 2010, CANCER RES, V70, P3638, DOI 10.1158/0008-5472.CAN-09-3341; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Peruzzi B, 2006, CLIN CANCER RES, V12, P3657, DOI 10.1158/1078-0432.CCR-06-0818; Ramalingam S, 1998, J CLIN ONCOL, V16, P651, DOI 10.1200/JCO.1998.16.2.651; Schaefer U, 2007, FRONT BIOSCI, V12, P3813, DOI 10.2741/2354; Segarra J, 2006, J BIOL CHEM, V281, P4771, DOI 10.1074/jbc.M508298200; Socinski MA, 2007, CHEST, V132, p277S, DOI 10.1378/chest.07-1381; Song H, 2006, NEUROSCI RES, V56, P29, DOI 10.1016/j.neures.2006.04.019; Sorrentino A, 2008, GYNECOL ONCOL, V111, P478, DOI 10.1016/j.ygyno.2008.08.017; Tulasne D, 2008, CELL DEATH DIFFER, V15, P427, DOI 10.1038/sj.cdd.4402229; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488	24	160	174	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	5					634	642		10.1038/onc.2011.260	http://dx.doi.org/10.1038/onc.2011.260			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21706050	Green Accepted			2022-12-17	WOS:000300221800009
J	Brenner, C; Grimm, S				Brenner, C.; Grimm, S.			The permeability transition pore complex in cancer cell death	ONCOGENE			English	Review						mitochondria; apoptosis; adenine nucleotide translocator; cyclophilin D; VDAC	ADENINE-NUCLEOTIDE TRANSLOCATOR; PERIPHERAL BENZODIAZEPINE-RECEPTOR; CYTOCHROME-C RELEASE; DEPENDENT ANION CHANNEL; INNER MITOCHONDRIAL-MEMBRANE; INTERMEMBRANE JUNCTIONAL COMPLEXES; HUMAN-BREAST-CANCER; CYCLOPHILIN-D; BAX TRANSLOCATION; OXIDATIVE STRESS	The permeability transition pore (PTP) is a multi-protein complex at contact sites of the inner with the outer mitochondrial membrane. Research over the past years has led to the concept that the PTP occupies a central role in cell death induction. Numerous apoptosis signals convert this protein aggregate into an unspecific pore, thus activating mitochondria for the cellular self-destruction process. Here, we describe the evidence for this and the various approaches being undertaken to elucidate its subunit composition and mode of regulation. In particular, we review data that indicate a role of specific PTP subunits for apoptosis inhibition during tumorigenesis.	Univ Versailles, CNRS, FRE 2445, F-78035 Versailles, France; Imperial Coll London, Hammersmith Campus, London W12 0NN, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Imperial College London	Brenner, C (corresponding author), Univ Versailles, CNRS, FRE 2445, 45 Ave Etats Unis, F-78035 Versailles, France.	catherinebrenner@yahoo.com			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Banker DE, 2002, LEUKEMIA RES, V26, P91, DOI 10.1016/S0145-2126(01)00112-6; Barros LF, 2001, COMP BIOCHEM PHYS A, V130, P401, DOI 10.1016/S1095-6433(01)00438-X; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Belzacq AS, 2003, CANCER RES, V63, P541; Belzacq AS, 2002, BIOCHIMIE, V84, P167, DOI 10.1016/S0300-9084(02)01366-4; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Belzacq AS, 2001, CANCER RES, V61, P1260; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Biaglow JE, 2005, CANCER BIOL THER, V4, P6; Boisvieux-Ulrich E, 2005, EXP CELL RES, V307, P76, DOI 10.1016/j.yexcr.2005.02.005; Bonod-Bidaud C, 2001, MITOCHONDRION, V1, P217, DOI 10.1016/S1567-7249(01)00017-4; BRDICZKA D, 1991, BIOCHIM BIOPHYS ACTA, V1071, P291, DOI 10.1016/0304-4157(91)90018-R; Brenner C, 2000, METHOD ENZYMOL, V322, P243; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Brustovetsky N, 2002, BIOCHEMISTRY-US, V41, P11804, DOI 10.1021/bi0200110; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; Cassarino DS, 1999, BRAIN RES REV, V29, P1, DOI 10.1016/S0165-0173(98)00046-0; Catasus L, 2000, CANCER, V88, P2290, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2290::AID-CNCR13>3.0.CO;2-I; Cesar MD, 2004, ARCH BIOCHEM BIOPHYS, V422, P191, DOI 10.1016/j.abb.2003.12.030; Chakraborti T, 1999, CELL SIGNAL, V11, P77, DOI 10.1016/S0898-6568(98)00025-4; Chandra J, 2002, BLOOD, V99, P655, DOI 10.1182/blood.V99.2.655; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Clarke SJ, 2002, J BIOL CHEM, V277, P34793, DOI 10.1074/jbc.M202191200; Clement MV, 1999, FREE RADICAL RES, V30, P247, DOI 10.1080/10715769900300271; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; De Giorgi F, 2002, FASEB J, V16, P607, DOI 10.1096/fj.01-0269fje; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Decaudin D, 2002, CANCER RES, V62, P1388; DELUCA M, 1981, BIOCHEM BIOPH RES CO, V99, P189, DOI 10.1016/0006-291X(81)91731-9; DENIAUD A, 2006, IN PRESS CURR PHARM; Don AS, 2003, CANCER CELL, V3, P497, DOI 10.1016/S1535-6108(03)00109-0; Dvorakova K, 2002, MOL CANCER THER, V1, P185; Eldering E, 2004, EUR J IMMUNOL, V34, P1950, DOI 10.1002/eji.200324817; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje; Ermak G, 2002, MOL IMMUNOL, V38, P713, DOI 10.1016/S0161-5890(01)00108-0; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Fantin VR, 2002, CANCER CELL, V2, P29, DOI 10.1016/S1535-6108(02)00082-X; FaureVigny H, 1996, MOL CARCINOGEN, V16, P165, DOI 10.1002/(SICI)1098-2744(199607)16:3<165::AID-MC7>3.0.CO;2-G; Faustin B, 2004, J BIOL CHEM, V279, P20411, DOI 10.1074/jbc.M314259200; Finucane DM, 1999, EXP CELL RES, V251, P166, DOI 10.1006/excr.1999.4527; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Genini D, 2000, BLOOD, V96, P3537; Gewies A, 2003, CANCER RES, V63, P682; Giraud S, 1998, J MOL BIOL, V281, P409, DOI 10.1006/jmbi.1998.1955; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; GUDNASON V, 1984, INT J CANCER, V34, P63, DOI 10.1002/ijc.2910340111; Halestrap A, 2005, NATURE, V434, P578, DOI 10.1038/434578a; Halestrap AP, 2004, CARDIOVASC RES, V61, P372, DOI 10.1016/S0008-6363(03)00533-9; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Halestrap AP, 2004, NATURE, V430, DOI 10.1038/nature02816; Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176; Halliwell B, 1999, FREE RADICAL RES, V31, P261, DOI 10.1080/10715769900300841; HALLIWELL B, 1999, FREE RADICALS BIOL; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haouzi D, 2002, APOPTOSIS, V7, P395, DOI 10.1023/A:1020026923038; Hardwick M, 1999, CANCER RES, V59, P831; Haridas V, 2001, P NATL ACAD SCI USA, V98, P5821, DOI 10.1073/pnas.101619098; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Heerdt BG, 2003, CANCER RES, V63, P6311; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; HUNTER DR, 1976, J BIOL CHEM, V251, P5069; Inoue K, 2001, LEUKEMIA RES, V25, P275, DOI 10.1016/S0145-2126(00)00121-1; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; Jan G, 2002, CELL DEATH DIFFER, V9, P179, DOI 10.1038/sj.cdd.4400935; KATZ Y, 1990, CLIN SCI, V78, P155, DOI 10.1042/cs0780155; Kim JS, 2003, CURR MOL MED, V3, P527, DOI 10.2174/1566524033479564; Kim JS, 2003, GASTROENTEROLOGY, V124, P494, DOI 10.1053/gast.2003.50059; Ko YH, 2003, J BIOL CHEM, V278, P12305, DOI 10.1074/jbc.C200703200; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kon K, 2004, HEPATOLOGY, V40, P1170, DOI 10.1002/hep.20437; Kornblau SM, 1999, CLIN CANCER RES, V5, P1758; Kowaltowski AJ, 1997, BBA-BIOENERGETICS, V1318, P395, DOI 10.1016/S0005-2728(96)00111-9; Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Le Bras M, 2005, HISTOL HISTOPATHOL, V20, P205, DOI 10.14670/HH-20.205; Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lemasters JJ, 1997, MOL CELL BIOCHEM, V174, P159, DOI 10.1023/A:1006827601337; Levin E, 2005, BIOCHEMISTRY-US, V44, P9924, DOI 10.1021/bi050150s; Li YM, 2004, BIOCHEM J, V383, P101, DOI 10.1042/BJ20040669; Lin DT, 2002, J BIOL CHEM, V277, P31134, DOI 10.1074/jbc.M112035200; Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272; Maaser K, 2005, BIOCHEM BIOPH RES CO, V332, P646, DOI 10.1016/j.bbrc.2005.05.005; Maaser K, 2005, CLIN CANCER RES, V11, P1751, DOI 10.1158/1078-0432.CCR-04-1955; Machida K, 2002, J BIOL CHEM, V277, P31243, DOI 10.1074/jbc.M204564200; Madeo F, 2004, CURR OPIN MICROBIOL, V7, P655, DOI 10.1016/j.mib.2004.10.012; Manion MK, 2003, CANCER BIOL THER, V2, pS105; Marchetti P, 1999, CANCER RES, V59, P6257; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Marzo I, 1998, FEBS LETT, V427, P198, DOI 10.1016/S0014-5793(98)00424-4; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; MIETTINEN H, 1995, CANCER RES, V55, P2691; Morgan J, 2004, BRIT J DERMATOL, V151, P846, DOI 10.1111/j.1365-2133.2004.06198.x; Mund T, 2003, FASEB J, V17, P696, DOI 10.1096/fj.02-0657fje; Nagahara Y, 2000, J IMMUNOL, V165, P3250, DOI 10.4049/jimmunol.165.6.3250; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nakamura Y, 2002, J BIOL CHEM, V277, P8492, DOI 10.1074/jbc.M109760200; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Nieminen AL, 1997, AM J PHYSIOL-CELL PH, V272, pC1286; Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089; Oudard S, 2003, J NEURO-ONCOL, V63, P81, DOI 10.1023/A:1023756707900; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; Pani G, 2004, CURR MED CHEM, V11, P1299, DOI 10.2174/0929867043365297; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004; Pervaiz S, 1999, BLOOD, V93, P4096, DOI 10.1182/blood.V93.12.4096.412k44_4096_4108; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; PFEIFFER DR, 1995, J BIOL CHEM, V270, P4923, DOI 10.1074/jbc.270.9.4923; Piret JP, 2004, MITOCHONDRION, V3, P261, DOI 10.1016/j.mito.2004.01.001; Poncet D, 2003, APOPTOSIS, V8, P521, DOI 10.1023/A:1025546525894; PRATT R, 1987, PATHOLOGY, V19, P162, DOI 10.3109/00313028709077128; Precht TA, 2005, CELL DEATH DIFFER, V12, P255, DOI 10.1038/sj.cdd.4401552; Prevarskaya N, 2004, BIOCHEM BIOPH RES CO, V322, P1326, DOI 10.1016/j.bbrc.2004.08.037; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rauen U, 2004, J HEPATOL, V40, P607, DOI 10.1016/j.jhep.2003.12.021; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Rempel A, 1996, CANCER RES, V56, P2468; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Rostovtseva TK, 2005, J BIOENERG BIOMEMBR, V37, P129, DOI 10.1007/s10863-005-6566-8; Rotem R, 2005, CANCER RES, V65, P1984, DOI 10.1158/0008-5472.CAN-04-3091; Sakurai K, 2001, J BIOL CHEM, V276, P26942, DOI 10.1074/jbc.M102029200; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schempp CM, 2002, ONCOGENE, V21, P1242, DOI 10.1038/sj.onc.1205190; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; SCHNEIDER MD, 2005, SCI STKE, pPE26; Schoenfeld N, 2004, FASEB J, V18, P158, DOI 10.1096/fj.03-0420fje; Schubert A, 2004, CANCER RES, V64, P85, DOI 10.1158/0008-5472.CAN-03-0476; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; SHINOHARA Y, 1991, FEBS LETT, V291, P55, DOI 10.1016/0014-5793(91)81102-E; Shinohara Y, 2000, EUR J BIOCHEM, V267, P6067, DOI 10.1046/j.1432-1327.2000.01687.x; Shoshan-Barmatz V, 2003, CELL BIOCHEM BIOPHYS, V39, P279, DOI 10.1385/CBB:39:3:279; Smaili SS, 2001, CELL DEATH DIFFER, V8, P909, DOI 10.1038/sj.cdd.4400889; SOURDEVAL M, IN PRESS APOPTOSIS; Sowter HM, 2001, CANCER RES, V61, P6669; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; Tafani M, 2001, CANCER RES, V61, P2459; Tanveer A, 1996, EUR J BIOCHEM, V238, P166, DOI 10.1111/j.1432-1033.1996.0166q.x; Tinhofer I, 2001, FASEB J, V15, P1613, DOI 10.1096/fj.00-0675fje; Townson JL, 2003, CURR MOL MED, V3, P631, DOI 10.2174/1566524033479483; Troyano A, 2003, CELL DEATH DIFFER, V10, P889, DOI 10.1038/sj.cdd.4401249; Valentijn AJ, 2004, J BIOL CHEM, V279, P32848, DOI 10.1074/jbc.M313375200; Valentijn AJ, 2003, J CELL BIOL, V162, P599, DOI 10.1083/jcb.200302154; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Venturini I, 1998, LIFE SCI, V63, P1269, DOI 10.1016/S0024-3205(98)00388-9; Verrier F, 2004, ONCOGENE, V23, P8049, DOI 10.1038/sj.onc.1208001; Vieira Helena L. A., 2002, Oncogene, V21, P1963, DOI 10.1038/sj.onc.1205270; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Weaver JGR, 2005, J CLIN INVEST, V115, P1828, DOI 10.1172/JCI22954; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weisinger G, 2004, BIOCHEMISTRY-US, V43, P12315, DOI 10.1021/bi030251v; Wondrak GT, 2006, J PHARMACOL EXP THER, V316, P805, DOI 10.1124/jpet.105.094953; Yang JC, 1998, BIOCHEM BIOPH RES CO, V250, P454, DOI 10.1006/bbrc.1998.9333; Yasuda S, 2004, J HEPATOL, V40, P117, DOI 10.1016/S0168-8278(03)00503-8; Zaid H, 2005, CELL DEATH DIFFER, V12, P751, DOI 10.1038/sj.cdd.4401599; Zamzami N, 2005, CELL DEATH DIFFER, V12, P1478, DOI 10.1038/sj.cdd.4401682; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zoratti M, 2005, BBA-BIOENERGETICS, V1706, P40, DOI 10.1016/j.bbabio.2004.10.006; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739; ZUNINO S, 2005, EPUB CANC LETT	195	160	168	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	34					4744	4756		10.1038/sj.onc.1209609	http://dx.doi.org/10.1038/sj.onc.1209609			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892087				2022-12-17	WOS:000239687000011
J	Foster, KW; Liu, ZL; Nail, CD; Li, XN; Fitzgerald, TJ; Bailey, SK; Frost, AR; Louro, ID; Townes, TM; Paterson, AJ; Kudlow, JE; Lobo-Ruppert, SM; Ruppert, JM				Foster, KW; Liu, ZL; Nail, CD; Li, XN; Fitzgerald, TJ; Bailey, SK; Frost, AR; Louro, ID; Townes, TM; Paterson, AJ; Kudlow, JE; Lobo-Ruppert, SM; Ruppert, JM			Induction of KLF4 in basal keratinocytes blocks the proliferation - differentiation switch and initiates squamous epithelial dysplasia	ONCOGENE			English	Article						KLF4; squamous cell carcinoma; dysplasia; doxycycline; MMTV	KRUPPEL-LIKE FACTOR; TRANSGENIC MICE; BREAST-CANCER; NECK-CANCER; MALIGNANT PROGRESSION; COLORECTAL-CANCER; GENE-EXPRESSION; MOUSE MODEL; C-MYC; SKIN	KLF4/GKLF normally functions in differentiating epithelial cells, but also acts as a transforming oncogene in vitro. To examine the role of this zinc finger protein in skin, we expressed the wild-type human allele from inducible and constitutive promoters. When induced in basal keratinocytes, KLF4 rapidly abolished the distinctive properties of basal and parabasal epithelial cells. KLF4 caused a transitory apoptotic response and the skin progressed through phases of hyperplasia and dysplasia. By 6 weeks, lesions exhibited nuclear KLF4 and other morphologic and molecular similarities to squamous cell carcinoma in situ. p53 determined the patch size sufficient to establish lesions, as induction in a mosaic pattern produced skin lesions only when p53 was deficient. Compared with p53 wild-type animals, p53 hemizygous animals had early onset of lesions and a pronounced fibrovascular response that included outgrowth of subcutaneous sarcoma. A KLF4-estrogen receptor fusion protein showed tamoxifen-dependent nuclear localization and conditional transformation in vitro. The results suggest that KLF4 can function in the nucleus to induce squamous epithelial dysplasia, and indicate roles for p53 and epithelial mesenchymal signaling in these early neoplastic lesions.	Univ Alabama Birmingham, Med Sch Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Ruppert, JM (corresponding author), Univ Alabama Birmingham, Med Sch Birmingham, Dept Med, Room 570 WTI,1824 6th Ave S, Birmingham, AL 35294 USA.	mruppert@uab.edu	Louro, Iuri D/I-8641-2012	Kammerud, Sarah/0000-0002-4808-1618; Louro, Iuri/0000-0001-5160-9615	NCI NIH HHS [CA094030, P50 CA089019, P30 CA013148, R01 CA094030, R29 CA065686, CA89019, R01 CA065686, P30CA13148, CA65686] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148, P50CA089019, R01CA094030, R01CA065686, R29CA065686] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; BOYLE JO, 1993, CANCER RES, V53, P4477; Brash DE, 1998, CANCER SURV, V32, P69; BROWN K, 1995, CANCER METAST REV, V14, P113, DOI 10.1007/BF00665795; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Coussens LM, 1996, AM J PATHOL, V149, P1899; Dang DT, 2003, ONCOGENE, V22, P3424, DOI 10.1038/sj.onc.1206413; DEAMANT FD, 1987, J CELL SCI, V88, P305; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Engel ME, 1998, J CELL BIOCHEM, P111; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Foster KW, 2000, CANCER RES, V60, P6488; Gao XH, 2002, J INVEST DERMATOL, V118, P998, DOI 10.1046/j.1523-1747.2002.01778.x; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hann B, 2001, CURR OPIN CELL BIOL, V13, P778, DOI 10.1016/S0955-0674(00)00283-0; Hennighausen L, 1995, J CELL BIOCHEM, V59, P463, DOI 10.1002/jcb.240590407; Hinnebusch BF, 2004, AM J PHYSIOL-GASTR L, V286, pG23, DOI 10.1152/ajpgi.00203.2003; Hoffman JA, 2003, CANCER CELL, V4, P383, DOI 10.1016/S1535-6108(03)00273-3; HORN TD, 1998, CUTANEOUS ONCOLOGY, P361; Jaubert J, 2003, DEVELOPMENT, V130, P2767, DOI 10.1242/dev.00477; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Katz JP, 2002, DEVELOPMENT, V129, P2619; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; King KE, 2003, J BIOL CHEM, V278, P11661, DOI 10.1074/jbc.M211337200; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu LH, 2001, J BIOL CHEM, V276, P26737, DOI 10.1074/jbc.C100275200; Louro ID, 2002, CANCER RES, V62, P5867; Mahatan CS, 1999, NUCLEIC ACIDS RES, V27, P4562, DOI 10.1093/nar/27.23.4562; Maillard I, 2003, CANCER CELL, V3, P203, DOI 10.1016/S1535-6108(03)00052-7; Mao L, 2004, CANCER CELL, V5, P311, DOI 10.1016/S1535-6108(04)00090-X; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; McGowan KM, 1998, J CELL BIOL, V143, P469, DOI 10.1083/jcb.143.2.469; NG YK, 1990, CELL DIFFER DEV, V30, P27, DOI 10.1016/0922-3371(90)90071-4; Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484; Sancho E, 2003, CURR OPIN CELL BIOL, V15, P763, DOI 10.1016/j.ceb.2003.10.012; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Ton-That H, 1997, FEBS LETT, V419, P239, DOI 10.1016/S0014-5793(97)01465-8; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; vanderVelden LA, 1997, EUR ARCH OTO-RHINO-L, V254, P376, DOI 10.1007/BF01642554; WEINBERG RA, 1989, CANCER RES, V49, P3713; Weiss RH, 2003, CANCER CELL, V4, P425, DOI 10.1016/S1535-6108(03)00308-8; Wu XM, 2001, TRENDS CELL BIOL, V11, pS2, DOI 10.1016/S0962-8924(01)82000-6; Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527; Xie W, 1999, ONCOGENE, V18, P3593, DOI 10.1038/sj.onc.1202673; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	63	160	171	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1491	1500		10.1038/sj.onc.1208307	http://dx.doi.org/10.1038/sj.onc.1208307			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674344	Green Accepted			2022-12-17	WOS:000227218200002
J	Iliopoulos, D; Guler, G; Han, SY; Johnston, D; Druck, T; McCorkell, KA; Palazzo, J; McCue, P; Baffa, R; Huebner, K				Iliopoulos, D; Guler, G; Han, SY; Johnston, D; Druck, T; McCorkell, KA; Palazzo, J; McCue, P; Baffa, R; Huebner, K			Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer	ONCOGENE			English	Article						CpG island methylation; WWOX; FHIT; methylation patterns; molecular markers	TUMOR-SUPPRESSOR GENE; ABERRANT PROMOTER METHYLATION; DNA METHYLATION; EXPRESSION; HYPERMETHYLATION; INACTIVATION; CARCINOMA; PROTEIN; SERUM; FRA16D	This study aimed to (a) determine if DNA methylation is a mechanism of WWOX (WW domain containing oxidoreductase) and FHIT ( fragile histidine triad) inactivation in lung, breast and bladder cancers; (b) examine distinct methylation patterns in neoplastic and adjacent tissues and (c) seek correlation of methylation patterns with disease status. Protein expression was detected by immunohistochemistry, and methylation status by methylation-specific PCR (MSP) and sequencing, in lung squamous cell carcinomas and adjacent tissues, invasive breast carcinomas, adjacent tissues and normal mammary tissues and bladder transitional cell carcinomas. Wwox and Fhit expression was reduced in cancers in association with hypermethylation. Differential patterns of WWOX and FHIT methylation were observed in neoplastic vs adjacent non-neoplastic tissues, suggesting that targeted MSP amplification could be useful in following treatment or prevention protocols. WWOX promoter MSP differentiates DNA of lung cancer from DNA of adjacent lung tissue. WWOX and FHIT promoter methylation is detected in tissue adjacent to breast cancer and WWOX exon 1 MSP distinguishes breast cancer DNA from DNA of adjacent and normal tissue. Differential methylation in cancerous vs adjacent tissues suggests that WWOX and FHIT hypermethylation analyses could enrich a panel of DNA methylation markers.	Dept Microbiol Immunol, Philadelphia, PA 19107 USA; Dept Pathol, Philadelphia, PA 19107 USA; Kimmel Canc Ctr, Dept Urol, Philadelphia, PA 19107 USA	Jefferson University	Huebner, K (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Wiseman Hall,Rm 455C,410 W 12th Ave, Columbus, OH 43210 USA.	K_Huebner@mail.jci.tju.edu	Iliopoulos, Dimitrios/AAE-9106-2019; GULER, GULNUR/I-9887-2013		NCI NIH HHS [CA77738, N01-CN-15128, N01-CN-15113, CA56036] Funding Source: Medline; NHLBI NIH HHS [T32-HLO7780] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077738, P30CA056036] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007780] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baffa R, 2000, AM J PATHOL, V156, P419, DOI 10.1016/S0002-9440(10)64745-1; Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Driouch K, 2002, ONCOGENE, V21, P1832, DOI 10.1038/sj.onc.1205273; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 1999, CANCER RES, V59, P793; Gatalica Z, 2000, CANCER-AM CANCER SOC, V88, P1378, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1378::AID-CNCR15>3.3.CO;2-9; Guler G, 2004, CANCER, V100, P1605, DOI 10.1002/cncr.20137; Hennessy BT, 2003, EXPERT OPIN INV DRUG, V12, P1985, DOI 10.1517/eoid.12.12.1985.21990; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Huebner K, 2003, BRIT J CANCER, V88, P1501, DOI 10.1038/sj.bjc.6600937; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Ingvarsson S, 1999, CANCER RES, V59, P2682; Ishii H, 2004, INT J HEMATOL, V79, P238, DOI 10.1532/IJH97.03145; Kim H, 2004, J CLIN ONCOL, V22, P2363, DOI 10.1200/JCO.2004.10.077; Kuroki T, 2004, CLIN CANCER RES, V10, P2459, DOI 10.1158/1078-0432.CCR-03-0096; Kuroki T, 2002, CANCER RES, V62, P2258; Maruyama R, 2001, CANCER RES, V61, P8659; McGregor F, 2002, CANCER RES, V62, P4757; Muller HM, 2003, CANCER RES, V63, P7641; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Palmisano WA, 2000, CANCER RES, V60, P5954; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; Skopelitou AS, 2001, IN VIVO, V15, P169; SORIA JC, 2000, CANCER RES, V62, P351; Sozzi G, 1998, CANCER RES, V58, P5032; Takai N, 2004, CLIN CANCER RES, V10, P1141, DOI 10.1158/1078-0432.CCR-03-0100; Tanaka H, 1998, CANCER RES, V58, P3429; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; Yang QF, 2002, CLIN CANCER RES, V8, P2890; Yendamuri S, 2003, CANCER RES, V63, P878; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	33	160	192	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1625	1633		10.1038/sj.onc.1208398	http://dx.doi.org/10.1038/sj.onc.1208398			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674328				2022-12-17	WOS:000227218200016
J	Tang, XH; Milyavsky, M; Shats, I; Erez, N; Goldfinger, N; Rotter, V				Tang, XH; Milyavsky, M; Shats, I; Erez, N; Goldfinger, N; Rotter, V			Activated p53 suppresses the histone methyltransferase EZH2 gene	ONCOGENE			English	Article						senescence; p53; EZH2; repression; HMTase; G2/M arrest	HUMAN-DIPLOID FIBROBLASTS; POLYCOMB-GROUP PROTEINS; LIFE-SPAN; CELL-DIFFERENTIATION; TELOMERASE ACTIVITY; SENESCENCE; MECHANISMS; EXPRESSION; PROLIFERATION; PATHWAY	Replicative senescence is an irreversible cell cycle arrest that limits the proliferation of damaged cells and may be an important tumor suppression mechanism in vivo. This process is regulated at critical steps by the tumor suppressor p53. To identify genes that may regulate the senescence process, we performed cDNA microarray analysis of gene expression in senescent, young proliferating, and hTERT-immortalized primary human fibroblasts. The histone methyltransferase (HMTase), EZH2, was specifically downregulated in senescent cells. Activated p53 suppressed EZH2 gene expression through repression of the EZH2 gene promoter. This activity of p53 requires intact p53 transactivation and DNA binding domains. Furthermore, the repression of EZH2 promoter by p53 is dependent on p53 transcriptional target p2l(waf1) inactivating RB/E2F pathways. In addition, the knockdown of EZH2 expression retards cell proliferation and induces G2/M arrest. We suggest that the p53-dependent suppression of EZH2 expression is a novel pathway that contributes to p53-mediated G2/M arrest. EZH2 associated complex possesses HMTase activity and is involved in epigenetic regulation. Activated p53 suppresses EZH2 expression, suggesting a further role for p53 in epigenetic regulation and in the maintenance of genetic stability. Suppression of EZH2 expression in tumors by p53 may lead to novel approaches to control cancer progression.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	varda.rotter@weizmann.ac.il	Tang, Xiaohu/AAX-4577-2021; Milyavsky, Michael/E-8306-2011; Shats, Igor/AAD-8775-2019	Shats, Igor/0000-0001-6449-5979; Erez, Neta/0000-0001-6506-9074				AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOND JA, 1994, ONCOGENE, V9, P1885; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Campisi J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/nrc1073; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Fukuyama T, 2000, BRIT J HAEMATOL, V108, P842, DOI 10.1046/j.1365-2141.2000.01914.x; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Hobert O, 1996, MOL CELL BIOL, V16, P3066; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Jones CA, 1998, MOL CELL BIOL, V18, P2825, DOI 10.1128/MCB.18.5.2825; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MACLEAN K, 1994, ONCOGENE, V9, P719; Mahmoudi T, 2001, ONCOGENE, V20, P3055, DOI 10.1038/sj.onc.1204330; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Offer H, 2002, CARCINOGENESIS, V23, P1025, DOI 10.1093/carcin/23.6.1025; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Raaphorst FM, 2000, J IMMUNOL, V164, P1, DOI 10.4049/jimmunol.164.1.1; Raaphorst FM, 2000, AM J PATHOL, V157, P709, DOI 10.1016/S0002-9440(10)64583-X; Rhodes DR, 2003, J NATL CANCER I, V95, P661, DOI 10.1093/jnci/95.9.661; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; Seluanov A, 2001, MOL CELL BIOL, V21, P1552, DOI 10.1128/MCB.21.5.1552-1564.2001; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAY JW, 1993, ONCOGENE, V8, P1407; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163; Zhang H, 2003, P NATL ACAD SCI USA, V100, P3251, DOI 10.1073/pnas.2627983100	66	160	186	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5759	5769		10.1038/sj.onc.1207706	http://dx.doi.org/10.1038/sj.onc.1207706			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15208672				2022-12-17	WOS:000222629800005
J	Liu, LM; Tommasi, S; Lee, DH; Dammann, R; Pfeifer, GP				Liu, LM; Tommasi, S; Lee, DH; Dammann, R; Pfeifer, GP			Control of microtubule stability by the RASSF1A tumor suppressor	ONCOGENE			English	Article						RASSF1A; mitosis; DNA methylation; microtubules; taxol	FREQUENT EPIGENETIC INACTIVATION; HUMAN-CHROMOSOME 3P21.3; PROMOTER HYPERMETHYLATION; CPG ISLAND; HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; BREAST CANCERS; BLADDER-CANCER; MITOTIC BLOCK; K-RAS	The RAS association domain family 1A ( RASSF1A) gene is silenced by DNA methylation in over 50% of all solid tumors of different histological types. However, the biochemical function of the RASSF1A protein is unknown. We show that RASSF1A colocalizes with microtubules in interphase and decorates spindles and centrosomes during mitosis. RASSF1A has a strong cytoprotective activity against the microtubule-destabilizing drug nocodazole, and against cold-treatment in vivo. Conversely, loss of RASSF1 in RASSF1(-/-) mouse embryonic fibroblasts renders the cells more sensitive to nocodazole-induced depolymerization of microtubules. The domain required for both microtubule association and stabilization was mapped to a 169 amino-acid fragment that contains the RAS association domain. Overexpression of RASSF1A induces mitotic arrest at metaphase with aberrant mitotic cells reminiscent of such produced by the microtubule-stabilizing drug paclitaxel (taxol), including monopolar spindles, or complete lack of a mitotic spindle. Altered microtubule stability in cells lacking RASSF1A is likely to affect spindle assembly and chromosome attachment, processes that need to be carefully controlled to protect cells from genomic instability and transformation. In addition, knowledge of the microtubule-targeting function of RASSF1 may aid in the development of new anticancer drugs.	City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA; Univ Halle Wittenberg, Inst Humangenet & Med Biol, D-06097 Halle Saale, Germany	City of Hope; Beckman Research Institute of City of Hope; Martin Luther University Halle Wittenberg	Pfeifer, GP (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.			Tommasi, Stella/0000-0001-6897-4985	NCI NIH HHS [CA88873] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088873] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBONDANZO SJ, 1993, METHOD ENZYMOL, V225, P803; Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan MWY, 2003, INT J CANCER, V104, P611, DOI 10.1002/ijc.10971; Chen Z, 2000, J BIOL CHEM, V275, P41251, DOI 10.1074/jbc.M006687200; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Honorio S, 2003, ONCOGENE, V22, P461, DOI 10.1038/sj.onc.1206119; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Jordan MA, 1996, CANCER RES, V56, P816; JORDAN MA, 1992, J CELL SCI, V102, P401; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kuzmin I, 2003, CANCER RES, V63, P1888; Kuzmin I, 2002, CANCER RES, V62, P3498; Lee MG, 2001, CANCER RES, V61, P6688; Lerman MI, 2000, CANCER RES, V60, P6116; Li YC, 2000, GENETICS, V156, P995; Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814; Lo KW, 2001, CANCER RES, V61, P3877; Lotti LV, 2002, GENE CHROMOSOME CANC, V35, P193, DOI 10.1002/gcc.10105; Lusher ME, 2002, CANCER RES, V62, P5906; Maruyama R, 2001, CANCER RES, V61, P8659; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Morrissey C, 2001, CANCER RES, V61, P7277; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Schagdarsurengin U, 2002, CANCER RES, V62, P3698; Schagdarsurengin U, 2003, ONCOGENE, V22, P1866, DOI 10.1038/sj.onc.1206338; Segal M, 2001, BIOESSAYS, V23, P307, DOI 10.1002/bies.1044; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Spugnardi M, 2003, CANCER RES, V63, P1639; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; Toyooka S, 2002, ONCOGENE, V21, P4340, DOI 10.1038/sj.onc.1205381; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Wagner KJ, 2002, ONCOGENE, V21, P7277, DOI 10.1038/sj.onc.1205922; Zhang YJ, 2002, MOL CARCINOGEN, V35, P85, DOI 10.1002/mc.10076; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	53	160	170	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8125	8136		10.1038/sj.onc.1206984	http://dx.doi.org/10.1038/sj.onc.1206984			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603253				2022-12-17	WOS:000186403400007
J	Hazlehurst, LA; Landowski, TH; Dalton, WS				Hazlehurst, LA; Landowski, TH; Dalton, WS			Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death	ONCOGENE			English	Review						drug resistance; adhesion; integains; microenvironment	FOCAL ADHESION KINASE; INTESTINAL EPITHELIAL-CELLS; MARROW STROMAL CELLS; U266 MYELOMA CELLS; FAMILY MEMBER BIM; CAM-DR; CYCLE PROGRESSION; ENDOTHELIAL-CELLS; MULTIPLE-MYELOMA; TYROSINE KINASE	The emergence of clinical drug resistance continues to be an obstacle for the successful treatment of cancer. Our current understanding of mechanisms associated with drug resistance has been ascertained by investigating drug-resistant models created by exposing a parental population to increasing concentrations of a cytotoxic. These unicellular drug-resistant models have been critical in elucidating drug-resistant mechanism and in some cases have aided in the identification of drug targets. However, these models do not address resistance mechanisms that contribute to de novo drug resistance. We propose that specific niches within the tumor microenvironment may provide a sanctuary for subpopulations of tumors cells that affords a survival advantage following initial drug exposure and may facilitate the acquisition of acquired drug resistance. More specifically, we propose that the bone marrow microenvironment is a sanctuary for hematopoietic cancers. This review will focus on the bone marrow microenvironment and its role in conferring resistance to cytotoxics and physiological mediators of cell death.	Univ S Florida, H Lee Moffitt Canc Ctr, Clin Invest Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Dalton, WS (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr, Clin Invest Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.							Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; Astier A, 1997, J BIOL CHEM, V272, P228; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; Blagosklonny MV, 2002, LEUKEMIA, V16, P570, DOI 10.1038/sj.leu.2402409; BOHNSACK JF, 1994, BLOOD, V83, P543; Bouillet P, 2002, J CELL SCI, V115, P1567; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CherbonnelLasserre C, 1996, ONCOGENE, V13, P1489; Coll ML, 2002, ONCOGENE, V21, P2908, DOI 10.1038/sj.onc.1205388; Cook G, 1997, ACTA HAEMATOL-BASEL, V97, P81; DALTON WS, 1992, HEMATOL ONCOL CLIN N, V6, P383, DOI 10.1016/S0889-8588(18)30351-4; Damiano JS, 2000, LEUKEMIA LYMPHOMA, V38, P71, DOI 10.3109/10428190009060320; Damiano JS, 2001, LEUKEMIA, V15, P1232, DOI 10.1038/sj.leu.2402179; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Dias S, 2002, BLOOD, V99, P2179, DOI 10.1182/blood.V99.6.2179; DURAND RE, 1972, EXP CELL RES, V71, P75, DOI 10.1016/0014-4827(72)90265-0; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; Fortney JE, 2001, LEUKEMIA RES, V25, P901, DOI 10.1016/S0145-2126(01)00051-0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; HAMDAN HF, 1992, ONCOL RES, V4, P210; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hazlehurst LA, 2001, CANCER METAST REV, V20, P43, DOI 10.1023/A:1013156407224; Hazlehurst LA, 2001, BLOOD, V98, P1897, DOI 10.1182/blood.V98.6.1897; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hochhaus A, 2001, SCIENCE, V293, P2163; Hoyt DG, 1996, CANCER RES, V56, P4146; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hurley RW, 1997, EXP HEMATOL, V25, P321; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; JENSEN GS, 1993, AM J HEMATOL, V43, P29, DOI 10.1002/ajh.2830430108; Jiang YH, 2000, BLOOD, V95, P846, DOI 10.1182/blood.V95.3.846.003k31_846_854; Jones CB, 2001, MOL PHARMACOL, V59, P69, DOI 10.1124/mol.59.1.69; KOOPMAN G, 1994, J IMMUNOL, V152, P3760; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Lundell BI, 1996, BLOOD, V87, P2450, DOI 10.1182/blood.V87.6.2450.bloodjournal8762450; MacGillivray MK, 2000, J BIOL CHEM, V275, P23509, DOI 10.1074/jbc.M003186200; NEFEDOVA Y, ASH ABSTR, V2983; Ohmori T, 1998, EXP CELL RES, V245, P350, DOI 10.1006/excr.1998.4261; Oloumi A, 2000, CANCER RES, V60, P5747; Oshiro MM, 2001, CLIN CANCER RES, V7, P4262; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Potocnik AJ, 2000, IMMUNITY, V12, P653, DOI 10.1016/S1074-7613(00)80216-2; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Sawyers CL, 2001, SCIENCE, V294, P1834; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Shain KH, 2002, J IMMUNOL, V168, P2544, DOI 10.4049/jimmunol.168.5.2544; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Simonian PL, 1997, BLOOD, V90, P1208, DOI 10.1182/blood.V90.3.1208.1208_1208_1216; St Croix B, 1998, CANCER LETT, V131, P35, DOI 10.1016/S0304-3835(98)00199-2; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; StCroix B, 1996, NAT MED, V2, P1204; Taylor ST, 2000, J NATL CANCER I, V92, P18, DOI 10.1093/jnci/92.1.18; TEICHER BA, 1990, SCIENCE, V247, P1457, DOI 10.1126/science.2108497; Teicher BA, 1997, IN VIVO, V11, P463; Tiberio R, 2002, FEBS LETT, V524, P139, DOI 10.1016/S0014-5793(02)03040-5; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Wang MWJ, 1998, CELL GROWTH DIFFER, V9, P105; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Xu WM, 2000, NAT CELL BIOL, V2, P339, DOI 10.1038/35014028	70	160	177	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 20	2003	22	47					7396	7402		10.1038/sj.onc.1206943	http://dx.doi.org/10.1038/sj.onc.1206943			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576847				2022-12-17	WOS:000186112500012
J	Kamsteeg, M; Rutherford, T; Sapi, E; Hanczaruk, B; Shahabi, S; Flick, M; Brown, D; Mor, G				Kamsteeg, M; Rutherford, T; Sapi, E; Hanczaruk, B; Shahabi, S; Flick, M; Brown, D; Mor, G			Phenoxodiol - an isoflavone analog - induces apoptosis in chemoresistant ovarian cancer cells	ONCOGENE			English	Article						phenoxodiol; apoptosis; XIAP; ovarian cancer; Fas	FAS/FAS-LIGAND SYSTEM; FAS-MEDIATED APOPTOSIS; CD95-MEDIATED APOPTOSIS; SIGNALING COMPLEX; TUMOR-CELLS; C-FLIP; DEATH; EXPRESSION; ESTROGEN; INHIBITION	Interference with the innate apoptotic activity is a hallmark of neoplastic transformation and tumor formation. In this study we characterize the cytotoxic effect of phenoxodiol, a synthetic anticancer drug analog of genestein, and demonstrate the mechanism of action by which phenoxodiol affects the components of the Fas apoptotic pathway on ovarian cancer cells. Primary ovarian cancer cells, isolated from ascitic fluids of ovarian cancer patients, resistant to conventional chemotherapy, undergo apoptosis following phenoxodiol treatment. This effect is dependent upon the activation of the caspase system, inhibiting XIAP, an inhibitor of apoptosis, and disrupting FLICE inhibitory protein (FLIP) expression through the Akt signal transduction pathway. We suggest that phenoxodiol is an efficient inducer of cell death in ovarian cancer cells and sensitizes the cancer cells to Fas-mediated apoptosis. We identified FLIP and XIAP signalling pathways as key factors regulating the survival of ovarian cancer cells. These findings demonstrate a novel nontoxic drug that controls FLIP/XIAP function and has the potential to eliminate tumor cells through Fas-mediated apoptosis.	Yale Univ, Sch Med, Dept Obstet & Gynecol, New Haven, CT 06520 USA	Yale University	Mor, G (corresponding author), Yale Univ, Sch Med, Dept Obstet & Gynecol, 333 Cedar St, New Haven, CT 06520 USA.		Kamsteeg, M./L-4422-2015		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037137] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA092435] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA92435-01] Funding Source: Medline; NICHD NIH HHS [R01 HD37137-01A2] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aschkenazi S, 2002, BIOL REPROD, V66, P1853, DOI 10.1095/biolreprod66.6.1853; Baldwin RL, 1999, GYNECOL ONCOL, V74, P265, DOI 10.1006/gyno.1999.5448; BERCHUCK A, 1994, J SOC GYNECOL INVEST, V1, P181, DOI 10.1177/107155769400100302; Constantinou AI, 2002, ANTICANCER RES, V22, P2581; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; FLICK M, UNPUB; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; GREENE MH, 1984, SEMIN ONCOL, V11, P209; Gutierrez LS, 1999, BREAST CANCER RES TR, V54, P245, DOI 10.1023/A:1006102601215; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HUGHES FM, 1991, ENDOCRINOLOGY, V129, P2415, DOI 10.1210/endo-129-5-2415; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Lamartiniere CA, 1998, P SOC EXP BIOL MED, V217, P358, DOI 10.3181/00379727-217-44245; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Mor G, 2002, BIOCHEM PHARMACOL, V64, P1305, DOI 10.1016/S0006-2952(02)01267-4; Mor G, 2001, AM J REPROD IMMUNOL, V46, P298, DOI 10.1034/j.1600-0897.2001.d01-16.x; Mori T, 1997, HORM RES, V48, P11, DOI 10.1159/000191295; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; ODWYER PJ, 1994, CANCER RES, V54, P724; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Peter M E, 1999, Results Probl Cell Differ, V23, P25; Quirk SM, 1997, ENDOCRINOLOGY, V138, P4558, DOI 10.1210/en.138.11.4558; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Rohn JL, 1998, ONCOGENE, V17, P2811, DOI 10.1038/sj.onc.1202393; Roughton SA, 1999, BIOL REPROD, V60, P797, DOI 10.1095/biolreprod60.4.797; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sapi E, 2002, J SOC GYNECOL INVEST, V9, P243, DOI 10.1016/S1071-5576(02)00162-4; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Song J, 2000, J CLIN INVEST, V106, P1209, DOI 10.1172/JCI10411; Song J, 2002, MOL HUM REPROD, V8, P447, DOI 10.1093/molehr/8.5.447; Song RXD, 2001, J NATL CANCER I, V93, P1714, DOI 10.1093/jnci/93.22.1714; Suhara T, 2001, CIRC RES, V89, P13, DOI 10.1161/hh1301.092506; Tilly J L, 1996, Rev Reprod, V1, P162, DOI 10.1530/revreprod/1.3.162; Tilly JL, 2001, NAT REV MOL CELL BIO, V2, P838, DOI 10.1038/35099086; Weber G, 2000, EUR J GYNAECOL ONCOL, V21, P231; Xerri L, 1997, J CLIN PATHOL-MOL PA, V50, P87, DOI 10.1136/mp.50.2.87	42	160	174	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2611	2620		10.1038/sj.onc.1206422	http://dx.doi.org/10.1038/sj.onc.1206422			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730675				2022-12-17	WOS:000182569000009
J	Thomas, M; Laura, R; Hepner, K; Guccione, E; Sawyers, C; Lasky, L; Banks, L				Thomas, M; Laura, R; Hepner, K; Guccione, E; Sawyers, C; Lasky, L; Banks, L			Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation	ONCOGENE			English	Article						HPV E6; MAGUK; PDZ; MAGI	LARGE TUMOR-SUPPRESSOR; PROTEASOME-MEDIATED DEGRADATION; DISCS LARGE PROTEIN; GUANYLATE-KINASE; PDZ DOMAIN; PHOSPHOINOSITIDE 3-KINASE; SIGNALING PATHWAYS; EPITHELIAL-CELLS; PLASMA-MEMBRANE; TIGHT JUNCTIONS	The E6 proteins from the high-risk human papillomavirus (HPV) types have previously been shown to target a number of PDZ domain-containing proteins for proteasome-mediated degradation. These include the hDIg tumour suppressor and the MAGI-I protein. In this study we show that high-risk HPV E6 proteins also target the related MAGI-2 and MAGI-3 proteins for degradation. Moreover, we show that the interaction is specific to one PDZ domain, and that co-expression of this domain can protect each of the full-length MAGI proteins from E6-mediated degradation. These data provide clear indicators for the potential design of compounds that could specifically inhibit the interaction of oncogenic HPV E6 proteins with an important class of target proteins.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA	International Center for Genetic Engineering & Biotechnology (ICGEB); Roche Holding; Genentech; University of California System; University of California Los Angeles	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	banks@icgeb.org	Sawyers, Charles/G-5327-2016; guccione, ernesto/G-9874-2011					Adey NB, 2000, CANCER RES, V60, P35; ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Choi J, 2002, J BIOL CHEM, V277, P12359, DOI 10.1074/jbc.M200528200; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Dobrosotskaya IY, 2001, BIOCHEM BIOPH RES CO, V283, P969, DOI 10.1006/bbrc.2001.4880; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; FRANCO EL, 1992, CANCER EPIDEM BIOMAR, V1, P499; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Kuhne C, 2000, ONCOGENE, V19, P5884, DOI 10.1038/sj.onc.1203988; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Leslie NR, 2001, BIOCHEM J, V357, P427, DOI 10.1042/0264-6021:3570427; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Li J, 1998, CANCER RES, V58, P5667; Mantovani F, 2001, J CELL SCI, V114, P4285; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; PIM D, 1994, ONCOGENE, V9, P1869; PIM D, 2001, VIRUSES CELL TRANSFO, P145; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shoji H, 2000, J BIOL CHEM, V275, P5485, DOI 10.1074/jbc.275.8.5485; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Tolkacheva T, 2000, ONCOGENE, V19, P680, DOI 10.1038/sj.onc.1203331; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199	56	160	171	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5088	5096		10.1038/sj.onc.1205668	http://dx.doi.org/10.1038/sj.onc.1205668			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140759				2022-12-17	WOS:000176975900007
J	Heckman, CA; Mehew, JW; Boxer, LM				Heckman, CA; Mehew, JW; Boxer, LM			NF-kappa B activates Bcl-2 expression in t(14;18) lymphoma cells	ONCOGENE			English	Article						bcl-2; lymphoma; transcription; NF-kappa B	UP-REGULATES BCL-2; ANTISENSE OLIGONUCLEOTIDES ENHANCE; BREAST-CANCER CELLS; TRANSCRIPTION FACTOR; FOLLICULAR LYMPHOMA; RESPONSE ELEMENT; CREB PROTEINS; E-SELECTIN; T-CELLS; C-REL	The t(14;18) translocation, which is characteristic of follicular lymphoma, results in the overexpression of the bcl-2 gene dependent upon regulatory elements within the bcl-2 5' flanking region and the immunoglobulin heavy chain gene enhancers. Conflicting evidence exists on the effects of NF-kappaB expression on Bel-2 levels in different cell types. Lymphoma cells with the t(141;18) translocation show high levels of nuclear NF-kappaB proteins. We observed decreased levels of endogenous Bcl-2 when the IkappaBchi-super-repressor was expressed in a t(14;18) cell line. Deletion analysis of the bcl-2 promoter indicated that the repressive effect of the IkappaBalpha-super-repressor occurred through a region that contained no NF-kappaB consensus sequences. This highly active region contained a c-AMP response element (CRE) and several Sp1 binding sites. Chromatin immunoprecipitation assays with antibodies specific for the NF-kappaB and CREB/ATF family members, as well as Sp1, resulted in the isolation of this IkappaBalpha-super-repressor responsive region of the bcl-2 promoter. Mutation of the CRE and the two Sp1 sites in different combinations in bel-2 reporter constructs resulted in the loss of bcl-2 promoter repression by the IkappaBalpha-super-repressor. We therefore conclude that the activation of bcl-2 by NF-kappaB in t(14;18) lymphoma cells is mediated through the CRE and Sp1 binding sites.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Ctr Mol Biol Med, Stanford, CA 94305 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Boxer, LM (corresponding author), Stanford Univ, Sch Med, Dept Med, CCSR 1155, Stanford, CA 94305 USA.			Heckman, Caroline/0000-0002-4324-8706	NATIONAL CANCER INSTITUTE [R01CA056764, R56CA056764] Funding Source: NIH RePORTER; NCI NIH HHS [CA 56764] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Butscher WG, 1998, J BIOL CHEM, V273, P552, DOI 10.1074/jbc.273.1.552; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CRAWFORD MJ, 2001, BIOCHEM BIOPH RES CO, V281, P1034; de Moissac D, 1999, J BIOL CHEM, V274, P29505, DOI 10.1074/jbc.274.41.29505; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Feng ZW, 1999, J BIOL CHEM, V274, P30341, DOI 10.1074/jbc.274.43.30341; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Goff LK, 2000, BRIT J HAEMATOL, V111, P618, DOI 10.1046/j.1365-2141.2000.02352.x; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Heckman C, 1997, J BIOL CHEM, V272, P19609, DOI 10.1074/jbc.272.31.19609; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; HEWITT SM, 1995, CANCER RES, V55, P5386; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; Klasa RJ, 2000, CLIN CANCER RES, V6, P2492; Konopleva M, 2000, BLOOD, V95, P3929; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; Munzert G, 2000, LEUKEMIA LYMPHOMA, V38, P395, DOI 10.3109/10428190009087031; Pepper C, 2001, LEUKEMIA LYMPHOMA, V42, P491, DOI 10.3109/10428190109064606; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Phan SC, 1996, MOL CELL BIOL, V16, P2387; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Romero F, 1999, EMBO J, V18, P3419, DOI 10.1093/emboj/18.12.3419; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SIF S, 1993, ONCOGENE, V8, P2501; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wacheck V, 2001, J MOL MED-JMM, V79, P587, DOI 10.1007/s001090100251; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	57	160	166	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3898	3908		10.1038/sj.onc.1205483	http://dx.doi.org/10.1038/sj.onc.1205483			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032828				2022-12-17	WOS:000175847200009
J	Segrelles, C; Ruiz, S; Perez, P; Murga, C; Santos, M; Budunova, IV; Martinez, J; Larcher, F; Slaga, TJ; Gutkind, JS; Jorcano, JL; Paramio, JM				Segrelles, C; Ruiz, S; Perez, P; Murga, C; Santos, M; Budunova, IV; Martinez, J; Larcher, F; Slaga, TJ; Gutkind, JS; Jorcano, JL; Paramio, JM			Functional roles of Akt signaling in mouse skin tumorigenesis	ONCOGENE			English	Article						skin carcinogenesis; signal transduction; ras; Akt; PTEN	INTEGRIN-LINKED KINASE; PROTEIN-COUPLED RECEPTORS; GROWTH-FACTOR RECEPTOR; TUMOR-SUPPRESSOR GENE; CYCLIN D1; PHOSPHOINOSITIDE 3-KINASE; PREMALIGNANT PROGRESSION; INCREASING COMPLEXITY; RAS TRANSFORMATION; CELL-PROLIFERATION	The mouse skin carcinogenesis protocol is a unique model for understanding the molecular events leading to oncogenic transformation. Mutations in the Ha-ras gene, and the presence of functional cyclin D1 and the EGF receptor, have proven to he important in this system. However, the signal transduction pathways connecting these elements during mouse skin carcinogenesis are poorly understood. This paper studies the relevance of the Akt and ERK pathways in the different stages of chemically induced mouse skin tumors. Akt activity increases throughout the entire process, and its early activation is detected prior to increased cyclin D1 expression. ERK activity rises only during the later stages of malignant conversion. The observed early increase in Akt activity appears to be due to raised PI-3K activity. Other factors acting on Akt such as ILK activation and decreased PTEN phosphatase activity appear to be involved at the conversion stage. To further confirm the involvement of Akt in this process, PB keratinocytes were transfected with Akt and subsequently injected into nude mice. The expression of Akt accelerates tumorigenesis and contributes to increased malignancy of these keratinocytes as demonstrated by the rate of appearance, the growth and the histological characteristics of the tumors. Collectively, these data provide evidence that Akt activation is one of the key elements during the different steps of mouse skin tumorigenesis.	CIEMAT, Program Cell & Mol Biol & Gene Therapy, E-28040 Madrid, Spain; NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; AMC Canc Res Ctr, Denver, CO 80214 USA	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); AMC Cancer Research Center	Paramio, JM (corresponding author), CIEMAT, Program Cell & Mol Biol & Gene Therapy, Ed 7,Av Complutense 22, E-28040 Madrid, Spain.		Larcher, Fernando/J-1527-2016; Paramio, Jesus M/M-8482-2014; Santos, Mirentxu/AAA-1727-2020; Murga, Cristina/E-1965-2014; Gutkind, J. Silvio/A-1053-2009; Perez, Paloma/K-8841-2017; Gutkind, J. Silvio/J-1201-2016; Segrelles, Carmen/E-3655-2016; Ruiz, Sergio/G-1561-2016	Larcher, Fernando/0000-0002-6771-3561; Paramio, Jesus M/0000-0001-7520-3177; Murga, Cristina/0000-0002-8964-4077; Perez, Paloma/0000-0002-7166-2824; Gutkind, J. Silvio/0000-0002-5150-4482; Segrelles, Carmen/0000-0001-9340-2102; Ruiz, Sergio/0000-0002-0177-6965	NATIONAL CANCER INSTITUTE [R01CA079065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558, Z01DE000551] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA79065-01, CA79065-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Conti C. J, 1994, HDB MOUSE MUTATIONS, P39; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; DIAZGUERRA M, 1992, CANCER RES, V52, P680; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DiGiovanni J, 2000, CANCER RES, V60, P1561; Dlugosz AA, 1997, CANCER RES, V57, P3180; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GIMENEZCONTI I, 1990, CARCINOGENESIS, V11, P1995, DOI 10.1093/carcin/11.11.1995; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; Hansen LA, 2000, CANCER RES, V60, P3328; HARPER JR, 1987, CARCINOGENESIS, V8, P1821, DOI 10.1093/carcin/8.12.1821; LARCHER F, 1992, MOL CARCINOGEN, V6, P112, DOI 10.1002/mc.2940060206; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Paramio JM, 1999, ONCOGENE, V18, P7462, DOI 10.1038/sj.onc.1203151; Paramio JM, 2001, MOL CELL BIOL, V21, P7449, DOI 10.1128/MCB.21.21.7449-7459.2001; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rodriguez-Puebla ML, 1999, CELL GROWTH DIFFER, V10, P467; Rodriguez-Puebla ML, 1998, ONCOGENE, V17, P2251, DOI 10.1038/sj.onc.1202131; Rodriguez-Puebla ML, 1999, MOL CARCINOGEN, V26, P150, DOI 10.1002/(SICI)1098-2744(199911)26:3<150::AID-MC3>3.0.CO;2-P; Rodriguez-Viciana P, 2001, METHOD ENZYMOL, V333, P37; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Tolkacheva T, 2000, ONCOGENE, V19, P680, DOI 10.1038/sj.onc.1203331; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Xie W, 1998, AM J PATHOL, V153, P367, DOI 10.1016/S0002-9440(10)65580-0; YUSPA SH, 1986, CARCINOGENESIS, V7, P949, DOI 10.1093/carcin/7.6.949; YUSPA SH, 1994, CANCER RES, V54, P1178; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	61	160	160	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2002	21	1					53	64		10.1038/sj.onc.1205032	http://dx.doi.org/10.1038/sj.onc.1205032			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791176				2022-12-17	WOS:000172887800006
J	Tsuchiya, T; Tamura, G; Sato, K; Endoh, Y; Sakata, K; Jin, Z; Motoyama, T; Usuba, O; Kimura, W; Nishizuka, S; Wilson, KT; James, SP; Yin, J; Fleisher, AS; Zou, TT; Silverberg, SG; Kong, DH; Meltzer, SJ				Tsuchiya, T; Tamura, G; Sato, K; Endoh, Y; Sakata, K; Jin, Z; Motoyama, T; Usuba, O; Kimura, W; Nishizuka, S; Wilson, KT; James, SP; Yin, J; Fleisher, AS; Zou, TT; Silverberg, SG; Kong, DH; Meltzer, SJ			Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia	ONCOGENE			English	Article						hvpermethylation; APC; gastric cancer	MUTATION CLUSTER REGION; POLYPOSIS-COLI GENE; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; BETA-CATENIN; CELL-LINES; HYPERMETHYLATION; IDENTIFICATION; CARCINOMA; STOMACH	The adenomatous polyposis coli (APC) tumor suppressor gene is mutationally inactivated in both familial and sporadic forms of colorectal cancers. In addition, hypermethylation of CpG islands in the upstream portion of APC, a potential alternative mechanism of tumor suppressor gene inactivation, has been described in colorectal cancer. Because a subset of both gastric and colorectal cancers display the CpG island methylator phenotype, we hypothesized that epigenetic inactivation of APC was likely to occur in at least some gastric cancers, APC exhibits two forms of transcripts from exons 1A and 1B in the stomach. Therefore, we investigated CpG island methylation in the sequences upstream off sons 1A and 1B, i.e., promoters 1A and 1B, respectively. We evaluated DNAs from 10 gastric cancer cell lines, 40 primary gastric cancers, and 40 matching non-cancerous gastric mucosae, Methylated alleles of promoter 1A were present in 10 (100%) of 10 gastric cancer cell lines, 33 (82.5%) of 40 primary gastric cancers, and 39 (97.5%) of 40 non-cancerous gastric mucosae. In contrast, promoter 1B was unmethylated in all of these same samples, APC transcripts from exon 1A were not expressed in nine of the 10 methylated gastric cancer cell lines, whereas APC transcripts were expressed from exon 1B. Thus, expression from a given promoter correlated well with its methylation status. We conclude that in contrast to the colon, methylation of promoter 1A is a normal el ent in the stomach; moreover, promoter 1B is protected from methylation in the stomach and thus probably does not participate in this form of epigenetic APC inactivation.	Yamagata Univ, Sch Med, Dept Pathol, Yamagata 9909585, Japan; Yamagata Univ, Sch Med, Dept Surg, Yamagata 9909585, Japan; Univ Calif Irvine, Irvine Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA	Yamagata University; Yamagata University; University of California System; University of California Irvine; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Tsuchiya, T (corresponding author), Yamagata Univ, Sch Med, Dept Pathol, 2-2-2 Iida Nishi, Yamagata 9909585, Japan.			Wilson, Keith/0000-0003-4421-1830	NATIONAL CANCER INSTITUTE [R01CA078843, U01CA085069, R01CA077057] Funding Source: NIH RePORTER; NCI NIH HHS [CA77057, CA85069, CA78843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Fleisher AS, 1999, CANCER RES, V59, P1090; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2; HORII A, 1993, HUM MOL GENET, V2, P283, DOI 10.1093/hmg/2.3.283; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kuismanen SA, 1999, P NATL ACAD SCI USA, V96, P12661, DOI 10.1073/pnas.96.22.12661; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; NISHIMURA K, 1995, INT J ONCOL, V7, P587; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Nishizuka S, 1998, J PATHOL, V185, P38, DOI 10.1002/(SICI)1096-9896(199805)185:1<38::AID-PATH58>3.0.CO;2-T; OGASAWARA S, 1994, VIRCHOWS ARCH, V424, P607, DOI 10.1007/BF01069740; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; OSHIMA M, 1993, CANCER RES, V53, P5589; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; POWELL SM, 1994, GASTROENTEROLOGY, V107, P1759, DOI 10.1016/0016-5085(94)90818-4; Powell SM, 1996, ONCOGENE, V12, P1953; RHYU MG, 1994, GASTROENTEROLOGY, V106, P1584, DOI 10.1016/0016-5085(94)90414-6; Sparks AB, 1998, CANCER RES, V58, P1130; Suzuki H, 1999, INT J CANCER, V83, P309, DOI 10.1002/(SICI)1097-0215(19991029)83:3<309::AID-IJC4>3.0.CO;2-Z; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569; Tamura G, 1996, CANCER RES, V56, P612; Toyota M, 1999, CANCER RES, V59, P2307; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681	29	160	169	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3642	3646		10.1038/sj.onc.1203704	http://dx.doi.org/10.1038/sj.onc.1203704			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951570				2022-12-17	WOS:000088568300010
J	Stickeler, E; Kittrell, F; Medina, D; Berget, SM				Stickeler, E; Kittrell, F; Medina, D; Berget, SM			Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis	ONCOGENE			English	Article						SR splicing factors; alternative splicing; CD44; mammary tumorigenesis; mouse model	HUMAN BREAST-CANCER; MESSENGER-RNA; VARIANT ISOFORMS; PREMESSENGER RNA; OVARIAN-CANCER; SITE SELECTION; PROTEIN FAMILY; CD44 ISOFORMS; CELL-LINES; IN-VIVO	Using a mouse model of mammary gland development and tumorigenesis ne examined changes in both alternative splicing and splicing factors in multiple stages of mammary cancer. The emphasis was on the SR family of splicing factors known to influence alternative splicing in a wide variety of genes, and on alternative splicing of the pre-mRNA encoding CD44, for which alternative splicing has been implicated as important in a number of human cancers, including breast cancer. We observed step-wise increases in expression of individual SR proteins and alternative splicing of CD44 mRNA during mammary gland tumorigenesis. Individual preneoplasias differed as to their expression patterns for SR proteins, often expressing only a sub-set of the family. In contrast, tumors demonstrated a complex pattern of SR expression. Little difference nas observed between neoplasias and their metastases. Alternative splicing of CD44 also changed through the disease paradigm such that tumors produced RNA containing a mixture of variable exons, whereas preneoplasias exhibited a more restricted exon inclusion pattern. In contrast, other standard splicing factors changed little in either concentration or splicing pattern in the same cells. These data suggest alterations in relative concentrations of specific splicing factors during early preneoplasia that become more pronounced during tumor formation. Given the ability of SR proteins to affect alternative processing decisions, our results suggest that a number of pre-mRNAs may undergo changes in alternative splicing during the early and intermediate stages of mammary cancer.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Berget, SM (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Houston, TX 77030 USA.		Stickeler, Elmar/AHE-9022-2022		NATIONAL CANCER INSTITUTE [R01CA047112] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47112] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bell MV, 1998, MOL CELL BIOL, V18, P5930, DOI 10.1128/MCB.18.10.5930; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BLACK DL, 1995, RNA, V1, P763; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CACERES JF, 1997, MAMMALIAN PRE MRNA S, P174; CANNISTRA SA, 1995, J CLIN ONCOL, V13, P1912, DOI 10.1200/JCO.1995.13.8.1912; CARDIFF RD, 1988, ANTICANCER RES, V8, P925; Chandler SD, 1997, P NATL ACAD SCI USA, V94, P3596, DOI 10.1073/pnas.94.8.3596; EAST JA, 1993, EUR J CANCER, V29A, P1921, DOI 10.1016/0959-8049(93)90442-I; FOX SB, 1994, CANCER RES, V54, P4539; FRIEDRICHS K, 1995, LANCET, V345, P1237, DOI 10.1016/S0140-6736(95)92018-8; FU XD, 1995, RNA, V1, P663; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; Gunthert U, 1993, Curr Top Microbiol Immunol, V184, P47; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HAYNES BF, 1991, CANCER CELL-MON REV, V3, P347; Heider KH, 1995, EUR J CANCER, V31A, P2385, DOI 10.1016/0959-8049(95)00420-3; JERRY DJ, 1993, CANCER RES, V53, P3374; JOENSUU H, 1993, AM J PATHOL, V143, P867; KAUFMANN M, 1995, LANCET, V345, P615, DOI 10.1016/S0140-6736(95)90521-9; KITTRELL FS, 1992, CANCER RES, V52, P1924; Konig H, 1998, EMBO J, V17, P2904, DOI 10.1093/emboj/17.10.2904; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Lee MP, 1997, CANCER RES, V57, P3131; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MEDINA D, 1996, MAMMARY TUMOR CELL C, P37; Moore M., 1993, RNA WORLD, P303; Muller W, 1997, J PATHOL, V183, P222, DOI 10.1002/(SICI)1096-9896(199710)183:2<222::AID-PATH923>3.0.CO;2-C; Neugebauer KM, 1997, GENE DEV, V11, P1148, DOI 10.1101/gad.11.9.1148; NORTON PA, 1994, J CELL SCI, V107, P1; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; RIO DC, 1993, CURR OPIN GENET DEV, V3, P574, DOI 10.1016/0959-437X(93)90093-5; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Sinn Hans-Peter, 1995, Breast Cancer Research and Treatment, V36, P307, DOI 10.1007/BF00713402; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; Stickeler E, 1997, ANTICANCER RES, V17, P1871; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; Tran TA, 1997, HUM PATHOL, V28, P809, DOI 10.1016/S0046-8177(97)90154-4; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; WANG J, 1995, RNA, V1, P335; WIELENGA VJM, 1993, CANCER RES, V53, P4754; ZAHLER AM, 1993, MOL CELL BIOL, V13, P4023, DOI 10.1128/MCB.13.7.4023; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; Zhu X, 1997, INT J CANCER, V72, P574, DOI 10.1002/(SICI)1097-0215(19970807)72:4<574::AID-IJC4>3.3.CO;2-Y	54	160	167	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	1999	18	24					3574	3582		10.1038/sj.onc.1202671	http://dx.doi.org/10.1038/sj.onc.1202671			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380879				2022-12-17	WOS:000080891700003
J	Williams, AC; Collard, TJ; Paraskeva, C				Williams, AC; Collard, TJ; Paraskeva, C			An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: implications for clonal selection during colorectal carcinogenesis	ONCOGENE			English	Article						pH; apoptosis; colon; p53; pRb	WILD-TYPE P53; INTRACELLULAR PH; TGF-BETA(1)-INDUCED APOPTOSIS; CANCER-CELLS; CYCLE ARREST; TUMOR; ENDONUCLEASE; EXPRESSION; INHIBITION; GROWTH	As tumours are known to acidify their microenvironment and fluctuations in lumenal pH have been reported in a number of colonic disease conditions, we investigated whether lass of p53 function, commonly associated with the adenoma to carcinoma transition in human colorectal epithelium, was implicated in the cellular response to changes in extracellular pH, Human colonic adenoma and carcinoma derived cell lines were incubated at an inital pH range of 5.5-8.0 and the attached cell yield and apoptotic cell yield determined after 4 days. Exposure of all cell lines to an acidic growth environment was associated with a G1 arrest, down regulation of the retinoblastoma protein (pRb) protein and snitch to the hypophosphorylated form of the protein, and increased expression of the p21 protein, However, induction of apoptosis, associated with increased p53 protein expression but not,vith changes in Bcl-2 expression was only detected in the adenoma derived BH/C1 and AA/C1 cell lines which express wild type p53 activity. Furthermore, this induction of apoptosis Has inhibited in the transfected cell line AA/273p53/B, in which the wild type p53 function has been abrogated. These results suggest that acidification of the microenvironment would provide a selective growth advantage for cells that have lost wild type p53 function, leading to clonal expansion of aberrant cell populations.	Univ Bristol, Sch Med Sci, CRC,Dept Pathol & Microbiol, Colorectal Tumour Biol Res Grp, Bristol BS8 1TD, Avon, England	University of Bristol	Williams, AC (corresponding author), Univ Bristol, Sch Med Sci, CRC,Dept Pathol & Microbiol, Colorectal Tumour Biol Res Grp, Univ Walk, Bristol BS8 1TD, Avon, England.			Williams, Ann/0000-0002-6009-7137				BAKER SJ, 1990, CANCER RES, V50, P7717; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BEDI A, 1995, CANCER RES, V55, P1811; BRACEY TS, 1995, ONCOGENE, V10, P2391; Butt AJ, 1997, CELL DEATH DIFFER, V4, P725, DOI 10.1038/sj.cdd.4400293; Collins MKL, 1996, J CELL SCI, V109, P2393; DESOIGNIE R, 1994, GASTROENTEROLOGY, V107, P347, DOI 10.1016/0016-5085(94)90158-9; Elder DJE, 1996, CANCER RES, V56, P2273; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gerweck LE, 1996, CANCER RES, V56, P1194; GOTTLIEB RA, 1995, BLOOD, V86, P2414, DOI 10.1182/blood.V86.6.2414.bloodjournal8662414; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRIFFITHS JR, 1991, BRIT J CANCER, V64, P425, DOI 10.1038/bjc.1991.326; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Hague A, 1998, CARCINOGENESIS, V19, P1691, DOI 10.1093/carcin/19.9.1691; HALL PA, 1994, J CELL SCI, V107, P3569; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; MANNING AM, 1991, ONCOGENE, V6, P1471; MORANA S, 1994, INT J ONCOL, V5, P153; OCONNOR PM, 1993, CANCER RES, V53, P4776; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; PEREZSALA D, 1995, J BIOL CHEM, V270, P6235, DOI 10.1074/jbc.270.11.6235; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; Sasaki Y, 1997, AM J GASTROENTEROL, V92, P114; SHEMTOV MM, 1995, J UROLOGY, V154, P269, DOI 10.1016/S0022-5347(01)67292-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; vanderStappen JWJ, 1996, INT J CANCER, V67, P547, DOI 10.1002/(SICI)1097-0215(19960807)67:4<547::AID-IJC14>3.0.CO;2-4; WILLIAMS AC, 1995, ONCOGENE, V11, P141; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; Wolf CM, 1997, CELL DEATH DIFFER, V4, P125, DOI 10.1038/sj.cdd.4400218; Zoran DL, 1997, NUTR CANCER, V27, P222, DOI 10.1080/01635589709514530	32	160	163	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	1999	18	21					3199	3204		10.1038/sj.onc.1202660	http://dx.doi.org/10.1038/sj.onc.1202660			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359525				2022-12-17	WOS:000080523800002
J	Chen, RH; Su, YH; Chuang, RLC; Chang, TY				Chen, RH; Su, YH; Chuang, RLC; Chang, TY			Suppression of transforming growth factor-beta-induced apoptosis through a phosphatidylinositol 3-kinase Akt-dependent pathway	ONCOGENE			English	Article						TGF-beta-induced apoptosis; insulin; PI 3-kinase; Akt	PROGRAMMED CELL-DEATH; PROTEIN-KINASE AKT; FACTOR-II; SIGNALING PATHWAY; RAT HEPATOCYTES; HEPATOMA-CELLS; RECEPTORS; EXPRESSION; INDUCTION; SURVIVAL	Insulin and insulin receptor substrate 1 (IRS-1) are capable of protecting liver cells from apoptosis induced by transforming growth factor-beta (TGF-beta), The Ras/mitogen-activated protein kinase (MAP kinase) and the phosphatidylinositol 3-kinase (PI 3-kinase)/Akt pathways are both activated upon insulin stimulation and can protect against apoptosis under certain circumstances. We investigated which of these pathways is responsible for the protective effect of insulin on TGF-beta-induced apoptosis. An activated Pas, although elicited a strong mitogenic effect, could not protect Hep3B cells from TGF-beta-induced apoptosis, Furthermore, PD98059, a selective inhibitor of MEK, did not suppress the antiapoptotic effect of insulin. In contrast, the PI 3-kinase inhibitor, LY294002, efficiently blocked the effect of insulin. Protection against TGF-beta-induced apoptosis conferred by PI 3-kinase was further verified by stable transfection of an activated PI 3-kinase, Downstream targets of PI 3-kinase involved in this protection was further investigated. An activated Akt mimicked the antiapoptotic effect of insulin, whereas a dominant-negative Akt inhibited such effect. However, rapamycin, the p70(S6) kinase inhibitor, had no effect on the protectivity of insulin against TGF-beta-induced apoptosis, suggesting that the antiapoptotic target of PI 3-kinase/Akt pathway is independent or lies upstream of the p70S6 kinase, The mechanism by which PI 3-kinase/Akt pathway interferes with the apoptotic signaling of TGF-beta was explored. Activation of PI 3-kinase did not lead to a suppression of Smad hetero-oligomerization or nuclear translocation but blocked TGF-beta-induced caspase-3-like activity. In summary, the PI 3-kinase/Akt pathway, but not the Ras/MAP kinase pathway, protects against TGF-beta-induced apoptosis by inhibiting a step downstream of Smad but upstream of caspase-3.	Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei 10764, Taiwan; Natl Taiwan Univ, Coll Sci, Inst Biol Chem, Taipei 10764, Taiwan	National Taiwan University; Academia Sinica - Taiwan; National Taiwan University	Chen, RH (corresponding author), Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei 10764, Taiwan.		Chen, Ruey-Hwa/G-6121-2019; Su, Yi-Hsien/F-2910-2014	Chen, Ruey-Hwa/0000-0001-8124-5832; 				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; CARIANI E, 1988, CANCER RES, V48, P6844; Chao JR, 1997, ONCOGENE, V14, P721, DOI 10.1038/sj.onc.1200884; CHEN RH, 1994, J BIOL CHEM, V269, P22868; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUANG LY, 1994, ANTICANCER RES, V14, P147; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Derynck R, 1994, CYTOKINE HDB, P319; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Fan GS, 1996, ONCOGENE, V12, P1909; FUKUDA K, 1993, HEPATOLOGY, V18, P945, DOI 10.1002/hep.1840180428; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; InayatHussain SH, 1997, HEPATOLOGY, V25, P1516, DOI 10.1002/hep.510250634; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; LIN JK, 1992, CANCER RES, V52, P385; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; TAKAGI H, 1992, CANCER RES, V52, P5171; TANAKA S, 1996, CANCER RES, V56, P391; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Ueda K, 1996, J VIROL, V70, P1375, DOI 10.1128/JVI.70.3.1375-1383.1996; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG CY, 1995, CANCER RES, V55, P5101; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG D, 1993, CANCER RES, V53, P2020; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	53	160	170	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1959	1968		10.1038/sj.onc.1202111	http://dx.doi.org/10.1038/sj.onc.1202111			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788439				2022-12-17	WOS:000076423500009
J	Cartwright, P; Muller, H; Wagener, C; Holm, K; Helin, K				Cartwright, P; Muller, H; Wagener, C; Holm, K; Helin, K			E2F-6: a novel member of the E2F family is an inhibitor of E2F-dependent transcription	ONCOGENE			English	Article						E2F-6; inhibitor; cell cycle	RETINOBLASTOMA GENE-PRODUCT; UBIQUITIN-PROTEASOME PATHWAY; CELL-CYCLE REGULATION; IN-VIVO; S-PHASE; GROWTH SUPPRESSION; E2F-BINDING SITE; BINDING PROTEIN; EXPRESSION; PROMOTER	The E2F family of transcription factors are essential for the regulation of genes required for appropriate progression through the cell cycle. Five members of the E2F family have been previously reported, namely E2F1-5. All five are key elements in transcriptional regulation of essential genes, and they can be divided into two functional groups, those that induce S-phase progression when overexpressed in quiescent cells (E2Fs 1-3), and those that do not (E2Fs 4-5). Here, we describe the identification of a novel member of this family, which we refer to as E2F-6, E2F-6 shares significant homology with E2Fs 1-5, especially within the DNA binding, heterodimerization and marked box domains. Unlike E2Fs 1-5, E2F-6 lacks a transactivation and a pocket protein binding domain, hence, forms a unique third group within the E2F family, E2F-6 is a nuclear protein that can form heterodimers with the DP proteins (both DP-I and DP-2) in vitro and in vivo. Our results show that the complex formed between E2F-6 and the DP proteins, possesses high DNA binding activity, displaying a preference for a TTTCCCGC E2F recognition site, which is slightly different to the E2F consensus site derived from the E2 promoter (TTTCGCGC). In contrast to the other members of the E2F family, ectopic expression of E2F-6 inhibits transcription from promoters possessing E2F recognition sites rather than activating transcription. In addition, overexpression of E2F-6 suppresses the transactivational effects of coexpression of E2F-1 and DP-1. The inhibitory effect of E2F-6 is dependent on its DIVA binding activity and its ability to form heterodimers with the DPs, Interestingly, ectopic expression of E2F-6 leads to accumulation of cells in S-phase, Our data suggest that E2F-6 expression delays the exit from S-phase rather than inducing S-phase, which further emphasizes the functional difference between E2F-6 and the previously known E2F family members.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Helin, K (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.		Helin, Kristian/HDM-8306-2022; Helin, Kristian/K-2526-2019	Helin, Kristian/0000-0003-1975-6097; Muller, Heiko/0000-0001-9873-3146				Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Botz J, 1996, MOL CELL BIOL, V16, P3401; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Geng Y, 1996, ONCOGENE, V12, P1173; Harlow E LD, 1988, ANTIBODIES LAB MANUA; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas J, 1996, MOL CELL BIOL, V16, P1047; MELLILO RM, 1994, MOL CELL BIOL, V14, P8241; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Muller H, 1997, MOL CELL BIOL, V17, P5508; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; OUELLETTE MM, 1992, ONCOGENE, V7, P1075; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wu CL, 1996, MOL CELL BIOL, V16, P3698; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZHU LG, 1995, MOL CELL BIOL, V15, P3552	61	160	164	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					611	623		10.1038/sj.onc.1201975	http://dx.doi.org/10.1038/sj.onc.1201975			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704927				2022-12-17	WOS:000075195300009
J	Gallahan, D; Callahan, R				Gallahan, D; Callahan, R			The mouse mammary tumor associated gene INT3 is a unique member of the NOTCH gene family (NOTCH4)	ONCOGENE			English	Article						INT3; NOTCH4; mammary tumor gene	OF-SPLIT COMPLEX; DROSOPHILA NOTCH; NEUROGENIC LOCUS; MAMMALIAN NOTCH; HUMAN HOMOLOG; PROTEIN GENE; ENHANCER; RECEPTOR; EXPRESSION; SEQUENCE	The INT3 gene is frequently rearranged in mouse mammary tumor virus (MMTV)-induced mammary tumors of the CzechII mouse strain, We have completed the nucleotide sequence of the normal 6.5 Kb INT3 RNA and defined the intron/exon boundaries of the gene, The open reading frame of INT3 RNA should encode a 200 kd protein which shares 60% homology with the mouse homologue of Drosophila NOTCH, INT3 is unique among other members of the NOTCH family by containing 29 instead of 36 EGF-like repeats in the extracellular domain of the gene product. Five novel EGF-like repeats have been created as consequence of apparent small deletions which have occurred within the coding region for the extracellular domain during evolution. Nucleotide sequence analysis of host-viral junction fragments from nine independent MMTV-induced mammary tumors containing a rearranged INT3 gene reveals that all of the integration events occur within a 174 bp region 3' of the sequences encoding the LIN12 repeats in the INT3 extracellular domain and 5' of the sequences encoding the transmembrane domain. Therefore, the only tumorigenic INT3 mutations resulting from MMTV proviral insertions are those which results in the expression of the intracellular domain. This strongly suggests that MMTV-induced activation of INT3 is manifest in the absence of the regulatory action of the extracellular domain, including the LIN12 repeat sequences, leaving the expressed intracellular domain constitutively free to function in its role in mammary tumorigenesis.	NCI, TUMOR IMMUNOL & BIOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; BURDON T, 1991, J BIOL CHEM, V266, P6909; Callahan R, 1996, BREAST CANCER RES TR, V39, P33, DOI 10.1007/BF01806076; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DELAMO FF, 1993, GENOMICS, V15, P259, DOI 10.1006/geno.1993.1055; DELIDAKIS C, 1991, GENETICS, V129, P803; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FURUKAWA T, 1992, CELL, V69, P1191, DOI 10.1016/0092-8674(92)90640-X; GALLAHAN D, 1987, J VIROL, V61, P66, DOI 10.1128/JVI.61.1.66-74.1987; Gallahan D, 1996, CANCER RES, V56, P1775; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; Heitzler P, 1996, DEVELOPMENT, V122, P161; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KNUST E, 1992, GENETICS, V132, P505; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; KORDON EC, 1995, J VIROL, V69, P8066, DOI 10.1128/JVI.69.12.8066-8069.1995; LARDELLI M, 1993, EXP CELL RES, V204, P364, DOI 10.1006/excr.1993.1044; LARDELLI M, 1994, MECH DEVELOP, V46, P123, DOI 10.1016/0925-4773(94)90081-7; Lardelli M, 1995, INT J DEV BIOL, V39, P769; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; MALLO M, 1993, MECH DEVELOP, V42, P67, DOI 10.1016/0925-4773(93)90099-J; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NYE JS, 1994, DEVELOPMENT, V120, P2421; PITTIUS CW, 1988, P NATL ACAD SCI USA, V85, P5874, DOI 10.1073/pnas.85.16.5874; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; SCHRONS H, 1992, GENETICS, V132, P481; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; SIMPSON P, 1994, NOTCH RECEPTORS, P10; SMITH GH, 1995, CELL GROWTH DIFFER, V6, P563; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SMITHIES O, 1981, CELL, V26, P345, DOI 10.1016/0092-8674(81)90203-8; STADEN R, 1980, NUCLEIC ACIDS RES, V8, P3673, DOI 10.1093/nar/8.16.3673; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6	50	160	174	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	1997	14	16					1883	1890		10.1038/sj.onc.1201035	http://dx.doi.org/10.1038/sj.onc.1201035			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150355				2022-12-17	WOS:A1997WV80400001
J	Somasundaram, K; ElDeiry, WS				Somasundaram, K; ElDeiry, WS			Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region	ONCOGENE			English	Article						E1A; p53; p21(WAF1/CIP1); transformation; checkpoint; cancer	E2F TRANSCRIPTION FACTOR; ADENOVIRUS TYPE-5 E1A; BINDING PROTEIN; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; GENE-EXPRESSION; P53; TRANSFORMATION; APOPTOSIS; DOMAINS	Cellular transformation by the adenovirus E1A oncoprotein requires its p300/CBP- and Rb-binding domains. We mapped inhibition of p53-mediated transactivation to the p300/CBP-binding region of E1A. An E1A mutant incapable of physically interacting with Rb retained the capacity to inhibit transactivation by p53, whereas E1A mutants of the p300/CBP-interacting domain failed to inhibit p53. The inhibitory effect of the p300/CBP-binding region of E1A on p53 was demonstrated with p53-activated reporters and endogenous p53 targets such as p21(WAF1/CIP1) or MDM2. E1A lacking the capacity to interact with Rb, but capable of p300/CBP interaction, was competent in suppression of a DNA-damage activated p53-dependent cell cycle checkpoint. Exogenous CBP and p300 were able to individually relieve EIA's inhibitory effect on p53-mediated transcription. Mutants of E1A that are not capable of interacting with p300 or CBP were found to efficiently stabilize endogenous p53 but were not competent in repression of p21 expression thus dissociating these two effects of E1A. Our results suggest that the p300/CBP-binding domain of E1A inhibits a p53-dependent cellular response which normally inhibits DNA replication following Adenovirus infection.	UNIV PENN,SCH MED,DEPT MED & GENET,LAB MOL ONCOL & CELL CYCLE REGUL,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; CTR COMPREHENS CANC,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Pennsylvania			El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266				BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BERNARDS R, 1986, VIROLOGY, V150, P126, DOI 10.1016/0042-6822(86)90272-2; Blagosklonny MV, 1996, INT J CANCER, V67, P386, DOI 10.1002/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO;2-6; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Hansen R, 1995, ONCOGENE, V11, P2535; HAYLEY KP, 1984, P NATL ACAD SCI USA, V81, P5734; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LITTLE JW, 1989, NATURE, V338, P39; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MAYR GA, 1995, CANCER RES, V55, P2410; MCLORIE W, 1991, J GEN VIROL, V72, P1467, DOI 10.1099/0022-1317-72-6-1467; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MYMRYK JS, 1994, ONCOGENE, V9, P1187; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SPITKOVSKY D, 1995, ONCOGENE, V10, P2421; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; TEODORO JG, 1995, ONCOGENE, V11, P467; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; White E, 1995, Curr Top Microbiol Immunol, V199 ( Pt 3), P34; Wu GS, 1996, CLIN CANCER RES, V2, P623; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Zeng YX, 1996, ONCOGENE, V12, P1557	54	160	168	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1047	1057		10.1038/sj.onc.1201002	http://dx.doi.org/10.1038/sj.onc.1201002			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070653				2022-12-17	WOS:A1997WM07000006
J	LANDERS, JE; HAINES, DS; STRAUSS, JF; GEORGE, DL				LANDERS, JE; HAINES, DS; STRAUSS, JF; GEORGE, DL			ENHANCED TRANSLATION - A NOVEL MECHANISM OF MDM2 ONCOGENE OVEREXPRESSION IDENTIFIED IN HUMAN TUMOR-CELLS	ONCOGENE			English	Note							WILD-TYPE P53; MONOCLONAL-ANTIBODY; TRANSFORMED-CELLS; SIMIAN VIRUS-40; GENE-EXPRESSION; MUTATIONS; AMPLIFICATION; ANTIGEN; PROTEIN; SARCOMAS	The cellular mdm2 gene, which has potential transforming activity that can be activated by overexpression, is amplified in a significant percentage of human sarcomas and in other mammalian tumors. Proteins encoded by the mdm2 gene can bind to, and inhibit the function of, the protein product of the p53 tumor suppressor gene. As reported here, we have identified human choriocarcinoma cell lines that express high levels of mdm2 proteins as well as the p53 protein. Several lines of evidence demonstrate that the p53 in these tumor cells has a wild-type nucleotide sequence, although the protein exhibits an extended half-life. Further, the more than 100-fold overexpression of mdm2 proteins in these cells cannot be explained by gene amplification, elevated RNA expression, or altered protein stability; rather our data indicate that elevated mdm2 protein levels in these choriocarcinoma cell lines result from enhanced translation. This mechanism has not previously been implicated in the regulation of mdm2 gene expression, and it represents a novel means by which the potential transforming,activity of the mdm2 oncogene could be activated.	UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT OBSTET & GYNECOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania				Landers, John/0000-0001-8084-5043	NATIONAL CANCER INSTITUTE [F32CA060390] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050786] Funding Source: NIH RePORTER; NCI NIH HHS [NCI 1F32CA60390] Funding Source: Medline; NHLBI NIH HHS [HL50786] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANKER L, 1993, INT J CANCER, V55, P982, DOI 10.1002/ijc.2910550618; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CORDONCARDO C, 1994, CANCER RES, V54, P794; DVIDOFF AM, 1992, ONCOGENE, V7, P127; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FELIX CA, 1992, J CLIN INVEST, V90, P653, DOI 10.1172/JCI115907; FELIX CA, 1992, CANCER RES, V52, P2243; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JUVEN T, 1993, ONCOGENE, V8, P3411; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LADANYI M, 1993, CANCER RES, V53, P16; LEACH FS, 1993, CANCER RES, V53, P2231; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1993, ONCOGENE, V8, P2001; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; MURPHY M, 1991, J NEUROSCI RES, V30, P475, DOI 10.1002/jnr.490300304; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OTTO A, 1993, ONCOGENE, V8, P2591; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REIFENBERGER G, 1993, CANCER RES, V53, P2736; REIHSAUS E, 1990, ONCOGENE, V5, P137; RUBIO MP, 1993, CANCER RES, V53, P3465; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	44	160	160	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2745	2750						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058341				2022-12-17	WOS:A1994PC05400039
J	BANNISTER, AJ; COOK, A; KOUZARIDES, T				BANNISTER, AJ; COOK, A; KOUZARIDES, T			INVITRO DNA-BINDING ACTIVITY OF FOS/JUN AND BZLF1 BUT NOT C/EBP IS AFFECTED BY REDOX CHANGES	ONCOGENE			English	Article								The leucine zipper family of proteins have a DNA binding domain composed of a leucine zipper dimerisation interface and a basic DNA binding structure. We show here that redox changes affect the in vitro DNA binding ability of a select subset of leucine zipper proteins. The bacterially expressed DNA binding domains of Fos/Jun and BZLF1 are unable to bind DNA under non-reducing conditions whereas binding of the C/EBP DNA binding domain is unaffected. Sensitivity to redox state is due to the presence of a conserved cysteine residue in the basic DNA binding motif of Fos, Jun and BZLF1 but not C/EBP. Under non-reducing conditions an intermolecular disulphide bridge is formed between the cysteine residues of each basic motif within a dimer, which prevents DNA binding. We show that oxidation of these C residues can be achieved enzymatically, using glutathione peroxidase, and that DNA binding protects them from oxidation. These data raise the possibility that intracellular changes in the redox state may differentially regulate the activity of leucine zipper family members. In addition the loss of DNA binding activity under non-reducing conditions has implications for the purification methods used to isolate proteins of the leucine zipper family for structural analysis.	UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT PATHOL, DIV VIROL, CAMBRIDGE CB2 2QQ, ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	KOUZARIDES, T (corresponding author), UNIV CAMBRIDGE, WELLCOME INST, CTR CANC RES, TENNIS COURT RD, CAMBRIDGE CB2 1QR, ENGLAND.			Bannister, Andrew/0000-0002-6312-4436; Kouzarides, Tony/0000-0002-8918-4162	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANGEL P, 1989, New Biologist, V1, P35; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V57, P209; BUSCH SJ, 1990, ONCOGENE, V5, P1549; CAPPEL RE, 1988, J BIOL CHEM, V263, P12204; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KOUZARIDES T, 1991, ONCOGENE, V6, P195; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MATSUI M, 1990, ONCOGENE, V5, P249; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; ROONEY CM, 1989, J VIROL, V63, P3109, DOI 10.1128/JVI.63.7.3109-3116.1989; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WALTERS DW, 1986, J BIOL CHEM, V261, P5372; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	47	160	163	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1991	6	7					1243	1250						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1907361				2022-12-17	WOS:A1991GV26000021
J	ZHOU, DJ; CASEY, G; CLINE, MJ				ZHOU, DJ; CASEY, G; CLINE, MJ			AMPLIFICATION OF HUMAN INT-2 IN BREAST CANCERS AND SQUAMOUS CARCINOMAS	ONCOGENE			English	Article									ICI PLC,CORP BIOSCI GRP,RUNCORN,CHESHIRE,ENGLAND		ZHOU, DJ (corresponding author), UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT MED,LOS ANGELES,CA 90024, USA.							CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DICKSON C, 1987, NATURE, V326, P823; JOHNSTON RN, 1983, P NATL ACAD SCI-BIOL, V80, P3711, DOI 10.1073/pnas.80.12.3711; JOKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806; KOO FT, 1987, P NATL ACAD SCI US, V84, P2877; MASUDA H, IN PRESS CLIN MOL ME; Moore D H, 1979, Adv Cancer Res, V29, P347, DOI 10.1016/S0065-230X(08)60850-7; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; PETERS G, 1984, NATURE, V309, P273, DOI 10.1038/309273a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VARMUS HE, 1982, CANCER SURV, V2, P309; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	14	160	163	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					279	282						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	2895446				2022-12-17	WOS:A1988M593100011
J	Wong, CC; Qian, Y; Yu, J				Wong, C. C.; Qian, Y.; Yu, J.			Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches	ONCOGENE			English	Review							NICOTINAMIDE N-METHYLTRANSFERASE; HEXOSAMINE BIOSYNTHETIC-PATHWAY; ATP-CITRATE LYASE; HISTONE DEACETYLASE SIRT6; SQUAMOUS-CELL CARCINOMA; ACUTE MYELOID-LEUKEMIA; TUMOR-SUPPRESSOR GENE; O-GLCNAC; ISOCITRATE DEHYDROGENASE; SUCCINATE-DEHYDROGENASE	Epigenetic and metabolic alterations in cancer cells are highly intertwined. Oncogene-driven metabolic rewiring modifies the epigenetic landscape via modulating the activities of DNA and histone modification enzymes at the metabolite level. Conversely, epigenetic mechanisms regulate the expression of metabolic genes, thereby altering the metabolome. Epigenetic-metabolomic interplay has a critical role in tumourigenesis by coordinately sustaining cell proliferation, metastasis and pluripotency. Understanding the link between epigenetics and metabolism could unravel novel molecular targets, whose intervention may lead to improvements in cancer treatment. In this review, we summarized the recent discoveries linking epigenetics and metabolism and their underlying roles in tumorigenesis; and highlighted the promising molecular targets, with an update on the development of small molecule or biologic inhibitors against these abnormalities in cancer.	[Wong, C. C.; Yu, J.] Chinese Univ Hong Kong, Dept Med & Therapeut, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci,Shenzhen Res Inst, Hong Kong, Hong Kong, Peoples R China; [Qian, Y.] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Gastroenterol, Hangzhou, Zhejiang, Peoples R China; [Qian, Y.] Zhejiang Univ, Inst Gastroenterol, Hangzhou, Zhejiang, Peoples R China	Chinese University of Hong Kong; Zhejiang University; Zhejiang University	Wong, CC; Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Li Ka Shing Inst Hlth Sci, Shenzhen Res Inst,Prince Wales Hosp, Rm 707A,7-F,Li Ka Shing Med Sci Bldg, Hong Kong, Hong Kong, Peoples R China.; Wong, CC; Yu, J (corresponding author), Chinese Univ Hong Kong, Dept Med & Therapeut, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci,Shenzhen Res Inst,Princ, Rm 707A,7-F,Li Ka Shing Med Sci Bldg, Hong Kong, Hong Kong, Peoples R China.	chichun.wong@cuhk.edu.hk; junyu@cuhk.edu.hk	Wong, Chi Chun/C-4636-2016; Jun, Yu/D-8569-2015	Jun, Yu/0000-0001-5008-2153	RGC-GRF from Hong Kong [14114615, 766613]; Shenzhen Municipal Science and Technology RD fund [JCYJ20130401151108652]; Shenzhen Virtual University Park Support Scheme to the Chinese University of Hong Kong, Shenzhen Research Institute; National Natural Science Foundation of China [81502064]	RGC-GRF from Hong Kong; Shenzhen Municipal Science and Technology RD fund; Shenzhen Virtual University Park Support Scheme to the Chinese University of Hong Kong, Shenzhen Research Institute; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This project was supported by research funds from RGC-GRF (14114615 and 766613) from Hong Kong; Shenzhen Municipal Science and Technology R&D fund (JCYJ20130401151108652) and Shenzhen Virtual University Park Support Scheme to the Chinese University of Hong Kong, Shenzhen Research Institute; National Natural Science Foundation of China (81502064).	Abdel-Wahab O, 2009, BLOOD, V114, P144, DOI 10.1182/blood-2009-03-210039; Ahmad A, 2011, CANCER RES, V71, P3400, DOI 10.1158/0008-5472.CAN-10-0965; Alcarraz-Vizan G, 2010, METABOLOMICS, V6, P229, DOI 10.1007/s11306-009-0192-0; Alvarez-Nunez F, 2006, THYROID, V16, P17, DOI 10.1089/thy.2006.16.17; Amoedo ND, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022264; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Bader AG, 2010, CANCER RES, V70, P7027, DOI 10.1158/0008-5472.CAN-10-2010; Balss J, 2008, ACTA NEUROPATHOL, V116, P597, DOI 10.1007/s00401-008-0455-2; Barber MF, 2012, NATURE, V487, P114, DOI 10.1038/nature11043; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; Borodovsky A, 2013, ONCOTARGET, V4, P1737, DOI 10.18632/oncotarget.1408; Braiteh F, 2008, CLIN CANCER RES, V14, P6296, DOI 10.1158/1078-0432.CCR-08-1247; Brown JM, 1998, CANCER RES, V58, P1408; Cairns RA, 2012, BLOOD, V119, P1901, DOI 10.1182/blood-2011-11-391748; Caldwell SA, 2010, ONCOGENE, V29, P2831, DOI 10.1038/onc.2010.41; Castoldi M, 2011, J CLIN INVEST, V121, P1386, DOI 10.1172/JCI44883; Chan SY, 2009, CELL METAB, V10, P273, DOI 10.1016/j.cmet.2009.08.015; Chen MQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025564; Chen Q, 2013, NATURE, V493, P561, DOI 10.1038/nature11742; CHEN W, 1992, BIOCHIMIE, V74, P867, DOI 10.1016/0300-9084(92)90070-U; Chen YH, 2013, DIABETES, V62, P2278, DOI 10.2337/db12-0963; Choi GCG, 2014, MOL CANCER RES, V12, P228, DOI 10.1158/1541-7786.MCR-13-0195; Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43; Christensen BC, 2011, JNCI-J NATL CANCER I, V103, DOI 10.1093/jnci/djq497; Chu BF, 2013, CANCER CHEMOTH PHARM, V71, P115, DOI 10.1007/s00280-012-1986-8; Chu CS, 2014, P NATL ACAD SCI USA, V111, P1355, DOI 10.1073/pnas.1323226111; Cluntun AA, 2015, CANCER METAB, V3, DOI 10.1186/s40170-015-0135-3; Cunningham JM, 1998, CANCER RES, V58, P3455; Dai DW, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-478; Dang CV, 2010, CELL CYCLE, V9, P3884, DOI 10.4161/cc.9.19.13302; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; Daud AI, 2009, CLIN CANCER RES, V15, P2479, DOI 10.1158/1078-0432.CCR-08-1931; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Davis MI, 2014, J BIOL CHEM, V289, P13717, DOI 10.1074/jbc.M113.511030; Dehennaut V, 2007, J BIOL CHEM, V282, P12527, DOI 10.1074/jbc.M700444200; Deng GJ, 2015, J BIOL CHEM, V290, P762, DOI 10.1074/jbc.M114.608497; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Desai S, 2014, ONCOTARGET, V5, P8202, DOI 10.18632/oncotarget.1159; DiNardo C, 2015, HAEMATOLOGICA, V100, P216; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Du W, 2013, ONCOGENE, V32, P3319, DOI 10.1038/onc.2012.359; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; Ebert MS, 2010, RNA, V16, P2043, DOI 10.1261/rna.2414110; Edmunds LR, 2014, J BIOL CHEM, V289, P25382, DOI 10.1074/jbc.M114.580662; Elhammali A, 2014, CANCER DISCOV, V4, P828, DOI 10.1158/2159-8290.CD-13-0572; Ellwood-Yen K, 2014, CANCER RES, V74, DOI 10.1158/1538-7445.AM2014-3116; Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227; Fang R, 2012, J BIOL CHEM, V287, P23227, DOI 10.1074/jbc.M112.373084; Fei X, 2012, FEBS LETT, V586, P392, DOI 10.1016/j.febslet.2012.01.006; Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142; Feldman JL, 2013, J BIOL CHEM, V288, P31350, DOI 10.1074/jbc.C113.511261; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Fong JJ, 2012, J BIOL CHEM, V287, P12195, DOI 10.1074/jbc.M111.315804; Fuchs BC, 2005, SEMIN CANCER BIOL, V15, P254, DOI 10.1016/j.semcancer.2005.04.005; Fujiki R, 2011, NATURE, V480, P557, DOI 10.1038/nature10656; Gambichler T, 2013, MELANOMA RES, V23, P218, DOI 10.1097/CMR.0b013e32835f9bd4; Garcia JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; GLAZER RI, 1986, BIOCHEM BIOPH RES CO, V135, P688, DOI 10.1016/0006-291X(86)90048-3; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Gregersen LH, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-232; Guillaumond F, 2013, P NATL ACAD SCI USA, V110, P3919, DOI 10.1073/pnas.1219555110; Guo JU, 2011, CELL, V145, P423, DOI 10.1016/j.cell.2011.03.022; Gupta V, 2014, CURR PHARM DESIGN, V20, P1706, DOI 10.2174/13816128113199990536; Haase C, 2007, J NUCL MED, V48, P2063, DOI 10.2967/jnumed.107.043620; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao HX, 2009, SCIENCE, V325, P1139, DOI 10.1126/science.1175689; Hattori M, 2015, EXP DERMATOL, V24, P841, DOI 10.1111/exd.12767; Hatzimichael E, 2010, EUR J HAEMATOL, V84, P47, DOI 10.1111/j.1600-0609.2009.01344.x; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hensen EF, 2011, FAM CANCER, V10, P355, DOI 10.1007/s10689-010-9402-1; Hensley CT, 2013, J CLIN INVEST, V123, P3678, DOI 10.1172/JCI69600; Herceg Z, 2011, EPIGENETICS-US, V6, P804, DOI 10.4161/epi.6.7.16262; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; Itkonen HM, 2013, CANCER RES, V73, P5277, DOI 10.1158/0008-5472.CAN-13-0549; Ito R, 2014, GENES CELLS, V19, P52, DOI 10.1111/gtc.12107; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Janeway KA, 2011, P NATL ACAD SCI USA, V108, P314, DOI 10.1073/pnas.1009199108; Jiang S, 2012, EMBO J, V31, P1985, DOI 10.1038/emboj.2012.45; Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019; Jin L, 2016, ONCOGENE, V35, P3619, DOI 10.1038/onc.2015.447; Johnson AB, 2008, MUTAT RES-FUND MOL M, V640, P174, DOI 10.1016/j.mrfmmm.2008.01.001; Johnson C, 2015, CANCER LETT, V356, P309, DOI 10.1016/j.canlet.2013.09.043; Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214; Kang YH, 2002, LAB INVEST, V82, P285, DOI 10.1038/labinvest.3780422; Kantorovich V, 2010, BEST PRACT RES CL EN, V24, P415, DOI 10.1016/j.beem.2010.04.001; Kefas B, 2010, NEURO-ONCOLOGY, V12, P1102, DOI 10.1093/neuonc/noq080; Kernytsky A, 2015, BLOOD, V125, P296, DOI 10.1182/blood-2013-10-533604; Killian JK, 2013, CANCER DISCOV, V3, P648, DOI 10.1158/2159-8290.CD-13-0092; Kim Hyo-Joon, 2015, J Cancer Prev, V20, P78, DOI 10.15430/JCP.2015.20.1.78; Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Kohli RM, 2013, NATURE, V502, P472, DOI 10.1038/nature12750; Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327; Kraus D, 2014, NATURE, V508, P258, DOI 10.1038/nature13198; Kudo Y, 2012, CANCER SCI, V103, P670, DOI 10.1111/j.1349-7006.2012.02213.x; Lee JV, 2014, CELL METAB, V20, P306, DOI 10.1016/j.cmet.2014.06.004; Lee SH, 2009, ONCOGENE, V28, P184, DOI 10.1038/onc.2008.377; Letouze E, 2013, CANCER CELL, V23, P739, DOI 10.1016/j.ccr.2013.04.018; Li H, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-110; Li L., 2015, J OCEAN WIND ENERGY, V2, P1, DOI DOI 10.1371/J0URNAL.P0NE.0133813; Li XL, 2011, INT J BIOL SCI, V7, P575, DOI 10.7150/ijbs.7.575; Li ZH, 2014, NAT REV DRUG DISCOV, V13, P622, DOI 10.1038/nrd4359; Lin SH, 2016, SCI REP-UK, V6, DOI 10.1038/srep21184; Liu PY, 2013, CELL DEATH DIFFER, V20, P503, DOI 10.1038/cdd.2012.147; Liu QY, 2011, MOL CANCER THER, V10, P1113, DOI 10.1158/1535-7163.MCT-10-1010; Liu WL, 2011, HEPATOLOGY, V53, P843, DOI 10.1002/hep.24124; Liu X, 2010, ONCOGENE, V29, P442, DOI 10.1038/onc.2009.332; Liu XS, 2015, ONCOTARGET, V6, P4214, DOI 10.18632/oncotarget.2929; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Lopez-Serra P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4608; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Lucena MC, 2016, J BIOL CHEM, V291, P12917, DOI 10.1074/jbc.M116.729236; Maddocks ODK, 2016, MOL CELL, V61, P210, DOI 10.1016/j.molcel.2015.12.014; Mariani CJ, 2014, CELL REP, V7, P1343, DOI 10.1016/j.celrep.2014.04.040; Martinez-Chantar ML, 2008, HEPATOLOGY, V47, P1191, DOI 10.1002/hep.22159; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Mentch SJ, 2015, CELL METAB, V22, P861, DOI 10.1016/j.cmet.2015.08.024; Migita T, 2008, CANCER RES, V68, P8547, DOI 10.1158/0008-5472.CAN-08-1235; Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013; Miyamoto S, 2008, CELL DEATH DIFFER, V15, P521, DOI 10.1038/sj.cdd.4402285; Momparler RL, 2015, EXPERT OPIN INV DRUG, V24, P1031, DOI 10.1517/13543784.2015.1051220; Momparler RL, 2014, CLIN EPIGENETICS, V6, DOI 10.1186/1868-7083-6-19; Momparler RL, 2012, LEUKEMIA RES, V36, P1049, DOI 10.1016/j.leukres.2012.03.001; Morani F, 2014, J MOL ENDOCRINOL, V53, P247, DOI 10.1530/JME-14-0118; Moussaieff A, 2015, CELL METAB, V21, P392, DOI 10.1016/j.cmet.2015.02.002; Mudd SH, 2001, J INHERIT METAB DIS, V24, P448, DOI 10.1023/A:1010577512912; Munoz-Pinedo C, 2013, CANCER RES, V73, P4185, DOI 10.1158/0008-5472.CAN-13-0512; Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156; Myers SA, 2011, P NATL ACAD SCI USA, V108, P9490, DOI 10.1073/pnas.1019289108; Nakagawa M, 2007, ONCOL REP, V18, P769; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Okoye-Okafor UC, 2015, NAT CHEM BIOL, V11, P878, DOI 10.1038/nchembio.1930; Olivier-Van Stichelen S, 2014, FASEB J, V28, P3325, DOI 10.1096/fj.13-243535; Olivier-Van Stichelen Stephanie, 2012, Am J Physiol Endocrinol Metab, V302, pE417, DOI 10.1152/ajpendo.00390.2011; Onodera Y, 2014, J CLIN INVEST, V124, P367, DOI 10.1172/JCI63146; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Paschka P, 2010, J CLIN ONCOL, V28, P3636, DOI 10.1200/JCO.2010.28.3762; Patel SA, 1997, MOL CELL BIOL, V17, P5813, DOI 10.1128/MCB.17.10.5813; Pereira DM, 2013, DRUG DISCOV TODAY, V18, P282, DOI 10.1016/j.drudis.2012.10.002; Peschiaroli A, 2013, ONCOGENE, V32, P797, DOI 10.1038/onc.2012.100; Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982; Place TL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014617; Pollard PJ, 2003, ANN MED, V35, P632, DOI 10.1080/07853890310018458; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Ramalingam SS, 2010, J CLIN ONCOL, V28, P56, DOI 10.1200/JCO.2009.24.9094; Ranuncolo SM, 2012, J BIOL CHEM, V287, P23549, DOI 10.1074/jbc.M111.330910; Rathore MG, 2012, INT J BIOCHEM CELL B, V44, P1448, DOI 10.1016/j.biocel.2012.05.011; Rawluszko AA, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-526; Ricketts CJ, 2012, J UROLOGY, V188, P2063, DOI 10.1016/j.juro.2012.08.030; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Robinson MM, 2007, BIOCHEM J, V406, P407, DOI 10.1042/BJ20070039; Rodrigues MF, 2015, J CELL BIOCHEM, V116, P797, DOI 10.1002/jcb.25036; Rodriguez-Paredes M, 2011, CANCER DISCOV, V1, P557, DOI 10.1158/2159-8290.CD-11-0271; Rohle D, 2013, SCIENCE, V340, P626, DOI 10.1126/science.1236062; Rzem R, 2004, P NATL ACAD SCI USA, V101, P16849, DOI 10.1073/pnas.0404840101; Sakabe K, 2010, J BIOL CHEM, V285, P34460, DOI 10.1074/jbc.M110.158170; Salvesen HB, 2001, INT J CANCER, V91, P22, DOI 10.1002/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S; Sasaki M, 2012, NATURE, V488, P656, DOI 10.1038/nature11323; Schmitt AM, 2009, ENDOCR-RELAT CANCER, V16, P1219, DOI 10.1677/ERC-08-0297; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Sebastian C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047; Selvakumar T, 2012, J BIOL CHEM, V287, P7039, DOI 10.1074/jbc.M111.285601; Shen LL, 2005, JNCI-J NATL CANCER I, V97, P1330, DOI 10.1093/jnci/dji275; Shih AH, 2014, BLOOD, V124, P237; Shim EH, 2014, CANCER DISCOV, V4, P1290, DOI 10.1158/2159-8290.CD-13-0696; Shin JY, 2013, CELL REP, V5, P654, DOI 10.1016/j.celrep.2013.10.007; Simpson NE, 2012, EPIGENETICS-US, V7, P1413, DOI 10.4161/epi.22713; Simpson NE, 2012, BREAST CANCER RES TR, V133, P959, DOI 10.1007/s10549-011-1871-x; Skowronski K, 2010, EPIGENETICS-US, V5, DOI 10.4161/epi.5.6.12400; Soria JC, 2002, CLIN CANCER RES, V8, P1178; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tang SW, 2011, CARCINOGENESIS, V32, P138, DOI 10.1093/carcin/bgq225; Terunuma A, 2014, J CLIN INVEST, V124, P398, DOI 10.1172/JCI71180; Thomas MG, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.200; Toro JR, 2003, AM J HUM GENET, V73, P95, DOI 10.1086/376435; Trojan J, 2000, GUT, V47, P272, DOI 10.1136/gut.47.2.272; Turcan S, 2013, ONCOTARGET, V4, P1729, DOI 10.18632/oncotarget.1412; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Ulanovskaya OA, 2013, NAT CHEM BIOL, V9, P300, DOI [10.1038/NCHEMBIO.1204, 10.1038/nchembio.1204]; Vanharanta S, 2013, NAT MED, V19, P50, DOI 10.1038/nm.3029; Venneti S, 2013, J NEUROPATH EXP NEUR, V72, P298, DOI 10.1097/NEN.0b013e3182898113; Villalba JM, 2012, BIOFACTORS, V38, P349, DOI 10.1002/biof.1032; Wang F, 2013, SCIENCE, V340, P622, DOI 10.1126/science.1234769; Wang J, 2005, EMBO J, V24, P368, DOI 10.1038/sj.emboj.7600521; Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009; Wang SY, 2013, GUT, V62, P833, DOI 10.1136/gutjnl-2011-301776; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Wardell SE, 2009, MOL ENDOCRINOL, V23, P388, DOI 10.1210/me.2008-0179; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199; Wellen KE, 2010, GENE DEV, V24, P2784, DOI 10.1101/gad.1985910; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Witta SE, 2012, J CLIN ONCOL, V30, P2248, DOI 10.1200/JCO.2011.38.9411; Wong CC, 2016, GASTROENTEROLOGY, V151, P945, DOI 10.1053/j.gastro.2016.07.011; Wong TS, 2008, INT J CANCER, V123, P251, DOI 10.1002/ijc.23583; Wu J, 2012, ONCOGENE, V31, P333, DOI 10.1038/onc.2011.227; Wu Y, 2008, ONCOGENE, V27, P6679, DOI 10.1038/onc.2008.264; Xiao CY, 2010, J BIOL CHEM, V285, P36776, DOI 10.1074/jbc.M110.168039; Xiao MT, 2012, GENE DEV, V26, P1326, DOI 10.1101/gad.191056.112; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yamasaki T, 2013, CANCER SCI, V104, P1411, DOI 10.1111/cas.12240; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67; Yen K, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.240.240; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Yoshino H, 2013, CANCER SCI, V104, P1567, DOI 10.1111/cas.12280; Yu J, 2013, ONCOGENE, V32, P307, DOI 10.1038/onc.2012.54; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229; Zaidi N, 2012, CANCER RES, V72, P3709, DOI 10.1158/0008-5472.CAN-11-4112; Zhang J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089202; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhang ZG, 2014, MOL MED REP, V9, P882, DOI 10.3892/mmr.2013.1879; Zhao SG, 2013, CANCER LETT, V333, P253, DOI 10.1016/j.canlet.2013.01.039; Zheng BS, 2013, ACS MED CHEM LETT, V4, P542, DOI 10.1021/ml400036z; Zhong L, 2010, TRANSCR-AUSTIN, V1, P17, DOI 10.4161/trns.1.1.12143; Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041; Zhou FX, 2016, J STEROID BIOCHEM, V159, P19, DOI 10.1016/j.jsbmb.2016.02.015	225	159	161	3	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3359	3374		10.1038/onc.2016.485	http://dx.doi.org/10.1038/onc.2016.485			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28092669	Green Published, hybrid			2022-12-17	WOS:000403340700001
J	Huang, J; Xiao, D; Li, G; Ma, J; Chen, P; Yuan, W; Hou, F; Ge, J; Zhong, M; Tang, Y; Xia, X; Chen, Z				Huang, J.; Xiao, D.; Li, G.; Ma, J.; Chen, P.; Yuan, W.; Hou, F.; Ge, J.; Zhong, M.; Tang, Y.; Xia, X.; Chen, Z.			EphA2 promotes epithelial-mesenchymal transition through the Wnt/beta-catenin pathway in gastric cancer cells	ONCOGENE			English	Article						EphA2; gastric cancer; epithelial-mensenchymal transition; Wnt/beta-catenin	DEPENDENT TRANSCRIPTION; COLORECTAL-CANCER; RECEPTOR; ACTIVATION; EXPRESSION	This study aims to investigate the significance of erythropoietin-producing hepatocellular (Eph)A2 expression and the mechanism by which EphA2 is involved in the epithelial-mensenchymal transition (EMT) of gastric cancer cells. EphA2 expression levels were upregulated and positively correlated with metastasis and EMT markers in human gastric cancer specimens. Modulation of EphA2 expression levels had distinct effects on cell proliferation, cell cycle, migration, invasion and morphology in the gastric cancer cell lines SGC7901 and AGS in vitro and in vivo. Overexpression of EphA2 resulted in the upregulation of the EMT molecular markers N-cadherin and Snail, as well as the Wnt/beta-catenin targets TCF4, Cyclin-D1 and c-Myc, while silencing EphA2 using short hairpin RNA had the opposite effect. Furthermore, inhibition of the Wnt/beta-catenin pathway by XAV939 negated the effect of EphA2 overexpression, whereas activation of the Wnt/beta-catenin pathway by LiCl impaired the effect of the EphA2 knockdown on EMT. These observations demonstrate that EphA2 upregulation is a common event in gastric cancer specimens that is closely correlated with cancer metastasis and that EphA2 promotes EMT of gastric cancer cells through activation of Wnt/beta-catenin signaling.	[Huang, J.; Zhong, M.; Tang, Y.] Cent S Univ, Xiangya Hosp, Dept Oncol, Changsha 410008, Hunan, Peoples R China; [Xiao, D.] Cent S Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Hunan, Peoples R China; [Li, G.; Ma, J.; Chen, P.] Cent S Univ, Hunan Key Lab Nonresolving Inflammat & Canc, Canc Res Inst, Changsha 410008, Hunan, Peoples R China; [Yuan, W.; Hou, F.; Ge, J.; Chen, Z.] Cent S Univ, Xiangya Hosp, Dept Gen Surg, Changsha 410008, Hunan, Peoples R China; [Xia, X.] Weill Cornell Sch Med, Methodist Hosp Res Inst, Ctr Genom Med, Houston, TX USA	Central South University; Central South University; Central South University; Central South University; Cornell University; The Methodist Hospital System; The Methodist Hospital - Houston; The Methodist Hospital Research Institute	Chen, Z (corresponding author), Cent S Univ, Xiangya Hosp, Dept Gen Surg, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.	zihuachenxy@126.com			Nature Scientific Foundation of China [81172297]; Ministry of Education (SRF for ROCS) [NCET-11-0520]; Hunan Province Natural Sciences Foundation of China [B2010-010]	Nature Scientific Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education (SRF for ROCS)(Scientific Research Foundation for the Returned Overseas Chinese Scholars); Hunan Province Natural Sciences Foundation of China(Natural Science Foundation of Hunan Province)	This work was supported by Nature Scientific Foundation of China (81172297), Ministry of Education (NCET-11-0520, SRF for ROCS) and Hunan Province Natural Sciences Foundation of China (B2010-010). We thank Yangchun Xie and Liyang Zhang for their technical help.	Amit I, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100195; Baeten CIM, 2009, DIS COLON RECTUM, V52, P2028, DOI 10.1007/DCR.0b013e3181beb4ff; Brannan JM, 2009, CLIN CANCER RES, V15, P4423, DOI 10.1158/1078-0432.CCR-09-0473; Cui XD, 2010, INT J CANCER, V126, P940, DOI 10.1002/ijc.24798; Fukuyama R, 2008, ONCOGENE, V27, P6044, DOI 10.1038/onc.2008.204; Howard S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023899; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Li X, 2010, TUMOR BIOL, V31, P477, DOI 10.1007/s13277-010-0060-6; Lovatt M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012794; Lu C, 2008, CANCER BIOL THER, V7, P1098, DOI 10.4161/cbt.7.7.6168; Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005; Malanchi I, 2008, NATURE, V452, P650, DOI 10.1038/nature06835; Menges CW, 2008, ONCOGENE, V27, P2934, DOI 10.1038/sj.onc.1210957; Merritt WM, 2010, CANCER BIOL THER, V10, P1306, DOI 10.4161/cbt.10.12.13582; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Pratt RL, 2002, ONCOGENE, V21, P7690, DOI 10.1038/sj.onc.1205758; Song SM, 2009, CANCER RES, V69, P1343, DOI 10.1158/0008-5472.CAN-08-4153; Sulman EP, 1997, GENOMICS, V40, P371, DOI 10.1006/geno.1996.4569; Sundaram Meera V, 2006, WormBook, P1; Taddei ML, 2011, MOL CANCER RES, V9, P149, DOI 10.1158/1541-7786.MCR-10-0298; Tandon M, 2011, EXPERT OPIN THER TAR, V15, P31, DOI 10.1517/14728222.2011.538682; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Udayakumar D, 2011, ONCOGENE, V30, P4921, DOI 10.1038/onc.2011.210; Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002; Wang Q, 2010, ONCOGENE, V29, P128, DOI 10.1038/onc.2009.302; Yuan W, 2012, NEOPLASMA, V59, P105, DOI 10.4149/neo_2012_014; Yuan WJ, 2009, DIGEST DIS SCI, V54, P2410, DOI 10.1007/s10620-008-0649-4; Yuan WJ, 2009, PATHOL ONCOL RES, V15, P473, DOI 10.1007/s12253-008-9132-y; Zhang GQ, 2008, CANCER RES, V68, P1691, DOI 10.1158/0008-5472.CAN-07-2372	31	159	180	2	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2737	2747		10.1038/onc.2013.238	http://dx.doi.org/10.1038/onc.2013.238			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23752181				2022-12-17	WOS:000337231700007
J	Kang, R; Tang, D; Schapiro, NE; Loux, T; Livesey, KM; Billiar, TR; Wang, H; Van Houten, B; Lotze, MT; Zeh, HJ				Kang, R.; Tang, D.; Schapiro, N. E.; Loux, T.; Livesey, K. M.; Billiar, T. R.; Wang, H.; Van Houten, B.; Lotze, M. T.; Zeh, H. J.			The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics	ONCOGENE			English	Article						HMGB1; RAGE; pancreatic cancer; inflammation; mitochondria; ATP	ADVANCED GLYCATION ENDPRODUCTS; GROUP BOX-1 PROTEIN; RAGE; RECEPTOR; CANCER; AUTOPHAGY; MIGRATION; RELEASE; IMMUNE; SIGNAL	Tumor cells require increased adenosine triphosphate (ATP) to support anabolism and proliferation. The precise mechanisms regulating this process in tumor cells are unknown. Here, we show that the receptor for advanced glycation endproducts (RAGE) and one of its primary ligands, high-mobility group box 1 (HMGB1), are required for optimal mitochondrial function within tumors. We found that RAGE is present in the mitochondria of cultured tumor cells as well as primary tumors. RAGE and HMGB1 coordinately enhanced tumor cell mitochondrial complex I activity, ATP production, tumor cell proliferation and migration. Lack of RAGE or inhibition of HMGB1 release diminished ATP production and slowed tumor growth in vitro and in vivo. These findings link, for the first time, the HMGB1-RAGE pathway with changes in bioenergetics. Moreover, our observations provide a novel mechanism within the tumor microenvironment by which necrosis and inflammation promote tumor progression.	[Kang, R.; Tang, D.; Schapiro, N. E.; Loux, T.; Livesey, K. M.; Billiar, T. R.; Lotze, M. T.; Zeh, H. J.] Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Dept Surg, Pittsburgh, PA 15219 USA; [Wang, H.] NYU, Sch Med, North Shore Univ Hosp, Manhasset, NY USA; [Van Houten, B.] Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Lab Mol & Cell Biol Program, Pittsburgh, PA 15219 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; New York University; Northwell Health; North Shore University Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Tang, D (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Dept Surg, 5117 Ctr Ave, Pittsburgh, PA 15219 USA.	tangd2@upmc.edu; lotzemt@upcm.edu; zehh@upmc.edu	Tang, Daolin/B-2905-2010; Wang, Haichao/AAU-2237-2021; Kang, Rui/ABD-5291-2021; Wang, Haichao/K-6310-2012; Tang, Daolin/ABD-5062-2021; Van Houten, Bennett/K-2284-2019	Wang, Haichao/0000-0002-0211-9000; Kang, Rui/0000-0003-2725-1574; Wang, Haichao/0000-0002-0211-9000; Tang, Daolin/0000-0002-1903-6180; Loux, Tara/0000-0002-7531-6363	National Institutes of Health [P01 CA 101944, R01CA160417]; University of Pittsburgh;  [P30CA047904]; NATIONAL CANCER INSTITUTE [P01CA101944, R01CA160417, P30CA047904] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Pittsburgh(University of Pittsburgh); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We dedicate this manuscript to the memory of Angelika Bierhaus, PhD, our friend and benefactor. She was a pioneering RAGE biologist, generous and kind in her dealings with colleagues, who provided us the mice with which we completed this work, and who sadly passed away on 15 April 2012 after a long and courageous battle with cancer. Angelika had a great love of life and she was generous, kind and warm hearted. She was always full of plans for scientific endeavors, even when her disease began to take its toll. She steadfastly denied that she would be defeated, recently celebrating her 50th birthday; however, she was aware that her remaining time was short. She dedicated herself to research, but despite her incredible strength, she was not able to overcome the disease, which tragically took her life. We thank Christine Heiner (University of Pittsburgh. Department of Surgery) for her critical reading of the manuscript. This project was supported by grants from the National Institutes of Health (P01 CA 101944 to MTL, R01CA160417 to DT) and the University of Pittsburgh (DT and HJZ). This project used University of Pittsburgh Cancer Institute shared resources that are supported in part by award P30CA047904. We also thank Dr Donna Stolz and Simon Watkins for providing the confocal microscopy facilities at the Center for Biologic Imaging at University of Pittsburgh School of Medicine.	Alonso M, 2004, J NEUROCHEM, V89, P248, DOI 10.1111/j.1471-4159.2004.02323.x; Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Arciuch VGA, 2009, ADV DRUG DELIVER REV, V61, P1234, DOI 10.1016/j.addr.2009.04.025; Bianchi ME, 2009, J LEUKOCYTE BIOL, V86, P573, DOI 10.1189/jlb.1008585; Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338; DiNorcia J, 2012, J GASTROINTEST SURG, V16, P104, DOI 10.1007/s11605-011-1754-9; Galli S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007541; Gebhardt C, 2008, J EXP MED, V205, P275, DOI 10.1084/jem.20070679; Gefter JV, 2009, CELL TISSUE RES, V337, P79, DOI 10.1007/s00441-009-0791-0; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Huang J, 2012, CANCER RES, V72, P230, DOI 10.1158/0008-5472.CAN-11-2001; Hudson BI, 2008, J BIOL CHEM, V283, P34457, DOI 10.1074/jbc.M801465200; Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149; Kang R., 2012, P NATL ACAD SCI US; Kang R, 2012, P NATL ACAD SCI USA, V109, P7031, DOI 10.1073/pnas.1113865109; Kang R, 2011, ANTIOXID REDOX SIGN, V15, P2175, DOI 10.1089/ars.2010.3378; Liliensiek B, 2004, J CLIN INVEST, V113, P1641, DOI 10.1172/JCI200418704; Livesey KM, 2012, CANCER RES, V72, P1996, DOI 10.1158/0008-5472.CAN-11-2291; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Mantovani A, 2009, NATURE, V457, P36, DOI 10.1038/457036b; Mitola S, 2006, J IMMUNOL, V176, P12, DOI 10.4049/jimmunol.176.1.12; Orlova VV, 2007, EMBO J, V26, P1129, DOI 10.1038/sj.emboj.7601552; Pagliarini DJ, 2006, TRENDS BIOCHEM SCI, V31, P26, DOI 10.1016/j.tibs.2005.11.005; Palumbo R, 2004, J CELL BIOL, V164, P441, DOI 10.1083/jcb.200304135; Poderoso C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001443; Praus M, 1999, GENE THER, V6, P227, DOI 10.1038/sj.gt.3300802; Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497; Rai V, 2012, J BIOL CHEM, V287, P5133, DOI 10.1074/jbc.M111.277731; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002; Sparvero LJ, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-17; Stumbo AC, 2008, CELL BIOL INT, V32, P235, DOI 10.1016/j.cellbi.2007.08.031; Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261; Tang DL, 2007, J IMMUNOL, V179, P1236, DOI 10.4049/jimmunol.179.2.1236; Tang DL, 2011, CELL METAB, V13, P701, DOI 10.1016/j.cmet.2011.04.008; Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078; Tang DL, 2010, BBA-GENE REGUL MECH, V1799, P131, DOI 10.1016/j.bbagrm.2009.11.014; Ulloa L, 2002, P NATL ACAD SCI USA, V99, P12351, DOI 10.1073/pnas.192222999; Vakkila J, 2004, NAT REV IMMUNOL, V4, P641, DOI 10.1038/nri1415; Wang SW, 2002, BIOCHEM J, V367, P729, DOI 10.1042/BJ20020752; Wegrzyn J, 2009, SCIENCE, V323, P793, DOI 10.1126/science.1164551; Zhang YS, 2012, BIOCHEM PHARMACOL, V84, P1492, DOI 10.1016/j.bcp.2012.09.015	44	159	168	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					567	577		10.1038/onc.2012.631	http://dx.doi.org/10.1038/onc.2012.631			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23318458	Green Accepted			2022-12-17	WOS:000331125100005
J	Clendening, JW; Penn, LZ				Clendening, J. W.; Penn, L. Z.			Targeting tumor cell metabolism with statins	ONCOGENE			English	Review						mevalonate; HMGCR; statins; metabolism; transformation; cancer	COA REDUCTASE INHIBITORS; LOVASTATIN-INDUCED APOPTOSIS; POTENTIATES ANTITUMOR-ACTIVITY; BREAST-CANCER RECURRENCE; CORONARY-ARTERY-DISEASE; HUMAN ENDOTHELIAL-CELLS; COENZYME-A REDUCTASE; HIGH-DOSE LOVASTATIN; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; MEVALONATE PATHWAY	The mevalonate pathway is a core biochemical process, crucial for the generation of cholesterol and other key metabolic end products. The rate-limiting enzyme of the mevalonate pathway, hydroxymethylglutaryl coenzyme A reductase (HMGCR), is safely and effectively targeted by the statin family of inhibitors to treat hypercholesterolemia. The anticancer activity of statins has also been widely reported, yet the tumor-selective mechanisms that mediate these antiproliferative effects remain largely unclear. The importance of altered metabolism in the context of tumorigenesis has received renewed attention as metabolic changes entwined with the molecular hallmarks of cancer have been elucidated. Although several metabolic pathways have been linked to cancer progression and etiology, it was only recently that HMGCR and the mevalonate pathway were also shown to have a distinct role in cellular transformation. In this review, we chart the historical progression of statins from cholesterol-lowering blockbusters to anticancer agents with imminent potential, and further discuss an emerging role for HMGCR and the mevalonate pathway in the metabolic reprogramming of cancer. Oncogene (2012) 31, 4967-4978; doi:10.1038/onc.2012.6; published online 6 February 2012	[Penn, L. Z.] Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Penn, LZ (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	lpenn@uhnres.utoronto.ca		Penn, Linda/0000-0001-8133-5459	Canada Research Chairs Program; Ontario Institute for Cancer Research through Province of Ontario; Canadian Breast Cancer Foundation, Ontario Region; Canadian Institutes for Health Research; Ontario Ministry of Health and Long Term Care	Canada Research Chairs Program(Canada Research Chairs); Ontario Institute for Cancer Research through Province of Ontario; Canadian Breast Cancer Foundation, Ontario Region; Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Ontario Ministry of Health and Long Term Care(Ministry of Health and Long-Term Care, Ontario)	We gratefully thank members of the Penn lab for helpful discussions and critical review of the manuscript. Financial support: This work was undertaken, in part, thanks to funding from the Canada Research Chairs Program (L.Z.P), the Ontario Institute for Cancer Research through funding provided by the Province of Ontario (L.Z.P.), the Canadian Breast Cancer Foundation, Ontario Region (L.Z.P.), the Excellence In Radiation Research for the 21st Century Strategic Training Initiative In Health Research from the Canadian Institutes for Health Research (J.W.C.), and the Ontario Ministry of Health and Long Term Care. The views expressed do not necessarily reflect those of the Ontario Ministry of Health and Long Term Care.	Abud-Mendoza C, 2003, LUPUS, V12, P607, DOI 10.1191/0961203303lu429oa; Ahern TP, 2011, JNCI-J NATL CANCER I, V103, P1461, DOI 10.1093/jnci/djr291; Ahn KS, 2008, BIOCHEM PHARMACOL, V75, P907, DOI 10.1016/j.bcp.2007.10.010; ALBERTS AW, 1989, CARDIOVASC DRUG REV, V7, P89, DOI 10.1111/j.1527-3466.1989.tb00519.x; Altenberg B, 2004, GENOMICS, V84, P1014, DOI 10.1016/j.ygeno.2004.08.010; Banker DE, 2004, BLOOD, V104, P1816, DOI 10.1182/blood-2004-01-0395; Bauer DE, 2005, ONCOGENE, V24, P6314, DOI 10.1038/sj.onc.1208773; Bischoff H, 1997, ATHEROSCLEROSIS, V135, P119, DOI 10.1016/S0021-9150(97)00188-3; BISCHOFF KM, 1992, BIOCHEM MED METAB B, V48, P149, DOI 10.1016/0885-4505(92)90060-C; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; Bonovas S, 2005, J CLIN ONCOL, V23, P8606, DOI 10.1200/JCO.2005.02.7045; Boudreau DM, 2007, CANCER EPIDEM BIOMAR, V16, P416, DOI 10.1158/1055-9965.EPI-06-0737; Boudreau DM, 2010, EXPERT OPIN DRUG SAF, V9, P603, DOI 10.1517/14740331003662620; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Brown MS, 2009, J LIPID RES, V50, pS15; BUCHWALD H, 1992, LANCET, V339, P1154, DOI 10.1016/0140-6736(92)90744-N; Burbelo P, 2004, BREAST CANCER RES TR, V84, P43, DOI 10.1023/B:BREA.0000018422.02237.f9; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Campbell MJ, 2006, CANCER RES, V66, P8707, DOI 10.1158/0008-5472.CAN-05-4061; Cao ZW, 2011, CANCER RES, V71, P2286, DOI 10.1158/0008-5472.CAN-10-3367; Cauley JA, 2006, J NATL CANCER I, V98, P700, DOI 10.1093/jnci/djj188; Celis JE, 2006, MOL CELL PROTEOMICS, V5, P462, DOI 10.1074/mcp.M500348-MCP200; Cernuda-Morollon E, 2006, CIRC RES, V98, P757, DOI 10.1161/01.RES.0000210579.35304.d3; Chan KKW, 2003, CLIN CANCER RES, V9, P10; CHAO FC, 1975, CANCER, V35, P1223, DOI 10.1002/1097-0142(197504)35:4<1223::AID-CNCR2820350429>3.0.CO;2-T; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Clendening JW, 2010, P NATL ACAD SCI USA, V107, P15051, DOI 10.1073/pnas.0910258107; Clendening JW, 2010, BLOOD, V115, P4787, DOI 10.1182/blood-2009-07-230508; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; CORSINI A, 1995, PHARMACOL RES, V31, P9, DOI 10.1016/1043-6618(95)80042-5; Cox G, 2001, ANTICANCER RES, V21, P4207; CUTTS JL, 1989, J CELL PHYSIOL, V139, P550, DOI 10.1002/jcp.1041390314; Dale KM, 2006, JAMA-J AM MED ASSOC, V295, P74, DOI 10.1001/jama.295.1.74; Davidson MH, 2001, DRUGS, V61, P197, DOI 10.2165/00003495-200161020-00005; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Dimitroulakos J, 1999, BLOOD, V93, P1308, DOI 10.1182/blood.V93.4.1308.404k08_1308_1318; Dimitroulakos J, 2001, CLIN CANCER RES, V7, P158; Dimitroulakos J, 1996, NAT MED, V2, P326, DOI 10.1038/nm0396-326; Dirks AJ, 2006, AM J PHYSIOL-CELL PH, V291, pC1208, DOI 10.1152/ajpcell.00226.2006; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Duncan Robin E., 2004, Journal of Pharmacological and Toxicological Methods, V50, P139, DOI 10.1016/j.vascn.2004.03.001; El-Serag HB, 2009, GASTROENTEROLOGY, V136, P1601, DOI 10.1053/j.gastro.2009.01.053; ENDO A, 1976, FEBS LETT, V72, P323, DOI 10.1016/0014-5793(76)80996-9; ENDO A, 1992, J LIPID RES, V33, P1569; Erickson JW, 2004, BIOCHEMISTRY-US, V43, P837, DOI 10.1021/bi036026v; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561; Feleszko W, 2000, CLIN CANCER RES, V6, P2044; Feleszko W, 2002, INT J CANCER, V100, P111, DOI 10.1002/ijc.10440; Fildes JE, 2009, CANCER IMMUNOL IMMUN, V58, P461, DOI 10.1007/s00262-008-0541-2; Forrester JS, 2007, AM J CARDIOL, V99, P732, DOI 10.1016/j.amjcard.2006.09.125; Fritz G, 2002, BRIT J CANCER, V87, P635, DOI 10.1038/sj.bjc.6600510; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Fritz G, 2003, INT J RADIAT BIOL, V79, P601, DOI 10.1080/09553000310001609233; Fritz G, 2009, CURR CANCER DRUG TAR, V9, P626, DOI 10.2174/156800909789057033; Fritz G, 2011, BRIT MED BULL, V97, P17, DOI 10.1093/bmb/ldq044; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; Garwood ER, 2010, BREAST CANCER RES TR, V119, P137, DOI 10.1007/s10549-009-0507-x; Gauthaman K, 2007, REPROD BIOMED ONLINE, V15, P566, DOI 10.1016/S1472-6483(10)60390-2; Goard CA, 2010, INT J CANCER, V127, P2936, DOI 10.1002/ijc.25295; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Graaf MR, 2004, J CLIN ONCOL, V22, P2388, DOI 10.1200/JCO.2004.02.027; Graf H, 2008, DIGESTION, V78, P34, DOI 10.1159/000156702; GrayBablin J, 1997, CANCER RES, V57, P604; Gronich N, 2004, J INVEST MED, V52, P335, DOI 10.1136/jim-52-05-34; GRUNDY SM, 1988, NEW ENGL J MED, V319, P24; Guan Jing-Zhi, 2004, J Atheroscler Thromb, V11, P56; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haria M, 1997, DRUGS, V53, P299, DOI 10.2165/00003495-199753020-00008; Hirsch HA, 2010, CANCER CELL, V17, P348, DOI 10.1016/j.ccr.2010.01.022; Holstein SA, 2006, CANCER CHEMOTH PHARM, V57, P155, DOI 10.1007/s00280-005-0013-8; Hu J, 2011, ANN ONCOL; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Istvan ES, 2001, SCIENCE, V292, P1160, DOI 10.1126/science.1059344; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; Jakobisiak M, 2010, MED RES REV, V30, P102, DOI 10.1002/med.20162; Janardhan S, 2006, CURR MED CHEM, V13, P1169, DOI 10.2174/092986706776360923; JONES KD, 1994, BIOCHEM BIOPH RES CO, V205, P1681, DOI 10.1006/bbrc.1994.2861; Jones P, 1998, AM J CARDIOL, V81, P582, DOI 10.1016/S0002-9149(97)00965-X; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; Kajinami K, 2000, EXPERT OPIN INV DRUG, V9, P2653, DOI 10.1517/13543784.9.11.2653; Kamai T, 2001, BJU INT, V87, P227, DOI 10.1046/j.1464-410x.2001.02030.x; Kamai T, 2004, CLIN CANCER RES, V10, P4799, DOI 10.1158/1078-0432.CCR-0436-03; KANEKO I, 1978, EUR J BIOCHEM, V87, P313; KANNEL WB, 1995, CIRCULATION, V92, P3350, DOI 10.1161/01.CIR.92.11.3350; Katz MS, 2005, INT J RADIAT ONCOL, V62, P1363, DOI 10.1016/j.ijrobp.2004.12.033; Katz MS, 2005, NAT CLIN PRACT ONCOL, V2, P82, DOI 10.1038/ncponc0097; Kawata S, 2001, BRIT J CANCER, V84, P886, DOI 10.1054/bjoc.2000.1716; KEYOMARSI K, 1991, CANCER RES, V51, P3602; Kikuchi H, 2009, CANCER RES, V69, P8499, DOI 10.1158/0008-5472.CAN-09-2213; Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501; Kim WS, 2001, INVEST NEW DRUG, V19, P81, DOI 10.1023/A:1006481423298; Kleer CG, 2002, AM J PATHOL, V160, P579, DOI 10.1016/S0002-9440(10)64877-8; Knox JJ, 2005, EUR J CANCER, V41, P523, DOI 10.1016/j.ejca.2004.12.013; Kok DEG, 2011, PROSTATE CANCER P D, V14, P340, DOI 10.1038/pcan.2011.30; Konings IRHM, 2010, EUR J CANCER, V46, P3200, DOI 10.1016/j.ejca.2010.07.036; Konstantinopoulos PA, 2007, NAT REV DRUG DISCOV, V6, P540, DOI 10.1038/nrd2221; Kornblau SM, 2007, BLOOD, V109, P2999, DOI 10.1182/blood-2006-08-044446; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Kuhajda FP, 2008, INT J OBESITY, V32, pS36, DOI 10.1038/ijo.2008.121; Kumar AS, 2008, CANCER EPIDEM BIOMAR, V17, P1028, DOI 10.1158/1055-9965.EPI-07-0726; Kuoppala J, 2008, EUR J CANCER, V44, P2122, DOI 10.1016/j.ejca.2008.06.025; Kwan ML, 2008, BREAST CANCER RES TR, V109, P573, DOI 10.1007/s10549-007-9683-8; Lamperti C, 2005, ARCH NEUROL-CHICAGO, V62, P1709, DOI 10.1001/archneur.62.11.1709; Landsberger M, 2007, ATHEROSCLEROSIS, V190, P43, DOI 10.1016/j.atherosclerosis.2006.02.009; Larner J, 1998, AM J CLIN ONCOL-CANC, V21, P579, DOI 10.1097/00000421-199812000-00010; Larsson O, 1996, CRIT REV ONCOL HEMAT, V22, P197, DOI 10.1016/1040-8428(96)00193-X; Lee J, 2009, CANCER CHEMOTH PHARM, V64, P657, DOI 10.1007/s00280-008-0913-5; Leoni V, 2002, NEUROSCI LETT, V331, P163, DOI 10.1016/S0304-3940(02)00887-X; Lersch C, 2004, HEPATO-GASTROENTEROL, V51, P1099; Li HY, 2003, BLOOD, V101, P3628, DOI 10.1182/blood-2002-07-2283; Li Y, 2011, CELL METAB, V13, P376, DOI 10.1016/j.cmet.2011.03.009; Locatelli S, 2002, ARCH NEUROL-CHICAGO, V59, P213, DOI 10.1001/archneur.59.2.213; Lopez-Aguilar E, 1999, ARCH MED RES, V30, P128, DOI 10.1016/S0188-0128(98)00018-9; Lopez-Aguilar E, 2008, ARCH MED RES, V39, P655, DOI 10.1016/j.arcmed.2008.05.008; Lucken-Ardjomande S, 2008, CELL DEATH DIFFER, V15, P484, DOI 10.1038/sj.cdd.4402280; Lupattelli G, 2004, METABOLISM, V53, P744, DOI 10.1016/j.metabol.2004.01.010; Macaulay RJB, 1999, J NEURO-ONCOL, V42, P1, DOI 10.1023/A:1006164406202; Malinowski JM, 1998, AM J HEALTH-SYST PH, V55, P2253, DOI 10.1093/ajhp/55.21.2253; Martirosyan A, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-103; Mason RP, 2005, AM J CARDIOL, V96, p11F, DOI 10.1016/j.amjcard.2005.06.008; Mathew B, 2011, AM J RESP CELL MOL, V44, P415, DOI 10.1165/rcmb.2010-0122OC; McCarey DW, 2004, LANCET, V363, P2015, DOI 10.1016/S0140-6736(04)16449-0; McTaggart F, 2001, AM J CARDIOL, V87, p28B; Meier CR, 2000, JAMA-J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205; Menon S, 2008, Oncogene, V27 Suppl 2, pS43, DOI 10.1038/onc.2009.352; Migita T, 2009, JNCI-J NATL CANCER I, V101, P519, DOI 10.1093/jnci/djp030; Minden MD, 2001, LEUKEMIA LYMPHOMA, V40, P659, DOI 10.3109/10428190109097663; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; Mo HB, 2004, EXP BIOL MED, V229, P567, DOI 10.1177/153537020422900701; Moorman PG, 2007, EPIDEMIOLOGY, V18, P194, DOI 10.1097/01.ede.0000254699.31405.e2; Morgan MA, 2005, BRIT J HAEMATOL, V130, P912, DOI 10.1111/j.1365-2141.2005.05696.x; Motoshima H, 2006, J PHYSIOL-LONDON, V574, P63, DOI 10.1113/jphysiol.2006.108324; Muller C, 1998, INT J ONCOL, V12, P717; Nabatov AA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000470; Newman A, 1997, LEUKEMIA LYMPHOMA, V24, P533, DOI 10.3109/10428199709055590; NEWMAN A, 1994, LEUKEMIA, V8, P2022; NIH Consensus Development Conference, 1985, WIS MED J, V84, P18; Nubel T, 2006, CLIN CANCER RES, V12, P933, DOI 10.1158/1078-0432.CCR-05-1903; OLIVER MF, 1994, LANCET, V344, P633; Ostrau C, 2009, RADIOTHER ONCOL, V92, P492, DOI 10.1016/j.radonc.2009.06.020; Otsuki T, 2004, ONCOL REP, V11, P1053; Pallottini V, 2008, J CELL BIOCHEM, V104, P701, DOI 10.1002/jcb.21757; Pan James G, 2007, Sci STKE, V2007, ppe14; Pedersen TR, 1996, ARCH INTERN MED, V156, P2085, DOI 10.1001/archinte.156.18.2085; PEDERSEN TR, 1994, LANCET, V344, P1383; PEREZSALA D, 1994, BIOCHEM BIOPH RES CO, V199, P1209, DOI 10.1006/bbrc.1994.1359; PITT B, 1995, J AM COLL CARDIOL, V26, P1133, DOI 10.1016/0735-1097(95)00301-0; PLOSKER GL, 1995, DRUGS, V50, P334, DOI 10.2165/00003495-199550020-00009; Plosker GL, 1996, DRUGS, V51, P433, DOI 10.2165/00003495-199651030-00011; Pocathikorn A, 2010, CLIN EXP PHARMACOL P, V37, P471, DOI 10.1111/j.1440-1681.2009.05337.x; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Poynter JN, 2005, NEW ENGL J MED, V352, P2184, DOI 10.1056/NEJMoa043792; Rao S, 1998, ONCOGENE, V17, P2393, DOI 10.1038/sj.onc.1202322; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Ray KK, 2005, J AM COLL CARDIOL, V46, P1425, DOI 10.1016/j.jacc.2005.05.086; Rubins JB, 1998, AM J RESP CRIT CARE, V157, P1616, DOI 10.1164/ajrccm.157.5.9709020; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SALONEN R, 1995, CIRCULATION, V92, P1758, DOI 10.1161/01.CIR.92.7.1758; Samson KTR, 2005, CELL IMMUNOL, V235, P136, DOI 10.1016/j.cellimm.2005.08.028; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sassano A, 2008, CANCER LETT, V260, P11, DOI 10.1016/j.canlet.2007.11.036; Schmidmaier R, 2007, EUR J HAEMATOL, V79, P240, DOI 10.1111/j.1600-0609.2007.00902.x; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Shitara Y, 2006, PHARMACOL THERAPEUT, V112, P71, DOI 10.1016/j.pharmthera.2006.03.003; Siperstein M D, 1970, Trans Am Clin Climatol Assoc, V81, P107; Sondergaard TE, 2009, HEMATOL ONCOL, V27, P17, DOI 10.1002/hon.869; Stanislaus R, 2002, NEUROSCI LETT, V333, P167, DOI 10.1016/S0304-3940(02)00943-6; Steinberg D, 1999, JAMA-J AM MED ASSOC, V282, P2043, DOI 10.1001/jama.282.21.2043; Stirewalt DL, 2003, LEUKEMIA RES, V27, P133, DOI 10.1016/S0145-2126(02)00085-1; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Tan N, 2011, J UROLOGY, V186, P86, DOI 10.1016/j.juro.2011.03.004; Tanaka T, 2007, INT IMMUNOL, V19, P163, DOI 10.1093/intimm/dxl133; Taylor ML, 2008, EUR J CANCER PREV, V17, P259, DOI 10.1097/CEJ.0b013e3282b721fe; Thibault A, 1996, CLIN CANCER RES, V2, P483; Tobert JA, 2003, NAT REV DRUG DISCOV, V2, P517, DOI 10.1038/nrd1112; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; TSUJITA Y, 1979, ATHEROSCLEROSIS, V32, P307, DOI 10.1016/0021-9150(79)90174-6; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; van de Donk NWCJ, 2002, LEUKEMIA, V16, P1362, DOI 10.1038/sj.leu.2402501; van der Spek E, 2007, HAEMATOLOGICA, V92, pE130, DOI 10.3324/haematol.12071; van der Spek E, 2006, HAEMATOLOGICA, V91, P542; Veillard NR, 2006, ATHEROSCLEROSIS, V188, P51, DOI 10.1016/j.atherosclerosis.2005.10.015; Wachtershauser A, 2001, CARCINOGENESIS, V22, P1061, DOI 10.1093/carcin/22.7.1061; Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009; Wang PS, 2000, JAMA-J AM MED ASSOC, V283, P3211, DOI 10.1001/jama.283.24.3211; Wang WG, 2002, FEBS LETT, V531, P415, DOI 10.1016/S0014-5793(02)03575-5; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959; Weng TC, 2010, J CLIN PHARM THER, V35, P139, DOI 10.1111/j.1365-2710.2009.01085.x; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Woditschka S, 2010, CANCER EPIDEM BIOMAR, V19, P2479, DOI 10.1158/1055-9965.EPI-10-0524; Wong WWL, 2007, MOL CANCER THER, V6, P1886, DOI 10.1158/1535-7163.MCT-06-0745; Wong WWL, 2002, LEUKEMIA, V16, P508, DOI 10.1038/sj.leu.2402476; Wong WWL, 2001, CLIN CANCER RES, V7, P2067; YAMAMOTO A, 1980, ATHEROSCLEROSIS, V35, P259, DOI 10.1016/0021-9150(80)90124-0; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhou Z, 2006, AM HEART J, V151, P273, DOI 10.1016/j.ahj.2005.04.003	207	159	164	1	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	48					4967	4978		10.1038/onc.2012.6	http://dx.doi.org/10.1038/onc.2012.6			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048CU	22310279				2022-12-17	WOS:000311888600001
J	Xing, F; Okuda, H; Watabe, M; Kobayashi, A; Pai, SK; Liu, W; Pandey, PR; Fukuda, K; Hirota, S; Sugai, T; Wakabayshi, G; Koeda, K; Kashiwaba, M; Suzuki, K; Chiba, T; Endo, M; Mo, YY; Watabe, K				Xing, F.; Okuda, H.; Watabe, M.; Kobayashi, A.; Pai, S. K.; Liu, W.; Pandey, P. R.; Fukuda, K.; Hirota, S.; Sugai, T.; Wakabayshi, G.; Koeda, K.; Kashiwaba, M.; Suzuki, K.; Chiba, T.; Endo, M.; Mo, Y-Y; Watabe, K.			Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells	ONCOGENE			English	Article						Jagged2; Notch; breast cancer; hypoxia; cancer stem-like cells	INDUCIBLE-FACTOR 1-ALPHA; NOTCH LIGANDS; ACTIVATION; BONE; SURVIVAL; GENE; AKT; OVEREXPRESSION; ADENOCARCINOMA; PROLIFERATION	Notch signaling is often and aberrantly activated by hypoxia during tumor progression; however, the exact pathological role of hypoxia-induced Notch signaling in tumor metastasis is as yet poorly understood. In this study, we aimed to define the mechanism of Notch-ligand activation by hypoxia in both primary tumor and bone stromal cells in the metastatic niche and to clarify their roles in tumor progression. We have analyzed the expression profiles of various Notch ligands in 779 breast cancer patients in GEO database and found that the expression of Jagged2 among all five ligands is most significantly correlated with the overall-and metastasis-free survival of breast cancer patients. The results of our immunohistochemical (IHC) analysis for Jagged2 in 61 clinical samples also revealed that both Jagged2 and Notch signaling were strongly upregulated at the hypoxic invasive front. Activation of Jagged2 by hypoxia in tumor cells induced EMT and also promoted cell survival in vitro. Notably, a c-secretase inhibitor significantly blocked Notch-mediated invasion and survival under hypoxia by promoting expression of E-cadherin and inhibiting Akt phosphorylation. Importantly, Jagged2 was also found to be upregulated in bone marrow stroma under hypoxia and promoted the growth of cancer stem-like cells by activating their Notch signaling. Therefore, hypoxia-induced Jagged2 activation in both tumor invasive front and normal bone stroma has a critical role in tumor progression and metastasis, and Jagged2 is considered to be a valuable prognostic marker and may serve as a novel therapeutic target for metastatic breast cancer. Oncogene (2011) 30, 4075-4086; doi:10.1038/onc.2011.122; published online 18 April 2011	[Xing, F.; Okuda, H.; Watabe, M.; Kobayashi, A.; Pai, S. K.; Liu, W.; Pandey, P. R.; Fukuda, K.; Mo, Y-Y; Watabe, K.] So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, Springfield, IL 62702 USA; [Hirota, S.; Sugai, T.; Wakabayshi, G.; Koeda, K.; Kashiwaba, M.; Suzuki, K.; Chiba, T.; Endo, M.] Iwate Med Univ, Sch Med, Morioka, Iwate, Japan	Southern Illinois University System; Southern Illinois University; Iwate Medical University	Watabe, K (corresponding author), So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, 751 N Rutledge St,POB 19626, Springfield, IL 62702 USA.	kwatabe@siumed.edu	Kobayashi, Aya/AAA-2530-2020; Mo, Yin-Yuan/R-8255-2019	Chiba, Toshimi/0000-0001-7072-3157; Okuda, Hiroshi/0000-0002-5747-8086	NIH [R01CA124650, R01CA129000]; US Department of Defense [BC085424, BC085590]; Susan Komen Foundation [KG080477]; NATIONAL CANCER INSTITUTE [R01CA124650, R01CA129000] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Defense(United States Department of Defense); Susan Komen Foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH (R01CA124650, R01CA129000 to KW), the US Department of Defense (BC085424, BC085590 to KW) and Susan Komen Foundation (KG080477 to KW).	Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bandyopadhyay S, 2006, CANCER RES, V66, P11983, DOI 10.1158/0008-5472.CAN-06-0943; Bedogni B, 2008, J CLIN INVEST, V118, P3660, DOI 10.1172/JCI36157; Bertout JA, 2009, CANCER RES, V69, P3213, DOI 10.1158/0008-5472.CAN-08-4223; Cejudo-Martin P, 2005, DEV CELL, V9, P575, DOI 10.1016/j.devcel.2005.10.001; Chen YB, 2007, CANCER RES, V67, P7954, DOI 10.1158/0008-5472.CAN-07-1229; Choi K, 2009, J BIOL CHEM, V284, P17766, DOI 10.1074/jbc.M109.003111; D'Souza B, 2010, CURR TOP DEV BIOL, V92, P73, DOI 10.1016/S0070-2153(10)92003-6; Das B, 2008, STEM CELLS, V26, P1818, DOI 10.1634/stemcells.2007-0724; Dickson BC, 2007, MODERN PATHOL, V20, P685, DOI 10.1038/modpathol.3800785; Eliasz S, 2010, ONCOGENE, V29, P2488, DOI 10.1038/onc.2010.7; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Felli MP, 1999, INT IMMUNOL, V11, P1017, DOI 10.1093/intimm/11.7.1017; Furuta E, 2008, CANCER RES, V68, P1003, DOI 10.1158/0008-5472.CAN-07-2489; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Haase VH, 2009, KIDNEY INT, V76, P492, DOI 10.1038/ki.2009.222; Horree N, 2007, HUM PATHOL, V38, P1232, DOI 10.1016/j.humpath.2007.01.008; Kiaris H, 2004, AM J PATHOL, V165, P695, DOI 10.1016/S0002-9440(10)63333-0; Klinakis A, 2006, P NATL ACAD SCI USA, V103, P9262, DOI 10.1073/pnas.0603371103; Koch U, 2007, CELL MOL LIFE SCI, V64, P2746, DOI 10.1007/s00018-007-7164-1; Kominsky SL, 2006, J CLIN ONCOL, V24, P2227, DOI 10.1200/JCO.2005.05.5319; Lambin P, 1998, ANAEROBE, V4, P183, DOI 10.1006/anae.1998.0161; Lee SH, 2007, APMIS, V115, P1357, DOI 10.1111/j.1600-0463.2007.00751.x; Leong KG, 2006, BLOOD, V107, P2223, DOI 10.1182/blood-2005-08-3329; Main H, 2010, EXP CELL RES, V316, P1610, DOI 10.1016/j.yexcr.2009.12.012; Maynard MA, 2007, CELL MOL LIFE SCI, V64, P2170, DOI 10.1007/s00018-007-7082-2; Mullendore ME, 2009, CLIN CANCER RES, V15, P2291, DOI 10.1158/1078-0432.CCR-08-2004; Nam DH, 2008, CLIN CANCER RES, V14, P4059, DOI 10.1158/1078-0432.CCR-07-4039; Parmar K, 2007, P NATL ACAD SCI USA, V104, P5431, DOI 10.1073/pnas.0701152104; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105; Schindl M, 2002, CLIN CANCER RES, V8, P1831; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Tomes L, 2003, BREAST CANCER RES TR, V81, P61, DOI 10.1023/A:1025476722493; Wang ZW, 2010, BBA-REV CANCER, V1806, P258, DOI 10.1016/j.bbcan.2010.06.001; Yin T, 2006, J CLIN INVEST, V116, P1195, DOI 10.1172/JCI28568; Yu XB, 2008, CELL STEM CELL, V2, P461, DOI 10.1016/j.stem.2008.03.001; Zhao NJ, 2010, ONCOL REP, V23, P1443, DOI 10.3892/or_00000782; Zhong H, 1999, CANCER RES, V59, P5830	41	159	166	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	39					4075	4086		10.1038/onc.2011.122	http://dx.doi.org/10.1038/onc.2011.122			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	826ME	21499308	Green Accepted			2022-12-17	WOS:000295357500003
J	Zhang, Y; Zhang, M; Dong, H; Yong, S; Li, X; Olashaw, N; Kruk, PA; Cheng, JQ; Bai, W; Chen, J; Nicosia, SV; Zhang, X				Zhang, Y.; Zhang, M.; Dong, H.; Yong, S.; Li, X.; Olashaw, N.; Kruk, P. A.; Cheng, J. Q.; Bai, W.; Chen, J.; Nicosia, S. V.; Zhang, X.			Deacetylation of cortactin by SIRT1 promotes cell migration	ONCOGENE			English	Article						SIRT1; cancer; migration; cortactin; deacetylation; p300	TYROSINE PHOSPHORYLATION; HISTONE DEACETYLASES; CALORIE RESTRICTION; EMS1 GENE; ACETYLATION; ACTIN; P53; OVEREXPRESSION; AMPLIFICATION; TRANSCRIPTION	Cortactin binds F-actin and promotes cell migration. We showed earlier that cortactin is acetylated. Here, we identify SIRT1 (a class III histone deacetylase) as a cortactin deacetylase and p300 as a cortactin acetylase. We show that SIRT1 deacetylates cortactin in vivo and in vitro and that the SIRT1 inhibitor EX-527 increases amounts of acetylated cortactin in ovarian cancer cells. We also show that p300 acetylates cortactin in vivo and that cells lacking or depleted of p300 express less-acetylated cortactin than do control cells. Deletion analysis mapped the SIRT1-binding domain of cortactin to its repeat region, which also binds F-actin. Mouse embryo fibroblasts (MEFs) lacking sir2 alpha (the mouse homolog of SIRT1) migrated more slowly than did wildtype cells. The expression of SIRT1 in sir2 alpha-null cells restored migratory capacity, as did expression of a deacetylation-mimetic mutant of cortactin. SIRT1 and cortactin were more abundant in breast tumor tissue than in their normal counterparts, whereas SIRT1 expression inversely correlates with the ratio of acetylation cortactin versus total cortactin. These data suggest that deacetylation of cortactin is associated with high levels of SIRT1 and tumorigenesis. Finally, breast and ovarian cancer cell lines expressing an acetylation mimetic mutant of cortactin are less motile than that of control cells, whereas cells expressing the deacetylation mimetic mutant of cortactin migrate faster than that of control cells in Transwell migration assays. In summary, our results suggest that cortactin is a novel substrate for SIRT1 and p300 and, for the first time, a possible role for SIRT1 in cell motility through deacetylation of cortactin.	[Zhang, Y.; Zhang, M.; Dong, H.; Yong, S.; Li, X.; Kruk, P. A.; Bai, W.; Nicosia, S. V.; Zhang, X.] Univ S Florida, Coll Med, Dept Pathol & Cell Biol, Tampa, FL 33612 USA; [Olashaw, N.; Kruk, P. A.; Cheng, J. Q.; Bai, W.; Chen, J.; Zhang, X.] H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL USA; [Nicosia, S. V.] H Lee Moffitt Canc Ctr & Res Inst, Expt Therapeut Program, Tampa, FL USA	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Zhang, X (corresponding author), Univ S Florida, Coll Med, Dept Pathol & Cell Biol, 12901 Bruce B Downs Blvd,MDC11, Tampa, FL 33612 USA.	xzhang1@health.usf.edu	Bai, Wenlong/A-8977-2013; Kruk, Patricia/I-6489-2012	Bai, Wenlong/0000-0002-9536-0556; 	USE College of Medicine; H Lee Moffitt Cancer Center; USE New Researcher grant; Marsha Rivkin Center Scientific Scholar award; Bankhead-Coley Biomedical Research Program New Investigator Research Grant	USE College of Medicine; H Lee Moffitt Cancer Center; USE New Researcher grant; Marsha Rivkin Center Scientific Scholar award; Bankhead-Coley Biomedical Research Program New Investigator Research Grant	We are indebted to Dr Edward Seto for sirtuins plasmids. We thank Dr Michael W McBurney for sir2 alpha<SUP>+/+</SUP> and sir2 alpha / MEFs; Dr James A DeCaprio for p300<SUP>+/+</SUP> and p300 / MEFs; Dr Don F Cameron for microscope usage; Drs Srikumar Chellappan, Gloria Ferreira, Mike Yuan, Zheng Shen, Mei Sun and Hua Yang for helpful discussions; Ms Kathleen Merkler for critical reading of this manuscript and Dr Ulmesh Jinwal for technical assistance. We also thank the H Lee Moffitt Cancer Center Analytic Microscopy Core Facility for their technical support and H Lee Moffitt Cancer Center Tissue Procurement for breast and ovarian tissues. This work was supported partly by 'Start-up' funds from the USE College of Medicine and H Lee Moffitt Cancer Center, an USE New Researcher grant, a Marsha Rivkin Center Scientific Scholar award for ovarian cancer research and a Bankhead-Coley Biomedical Research Program New Investigator Research Grant to XZ.	Aizawa H, 2004, SCIENCE, V303, P197, DOI 10.1126/science.1089845; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Bringuier PP, 1996, ONCOGENE, V12, P1747; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Bryce NS, 2005, CURR BIOL, V15, P1276, DOI 10.1016/j.cub.2005.06.043; Buday L, 2007, BBA-REV CANCER, V1775, P263, DOI 10.1016/j.bbcan.2006.12.002; Campbell DH, 1999, CANCER RES, V59, P5376; Cao H, 2005, NAT CELL BIOL, V7, P483, DOI 10.1038/ncb1246; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gregoretti IV, 2004, J MOL BIOL, V338, P17, DOI 10.1016/j.jmb.2004.02.006; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Guarente L, 2005, MECH AGEING DEV, V126, P923, DOI 10.1016/j.mad.2005.03.013; Hallows WC, 2006, P NATL ACAD SCI USA, V103, P10230, DOI 10.1073/pnas.0604392103; Head JA, 2003, MOL BIOL CELL, V14, P3216, DOI 10.1091/mbc.e02-11-0753; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Jin QH, 2007, J CELL PHYSIOL, V213, P88, DOI 10.1002/jcp.21091; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Kessels MM, 2005, NAT CELL BIOL, V7, P448, DOI 10.1038/ncb0505-448; Krubasik D, 2006, BRIT J CANCER, V94, P1326, DOI 10.1038/sj.bjc.6603101; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Leipe DD, 1997, NUCLEIC ACIDS RES, V25, P3693, DOI 10.1093/nar/25.18.3693; Li YS, 2001, CANCER RES, V61, P6906; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Martin KH, 2006, J CELL SCI, V119, P2851, DOI 10.1242/jcs03034; Martinez-Quiles N, 2004, MOL CELL BIOL, V24, P5269, DOI 10.1128/MCB.24.12.5269-5280.2004; Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Moynihan KA, 2005, CELL METAB, V2, P105, DOI 10.1016/j.cmet.2005.07.001; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Ohsawa S, 2006, FEBS LETT, V580, P5875, DOI 10.1016/j.febslet.2006.09.051; Patel AM, 1996, ONCOGENE, V12, P31; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rodrigo JP, 2000, CLIN CANCER RES, V6, P3177; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; Solomon JM, 2006, MOL CELL BIOL, V26, P28, DOI 10.1128/MCB.26.1.28-38.2006; Stuenkel Walter, 2007, Biotechnology Journal, V2, P1360, DOI 10.1002/biot.200700087; Tanno M, 2007, J BIOL CHEM, V282, P6823, DOI 10.1074/jbc.M609554200; Timpson P, 2005, CANCER RES, V65, P3273, DOI 10.1158/0008-5472.CAN-04-2118; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; Wolf G, 2006, NUTR REV, V64, P89, DOI [10.1111/j.1753-4887.2006.tb00192.x, 10.1301/nr.2006.feb.89-92]; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yuan BZ, 2003, J MOL DIAGN, V5, P48, DOI 10.1016/S1525-1578(10)60451-5; Zhang XH, 2007, MOL CELL, V27, P197, DOI 10.1016/j.molcel.2007.05.033	60	159	162	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					445	460		10.1038/onc.2008.388	http://dx.doi.org/10.1038/onc.2008.388			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18850005				2022-12-17	WOS:000262550300012
J	Wozniak, RJ; Klimecki, WT; Lau, SS; Feinstein, Y; Futscher, BW				Wozniak, R. J.; Klimecki, W. T.; Lau, S. S.; Feinstein, Y.; Futscher, B. W.			5-Aza-2 '-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3K9 di-methylation levels are linked to tumor suppressor gene reactivation	ONCOGENE			English	Article						5-aza-2 '-deoxycytidine; H3K9 methylation; cytosine methylation; tumor suppressor; breast cancer; G9A histone methyltransferase	ABERRANT CYTOSINE METHYLATION; RISK MYELODYSPLASTIC SYNDROME; CPG-BINDING-PROTEIN; HUMAN BREAST-CANCER; DNA METHYLATION; PROMOTER HYPERMETHYLATION; HYPOMETHYLATING AGENT; COLORECTAL-CANCER; BRCA1 PROMOTER; LUNG-CANCER	The epigenetic silencing of tumor suppressor genes is a common event during carcinogenesis, and often involves aberrant DNA methylation and histone modi. cation of gene regulatory regions, resulting in the formation of a transcriptionally repressive chromatin state. Two examples include the antimetastatic, tumor suppressor genes, desmocollin 3 (DSC3) and MASPIN, which are frequently silenced in this manner in human breast cancer. Treatment of the breast tumor cell lines MDA-MB-231 and UACC 1179 with 5-aza-20-deoxycytidine (5-aza-CdR) induced transcriptional reactivation of both genes in a dose-dependent manner. Importantly, DSC3 and MASPIN reactivation was closely and consistently linked with significant decreases in promoter H3 K9 di-methylation. Moreover, 5-aza-CdR treatment also resulted in global decreases in H3 K9 di-methylation, an effect that was linked to its ability to mediate dose-dependent, post-transcriptional decreases in the key enzyme responsible for this epigenetic modification, G9A. Finally, small interfering RNA (siRNA)-mediated knockdown of G9A and DNMT1 led to increased MASPIN expression in MDA-MB-231 cells, to levels that were supra-additive, verifying the importance of these enzymes in maintaining multiple layers of epigenetic repression in breast tumor cells. These results highlight an additional, complimentary mechanism of action for 5-aza-CdR in the reactivation of epigenetically silenced genes, in a manner that is independent of its effects on DNA methylation, further supporting an important role for H3 K9 methylation in the aberrant repression of tumor suppressor genes in human cancer.	Univ Arizona, Arizona Canc Ctr, Dept Pharmacol & Toxicol, Tucson, AZ 85724 USA; Univ Arizona, Arizona Resp Sci Ctr, Tucson, AZ USA; Univ Arizona, Arizona Canc Ctr, SW Environm Hlth Sci Ctr Prote Core, Tucson, AZ USA	Arizona Center Cancer Care; University of Arizona; University of Arizona; Arizona Center Cancer Care; University of Arizona	Futscher, BW (corresponding author), Univ Arizona, Arizona Canc Ctr, Dept Pharmacol & Toxicol, 1515 N Campbell Ave, Tucson, AZ 85724 USA.	bfutscher@azcc.arizona.edu			NCI NIH HHS [R01 CA065662, CA65662, T32-CA09213] Funding Source: Medline; NIEHS NIH HHS [P30 ES06694, P30 ES006694, T32 ES007091, ES007091] Funding Source: Medline; PHS HHS [P30023074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009213, R29CA065662, R01CA065662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007091, P30ES006694] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAYLIN SB, 1986, CANCER RES, V46, P2917; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bender CM, 1998, CANCER RES, V58, P95; Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Coombes MM, 2003, ONCOGENE, V22, P8902, DOI 10.1038/sj.onc.1207050; CREUSOT F, 1982, J BIOL CHEM, V257, P2041; Daskalakis M, 2002, BLOOD, V100, P2957, DOI 10.1182/blood.V100.8.2957; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Fahrner JA, 2002, CANCER RES, V62, P7213; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Futscher BW, 2004, NEOPLASIA, V6, P380, DOI 10.1593/neo.04115; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Geiman TM, 2004, BIOCHEM BIOPH RES CO, V318, P544, DOI 10.1016/j.bbrc.2004.04.058; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hsi LC, 2005, MOL CANCER THER, V4, P1740, DOI 10.1158/1535-7163.MCT-05-0218; Huang C, 2003, CURR OPIN GENET DEV, V13, P246, DOI 10.1016/S0959-437X(03)00054-6; Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kantarjian HM, 2005, SEMIN HEMATOL, V42, pS17, DOI 10.1053/j.seminhematol.2005.05.006; Kantarjian HM, 2003, CANCER, V98, P522, DOI 10.1002/cncr.11543; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; KOCH PJ, 1994, CURR OPIN CELL BIOL, V6, P682, DOI 10.1016/0955-0674(94)90094-9; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Kondo Y, 2004, P NATL ACAD SCI USA, V101, P7398, DOI 10.1073/pnas.0306641101; Koul Sanjay, 2002, Mol Cancer, V1, P8, DOI 10.1186/1476-4598-1-8; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Lubbert M, 2001, BRIT J HAEMATOL, V114, P349, DOI 10.1046/j.1365-2141.2001.02933.x; Miao F, 2005, MOL CELL BIOL, V25, P4650, DOI 10.1128/MCB.25.11.4650-4661.2005; MICHALOWSKY LA, 1987, MOL CELL BIOL, V7, P3076, DOI 10.1128/MCB.7.9.3076; MOMPARLER RL, 1985, LEUKEMIA RES, V9, P1361, DOI 10.1016/0145-2126(85)90123-7; Mund C, 2005, CANCER RES, V65, P7086, DOI 10.1158/0008-5472.CAN-05-0695; Nguyen CT, 2002, CANCER RES, V62, P6456; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Oshiro MM, 2005, BREAST CANCER RES, V7, pR669, DOI 10.1186/bcr1273; Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Oue N, 2001, INT J CANCER, V93, P805, DOI 10.1002/ijc.1403; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; PLIML J, 1964, COLLECT CZECH CHEM C, V29, P2576; Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761; Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rosenfeld CS, 2005, SEMIN ONCOL, V32, P465, DOI 10.1053/j.seminoncol.2005.07.002; Samlowski WE, 2005, J CLIN ONCOL, V23, P3897, DOI 10.1200/JCO.2005.06.118; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Scott SA, 2006, LEUKEMIA RES, V30, P69, DOI 10.1016/j.leukres.2005.05.010; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Suzuki Y, 2001, EMBO REP, V2, P388, DOI 10.1093/embo-reports/kve085; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; TAMAME M, 1983, MOL CELL BIOL, V3, P2287, DOI 10.1128/MCB.3.12.2287; TAMAME M, 1988, MOL CELL BIOL, V8, P3043, DOI 10.1128/MCB.8.8.3043; TRENT J, 1993, GENE CHROMOSOME CANC, V7, P194, DOI 10.1002/gcc.2870070403; Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956; Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970	65	159	170	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 4	2007	26	1					77	90		10.1038/sj.onc.1209763	http://dx.doi.org/10.1038/sj.onc.1209763			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799634				2022-12-17	WOS:000243236500008
J	Baker, EK; Johnstone, RW; Zalcberg, JR; El-Osta, A				Baker, EK; Johnstone, RW; Zalcberg, JR; El-Osta, A			Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs	ONCOGENE			English	Article						cancer; chemotherapy; multidrug resistance; epigenetic modifications; chromatin	ACUTE MYELOID-LEUKEMIA; P-GLYCOPROTEIN EXPRESSION; MESSENGER-RNA STABILIZATION; MULTIDRUG-RESISTANCE MDR1; GENE-EXPRESSION; HISTONE H3; PROMOTER REGION; ANTHRACYCLINE ANALOGS; DEOXYCYTIDINE KINASE; METHYLATION PATTERNS	The mechanism of action of chemotherapeutic drugs and their ability to induce multidrug resistance (MDR) are of relevance to cancer treatment. Overexpression of P-glycoprotein (Pgp) encoded by the MDR1 gene following chemotherapy can severely limit the efficacy of anticancer agents; however, the manner by which cells acquire high levels of Pgp has not been defined. Herein, we demonstrate that chemotherapeutic drugs induce specific epigenetic modifications at the MDR1 locus, concomitant with MDR1 upregulation mediated by transcriptional activation, and a potential post-transcriptional component. We have established that the mechanisms are not mutually exclusive and are dependent on the methylation state of the MDR1 promoter. MDR1 upregulation did not result in further changes to the CpG methylation profile. However, dramatic changes in the temporal and spatial patterning of histone modi. cations occurred within the 50 hypomethylated region of MDR1, directly correlating with MDR1 upregulation. Specifically, drug-induced upregulation of MDR1 was associated with increases in H3 acetylation and induction of methylated H3K4 within discrete regions of the MDR1 locus. Our results demonstrate that chemotherapeutic drugs can actively induce epigenetic changes within the MDR1 promoter, and enhance the MDR phenotype.	Baker Med Res Inst, Alfred Med Res & Educ Project, Epigenet Human Hlth & Dis Lab, Prahran, Vic 3181, Australia; Peter MacCallum Canc Ctr, Canc Immunol Program, Gene Regulat Lab, Melbourne 3002, Australia; Peter MacCallum Canc Ctr, Dept Med Oncol & Haematol, Melbourne 3002, Australia	Baker Heart and Diabetes Institute; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center	El-Osta, A (corresponding author), Baker Med Res Inst, Alfred Med Res & Educ Project, Epigenet Human Hlth & Dis Lab, Commercial Rd, Prahran, Vic 3181, Australia.	assam.el-osta@baker.edu.au	Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237; El-Osta, Assam/0000-0003-2969-9137; Zalcberg, John/0000-0002-6624-0782; El-Osta, Assam/0000-0001-7968-7375				Abolhoda A, 1999, CLIN CANCER RES, V5, P3352; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; CAMPOS L, 1992, BLOOD, V79, P473; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Christenson LK, 2001, J BIOL CHEM, V276, P27392, DOI 10.1074/jbc.M101650200; El-Osta A, 2001, MOL BIOL REP, V28, P209, DOI 10.1023/A:1015744625049; El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002; FERGUSON PJ, 1988, CANCER RES, V48, P5956; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Garcia-Manero G, 2002, CLIN CANCER RES, V8, P2217; GOLDIE JH, 1984, CANCER RES, V44, P3643; Harikrishnan KN, 2005, NAT GENET, V37, P254, DOI 10.1038/ng1516; Hu XF, 1999, BLOOD, V93, P4086, DOI 10.1182/blood.V93.12.4086.412k43_4086_4095; HU XF, 1995, BRIT J CANCER, V71, P931, DOI 10.1038/bjc.1995.180; Hu XF, 1999, BRIT J CANCER, V79, P831, DOI 10.1038/sj.bjc.6690133; Iervolino A, 2002, FASEB J, V16, P1453, DOI 10.1096/fj.02-0122fje; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kantharidis P, 1997, CLIN CANCER RES, V3, P2025; Kinkel MD, 2003, J CELL BIOCHEM, V88, P941, DOI 10.1002/jcb.10442; Kusaba H, 1999, EUR J BIOCHEM, V262, P924, DOI 10.1046/j.1432-1327.1999.00469.x; KUWAZURU Y, 1990, CANCER, V66, P868, DOI 10.1002/1097-0142(19900901)66:5<868::AID-CNCR2820660510>3.0.CO;2-Z; Leegwater PAJ, 1998, CANCER LETT, V130, P169, DOI 10.1016/S0304-3835(98)00131-1; Leith CP, 1997, BLOOD, V89, P3323; Li JW, 2002, MOL CELL BIOL, V22, P5688, DOI 10.1128/MCB.22.16.5688-5697.2002; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Mansson E, 2002, LEUKEMIA, V16, P386, DOI 10.1038/sj.leu.2402388; MARIE JP, 1991, BLOOD, V78, P586; Nakayama M, 1998, BLOOD, V92, P4296, DOI 10.1182/blood.V92.11.4296.423k25_4296_4307; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; PIRKER R, 1991, J NATL CANCER I, V83, P708, DOI 10.1093/jnci/83.10.708; Radosevic N, 2001, LEUKEMIA, V15, P559, DOI 10.1038/sj.leu.2402092; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Tada Y, 2000, CLIN CANCER RES, V6, P4618; TEBOEKHORST PAW, 1993, BLOOD, V82, P3157; Toyota M, 2001, BLOOD, V97, P2823, DOI 10.1182/blood.V97.9.2823; van den Heuvel-Eibrink MM, 2002, LEUKEMIA, V16, P833, DOI 10.1038/sj.leu.2402496; vandenHeuvelEibrink MM, 1997, BRIT J HAEMATOL, V99, P76, DOI 10.1046/j.1365-2141.1997.3343148.x; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; WOOD P, 1994, BRIT J HAEMATOL, V87, P509, DOI 10.1111/j.1365-2141.1994.tb08305.x; Yague E, 2003, J BIOL CHEM, V278, P10344, DOI 10.1074/jbc.M211093200; ZHOU DC, 1992, LEUKEMIA, V6, P879; ZOCHBAUER S, 1994, LEUKEMIA, V8, P974	52	159	176	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					8061	8075		10.1038/sj.onc.1208955	http://dx.doi.org/10.1038/sj.onc.1208955			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16091741				2022-12-17	WOS:000233656600012
J	Jeong, SJ; Pise-Masison, CA; Radonovich, MF; Park, HU; Brady, JN				Jeong, SJ; Pise-Masison, CA; Radonovich, MF; Park, HU; Brady, JN			Activated AKT regulates NF-kappa B activation, p53 inhibition and cell survival in HTLV-1-transformed cells	ONCOGENE			English	Article						HTLV-1; p53; NF-kappa B; AKT; p65; IKK	VIRUS TYPE-I; SERINE-THREONINE KINASE; HTLV-I; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTIONAL ACTIVITY; CLINICAL ENTITY; HUMAN CANCER; IKK-BETA; PATHWAY; LEUKEMIA	AKT activation enhances resistance to apoptosis and induces cell survival signaling through multiple downstream pathways. We now present evidence that AKT is activated in HTLV-1-transformed cells and that Tax activation of AKT is linked to NF-kappa B activation, p53 inhibition and cell survival. Overexpression of AKT wild type (WT), but not a kinase dead (KD) mutant, resulted in increased Tax-mediated NF-kappa B activation. Blocking AKT with the PI3K/AKT inhibitor LY294002 or AKT SiRNA prevented NF-kappa B activation and inhibition of p53. Treatment of C81 cells with LY294002 resulted in an increase in the p53-responsive gene MDM2, suggesting a role for AKT in the Tax-mediated regulation of p53 transcriptional activity. Further, we show that LY294002 treatment of C81cells abrogates in vitro IKK beta phosphorylation of p65 and causes a reduction of p65 Ser-536 phosphorylation in vivo, steps critical to p53 inhibition. Interestingly, blockage of AKT function did not affect IKKb phosphorylation of I kappa Ba in vitro suggesting selective activity of AKT on the IKKb complex. Finally, AKT prosurvival function in HTLV-1-transformed cells is linked to expression of Bcl-xL. We suggest that AKT plays a role in the activation of prosurvival pathways in HTLV-1-transformed cells, possibly through NF-kappa B activation and inhibition of p53 transcription activity.	Natl Canc Inst, Virus Tumor Biol Sect, Cellular Oncol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Brady, JN (corresponding author), Natl Canc Inst, Virus Tumor Biol Sect, Cellular Oncol Lab, Ctr Canc Res,NIH, Bldg 41-B201,9000 Rockville Pike, Bethesda, MD 20892 USA.	bradyj@exchange.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC005691, Z01BC005691] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; GESSAIN A, 1985, LANCET, V2, P407; Gills JJ, 2004, EXPERT OPIN INV DRUG, V13, P787, DOI 10.1517/13543784.13.7.787; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; Hovelmann S, 2004, BRIT J CANCER, V90, P2370, DOI 10.1038/sj.bjc.6601876; Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200; Jeong SJ, 2004, BLOOD, V104, P1490, DOI 10.1182/blood-2003-12-4174; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu Y, 2001, ONCOGENE, V20, P2514, DOI 10.1038/sj.onc.1204364; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; MOCHIZUKI M, 1992, JPN J CANCER RES, V83, P236, DOI 10.1111/j.1349-7006.1992.tb00092.x; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NISHIOKA K, 1989, LANCET, V1, P441; OSAME M, 1986, LANCET, V1, P1031; Ozes ON, 1999, NATURE, V401, P82; Parsons R, 2004, SEMIN CELL DEV BIOL, V15, P171, DOI 10.1016/j.semcdb.2003.12.021; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Raina D, 2004, J BIOL CHEM, V279, P20607, DOI 10.1074/jbc.M310538200; Ren S, 2003, BIOCHEM BIOPH RES CO, V308, P120, DOI 10.1016/S0006-291X(03)01309-3; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Thompson JE, 2004, J CLIN ONCOL, V22, P4217, DOI 10.1200/jco.2004.01.103; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; VERNANT JC, 1988, LANCET, V1, P177; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	44	159	168	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6719	6728		10.1038/sj.onc.1208825	http://dx.doi.org/10.1038/sj.onc.1208825			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007163				2022-12-17	WOS:000232367800013
J	Taylor, GP; Matsuoka, M				Taylor, GP; Matsuoka, M			Natural history of adult T-cell leukemia/lymphoma and approaches to therapy	ONCOGENE			English	Review						ATLL; HTLV-I; tax; chemotherapy; transplantation; prevention	VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; LEUKEMIA-LYMPHOMA; HTLV-I; COMBINATION CHEMOTHERAPY; MONOCLONAL-ANTIBODY; INFECTED-CELLS; KAPPA-B; PROTEASOME INHIBITOR; RECEPTOR ACTIVATOR	After cell-to-cell transmission, HTLV-I increases its viral genome by de novo infection and proliferation of infected cells. Proliferation of infected cells is clonal and persistent in vivo. During the carrier state, infected cells are selected in vivo by the host's immune system, the genetic and epigenetic environment of proviral integration sites, and other factors. In leukemic cells, tax gene expression is frequently impaired by genetic and epigenetic mechanisms. Such loss of Tax expression enables ATL cells to escape the host immune system. On the other hand, ATL cells acquire the ability to proliferate without Tax by intracellular genetic and epigenetic changes. Despite advances in support and the development of novel treatment agents, the prognosis for ATLL remains poor. A number of therapies, however, do appear to improve prognosis compared to CHOP (VEPA). These include interferon-alpha plus zidovudine (probably after 1-2 cycles of CHOP), intensive chemotherapy as in LSG-15 with G-CSF support and Allo-SCT (which includes the potential for cure). Emerging novel approaches include HDAC inhibitors, monoclonal antibodies, and proteasome inhibitors. Comparison between different therapeutic approaches is complicated by the range of natural history of ATLL, different recruitments of naive-to-therapy, refractory or relapsed patients, and variations in the reporting of outcome that frequently excludes difficult-to-evaluate patients. Moreover, results from relatively small proof-of-principle studies have not been extended with randomized, controlled trials. As a result, currently, there is no clear evidence to support the value of any particular treatment approach over others. To avoid further unnecessary patient suffering and to identify optimal therapy as rapidly as possible, large randomized, controlled trials encompassing multicenter, international collaborations will be necessary.	Kyoto Univ, Inst Virus Res, Ctr AIDS Res, Lab Virus Immunol,Sakyo Ku, Kyoto 6068507, Japan; Imperial Coll Sch Med, Fac Med, Dept GU Med & Communicable Dis, London W2 1PG, England	Kyoto University; Imperial College London	Matsuoka, M (corresponding author), Kyoto Univ, Inst Virus Res, Ctr AIDS Res, Lab Virus Immunol,Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	mmatsuok@virus.kyoto-u.ac.jp		Matsuoka, Masao/0000-0002-0473-754X				Ando Y, 2004, J OBSTET GYNAECOL RE, V30, P436, DOI 10.1111/j.1447-0756.2004.00227.x; Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741; Arima N, 1999, Gan To Kagaku Ryoho, V26, P619; Arisawa K, 2002, CANCER CAUSE CONTROL, V13, P657, DOI 10.1023/A:1019511224501; Arnulf B, 2004, LEUKEMIA, V18, P126, DOI 10.1038/sj.leu.2403176; Bangham CRM, 2003, INT J HEMATOL, V78, P297, DOI 10.1007/BF02983553; BARNARD AL, 2005, BLOOD           0414; Besson C, 2002, LEUKEMIA LYMPHOMA, V43, P2275, DOI 10.1080/1042819021000039983; Blaheta RA, 2002, MED RES REV, V22, P492, DOI 10.1002/med.10017; Borg A, 1996, BRIT J HAEMATOL, V94, P713, DOI 10.1046/j.1365-2141.1996.02338.x; Cavrois M, 1998, ONCOGENE, V17, P77, DOI 10.1038/sj.onc.1201906; Dierov J, 1999, CLIN CANCER RES, V5, P2540; DOI K, 2005, BLOOD, V19; Etoh K, 1999, INT J CANCER, V81, P859, DOI 10.1002/(SICI)1097-0215(19990611)81:6<859::AID-IJC4>3.0.CO;2-K; Etoh K, 1997, CANCER RES, V57, P4862; EZAKI K, 1991, CANCER, V68, P695, DOI 10.1002/1097-0142(19910815)68:4<695::AID-CNCR2820680405>3.0.CO;2-K; Fontenot JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179; Franchini G, 2003, INT J HEMATOL, V78, P280, DOI 10.1007/BF02983552; Fukushima T, 2005, LEUKEMIA, V19, P829, DOI 10.1038/sj.leu.2403682; Furukawa Y, 2001, BLOOD, V97, P987, DOI 10.1182/blood.V97.4.987; Gatza ML, 2003, ONCOGENE, V22, P5141, DOI 10.1038/sj.onc.1206549; GILL PS, 1995, NEW ENGL J MED, V332, P1744, DOI 10.1056/NEJM199506293322603; Han YF, 2004, J VIROL, V78, P6122, DOI 10.1128/JVI.78.12.6122-6133.2004; Harasawa H, 2002, LEUKEMIA, V16, P1799, DOI 10.1038/sj.leu.2402570; Harashima N, 2004, CANCER RES, V64, P391, DOI 10.1158/0008-5472.CAN-03-1452; Hermine O, 2004, HEMATOL J, V5, P130, DOI 10.1038/sj.thj.6200374; HERMINE O, 1995, NEW ENGL J MED, V332, P1749, DOI 10.1056/NEJM199506293322604; Hermine Olivier, 2002, Hematol J, V3, P276, DOI 10.1038/sj.thj.6200195; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; Jones KS, 2005, J IMMUNOL, V174, P4262, DOI 10.4049/jimmunol.174.7.4262; Jordan A, 2003, EMBO J, V22, P1868, DOI 10.1093/emboj/cdg188; Kami M, 2003, BRIT J HAEMATOL, V120, P304, DOI 10.1046/j.1365-2141.2003.04054.x; Kannagi Mari, 2004, Expert Rev Anticancer Ther, V4, P369, DOI 10.1586/14737140.4.3.369; Karube K, 2004, BRIT J HAEMATOL, V126, P81, DOI 10.1111/j.1365-2141.2004.04999.x; KATSUKI T, 1987, JPN J CANCER RES, V78, P639; KIKUCHI K, 1982, JPN J CLIN ONCOL, V12, P227; KIYOKAWA T, 1987, CANCER, V59, P1187, DOI 10.1002/1097-0142(19870315)59:6<1187::AID-CNCR2820590626>3.0.CO;2-8; Koiwa T, 2002, J VIROL, V76, P9389, DOI 10.1128/JVI.76.18.9389-9397.2002; Krueger A, 2003, IMMUNOL REV, V193, P58, DOI 10.1034/j.1600-065X.2003.00047.x; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; KUWAZURU Y, 1990, BLOOD, V76, P2065; Li HC, 2004, J INFECT DIS, V190, P1275, DOI 10.1086/423941; Mahieux R, 2005, LEUKEMIA LYMPHOMA, V46, P347, DOI 10.1080/10428190400019966; Makino T, 1994, Rinsho Ketsueki, V35, P42; Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X; Matsuoka M, 2005, CANCER RES, V65, P4467, DOI 10.1158/0008-5472.CAN-05-0559; Matsushita K, 1999, LEUKEMIA LYMPHOMA, V36, P67, DOI 10.3109/10428199909145950; Matutes E, 2001, BRIT J HAEMATOL, V113, P779, DOI 10.1046/j.1365-2141.2001.02794.x; MERCIECA J, 1994, J CLIN ONCOL, V12, P2588, DOI 10.1200/JCO.1994.12.12.2588; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; Mori N, 2004, J VIROL, V78, P4582, DOI 10.1128/JVI.78.9.4582-4590.2004; Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151; MORRIS JC, 2001, 10 INT C HUM RETR S, V17, pS29; Nakane M, 1999, BONE MARROW TRANSPL, V24, P219, DOI 10.1038/sj.bmt.1701870; Nasr R, 2003, BLOOD, V101, P4576, DOI 10.1182/blood-2002-09-2986; Nosaka K, 2002, BLOOD, V99, P634, DOI 10.1182/blood.V99.2.634; Ogata M, 2002, BONE MARROW TRANSPL, V30, P699, DOI 10.1038/sj.bmt.1703702; Ohashi T, 2000, J VIROL, V74, P9610, DOI 10.1128/JVI.74.20.9610-9616.2000; OHNO R, 1993, CANCER, V71, P2217, DOI 10.1002/1097-0142(19930401)71:7<2217::AID-CNCR2820710709>3.0.CO;2-8; Okamura J, 2005, BLOOD, V105, P4143, DOI 10.1182/blood-2004-11-4193; Okayama A, 2004, INT J CANCER, V110, P621, DOI 10.1002/ijc.20144; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; Pawson R, 1998, LEUKEMIA LYMPHOMA, V31, P177, DOI 10.3109/10428199809057597; Sasaki H, 2005, BLOOD, V105, P1204, DOI 10.1182/blood-2004-03-1222; Satou Y, 2004, LEUKEMIA, V18, P1357, DOI 10.1038/sj.leu.2403400; SHIMOYAMA M, 1988, J CLIN ONCOL, V6, P1088, DOI 10.1200/JCO.1988.6.7.1088; Shimoyama M., 1992, ADV ADULT T CELL LEU, P43; Siegel R S, 2001, Curr Treat Options Oncol, V2, P291, DOI 10.1007/s11864-001-0022-8; Taguchi H, 1996, J ACQ IMMUN DEF SYND, V12, P182, DOI 10.1097/00042560-199606010-00012; Tajima K, 2000, INT J HEMATOL, V71, P290; Takeda S, 2004, INT J CANCER, V109, P559, DOI 10.1002/ijc.20007; Tamiya S, 1996, BLOOD, V88, P3065, DOI 10.1182/blood.V88.8.3065.bloodjournal8883065; TAMIYA S, 1995, LEUKEMIA, V9, P1768; Tan C, 2002, CANCER RES, V62, P1083; Tanaka G, 2005, J INFECT DIS, V191, P1140, DOI 10.1086/428625; Taylor GP, 2001, AIDS RES HUM RETROV, V17, pS69; TGUCHI T, 1997, GAN TO KAGAKU RYOHO, V24, P1263; Thompson C, 2004, CURR OPIN PHARMACOL, V4, P408, DOI 10.1016/j.coph.2004.05.001; Tobinai K, 2003, INT J HEMATOL, V77, P512, DOI 10.1007/BF02986621; TOBINAI K, 1992, JPN J CLIN ONCOL, V22, P164; Tobinai K, 1994, P AN M AM SOC CLIN, V13, P378; Toyota M, 1999, CANCER RES, V59, P2307; TSUDA H, 1994, BRIT J CANCER, V70, P771, DOI 10.1038/bjc.1994.394; Tsukasaki K, 2003, INT J HEMATOL, V77, P164, DOI 10.1007/BF02983215; TSUKASAKI K, 1993, LEUKEMIA RES, V17, P157, DOI 10.1016/0145-2126(93)90061-O; Uike N, 1998, INTERNAL MED, V37, P411, DOI 10.2169/internalmedicine.37.411; UOZUMI K, 1995, LEUKEMIA LYMPHOMA, V18, P317, DOI 10.3109/10428199509059624; Utsunomiya A, 2001, BONE MARROW TRANSPL, V27, P15, DOI 10.1038/sj.bmt.1702731; WALDMANN TA, 1993, BLOOD, V82, P1701; WALDMANN TA, 1995, BLOOD, V86, P4063, DOI 10.1182/blood.V86.11.4063.bloodjournal86114063; WALDMANN TA, 1988, BLOOD, V72, P1805; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; WELLES SL, 1994, INT J CANCER, V56, P337, DOI 10.1002/ijc.2910560307; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Yamada Y, 2001, BRIT J HAEMATOL, V113, P375, DOI 10.1046/j.1365-2141.2001.02737.x; Yamada Y, 1997, J CLIN ONCOL, V15, P1778, DOI 10.1200/JCO.1997.15.5.1778; Yamada Y, 2003, LEUKEMIA LYMPHOMA, V44, P611, DOI 10.1080/1042819021000055039; Yasunaga J, 2004, CANCER RES, V64, P6002, DOI 10.1158/0008-5472.CAN-04-1422; Yasunaga J, 2001, BLOOD, V97, P3177, DOI 10.1182/blood.V97.10.3177; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Yoshida M, 2004, BLOOD, V103, P2753, DOI 10.1182/blood-2003-07-2482; Zhang Z, 2003, CANCER RES, V63, P6453	103	159	163	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2005	24	39					6047	6057		10.1038/sj.onc.1208979	http://dx.doi.org/10.1038/sj.onc.1208979			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155611				2022-12-17	WOS:000231623400014
J	Mollaaghababa, R; Pavan, WJ				Mollaaghababa, R; Pavan, WJ			The importance of having your SOX on: role of SOX10 in the development of neural crest-derived melanocytes and glia	ONCOGENE			English	Article						SOX10; neural crest; glia; melanocytes; differentiation; transcription factor	TRANSCRIPTION FACTOR SOX10; CENTRAL-NERVOUS-SYSTEM; SRY-RELATED GENE; WAARDENBURG-SYNDROME; HIRSCHSPRUNG-DISEASE; DOMINANT MEGACOLON; MOUSE DEVELOPMENT; STEM-CELLS; EXPRESSION; FAMILY	SOX10(+) is a member of the high-mobility group-domain SOX family of transcription factors, which are ubiquitously found in the animal kingdom. Disruption of neural crest development in the Dominant megacolon (Dom) mice is associated with a Sox10 mutation. Mutations in human Sox10(+) gene have also been linked with the occurrence of neurocristopathies in the Waardenburg-Shah syndrome type IV (WS-IV), for which the Sox10(Dom) mice serve as a murine model. The neural crest disorders in the Sox10(Dom) mice and WS-IV patients consist of hypopigmentation, cochlear neurosensory deafness, and enteric aganglionosis. Consistent with these observations, a critical role for SOX10 in the proper differentiation of neural crest-derived melanocytes and glia has been demonstrated. Emerging data also show an important role for SOX10 in promoting the survival of neural crest precursor cells prior to lineage commitment. Several genes whose regulation is dependent on SOX10 function have been identified in the peripheral nervous system and in melanocytes, helping to begin the identification of the multiple pathways that appear to be modulated by SOX10 activity. In this review, we will discuss the biological relevance of these target genes to neural crest development and the properties of Sox10 as a transcription factor.	NHGRI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Pavan, WJ (corresponding author), NHGRI, NIH, 49 Convent Dr, Bethesda, MD 20892 USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000136, ZIAHG000070, ZIAHG000136, Z01HG000070] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Adlkofer K, 2000, GLIA, V29, P104, DOI 10.1002/(SICI)1098-1136(20000115)29:2<104::AID-GLIA2>3.0.CO;2-2; BADNER JA, 1990, AM J MED GENET, V35, P100, DOI 10.1002/ajmg.1320350119; Bianchi ME, 2000, EMBO REP, V1, P109, DOI 10.1093/embo-reports/kvd030; Bondurand N, 2000, HUM MOL GENET, V9, P1907, DOI 10.1093/hmg/9.13.1907; Bondurand N, 1999, HUM MOL GENET, V8, P1785, DOI 10.1093/hmg/8.9.1785; Bondurand N, 2001, HUM MOL GENET, V10, P2783, DOI 10.1093/hmg/10.24.2783; Bondurand N, 1998, FEBS LETT, V432, P168, DOI 10.1016/S0014-5793(98)00843-6; Bowles J, 2000, DEV BIOL, V227, P239, DOI 10.1006/dbio.2000.9883; Britsch S, 2001, GENE DEV, V15, P66, DOI 10.1101/gad.186601; Cheng YC, 2000, DEV BRAIN RES, V121, P233, DOI 10.1016/S0165-3806(00)00049-3; CONROY WG, 1992, NEURON, V9, P679, DOI 10.1016/0896-6273(92)90031-8; CONROY WG, 1995, J BIOL CHEM, V270, P4424, DOI 10.1074/jbc.270.9.4424; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; Dunn KJ, 2000, P NATL ACAD SCI USA, V97, P10050, DOI 10.1073/pnas.97.18.10050; Dutton KA, 2001, DEVELOPMENT, V128, P4113; Erickson CA, 1998, CURR TOP DEV BIOL, V40, P177, DOI 10.1016/S0070-2153(08)60367-1; Gabriel SB, 2002, NAT GENET, V31, P89, DOI 10.1038/ng868; Goding CR, 2000, GENE DEV, V14, P1712; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; Herbarth B, 1998, P NATL ACAD SCI USA, V95, P5161, DOI 10.1073/pnas.95.9.5161; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; Inoue K, 1999, ANN NEUROL, V46, P313, DOI 10.1002/1531-8249(199909)46:3<313::AID-ANA6>3.0.CO;2-7; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Kanai Y, 1996, J CELL BIOL, V133, P667, DOI 10.1083/jcb.133.3.667; Kapur RP, 1996, DEV BIOL, V174, P360, DOI 10.1006/dbio.1996.0080; Kapur RP, 1999, PEDIATR DEVEL PATHOL, V2, P559, DOI 10.1007/s100249900162; Knecht AK, 2002, NAT REV GENET, V3, P453, DOI 10.1038/nrg819; Korsch E, 2001, EUR J PEDIATR, V160, P68, DOI 10.1007/s004310000624; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P16050, DOI 10.1074/jbc.273.26.16050; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P23033, DOI 10.1074/jbc.273.36.23033; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; LaBonne C, 1998, J NEUROBIOL, V36, P175, DOI 10.1002/(SICI)1097-4695(199808)36:2<175::AID-NEU6>3.0.CO;2-Z; LANE PW, 1984, J HERED, V75, P435, DOI 10.1093/oxfordjournals.jhered.a109980; Lang D, 2000, J CLIN INVEST, V106, P963, DOI 10.1172/JCI10828; Le Douarin NM, 1999, NEURAL CREST; Lee M, 2000, J BIOL CHEM, V275, P37978, DOI 10.1074/jbc.M003816200; Liu Q, 1999, J NEUROSCI, V19, P9747; Loftus SK, 1999, P NATL ACAD SCI USA, V96, P9277, DOI 10.1073/pnas.96.16.9277; Loh SHY, 2000, MECH DEVELOP, V93, P185, DOI 10.1016/S0925-4773(00)00258-6; Lu QR, 2000, NEURON, V25, P317, DOI 10.1016/S0896-6273(00)80897-1; Lu QR, 2002, CELL, V109, P75, DOI 10.1016/S0092-8674(02)00678-5; Melnikova IN, 2000, NEUROPHARMACOLOGY, V39, P2615, DOI 10.1016/S0028-3908(00)00125-8; Melnikova IN, 2000, EUR J PHARMACOL, V393, P75, DOI 10.1016/S0014-2999(99)00884-5; Mertin S, 1999, NUCLEIC ACIDS RES, V27, P1359, DOI 10.1093/nar/27.5.1359; Meyer J, 1996, CYTOGENET CELL GENET, V72, P246, DOI 10.1159/000134200; Osaki E, 1999, NUCLEIC ACIDS RES, V27, P2503, DOI 10.1093/nar/27.12.2503; Pani L, 2002, GENE DEV, V16, P676, DOI 10.1101/gad.969302; Paratore C, 2001, DEVELOPMENT, V128, P3949; Parisi MA, 2000, CURR OPIN PEDIATR, V12, P610, DOI 10.1097/00008480-200012000-00017; PAVAN WJ, 1994, P NATL ACAD SCI USA, V91, P7159, DOI 10.1073/pnas.91.15.7159; Peirano RI, 2000, NUCLEIC ACIDS RES, V28, P3047, DOI 10.1093/nar/28.16.3047; Peirano RI, 2000, MOL CELL BIOL, V20, P3198, DOI 10.1128/MCB.20.9.3198-3209.2000; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; Pingault V, 2000, ANN NEUROL, V48, P671, DOI 10.1002/1531-8249(200010)48:4<671::AID-ANA17>3.0.CO;2-8; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; Potterf SB, 2000, HUM GENET, V107, P1, DOI 10.1007/s004390050001; Potterf SB, 2001, DEV BIOL, V237, P245, DOI 10.1006/dbio.2001.0372; Prior HM, 1996, MOL MED, V2, P405, DOI 10.1007/BF03401900; Pusch C, 1998, HUM GENET, V103, P115, DOI 10.1007/s004390050793; Read AP, 2000, ADV OTO-RHINO-LARYNG, V56, P32; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; Scherer SS, 1995, J NEUROSCI, V15, P8281; SHAH KN, 1981, J PEDIATR-US, V99, P432, DOI 10.1016/S0022-3476(81)80339-3; Shah NM, 1997, P NATL ACAD SCI USA, V94, P11369, DOI 10.1073/pnas.94.21.11369; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; Sham MH, 2001, J MED GENET, V38, DOI 10.1136/jmg.38.9.e30; Sham MH, 2001, GUT, V49, P220, DOI 10.1136/gut.49.2.220; Sonnenberg-Riethmacher E, 2001, MECH DEVELOP, V109, P253, DOI 10.1016/S0925-4773(01)00547-0; Southard-Smith EM, 1999, MAMM GENOME, V10, P744, DOI 10.1007/s003359901083; Southard-Smith EM, 1998, NAT GENET, V18, P60, DOI 10.1038/ng0198-60; Southard-Smith EM, 1999, GENOME RES, V9, P215; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; Stolt CC, 2002, GENE DEV, V16, P165, DOI 10.1101/gad.215802; SUTER U, 1995, ANNU REV NEUROSCI, V18, P45, DOI 10.1146/annurev.ne.18.030195.000401; Touraine RL, 2000, AM J HUM GENET, V66, P1496, DOI 10.1086/302895; Uchikawa M, 1999, MECH DEVELOP, V84, P103, DOI 10.1016/S0925-4773(99)00083-0; VANDEWETERING M, 1993, NUCLEIC ACIDS RES, V21, P1669, DOI 10.1093/nar/21.7.1669; Verastegui C, 2000, J BIOL CHEM, V275, P30757, DOI 10.1074/jbc.C000445200; Watanabe K, 2000, MOL BRAIN RES, V84, P141, DOI 10.1016/S0169-328X(00)00236-9; Watanabe KI, 2002, PIGM CELL RES, V15, P201, DOI 10.1034/j.1600-0749.2002.01080.x; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Weiss MA, 2001, MOL ENDOCRINOL, V15, P353, DOI 10.1210/me.15.3.353; WRIGHT EM, 1993, NUCLEIC ACIDS RES, V21, P744, DOI 10.1093/nar/21.3.744; Zhou Q, 2000, NEURON, V25, P331, DOI 10.1016/S0896-6273(00)80898-3; Zhou Q, 2002, CELL, V109, P61, DOI 10.1016/S0092-8674(02)00677-3	87	159	166	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 19	2003	22	20					3024	3034		10.1038/sj.onc.1206442	http://dx.doi.org/10.1038/sj.onc.1206442			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789277				2022-12-17	WOS:000183096600002
J	Ducrest, AL; Szutorisz, H; Lingner, J; Nabholz, M				Ducrest, AL; Szutorisz, H; Lingner, J; Nabholz, M			Regulation of the human telomerase reverse transcriptase gene	ONCOGENE			English	Review						telomerase; hTERT; regulation; transcription; repression; tumor	NORMAL HUMAN-CELLS; MESSENGER-RNA EXPRESSION; CATALYTIC SUBUNIT; HTERT GENE; CANCER-CELLS; CELLULAR SENESCENCE; HUMAN FIBROBLASTS; IMMORTAL CELLS; TUMOR-CELLS; LIFE-SPAN	Most somatic human cells lack telomerase activity because they do not express the telomerase reverse transcriptase (hTERT) gene. Conversely, most cancer cells express hTERT and are telomerase positive. For most tumors it is not clear whether hTERT expression is due to their origin from telomerase positive stem cells or to reactivation of the gene during tumorigenesis. Telomerase negative cells lack detectable cytoplasmic and nuclear hTERT transcripts; in telomerase positive cells 0.2 to 6 mRNA molecules/cell can be detected. This suggests that expression is regulated by changes in the rate of hTERT gene transcription. In tumor cell lines hTERT expression behaves like a recessive trait, indicating that lack of expression in normal cells is due to one or several repressors. Studies with monochromosomal hybrids indicate that several chromosomes may code for such repressors. A number of transcription factors, tumor suppressors, cell cycle inhibitors, cell fate determining molecules, hormone receptors and viral proteins have been implicated in the control of hTERT expression; but these studies have not yet provided a clear explanation for the tumor specific expression of the hTERT gene, and the cis-acting elements which are the targets of repression in normal cells still have to be identified.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research	Nabholz, M (corresponding author), Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland.			Lingner, Joachim/0000-0002-2853-5803				Aldous WK, 1999, CANCER, V85, P1523, DOI 10.1002/(SICI)1097-0142(19990401)85:7<1523::AID-CNCR13>3.3.CO;2-G; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Backsch C, 2001, GENE CHROMOSOME CANC, V31, P196, DOI 10.1002/gcc.1134; Baur JA, 2001, SCIENCE, V292, P2075, DOI 10.1126/science.1062329; Bednarek AK, 1998, ONCOGENE, V16, P381, DOI 10.1038/sj.onc.1201553; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Braunstein I, 2001, CANCER RES, V61, P5529; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryce LA, 2000, NEOPLASIA, V2, P197, DOI 10.1038/sj.neo.7900092; Carroll T, 1999, J PATHOL, V188, P395; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; CUTHBERT AP, 1995, CYTOGENET CELL GENET, V71, P68, DOI 10.1159/000134066; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; Dessain SK, 2000, CANCER RES, V60, P537; Devereux TR, 1999, CANCER RES, V59, P6087; Ducrest AL, 2001, CANCER RES, V61, P7594; Duncan EL, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1263; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Evans SK, 2000, J CELL SCI, V113, P3357; Ferreira MG, 2001, MOL CELL, V7, P55, DOI 10.1016/S1097-2765(01)00154-X; Friedmann T, 2000, MOL THER, V1, P9, DOI 10.1006/mthe.1999.0015; Fujimoto K, 2000, NUCLEIC ACIDS RES, V28, P2557, DOI 10.1093/nar/28.13.2557; Gewin L, 2001, J VIROL, V75, P7198, DOI 10.1128/JVI.75.15.7198-7201.2001; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Greaves M, 1996, TRENDS GENET, V12, P127, DOI 10.1016/0168-9525(96)30016-4; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Gunes C, 2000, CANCER RES, V60, P2116; Hackett JA, 2001, CELL, V106, P275, DOI 10.1016/S0092-8674(01)00457-3; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hande MP, 1998, MUTAT RES-FUND MOL M, V404, P205, DOI 10.1016/S0027-5107(98)00115-8; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; Hilakivi-Clarke L, 2000, CANCER RES, V60, P4993; Horikawa I, 2001, J NATL CANCER I, V93, P1171, DOI 10.1093/jnci/93.15.1171; Horikawa I, 1998, MOL CARCINOGEN, V22, P65, DOI 10.1002/(SICI)1098-2744(199806)22:2<65::AID-MC1>3.0.CO;2-J; Horikawa I, 1999, CANCER RES, V59, P826; Huffman KE, 2000, J BIOL CHEM, V275, P19719, DOI 10.1074/jbc.M002843200; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; Kharbanda S, 2000, CURR BIOL, V10, P568, DOI 10.1016/S0960-9822(00)00483-8; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kitagawa Y, 2000, CLIN CANCER RES, V6, P2868; Knight JS, 2001, J BIOL CHEM, V276, P22971, DOI 10.1074/jbc.M101890200; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Kugoh H, 1999, DNA Res, V6, P165, DOI 10.1093/dnares/6.3.165; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Kyo S, 1997, CANCER RES, V57, P610; Kyo S, 1999, CANCER RES, V59, P5917; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Liehr JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/er.21.1.40; Liu KB, 2001, J IMMUNOL, V166, P4826, DOI 10.4049/jimmunol.166.8.4826; Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3; McClintock B, 1941, GENETICS, V26, P234; Meeker AK, 1996, ENDOCRINOLOGY, V137, P5743, DOI 10.1210/en.137.12.5743; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Misiti S, 2000, MOL CELL BIOL, V20, P3764, DOI 10.1128/MCB.20.11.3764-3771.2000; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nakabayashi K, 1999, EXP CELL RES, V252, P376, DOI 10.1006/excr.1999.4619; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; NING Y, 1992, CYTOGENET CELL GENET, V60, P79, DOI 10.1159/000133300; Nishimoto A, 2001, ONCOGENE, V20, P828, DOI 10.1038/sj.onc.1204165; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Oh S, 1999, BIOCHEM BIOPH RES CO, V263, P361, DOI 10.1006/bbrc.1999.1366; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; Oh ST, 2001, J VIROL, V75, P5559, DOI 10.1128/JVI.75.12.5559-5566.2001; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7; Parshad R, 2001, CRIT REV ONCOL HEMAT, V37, P87, DOI 10.1016/S1040-8428(00)00111-6; Pendino F, 2001, P NATL ACAD SCI USA, V98, P6662, DOI 10.1073/pnas.111464998; Reddel RR, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1254; Russo I, 1998, ONCOGENE, V17, P3417, DOI 10.1038/sj.onc.1202261; Saito T, 1997, BIOCHEM BIOPH RES CO, V231, P610, DOI 10.1006/bbrc.1997.6164; Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014; Shay JW, 1996, TRENDS GENET, V12, P129, DOI 10.1016/0168-9525(96)30018-8; Steenbergen RDM, 2001, JNCI-J NATL CANCER I, V93, P865, DOI 10.1093/jnci/93.11.865; Szutorisz H, 2001, ONCOGENE, V20, P2600, DOI 10.1038/sj.onc.1204346; Takakura M, 1999, CANCER RES, V59, P551; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; Tanaka H, 1999, MOL CARCINOGEN, V25, P249, DOI 10.1002/(SICI)1098-2744(199908)25:4<249::AID-MC3>3.0.CO;2-Z; Tanaka H, 1998, GENE CHROMOSOME CANC, V23, P123, DOI 10.1002/(SICI)1098-2264(199810)23:2<123::AID-GCC5>3.0.CO;2-4; Ulaner GA, 2001, INT J CANCER, V91, P644, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1103>3.0.CO;2-V; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Varley H, 2000, AM J HUM GENET, V67, P610, DOI 10.1086/303050; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wang Z, 2000, CANCER RES, V60, P5376; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Wright WE, 1996, DEV GENET, V18, P173; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yan P, 1999, CANCER RES, V59, P3166; Yan P, 2001, J PATHOL, V193, P21, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH728>3.0.CO;2-G; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yang XQ, 1999, INT J ONCOL, V15, P629; Yu CC, 2001, BIOCHEM J, V355, P459, DOI 10.1042/0264-6021:3550459; Zhang AJ, 2000, CANCER RES, V60, P6230	110	159	176	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					541	552		10.1038/sj.onc.1205081	http://dx.doi.org/10.1038/sj.onc.1205081			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850779	Green Submitted			2022-12-17	WOS:000173390500006
J	Ladanyi, M				Ladanyi, M			Fusions of the SYT and SSX genes in synovial sarcoma	ONCOGENE			English	Article						chromosomal translocation; transcription factor; nuclear localization	HEPATOCYTE GROWTH-FACTOR; KRUPPEL-ASSOCIATED BOX; POLYMERASE CHAIN-REACTION; SOFT-TISSUE TUMORS; X-CHROMOSOME; TRANSCRIPTIONAL REPRESSION; TRANSLOCATION BREAKPOINTS; NUCLEAR-LOCALIZATION; EWINGS-SARCOMA; PROTEINS	Synovial sarcomas are high grade spindle cell tumors that are divided into two major histologic subtypes, biphasic and monophasic, according to the respective presence or absence of a well-developed glandular epithelial component. They contain in essentially all cases a t(X;18) representing the fusion of SYT (at 18q11) with either SSX1 or SSX2 (both at Xp11). Neither SYT, nor the SSX proteins contain DNA-binding domains. Instead, they appear to be transcriptional regulators whose actions are mediated primarily through protein-protein interactions, with BRM in the case of SYT, and with Polycomb group repressors in the case of SSX. Ongoing work on the SYT-SSX fusion and synovial sarcoma should yield a variety of data of broader biological interest, in areas such as BRM and Polycomb group function and dysfunction, transcriptional targets of SYT-SSX proteins and their native counterparts, differential gene regulation by SYT-SSX1 and SYT-SSX2, control of glandular morphogenesis, among others.	Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Ladanyi, M (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.	ladanyim@mskcc.org	Ladanyi, Marc/AAG-8585-2019		NCI NIH HHS [P01 CA47179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA047179] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allander Susanne V., 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P430; Antonescu CR, 2000, DIAGN MOL PATHOL, V9, P1, DOI 10.1097/00019606-200003000-00001; Barr FG, 1998, NAT GENET, V19, P121, DOI 10.1038/475; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Birdsall S, 1999, INT J CANCER, V82, P605, DOI 10.1002/(SICI)1097-0215(19990812)82:4<605::AID-IJC22>3.3.CO;2-8; BOUFFLER S, 1993, BIOESSAYS, V15, P409, DOI 10.1002/bies.950150607; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; Castagnino P, 2000, ONCOGENE, V19, P640, DOI 10.1038/sj.onc.1203357; Chand A, 1995, GENOMICS, V30, P545, DOI 10.1006/geno.1995.1275; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; de Alava E, 1998, J CLIN ONCOL, V16, P1248, DOI 10.1200/JCO.1998.16.4.1248; deBruijn DRH, 1996, ONCOGENE, V13, P643; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; deLeeuw B, 1996, CYTOGENET CELL GENET, V73, P179, DOI 10.1159/000134334; DELEEUW B, 1994, CANCER GENET CYTOGEN, V73, P89, DOI 10.1016/0165-4608(94)90191-0; dos Santos NR, 2000, EXP CELL RES, V256, P192, DOI 10.1006/excr.2000.4813; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; Frisch SM, 1997, BIOESSAYS, V19, P705, DOI 10.1002/bies.950190811; Guillou L, 2001, HUM PATHOL, V32, P105, DOI 10.1053/hupa.2001.21130; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Hashimoto N, 2000, CANCER LETT, V149, P31, DOI 10.1016/S0304-3835(99)00336-5; Hiraga H, 1998, DIAGN MOL PATHOL, V7, P102, DOI 10.1097/00019606-199804000-00007; Illei P, 2001, MODERN PATHOL, V14, p13A; Inagaki H, 1999, AM J CLIN PATHOL, V111, P528; JANZ M, 1995, J PATHOL, V175, P391, DOI 10.1002/path.1711750405; Kas K, 2000, J BIOL CHEM, V275, P2986, DOI 10.1074/jbc.275.4.2986; Kasai T, 2000, J CLIN PATHOL-MOL PA, V53, P107, DOI 10.1136/mp.53.2.107; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; Kelly KM, 1997, J CLIN ONCOL, V15, P1831, DOI 10.1200/JCO.1997.15.5.1831; Kuhnen C, 1998, VIRCHOWS ARCH, V432, P337, DOI 10.1007/s004280050175; Ladanyi M, 2000, HUM PATHOL, V31, P532, DOI 10.1053/hp.2000.6706; Lee SB, 1997, NAT GENET, V17, P309, DOI 10.1038/ng1197-309; Lewis JJ, 2000, J CLIN ONCOL, V18, P2087, DOI 10.1200/JCO.2000.18.10.2087; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Lin PP, 1999, CANCER RES, V59, P1428; Mancuso T, 2000, LAB INVEST, V80, P805, DOI 10.1038/labinvest.3780085; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MILLER AP, 1995, HUM MOL GENET, V4, P731, DOI 10.1093/hmg/4.4.731; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nielsen TO, 2001, MODERN PATHOL, V14, p16A; Nilsson G, 1999, CANCER RES, V59, P3180; Oda Y, 2000, HUM PATHOL, V31, P185, DOI 10.1016/S0046-8177(00)80218-X; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; RENWICK PJ, 1995, CYTOGENET CELL GENET, V70, P58, DOI 10.1159/000133992; Shipley J, 1996, AM J PATHOL, V148, P559; SHIPLEY JM, 1994, ONCOGENE, V9, P1447; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Sonobe H, 1999, INT J CANCER, V82, P459, DOI 10.1002/(SICI)1097-0215(19990730)82:3<459::AID-IJC21>3.0.CO;2-B; Soulez M, 1999, ONCOGENE, V18, P2739, DOI 10.1038/sj.onc.1202613; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; Tureci O, 1996, CANCER RES, V56, P4766; Tureci O, 1998, INT J CANCER, V77, P19, DOI 10.1002/(SICI)1097-0215(19980703)77:1<19::AID-IJC4>3.0.CO;2-2; van de Rijn M, 1999, AM J CLIN PATHOL, V112, P43; vanKessel AG, 1997, CANCER GENET CYTOGEN, V95, P67, DOI 10.1016/S0165-4608(96)00241-5; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245	63	159	171	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5755	5762		10.1038/sj.onc.1204601	http://dx.doi.org/10.1038/sj.onc.1204601			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607825				2022-12-17	WOS:000170887500016
J	Jackson, S; Storey, A				Jackson, S; Storey, A			E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage	ONCOGENE			English	Article						HPV; UV; apoptosis; skin	RENAL-TRANSPLANT RECIPIENTS; HUMAN PAPILLOMAVIRUS TYPE-16; NONMELANOMA SKIN CANCERS; CARCINOMA CELL-LINES; EPIDERMODYSPLASIA-VERRUCIFORMIS; IMMUNOSUPPRESSED PATIENTS; P53; UBIQUITINATION; ASSOCIATION; LESIONS	In addition to their role in anogenital cancer, human papillomaviruses (HPVs) are also involved in the development of a range of cutaneous lesions. HPV types 5 and 8 are associated with the development of skin cancers in individuals with Epidermodysplasia verruciformis (EV). A broad spectrum of NPV types are also commonly found in non-melanoma skin cancers in immunocompromised individuals, such as organ transplant recipients. The skin cancers in EV and immunocompromised patients occur predominantly at body sites exposed to ultra violet (UV) radiation, pointing to a key role for UV in their development, Here rye show that the E6 protein from a range of cutaneous NPV types effectively inhibits apoptosis in response to UV damage, This occurs in both p53 null and wild type cells and does not require p53 degradation.	Ctr Cutaneous Res, Imperial Canc Res Fund, Skin Tumour Lab, London E1 2AT, England	Cancer Research UK	Storey, A (corresponding author), Ctr Cutaneous Res, Imperial Canc Res Fund, Skin Tumour Lab, 2 Newark St, London E1 2AT, England.		高, 雨莉/HGU-8187-2022	Storey, Alan/0000-0003-2001-9772				Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; BERKHOUT RJM, 1995, J CLIN MICROBIOL, V33, P690, DOI 10.1128/JCM.33.3.690-695.1995; CAMPBELL C, 1993, CANCER RES, V53, P2697; CROOK T, 1991, ONCOGENE, V6, P873; DEJONGTIEBEN LM, 1995, J INVEST DERMATOL, V105, P367, DOI 10.1111/1523-1747.ep12320803; Delius H, 1998, VIROLOGY, V240, P359, DOI 10.1006/viro.1997.8943; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Elbel M, 1997, VIROLOGY, V239, P132, DOI 10.1006/viro.1997.8860; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAVRE M, 1989, J VIROL, V63, P4909, DOI 10.1128/JVI.63.11.4909-.1989; Grossman D, 1997, ARCH DERMATOL, V133, P1263, DOI 10.1001/archderm.133.10.1263; HALL PA, 1993, ONCOGENE, V8, P203; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hopfl R, 1997, J INVEST DERMATOL, V108, P53, DOI 10.1111/1523-1747.ep12285630; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JABLONSKA S, 1972, CANCER RES, V32, P583; JABLONSKA S, 1990, PAPILLOMAVIRUSES HUM, P46; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; MAJEWSKI S, 1995, ARCH DERMATOL, V131, P1312, DOI 10.1001/archderm.131.11.1312; OBALEK S, 1992, J INVEST DERMATOL, V98, P936, DOI 10.1111/1523-1747.ep12460892; OKAN I, 1995, ONCOGENE, V11, P1027; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; ORTH G, 1979, CANCER RES, V39, P1074; ORTH G, 1987, PAPOVAVIRIDAE, P189; Petrocelli T, 1996, ONCOGENE, V12, P1387; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PROBY C, 1996, PAPILLOMAVIRUS REPOR, V7, P53; PURDIE KJ, 1993, CANCER RES, V53, P5328; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Shamanin V, 1996, JNCI-J NATL CANCER I, V88, P802, DOI 10.1093/jnci/88.12.802; SHAMANIN V, 1994, CANCER RES, V54, P4610; SMITH ML, 1995, ONCOGENE, V10, P1053; STEGER G, 1992, ARCH VIROL, V125, P355, DOI 10.1007/BF01309654; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Surentheran T, 1998, J CLIN PATHOL, V51, P606, DOI 10.1136/jcp.51.8.606; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	44	159	166	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 27	2000	19	4					592	598		10.1038/sj.onc.1203339	http://dx.doi.org/10.1038/sj.onc.1203339			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698529				2022-12-17	WOS:000085104200013
J	Karni, R; Jove, R; Levitzki, A				Karni, R; Jove, R; Levitzki, A			Inhibition of pp60(c-Src) reduces Bcl-X-L expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors	ONCOGENE			English	Article						c-Src; Bcl-X; EGFR; HER-2	GROWTH-FACTOR RECEPTOR; PROTEIN-TYROSINE KINASES; HUMAN BREAST-CANCER; SRC-FAMILY KINASES; C-SRC; V-SRC; SIGNAL-TRANSDUCTION; STAT3 ACTIVATION; FACTOR-I; GENE	Tumors that overexpress HER-2/neu receptor or exhibit enhanced EGFR signaling have been reported to possess constitutively activated Src family kinases especially pp60(c-Srcs). High levels of pp60(c-Src) activity have also been reported for cell lines that overexpress the EGFR or the chimeric EGFR-HER-2 receptor. It has therefore been suggested that Src kinases may contribute significantly to the oncogenic phenotype of these cells and to the degree of malignancy of tumors that overexpress EGFR family receptors, In this study we show that the induced expression of c-SRC antisense RNA or the application of a selective Src kinase inhibitor induces growth arrest, programmed cell death and reverses the transformed properties of cells that overexpress EGFR or HER-2 receptors. We show that inhibition of Src kinase expression or activity results in the reduction of Stat3 tyrosine phosphorylation, decline of Bcl-X-1, expression, and induction of cell death. Using a construct in which the promoter of Bcl-X, which possesses putative Stat3 sites, is tethered to the luciferase reporter gene, we show that inhibition of Src activity or expression induces a decline in Bcl-S expression. We also show that the expression of activated Src induces activation of the Bcl-X promoter. This activation is inhibited by the expression of kinase dead Src or of Stat3 beta, the dominant-negative form of Stall, Taken together, these results support the hypothesis that Src positively regulates the transformed phenotype of cells overexpressing EGFR family kinases, Furthermore, these results also suggest that Src positively regulates Bcl-X-L, expression via Stat3 activation and thus acts not only as a potent mitogenic signaling element, but also as an anti-apoptotic signaling protein. The combination of both activities probably confers upon activated Src its oncogenic activity. Since Src kinase is activated in many tumors, pp60(c-Src) kinase inhibitors may prole useful as anti-cancer agents for mana types of cancer.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	Hebrew University of Jerusalem; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Levitzki, A (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.							Ben-Bassat H, 1995, Exp Dermatol, V4, P82, DOI 10.1111/j.1600-0625.1995.tb00227.x; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BROOME MA, 1996, J BIOL CHEM, V271, P16796; Brunton VG, 1997, ONCOGENE, V14, P283, DOI 10.1038/sj.onc.1200827; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRILLOT DA, 1997, J IMMUNOL, V158, P4759; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; IMAMOTO A, 1994, CURR OPIN GENET DEV, V4, P40, DOI 10.1016/0959-437X(94)90089-2; Levitzki A, 1996, CURR OPIN CELL BIOL, V8, P239, DOI 10.1016/S0955-0674(96)80071-8; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Mangeney M, 1996, ONCOGENE, V13, P1441; McGill G, 1997, J CELL BIOL, V138, P901, DOI 10.1083/jcb.138.4.901; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1355, DOI 10.1210/en.138.3.1355; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; Sabe H, 1997, ONCOGENE, V14, P1779, DOI 10.1038/sj.onc.1201022; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SATO KI, 1995, BIOCHEM BIOPH RES CO, V210, P844, DOI 10.1006/bbrc.1995.1735; SCHINDLER T, 1999, IN PRESS MOL CELL; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	32	159	164	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4654	4662		10.1038/sj.onc.1202835	http://dx.doi.org/10.1038/sj.onc.1202835			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467412				2022-12-17	WOS:000082154400002
J	Soder, AI; Hoare, SF; Muir, S; Going, JJ; Parkinson, EK; Keith, WN				Soder, AI; Hoare, SF; Muir, S; Going, JJ; Parkinson, EK; Keith, WN			Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer	ONCOGENE			English	Article						telomerase; gene amplification; in situ hybridisation; gene expression; hTR	SQUAMOUS-CELL CARCINOMAS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER; IMMORTAL CELLS; IN-SITU; HEAD; NECK; TUMORS; IDENTIFICATION; PROGRESSION	Telomere length is maintained by the enzyme, telomerase, which has been linked to cellular immortality and tumour progression, However, the reasons for the high levels of telomerase found in human tumours are unknown, We have mapped the human telomerase RNA gene, (hTR), to chromosome 3q26.3 and show the hTR gene to be amplified in four carcinomas, (2/33 cervix, 1/31 head and neck, 1/9 lung), In addition, increased copy numbers of the hTR locus was also observed in 97% of tumours, By in situ hybridisation, the histological distribution of high levels of hTR expression could be demonstrated in a lung tumour and its metastasis with hTR amplification, These results are the first report of genetic alterations involving a known component of telomerase in human cancer, Indeed, it is also the first report of the amplification of a specific locus within the chromosome 3q region frequently subject to copy number gains in human tumours, In addition, we also show for the first time the histological distribution of the RNA component of telomerase in human tumours.	UNIV GLASGOW,CRC DEPT MED ONCOL,BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND; UNIV GLASGOW,GLASGOW ROYAL INFIRM,DEPT PATHOL,GLASGOW G4 0SF,LANARK,SCOTLAND; BEATSON INST CANC RES,CRC,BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND	Beatson Institute; University of Glasgow; University of Glasgow; Beatson Institute			Keith, Nicol/D-3325-2009	Keith, Nicol/0000-0001-7862-3580; Going, James/0000-0001-9120-919X				Arnold N, 1996, GENE CHROMOSOME CANC, V16, P46, DOI 10.1002/(SICI)1098-2264(199605)16:1<46::AID-GCC7>3.0.CO;2-3; Avilion AA, 1996, CANCER RES, V56, P645; BACCHETTI S, 1995, INT J ONCOL, V7, P423; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; BRZOSKA PM, 1995, CANCER RES, V55, P3055; Collins K, 1996, CURR OPIN CELL BIOL, V8, P374, DOI 10.1016/S0955-0674(96)80013-5; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUTTS J, 1993, BRIT J CANCER, V68, P793, DOI 10.1038/bjc.1993.430; EDINGTON KG, 1995, MOL CARCINOGEN, V13, P254, DOI 10.1002/mc.2940130408; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FITZPATRICK DR, 1990, DEVELOPMENT, V109, P585; Greaves M, 1996, TRENDS GENET, V12, P127, DOI 10.1016/0168-9525(96)30016-4; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hermsen MAJA, 1996, GENE CHROMOSOME CANC, V15, P1; Heselmeyer K, 1996, P NATL ACAD SCI USA, V93, P479, DOI 10.1073/pnas.93.1.479; Hoare SF, 1997, BRIT J CANCER, V75, P275, DOI 10.1038/bjc.1997.45; IWABUCHI H, 1995, CANCER RES, V55, P6172; JOOS S, 1993, HUM GENET, V90, P584, DOI 10.1007/BF00202475; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1995, NAT GENET, V9, P104, DOI 10.1038/ng0295-104; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; LEVIN NA, 1995, GENE CHROMOSOME CANC, V13, P175, DOI 10.1002/gcc.2870130307; LEVIN NA, 1994, CANCER RES, V54, P5086; McLeod HL, 1996, BRIT J CANCER, V74, P508, DOI 10.1038/bjc.1996.394; MURPHY DS, 1995, INT J CANCER, V64, P18, DOI 10.1002/ijc.2910640106; MURPHY DS, 1995, J NATL CANCER I, V87, P1694, DOI 10.1093/jnci/87.22.1694; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; Parkinson EK, 1996, BRIT J CANCER, V73, P1, DOI 10.1038/bjc.1996.1; RHYU MS, 1995, J NATL CANCER I, V87, P884, DOI 10.1093/jnci/87.12.884; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; RIED T, 1994, CANCER RES, V54, P1801; RIED T, 1995, CANCER RES, V55, P5414; Robertson KW, 1996, CANCER RES, V56, P3823; Shay Jerry W., 1996, Current Opinion in Oncology, V8, P66, DOI 10.1097/00001622-199601000-00012; Shay JW, 1996, TRENDS GENET, V12, P129, DOI 10.1016/0168-9525(96)30018-8; SODER AI, 1995, CANCER RES, V55, P5030; SPEICHER MR, 1995, CANCER RES, V55, P1010; SREEKANTAIAH C, 1994, GENE CHROMOSOME CANC, V11, P29, DOI 10.1002/gcc.2870110106; VANDYKE DL, 1994, GENE CHROMOSOME CANC, V9, P192, DOI 10.1002/gcc.2870090308; WARD PB, 1996, GENOMICS, V32, P1; Wright WE, 1996, DEV GENET, V18, P173; WRIGHT WE, 1995, TRENDS CELL BIOL, V5, P293, DOI 10.1016/S0962-8924(00)89044-3	46	159	167	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1013	1021		10.1038/sj.onc.1201066	http://dx.doi.org/10.1038/sj.onc.1201066			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070649				2022-12-17	WOS:A1997WM07000002
J	Kitada, S; Krajewski, S; Miyashita, T; Krajewska, M; Reed, JC				Kitada, S; Krajewski, S; Miyashita, T; Krajewska, M; Reed, JC			gamma-Radiation induces upregulation of Bax protein and apoptosis in radiosensitive cells in vivo	ONCOGENE			English	Article						Bax; Bcl-2; apoptosis; radiation	INDUCTION; P53; AGENTS; DEATH	Lymphoid cells and small intestinal epithelial (SIE) cells are among the most radiosensitive in the body. The factors that account for the differential sensitivity to gamma-radiation among different tissue-types remain poorly understood, but can only partly be explained by differences in rates of cell proliferation. Here we demonstrate that exposure of mice to 800 cGy of gamma-radiation results in rapid elevations in the levels of the Bax protein, a pro-apoptotic member of the Bcl-2 protein family, in lymphoid cells and SIEs. gamma-Radiation-induced increases in Bax protein were evident within 2 h and persisted for at least 24 h, as determined by immunoblotting and immunohistochemical assays. Increases in Bax were followed by massive apoptosis in lymphoid organs and in the small intestinal crypts, as determined by morphological criteria and in situ end-labeling of fragmented nuclear DNA by terminal deoxynucleotidyl transferase (TUNEL method). Radiation did not induce elevations in Bax or apoptosis in radioresistant tissues such as heart, skeletal muscle, brain, kidney, liver, lung, vascular smooth muscle and connective tissue. The findings suggest that Bax may be one of the mediators of radiation-induced apoptosis in vivo.	LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [CA-60381] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRISTOW RG, 1994, ONCOGENE, V9, P1527; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; GORCZYCA W, 1992, INT J ONCOL, V1, P639; Hill R. P., 1992, BASIC SCI ONCOLOGY, P259; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HORNING SJ, 1993, SEMIN ONCOL, V20, P75; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MERRITT AJ, 1994, CANCER RES, V54, P614; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PEZZELLA F, 1990, AM J PATHOL, V137, P225; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; POTTEN CS, 1983, CYTOTOXIC INSULT TIS; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, ONCOGENE, V9, P3743	26	159	167	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					187	192						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552390				2022-12-17	WOS:A1996TQ01400023
J	CECCHERINI, I; HOFSTRA, RMW; LUO, Y; STULP, RP; BARONE, V; STELWAGEN, T; BOCCIARDI, R; NIJVEEN, H; BOLINO, A; SERI, M; RONCHETTO, P; PASINI, B; BOZZANO, M; BUYS, CHCM; ROMEO, G				CECCHERINI, I; HOFSTRA, RMW; LUO, Y; STULP, RP; BARONE, V; STELWAGEN, T; BOCCIARDI, R; NIJVEEN, H; BOLINO, A; SERI, M; RONCHETTO, P; PASINI, B; BOZZANO, M; BUYS, CHCM; ROMEO, G			DNA POLYMORPHISMS AND CONDITIONS FOR SSCP ANALYSIS OF THE 20 EXONS OF THE RET PROTOONCOGENE	ONCOGENE			English	Note							SINGLE BASE SUBSTITUTIONS; POINT MUTATIONS; PROTOONCOGENE; MISMATCHES; LINE	Recently identified mutations affecting different domains of the RET proto-oncogene are associated with Multiple Endocrine Neoplasia type 2A (MEN 2A) and type 2B (MEN 2B), familial and sporadic Medullary Thyroid Carcinomas (MTC) and Hirschsprung disease (HSCR). In order to facilitate the screening for RET mutations, and to study possible genotype-phenotype correlations, we established exon-intron junctions and extended the intronic sequences flanking the 20 exons of this gene. This made it possible to design primers and to develop PCR conditions useful for SSCP analysis of the whole RET coding sequence. Nine conformational variants were observed which after sequencing turned out to be 8 silent mutations and a conservative amino acid substitution. Restriction analysis performed on DNA samples from unrelated controls confirmed the polymorphic nature of six of these nucleotide changes and made it possible to estimate the frequency of the corresponding alleles.	IST GIANNINA GASLINI,GENET MOLEC LAB,I-16148 GENOA,ITALY; UNIV GRONINGEN,DEPT MED GENET,9713 AW GRONINGEN,NETHERLANDS	University of Genoa; IRCCS Istituto Giannina Gaslini; University of Groningen			Bocciardi, Renata/J-8577-2016; Ceccherini, Isabella/P-8195-2014; Bolino, Alessandra/O-2933-2013; Barone, Virginia/K-8782-2015; Pasini, Barbara/AHI-2004-2022; Nijveen, Harm/L-2272-2014; Ronchetto, Patrizia/AAA-7742-2020; Seri, Marco/A-4339-2014	Bocciardi, Renata/0000-0001-8415-3802; Ceccherini, Isabella/0000-0001-8732-1955; Barone, Virginia/0000-0001-8794-9291; Pasini, Barbara/0000-0002-4373-1212; Nijveen, Harm/0000-0002-9167-4945; Bolino, Alessandra/0000-0002-8980-4878; Hofstra, Robert/0000-0001-7498-3829; Ronchetto, Patrizia/0000-0002-2606-3398; Seri, Marco/0000-0003-2425-2176				BUDOWLE B, 1991, AM J HUM GENET, V48, P137; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CECCHERINI I, 1994, J ENDOCRINOL INVEST, V17, P201; CECCHERINI I, 1993, BIOCHEM BIOPH RES CO, V196, P1288, DOI 10.1006/bbrc.1993.2392; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DANENBERG PV, 1992, NUCLEIC ACIDS RES, V20, P573, DOI 10.1093/nar/20.3.573; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; GLAVAC D, 1993, HUM MUTAT, V2, P404, DOI 10.1002/humu.1380020513; HAYASHI K, 1993, HUM MUTAT, V2, P338, DOI 10.1002/humu.1380020503; HEARNE CM, 1992, TRENDS GENET, V8, P288, DOI 10.1016/0168-9525(92)90256-4; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; LO YMD, 1992, NUCLEIC ACIDS RES, V20, P1005, DOI 10.1093/nar/20.5.1005; MAHAFFEY SM, 1990, J PEDIATR SURG, V25, P101, DOI 10.1016/S0022-3468(05)80172-1; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; MYERS RM, 1985, NATURE, V313, P495, DOI 10.1038/313495a0; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; VERDY M, 1982, J PEDIATR GASTR NUTR, V1, P603, DOI 10.1097/00005176-198212000-00027; WHITE MB, 1992, GENOMICS, V12, P301, DOI 10.1016/0888-7543(92)90377-5	26	159	162	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3025	3029						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084609				2022-12-17	WOS:A1994PG82200032
J	BELLACOSA, A; FRANKE, TF; GONZALEZPORTAL, ME; DATTA, K; TAGUCHI, T; GARDNER, J; CHENG, JQ; TESTA, JR; TSICHLIS, PN				BELLACOSA, A; FRANKE, TF; GONZALEZPORTAL, ME; DATTA, K; TAGUCHI, T; GARDNER, J; CHENG, JQ; TESTA, JR; TSICHLIS, PN			STRUCTURE, EXPRESSION AND CHROMOSOMAL MAPPING OF C-AKT - RELATIONSHIP TO V-AKT AND ITS IMPLICATIONS	ONCOGENE			English	Article							PROTEIN KINASE-C; SEQUENCE; HYBRIDIZATION; FAMILY	Sequence analysis of a nearly full-length murine c-akt cDNA clone and comparison with v-akt revealed the following: (a) The entire coding region of c-akt is identical to that of v-akt with the exception of five G to A transitions that do not alter the reading frame. The 3' untranslated regions of v-akt and c-akt are also identical with the exception of three single-base differences. (b) The recombination event that gave rise to v-akt occurred between the virus at nucleotide 785 from the Gag ATG codon and the 5' untranslated region of c-akt to 60 bp 5' from the c-akt ATG codon. (c) Three nucleotides absent from both Gag and c-akt were inserted at the junction between the two genes. The outcome of these events was to place, in frame, a 63-bp fragment between Gag and Akt. The resulting v-akt oncogene is predicted to encode a tripartite Gag (p12, p15, DELTAp30)-X-c-akt protein product. The c-akt protein contains, starting from its amino terminus, a src homology 2-like (SH2-like) domain, a domain rich in glutamic acid residues, part of which is predicted to form an amphipathic helix, and a kinase domain encoding a serine-threonine kinase with high degree of homology to members of the protein kinase C (PKC) family. The mouse c-akt is 90% homologous to human AKT1/RAC at the nucleic acid level and 98% homologous at the amino acid level. c-akt in the mouse is composed of 13 exons. The first exon contains a 5' untranslated GC-rich region. Since the recombination that gave rise to v-akt occurred with the 5' untranslated region, we hypothesize that the transduction of c-akt was preceded by provirus insertion upstream from or within the 5' untranslated region and in the same transcriptional orientation as the gene. c-akt was mapped by fluorescence in situ hybridization (FISH) to mouse chromosome 12 and rat chromosome 6 in close proximity to the Igh locus.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19111	Fox Chase Cancer Center			Gonzalez, Maria Eugenia/B-5146-2008	Gonzalez, Maria Eugenia/0000-0003-0355-5469	NCI NIH HHS [CA-38047, CA-06927] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA038047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLACOSA A, 1991, MOL CELL BIOL, V11, P2864, DOI 10.1128/MCB.11.5.2864; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BISHOP JM, 1985, RNA TUMOR VIRUSES S, V2, P249; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCH CA, 1991, SCIENCE, V252, P688; LIM HM, 1988, GENE ANAL TECH, V5, P32, DOI 10.1016/0735-0651(88)90024-6; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; ONO Y, 1988, J BIOL CHEM, V263, P6927; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; Staal SP, 1988, GENOMICS, V2, P96, DOI 10.1016/0888-7543(88)90114-0; TESTA JR, 1993, IN PRESS CYTOGENET C; Tsichlis P N, 1991, Curr Top Microbiol Immunol, V171, P95; WEISS R, 1985, RNA TUMOR VIRUSES, V2, P139	33	159	165	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					745	754						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437858				2022-12-17	WOS:A1993KN00800027
J	CARBONE, D; CHIBA, I; MITSUDOMI, T				CARBONE, D; CHIBA, I; MITSUDOMI, T			POLYMORPHISM AT CODON-213 WITHIN THE P53-GENE	ONCOGENE			English	Note							P53 GENE; LUNG-CANCER; MUTATIONS; FREQUENT; PROTEIN; MUTANT	This report describes a rare polymorphism at codon 213 (silent alteration of CGA to CGG) within the coding region of the p53 gene. The rare polymorphic allele was present in six cases out of 189 lung and breast cancer DNAs analyzed (3.2%) and resulted in the loss of a TaqI site. This allele could be mistaken for a mutation when screening methods of mutation analysis are used without comparison with normal tissue DNA.	USN,MED ONCOL BRANCH,BETHESDA,MD 20889	United States Department of Defense; United States Navy	CARBONE, D (corresponding author), UNIV TEXAS,SW MED CTR,SIMMONS CANC CTR,2523 HARRY HINES BLVD,DALLAS,TX 75235, USA.			Mitsudomi, Tetsuya/0000-0001-9860-8505				AHUJA HG, 1990, ONCOGENE, V5, P1409; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHIBA I, 1990, ONCOGENE, V5, P1603; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; GROMPE M, 1989, P NATL ACAD SCI USA, V86, P5888, DOI 10.1073/pnas.86.15.5888; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494	14	159	160	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1691	1692						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923533				2022-12-17	WOS:A1991GX27400027
J	Li, ZH; Jiang, P; Li, J; Peng, MJ; Zhao, X; Zhang, X; Chen, K; Zhang, YJ; Liu, H; Gan, L; Bi, HQ; Zhen, P; Zhu, J; Li, XW				Li, Zhonghu; Jiang, Peng; Li, Jie; Peng, Minjie; Zhao, Xin; Zhang, Xi; Chen, Kai; Zhang, Yujun; Liu, Hui; Gan, Lang; Bi, Huaqiang; Zhen, Ping; Zhu, Jin; Li, Xiaowu			Tumor-derived exosomal lnc-Sox2ot promotes EMT and stemness by acting as a ceRNA in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; CANCER; RNA; METASTASIS; CELLS; BIOMARKERS; MARKERS; MIRNA; GENE; SOX2	Long noncoding RNAs (lncRNAs) or exosomes have recently been shown to play vital regulatory or communication roles in cancer biology. However, the roles and mechanisms of exosomal lncRNAs in tumor invasion or metastasis of pancreatic ductal adenocarcinoma (PDAC) remain unknown. In this study, we aimed to investigate the detailed roles and mechanisms of tumor-generated exosomes in progression and metastasis of PDAC in vitro and in vivo. We identified a lncRNA-Sox2ot from exosomes of highly invasive PDAC cells, and analyzed the expression of Sox2ot in the plasma samples and found that the plasma exosomal Sox2ot expression was high and correlated with TNM stage and overall survival rate of PDAC patients. Further research showed that Sox2ot promotes epithelial-mesenchymal transition (EMT) and stem cell like properties by regulating Sox2 expression. Sox2ot competitively binds to the miR-200 family to regulate the expression of Sox2, thus promoting invasion and metastasis of PDAC. We also confirmed the transmission of the exosomes from producer cells to recipient PDAC cells, exosomal Sox2ot can promote tumor invasion and metastasis in vitro and in vivo. We further confirmed tumor generated exosomes could excrete to tumor cell or blood circulation in vivo condition. Finally, we observed a decreased exosomal Sox2ot expression in postoperative blood samples of PDAC patients. The exosomal lncRNA Sox2ot plays important roles in tumor progression and may be a useful maker for pancreatic cancer prognosis.	[Li, Zhonghu; Jiang, Peng; Li, Jie; Peng, Minjie; Zhao, Xin; Zhang, Xi; Chen, Kai; Zhang, Yujun; Liu, Hui; Gan, Lang; Bi, Huaqiang; Zhen, Ping; Zhu, Jin; Li, Xiaowu] Third Mil Med Univ, Southwest Hosp, Hepatobiliary Surg Inst, Chongqing, Peoples R China	Army Medical University	Li, XW (corresponding author), Third Mil Med Univ, Southwest Hosp, Hepatobiliary Surg Inst, Chongqing, Peoples R China.	lixw1966@163.com	bi, huaqiang/GYJ-5005-2022; Li, Xiaowu/AAF-2769-2020		National Natural Science Foundation of China [81430063]; Natural Science Foundation of Southwest Hospital [SWH2016JCYB-46]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Southwest Hospital	This work was supported by the National Natural Science Foundation of China under Grant 81430063, and the Natural Science Foundation of Southwest Hospital under Grant SWH2016JCYB-46.	Azmi AS, 2013, CANCER METAST REV, V32, P623, DOI 10.1007/s10555-013-9441-9; Cech TR, 2014, CELL, V157, P77, DOI 10.1016/j.cell.2014.03.008; Chen IH, 2017, P NATL ACAD SCI USA, V114, P3175, DOI 10.1073/pnas.1618088114; Chen T, 2017, J CELL PHYSIOL, V232, P3261, DOI 10.1002/jcp.25797; Conroy T, 2016, EUR J CANCER, V57, P10, DOI 10.1016/j.ejca.2015.12.026; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Dhamija S, 2016, INT J CANCER, V139, P269, DOI 10.1002/ijc.30039; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Ge QY, 2014, MOLECULES, V19, P1568, DOI 10.3390/molecules19021568; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Henderson MC, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00038; Herreros-Villanueva M, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.23; Huang XY, 2015, EUR UROL, V67, P33, DOI 10.1016/j.eururo.2014.07.035; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Joyce DP, 2016, INT J CANCER, V139, P1443, DOI 10.1002/ijc.30179; Lennon AM, 2014, CANCER RES, V74, P3381, DOI 10.1158/0008-5472.CAN-14-0734; Li XF, 2013, CANCER LETT, V336, P379, DOI 10.1016/j.canlet.2013.03.027; Lugea A, 2017, PANCREAS, V46, P1, DOI 10.1097/MPA.0000000000000686; Madhavan B, 2015, INT J CANCER, V136, P2616, DOI 10.1002/ijc.29324; Matsushita H, 2016, GASTROENTEROLOGY, V150, pS1086, DOI 10.1053/j.gastro.2016.02.051; Momen-Heravi F, 2014, NANOMED-NANOTECHNOL, V10, P1517, DOI 10.1016/j.nano.2014.03.014; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Pope SM, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.22484; Qu L, 2016, CANCER CELL, V29, P653, DOI 10.1016/j.ccell.2016.03.004; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rosa A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1797692; Schaeffer D, 2010, ADV EXP MED BIOL, V702, P79, DOI 10.1007/978-1-4419-7841-7_7; Schmitz SU, 2016, CELL MOL LIFE SCI, V73, P2491, DOI 10.1007/s00018-016-2174-5; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Singh SK, 2015, EMBO J, V34, P517, DOI 10.15252/embj.201489574; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Syn N, 2016, TRENDS PHARMACOL SCI, V37, P606, DOI 10.1016/j.tips.2016.04.006; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; TRAMS EG, 1981, BIOCHIM BIOPHYS ACTA, V645, P63, DOI 10.1016/0005-2736(81)90512-5; Umezu T, 2013, ONCOGENE, V32, P2747, DOI 10.1038/onc.2012.295; van den Boorn JG, 2013, ADV DRUG DELIVER REV, V65, P331, DOI 10.1016/j.addr.2012.06.011; Velpula KK, 2011, ONCOTARGET, V2, P1028; Wolfgang CL, 2013, CA-CANCER J CLIN, V63, P318, DOI 10.3322/caac.21190; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zou YK, 2015, CARCINOGENESIS, V36, P676, DOI 10.1093/carcin/bgv027	42	158	162	2	38	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2018	37	28					3822	3838		10.1038/s41388-018-0237-9	http://dx.doi.org/10.1038/s41388-018-0237-9			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM8HR	29643475				2022-12-17	WOS:000438465600005
J	Zhang, N; Li, X; Wu, CW; Dong, Y; Cai, M; Mok, MTS; Wang, H; Chen, J; Ng, SSM; Chen, M; Sung, JJY; Yu, J				Zhang, N.; Li, X.; Wu, C. W.; Dong, Y.; Cai, M.; Mok, M. T. S.; Wang, H.; Chen, J.; Ng, S. S. M.; Chen, M.; Sung, J. J. Y.; Yu, J.			microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis	ONCOGENE			English	Article						miR-7; YY1; p53; Wnt; colorectal cancer	COLON-CANCER CELLS; NEGATIVE REGULATOR; CERVICAL CANCERS; P53; APOPTOSIS; EXPRESSION; GENE; ACTIVATION; YIN-YANG-1; PROGRESSION	Using microRNA (miRNA) expression array, we identified that miR-7 was deregulated in colorectal cancer (CRC). We studied the biological role and molecular target of miR-7 in CRC. miR-7 was downregulated in six out of seven colon cancer cell lines. Ectopic expression of miR-7 suppressed colon cancer cell proliferation (P<0.05), induced apoptosis (P<0.05) and caused cell-cycle arrest in G1 phase (P<0.05). The tumor suppressive function of miR-7 was further confirmed in nude mice (P<0.05). The 3'-untranslated region (3'UTR) of Yin Yang 1 (YY1) mRNA contains an evolutionarily conserved miR-7 binding site using in silico searches, luciferase reporter assay and western blot analysis confirmed that miR-7 directly bound to YY1 3'UTR to negatively regulate the protein expression of YY1 in colon cancer cell lines HCT116 and LOVO. Intriguingly, knock-down of YY1 in three colon cancer cell lines (HCT116, LOVO and DLD1) consistently suppressed cell proliferation (P<0.01) and induced apoptosis (P<0.01), indicating the opposite functions of miR-7 and YY1 in CRC. Consistent with these data, ectopic expression of YY1 promoted cell growth by increasing proliferation (P<0.01) and suppressing apoptosis (P<0.001). The tumorigenic ability of YY1 was further confirmed in vivo in xenograft-nude mouse model (P<0.01). In addition, pathway analyses revealed that the oncogenic effect by YY1 was associated with inhibiting p53 and modulating its downstream effectors p15, caspase cascades and C-Jun, and activating Wnt signaling pathway through activating beta-catenin, anti-apoptotic survivin and fibroblast growth factor 4. Furthermore, multivariate analysis revealed that patients with YY1 protein high expression had a significant decrease in overall survival, and Kaplan-Meier survival curves showed that these patients had significantly shorter survival than others (P<0.0001). In conclusion, MiR-7 is a novel miRNA with tumor suppressive function in colon cancer by targeting oncogenic YY1. YY1 promotes colon cancer growth through inhibiting p53 and promoting Wnt signaling pathways and serves as an independent prognostic biomarker for CRC patients.	[Zhang, N.; Li, X.; Wu, C. W.; Dong, Y.; Mok, M. T. S.; Sung, J. J. Y.; Yu, J.] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China; [Zhang, N.; Chen, J.; Chen, M.] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol, Guangzhou 510275, Guangdong, Peoples R China; [Dong, Y.; Ng, S. S. M.] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Dept Surg, Shatin, Hong Kong, Peoples R China; [Cai, M.] Sun Yat Sen Univ, Ctr Canc, Dept Pathol, Guangzhou 510275, Guangdong, Peoples R China; [Wang, H.] Chinese Univ Hong Kong, Sch Publ Hlth & Primary Care, Stanley Ho Ctr Emerging Infect Dis, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Sun Yat Sen University; Chinese University of Hong Kong; Sun Yat Sen University; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Inst Digest Dis, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.	chenminhu@vip.163.com; junyu@cuhk.edu.hk	Sung, Joseph J. Y./R-3203-2018; Ng, Simon S. M./M-1219-2018; Li, Xiao-xing/B-9114-2008; Mok, Myth/M-2958-2013; Wang, Huating/C-6719-2014; Yu, Jun/D-8569-2015	Sung, Joseph J. Y./0000-0003-3125-5199; Ng, Simon S. M./0000-0002-5389-9297; Li, Xiao-xing/0000-0001-8791-7505; Mok, Myth/0000-0003-3156-4944; Wang, Huating/0000-0001-5474-2905; Yu, Jun/0000-0001-5008-2153	National High-tech R&D Program of China (863 program) [2012AA02A203, 2012AA02A506]; Innovation and Technology Fund Hong Kong [ITS/276/11]; CUHK [2010.1.085]; National Natural Science Foundation of China [81072048]	National High-tech R&D Program of China (863 program)(National High Technology Research and Development Program of China); Innovation and Technology Fund Hong Kong; CUHK(Chinese University of Hong Kong); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This project was supported by National High-tech R&D Program of China (863 program, 2012AA02A203; 863 program, 2012AA02A506), Innovation and Technology Fund Hong Kong (ITS/276/11), CUHK direct grant (2010.1.085) and National Natural Science Foundation of China (81072048).	Akao Y, 2006, BIOL PHARM BULL, V29, P903, DOI 10.1248/bpb.29.903; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Balaguer F, 2010, CANCER RES, V70, P6609, DOI 10.1158/0008-5472.CAN-10-0622; Balciunaite G, 2002, NAT IMMUNOL, V3, P1102, DOI 10.1038/ni850; Baritaki S, 2007, INT J ONCOL, V31, P69; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Begon DY, 2005, J BIOL CHEM, V280, P24428, DOI 10.1074/jbc.M503790200; Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003-0498; Buckland RA, 1998, MECH DEVELOP, V71, P143, DOI 10.1016/S0925-4773(98)00008-2; Chen X, 2009, ONCOGENE, V28, P1385, DOI 10.1038/onc.2008.474; Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4; Dale TC, 1998, BIOCHEM J, V329, P209; DONG XP, 1994, INT J CANCER, V58, P803, DOI 10.1002/ijc.2910580609; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; Jiang L, 2010, BIOCHEM J, V432, P199, DOI 10.1042/BJ20100859; Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639; Kimura Y, 1997, GENOMICS, V41, P477, DOI 10.1006/geno.1997.4680; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; MAY M, 1994, EMBO J, V13, P1460, DOI 10.1002/j.1460-2075.1994.tb06400.x; Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817; Nugent M, 2011, EJSO-EUR J SURG ONC, V37, P649, DOI 10.1016/j.ejso.2011.05.005; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Pritchard CC, 2011, GUT, V60, P116, DOI 10.1136/gut.2009.206250; Reddy SDN, 2008, CANCER RES, V68, P8195, DOI 10.1158/0008-5472.CAN-08-2103; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Seligson D, 2005, INT J ONCOL, V27, P131; Su DM, 2003, NAT IMMUNOL, V4, P1128, DOI 10.1038/ni983; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Tago K, 2000, GENE DEV, V14, P1741; Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104; Thorne CA, 2010, NAT CHEM BIOL, V6, P829, DOI 10.1038/NCHEMBIO.453; Walther A, 2009, NAT REV CANCER, V9, P489, DOI 10.1038/nrc2645; Wang P, 2009, CANCER RES, V69, P8157, DOI 10.1158/0008-5472.CAN-09-1996; Wieler S, 2003, J BIOL CHEM, V278, P18914, DOI 10.1074/jbc.M211641200; Wu CW, 2012, GUT, V61, P739, DOI 10.1136/gut.2011.239236; Wu WKK, 2011, CARCINOGENESIS, V32, P247, DOI 10.1093/carcin/bgq243; Yokoyama NN, 2010, NUCLEIC ACIDS RES, V38, P6375, DOI 10.1093/nar/gkq492	40	158	179	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5078	5088		10.1038/onc.2012.526	http://dx.doi.org/10.1038/onc.2012.526			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23208495				2022-12-17	WOS:000325937900009
J	Wang, YN; Yamaguchi, H; Hsu, JM; Hung, MC				Wang, Y-N; Yamaguchi, H.; Hsu, J-M; Hung, M-C			Nuclear trafficking of the epidermal growth factor receptor family membrane proteins	ONCOGENE			English	Review						EGFR family receptors; nuclear trafficking; integral membrane proteins	TYROSINE KINASE INHIBITORS; CLATHRIN-INDEPENDENT ENDOCYTOSIS; CELL-SURFACE RECEPTORS; BREAST-CANCER; INTRACELLULAR DOMAIN; NUCLEOCYTOPLASMIC TRANSPORT; GENE-EXPRESSION; EGF RECEPTOR; LUNG-CANCER; SIGNAL-TRANSDUCTION	Multiple membrane-bound receptor tyrosine kinases (RTKs), such as the epidermal growth factor receptor (EGFR) and ErbB-2, have been reported to be localized in the nucleus, where emerging evidence suggests that they are involved in transcriptional regulation, cell proliferation, DNA repair and chemo-and radio-resistance. Recent studies have shown that endocytosis and endosomal sorting are involved in the nuclear transport of cell surface RTKs. However, the detailed mechanism by which the full-length receptors embedded in the endosomal membrane travel all the way from the cell surface to the early endosomes and pass through the nuclear pore complexes is unknown. This important area has been overlooked for decades, which has hindered progress in our understanding of nuclear RTKs' functions. Here, we discuss the putative mechanisms by which EGFR family RTKs are shuttled into the nucleus. Understanding the trafficking mechanisms as to how RTKs are transported from the cell surface to the nucleus will significantly contribute to understanding the functions of the nuclear RTKs. Oncogene (2010) 29, 3997-4006; doi:10.1038/onc.2010.157; published online 17 May 2010	[Wang, Y-N; Yamaguchi, H.; Hsu, J-M; Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Hsu, J-M; Hung, M-C] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA; [Hung, M-C] China Med Univ & Hosp, Ctr Mol Med, Taichung, Taiwan; [Hung, M-C] China Med Univ & Hosp, Grad Inst Canc Biol, Taichung, Taiwan; [Hung, M-C] Asia Univ, Taichung, Taiwan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Asia University Taiwan	Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Unit 079, Houston, TX 77030 USA.	mhung@mdanderson.org	Hsu, Jung-Mao/AAP-8045-2020; Hung, Mien-Chie/ABD-5911-2021; Hsu, Jung-Mao/AAC-9527-2019	Hung, Mien-Chie/0000-0003-4317-4740; Wang, Ying-Nai/0000-0002-5275-6729	National Institutes of Health [RO1 109311]; National Breast Cancer Foundation Inc.; China Medical University Hospital; Cancer Center Research of Excellence Taiwan [DOH TD-C-111-005]; National Science Council Taiwan [TMS-94-2B-001]; MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE [R01CA109311, P01CA099031] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Breast Cancer Foundation Inc.; China Medical University Hospital; Cancer Center Research of Excellence Taiwan; National Science Council Taiwan(Ministry of Science and Technology, Taiwan); MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the National Institutes of Health Grants RO1 109311; the National Breast Cancer Foundation Inc.; the Sister Institutional fund from China Medical University Hospital and MD Anderson Cancer Center; Cancer Center Research of Excellence DOH TD-C-111-005 (Taiwan) (to M-CH), and National Science Council Taiwan Merit Postdoctoral Scholarship TMS-94-2B-001 (to Y-NW). In memoriam, Mrs Serena Lin-Guo for her courageous battle in breast cancer.	Adam RM, 2003, CANCER RES, V63, P484; Arasada RR, 2005, J BIOL CHEM, V280, P30783, DOI 10.1074/jbc.M506057200; Bailey KE, 2007, J NUCL MED, V48, P1562, DOI 10.2967/jnumed.107.044073; Baldys A, 2009, BIOCHEMISTRY-US, V48, P9321, DOI 10.1021/bi900865u; Bao JX, 2003, J CELL BIOL, V161, P1133, DOI 10.1083/jcb.200212085; Bryant DM, 2005, TRAFFIC, V6, P947, DOI 10.1111/j.1600-0854.2005.00332.x; Bueter W, 2006, CYTOKINE, V36, P267, DOI 10.1016/j.cyto.2007.02.002; Carpenter G, 2003, CURR OPIN CELL BIOL, V15, P143, DOI 10.1016/S0955-0674(03)00015-2; Carpenter G, 2009, EXP CELL RES, V315, P1556, DOI 10.1016/j.yexcr.2008.09.027; Ceresa BP, 2006, HISTOL HISTOPATHOL, V21, P987, DOI 10.14670/HH-21.987; Ceresa BP, 2006, J BIOL CHEM, V281, P1099, DOI 10.1074/jbc.M504175200; Chen DJ, 2007, CLIN CANCER RES, V13, P6555, DOI 10.1158/1078-0432.CCR-07-1610; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cook A, 2007, ANNU REV BIOCHEM, V76, P647, DOI 10.1146/annurev.biochem.76.052705.161529; Das AK, 2007, CANCER RES, V67, P5267, DOI 10.1158/0008-5472.CAN-07-0242; de la Iglesia N, 2008, GENE DEV, V22, P449, DOI 10.1101/gad.1606508; Di Cosimo S, 2010, NAT REV CLIN ONCOL, V7, P139, DOI 10.1038/nrclinonc.2009.234; Dittmann K, 2005, J BIOL CHEM, V280, P31182, DOI 10.1074/jbc.M506591200; Dittmann K, 2005, RADIOTHER ONCOL, V76, P157, DOI 10.1016/j.radonc.2005.06.022; Dittmann K, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-69; Klaus HD, 2008, INT J RADIAT ONCOL, V70, P203, DOI 10.1016/j.ijrobp.2007.08.065; Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540; Edwards J, 2006, CLIN CANCER RES, V12, P123, DOI 10.1158/1078-0432.CCR-05-1445; Esteva FJ, 2010, NAT REV CLIN ONCOL, V7, P98, DOI 10.1038/nrclinonc.2009.216; Fang XH, 2005, J BIOL CHEM, V280, P28451, DOI 10.1074/jbc.M504400200; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Grant BD, 2009, NAT REV MOL CELL BIO, V10, P597, DOI 10.1038/nrm2755; Grasl-Kraupp B, 2002, HEPATOLOGY, V35, P1372, DOI 10.1053/jhep.2002.33203; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Hanada N, 2006, MOL CARCINOGEN, V45, P10, DOI 10.1002/mc.20147; Harel A, 2004, MOL CELL, V16, P319, DOI 10.1016/j.molcel.2004.10.026; Hieda M, 2008, J CELL BIOL, V180, P763, DOI 10.1083/jcb.200710022; Higashiyama S, 2008, CANCER SCI, V99, P214, DOI 10.1111/j.1349-7006.2007.00676.x; Hoelz A, 2004, NATURE, V432, P815, DOI 10.1038/432815a; Hoshino M, 2007, PATHOBIOLOGY, V74, P15, DOI 10.1159/000101047; Hsu SC, 2007, J BIOL CHEM, V282, P10432, DOI 10.1074/jbc.M610014200; Hsu SC, 2009, AM J TRANSL RES, V1, P249; Hu SH, 2009, CELL, V139, P610, DOI 10.1016/j.cell.2009.08.037; Huang PH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.287re6; Hung LY, 2008, NUCLEIC ACIDS RES, V36, P4337, DOI 10.1093/nar/gkn417; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Irmer D, 2007, ONCOGENE, V26, P5693, DOI 10.1038/sj.onc.1210383; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Johannes L, 2008, CELL, V135, P1175, DOI 10.1016/j.cell.2008.12.009; Jones FE, 2008, J MAMMARY GLAND BIOL, V13, P247, DOI 10.1007/s10911-008-9076-6; Kim HP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005933; Kim J, 2007, CANCER RES, V67, P9229, DOI 10.1158/0008-5472.CAN-07-1333; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; King MC, 2006, NATURE, V442, P1003, DOI 10.1038/nature05075; Klein C, 2004, BIOCHEMISTRY-US, V43, P15873, DOI 10.1021/bi048604t; Li C, 2009, ONCOGENE, V28, P3801, DOI 10.1038/onc.2009.234; Liao HJ, 2007, MOL BIOL CELL, V18, P1064, DOI 10.1091/mbc.E06-09-0802; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Linardou H, 2009, NAT REV CLIN ONCOL, V6, P352, DOI 10.1038/nrclinonc.2009.62; Linggi B, 2006, J BIOL CHEM, V281, P25373, DOI 10.1074/jbc.M603998200; Lo HW, 2006, J CELL BIOCHEM, V98, P1570, DOI 10.1002/jcb.20876; Lo HW, 2010, MOL CANCER RES, V8, P232, DOI 10.1158/1541-7786.MCR-09-0391; Lo HW, 2006, BRIT J CANCER, V94, P184, DOI 10.1038/sj.bjc.6602941; Lo HW, 2006, BREAST CANCER RES TR, V95, P211, DOI 10.1007/s10549-005-9011-0; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Lo HW, 2005, CANCER RES, V65, P338; Lusk CP, 2007, NAT REV MOL CELL BIO, V8, P414, DOI 10.1038/nrm2165; MARTI U, 1995, J HEPATOL, V23, P318, DOI 10.1016/S0168-8278(95)80011-5; MARTI U, 1991, HEPATOLOGY, V13, P15, DOI 10.1016/0270-9139(91)90210-M; Marti Ulrich, 2000, Molecular Cell Biology Research Communications, V3, P8, DOI 10.1006/mcbr.2000.0177; Massie C, 2006, NAT REV CANCER, V6, P403, DOI 10.1038/nrc1882; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Mayor S, 2007, NAT REV MOL CELL BIO, V8, P603, DOI 10.1038/nrm2216; Miaczynska M, 2004, CELL, V116, P445, DOI 10.1016/S0092-8674(04)00117-5; Mills IG, 2005, J CELL BIOL, V170, P191, DOI 10.1083/jcb.200503106; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Muraoka-Cook RS, 2008, J MAMMARY GLAND BIOL, V13, P235, DOI 10.1007/s10911-008-9080-x; Myers JM, 2003, J CELL BIOCHEM, V88, P1273, DOI 10.1002/jcb.10476; Naresh A, 2008, CANCER RES, V68, P6387, DOI 10.1158/0008-5472.CAN-08-0538; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Offterdinger M, 2002, J CELL BIOL, V157, P929, DOI 10.1083/jcb.200109033; Orth JD, 2006, CANCER RES, V66, P3603, DOI 10.1158/0008-5472.CAN-05-2916; Peng H, 2002, J NEUROCHEM, V81, P506, DOI 10.1046/j.1471-4159.2002.00833.x; Pilecka I, 2007, EUR J CELL BIOL, V86, P533, DOI 10.1016/j.ejcb.2007.04.004; Psyrri A, 2005, CLIN CANCER RES, V11, P5856, DOI 10.1158/1078-0432.CCR-05-0420; RAPER SE, 1987, GASTROENTEROLOGY, V92, P1243, DOI 10.1016/S0016-5085(87)91084-5; Reilly JF, 2001, J CELL BIOL, V152, P1307, DOI 10.1083/jcb.152.6.1307; Rink J, 2005, CELL, V122, P735, DOI 10.1016/j.cell.2005.06.043; Saftig P, 2009, NAT REV MOL CELL BIO, V10, P623, DOI 10.1038/nrm2745; Saksena S, 2006, NAT STRUCT MOL BIOL, V13, P500, DOI 10.1038/nsmb1098; Sandvig K, 2002, ANNU REV CELL DEV BI, V18, P1, DOI 10.1146/annurev.cellbio.18.011502.142107; Sardi SP, 2006, CELL, V127, P185, DOI 10.1016/j.cell.2006.07.037; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Sehat B, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000628; Sequist LV, 2008, ANNU REV MED, V59, P429, DOI 10.1146/annurev.med.59.090506.202405; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Sorkin A, 2004, CURR OPIN CELL BIOL, V16, P392, DOI 10.1016/j.ceb.2004.06.001; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Spooner RA, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-26; Stachowiak MK, 2007, DNA CELL BIOL, V26, P811, DOI 10.1089/dna.2007.0664; Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1; Stewart CL, 2007, SCIENCE, V318, P1408, DOI 10.1126/science.1142034; Stewart M, 2007, NAT REV MOL CELL BIO, V8, P195, DOI 10.1038/nrm2114; Terry LJ, 2007, SCIENCE, V318, P1412, DOI 10.1126/science.1142204; Thompson M, 2007, BRAIN RES, V1139, P95, DOI 10.1016/j.brainres.2006.11.047; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Wang SC, 2006, NAT CELL BIOL, V8, P1359, DOI 10.1038/ncb1501; Wang SC, 2009, CLIN CANCER RES, V15, P6484, DOI 10.1158/1078-0432.CCR-08-2813; Wang ZH, 1998, ANTICANCER RES, V18, P4329; Wanner G, 2008, RADIOTHER ONCOL, V86, P383, DOI 10.1016/j.radonc.2007.10.041; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Wells A, 2002, NAT REV MOL CELL BIO, V3, P697, DOI 10.1038/nrm905; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Williams RL, 2007, NAT REV MOL CELL BIO, V8, P355, DOI 10.1038/nrm2162; Woodman P, 2009, BIOCHEM SOC T, V37, P146, DOI 10.1042/BST0370146; Xia WY, 2009, MOL CARCINOGEN, V48, P610, DOI 10.1002/mc.20504; XIE YM, 1994, BIOCHEM BIOPH RES CO, V203, P1589, DOI 10.1006/bbrc.1994.2368; Xu YR, 2009, J CELL BIOCHEM, V107, P873, DOI 10.1002/jcb.22195; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zuleger N, 2008, BIOCHEM SOC T, V36, P1373, DOI 10.1042/BST0361373	121	158	167	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2010	29	28					3997	4006		10.1038/onc.2010.157	http://dx.doi.org/10.1038/onc.2010.157			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	625JW	20473332	Green Accepted			2022-12-17	WOS:000279892400001
J	Fujiwara, M; Marusawa, H; Wang, HQ; Iwai, A; Ikeuchi, K; Imai, Y; Kataoka, A; Nukina, N; Takahashi, R; Chiba, T				Fujiwara, M.; Marusawa, H.; Wang, H-Q; Iwai, A.; Ikeuchi, K.; Imai, Y.; Kataoka, A.; Nukina, N.; Takahashi, R.; Chiba, T.			Parkin as a tumor suppressor gene for hepatocellular carcinoma	ONCOGENE			English	Article						parkin; hepatocellular carcinoma; follistatin	NF-KAPPA-B; DEFICIENT MICE; ACTIVIN; DISEASE; LIVER; EXPRESSION; MECHANISMS; APOPTOSIS; UBIQUITIN; OVARIAN	The parkin was first identified as a gene implicated in autosomal recessive juvenile Parkinsonism. Deregulation of the parkin gene, however, has been observed in various human cancers, suggesting that the parkin gene may be important in tumorigenesis. To gain insight into the physiologic role of parkin, we generated parkin-/- mice lacking exon 3 of the parkin gene. We demonstrated here that parkin-/- mice had enhanced hepatocyte proliferation and developed macroscopic hepatic tumors with the characteristics of hepatocellular carcinoma. Microarray analyses revealed that parkin deficiency caused the alteration of gene expression profiles in the liver. Among them, endogenous follistatin is commonly upregulated in both nontumorous and tumorous liver tissues of parkin deficient mice. Parkin deficiency resulted in suppression of caspase activation and rendered hepatocytes resistant to apoptosis in a follistatin-dependent manner. These results suggested that parkin deficiency caused enhanced hepatocyte proliferation and resistance to apoptosis, resulting in hepatic tumor development, partially through the upregulation of endogenous follistatin. The finding that parkin deficient mice are susceptible to hepatocarcinogenesis provided the first evidence showing that parkin is indeed a tumor suppressor gene.	[Fujiwara, M.; Marusawa, H.; Iwai, A.; Ikeuchi, K.; Chiba, T.] Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan; [Wang, H-Q; Takahashi, R.] Kyoto Univ, Grad Sch Med, Dept Neurol, Sakyo Ku, Kyoto 6068507, Japan; [Imai, Y.; Kataoka, A.] RIKEN, Brain Sci Inst, Lab Motor Syst Neurodegenerat, Saitama, Japan; [Nukina, N.] RIKEN, Brain Sci Inst, Lab Struct Neuropathol, Saitama, Japan	Kyoto University; Kyoto University; RIKEN; RIKEN	Marusawa, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, 54 Kawara Cho, Kyoto 6068507, Japan.	maru@kuhp.kyoto-u.ac.jp; ryosuket@kuhp.kyoto-u.ac.jp	Nukina, Nobuyuki/GPP-6265-2022; Imai, Yuzuru/AAA-6472-2019	Imai, Yuzuru/0000-0003-2924-5231; Marusawa, Hiroyuki/0000-0002-4286-2712				Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; de Groot E, 2000, MOL BIOL REP, V27, P129, DOI 10.1023/A:1007159031000; Denison SR, 2003, ONCOGENE, V22, P8370, DOI 10.1038/sj.onc.1207072; Endo Y, 2007, ONCOGENE, V26, P5587, DOI 10.1038/sj.onc.1210344; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Farrer MJ, 2006, NAT REV GENET, V7, P306, DOI 10.1038/nrg1831; Feitelson MA, 2002, ONCOGENE, V21, P2593, DOI 10.1038/sj.onc.1205434; Germann A, 2003, INT J CANCER, V106, P187, DOI 10.1002/ijc.11215; Goldberg MS, 2003, J BIOL CHEM, V278, P43628, DOI 10.1074/jbc.M308947200; Grusch M, 2006, J HEPATOL, V45, P673, DOI 10.1016/j.jhep.2006.06.014; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Harrison CA, 2005, TRENDS ENDOCRIN MET, V16, P73, DOI 10.1016/j.tem.2005.01.003; HULLY JR, 1994, HEPATOLOGY, V20, P854, DOI 10.1002/hep.1840200413; Itier JM, 2003, HUM MOL GENET, V12, P2277, DOI 10.1093/hmg/ddg239; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jiang HB, 2006, J BIOL CHEM, V281, P8591, DOI 10.1074/jbc.M510926200; Kahle PJ, 2004, EMBO REP, V5, P681, DOI 10.1038/sj.embor.7400188; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kitao Y, 2007, HUM MOL GENET, V16, P50, DOI 10.1093/hmg/ddl439; Kogure K, 2000, HEPATOLOGY, V31, P916, DOI 10.1053/he.2000.6100; Kong FM, 2000, ONCOGENE, V19, P1572, DOI 10.1038/sj.onc.1203437; Kou T, 2007, INT J CANCER, V120, P469, DOI 10.1002/ijc.22292; Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Marusawa H, 2003, EMBO J, V22, P2729, DOI 10.1093/emboj/cdg263; Matsumoto T, 2006, FEBS LETT, V580, P731, DOI 10.1016/j.febslet.2005.12.081; MILLIKIN D, 1991, CANCER RES, V51, P5449; Morett E, 1999, TRENDS BIOCHEM SCI, V24, P229, DOI 10.1016/S0968-0004(99)01381-X; MORITA R, 1991, CANCER RES, V51, P5817; NEGRINI M, 1994, CANCER RES, V54, P1331; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200; Patella S, 2006, AM J PHYSIOL-GASTR L, V290, pG137, DOI 10.1152/ajpgi.00080.2005; Perez FA, 2005, P NATL ACAD SCI USA, V102, P2174, DOI 10.1073/pnas.0409598102; Picchio MC, 2004, CLIN CANCER RES, V10, P2720, DOI 10.1158/1078-0432.CCR-03-0086; Rodgarkia-Dara C, 2006, MUTAT RES-REV MUTAT, V613, P123, DOI 10.1016/j.mrrev.2006.07.002; Rodriguez C, 2000, GENE CHROMOSOME CANC, V27, P76, DOI 10.1002/(SICI)1098-2264(200001)27:1<76::AID-GCC10>3.0.CO;2-E; Rossmanith W, 2002, MOL CARCINOGEN, V35, P1, DOI 10.1002/mc.10068; Saito S, 1996, CANCER RES, V56, P5586; SCHWALL RH, 1993, HEPATOLOGY, V18, P347, DOI 10.1016/0270-9139(93)90018-I; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Takabe K, 2003, HEPATOLOGY, V38, P1107, DOI 10.1053/jhep.2003.50483; Takahashi R, 2003, ANN NY ACAD SCI, V991, P101; Tanaka Y, 2006, BIOCHEM BIOPH RES CO, V341, P314, DOI 10.1016/j.bbrc.2005.12.192; Tibiletti MG, 1996, CANCER RES, V56, P4493; Toda Y, 1999, PATHOL INT, V49, P479, DOI 10.1046/j.1440-1827.1999.00875.x; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; von Coelln R, 2004, P NATL ACAD SCI USA, V101, P10744, DOI 10.1073/pnas.0401297101; Wang F, 2004, GENE CHROMOSOME CANC, V40, P85, DOI 10.1002/gcc.20020; West AB, 2005, TRENDS NEUROSCI, V28, P348, DOI 10.1016/j.tins.2005.05.002; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8	54	158	165	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2008	27	46					6002	6011		10.1038/onc.2008.199	http://dx.doi.org/10.1038/onc.2008.199			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	358BO	18574468	Green Submitted			2022-12-17	WOS:000259891600003
J	Lien, HC; Hsiao, YH; Lin, YS; Yao, YT; Juan, HF; Kuo, WH; Hung, MC; Chang, KJ; Hsieh, FJ				Lien, H. C.; Hsiao, Y. H.; Lin, Y. S.; Yao, Y. T.; Juan, H. F.; Kuo, W. H.; Hung, Mien-Chie; Chang, K. J.; Hsieh, F. J.			Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition	ONCOGENE			English	Article						oligonucleotide microarray; metaplastic carcinoma of breast; epithelial-mesenchymal transition	PROGNOSTIC MARKERS; TGF-BETA; EXPRESSION; CANCER; CELLS; CARTILAGE; TISSUE; DIFFERENTIATION; MORPHOGENESIS; METASTASIS	Metaplastic carcinoma of the breast (MCB) is a poorly understood subtype of breast cancer. It is generally characterized by the coexistence of ductal carcinomatous and transdifferentiated sarcomatous components, but the underlying molecular alterations, possibly related to epithelial-mesenchymal transition (EMT), remain elusive. We performed transcriptional pro. ling using half-a-genome oligonucleotide microarrays to elucidate genetic profiles of MCBs and their differences to those of ductal carcinoma of breasts (DCBs) using discarded specimens of four MCBs and 34 DCBs. Unsupervised clustering disclosed distinctive expression profiles between MCBs and DCBs. Supervised analysis identified gene signatures discriminating MCBs from DCBs and between MCB subclasses. Notably, many of the discriminator genes were associated with downregulation of epithelial phenotypes and with synthesis, remodeling and adhesion of extracellular matrix, with some of them have known or inferred roles related to EMT. Importantly, several of the discriminator genes were upregulated in a mutant Snail-transfected MCF7 cell known to exhibit features of EMT, thereby indicating a crucial role for EMT in the pathogenesis of MCBs. Finally, the identification of SPARC and vimentin as poor prognostic factors reinforced the role of EMT in cancer progression. These data advance our understanding of MCB and offer clues to the molecular alterations underlying EMT.	[Kuo, W. H.; Chang, K. J.] Natl Taiwan Univ, Dept Surg, Coll Med, Taipei 10764, Taiwan; [Lien, H. C.; Yao, Y. T.] Natl Taiwan Univ, Dept Pathol, Coll Med, Taipei 10764, Taiwan; [Hsiao, Y. H.] Changhua Christian Hosp, Dept Obstet & Gynecol, Changhua, Taiwan; [Hsiao, Y. H.] Chang Jung Christian Univ, Inst Med Res, Tainan, Taiwan; [Lin, Y. S.] Welgene Biotech Co Ltd, Taipei, Taiwan; [Juan, H. F.; Hsieh, F. J.] Natl Taiwan Univ, Ctr Syst Biol & Bioinformat, Taipei 10764, Taiwan; [Juan, H. F.; Hsieh, F. J.] Natl Taiwan Univ, Dept Life Sci, Taipei 10764, Taiwan; [Hung, Mien-Chie] China Med Univ Hosp, Ctr Mol Med, Taichung, Taiwan; [Hung, Mien-Chie] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX USA; [Hsieh, F. J.] Natl Taiwan Univ, Coll Med, Dept Obstet & Gynecol, Taipei 10764, Taiwan	National Taiwan University; National Taiwan University; Changhua Christian Hospital; Chang Jung Christian University; National Taiwan University; National Taiwan University; China Medical University Taiwan; China Medical University Hospital - Taiwan; University of Texas System; UTMD Anderson Cancer Center; National Taiwan University	Chang, KJ (corresponding author), Natl Taiwan Univ, Dept Surg, Coll Med, 1-1 Jen Ai Rd, Taipei 10764, Taiwan.	kingjen@ha.mc.ntu.edu.tw; fjhsieh@ha.mc.ntu.edu.tw	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Chang, King jen/0000-0001-9811-3422; KUO, WEN-HUNG/0000-0002-9881-4605; JUAN, HSUEH-FEN/0000-0003-4876-3309; LIEN, HUANG-CHUN/0000-0003-1472-1231				Al Sayed AD, 2006, ACTA ONCOL, V45, P188, DOI 10.1080/02841860500513235; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Barnes PJ, 2005, BREAST CANCER RES TR, V91, P173, DOI 10.1007/s10549-004-7260-y; Bilanges B, 1999, ONCOGENE, V18, P3979, DOI 10.1038/sj.onc.1202933; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; Carter MR, 2006, AM J SURG PATHOL, V30, P300; Doane AS, 2006, ONCOGENE, V25, P3994, DOI 10.1038/sj.onc.1209415; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; Framson PE, 2004, J CELL BIOCHEM, V92, P679, DOI 10.1002/jcb.20091; Fujiwara S, 2001, J BIOL CHEM, V276, P13340, DOI 10.1074/jbc.M011386200; Gersch RP, 2005, J ORTHOP RES, V23, P882, DOI 10.1016/j.orthres.2005.02.005; Jansen S, 2005, J CELL SCI, V118, P3081, DOI 10.1242/jcs.02438; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Jones C, 2004, CANCER RES, V64, P3037, DOI 10.1158/0008-5472.CAN-03-2028; Korsching E, 2005, J PATHOL, V206, P451, DOI 10.1002/path.1797; Kusafuka K, 2004, J PATHOL, V203, P953, DOI 10.1002/path.1599; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lemmers C, 2004, MOL BIOL CELL, V15, P1324, DOI 10.1091/mbc.E03-04-0235; Lien HC, 2004, J PATHOL, V204, P131, DOI 10.1002/path.1624; Liu Y, 2000, J CELL SCI, V113, P2363; Ma LJ, 2005, DEVELOPMENT, V132, P5601, DOI 10.1242/dev.02156; Oehler MK, 2003, BRIT J CANCER, V89, P1927, DOI 10.1038/sj.bjc.6601397; Pezzi CM, 2007, ANN SURG ONCOL, V14, P166, DOI 10.1245/s10434-006-9124-7; Pfister BE, 2001, BIOCHEM BIOPH RES CO, V286, P268, DOI 10.1006/bbrc.2001.5377; Reinholz MM, 2002, BREAST CANCER RES TR, V74, P255, DOI 10.1023/A:1016339120506; Reis JS, 2003, APPL IMMUNOHISTO M M, V11, P1, DOI 10.1097/00022744-200303000-00001; ROSAI J, 2004, ROSAI ACKERMANS SURG, P1828; Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011; Saika S, 2003, INVEST OPHTH VIS SCI, V44, P2094, DOI 10.1167/iovs.02-1059; Siddiq F, 2004, LUNG CANCER, V45, P197, DOI 10.1016/j.lungcan.2004.01.020; Soda H, 1998, ANTI-CANCER DRUG, V9, P327, DOI 10.1097/00001813-199804000-00006; Stanton H, 2005, NATURE, V434, P648, DOI 10.1038/nature03417; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Wilson CA, 2004, BREAST CANCER RES, V6, P192, DOI 10.1186/bcr917; Xu X, 2005, DEV DYNAM, V232, P75, DOI 10.1002/dvdy.20197; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhuang ZP, 1997, MODERN PATHOL, V10, P354	38	158	165	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2007	26	57					7859	7871		10.1038/sj.onc.1210593	http://dx.doi.org/10.1038/sj.onc.1210593			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17603561	Green Published			2022-12-17	WOS:000252163500004
J	Xiao, D; Herman-Antosiewicz, A; Antosiewicz, J; Xiao, H; Brisson, M; Lazo, JS; Singh, SV				Xiao, D; Herman-Antosiewicz, A; Antosiewicz, J; Xiao, H; Brisson, M; Lazo, JS; Singh, SV			Diallyl trisulfide-induced G(2)-M phase cell cycle arrest in human prostate cancer cells is caused by reactive oxygen species-dependent destruction and hyperphosphorylation of Cdc25C	ONCOGENE			English	Article						diallyl trisulfide; ROS; Cdc25C; cell cycle arrest; prostate cancer; chemoprevention	OCCURRING ORGANOSULFUR COMPOUNDS; P34(CDC2) KINASE-ACTIVITY; 14-3-3 PROTEIN-BINDING; DNA-DAMAGE; ALLIUM VEGETABLES; COLON-CANCER; S-ALLYLMERCAPTOCYSTEINE; MAMMARY CARCINOGENESIS; APOPTOSIS INDUCTION; CHECKPOINT PATHWAY	Molecular mechanism of cell cycle arrest caused by diallyl trisulfide (DATS), a garlic-derived cancer chemopreventive agent, has been investigated using PC-3 and DU145 human prostate cancer cells as a model. Treatment of PC-3 and DU145 cells, but not a normal prostate epithelial cell line (PrEC), with growth suppressive concentrations of DATS caused enrichment of the G(2)-M fraction. The DATS-induced cell cycle arrest in PC-3 cells was associated with increased Tyr(15) phosphorylation of cyclin-dependent kinase 1 (Cdk1) and inhibition of Cdk1/cyclinB1 kinase activity. The DATS-treated PC-3 and DU145 cells also exhibited a decrease in the protein level of Cdc25C and an increase in its Ser(216) phosphorylation. The DATS-mediated decrease in protein level and Ser216 phosphorylation of Cdc25C as well as G(2)-M phase cell cycle arrest were significantly attenuated in the presence of N-acetylcysteine implicating reactive oxygen species (ROS) in cell cycle arrest caused by DATS. ROS generation was observed in DATS-treated PC-3 and DU145 cells. DATS treatment also caused an increase in the protein level of Cdk inhibitor p21, but DATS-induced G(2)-M phase arrest was not affected by antisense-mediated suppression of p21 protein level. In conclusion, the results of the present study indicate that DATS-induced G(2)-M phase cell cycle arrest in human prostate cancer cells is caused by ROS-mediated destruction and hyperphosphorylation of Cdc25C.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Inst Canc, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Singh, SV (corresponding author), 2 32A Hillman Canc Ctr Res Pavil,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	singhs@upmc.edu		Herman-Antosiewicz, Anna/0000-0003-0526-2168	NCI NIH HHS [R01 CA113363-01, R01 CA101753-02, R01 CA076348-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076348, R01CA113363, R01CA101753] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal KC, 1996, MED RES REV, V16, P111, DOI 10.1002/(SICI)1098-1128(199601)16:1&lt;111::AID-MED4&gt;3.0.CO;2-5; BLOCK E, 1992, ANGEW CHEM INT EDIT, V31, P1135, DOI 10.1002/anie.199211351; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Campbell CL, 1999, INT J CANCER, V80, P868, DOI 10.1002/(SICI)1097-0215(19990315)80:6<868::AID-IJC12>3.0.CO;2-1; Challier B, 1998, EUR J EPIDEMIOL, V14, P737, DOI 10.1023/A:1007512825851; Charrier-Savournin FB, 2004, MOL BIOL CELL, V15, P3965, DOI 10.1091/mbc.E03-12-0871; Chen LM, 2001, PROSTATE, V48, P93, DOI 10.1002/pros.1085; Choi S, 2005, CANCER RES, V65, P2035, DOI 10.1158/0008-5472.CAN-04-3616; DAUSCH JG, 1990, PREV MED, V19, P346, DOI 10.1016/0091-7435(90)90034-H; Druesne N, 2004, CARCINOGENESIS, V25, P1227, DOI 10.1093/carcin/bgh123; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Eckstein J., 1997, BIOCHIM BIOPHYS ACTA, V1332, P53; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Filomeni G, 2003, CANCER RES, V63, P5940; Freemerman AJ, 1997, LEUKEMIA, V11, P504, DOI 10.1038/sj.leu.2400625; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gao CM, 1999, JPN J CANCER RES, V90, P614, DOI 10.1111/j.1349-7006.1999.tb00791.x; Garraway LA, 2003, PROSTATE, V55, P206, DOI 10.1002/pros.10244; HARPER JW, 1993, CELL, V75, P805; Herman-Antosiewicz A, 2004, MUTAT RES-FUND MOL M, V555, P121, DOI 10.1016/j.mrfmmm.2004.04.016; Hsing AW, 2002, J NATL CANCER I, V94, P1648, DOI 10.1093/jnci/94.21.1648; Knowles LM, 1998, NUTR CANCER, V30, P169, DOI 10.1080/01635589809514659; Knowles LM, 2000, CARCINOGENESIS, V21, P1129, DOI 10.1093/carcin/21.6.1129; Kwon KB, 2002, BIOCHEM PHARMACOL, V63, P41, DOI 10.1016/S0006-2952(01)00860-7; Lan H, 2004, ACTA PHARMACOL SIN, V25, P219; Li Y, 2002, DNA CELL BIOL, V21, P771, DOI 10.1089/104454902320908423; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Milner JA, 2001, J NUTR, V131, p1027S, DOI 10.1093/jn/131.3.1027S; Mitchell S, 2000, BJU INT, V85, P932, DOI 10.1046/j.1464-410x.2000.00606.x; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; Molinari M, 2000, CELL PROLIFERAT, V33, P261, DOI 10.1046/j.1365-2184.2000.00191.x; NAGAE S, 1994, PLANTA MED, V60, P214, DOI 10.1055/s-2006-959461; Nakagawa H, 2001, CARCINOGENESIS, V22, P891, DOI 10.1093/carcin/22.6.891; NAKAMOTO T, 1992, CANCER RES, V52, P571; Narayanan PK, 1997, CANCER RES, V57, P3963; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; REDDY BS, 1993, CANCER RES, V53, P3493; Robert V, 2001, CARCINOGENESIS, V22, P1155, DOI 10.1093/carcin/22.8.1155; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Savitsky PA, 2002, J BIOL CHEM, V277, P20535, DOI 10.1074/jbc.M201589200; Schaffer EM, 1996, CANCER LETT, V102, P199, DOI 10.1016/0304-3835(96)04160-2; SHERWOOD SW, 1994, EXP CELL RES, V211, P275, DOI 10.1006/excr.1994.1087; Shirin H, 2001, CANCER RES, V61, P725; Singh SV, 2004, J BIOL CHEM, V279, P25813, DOI 10.1074/jbc.M313538200; SPARNINS VL, 1988, CARCINOGENESIS, V9, P131, DOI 10.1093/carcin/9.1.131; SUMIYOSHI H, 1990, CANCER RES, V50, P5084; Sundaram SG, 1996, CARCINOGENESIS, V17, P669, DOI 10.1093/carcin/17.4.669; Suzui N, 1997, JPN J CANCER RES, V88, P705, DOI 10.1111/j.1349-7006.1997.tb00440.x; TAKAHASHI S, 1992, CARCINOGENESIS, V13, P1513, DOI 10.1093/carcin/13.9.1513; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vogt A, 2000, J PHARMACOL EXP THER, V294, P1070; WARGOVICH MJ, 1987, CARCINOGENESIS, V8, P487, DOI 10.1093/carcin/8.3.487; WARGOVICH MJ, 1988, CANCER RES, V48, P6872; WATTENBERG LW, 1989, CANCER RES, V49, P2689; Webber MM, 1997, PROSTATE, V30, P58; Webber MM, 1997, PROSTATE, V30, P136, DOI 10.1002/(SICI)1097-0045(19970201)30:2<136::AID-PROS9>3.0.CO;2-M; Widrow RJ, 1997, CYTOMETRY, V27, P250, DOI 10.1002/(SICI)1097-0320(19970301)27:3<250::AID-CYTO6>3.0.CO;2-I; Winters ZE, 1998, ONCOGENE, V17, P673, DOI 10.1038/sj.onc.1201991; Xiao D, 2004, ONCOGENE, V23, P5594, DOI 10.1038/sj.onc.1207747; Xiao D, 2002, CANCER RES, V62, P3615; Xiao DH, 2003, CANCER RES, V63, P6825; YOU WC, 1989, J NATL CANCER I, V81, P162, DOI 10.1093/jnci/81.2.162	67	158	164	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6256	6268		10.1038/sj.onc.1208759	http://dx.doi.org/10.1038/sj.onc.1208759			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	15940258				2022-12-17	WOS:000231877100007
J	Shupnik, MA				Shupnik, MA			Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation	ONCOGENE			English	Review						estrogen receptor; progesterone receptor; IGF-1 receptor; EGF-receptor; transcription; cell proliferation	EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER CELLS; HUMAN PROGESTERONE-RECEPTORS; ALPHA ER-ALPHA; ESTROGEN-RECEPTOR; SIGNALING PATHWAYS; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVITY; TRANSACTIVATION FUNCTION; MEDIATED TRANSCRIPTION	Both steroids and growth factors stimulate proliferation of steroid-dependent tumor cells, and interaction between these signaling pathways may occur at several levels. Steroid receptors are typically classified as ligand-activated transcription factors, and steps by which they bind ligand, dimerize, recruit coregulatory molecules, and activate target gene transcription are well understood. Several steroid responses are functionally linked to c-Src or tyrosine kinase receptors, and the physiological impact and the precise molecular pathways involved in these responses are under intensive investigation. Ligand-independent stimulation of steroid receptor-mediated transcription by growth factors is now believed to occur through activated protein kinases that phosphorylate the receptors and receptor coregulators. Recently, steroid hormones themselves have been shown to rapidly activate intracellular signaling cascades, via binding to cognate cytoplasmic or membrane-associated receptors. In some contexts, steroid receptors interact directly with c-Src and other cytoplasmic signaling molecules, such as Shc, PI3K, and p130 Cas. Crosstalk between growth factors and steroids in both the cytoplasm and nucleus could have profound impact on complex biological processes such as cell growth, and play a significant role in the treatment of steroid-dependent cancers. The potential roles of progesterone and estrogen receptors in this crosstalk are discussed in this review.	Univ Virginia, Sch Med, Dept Internal Med, Div Endocrinol & Metab, Charlottesville, VA 22908 USA	University of Virginia	Shupnik, MA (corresponding author), Univ Virginia, Sch Med, Dept Internal Med, Div Endocrinol & Metab, Box 800578 HSC, Charlottesville, VA 22908 USA.	mas3x@virginia.edu						Adesanya OO, 1999, P NATL ACAD SCI USA, V96, P3287, DOI 10.1073/pnas.96.6.3287; Ahola TM, 2002, ENDOCRINOLOGY, V143, P3376, DOI 10.1210/en.2001-211445; Ankrapp DP, 1998, J CELL PHYSIOL, V174, P251, DOI 10.1002/(SICI)1097-4652(199802)174:2<251::AID-JCP12>3.0.CO;2-F; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; Ballare C, 2003, MOL CELL BIOL, V23, P1994, DOI 10.1128/MCB.23.6.1994-2008.2003; Bamberger AM, 1996, P NATL ACAD SCI USA, V93, P6169, DOI 10.1073/pnas.93.12.6169; Barletta F, 2004, MOL ENDOCRINOL, V18, P1096, DOI 10.1210/me.2003-0335; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Bjornstrom L, 2002, MOL ENDOCRINOL, V16, P2202, DOI 10.1210/me.2002-0072; Bjornstrom L, 2001, J MOL ENDOCRINOL, V27, P93, DOI 10.1677/jme.0.0270093; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Brinkman A, 2000, JNCI-J NATL CANCER I, V92, P112, DOI 10.1093/jnci/92.2.112; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Cabodi S, 2004, J CELL SCI, V117, P1603, DOI 10.1242/jcs.01025; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; Clarke R, 2001, PHARMACOL REV, V53, P25; Clarkl DE, 2001, EMBO J, V20, P3484, DOI 10.1093/emboj/20.13.3484; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Curtis SW, 1996, P NATL ACAD SCI USA, V93, P12626, DOI 10.1073/pnas.93.22.12626; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; DICKSON RB, 1986, ENDOCRINOLOGY, V118, P138, DOI 10.1210/endo-118-1-138; Dutertre M, 2003, MOL ENDOCRINOL, V17, P1296, DOI 10.1210/me.2001-0316; EDWARDS DP, 1993, BREAST CANCER RES TR, V27, P41, DOI 10.1007/BF00683192; Faulds MH, 2004, MOL ENDOCRINOL, V18, P412, DOI 10.1210/me.2003-0290; Faulds MH, 2001, MOL ENDOCRINOL, V15, P1929, DOI 10.1210/me.15.11.1929; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; Foley EF, 2000, CANCER RES, V60, P245; Frasor J, 2004, CANCER RES, V64, P1522, DOI 10.1158/0008-5472.CAN-03-3326; Fuqua SAW, 2003, CANCER RES, V63, P2434; Gothard LQ, 1996, MOL ENDOCRINOL, V10, P185, DOI 10.1210/me.10.2.185; Gu Q, 1999, ENDOCRINOLOGY, V140, P660, DOI 10.1210/en.140.2.660; Hom YK, 1998, ENDOCRINOLOGY, V139, P913, DOI 10.1210/en.139.3.913; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; Jazaeri AA, 2001, ONCOGENE, V20, P6965, DOI 10.1038/sj.onc.1204809; Jeng MH, 1998, ENDOCRINOLOGY, V139, P4164, DOI 10.1210/en.139.10.4164; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; JORDAN VC, 1988, CRC CR REV CL LAB SC, V26, P97, DOI 10.3109/10408368809106860; Kahlert S, 2000, J BIOL CHEM, V275, P18447, DOI 10.1074/jbc.M910345199; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; Klotz DM, 2002, J BIOL CHEM, V277, P8531, DOI 10.1074/jbc.M109592200; Klotz DM, 2000, ENDOCRINOLOGY, V141, P3430, DOI 10.1210/en.141.9.3430; Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Labriola L, 2003, MOL CELL BIOL, V23, P1095, DOI 10.1128/MCB.23.3.1095-1111.2003; Lange CA, 2004, MOL ENDOCRINOL, V18, P269, DOI 10.1210/me.2003-0331; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Lange CA, 1999, MOL ENDOCRINOL, V13, P829, DOI 10.1210/me.13.6.829; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Levin ER, 2003, MOL ENDOCRINOL, V17, P309, DOI 10.1210/me.2002-0368; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marsaud V, 2003, MOL ENDOCRINOL, V17, P2013, DOI 10.1210/me.2002-0269; Martin MB, 2000, ENDOCRINOLOGY, V141, P4503, DOI 10.1210/en.141.12.4503; McClelland RA, 2001, ENDOCRINOLOGY, V142, P2776, DOI 10.1210/en.142.7.2776; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Moe-Behrens GHG, 2003, MOL ENDOCRINOL, V17, P2630, DOI 10.1210/me.2003-0006; Nawaz Z, 2004, MOL ENDOCRINOL, V18, P493, DOI 10.1210/me.2003-0388; Nicholson RI, 1999, ENDOCR-RELAT CANCER, V6, P373, DOI 10.1677/erc.0.0060373; Norris JD, 1997, MOL ENDOCRINOL, V11, P747, DOI 10.1210/me.11.6.747; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Pearce ST, 2004, CRIT REV ONCOL HEMAT, V50, P3, DOI 10.1016/j.critrevonc.2003.09.003; Petz LN, 2002, ENDOCRINOLOGY, V143, P4583, DOI 10.1210/en.2002-220369; Petz LN, 2000, MOL ENDOCRINOL, V14, P972, DOI 10.1210/me.14.7.972; Qiu M, 2003, J STEROID BIOCHEM, V85, P147, DOI 10.1016/S0960-0760(03)00221-8; Qiu M, 2003, MOL ENDOCRINOL, V17, P628, DOI 10.1210/me.2002-0378; Razandi M, 2003, MOL CELL BIOL, V23, P1633, DOI 10.1128/MCB.23.5.1633-1646.2003; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Richards RG, 1996, P NATL ACAD SCI USA, V93, P12002, DOI 10.1073/pnas.93.21.12002; Richer JK, 1998, J BIOL CHEM, V273, P31317, DOI 10.1074/jbc.273.47.31317; RICKETTS D, 1991, CANCER RES, V51, P1817; Riggins RB, 2003, J BIOL CHEM, V278, P28264, DOI 10.1074/jbc.M303535200; Salh B, 1999, ANTICANCER RES, V19, P731; SARTORIUS CA, 1994, MOL ENDOCRINOL, V8, P1347, DOI 10.1210/me.8.10.1347; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; Segars JH, 2002, TRENDS ENDOCRIN MET, V13, P349, DOI 10.1016/S1043-2760(02)00633-1; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shen TJ, 2001, MOL CELL BIOL, V21, P6122, DOI 10.1128/MCB.21.18.6122-6131.2001; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shim WS, 2000, ENDOCRINOLOGY, V141, P396, DOI 10.1210/en.141.1.396; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Singleton DW, 2003, ENDOCRINOLOGY, V144, P121, DOI 10.1210/en.2002-220625; Song RX, 2004, P NATL ACAD SCI USA, V101, P2076, DOI 10.1073/pnas.0308334100; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Stoica GE, 2003, MOL ENDOCRINOL, V17, P818, DOI 10.1210/me.2002-0330; Stoner M, 2004, ONCOGENE, V23, P1052, DOI 10.1038/sj.onc.1207201; STRAWN EY, 1995, AM J OBSTET GYNECOL, V172, P1837, DOI 10.1016/0002-9378(95)91420-X; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Sun M, 2001, CANCER RES, V61, P5985; Sutherland RL, 1998, J MAMMARY GLAND BIOL, V3, P63, DOI 10.1023/A:1018774302092; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Toran-Allerand CD, 2004, ENDOCRINOLOGY, V145, P1069, DOI 10.1210/en.2003-1462; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; Tsai HW, 2004, ENDOCRINOLOGY, V145, P2730, DOI 10.1210/en.2003-1470; van der Flier S, 2000, INT J CANCER, V89, P465, DOI 10.1002/1097-0215(20000920)89:5<465::AID-IJC11>3.0.CO;2-O; van der Flier S, 2001, INT J BIOL MARKER, V16, P172, DOI 10.1177/172460080101600303; Watson CS, 1999, STEROIDS, V64, P5, DOI 10.1016/S0039-128X(98)00107-X; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Weigel NL, 1998, J MOL MED, V76, P469, DOI 10.1007/s001090050241; Westin S, 2000, ADV PHARMACOL, V47, P89; WONG CW, 2002, P NATL ACAD SCI USA, V192, P5696; Yamashita H, 2003, ONCOGENE, V22, P1638, DOI 10.1038/sj.onc.1206277; Yue W, 2002, ENDOCRINOLOGY, V143, P3221, DOI 10.1210/en.2002-220186; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100	125	158	166	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2004	23	48					7979	7989		10.1038/sj.onc.1208076	http://dx.doi.org/10.1038/sj.onc.1208076			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863JR	15489915				2022-12-17	WOS:000224558300008
J	Moon, C; Soria, JC; Jang, SJ; Lee, J; Hoque, MO; Sibony, M; Trink, B; Chang, YS; Sidransky, D; Mao, L				Moon, C; Soria, JC; Jang, SJ; Lee, J; Hoque, MO; Sibony, M; Trink, B; Chang, YS; Sidransky, D; Mao, L			Involvement of aquaporins in colorectal carcinogenesis	ONCOGENE			English	Article						aquaporin; in situ hybridization; RT-PCR; colon cancer; carcinogenesis	WATER CHANNELS; PERMEABILITY; EXPRESSION; GENE	Aquaporins (AQPs) are important in controlling water permeability. As AQP1 is known as a serum-responsive gene, we hypothesized that AQP expression may be involved in the development of human cancer. By reverse transcriptase-polymerase chain reaction analysis, expression of AQPs 1, 3, and 5 was found in seven colon and colorectal cancer cell lines. Western blot analysis confirmed their expression in four of these cell lines. In situ hybridization demonstrated that during colorectal carcinogenesis, the expression of AQPs 1 and 5 was induced in early-stage disease ( early dysplasia) and maintained through the late stages of colon cancer development. Expression of AQPs 1 and 5 was maintained even in metastatic lesions in the liver. These findings demonstrate that the expression of several AQPs is found in tumor cells and is associated with an early stage of colorectal cancer development. These novel observations suggest that multiple AQP expression may be advantageous to tumorigenesis, which may lead to a better understanding of colorectal carcinogenesis.	Johns Hopkins Univ, Sch Med, Head & Neck Canc Res Div, Dept Otolaryngol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehans Canc Ctr, Baltimore, MD 21205 USA; Inst Gustave Roussy, Dvi Canc Med, F-94805 Villejuif, France; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Mol Biol Lab, Houston, TX 77030 USA; Hosp Tenon, APHP, Dept Pathol, F-75020 Paris, France	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; UNICANCER; Gustave Roussy; University of Texas System; UTMD Anderson Cancer Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite	Moon, C (corresponding author), Johns Hopkins Univ, Sch Med, Head & Neck Canc Res Div, Dept Otolaryngol, 818 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	cmoon5@jhmi.edu	Mao, Li/C-7570-2011; Soria, Jean-Charles/F-3619-2014	Mao, Li/0000-0001-7263-3358; Hoque, Mohammad Obaidul/0000-0001-6701-9978; Chang, Yoon Soo/0000-0003-3340-4223	NCI NIH HHS [P50 CA96784-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA096784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGRE P, 1995, CURR OPIN CELL BIOL, V7, P472, DOI 10.1016/0955-0674(95)80003-4; Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; Bai CX, 1999, J CLIN INVEST, V103, P555, DOI 10.1172/JCI4138; Calamita G, 1998, P NATL ACAD SCI USA, V95, P3627, DOI 10.1073/pnas.95.7.3627; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Heymann JB, 1998, J STRUCT BIOL, V121, P191, DOI 10.1006/jsbi.1997.3951; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.physiol.58.1.619; King LS, 1997, AM J PHYSIOL-CELL PH, V273, pC1541, DOI 10.1152/ajpcell.1997.273.5.C1541; King LS, 2000, MOL MED TODAY, V6, P60, DOI 10.1016/S1357-4310(99)01636-6; Ma TH, 1999, J PHYSIOL-LONDON, V517, P317, DOI 10.1111/j.1469-7793.1999.0317t.x; Marples D, 2000, LANCET, V355, P1571, DOI 10.1016/S0140-6736(00)02209-1; Maurel C, 1997, ANNU REV PLANT PHYS, V48, P399, DOI 10.1146/annurev.arplant.48.1.399; MOON C, 1995, GENOMICS, V30, P354, DOI 10.1006/geno.1995.0029; MOON C, 1993, J BIOL CHEM, V268, P15772; MOON C, 1997, AM J PHYSIOL-CELL PH, V273, pC1562; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543, DOI 10.1152/ajpcell.1998.274.2.C543; Nielsen S, 1997, AM J PHYSIOL-CELL PH, V273, pC1549, DOI 10.1152/ajpcell.1997.273.5.C1549; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; Saadoun S, 2002, BRIT J CANCER, V87, P621, DOI 10.1038/sj.bjc.6600512; Splinter PL, 2003, J BIOL CHEM, V278, P6268, DOI 10.1074/jbc.M212079200; Zheng XJ, 2001, FEBS LETT, V489, P4, DOI 10.1016/S0014-5793(00)02437-6	23	158	199	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2003	22	43					6699	6703		10.1038/sj.onc.1206762	http://dx.doi.org/10.1038/sj.onc.1206762			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555983				2022-12-17	WOS:000185799300005
J	Bennett, DC				Bennett, DC			Human melanocyte senescence and melanoma susceptibility genes	ONCOGENE			English	Article						melanoma; senescence; genetics; progression; p16INK4A; CDK4	TELOMERASE ACTIVITY; CELLULAR SENESCENCE; TUMOR SUPPRESSION; INK4A LOCUS; IN-VITRO; P16(INK4A); RAS; DIFFERENTIATION; ACTIVATION; MECHANISMS	The molecular mechanisms and biology of cellular senescence in human melanocytes are discussed, including similarities to and differences from senescence in fibroblasts and other cell lineages. Special reference is made to the fact that the known melanoma susceptibility genes in the human, Inhibitor A of [cyclin-dependent] kinase 4-alternative reading frame (INK4A-ARF) and cyclin-dependent kinase 4, are involved in the regulation of cellular senescence, and possible reasons why this should be so. Based on the evidence including growth and survival kinetics of human and mouse melanocytes carrying germline deficiencies in the INK4A sequence, it is suggested that an 'MO' or p16/RB-dependent form of senescence may be particularly important in melanocytes. A speculative model is proposed, relating current concepts of early melanoma progression to the processes of cellular senescence and immortalization. This includes the suggestion that moles or nevi are senescent clones of melanocytes.	St George Hosp, Sch Med, Dept Basic Med Sci, London SW17 0RE, England	St Georges University London	Bennett, DC (corresponding author), St George Hosp, Sch Med, Dept Basic Med Sci, London SW17 0RE, England.	dbennett@sghms.ac.uk	Bennett, Dorothy C/C-2418-2008	Bennett, Dorothy C/0000-0002-3639-7527				Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Bandyopadhyay D, 2001, EXP GERONTOL, V36, P1265, DOI 10.1016/S0531-5565(01)00098-5; Bartkova J, 1996, CANCER RES, V56, P5475; Bastiaens M, 2001, HUM MOL GENET, V10, P1701, DOI 10.1093/hmg/10.16.1701; BENNETT DC, 1985, J CELL SCI, V77, P167; Bennett DC, 2002, PIGM CELL RES, V15, P242, DOI 10.1034/j.1600-0749.2002.02036.x; BENNETT DC, 1989, ENVIRON HEALTH PERSP, V80, P49, DOI 10.2307/3430731; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Easty DJ, 2000, MELANOMA RES, V10, P401, DOI 10.1097/00008390-200010000-00001; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; GILCHREST BA, 1984, J INVEST DERMATOL, V83, P370, DOI 10.1111/1523-1747.ep12264638; Glaessl A, 1999, ARCH DERMATOL RES, V291, P81, DOI 10.1007/s004030050387; Goding CR, 2000, GENE DEV, V14, P1712; GRAEVEN U, 1992, J IMMUNOTHER, V12, P199, DOI 10.1097/00002371-199210000-00012; Haddad M M, 1998, J Investig Dermatol Symp Proc, V3, P36; Haddad MM, 1999, EXP CELL RES, V253, P561, DOI 10.1006/excr.1999.4688; HALABAN R, 1986, J INVEST DERMATOL, V87, P95, DOI 10.1111/1523-1747.ep12523594; HALABAN R, 1983, J CELL BIOL, V97, P480, DOI 10.1083/jcb.97.2.480; Halaban R, 2000, J EXP MED, V191, P1005, DOI 10.1084/jem.191.6.1005; Halachmi S, 2001, CURR OPIN ONCOL, V13, P129, DOI 10.1097/00001622-200103000-00008; Hayward N, 2000, Curr Oncol Rep, V2, P300, DOI 10.1007/s11912-000-0022-z; HERLYN M, 1985, CANCER RES, V45, P5670; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Keller-Melchior R, 1998, J INVEST DERMATOL, V110, P932, DOI 10.1046/j.1523-1747.1998.00211.x; Kennedy C, 2001, J INVEST DERMATOL, V117, P294, DOI 10.1046/j.0022-202x.2001.01421.x; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Le Poole IC, 2000, IN VITRO CELL DEV-AN, V36, P309; MEDRANO EE, 1994, MOL BIOL CELL, V5, P497, DOI 10.1091/mbc.5.4.497; MOOI W, 1992, BIOPSY PATHOLOGY MEL; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Papp T, 1999, J MED GENET, V36, P610; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Rizos H, 2001, J BIOL CHEM, V276, P41424, DOI 10.1074/jbc.M105299200; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Rudolph P, 2000, AM J PATHOL, V156, P1425, DOI 10.1016/S0002-9440(10)65011-0; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Smalley KSM, 2002, MELANOMA RES, V12, P187, DOI 10.1097/00008390-200206000-00001; Sviderskaya EV, 2002, JNCI-J NATL CANCER I, V94, P446; SVIDERSKAYA EV, 2003, IN PRESS J NATL CANC, V95; Walker GJ, 1998, GENE CHROMOSOME CANC, V22, P157, DOI 10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; WONG G, 1975, NATURE, V255, P644, DOI 10.1038/255644a0; Wynford-Thomas D, 1999, J PATHOL, V187, P100; YAVUZER U, 1995, ONCOGENE, V10, P123; ZEPTER K, 1995, J INVEST DERMATOL, V104, P755, DOI 10.1111/1523-1747.ep12606981	57	158	165	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3063	3069		10.1038/sj.onc.1206446	http://dx.doi.org/10.1038/sj.onc.1206446			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789281				2022-12-17	WOS:000183096600006
J	Su, ZZ; Lebedeva, IV; Sarkar, D; Gopalkrishnan, RV; Sauane, M; Sigmon, C; Yacoub, A; Valerie, K; Dent, P; Fisher, PB				Su, ZZ; Lebedeva, IV; Sarkar, D; Gopalkrishnan, RV; Sauane, M; Sigmon, C; Yacoub, A; Valerie, K; Dent, P; Fisher, PB			Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner	ONCOGENE			English	Article						cancer gene therapy; malignant brain tumors; apoptosis; radiosensitization	IMMUNODEFICIENCY-VIRUS TYPE-1; SUBTRACTION HYBRIDIZATION; MITOCHONDRIAL DYSFUNCTION; TRANSGENE EXPRESSION; MDA-7 EXPRESSION; LEUKEMIA-CELLS; CANCER CELLS; THERAPY; DNA; IDENTIFICATION	Malignant gliomas are extremely aggressive cancers currently lacking effective treatment modalities. Gene therapy represents a promising approach for this disease. A requisite component for improving gene-based therapies of brain cancer includes tumor suppressor genes that exhibit cancer constrained inhibitory activity. Subtraction hybridization identified melanoma differentiation associated gene-7 (mda-7) as a gene associated with melanoma cell growth, differentiation and progression. Ectopic expression of mda-7 by means of a replication-incompetent adenovirus (Ad), Ad.mda-7, induces growth suppression and apoptosis selectively in diverse human cancers, without producing any apparent harmful effect in normal cells. We presently demonstrate that Ad.mda-7 induces growth inhibition and apoptosis in malignant human gliomas expressing both mutant and wild-type p53, and these effects correlate with an elevation in expression of members of the growth arrest and DNA damage (GADD) gene family. In contrast, infection with a recombinant Ad expressing wild-type p53, Ad.wtp53, specifically affects mutant p53 expressing gliomas. When tested in early passage normal and immortal human fetal astrocytes, growth inhibition resulting from infection with Ad.mda-7 or Ad.wtp53 is significantly less than in malignant gliomas and no toxicity is evident in these normal cells. Moreover, infection of gliomas with Ad.mda-7 or treatment with purified GST-MDA-7 protein sensitizes both wild-type and mutant p53 expressing tumor cells to the growth inhibitory and antisurvival effects of ionizing radiation, and this response correlates with increased expression of specific members of the GADD gene family. Since heterogeneity in p53 expression is common in evolving gliomas, the present findings suggest that Ad.mda-7 may, in many instances, prove more beneficial for the gene-based therapy of malignant gliomas than administration of wild-type p53.	Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Columbia Univ, Coll Phys & Surg, Dept Urol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Neurosurg, New York, NY 10032 USA	Columbia University; Virginia Commonwealth University; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol, BB-1501,630 W 168th St, New York, NY 10032 USA.	pbf1@columbia.edu	Valerie, Kristoffer/AAL-8299-2021; Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392	NATIONAL CANCER INSTITUTE [R01CA035675, R01CA097318, R01CA088906] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031492] Funding Source: NIH RePORTER; NCI NIH HHS [CA35675, CA88906, CA97318] Funding Source: Medline; NIDDK NIH HHS [DK52825] Funding Source: Medline; NINDS NIH HHS [NS31492] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alavi JB, 1998, HEMATOL ONCOL CLIN N, V12, P617, DOI 10.1016/S0889-8588(05)70011-3; Alemany R, 1999, EXP CELL RES, V252, P1, DOI 10.1006/excr.1999.4623; Alexander E, 1998, SEMIN SURG ONCOL, V14, P43; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Bencheikh M, 1999, J NEUROVIROL, V5, P115, DOI 10.3109/13550289909021993; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Broaddus WC, 1999, J NEUROSURG, V91, P997, DOI 10.3171/jns.1999.91.6.0997; Canki M, 2001, J VIROL, V75, P7925, DOI 10.1128/JVI.75.17.7925-7933.2001; Carrier F, 1998, BIOCHEM PHARMACOL, V55, P853, DOI 10.1016/S0006-2952(97)00592-3; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Caudell EG, 2002, J IMMUNOL, V168, P6041, DOI 10.4049/jimmunol.168.12.6041; Chadbourne DE, 2001, POPTRONICS, V2, P3; Chaiken IM, 1996, TRENDS BIOTECHNOL, V14, P369, DOI 10.1016/0167-7799(96)10050-0; Cirielli C, 1999, J NEURO-ONCOL, V43, P99, DOI 10.1023/A:1006289505801; Dai Y, 2001, CANCER RES, V61, P5106; Dumoutier L, 2001, J IMMUNOL, V167, P3545, DOI 10.4049/jimmunol.167.7.3545; Ekmekcioglu S, 2001, INT J CANCER, V94, P54, DOI 10.1002/ijc.1437; Ellerhorst JA, 2002, J CLIN ONCOL, V20, P1069, DOI 10.1200/JCO.2002.20.4.1069; FALCKPEDERSEN E, 1994, MOL PHARMACOL, V45, P684; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Fechner H, 2000, GENE THER, V7, P1954, DOI 10.1038/sj.gt.3301321; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; Gomez-Navarro J, 1999, EUR J CANCER, V35, P2039, DOI 10.1016/S0959-8049(99)00300-7; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hidaka C, 1999, J CLIN INVEST, V103, P579, DOI 10.1172/JCI5309; Hollander MC, 1997, J BIOL CHEM, V272, P13731, DOI 10.1074/jbc.272.21.13731; Hong YK, 2000, J KOREAN MED SCI, V15, P315, DOI 10.3346/jkms.2000.15.3.315; Huang EY, 2001, ONCOGENE, V20, P7051, DOI 10.1038/sj.onc.1204897; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Kotenko SV, 2001, J BIOL CHEM, V276, P2725, DOI 10.1074/jbc.M007837200; KOTENKO SV, 2002, CYTOKINE GROWTH F R, V217, P1; Kultz D, 1998, J BIOL CHEM, V273, P13645, DOI 10.1074/jbc.273.22.13645; Kurihara H, 2000, GENE THER, V7, P686, DOI 10.1038/sj.gt.3301129; Kyritsis AP, 1996, MOL CARCINOGEN, V15, P1; LANG FF, 1994, ONCOGENE, V9, P949; Lang FF, 1999, NEUROSURGERY, V45, P1093, DOI 10.1097/00006123-199911000-00016; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; LEBEDEVA IV, 2003, IN PRESS SEM CANC BI; Levin VA, 1997, CANC PRINCIPLES PRAC; Li DQ, 1999, CLIN CANCER RES, V5, P4175; Madireddi MT, 2000, ADV EXP MED BIOL, V465, P239; McCormick F, 2001, NAT REV CANCER, V1, P130, DOI 10.1038/35101008; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Mhashilkar AM, 2001, MOL MED, V7, P271, DOI 10.1007/BF03401847; Oh-Hashi K, 2001, FREE RADICAL BIO MED, V30, P213, DOI 10.1016/S0891-5849(00)00461-5; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Parr MJ, 1997, NAT MED, V3, P1145, DOI 10.1038/nm1097-1145; Pataer A, 2002, CANCER RES, V62, P2239; Pearson AS, 1999, CLIN CANCER RES, V5, P4208; PESTKA S, 2002, ENCY HORMONES; Rosato RR, 2001, INT J ONCOL, V19, P181; Saeki T, 2002, ONCOGENE, V21, P4558, DOI 10.1038/sj.onc.1205553; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Sarkar D, 2002, BIOTECHNIQUES, P30; Sauane M, 2003, CYTOKINE GROWTH F R, V14, P35, DOI 10.1016/S1359-6101(02)00074-6; Shono T, 2002, CANCER RES, V62, P1069; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; Su ZZ, 2001, P NATL ACAD SCI USA, V98, P10332, DOI 10.1073/pnas.171315198; Su ZZ, 2002, ONCOGENE, V21, P3592, DOI 10.1038/sj.onc.1205445; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; VOLKERT FC, 1983, VIROLOGY, V125, P175, DOI 10.1016/0042-6822(83)90072-7; VONDEIMLING A, 1993, BRAIN PATHOL, V3, P19; Vrana JA, 1999, RADIAT RES, V151, P559, DOI 10.2307/3580032; Wang M, 2002, J BIOL CHEM, V277, P7341, DOI 10.1074/jbc.M106043200; WU JK, 1993, AM J HUM GENET, V52, P1273; Xie MH, 2000, J BIOL CHEM, V275, P31335, DOI 10.1074/jbc.M005304200; YOUNG IT, 1977, J HISTOCHEM CYTOCHEM, V25, P935, DOI 10.1177/25.7.894009; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang R, 2000, J BIOL CHEM, V275, P24436, DOI 10.1074/jbc.M001958200	76	158	188	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2003	22	8					1164	1180		10.1038/sj.onc.1206062	http://dx.doi.org/10.1038/sj.onc.1206062			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606943				2022-12-17	WOS:000181249700005
J	Zhou, YQ; He, C; Chen, YQ; Wang, D; Wang, MH				Zhou, YQ; He, C; Chen, YQ; Wang, D; Wang, MH			Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential	ONCOGENE			English	Article						receptor tyrosine kinase; splicing variants; colon cancer; oncogenesis	MACROPHAGE-STIMULATING PROTEIN; POINT MUTATIONS; GROWTH-FACTOR; C-MET; GENE; OVEREXPRESSION; IDENTIFICATION; CANCER; ACTIVATION; PRODUCT	The RON receptor tyrosine kinase is a member of the MET proto-oncogene family that has been implicated in regulating motile-invasive phenotypes in certain types of epithelial cancers. The purpose of this study was to determine if RON expression is altered in primary human colorectal adenocarcinomas. Results from immuohistochemical staining showed that RON is highly expressed in the majority of colorectal adenocarcinomas (29/49 cases). Accumulated RON is also constitutively active with autophosphorylation in tyrosine residues. Moreover, three splicing, variants of RON, namely RONDelta165, RONDelta160, and RONDelta155 were detected and cloned from two primary colon cancer samples. These RON variants were generated by deletions in different regions in extracellular domains of the RON beta chain. Functional studies showed that expression of RONDelta160 or RONDelta155 in Martin-Darby canine kidney cells resulted in increased cell dissociation (scatter-like activity). RON variants, RONDelta160 and RONDelta155, also exerted the ability to induce multiple focus formation and sustain anchorage-independent growth of transfected NIH3T3 cells. Moreover, NIH3T3 cells expressing RONDelta160 or RONDelta155 formed tumors in athymic nude mice and colonized in the lungs. These data suggest that RON expression is altered in certain primary colon cancers. Abnormal accumulation of RON variants may play a role in the progression of certain colorectal cancers in vivo.	Univ Colorado, Hlth Sci Ctr, Denver Hlth Med Ctr, Dept Med, Denver, CO 80204 USA; Zhejiang Univ, Sch Med, Div Neurosurg, Affiliated Hosp 1, Hangzhou 310027, Peoples R China; Zhejiang Univ, Sch Med, Dept Surg, Sir Run Run Shaw Hosp, Hangzhou 310027, Peoples R China; Univ Colorado, Sch Med, Dept Med, Denver, CO USA; Univ Colorado, Sch Med, CU Canc Ctr, Denver, CO USA	Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Zhejiang University; Zhejiang University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Wang, MH (corresponding author), Univ Colorado, Hlth Sci Ctr, Denver Hlth Med Ctr, Dept Med, 777 Bannock St,Mail 4000, Denver, CO 80204 USA.	ming-hai.wang@uchsc.edu			NATIONAL CANCER INSTITUTE [R01CA091980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043516] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA91980] Funding Source: Medline; NIAID NIH HHS [R01 AI43516] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allred DC, 1998, MODERN PATHOL, V11, P155; Angeloni D, 2000, GENE CHROMOSOME CANC, V29, P147, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.3.CO;2-E; Birchmeier W, 1997, CIBA F SYMP, V212, P230; Chen YQ, 2000, EXP CELL RES, V261, P229, DOI 10.1006/excr.2000.5012; Collesi C, 1996, MOL CELL BIOL, V16, P5518; Comoglio PM, 1999, EXP CELL RES, V253, P88, DOI 10.1006/excr.1999.4684; Crawford J., 1994, GASTROINTESTINAL TRA; Dorudi Sina, 1993, Current Opinion in Oncology, V5, P130; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; Kinzler KW, 1998, GENETIC BASIS HUMAN, P565; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Montero-Julian FA, 1998, HYBRIDOMA, V17, P541, DOI 10.1089/hyb.1998.17.541; Okino T, 1999, INT J ONCOL, V15, P709; Peace BE, 2001, ONCOGENE, V20, P6142, DOI 10.1038/sj.onc.1204836; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Portera CA, 1998, SURG ONCOL, V7, P183, DOI 10.1016/S0960-7404(99)00020-1; RONSIN C, 1993, ONCOGENE, V8, P1195; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Wang MH, 2000, CARCINOGENESIS, V21, P1507, DOI 10.1093/carcin/21.8.1507; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WANG MH, 1994, J BIOL CHEM, V269, P3436; Williams TA, 1999, J CELL PHYSIOL, V181, P507, DOI 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q; Xiao ZQ, 2000, BIOCHEM BIOPH RES CO, V267, P669, DOI 10.1006/bbrc.1999.2011; Yokota J, 2000, CARCINOGENESIS, V21, P497, DOI 10.1093/carcin/21.3.497	31	158	177	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2003	22	2					186	197		10.1038/sj.onc.1206075	http://dx.doi.org/10.1038/sj.onc.1206075			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527888				2022-12-17	WOS:000180322400004
J	Gros, L; Saparbaev, MK; Laval, J				Gros, L; Saparbaev, MK; Laval, J			Enzymology of the repair of free radicals-induced DNA damage	ONCOGENE			English	Review						oxygen free radicals; oxidative DNA damage; DNA glycosylase; base excision; 8-oxoguanine; AP endonuclease	BASE-EXCISION-REPAIR; COLI ENDONUCLEASE-III; HUMAN APURINIC/APYRIMIDINIC ENDONUCLEASE; HUMAN APURINIC ENDONUCLEASE; CELL NUCLEAR ANTIGEN; TRANSCRIPTION-COUPLED REPAIR; DOUBLE-STRAND BREAKS; HUMAN MUTT HOMOLOG; HUMAN ALKYLADENINE GLYCOSYLASE; RING FRAGMENTATION PRODUCT	A number of intrinsic and extrinsic mutagens induce structural damage in cellular DNA. These DNA damages are cytotoxic, miscoding or both and are believed to be at the origin of cell lethality, tissue degeneration, ageing and cancer. In order to counteract immediately the deleterious effects of such lesions, leading to genomic instability, cells have evolved a number of DNA repair mechanisms including the direct reversal of the lesion, sanitation of the dNTPs pools, mismatch repair and several DNA excision pathways including the base excision repair (BER) nucleotide excision repair (NER) and the nucleotide incision repair (NIR). These repair pathways are universally present in living cells and extremely well conserved. This review is focused on the repair of lesions induced by free radicals and ionising radiation. The BER pathway removes most of these DNA lesions, although recently it was shown that other pathways would also be efficient in the removal of oxidised bases. In the BER pathway the process is initiated by a DNA glycosylase excising the modified and mismatched base by hydrolysis of the glycosidic bond between the base and the deoxyribose of the DNA, generating a free base and an abasic site (AP-site) which in turn is repaired since it is cytotoxic and mutagenic.	Inst Gustave Roussy, UMR 8532 CNRS, ENS Cachan, LBPA,Grp Reparat ADN, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Laval, J (corresponding author), Inst Gustave Roussy, UMR 8532 CNRS, ENS Cachan, LBPA,Grp Reparat ADN, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	jlaval@igr.fr	Saparbaev, Murat K/N-3225-2015; Saparbaev, Murat/AAC-5478-2020	Saparbaev, Murat K/0000-0002-4630-1074; Saparbaev, Murat/0000-0002-4630-1074				AHNSTROM G, 1982, INT J RADIAT BIOL, V41, P671, DOI 10.1080/09553008214550761; Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; Allinson SL, 2001, EMBO J, V20, P6919, DOI 10.1093/emboj/20.23.6919; Alseth I, 1999, MOL CELL BIOL, V19, P3779; Aravind L, 2000, GENOME BIOL, V1, P1, DOI DOI 10.1186/GB-2000-1-4-RESEARCH0007; ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P4444, DOI 10.1021/bi00436a048; Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; Augeri L, 1997, BIOCHEMISTRY-US, V36, P721, DOI 10.1021/bi9625511; Baeuerle PA, 1996, PATHOL BIOL, V44, P29; BAILLY V, 1987, BIOCHEM J, V242, P565, DOI 10.1042/bj2420565; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; BARZILAY G, 1995, NUCLEIC ACIDS RES, V23, P1544, DOI 10.1093/nar/23.9.1544; BARZILAY G, 1995, BIOESSAYS, V17, P713, DOI 10.1002/bies.950170808; Bauche C, 1999, J BACTERIOL, V181, P262, DOI 10.1128/JB.181.1.262-269.1999; Bennett RAO, 1999, MOL CELL BIOL, V19, P1800; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Bessho T, 1999, NUCLEIC ACIDS RES, V27, P979, DOI 10.1093/nar/27.4.979; Bhagwat M, 1996, BIOCHEMISTRY-US, V35, P659, DOI 10.1021/bi9522662; BJELLAND S, 1993, NUCLEIC ACIDS RES, V21, P2045, DOI 10.1093/nar/21.9.2045; BJELLAND S, 1995, BIOCHEMISTRY-US, V34, P14758, DOI 10.1021/bi00045a017; BJELLAND S, 1994, J BIOL CHEM, V269, P30489; Blaisdell JO, 1999, J BACTERIOL, V181, P6396, DOI 10.1128/JB.181.20.6396-6402.1999; Blaisdell JO, 2001, RADIAT PROT DOSIM, V97, P25, DOI 10.1093/oxfordjournals.rpd.a006634; Blaisdell JO, 2001, P NATL ACAD SCI USA, V98, P7426, DOI 10.1073/pnas.131077798; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; Boiteux S, 2000, ARCH BIOCHEM BIOPHYS, V377, P1, DOI 10.1006/abbi.2000.1773; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BOITEUX S, 1993, J PHOTOCH PHOTOBIO B, V19, P87, DOI 10.1016/1011-1344(93)87101-R; BOITEUX S, 1982, BIOCHEMISTRY-US, V21, P6746, DOI 10.1021/bi00269a020; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; Boldogh I, 2001, NUCLEIC ACIDS RES, V29, P2802, DOI 10.1093/nar/29.13.2802; BONURA T, 1975, P NATL ACAD SCI USA, V72, P4265, DOI 10.1073/pnas.72.11.4265; BOORSTEIN RJ, 1992, MOL CELL BIOL, V12, P5536, DOI 10.1128/MCB.12.12.5536; Boorstein RJ, 2001, J BIOL CHEM, V276, P41991, DOI 10.1074/jbc.M106953200; Brooks PJ, 2000, J BIOL CHEM, V275, P22355, DOI 10.1074/jbc.M002259200; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; Budworth H, 2002, J BIOL CHEM, V277, P21300, DOI 10.1074/jbc.M201918200; Burgess S, 2002, J BIOL CHEM, V277, P2938, DOI 10.1074/jbc.M110499200; Cadet J, 1999, MUTAT RES-FUND MOL M, V424, P9, DOI 10.1016/S0027-5107(99)00004-4; Cerda SR, 1998, FEBS LETT, V431, P12, DOI 10.1016/S0014-5793(98)00697-8; CHAN E, 1987, P NATL ACAD SCI USA, V84, P3189, DOI 10.1073/pnas.84.10.3189; Chang DY, 2002, J BIOL CHEM, V277, P11853, DOI 10.1074/jbc.M111739200; Chang DY, 2001, MOL GENET GENOMICS, V266, P336, DOI 10.1007/s004380100567; CHARKOV DO, 2002, EMBO J, V21, P789; Chaudhry MA, 1997, J BIOL CHEM, V272, P15650, DOI 10.1074/jbc.272.25.15650; CHAUDHRY MA, 1995, J MOL BIOL, V249, P914; Chen LW, 2002, CHEM BIOL, V9, P345, DOI 10.1016/S1074-5521(02)00120-5; Chevillard S, 1998, ONCOGENE, V16, P3083, DOI 10.1038/sj.onc.1202096; Chmiel NH, 2001, NUCLEIC ACIDS RES, V29, P553, DOI 10.1093/nar/29.2.553; Chou KM, 2000, J BIOL CHEM, V275, P31009, DOI 10.1074/jbc.M004082200; Chou KM, 2002, NATURE, V415, P655, DOI 10.1038/415655a; Colussi C, 2002, CURR BIOL, V12, P912, DOI 10.1016/S0960-9822(02)00863-1; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cunniffe S, 1999, RADIAT RES, V152, P421, DOI 10.2307/3580227; CUNNINGHAM RP, 1985, P NATL ACAD SCI USA, V82, P474, DOI 10.1073/pnas.82.2.474; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; CZECZOT H, 1991, J BACTERIOL, V173, P3419, DOI 10.1128/jb.173.11.3419-3424.1991; D'Ham C, 1999, BIOCHEMISTRY-US, V38, P3335, DOI 10.1021/bi981982b; Dantzer F, 2002, NUCLEIC ACIDS RES, V30, P2349, DOI 10.1093/nar/30.11.2349; David SS, 1998, CHEM REV, V98, P1221, DOI 10.1021/cr980321h; David-Cordonnier MH, 2000, J BIOL CHEM, V275, P11865, DOI 10.1074/jbc.275.16.11865; David-Cordonnier MH, 2002, BIOCHEMISTRY-US, V41, P634, DOI 10.1021/bi011682l; David-Cordonnier MH, 2001, BIOCHEMISTRY-US, V40, P11811, DOI 10.1021/bi0112356; David-Cordonnier MH, 2001, NUCLEIC ACIDS RES, V29, P1107, DOI 10.1093/nar/29.5.1107; de Souza-Pinto NC, 2001, CANCER RES, V61, P5378; DEMPLE B, 1983, J BACTERIOL, V153, P1079, DOI 10.1128/JB.153.2.1079-1082.1983; DEMPLE B, 1986, P NATL ACAD SCI USA, V83, P7731, DOI 10.1073/pnas.83.20.7731; DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DEMPLE B, 1980, NATURE, V287, P203, DOI 10.1038/287203a0; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DEUTSCH WA, 1982, J BIOL CHEM, V257, P3366; DEVASAGAYAM TPA, 1991, BIOCHEMISTRY-US, V30, P6283, DOI 10.1021/bi00239a029; Dherin C, 1999, NUCLEIC ACIDS RES, V27, P4001, DOI 10.1093/nar/27.20.4001; Dherin C, 2000, NUCLEIC ACIDS RES, V28, P4583, DOI 10.1093/nar/28.23.4583; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Dianova II, 2001, BIOCHEMISTRY-US, V40, P12639, DOI 10.1021/bi011117i; DIRKSEN ML, 1988, INT J RADIAT BIOL, V54, P195, DOI 10.1080/09553008814551631; Dizdaroglu M, 1999, BIOCHEMISTRY-US, V38, P243, DOI 10.1021/bi9819071; DIZDAROGLU M, 1977, INT J RADIAT BIOL, V32, P481, DOI 10.1080/09553007714551241; Dizdaroglu M, 2001, BIOCHEMISTRY-US, V40, P12150, DOI 10.1021/bi015552o; DIZDAROGLU M, 1993, BIOCHEMISTRY-US, V32, P12105, DOI 10.1021/bi00096a022; DODSON ML, 1994, J BIOL CHEM, V269, P32709; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; DUGLE DL, 1976, P NATL ACAD SCI USA, V73, P809, DOI 10.1073/pnas.73.3.809; DUWAT P, 1995, MICROBIOL-UK, V141, P411, DOI 10.1099/13500872-141-2-411; Eide L, 1996, P NATL ACAD SCI USA, V93, P10735, DOI 10.1073/pnas.93.20.10735; Eide L, 2001, BIOCHEMISTRY-US, V40, P6653, DOI 10.1021/bi0028901; Elder RH, 1998, MOL CELL BIOL, V18, P5828, DOI 10.1128/MCB.18.10.5828; ELGHISSASSI F, 1995, CHEM RES TOXICOL, V8, P278, DOI 10.1021/tx00044a013; Engelward BP, 1997, P NATL ACAD SCI USA, V94, P13087, DOI 10.1073/pnas.94.24.13087; Fink SP, 1997, P NATL ACAD SCI USA, V94, P8652, DOI 10.1073/pnas.94.16.8652; Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230; Frenkel K, 1998, CANCER EPIDEM BIOMAR, V7, P49; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Fromme JC, 2002, NAT STRUCT BIOL, V9, P544, DOI 10.1038/nsb809; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Fujii Y, 1999, J BIOL CHEM, V274, P38251, DOI 10.1074/jbc.274.53.38251; Fujikawa K, 1999, J BIOL CHEM, V274, P18201, DOI 10.1074/jbc.274.26.18201; Fujikawa K, 2001, NUCLEIC ACIDS RES, V29, P449, DOI 10.1093/nar/29.2.449; FURUICHI M, 1994, GENOMICS, V24, P485, DOI 10.1006/geno.1994.1657; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; Garcia-Ortiz MV, 2001, PLANT MOL BIOL, V47, P795, DOI 10.1023/A:1013644026132; GELLON L, 2002, J BIOL CHEM; Georgakilas AG, 2002, NUCLEIC ACIDS RES, V30, P2800, DOI 10.1093/nar/gkf393; Gilboa R, 2002, J BIOL CHEM, V277, P19811, DOI 10.1074/jbc.M202058200; GILONI L, 1981, J BIOL CHEM, V256, P8608; Girard PM, 1997, NUCLEIC ACIDS RES, V25, P3204, DOI 10.1093/nar/25.16.3204; Girard PM, 1997, BIOCHIMIE, V79, P559, DOI 10.1016/S0300-9084(97)82004-4; GONG Z, 2002, IN PRESS CELL, V111; GOODHEAD DT, 1994, INT J RADIAT BIOL, V65, P7, DOI 10.1080/09553009414550021; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; Greenberg RB, 2001, J BIOL CHEM, V276, P31551, DOI 10.1074/jbc.M103588200; Gu YS, 2002, J BIOL CHEM, V277, P11135, DOI 10.1074/jbc.M108618200; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; HABRAKEN Y, 1991, CARCINOGENESIS, V12, P1971, DOI 10.1093/carcin/12.10.1971; Hadi MZ, 2000, ENVIRON MOL MUTAGEN, V36, P312, DOI 10.1002/1098-2280(2000)36:4<312::AID-EM7>3.0.CO;2-K; HALLIWELL B, 1982, CELL BIOL INT REP, V6, P529, DOI 10.1016/0309-1651(82)90175-8; Hanawalt PC, 2000, NATURE, V405, P415, DOI 10.1038/35013197; Hang B, 1998, P NATL ACAD SCI USA, V95, P13561, DOI 10.1073/pnas.95.23.13561; Hang B, 1997, P NATL ACAD SCI USA, V94, P12869, DOI 10.1073/pnas.94.24.12869; Hang B, 2002, BIOCHEMISTRY-US, V41, P2158, DOI 10.1021/bi011542b; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Hardeland U, 2002, EMBO J, V21, P1456, DOI 10.1093/emboj/21.6.1456; Harrison L, 1998, NUCLEIC ACIDS RES, V26, P932, DOI 10.1093/nar/26.4.932; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; Haushalter KA, 1999, CURR BIOL, V9, P174, DOI 10.1016/S0960-9822(99)80087-6; Hayakawa H, 1999, BIOCHEMISTRY-US, V38, P3610, DOI 10.1021/bi982361l; Hayashi H, 2002, CURR BIOL, V12, P335, DOI 10.1016/S0960-9822(02)00686-3; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; Hazra TK, 2001, PROG NUCLEIC ACID RE, V68, P193; Hazra TK, 2000, J BIOL CHEM, V275, P27762; HENNER WD, 1983, J BIOL CHEM, V258, P711; Hilbert TP, 1997, J BIOL CHEM, V272, P6733, DOI 10.1074/jbc.272.10.6733; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Holley WR, 1996, RADIAT RES, V145, P188, DOI 10.2307/3579174; Hollis T, 2000, MUTAT RES-DNA REPAIR, V460, P201, DOI 10.1016/S0921-8777(00)00027-6; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; Ischenko AA, 2002, NATURE, V415, P183, DOI 10.1038/415183a; Ishikawa T, 2001, MUTAT RES-FUND MOL M, V477, P41, DOI 10.1016/S0027-5107(01)00094-X; Janssen K, 2001, MUTAT RES-DNA REPAIR, V486, P207, DOI 10.1016/S0921-8777(01)00096-9; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; Jiang DY, 1997, J BACTERIOL, V179, P3773, DOI 10.1128/jb.179.11.3773-3782.1997; JOHNSON AW, 1988, J BIOL CHEM, V263, P18017; JOHNSON AW, 1988, J BIOL CHEM, V263, P18009; Johnson RE, 1998, GENE DEV, V12, P3137, DOI 10.1101/gad.12.19.3137; Jurado J, 1998, BIOCHEMISTRY-US, V37, P7757, DOI 10.1021/bi972982z; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; KAMIYA H, 1995, NUCL ACIDS S SER, V34, P233; KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659; Karahalil B, 1998, NUCLEIC ACIDS RES, V26, P1228, DOI 10.1093/nar/26.5.1228; KASAI H, 1990, MUTAT RES, V243, P249, DOI 10.1016/0165-7992(90)90139-B; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; Kim JE, 2001, BIOCHEM BIOPH RES CO, V285, P1186, DOI 10.1006/bbrc.2001.5305; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; Koukourakis MI, 2001, INT J RADIAT ONCOL, V50, P27, DOI 10.1016/S0360-3016(00)01561-3; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; Krokan HE, 1997, BIOCHEM J, V325, P1; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Kuninger DT, 2002, NUCLEIC ACIDS RES, V30, P823, DOI 10.1093/nar/30.3.823; KUNZ BA, 1994, P NATL ACAD SCI USA, V91, P8165, DOI 10.1073/pnas.91.17.8165; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; Kuraoka I, 2000, P NATL ACAD SCI USA, V97, P3832, DOI 10.1073/pnas.070471597; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; Lau AY, 2000, P NATL ACAD SCI USA, V97, P13573, DOI 10.1073/pnas.97.25.13573; LAVAL F, 1994, NUCLEIC ACIDS RES, V22, P4943, DOI 10.1093/nar/22.23.4943; Laval J, 1998, MUTAT RES-FUND MOL M, V402, P93, DOI 10.1016/S0027-5107(97)00286-8; LAVAL J, 1977, NATURE, V269, P829, DOI 10.1038/269829a0; Lavrukhin OV, 2000, BIOCHEMISTRY-US, V39, P15266, DOI 10.1021/bi001587x; Le Marchand L, 2002, CANCER EPIDEM BIOMAR, V11, P409; Le Page F, 2000, P NATL ACAD SCI USA, V97, P8397, DOI 10.1073/pnas.140137297; Le Page F, 2000, CANCER RES, V60, P5548; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; LEVIN JD, 1988, J BIOL CHEM, V263, P8066; Levine RL, 2001, J BIOL CHEM, V276, P18717, DOI 10.1074/jbc.M102158200; Lim DS, 1996, MOL CELL BIOL, V16, P7133; LIN JJ, 1989, BIOCHEMISTRY-US, V28, P7979, DOI 10.1021/bi00446a002; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; LINDAHL T, 1976, NATURE, V259, P64, DOI 10.1038/259064a0; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; Lindahl T., 2001, PROG NUCL ACID RES M, V68, P27; LJUNGQUIST S, 1977, J BIOL CHEM, V252, P2808; Lu AL, 1998, J BIOL CHEM, V273, P25098, DOI 10.1074/jbc.273.39.25098; Luna L, 2000, MUTAT RES-DNA REPAIR, V460, P95, DOI 10.1016/S0921-8777(00)00015-X; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Marenstein DR, 2001, J BIOL CHEM, V276, P21242, DOI 10.1074/jbc.M101594200; Marnett LJ, 1999, MUTAT RES-FUND MOL M, V424, P83, DOI 10.1016/S0027-5107(99)00010-X; Marnett LJ, 2001, TRENDS GENET, V17, P214, DOI 10.1016/S0168-9525(01)02239-9; MARNETT LJ, 1994, DNA ADDUCTS IDENTIFI, P151; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Matsumoto Y, 2001, NUCLEIC ACIDS RES, V29, P1975, DOI 10.1093/nar/29.9.1975; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; MCCORD JM, 1987, FASEB J, V46, P2402; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; Mckenzie JA, 2001, BIOCHEMISTRY-US, V40, P13254, DOI 10.1021/bi015587o; Meira LB, 2001, CANCER RES, V61, P5552; MELAMEDE RJ, 1994, BIOCHEMISTRY-US, V33, P1255, DOI 10.1021/bi00171a028; Miao F, 2000, J BIOL CHEM, V275, P28433, DOI 10.1074/jbc.M001064200; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; Milligan JR, 2000, INT J RADIAT BIOL, V76, P1475; Missero C, 2001, J BIOL CHEM, V276, P33569, DOI 10.1074/jbc.M104963200; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Nakabeppu Y, 2001, PROG NUCLEIC ACID RE, V68, P75; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Ni TT, 1999, MOL CELL, V4, P439, DOI 10.1016/S1097-2765(00)80346-9; Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3; Nilsen H, 2001, EMBO J, V20, P4278, DOI 10.1093/emboj/20.15.4278; Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637; NUNOSHIBA T, 1993, J BACTERIOL, V175, P7492, DOI 10.1128/JB.175.22.7492-7494.1993; OCONNOR TR, 1993, J BIOL CHEM, V268, P9063; OCONNOR TR, 1991, BIOCHEM BIOPH RES CO, V176, P1170, DOI 10.1016/0006-291X(91)90408-Y; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; Oda H, 1997, J BIOL CHEM, V272, P17843, DOI 10.1074/jbc.272.28.17843; Oda H, 1999, NUCLEIC ACIDS RES, V27, P4335, DOI 10.1093/nar/27.22.4335; Ohtsubo T, 2000, NUCLEIC ACIDS RES, V28, P1355, DOI 10.1093/nar/28.6.1355; Okochi E, 2002, JPN J CANCER RES, V93, P501, DOI 10.1111/j.1349-7006.2002.tb01284.x; Olive PL, 1998, RADIAT RES, V150, pS42, DOI 10.2307/3579807; Osterod M, 2001, CARCINOGENESIS, V22, P1459, DOI 10.1093/carcin/22.9.1459; Otterlei M, 2000, EMBO J, V19, P5542, DOI 10.1093/emboj/19.20.5542; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; Parlanti E, 2002, ONCOGENE, V21, P5204, DOI 10.1038/sj.onc.1205561; Pascucci B, 2002, NUCLEIC ACIDS RES, V30, P2124, DOI 10.1093/nar/30.10.2124; Pascucci B, 1999, J BIOL CHEM, V274, P33696, DOI 10.1074/jbc.274.47.33696; PENDLEBURY A, 1994, CARCINOGENESIS, V15, P2957, DOI 10.1093/carcin/15.12.2957; Pope MA, 2002, J BIOL CHEM, V277, P22605, DOI 10.1074/jbc.M203037200; POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Privezentzev CV, 2001, MUTAT RES-FUND MOL M, V480, P277, DOI 10.1016/S0027-5107(01)00186-5; Privezentzev CV, 2000, BIOCHEMISTRY-US, V39, P14263, DOI 10.1021/bi001337g; Rabow LE, 1997, BIOCHEMISTRY-US, V36, P5084, DOI 10.1021/bi963005a; RADMAN M, 1976, J BIOL CHEM, V251, P1438; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; RASOULINIA A, 2001, MICROS 2001; Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; ROGERS SG, 1980, GENE, V11, P187, DOI 10.1016/0378-1119(80)90059-1; Roldan-Arjona T, 2000, PLANT MOL BIOL, V44, P43, DOI 10.1023/A:1006429114451; Roth RB, 2002, CANCER RES, V62, P656; Rothwell DG, 1997, ONCOL RES, V9, P275; Roy R, 1998, BIOCHEMISTRY-US, V37, P580, DOI 10.1021/bi972313l; Roy R, 1996, CARCINOGENESIS, V17, P2177, DOI 10.1093/carcin/17.10.2177; SAMSON L, 1991, P NATL ACAD SCI USA, V88, P9127, DOI 10.1073/pnas.88.20.9127; Sandigursky M, 1999, CURR BIOL, V9, P531, DOI 10.1016/S0960-9822(99)80237-1; Sandigursky M, 2000, J BIOL CHEM, V275, P19146, DOI 10.1074/jbc.M001995200; Saparbaev M, 1998, P NATL ACAD SCI USA, V95, P8508, DOI 10.1073/pnas.95.15.8508; SAPARBAEV M, 1995, NUCLEIC ACIDS RES, V23, P3750, DOI 10.1093/nar/23.18.3750; Saparbaev M, 2002, J BIOL CHEM, V277, P26987, DOI 10.1074/jbc.M111100200; Saparbaev M, 2002, ENVIRON MOL MUTAGEN, V39, P10, DOI 10.1002/em.10041; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; Sard L, 1997, GENOMICS, V44, P222, DOI 10.1006/geno.1997.4843; Sartori AA, 2002, EMBO J, V21, P3182, DOI 10.1093/emboj/cdf309; Scharer OD, 1997, CURR OPIN CHEM BIOL, V1, P526, DOI 10.1016/S1367-5931(97)80048-8; Scharer OD, 2001, BIOESSAYS, V23, P270, DOI 10.1002/1521-1878(200103)23:3<270::AID-BIES1037>3.0.CO;2-J; SCHUCHMANN MN, 1984, INT J RADIAT BIOL, V46, P225, DOI 10.1080/09553008414551341; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Senturker S, 1998, NUCLEIC ACIDS RES, V26, P5270, DOI 10.1093/nar/26.23.5270; Senturker S, 1999, BIOCHEMISTRY-US, V38, P9435, DOI 10.1021/bi990680m; Serre L, 2002, EMBO J, V21, P2854, DOI 10.1093/emboj/cdf304; Shida T, 1996, NUCLEIC ACIDS RES, V24, P4572, DOI 10.1093/nar/24.22.4572; Sidorkina OM, 1998, NUCLEIC ACIDS RES, V26, P5351, DOI 10.1093/nar/26.23.5351; Sidorkina OM, 2000, J BIOL CHEM, V275, P9924, DOI 10.1074/jbc.275.14.9924; SINGER B, 1992, P NATL ACAD SCI USA, V89, P9386, DOI 10.1073/pnas.89.20.9386; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; Slupska MM, 1999, J BACTERIOL, V181, P6210, DOI 10.1128/JB.181.19.6210-6213.1999; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; STRAUSS BS, 1991, BIOESSAYS, V13, P79, DOI 10.1002/bies.950130206; Sugahara M, 2000, EMBO J, V19, P3857, DOI 10.1093/emboj/19.15.3857; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; Sung JS, 2000, BIOCHEMISTRY-US, V39, P10224, DOI 10.1021/bi0007066; Sutherland BM, 2001, ENVIRON MOL MUTAGEN, V38, P159, DOI 10.1002/em.1067; Sutherland BM, 2001, RADIAT PROT DOSIM, V97, P33, DOI 10.1093/oxfordjournals.rpd.a006635; Sutherland BM, 2000, P NATL ACAD SCI USA, V97, P103, DOI 10.1073/pnas.97.1.103; Sutherland BM, 2000, BIOCHEMISTRY-US, V39, P8026, DOI 10.1021/bi9927989; Sutton MD, 2000, ANNU REV GENET, V34, P479, DOI 10.1146/annurev.genet.34.1.479; Taddei F, 1997, SCIENCE, V278, P128, DOI 10.1126/science.278.5335.128; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; Takama F, 2000, INT J ONCOL, V17, P467; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; Takao M, 2002, EMBO J, V21, P3486, DOI 10.1093/emboj/cdf350; Takezaki T, 2002, INT J CANCER, V99, P624, DOI 10.1002/ijc.10400; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TERASHIMA I, 1998, MOL GEN GENET, V259, P577; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; THOMAS L, 1982, BIOCHEMISTRY-US, V21, P1162, DOI 10.1021/bi00535a009; Tini M, 2002, MOL CELL, V9, P265, DOI 10.1016/S1097-2765(02)00453-7; Tom S, 2001, J BIOL CHEM, V276, P48781, DOI 10.1074/jbc.M109626200; TRUSH MA, 1991, FREE RADICAL BIO MED, V10, P201, DOI 10.1016/0891-5849(91)90077-G; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; TSAIWU JYYJ, 1991, J BACTERIOL, V173, P1902, DOI 10.1128/jb.173.6.1902-1910.1991; TSANEVA IR, 1990, J BACTERIOL, V172, P4197, DOI 10.1128/jb.172.8.4197-4205.1990; Tsuchimoto D, 2001, NUCLEIC ACIDS RES, V29, P2349, DOI 10.1093/nar/29.11.2349; Tsuzuki T, 2001, P NATL ACAD SCI USA, V98, P11456, DOI 10.1073/pnas.191086798; Um S, 1998, J BIOL CHEM, V273, P20728, DOI 10.1074/jbc.273.33.20728; Unk I, 2000, J BIOL CHEM, V275, P22427, DOI 10.1074/jbc.M002845200; Unk I, 2001, MOL CELL BIOL, V21, P1656, DOI 10.1128/MCB.21.5.1656-1661.2001; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Vaisman A, 2001, EMBO J, V20, P6520, DOI 10.1093/emboj/20.22.6520; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; VERLY WG, 1972, CAN J BIOCHEM CELL B, V50, P217, DOI 10.1139/o72-029; VICKERS MA, 1993, P NATL ACAD SCI USA, V90, P3437, DOI 10.1073/pnas.90.8.3437; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; Vidal AE, 2001, NUCLEIC ACIDS RES, V29, P1285, DOI 10.1093/nar/29.6.1285; VONSONNTAG C, 1994, METHOD ENZYMOL, V233, P47; WARD JF, 1995, RADIAT RES, V142, P362, DOI 10.2307/3579145; WARD JF, 1981, RADIAT RES, V86, P185, DOI 10.2307/3575500; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; Weinfeld M, 2001, RADIAT RES, V156, P584, DOI 10.1667/0033-7587(2001)156[0584:ROBERE]2.0.CO;2; WEISS B, 1987, ADV ENZYMOL RAMB, V60, P1; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wilson DM, 1995, NUCLEIC ACIDS RES, V23, P5027; Wilson DM, 1997, P NATL ACAD SCI USA, V94, P12754, DOI 10.1073/pnas.94.24.12754; WINK DA, 1994, ANN NY ACAD SCI, V738, P265; WU C, 1995, BIOCHEM BIOPH RES CO, V214, P1239, DOI 10.1006/bbrc.1995.2419; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919; Yamagata Y, 1996, CELL, V86, P311, DOI 10.1016/S0092-8674(00)80102-6; Yang HJ, 2001, NUCLEIC ACIDS RES, V29, P743, DOI 10.1093/nar/29.3.743; You HJ, 1999, BIOCHEMISTRY-US, V38, P11298, DOI 10.1021/bi991121i; Zharkov DO, 2000, J BIOL CHEM, V275, P28607, DOI 10.1074/jbc.M002441200; Zharkov DO, 1998, BIOCHEMISTRY-US, V37, P12384, DOI 10.1021/bi981066y; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	343	158	169	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2002	21	58					8905	8925		10.1038/sj.onc.1206005	http://dx.doi.org/10.1038/sj.onc.1206005			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483508				2022-12-17	WOS:000179889500003
J	Tsai, MS; Bogart, DF; Castaneda, JM; Li, P; Lupu, R				Tsai, MS; Bogart, DF; Castaneda, JM; Li, P; Lupu, R			Cyr61 promotes breast tumorigenesis and cancer progression	ONCOGENE			English	Article						Cyr61; invasiveness; estrogen-dependence; antiestrogen-resistance; breast cancer	IMMEDIATE-EARLY GENE; TISSUE GROWTH-FACTOR; MESSENGER RIBONUCLEIC-ACID; CELL-LINES; ESTROGEN-RECEPTOR; INTEGRIN ALPHA(V)BETA(3); TUMOR PROGRESSION; DRUG-RESISTANCE; PROTEIN-LEVELS; EXPRESSION	Cyr61, a member of the CCN family of genes, is an angiogenic factor. We have shown that it is over-expressed in invasive and metastatic human breast cancer cells and tissues. Here, we investigated whether Cyr61 is necessary and/or sufficient to bypass the 'normal' estrogen (E2) requirements for breast cancer cell growth. Our results demonstrate that Cyr61 is sufficient to induce MCF-7 cells to grow in the absence of E2. Cyr61-transfected MCF-7 cells (MCF-7/Cyr61) became E2-independent but still E2-responsive. On the other hand, MCF-7 cells transfected with the vector DNA (MCF-7/V) remain E2-dependent. MCF-7/Cyr61 cells acquire an antiestrogen-resistant phenotype, one of the most common clinical occurrences during breast cancer progression. MCF-7/Cyr61 cells are anchorage-independent and capable of forming Matrigel outgrowth patterns in the absence of E2. ERalpha expression in MCF7/Cyr61 cells is decreased although still functional. Moreover, MCF-7/Cyr61 cells are tumorigenic in ovariectomized athymic nude mice. The tumors resemble human invasive carcinomas with increased vascularization and overexpression of vascular endothelial growth factor (VEGF). Our results demonstrate that Cyr61 is a tumor-promoting factor and a key regulator of breast cancer progression. This study provides evidence that Cyr61. is sufficient to induce E2-independence and antiestrogen-resistance, and to promote invasiveness in vitro, and to induce tumorigenesis in vivo, all of which are characteristics of an aggressive breast cancer phenotype.	Univ Calif Berkeley, Ernest Orlando Lawrence Berkely Natl Lab, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Lupu, R (corresponding author), Evanston NW Healthcare Res Inst, 1001 Univ Pl, Evanston, IL 60201 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049049] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49049] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babic AM, 1999, MOL CELL BIOL, V19, P2958; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; BROWER ST, 1999, BREAST CANC, P273; Cardillo M., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P262; CAVAILLES V, 1988, NUCLEIC ACIDS RES, V16, P1903, DOI 10.1093/nar/16.5.1903; Chen CC, 2001, J BIOL CHEM, V276, P47329, DOI 10.1074/jbc.M107666200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Gasparini G, 1998, CLIN CANCER RES, V4, P2625; Govind AP, 2001, J CELL BIOCHEM, V80, P571, DOI 10.1002/1097-4644(20010315)80:4<571::AID-JCB1011>3.0.CO;2-H; Guerra-Vladusic FK, 1999, INT J ONCOL, V15, P883; Hijazi MM, 2000, INT J ONCOL, V17, P629; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Kolesnikova TV, 1998, ONCOGENE, V16, P747, DOI 10.1038/sj.onc.1201572; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; LUPU R, 1995, SEMIN CANCER BIOL, V6, P135, DOI 10.1006/scbi.1995.0016; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; MacGregor JI, 1998, PHARMACOL REV, V50, P151; Meyer T, 1998, BRIT J CANCER, V77, P530, DOI 10.1038/bjc.1998.86; NARDULLI AM, 1988, ENDOCRINOLOGY, V122, P935, DOI 10.1210/endo-122-3-935; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; PRATT SE, 1993, CANCER RES, V53, P5193; READ LD, 1989, MOL ENDOCRINOL, V3, P295, DOI 10.1210/mend-3-2-295; Saceda M, 1996, ENDOCRINOLOGY, V137, P4322, DOI 10.1210/en.137.10.4322; Sampath D, 2001, ENDOCRINOLOGY, V142, P2540, DOI 10.1210/en.142.6.2540; SOMMERS CL, 1991, CELL GROWTH DIFFER, V2, P365; Tang CK, 1996, CANCER RES, V56, P3350; Tsai MS, 2002, ONCOGENE, V21, P964, DOI 10.1038/sj/onc/1205131; Tsai MS, 2000, CANCER RES, V60, P5603; Vladusic EA, 2000, ONCOL REP, V7, P157; WEAVER CA, 1988, MOL ENDOCRINOL, V2, P936, DOI 10.1210/mend-2-10-936; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351	36	158	164	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	2002	21	53					8178	8185		10.1038/sj.onc.1205682	http://dx.doi.org/10.1038/sj.onc.1205682			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444554	Green Submitted			2022-12-17	WOS:000179231400012
J	von Haefen, C; Wieder, T; Gillissen, B; Starck, L; Graupner, V; Dorken, B; Daniel, PT				von Haefen, C; Wieder, T; Gillissen, B; Starck, L; Graupner, V; Dorken, B; Daniel, PT			Ceramide induces mitochondrial activation and apoptosis via a Bax-dependent pathway in human carcinoma cells	ONCOGENE			English	Article						proapoptotic genes; Bax; ceramide; mitochondria; DU 145 cells; HCT116 cells	CYTOCHROME-C RELEASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; ETOPOSIDE-INDUCED APOPTOSIS; DRUG-INDUCED APOPTOSIS; BCL-2 FAMILY MEMBERS; HUMAN-MELANOMA CELLS; GENE BAX; CANCER-CHEMOTHERAPY; CASPASE ACTIVATION; MEDIATED APOPTOSIS	The intracellular pathways leading to mitochondrial activation and subsequent cell death in the ceramide-mediated stress response have been intensively studied in recent years. Experimental evidence has been provided that ceramide-induced apoptosis is inhibited by overexpression of antiapoptotic proteins of the Bcl-2 family. However, the direct effect of proapoptotic gene products, e.g. Bax, on ceramide-induced death signalling has not yet been studied in detail. In the present work, we show by measurement of mitochondrial permeability transition, cytochrome c release, activation of caspase-3 and DNA fragmentation that ceramide-induced apoptosis is marginal in Bax-negative DU 145 cells. Reconstitution of Bax by generation of DU 145 cells stably expressing this proapoptotic factor, clearly enhanced ceramide-induced apoptosis at all levels of the mitochondrial signalling cascade. Using the broad-range caspase inhibitor zVAD-fmk and zDEVD-fmk, an inhibitor of caspase-3-like activities, we demonstrate that the ceramide-induced mitochondrial activation in Bax-transfected DU 145 cells is caspase-independent. On the other hand, apoptotic events located downstream of the mitochondria, e.g. DNA fragmentation, were shown to be caspase-dependent. This influence of Bax on ceramide-induced apoptosis was confirmed in another cellular system: whereas Bax-positive HCT116 wild type cells were very sensitive towards induction of cell death by C-2-ceramide, sensitivity of Bax knock-out HCT116 cells was significantly reduced. Thus, we conclude that Bax is a key activator of ceramide-mediated death pathways.	Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Daniel, PT (corresponding author), Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mde-berlin.de		Gillissen, Bernhard/0000-0002-1815-2091				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; Belaud-Rotureau MA, 2000, APOPTOSIS, V5, P551, DOI 10.1023/A:1009693630664; BIELAWSKA A, 1992, J BIOL CHEM, V267, P18493; Blagosklonny MV, 2000, LEUKEMIA, V14, P1502, DOI 10.1038/sj.leu.2401864; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Engedal N, 2001, PROSTATE, V46, P289, DOI 10.1002/1097-0045(20010301)46:4<289::AID-PROS1035>3.0.CO;2-K; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Geilen CC, 1996, FEBS LETT, V378, P88, DOI 10.1016/0014-5793(95)01421-7; Geilen CC, 1997, ARCH DERMATOL RES, V289, P559, DOI 10.1007/s004030050240; Geilen GC, 1997, J BIOL CHEM, V272, P8997, DOI 10.1074/jbc.272.14.8997; Geley S, 1997, FEBS LETT, V400, P15, DOI 10.1016/S0014-5793(96)01284-7; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; Jafrezou JP, 2001, FASEB J, V15, P123, DOI 10.1096/fj.00-0305com; Kim HJ, 2001, FEBS LETT, V505, P264, DOI 10.1016/S0014-5793(01)02836-8; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee Y, 2000, APOPTOSIS, V5, P523, DOI 10.1023/A:1009637512917; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu B, 1997, SEMIN CELL DEV BIOL, V8, P311, DOI 10.1006/scdb.1997.0153; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; Lucci A, 1999, INT J ONCOL, V15, P541; Lucci A, 1999, INT J ONCOL, V15, P535; Malisan F, 1999, FEBS LETT, V452, P100, DOI 10.1016/S0014-5793(99)00543-8; Marcelli M, 2000, PROSTATE, V42, P260, DOI 10.1002/(SICI)1097-0045(20000301)42:4<260::AID-PROS3>3.0.CO;2-0; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; MIYASHITA T, 1993, BLOOD, V81, P151; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Peltenburg LTC, 2000, Q J NUCL MED, V44, P355; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Raisova M, 2000, FEBS LETT, V473, P27, DOI 10.1016/S0014-5793(00)01491-5; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Sawada M, 2000, ONCOGENE, V19, P3508, DOI 10.1038/sj.onc.1203699; Sawada N, 2000, CELL DEATH DIFFER, V7, P761, DOI 10.1038/sj.cdd.4400711; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364; Weinmann P, 1997, EUR J IMMUNOL, V27, P2466, DOI 10.1002/eji.1830270947; Wieder T, 1997, FEBS LETT, V411, P260, DOI 10.1016/S0014-5793(97)00717-5; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	62	158	162	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2002	21	25					4009	4019		10.1038/sj.onc.1205497	http://dx.doi.org/10.1038/sj.onc.1205497			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037683				2022-12-17	WOS:000175869900007
J	Yokota, Y				Yokota, Y			Id and development	ONCOGENE			English	Article						Id; basic helix-loop-helix (bHLR); differentiation; proliferation; development	LOOP-HELIX PROTEIN; NATURAL-KILLER-CELLS; PERIPHERAL LYMPHOID ORGANS; T-CELL; DNA-BINDING; MICE LACKING; TRANSCRIPTION FACTOR; EXPRESSION PATTERN; REGULATORY ROLES; GENE-EXPRESSION	During development, it is obvious that enormous multiplication and diversification of cells is required to build a body plan from a single fertilized egg and that these two processes, proliferation and differentiation, must be coordinated properly. Id proteins, negative regulators of basic helix -loop - helix transcription factors, possess the ability to inhibit differentiation and to stimulate proliferation, and are useful molecules for investigating the mechanisms regulating development. In the past few years, our understanding of the roles of Id proteins has been substantially enhanced by the detailed investigation of genetically modified animals. The data have indicated that the functions of Id proteins in vivo are functionally related to those revealed by earlier work in cell culture systems. However, unexpected organs and cell types have also been found to require Id proteins for their normal development. This review looks at the advances made in our understanding of the in vivo functions of Id proteins. The topics discussed include neurogenesis, natural killer cell development, lymphoid organogenesis, mammary gland development and spermatogenesis.	Fukui Med Univ, Dept Biochem, Fukui 9101193, Japan	University of Fukui	Yokota, Y (corresponding author), Fukui Med Univ, Dept Biochem, Shimoaizuki 23-3, Fukui 9101193, Japan.	yyokota@fmsrsa.fukui-med.ac.jp						Andres-Barquin PJ, 2000, HISTOL HISTOPATHOL, V15, P603, DOI 10.14670/HH-15.603; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BARRES BA, 1994, DEVELOPMENT, V120, P1097; Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Blom B, 1999, EMBO J, V18, P2793, DOI 10.1093/emboj/18.10.2793; Cai L, 2000, DEVELOPMENT, V127, P3021; Carlyle JR, 1998, IMMUNOL REV, V165, P63, DOI 10.1111/j.1600-065X.1998.tb01230.x; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; DUNCAN M, 1992, DEV BIOL, V154, P1, DOI 10.1016/0012-1606(92)90042-F; Duncan MK, 1997, DEV DYNAM, V208, P107, DOI 10.1002/(SICI)1097-0177(199701)208:1<107::AID-AJA10>3.0.CO;2-3; Durand B, 2000, BIOESSAYS, V22, P64; EVANS SM, 1993, DEV BIOL, V159, P485, DOI 10.1006/dbio.1993.1258; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Heemskerk MHM, 1997, J EXP MED, V186, P1597, DOI 10.1084/jem.186.9.1597; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Horseman ND, 1997, EMBO J, V16, P6926, DOI 10.1093/emboj/16.23.6926; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Ikawa T, 1999, J EXP MED, V190, P1617, DOI 10.1084/jem.190.11.1617; Ikawa T, 2001, P NATL ACAD SCI USA, V98, P5164, DOI 10.1073/pnas.091537598; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Inoue T, 1999, BIOCHEM BIOPH RES CO, V266, P147, DOI 10.1006/bbrc.1999.1779; Inoue T, 2000, GENES CELLS, V5, P699, DOI 10.1046/j.1365-2443.2000.00362.x; Jen Y, 1996, DEV DYNAM, V207, P235; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Jen Y, 1997, DEV DYNAM, V208, P92, DOI 10.1002/(SICI)1097-0177(199701)208:1<92::AID-AJA9>3.0.CO;2-X; Kim D, 1999, MOL CELL BIOL, V19, P8240; Kondo T, 2000, EMBO J, V19, P1998, DOI 10.1093/emboj/19.9.1998; Kondo T, 2000, DEVELOPMENT, V127, P2989; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Lu QR, 2000, NEURON, V25, P317, DOI 10.1016/S0896-6273(00)80897-1; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Martinsen BJ, 1998, SCIENCE, V281, P988, DOI 10.1126/science.281.5379.988; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Mebius RE, 1997, IMMUNITY, V7, P493, DOI 10.1016/S1074-7613(00)80371-4; Mebius RE, 2001, J IMMUNOL, V166, P6593, DOI 10.4049/jimmunol.166.11.6593; Mori S, 2000, EMBO J, V19, P5772, DOI 10.1093/emboj/19.21.5772; Morrow MA, 1999, MOL IMMUNOL, V36, P491, DOI 10.1016/S0161-5890(99)00071-1; NEUMAN T, 1993, DEV BIOL, V160, P186, DOI 10.1006/dbio.1993.1297; Neville M. C., 1987, MAMMARY GLAND DEV RE; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; OAKBERG EF, 1956, AM J ANAT, V99, P507, DOI 10.1002/aja.1000990307; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; RIECHMANN V, 1995, CELL GROWTH DIFFER, V6, P837; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Robinson L, 1997, P NATL ACAD SCI USA, V94, P7170, DOI 10.1073/pnas.94.14.7170; RUSSELL LD, 1990, HIST HISTOPATHOLOGIC; Sablitzky F, 1998, CELL GROWTH DIFFER, V9, P1015; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sharpe Richard M., 1994, P1363; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; SHOJI W, 1995, J BIOL CHEM, V270, P24818, DOI 10.1074/jbc.270.42.24818; Shortman K, 1996, ANNU REV IMMUNOL, V14, P29, DOI 10.1146/annurev.immunol.14.1.29; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Spits H, 1998, IMMUNOL REV, V165, P75, DOI 10.1111/j.1600-065X.1998.tb01231.x; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Sun ZM, 2000, SCIENCE, V288, P2369, DOI 10.1126/science.288.5475.2369; TEMPLE S, 1986, CELL, V44, P773, DOI 10.1016/0092-8674(86)90843-3; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; Tournay O, 1996, MOL CELL BIOL, V16, P2418; Tzeng SF, 1998, GLIA, V24, P372, DOI 10.1002/(SICI)1098-1136(199812)24:4<372::AID-GLIA2>3.0.CO;2-B; Wang SL, 2001, NEURON, V29, P603, DOI 10.1016/S0896-6273(01)00237-9; Wice BM, 1998, J BIOL CHEM, V273, P25310, DOI 10.1074/jbc.273.39.25310; Williams NS, 1998, IMMUNOL REV, V165, P47, DOI 10.1111/j.1600-065X.1998.tb01229.x; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; Yoshida H, 1999, INT IMMUNOL, V11, P643, DOI 10.1093/intimm/11.5.643; Zhou Q, 2000, NEURON, V25, P331, DOI 10.1016/S0896-6273(00)80898-3; ZHU WJ, 1995, MOL BRAIN RES, V30, P312, DOI 10.1016/0169-328X(95)00017-M; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898; Zhuang YA, 1998, MOL CELL BIOL, V18, P3340, DOI 10.1128/MCB.18.6.3340	88	158	166	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 20	2001	20	58					8290	8298		10.1038/sj.onc.1205090	http://dx.doi.org/10.1038/sj.onc.1205090			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512HT	11840321				2022-12-17	WOS:000173319500002
J	Lopez-Ocejo, O; Viloria-Petit, A; Bequet-Romero, M; Mukhopadhyay, D; Rak, J; Kerbel, RS				Lopez-Ocejo, O; Viloria-Petit, A; Bequet-Romero, M; Mukhopadhyay, D; Rak, J; Kerbel, RS			Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner	ONCOGENE			English	Article						tumor; angiogenesis; oncogenes; cervical cancer	HUMAN-PAPILLOMAVIRUS TYPE-16; K14-HPV16 TRANSGENIC MICE; CERVICAL-CARCINOMA CELLS; FACTOR MESSENGER-RNA; FACTOR RECEPTOR; PERMEABILITY FACTOR; FACTOR EXPRESSION; HUMAN KERATINOCYTES; SUPPRESSOR GENE; DNA-BINDING	Like other types of pre-malignant lesions and carcinoma, angiogenesis is associated with high-grade cervical dysplasia and with invasive squamous carcinoma of the cervix, Vascular endothelial cell growth factor (VEGF) is known to be one of the most important inducers of angiogenesis and is upregulated in carcinoma of the cervix, Human Papilloma Virus 16 (HPV-16) has been etiologically linked to human cervical cancer, and the major oncogenic proteins encoded by the viral genome, E6 and E7, are involved in the immortalization of target cells, Because several oncogenes including mutant ras, EGF receptor, ErbB2/Her2, c-myc and v-src upregulate VEGF expression, we asked whether HVP-16 E6 oncoprotein could act in a similar fashion. We found that HPV-16 E6-positive cells generally express high levels of VEGF message. Furthermore, co-expression of the VEGF promoter-Luc (luciferase) reporter gene with E6 in both human keratinocytes and mouse fibroblast showed that E6 oncoprotein upregulates VEGF promoter activity, and does so in a p53 independent manner. An E6 responsive region which comprises four Sp-1 sites, between -194 and -50 bp of the VEGF promoter, is also necessary for constitutive VEGF transcription, Taken together, our results suggest the possibility that the HPV oncoprotein E6 may contribute to tumor angiogenesis by direct stimulation of the VEGF gene.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Canc Biol Res, Toronto, ON M4N 3M5, Canada; Int Ctr Genet Engn & Biotechnol, Vaccine Div, Havana 10600, Cuba; Int Ctr Genet Engn & Biotechnol, Div Pharmaceut, Havana 10600, Cuba; Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Med Biophys,Div Canc Biol Res, Toronto, ON M4N 3M5, Canada; Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; McMaster Univ, Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8W 1C3, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; McMaster University	Kerbel, RS (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Canc Biol Res, S-218,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.		Bequet-Romero, Monica/M-3356-2017	Bequet-Romero, Monica/0000-0003-0351-857X	NATIONAL CANCER INSTITUTE [R01CA041233] Funding Source: NIH RePORTER; NCI NIH HHS [CA-41233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BARBOSA MS, 1989, ONCOGENE, V4, P1529; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; BenBassat H, 1997, CANCER RES, V57, P3741; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; CHOO KB, 1987, VIROLOGY, V161, P259, DOI 10.1016/0042-6822(87)90195-4; Coussens LM, 1996, AM J PATHOL, V149, P1899; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; Davis S, 1999, CURR TOP MICROBIOL, V237, P173; DERYNCK R, 1987, CANCER RES, V47, P707; DESAINTES C, 1992, J VIROL, V66, P325, DOI 10.1128/JVI.66.1.325-333.1992; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; Dey A, 1997, VIROLOGY, V228, P190, DOI 10.1006/viro.1996.8363; DURST M, 1987, ONCOGENE, V1, P251; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Ellis LM, 1998, J BIOL CHEM, V273, P1052, DOI 10.1074/jbc.273.2.1052; FAN Z, 1993, CANCER RES, V53, P4637; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; Goldstein NI, 1995, CLIN CANCER RES, V1, P1311; GUIDI AJ, 1995, J NATL CANCER I, V87, P1237, DOI 10.1093/jnci/87.16.1237; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Herrington CS, 1999, J PATHOL, V189, P1; Hove MGM, 1999, J REPROD MED, V44, P493; Hu GY, 1997, JNCI-J NATL CANCER I, V89, P1271, DOI 10.1093/jnci/89.17.1271; Kerbel RS, 1998, MOL MED, V4, P286, DOI 10.1007/BF03401737; Kersemaekers AMF, 1999, CLIN CANCER RES, V5, P577; KIESER A, 1994, ONCOGENE, V9, P963; Kinoshita T, 1997, VIROLOGY, V232, P53, DOI 10.1006/viro.1997.8536; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; Kraemer M, 1999, CELL GROWTH DIFFER, V10, P193; Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; MALLON RG, 1987, J VIROL, V61, P1655, DOI 10.1128/JVI.61.5.1655-1660.1987; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; Mateo C, 1997, IMMUNOTECHNOLOGY, V3, P71, DOI 10.1016/S1380-2933(97)00065-1; Mazure NM, 1996, CANCER RES, V56, P3436; MILTENBERGER RJ, 1995, CELL GROWTH DIFFER, V6, P549; MOROSOV A, 1994, J BIOL CHEM, V269, P18434; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; MUNGER K, 1989, J VIROL, V63, P4417; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609; PARK NH, 1995, ONCOGENE, V10, P2145; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Petit AMV, 1997, AM J PATHOL, V151, P1523; RAK J, 1995, CANCER RES, V55, P4575; Rak J, 1995, CANCER METAST REV, V14, P263, DOI 10.1007/BF00690598; Ravi R, 2000, GENE DEV, V14, P34; ROHLFS M, 1991, VIROLOGY, V183, P331, DOI 10.1016/0042-6822(91)90146-3; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SIF S, 1993, ONCOGENE, V8, P2501; SILLMAN F, 1981, AM J OBSTET GYNECOL, V139, P154, DOI 10.1016/0002-9378(81)90438-5; SmithMcCune K, 1997, CANCER RES, V57, P1294; SMITHMCCUNE KK, 1994, CANCER RES, V54, P800; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Song SY, 1998, P NATL ACAD SCI USA, V95, P2290, DOI 10.1073/pnas.95.5.2290; Stoler MH, 2000, INT J GYNECOL PATHOL, V19, P16, DOI 10.1097/00004347-200001000-00004; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Tokumo K, 1998, GYNECOL ONCOL, V68, P38, DOI 10.1006/gyno.1997.4876; Volpert OV, 1997, ONCOGENE, V14, P1495, DOI 10.1038/sj.onc.1200977; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Webster NJG, 1996, CANCER RES, V56, P2781; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; White FC, 1997, GROWTH FACTORS, V14, P199, DOI 10.3109/08977199709021520; WOODWORTH CD, 1988, CANCER RES, V48, P4620; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	82	158	175	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2000	19	40					4611	4620		10.1038/sj.onc.1203817	http://dx.doi.org/10.1038/sj.onc.1203817			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030150	Bronze			2022-12-17	WOS:000089438200007
J	Kaelin, WG				Kaelin, WG			The p53 gene family	ONCOGENE			English	Review						p53; p73; p63; KET; p51; p40	P53-RELATED PROTEIN; P73 GENE; EXPRESSION; HOMOLOG; NEUROBLASTOMA; ONCOPROTEINS; MUTATIONS; APOPTOSIS; CANCERS; TUMORS	p73 and p63 are two recently discovered p53 homologs, Like p53, these proteins can recognize canonical p53 DNA-binding sites and, when overproduced, can activate p53-responsive target genes and induce apoptosis. Unlike p53, these genes undergo complex alternative splicing which, at least in the case of p63, yields proteins with widely divergent biological properties. In addition p73 and p63 are, in contrast to p53, rarely mutated in human cancer. Furthermore, p73 inactivation is not required for viral transformation. Thus, there is currently no firm evidence that p63 and p73 should be considered tumor suppressors, The early suggestion that monoallelic expression of p73 contributed to carcinogenesis needs to be interpreted cautiously in light of data showing interindividual and intraindividual variation with respect to monoallelic expression of p73 and the finding that p73 mRNA levels are generally increased, rather than decreased, in a host of tumors relative to normal cells.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kaelin, WG (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.							Adams PD, 1998, CURR OPIN CELL BIOL, V10, P791, DOI 10.1016/S0955-0674(98)80123-3; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dobbelstein M, 1998, J GEN VIROL, V79, P3079, DOI 10.1099/0022-1317-79-12-3079; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kong Xiao-Tang, 1999, Neoplasia (New York), V1, P80, DOI 10.1038/sj.neo.7900010; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Kroiss MM, 1998, MELANOMA RES, V8, P504, DOI 10.1097/00008390-199812000-00005; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; Lo Cunsolo C, 1998, CYTOGENET CELL GENET, V82, P199, DOI 10.1159/000015099; Mai M, 1998, CANCER RES, V58, P2347; Mai M, 1998, ONCOGENE, V17, P1739, DOI 10.1038/sj.onc.1202099; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Nimura Y, 1998, INT J CANCER, V78, P437, DOI 10.1002/(SICI)1097-0215(19981109)78:4<437::AID-IJC8>3.0.CO;2-V; Nomoto S, 1998, CANCER RES, V58, P1380; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Prabhu NS, 1998, INT J ONCOL, V13, P5; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; SHAULSKY G, 1991, CANCER RES, V51, P5232; Takahashi H, 1998, CANCER RES, V58, P2076; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Tsao H, 1999, CANCER RES, V59, P172; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, CANCER RES, V58, P5061	33	158	163	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	1999	18	53					7701	7705		10.1038/sj.onc.1202955	http://dx.doi.org/10.1038/sj.onc.1202955			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DD	10618710				2022-12-17	WOS:000084634500009
J	Luscher, B; Larsson, LG				Luscher, B; Larsson, LG			The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: Function and regulation	ONCOGENE			English	Review						Myc; DNA binding; E box; transcription; genes	CASEIN KINASE-II; TRANSCRIPTION FACTOR AP-2; C-MYC/MAX HETERODIMERS; BOX-BINDING PROTEINS; DNA-BINDING; IN-VIVO; N-MYC; RAS COTRANSFORMATION; HELIX PROTEIN; EPIDERMAL DIFFERENTIATION	A large body of evidence has been accumulated that demonstrates dominant effects of Myc proto-oncoproteins on different aspects of cellular growth, Myc is one of the few proteins that is sufficient to drive resting cells into the cell cycle and promote DNA synthesis. In line with this finding is that the constitutive expression of Myc in cells blocks their differentiation. These growth stimulating properties are most likely responsible for Myc's ability to initiate and promote tumor formation, Interestingly Myc can also sensitize cells to apoptosis, suggesting that this protein is part of a life-and-death switch. Molecularly Myc functions as a transcriptional regulator that needs to heterodimerize with Max to exert the biological activities described above and to regulate gene transcription, Myc and Max are just two members of a growing family of proteins referred to as the Myc/Max/Mad network. A hallmark of these proteins is that they possess a C-terminal basic region/helix-loophelix/leucine zipper domain (bHLHZip). The bHLHZip domain specifies dimerization within the network and determines sequence specific DNA binding. Importantly this domain together with the N-terminal transactivation domain is essential for Myc biology. Here we have summarized the structural, functional, and regulatory aspects of the bHLHZip domain of Myc proteins.	Med Hsch Hannover, Inst Mol Biol, D-30623 Hannover, Germany; Uppsala Genet Ctr, Dept Plant Biol, S-75007 Uppsala, Sweden	Hannover Medical School	Luscher, B (corresponding author), Med Hsch Hannover, Inst Mol Biol, Carl Neuberg Str 1, D-30623 Hannover, Germany.		Larsson, Lars-Gunnar/D-9747-2012; Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; ARSURA M, 1995, MOL CELL BIOL, V15, P6702; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; Austen M, 1998, ONCOGENE, V17, P511, DOI 10.1038/sj.onc.1201968; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; AYER DE, 1993, CELL, V72, P1; BAHRAM F, 1999, IN PRESS BLOOD; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; BERBERICH S, 1992, ONCOGENE, V7, P775; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOUSSET K, 1993, ONCOGENE, V8, P3211; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; Brownlie P, 1997, STRUCTURE, V5, P509, DOI 10.1016/S0969-2126(97)00207-4; Burgin A, 1998, Results Probl Cell Differ, V22, P181; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CERNI C, 1995, ONCOGENE, V11, P587; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; Dang CV, 1999, MOL CELL BIOL, V19, P1; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KIERMAIER A, 1997, CURR BIOL, V7, P505; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KING MW, 1993, CELL GROWTH DIFFER, V4, P85; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; Larsson LG, 1997, ONCOGENE, V15, P737, DOI 10.1038/sj.onc.1201390; LARSSON LG, 1994, ONCOGENE, V9, P1247; Lemaitre JM, 1996, ADV CANCER RES, V70, P95, DOI 10.1016/S0065-230X(08)60873-8; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LUSCHER B, 1997, TRANSCRIPTION FACTOR; Lutterbach B, 1997, ONCOGENE, V14, P967, DOI 10.1038/sj.onc.1200920; MA A, 1993, ONCOGENE, V8, P1093; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OU SHI, 1994, J VIROL, V68, P7188, DOI 10.1128/JVI.68.11.7188-7199.1994; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; Patikoglou G, 1997, ANNU REV BIOPH BIOM, V26, P289, DOI 10.1146/annurev.biophys.26.1.289; PEARSONWHITE SH, 1991, NUCLEIC ACIDS RES, V19, P1148, DOI 10.1093/nar/19.5.1148; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PULVERER BJ, 1994, ONCOGENE, V9, P59; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; Rhei E, 1998, CANCER RES, V58, P3193; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2765, DOI 10.1128/MCB.13.5.2765; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SOLLENBERGER KG, 1994, ONCOGENE, V9, P661; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STREET AJ, 1990, CURR TOP MICROBIOL, V166, P251; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; VASTRIK I, 1993, ONCOGENE, V8, P503; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; VENNSTROM B, 1982, J VIROL, V42, P773, DOI 10.1128/JVI.42.3.773-779.1982; Walhout AJM, 1997, NUCLEIC ACIDS RES, V25, P1493, DOI 10.1093/nar/25.8.1493; Walhout AJM, 1998, BBA-GENE STRUCT EXPR, V1397, P189, DOI 10.1016/S0167-4781(97)00227-3; WALKER CW, 1992, ONCOGENE, V7, P2007; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; WECHSLER DS, 1994, MOL CELL BIOL, V14, P4097, DOI 10.1128/MCB.14.6.4097; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yuan J, 1998, ONCOGENE, V17, P1109, DOI 10.1038/sj.onc.1202036; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhao JH, 1998, ONCOGENE, V17, P1009, DOI 10.1038/sj.onc.1202026	110	158	186	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 13	1999	18	19					2955	2966		10.1038/sj.onc.1202750	http://dx.doi.org/10.1038/sj.onc.1202750			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378692				2022-12-17	WOS:000080387800006
J	Fuchs, SY; Chen, A; Xiong, Y; Pan, ZQ; Ronai, Z				Fuchs, SY; Chen, A; Xiong, Y; Pan, ZQ; Ronai, Z			HOS, a human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylation-dependent degradation of I kappa B and beta-catenin	ONCOGENE			English	Article						ubiquitination; SCF E2 ligase; I kappa B; beta-catenin; phosphorylation; degradation	UBIQUITIN-PROTEASOME PATHWAY; F-BOX; PROTEINS; ACTIVATION; FAMILY; KINASE; ALPHA; CDC4P; APC	SCF E3 ubiquitin ligases mediate ubiquitination and proteasome-dependent degradation of phosphorylated substrates. We identified a human F-box/WD40 repeats protein (HOS), which is homologous to Slimb/h beta TrCP. Being a part of SCF complex with Skp1 and Cullin1, HOS specifically interacted with the phosphorylated I kappa B and beta-catenin, targeting these proteins for proteasome-dependent degradation in vivo, This targeting required Cullin1 as expression of a mutant Cullin1 abrogated the degradation of I kappa B and of beta-catenin. Mutant HOS which lacks the F-box blocked TNF alpha-induced degradation of I kappa B as well as GSK3 beta-mediated degradation of beta-catenin. This mutant also inhibited NF-kappa B transactivation and increased the beta-catenine-dependent transcription activity of Tcf. These results demonstrate that SCFHOS E3 ubiquitin ligase regulate both NF-kappa B and beta-catenin signaling pathways.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Fuchs, SY (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, 1 Gustave L Levy Pl, New York, NY 10029 USA.			RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R01CA078419] Funding Source: NIH RePORTER; NCI NIH HHS [CA 78419] Funding Source: Medline; NIGMS NIH HHS [GM 55059] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Elledge SJ, 1998, BBA-REV CANCER, V1377, pM61, DOI 10.1016/S0304-419X(98)00005-5; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	37	158	164	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	1999	18	12					2039	2046		10.1038/sj.onc.1202760	http://dx.doi.org/10.1038/sj.onc.1202760			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321728				2022-12-17	WOS:000079346200001
J	Wenger, C; Ellenrieder, V; Alber, B; Lacher, U; Menke, A; Hameister, H; Wilda, M; Iwamura, T; Beger, HG; Adler, G; Gress, TM				Wenger, C; Ellenrieder, V; Alber, B; Lacher, U; Menke, A; Hameister, H; Wilda, M; Iwamura, T; Beger, HG; Adler, G; Gress, TM			Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells	ONCOGENE			English	Article						CTGF; pancreatic cancer; fibrosis; TGF alpha; TGF beta	FACTOR GENE-EXPRESSION; IMMEDIATE-EARLY GENE; INHIBITION; PROTEIN; LOCALIZATION; SECTIONS; PRODUCT; MATRIX; ALPHA; CYR61	CTGF is an immediate early growth responsive gene that has been shown to be a downstream mediator of TGF beta actions in fibroblasts and vascular endothelial cells, In the present study hCTGF was isolated as immediate early target gene of EGF/TGF alpha in human pancreatic cancer cells by suppression hybridization, CTGF transcripts were found in 13/15 pancreatic cancer cell lines incubated with 10% serum, In 3/7 pancreatic cancer cell lines EGF/TGF alpha induced a significant rise of CTGF transcript levels peaking 1-2 h after the start of treatment. TGF beta increased CTGF transcript levels in 2/7 pancreatic cancer cell lines after 4 h of treatment and this elevation was sustained after 24 h, Only treatment with TGF beta was accompanied by a parallel induction of collagen type I transcription. 15/19 human pancreatic cancer tissues were shown to overexpress high levels of CTGF transcripts. CTGF transcript levels in pancreatic cancer tissues and nude mouse xenograft tumors showed a good correlation to the degree of fibrosis, III situ hybridization and the nude mouse experiments revealed that in pancreatic cancer tissues, fibroblasts are the predominant site of CTGF transcription, whereas the tumor cells appear to contribute to a lesser extent. We conclude that CTGF may be of paramount importance for the development of the characteristic desmoplastic reaction in pancreatic cancer tissues.	Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Univ Ulm, Dept Med Genet, D-89070 Ulm, Germany; Univ Ulm, Dept Gen Surg, D-89070 Ulm, Germany; Miyazaki Prefectural Gen Hosp, Miyazaki 880, Japan	Ulm University; Ulm University; Ulm University	Wenger, C (corresponding author), Univ Ulm, Dept Internal Med 1, Robert Koch Str 8, D-89081 Ulm, Germany.			Gress, Thomas/0000-0002-9333-5461				Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B; BOCKMAN DE, 1992, GASTROENTEROLOGY, V103, P1883, DOI 10.1016/0016-5085(92)91448-D; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Grau AM, 1997, CANCER RES, V57, P3929; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; IGARASHI A, 1995, J INVEST DERMATOL, V105, P280, DOI 10.1111/1523-1747.ep12318465; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; LOPEZDELEON A, 1985, J HISTOCHEM CYTOCHEM, V33, P737, DOI 10.1177/33.8.2410480; Menke A, 1997, GASTROENTEROLOGY, V113, P295, DOI 10.1016/S0016-5085(97)70107-0; Oemar BS, 1997, ARTERIOSCL THROM VAS, V17, P1483, DOI 10.1161/01.ATV.17.8.1483; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Sanvito F, 1995, BIOCHEM BIOPH RES CO, V217, P1279, DOI 10.1006/bbrc.1995.2906; Schutte M, 1996, CANCER RES, V56, P2527; TANIGUCHI S, 1992, CLIN EXP METASTAS, V10, P259; VANLAETHEM JL, 1995, GASTROENTEROLOGY, V108, P1873, DOI 10.1016/0016-5085(95)90152-3; Xin LW, 1996, J CLIN PATHOL-CL MOL, V49, pM91	22	158	168	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1073	1080		10.1038/sj.onc.1202395	http://dx.doi.org/10.1038/sj.onc.1202395			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023684				2022-12-17	WOS:000078510600025
J	Stucki, M; Pascucci, B; Parlanti, E; Fortini, P; Wilson, SH; Hubscher, U; Dogliotti, E				Stucki, M; Pascucci, B; Parlanti, E; Fortini, P; Wilson, SH; Hubscher, U; Dogliotti, E			Mammalian base excision repair by DNA polymerases delta and epsilon	ONCOGENE			English	Article						DNA repair; DNA polymerases; abasic sites	CELL NUCLEAR ANTIGEN; REPLICATION PROTEIN-A; MISMATCH REPAIR; ESCHERICHIA-COLI; CALF THYMUS; LIGASE-I; FACTOR-C; BETA; REQUIREMENT; BINDING	Two distinct pathways for completion of base excision repair (BER) have been discovered in eukaryotes: the DNA polymerase beta (Pol beta)-dependent short-patch pathway that involves the replacement of a single nucleotide and the long-patch pathway that entails the resynthesis of 2-6 nucleotides and requires PCNA, We have used cell extracts from Pol beta-deleted mouse fibroblasts to separate subfractions containing either Pol delta or Pol epsilon. These fractions were then tested for their ability to perform both short- and long-patch BER in an in vitro repair assay, using a circular DNA template, containing a single abasic site at a defined position. Remarkably, both Pol delta and Pol epsilon were able to replace a single nucleotide at the lesion site, but the repair reaction is delayed compared to single nucleotide replacement by Pol beta, Furthermore, our observations indicated, that either Pol delta and/or Pol epsilon participate in the long-patch BER. PCNA and RF-C, but not RP-A are required for this process. Our data show for the first time that Pol delta and/or Pol epsilon are directly involved in the long-patch BER of abasic sites and might function as back-up system for Pol beta in one-gap filling reactions.	Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, I-00161 Rome, Italy; Univ Zurich, Inst Vet Biochem, CH-8057 Zurich, Switzerland; NIEHS, Struct Biol Lab, Res Triangle Pk, NC 27709 USA	Istituto Superiore di Sanita (ISS); University of Zurich; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Dogliotti, E (corresponding author), Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, Vle Regina Elena 299, I-00161 Rome, Italy.		Stucki, Manuel/H-4739-2017; Parlanti, Eleonora/AAC-5978-2021; Fortini, Paola/K-1197-2018; Wilson, Samuel H/E-6644-2019	Fortini, Paola/0000-0001-6206-8498; Wilson, Samuel H/0000-0002-1702-5293; PASCUCCI, BARBARA/0000-0002-8383-8751				CHEN M, 1992, P NATL ACAD SCI USA, V89, P2516, DOI 10.1073/pnas.89.7.2516; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; CULLMANN G, 1993, GENE, V134, P191, DOI 10.1016/0378-1119(93)90093-I; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; FROSINA G, 1994, BIOCHEM J, V304, P699, DOI 10.1042/bj3040699; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HUBSCHER U, 1979, P NATL ACAD SCI USA, V76, P6284, DOI 10.1073/pnas.76.12.6284; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; JONSSON ZO, 1998, IN PRESS EMBO J; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Longley MJ, 1997, J BIOL CHEM, V272, P10917; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; UITTO L, 1995, NUCLEIC ACIDS RES, V23, P244, DOI 10.1093/nar/23.2.244; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Wang ZG, 1997, J BIOL CHEM, V272, P24064, DOI 10.1074/jbc.272.38.24064; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WEISER T, 1991, J BIOL CHEM, V266, P10420; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919	38	158	162	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					835	843		10.1038/sj.onc.1202001	http://dx.doi.org/10.1038/sj.onc.1202001			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780000				2022-12-17	WOS:000075448800005
J	Vogt, A; Qian, YM; McGuire, TF; Hamilton, AD; Sebti, SM				Vogt, A; Qian, YM; McGuire, TF; Hamilton, AD; Sebti, SM			Protein geranylgeranylation, not farnesylation, is required for the G(1) to S phase transition in mouse fibroblasts	ONCOGENE			English	Article						cell cycle; prenylation; Ras; farnesyltransferase; geranylgeranyltransferase	GTP-BINDING PROTEIN; CELLULAR RAS ACTIVITY; ACTIN STRESS FIBERS; FARNESYLTRANSFERASE INHIBITORS; SELECTIVE-INHIBITION; CDC42 GTPASES; MAP KINASE; 3T3 CELLS; GROWTH; LOVASTATIN	In order to assess the relative contributions of farnesylated and/or geranylgeranylated proteins on cell cycle progression from G(1) to S phase we designed potent and selective farnesyltransferase (FTI-277) and geranyl-geranyltransferase-I (GGTI-298) inhibitors. Flow cytometry studies showed that treatment of NIH3T3 cells with GGTI-298 or lovastatin, which inhibits both protein farnesylation and geranylgeranylation, arrested cells in G(0)/G(1) whereas cells treated with FTI-277 progressed normally through the cell cycle. [H-3]thymidine incorporation studies showed that mevalonate and geranylgeraniol, but not farnesol, released the lovastatin G(1) block. Furthermore, mevalonate release of the lovastatin G(1) block was inhibited by GGTI-298 but not by FTI-277, These results demonstrate that geranylgeranylated proteins are required for cells to proceed from G(1) to S phase, and that farnesylated proteins do not play an essential role in the G(1) to S phase transition	UNIV PITTSBURGH,SCH MED,DEPT PHARMACOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH ARTS & SCI,DEPT CHEM,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CANCER INSTITUTE [R01CA055823, U19CA067771] Funding Source: NIH RePORTER; NCI NIH HHS [U19-CA-67771, CA-55823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; ALBERTS AW, 1988, AM J CARDIOL, V62, pJ10, DOI 10.1016/0002-9149(88)90002-1; ARMSTRONG SA, 1995, J BIOL CHEM, V270, P7864, DOI 10.1074/jbc.270.14.7864; CASEY PJ, 1994, RECENT PROG HORM RES, V49, P215; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; COX AD, 1994, J BIOL CHEM, V269, P19203; DECLUE JE, 1991, CANCER RES, V51, P712; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRUNLER J, 1994, BBA-LIPID LIPID MET, V1212, P259, DOI 10.1016/0005-2760(94)90200-3; HOWE PH, 1993, J BIOL CHEM, V268, P21448; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1994, J BIOL CHEM, V269, P27705; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; Jani J. P., 1994, Cellular Pharmacology, V1, P67; KATAYAMA M, 1991, J BIOL CHEM, V266, P12639; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; LU KH, 1992, P NATL ACAD SCI USA, V89, P3889, DOI 10.1073/pnas.89.9.3889; Macchia M, 1996, J MED CHEM, V39, P1352, DOI 10.1021/jm960127s; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCGUIRE TF, 1995, BIOCHEM BIOPH RES CO, V214, P295, DOI 10.1006/bbrc.1995.2287; MCGUIRE TF, 1996, IN PRESS ONCOGENE; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Qian YM, 1996, J MED CHEM, V39, P217, DOI 10.1021/jm950414g; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIDLEY AJ, 1994, J CELL SCI S, V18, P127; SEBTI SM, 1991, CANCER COMMUN, V3, P141, DOI 10.3727/095535491820873371; SINENSKY M, 1990, J BIOL CHEM, V265, P19937; STACEY DW, 1991, ONCOGENE, V6, P2297; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; SUN JZ, 1995, CANCER RES, V55, P4243; VOGT A, 1995, J BIOL CHEM, V270, P660, DOI 10.1074/jbc.270.2.660; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; ZUBIAUR M, 1995, J BIOL CHEM, V270, P17221, DOI 10.1074/jbc.270.29.17221	50	158	161	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1991	1999						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934546				2022-12-17	WOS:A1996VR79500019
J	Gress, TM; MullerPillasch, F; Geng, M; Zimmerhackl, F; Zehetner, G; Friess, H; Buchler, M; Adler, G; Lehrach, H				Gress, TM; MullerPillasch, F; Geng, M; Zimmerhackl, F; Zehetner, G; Friess, H; Buchler, M; Adler, G; Lehrach, H			A pancreatic cancer-specific expression profile	ONCOGENE			English	Article						pancreatic cancer; EST; differential expression; cDNA; database	GENE-EXPRESSION; SEQUENCE TAGS; MOLECULAR-CLONING; HUMAN CARCINOMAS; MESSENGER-RNA; GROWTH-FACTOR; HUMAN GENOME; HUMAN BRAIN; CELL-LINES; IDENTIFICATION	We present an approach making use of technology established in the context of the genome project to describe a pancreatic cancer-specific expression profile and to identify new potential disease genes or disease-associated-genes, By use of gridded arrays of pancreatic cancer cDNA libraries and differential hybridizations we show that 4% the gridded cDNA library clones contain sequences preferentially expressed in pancreatic cancer. EST-sequencing of 369 distinct (408 total), differentially expressed sequences identified novel genes (32.5%) or homologs to EST-sequences with unknown function (26.3%). Homologies to known genes allow to determine a pancreatic cancer-specific expression profile, which provides for the first time evidence for complex primary and secondary alterations of gene expression responsible for the development of the phenotype of pancreatic cancer cells. In addition this has led to the identification of novel differentially expressed genes, which represent potential oncogenes or disease-associated markers and may be helpful for the development of therapeutic or diagnostic modalities.	UNIV ULM,DEPT INTERNAL MED 1,D-89081 ULM,GERMANY; MAX PLANCK INST MOL GENET,D-14195 BERLIN,GERMANY; UNIV BERN,INSELSPITAL,DEPT VISZERAL & TRANSPLANTAT SURG,CH-3010 BERN,SWITZERLAND	Ulm University; Max Planck Society; University of Bern; University Hospital of Bern				Gress, Thomas/0000-0002-9333-5461				ADACHI Y, 1994, J BIOL CHEM, V269, P2258; ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; ALTSCHUL SF, 1990, J MOL BIOL, V215, P402; AUGENLICHT LH, 1987, CANCER RES, V47, P6017; BALDWIN GS, 1994, P NATL ACAD SCI USA, V91, P7593, DOI 10.1073/pnas.91.16.7593; BARTKOVA J, 1995, CANCER RES, V55, P949; BARTSCH S, 1995, FEBS LETT, V357, P255, DOI 10.1016/0014-5793(94)01303-I; CHEN JS, 1995, CANCER RES, V55, P174; DRAPER MP, 1995, MOL CELL BIOL, V15, P3487; EDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186; ELSASSER HP, 1992, VIRCHOWS ARCH B, V61, P295, DOI 10.1007/BF02890431; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; FORNEROD M, 1995, ONCOGENE, V10, P1739; GIBSON S, 1993, BLOOD, V82, P1561; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GRANT AG, 1992, INT J CANCER, V51, P740; GRESS TM, 1992, MAMM GENOME, V3, P609, DOI 10.1007/BF00352477; GRESS TM, 1994, EUR J CANCER, V30A, P1391, DOI 10.1016/0959-8049(94)90191-0; GROUDINE M, 1980, P NATL ACAD SCI-BIOL, V77, P5351, DOI 10.1073/pnas.77.9.5351; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HARA E, 1993, ANAL BIOCHEM, V214, P58, DOI 10.1006/abio.1993.1456; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; HOOG C, 1991, NUCLEIC ACIDS RES, V19, P6123, DOI 10.1093/nar/19.22.6123; INKI P, 1994, BRIT J CANCER, V70, P319, DOI 10.1038/bjc.1994.300; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KLEVER P, 1992, LANCET, V340, P1158, DOI 10.1016/0140-6736(92)93183-N; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; KOTHS K, 1993, J BIOL CHEM, V268, P1425; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; LEWIN B, 1994, GENES, V5; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIU QY, 1995, ONCOGENE, V10, P619; MAIER E, 1992, NAT GENET, V1, P273, DOI 10.1038/ng0792-273; MEIEREWERT S, 1993, NATURE, V361, P375, DOI 10.1038/361375a0; MIYAGI Y, 1995, CANCER LETT, V91, P247, DOI 10.1016/0304-3835(95)03737-H; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURPHY D, 1983, CELL, V35, P865, DOI 10.1016/0092-8674(83)90119-8; MURR MM, 1994, CA-CANCER J CLIN, V44, P304, DOI 10.3322/canjclin.44.5.304; MYERS MH, 1989, CA-CANCER J CLIN, V39, P21, DOI 10.3322/canjclin.39.1.21; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; NEKARDA H, 1994, CANCER RES, V54, P2900; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; SARGENT T D, 1983, Science (Washington D C), V222, P135, DOI 10.1126/science.6688681; SCHRAML P, 1994, CANCER RES, V54, P5236; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCOTT MRD, 1983, CELL, V34, P556; SIMON B, 1994, GASTROENTEROLOGY, V106, P1645, DOI 10.1016/0016-5085(94)90422-7; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; TAKAGI S, 1995, INT J CANCER, V61, P706, DOI 10.1002/ijc.2910610519; TAKEDA J, 1993, HUM MOL GENET, V2, P1793, DOI 10.1093/hmg/2.11.1793; TAWARAGI Y, 1988, BIOCHEM BIOPH RES CO, V150, P89, DOI 10.1016/0006-291X(88)90490-1; VANERP HE, 1991, CANCER, V15, P2595; VIDAL F, 1993, P NATL ACAD SCI USA, V90, P208, DOI 10.1073/pnas.90.1.208; Vila Maya R., 1994, Zentralblatt fuer Pathologie, V140, P225; VISHWANATHA JK, 1993, CARCINOGENESIS, V14, P2575, DOI 10.1093/carcin/14.12.2575; Wagner R. P., 1993, CHROMOSOMES SYNTHESI; WATSON MA, 1994, CANCER RES, V54, P4598; WEINHOUSE S, 1983, ADV ENZYME REGUL, V21, P369, DOI 10.1016/0065-2571(83)90024-9; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; ZEHETNER G, 1994, NATURE, V367, P489, DOI 10.1038/367489a0	64	158	184	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1819	1830						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895530				2022-12-17	WOS:A1996VM88700029
J	Vairapandi, M; Balliet, AG; Fornace, AJ; Hoffman, B; Liebermann, DA				Vairapandi, M; Balliet, AG; Fornace, AJ; Hoffman, B; Liebermann, DA			The differentiation primary response gene MyD118, related to GADD45, encodes for a nuclear protein which interacts with PCNA and p21(WAF1/CIP1)	ONCOGENE			English	Article						MyD118; p21(WAF1); PCNA; Gadd45; myeloid differentiation; apoptosis	LEUKEMIA INHIBITORY FACTOR; IMMEDIATE EARLY RESPONSE; CYCLIN-DEPENDENT KINASES; TERMINAL DIFFERENTIATION; GROWTH-ARREST; CELL-DEATH; C-MYC; DNA-REPLICATION; APOPTOSIS; P53	Towards dissecting the regulation of terminal differentiation, including growth arrest and apoptosis, myeloid differentiation primary response (MyD) genes, induced in the absence of de novo protein synthesis following induction of M1 myeloblastic leukemia cells for terminal differentiation have been isolated. MyD118 was one of the novel MyD genes cloned, subsequently observed also to be a primary response gene to TGF-beta, which induces M1 cells for growth arrest and apoptosis uncoupled from differentiation. The MyD118 encoded protein was observed to be remarkably similar to the protein encoded by Gadd45, a growth arrest and DNA damage induced gene, regulated in part by the tumor suppressor p53, Though evidence has accumulated that MyD118 functions as an important modulator of negative growth control both in hematopoietic and non-hematopoietic cells, its mechanism of action is unknown, To better understand the role(s) of MyD118 in negative growth control, we have analysed the expression and biological characteristics of the MyD118 protein, compared to the Gadd45 protein, in distinct pathways of growth arrest and apoptosis, including p53 dependent and independent pathways either coupled or uncoupled from differentiation. It is shown that MyD118 and Gadd45 differentially accumulated upon induction of distinct pathways of growth arrest and apoptosis; notably, MyD118, but not Gadd45, was induced by TGF-beta, whereas Gadd45, but not MyD118, was induced by activating wild type (wt) p53 function, It is also shown that MyD118 is a nuclear protein, which regardless of the pathway induced, predominantly localized within the cell nucleus, and interacted with the DNA replication and repair protein PCNA and the cyclin dependent kinase inhibitor P21(WAF1/CIP1). MyD118 also modestly stimulated DNA repair in vitro. All of these characteristics were shared with Gadd45, Finally, it is demonstrated that MyD118, Gadd45 and p21 synergized in the suppression of colony formation by NIH3T3 cells, Taken together, these findings demonstrate that MyD118 and Gadd45 are representative of a new protein family that share remarkable functional similarities in the control of distinct pathways of negative growth, including the suppression of cellular growth and programmed cell death.	TEMPLE UNIV, SCH MED, FELS INST CANC & MOLEC BIOL, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA; NCI, DIV CANC TREATMENT, MOLEC PHARMACOL LAB, NIH, BETHESDA, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	NATIONAL CANCER INSTITUTE [R01CA043618, P30CA012227] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA43618, 5P30 CA12227] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CHEN IT, 1995, ONCOGENE, V11, P1931; COWLING GJ, 1994, PHILOS T ROY SOC B, V345, P257, DOI 10.1098/rstb.1994.0103; DIETRICH DR, 1993, CRIT REV TOXICOL, V23, P77, DOI 10.3109/10408449309104075; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; GRANA X, 1995, ONCOGENE, V11, P211; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALL PA, 1995, ONCOGENE, V10, P2427; HARPER JW, 1993, CELL, V75, P805; HAWELY RG, 1994, GENE THER, V1, P36; HE B, IN RPESS J VIROLOGY; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAZANTSEV A, 1995, SCIENCE, V270, P1003, DOI 10.1126/science.270.5238.1003; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KEARSEY JM, 1995, SCIENCE, V270, P1004; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KORSMEYER SJ, 1992, BLOOD, V80, P879; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Liebermann D A, 1994, Curr Opin Hematol, V1, P24; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARX J, 1993, SCIENCE, V259, P60; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; OLTAVI NZ, 1994, CELL, V79, P189; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; QUENSBERY PJ, 1994, EILLIAMS HEMATOLOGY, pCH22; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SMITH ML, 1995, SCIENCE, V270, P1005; STANBRIDGE EJ, 1990, CELL, V63, P867, DOI 10.1016/0092-8674(90)90490-6; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1995, INT J ONCOL, V6, P937	78	158	160	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2579	2594						16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700517				2022-12-17	WOS:A1996UW48700012
J	Marin, MC; Fernandez, A; Bick, RJ; Brisbay, S; Buja, M; Snuggs, M; McConkey, DJ; vonEschenbach, AC; Keating, MJ; McDonnell, TJ				Marin, MC; Fernandez, A; Bick, RJ; Brisbay, S; Buja, M; Snuggs, M; McConkey, DJ; vonEschenbach, AC; Keating, MJ; McDonnell, TJ			Apoptosis suppression by bcl-2 is correlated with the regulation of nuclear and cytosolic Ca2+	ONCOGENE			English	Article						apoptosis; cell death; bcl-2; calcium	PROGRAMMED CELL-DEATH; RAT-LIVER NUCLEI; DNA FRAGMENTATION; ENDOPLASMIC-RETICULUM; CA-2+ CONCENTRATION; OXIDATIVE STRESS; PROSTATE-CANCER; CALCIUM; PROTEIN; ONCOPROTEIN	Bcl-2 expression is associated with the progression of prostate cancer from androgen-dependence to androgen-independence, Bcl-2 is an integral membrane protein which localizes to mitochondria, endoplasmic reticulum, and the nuclear envelope, Using spectrofluorometry and laser confocal microscopy, the ability of bcl-2 to modulate intracellular Ca2+ was examined in the Dunning G prostate carcinoma cell line following apoptosis induction by adriamycin, Adriamycin and thapsigargin, an endoplasmic reticulum Ca2+-pump inhibitor, were effective inducers of apoptosis in control, but not bcl-2 transfected, cells, Treatment with adriamycin was accompanied by a sustained rise in cytoplasmic Ca2+ in control and bcl-2 transfected cells, An increase in intranuclear Ca2+ was observed in control cells only, Apoptosis induction by thapsigargin was associated with an increase in cytoplasmic Ca2+ in control cells that was not detected in the resistant bcl-2 transfectants, Ca2+ was excluded from nuclei isolated from bcl-2 expressing cells, but was sequestered in control nuclei, following the addition of ATP, These findings suggest that bcl-2 may regulate levels of intranuclear Ca2+ independently of cytosolic Ca2+ levels, The ability of bcl-2 to modulate, directly or indirectly, sustained increases in both cytosolic and intranuclear Ca2+ may provide a common basis for bcl-2 function in different subcellular compartments.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT UROL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL & LAB MED,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston			Marín Vieira, María del Carmen/B-8108-2015; Marin, Maria C/G-1040-2010	Marín Vieira, María del Carmen/0000-0002-7149-287X; Marin, Maria C/0000-0002-7149-287X; Buja, Louis Maximilian/0000-0001-8386-7029	NATIONAL CANCER INSTITUTE [R01CA062597] Funding Source: NIH RePORTER; NCI NIH HHS [CA62597, CA09255] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLBRITTON NL, 1994, P NATL ACAD SCI USA, V91, P12458, DOI 10.1073/pnas.91.26.12458; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bornkamm G W, 1995, Curr Top Microbiol Immunol, V194, P323; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; COLOMBEL M, 1993, AM J PATHOL, V143, P390; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; DEJONG D, 1994, CANCER RES, V54, P256; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ENGLISH HF, 1989, PROSTATE, V15, P233, DOI 10.1002/pros.2990150304; FERNANDEZ A, 1995, J IMMUNOL, V155, P5133; FERNANDEZ A, 1995, ONCOGENE, V10, P769; FURUYA Y, 1994, CANCER RES, V54, P6167; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; GIVOL I, 1994, CELL GROWTH DIFFER, V5, P419; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; JONES DP, 1983, J BIOL CHEM, V258, P6390; JONES DP, 1989, J BIOL CHEM, V264, P6398; KAMADA S, 1995, CANCER RES, V55, P354; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KASS GEN, 1992, BIOCHEM PHARMACOL, V44, P1995, DOI 10.1016/0006-2952(92)90102-O; KERR JFR, 1972, BRIT J CANCER, V26, P238; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KYPRIANOU N, 1988, PROSTATE, V13, P103, DOI 10.1002/pros.2990130203; KYPRIANOU N, 1990, CANCER RES, V50, P3748; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; LING YH, 1993, CANCER RES, V53, P1845; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARTIKAINEN P, 1990, PROSTATE, V17, P175, DOI 10.1002/pros.2990170302; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MIYASHITA T, 1992, CANCER RES, V52, P5407; MOCALI A, 1995, EXP CELL RES, V216, P388, DOI 10.1006/excr.1995.1049; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P255; MUSCHEL RJ, 1995, CANCER RES, V55, P995; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; NICOTERA P, 1988, TOXICOLOGY, V52, P55, DOI 10.1016/0300-483X(88)90196-5; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; POTMESIL M, 1988, ANTHRACYCLINE ANTHRA, P447; Powis G., 1987, METABOLISM ACTION AN, P211; ROCHE E, 1994, CELL CALCIUM, V16, P331, DOI 10.1016/0143-4160(94)90097-3; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; SKLADANOWSKI A, 1993, BIOCHEM PHARMACOL, V46, P375, DOI 10.1016/0006-2952(93)90512-U; STEHNOBITTEL L, 1995, NEURON, V14, P163, DOI 10.1016/0896-6273(95)90250-3; STEINMAN HM, 1995, J BIOL CHEM, V270, P3487; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOTI FM, 1983, J CLIN ONCOL, V1, P477; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TU SM, 1995, CANCER LETT, V93, P147, DOI 10.1016/0304-3835(95)03795-X; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN JY, 1992, DEVELOPMENT, V116, P309	73	158	162	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2259	2266						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649765				2022-12-17	WOS:A1996UQ22000002
J	FATTAEY, AR; HELIN, K; DEMBSKI, MS; DYSON, N; HARLOW, E; VUOCOLO, GA; HANOBIK, MG; HASKELL, KM; OLIFF, A; DEFEOJONES, D; JONES, RE				FATTAEY, AR; HELIN, K; DEMBSKI, MS; DYSON, N; HARLOW, E; VUOCOLO, GA; HANOBIK, MG; HASKELL, KM; OLIFF, A; DEFEOJONES, D; JONES, RE			CHARACTERIZATION OF THE RETINOBLASTOMA BINDING-PROTEINS RBP1 AND RBP2	ONCOGENE			English	Note							CELLULAR TRANSCRIPTION FACTOR; ADENOVIRUS E1A PROTEINS; LARGE T-ANTIGEN; GENE-PRODUCT; TUMOR SUPPRESSOR; CARCINOMA-CELLS; DNA-BINDING; 2 DISTINCT; FACTOR E2F; IDENTIFICATION	The retinoblastoma gene product, pRB, regulates cell proliferation by binding to and inhibiting the activity of key growth promoting proteins. Several cellular proteins have been shown to bind directly to pRB and the genes encoding a number of them have been isolated. The protein product of one of these genes is the transcription factor E2F. We have now isolated cDNA clones that contain the full-length coding sequence of two other proteins, RBP1 and RBP2, cloned originally by their interaction with pRB. The products of the RBP1 and RBP2 genes are ubiquotosly expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation. In addition we have been able to identify complexes of pRB and RBP1 in vivo that are dissociated in the presence of purified human papillomavirus E7 protein.	MERCK & CO INC,RES LABS,DEPT CANC RES,W POINT,PA 19486	Merck & Company	FATTAEY, AR (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,BLDG 149,13TH ST,BOSTON,MA 02129, USA.		Helin, Kristian/K-2526-2019; Helin, Kristian/HDM-8306-2022	Helin, Kristian/0000-0003-1975-6097				Ausubel FM, 1988, CURRENT PROTOCOLS MO, V1; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, IN PRESS MOL CELL BI; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PETERSON MG, 1991, NATURE, V354, P369; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; STIRDIVANT SM, 1992, MOL CELL BIOL, V12, P1905, DOI 10.1128/MCB.12.5.1905; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; WANG PN, 1993, ONCOGENE, V8, P279; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	48	158	167	1	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3149	3156						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414517				2022-12-17	WOS:A1993MC09300032
J	DUMONT, DJ; GRADWOHL, GJ; FONG, GH; AUERBACH, R; BREITMAN, ML				DUMONT, DJ; GRADWOHL, GJ; FONG, GH; AUERBACH, R; BREITMAN, ML			THE ENDOTHELIAL-SPECIFIC RECEPTOR TYROSINE KINASE, TEK, IS A MEMBER OF A NEW SUBFAMILY OF RECEPTORS	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTORS; IMMUNOGLOBULIN SUPERFAMILY; BINDING-SITE; CELL-LINE; HETEROGENEITY; SEQUENCE; DOMAINS; GAP; DNA	We have cloned a 4.2-kb murine cDNA encoding the Tek receptor tyrosine kinase (RTK), which is expressed in endothelial cells and their progenitors. The 1122-residue protein contains an extracellular domain comprising three fibronectin type III repeats fused to two immunoglobulin-like loops that are in turn separated by three epidermal growth factor-like repeats. The association of these different structural motifs and their characteristic arrangement in the Tek extracellular domain has been reported for only one other RTK, Tie, an endothelial-specific RTK of human origin. We show here that Tek and Tie are encoded by distinct genes and that, together, these receptors define a new subfamily of RTKs. In addition, we demonstrate that the tek cDNA, when introduced into COS cells, encodes a product of 140 kDa and that this protein and/or tek transcripts are detectable in highly vascularized embryonic tissues and in some, but not all, cell lines of endothelial origin.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV WISCONSIN,CTR DEV BIOL,MADISON,WI 53706	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Wisconsin System; University of Wisconsin Madison			Gradwohl, Gérard/H-8543-2014; Gradwohl, Gérard/AFM-9024-2022	Gradwohl, Gérard/0000-0002-6730-2615; Gradwohl, Gérard/0000-0002-6730-2615				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUBOIS NA, 1991, EXP CELL RES, V196, P302, DOI 10.1016/0014-4827(91)90265-V; DUMONT JD, 1992, ONCOGENE, V7, P1471; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GERRITSEN ME, 1987, BIOCHEM PHARMACOL, V36, P2701, DOI 10.1016/0006-2952(87)90252-8; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; GUMKOWSKI F, 1987, BLOOD VESSELS, V24, P11; HARLOW E, 1988, ANTIBODIES LABORATOR; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097; NODEN DM, 1988, DEVELOPMENT, V103, P121; OBESO J, 1990, LAB INVEST, V63, P259; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PENDL J, 1992, IN PRESS DEV BIOL; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Sambrook J., 1989, MOL CLONING LAB MANU; SCWARZBAUER JE, 1987, EMBO J, V6, P2573; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TERMAN BI, 1991, ONCOGENE, V6, P1677; WAGNER RC, 1980, ADV MICROCIRCULAT, V9, P45; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YAMAGUCHI TP, 1993, IN PRESS DEVELOPMENT	32	158	180	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1293	1301						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8386827				2022-12-17	WOS:A1993KY32800022
J	WATERS, CM; LITTLEWOOD, TD; HANCOCK, DC; MOORE, JP; EVAN, GI				WATERS, CM; LITTLEWOOD, TD; HANCOCK, DC; MOORE, JP; EVAN, GI			C-MYC PROTEIN EXPRESSION IN UNTRANSFORMED FIBROBLASTS	ONCOGENE			English	Article							MESSENGER-RNA; CELL-CYCLE; ENCODED PROTEINS; GROWTH-FACTORS; ONCOGENE; TRANSCRIPTION; SERUM; GENE; LOCALIZATION; IDENTIFICATION	We have examined and quantitated the expression of c-myc protein in two untransformed fibroblast cell lines, murine Swiss 3T3 and human MRC-5. c-myc protein is not detectable in quiescent cells, but it is rapidly induced upon mitogenic stimulation. Peak expression is seen about 3-5 h after serum stimulation, and corresponds to about 3-6000 molecules per cell (mpc). Thereafter, levels fall back to a quiescent level in confluent fibroblasts, but remain elevated at 1-3000 mpc in subconfluent cells. The c-myc protein is phosphorylated and has the same size and short half-life as seen in tumour cells. Removal of serum growth factors from the culture medium causes very rapid loss of the c-myc protein from all cells, irrespective of their positions in the cell cycle. Thus, c-myc expression is continuously dependent upon the presence of mitogens. However, no single tested mitogen is obligatory for maintenance of expression in proliferating cells. Growth arrest of cells, either by metabolite starvation or by drugs which inhibit DNA synthesis, does not affect expression of the c-myc protein, which remains completely dependent upon the presence of mitogens. These data are consistent with the c-myc protein's having a continuous role in proliferating cells as an intracellular integrator of growth regulatory signalling pathways.			EVAN, GI (corresponding author), IMPERIAL CANC RES FUND, DOMINION HOUSE, 59 BARTHOLOMEW CLOSE, LONDON EC1A 7BE, ENGLAND.							ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEAN M, 1986, J BIOL CHEM, V261, P9161; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EISENMAN RN, 1985, MOL CELL BIOL, V5, P114, DOI 10.1128/MCB.5.1.114; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EVAN GI, 1986, CURR TOP MICROBIOL, V132, P362; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; JONAK GJ, 1984, P NATL ACAD SCI-BIOL, V81, P1747, DOI 10.1073/pnas.81.6.1747; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; KRONKE M, 1987, P NATL ACAD SCI USA, V84, P469, DOI 10.1073/pnas.84.2.469; LARSSON O, 1985, J CELL SCI, V75, P259; LUSCHER B, 1986, INT S PRINCESS TAKAM, V17, P291; MOORE JP, 1987, ONCOGENE RES, V2, P65; OKUDA A, 1989, EXP CELL RES, V185, P258, DOI 10.1016/0014-4827(89)90054-2; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PERSSON H, 1985, MOL CELL BIOL, V5, P2903, DOI 10.1128/MCB.5.11.2903; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; WATERS CM, 1990, ONCOGENE, V5, P669	32	158	162	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1991	6	5					797	805						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	2052358				2022-12-17	WOS:A1991GT82500016
J	VISVADER, J; BEGLEY, CG; ADAMS, JM				VISVADER, J; BEGLEY, CG; ADAMS, JM			DIFFERENTIAL EXPRESSION OF THE LYL, SCL AND E2A HELIX-LOOP-HELIX GENES WITHIN THE HEMATOPOIETIC SYSTEM	ONCOGENE			English	Article							T-CELL LEUKEMIA; DNA-BINDING MOTIF; CHROMOSOMAL TRANSLOCATION; DROSOPHILA-MELANOGASTER; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS; ENHANCER BINDING; MESSENGER-RNA; PROTEIN; MYC	The helix-loop-helix genes LYL, SCL and E2A are associated with chromosome translocations found in human lymphoid leukemias. To establish their hematopoietic expression patterns, we have isolated murine LYL and SCL cDNA clones and investigated the expression of all three genes by Northern blot analysis of 58 murine hemopoietic cell lines and tissues. The nucleotide sequences of LYL cDNA clones revealed alternative 5' untranslated sequences and differential splicing within the 5' portion of the coding region that may produce a LYL polypeptide lacking an N-terminal segment. The LYL gene was expressed in most myeloid, erythroid and B lymphocyte cell lines and displayed two alternative size classes of transcripts, the smaller size class (1.5-1.8 kb) being typical of the erythroid lineage and the larger class (2.0-2.3 kb) of the B cell lineage. These two size classes were found to differ in the 5' untranslated region. Thus, expression of the LYL gene appears to be differentially regulated in different hemopoietic cell types. In contrast, the E2A gene was expressed throughout the hemopoietic compartment as a single dominant transcript (3.5 kb). SCL expression was restricted to erythroid, mast and early myeloid cell lines, and the level of SCL transcripts (3.0 and 4.7 kb species) increased markedly during DMSO-induced differentiation of erythroleukemia cells. Hence the SCL gene product may be an important regulatory factor for the erythroid lineage. The low or undetectable expression of both SCL and LYL in most T lymphoid cell sources is consistent with the view that the translocations of these genes in human T cell leukemias alter their normal regulation and may thereby contribute to neoplasia.			VISVADER, J (corresponding author), ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA.		Adams, Jerry M/E-1199-2013	Adams, Jerry/0000-0002-4360-8628	NATIONAL CANCER INSTITUTE [R01CA012421] Funding Source: NIH RePORTER; NCI NIH HHS [CA12421] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ANDERSSON J, 1972, EUR J IMMUNOL, V2, P349, DOI 10.1002/eji.1830020410; ANDRE C, 1989, ONCOGENE, V4, P1047; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CULVENOR JG, 1981, J IMMUNOL, V126, P1974; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DUBE SK, 1975, P NATL ACAD SCI USA, V72, P1863, DOI 10.1073/pnas.72.5.1863; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; HAMILTON JA, 1988, BLOOD, V71, P1574; HARRIS AW, 1988, CURR TOP MICROBIOL, V141, P82; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kelso A, 1989, GROWTH FACTORS, V1, P165, DOI 10.3109/08977198909029126; Kinashi T, 1989, INT IMMUNOL, V1, P11, DOI 10.1093/intimm/1.1.11; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MELLENTIN JD, 1989, SCIENCE, V246, P379, DOI 10.1126/science.2799390; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PERKINS A, 1990, IN PRESS P NATL ACAD; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; STRASSER A, 1990, IN PRESS NATURE; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8	41	158	160	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1991	6	2					187	194						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	2000219				2022-12-17	WOS:A1991FZ13400002
J	Horiguchi, K; Sakamoto, K; Koinuma, D; Semba, K; Inoue, A; Inoue, S; Fujii, H; Yamaguchi, A; Miyazawa, K; Miyazono, K; Saitoh, M				Horiguchi, K.; Sakamoto, K.; Koinuma, D.; Semba, K.; Inoue, A.; Inoue, S.; Fujii, H.; Yamaguchi, A.; Miyazawa, K.; Miyazono, K.; Saitoh, M.			TGF-beta drives epithelial-mesenchymal transition through delta EF1-mediated downregulation of ESRP	ONCOGENE			English	Article						alternative splicing; delta EF1; EMT; TGF-beta; ESRP; breast cancer	GROWTH-FACTOR-BETA; BREAST-CANCER; CELL-LINES; METASTASIS; NETWORKS; PROGRESSION; EXPRESSION; RECEPTORS; INDUCTION; INSIGHTS	Epithelial-mesenchymal transition (EMT) is a crucial event in wound healing, tissue repair and cancer progression in adult tissues. We have recently shown that transforming growth factor (TGF)-beta-induced EMT involves isoform switching of fibroblast growth factor receptors by alternative splicing. We performed a microarray-based analysis at single exon level to elucidate changes in splicing variants generated during TGF-beta-induced EMT, and found that TGF-beta induces broad alteration of splicing patterns by downregulating epithelial splicing regulatory proteins (ESRPs). This was achieved by TGF-beta-mediated upregulation of delta EF1 family proteins, delta EF1 and SIP1. delta EF1 and SIP1 each remarkably repressed ESRP2 transcription through binding to the ESRP2 promoter in NMuMG cells. Silencing of both delta EF1 and SIP1, but not either alone, abolished the TGF-beta-induced ESRP repression. The expression profiles of ESRPs were inversely related to those of delta EF1 and SIP in human breast cancer cell lines and primary tumor specimens. Further, overexpression of ESRPs in TGF-beta-treated cells resulted in restoration of the epithelial splicing profiles as well as attenuation of certain phenotypes of EMT. Therefore, delta EF1 family proteins repress the expression of ESRPs to regulate alternative splicing during TGF-beta-induced EMT and the progression of breast cancers. Oncogene (2012) 31, 3190-3201; doi:10.1038/onc.2011.493; published online 31 October 2011	[Miyazono, K.] Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan; [Sakamoto, K.; Yamaguchi, A.] Tokyo Med & Dent Univ, Sect Oral Pathol, Grad Sch Med & Dent Sci, Tokyo, Japan; [Semba, K.] Waseda Univ, Dept Life Sci & Med Biosci, Tokyo, Japan; [Inoue, A.; Inoue, S.; Fujii, H.] Univ Yamanashi, Dept Surg 1, Interdisciplinary Grad Sch Med & Engn, Tamaho, Yamanashi, Japan; [Miyazawa, K.; Saitoh, M.] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Biochem, Tamaho, Yamanashi, Japan	University of Tokyo; Tokyo Medical & Dental University (TMDU); Waseda University; University of Yamanashi; University of Yamanashi	Miyazono, K (corresponding author), Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono@m.u-tokyo.ac.jp; msaitoh-ind@umin.ac.jp	MIYAZAWA, KEIJI/I-9713-2014; Koinuma, Daizo/Y-8716-2018	Koinuma, Daizo/0000-0001-5611-2122	University of Yamanashi from Ministry of Education, Culture, Sports, Science and Technology of Japan; Japan Society for the Promotion of Science; Waseda University from the Ministry of Education, Culture, Sports, Science and Technology of Japan; Grants-in-Aid for Scientific Research [22249061, 22112002, 09J05735, 22390052, 11F01113] Funding Source: KAKEN	University of Yamanashi from Ministry of Education, Culture, Sports, Science and Technology of Japan; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Waseda University from the Ministry of Education, Culture, Sports, Science and Technology of Japan; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Drs T Shirakihara, S Ehata, M Morikawa and C Iwata for their helpful discussions. This work was supported by KAKENHI (Grants-in-Aid for Scientific Research) and Cooperative Program for Graduate Student Education between University of Yamanashi and Waseda University from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms) from the Japan Society for the Promotion of Science.	Blencowe BJ, 2006, CELL, V126, P37, DOI 10.1016/j.cell.2006.06.023; Chaffer CL, 2007, DIFFERENTIATION, V75, P831, DOI 10.1111/j.1432-0436.2007.00210.x; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Coumoul Xavier, 2003, Birth Defects Research, V69, P286, DOI 10.1002/bdrc.10025; Dutertre M, 2010, CANCER RES, V70, P896, DOI 10.1158/0008-5472.CAN-09-2703; Ehata S, 2007, CANCER RES, V67, P9694, DOI 10.1158/0008-5472.CAN-07-1522; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Horiguchi K, 2009, J BIOL CHEM, V284, P245, DOI 10.1074/jbc.M804777200; Hoshino Y, 2011, J BIOCHEM, V149, P55, DOI 10.1093/jb/mvq114; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Koinuma D, 2009, MOL CELL BIOL, V29, P172, DOI 10.1128/MCB.01038-08; Lee B, 2008, BIOINFORMATICS, V24, P1026, DOI 10.1093/bioinformatics/btn068; Licatalosi DD, 2010, NAT REV GENET, V11, P75, DOI 10.1038/nrg2673; Matlin AJ, 2005, NAT REV MOL CELL BIO, V6, P386, DOI 10.1038/nrm1645; Miyazono K, 2009, P JPN ACAD B-PHYS, V85, P314, DOI 10.2183/pjab.85.314; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Philippar U, 2008, DEV CELL, V15, P813, DOI 10.1016/j.devcel.2008.09.003; Rasche A, 2010, BIOINFORMATICS, V26, P84, DOI 10.1093/bioinformatics/btp626; Shirakihara T, 2007, MOL BIOL CELL, V18, P3533, DOI 10.1091/mbc.E07-03-0249; Shirakihara T, 2011, EMBO J, V30, P783, DOI 10.1038/emboj.2010.351; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang GS, 2007, NAT REV GENET, V8, P749, DOI 10.1038/nrg2164; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Warzecha CC, 2009, RNA BIOL, V6, P546, DOI 10.4161/rna.6.5.9606; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Yamaguchi N, 2008, BIOCHEM BIOPH RES CO, V365, P711, DOI 10.1016/j.bbrc.2007.11.064; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	33	157	160	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	26					3190	3201		10.1038/onc.2011.493	http://dx.doi.org/10.1038/onc.2011.493			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	967UX	22037216	hybrid, Green Published			2022-12-17	WOS:000305934400007
J	Tong, ZT; Cai, MY; Wang, XG; Kong, LL; Mai, SJ; Liu, YH; Zhang, HB; Liao, YJ; Zheng, F; Zhu, W; Liu, TH; Bian, XW; Guan, XY; Lin, MC; Zeng, MS; Zeng, YX; Kung, HF; Xie, D				Tong, Z-T; Cai, M-Y; Wang, X-G; Kong, L-L; Mai, S-J; Liu, Y-H; Zhang, H-B; Liao, Y-J; Zheng, F.; Zhu, W.; Liu, T-H; Bian, X-W; Guan, X-Y; Lin, M. C.; Zeng, M-S; Zeng, Y-X; Kung, H-F; Xie, D.			EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin	ONCOGENE			English	Article						nasopharyngeal carcinoma; EZH2; E-cadherin; HDAC; Snail	TRANSCRIPTION FACTOR SNAIL; EMBRYONIC STEM-CELLS; GROUP PROTEIN EZH2; ZESTE HOMOLOG-2; DEVELOPMENTAL REGULATORS; HEPATOCELLULAR-CARCINOMA; GENE-EXPRESSION; POOR-PROGNOSIS; GASTRIC-CANCER; POLYCOMB	The enhancer of zeste homolog 2 (EZH2) is upregulated and has an oncogenic role in several types of human cancer. However, the abnormalities of EZH2 and its underlying mechanisms in the pathogenesis of nasopharyngeal carcinoma (NPC) remain unknown. In this study, we found that high expression of EZH2 in NPC was associated closely with an aggressive and/or poor prognostic phenotype (P<0.05). In NPC cell lines, knockdown of EZH2 by short hairpin RNA was sufficient to inhibit cell invasiveness/metastasis both in vitro and in vivo, whereas ectopic overexpression of EZH2 supported NPC cell invasive capacity with a decreased expression of E-cadherin. In addition, ablation of endogenous Snail in NPC cells virtually totally prevented the repressive activity of EZH2 to E-cadherin, indicating that Snail might be a predominant mediator of EZH2 to suppress E-cadherin. Furthermore, co-immunoprecipitation (IP), chromatin IP and luciferase reporter assays demonstrated that in NPC cells, (1) EZH2 interacted with HDAC1/HDAC2 and Snail to form a repressive complex; (2) these components interact in a linear fashion, not in a triangular fashion, that is, HDAC1 or HDAC2 bridge the interaction between EZH2 and Snail; and (3) the EZH2/HDAC1/2/Snail complex could closely bind to the E-cadherin promoter by Snail, but not YY1, to repress E-cadherin. The data provided in this report suggest a critical role of EZH2 in the control of cell invasion and/or metastasis by forming a co-repressor complex with HDAC1/HDAC2/Snail to repress E-cadherin, an activity that might be responsible, at least in part, for the development and/or progression of human NPCs. Oncogene (2012) 31, 583-594; doi:10.1038/onc.2011.254; published online 20 June 2011	[Tong, Z-T; Cai, M-Y; Mai, S-J; Liao, Y-J; Zheng, F.; Zhu, W.; Liu, T-H; Guan, X-Y; Zeng, M-S; Zeng, Y-X; Kung, H-F; Xie, D.] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, Guangzhou 510060, Guangdong, Peoples R China; [Tong, Z-T; Mai, S-J; Liao, Y-J; Zheng, F.; Zhu, W.; Liu, T-H; Guan, X-Y; Zeng, M-S; Zeng, Y-X; Xie, D.] Sun Yat Sen Univ, Ctr Canc, Dept Expt Res, Guangzhou 510060, Guangdong, Peoples R China; [Tong, Z-T; Kong, L-L] An Hui Med Univ, Affiliated Hosp 1, Dept Radiotherapy, Hefei, Peoples R China; [Wang, X-G] Sun Yat Sen Univ, Zhong Shan Sch Med, Dept Pharmacol, Guangzhou 510060, Guangdong, Peoples R China; [Liu, Y-H] Guangdong Prov Peoples Hosp, Dept Pathol, Guangzhou, Guangdong, Peoples R China; [Zhang, H-B] Guangdong Prov Peoples Hosp, Dept Otolaryngol, Guangzhou, Guangdong, Peoples R China; [Bian, X-W] Third Mil Med Univ, SW Hosp, Inst Pathol, Chongqing, Peoples R China; [Bian, X-W] Third Mil Med Univ, SW Hosp, SW Canc Ctr, Chongqing, Peoples R China; [Lin, M. C.; Kung, H-F] Chinese Univ Hong Kong, State Key Lab Oncol S China, Hong Kong, Hong Kong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Anhui Medical University; Sun Yat Sen University; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Army Medical University; Army Medical University; Chinese University of Hong Kong	Xie, D (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, 651 Dongfeng Rd E,Room 634, Guangzhou 510060, Guangdong, Peoples R China.	xied@mail.sysu.edu.cn	LIAO, YIJI/Z-4902-2019; Bian, Xiu-Wu/D-4736-2017; mai, sj/HGE-8908-2022; /A-3639-2009; Guan, Xin-Yuan/A-3639-2009	LIAO, YIJI/0000-0002-0849-4573; Bian, Xiu-Wu/0000-0003-4383-0197; zeng, musheng/0000-0003-3509-5591; /0000-0003-1874-9805; Guan, Xin-Yuan/0000-0002-4485-6017; Zhu, Wei-Guo/0000-0001-8385-6581	Foundation of Guangzhou Science and Technology Bureau, China [2005Z1-E0131]; 973 Project of China [2010CB912802, 2010CB529400]	Foundation of Guangzhou Science and Technology Bureau, China; 973 Project of China(National Basic Research Program of China)	We thank Dr Clifford W Welsch (Michigan State University) for his valuable comments and extensive edit for the paper. This work was supported by the Foundation of Guangzhou Science and Technology Bureau, China (2005Z1-E0131 to DX and HFK) and the 973 Project of China (2010CB912802 to HFK and 2010CB529400 to XWB and MCL).	Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Cai MY, 2011, GUT, V60, P967, DOI 10.1136/gut.2010.231993; Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904; Chen YC, 2007, HEPATOLOGY, V46, P200, DOI 10.1002/hep.21668; Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533; FANDI A, 1994, SEMIN ONCOL, V21, P382; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fujii S, 2008, CANCER SCI, V99, P738, DOI 10.1111/j.1349-7006.2008.00743.x; He LR, 2010, INT J CANCER, V127, P138, DOI 10.1002/ijc.25031; Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08; Kidani K, 2009, ORAL ONCOL, V45, P39, DOI 10.1016/j.oraloncology.2008.03.016; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lo KW, 2004, CANCER CELL, V5, P423, DOI 10.1016/S1535-6108(04)00119-9; Matsukawa Y, 2006, CANCER SCI, V97, P484, DOI 10.1111/j.1349-7006.2006.00203.x; Mimori K, 2005, EJSO-EUR J SURG ONC, V31, P376, DOI 10.1016/j.ejso.2004.11.001; Muller J, 2006, CURR OPIN GENET DEV, V16, P476, DOI 10.1016/j.gde.2006.08.005; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Raman JD, 2005, CLIN CANCER RES, V11, P8570, DOI 10.1158/1078-0432.CCR-05-1047; Rao ZY, 2010, CARCINOGENESIS, V31, P1576, DOI 10.1093/carcin/bgq150; Satijn DPE, 2001, MOL CELL BIOL, V21, P1360, DOI 10.1128/MCB.21.4.1360-1369.2001; Schwartz YB, 2007, NAT REV GENET, V8, P9, DOI 10.1038/nrg1981; Schwartz YB, 2006, NAT GENET, V38, P700, DOI 10.1038/ng1817; Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531; Tiwari VK, 2008, PLOS BIOL, V6, P2911, DOI 10.1371/journal.pbio.0060306; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004; Wang L, 2004, MOL CELL, V14, P637, DOI 10.1016/j.molcel.2004.05.009; Wei William I, 2007, Curr Opin Otolaryngol Head Neck Surg, V15, P99, DOI 10.1097/MOO.0b013e3280148a06; Wilkinson F, 2010, J CELL BIOCHEM, V109, P478, DOI 10.1002/jcb.22424; Xie D, 2003, INT J CANCER, V107, P896, DOI 10.1002/ijc.11514	40	157	175	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	5					583	594		10.1038/onc.2011.254	http://dx.doi.org/10.1038/onc.2011.254			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21685935				2022-12-17	WOS:000300221800005
J	Hwang-Verslues, WW; Chang, PH; Wei, PC; Yang, CY; Huang, CK; Kuo, WH; Shew, JY; Chang, KJ; Lee, EYHP; Lee, WH				Hwang-Verslues, W. W.; Chang, P-H; Wei, P-C; Yang, C-Y; Huang, C-K; Kuo, W-H; Shew, J-Y; Chang, K-J; Lee, E. Y-H P.; Lee, W-H			miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1	ONCOGENE			English	Article						miR-495; breast cancer stem cell; REDD1; E-cadherin; E12/E47; hypoxia resistance	INDUCIBLE FACTORS; SELF-RENEWAL; EXPRESSION; MICRORNA; METASTASIS; GROWTH; GENES; MTOR; PROLIFERATION; ACTIVATION	MicroRNAs (miRNAs) are involved in tumorigenecity by regulating specific oncogenes and tumor suppressor genes, and their roles in breast cancer stem cells (BCSCs) are becoming apparent. Distinct from the CD44(+)/CD24(-/low) sub-population, we have isolated a novel PROCR(+)/ESA(+) BCSC sub-population. To explore miRNA-regulatory mechanisms in this sub-population, we performed miRNA expression profiling and found miR-495 as the most highly upegulated miRNA in PROCR(+)/ESA(+) cells. Coincidently, high upregulation of miR-495 was also found in CD44(+)/CD24(-/low) BCSCs, reflecting its potential importance in maintaining common BCSC properties. Ectopic expression of miR-495 in breast cancer cells promoted their colony formation in vitro and tumorigenesis in mice. miR-495 directly suppressed E-cadherin expression to promote cell invasion and inhibited REDD1 expression to enhance cell proliferation in hypoxia through post-transcriptional mechanism. miR-495 expression was directly modulated by transcription factor E12/E47, which itself is highly expressed in BCSCs. These findings reveal a novel regulatory pathway centered on miR-495 that contributes to BCSC properties and hypoxia resistance. Oncogene (2011) 30, 2463-2474; doi:10.1038/onc.2010.618; published online 24 January 2011	[Lee, W-H] Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; [Hwang-Verslues, W. W.; Chang, P-H; Wei, P-C; Yang, C-Y; Huang, C-K; Shew, J-Y; Lee, E. Y-H P.; Lee, W-H] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Kuo, W-H; Chang, K-J] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; [Chang, K-J] Cheng Ching Gen Hosp, Taichung, Taiwan; [Lee, E. Y-H P.] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA	University of California System; University of California Irvine; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University Hospital; University of California System; University of California Irvine	Lee, WH (corresponding author), Univ Calif Irvine, Dept Biol Chem, 124 Sprague Hall, Irvine, CA 92697 USA.	whlee@uci.edu		Wei, Pei-Chi/0000-0002-3309-0511; Hwang-Verslues, Wendy/0000-0002-0383-1710; KUO, WEN-HUNG/0000-0002-9881-4605; Chang, King jen/0000-0001-9811-3422	Academia Sinica [2371, 4012]; Postdocotral Research Fellowship; NATIONAL CANCER INSTITUTE [R01CA094170] Funding Source: NIH RePORTER	Academia Sinica(Academia Sinica - Taiwan); Postdocotral Research Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Academia Sinica Peak Project (grant number 2371, 4012); and an Academia Sinica Distinguished Postdocotral Fellowship and a Postdocotral Research Fellowship to WWHV. We thank Dr Paul E Verslues (Institute of Plant and Microbial Biology, Academia Sinica) for critical proofreading of the manuscript and Ms Meng-Han Wang for her kind assistance through this study.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; DeYoung MP, 2008, GENE DEV, V22, P239, DOI 10.1101/gad.1617608; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Guttilla IK, 2009, J BIOL CHEM, V284, P23204, DOI 10.1074/jbc.M109.031427; Heddleston JM, 2010, BRIT J CANCER, V102, P789, DOI 10.1038/sj.bjc.6605551; Heddleston JM, 2009, CELL CYCLE, V8, P3274, DOI 10.4161/cc.8.20.9701; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Hwang-Verslues WW, 2008, MOL ENDOCRINOL, V22, P78, DOI 10.1210/me.2007-0298; Hwang-Verslues WW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008377; Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317; Karolchik D, 2004, NUCLEIC ACIDS RES, V32, pD493, DOI 10.1093/nar/gkh103; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Mattie MD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-24; McCord AM, 2009, MOL CANCER RES, V7, P489, DOI 10.1158/1541-7786.MCR-08-0360; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Pietersen AM, 2008, CURR BIOL, V18, P1094, DOI 10.1016/j.cub.2008.06.070; Place RF, 2008, P NATL ACAD SCI USA, V105, P1608, DOI 10.1073/pnas.0707594105; Qi JL, 2009, CELL CYCLE, V8, P3729, DOI 10.4161/cc.8.22.10033; Reiling JH, 2004, GENE DEV, V18, P2879, DOI 10.1101/gad.322704; Semerad CL, 2009, P NATL ACAD SCI USA, V106, P1930, DOI 10.1073/pnas.0808866106; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Slattery C, 2006, FEBS LETT, V580, P4021, DOI 10.1016/j.febslet.2006.06.039; Soeda A, 2009, ONCOGENE, V28, P3949, DOI 10.1038/onc.2009.252; Stefani G, 2008, NAT REV MOL CELL BIO, V9, P219, DOI 10.1038/nrm2347; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Winter SL, 2007, NEOPLASIA, V9, P797, DOI 10.1593/neo.07595; Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855; Yang XM, 2009, BREAST CANCER RES TR, V117, P423, DOI 10.1007/s10549-008-0133-z; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054	44	157	164	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	21					2463	2474		10.1038/onc.2010.618	http://dx.doi.org/10.1038/onc.2010.618			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	769JF	21258409				2022-12-17	WOS:000291008000008
J	Ewald, B; Sampath, D; Plunkett, W				Ewald, B.; Sampath, D.; Plunkett, W.			Nucleoside analogs: molecular mechanisms signaling cell death	ONCOGENE			English	Review						stalled replication forks; DNA damage; DNA repair; sensors; checkpoints; DNA methylation	CHRONIC LYMPHOCYTIC-LEUKEMIA; S-PHASE CHECKPOINT; NIJMEGEN BREAKAGE SYNDROME; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; NUCLEOTIDE EXCISION-REPAIR; STALLED REPLICATION FORKS; EARLY EMBRYONIC LETHALITY; HUMAN DNA-POLYMERASES; DOUBLE-STRAND BREAKS; HISTONE DEACETYLASE INHIBITORS	Nucleoside analogs are structurally similar antimetabolites that have a broad range of action and are clinically active in both solid tumors and hematological malignancies. Many of these agents are incorporated into DNA by polymerases during normal DNA synthesis, an action that blocks further extension of the nascent strand and causes stalling of replication forks. The molecular mechanisms that sense stalled replication forks activate cell cycle checkpoints and DNA repair processes, which may contribute to drug resistance. When replication forks are not stabilized by these molecules or when subsequent DNA repair processes are overwhelmed, apoptosis is initiated either by these same DNA damage sensors or by alternative mechanisms. Recently, strategies aimed at targeting DNA damage checkpoints or DNA repair processes have demonstrated effectiveness in sensitizing cells to nucleoside analogs, thus offering a means to elude drug resistance. In addition to their DNA synthesis-directed actions many nucleoside analogs trigger apoptosis by unique mechanisms, such as causing epigenetic modi. cations or by direct activation of the apoptosome. A review of the cellular and molecular responses to clinically relevant agents provides an understanding of the mechanisms that cause apoptosis and may provide rationale for the development of novel therapeutic strategies.	[Plunkett, W.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 71, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Plunkett, W (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 71, 1515 Holcombe Blvd, Houston, TX 77030 USA.	wplunket@mdanderson.org	Sampath, Deepa/J-3298-2016; Sampath, Deepa/T-5069-2019	Sampath, Deepa/0000-0002-4366-8436	National Cancer Institute [CA28596, CA32839, CA81534, CA100632]; NIH; NATIONAL CANCER INSTITUTE [R21CA100623, R01CA028596, R01CA032839, P20CA081534, P01CA081534] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Lisa S Chen for her assistance with chemical structures. Portions of the work described from the authors' laboratories were supported by Grants CA28596, CA32839, CA81534, and CA100632 from the National Cancer Institute, NIH.	Achanta G, 2001, CANCER RES, V61, P8723; AGARWAL RP, 1982, PHARMACOL THERAPEUT, V17, P399, DOI 10.1016/0163-7258(82)90023-7; Ahluwalia A, 2001, GYNECOL ONCOL, V82, P261, DOI 10.1006/gyno.2001.6291; Azuma A, 2001, MOL PHARMACOL, V59, P725, DOI 10.1124/mol.59.4.725; BAKER CH, 1991, J MED CHEM, V34, P1879, DOI 10.1021/jm00110a019; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Balakrishnan K, 2006, BLOOD, V108, P2392, DOI 10.1182/blood-2006-03-007468; Bantia S, 2003, INT IMMUNOPHARMACOL, V3, P879, DOI 10.1016/S1567-5769(03)00076-6; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Bellosillo B, 2002, BLOOD, V100, P1810, DOI 10.1182/blood-2001-12-0327; BIANCHI V, 1992, EXP CELL RES, V199, P120, DOI 10.1016/0014-4827(92)90469-O; Brown EJ, 2000, GENE DEV, V14, P397; Brueckner B, 2007, CANCER J, V13, P17, DOI 10.1097/PPO.0b013e31803c7245; Bueno MJ, 2008, CANCER CELL, V13, P496, DOI 10.1016/j.ccr.2008.04.018; Burma S, 2004, DNA REPAIR, V3, P909, DOI 10.1016/j.dnarep.2004.03.021; Buschfort C, 1997, CANCER RES, V57, P651; Busino L, 2004, ONCOGENE, V23, P2050, DOI 10.1038/sj.onc.1207394; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CARSON DA, 1986, EXP CELL RES, V164, P273, DOI 10.1016/0014-4827(86)90028-5; CARSON DA, 1992, P NATL ACAD SCI USA, V89, P2970, DOI 10.1073/pnas.89.7.2970; CARSON DA, 1983, BLOOD, V62, P737; CARSON DA, 1990, SEMIN HEMATOL, V27, P260; Catovsky D, 2007, LANCET, V370, P230, DOI 10.1016/S0140-6736(07)61125-8; Chaney SG, 1996, JNCI-J NATL CANCER I, V88, P1346, DOI 10.1093/jnci/88.19.1346; CHANG CN, 1992, J BIOL CHEM, V267, P13938; Chen R, 2005, BLOOD, V106, P2513, DOI 10.1182/blood-2005-04-1678; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399; Chou KM, 2000, J BIOL CHEM, V275, P31009, DOI 10.1074/jbc.M004082200; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Costanzo V, 2001, MOL CELL, V8, P137, DOI 10.1016/S1097-2765(01)00294-5; Crews KR, 2002, J CLIN ONCOL, V20, P4217, DOI 10.1200/JCO.2002.10.006; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; de Toledo SM, 2000, ONCOGENE, V19, P6185, DOI 10.1038/sj.onc.1204020; Delacroix S, 2007, GENE DEV, V21, P1472, DOI 10.1101/gad.1547007; Dewson G, 2003, ONCOGENE, V22, P2643, DOI 10.1038/sj.onc.1206326; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Eastman A, 2002, MOL CANCER THER, V1, P1067; Eichhorst BF, 2006, BLOOD, V107, P885, DOI 10.1182/blood-2005-06-2395; EWALD B, 2008, CANC RES IN PRESS; Ewald B, 2007, MOL CANCER THER, V6, P1239, DOI 10.1158/1535-7163.MCT-06-0633; Flinn IW, 2007, J CLIN ONCOL, V25, P793, DOI 10.1200/JCO.2006.08.0762; Gandhi V, 2007, SEMIN ONCOL, V34, pS8, DOI 10.1053/j.seminoncol.2007.11.003; GELEZIUNAS R, 1991, J NATL CANCER I, V83, P557, DOI 10.1093/jnci/83.8.557; Genini D, 2000, BLOOD, V96, P3537; Genini D, 2000, J BIOL CHEM, V275, P29, DOI 10.1074/jbc.275.1.29; Goodman GR, 2003, J CLIN ONCOL, V21, P891, DOI 10.1200/JCO.2003.05.093; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Gourdeau H, 2001, CANCER RES, V61, P7217; Gourdeau H, 2001, CANCER CHEMOTH PHARM, V47, P236, DOI 10.1007/s002800000223; Grant S, 1998, ADV CANCER RES, V72, P197; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Grove KL, 1996, CANCER RES, V56, P4187; GROVE KL, 1995, CANCER RES, V55, P3008; Han L, 2007, CANCER BIOL THER, V6, P1284; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; HEINEMANN V, 1992, CANCER RES, V52, P533; HEINEMANN V, 1990, MOL PHARMACOL, V38, P567; HEINEMANN V, 1988, CANCER RES, V48, P4024; Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342; HENTOSH P, 1990, J BIOL CHEM, V265, P4033; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1997, CANCER RES, V57, P837; HERTEL LW, 1990, CANCER RES, V50, P4417; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hotte SJ, 2006, ANN ONCOL, V17, P334, DOI 10.1093/annonc/mdj076; Hsi LC, 2005, MOL CANCER THER, V4, P1740, DOI 10.1158/1535-7163.MCT-05-0218; Huang P, 2000, LEUKEMIA, V14, P1405, DOI 10.1038/sj.leu.2401845; HUANG P, 1991, CANCER RES, V51, P6110; HUANG P, 1990, J BIOL CHEM, V265, P16617; HUANG P, 1991, MOL PHARMACOL, V39, P449; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jeong SY, 2003, J BIOL CHEM, V278, P46782, DOI 10.1074/jbc.M304551200; Jiemjit A, 2008, ONCOGENE, V27, P3615, DOI 10.1038/sj.onc.1211018; Johnson S A, 2001, Expert Opin Pharmacother, V2, P929, DOI 10.1517/14656566.2.6.929; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134; Kamiya K, 1996, J BIOL CHEM, V271, P19428, DOI 10.1074/jbc.271.32.19428; Kanda T, 2005, ONCOL REP, V14, P975; KANTARJIAN H, 2007, ASH ANN M, V110, P884; Kantarjian H, 2007, BLOOD, V109, P52, DOI 10.1182/blood-2006-05-021162; Karnitz LM, 2005, MOL PHARMACOL, V68, P1636, DOI 10.1124/mol.105.012716; Kawabe T, 2004, MOL CANCER THER, V3, P513; Kicska GA, 2001, P NATL ACAD SCI USA, V98, P4593, DOI 10.1073/pnas.071050798; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Kohn EA, 2002, J BIOL CHEM, V277, P26553, DOI 10.1074/jbc.M202040200; Konopleva M, 2000, BLOOD, V95, P3929; Kortmansky J, 2005, J CLIN ONCOL, V23, P1875, DOI 10.1200/JCO.2005.03.116; Kozlov SV, 2006, EMBO J, V25, P3504, DOI 10.1038/sj.emboj.7601231; KRENITSKY TA, 1967, MOL PHARMACOL, V3, P526; Krishnan P, 2003, J BIOL CHEM, V278, P36726, DOI 10.1074/jbc.M307052200; Krishnan P, 2002, J BIOL CHEM, V277, P5453, DOI 10.1074/jbc.M109025200; KUFE DW, 1984, MOL PHARMACOL, V25, P322; KUFE DW, 1980, J BIOL CHEM, V255, P8997; KUKHANOVA M, 1995, J BIOL CHEM, V270, P23055, DOI 10.1074/jbc.270.39.23055; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Lara PN, 2005, CLIN CANCER RES, V11, P4444, DOI 10.1158/1078-0432.CCR-04-2602; Lee J, 2007, J BIOL CHEM, V282, P28036, DOI 10.1074/jbc.M704635200; Leoni LM, 1998, P NATL ACAD SCI USA, V95, P9567, DOI 10.1073/pnas.95.16.9567; LI LH, 1970, CANCER RES, V30, P2760; Liu XJ, 2008, MOL CANCER THER, V7, P133, DOI 10.1158/1535-7163.MCT-07-0416; Liu XJ, 2005, CANCER RES, V65, P6874, DOI 10.1158/0008-5472.CAN-05-0288; Liu ZF, 2006, RAPID COMMUN MASS SP, V20, P1117, DOI 10.1002/rcm.2423; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; MATSUDA A, 1991, J MED CHEM, V34, P2917, DOI 10.1021/jm00113a034; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; Matthews DJ, 2007, CELL CYCLE, V6, P104, DOI 10.4161/cc.6.1.3699; McDermott KM, 2006, PLOS BIOL, V4, P350, DOI 10.1371/journal.pbio.0040051; Mertens D, 2006, P NATL ACAD SCI USA, V103, P7741, DOI 10.1073/pnas.0600494103; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Mirzoeva OK, 2003, MOL CANCER RES, V1, P207; MIYASHITA T, 1993, BLOOD, V81, P151; MONTGOMERY JA, 1992, J MED CHEM, V35, P397, DOI 10.1021/jm00080a029; Moreno-Herrero F, 2005, NATURE, V437, P440, DOI 10.1038/nature03927; Morita S, 2006, ONCOLOGY-BASEL, V71, P437, DOI 10.1159/000107110; Moufarij MA, 2006, BLOOD, V108, P4187, DOI 10.1182/blood-2006-05-023259; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; Nakatsuka S, 2003, CANCER SCI, V94, P87, DOI 10.1111/j.1349-7006.2003.tb01357.x; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; OHNO Y, 1988, CANCER RES, V48, P1494; Oki Y, 2006, REV RECENT CLIN TRIA, V1, P169, DOI 10.2174/157488706776876490; Olson E, 2007, MOL CELL BIOL, V27, P6053, DOI 10.1128/MCB.00532-07; Palii SS, 2008, MOL CELL BIOL, V28, P752, DOI 10.1128/MCB.01799-07; PARKER WB, 1991, CANCER RES, V51, P2386; PARKER WB, 1988, MOL PHARMACOL, V34, P485; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Paulsen RD, 2007, DNA REPAIR, V6, P953, DOI 10.1016/j.dnarep.2007.02.015; Perez RP, 2006, CLIN CANCER RES, V12, P7079, DOI 10.1158/1078-0432.CCR-06-0197; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; Plunkett W, 1996, SEMIN ONCOL, V23, P3; Plunkett W, 2001, Cancer Chemother Biol Response Modif, V19, P21; PLUNKETT W, 1995, SEMIN ONCOL, V22, P3; PLUNKETT W, 1982, CANCER RES, V42, P2092; Pogribny IP, 2002, CANCER LETT, V176, P169, DOI 10.1016/S0304-3835(01)00748-0; Raj K, 2007, LEUKEMIA, V21, P1937, DOI 10.1038/sj.leu.2404796; Rao VA, 2003, CLIN CANCER RES, V9, P3204; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Richon VM, 2002, CLIN CANCER RES, V8, P662; Riedl SJ, 2007, NAT REV MOL CELL BIO, V8, P405, DOI 10.1038/nrm2153; ROBERTSON LE, 1993, BLOOD, V81, P143; Robinson HMR, 2006, ONCOGENE, V25, P5359, DOI 10.1038/sj.onc.1209532; Robison JG, 2005, J BIOL CHEM, V280, P12927, DOI 10.1074/jbc.M414391200; Robison JG, 2004, J BIOL CHEM, V279, P34802, DOI 10.1074/jbc.M404750200; ROSS DD, 1990, CANCER RES, V50, P2658; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Sampath D, 2006, BLOOD, V107, P2517, DOI 10.1182/blood-2005-08-3351; Sampath D, 2002, MOL PHARMACOL, V62, P680, DOI 10.1124/mol.62.3.680; Sandoval A, 1996, CLIN CANCER RES, V2, P1731; SCHINAZI RF, 1992, ANTIMICROB AGENTS CH, V36, P672, DOI 10.1128/AAC.36.3.672; Schmelz K, 2005, INT J CANCER, V114, P683, DOI 10.1002/ijc.20797; SETO S, 1985, J CLIN INVEST, V75, P377, DOI 10.1172/JCI111710; SETO S, 1986, J IMMUNOL, V136, P2839; Shao RG, 1997, CANCER RES, V57, P4029; Shen LL, 2003, BLOOD, V101, P4131, DOI 10.1182/blood-2002-08-2466; Shi Z, 2001, CANCER RES, V61, P1065; Shieh SY, 2000, GENE DEV, V14, P289; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; SNYDER RD, 1984, CHEM-BIOL INTERACT, V50, P1, DOI 10.1016/0009-2797(84)90127-3; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stracker TH, 2004, DNA REPAIR, V3, P845, DOI 10.1016/j.dnarep.2004.03.014; Stresemann C, 2008, INT J CANCER, V123, P8, DOI 10.1002/ijc.23607; Sugiyama K, 2000, INT J CANCER, V85, P703, DOI 10.1002/(SICI)1097-0215(20000301)85:5<703::AID-IJC17>3.0.CO;2-7; Sun YL, 2007, MOL CELL BIOL, V27, P8502, DOI 10.1128/MCB.01382-07; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Tang XM, 2004, MOL CANCER RES, V2, P685; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tili Esmerina, 2007, Future Oncol, V3, P521, DOI 10.2217/14796694.3.5.521; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330; Toyooka S, 2003, CLIN CANCER RES, V9, P3034; Trenz K, 2006, EMBO J, V25, P1764, DOI 10.1038/sj.emboj.7601045; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Tse AN, 2007, CLIN CANCER RES, V13, P1955, DOI 10.1158/1078-0432.CCR-06-2793; TSENG WC, 1982, MOL PHARMACOL, V21, P474; Tsimberidou AM, 2008, J CLIN ONCOL, V26, P196, DOI 10.1200/JCO.2007.11.8513; van den Bosch M, 2003, EMBO REP, V4, P844, DOI 10.1038/sj.embor.embor925; van der Donk WA, 1998, BIOCHEMISTRY-US, V37, P6419, DOI 10.1021/bi9729357; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; VESELY J, 1977, VOP ONKOL+, V23, P65; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Walton TJ, 2008, PROSTATE, V68, P210, DOI 10.1002/pros.20673; Wang JL, 2002, CELL CYCLE, V1, P267, DOI 10.4161/cc.1.4.137; Wang J, 2007, P NATL ACAD SCI USA, V104, P14324, DOI 10.1073/pnas.0706803104; Wang JH, 2008, CHEM MATER, V20, P20, DOI 10.1021/cm702375e; Wang Y, 2000, GENE DEV, V14, P927; Wang YQ, 2008, CANCER RES, V68, P3881, DOI 10.1158/0008-5472.CAN-07-6885; Welch S, 2007, GYNECOL ONCOL, V106, P305, DOI 10.1016/j.ygyno.2007.02.018; Wen Q, 2008, MOL BIOL CELL, V19, P1693, DOI 10.1091/mbc.E07-09-0975; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Xiao Z, 2005, ONCOGENE, V24, P1403, DOI 10.1038/sj.onc.1208309; XIE CX, 1995, CANCER RES, V55, P2847; Xie KC, 1996, CANCER RES, V56, P3030; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619; Yamauchi T, 2001, CLIN CANCER RES, V7, P3580; Yan PS, 2001, CANCER RES, V61, P8375; YANG SW, 1992, J BIOL CHEM, V267, P2345; Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105; Zhang YW, 2006, CELL CYCLE, V5, P125, DOI 10.4161/cc.5.2.2308; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhao M, 2004, J CHROMATOGR B, V813, P81, DOI 10.1016/j.jchromb.2004.09.012; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7; Zhu WG, 2001, CANCER RES, V61, P1327; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	214	157	164	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 27	2008	27	50					6522	6537		10.1038/onc.2008.316	http://dx.doi.org/10.1038/onc.2008.316			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RR	18955977				2022-12-17	WOS:000260501600010
J	Lee, JO; Kwun, HJ; Jung, JK; Choi, KH; Min, DS; Jang, KL				Lee, JO; Kwun, HJ; Jung, JK; Choi, KH; Min, DS; Jang, KL			Hepatitis B virus X protein represses E-cadherin expression via activation of DNA methyltransferase 1	ONCOGENE			English	Article						DNA methyltransferase 1; E-cadherin; hepatitis B virus X; hepatocellular carcinoma; metastasis; tumor invasion	CELL-CELL-ADHESION; HEPATOCELLULAR-CARCINOMA; CPG METHYLATION; HBX PROTEIN; TRANSCRIPTIONAL ACTIVITY; DOWN-REGULATION; GENE; CANCER; INVASION; SYSTEM	E-cadherin is a key cell adhesion molecule implicated as a tumor suppressor, which is frequently altered in hepatocellular carcinoma, especially in hepatitis B virus (HBV)-related tumors. Here, we report that HBV X protein (HBx) represses E-cadherin expression at the transcription level. Based on the differential effects of HBx natural variants, we determined that Lys-130 in the transactivation domain of HBx is critical for the E-cadherin repression. The repression effect of HBx was abolished after treatment with DNA methyltransferase inhibitor, 5'-Aza-2'dC. In addition, methylation-specific PCR analysis revealed that the CpG island 1 of E-cadherin promoter is hypermethylated by HBx. Furthermore, HBx induces DNA methyltransferase 1 expression by stimulating its transcription. Therefore, we conclude that HBx represses E-cadherin expression by inducing methylation-mediated promoter inactivation. The reduced E-cadherin expression results in dramatic morphological changes of the HBx-expressing cells. In addition, HBx-expressing cells aggregate poorly in suspension culture, reflecting their altered intercellular interactions. The biological significance was further demonstrated by the increased collagen invasion ability of HBx-expressing cells. Therefore, the present study suggests that HBx plays a role during hepatocellular carcinogenesis by favoring cell detachment from the surrounding cells and migration outside of the primary tumor site.	Pusan Natl Univ, Coll Nat Sci, Div Biol Sci, Pusan 609735, South Korea	Pusan National University	Jang, KL (corresponding author), Pusan Natl Univ, Coll Nat Sci, Div Biol Sci, Pusan 609735, South Korea.	kljang@pusan.ac.kr	Kwun, Hyun jin/AAJ-3365-2020; Kwun, Hyun Jin/F-5511-2011; Kwun, Hyun Jin/AAH-2706-2020	Kwun, Hyun jin/0000-0002-8926-746X; Kwun, Hyun Jin/0000-0002-8926-746X; 				Anzola M, 2004, J VIRAL HEPATITIS, V11, P383, DOI 10.1111/j.1365-2893.2004.00521.x; Baptista M, 1999, HEPATOLOGY, V29, P946, DOI 10.1002/hep.510290336; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Berx G, 1996, ONCOGENE, V13, P1919; Bigey P, 2000, GENE, V242, P407, DOI 10.1016/S0378-1119(99)00501-6; Block TM, 2003, ONCOGENE, V22, P5093, DOI 10.1038/sj.onc.1206557; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chan CF, 2004, CLIN CANCER RES, V10, P4140, DOI 10.1158/1078-0432.CCR-03-0574; Chu CHC, 1996, LANCET, V348, P625, DOI 10.1016/S0140-6736(05)64851-9; Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje; Diao JY, 2001, CYTOKINE GROWTH F R, V12, P189, DOI 10.1016/S1359-6101(00)00034-4; Feitelson MA, 1997, AM J PATHOL, V150, P1141; Foty RA, 2004, INT J DEV BIOL, V48, P397, DOI 10.1387/ijdb.041810rf; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Jia L, 1999, INT J CANCER, V80, P875, DOI 10.1002/(SICI)1097-0215(19990315)80:6<875::AID-IJC13>3.0.CO;2-Z; Kanai Y, 1997, INT J CANCER, V71, P355; KAWANISHI J, 1995, MOL CELL BIOL, V15, P1175; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kwun HJ, 2004, NUCLEIC ACIDS RES, V32, P2202, DOI 10.1093/nar/gkh553; Lara-Pezzi E, 2002, J CLIN INVEST, V110, P1831, DOI 10.1172/JCI200215887; Lara-Pezzi E, 2001, HEPATOLOGY, V33, P1270, DOI 10.1053/jhep.2001.1270; Lara-Pezzi E, 2001, J HEPATOL, V34, P409, DOI 10.1016/S0168-8278(00)00090-8; Lara-Pezzi E, 2001, ONCOGENE, V20, P3323, DOI 10.1038/sj.onc.1204451; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Matsumura T, 2001, CLIN CANCER RES, V7, P594; Melki JR, 2000, BLOOD, V95, P3208; MIYASAKA M, 1995, CLIN ORTHOP RELAT R, V312, P10; Nabi IR, 1999, J CELL SCI, V112, P1803; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Sanders DSA, 1999, J CLIN PATHOL-MOL PA, V52, P151, DOI 10.1136/mp.52.3.151; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; Silye R, 1998, J PATHOL, V186, P350, DOI 10.1002/(SICI)1096-9896(199812)186:4<350::AID-PATH181>3.0.CO;2-K; Takahashi K, 1998, ARCH VIROL, V143, P2313, DOI 10.1007/s007050050463; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Tsai CN, 2002, P NATL ACAD SCI USA, V99, P10084, DOI 10.1073/pnas.152059399; Venard V, 2000, J MED VIROL, V62, P177, DOI 10.1002/1096-9071(200010)62:2&lt;177::AID-JMV8&gt;3.0.CO;2-V; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Wei Y, 2002, HEPATOLOGY, V36, P692, DOI 10.1053/jhep.2002.35342; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Yoo YG, 2003, J BIOL CHEM, V278, P39076, DOI 10.1074/jbc.M305101200; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	48	157	174	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6617	6625		10.1038/sj.onc.1208827	http://dx.doi.org/10.1038/sj.onc.1208827			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007161				2022-12-17	WOS:000232367800003
J	Caldas, H; Jiang, YY; Holloway, MP; Fangusaro, J; Mahotka, C; Conway, EM; Altura, RA				Caldas, H; Jiang, YY; Holloway, MP; Fangusaro, J; Mahotka, C; Conway, EM; Altura, RA			Survivin splice variants regulate the balance between proliferation and cell death	ONCOGENE			English	Article						apoptosis; cell division; drug therapy; mitosis; neoplasms	ANTI-APOPTOSIS GENE; SUBCELLULAR-LOCALIZATION; HUMAN NEUROBLASTOMA; PROTEIN SURVIVIN; EXPRESSION; CYCLE; IDENTIFICATION; CANCER; BRAIN; OVEREXPRESSION	Survivin is an inhibitor of apoptosis protein that also plays critical roles in regulating the cell cycle and mitosis. Its prominent expression in essentially all human malignancies, and low or absent expression in most normal tissues, suggests that it would be an ideal target for cancer-directed therapy. Impeding development of safe and effective survivin antagonists for clinical use is a lack of understanding of the molecular mechanisms by which survivin differentially affects apoptosis and cell division, in normal and malignant cells. We show that the diverse functional roles of survivin can be explained, in part, by its heterodimerization with survivin splice variants in tumor cells. Survivin and survivin-Delta Ex3 interact within the mitochondria where they may inhibit mitochondrial-dependent apoptosis. If the expression of all survivin forms is eliminated by siRNA transfections, cells undergo both apoptosis and defective cell division. Overall, we provide new insights suggesting that targeting specific survivin isoforms, rather than survivin alone, may selectively and effectively destroy tumor cells. These findings are likely to have a significant impact in the design of biologic agents for clinical therapy.	Ohio State Univ, Ctr Childhood Canc, Columbus Childrens Res Inst, Columbus, OH 43205 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Univ Dusseldorf, Inst Pathol, D-4000 Dusseldorf, Germany; Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; Heinrich Heine University Dusseldorf; Flanders Institute for Biotechnology (VIB); KU Leuven	Altura, RA (corresponding author), Ohio State Univ, Ctr Childhood Canc, Columbus Childrens Res Inst, 700 Childrens Dr,Rm WA5021, Columbus, OH 43205 USA.	alturar@pediatrics.ohio-state.edu		Conway, Edward/0000-0003-0081-0305				Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Altura RA, 2003, BRIT J CANCER, V89, P1743, DOI 10.1038/sj.bjc.6601334; Altznauer F, 2004, J EXP MED, V199, P1343, DOI 10.1084/jem.20032033; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Armit CJ, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-27; Badran A, 2004, BIOCHEM BIOPH RES CO, V314, P902, DOI 10.1016/j.bbrc.2003.12.178; Bronfman M, 1998, ANAL BIOCHEM, V255, P252, DOI 10.1006/abio.1997.2453; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chakravarti A, 2002, J CLIN ONCOL, V20, P1063, DOI 10.1200/JCO.20.4.1063; Chen J, 2003, J BIOL CHEM, V278, P486, DOI 10.1074/jbc.M211119200; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Conway EM, 2003, AM J PATHOL, V163, P935, DOI 10.1016/S0002-9440(10)63453-0; Conway EM, 2002, GASTROENTEROLOGY, V123, P619, DOI 10.1053/gast.2002.34753; Dohi T, 2004, J CLIN INVEST, V114, P1117, DOI 10.1172/JCI200422222; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P147; HS U, 1998, NEUROSCI LETT, V244, P411; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Islam A, 2000, MED PEDIATR ONCOL, V35, P550, DOI 10.1002/1096-911X(20001201)35:6<550::AID-MPO12>3.0.CO;2-Y; JACOBSEN PF, 1985, J NEUROPATH EXP NEUR, V44, P472, DOI 10.1097/00005072-198509000-00003; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Krieg A, 2002, BRIT J CANCER, V86, P737, DOI 10.1038/sj.bjc.6600153; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lee SH, 2001, CHILD NERV SYST, V17, P134, DOI 10.1007/s003810000341; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Mahotka C, 1999, CANCER RES, V59, P6097; Mahotka C, 2002, CELL DEATH DIFFER, V9, P1334, DOI 10.1038/sj.cdd.4401091; Mahotka C, 2002, INT J CANCER, V100, P30, DOI 10.1002/ijc.10450; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pennartz S, 2004, MOL CELL NEUROSCI, V25, P692, DOI 10.1016/j.mcn.2003.12.011; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2001, GENOME BIOL, V2; Wang HW, 2002, EMBO J, V21, P2602, DOI 10.1093/emboj/21.11.2602; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X; Yamada Y, 2003, J NEUROSURG, V99, P738, DOI 10.3171/jns.2003.99.4.0738	49	157	176	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					1994	2007		10.1038/sj.onc.1208350	http://dx.doi.org/10.1038/sj.onc.1208350			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688031				2022-12-17	WOS:000227681900004
J	Sultan, AS; Xie, JW; LeBaron, MJ; Ealley, EL; Nevalainen, MT; Rui, H				Sultan, AS; Xie, JW; LeBaron, MJ; Ealley, EL; Nevalainen, MT; Rui, H			Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells	ONCOGENE			English	Article						Stat5; breast cancer; E-cadherin; invasion; adhesion; metastasis	MAMMARY EPITHELIAL-CELLS; PROLACTIN SIGNAL-TRANSDUCTION; E-CADHERIN EXPRESSION; MATRIX METALLOPROTEINASES; TYROSINE PHOSPHORYLATION; CONDITIONAL KNOCKOUT; GLAND DEVELOPMENT; GENE-EXPRESSION; BETA-CATENIN; GROWTH	Signal transducer and activator of transcription-5 (Stat5) mediates prolactin (PRL)-induced differentiation and growth of breast epithelial cells. We have recently identified active Stat5 as a tumor marker of favorable prognosis in human breast cancer, and determined that Stat5 activation is lost during metastatic progression. Here we provide novel evidence for an invasion-suppressive role of Stat5 in human breast cancer. Activation of Stat5 by PRL in human breast cancer lines was associated with increased surface levels of the invasion-suppressive adhesion molecule E-cadherin in vitro and in xenotransplant tumors in vivo. Inducible E-cadherin was blocked by dominant-negative (Dn) Stat5 or Dn-Jak2, but not by Dn-Stat3. Further experimental data indicated a role of Stat5 as a coordinate regulator of additional invasion-related characteristics of human breast cancer cells, including cell surface association of beta-catenin, homotypic cell clustering, invasion through Matrigel, cell migration, and matrix metalloproteinase activity. A role of Stat5 as a suppressor of breast cancer invasion and metastatic progression provides a biological mechanism to explain the favorable prognosis associated with active Stat5 in human breast cancer.	Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA	Georgetown University	Rui, H (corresponding author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Oncol, NRB E504,3970 Reservoir Rd NW, Washington, DC 20057 USA.	ruih@georgetown.edu	Sultan, Prof. Ahmed S/AFH-7788-2022	Sultan, Prof. Ahmed S/0000-0001-6568-1757; Sultan, Ahmad/0000-0001-5776-1837	NCI NIH HHS [CA101841, 1P30-CA-51008] Funding Source: Medline; NIDDK NIH HHS [DK52013] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA051008, R01CA101841] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422; Ahonen TJ, 2003, J BIOL CHEM, V278, P27287, DOI 10.1074/jbc.M304307200; ALBINI A, 1987, J CELL BIOL, V105, P1867, DOI 10.1083/jcb.105.4.1867; Arihiro K, 2000, Breast Cancer, V7, P221, DOI 10.1007/BF02967464; Badache A, 2001, CANCER RES, V61, P383; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Benitah SA, 2003, MOL BIOL CELL, V14, P40, DOI 10.1091/mbc.E02-08-0454; Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309; Bukholm IK, 1998, J PATHOL, V185, P262, DOI 10.1002/(SICI)1096-9896(199807)185:3<262::AID-PATH97>3.0.CO;2-Y; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Cotarla I, 2004, INT J CANCER, V108, P665, DOI 10.1002/ijc.11619; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; Das R, 1996, ONCOGENE, V13, P1139; DUHE RJ, 1995, GENE, V158, P281, DOI 10.1016/0378-1119(95)00041-4; ERWIN RA, 1995, ENDOCRINOLOGY, V136, P3512, DOI 10.1210/en.136.8.3512; Fearon ER, 2003, CANCER CELL, V3, P307, DOI 10.1016/S1535-6108(03)00087-4; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Grimley PM, 1999, CYTOKINE GROWTH F R, V10, P131, DOI 10.1016/S1359-6101(99)00011-8; Groner B, 2000, BREAST CANCER RES, V2, P149, DOI 10.1186/bcr47; Humphreys RC, 1999, CELL GROWTH DIFFER, V10, P685; Iavnilovitch E, 2002, MOL CANCER RES, V1, P32; Kabotyanski EB, 2003, J BIOL CHEM, V278, P17218, DOI 10.1074/jbc.M301578200; KAZANSKY AV, 1995, MOL ENDOCRINOL, V9, P1598, DOI 10.1210/me.9.11.1598; KEMLER R, 1989, BIOESSAYS, V11, P88, DOI 10.1002/bies.950110403; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Lilien J, 2002, DEV DYNAM, V224, P18, DOI 10.1002/dvdy.10087; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Liu XW, 1998, CELL GROWTH DIFFER, V9, P795; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; Maus MV, 1999, ENDOCRINOLOGY, V140, P5447, DOI 10.1210/en.140.11.5447; Mbalaviele G, 1996, CANCER RES, V56, P4063; Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065; Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046; Nevalainen MT, 2002, MOL ENDOCRINOL, V16, P1108, DOI 10.1210/mend.16.5.0839; Papkoff J, 1997, J BIOL CHEM, V272, P4536; Paterson AD, 2003, J BIOL CHEM, V278, P21050, DOI 10.1074/jbc.M300082200; Philips N, 2004, CANCER LETT, V206, P63, DOI 10.1016/j.canlet.2003.10.019; Ren SX, 2002, ONCOGENE, V21, P4335, DOI 10.1038/sj.onc.1205484; Schaber JD, 1998, CANCER RES, V58, P1914; SCHMIDHAUSER C, 1992, MOL BIOL CELL, V3, P699, DOI 10.1091/mbc.3.6.699; SHIU RPC, 1984, CANCER RES, V44, P1178; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Sultan AS, 1997, J BIOL CHEM, V272, P2866, DOI 10.1074/jbc.272.5.2866; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Wagner KU, 2004, MOL CELL BIOL, V24, P5510, DOI 10.1128/MCB.24.12.5510-5520.2004; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Xie J, 2002, J BIOL CHEM, V277, P14020, DOI 10.1074/jbc.M112399200; Yamashita H, 1999, J BIOL CHEM, V274, P14699, DOI 10.1074/jbc.274.21.14699; Yamashita H, 2003, ONCOGENE, V22, P1638, DOI 10.1038/sj.onc.1206277; YASUMITSU H, 1992, J BIOCHEM-TOKYO, V111, P74, DOI 10.1093/oxfordjournals.jbchem.a123721; Zhang SS, 1999, J CELL SCI, V112, P2693	58	157	163	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					746	760		10.1038/sj.onc.1208203	http://dx.doi.org/10.1038/sj.onc.1208203			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15592524				2022-12-17	WOS:000226577100002
J	Chen, YH; Zheng, Y; Foster, DA				Chen, YH; Zheng, Y; Foster, DA			Phospholipase D confers rapamycin resistance in human breast cancer cells	ONCOGENE			English	Article						phospholipase D; rapamycin; mTOR	GROWTH-FACTOR RECEPTOR; PHOSPHATIDIC-ACID; V-SRC; MAMMALIAN TARGET; DEPENDENT ACTIVATION; SIGNALING PATHWAY; TRANSFORMED-CELLS; RAT FIBROBLASTS; PROTEIN; KINASE	mTOR (mammalian target of rapamycin) is a protein kinase that regulates cell cycle progression and cell growth. Rapamycin is a highly specific inhibitor of mTOR in clinical trials for the treatment of breast and other cancers. mTOR signaling was reported to require phosphatidic acid (PA), the metabolic product of phospholipase D (PLD). PLD, like mTOR, has been implicated in survival signaling and the regulation of cell cycle progression. PLD activity is frequently elevated in breast cancer. We have investigated the effect of rapamycin on breast cancer cell lines with different levels of PLD activity. MCF-7 cells, with relatively low levels of PLD activity, were highly sensitive to the growth-arresting effects of rapamycin, whereas MDA-MB-231 cells, with a 10-fold higher PLD activity than MCF-7 cells, were highly resistant to rapamycin. Elevating PLD activity in MCF-7 cells led to rapamycin resistance; and inhibition of PLD activity in MDA-MB-231 cells increased rapamycin sensitivity. Elevated PLD activity in MCF-7 cells also caused rapamycin resistance for S6 kinase phosphorylation and serum-induced Myc expression. These data implicate mTOR as a critical target for survival signals generated by PLD and suggest that PLD levels in breast cancer could be a valuable indicator of the likely efficacy of rapamycin treatment.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Foster, DA (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.				NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline; NIGMS NIH HHS [GM60654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA046677, R01CA046677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM060654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chen J, 2002, BIOCHEM PHARMACOL, V64, P1071, DOI 10.1016/S0006-2952(02)01263-7; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Frankel P, 1999, BIOCHEM BIOPH RES CO, V255, P502, DOI 10.1006/bbrc.1999.0234; Fry MJ, 2001, BREAST CANCER RES, V3, P304, DOI 10.1186/bcr312; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Hornia A, 1999, MOL CELL BIOL, V19, P7672; Huang S, 2001, DRUG RESIST UPDATE, V4, P378, DOI 10.1054/drup.2002.0227; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; Joseph T, 2001, BIOCHEM BIOPH RES CO, V289, P1019, DOI 10.1006/bbrc.2001.6118; Joseph T, 2002, ONCOGENE, V21, P3651, DOI 10.1038/sj.onc.1205380; Kuruvilla FG, 1999, CHEM BIOL, V6, pR129, DOI 10.1016/S1074-5521(99)80070-2; Lei XF, 2002, ONCOGENE, V21, P7514, DOI 10.1038/sj.onc.1205966; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Mills GB, 2001, P NATL ACAD SCI USA, V98, P10031, DOI 10.1073/pnas.191379498; Min DS, 2001, CARCINOGENESIS, V22, P1641, DOI 10.1093/carcin/22.10.1641; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Noh DY, 2000, CANCER LETT, V161, P207, DOI 10.1016/S0304-3835(00)00612-1; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SANTOS GF, 1988, J BIOL CHEM, V263, P9565; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Sekulic A, 2000, CANCER RES, V60, P3504; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Shome K, 1997, CURR BIOL, V7, P387, DOI 10.1016/S0960-9822(06)00186-2; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; SONG JG, 1994, CELL GROWTH DIFFER, V5, P79; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Tsai EM, 2001, CANCER RES, V61, P8390; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; Yu K, 2001, ENDOCR-RELAT CANCER, V8, P249, DOI 10.1677/erc.0.0080249; Zhong MG, 2003, BIOCHEM BIOPH RES CO, V302, P615, DOI 10.1016/S0006-291X(03)00229-8	50	157	163	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2003	22	25					3937	3942		10.1038/sj.onc.1206565	http://dx.doi.org/10.1038/sj.onc.1206565			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813467				2022-12-17	WOS:000183612000013
J	Osada, H; Takahashi, T				Osada, H; Takahashi, T			Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer	ONCOGENE			English	Review						tumor suppressor; oncogene; lung cancer	NON-SMALL-CELL; ENDOTHELIAL GROWTH-FACTOR; RETINOBLASTOMA SUSCEPTIBILITY GENE; RECEPTOR TYROSINE KINASES; MESSENGER-RNA EXPRESSION; MITOTIC CHECKPOINT GENES; MYC FAMILY ONCOGENE; IN-VIVO ALTERATIONS; K-RAS MUTATIONS; PROTEIN EXPRESSION	Lung cancer has become the leading cause of cancer death in many economically well-developed countries. Recent molecular biological studies have revealed that overt lung cancers frequently develop through sequential morphological steps, with the accumulation of multiple genetic and epigenetic alterations affecting both tumor suppressor genes and dominant oncogenes. Cell cycle progression needs to be properly regulated, while cells have built-in complex and minute mechanisms such as cell cycle checkpoints to maintain genomic integrity. Genes in the p16INK4A-RB and p14ARF-p53 pathways appear to be a major target for genetic alterations involved in the pathogenesis of lung cancer. Several oncogenes are also known to be altered in lung cancer, leading to the stimulation of autocrine/paracrine loops and activation of multiple signaling pathways. It is widely acknowledged that carcinogens in cigarette smoke are deeply involved in these multiple genetic alterations, mainly through the formation of DNA adducts. A current understanding of the molecular mechanisms of lung cancer pathogenesis and progression is presented in relation to cigarette smoking, an absolute major risk factor for lung cancer development, by reviewing genetic alterations of various tumor suppressor genes and oncogenes thus far identified in lung cancer, with brief summaries of their functions and regulation.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	tak@aichi-cc.jp	Takahashi, Takashi/I-7262-2014; Osada, Hiroyuki/AAY-6254-2020	Takahashi, Takashi/0000-0003-0615-7001; 				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Al Moustafa AE, 1999, ANTICANCER RES, V19, P481; Albanell J, 1997, JNCI-J NATL CANCER I, V89, P1609, DOI 10.1093/jnci/89.21.1609; Artandi SE, 2000, NAT MED, V6, P852, DOI 10.1038/78595; Barr LF, 2000, CANCER RES, V60, P143; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Brognard J, 2001, CANCER RES, V61, P3986; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Cagle PT, 1997, AM J PATHOL, V150, P393; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CLINE MJ, 1987, CANCER, V60, P2669, DOI 10.1002/1097-0142(19871201)60:11<2669::AID-CNCR2820601116>3.0.CO;2-4; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Cooper CA, 1997, J PATHOL, V181, P401, DOI 10.1002/(SICI)1096-9896(199704)181:4<401::AID-PATH799>3.0.CO;2-Y; Croce CM, 1999, J CLIN ONCOL, V17, P1618, DOI 10.1200/JCO.1999.17.5.1618; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Decaussin M, 1999, J PATHOL, V188, P369; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eymin B, 2001, ONCOGENE, V20, P1678, DOI 10.1038/sj.onc.1204242; Fontanini G, 1999, BRIT J CANCER, V79, P363, DOI 10.1038/sj.bjc.6690058; Fontanini G, 1998, CLIN CANCER RES, V4, P241; Forgacs E, 1998, ONCOGENE, V17, P1557, DOI 10.1038/sj.onc.1202070; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; GAZZERI S, 1994, INT J CANCER, V58, P24, DOI 10.1002/ijc.2910580106; GAZZERI S, 1990, CANCER RES, V50, P1566; Geradts J, 2000, BRIT J CANCER, V82, P1191, DOI 10.1054/bjoc.1999.1062; Giatromanolaki A, 2001, BRIT J CANCER, V85, P881, DOI 10.1054/bjoc.2001.2018; Guo QM, 2000, CANCER RES, V60, P5922; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARPER JW, 1993, CELL, V75, P805; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; Haruki N, 2000, CANCER RES, V60, P4689; Haruki N, 2001, AM J PATHOL, V159, P1345, DOI 10.1016/S0002-9440(10)62521-7; Hatanaka H, 2001, CLIN CANCER RES, V7, P1287; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HENSEL CH, 1990, CANCER RES, V50, P3067; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HIBI K, 1992, ONCOGENE, V7, P445; Higashiyama M, 1997, BRIT J CANCER, V75, P1302, DOI 10.1038/bjc.1997.221; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hussain SP, 2001, CANCER RES, V61, P6350; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Ishikawa S, 1997, DNA Res, V4, P35, DOI 10.1093/dnares/4.1.35; Jiang YX, 2001, ONCOGENE, V20, P2254, DOI 10.1038/sj.onc.1204293; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; JOHNSON BE, 1996, LUNG CANC PRINCIPLES, P83; Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005; Kajita T, 2001, BRIT J CANCER, V85, P255, DOI 10.1054/bjoc.2001.1882; Kalma Y, 2001, ONCOGENE, V20, P1379, DOI 10.1038/sj.onc.1204230; Karkkainen MJ, 2000, ONCOGENE, V19, P5598, DOI 10.1038/sj.onc.1203855; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; KERN JA, 1990, CANCER RES, V50, P5184; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Ko JL, 2000, INT J CANCER, V89, P265, DOI 10.1002/1097-0215(20000520)89:3<265::AID-IJC9>3.0.CO;2-N; Kohno T, 1998, GENE CHROMOSOME CANC, V22, P152, DOI 10.1002/(SICI)1098-2264(199806)22:2<152::AID-GCC10>3.0.CO;2-S; Kohno T, 1999, CANCER RES, V59, P4170; Konishi H, 2002, CANCER RES, V62, P271; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; LADANYI M, 1993, CANCER RES, V53, P16; LATIF F, 1992, GENE CHROMOSOME CANC, V5, P119, DOI 10.1002/gcc.2870050205; Lerman MI, 2000, CANCER RES, V60, P6116; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Mao L, 1997, J NATL CANCER I, V89, P857, DOI 10.1093/jnci/89.12.857; Marrogi AJ, 2000, CLIN CANCER RES, V6, P4739; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Masuda A, 2001, AM J PATHOL, V158, P87, DOI 10.1016/S0002-9440(10)63947-8; MILLS NE, 1995, J NATL CANCER I, V87, P1056, DOI 10.1093/jnci/87.14.1056; MINNA JD, 1997, CANC PRINCIPLES PRAC, V1, P849; Mitsudomi T, 2000, CLIN CANCER RES, V6, P4055; MIYASHITA T, 1995, CELL, V80, P293; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; Nadav L, 2001, INT J ONCOL, V19, P237; Nagatake M, 1996, CANCER RES, V56, P2718; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141; O'Byrne KJ, 2000, BRIT J CANCER, V82, P1427, DOI 10.1054/bjoc.1999.1129; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; Okami K, 1998, CANCER RES, V58, P509; Osada H, 2001, CANCER RES, V61, P8331; Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; RACHWAL WJ, 1995, BRIT J CANCER, V72, P56, DOI 10.1038/bjc.1995.277; REISSMANN PT, 1993, ONCOGENE, V8, P1913; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; RICHARDSON GE, 1993, SEMIN ONCOL, V20, P105; Robles AI, 2001, CANCER RES, V61, P6660; RODENHUIS S, 1990, AM REV RESPIR DIS, V142, pS27, DOI 10.1164/ajrccm/142.6_Pt_2.S27; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; RUSCH V, 1993, CANCER RES, V53, P2379; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; Sato M, 2000, JPN J CANCER RES, V91, P504, DOI 10.1111/j.1349-7006.2000.tb00974.x; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; SHIMIZU E, 1994, ONCOGENE, V9, P2441; SHIRAISHI M, 1989, CANCER RES, V49, P6474; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; Slichenmyer WJ, 2001, SEMIN ONCOL, V28, P67, DOI 10.1053/sonc.2001.28557; Sozzi G, 1997, CANCER RES, V57, P2121; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; *STAT INF DEP MIN, 1999, VIT STAT JAP 1999, V3, P398; SUGIO K, 1994, CANCER RES, V54, P5811; Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103; Takahama M, 1999, CLIN CANCER RES, V5, P2506; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Takenoshita S, 1997, CARCINOGENESIS, V18, P1427, DOI 10.1093/carcin/18.7.1427; Tani M, 1997, CARCINOGENESIS, V18, P1119, DOI 10.1093/carcin/18.5.1119; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; TESTA JR, 1996, LUNG CANC PRINCIPLES, P55; Tomizawa Y, 1998, CANCER RES, V58, P5478; Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898; Tseng JE, 1999, CANCER RES, V59, P4798; TSUCHIYA E, 1995, J CANCER RES CLIN, V121, P577, DOI 10.1007/BF01197773; Uchida K, 1996, CANCER RES, V56, P5583; Urban T, 2000, BRIT J CANCER, V82, P412; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vonlanthen S, 2001, BRIT J CANCER, V84, P1372, DOI 10.1054/bjoc.2001.1791; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Wang SSQ, 1999, GENE CHROMOSOME CANC, V25, P154, DOI 10.1002/(SICI)1098-2264(199906)25:2<154::AID-GCC11>3.3.CO;2-N; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WEINER DB, 1990, CANCER RES, V50, P421; Westra WH, 1996, CANCER RES, V56, P2224; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xian J, 2001, P NATL ACAD SCI USA, V98, P15062, DOI 10.1073/pnas.251407098; Xiao L, 2000, CANCER RES, V60, P400; Xu HJ, 1996, CLIN CANCER RES, V2, P1169; XU HJ, 1991, CANCER RES, V51, P2735; Yamada KM, 2001, J CELL SCI, V114, P2375; Yamaguchi K, 1999, CANCER LETT, V139, P183, DOI 10.1016/S0304-3835(99)00035-X; Yamaguchi T, 2001, CANCER RES, V61, P8256; Yano T, 2000, EUR J CANCER, V36, P601, DOI 10.1016/S0959-8049(99)00327-5; Yatabe Y, 1998, CANCER RES, V58, P1042; Yi ES, 1997, MODERN PATHOL, V10, P142; Yokomizo A, 1998, ONCOGENE, V17, P475, DOI 10.1038/sj.onc.1201956; YOKOTA J, 1988, ONCOGENE, V3, P471; YONEDA K, 1993, HUM PATHOL, V24, P1180, DOI 10.1016/0046-8177(93)90213-Z; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yuan A, 2000, INT J CANCER, V89, P475, DOI 10.1002/1097-0215(20001120)89:6<475::AID-IJC2>3.0.CO;2-T; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	176	157	171	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2002	21	48					7421	7434		10.1038/sj.onc.1205802	http://dx.doi.org/10.1038/sj.onc.1205802			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379883				2022-12-17	WOS:000178618000013
J	Balsara, BR; Testa, JR				Balsara, BR; Testa, JR			Chromosomal imbalances in human lung cancer	ONCOGENE			English	Article						small cell lung carcinoma; non-small cell lung carcinoma; cytogenetics; CGH analysis	SMALL-CELL-CARCINOMA; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER; MOLECULAR CYTOGENETIC ANALYSIS; FHIT GENE; EPIGENETIC INACTIVATION; SOLID TUMORS; SHORT ARM; N-MYC; ABNORMALITIES	A wealth of cytogenetic data has demonstrated that numerous somatic genetic changes are involved in the pathogenesis of human lung cancer. Despite the complexity of the genomic changes observed in these neoplasms, recurrent chromosomal patterns have emerged. In this review, we summarize chromosomal alterations identified in small cell and non-small cell lung cancer, using classical and molecular cytogenetic techniques. These analyses have uncovered a set of chromosome regions implicated in lung cancer development and progression. However, many of the target genes remain unknown. Newer technology, such as array-CGH, when combined with cDNA microarrays and tissue microarrays, will facilitate the integration of genomic and gene expression data and pave the way toward a molecular classification of lung carcinomas. The molecular implications of consistent chromosome imbalances found in lung cancer to date are also discussed.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NCI NIH HHS [CA-58184, CA-06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, P50CA058184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Bjorkqvist AM, 1998, BRIT J CANCER, V77, P260, DOI 10.1038/bjc.1998.42; Brass N, 1996, EUR J CANCER, V32A, P1205, DOI 10.1016/0959-8049(96)00016-0; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BRENNAN J, 1991, CANCER RES, V51, P1708; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; DEFUSCO PA, 1989, MAYO CLIN PROC, V64, P168, DOI 10.1016/S0025-6196(12)65671-7; Feder M, 1998, CANCER GENET CYTOGEN, V102, P25, DOI 10.1016/S0165-4608(97)00274-4; GEMMA A, 1988, CANCER RES, V48, P6025; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Heim S, 1995, CANC CYTOGENETICS; Heselmeyer K, 1996, P NATL ACAD SCI USA, V93, P479, DOI 10.1073/pnas.93.1.479; Ji L, 1999, CANCER RES, V59, P3333; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEE JS, 1987, CANCER RES, V47, P6349; LEVIN NA, 1995, GENE CHROMOSOME CANC, V13, P175, DOI 10.1002/gcc.2870130307; LEVIN NA, 1994, CANCER RES, V54, P5086; Luk C, 2001, CANCER GENET CYTOGEN, V125, P87, DOI 10.1016/S0165-4608(00)00363-0; LUKEIS R, 1990, GENE CHROMOSOME CANC, V2, P116, DOI 10.1002/gcc.2870020207; MIURA I, 1992, CANCER RES, V52, P1322; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Pei JM, 2001, GENE CHROMOSOME CANC, V31, P282, DOI 10.1002/gcc.1145; Petersen I, 1997, CANCER RES, V57, P2331; RIED T, 1994, CANCER RES, V54, P1801; Roche J, 1996, ONCOGENE, V12, P1289; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; SEKIDO Y, 2001, CANC PRINCIPLES PRAC, P917; SHAPIRO GI, 1995, CANCER RES, V55, P505; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; SOZZI G, 1987, CANCER GENET CYTOGEN, V27, P45, DOI 10.1016/0165-4608(87)90259-7; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Testa JR, 1997, CANCER GENET CYTOGEN, V95, P20, DOI 10.1016/S0165-4608(96)00337-8; TESTA JR, 1993, CANCER DETECT PREV, V17, P267; TESTA JR, 1994, GENE CHROMOSOME CANC, V11, P178, DOI 10.1002/gcc.2870110307; Todd S, 1997, CANCER RES, V57, P1344; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659; WURSTERHILL DH, 1984, CANCER GENET CYTOGEN, V13, P303, DOI 10.1016/0165-4608(84)90075-X; Yokomizo A, 1998, ONCOGENE, V17, P475, DOI 10.1038/sj.onc.1201956; YOKOTA J, 1988, ONCOGENE, V2, P607	53	157	165	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	2002	21	45					6877	6883		10.1038/sj.onc.1205836	http://dx.doi.org/10.1038/sj.onc.1205836			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604UV	12362270				2022-12-17	WOS:000178640200003
J	Lin, YM; Furukawa, Y; Tsunoda, T; Yue, CT; Yang, KC; Nakamura, Y				Lin, YM; Furukawa, Y; Tsunoda, T; Yue, CT; Yang, KC; Nakamura, Y			Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas	ONCOGENE			English	Article						colon cancer; adenoma-carcinoma sequence; cDNA microarray; expression profile	CDNA MICROARRAY; CANCER-CELLS; HYPOXIA; IDENTIFICATION; CARCINOGENESIS; RIBOSOME	Most colon cancers are thought to develop through the 'adenoma-to-carcinoma sequence' model. To elucidate the mechanisms underlying this pathway, we analysed gene-expression profiles of 20 colorectal tumors (nine adenomas and 11 differentiated adenocarcinomas) by means of a cDNA microarray representing 23 040 genes coupled with laser-capture micro dissection. A two-dimensional hierarchical clustering analysis of expression profiles of the 20 tumors correctly separated the carcinoma group from the adenoma group. Furthermore we identified 51 genes whose expression was commonly up-regulated, 376 that were commonly down-regulated in both types of tumors as opposed to normal colonic epithelium and 50 whose expression levels were significantly different between adenomas and carcinomas. On the basis of expression profiles of the 50 discriminating genes, we established a scoring system to separate adenomas from carcinomas. Application of this scoring system for evaluating five additional colorectal tumors correctly predicted their histological features. The genome-wide information reported here should contribute to a more profound understanding of colorectal tumorigenesis, particularly of adenoma-carcinoma progression, and provide indicators for developing novel strategies to diagnose, treat, and ultimately prevent colorectal carcinomas.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 1088639, Japan; Shin Kong Wu Ho Su Mem Hosp, Dept Internal Med, Taipei 11160, Taiwan; RIKEN, Inst Phys & Chem Res, SNP Res Ctr, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; Shin Kong Wu Ho Su Memorial Hospital; RIKEN	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Tsunoda, Tatsuhiko/K-2061-2014	Tsunoda, Tatsuhiko/0000-0002-5439-7918				Afshari CA, 1999, CANCER RES, V59, P4759; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; CHU FF, 1993, J BIOL CHEM, V268, P2571; Denko N, 2000, CLIN CANCER RES, V6, P480; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hoeren FU, 1998, GENETICS, V149, P479; Kallioniemi OP, 2001, ANN MED, V33, P142, DOI 10.3109/07853890109002069; Kitahara O, 2001, CANCER RES, V61, P3544; Lawrance IC, 2001, HUM MOL GENET, V10, P445, DOI 10.1093/hmg/10.5.445; Maguire BA, 2001, CELL, V104, P813, DOI 10.1016/S0092-8674(01)00278-1; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; Notterman DA, 2001, CANCER RES, V61, P3124; Ogiso Y, 1999, BIOCHEM BIOPH RES CO, V258, P448, DOI 10.1006/bbrc.1999.0635; Okabe H, 2001, CANCER RES, V61, P2129; Ono K, 2000, CANCER RES, V60, P5007; Schlemper RJ, 2000, GUT, V47, P251, DOI 10.1136/gut.47.2.251; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; UHLIG S, 1992, LIFE SCI, V51, P1083, DOI 10.1016/0024-3205(92)90509-N; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Wodopia R, 2000, AM J PHYSIOL-LUNG C, V279, pL1110, DOI 10.1152/ajplung.2000.279.6.L1110; Zhong H, 1999, BIOCHEM BIOPH RES CO, V259, P523, DOI 10.1006/bbrc.1999.0815	22	157	172	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4120	4128		10.1038/sj.onc.1205518	http://dx.doi.org/10.1038/sj.onc.1205518			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037668				2022-12-17	WOS:000176186000006
J	Fang, L; Igarashi, M; Leung, J; Sugrue, MM; Lee, SW; Aaronson, SA				Fang, L; Igarashi, M; Leung, J; Sugrue, MM; Lee, SW; Aaronson, SA			p21(Waf1/Cip1/Sdi1) induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53	ONCOGENE			English	Article						p21(Waf1/Cip1/Sdi1); replicative senescence; EJ; tetracycline-regulatable expression system; mitomycin C	CYCLIN-DEPENDENT KINASES; NUCLEOTIDE EXCISION-REPAIR; INHIBITS DNA-REPLICATION; HUMAN FIBROBLASTS; P53-INDEPENDENT PATHWAY; WILD-TYPE; NUCLEAR ANTIGEN; GENE-EXPRESSION; MAMMALIAN-CELLS; CDK INHIBITORS	We have shown previously that wild type p53 can rapidly induce replicative senescence in EJ human bladder carcinoma cells lacking functional p53, A major effector of p53 functions is p21(Waf1/Cip1/Sdi1), a potent cyclin-dependent kinase inhibitor. p21(Waf1/Cip1/Sdi1) has been shown to be involved in both p53 dependent and independent control of cell proliferation, differentiation and death. To directly investigate the effects of p21(Waf1/Cip1/Sid1) in the p53 response observed in EJ tumor cells, we established p21(Waf1/Cip1/Sdi1) inducible lines using the tetracycline-regulatable vector system. p21(Waf1/Cip1/Sdi1) induction caused irreversible cell cycle arrest in both G1 and G2/M, and diminished Cdk2 kinase activity. In addition, p21(Waf1/Cip1/Sdi1) induction led to morphological alterations characteristic of cells undergoing replicative senescence with morphological, biochemical and ultrastructural markers of the senescent phenotype, Furthermore, sustained p21(Waf1/Cip1/Sdi1) induction sensitized EJ cells to apoptotic cell death induced by mitomycin C, a cross-linking DNA damaging agent, These findings support the function of p21(Waf1/Cip1/Sdi1) as an inducer of replicative senescence and a major mediator of this phenomenon in response to p53. Moreover, our results imply that therapeutic intervention in human cancers might be aimed at sustained elevation Of p21(Waf1/Cip1/Sid1) expression.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Aaronson, SA (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA.				NATIONAL CANCER INSTITUTE [R01CA066654, R01CA066271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG008812, P30AG008812] Funding Source: NIH RePORTER; NCI NIH HHS [CA66271-01, CA66654] Funding Source: Medline; NIA NIH HHS [AG08812] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Alpan RS, 1996, CELL GROWTH DIFFER, V7, P893; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erhardt JA, 1998, ONCOGENE, V16, P443, DOI 10.1038/sj.onc.1201577; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GHADIALLY FN, 1975, ULTRASTRUCT PATHOL, P306; Gorospe M, 1996, CANCER RES, V56, P475; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRANA X, 1995, ONCOGENE, V11, P211; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; JIANG HP, 1994, ONCOGENE, V9, P3397; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Medcalf ASC, 1996, CANCER RES, V56, P4582; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; MICHIELI P, 1994, CANCER RES, V54, P3391; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Pignolo RJ, 1998, EXP GERONTOL, V33, P67, DOI 10.1016/S0531-5565(97)00090-9; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RIEGER KM, 1995, BRIT J CANCER, V72, P683, DOI 10.1038/bjc.1995.394; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; Sekiguchi T, 1998, ONCOGENE, V16, P369, DOI 10.1038/sj.onc.1201539; SHARMA S, 1993, CELL GROWTH DIFFER, V4, P861; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAHARA H, 1995, ONCOGENE, V10, P835; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG E, 1995, CANCER RES, V55, P2284; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG LQ, 1995, EXP CELL RES, V221, P126, DOI 10.1006/excr.1995.1359; YANISHEVSKY R, 1974, J CELL PHYSIOL, V84, P165, DOI 10.1002/jcp.1040840202; YU Y, 1998, ONCOGENE, V16, P705	65	157	164	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	1999	18	18					2789	2797		10.1038/sj.onc.1202615	http://dx.doi.org/10.1038/sj.onc.1202615			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362249				2022-12-17	WOS:000080125100001
J	Bottger, V; Bottger, A; Garcia-Echeverria, C; Ramos, YFM; van der Eb, AJ; Jochemsen, AG; Lane, DP				Bottger, V; Bottger, A; Garcia-Echeverria, C; Ramos, YFM; van der Eb, AJ; Jochemsen, AG; Lane, DP			Comparative study of the p53-mdm2 and p53-MDMX interfaces	ONCOGENE			English	Article						p53; mdm2; MDMX; phage display; phosphorylated peptides	DEPENDENT PROTEIN-KINASE; WILD-TYPE P53; DNA-DAMAGE; MONOCLONAL-ANTIBODIES; PHAGE DISPLAY; MDM2 BINDING; IMMUNOCHEMICAL ANALYSIS; TRANSACTIVATION DOMAIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE	Mdm2 and MDMX are two structurally related p53-binding proteins which show the highest level of sequence similarity in the N-terminal p53-binding domains, Apart from its ability to inhibit p53 mediated transcription, a feature it shares with mdm2, very little is known about the physiological functions of MDMX, It is clearly distinct from mdm2 since its expression appears not to be regulated by p53 and it cannot compensate for lack of mdm2 in early development. We present data on the structural similarity between the p53 binding pockets of mdm2 and MDMX using p53- and phage-selected peptides, From the results we conclude that our recently devised innovative approach to reverse the mdm2-mediated inhibition of p53's transactivation function in vivo would probably target MDMX as well. Strategies for selectively targeting mdm2 and MDMX are suggested and a possible mechanism for regulating the p53-mdm2/MDMX interactions by protein phosphorylation is discussed.	Univ Dundee, Canc Res Campaign Labs, Dundee DD1 4HN, Scotland; Leiden Univ, Med Ctr, Dept Mol Cell Biol, Mol Carcinogenesis Lab, NL-2300 RA Leiden, Netherlands; Novartis Pharma AG, Oncol Res, CH-4002 Basel, Switzerland	University of Dundee; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Novartis	Bottger, V (corresponding author), Univ Dundee, Canc Res Campaign Labs, Dundee DD1 4HN, Scotland.		Ramos, Yolande F. M./C-3774-2018; Lane, David P/C-4920-2008	Ramos, Yolande F. M./0000-0003-1459-413X; Lane, David/0000-0003-0551-3545; Bottger, Angelika/0000-0003-3273-9558				BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARTEK J, 1993, J PATHOL, V169, P27, DOI 10.1002/path.1711690106; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; BOTTGER V, 1995, J MOL BIOL, V247, P932, DOI 10.1006/jmbi.1995.0191; Bottger V, 1996, ONCOGENE, V13, P2141; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHAN S, 1987, MOL CELL PROBE, V1, P73, DOI 10.1016/0890-8508(87)90008-9; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; GARCIAECHEVERRI.C, 1995, LETT PEPT SCI, V2, P369; GARCIAECHEVERRIA C, 1995, LETT PEPT SCI, V2, P93, DOI 10.1007/BF00128503; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Knippschild U, 1996, ONCOGENE, V13, P1387; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LUNA RMD, 1995, NATURE, V378, P203; Mayo LD, 1997, CANCER RES, V57, P5013; MCCAFFERTY J, 1994, APPL BIOCHEM BIOTECH, V47, P157, DOI 10.1007/BF02787932; Meek DW, 1997, BIOCHEM SOC T, V25, P416, DOI 10.1042/bst0250416; MICHEEL B, 1994, J IMMUNOL METHODS, V171, P103, DOI 10.1016/0022-1759(94)90233-X; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MILNE DM, 1992, ONCOGENE, V7, P1361; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Rathmell WK, 1997, CANCER RES, V57, P68; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A	37	157	160	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					189	199		10.1038/sj.onc.1202281	http://dx.doi.org/10.1038/sj.onc.1202281			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926934				2022-12-17	WOS:000078166000021
J	Chen, ZH; Seimiya, H; Naito, M; Mashima, T; Kizaki, A; Dan, S; Imaizumi, M; Ichijo, H; Miyazono, K; Tsuruo, T				Chen, ZH; Seimiya, H; Naito, M; Mashima, T; Kizaki, A; Dan, S; Imaizumi, M; Ichijo, H; Miyazono, K; Tsuruo, T			ASK1 mediates apoptotic cell death induced by genotoxic stress	ONCOGENE			English	Article						ASK1; apoptosis; kinase cascades; genotoxic stress	ACTIVATED PROTEIN-KINASE; CHEMOTHERAPY-INDUCED APOPTOSIS; CERAMIDE-INDUCED APOPTOSIS; LEUKEMIA U937 CELLS; C-JUN; JNK ACTIVATION; POLY(ADP-RIBOSE) POLYMERASE; SIGNALING PATHWAY; GAMMA-RADIATION; TNF RECEPTOR-1	Genotoxic stress-induced apoptosis is mediated by caspase family proteases as triggered by other stimuli. In this study, we found that the DNA-damaging agent cisplatin (cDDP) activated MAP kinase kinase kinase ASK1 and subsequent downstream subgroups of MAP kinase kinase, SEK1 (or MKK4) and MKK3/MKK6, which in turn activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK) and p38 MAP kinase prior to caspase family protease activation and the onset of apoptosis in human ovarian carcinoma (OVCAR-3) and human kidney (293T) cells. As reported previously, benzyloxy carbonyl-Asp-CH2OC(O)-2, 6-dichlorobenzene (Z-Asp), a preferential inhibitor of caspase family proteases, blocked the apoptosis of OVCAR-3 cells induced by the genotoxic stress cDDP. Z-Asp, however, did not inhibit ASK1 activation and the subsequent kinase cascades. Overexpression of kinase-negative ASK1 (K709R), which inhibited ASK1 activation and the downstream MKK3-p38 and MKK4-JNK1 pathways, also suppressed the caspase protease activation and apoptosis induced by cDDP. These results indicate that the ASK1 pathway is involved in genotoxic stress-induced apoptosis and mediates apoptosis at a step upstream of caspase protease activation.	Univ Tokyo, Inst Mol & Cellular Biosci, Biomed Res Lab, Bunkyo Ku, Tokyo 113, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 170, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Biomed Res Lab, Bunkyo Ku, Tokyo 113, Japan.			Ichijo, Hidenori/0000-0002-5005-6438; Seimiya, Hiroyuki/0000-0003-3314-9736				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Dong JA, 1997, ONCOGENE, V15, P639, DOI 10.1038/sj.onc.1201237; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; MEYN RE, 1994, CANCER CHEMOTH PHARM, V33, P410, DOI 10.1007/BF00686270; MEYN RE, 1995, ANTI-CANCER DRUG, V6, P443, DOI 10.1097/00001813-199506000-00013; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; SEARLE J, 1975, J PATHOL, V116, P129, DOI 10.1002/path.1711160302; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Teng DHF, 1997, CANCER RES, V57, P4177; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	49	157	162	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					173	180		10.1038/sj.onc.1202276	http://dx.doi.org/10.1038/sj.onc.1202276			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926932				2022-12-17	WOS:000078166000019
J	Nathan, CAO; Liu, L; Li, BD; Abreo, FW; Nandy, I; DeBenedetti, A				Nathan, CAO; Liu, L; Li, BD; Abreo, FW; Nandy, I; DeBenedetti, A			Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer	ONCOGENE			English	Article						eIF4E; carcinomas; head and neck; surgical margins	SQUAMOUS-CELL CARCINOMA; EXPRESSION; OVEREXPRESSION; TRANSFORMATION; PROTOONCOGENE	Head and neck squamous cell cancers (HNSCC) have a high local recurrence rate due to incomplete tumor resection. The use of molecular markers to establish surgical margins may decrease local recurrence. Surgical margins are determined by histopathologic analysis on frozen sections, We postulate that genetic and molecular changes precede gross histologic alterations. Tumor markers may improve the reliability of pathology examination, but those evaluated to date lack the sensitivity needed for routine clinical use. Western blot analysis showed elevated eIF4E in all 26 HNSCC in contrast to its low expression in benign lesions. Surgical margins were analysed for eIF4E in 23 patients. Twelve patients showed elevated eIF4E in histologically negative margins. Cancer has recurred in 5 of the 12 patients as opposed to none of the 11 patients with eIF4E negative margins (P = 0.02, Log rank test). This is the first report of eIF4E in HNSCC, as a sensitive and specific marker for HNSCC, with potential for defining clear resection margins. The correlation between elevated levels of eIF4E at the margins and recurrence highlights its ability to detect malignant cells prior to clear-cut alterations in morphology, The accuracy and simplicity of these assays underscore the usefulness of eIF4E in managing HNSCC.	VAMC, SHREVEPORT, LA USA; LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM & MOL BIOL, SHREVEPORT, LA 71130 USA; LOUISIANA STATE UNIV, MED CTR, DEPT SURG, SHREVEPORT, LA 71130 USA; LOUISIANA STATE UNIV, MED CTR, DEPT PATHOL, SHREVEPORT, LA 71130 USA; LOUISIANA STATE UNIV, MED CTR, DEPT BIOMETRY & ACAD COMP, SHREVEPORT, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Nathan, CAO (corresponding author), LOUISIANA STATE UNIV, MED CTR, DEPT OTOLARYNGOL HEAD & NECK SURG, SHREVEPORT, LA 71130 USA.			de benedetti, arrigo/0000-0002-4198-8647	NCI NIH HHS [CA69148-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA069148] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anthony B, 1996, INT J CANCER, V65, P858, DOI 10.1002/(SICI)1097-0215(19960315)65:6<858::AID-IJC25>3.0.CO;2-Z; BECHHARDT RN, 1995, ARCH OTOLARYNGOL, V121, P1265; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; DAVIDSON TM, 1981, OTOLARYNG HEAD NECK, V89, P244, DOI 10.1177/019459988108900219; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; FIELD JK, 1989, ONCOGENE, V4, P1463; Folkman J, 1976, Int Rev Exp Pathol, V16, P207; GANDOUREDWARDS RF, 1993, HEAD NECK-J SCI SPEC, V15, P373, DOI 10.1002/hed.2880150502; GILBERT H, 1974, J SURG ONCOL, V6, P357, DOI 10.1002/jso.2930060502; HARLOW E, 1988, ANTIBODIES LABORATOR, P403; JESSE RH, 1976, AM J SURG, V132, P435, DOI 10.1016/0002-9610(76)90314-7; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; Kevil C, 1995, ONCOGENE, V11, P2339; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; KIARIS H, 1995, BRIT J CANCER, V72, P123, DOI 10.1038/bjc.1995.287; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LOOSER KG, 1978, HEAD NECK SURG, V1, P107, DOI 10.1002/hed.2890010203; MAESTRO R, 1992, ONCOGENE, V7, P1159; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; Rousseau D, 1996, ONCOGENE, V13, P2415; SHANTZ LM, 1994, CANCER RES, V54, P2313; Sonenberg N, 1993, CURR OPIN CELL BIOL, V5, P955, DOI 10.1016/0955-0674(93)90076-3	23	157	167	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	1997	15	5					579	584		10.1038/sj.onc.1201216	http://dx.doi.org/10.1038/sj.onc.1201216			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247311				2022-12-17	WOS:A1997XN25500009
J	Sakamuro, D; Eviner, V; Elliott, KJ; Showe, L; White, E; Prendergast, GC				Sakamuro, D; Eviner, V; Elliott, KJ; Showe, L; White, E; Prendergast, GC			c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms	ONCOGENE			English	Article						Myc; p53; apoptosis; epithelial cells	ORNITHINE DECARBOXYLASE; ADENOVIRUS E1A; P53; BCL-2; GENE; EXPRESSION; PROLIFERATION; MUTATIONS; LYMPHOMA; DEATH	We tested the hypothesis that wild-type p53 activity is required for c-Myc-dependent apoptosis in epithelial cells, Primary baby rat kidney epithelial cell lines were generated by immortalization through the concerted action of c-Myc and a temperature-sensitive (ts) dominant inhibitory mutant allele of p53 (BRK myc/p53ts cells), When shifted to the permissive temperature for wild-type p53 activity, the BRK myc/p53ts cells underwent growth arrest and apoptosis, However, apoptosis also could be induced by serum deprivation at the nonpermissive temperature, when p53 was in the mutant state, Bcl-2 suppressed both modes of cell death, Apoptosis induced by wild-type p53 but not by serum deprivation was accompanied by G1 cell cycle arrest and increased expression of the Bcl-2 antagonist Bar. We concluded that c-Myc could induce apoptosis in epithelial cells by at least two mechanisms that could be distinguished by their p53 requirement, Our results support the possibility that c-Myc-dependent cell death might be exploited for therapeutic ends during carcinoma development, without regard to p53 status of the target cell.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,MOLEC BIOL GRAD GRP,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104; CTR ADV BIOCHEM & MED,PISCATAWAY,NJ 08854; RUTGERS STATE UNIV,DEPT BIOMED SCI,PISCATAWAY,NJ 08854	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; Rutgers State University New Brunswick			White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065; Eviner, Valerie/0000-0001-5530-9417	NCI NIH HHS [CA-10815-28, CA-53370] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053370, P30CA010815, R01CA053370] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERT T, 1994, ONCOGENE, V9, P759; ASKEW DS, 1993, BLOOD, V82, P2079; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FRYKBERG L, 1987, ONCOGENE, V1, P415; GIBSON AW, 1995, EXP CELL RES, V218, P351, DOI 10.1006/excr.1995.1166; HARPER JW, 1993, CELL, V75, P805; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; RAJCHEL A, 1987, NUCLEIC ACIDS RES, V16, P2347; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; TEODORO JG, 1995, ONCOGENE, V11, P467; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WANG YS, 1993, ONCOGENE, V8, P3427; YANO T, 1993, ONCOGENE, V8, P2741	53	157	160	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2411	2418						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570193				2022-12-17	WOS:A1995TK70200026
J	HAUPT, Y; ROWAN, S; OREN, M				HAUPT, Y; ROWAN, S; OREN, M			P53-MEDIATED APOPTOSIS IN HELA-CELLS CAN BE OVERCOME BY EXCESS PRB	ONCOGENE			English	Article						P53; APOPTOSIS; PRB; TUNEL; TUMOR SUPPRESSION	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; TUMOR-SUPPRESSOR GENE; DNA-DAMAGING AGENTS; CYCLE CONTROL; GROWTH SUPPRESSION; PROTEIN; DEATH; IDENTIFICATION	Studies on DNA tumor viruses have suggested a link between p53 and pRB in the control of cell growth and apoptosis. We examined the role of pRB in the control of p53-mediated apoptosis in HeLa cells, in which the activities of p53 and members of the pRB family are very low, Transient overexpression of wild type (wt) p53 in HeLa cells induced apoptotic cell death. Importantly, coexpression of functional pRB resulted in significant protection of HeLa cells from p53-mediated apoptosis, without interfering with the transcriptional activity of wt p53. These results suggest that pRB, and possibly other pRB-related proteins, play a major role in the decision of whether cells respond to activated p53 by undergoing growth arrest or apoptosis. Our findings demonstrate a direct link between these two tumor suppressors in the control of cell growth and cell death.			HAUPT, Y (corresponding author), WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL.		Rowan, Sheldon/AAA-3271-2019	Rowan, Sheldon/0000-0002-1123-6743	NCI NIH HHS [R01 CA 4009] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BERNS A, 1994, CURR BIOL, V4, P137, DOI 10.1016/S0960-9822(94)00031-X; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FANNING E, 1992, MALIGNANT TRANSFORMA, P1; Farthing Alan J., 1994, Trends in Microbiology, V2, P170, DOI 10.1016/0966-842X(94)90667-X; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANNON JV, 1991, NATURE, V349, P802; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GORCZYCA W, 1993, CANCER RES, V53, P1945; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEVY N, 1993, MOL CELL BIOL, V13, P7942, DOI 10.1128/MCB.13.12.7942; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHAELMICHALOV.D, 1991, J VIROL, V65, P4160; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; OREN M, 1994, CANCER BIOL, V5, P1; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; STRATTON MR, 1990, ONCOGENE, V5, P1297; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; VOGELSTEIN B, 1994, NATURE, V370, P174, DOI 10.1038/370174a0; VOUDSEN KH, 1993, ONCOGENE, V8, P1697; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WHITE E, 1993, GENE DEV, V7, P2277, DOI 10.1101/gad.7.12a.2277; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WIMAN KG, 1993, FASEB J, V7, P841, DOI 10.1096/fasebj.7.10.8393817; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; YONISHROUACH E, 1993, PROGRAMMED CELL DEAT, P187; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	79	157	158	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1563	1571						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731711				2022-12-17	WOS:A1995QU68100012
J	Ramos, P; Bentires-Alj, M				Ramos, P.; Bentires-Alj, M.			Mechanism-based cancer therapy: resistance to therapy, therapy for resistance	ONCOGENE			English	Review							METASTATIC BREAST-CANCER; PATIENTS RECEIVING IMATINIB; MEDIATED DRUG-RESISTANCE; CHRONIC MYELOID-LEUKEMIA; CELL LUNG-CANCER; TRASTUZUMAB RESISTANCE; ACQUIRED-RESISTANCE; TUMOR MICROENVIRONMENT; PI3K INHIBITORS; MEK INHIBITORS	The introduction of targeted therapy promised personalized and efficacious cancer treatments. However, although some targeted therapies have undoubtedly improved prognosis and outcome for specific cancer patients, the recurrent problem of therapeutic resistance subdues present revolutionary claims in this field. The plasticity of tumor cells leads to the development of drug resistance by distinct mechanisms: (1) mutations in the target, (2) reactivation of the targeted pathway, (3) hyperactivation of alternative pathways and (4) cross-talk with the microenvironment. Moreover, the intra-tumor heterogeneity of most tumors can also limit therapeutic response. Interestingly, the early identification of some mechanisms of resistance led to the use of alternative agents that improved clinical benefit, demonstrating that an understanding of the molecular mechanisms driving resistance to specific therapies is of paramount importance. Here we review the most generalized mechanisms of resistance to targeted therapies, together with some experimental strategies employed to identify such mechanisms. Therapeutic failure is not an option and we need to understand the dynamics of tumor adaptation in order to adequately adjust therapies; in essence 'to fight fire with fire'.	[Ramos, P.; Bentires-Alj, M.] Friedrich Miescher Inst Biomed Res FMI, Mechanisms Canc, Basel, Switzerland; [Ramos, P.] Novartis Inst Biomed Res, Oncol, Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; Novartis	Bentires-Alj, M (corresponding author), Friedrich Miescher Inst Biomed Res, Mechanisms Canc, Maulbeerstr 66, CH-4058 Basel, Switzerland.	bentires@fmi.ch	Bentires-Alj, Mohamed/F-4484-2015	Bentires-Alj, Mohamed/0000-0001-6344-1127	Novartis Research Foundation; European Research Council (ERC) [243211-PTP5BDC]; Swiss Cancer League; Swiss national science foundation; Krebsliga Beider Basel; 'Novartis presidential postdoc fellowship'	Novartis Research Foundation; European Research Council (ERC)(European Research Council (ERC)European Commission); Swiss Cancer League; Swiss national science foundation(Swiss National Science Foundation (SNSF)European Commission); Krebsliga Beider Basel; 'Novartis presidential postdoc fellowship'	Research in the laboratory of MB-A is supported by the Novartis Research Foundation, the European Research Council (ERC starting grant 243211-PTP5BDC), the Swiss Cancer League, the Swiss national science foundation and the Krebsliga Beider Basel. PR recevied a 'Novartis presidential postdoc fellowship'.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Aftimos PG, 2013, INT J ONCOL, V43, P919, DOI 10.3892/ijo.2013.2008; Alba E, 2014, BRIT J CANCER, V110, P1139, DOI 10.1038/bjc.2013.831; Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; Andre F, 2010, J CLIN ONCOL, V28, P5110, DOI 10.1200/JCO.2009.27.8549; Barok M, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2868; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Beaver JA, 2012, FUTURE ONCOL, V8, P651, DOI [10.2217/fon.12.49, 10.2217/FON.12.49]; Bedard PL, 2013, NATURE, V501, P355, DOI 10.1038/nature12627; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Blencke S, 2004, CHEM BIOL, V11, P691, DOI 10.1016/j.chembiol.2004.02.029; Bousquet G, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3615; Britschgi A, 2013, DRUG RESIST UPDATE, V16, P68, DOI 10.1016/j.drup.2013.10.001; Britschgi A, 2012, CANCER CELL, V22, P796, DOI 10.1016/j.ccr.2012.10.023; Burris HA, 2013, CANCER CHEMOTH PHARM, V71, P829, DOI 10.1007/s00280-012-2043-3; Burris HA, 2011, J CLIN ONCOL, V29, P398, DOI 10.1200/JCO.2010.29.5865; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Chandarlapaty S, 2012, CLIN CANCER RES, V18, P6784, DOI 10.1158/1078-0432.CCR-12-1785; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chen L, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-93; Collier LS, 2005, NATURE, V436, P272, DOI 10.1038/nature03681; Cools J, 2004, CANCER RES, V64, P6385, DOI 10.1158/0008-5472.CAN-04-2148; Corcoran RB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001148; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Damiano JS, 2001, LEUKEMIA, V15, P1232, DOI 10.1038/sj.leu.2402179; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; De Luca A, 2012, EXPERT OPIN THER TAR, V16, pS17, DOI 10.1517/14728222.2011.639361; Dhillon S, 2013, DRUGS, V73, P475, DOI 10.1007/s40265-013-0034-2; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Dupuy AJ, 2005, NATURE, V436, P221, DOI 10.1038/nature03691; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Ercan D, 2010, ONCOGENE, V29, P2346, DOI 10.1038/onc.2009.526; Esteva FJ, 2010, AM J PATHOL, V177, P1647, DOI 10.2353/ajpath.2010.090885; Fang H, 2013, CANCER RES, V73, P4965, DOI 10.1158/0008-5472.CAN-13-0661; Galizia G, 2007, ONCOGENE, V26, P3654, DOI 10.1038/sj.onc.1210381; Gallardo A, 2012, BRIT J CANCER, V106, P1367, DOI 10.1038/bjc.2012.85; Gambacorti-Passerini C, 2011, JNCI-J NATL CANCER I, V103, P553, DOI 10.1093/jnci/djr060; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Gillies RJ, 2012, NAT REV CANCER, V12, P487, DOI 10.1038/nrc3298; Grant S, 2008, J CLIN INVEST, V118, P3003, DOI 10.1172/JCI36898; Gridelli C, 2007, ONCOLOGIST, V12, P840, DOI 10.1634/theoncologist.12-7-840; Haber DA, 2011, CELL, V145, P19, DOI 10.1016/j.cell.2011.03.026; Hafsi S, 2012, INT J ONCOL, V40, P639, DOI 10.3892/ijo.2011.1312; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harbinski F, 2012, CANCER DISCOV, V2, P948, DOI 10.1158/2159-8290.CD-12-0237; Hidalgo M, 2011, MOL CANCER THER, V10, P1311, DOI 10.1158/1535-7163.MCT-11-0233; Ho WJ, 2010, CANCER SCI, V101, P2637, DOI 10.1111/j.1349-7006.2010.01723.x; Hochhaus A, 2009, LEUKEMIA, V23, P1054, DOI 10.1038/leu.2009.38; Hoeflich KP, 2012, CANCER RES, V72, P210, DOI 10.1158/0008-5472.CAN-11-1515; Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317; Hongisto V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077232; Huang C, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2936; Janne PA, 2009, NAT REV DRUG DISCOV, V8, P709, DOI 10.1038/nrd2871; Janku F, 2014, THER ADV MED ONCOL, V6, P43, DOI 10.1177/1758834013517414; Janku F, 2013, CANCER RES, V73, P276, DOI 10.1158/0008-5472.CAN-12-1726; Jin K, 2012, INT J ONCOL, V41, P583, DOI 10.3892/ijo.2012.1469; Joensuu H, 2006, NEW ENGL J MED, V354, P809, DOI 10.1056/NEJMoa053028; Jordan VC, 2008, EUR J CANCER, V44, P30, DOI 10.1016/j.ejca.2007.11.002; JORDAN VC, 1976, CANCER TREAT REP, V60, P1409; Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626; Junttila TT, 2011, BREAST CANCER RES TR, V128, P347, DOI 10.1007/s10549-010-1090-x; Karvela M, 2012, EXPERT REV ANTICANC, V12, P381, DOI [10.1586/ERA.12.10, 10.1586/era.12.10]; Kinkade CW, 2008, J CLIN INVEST, V118, P3051, DOI 10.1172/JCI34764; Klein CA, 2013, NATURE, V501, P365, DOI 10.1038/nature12628; Krop IE, 2010, J CLIN ONCOL, V28, P2698, DOI 10.1200/JCO.2009.26.2071; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Legrier ME, 2007, CANCER RES, V67, P11300, DOI 10.1158/0008-5472.CAN-07-0702; Li FF, 2014, INT J CANCER, V134, P1257, DOI 10.1002/ijc.28261; Lin D, 2014, CANCER RES, V74, P1272, DOI 10.1158/0008-5472.CAN-13-2921-T; Liu PX, 2011, NAT MED, V17, P1116, DOI 10.1038/nm.2402; Lu CH, 2007, CLIN CANCER RES, V13, P5883, DOI 10.1158/1078-0432.CCR-06-2837; Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; McCubrey JA, 2012, ONCOTARGET, V3, P1068, DOI 10.18632/oncotarget.659; McCubrey JA, 2011, J CELL PHYSIOL, V226, P2762, DOI 10.1002/jcp.22647; Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714; Miller TW, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3039; Mori Y, 2004, BLOOD, V104, P2149, DOI 10.1182/blood-2004-01-0236; Muellner MK, 2011, NAT CHEM BIOL, V7, P787, DOI 10.1038/nchembio.695; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; Murtaza M, 2013, NATURE, V497, P108, DOI 10.1038/nature12065; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509; Nardi V, 2004, CURR OPIN HEMATOL, V11, P35, DOI 10.1097/00062752-200401000-00006; Navin N, 2010, GENOME RES, V20, P68, DOI 10.1101/gr.099622.109; NICHOLSON RI, 1975, EUR J CANCER, V11, P571, DOI 10.1016/0014-2964(75)90129-2; Nielsen DL, 2013, BREAST, V22, P1, DOI 10.1016/j.breast.2012.09.008; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Park CC, 2008, CANCER RES, V68, P4398, DOI 10.1158/0008-5472.CAN-07-6390; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Quintas-Cardama A, 2013, LEUKEMIA RES, V37, P487, DOI 10.1016/j.leukres.2013.01.006; Rad R, 2010, SCIENCE, V330, P1104, DOI 10.1126/science.1193004; Rahrmann EP, 2013, NAT GENET, V45, P756, DOI 10.1038/ng.2641; Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schwartz MA, 2008, CLIN CANCER RES, V14, P6193, DOI 10.1158/1078-0432.CCR-08-1285; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sridhar SS, 2003, LANCET ONCOL, V4, P397, DOI 10.1016/S1470-2045(03)01137-9; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Swanton C, 2012, CANCER RES, V72, P4875, DOI 10.1158/0008-5472.CAN-12-2217; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Turajlic S, 2012, GENOME RES, V22, P196, DOI 10.1101/gr.125591.111; Vecchione L, 2011, EXP CELL RES, V317, P2765, DOI 10.1016/j.yexcr.2011.08.021; Vignot S, 2013, J CLIN ONCOL, V31, P2167, DOI 10.1200/JCO.2012.47.7737; Vignot S, 2012, CRIT REV ONCOL HEMAT, V84, P301, DOI 10.1016/j.critrevonc.2012.05.002; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang LP, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-248; Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765; Will M, 2014, CANCER DISCOV, V4, P334, DOI 10.1158/2159-8290.CD-13-0611; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yauch RL, 2012, CURR OPIN GENET DEV, V22, P45, DOI 10.1016/j.gde.2012.01.003; Yu K, 2008, CANCER BIOL THER, V7, P307	128	156	161	1	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3617	3626		10.1038/onc.2014.314	http://dx.doi.org/10.1038/onc.2014.314			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25263438				2022-12-17	WOS:000357679100001
J	Jones, RM; Mortusewicz, O; Afzal, I; Lorvellec, M; Garcia, P; Helleday, T; Petermann, E				Jones, R. M.; Mortusewicz, O.; Afzal, I.; Lorvellec, M.; Garcia, P.; Helleday, T.; Petermann, E.			Increased replication initiation and conflicts with transcription underlie Cyclin E-induced replication stress	ONCOGENE			English	Article						Cyclin E; replication fork; origin firing; DNA damage; homologous recombination	DNA-DAMAGE RESPONSE; ONCOGENE-INDUCED SENESCENCE; GENOMIC INSTABILITY; HUMAN-CELLS; S-PHASE; FORK PROGRESSION; MAMMALIAN-CELLS; ANTICANCER BARRIER; CANCER DEVELOPMENT; TUMOR SUPPRESSION	It has become increasingly clear that oncogenes not only provide aberrant growth signals to cells but also cause DNA damage at replication forks (replication stress), which activate the ataxia telangiectasia mutated (ATM)/p53-dependent tumor barrier. Here we studied underlying mechanisms of oncogene-induced replication stress in cells overexpressing the oncogene Cyclin E. Cyclin E overexpression is associated with increased firing of replication origins, impaired replication fork progression and DNA damage that activates RAD51-mediated recombination. By inhibiting replication initiation factors, we show that Cyclin E-induced replication slowing and DNA damage is a consequence of excessive origin firing. A significant amount of Cyclin E-induced replication slowing is due to interference between replication and transcription, which also underlies the activation of homologous recombination. Our data suggest that Cyclin E-induced replication stress is caused by deregulation of replication initiation and increased interference between replication and transcription, which results in impaired replication fork progression and DNA damage triggering the tumor barrier or cancer-promoting mutations.	[Jones, R. M.; Afzal, I.; Petermann, E.] Univ Birmingham, Inst Biomed Res, Coll Med & Dent Sci, Sch Canc Sci, Birmingham B15 2TT, W Midlands, England; [Mortusewicz, O.] Univ Oxford, Dept Oncol, Gray Inst Radiat Oncol & Biol, Oxford, England; [Lorvellec, M.; Garcia, P.] Univ Birmingham, Coll Med & Dent Sci, Sch Immun & Infect, Birmingham B15 2TT, W Midlands, England; [Helleday, T.] Karolinska Inst, Dept Med Biochem & Biophys, Sci Life Lab, Div Translat Med & Chem Biol, S-17121 Stockholm, Sweden	University of Birmingham; University of Oxford; University of Birmingham; Karolinska Institutet	Helleday, T (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Sci Life Lab, Div Translat Med & Chem Biol, S-17121 Stockholm, Sweden.	thomas.helleday@scilifelab.se; e.petermann@bham.ac.uk	Garcia, Paloma/AFO-2595-2022; Petermann, Eva/AAR-3368-2021	Petermann, Eva/0000-0002-5746-213X; Lorvellec, Maelle/0000-0002-7566-1415; Garcia, Paloma/0000-0001-5582-8575; Helleday, Thomas/0000-0002-7384-092X; Jones, Rebecca M/0000-0002-5310-8475	EMBO; Cancer Research UK	EMBO(European Molecular Biology Organization (EMBO)); Cancer Research UK(Cancer Research UK)	OM is supported by an EMBO Long-Term Fellowship. We thank Cancer Research UK for supporting this work financially, Dr Anastasia Zlatanou for cells and materials and Dr Agnieszka Gambus for helpful discussions.	Akli S, 2007, CANCER RES, V67, P7212, DOI 10.1158/0008-5472.CAN-07-0599; Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; Bartek J, 2007, CELL CYCLE, V6, P2344, DOI 10.4161/cc.6.19.4754; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Dereli-Oz A, 2011, MOL ONCOL, V5, P308, DOI 10.1016/j.molonc.2011.05.002; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Fang Y, 2004, EMBO J, V23, P3164, DOI 10.1038/sj.emboj.7600315; Gan WJ, 2011, GENE DEV, V25, P2041, DOI 10.1101/gad.17010011; Garcia P, 2000, ONCOGENE, V19, P1820, DOI 10.1038/sj.onc.1203494; Ge XQ, 2007, GENE DEV, V21, P3331, DOI 10.1101/gad.457807; Geng Y, 2007, MOL CELL, V25, P127, DOI 10.1016/j.molcel.2006.11.029; Gilbert DM, 2007, CHROMOSOMA, V116, P341, DOI 10.1007/s00412-007-0105-9; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gottipati P, 2008, MOL CELL BIOL, V28, P154, DOI 10.1128/MCB.00816-07; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Helmrich A, 2011, MOL CELL, V44, P966, DOI 10.1016/j.molcel.2011.10.013; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; JACKSON DA, 1995, EXP CELL RES, V220, P62, DOI 10.1006/excr.1995.1292; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; Kawabata T, 2011, MOL CELL, V41, P543, DOI 10.1016/j.molcel.2011.02.006; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Lorvellec M, 2010, STEM CELLS, V28, P1751, DOI 10.1002/stem.496; Lukas C, 2011, NAT CELL BIOL, V13, P243, DOI 10.1038/ncb2201; Lundin C, 2002, MOL CELL BIOL, V22, P5869, DOI 10.1128/MCB.22.16.5869-5878.2002; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Mechali M, 2010, NAT REV MOL CELL BIO, V11, P728, DOI 10.1038/nrm2976; Montagnoli A, 2008, NAT CHEM BIOL, V4, P357, DOI 10.1038/nchembio.90; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Nimonkar AV, 2011, GENE DEV, V25, P350, DOI 10.1101/gad.2003811; Petermann E, 2006, MOL CELL BIOL, V26, P3319, DOI 10.1128/MCB.26.8.3319-3326.2006; Petermann E, 2010, P NATL ACAD SCI USA, V107, P16090, DOI 10.1073/pnas.1005031107; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Shechter D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/ncb1145; Sorensen CS, 2004, CELL CYCLE, V3, P941; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Thomson AM, 2010, J CELL BIOL, V188, P209, DOI 10.1083/jcb.200911037; Tuduri S, 2010, CELL CYCLE, V9, P1886, DOI 10.4161/cc.9.10.11539; Tuduri S, 2009, NAT CELL BIOL, V11, P1315, DOI 10.1038/ncb1984; Woo RA, 2003, CELL CYCLE, V2, P316, DOI 10.4161/cc.2.4.468; Zlatanou A, 2011, MOL CELL, V43, P649, DOI 10.1016/j.molcel.2011.06.023	50	156	156	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2013	32	32					3744	3753		10.1038/onc.2012.387	http://dx.doi.org/10.1038/onc.2012.387			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	198EH	22945645				2022-12-17	WOS:000322904400009
J	McGivern, DR; Lemon, SM				McGivern, D. R.; Lemon, S. M.			Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer	ONCOGENE			English	Review						hepatitis C virus; hepatocellular carcinoma; cirrhosis; tumor suppressor	BOX RNA HELICASE; NF-KAPPA-B; HEPATOCELLULAR-CARCINOMA INCIDENCE; RETINOBLASTOMA TUMOR-SUPPRESSOR; CORE PROTEIN INTERACTS; OXIDATIVE STRESS; GENE-EXPRESSION; UNITED-STATES; ADAPTER PROTEIN; MOUSE MODEL	The development of hepatocellular carcinoma (HCC) in persons who are persistently infected with hepatitis C virus (HCV) is a growing problem worldwide. Current antiviral therapies are not effective in many patients with chronic hepatitis C, and a greater understanding of the factors leading to progression of HCC will be necessary to design novel approaches to prevention of HCV-associated HCC. The lack of a small animal model of chronic HCV infection has hampered understanding of these factors. As HCV is an RNA virus with little potential for integration of its genetic material into the host genome, the mechanisms underlying HCV promotion of cancer are likely to differ from other models of viral carcinogenesis. In patients persistently infected with HCV, chronic inflammation resulting from immune responses against infected hepatocytes is associated with progressive fibrosis and cirrhosis. Cirrhosis is an important risk factor for HCC independent of HCV infection, and a majority of HCV-associated HCC arises in the setting of cirrhosis. However, a significant minority arises in the absence of cirrhosis, indicating that cirrhosis is not a prerequisite for cancer. Other lines of evidence suggest that direct, virus-specific mechanisms may be involved. Transgenic mice expressing HCV proteins develop cancer in the absence of inflammation or immune recognition of the transgene. In vitro studies have revealed multiple interactions of HCV-encoded proteins with cell cycle regulators and tumor suppressor proteins, raising the possibility that HCV can disrupt control of cellular proliferation, or impair the cell's response to DNA damage. A combination of virus-specific, host genetic, environmental and immune-related factors are likely to determine the progression to HCC in patients who are chronically infected with HCV. Here, we summarize current knowledge of the virus-specific mechanisms that may contribute to HCV-associated HCC. Oncogene (2011) 30, 1969-1983; doi:10.1038/onc.2010.594; published online 24 January 2011	[Lemon, S. M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Infect Dis, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Ctr Translat Res, Inflammatory Dis Inst, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	McGivern, DR (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Infect Dis, Dept Med, Chapel W Dr,8-034 Burnett Womack, Chapel Hill, NC 27599 USA.	smlemon@med.unc.edu	Ibrahim, Essam Hassan/G-1960-2018; Mcgivern, David/H-6210-2019	Ibrahim, Essam Hassan/0000-0003-0130-2257; Mcgivern, David/0000-0003-3497-5087	University Cancer Research Fund; National Institutes of Health [P20-CA127004, R21-AI081058]; NATIONAL CANCER INSTITUTE [P20CA150343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI081058] Funding Source: NIH RePORTER	University Cancer Research Fund; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported in part by the University Cancer Research Fund and grants from the National Institutes of Health: P20-CA127004 and R21-AI081058.	Altekruse SF, 2009, J CLIN ONCOL, V27, P1485, DOI 10.1200/JCO.2008.20.7753; Angus AGN, 2010, J GEN VIROL, V91, P122, DOI 10.1099/vir.0.015909-0; Ariumi Y, 2008, J VIROL, V82, P9639, DOI 10.1128/JVI.00351-08; Ariumi Y, 2007, J VIROL, V81, P13922, DOI 10.1128/JVI.01517-07; Armstrong GL, 2006, ANN INTERN MED, V144, P705, DOI 10.7326/0003-4819-144-10-200605160-00004; Azechi H, 2001, ONCOLOGY-BASEL, V60, P346, DOI 10.1159/000058531; Bai SM, 2009, J BIOL CHEM, V284, P32015, DOI 10.1074/jbc.M109.016774; Baroni GS, 1999, LIVER, V19, P212, DOI 10.1111/j.1478-3231.1999.tb00038.x; Bartsch H, 2004, CANCER DETECT PREV, V28, P385, DOI 10.1016/j.cdp.2004.07.004; Bataller R, 2004, GASTROENTEROLOGY, V126, P529, DOI 10.1053/j.gastro.2003.11.018; Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550; Battaglia S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004355; Bigger CB, 2004, J VIROL, V78, P13779, DOI 10.1128/JVI.78.24.13779-13792.2004; Botlagunta M, 2008, ONCOGENE, V27, P3912, DOI 10.1038/onc.2008.33; Bowen DG, 2005, NATURE, V436, P946, DOI 10.1038/nature04079; Bralet MP, 2000, HEPATOLOGY, V32, P200, DOI 10.1053/jhep.2000.9033; Brenner David A, 2009, Trans Am Clin Climatol Assoc, V120, P361; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; Chang Jinhong, 2004, RNA Biol, V1, P106, DOI 10.4161/rna.1.2.1066; Chang PC, 2006, ONCOGENE, V25, P1991, DOI 10.1038/sj.onc.1209239; Chao CH, 2006, CANCER RES, V66, P6579, DOI 10.1158/0008-5472.CAN-05-2415; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Cheng PL, 2004, ONCOGENE, V23, P7821, DOI 10.1038/sj.onc.1208066; Chou AH, 2005, J IMMUNOL, V174, P2160, DOI 10.4049/jimmunol.174.4.2160; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Coulouarn C, 2009, ONCOGENE, V28, P3526, DOI 10.1038/onc.2009.211; Cross TJS, 2010, HEPATOL RES, V40, P237, DOI 10.1111/j.1872-034X.2010.00626.x; Davis GL, 2010, GASTROENTEROLOGY, V138, P513, DOI 10.1053/j.gastro.2009.09.067; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Degos F, 2000, GUT, V47, P131, DOI 10.1136/gut.47.1.131; Deng L, 2008, J VIROL, V82, P10375, DOI 10.1128/JVI.00395-08; Deng L, 2006, J GEN VIROL, V87, P1703, DOI 10.1099/vir.0.81735-0; Dharel N, 2008, HEPATOLOGY, V47, P1136, DOI 10.1002/hep.22176; Diamond DL, 2007, HEPATOLOGY, V46, P649, DOI 10.1002/hep.21751; Dolganiuc A, 2004, GASTROENTEROLOGY, V127, P1513, DOI 10.1053/j.gastro.2004.08.067; Dutta U, 1998, HUM PATHOL, V29, P1279, DOI 10.1016/S0046-8177(98)90257-X; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Edamoto Y, 2003, INT J CANCER, V106, P334, DOI 10.1002/ijc.11254; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Erdtmann L, 2003, J BIOL CHEM, V278, P18256, DOI 10.1074/jbc.M209732200; Farinati F, 1996, HEPATOLOGY, V23, P1468; Fornari F, 2009, CANCER RES, V69, P5761, DOI 10.1158/0008-5472.CAN-08-4797; Fox JG, 2010, GUT, V59, P88, DOI 10.1136/gut.2009.183749; Furutani T, 2006, GASTROENTEROLOGY, V130, P2087, DOI 10.1053/j.gastro.2006.02.060; Gale M, 1999, J VIROL, V73, P6506, DOI 10.1128/JVI.73.8.6506-6516.1999; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; Gao YZ, 2009, CARCINOGENESIS, V30, P2064, DOI 10.1093/carcin/bgp283; Ghosh AK, 1999, J GEN VIROL, V80, P1179, DOI 10.1099/0022-1317-80-5-1179; Goh PY, 2004, J VIROL, V78, P5288, DOI 10.1128/JVI.78.10.5288-5298.2004; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Gramantieri L, 2007, CANCER RES, V67, P6092, DOI 10.1158/0008-5472.CAN-06-4607; Henke JI, 2008, EMBO J, V27, P3300, DOI 10.1038/emboj.2008.244; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Honda A, 1999, J MED VIROL, V59, P281, DOI 10.1002/(SICI)1096-9071(199911)59:3<281::AID-JMV4>3.0.CO;2-S; Honda M, 2000, HEPATOLOGY, V31, P1351, DOI 10.1053/jhep.2000.7985; Ishido S, 1998, FEBS LETT, V438, P258, DOI 10.1016/S0014-5793(98)01312-X; Jangra RK, 2010, J VIROL, V84, P6810, DOI 10.1128/JVI.00397-10; Jangra RK, 2010, J VIROL, V84, P6615, DOI 10.1128/JVI.00417-10; Jopling CL, 2008, CELL HOST MICROBE, V4, P77, DOI 10.1016/j.chom.2008.05.013; Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329; Joyce MA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000291; Kamegaya Y, 2005, HEPATOLOGY, V41, P660, DOI 10.1002/hep.20621; Kao CF, 2004, ONCOGENE, V23, P2472, DOI 10.1038/sj.onc.1207368; Kato T, 2003, CANCER SCI, V94, P679, DOI 10.1111/j.1349-7006.2003.tb01502.x; Kawamura T, 1997, HEPATOLOGY, V25, P1014, DOI 10.1002/hep.510250437; Keasler VV, 2006, VIROLOGY, V347, P466, DOI 10.1016/j.virol.2005.11.050; Khidr L, 2006, ONCOGENE, V25, P5210, DOI 10.1038/sj.onc.1209612; Kim TY, 2003, J BIOL CHEM, V278, P15272, DOI 10.1074/jbc.M205792200; Klopstock N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005025; KOIKE K, 1995, J GEN VIROL, V76, P3031, DOI 10.1099/0022-1317-76-12-3031; Korenaga M, 2005, J BIOL CHEM, V280, P37481, DOI 10.1074/jbc.M506412200; Koskinas J, 2005, J VIRAL HEPATITIS, V12, P635, DOI 10.1111/j.1365-2893.2005.00635.x; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kutay H, 2006, J CELL BIOCHEM, V99, P671, DOI 10.1002/jcb.20982; Kwun HJ, 2001, J GEN VIROL, V82, P2235, DOI 10.1099/0022-1317-82-9-2235; Lai CK, 2008, VIROLOGY, V370, P295, DOI 10.1016/j.virol.2007.08.037; Lan KH, 2002, ONCOGENE, V21, P4801, DOI 10.1038/sj.onc.1205589; Lanford RE, 2011, HEPATITIS C: ANTIVIRAL DRUG DISCOVERY AND DEVELOPMENT, P103; Lanford RE, 2010, SCIENCE, V327, P198, DOI 10.1126/science.1178178; Lavanchy D, 2009, LIVER INT, V29, P74, DOI 10.1111/j.1478-3231.2008.01934.x; Lee SH, 2005, J IMMUNOL, V175, P8226, DOI 10.4049/jimmunol.175.12.8226; LEMON SM, 2007, FIELDS VIROLOGY, P1253; Lemon SM, 2010, J BIOL CHEM, V285, P22739, DOI 10.1074/jbc.R109.099556; Lentini L, 2002, NEOPLASIA, V4, P380, DOI 10.1038/sj.neo.7900256; Lerat H, 2002, GASTROENTEROLOGY, V122, P352, DOI 10.1053/gast.2002.31001; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Li K, 2002, HEPATOLOGY, V35, P1237, DOI 10.1053/jhep.2002.32968; Li XD, 2005, P NATL ACAD SCI USA, V102, P17717, DOI 10.1073/pnas.0508531102; Liang YQ, 2009, GASTROENTEROLOGY, V137, P1448, DOI 10.1053/j.gastro.2009.07.050; Lindenbach BD, 2005, NATURE, V436, P933, DOI 10.1038/nature04077; Liu XY, 2010, VIROLOGY, V398, P57, DOI 10.1016/j.virol.2009.11.036; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lok AS, 2009, GASTROENTEROLOGY, V136, P138, DOI 10.1053/j.gastro.2008.09.014; Lu W, 1999, VIROLOGY, V264, P134, DOI 10.1006/viro.1999.9979; Macdonald A, 2004, J GEN VIROL, V85, P721, DOI 10.1099/vir.0.19691-0; Machida K, 2009, J VIROL, V83, P12590, DOI 10.1128/JVI.02643-08; Machida K, 2009, P NATL ACAD SCI USA, V106, P1548, DOI 10.1073/pnas.0807390106; Majumder M, 2003, FEBS LETT, V555, P528, DOI 10.1016/S0014-5793(03)01337-1; Majumder M, 2001, J VIROL, V75, P1401, DOI 10.1128/JVI.75.3.1401-1407.2001; Mamiya N, 1999, J BIOL CHEM, V274, P15751, DOI 10.1074/jbc.274.22.15751; Marukian S, 2008, HEPATOLOGY, V48, P1843, DOI 10.1002/hep.22550; Masuzaki R, 2008, BEST PRACT RES CL GA, V22, P1137, DOI 10.1016/j.bpg.2008.11.005; Mateu G, 2008, VIROLOGY, V376, P397, DOI 10.1016/j.virol.2008.03.027; Mazzocca A, 2005, J BIOL CHEM, V280, P11329, DOI 10.1074/jbc.M410161200; McGivern DR, 2009, J VIROL, V83, P7422, DOI 10.1128/JVI.00262-09; McHutchison John G, 2003, Clin Liver Dis, V7, P149, DOI 10.1016/S1089-3261(02)00077-6; Mercer DF, 2001, NAT MED, V7, P927, DOI 10.1038/90968; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Milward A, 2010, J GEN VIROL, V91, P373, DOI 10.1099/vir.0.015305-0; Moradpour D, 2007, NAT REV MICROBIOL, V5, P453, DOI 10.1038/nrmicro1645; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Moriya K, 2001, CANCER RES, V61, P4365; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Munakata T, 2005, P NATL ACAD SCI USA, V102, P18159, DOI 10.1073/pnas.0505605102; Munakata T, 2007, PLOS PATHOG, V3, P1335, DOI 10.1371/journal.ppat.0030139; Naas T, 2005, J GEN VIROL, V86, P2185, DOI 10.1099/vir.0.80969-0; Nakamoto Y, 1998, J EXP MED, V188, P341, DOI 10.1084/jem.188.2.341; Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103; Nomura-Takigawa Y, 2006, J GEN VIROL, V87, P1935, DOI 10.1099/vir.0.81701-0; Norman KL, 2010, J VIROL, V84, P666, DOI 10.1128/JVI.01156-09; O'Connor S., 2010, Morbidity and Mortality Weekly Report, V59, P517; Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983; Oshiumi H, 2010, EUR J IMMUNOL, V40, P940, DOI 10.1002/eji.200940203; Otsuka M, 2000, J BIOL CHEM, V275, P34122, DOI 10.1074/jbc.M000578200; Owsianka AM, 1999, VIROLOGY, V257, P330, DOI 10.1006/viro.1999.9659; Park CY, 2009, J HEPATOL, V51, P853, DOI 10.1016/j.jhep.2009.06.026; Pasquinelli C, 1997, HEPATOLOGY, V25, P719, DOI 10.1002/hep.510250338; Pavio N, 2005, ONCOGENE, V24, P6119, DOI 10.1038/sj.onc.1208749; Perz JF, 2006, J HEPATOL, V44, P441, DOI 10.1016/j.jhep.2005.12.007; Pineau P, 2010, P NATL ACAD SCI USA, V107, P264, DOI 10.1073/pnas.0907904107; Prikhod'ko EA, 2004, VIROLOGY, V329, P53, DOI 10.1016/j.virol.2004.08.012; Qadri I, 2002, BBA-MOL CELL RES, V1592, P193, DOI 10.1016/S0167-4889(02)00315-4; Quinkert D, 2005, J VIROL, V79, P13594, DOI 10.1128/JVI.79.21.13594-13605.2005; Randall G, 2007, P NATL ACAD SCI USA, V104, P12884, DOI 10.1073/pnas.0704894104; Ray RB, 1998, GENE, V208, P331, DOI 10.1016/S0378-1119(98)00030-4; Sacco R, 2003, VIROLOGY, V317, P24, DOI 10.1016/j.virol.2003.08.028; Saito T, 2008, NATURE, V454, P523, DOI 10.1038/nature07106; Sato Y, 2006, GUT, V55, P1801, DOI 10.1136/gut.2005.070417; Schroder M, 2008, EMBO J, V27, P2147, DOI 10.1038/emboj.2008.143; Shackel NA, 2002, AM J PATHOL, V160, P641, DOI 10.1016/S0002-9440(10)64884-5; Shih JW, 2008, ONCOGENE, V27, P700, DOI 10.1038/sj.onc.1210687; Shimakami T, 2009, CURR OPIN PHARMACOL, V9, P537, DOI 10.1016/j.coph.2009.08.008; Shimizu YK, 1998, J GEN VIROL, V79, P1383, DOI 10.1099/0022-1317-79-6-1383; Street A, 2005, J VIROL, V79, P5006, DOI 10.1128/JVI.79.8.5006-5016.2005; Street A, 2004, J BIOL CHEM, V279, P12232, DOI 10.1074/jbc.M312245200; Sun B, 2008, ONCOGENE, V27, P6228, DOI 10.1038/onc.2008.300; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Takahashi K, 2010, P NATL ACAD SCI USA, V107, P7431, DOI 10.1073/pnas.1002301107; Takahashi Y, 2000, GENE DEV, V14, P804; Tan SL, 1999, P NATL ACAD SCI USA, V96, P5533, DOI 10.1073/pnas.96.10.5533; Tanaka M, 2006, BIOCHEM BIOPH RES CO, V340, P792, DOI 10.1016/j.bbrc.2005.12.076; Tanaka Y, 2002, P NATL ACAD SCI USA, V99, P15584, DOI 10.1073/pnas.242608099; Taura M, 2008, MOL CELL BIOL, V28, P6557, DOI 10.1128/MCB.01202-08; Teufel A, 2009, WORLD J GASTROENTERO, V15, P578, DOI 10.3748/wjg.15.578; Thenappan A, 2010, HEPATOLOGY, V51, P1373, DOI 10.1002/hep.23449; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Umemura T, 2009, J GASTROENTEROL, V44, P102, DOI 10.1007/s00535-008-2251-0; Ura S, 2009, HEPATOLOGY, V49, P1098, DOI 10.1002/hep.22749; Varnholt H, 2008, HEPATOLOGY, V47, P1223, DOI 10.1002/hep.22158; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Walters KA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000269; Wang AG, 2009, J PATHOL, V219, P253, DOI 10.1002/path.2592; Wang N, 2009, J VIROL, V83, P9824, DOI 10.1128/JVI.01125-09; Waris G, 2005, J VIROL, V79, P1569, DOI 10.1128/JVI.79.3.1569-1580.2005; Waris G, 2003, J BIOL CHEM, V278, P40778, DOI 10.1074/jbc.M303248200; Waris G, 2002, BIOCHEM PHARMACOL, V64, P1425, DOI 10.1016/S0006-2952(02)01300-X; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Yeh MM, 2010, MODERN PATHOL, V23, P276, DOI 10.1038/modpathol.2009.174; Yeoman AD, 2008, HEPATOLOGY, V48, P863, DOI 10.1002/hep.22432; Yi M, 2006, P NATL ACAD SCI USA, V103, P2310, DOI 10.1073/pnas.0510727103; Yoshizawa H, 2002, ONCOLOGY-BASEL, V62, P8, DOI 10.1159/000048270; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	176	156	166	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	17					1969	1983		10.1038/onc.2010.594	http://dx.doi.org/10.1038/onc.2010.594			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL	21258404	Green Accepted, Green Submitted			2022-12-17	WOS:000289977400001
J	Zhang, H; Li, Y; Lai, M				Zhang, H.; Li, Y.; Lai, M.			The microRNA network and tumor metastasis	ONCOGENE			English	Review						microRNA; tumor; metastasis	BREAST-CANCER METASTASIS; EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR RECEPTOR; SUPPRESSOR GENE; MIR-200 FAMILY; PROSTATE-CANCER; LUNG-CANCER; REDUCED EXPRESSION; MIRNA EXPRESSION; REPRESSORS ZEB1	Metastasis is the most significant process affecting the clinical management of cancer patients and occurs in multiple sequential steps. However, the molecular pathways underlying each step still remain obscure. Recent research has shown that there is a microRNA (miRNA) network that functions as a regulator of tumor metastasis. In this paper, we review the role of miRNAs in tumor metastasis, including control of epithelial-mesenchymal transition, regulation of metastasis-associated genes and epigenetic alterations. More information on miRNAs will promote a better understanding of the molecular mechanism of metastasis. Oncogene (2010) 29, 937-948; doi:10.1038/onc.2009.406; published online 23 November 2009	[Zhang, H.; Li, Y.; Lai, M.] Zhejiang Univ, Sch Med, Dept Pathol, Hangzhou 310058, Zhejiang, Peoples R China	Zhejiang University	Lai, M (corresponding author), Zhejiang Univ, Sch Med, Dept Pathol, Hangzhou 310058, Zhejiang, Peoples R China.	lmp@zju.edu.cn						Acloque H, 2008, EMBO REP, V9, P322, DOI 10.1038/embor.2008.30; Albini A, 2008, CANCER METAST REV, V27, P75, DOI 10.1007/s10555-007-9111-x; Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Bandres E, 2009, CLIN CANCER RES, V15, P2281, DOI 10.1158/1078-0432.CCR-08-1818; Bandyopadhyay S, 2004, CANCER RES, V64, P7655, DOI 10.1158/0008-5472.CAN-04-1623; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Carrio M, 2005, CANCER RES, V65, P7177, DOI 10.1158/0008-5472.CAN-04-1717; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen Y, 2008, BLOOD, V111, P1217, DOI 10.1182/blood-2007-07-104133; Christoffersen NR, 2007, RNA, V13, P1172, DOI 10.1261/rna.586807; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585; Coulouarn C, 2009, ONCOGENE, V28, P3526, DOI 10.1038/onc.2009.211; Crawford M, 2008, BIOCHEM BIOPH RES CO, V373, P607, DOI 10.1016/j.bbrc.2008.06.090; Dai RJ, 2008, BLOOD, V112, P4591, DOI 10.1182/blood-2008-04-152488; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1996, CANCER RES, V56, P4387; Du J, 2009, CELL RES, V19, P487, DOI 10.1038/cr.2009.34; Duursma AM, 2008, RNA, V14, P872, DOI 10.1261/rna.972008; Edmonds MD, 2009, INT J CANCER, V125, P1778, DOI 10.1002/ijc.24616; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Foekens JA, 2008, P NATL ACAD SCI USA, V105, P13021, DOI 10.1073/pnas.0803304105; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Friedman JM, 2009, CANCER RES, V69, P2623, DOI 10.1158/0008-5472.CAN-08-3114; Fujita S, 2008, J MOL BIOL, V378, P492, DOI 10.1016/j.jmb.2008.03.015; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Gebeshuber CA, 2009, EMBO REP, V10, P400, DOI 10.1038/embor.2009.9; Gee HE, 2008, NATURE, V455, DOI 10.1038/nature07362; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Hunter Kent W, 2008, Breast Cancer Res, V10 Suppl 1, pS2, DOI 10.1186/bcr1988; Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559; Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639; Kim YI, 2009, ONCOL REP, V21, P159, DOI 10.3892/or_00000203; Kondo N, 2008, CANCER RES, V68, P5004, DOI 10.1158/0008-5472.CAN-08-0180; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Krichevsky AM, 2009, J CELL MOL MED, V13, px, DOI 10.1111/j.1582-4934.2008.00556.x; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lee DY, 2007, P NATL ACAD SCI USA, V104, P20350, DOI 10.1073/pnas.0706901104; Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251; Li T, 2009, BIOCHEM BIOPH RES CO, V383, P280, DOI 10.1016/j.bbrc.2009.03.077; Li XF, 2009, ONCOGENE, V28, P3937, DOI 10.1038/onc.2009.245; Liu XD, 2009, BIOCHEM BIOPH RES CO, V380, P177, DOI 10.1016/j.bbrc.2009.01.066; Liu Xiqiang, 2009, Cancer Genomics & Proteomics, V6, P131; Liu YQ, 2008, DEVELOPMENT, V135, P579, DOI 10.1242/dev.007047; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Lukes L, 2009, CANCER RES, V69, P310, DOI 10.1158/0008-5472.CAN-08-3520; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Merkerova M, 2008, EUR J HAEMATOL, V81, P304, DOI 10.1111/j.1600-0609.2008.01111.x; Miska EA, 2005, CURR OPIN GENET DEV, V15, P563, DOI 10.1016/j.gde.2005.08.005; Myers C, 2002, AM J PATHOL, V161, P2099, DOI 10.1016/S0002-9440(10)64488-4; Neilson JR, 2007, GENE DEV, V21, P578, DOI 10.1101/gad.1522907; Nuyten Dimitry S A, 2006, Breast Dis, V26, P149; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Park SY, 2009, NAT STRUCT MOL BIOL, V16, P23, DOI 10.1038/nsmb.1533; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Reddy SDN, 2008, CANCER RES, V68, P8195, DOI 10.1158/0008-5472.CAN-08-2103; Rinker-Schaeffer CW, 2006, CLIN CANCER RES, V12, P3882, DOI 10.1158/1078-0432.CCR-06-1014; Roldo C, 2006, J CLIN ONCOL, V24, P4677, DOI 10.1200/JCO.2005.05.5194; Rybak A, 2008, NAT CELL BIOL, V10, P987, DOI 10.1038/ncb1759; Salvi A, 2009, FEBS J, V276, P2966, DOI 10.1111/j.1742-4658.2009.07014.x; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Sayed D, 2008, MOL BIOL CELL, V19, P3272, DOI 10.1091/mbc.E08-02-0159; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Selaru FM, 2009, HEPATOLOGY, V49, P1595, DOI 10.1002/hep.22838; Sengupta S, 2008, P NATL ACAD SCI USA, V105, P5874, DOI 10.1073/pnas.0801130105; Song GS, 2009, J BIOL CHEM, V284, P31921, DOI 10.1074/jbc.M109.046862; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Talmadge JE, 2007, CANCER RES, V67, P11471, DOI 10.1158/0008-5472.CAN-07-2496; Talotta F, 2009, ONCOGENE, V28, P73, DOI 10.1038/onc.2008.370; Tam W, 1997, MOL CELL BIOL, V17, P1490, DOI 10.1128/MCB.17.3.1490; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tomida S, 2007, ONCOGENE, V26, P4600, DOI 10.1038/sj.onc.1210242; Tsai WC, 2009, HEPATOLOGY, V49, P1571, DOI 10.1002/hep.22806; Tsuchiya S, 2009, NUCLEIC ACIDS RES, V37, P3821, DOI 10.1093/nar/gkp255; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Veerla S, 2009, INT J CANCER, V124, P2236, DOI 10.1002/ijc.24183; Venturini L, 2007, BLOOD, V109, P4399, DOI 10.1182/blood-2006-09-045104; Vigorito E, 2007, IMMUNITY, V27, P847, DOI 10.1016/j.immuni.2007.10.009; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Wang GF, 2008, FEBS LETT, V582, P3663, DOI 10.1016/j.febslet.2008.09.051; Watanabe S, 2009, AM J PATHOL, V174, P854, DOI 10.2353/ajpath.2009.080523; Webster RJ, 2009, J BIOL CHEM, V284, P5731, DOI 10.1074/jbc.M804280200; Wickramasinghe NS, 2009, NUCLEIC ACIDS RES, V37, P2584, DOI 10.1093/nar/gkp117; Williams AE, 2007, DEV DYNAM, V236, P572, DOI 10.1002/dvdy.21047; Xia HP, 2009, BRAIN RES, V1269, P158, DOI 10.1016/j.brainres.2009.02.037; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yang K, 2009, INT J CLIN EXP PATHO, V2, P361; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zhang XY, 2009, HEPATOLOGY, V50, P490, DOI 10.1002/hep.23008; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24; Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200	120	156	177	0	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					937	948		10.1038/onc.2009.406	http://dx.doi.org/10.1038/onc.2009.406			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19935707				2022-12-17	WOS:000274604400001
J	Liu, G; Bollig-Fischer, A; Kreike, B; van de Vijver, MJ; Abrams, J; Ethier, SP; Yang, ZQ				Liu, G.; Bollig-Fischer, A.; Kreike, B.; van de Vijver, M. J.; Abrams, J.; Ethier, S. P.; Yang, Z-Q			Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer	ONCOGENE			English	Article						GASC1; gene amplification; histone demethylase	MAMMARY EPITHELIAL-CELLS; ERBB-2 OVEREXPRESSION; STEM/PROGENITOR CELLS; LYSINE METHYLATION; GLAND DEVELOPMENT; SELF-RENEWAL; STEM-CELLS; EXPRESSION; JMJD2C; 9P23-24	Earlier, mapping of the 9p23-24 amplicon in esophageal cancer cell lines led us to the positional cloning of gene amplified in squamous cell carcinoma 1 (GASC1), which encodes a nuclear protein with a Jumonji C domain that catalyzes lysine (K) demethylation of histones. However, the transforming roles of GASC1 in breast cancer remain to be determined. In this study, we identified GASC1 as one of the amplified genes for the 9p23-24 region in breast cancer, particularly in basal-like subtypes. The levels of GASC1 transcript expression were significantly higher in aggressive, basal- like breast cancers compared with nonbasal-like breast cancers. Our in vitro assays demonstrated that GASC1 induces transformed phenotypes, including growth factor-independent proliferation, anchorage-independent growth, altered morphogenesis in Matrigel, and mammosphere forming ability, when overexpressed in immortalized, non-transformed mammary epithelial MCF10A cells. Additionally, GASC1 demethylase activity regulates the expression of genes critical for stem cell self-renewal, including NOTCH1, and may be linked to the stem cell phenotypes in breast cancer. Thus, GASC1 is a driving oncogene in the 9p23-24 amplicon in human breast cancer and targeted inhibition of GASC1 histone demethylase in cancer could provide potential new avenues for therapeutic development. Oncogene (2009) 28, 4491-4500; doi:10.1038/onc.2009.297; published online 28 September 2009	[Liu, G.; Bollig-Fischer, A.; Ethier, S. P.; Yang, Z-Q] Wayne State Univ, Breast Canc Program, Dept Pathol, Karmanos Canc Inst, Detroit, MI 48201 USA; [Kreike, B.] Netherlands Canc Inst, Div Radiat Oncol & Expt Therapy, Amsterdam, Netherlands; [van de Vijver, M. J.] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; [Abrams, J.] Wayne State Univ, Dept Internal Med, Karmanos Canc Inst, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Barbara Ann Karmanos Cancer Institute; Wayne State University	Yang, ZQ (corresponding author), Wayne State Univ, Breast Canc Program, Dept Pathol, Karmanos Canc Inst, 4100 John R HWCRC 815, Detroit, MI 48201 USA.	yangz@karmanos.org	LIU, GANG/AAR-4584-2021	LIU, GANG/0000-0001-6620-176X; Kreike, Bas/0000-0003-0030-8200; van de Vijver, Marc/0000-0002-0385-4787; Bollig-Fischer, Aliccia/0000-0003-4832-9457	NATIONAL CANCER INSTITUTE [R01CA100724] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA100724, R01 CA100724-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bannister AJ, 2005, J BIOL CHEM, V280, P17732, DOI 10.1074/jbc.M500796200; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5; Forozan F, 1999, BRIT J CANCER, V81, P1328, DOI 10.1038/sj.bjc.6695007; Geli J, 2005, INT J ONCOL, V26, P1385; Han W, 2008, GENE CHROMOSOME CANC, V47, P490, DOI 10.1002/gcc.20550; Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005; Hu CY, 2006, AM J PATHOL, V168, P973, DOI 10.2353/ajpath.2006.050416; Ignatoski KMW, 2003, MOL CANCER RES, V1, P551; Ignatoski KMW, 1999, ENDOCRINOLOGY, V140, P3615, DOI 10.1210/en.140.8.3615; Ignatoski KMW, 2000, BRIT J CANCER, V82, P666, DOI 10.1054/bjoc.1999.0979; Italiano A, 2006, CANCER GENET CYTOGEN, V167, P122, DOI 10.1016/j.cancergencyto.2006.01.004; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Katoh Y, 2007, INT J MOL MED, V20, P269; Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143; Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945; Knuutila S, 1998, AM J PATHOL, V152, P1107; Kreike B, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1771; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Lal G, 2006, CANCER, V107, P2752, DOI 10.1002/cncr.22325; Loh YH, 2007, GENE DEV, V21, P2545, DOI 10.1101/gad.1588207; Moffa AB, 2004, MOL CANCER RES, V2, P643; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Pierga JY, 2007, BRIT J CANCER, V96, P341, DOI 10.1038/sj.bjc.6603483; Poetsch M, 2002, ONCOGENE, V21, P3038, DOI 10.1038/sj.onc.1205457; Politi K, 2004, SEMIN CANCER BIOL, V14, P341, DOI 10.1016/j.semcancer.2004.04.013; Rizzo P, 2008, ONCOGENE, V27, P5124, DOI 10.1038/onc.2008.226; Sansone P, 2007, STEM CELLS, V25, P807, DOI 10.1634/stemcells.2006-0442; Savelyeva L, 2001, CANCER RES, V61, P5179; Savelyeva L, 1999, GENE CHROMOSOME CANC, V24, P87, DOI 10.1002/(SICI)1098-2264(199901)24:1<87::AID-GCC13>3.0.CO;2-5; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010; Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101; Vinatzer U, 2008, CLIN CANCER RES, V14, P6426, DOI 10.1158/1078-0432.CCR-08-0702; Wang GG, 2007, NAT CELL BIOL, V9, P804, DOI 10.1038/ncb1608; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Yang ZQ, 2006, CANCER RES, V66, P11632, DOI 10.1158/0008-5472.CAN-06-2946; Yang ZQ, 2001, JPN J CANCER RES, V92, P423, DOI 10.1111/j.1349-7006.2001.tb01112.x; Yang ZQ, 2000, CANCER RES, V60, P4735	47	156	161	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	2009	28	50					4491	4500		10.1038/onc.2009.297	http://dx.doi.org/10.1038/onc.2009.297			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DU	19784073	Bronze, Green Accepted			2022-12-17	WOS:000272876500008
J	Botlagunta, M; Vesuna, F; Mironchik, Y; Raman, A; Lisok, A; Winnard, P; Mukadam, S; Van Diest, P; Chen, JH; Farabaugh, P; Patel, AH; Raman, V				Botlagunta, M.; Vesuna, F.; Mironchik, Y.; Raman, A.; Lisok, A.; Winnard, P., Jr.; Mukadam, S.; Van Diest, P.; Chen, J. H.; Farabaugh, P.; Patel, A. H.; Raman, V.			Oncogenic role of DDX3 in breast cancer biogenesis	ONCOGENE			English	Article						DDX3; breast cancer; BPDE	BOX RNA HELICASE; MAMMARY EPITHELIAL-CELLS; HEPATOCELLULAR-CARCINOMA; MESENCHYMAL TRANSITION; TOBACCO-SMOKE; DIOL-EPOXIDE; DNA-DAMAGE; IN-VITRO; EXPRESSION; TRANSFORMATION	Benzo[a] pyrene diol epoxide (BPDE), the active metabolite of benzo[a] pyrene present in tobacco smoke, is a major cancer-causing compound. To evaluate the effects of BPDE on human breast epithelial cells, we exposed an immortalized human breast cell line, MCF 10A, to BPDE and characterized the gene expression pattern. Of the differential genes expressed, we found consistent activation of DDX3, a member of the DEAD box RNA helicase family. Overexpression of DDX3 in MCF 10A cells induced an epithelial-mesenchymal- like transformation, exhibited increased motility and invasive properties, and formed colonies in soft-agar assays. Besides the altered phenotype, MCF 10A-DDX3 cells repressed E-cadherin expression as demonstrated by both immunoblots and by E-cadherin promoter-reporter assays. In addition, an in vivo association of DDX3 and the E-cadherin promoter was demonstrated by chromatin immunoprecipitation assays. Collectively, these results demonstrate that the activation of DDX3 by BPDE, can promote growth, proliferation and neoplastic transformation of breast epithelial cells.	[Botlagunta, M.; Vesuna, F.; Mironchik, Y.; Lisok, A.; Winnard, P., Jr.; Mukadam, S.] Johns Hopkins Univ, Sch Med, Dept Radiol & Radiol Sci, Baltimore, MD 21205 USA; [Raman, A.] Univ Maryland, Dept Biol, Baltimore, MD 21201 USA; [Van Diest, P.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands; [Chen, J. H.] Tzu Chi Univ, Dept Life Sci, Hualien, Taiwan; [Patel, A. H.] Arvind Patel Inst Virol, Glasgow G11, Lanark, Scotland; [Raman, V.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; Utrecht University; Utrecht University Medical Center; Tzu Chi University; Johns Hopkins University	Raman, V (corresponding author), Johns Hopkins Univ, Sch Med, Dept Radiol & Radiol Sci, 720 Rutlands Ave,340 Traylor Bldg, Baltimore, MD 21205 USA.	vraman2@jhmi.edu	Vesuna, Farhad/G-3179-2010; Botlagunta, Mahendran/R-5140-2018	Vesuna, Farhad/0000-0002-0356-5096; Botlagunta, Mahendran/0000-0002-0490-2832; Farabaugh, Philip/0000-0002-5658-7141	Medical Research Council [MC_U130184144] Funding Source: Medline; NCI NIH HHS [R01 CA097226] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097226] Funding Source: NIH RePORTER; MRC [MC_U130184144] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abdelhaleem M, 2005, CLIN BIOCHEM, V38, P499, DOI 10.1016/j.clinbiochem.2005.01.010; Boffetta P, 2006, INT J CANCER, V119, P884, DOI 10.1002/ijc.21903; Bonner MR, 2005, CANCER CAUSE CONTROL, V16, P683, DOI 10.1007/s10552-005-1906-x; Burdick AD, 2006, CARCINOGENESIS, V27, P2331, DOI 10.1093/carcin/bgl083; Caruso JA, 2001, MUTAT RES-FUND MOL M, V473, P85, DOI 10.1016/S0027-5107(00)00140-8; Chang PC, 2006, ONCOGENE, V25, P1991, DOI 10.1038/sj.onc.1209239; Chao CH, 2006, CANCER RES, V66, P6579, DOI 10.1158/0008-5472.CAN-05-2415; Cordin O, 2006, GENE, V367, P17, DOI 10.1016/j.gene.2005.10.019; Duriseti S, 2006, NEOPLASIA, V8, P250, DOI 10.1593/neo.05766; Huang JS, 2004, BIOCHEM BIOPH RES CO, V315, P950, DOI 10.1016/j.bbrc.2004.01.151; Jeffy BD, 2002, CANCER RES, V62, P113; Jung JW, 2007, EUR J CANCER, V43, P1214, DOI 10.1016/j.ejca.2007.01.034; KROLEWSKI B, 1988, TERATOGEN CARCIN MUT, V8, P127, DOI 10.1002/tcm.1770080302; Linder P, 2006, NUCLEIC ACIDS RES, V34, P4168, DOI 10.1093/nar/gkl468; Marchetti A, 1996, ONCOGENE, V12, P1319; Margulis A, 2005, CANCER RES, V65, P1783, DOI 10.1158/0008-5472.CAN-04-3399; Mei JX, 2003, BREAST CANCER RES TR, V79, P95, DOI 10.1023/A:1023326121951; Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008-5472.CAN-05-0712; Myohanen S, 2001, J BIOL CHEM, V276, P1634, DOI 10.1074/jbc.M004481200; Norsa'adah B., 2005, SMJ Singapore Medical Journal, V46, P698; Owsianka AM, 1999, VIROLOGY, V257, P330, DOI 10.1006/viro.1999.9659; Parkin D M, 1992, IARC Sci Publ, P45; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; PHILLIPS PH, 1991, AM J EPIDEMIOL, V133, P757, DOI 10.1093/oxfordjournals.aje.a115954; Pirkle James L., 1996, JAMA (Journal of the American Medical Association), V275, P1233, DOI 10.1001/jama.275.16.1233; Rajendran RR, 2003, J BIOL CHEM, V278, P4628, DOI 10.1074/jbc.M210066200; Reynolds P, 2004, JNCI-J NATL CANCER I, V96, P29, DOI 10.1093/jnci/djh002; Sasco AJ, 2001, APMIS, V109, P321, DOI 10.1034/j.1600-0463.2001.090501.x; Sekiguchi T, 2007, BIOCHEM BIOPH RES CO, V356, P668, DOI 10.1016/j.bbrc.2007.03.038; SHIMOYAMA Y, 1989, CANCER RES, V49, P2128; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.bi.59.070190.001321; Toretsky JA, 2006, CANCER RES, V66, P5574, DOI 10.1158/0008-5472.CAN-05-3293; Wang AJ, 2003, CARCINOGENESIS, V24, P225, DOI 10.1093/carcin/24.2.225; Whitbread AK, 2006, BIOL CHEM, V387, P707, DOI 10.1515/BC.2006.089; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; YANG DJ, 1992, P NATL ACAD SCI USA, V89, P2237, DOI 10.1073/pnas.89.6.2237; Yang LQ, 2007, J BIOL CHEM, V282, P16811, DOI 10.1074/jbc.M610488200; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yang LQ, 2005, MOL CANCER RES, V3, P355, DOI 10.1158/1541-7786.MCR-05-0022; Yokoyama K, 2003, INT J ONCOL, V22, P891; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	41	156	163	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	28					3912	3922		10.1038/onc.2008.33	http://dx.doi.org/10.1038/onc.2008.33			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18264132	Green Accepted			2022-12-17	WOS:000257089000003
J	Burgering, B				Burgering, Bmth			A brief introduction to FOXOlogy	ONCOGENE			English	Editorial Material						transcription; insulin; aging; cell cycle; cell death; evolution	PROTEIN-KINASE-B; INSULIN-RECEPTOR SUBSTRATE; EXTENDS LIFE-SPAN; FORK HEAD DOMAIN; AGE-1 PI3 KINASE; CAENORHABDITIS-ELEGANS; TRANSCRIPTION FACTORS; AKT PROTOONCOGENE; ACTIVATION; LONGEVITY	Members of the Forkhead box O (FOXO) class of transcription factors are key players in the regulation of cell-fate decisions, such as cell death, cell proliferation and cell metabolism. Furthermore, in model organisms, it has by now been demonstrated that FOXO function affects the life span of these organisms. Multiple signal transduction pathways regulate FOXO function, but most importantly, they are negatively regulated by protein kinase B (PKB/AKT)-mediated phosphorylation and constitute, therefore, an important downstream component of insulin signalling. This review issue provides a timely overview of our understanding of FOXO function and how signalling affects FOXO function. Taken together, the reviewed studies on FOXO function and regulation provide compelling evidence that FOXOs act at the crossroad between aging and age-related diseases including diabetes and cancer. With this perspective, further studies on FOXO function and regulation may shed light on how age impacts on the onset and progression of disease.	Univ Med Ctr Utretch, Phys Chem Lab, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Burgering, B (corresponding author), Univ Med Ctr Utretch, Phys Chem Lab, Universiteitweg 100, NL-3584 CG Utrecht, Netherlands.	burgering@umcutrecht.nl						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; CASSADA RC, 1975, DEV BIOL, V46, P326, DOI 10.1016/0012-1606(75)90109-8; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; DAVIS RJ, 1994, CANCER RES, V54, P2869; DORMAN JB, 1995, GENETICS, V141, P1399; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; HAFEN E, 1993, PHILOS T R SOC B, V340, P273, DOI 10.1098/rstb.1993.0068; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Jacobs FMJ, 2003, J BIOL CHEM, V278, P35959, DOI 10.1074/jbc.M302804200; Kaestner KH, 2000, GENE DEV, V14, P142; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Oh SW, 2005, P NATL ACAD SCI USA, V102, P4494, DOI 10.1073/pnas.0500749102; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Plas DR, 2002, TRENDS ENDOCRIN MET, V13, P74; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Teleman AA, 2005, DEV CELL, V9, P271, DOI 10.1016/j.devcel.2005.07.004; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; Wang MC, 2005, CELL, V121, P115, DOI 10.1016/j.cell.2005.02.030; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; Wolff S, 2006, CELL, V124, P1039, DOI 10.1016/j.cell.2005.12.042; Wolkow CA, 2002, J BIOL CHEM, V277, P49591, DOI 10.1074/jbc.M207866200; Yang ZY, 2002, J BIOL CHEM, V277, P8068, DOI 10.1074/jbc.M106091200	55	156	158	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2008	27	16					2258	2262		10.1038/onc.2008.29	http://dx.doi.org/10.1038/onc.2008.29			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	285NE	18391968				2022-12-17	WOS:000254782700001
J	Yin, X; DeWille, JW; Hai, T				Yin, X.; DeWille, J. W.; Hai, T.			A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development	ONCOGENE			English	Article						ATF3; transcriptional regulation; cancer cell dichotomy; cell motility; breast cancer; adaptive response	ACTIVATING TRANSCRIPTION FACTOR-3; RNA-POLYMERASE-II; BREAST-CANCER; BETA; CELLS; EXPRESSION; IDENTIFICATION; AMPLIFICATION; METASTASIS; SUPPRESSOR	Activating transcription factor 3 (ATF3) is a member of the ATF/cyclic AMP response element-binding family of transcription factors. We present evidence that ATF3 has a dichotomous role in cancer development. By both gain- and loss-of-function approaches, we found that ATF3 enhances apoptosis in the untransformed MCF10A mammary epithelial cells, but protects the aggressive MCF10CA1a cells and enhances its cell motility. Array analyses indicated that ATF3 upregulates the expression of several genes in the tumor necrosis factor pathway in the MCF10A cells but upregulates the expression of several genes implicated in tumor metastasis, including TWIST1, fibronectin (FN)-1, plasminogen activator inhibitor-1, urokinase-type plasminogen activator, caveolin-1 and Slug, in the MCF10CA1a cells. We present evidence that ATF3 binds to the endogenous promoters and regulates the transcription of the TWIST1, FN-1, Snail and Slug genes. Furthermore, conditioned medium experiments indicated that ATF3 has a paracrine/autocrine effect, consistent with its upregulation of genes encoding secreted factors. Finally, ATF3 gene copy number is > 2 in similar to 80% of the breast tumors examined (N = 48) and its protein level is elevated in similar to 50% of the tumors. These results provided a correlative argument that it is advantageous for the malignant cancer cells to express ATF3, consistent with its oncogenic roles suggested by the MCF10CA1a cell data.	[Yin, X.; Hai, T.] Ohio State Univ, Neurobiotechnol Ctr, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; [Yin, X.; DeWille, J. W.; Hai, T.] Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA; [Yin, X.; Hai, T.] Ohio State Univ, Ctr Mol Neurobiol, Columbus, OH 43210 USA; [DeWille, J. W.] Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Hai, T (corresponding author), Ohio State Univ, Neurobiotechnol Ctr, Dept Mol & Cellular Biochem, 174 Rightmire Hall,1060 Carmack Rd, Columbus, OH 43210 USA.	hai.2@osu.edu	Hai, Tsonwin/H-4480-2011; Hai, Tsonwin/E-3185-2011	Hai, Tsonwin/0000-0003-4510-0315; Hai, Tsonwin/0000-0003-4510-0315	NCI NIH HHS [R01 CA118306] Funding Source: Medline; NIDDK NIH HHS [R01 DK064938, R01 DK059605] Funding Source: Medline; NINDS NIH HHS [P30-NS045758] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA118306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059605, R01DK064938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS045758] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albertson DG, 2003, BREAST CANCER RES TR, V78, P289, DOI 10.1023/A:1023025506386; Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007; Ameri K, 2007, ONCOGENE, V26, P284, DOI 10.1038/sj.onc.1209781; Baek SJ, 2004, CARCINOGENESIS, V25, P2425, DOI 10.1093/carcin/bgh255; Bandyopadhyay S, 2006, CANCER RES, V66, P11983, DOI 10.1158/0008-5472.CAN-06-0943; Bottone FG, 2003, J BIOL CHEM, V278, P25790, DOI 10.1074/jbc.M301002200; Bottone FG, 2005, MOL CANCER THER, V4, P693, DOI 10.1158/1535-7163.MCT-04-0337; Cheng CH, 2003, MOL CELL BIOL, V23, P1961, DOI 10.1128/MCB.23.6.1961-1967.2003; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; HAI T, 2006, GENE EXPRESSION REGU, P322; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Ishiguro T, 1996, CANCER RES, V56, P875; Ishiguro T, 2000, JPN J CANCER RES, V91, P833, DOI 10.1111/j.1349-7006.2000.tb01021.x; Ishiguro T, 2000, ONCOL RES, V12, P343, DOI 10.3727/096504001108747792; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Loeb LA, 2001, CANCER RES, V61, P3230; Lu D, 2006, J BIOL CHEM, V281, P10473, DOI 10.1074/jbc.M509278200; Lu D, 2007, BIOCHEM J, V401, P559, DOI 10.1042/BJ20061081; Mallory JC, 2005, MOL PHARMACOL, V68, P1747, DOI 10.1124/mol.105.016519; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Pauletti G, 1996, ONCOGENE, V13, P63; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Rooney PH, 1999, BRIT J CANCER, V80, P862, DOI 10.1038/sj.bjc.6690433; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; SOULE HD, 1990, CANCER RES, V50, P6075; Syed V, 2005, ONCOGENE, V24, P1774, DOI 10.1038/sj.onc.1207991; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Yamaguchi K, 2006, CANCER RES, V66, P2376, DOI 10.1158/0008-5472.CAN-05-1987; Yan CH, 2005, MOL CANCER THER, V4, P233; Yu R, 1996, CANCER LETT, V107, P73, DOI 10.1016/0304-3835(96)04345-5	38	156	159	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2008	27	15					2118	2127		10.1038/sj.onc.1210861	http://dx.doi.org/10.1038/sj.onc.1210861			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17952119				2022-12-17	WOS:000254621300002
J	Dai, B; Kang, SH; Gong, W; Liu, M; Aldape, KD; Sawaya, R; Huang, S				Dai, B.; Kang, S-H; Gong, W.; Liu, M.; Aldape, K. D.; Sawaya, R.; Huang, S.			Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells	ONCOGENE			English	Article						FoxM1B; MMP-2; glioma; invasion	GENE-EXPRESSION; IV COLLAGENASE; MALIGNANT GLIOMAS; GELATINASE-A; ACTIVATION; ANGIOPOIETIN-2; GROWTH; STAT3; TUMORIGENICITY; INVASIVENESS	We recently showed that FoxM1 is overexpressed in human glioblastomas and that forced FoxM1B expression in anaplastic astrocytoma cells leads to the formation of highly invasive glioblastoma multiforme (GBM) in nude mice. However, the molecular mechanisms by which FoxM1 enhances glioma invasion are unknown. In this study, we found that FoxM1 overexpression increased matrix metalloproteinase (MMP)-2 expression in glioma cells, whereas blockade of FoxM1 expression suppressed MMP-2 expression. Transfection of FoxM1 into glioma cells directly activated the MMP-2 promoter, whereas inhibition of FoxM1 expression by FoxM1-siRNA suppressed its activation. We identified a FoxM1-binding site in the MMP-2 promoter and demonstrated that FoxM1 protein bound directly to it. Mutation of this FoxM1-binding site significantly attenuated MMP-2 promoter activity. Furthermore, FoxM1 overexpression increased the invasiveness of glioma cells, whereas inhibition of FoxM1 expression suppressed the invasiveness of GBM cells. Inhibition of MMP-2 by a specific MMP-2 inhibitor reversed the invasive phenotype of glioma cells overexpressing FoxM1. Finally, immunohistochemical analysis of 45 human GBM specimens showed a significant correlation between FoxM1 overexpression and elevated MMP-2 expression. Collectively, these findings provide evidence that FoxM1 contributes to glioma progression by enhancing MMP-2 gene transcription and thus tumor-cell invasion.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX USA; Univ Texas, Grad Sch Biomed Sci, Program Canc Biol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Huang, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, 1515 Holcombe Blvd, Houston, TX 77030 USA.	suhuang@mdanderson.org	Dai, Bingbing/B-8417-2012	gang, sinhyeog/0000-0002-8912-7985	NCI NIH HHS [CA 16672, R01-CA116528] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA116528] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE T, 1994, CLIN EXP METASTAS, V12, P296, DOI 10.1007/BF01753836; Allred DC, 1998, MODERN PATHOL, V11, P155; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Emonard H, 1999, ANN NY ACAD SCI, V878, P647, DOI 10.1111/j.1749-6632.1999.tb07751.x; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Guo P, 2003, AM J PATHOL, V162, P1083, DOI 10.1016/S0002-9440(10)63905-3; Hu B, 2006, CANCER RES, V66, P775, DOI 10.1158/0008-5472.CAN-05-1149; Hu B, 2003, P NATL ACAD SCI USA, V100, P8904, DOI 10.1073/pnas.1533394100; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang SY, 2002, J NATL CANCER I, V94, P1134; Konnikova L, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-23; Korver W, 1997, GENOMICS, V46, P435, DOI 10.1006/geno.1997.5065; Koul D, 2001, ONCOGENE, V20, P6669, DOI 10.1038/sj.onc.1204799; Lampert K, 1998, AM J PATHOL, V153, P429, DOI 10.1016/S0002-9440(10)65586-1; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Liu MG, 2006, CANCER RES, V66, P3593, DOI 10.1158/0008-5472.CAN-05-2912; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Park CM, 2006, CANCER RES, V66, P8511, DOI 10.1158/0008-5472.CAN-05-4340; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Rickman DS, 2001, CANCER RES, V61, P6885; Sawaya RE, 1996, CLIN EXP METASTAS, V14, P35, DOI 10.1007/BF00157684; Tan YJ, 2007, MOL CELL BIOL, V27, P1007, DOI 10.1128/MCB.01068-06; Teh MT, 2002, CANCER RES, V62, P4773; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; Wang H, 2003, CANCER RES, V63, P4315; Wang HM, 2004, LAB INVEST, V84, P941, DOI 10.1038/labinvest.3700123; Wild-Bode C, 2001, CANCER RES, V61, P2744; Wild-Bode C, 2001, J NEUROSURG, V94, P976, DOI 10.3171/jns.2001.94.6.0978; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059; Xie TX, 2004, ONCOGENE, V23, P3550, DOI 10.1038/sj.onc.1207383; Yao KM, 1997, J BIOL CHEM, V272, P19827, DOI 10.1074/jbc.272.32.19827; Ye HG, 1999, MOL CELL BIOL, V19, P8570; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626	33	156	164	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6212	6219		10.1038/sj.onc.1210443	http://dx.doi.org/10.1038/sj.onc.1210443			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17404569				2022-12-17	WOS:000249401300012
J	Vaira, V; Lee, CW; Goel, HL; Bosari, S; Languino, LR; Altieri, DC				Vaira, V.; Lee, C. W.; Goel, H. L.; Bosari, S.; Languino, L. R.; Altieri, D. C.			Regulation of survivin expression by IGF-1/mTOR signaling	ONCOGENE			English	Article						survivin; IGF-1; prostate cancer; mTOR; rapamycin	RECEPTOR TYROSINE KINASE; PROSTATE-CANCER CELLS; FACTOR-I RECEPTOR; WILD-TYPE P53; NF-KAPPA-B; INDUCED APOPTOSIS; AKT; PHOSPHORYLATION; PATHWAYS; GENE	Survivin is a dual regulator of cell proliferation and cell viability overexpressed in most human tumors. Although strategies to lower survivin levels have been pursued for rational cancer therapy, the molecular circuitries controlling survivin expression in tumors have not been completely elucidated. Here, we show that stimulation with insulin-like growth factor-1 (IGF-1) results in increased survivin expression in prostate cancer cells. This response is independent of de novo gene transcription, changes in mRNA expression or modi. cations of survivin protein stability. Instead, IGF-1 induced persistence and translation of a pool of survivin mRNA, in a reaction abolished by the mTOR (mammalian target of rapamycin) inhibitor, rapamycin. Forced expression of the mTOR target p70S6K1 reproduced the increase in survivin expression in prostate cancer cells, whereas acute ablation of endogenous p70S6K1 by small interfering RNA down-regulated survivin levels. Rapamycin, alone or in combination with suboptimal concentrations of taxol reduced survivin protein levels, and decreased viability of prostate cancer cells. Therefore, IGF-1/mTOR signaling elevates survivin in prostate cancer cells via rapid changes in mRNA translation. Antagonists of this pathway may be beneficial to lower an antiapoptotic threshold maintained by survivin in prostate cancer.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01605 USA; Univ Milan, AOS Paolo & Fdn Osped Maggiore Policlin Regina El, Div Pathol, Dept Med Surg & Dent, Milan, Italy	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Altieri, DC (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, LRB428,364 Plantat St, Worcester, MA 01605 USA.	dario.altieri@umassmed.edu	Vaira, Valentina/K-6499-2016; Bosari, Silvano/K-7744-2016	Vaira, Valentina/0000-0003-4416-6216; Bosari, Silvano/0000-0002-9744-6951; Languino, Lucia/0000-0001-9011-7031	NCI NIH HHS [CA78810, F31 CA132622, CA109874, CA90917] Funding Source: Medline; NHLBI NIH HHS [HL54131] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F31CA132622, R01CA090917, R01CA078810, R01CA109874] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL054131, R01HL054131] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altieri DC, 2006, MOL CANCER THER, V5, P478, DOI 10.1158/1535-7163.MCT-05-0436; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Dan HC, 2004, ONCOGENE, V23, P706, DOI 10.1038/sj.onc.1207171; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Decker T, 2003, BLOOD, V101, P278, DOI 10.1182/blood-2002-01-0189; Dohi T, 2004, J CLIN INVEST, V114, P1117, DOI 10.1172/JCI200422222; Fornaro M, 2003, J BIOL CHEM, V278, P50402, DOI 10.1074/jbc.M307627200; Goswami A, 2005, MOL CELL, V20, P33, DOI 10.1016/j.molcel.2005.08.016; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Hopfner M, 2006, BIOCHEM PHARMACOL, V71, P1435, DOI 10.1016/j.bcp.2006.02.006; Kane LP, 2002, MOL CELL BIOL, V22, P5962, DOI 10.1128/MCB.22.16.5962-5974.2002; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Krajewska M, 2003, CLIN CANCER RES, V9, P4914; Levine AJ, 2006, GENE DEV, V20, P267, DOI 10.1101/gad.1363206; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li SW, 1996, J BIOL CHEM, V271, P12254, DOI 10.1074/jbc.271.21.12254; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Nam S, 2005, P NATL ACAD SCI USA, V102, P5998, DOI 10.1073/pnas.0409467102; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; Stromberg T, 2006, BLOOD, V107, P669, DOI 10.1182/blood-2005-01-0306; Vong QP, 2005, SCIENCE, V310, P1499, DOI 10.1126/science.1120160; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yang SX, 2006, CANCER RES, V66, P4285, DOI 10.1158/0008-5472.CAN-05-4456; Zhang M, 2005, ONCOGENE, V24, P2474, DOI 10.1038/sj.onc.1208490	38	156	166	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2007	26	19					2678	2684		10.1038/sj.onc.1210094	http://dx.doi.org/10.1038/sj.onc.1210094			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17072337				2022-12-17	WOS:000246210600002
J	Selivanova, G; Wiman, KG				Selivanova, G.; Wiman, K. G.			Reactivation of mutant p53: molecular mechanisms and therapeutic potential	ONCOGENE			English	Review						mutant p53; apoptosis; cancer therapy	TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING DOMAIN; CYTOPROTECTIVE AMINOTHIOL WR1065; TEMPERATURE-SENSITIVE MUTANT; C-TERMINAL PEPTIDE; HUMAN CANCER-CELLS; CORE DOMAIN; WILD-TYPE; IN-VITRO; CRYSTAL-STRUCTURE	The p53 tumor suppressor gene is the most frequently mutated gene in cancer. Most p53 mutations are missense point mutations that cluster in the DNA-binding core domain. This results in distortion of core domain folding and disruption of DNA binding and transcriptional transactivation of p53 target genes. Structural studies have demonstrated that mutant p53 core domain unfolding is not irreversible. Mutant p53 is expressed at high levels in many tumors. Therefore, mutant p53 is a promising target for novel cancer therapy. Mutant p53 reactivation will restore p53-dependent apoptosis, resulting in efficient removal of tumor cells. A number of strategies for targeting mutant p53 have been designed, including peptides and small molecules that restore the active conformation and DNA binding to mutant p53 and induce p53-dependent suppression of tumor cell growth in vitro and in vivo. This opens possibilities for the clinical application of mutant p53 reactivation in the treatment of cancer.	Karolinska Inst, Dept Oncol Pathol, Canc Ctr, Stockholm, Sweden; Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Wiman, KG (corresponding author), Karolinska Inst, Dept Oncol Pathol, Canc Ctr, Stockholm, Sweden.	Galina.Selivanova@ki.se; Klas.Wiman@ki.se	Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Selivanova, Galina/0000-0002-8698-4332				ABARZUA P, 1995, CANCER RES, V55, P3490; Ang HC, 2006, J BIOL CHEM, V281, P21934, DOI 10.1074/jbc.M604209200; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Bell S, 2002, J MOL BIOL, V322, P917, DOI 10.1016/S0022-2836(02)00848-3; Bensaad K, 2003, J BIOL CHEM, V278, P10546, DOI 10.1074/jbc.M208233200; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Butler JS, 2003, BIOCHEMISTRY-US, V42, P2396, DOI 10.1021/bi026635n; Buzek J, 2002, NUCLEIC ACIDS RES, V30, P2340, DOI 10.1093/nar/30.11.2340; Bykov VJN, 2005, J BIOL CHEM, V280, P30384, DOI 10.1074/jbc.M501664200; Bykov VJN, 2005, ONCOGENE, V24, P3484, DOI 10.1038/sj.onc.1208419; Bykov VJN, 2003, EUR J CANCER, V39, P1828, DOI 10.1016/S0959-8049(03)00454-4; Bykov VJN, 2002, CARCINOGENESIS, V23, P2011, DOI 10.1093/carcin/23.12.2011; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Canadillas JMP, 2006, P NATL ACAD SCI USA, V103, P2109, DOI 10.1073/pnas.0510941103; Chen Yabing, 2002, Int J Exp Diabetes Res, V3, P109, DOI 10.1080/15604280214488; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Christophorou MA, 2005, NAT GENET, V37, P718, DOI 10.1038/ng1572; Cohen PA, 1999, FEBS LETT, V463, P179, DOI 10.1016/S0014-5793(99)01603-8; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; de Fromentel CC, 1999, ONCOGENE, V18, P551, DOI 10.1038/sj.onc.1202338; Di Como CJ, 1998, ONCOGENE, V16, P2527; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Friedler A, 2003, J BIOL CHEM, V278, P24108, DOI 10.1074/jbc.M302458200; Friedler A, 2002, P NATL ACAD SCI USA, V99, P937, DOI 10.1073/pnas.241629998; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; Hansen S, 1996, J BIOL CHEM, V271, P3917; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; Issaeva N, 2003, P NATL ACAD SCI USA, V100, P13303, DOI 10.1073/pnas.1835733100; Joerger AC, 2005, J BIOL CHEM, V280, P16030, DOI 10.1074/jbc.M500179200; Joerger AC, 2004, J BIOL CHEM, V279, P1291, DOI 10.1074/jbc.M309732200; Joerger AC, 2005, 25 YEARS OF P53 RESEARCH, P377, DOI 10.1007/1-4020-2922-5_17; Joerger AC, 2006, P NATL ACAD SCI USA, V103, P15056, DOI 10.1073/pnas.0607286103; Kim AL, 1999, J BIOL CHEM, V274, P34924, DOI 10.1074/jbc.274.49.34924; Lane DP, 2002, TRENDS MOL MED, V8, pS38, DOI 10.1016/S1471-4914(02)02309-2; Li Y, 2005, MOL CANCER THER, V4, P901, DOI 10.1158/1535-7163.MCT-04-0206; Liu WL, 2001, J MOL BIOL, V313, P711, DOI 10.1006/jmbi.2001.5082; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Luu Y, 2002, EXP CELL RES, V276, P214, DOI 10.1006/excr.2002.5526; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; McCormick F, 2001, NAT REV CANCER, V1, P130, DOI 10.1038/35101008; McKinney K, 2004, MOL CELL, V16, P413, DOI 10.1016/j.molcel.2004.09.032; McKinney K, 2002, MOL CELL BIOL, V22, P6797, DOI 10.1128/MCB.22.19.6797-6808.2002; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; MILNER J, 1990, ONCOGENE, V5, P1683; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Nahi H, 2004, BRIT J HAEMATOL, V127, P285, DOI 10.1111/j.1365-2141.2004.05210.x; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nichols NM, 2002, BIOCHEMISTRY-US, V41, P170, DOI 10.1021/bi011736r; NIEWOLIK D, 1995, ONCOGENE, V10, P881; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; North S, 2002, MOL CARCINOGEN, V33, P181, DOI 10.1002/mc.10038; Okorokov AL, 2006, EMBO J, V25, P5191, DOI 10.1038/sj.emboj.7601382; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Pluquet O, 2003, BIOCHEM PHARMACOL, V65, P1129, DOI 10.1016/S0006-2952(02)01655-6; Rehman A, 2005, BREAST CANCER RES, V7, pR765, DOI 10.1186/bcr1290; Rippin TM, 2002, ONCOGENE, V21, P2119, DOI 10.1038/sj.onc.1205362; ROKAEUS N, 2006, ONCOGENE; Roth J, 2000, ONCOGENE, V19, P1834, DOI 10.1038/sj.onc.1203500; Rudiger S, 2002, P NATL ACAD SCI USA, V99, P11085, DOI 10.1073/pnas.132393699; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Selivanova G, 1998, SEMIN CANCER BIOL, V8, P369, DOI 10.1006/scbi.1998.0099; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Selivanova G, 2001, Curr Opin Investig Drugs, V2, P1136; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SELIVANOVA G, 2001, TUMOR SUPPRESSING VI, P397; Seo YR, 2002, P NATL ACAD SCI USA, V99, P14548, DOI 10.1073/pnas.212319799; Sharp S, 2006, ADV CANCER RES, V95, P323, DOI 10.1016/S0065-230X(06)95009-X; Shiraishi K, 2004, J BIOL CHEM, V279, P348, DOI 10.1074/jbc.M310815200; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Snyder EL, 2004, PLOS BIOL, V2, P186, DOI 10.1371/journal.pbio.0020036; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Takimoto R, 2002, CANCER BIOL THER, V1, P47, DOI 10.4161/cbt.1.1.41; Vives V, 2006, CELL CYCLE, V5, P2187, DOI 10.4161/cc.5.19.3266; VOJTESEK B, 1995, ONCOGENE, V10, P389; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Walerych D, 2004, J BIOL CHEM, V279, P48836, DOI 10.1074/jbc.M407601200; Wang PL, 2001, ONCOGENE, V20, P2318, DOI 10.1038/sj.onc.1204316; Wang WG, 2006, P NATL ACAD SCI USA, V103, P11003, DOI 10.1073/pnas.0604507103; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; Wiman KG, 2006, CELL DEATH DIFFER, V13, P921, DOI 10.1038/sj.cdd.4401921; Wischhusen J, 2003, ONCOGENE, V22, P8233, DOI 10.1038/sj.onc.1207198; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; Zheleva DI, 2003, MINI-REV MED CHEM, V3, P257, DOI 10.2174/1389557033488178	101	156	166	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	2007	26	15					2243	2254		10.1038/sj.onc.1210295	http://dx.doi.org/10.1038/sj.onc.1210295			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE	17401433				2022-12-17	WOS:000245394800013
J	Xu, L; Chen, S; Bergan, RC				Xu, L.; Chen, S.; Bergan, R. C.			MAPKAPK2 and HSP27 are downstream effectors of p38MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer	ONCOGENE			English	Article						transforming growth factor beta; prostate cancer; invasion; mitogen-activated protein kinase-activated protein kinase 2; heat-shock protein 27; matrix metalloproteinase-2	HEAT-SHOCK PROTEINS; MAP KINASE; SIGNAL-TRANSDUCTION; FOCAL ADHESION; SMOOTH-MUSCLE; EXPRESSION; HEAT-SHOCK-PROTEIN-27; PHOSPHORYLATION; INHIBITOR; MECHANISMS	Although cell invasion is a necessary early step in cancer metastasis, its regulation is not well understood. We have previously shown, in human prostate cancer, that transforming growth factor ss (TGF ss)-mediated increases in cell invasion are dependent upon activation of the serine/threonine kinase, p38 MAP kinase. In the current study, downstream effectors of p38 MAP kinase were sought by first screening for proteins phosphorylated after TGF ss treatment, only in the absence of chemical inhibitors of p38 MAP kinase. This led us to investigate mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2), a known substrate of p38 MAP kinase, as well as heat-shock protein 27 (HSP27), a known substrate of MAPKAPK2, in both PC3 and PC3-M human prostate cells. After transient transfection, wildtype MAPKAPK2 and HSP27 both increased TGF ss-mediated matrix metalloproteinase type 2 (MMP-2) activity, as well as cell invasion, which in turn was inhibited by SB203580, an inhibitor of p38 MAP kinase. Conversely, dominant-negative MAPKAPK2 blocked phosphorylation of HSP27, whereas dominant-negative MAPKAPK2 or mutant, non-phosphorylateable, HSP27 each blocked TGF ss-mediated increases in MMP-2, as well as cell invasion. Similarly, knock down of MAPKAPK2, HSP27 or both together, by siRNA, also blocked TGF ss-mediated cell invasion. This study demonstrates that both MAPKAPK2 and HSP27 are necessary for TGF ss-mediated increases in MMP-2 and cell invasion in human prostate cancer.	Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Canc Ctr, Chicago, IL USA	Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Bergan, RC (corresponding author), Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, McGaw 2301,240 E Huron St, Chicago, IL 60611 USA.	r-bergan@northwestern.edu	xu, li/D-5310-2009	xu, li/0000-0002-2153-1471	NATIONAL CANCER INSTITUTE [P50CA090386] Funding Source: NIH RePORTER; NCI NIH HHS [CA90386] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aldrian S, 2002, CELL STRESS CHAPERON, V7, P177, DOI 10.1379/1466-1268(2002)007<0177:OOHATM>2.0.CO;2; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; CARROLL PR, 2001, CANC PRINCIPLES PRAC, P1418; Cornford PA, 2000, CANCER RES, V60, P7099; Gerthoffer WT, 2001, J APPL PHYSIOL, V91, P963, DOI 10.1152/jappl.2001.91.2.963; Guay J, 1997, J CELL SCI, V110, P357; Hansen RK, 2001, BIOCHEM BIOPH RES CO, V282, P186, DOI 10.1006/bbrc.2001.4548; Hatakeyama D, 2002, BBA-MOL CELL RES, V1589, P15, DOI 10.1016/S0167-4889(01)00183-5; Hayes SA, 2003, ONCOGENE, V22, P4841, DOI 10.1038/sj.onc.1206730; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Huang XK, 2005, CANCER RES, V65, P3470, DOI 10.1158/0008-5472.CAN-04-2807; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kotlyarov A, 2002, MOL CELL BIOL, V22, P4827, DOI 10.1128/MCB.22.13.4827-4835.2002; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; Liu YQ, 2001, PROSTATE CANCER P D, V4, P81, DOI 10.1038/sj.pcan.4500506; Liu YQ, 2000, CLIN EXP METASTAS, V18, P203, DOI 10.1023/A:1006729106034; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; Munshi HG, 2004, J BIOL CHEM, V279, P39042, DOI 10.1074/jbc.M404958200; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Rocchi P, 2004, CANCER RES, V64, P6595, DOI 10.1158/0008-5472.CAN-03-3998; Ruoslahti E, 1996, SCI AM, V275, P72, DOI 10.1038/scientificamerican0996-72; Schafer C, 1999, AM J PHYSIOL-CELL PH, V277, pC1032; Schwartz GN, 1998, ANTISENSE NUCLEIC A, V8, P329, DOI 10.1089/oli.1.1998.8.329; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F	33	156	183	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					2987	2998		10.1038/sj.onc.1209337	http://dx.doi.org/10.1038/sj.onc.1209337			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407830				2022-12-17	WOS:000237950800003
J	Natarajan, M; Stewart, JE; Golemis, EA; Pugacheva, EN; Alexandropoulos, K; Cox, BD; Wang, W; Grammer, JR; Gladson, CL				Natarajan, M; Stewart, JE; Golemis, EA; Pugacheva, EN; Alexandropoulos, K; Cox, BD; Wang, W; Grammer, JR; Gladson, CL			HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells	ONCOGENE			English	Article						FAK; HEF1; CAS; Crk-associated substrate; glioblastoma; migration	FOCAL ADHESION KINASE; SRC FAMILY KINASES; GROWTH-FACTOR; IN-VIVO; TYROSINE PHOSPHORYLATION; DOCKING PROTEIN; ASTROCYTIC TUMORS; SIGNALING PATHWAY; COMPLEX-FORMATION; V-SRC	The highly invasive behavior of glioblastoma cells contributes to the morbidity and mortality associated with these tumors. The integrin-mediated adhesion and migration of glioblastoma cells on brain matrix proteins is enhanced by stimulation with growth factors, including platelet-derived growth factor (PDGF). As focal adhesion kinase (FAK), a nonreceptor cytoplasmic tyrosine kinase, has been shown to promote cell migration in various other cell types, we analysed its role in glioblastoma cell migration. Forced overexpression of FAK in serum-starved glioblastoma cells plated on recombinant (rec)osteopontin resulted in a twofold enhancement of basal migration and a ninefold enhancement of PDGF-BB-stimulated migration. Both expression of mutant FAK(397F) and the downregulation of FAK with small interfering(si) RNA inhibited basal and PDGF-stimulated migration. FAK overexpression and PDGF stimulation was found to increase the phosphorylation of the Crk-associated substrate (CAS) family member human enhancer of filamentation 1 (HEF1), but not p130CAS or Src-interacting protein (Sin)/Efs, although the levels of expression of these proteins was similar. Moreover downregulation of HEF1 with siRNA, but not p130CAS, inhibited basal and PDGF-stimulated migration. The phosphorylated HEF1 colocalized with vinculin and was associated almost exclusively with 0.1% Triton X-100 insoluble material, consistent with its signaling at focal adhesions. FAK overexpression promoted invasion through normal brain homogenate and siHEF1 inhibited this invasion. Results presented here suggest that HEF1 acts as a necessary and specific downstream effector of FAK in the invasive behavior of glioblastoma cells and may be an effective target for treatment of these tumors.	Univ Alabama, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA; Fox Chase Canc Ctr, Div Basic Sci, Philadelphia, PA 19111 USA; Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY USA; Univ Alabama, Dept Med, Div Hematol Oncol, Biostat Sect, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; Fox Chase Cancer Center; Columbia University; University of Alabama System; University of Alabama Birmingham	Gladson, CL (corresponding author), Univ Alabama, Dept Pathol, Div Neuropathol, LHRB 567,701 S 19th St, Birmingham, AL 35294 USA.	gladson@uab.edu		Golemis, Erica/0000-0003-3618-3673; McFarland, Braden C./0000-0002-7517-9688	NCI NIH HHS [CA97247, CA97110, CA109748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097110, P50CA097247, R01CA109748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 2003, IMMUNOL REV, V192, P181, DOI 10.1034/j.1600-065X.2003.00021.x; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; Brabek J, 2004, ONCOGENE, V23, P7406, DOI 10.1038/sj.onc.1207965; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Cooper LA, 2003, MOL CELL BIOL, V23, P8030, DOI 10.1128/MCB.23.22.8030-8041.2003; Ding Q, 2005, J BIOL CHEM, V280, P6802, DOI 10.1074/jbc.M409180200; Ding Q, 2003, J BIOL CHEM, V278, P39882, DOI 10.1074/jbc.M304685200; Ding Q, 2002, CANCER RES, V62, P5336; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Fashena SJ, 2002, J CELL SCI, V115, P99; ffrench-Constant C, 2004, TRENDS CELL BIOL, V14, P678, DOI 10.1016/j.tcb.2004.10.005; GLADSON CL, 1995, J CELL SCI, V108, P947; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Haskell H, 2003, CLIN CANCER RES, V9, P2157; Hauck CR, 2000, J BIOL CHEM, V275, P41092, DOI 10.1074/jbc.M005450200; Hecker TP, 2004, ONCOGENE, V23, P3962, DOI 10.1038/sj.onc.1207541; Hecker TP, 2002, CANCER RES, V62, P2699; HERMANSON M, 1992, CANCER RES, V52, P3213; Ishino M, 1995, ONCOGENE, V11, P2331; Jones G, 2001, CANCER RES, V61, P4978; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Law SF, 1996, MOL CELL BIOL, V16, P3327; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Lee JW, 2002, BBA-MOL CELL RES, V1542, P23, DOI 10.1016/S0167-4889(01)00161-6; Lipinski CA, 2003, MOL CANCER RES, V1, P323; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; MERLO A, 2004, SCI STKE, V229, P18; Merrill RA, 2004, DEV DYNAM, V231, P564, DOI 10.1002/dvdy.20159; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; van Seventer GA, 2001, EUR J IMMUNOL, V31, P1417, DOI 10.1002/1521-4141(200105)31:5<1417::AID-IMMU1417>3.0.CO;2-C; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang DY, 2000, J CELL SCI, V113, P4221; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Zagzag D, 2000, PEDIATR NEUROSURG, V33, P49, DOI 10.1159/000028975; Zrihan-Licht S, 2004, INT J ONCOL, V24, P153	50	156	164	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1721	1732		10.1038/sj.onc.1209199	http://dx.doi.org/10.1038/sj.onc.1209199			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16288224				2022-12-17	WOS:000236013700004
J	Liu, YN; Lee, WW; Wang, CY; Chao, TH; Chen, Y; Chen, JH				Liu, YN; Lee, WW; Wang, CY; Chao, TH; Chen, Y; Chen, JH			Regulatory mechanisms controlling human E-cadherin gene expression	ONCOGENE			English	Article						E-cadherin; gene expression; HNF3 (Hepatocyte Nuclear Factor); metastasis	EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTION FACTOR SNAIL; TUMOR-SUPPRESSOR GENE; BREAST-CANCER; GASTRIC-CANCER; P-CADHERIN; PROMOTER; BINDING; REPRESSION; CELLS	In cancer cells, loss of E-cadherin gene expression caused dysfunction of the cell-cell junction system, triggering cancer invasion and metastasis. Therefore, E-cadherin is an important tumor-suppressor gene. To understand how E-cadherin gene expression is regulated in cancer cells, we have used E-cadherin-positive and -negative expressing cells to find out the possible up- or downregulating transcription factors in human E-cadherin regulatory sequences. Functional analysis of human E-cadherin regulatory sequences constructs indicated that AML1, Sp1, and p300 may play important roles in promoting E-cadherin expression. In addition, we found there are four HNF3-binding sites in human E-cadherin regulatory sequences. The exogenous HNF3 can enhance the E-cadherin promoter activity in metastatic breast cancer cells and the metastatic breast cancer cells stably transfected with HNF3 showed re-expression of E-cadherin. The HNF3 stable transfectants changed from mesenchymal-like into epithelial morphology. The transwell assays showed the re-expressed E-cadherin reduced cell motility of metastatic breast cancer cells. These results suggested HNF3 may play important roles in the upregulation of the E-cadherin promoter, with the consequent re-expression of E-cadherin, thus reducing the metastatic potential of breast cancer cells. These findings suggested HNF3 plays important roles in the upregulation of the E-cadherin gene and may be able to reduce the motility of metastatic breast cancer cells.	Tzu Chi Univ, Coll Life Sci, Grad Inst Mol & Cell Biol, Hualien 970, Taiwan; Tzu Chi Univ, Grad Inst Med Sci, Hualien 970, Taiwan; Tzu Chi Univ, Dept Life Sci, Hualien 970, Taiwan	Tzu Chi University; Tzu Chi University; Tzu Chi University	Chen, JH (corresponding author), Tzu Chi Univ, Coll Life Sci, Grad Inst Mol & Cell Biol, 701 Chung Yang Rd Sec 3, Hualien 970, Taiwan.	jhc@mail.tcu.edu.tw						Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BECKER KF, 1994, CANCER RES, V54, P3845; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Braun H, 1998, J BIOL CHEM, V273, P9821, DOI 10.1074/jbc.273.16.9821; BUSSEMAKERS MJG, 1994, BIOCHEM BIOPH RES CO, V203, P1291, DOI 10.1006/bbrc.1994.2322; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; CHANG HW, 2000, CANCER, V94, P386; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Duband JL, 1995, ACTA ANAT, V154, P63; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Faraldo MLM, 1997, MOL CARCINOGEN, V20, P33, DOI 10.1002/(SICI)1098-2744(199709)20:1<33::AID-MC5>3.0.CO;2-J; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; GRAFF JR, 1995, CANCER RES, V55, P5195; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Halmos B, 2004, CANCER RES, V64, P4137, DOI 10.1158/0008-5472.CAN-03-4052; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hemavathy K, 2000, MOL CELL BIOL, V20, P5087, DOI 10.1128/MCB.20.14.5087-5095.2000; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; HENNIG G, 1995, ONCOGENE, V11, P475; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lelievre E, 2000, ONCOGENE, V19, P2438, DOI 10.1038/sj.onc.1203563; Liu YN, 2004, ONCOGENE, V23, P278, DOI 10.1038/sj.onc.1207022; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; Parviz F, 2003, NAT GENET, V34, P292, DOI 10.1038/ng1175; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; Sarrio D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; SHIGEAKI L, 2002, FASEB J, V16, P1444; Si HX, 2001, CANCER LETT, V173, P71, DOI 10.1016/S0304-3835(01)00646-2; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; Soutoglou E, 2001, EMBO J, V20, P1984, DOI 10.1093/emboj/20.8.1984; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Viebahn C, 1995, ACTA ANAT, V154, P79; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	53	156	169	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8277	8290		10.1038/sj.onc.1208991	http://dx.doi.org/10.1038/sj.onc.1208991			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16116478				2022-12-17	WOS:000233956500007
J	Navarro, C; Nola, S; Audebert, S; Santoni, MJ; Arsanto, JP; Ginestier, C; Marchetto, S; Jacquemier, J; Isnardon, D; Le Bivic, A; Birnbaum, D; Borg, JP				Navarro, C; Nola, S; Audebert, S; Santoni, MJ; Arsanto, JP; Ginestier, C; Marchetto, S; Jacquemier, J; Isnardon, D; Le Bivic, A; Birnbaum, D; Borg, JP			Junctional recruitment of mammalian Scribble relies on E-cadherin engagement	ONCOGENE			English	Article						carcinoma; scribble; breast; PDZ domain; E-cadherin	TUMOR-SUPPRESSOR SCRIBBLE; BASOLATERAL PDZ PROTEIN; EPITHELIAL-CELLS; ADHERENS JUNCTIONS; GENE-EXPRESSION; POLARITY; LOCALIZATION; COMPLEX; BREAST; DOMAIN	Members of the LAP protein family, LET-413 in Caenorhabditis elegans, Scribble in Drosophila melanogaster, and Erbin, Lano, Densin-180 and hScrib in mammals, have conserved structural features. LET-413 and Scribble are junctional proteins involved in establishing and maintaining epithelial cell polarity. scribble also behaves as a neoplastic tumor suppressor gene. We show here that, in epithelial cells, hScrib is recruited at cell-cell junctions in an E-cadherin-dependent manner as shown by calcium switch assays in MDCK cells, re-expression of E-cadherin in MDA-231 cells treated by 5-Aza-2'-deoxycytidine (5Aza), and siRNA experiments. hScrib is restricted at the basolateral membrane of epithelial cells by its LRR domain, and is enriched in Triton X-100-insoluble fractions. In breast cancers, most lobular tumors did not express hScrib and E-cadherin while ductal tumors had a less frequent downregulation of hScrib. Our data provide additional insights on the modalities of recruitment of hScrib at the cell-cell junctions, and establish a potential link between the E-cadherin and hScrib tumor suppressors.	Inst J Paoli I Calmettes, INSERM, UMR 599, Marseille Canc Inst, F-13009 Marseille, France; Fac Sci Luminy, NMDA, F-13288 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite	Borg, JP (corresponding author), Inst J Paoli I Calmettes, INSERM, UMR 599, Marseille Canc Inst, 27 Blvd Lei Roure, F-13009 Marseille, France.	borg@marseille.inserm.fr	Borg, Jean-Paul/AAX-8096-2020; Nola, Sebastien/D-6518-2017; Ginestier, Christophe/M-8828-2017	Borg, Jean-Paul/0000-0001-8418-3382; Nola, Sebastien/0000-0002-6485-9856; Ginestier, Christophe/0000-0002-7477-3837; Santoni, Marie-Josee/0000-0002-2619-7257; Audebert, Stephane/0000-0002-9409-2588				Albertson R, 2004, J CELL SCI, V117, P6061, DOI 10.1242/jcs.01525; Audebert S, 2004, CURR BIOL, V14, P987, DOI 10.1016/j.cub.2004.05.051; Baas AF, 2004, TRENDS CELL BIOL, V14, P312, DOI 10.1016/j.tcb.2004.04.001; Benton R, 2003, CURR BIOL, V13, P1330, DOI 10.1016/S0960-9822(03)00508-6; Bertucci F, 2004, ONCOGENE, V23, P2564, DOI 10.1038/sj.onc.1207361; Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Dow LE, 2003, ONCOGENE, V22, P9225, DOI 10.1038/sj.onc.1207154; Droufakou S, 2001, INT J CANCER, V92, P404, DOI 10.1002/ijc.1208; Ginestier C, 2002, AM J PATHOL, V161, P1223, DOI 10.1016/S0002-9440(10)64399-4; GRAFF JR, 1995, CANCER RES, V55, P5195; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Huang YZ, 2001, J BIOL CHEM, V276, P19318, DOI 10.1074/jbc.M100494200; Jaulin-Bastard F, 2002, J BIOL CHEM, V277, P2869, DOI 10.1074/jbc.M109652200; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Laprise P, 2004, J BIOL CHEM, V279, P10157, DOI 10.1074/jbc.M309843200; Lee S, 2002, MOL CELL BIOL, V22, P1778, DOI 10.1128/MCB.22.6.1778-1791.2002; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; Legouis R, 2003, EMBO REP, V4, P1096, DOI 10.1038/sj.embor.7400006; Mantovani F, 2001, J CELL SCI, V114, P4285; Mathew D, 2002, CURR BIOL, V12, P531, DOI 10.1016/S0960-9822(02)00758-3; Mizuno K, 2003, J BIOL CHEM, V278, P31240, DOI 10.1074/jbc.M303593200; Musch A, 2002, MOL BIOL CELL, V13, P158, DOI 10.1091/mbc.01-10-0496; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Nourry Claire, 2003, Sci STKE, V2003, pRE7; Ohno H, 2002, ONCOGENE, V21, P7042, DOI 10.1038/sj.onc.1205852; Roche JP, 2002, J NEUROSCI, V22, P6471, DOI 10.1523/jneurosci.22-15-06471.2002; Santoni MJ, 2002, TRENDS GENET, V18, P494, DOI 10.1016/S0168-9525(02)02738-5; Strathdee G, 2002, SEMIN CANCER BIOL, V12, P373, DOI 10.1016/S1044-579X(02)00057-3; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; Walikonis RS, 2001, J NEUROSCI, V21, P423, DOI 10.1523/JNEUROSCI.21-02-00423.2001; Zeitler J, 2004, J CELL BIOL, V167, P1137, DOI 10.1083/jcb.200407158	36	156	163	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4330	4339		10.1038/sj.onc.1208632	http://dx.doi.org/10.1038/sj.onc.1208632			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806148				2022-12-17	WOS:000229976900002
J	Thun, MJ; Henley, SJ; Calle, EE				Thun, MJ; Henley, SJ; Calle, EE			Tobacco use and cancer: an epidemiologic perspective for geneticists	ONCOGENE			English	Review						tobacco; cancer; genetic epidemiology	SQUAMOUS-CELL CARCINOMA; N-ACETYLTRANSFERASE 2; REPAIR GENE XRCC1; LUNG-CANCER; CIGARETTE-SMOKING; HISTOLOGIC-CHANGES; BREAST-CANCER; BRONCHIAL EPITHELIUM; BLADDER-CANCER; MOLECULAR EPIDEMIOLOGY	Much of what is known about the deleterious effects of tobacco use on health was learned from epidemiologic studies over the last half century. These studies establish unequivocally that tobacco use, particularly manufactured cigarette smoking, causes most cancers of the lung, oropharynx, larynx, and esophagus in the USA, and approximately one-third of all cancers of the pancreas, kidney, urinary bladder and uterine cervix. More recent evidence also implicates smoking with cancers of the stomach, liver and colorectum. While over half of the estimated 440 000 smoking-attributable deaths that occur annually in the USA involve non-malignant cardiovascular and respiratory conditions, smoking-attributable cancers are more recognized and feared. Geneticists increasingly study tobacco use as a model for environmental carcinogenicity. Tobacco-exposed populations provide opportunities to characterize the somatic mutations that give rise to specific cancers and to identify the inherited genetic traits that confer susceptibility or resistance. Studies to identify the genetic determinants of addiction may be particularly important. Future research to identify other susceptibility factors, such as genes that modify carcinogen metabolism or DNA repair, will need to be substantially larger and to quantify lifetime tobacco exposure with more precision than have past studies in order to distinguish gradations in risk due to exposure from those caused by genetic susceptibility. This review considers: (a) the epidemiology of tobacco use; (b) cancers presently classified as smoking-attributable by the US Surgeon General; (c) the magnitude of the epidemic of cancers and other diseases caused by tobacco use; (d) selected issues in the epidemiology of lung cancer; and (e) the interface of genetics and epidemiology in understanding, preventing, and treating tobacco-attributable disease.	Amer Canc Soc, Dept Epidemiol & Surveillance Res, Atlanta, GA 30329 USA	American Cancer Society	Thun, MJ (corresponding author), Amer Canc Soc, Dept Epidemiol & Surveillance Res, 1599 Clifton Rd, Atlanta, GA 30329 USA.	Mthun@cancer.org	Henley, Jane/A-4698-2010	Henley, S Jane/0000-0002-2420-306X				Ahsan H, 1997, CANCER EPIDEM BIOMAR, V6, P779; Ambrosone CB, 1996, JAMA-J AM MED ASSOC, V276, P1494, DOI 10.1001/jama.276.18.1494; AUERBACH O, 1986, DIGEST DIS SCI, V31, P1014, DOI 10.1007/BF01300252; AUERBACH O, 1961, NEW ENGL J MED, V265, P253, DOI 10.1056/NEJM196108102650601; AUERBACH O, 1962, NEW ENGL J MED, V267, P119, DOI 10.1056/NEJM196207192670302; AUERBACH O, 1965, ARCH ENVIRON HEALTH, V11, P4, DOI 10.1080/00039896.1965.10664163; AUERBACH O, 1970, CANCER-AM CANCER SOC, V25, P92, DOI 10.1002/1097-0142(197001)25:1<92::AID-CNCR2820250114>3.0.CO;2-E; AUERBACH O, 1964, AM REV RESPIR DIS, V90, P867; AUERBACH O, 1979, NEW ENGL J MED, V300, P381, DOI 10.1056/NEJM197902223000801; Baron JA, 1996, BRIT MED BULL, V52, P58, DOI 10.1093/oxfordjournals.bmb.a011533; Bartsch H, 2000, CANCER EPIDEM BIOMAR, V9, P3; Bennett WP, 1999, JNCI-J NATL CANCER I, V91, P2009, DOI 10.1093/jnci/91.23.2009; BENOWITZ N, 2001, 025074 NIH US DEP HL; Benowitz NL, 2002, J NATL CANCER I, V94, P108, DOI 10.1093/jnci/94.2.108; Bergen AW, 1999, JNCI-J NATL CANCER I, V91, P1365, DOI 10.1093/jnci/91.16.1365; BERKSON J, 1958, J AM STAT ASSOC, V53, P28, DOI 10.2307/2282563; BERKSON J, 1955, P STAFF M MAYO CLIN, V30, P319; BEST E. W. R., 1961, Canadian Journal of Public Health, V52, P99; Brockton N, 2000, AM J EPIDEMIOL, V151, P846; BROWNSON RC, 1992, EPIDEMIOLOGY, V3, P61, DOI 10.1097/00001648-199201000-00012; BURNS D, 1997, CIGARETTE SMOKING BE; Califano J, 1999, CLIN CANCER RES, V5, P1862; Califano J, 1996, CANCER RES, V56, P2488; Califano J, 2000, CLIN CANCER RES, V6, P347; Cardon LR, 2001, NAT REV GENET, V2, P91, DOI 10.1038/35052543; Castelao JE, 2001, JNCI-J NATL CANCER I, V93, P538, DOI 10.1093/jnci/93.7.538; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P1217; *CDC, 2002, MMWR-MORBID MORTAL W, V51, P300; CLEMMESEN J, 1965, STAT STUDIES AETIOLO; Cohn BA, 1996, J NATL CANCER I, V88, P1867, DOI 10.1093/jnci/88.24.1867; Cooper EA, 1932, J HYG-CAMBRIDGE, V32, P293; Corrao MA, 2000, B WORLD HEALTH ORGAN, V78, P884; CORRAO MA, 2000, TOBACCO CONTROL COUN; COSMA G, 1993, CANCER EPIDEM BIOMAR, V2, P53; CROFTS F, 1993, CARCINOGENESIS, V14, P1729, DOI 10.1093/carcin/14.9.1729; CRONINGER AB, 1958, CANCER RES, V18, P1263; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Djordjevic MV, 2000, JNCI-J NATL CANCER I, V92, P106, DOI 10.1093/jnci/92.2.106; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; DOLL R, 1964, BRIT MED J, V1, P1399, DOI 10.1136/bmj.1.5395.1399; DOLL R, 1957, BRIT J CANCER, V11, P43, DOI 10.1038/bjc.1957.6; Doll R, 1998, Stat Methods Med Res, V7, P87, DOI 10.1191/096228098668199908; DOLL R, 1978, J EPIDEMIOL COMMUN H, V32, P303, DOI 10.1136/jech.32.4.303; DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739; DOLL R, 1954, BMJ-BRIT MED J, V1, P1451, DOI 10.1136/bmj.1.4877.1451; DOLL R, 1956, BRIT MED J, V2, P1071, DOI 10.1136/bmj.2.5001.1071; Doll R, 1996, BRIT MED BULL, V52, P35, DOI 10.1093/oxfordjournals.bmb.a011531; DORN HF, 1959, PUBLIC HEALTH REP, V74, P581, DOI 10.2307/4590516; EBERHARDT MS, 2001, URBAN RURAL HLTH CHA; ENGELBRETH-HOLM J., 1957, ACTA PATH ET MICROBIOL SCAND, V41, P267; FORD B, 1994, SMOKE SCREEN GUIDE P; FRAUMENI JF, 1974, J NATL CANCER I, V52, P659, DOI 10.1093/jnci/52.3.659; GAFFNEY M, 1988, J NATL CANCER I, V80, P925, DOI 10.1093/jnci/80.12.925; Gammon MD, 1997, J NATL CANCER I, V89, P1277, DOI 10.1093/jnci/89.17.1277; Garcia-Closas M, 1999, AM J EPIDEMIOL, V149, P689; Garte S, 2001, CANCER EPIDEM BIOMAR, V10, P1233; Geisler SA, 2001, AM J EPIDEMIOL, V154, P95, DOI 10.1093/aje/154.2.95; Giovannucci E, 2001, CANCER EPIDEM BIOMAR, V10, P725; GLANTZ SA, 1996, CIGARETTE PAPERS, P1; Green J, 2000, BRIT J CANCER, V83, P412, DOI 10.1054/bjoc.2000.1265; GUERIN M, 1957, Bull Assoc Fr Etud Cancer, V44, P387; Guo ZM, 2001, CLIN CANCER RES, V7, P1963; HAENSZEL W, 1956, 463 PHS; HAMMOND E. CUYLER, 1966, NAT CANCER INST MONOGR, V19, P127; HAMMOND EC, 1958, JAMA-J AM MED ASSOC, V166, P1294, DOI 10.1001/jama.1958.02990110030007; HARRIS JE, 1983, JNCI-J NATL CANCER I, V71, P473; HARRIS RE, 1993, INT J EPIDEMIOL, V22, P592, DOI 10.1093/ije/22.4.592; Heath AC, 1995, BEHAV GENETIC APPROA, P45; Hecht SS, 2000, J NATL CANCER I, V92, P782, DOI 10.1093/jnci/92.10.782; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Henningfield J. E., 1993, NICOTINE ADDICTION P, P24; Hickey K, 2001, EPIDEMIOL REV, V23, P115, DOI 10.1093/oxfordjournals.epirev.a000776; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Hopper JL, 1999, CANCER EPIDEM BIOMAR, V8, P741; Houlston RS, 1999, CANCER EPIDEM BIOMAR, V8, P675; IARC, 1987, IARC MON EV CARC RIS, V1-42; International Agency for Research on Cancer Tobacco smoking IARC, 1986, IARC MON EV CARC RIS, V38; KAHN HA, 1966, MONOGR NAT CANCER I, V19, P1; King TE, 1999, NEW ENGL J MED, V341, P1231, DOI 10.1056/NEJM199910143411612; KREYBERG L, 1962, ACTA PATHOL MIC SC, P11; Lagergren J, 2000, INT J CANCER, V85, P340; Lam TH, 2001, BRIT MED J, V323, P361, DOI 10.1136/bmj.323.7309.361; Landi M T, 1999, IARC Sci Publ, P173; Lang M, 1999, IARC Sci Publ, P13; LAW CH, 1976, INT J CANCER, V17, P304, DOI 10.1002/ijc.2910170305; Lee JJ, 2000, CLIN CANCER RES, V6, P1702; LEITCH A, 1928, 5 ANN REPORT BRIT EM, P26; LEVIN ML, 1950, JAMA-J AM MED ASSOC, V143, P336, DOI 10.1001/jama.1950.02910390008002; Liu BQ, 1998, BMJ-BRIT MED J, V317, P1411, DOI 10.1136/bmj.317.7170.1411; London SJ, 1999, LANCET, V353, P898, DOI 10.1016/S0140-6736(98)04984-8; LUBIN JH, 1984, JNCI-J NATL CANCER I, V73, P383, DOI 10.1093/jnci/73.2.383; MABRY M, 1998, GENETIC BASIC HUMAN, P671; Malone KE, 1998, JAMA-J AM MED ASSOC, V279, P922, DOI 10.1001/jama.279.12.922; Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682; Martin GC, 1999, J AM DENT ASSOC, V130, P945, DOI 10.14219/jada.archive.1999.0335; MATTSON ME, 1987, AM J PUBLIC HEALTH, V77, P425, DOI 10.2105/AJPH.77.4.425; MCDUFFIE HH, 1991, J CLIN EPIDEMIOL, V44, P537, DOI 10.1016/0895-4356(91)90217-W; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MILLS CA, 1950, CANCER RES, V10, P539; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Montague M, 1997, FOCUS EXCEPT CHILD, V30, P1; MOOLGAVKAR SH, 1990, RISK ANAL, V10, P323, DOI 10.1111/j.1539-6924.1990.tb01053.x; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Newman B, 1998, JAMA-J AM MED ASSOC, V279, P915, DOI 10.1001/jama.279.12.915; Niu SR, 1998, BRIT MED J, V317, P1423, DOI 10.1136/bmj.317.7170.1423; NOVOTNY TE, 1988, AM J PUBLIC HEALTH, V78, P1187, DOI 10.2105/AJPH.78.9.1187; OSANN KE, 1993, INT J CANCER, V54, P44, DOI 10.1002/ijc.2910540108; PASSEY RD, 1929, 6 REPORT BRIT EMPIRE, P85; Perera FP, 1996, JNCI-J NATL CANCER I, V88, P496, DOI 10.1093/jnci/88.8.496; Perez-Stable EJ, 1998, JAMA-J AM MED ASSOC, V280, P152, DOI 10.1001/jama.280.2.152; Perneger TV, 2001, J NATL CANCER I, V93, P1600, DOI 10.1093/jnci/93.21.1600; Peto R, 1985, IARC Sci Publ, P43; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; Peto R, 1994, MORTALITY SMOKING DE; PIKE MC, 1965, LANCET, V1, P665; Prescott E, 1998, EPIDEMIOLOGY, V9, P79, DOI 10.1097/00001648-199801000-00016; Ratnasinghe D, 2001, CANCER EPIDEM BIOMAR, V10, P119; Richie JP, 1997, CANCER EPIDEM BIOMAR, V6, P783; Ries LAG .M.K.C, 2001, SEER CANC STAT REV 1; RISCH HA, 1993, AM J EPIDEMIOL, V138, P281, DOI 10.1093/oxfordjournals.aje.a116857; ROFFO A. H., 1931, ZEITSCHR KREBSFORSCH, V33, P321, DOI 10.1007/BF01792286; Rothman KJ, 1998, MODERN EPIDEMIOLOGY, P7; RYBERG D, 1994, CANCER RES, V54, P5801; SCHREK R, 1950, CANCER RES, V10, P49; SHIELDS PG, 1993, CANCER EPIDEM BIOMAR, V2, P481; Shriver SP, 2000, JNCI-J NATL CANCER I, V92, P24, DOI 10.1093/jnci/92.1.24; Sidransky D, 1995, J Natl Cancer Inst Monogr, P27; SILVERMAN S, 1998, ORAL CANC, P25; SLADE J, 1993, NICOTINE ADDICTION P, P3; Smith SS, 1999, PRIMARY CARE, V26, P433, DOI 10.1016/S0095-4543(05)70112-3; SOMMERING S, 1995, MORBIS VASORUM ABSOR; Spivack SD, 1997, CRIT REV TOXICOL, V27, P319, DOI 10.3109/10408449709089898; Stellman SD, 2001, CANCER EPIDEM BIOMAR, V10, P1193; Stern MC, 2001, CANCER EPIDEM BIOMAR, V10, P125; Stewart JH, 2001, CANCER-AM CANCER SOC, V91, P2476, DOI 10.1002/1097-0142(20010615)91:12<2476::AID-CNCR1283>3.0.CO;2-Z; Strange R C, 1999, IARC Sci Publ, P231; Straub RE, 1999, MOL PSYCHIATR, V4, P129, DOI 10.1038/sj.mp.4000518; STRONG LC, 1996, CANC EPIDEMIOLOGY PR, P559; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; SUGIURA K, 1956, Gan, V47, P243; Taioli E, 1998, CARCINOGENESIS, V19, P813, DOI 10.1093/carcin/19.5.813; Thun M. J, 1997, MONOGRAPH, V8; Thun MJ, 1997, JNCI-J NATL CANCER I, V89, P1580, DOI 10.1093/jnci/89.21.1580; Thun MJ, 1998, TOB CONTROL, V7, P223, DOI 10.1136/tc.7.3.223; Thun MJ, 2000, CANCER EPIDEM BIOMAR, V9, P861; Thun MJ, 1997, NATL CANCER I MONOGR, P305; Tredaniel J, 1997, INT J CANCER, V72, P565, DOI 10.1002/(SICI)1097-0215(19970807)72:4<565::AID-IJC3>3.0.CO;2-O; *US DEP HHS, 1988, RED HLTH CONS SMOK 2; *US DEP HHS, 1990, DHHS PUBLICATION; US Department of Health and Human Services [Internet], 1990, HLTH BEN SMOK CESS R; US Public Health Service, 1964, SMOK HLTH REP ADV CO; *USDA, 2001, USDA COMM EC DIV RES; Wakai K, 2001, JPN J CANCER RES, V92, P821, DOI 10.1111/j.1349-7006.2001.tb01167.x; Weinberg CR, 1999, J NATL CANCER I, V91, P1985, DOI 10.1093/jnci/91.23.1985; Westra WH, 1998, J NATL CANCER I, V90, P1500, DOI 10.1093/jnci/90.20.1500; Wu-Williams AH, 1994, EPIDEMIOLOGY LUNG CA, P71; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P329, DOI 10.1001/jama.1950.02910390001001; WYNDER EL, 1953, CANCER RES, V13, P855; WYNDER EL, 1955, CANCER RES, V15, P445; Yuan JM, 1996, JAMA-J AM MED ASSOC, V275, P1646, DOI 10.1001/jama.275.21.1646; Zang EA, 1996, JNCI-J NATL CANCER I, V88, P183, DOI 10.1093/jnci/88.3-4.183; ZANG EA, 1992, CANCER, V70, P69, DOI 10.1002/1097-0142(19920701)70:1<69::AID-CNCR2820700112>3.0.CO;2-A	163	156	159	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2002	21	48					7307	7325		10.1038/sj.onc.1205807	http://dx.doi.org/10.1038/sj.onc.1205807			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379875				2022-12-17	WOS:000178618000005
J	van Engeland, M; Roemen, GMJM; Brink, M; Paachen, MMM; Weijenberg, MP; de Bruine, AP; Arends, JW; van den Brandt, PA; de Goeij, AFPM; Herman, JG				van Engeland, M; Roemen, GMJM; Brink, M; Paachen, MMM; Weijenberg, MP; de Bruine, AP; Arends, JW; van den Brandt, PA; de Goeij, AFPM; Herman, JG			K-ras mutations and RASSF1A promoter methylation in colorectal cancer	ONCOGENE			English	Article						K-Ras; methylation; RASSF1A; silencing	TUMOR-SUPPRESSOR GENE; FREQUENT EPIGENETIC INACTIVATION; CPG ISLAND; HYPERMETHYLATION; 3P21.3; LUNG; CELL; BREAST; PROTEIN; OVARIAN	Human cancer is characterized by genetic and epigenetic alterations. In this study we provide evidence for the interruption of Ras signaling in sporadic colorectal cancer (CRC) by either genetic activation of the K-ras oncogene or epigenetic silencing of the putative tumor suppressor gene RASSF1A. Paraffin embedded tumor tissue samples from 222 sporadic CRC patients were analysed for K-ras codon 12 and codon 13 activating mutations and RASSF1A promoter hypermethylation. Overall, K-ras mutations were observed in 87 of 222 (39%) and RASSF1A methylation was observed in 45 of 222 (20%) of CRCs. Mutation of K-ras alone was detected in 76 of 222 (34%) CRCs. RASSF1A promoter methylation with wild-type K-ras was observed in 34 of 222 (15%) CRCs. In 101 of 222 (46%) CRCs neither K-ras mutations nor RASSF1A methylation was observed and 11 of 222 (5%) CRCs showed both K-ras mutations and RASSF1A methylation. These data show that the majority of the studied CRCs with K-ras mutations lack RASSF1A promoter methylation, an event which occurs predominantly in K-ras wild-type CRCs (P=0.023, Chi-square test).	Johns Hopkins Oncol Ctr, 1650 Orleans St,Room 543, Baltimore, MD 21231 USA; Univ Maastricht, Dept Pathol, NL-6200 MD Maastricht, Netherlands; Univ Maastricht, Dept Epidemiol, NL-6200 MD Maastricht, Netherlands	Johns Hopkins University; Johns Hopkins Medicine; Maastricht University; Maastricht University	Herman, JG (corresponding author), Johns Hopkins Oncol Ctr, 1650 Orleans St,Room 543, Baltimore, MD 21231 USA.	hermanji@jhmi.edu	van Engeland, Manon/A-7479-2009	van Engeland, Manon/0000-0002-7952-6843; van den Brandt, Piet/0000-0001-8781-8099				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; BOS JL, 1989, CANCER RES, V49, P4682; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Esteller M, 2000, CANCER RES, V60, P129; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Lee MG, 2001, CANCER RES, V61, P6688; Lo KW, 2001, CANCER RES, V61, P3877; Maruyama R, 2001, CANCER RES, V61, P8659; Morrissey C, 2001, CANCER RES, V61, P7277; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Sparks AB, 1998, CANCER RES, V58, P1130; VANDENBRANDT PA, 1990, J CLIN EPIDEMIOL, V43, P285, DOI 10.1016/0895-4356(90)90009-E; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466	25	156	170	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3792	3795		10.1038/sj.onc.1205466	http://dx.doi.org/10.1038/sj.onc.1205466			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032847	Bronze, Green Submitted			2022-12-17	WOS:000175676000014
J	Wade, PA				Wade, PA			Methyl CpG binding proteins: coupling chromatin architecture to gene regulation	ONCOGENE			English	Review						DNA methylation; MeCP2; Rett syndrome; histone deacetylase; chromatin	TRANSCRIPTIONAL REPRESSOR MECP2; HISTONE DEACETYLASE COMPLEX; LINKED MENTAL-RETARDATION; RETT-SYNDROME MUTATIONS; DNA METHYLATION; CHROMOSOMAL PROTEIN; DOMAIN; MBD4; METHYLTRANSFERASES; GIRLS	A correlation between DNA methylation and transcriptional silencing has existed for many Sears. Recently, substantial progress has been reported in the search for proteins that interpret the regulatory information inherent in DNA methylation and translate this information into functional states, resulting in the identification of a family of highly conserved proteins, the MBD family. Direct connections between these proteins and histone modification enzymes have emerged as a common theme, implying that DNA methylation exerts its effects primarily through repressive chromatin architecture. Recent structural determinations of the DNA binding domain of two MBD family members, MeCP2 and MBD1, provide a framework to model the interactions of this family with DNA, Comparative sequence analysis and experimental DNA binding data can be interpreted using this structural framework allowing one to contrast the members of the MBD family with each other and to predict the properties of new family members. The identification of mutations in MeCP2, the founding member of this family, as causal for the neurological developmental disorder Rett Syndrome provides additional information regarding amino acid residues crucial to the functions of this interesting protein family.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Emory University	Wade, PA (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Woodruff Mem Res Bldg,Room 7105B,1639 Pierce Dr, Atlanta, GA 30322 USA.		Wade, Paul A/D-2374-2019	Wade, Paul A/0000-0002-6042-357X	NICHD NIH HHS [1K22 HD01238-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K22HD001238] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Amir RE, 2000, ANN NEUROL, V47, P670, DOI 10.1002/1531-8249(200005)47:5<670::AID-ANA20>3.3.CO;2-6; Bader S, 1999, ONCOGENE, V18, P8044, DOI 10.1038/sj.onc.1203229; Ballestar E, 2000, BIOCHEMISTRY-US, V39, P7100, DOI 10.1021/bi0001271; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bienvenu T, 2000, HUM MOL GENET, V9, P1377, DOI 10.1093/hmg/9.9.1377; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Boeke J, 2000, J BIOL CHEM, V275, P34963, DOI 10.1074/jbc.M005929200; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; Buyse IM, 2000, AM J HUM GENET, V67, P1428, DOI 10.1086/316913; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chandler SP, 1999, BIOCHEMISTRY-US, V38, P7008, DOI 10.1021/bi990224y; Cheadle JP, 2000, HUM MOL GENET, V9, P1119, DOI 10.1093/hmg/9.7.1119; COOPER DN, 1989, HUM GENET, V83, P181, DOI 10.1007/BF00286715; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Dragich J, 2000, HUM MOL GENET, V9, P2365, DOI 10.1093/hmg/9.16.2365; Free A, 2001, J BIOL CHEM, V276, P3353, DOI 10.1074/jbc.M007224200; Fujita N, 1999, MOL CELL BIOL, V19, P6415; HAGBERG B, 1983, ANN NEUROL, V14, P471, DOI 10.1002/ana.410140412; HAGBERG B, 1985, ACTA PAEDIATR SCAND, V74, P405, DOI 10.1111/j.1651-2227.1985.tb10993.x; Hampson K, 2000, J MED GENET, V37, P610, DOI 10.1136/jmg.37.8.610; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 1999, MAMM GENOME, V10, P906, DOI 10.1007/s003359901112; Hendrich B, 2000, CURR TOP MICROBIOL, V249, P55; Huppke P, 2000, HUM MOL GENET, V9, P1369, DOI 10.1093/hmg/9.9.1369; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; Kim SJ, 2000, HUM MUTAT, V15, P382, DOI 10.1002/(SICI)1098-1004(200004)15:4<382::AID-HUMU16>3.0.CO;2-8; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Macleod D, 1999, NAT GENET, V23, P139, DOI 10.1038/13767; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; Meloni I, 2000, AM J HUM GENET, V67, P982, DOI 10.1086/303078; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Obata K, 2000, J MED GENET, V37, P608, DOI 10.1136/jmg.37.8.608; Ohki I, 1999, EMBO J, V18, P6653, DOI 10.1093/emboj/18.23.6653; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Orrico A, 2000, FEBS LETT, V481, P285, DOI 10.1016/S0014-5793(00)01994-3; Petronzelli F, 2000, J BIOL CHEM, V275, P32422, DOI 10.1074/jbc.M004535200; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Rett A, 1966, Wien Med Wochenschr, V116, P723; Riccio A, 1999, NAT GENET, V23, P266, DOI 10.1038/15443; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Stancheva I, 2000, GENE DEV, V14, P313; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wakefield RID, 1999, J MOL BIOL, V291, P1055, DOI 10.1006/jmbi.1999.3023; Wan MM, 1999, AM J HUM GENET, V65, P1520, DOI 10.1086/302690; Xiang FQ, 2000, J MED GENET, V37, P250, DOI 10.1136/jmg.37.4.250; Yusufzai TM, 2000, NUCLEIC ACIDS RES, V28, P4172, DOI 10.1093/nar/28.21.4172; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	60	156	164	0	17	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3166	3173		10.1038/sj.onc.1204340	http://dx.doi.org/10.1038/sj.onc.1204340			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420733				2022-12-17	WOS:000169308500021
J	Liew, CT; Li, HM; Lo, KW; Leow, CK; Chan, JYH; Hin, LY; Lau, WY; Lai, PBS; Lim, BK; Huang, J; Leung, WT; Wu, S; Lee, JCK				Liew, CT; Li, HM; Lo, KW; Leow, CK; Chan, JYH; Hin, LY; Lau, WY; Lai, PBS; Lim, BK; Huang, J; Leung, WT; Wu, S; Lee, JCK			High frequency of p16(INK4A) gene alterations in hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; p16; hypermethylation; homozygous deletion; mutation	HOMOZYGOUS DELETIONS; DNA METHYLATION; MUTATIONS; INACTIVATION; INHIBITION; MDM2	The tumor suppressor gene p16 (CDKN2/MTS-1/INK4A) is an important component of the cell cycle and inactivation of the gene has been found in a variety of human cancers. In order to investigate the role of p16 gene in the tumorigenesis of hepatocellular carcinoma (HCC), 48 cases of HCC were analysed for p16 alterations by: methylation-specific PCR (MSP) to determine the methylation status of the p16 promoter region; comparative multiplex PCR to detect homozygous deletion; PCR-SSCP and DNA sequencing analysis to identify mutation of the p16 gene. We found high frequency of hypermethylation of the 5' CpG island of the p16 gene in 30 of 48 cases (62.5%) of HCC tumors. Moreover, homozygous deletion at p16 region were present in five of 48 cases (10.4%); and missense mutation were detected in three of 48 cases (6.3%), The overall frequency of p16 alterations, including homozygous deletion, mutation and hypermethylation, in HCC tumors was 70.8% (34 of 48 cases), These findings suggest that: (a) the inactivation of the p16 is a frequent event in HCC; (b) the p16 gene is inactivated by multiple mechanisms including homozygous deletion, promoter hypermethylation and point mutation; (c) the most common somatic alteration of the p16 gene in HCC is de novo hypermethylation of the 5' CpG island; and (d) in contrast to other studies, high frequency of genomic alterations are not uncommon in the 9p21 of the p16 gene. Our results strongly suggest that the p16 gene plays an important role in the pathogenesis of HCC.	Prince Wales Hosp, Chinese Univ Hong Kong, Fac Med, Dept Anat & Cellular Pathol, Shatin, Peoples R China; Prince Wales Hosp, Chinese Univ Hong Kong, Fac Med, Dept Surg, Shatin, Peoples R China; Prince Wales Hosp, Chinese Univ Hong Kong, Fac Med, Dept Clin Oncol, Shatin, Peoples R China; Prince Wales Hosp, Chinese Univ Hong Kong, Fac Med, Dept Obstet & Gynecol, Shatin, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital	Liew, CT (corresponding author), Prince Wales Hosp, Chinese Univ Hong Kong, Fac Med, Dept Anat & Cellular Pathol, Shatin, Peoples R China.		Hin, Lin Yee/B-1204-2009; Lai, Paul BS/K-8556-2015	Hin, Lin Yee/0000-0002-6125-4632; Lai, Paul BS/0000-0002-9469-6728; Lo, Kwok Wai/0000-0002-3488-6124				Baylin SB, 1998, ADV CANCER RES, V72, P141; Biden K, 1997, HEPATOLOGY, V25, P593, DOI 10.1002/hep.510250317; CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Chaubert P, 1997, HEPATOLOGY, V25, P1376, DOI 10.1002/hep.510250613; GERBER MA, 1992, AM J PATHOL, V141, P1271; HERMAN JG, 1995, CANCER RES, V55, P4525; *HONG KONG HOSP AU, 1998, CANC INC MORT HONG K; Hui AM, 1996, HEPATOLOGY, V24, P575, DOI 10.1053/jhep.1996.v24.pm0008781327; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kita R, 1996, INT J CANCER, V67, P176, DOI 10.1002/(SICI)1097-0215(19960717)67:2<176::AID-IJC4>3.0.CO;2-Q; MARX J, 1994, SCIENCE, V264, P1846, DOI 10.1126/science.8009205; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MISCHIATI C, 1993, BIOTECHNIQUES, V15, P146; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Qin LX, 1996, ONCOL REP, V3, P405; Reed AL, 1996, CANCER RES, V56, P3630; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; TOMIMATSU M, 1993, CANCER, V72, P683, DOI 10.1002/1097-0142(19930801)72:3<683::AID-CNCR2820720310>3.0.CO;2-C; WEISING K, 1991, ELECTROPHORESIS, V12, P159, DOI 10.1002/elps.1150120211; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	27	156	170	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					789	795		10.1038/sj.onc.1202359	http://dx.doi.org/10.1038/sj.onc.1202359			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989830				2022-12-17	WOS:000078394400025
J	Fan, SJ; Chang, JK; Smith, ML; Duba, D; Fornace, AJ; OConnor, PM				Fan, SJ; Chang, JK; Smith, ML; Duba, D; Fornace, AJ; OConnor, PM			Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard	ONCOGENE			English	Article						cell cycle checkpoints; chemosensitivity; p53; CIP1/WAF1; radiation; DNA repair	NUCLEOTIDE EXCISION-REPAIR; CYCLIN-DEPENDENT KINASES; P53-MEDIATED G(1) ARREST; P53 TUMOR-SUPPRESSOR; DNA-REPLICATION; CROSS-LINKS; P21; INHIBITOR; PROTEIN; LINES	We have previously shown that p53 disruption sensitizes certain cancer cell types to cisplatin (CDDP) (Fan et al., 1995). In the present study we investigated the role of the p53 downstream effector, p21(CIP1/WAF1) (p21), in this sensitization, Studies were performed in human colon cancer HCT-116 cells and murine embryonic fibroblasts (MEF) with intact versus disrupted p21 genes, For comparison, HCT-116 cells lacking p53 function were also prepared through stable transfection with the human papillomavirus type-16 E6 gene. HCT-116/E6 cells were found to be more sensitive than control transfectants to CDDP and another DNA crosslinking agent, nitrogen mustard (HN2). HCT-116 cells with disrupted p21 genes also exhibited greater CDDP and HN2-sensitivity than parental HCT-116 cells. In contrast, the clonogenic survival of HCT-116 cells exposed to ionizing radiation, adriamycin, taxol or vincristine was not affected by p53 or p21 disruption. Sensitization of HCT-116/p21(-/-) cells to CDDP and HN2 was not limited to the HCT-116 cell background since MEF from p21 knockout mice were also more sensitive to these DNA crosslinking agents. Investigations into a possible cause of this enhanced sensitivity revealed that HCT-116 cells lacking p53 or p21 function exhibited a reduced ability to repair cisplatin-damaged CAT-reporter plasmids transfected into the cells. In addition, we found that HCT-116/p21(-/-) cells were much more susceptible to HN2-induced cell cycle delay than parental cells. Our results suggest that p21 disruption preferentially sensitizes at least some cell types to DNA crosslinking agents.	NCI,NIH,MOL PHARMACOL LAB,BETHESDA,MD 20892; NCI,NIH,DIV BASIC SCI,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X				BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEN IT, 1995, ONCOGENE, V11, P1931; CROOK T, 1991, ONCOGENE, V6, P873; DABHOLKAR M, 1990, CARCINOGENESIS, V11, P1761, DOI 10.1093/carcin/11.10.1761; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN SJ, 1995, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; Hawkins DS, 1996, CANCER RES, V56, P892; KASTAN MB, 1991, CANCER RES, V51, P6304; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; McDonald E, 1996, CANCER RES, V56, P2250; OCONNOR PM, 1993, CANCER RES, V53, P4776; OCONNOR PM, 1991, CANCER RES, V51, P6550; OCONNOR PM, IN PRESS PROGR CELL; OCONNOR PM, 1996, ANTI-CANCER DRUG, V7, P135; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PROTIC M, 1988, SOMAT CELL MOLEC GEN, V14, P351, DOI 10.1007/BF01534643; ROBBINS JH, 1974, ANN INTERN MED, V80, P221, DOI 10.7326/0003-4819-80-2-221; SHEIKH MS, 1997, IN PRESS ONCOGENE; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1996, ONCOGENE, V13, P2255; TorresRamos CA, 1996, P NATL ACAD SCI USA, V93, P9676, DOI 10.1073/pnas.93.18.9676; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZHEN WP, 1992, MOL CELL BIOL, V12, P3689, DOI 10.1128/MCB.12.9.3689	40	156	159	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 8	1997	14	18					2127	2136		10.1038/sj.onc.1201052	http://dx.doi.org/10.1038/sj.onc.1201052			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174048				2022-12-17	WOS:A1997WX93800001
J	Katoh, M; Hirai, M; Sugimura, T; Terada, M				Katoh, M; Hirai, M; Sugimura, T; Terada, M			Cloning, expression and chromosomal localization of Wnt-13, a novel member of the Wnt gene family	ONCOGENE			English	Article						Wnt gene family; human carcinogenesis; gastric cancer	RECEPTOR TYROSINE KINASE; TRANSGENIC MICE; MAMMARY CARCINOGENESIS; MOLECULAR-CLONING; SEQUENCE; INT-1; INT-2/FGF-3; ONCOGENE; WELL	The Wnt genes, encoding structurally-related secreted glycoproteins, are implicated in mammary carcinogenesis induced by mouse mammary tumor virus, In search of the Wnt gene(s) expressed in human gastric cancer, a WTGC1 cDNA fragment sharing 66.9% amino-acid homology with human and mouse Wnt-2 was isolated by degenerate polymerase chain reaction. The human gene corresponding to WTGC1 was designated as Wnt-13 and overlapping Wnt-13 cDNAs were cloned, Nucleotide sequence analysis indicated that the Wnt-13 gene encodes the protein of 372 amino acids, including a signal peptide, two potential N-glycosylation sites and 24 cystein residues highly conserved among members of the Wnt gene family, The Wnt-13 mRNA of 2.5 kb in size was detected in heart, brain, placenta, lung, prostate, testis, ovary, small intestine and colon of adult human and also in brain, lung and kidney of fetal human, Among various cancer cell lines, the Wnt-13 mRNA was detected in HeLa (cervical cancer), MKN28 and MKN74 (gastric cancer), The Wnt-13 gene has been mapped to human chromosome 1p13, These results suggest that the Wnt-13 gene may be involved in normal human development or differentiation as well as in human carcinogenesis.	NATL CANC CTR,RES INST,DIV GENET,CHUO KU,TOKYO 104,JAPAN; UNIV TOKYO,GRAD SCH SCI,DEPT ANTHROPOL,BUNKYO KU,TOKYO 113,JAPAN	National Cancer Center - Japan; University of Tokyo								ADAMSON MC, 1994, GENOMICS, V24, P9, DOI 10.1006/geno.1994.1575; CLARK CC, 1993, GENOMICS, V18, P249, DOI 10.1006/geno.1993.1463; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HIRAI M, 1994, CYTOGENET CELL GENET, V66, P149, DOI 10.1159/000133687; HUGUET EL, 1994, CANCER RES, V54, P2615; IOZZO RV, 1995, CANCER RES, V55, P3495; KATOH M, 1995, ONCOGENE, V10, P1447; KATOH M, 1992, P NATL ACAD SCI USA, V89, P2960, DOI 10.1073/pnas.89.7.2960; KATOH M, 1993, BIOCHEM BIOPH RES CO, V192, P1189, DOI 10.1006/bbrc.1993.1542; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; NAKATANI H, 1990, JPN J CANCER RES, V81, P707, DOI 10.1111/j.1349-7006.1990.tb02631.x; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; ROELINK H, 1993, GENOMICS, V17, P790, DOI 10.1006/geno.1993.1412; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANOOYEN A, 1985, EMBO J, V4, P2905, DOI 10.1002/j.1460-2075.1985.tb04021.x; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x; WOLDA SL, 1992, ONCOGENE, V7, P1941; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278	23	156	163	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					873	876						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761309				2022-12-17	WOS:A1996VD43300023
J	KINOSHITA, T; YOKOTA, T; ARAI, KI; MIYAJIMA, A				KINOSHITA, T; YOKOTA, T; ARAI, KI; MIYAJIMA, A			REGULATION OF BCL-2 EXPRESSION BY ONCOGENIC RAS PROTEIN IN HEMATOPOIETIC-CELLS	ONCOGENE			English	Article						APOPTOSIS; INTERLEUKIN; COLONY-STIMULATING FACTOR; BCL-X; CELL SURVIVAL	COLONY-STIMULATING FACTOR; COMMON BETA-SUBUNIT; C-MYC; SIGNAL-TRANSDUCTION; TYROSINE KINASE; BONE-MARROW; GM-CSF; APOPTOSIS; DEATH; INTERLEUKIN-3	Interleukin 3 (IL-3) and granulocyte-macrophage colony stimulating factor (GM-CSF) induce DNA synthesis and suppress apoptosis of hematopoietic cells. IL3/GM-CSF exert pleiotropic functions by activating multiple signaling cascades through distinct domains of the common receptor subunit. As we previously reported, the Ras signaling pathway plays a pivotal role in suppressing apoptotic death rather than stimulating DNA synthesis in IL-3 dependent hematopoietic cells. In order to clarify the molecular basis of Ras-induced cell survival, we investigated the effect of Ras activation on the expression of Bcl-2 and its related molecules. Activation of the Ras pathway by using an inducible oncogenic Ras resulted in the rapid up-regulation of bcl-2 and bcl-x(L), and the level of expression was nearly equivalent to that observed in growing cells. On the other hand, expression of bar, an antagonistic bcl-2 homologue, was not affected by oncogenic Ras or IL-3-deprivation. Thus, the Ras pathway regulates the expression of Bcl-2 and its related survival protein, and this appears to underlie the mechanism by which IL3/GM-CSF inhibit apoptosis through activation of the Ras pathway.	DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT CELL BIOL,PALO ALTO,CA 94304; UNIV TOKYO,INST MED SCI,DEPT MOLEC & DEV BIOL,MINATO KU,TOKYO 108,JAPAN; UNIV TOKYO,INST MOLEC & CELLULAR BISCI,BUNKYO KU,TOKYO 113,JAPAN	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University of Tokyo; University of Tokyo			Yokota, Takashi/J-8483-2015					ALLEN PD, 1993, BLOOD REV, V7, P63, DOI 10.1016/0268-960X(93)90025-Y; ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; ASKEW DS, 1991, ONCOGENE, V6, P1915; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CARSON WE, 1994, P NATL ACAD SCI USA, V91, P7553, DOI 10.1073/pnas.91.16.7553; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; Cormier F, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104811; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; ITOH N, 1993, J IMMUNOL, V151, P621; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIYAJIMA A, 1993, BLOOD, V82, P1960; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NUNEZ G, 1990, J IMMUNOL, V14, P3602; OKUDA K, 1994, J BIOL CHEM, V269, P24602; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; REED JC, 1994, J CELL BIOL, V124, P537; SAKAMAKI, 1994, FEBS LETT, V353, P133; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIROUZU M, 1992, ONCOGENE, V7, P475; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TORIGOE T, 1992, BLOOD, V80, P617; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1057; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WATANABE S, 1993, MOL BIOL CELL, V4, P983, DOI 10.1091/mbc.4.10.983; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	47	156	158	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2207	2212						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784065				2022-12-17	WOS:A1995RB70300016
J	HAUPT, Y; BATH, ML; HARRIS, AW; ADAMS, JM				HAUPT, Y; BATH, ML; HARRIS, AW; ADAMS, JM			BMI-1 TRANSGENE INDUCES LYMPHOMAS AND COLLABORATES WITH MYC IN TUMORIGENESIS	ONCOGENE			English	Note							V-ETS; MICE; ONCOGENE; COOPERATION; EXPRESSION; LEUKEMIA; MODELS; VIRUS	The bmi-1 gene was discovered as a frequent target of Moloney virus insertion in virally accelerated B-lymphoid tumors of Emu-myc transgenic mice and hence is thought to collaborate with the myc gene in lymphomagenesis, but its oncogenic potential has not previously been tested directly. To determine whether bmi-1 overexpression can contribute to hematopoietic neoplasia in vivo, strains of transgenic mice were generated in which bmi-1 expression was directed to the lymphoid compartment by a coupled immunoglobulin heavy chain enhancer (Emu). Although the Emu-bmi-1 transgene was expressed in both B and T cells, lymphoid development was not perturbed. Nevertheless, 14% of the mice in the strain with highest expression have developed lymphoma. Unexpectedly, most tumors were of the T-cell lineage, although one case of B lymphoma was observed. Furthermore, cross breeding Emu-bmi-1 and Emu-myc mice established that the bmi-1 transgene markedly accelerated the onset of pre-B and B lymphomas. These results demonstrate directly that bmi-1 can contribute to lymphomagenesis in the T and B cell lineages and collaborate with the myc gene in tumor development.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PO ROYAL MELBOURNE HOSP,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute			Adams, Jerry M/E-1199-2013	Adams, Jerry/0000-0002-4360-8628	NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER; NCI NIH HHS [CA43540] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1992, CANCER SURV, V15, P119; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HAUPT Y, 1992, THESIS U MELBOURNE; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEVY LS, 1992, J VIROL, V66, P2885, DOI 10.1128/JVI.66.5.2885-2892.1992; LEVY LS, 1993, IN PRESS ONCOGENE; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1992, ONCOGENE, V7, P597; STRASSER A, 1990, CURR TOP MICROBIOL, V166, P175; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; WEINBERG RA, 1989, CANCER RES, V49, P3713	21	156	167	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3161	3164						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414519				2022-12-17	WOS:A1993MC09300034
J	Casazza, A; Di Conza, G; Wenes, M; Finisguerra, V; Deschoemaeker, S; Mazzone, M				Casazza, A.; Di Conza, G.; Wenes, M.; Finisguerra, V.; Deschoemaeker, S.; Mazzone, M.			Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment	ONCOGENE			English	Review						tumor stroma; hypoxia; cancer progression; TAM; CAF; angiogenesis	CANCER-ASSOCIATED FIBROBLASTS; LYMPHATIC ENDOTHELIAL-CELLS; CHEMOKINE RECEPTOR CXCR4; HUMAN BREAST-CANCER; B-CELLS; MESENCHYMAL TRANSITION; GROWTH-FACTOR; NEUTROPHIL SURVIVAL; OXYGEN-TENSION; C EXPRESSION	A lot of effort has been done to study how cancer cells react to low-oxygen tension, a condition known as hypoxia. Indeed, abnormal and dysfunctional blood vessels in the tumor are incapable to restore oxygenation, therefore perpetuating hypoxia, which, in turn, will fuel tumor progression, metastasis and resistance to antitumor therapies. Nevertheless, how stromal components including blood and lymphatic endothelial cells, pericytes and fibroblasts, as well as hematopoietic cells, respond to low-oxygen tension in comparison with their normoxic counterparts has been a matter of investigation in the last few years only and, to date, this field of research remains poorly understood. In general, opposing phenotypes can arise from the same stromal component when embedded in different tumor microenvironments, and, vice versa, different stromal components can have opposite reaction to the same tumor microenvironment. In this article, we will discuss the emerging link between tumor stroma and hypoxia, and how this complexity is translated at the molecular level.	[Casazza, A.; Di Conza, G.; Wenes, M.; Finisguerra, V.; Deschoemaeker, S.; Mazzone, M.] VIB, Vesalius Res Ctr, Lab Mol Oncol & Angiogenesis, Louvain, Belgium; [Casazza, A.; Di Conza, G.; Wenes, M.; Finisguerra, V.; Deschoemaeker, S.; Mazzone, M.] Katholieke Univ Leuven, Vesalius Res Ctr, Lab Mol Oncol & Angiogenesis, B-3000 Louvain, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven	Mazzone, M (corresponding author), Katholieke Univ Leuven, VIB, Vesalius Res Ctr, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	massimiliano.mazzone@vib-kuleuven.be	Di Conza, Giusy/GPP-1438-2022; Deschoemaeker, Sofie/AAE-1359-2022; Finisguerra, Veronica/AGS-6956-2022; Deschoemaeker, Sofie/AAF-8321-2020	Deschoemaeker, Sofie/0000-0001-5449-282X; Deschoemaeker, Sofie/0000-0001-5449-282X; Mazzone, Massimiliano/0000-0001-8824-4015; Wenes, Mathias/0000-0001-8478-8592; Di Conza, Giusy/0000-0003-1353-5867	EMBO; FWO; ERC starting-Grant; FWO [G083613N, G068612N, G071810N]	EMBO(European Molecular Biology Organization (EMBO)); FWO(FWO); ERC starting-Grant; FWO(FWO)	We thank Sandy Smets for technical assistance. AC is granted by EMBO; GDC and VF are granted by FWO. MM was supported by an ERC starting-Grant and FWO (G083613N; G068612N; G071810N).	Acosta-Iborra B, 2009, J IMMUNOL, V182, P3155, DOI 10.4049/jimmunol.0801710; Andreu P, 2010, CANCER CELL, V17, P121, DOI 10.1016/j.ccr.2009.12.019; ARNOLD F, 1987, BRIT J EXP PATHOL, V68, P569; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Ben-Shoshan J, 2008, EUR J IMMUNOL, V38, P2412, DOI 10.1002/eji.200838318; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Boes M, 1998, J EXP MED, V188, P2381, DOI 10.1084/jem.188.12.2381; Branco-Price C, 2012, CANCER CELL, V21, P52, DOI 10.1016/j.ccr.2011.11.017; Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455; Carraro F, 2007, J CELL PHYSIOL, V211, P439, DOI 10.1002/jcp.20951; Cascone T, 2012, J CLIN ONCOL, V30, P441, DOI 10.1200/JCO.2011.38.7621; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chappell JC, 2009, DEV CELL, V17, P377, DOI 10.1016/j.devcel.2009.07.011; Chiavarina B, 2010, CELL CYCLE, V9, P3534, DOI 10.4161/cc.9.17.12908; Cooke VG, 2012, CANCER CELL, V21, P66, DOI 10.1016/j.ccr.2011.11.024; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Dang EV, 2011, CELL, V146, P772, DOI 10.1016/j.cell.2011.07.033; De Bock K, 2011, NAT REV CLIN ONCOL, V8, P393, DOI 10.1038/nrclinonc.2011.83; De Falco E, 2004, BLOOD, V104, P3472, DOI 10.1182/blood-2003-12-4423; de Oliveira RL, 2012, CANCER CELL, V22, P263, DOI 10.1016/j.ccr.2012.06.028; de Oliveira RL, 2011, MOL ASPECTS MED, V32, P71, DOI 10.1016/j.mam.2011.04.001; De Palma M, 2011, NATURE, V472, P303, DOI 10.1038/472303a; Denko NC, 2001, CANCER RES, V61, P795; Di Carlo E, 2001, J HEMATOTH STEM CELL, V10, P739, DOI 10.1089/152581601317210836; Doedens AL, 2010, CANCER RES, V70, P7465, DOI 10.1158/0008-5472.CAN-10-1439; Donohue PJ, 2003, ARTERIOSCL THROM VAS, V23, P594, DOI 10.1161/01.ATV.0000062883.93715.37; Dore-Duffy P, 2007, ANTIOXID REDOX SIGN, V9, P1363, DOI 10.1089/ars.2007.1713; Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034; Dutta D, 2008, J BIOL CHEM, V283, P25404, DOI 10.1074/jbc.M804349200; Elfiky AA, 2012, DISCOV MED, V13, P461; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Elwood PC, 2009, LANCET, V373, P1301, DOI 10.1016/S0140-6736(09)60243-9; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Facciabene A, 2011, NATURE, V475, P226, DOI 10.1038/nature10169; Fainaru O, 2010, FASEB J, V24, P1411, DOI 10.1096/fj.09-147025; Fang HY, 2009, BLOOD, V114, P844, DOI 10.1182/blood-2008-12-195941; Feng WY, 2011, BLOOD, V117, P3893, DOI 10.1182/blood-2010-08-304808; Fink T, 2003, SCAND J IMMUNOL, V58, P607, DOI 10.1111/j.1365-3083.2003.01347.x; Finlay DK, 2012, J EXP MED, V209, P2441, DOI 10.1084/jem.20112607; Fox CJ, 2005, NAT REV IMMUNOL, V5, P844, DOI 10.1038/nri1710; Fraisl P, 2009, NAT REV DRUG DISCOV, V8, P139, DOI 10.1038/nrd2761; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Gay LJ, 2011, NAT REV CANCER, V11, P123, DOI 10.1038/nrc3004; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; GERRARD TL, 1981, J NATL CANCER I, V66, P483; Geudens I, 2010, ARTERIOSCL THROM VAS, V30, P1695, DOI 10.1161/ATVBAHA.110.203034; GODA F, 1995, CANCER RES, V55, P2249; Goda N, 2003, MOL CELL BIOL, V23, P359, DOI 10.1128/MCB.23.1.359-369.2003; Goetz JG, 2011, CELL, V146, P148, DOI 10.1016/j.cell.2011.05.040; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; Graven KK, 1997, KIDNEY INT, V51, P426, DOI 10.1038/ki.1997.57; Griffiths L, 2000, GENE THER, V7, P255, DOI 10.1038/sj.gt.3301058; Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036; Hagemann T, 2008, J EXP MED, V205, P1261, DOI 10.1084/jem.20080108; Hangai-Hoger N, 2004, AM J PHYSIOL-HEART C, V286, pH878, DOI 10.1152/ajpheart.00913.2003; HANNAH S, 1995, FEBS LETT, V372, P233, DOI 10.1016/0014-5793(95)00986-J; Harris DP, 2000, NAT IMMUNOL, V1, P475, DOI 10.1038/82717; HARRIS JW, 1976, CANCER RES, V36, P2733; Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Houghton AM, 2010, NAT MED, V16, P219, DOI 10.1038/nm.2084; Imahayashi S, 2000, CANCER INVEST, V18, P530, DOI 10.3109/07357900009012192; Imtiyaz HZ, 2010, J CLIN INVEST, V120, P2699, DOI 10.1172/JCI39506; Irigoyen M, 2007, BBA-MOL CELL RES, V1773, P880, DOI 10.1016/j.bbamcr.2007.03.001; Italiano JE, 2008, BLOOD, V111, P1227, DOI 10.1182/blood-2007-09-113837; Jakobsson L, 2010, NAT CELL BIOL, V12, P943, DOI 10.1038/ncb2103; Jantsch J, 2008, J IMMUNOL, V180, P4697, DOI 10.4049/jimmunol.180.7.4697; Kaiser J, 2012, SCIENCE, V337, P1471, DOI 10.1126/science.337.6101.1471; Kempner W, 1939, J CLIN INVEST, V18, P291, DOI 10.1172/JCI101045; Kim JW, 2012, CANCER RES, V72, P3187, DOI 10.1158/0008-5472.CAN-12-0534; Klement GL, 2009, BLOOD, V113, P2835, DOI 10.1182/blood-2008-06-159541; Koivunen P, 2004, J BIOL CHEM, V279, P9899, DOI 10.1074/jbc.M312254200; Kojima H, 2002, P NATL ACAD SCI USA, V99, P2170, DOI 10.1073/pnas.052706699; Kojima H, 2010, J IMMUNOL, V184, P154, DOI 10.4049/jimmunol.0800167; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Kunz M, 1999, AM J PATHOL, V155, P753, DOI 10.1016/S0002-9440(10)65174-7; Le Bras A, 2007, ONCOGENE, V26, P7480, DOI 10.1038/sj.onc.1210566; Li Q, 2009, J IMMUNOL, V183, P3195, DOI 10.4049/jimmunol.0803773; Liang XH, 2008, ANTICANCER RES, V28, P1659; Lim Kok Haw Jonathan, 2010, Cancer Immun, V10, P3; Liu DF, 2012, J CLIN INVEST, V122, P2221, DOI 10.1172/JCI59535; LOEFFLER DA, 1991, INT J CANCER, V48, P895, DOI 10.1002/ijc.2910480617; LOEFFLER DA, 1992, BRIT J CANCER, V66, P619, DOI 10.1038/bjc.1992.326; Lynch CN, 1999, J BIOL CHEM, V274, P8455, DOI 10.1074/jbc.274.13.8455; Maftei CA, 2011, RADIOTHER ONCOL, V101, P209, DOI 10.1016/j.radonc.2011.05.023; Maftei CA, 2011, STRAHLENTHER ONKOL, V187, P260, DOI 10.1007/s00066-010-2216-0; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3515, DOI 10.4161/cc.9.17.12928; Mazzone M, 2009, CELL, V136, P839, DOI 10.1016/j.cell.2009.01.020; McGovern NN, 2011, J IMMUNOL, V186, P453, DOI 10.4049/jimmunol.1002213; Mercier I, 2008, CANCER BIOL THER, V7, P1212, DOI 10.4161/cbt.7.8.6220; Milne K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006412; Mishra PJ, 2008, CANCER RES, V68, P4331, DOI 10.1158/0008-5472.CAN-08-0943; Morote-Garcia JC, 2012, P NATL ACAD SCI USA, V109, P14146, DOI 10.1073/pnas.1202165109; Movahedi K, 2012, CANCER RES, V72, P4165, DOI 10.1158/0008-5472.CAN-11-2994; Movahedi K, 2010, CANCER RES, V70, P5728, DOI 10.1158/0008-5472.CAN-09-4672; Mueller L, 2007, AM J PATHOL, V171, P1608, DOI 10.2353/ajpath.2007.060661; Munder M, 2009, BRIT J PHARMACOL, V158, P638, DOI 10.1111/j.1476-5381.2009.00291.x; Murdoch C, 2005, J IMMUNOL, V175, P6257, DOI 10.4049/jimmunol.175.10.6257; Naldini A, 2012, J CELL PHYSIOL, V227, P587, DOI 10.1002/jcp.22761; Naldini A, 2010, J LEUKOCYTE BIOL, V87, P365, DOI 10.1189/jlb.0709460; NATHAN CF, 1982, J IMMUNOL, V129, P2164; Nelson BH, 2010, J IMMUNOL, V185, P4977, DOI 10.4049/jimmunol.1001323; NIBBERING PH, 1987, IMMUNOLOGY, V62, P171; Ohta Y, 1999, BRIT J CANCER, V81, P54, DOI 10.1038/sj.bjc.6690650; Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112; Ota H, 2007, FEBS LETT, V581, P5220, DOI 10.1016/j.febslet.2007.10.009; Ozerdem U, 2006, PROSTATE, V66, P294, DOI 10.1002/pros.20346; Palazon A, 2012, CLIN CANCER RES, V18, P1207, DOI 10.1158/1078-0432.CCR-11-1591; Pearce EL, 2010, CURR OPIN IMMUNOL, V22, P314, DOI 10.1016/j.coi.2010.01.018; Petersen OW, 2003, AM J PATHOL, V162, P391, DOI 10.1016/S0002-9440(10)63834-5; Piccard H, 2012, CRIT REV ONCOL HEMAT, V82, P296, DOI 10.1016/j.critrevonc.2011.06.004; Polet F, 2013, J INTERN MED, V273, P156, DOI 10.1111/joim.12016; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Quintero M, 2006, P NATL ACAD SCI USA, V103, P5379, DOI 10.1073/pnas.0601026103; Rama I, 2008, KIDNEY INT, V73, P816, DOI 10.1038/sj.ki.5002792; Ran S, 2010, PATHOPHYSIOLOGY, V17, P229, DOI DOI 10.1016/J.PATH0PHYS.2009.11.003; Rauch PJ, 2012, SCIENCE, V335, P597, DOI 10.1126/science.1215173; Saccani A, 2006, CANCER RES, V66, P11432, DOI 10.1158/0008-5472.CAN-06-1867; Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267; Schito L, 2012, P NATL ACAD SCI USA, V109, pE2707, DOI 10.1073/pnas.1214019109; Schoppmann SF, 2006, BREAST CANCER RES TR, V99, P135, DOI 10.1007/s10549-006-9190-3; Schoppmann SF, 2001, ANTICANCER RES, V21, P2351; Scott AM, 2003, CLIN CANCER RES, V9, P1639; Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278; Shi Q, 1999, CLIN CANCER RES, V5, P3711; Sierko E, 2007, SEMIN THROMB HEMOST, V33, P712, DOI 10.1055/s-2007-991540; Sitia G, 2012, P NATL ACAD SCI USA, V109, pE2165, DOI 10.1073/pnas.1209182109; Skuli N, 2012, J CLIN INVEST, V122, P1427, DOI 10.1172/JCI57322; Skuli N, 2009, BLOOD, V114, P469, DOI 10.1182/blood-2008-12-193581; Sotgia F, 2012, ANNU REV PATHOL-MECH, V7, P423, DOI 10.1146/annurev-pathol-011811-120856; Spinella F, 2009, CANCER RES, V69, P2669, DOI 10.1158/0008-5472.CAN-08-1879; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Stockmann C, 2008, NATURE, V456, P814, DOI 10.1038/nature07445; Suzuki A, 2005, J BIOL CHEM, V280, P31557, DOI 10.1074/jbc.M503714200; Takeda N, 2010, GENE DEV, V24, P491, DOI 10.1101/gad.1881410; Takeda Y, 2011, NATURE, V479, P122, DOI 10.1038/nature10507; Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026; Toullec A, 2010, EMBO MOL MED, V2, P211, DOI 10.1002/emmm.201000073; Verheul HMW, 1997, CLIN CANCER RES, V3, P2187; Vivier E, 2012, NAT REV IMMUNOL, V12, P239, DOI 10.1038/nri3174; Walmsley SR, 2006, BLOOD, V108, P3176, DOI 10.1182/blood-2006-04-018796; Walmsley SR, 2011, J CLIN INVEST, V121, P1053, DOI 10.1172/JCI43273; Walmsley SR, 2005, J EXP MED, V201, P105, DOI 10.1084/jem.20040624; Werno C, 2010, CARCINOGENESIS, V31, P1863, DOI 10.1093/carcin/bgq088; Wong BW, 2013, TRENDS BIOCHEM SCI, V38, P3, DOI 10.1016/j.tibs.2012.10.004; Xian XJ, 2006, J CLIN INVEST, V116, P642, DOI 10.1172/JCI25705; Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327; Zaslavsky A, 2010, BLOOD, V115, P4605, DOI 10.1182/blood-2009-09-242065; Zeisberg EM, 2007, CANCER RES, V67, P10123, DOI 10.1158/0008-5472.CAN-07-3127; ZHANG H, 1995, CANCER RES, V55, P3584; Zhong XM, 2007, EUR J IMMUNOL, V37, P2400, DOI 10.1002/eji.200737296	153	155	163	1	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1743	1754		10.1038/onc.2013.121	http://dx.doi.org/10.1038/onc.2013.121			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23604130				2022-12-17	WOS:000334345500001
J	Ye, X; Li, Y; Stawicki, S; Couto, S; Eastham-Anderson, J; Kallop, D; Weimer, R; Wu, Y; Pei, L				Ye, X.; Li, Y.; Stawicki, S.; Couto, S.; Eastham-Anderson, J.; Kallop, D.; Weimer, R.; Wu, Y.; Pei, L.			An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies	ONCOGENE			English	Article						monoclonal antibody; tumor stroma; combination therapies	RECEPTOR TYROSINE KINASE; CELL LUNG-CANCER; BREAST-CANCER; THERAPEUTIC TARGET; PROLONGS SURVIVAL; MYELOID-LEUKEMIA; EXPRESSION; INFLAMMATION; PROGRESSION; METASTASIS	Axl is expressed in various types of cancer and is involved in multiple processes of tumorigenesis, including promoting tumor cell growth, migration, invasion, metastasis as well as angiogenesis. To evaluate further the mechanisms involved in the expression/activation of Axl in various aspects of tumorigenesis, especially its roles in modulating tumor stromal functions, we have developed a phage-derived mAb (YW327.6S2) that recognizes both human and murine Axl. YW327.6S2 binds to both human and murine Axl with high affinity. It blocks the ligand Gas6 binding to the receptor, downregulates receptor expression, inhibits receptor activation and downstream signaling. In A549 non-small-cell lung cancer (NSCLC) and MDA-MB-231 breast cancer models, YW327.6S2 attenuates xenograft tumor growth and potentiates the effect of anti-VEGF treatment. In NSCLC models, YW327.6S2 also enhances the effect of erlotinib and chemotherapy in reducing tumor growth. Furthermore, YW327.6S2 reduces the metastasis of MDA-MB-231 breast cancer cells to distant organs. YW327.6S2 induces tumor cell apoptosis in NSCLC, reduces tumor-associated vascular density and inhibits the secretion of inflammatory cytokines and chemokines from tumor-associated macrophages in the breast cancer model. In conclusion, anti-Axl mAb can enhance the therapeutic efficacy of anti-VEGF, EGFR small-molecule inhibitors as well as chemotherapy. Axl mAb affects not only tumor cells but also tumor stroma through its modulation of tumor-associated vasculature and immune cell functions. Oncogene (2010) 29, 5254-5264; doi:10.1038/onc.2010.268; published online 5 July 2010	[Ye, X.; Li, Y.; Pei, L.] Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; [Stawicki, S.; Wu, Y.] Genentech Inc, Dept Antibody Engn, San Francisco, CA 94080 USA; [Couto, S.; Eastham-Anderson, J.] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA; [Kallop, D.; Weimer, R.] Genentech Inc, Dept Biomed Imaging, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Pei, L (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	lpei@gene.com						Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Berclaz G, 2001, ANN ONCOL, V12, P819, DOI 10.1023/A:1011126330233; Brey EM, 2003, J HISTOCHEM CYTOCHEM, V51, P575, DOI 10.1177/002215540305100503; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Chung BI, 2003, DNA CELL BIOL, V22, P533, DOI 10.1089/10445490360708946; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Giaccone G, 2005, J CLIN ONCOL, V23, P3235, DOI 10.1200/JCO.2005.08.409; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Haghnegahdar H, 2000, J LEUKOCYTE BIOL, V67, P53, DOI 10.1002/jlb.67.1.53; Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997; Holland SJ, 2005, CANCER RES, V65, P9294, DOI 10.1158/0008-5472.CAN-05-0993; Hong CC, 2008, CANCER LETT, V268, P314, DOI 10.1016/j.canlet.2008.04.017; Hutterer M, 2008, CLIN CANCER RES, V14, P130, DOI 10.1158/1078-0432.CCR-07-0862; Ito T, 1999, THYROID, V9, P563, DOI 10.1089/thy.1999.9.563; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; Koorstra JBM, 2009, CANCER BIOL THER, V8, P618, DOI 10.4161/cbt.8.7.7923; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; Lee CV, 2004, J MOL BIOL, V340, P1073, DOI 10.1016/j.jmb.2004.05.051; Li Y, 2009, ONCOGENE, V28, P3442, DOI 10.1038/onc.2009.212; Liang WC, 2006, J BIOL CHEM, V281, P951, DOI 10.1074/jbc.M508199200; Liang WC, 2007, J MOL BIOL, V366, P815, DOI 10.1016/j.jmb.2006.11.021; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Loges S, 2010, BLOOD, V115, P2264, DOI 10.1182/blood-2009-06-228684; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mahadevan D, 2007, ONCOGENE, V26, P3909, DOI 10.1038/sj.onc.1210173; Meric F, 2002, CLIN CANCER RES, V8, P361; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Sainaghi PP, 2005, J CELL PHYSIOL, V204, P36, DOI 10.1002/jcp.20265; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; Sidhu SS, 2004, J MOL BIOL, V338, P299, DOI 10.1016/j.jmb.2004.02.050; Sun WS, 2004, ONCOLOGY-BASEL, V66, P450, DOI 10.1159/000079499; Tai KY, 2008, ONCOGENE, V27, P4044, DOI 10.1038/onc.2008.57; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; Wu CW, 2002, ANTICANCER RES, V22, P1071; Yauch RL, 2005, CLIN CANCER RES, V11, P8686, DOI 10.1158/1078-0432.CCR-05-1492; Zhang YX, 2008, CANCER RES, V68, P1905, DOI 10.1158/0008-5472.CAN-07-2661	44	155	179	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	38					5254	5264		10.1038/onc.2010.268	http://dx.doi.org/10.1038/onc.2010.268			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	653KE	20603615				2022-12-17	WOS:000282089100004
J	Bleeker, FE; Felicioni, L; Buttitta, F; Lamba, S; Cardone, L; Rodolfo, M; Scarpa, A; Leenstra, S; Frattini, M; Barbareschi, M; Del Grammastro, M; Sciarrotta, MG; Zanon, C; Marchetti, A; Bardelli, A				Bleeker, F. E.; Felicioni, L.; Buttitta, F.; Lamba, S.; Cardone, L.; Rodolfo, M.; Scarpa, A.; Leenstra, S.; Frattini, M.; Barbareschi, M.; Del Grammastro, M.; Sciarrotta, M. G.; Zanon, C.; Marchetti, A.; Bardelli, A.			AKT1(E17K) in human solid tumours	ONCOGENE			English	Article						AKT1; PIK3CA; mutation; cancer	PIK3CA MUTATIONS; HUMAN BREAST; GENE; PTEN	The serine- threonine kinase AKT1 is a central player in the oncogenic pathway controlled by PI3K. Recently, a somatic mutation in AKT1 (E17K) has been detected in breast, colorectal, lung and ovarian cancers. The E17K change results in constitutive AKT1 activation and induces leukaemia in mice. We determined the occurrence of the E17K variant in a panel of 764 tumour samples. These included breast, lung, ovarian, colorectal and pancreatic carcinomas as well as melanomas and glioblastomas. Despite the fact that these tumours are known to bear alterations in genes involved in the PI3K signalling pathway, AKT1(E17K) was detected only in breast (16/273), colorectal (1/88) and lung(1/155) cancers. Within the neoplasms of breast origin, the AKT1(E17K) variant was mutually exclusive with respect to the PIK3CA(E454K) (or H1047R) alleles and was present only in ductal and lobular histotypes. Our results, showing that AKT1 mutations seem to occur in a tissue-specific fashion have basic and clinical implications. First, the activity of mutated AKT1 in oncogenic PI3K signalling could be strictly dependent on the cell and tissue milieu. Second, therapeutic efforts aimed at selective targeting the AKT1(E17K) variant could be effective mainly in specific cancer types.	[Bleeker, F. E.; Lamba, S.; Cardone, L.; Zanon, C.; Bardelli, A.] Univ Turin, Sch Med, Mol Genet Lab, Oncogenom Ctr,Inst Canc Res & Treatment, Candiolo, Italy; [Bleeker, F. E.] Locat Acad Med Ctr, Neurosurg Ctr Amsterdam, Amsterdam, Netherlands; [Felicioni, L.; Buttitta, F.; Del Grammastro, M.; Sciarrotta, M. G.; Marchetti, A.] Univ Fdn, Ctr Excellence Aging, Clin Res Ctr, Chieti, Italy; [Rodolfo, M.; Frattini, M.] Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; [Scarpa, A.] Univ Verona, Dept Pathol, Sect Anat Pathol, I-37100 Verona, Italy; [Leenstra, S.] St Elizabeth Hosp, Dept Neurosurg, Tilburg, Netherlands; [Frattini, M.] Osped San Giovanni Bellinzona, Oncol Inst So Switzerland, Bellinzona, Switzerland; [Barbareschi, M.] Santa Chiara Hosp, Unit Surg Pathol, Trento, Italy; [Bardelli, A.] FIRC Inst Mol Oncol, Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Verona; Elisabeth-TweeSteden Ziekenhuis (ETZ); Institute of Oncology Research (IOR); Regional Hospital of Bellinzona & Valleys, San Giovanni; Santa Chiara Hospital; IFOM - FIRC Institute of Molecular Oncology	Bardelli, A (corresponding author), Univ Turin, Sch Med, Mol Genet Lab, Oncogenom Ctr,Inst Canc Res & Treatment, Str Prov 142 Km 3-95, I-10060 Turin, Italy.	a.bardelli@unito.it	scarpa, aldo/K-6832-2016; Barbareschi, Mattia/AAF-2043-2020; rodolfo, monica/H-2671-2012; BARDELLI, Alberto/J-9721-2018	scarpa, aldo/0000-0003-1678-739X; rodolfo, monica/0000-0002-9196-0298; Lamba, Simona Elena/0000-0003-3207-1594; Zanon, Carlo/0000-0003-2539-7238; BARDELLI, Alberto/0000-0003-1647-5070; Cardone, Luca/0000-0001-8184-2856	Italian Association for Cancer Research; Italian Ministry of Health; Regione Piemonte; Italian Ministry of University and Research and Association for International Cancer Research (AICR- UK, A Bardelli); EU FP6 [037297]; Netherlands Genomic Initiative Fellowship	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health(Ministry of Health, Italy); Regione Piemonte(Regione Piemonte); Italian Ministry of University and Research and Association for International Cancer Research (AICR- UK, A Bardelli); EU FP6(European Commission); Netherlands Genomic Initiative Fellowship	We thank Dr T Hulsebos and Professor Dr Troost for making glioblastoma tumour samples available. We thank Dr S Pilotti and Dr M Pierotti for providing the colorectal cancer samples. This work was supported by grants from Italian Association for Cancer Research (AIRC, A Bardelli), Italian Ministry of Health, Regione Piemonte (A Bardelli), Italian Ministry of University and Research and Association for International Cancer Research (AICR- UK, A Bardelli), EU FP6 contract 037297 (A Bardelli) and MolDiagPaca (AS). FB is supported by a Netherlands Genomic Initiative Fellowship.	Balakrishnan A, 2007, CANCER RES, V67, P3545, DOI 10.1158/0008-5472.CAN-07-0065; Barbareschi M, 2007, CLIN CANCER RES, V13, P6064, DOI 10.1158/1078-0432.CCR-07-0266; Benvenuti S, 2008, HUM MUTAT, V29, P284, DOI 10.1002/humu.20648; Brugge J, 2007, CANCER CELL, V12, P104, DOI 10.1016/j.ccr.2007.07.014; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Frattini M, 2005, CANCER RES, V65, P11227, DOI 10.1158/0008-5472.CAN-05-2780; Guldberg P, 1997, CANCER RES, V57, P3660; Karakas B, 2006, BRIT J CANCER, V94, P455, DOI 10.1038/sj.bjc.6602970; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Malanga D, 2008, CELL CYCLE, V7, P665, DOI 10.4161/cc.7.5.5485; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schonleben F, 2006, CLIN CANCER RES, V12, P3851, DOI 10.1158/1078-0432.CCR-06-0292; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720	14	155	156	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2008	27	42					5648	5650		10.1038/onc.2008.170	http://dx.doi.org/10.1038/onc.2008.170			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KX	18504432				2022-12-17	WOS:000259280800011
J	Kidokoro, T; Tanikawa, C; Furukawa, Y; Katagiri, T; Nakamura, Y; Matsuda, K				Kidokoro, T.; Tanikawa, C.; Furukawa, Y.; Katagiri, T.; Nakamura, Y.; Matsuda, K.			CDC20, a potential cancer therapeutic target, is negatively regulated by p53	ONCOGENE			English	Article						CDC20; p53; p21; therapeutic target; spindle checkpoint	GENE-EXPRESSION PROFILES; WIDE CDNA MICROARRAY; WILD-TYPE P53; CELL LUNG CANCERS; DNA-DAMAGE; TRANSCRIPTIONAL REPRESSION; NEOADJUVANT CHEMOTHERAPY; P53-DEPENDENT APOPTOSIS; MYELOID-LEUKEMIA; BREAST-CANCER	The p53 protein inhibits malignant transformation through direct and indirect regulation of transcription of many genes related to cell cycle, apoptosis and cellular senescence. A number of genes induced by p53 have been well characterized, but biological significance of genes whose expression was suppressed by p53 is still largely undisclosed. To clarify the roles of p53-suppressive genes in carcinogenesis, we analysed two data sets of whole-genome expression profiles, one for cells in which wildtype p53 was exogenously introduced and the other for a large number of clinical cancer tissues. Here, we identified CDC20 that was frequently upregulated in many types of malignancies and remarkably suppressed by ectopic introduction of p53. CDC20 expression was suppressed by genotoxic stresses in p53- and p21-dependent manners through CDE-CHR elements in the CDC20 promoter. Furthermore, small interference RNA (siRNA)-mediated silencing of p53 induced CDC20 expression in normal human dermal. broblast cells. As we expected, treatment of cancer cells with siRNA against CDC20 induced G(2)/M arrest and suppressed cell growth. Our results indicate that p53 inhibits tumor cell growth through the indirect regulation of CDC20 and that CDC20 might be a good potential therapeutic target for a broad spectrum of human cancer.	[Kidokoro, T.; Tanikawa, C.; Katagiri, T.; Nakamura, Y.; Matsuda, K.] Univ Tokyo, Ctr Human Genome, Inst Med Sci, Mol Med Lab, Tokyo 1088639, Japan; [Furukawa, Y.] Univ Tokyo, Ctr Human Genome, Inst Med Sci, Promot Genome Based Med Project, Tokyo, Japan	University of Tokyo; University of Tokyo	Kidokoro, T (corresponding author), Univ Tokyo, Ctr Human Genome, Inst Med Sci, Mol Med Lab, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	koichima@ims.u-tokyo.ac.jp	Katagiri, Toyomasa/I-7344-2012; Matsuda, Koichi/D-4597-2011	Matsuda, Koichi/0000-0001-7292-2686; Tanikawa, Chizu/0000-0003-4759-4793				Ashida S, 2004, CANCER RES, V64, P5963, DOI 10.1158/0008-5472.CAN-04-0020; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fung TK, 2005, SEMIN CELL DEV BIOL, V16, P335, DOI 10.1016/j.semcdb.2005.02.014; Hasegawa S, 2002, CANCER RES, V62, P7012; Hirota E, 2006, INT J ONCOL, V29, P799; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Innocente SA, 2005, FEBS LETT, V579, P1001, DOI 10.1016/j.febslet.2004.12.073; Issaeva N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146; Jinawath N, 2004, ONCOGENE, V23, P6830, DOI 10.1038/sj.onc.1207886; Kaneta Y, 2002, JPN J CANCER RES, V93, P849, DOI 10.1111/j.1349-7006.2002.tb01328.x; Kikuchi T, 2003, ONCOGENE, V22, P2192, DOI 10.1038/sj.onc.1206288; Kim JM, 2005, CLIN CANCER RES, V11, P473; Kitahara O, 2002, NEOPLASIA, V4, P295, DOI 10.1038/sj.neo.7900251; Kitahara O, 2001, CANCER RES, V61, P3544; MAITY SN, 1992, J BIOL CHEM, V267, P16574; Matsuda K, 2002, CANCER RES, V62, P2883; Mondal G, 2007, CARCINOGENESIS, V28, P81, DOI 10.1093/carcin/bgl100; Nagayama S, 2002, CANCER RES, V62, P5859; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Nakamura Y, 2004, CANCER SCI, V95, P7, DOI 10.1111/j.1349-7006.2004.tb03163.x; Nishidate T, 2004, INT J ONCOL, V25, P797; Obama K, 2005, HEPATOLOGY, V41, P1339, DOI 10.1002/hep.20718; Ochi K, 2004, INT J ONCOL, V24, P647; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okabe H, 2001, CANCER RES, V61, P2129; Okada K, 2003, INT J ONCOL, V23, P1615; Okutsu J, 2002, MOL CANCER THER, V1, P1035; Ono K, 2000, CANCER RES, V60, P5007; Roth JA, 2006, EXPERT OPIN BIOL TH, V6, P55, DOI 10.1517/14712598.6.1.55; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Soussi T, 2006, CLIN CANCER RES, V12, P62, DOI 10.1158/1078-0432.CCR-05-0413; St Clair S, 2004, MOL CELL, V16, P725; Takata R, 2005, CLIN CANCER RES, V11, P2625, DOI 10.1158/1078-0432.CCR-04-1988; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tanikawa C, 2003, NAT CELL BIOL, V5, P216, DOI 10.1038/ncb943; Taniwaki M, 2006, INT J ONCOL, V29, P567; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Yamabuki T, 2006, INT J ONCOL, V28, P1375; Yi S, 2006, MOL CARCINOGEN, V45, P409, DOI 10.1002/mc.20231; Zaffaroni N, 2005, J CELL MOL MED, V9, P360, DOI 10.1111/j.1582-4934.2005.tb00361.x; ZHOU MX, 1995, BLOOD, V85, P1608, DOI 10.1182/blood.V85.6.1608.bloodjournal8561608; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	50	155	164	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2008	27	11					1562	1571		10.1038/sj.onc.1210799	http://dx.doi.org/10.1038/sj.onc.1210799			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17873905				2022-12-17	WOS:000253815800008
J	Kroemer, G				Kroemer, G.			Mitochondria in cancer	ONCOGENE			English	Editorial Material							CELL-DEATH	Prominent features of cancer cells include metabolic imbalances and enhanced resistance to mitochondrial apoptosis. The fact that tumors rely heavily on glycolysis to meet their metabolic demands has been recognized since the beginning of the twentieth century, yet a complete elucidation of the so-called Warburg effect has not been achieved. Several mechanisms have been proposed to explain this phenomenon, including the upregulation of rate-limiting steps of glycolysis, the accumulation of mutations in the mitochondrial genome, the hypoxia-induced switch from mitochondrial respiration to glycolysis or the metabolic reprogramming resulting from the loss-of-function of enzymes like fumarate and succinate dehydrogenases. How aerobic glycolysis and apoptosis resistance are linked remains to be elucidated. On the one hand, these alterations may be acquired independently by cancer cells during multistep oncogenesis. On the other hand, the suppression of the intrinsic apoptotic program may be achieved through mechanisms that directly lead to the Warburg phenotype. Cancer-specific mitochondrial alterations and bioenergetics may be taken advantage for the development of two novel classes of antineoplastic agents. A first approach would target glycolysis and/or revert the Warburg phenomenon, whereas a second approach would aim at inducing apoptosis by targeting mitochondrial proteins and membranes. In both instances, encouraging pre-clinical results have been obtained.	Inst Gustave Roussy, CNRS, FRE2939, F-94800 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, FRE2939, Rue Camille Desmoulins, F-94800 Villejuif, France.		KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; 				Alirol E, 2006, ONCOGENE, V25, P4706, DOI 10.1038/sj.onc.1209600; Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607; Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609; Cereghetti GM, 2006, ONCOGENE, V25, P4717, DOI 10.1038/sj.onc.1209605; Chatterjee A, 2006, ONCOGENE, V25, P4663, DOI 10.1038/sj.onc.1209604; Cheng WC, 2006, ONCOGENE, V25, P4697, DOI 10.1038/sj.onc.1209596; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Fantin VR, 2006, ONCOGENE, V25, P4787, DOI 10.1038/sj.onc.1209599; Fontenay M, 2006, ONCOGENE, V25, P4757, DOI 10.1038/sj.onc.1209606; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; King A, 2006, ONCOGENE, V25, P4675, DOI 10.1038/sj.onc.1209594; Mathupala SP, 2006, ONCOGENE, V25, P4777, DOI 10.1038/sj.onc.1209603; Moll UM, 2006, ONCOGENE, V25, P4725, DOI 10.1038/sj.onc.1209601; Ohta S, 2006, ONCOGENE, V25, P4768, DOI 10.1038/sj.onc.1209602; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Robey RB, 2006, ONCOGENE, V25, P4683, DOI 10.1038/sj.onc.1209595; Warburg O. H., 1930, METABOLISM TUMOURS I; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; ZHIVOTOVSKY B, 2004, NAT REV MOL CELL BIO, V117, P4461	21	155	178	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	34					4630	4632		10.1038/sj.onc.1209589	http://dx.doi.org/10.1038/sj.onc.1209589			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892077				2022-12-17	WOS:000239687000001
J	Buchholz, M; Braun, M; Heidenblut, A; Kestler, HA; Kloppel, G; Schmiegel, W; Hahn, SA; Luttges, J; Gress, TM				Buchholz, M; Braun, M; Heidenblut, A; Kestler, HA; Kloppel, G; Schmiegel, W; Hahn, SA; Luttges, J; Gress, TM		German Pancreatic Cancer Net Deuts	Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions	ONCOGENE			English	Article						PanIN progression; gene expression; early diagnosis; target genes	K-RAS MUTATIONS; DUCTAL ADENOCARCINOMA; EXTRACELLULAR-MATRIX; CANCER; EXPRESSION; INACTIVATION; RESECTION; TUMORS; MODEL; CLASSIFICATION	Pancreatic ductal adenocarcinoma (PDAC) carries the most dismal prognosis of all solid tumours. Both the late clinical presentation of patients, due to lack of early symptoms, as well as the rapid and aggressive course of the disease contribute to the extremely high mortality of this malignancy. Recently, a multistep progression model for PDAC integrating morphological, clinical and molecular evidence has been proposed. Putative precursor lesions, termed pancreatic intraepithelial neoplasia (PanIN), are classified into three different grades (PanIN-1 through -3) based on the degree of cellular atypia they display. We have conducted large-scale expression pro. ling analyses of microdissected cells from normal pancreatic ducts, PanINs of different grades and PDACs using whole-genome oligonucleotide microarrays. Veri. cation of hybridisation results for selected genes was performed using quantitative real-time PCR and immunohistochemical analyses on PanIN tissue microarrays. Comparison of the expression profiles demonstrated that the greatest changes in gene expression occur between PanIN stages 1B and 2, suggesting that PanIN-2 may represent the first truly preneoplastic stage in PDAC progression. Our results identify a large number of potential target genes for the development of novel molecular diagnostic and therapeutic tools for the prevention and early diagnosis of PDAC and provide novel insights into the pathophysiological mechanisms involved in tumour progression in the pancreas.	Univ Hosp Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Ruhr Univ Bochum, Dept Internal Med, D-4630 Bochum, Germany; Univ Kiel, Dept Pathol, D-2300 Kiel, Germany	Ulm University; Ruhr University Bochum; University of Kiel	Gress, TM (corresponding author), Univ Hosp Ulm, Dept Internal Med 1, Robert Koch Str 8, D-89081 Ulm, Germany.	thomas.gress@medizin.uni-ulm.de	Hahn, Stephan/E-3880-2010; Kestler, Hans A./D-5799-2012; Hahn, Stephan A./AAV-6062-2021	Hahn, Stephan/0000-0003-0855-9741; Kestler, Hans A./0000-0002-4759-5254; Hahn, Stephan A./0000-0003-0855-9741; Gress, Thomas/0000-0002-9333-5461				Bramhall SR, 1997, J PATHOL, V182, P347, DOI 10.1002/(SICI)1096-9896(199707)182:3<347::AID-PATH848>3.0.CO;2-J; Brentnall TA, 1999, ANN INTERN MED, V131, P247, DOI 10.7326/0003-4819-131-4-199908170-00003; Bubendorf L, 2001, J PATHOL, V195, P72, DOI 10.1002/path.893; Buchholz M, 2003, CANCER RES, V63, P4945; Canto MI, 2004, CLIN GASTROENTEROL H, V2, P606, DOI 10.1016/S1542-3565(04)00244-7; Conlon KC, 1996, ANN SURG, V223, P273, DOI 10.1097/00000658-199603000-00007; Crnogorac-Jurcevic T, 2003, J PATHOL, V201, P63, DOI 10.1002/path.1418; Ellenrieder V, 2000, INT J CANCER, V85, P14, DOI 10.1002/(SICI)1097-0215(20000101)85:1<14::AID-IJC3>3.0.CO;2-O; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Goggins M, 2000, AM J PATHOL, V156, P1767, DOI 10.1016/S0002-9440(10)65047-X; Gronborg M, 2004, J PROTEOME RES, V3, P1042, DOI 10.1021/pr0499085; Heinmoller E, 2000, AM J PATHOL, V157, P83, DOI 10.1016/S0002-9440(10)64520-8; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Hruban RH, 2000, AM J PATHOL, V156, P1821, DOI 10.1016/S0002-9440(10)65054-7; Hruban RH, 2004, AM J SURG PATHOL, V28, P977, DOI 10.1097/01.pas.0000126675.59108.80; Hruban RH, 2001, DIGEST DIS, V19, P76, DOI 10.1159/000050656; Huflejt ME, 2003, GLYCOCONJUGATE J, V20, P247, DOI 10.1023/B:GLYC.0000025819.54723.a0; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kawakami K, 2001, CANCER RES, V61, P6194; Kloppel Gunter, 2004, Curr Gastroenterol Rep, V6, P111, DOI 10.1007/s11894-004-0037-y; Kos J, 2000, INT J BIOL MARKER, V15, P84, DOI 10.1177/172460080001500116; Kristiansen G, 2005, J PATHOL, V205, P359, DOI 10.1002/path.1676; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Luttges J, 2004, CANCER-AM CANCER SOC, V100, P173, DOI 10.1002/cncr.11860; Luttges J, 2000, CANCER, V88, P2495, DOI 10.1002/1097-0142(20000601)88:11<2495::AID-CNCR10>3.0.CO;2-B; Luttges J, 2001, AM J PATHOL, V158, P1677, DOI 10.1016/S0002-9440(10)64123-5; Luttges J, 1999, VIRCHOWS ARCH, V435, P461, DOI 10.1007/s004280050428; LYNCH HT, 1994, ARCH SURG-CHICAGO, V129, P266; LYNCH HT, 1990, AM J GASTROENTEROL, V85, P54; Lynch HT, 1996, SEMIN ONCOL, V23, P251; Maitra A, 2003, MODERN PATHOL, V16, P902, DOI 10.1097/01.MP.0000086072.56290.FB; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; Pupa SM, 2002, J CELL PHYSIOL, V192, P259, DOI 10.1002/jcp.10142; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Sperti C, 1997, WORLD J SURG, V21, P195, DOI 10.1007/s002689900215; Stepanova L, 2000, ONCOGENE, V19, P2186, DOI 10.1038/sj.onc.1203561; Strojan P, 2004, CLIN CHIM ACTA, V344, P155, DOI 10.1016/j.cccn.2004.02.011; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Suomela S, 2004, J INVEST DERMATOL, V122, P717, DOI 10.1111/j.0022-202X.2004.22322.x; Terris B, 2002, AM J PATHOL, V160, P1745, DOI 10.1016/S0002-9440(10)61121-2; Trede M, 2001, SURG CLIN N AM, V81, P595, DOI 10.1016/S0039-6109(05)70146-8; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vimalachandran Dale, 2004, Cancer Control, V11, P6; Wilentz RE, 1998, CANCER RES, V58, P4740; Wilentz RE, 2000, CANCER RES, V60, P2002; Yamakawa T, 1998, BBA-GENE STRUCT EXPR, V1395, P202, DOI 10.1016/S0167-4781(97)00149-8; Yeo CJ, 1998, LANGENBECK ARCH SURG, V383, P129, DOI 10.1007/s004230050104; Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r28	48	155	161	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6626	6636		10.1038/sj.onc.1208804	http://dx.doi.org/10.1038/sj.onc.1208804			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16103885				2022-12-17	WOS:000232367800004
J	Wang, HQ; Altomare, DA; Skele, KL; Poulikakos, PI; Kuhajda, FP; Di Cristofano, A; Testa, JR				Wang, HQ; Altomare, DA; Skele, KL; Poulikakos, PI; Kuhajda, FP; Di Cristofano, A; Testa, JR			Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells	ONCOGENE			English	Article						apoptosis; AKT/protein kinase B; fatty acid synthase; ovarian cancer	BREAST-CANCER CELLS; CHEMOTHERAPY-INDUCED APOPTOSIS; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; THERAPEUTIC TARGET; CELLULAR-SURVIVAL; INHIBITION; RESISTANCE; PROSTATE; PATHWAY	Activation of AKT and overexpression of fatty acid synthase (FAS) are frequently observed in human ovarian cancer. To explore a possible connection between AKT and FAS, immunohistochemical analyses were conducted on an ovarian cancer tissue microarray, which revealed a significant correlation between phosphorylated AKT (phospho-AKT) and expression of FAS. To investigate the relationship between phospho-AKT and FAS in vitro, a variety of experiments employing a specific phosphatidylinositol 3-OH kinase (PI3K) inhibitor (LY294002), inducible PTEN expression in PTEN-null cells, or AKT1 siRNA demonstrated that phosphatidylinositol-3 kinase (PI3K)/AKT signaling modulates FAS expression. In contrast, inhibition of FAS activity by the drug C75 resulted in downregulation of phospho-AKT and increased cell death. To explore the functional relationship between phospho-AKT and FAS, we used SKOV3, C200, and OVCAR10 ovarian carcinoma cells, which have constitutively active AKT, and OVCAR5 cells, which have very low basal phospho-AKT levels. Treatment with LY294002 abolished AKT activity and potentiated apoptosis induced by FAS inhibitors cerulenin or C75 only in cells with constitutively active AKT, suggesting that constitutive activation of AKT protects against FAS inhibitor-induced cell death. Furthermore, inhibition of FAS activity by cerulenin or C75 resulted in downregulation of phospho-AKT, which preceded the induction of apoptosis. To investigate the relationship between phospho-AKT and FAS in vivo, severe combined immunodeficient mice injected intraperitoneally with SKOV3 cells were treated with C75. Growth of SKOV3 xenografts was markedly inhibited by C75. Analysis of the levels of phospho-AKT and FAS in C75-treated tumors revealed concordant downregulation of phospho-AKT and FAS. Collectively, our findings are consistent with a working model in which AKT activation regulates FAS expression, at least in part, whereas FAS activity modulates AKT activation.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21224 USA	Fox Chase Cancer Center; Johns Hopkins University	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	joseph.testa@fccc.edu	Di Cristofano, Antonio/B-4148-2016; di cristofano, antonio/AAJ-3796-2020	di cristofano, antonio/0000-0003-2537-3228	NATIONAL CANCER INSTITUTE [R01CA077429, P50CA083638, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA006927, CA06927, CA83638, R01 CA077429, CA-09035-28, P50 CA083638, CA77429] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; Alo PL, 2000, ONCOL REP, V7, P1383; Aunoble B, 2000, INT J ONCOL, V16, P567; Brognard J, 2001, CANCER RES, V61, P3986; Camassei FD, 2003, INVEST OPHTH VIS SCI, V44, P2399, DOI 10.1167/iovs.02-0934; Camassei FD, 2003, MED PEDIATR ONCOL, V40, P302, DOI 10.1002/mpo.10274; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Clark AS, 2002, MOL CANCER THER, V1, P707; DAGNOLO G, 1973, BIOCHIM BIOPHYS ACTA, V326, P155, DOI 10.1016/0005-2760(73)90241-5; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; De Schrijver E, 2003, CANCER RES, V63, P3799; EPSTEIN JI, 1995, UROLOGY, V45, P81, DOI 10.1016/S0090-4295(95)96904-7; Gabrielson EW, 2001, CLIN CANCER RES, V7, P153; Gansler TS, 1997, HUM PATHOL, V28, P686, DOI 10.1016/S0046-8177(97)90177-5; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Hu LM, 2002, CANCER RES, V62, P1087; Jackowski S, 2000, BBA-MOL CELL BIOL L, V1483, P301, DOI 10.1016/S1388-1981(99)00203-6; Jin W, 2003, BRIT J CANCER, V89, P185, DOI 10.1038/sj.bjc.6601048; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Kusakabe T, 2002, HISTOPATHOLOGY, V40, P71, DOI 10.1046/j.1365-2559.2002.01289.x; Ng SSW, 2000, CANCER RES, V60, P5451; Page C, 2000, ANTICANCER RES, V20, P407; Philp AJ, 2001, CANCER RES, V61, P7426; Piyathilake CJ, 2000, HUM PATHOL, V31, P1068, DOI 10.1053/hupa.2000.9842; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 2000, CANCER RES, V60, P213; Pizer ES, 1996, CANCER RES, V56, P2745; Pizer ES, 1998, CANCER RES, V58, P4611; Pizer ES, 2001, PROSTATE, V47, P102, DOI 10.1002/pros.1052; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Schmidt M, 2002, BRIT J CANCER, V87, P924, DOI 10.1038/sj.bjc.6600566; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Swinnen JV, 2003, BIOCHEM BIOPH RES CO, V302, P898, DOI 10.1016/S0006-291X(03)00265-1; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; Van de Sande T, 2002, CANCER RES, V62, P642; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Wang HQ, 1999, J CELL SCI, V112, P3497; Yang YA, 2002, EXP CELL RES, V279, P80, DOI 10.1006/excr.2002.5600; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598; Zhou WB, 2003, CANCER RES, V63, P7330; Zhuang LY, 2002, CANCER RES, V62, P2227	46	155	166	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3574	3582		10.1038/sj.onc.1208463	http://dx.doi.org/10.1038/sj.onc.1208463			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15806173				2022-12-17	WOS:000229221800005
J	Betz, BL; Strobeck, MW; Reisman, DN; Knudsen, ES; Weissman, BE				Betz, BL; Strobeck, MW; Reisman, DN; Knudsen, ES; Weissman, BE			Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G(1) arrest associated with induction of p16ink4a and activation of RB	ONCOGENE			English	Article						rhabdoid; SWI/SNF; hSNF5/INI1/BAF47; RB; p16ink4a	SENESCENT HUMAN FIBROBLASTS; SWI-SNF COMPLEX; CHROMATIN-REMODELING COMPLEXES; HUMAN-DIPLOID FIBROBLASTS; MALIGNANT RHABDOID TUMOR; RETINOBLASTOMA-PROTEIN; CELLULAR SENESCENCE; CYCLE ARREST; TRANSCRIPTIONAL ACTIVATION; REPLICATIVE SENESCENCE	Truncating mutations and homozygous deletions in the hSNF5/INI1/BAF47 subunit of human SWI/SNF complexes occur in most malignant rhabdoid tumors and some other malignancies. How loss of hSNF5 contributes to tumorigenesis remains unknown. Because the SWI/ SNF subunit BRG1 is required for RB-mediated cell cycle arrest, we hypothesized that hSNF5 deficiency disrupts RB signaling. Here we demonstrate that unlike BRG1, hSNF5 deficient cells retain functional RB since ectopic expression of either p16ink4a or a constitutively active form of RB (PSM - RB) led to cell cycle arrest. To determine how hSNF5 loss might contribute to tumorigenesis, we used a retrovirus to introduce hSNF5 into multiple deficient cell lines. In all cases, re-expression inhibited colony formation and induced cell cycle arrest characterized by a flattened morphology. Flow cytometry revealed that these cells accumulated in G(0)/G(1). Importantly, arrested cells exhibited strong induction of p16ink4a, hypophosphorylated RB, and down-regulation of cyclin A, suggesting that hSNF5 signals upstream of RB to induce growth arrest. Co-expression of SV40 T/t abolished hSNF5-induced G(1) arrest and activation of RB. Likewise, HPV-16 E7 was sufficient to partially overcome cell cycle arrest. These results suggest that hSNF5 loss is not equivalent to BRG1/BRM loss in human tumor cell lines. Furthermore, hSNF5-induced cell cycle arrest of deficient cells is mediated in part through activation of p16ink4a expression. These findings provide insight into mechanisms of hSNF5-mediated tumor suppression.	Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Cincinnati, Coll Med, Dept Cell Biol, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University System of Ohio; University of Cincinnati	Weissman, BE (corresponding author), Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.				NATIONAL CANCER INSTITUTE [R01CA091048, R01CA082525, T32CA071341] Funding Source: NIH RePORTER; NCI NIH HHS [CA82525, CA71341, CA91048] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Biegel JA, 1999, CANCER RES, V59, P74; Biegel Jaclyn A., 2002, Cancer Research, V62, P323; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Dai CY, 2000, ONCOGENE, V19, P1613, DOI 10.1038/sj.onc.1203438; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; GARVIN AJ, 1993, AM J PATHOL, V142, P375; GOLDSTEIN S, 1994, J CELL PHYSIOL, V161, P571, DOI 10.1002/jcp.1041610321; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jiang H, 2000, ONCOGENE, V19, P3878, DOI 10.1038/sj.onc.1203722; KARNES PS, 1991, CANCER GENET CYTOGEN, V56, P31, DOI 10.1016/0165-4608(91)90359-3; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LITZKAS P, 1984, MOL CELL BIOL, V4, P2549, DOI 10.1128/MCB.4.11.2549; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morisaki H, 1999, EXP CELL RES, V253, P503, DOI 10.1006/excr.1999.4698; MU XC, 1995, J CELL PHYSIOL, V165, P647, DOI 10.1002/jcp.1041650324; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Neely KE, 2002, MOL CELL BIOL, V22, P1615, DOI 10.1128/MCB.22.6.1615-1625.2002; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; OTA S, 1993, CANCER-AM CANCER SOC, V71, P2862, DOI 10.1002/1097-0142(19930501)71:9<2862::AID-CNCR2820710930>3.0.CO;2-D; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; PEEBLES PT, 1978, PEDIATR RES, V12, P485, DOI 10.1203/00006450-197804001-00732; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; ROBBINS E, 1970, J EXP MED, V131, P1211, DOI 10.1084/jem.131.6.1211; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2002, J BIOL CHEM, V277, P4782, DOI 10.1074/jbc.M109532200; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Sullivan EK, 2001, MOL CELL BIOL, V21, P5826, DOI 10.1128/MCB.21.17.5826-5837.2001; Suzuki A, 1997, DIAGN MOL PATHOL, V6, P326, DOI 10.1097/00019606-199712000-00004; Taylor MD, 2000, AM J HUM GENET, V66, P1403, DOI 10.1086/302833; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wong AKC, 2000, CANCER RES, V60, P6171; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Xue YT, 2000, P NATL ACAD SCI USA, V97, P13015, DOI 10.1073/pnas.240208597; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	82	155	163	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2002	21	34					5193	5203		10.1038/sj.onc.1205706	http://dx.doi.org/10.1038/sj.onc.1205706			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149641				2022-12-17	WOS:000177193900001
J	Ugolini, F; Charafe-Jauffret, E; Bardou, VJ; Geneix, J; Adelaide, J; Labat-Moleur, F; Penault-Llorca, F; Longy, M; Jacquemier, J; Birnbaum, D; Pebusque, MJ				Ugolini, F; Charafe-Jauffret, E; Bardou, VJ; Geneix, J; Adelaide, J; Labat-Moleur, F; Penault-Llorca, F; Longy, M; Jacquemier, J; Birnbaum, D; Pebusque, MJ			WNT pathway and mammary carcinogenesis: Loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type	ONCOGENE			English	Article						breast cancer; tumor suppressor gene; in situ hybridization; chromosome 8	BREAST-CANCER; CYCLIN D1; ESTROGEN-RECEPTOR; DIFFERENTIAL EXPRESSION; SPEMANN ORGANIZER; TISSUE-SECTIONS; BETA-CATENIN; FOLLOW-UP; IN-SITU; GROWTH	Secreted Frizzled-related protein 1 (SFRP1) encodes a member of a protein family that contains a cysteine-rich domain similar to the WNT-binding site of Frizzled receptors and regulates the WNT pathway. The WNT pathway is frequently altered in human cancers. We have defined the pattern of SFRP1 mRNA expression in the progression of breast cancer. We show that SFRP1 is expressed in the epithelial component of normal breast, in the in situ component of ductal carcinomas and is lost in more than 80% of invasive breast carcinomas except the medullary type. Loss of SFRP1 expression is correlated with the presence of hormonal receptors. Conversely, the maintenance of SFRP1 in carcinomas is correlated with the presence of lymphoplasmocytic stroma. No significant association was observed between SFRP1 status and the level of apoptosis in tumoral cells.	INSERM, U119, IFR 57, Oncol Mol Lab, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Anat Pathol, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Biostat, F-13009 Marseille, France; Inst J Paoli I Calmettes, Lab Biol Tumeurs, F-13009 Marseille, France; CHRU, Pathol Cellulaire Lab, Grenoble, France; Ctr Jean Perrin, Anat Pathol Lab, Clermont Ferrand, France; Inst Bergonie, Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); CHU Grenoble Alpes; UNICANCER; Centre Jean Perrin; UNICANCER; Institut Bergonie	Pebusque, MJ (corresponding author), INSERM, U119, IFR 57, Oncol Mol Lab, 27 Bd Lei Roure, F-13009 Marseille, France.	pebusque@marseille.inserm.fr	ADELAIDE, José JA/O-4390-2017; Charafe-Jauffret, emmanuelle/P-6009-2017	ADELAIDE, José JA/0000-0003-4364-9857; Birnbaum, Daniel/0000-0001-7920-9883; Charafe-Jauffret, emmanuelle/0000-0002-0286-1299				Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; CHURCH GM, 1984, P NATL ACAD SCI USA, V81, P945; Dale TC, 1996, CANCER RES, V56, P4320; de Cremoux P, 1999, J NATL CANCER I, V91, P641, DOI 10.1093/jnci/91.7.641; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; GOLD R, 1993, J HISTOCHEM CYTOCHEM, V41, P1023, DOI 10.1177/41.7.8515045; Gumbiner BM, 1998, CURR OPIN GENET DEV, V8, P430, DOI 10.1016/S0959-437X(98)80114-7; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HUGUET EL, 1994, CANCER RES, V54, P2615; Ingvarsson S, 1999, SEMIN CANCER BIOL, V9, P277, DOI 10.1006/scbi.1999.0124; Jacquemier JD, 1998, J PATHOL, V184, P130; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Labat-Moleur F, 1998, J HISTOCHEM CYTOCHEM, V46, P327, DOI 10.1177/002215549804600306; Lakhani SR, 1999, J PATHOL, V187, P272, DOI 10.1002/(SICI)1096-9896(199902)187:3<272::AID-PATH265>3.0.CO;2-2; Leach RJ, 1996, CYTOGENET CELL GENET, V75, P71, DOI 10.1159/000134460; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Pedersen L, 1997, APMIS, V105, P4; Pennisi E, 1998, SCIENCE, V281, P1438, DOI 10.1126/science.281.5382.1438; PHILIPPE JM, 1998, TECHNICAL TIPS LINE; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; RIDOLFI RL, 1977, CANCER, V40, P1365, DOI 10.1002/1097-0142(197710)40:4<1365::AID-CNCR2820400402>3.0.CO;2-N; Ross JS, 1999, AM J CLIN PATHOL, V112, pS53; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Seshadri R, 1996, CLIN CANCER RES, V2, P1177; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shoker BS, 1999, HISTOPATHOLOGY, V35, P393; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Simpson JF, 2000, AM J PATHOL, V156, P5, DOI 10.1016/S0002-9440(10)64698-6; Takano Y, 1999, J CANCER RES CLIN, V125, P505, DOI 10.1007/s004320050309; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THEILLET C, 1990, ONCOGENE, V5, P147; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; vanDiest PJ, 1997, AM J PATHOL, V150, P705; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Vos CBJ, 1999, J PATHOL, V187, P279; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wang XZ, 1999, ONCOGENE, V18, P5718, DOI 10.1038/sj.onc.1202950; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4; Zorn AM, 1997, CURR BIOL, V7, pR501, DOI 10.1016/S0960-9822(06)00248-X; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	48	155	165	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2001	20	41					5810	5817		10.1038/sj.onc.1204706	http://dx.doi.org/10.1038/sj.onc.1204706			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593386				2022-12-17	WOS:000171037200004
J	Gayet, J; Zhou, XP; Duval, A; Rolland, S; Hoang, JM; Cottu, P; Hamelin, R				Gayet, J; Zhou, XP; Duval, A; Rolland, S; Hoang, JM; Cottu, P; Hamelin, R			Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines	ONCOGENE			English	Article						colorectal cancer; cell lines; genetic alterations	MICROSATELLITE MUTATOR PHENOTYPE; GRADIENT GEL-ELECTROPHORESIS; NONPOLYPOSIS COLON-CANCER; FAMILIAL ADENOMATOUS POLYPOSIS; BETA-CATENIN GENE; II RECEPTOR GENE; FRAMESHIFT MUTATIONS; SOMATIC MUTATIONS; K-RAS; INSTABILITY	A number of genetic alterations have been described in colorectal cancers. They include allelic losses on specific chromosomal arms, mutations of oncogenes, tumor suppressor genes and mismatch repair genes, microsatellite instability in coding repeat sequences of target genes and methylation defects in gene promoters. Since these alterations have been reported by different groups on different tumors and cell lines, the complete repertoire of genetic alterations for any given tumor sample remains unknown. In the present study, we analysed a series of 22 colorectal cancer cell lines for 31 different genetic alterations. We found significant correlations between mutational profiles in these colorectal cell lines associated with differences in mismatch repair status. This panel of colon cancer cell lines is representative of the genetic heterogeneity occurring in sporadic colorectal carcinoma. Our results may prove to be very useful for understanding the different biological pathways involved in the development of colon cancer, and for groups studying cellular biology and pharmacology on the same cell lines.	INSERM, U434, CEPH, F-75010 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Hamelin, R (corresponding author), INSERM, U434, CEPH, 27 Rue Juliette Dodu, F-75010 Paris, France.		Cottu, Paul/ABC-8595-2020					AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BELGRADER P, 1994, MOL CELL BIOL, V14, P8219, DOI 10.1128/MCB.14.12.8219; Boland CR, 1998, CANCER RES, V58, P5248; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Casares S, 1995, ONCOGENE, V11, P2303; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; COTTRELL S, 1992, LANCET, V340, P626, DOI 10.1016/0140-6736(92)92169-G; Cottu PH, 1996, ONCOGENE, V13, P2727; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Deng GR, 1999, CANCER RES, V59, P2029; Duval A, 1999, CANCER RES, V59, P4213; Duval A, 2001, HUM MOL GENET, V10, P513, DOI 10.1093/hmg/10.5.513; Duval A, 2000, CANCER RES, V60, P3872; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Georgiades IB, 1999, ONCOGENE, V18, P7933, DOI 10.1038/sj.onc.1203368; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAMELIN R, 1993, ONCOGENE, V8, P2213; HEINEN CD, 1995, CANCER RES, V55, P4797; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hoang JM, 1997, CANCER RES, V57, P300; Ilyas M, 1999, EUR J CANCER, V35, P335, DOI 10.1016/S0959-8049(98)00431-6; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Iwao K, 1998, CANCER RES, V58, P1021; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kane MF, 1997, CANCER RES, V57, P808; Kitaeva MN, 1997, CANCER RES, V57, P4478; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lerebours F, 1999, GENE CHROMOSOME CANC, V25, P147, DOI 10.1002/(SICI)1098-2264(199906)25:2<147::AID-GCC10>3.0.CO;2-Z; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; LI YJ, 1995, ONCOGENE, V11, P597; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LUCE MC, 1995, GASTROENTEROLOGY, V109, P1368, DOI 10.1016/0016-5085(95)90600-2; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muzeau F, 1997, BRIT J CANCER, V75, P1336, DOI 10.1038/bjc.1997.226; Myohanen SK, 1998, CANCER RES, V58, P591; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Olschwang S, 1997, P NATL ACAD SCI USA, V94, P12122, DOI 10.1073/pnas.94.22.12122; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, CANCER RES, V55, P5548; PEINADO MA, 1993, INT J ONCOL, V2, P123; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; RIDANPAA M, 1993, HUM MOL GENET, V2, P639, DOI 10.1093/hmg/2.6.639; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; Schwartz S, 1999, CANCER RES, V59, P2995; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Sparks AB, 1998, CANCER RES, V58, P1130; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Yoshitaka T, 1996, BIOCHEM BIOPH RES CO, V227, P553, DOI 10.1006/bbrc.1996.1544; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhou XP, 1997, ONCOGENE, V15, P1713, DOI 10.1038/sj.onc.1201337	63	155	159	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					5025	5032		10.1038/sj.onc.1204611	http://dx.doi.org/10.1038/sj.onc.1204611			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526487				2022-12-17	WOS:000170439800012
J	Mahyar-Roemer, M; Roemer, K				Mahyar-Roemer, M; Roemer, K			p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents	ONCOGENE			English	Article						p21; p53; colon cancer; butyrate; chemotherapy	CHAIN FATTY-ACIDS; NITRIC-OXIDE SYNTHASE; DIETARY FIBER; CYCLE ARREST; CANCER-CELLS; P53; BUTYRATE; GROWTH; P21(WAF1/CIP1); DEATH	The molecular basis for the sensitivity of tumor cells to chemopreventive natural food compounds and commonly used chemotherapeutic agents is not well understood, not least because studies are frequently confounded by the diversity among cell lines or rely on experimental protein overexpression. Here we investigated the effects of n-butyrate, a cancer-preventive short-chain fatty acid produced by anaerobic bacteria in the gastrointestinal tract, on the human wild-type p53 and p21 expressing HCT116 colon carcinoma cell line and on HCT116 cells with either p53 or p21 alleles inactivated by homologous recombination. The effects of n-butyrate were then compared with those elicited by cytotoxic drugs and the natural chemopreventive phytoalexin of wine and grapes, resveratrol. We document that physiological concentrations of n-butyrate stimulate p21 expression and induce apoptosis independently of p53, and that the absence of p21 increases apoptosis drastically. The apoptosis is mediated through the mitochondria and is accompanied by mitochondrial proliferation and membrane potential changes. Adriamycin, etoposide, cisplatinum, colcemid and resveratrol induce distinct cellular responses; however, absence of p21 favors apoptosis-induction by adriamycin, etoposide and colcemid. Thus, control of p21 expression may support chemoprevention and certain tumor therapies.	Univ Saarland, Sch Med, Dept Virol, D-66421 Homburg, Germany	Saarland University	Roemer, K (corresponding author), Univ Saarland, Sch Med, Dept Virol, Bldg 47, D-66421 Homburg, Germany.							Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Attardi LD, 2000, GENE DEV, V14, P704; Atz J, 2000, J CELL BIOCHEM, V76, P572, DOI 10.1002/(SICI)1097-4644(20000315)76:4<572::AID-JCB6>3.0.CO;2-6; BARNES PJ, 1994, CL ALLER IM, V4, P501; Barshishat M, 2000, BRIT J CANCER, V82, P195; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; BOFFA LC, 1992, CANCER RES, V52, P5906; Brown JM, 1999, CANCER RES, V59, P1391; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CUMMINGS JH, 1981, GUT, V22, P763, DOI 10.1136/gut.22.9.763; CUPLER EJ, 1995, ACTA NEUROPATHOL, V90, P1; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HEERDT BG, 1994, CANCER RES, V54, P3288; Hodin RA, 1996, CELL GROWTH DIFFER, V7, P647; Hsieh TC, 1999, CANCER RES, V59, P2596; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; Huang YQ, 2000, J BIOL CHEM, V275, P6462, DOI 10.1074/jbc.275.9.6462; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Litvak DA, 1998, SURGERY, V124, P161, DOI 10.1067/msy.1998.90365; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Mancini M, 1997, J CELL BIOL, V138, P449, DOI 10.1083/jcb.138.2.449; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; McBain JA, 1997, BIOCHEM PHARMACOL, V53, P1357, DOI 10.1016/S0006-2952(96)00904-5; MCINTYRE A, 1993, GUT, V34, P386, DOI 10.1136/gut.34.3.386; MIYASHITA T, 1995, CELL, V80, P293; Mortensen K, 1999, J BIOL CHEM, V274, P37679, DOI 10.1074/jbc.274.53.37679; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; REIPERT S, 1995, EXP CELL RES, V221, P281, DOI 10.1006/excr.1995.1376; SCHWARTZ B, 1992, INT J CANCER, V52, P60, DOI 10.1002/ijc.2910520113; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Tian H, 2000, CANCER RES, V60, P679; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang H, 1999, J CELL PHYSIOL, V178, P173, DOI 10.1002/(SICI)1097-4652(199902)178:2<173::AID-JCP6>3.3.CO;2-H; Wang YC, 1999, ONCOGENE, V18, P2643, DOI 10.1038/sj.onc.1202632; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648	57	155	161	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2001	20	26					3387	3398		10.1038/sj.onc.1204440	http://dx.doi.org/10.1038/sj.onc.1204440			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423989				2022-12-17	WOS:000169248800009
J	Li, RZ; Pei, HP; Watson, DK; Papas, TS				Li, RZ; Pei, HP; Watson, DK; Papas, TS			EAP1/Daxx interacts with ETS1 and represses transcriptional activation of ETS1 target genes	ONCOGENE			English	Article						ETS1; EAP1/Daxx; protein interaction; transcriptional repression; DID motif	MATRIX METALLOPROTEINASE-1; ONCOGENIC ACTIVITY; BINDING PROTEIN; EXPRESSION; PROMOTER; CELLS; PROTOONCOGENE; FAMILY; FORM; DAXX	ETS1 is a member of the evolutionarily conserved family of ets genes, which are transcription factors that bind to unique DNA sequences, either alone or by association with other proteins. In this study, we have used the yeast two-hybrid system to identify an ETS1 interacting protein. The ETS1 N-terminal amino acid region was used as bait and an interaction was identified with the Daxx protein, referred to as EAP1 (ETS1 Associated Protein 1)/Daxx. This interactin has been shown to exist in yeast and in vitro. EAP1/Daxx and ETS1 are colocalized in the nucleus of mammalian cells. The region in EAP1/Daxx which specifically binds to ETS1 is located within its carboxy terminal 173 amino acid region. The ETS1 interaction region is located within its N-terminal 139 amino acids and is referred as the Daxx Interaction Domain (DID). The DID appears to be conserved in several other ets family members, as well as in other proteins known to interact with Daxx. The EAP1/Daxx interacts with both isoforms of ETS1, p51-ETS1 and p42-ETS1. Interaction of EAP1/Daxx with ETS1 causes the repression of transcriptional activation of the MMP1 and BCL2 genes. The interaction domains of both ETS1 and EAP1/Daxx are required for this repression and deletion of either domain abolishes this activity.	Med Univ S Carolina, Hollings Canc Ctr, CMSB, Charleston, SC 29425 USA; Med Univ S Carolina, Ctr Mol & Struct Biol, Dept Med, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Li, RZ (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, CMSB, Romm 334,86 Jonathan Lucas St, Charleston, SC 29425 USA.				NATIONAL CANCER INSTITUTE [P01CA078582, R01CA076231] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA78582, R01CA76231] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Athanasiou M, 1996, CELL GROWTH DIFFER, V7, P1525; Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; Bhat NK, 1996, INT J ONCOL, V8, P841; BHAT NK, 1994, CHALLENGES MODERN ME, V5, P63; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; GHYSDAEL J, 1997, ETS FAMILY TRANSCRIP; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Halle JP, 1997, MOL CELL BIOL, V17, P4220, DOI 10.1128/MCB.17.8.4220; Herberg JA, 1998, J MOL BIOL, V277, P839, DOI 10.1006/jmbi.1998.1637; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; JORCYK CL, 1991, ONCOGENE, V6, P523; Kiriakidou M, 1997, DNA CELL BIOL, V16, P1289, DOI 10.1089/dna.1997.16.1289; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Moore DD, 1995, GLOB MOB SURV; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Pluta AF, 1998, J CELL SCI, V111, P2029; PRIBYL LJ, 1991, ONCOGENE, V6, P1175; PRIBYL LJ, 1988, DEV BIOL, V127, P45, DOI 10.1016/0012-1606(88)90187-X; Rutter JL, 1998, CANCER RES, V58, P5321; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9	43	155	162	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2000	19	6					745	753		10.1038/sj.onc.1203385	http://dx.doi.org/10.1038/sj.onc.1203385			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698492				2022-12-17	WOS:000085192100004
J	Ishidate, T; Matsumine, A; Toyoshima, K; Akiyama, T				Ishidate, T; Matsumine, A; Toyoshima, K; Akiyama, T			The APC-hDLG complex negatively regulates cell cycle progression from the G0/G1 to S phase	ONCOGENE			English	Article						APC; hDLG; cell cycle; tumor suppressor	TUMOR-SUPPRESSOR PROTEIN; WNT SIGNALING PATHWAY; ADENOMATOUS POLYPOSIS-COLI; BETA-CATENIN; HUMAN HOMOLOG; DISCS LARGE; POSTSYNAPTIC DENSITY; GENE-PRODUCT; INTERACTS; AXIN	The adenomatous polyposis coli (APC) gene is mutated in familial adenomatous polyposis and in many sporadic colorectal tumors. The carboxyl-terminal S/TXV motif of the APC gene product interacts with the PDZ domain of hDLG, the human homolog of the Drosophila lethal (I) discs large-1 (dlg) tumor suppressor. In the present study, we found that overexpression of hDLG suppresses cell proliferation by blocking cell cycle progression from the G0/G1 to S phase. This inhibition of cell cycle progression was abolished when the PDZ, SH3 or guanylate kinase-like domain of hDLG was mutated. Moreover, overexpression of these mutant hDLGs partially interfered with the cell cycle blocking activity of APC. Consistent with this result, mutant APC lacking the S/TXV motif exhibited weaker cell cycle blocking activity than the intact APC, These results suggest that APC-hDLG complex formation plays an important role in transducing the APC cell cycle blocking signal.	Univ Tokyo, Dept Mol & Genet Informat, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 113, Japan; Osaka Univ, Dept Oncogene Res, Inst Microbial Dis, Suita, Osaka 565, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Higashinari Ku, Osaka 537, Japan	University of Tokyo; Osaka University; Osaka Medical Center for Cancer & Cardiovascular Diseases	Akiyama, T (corresponding author), Univ Tokyo, Dept Mol & Genet Informat, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 113, Japan.							BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; KISTNER U, 1995, FEBS LETT, V359, P159, DOI 10.1016/0014-5793(95)00030-D; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Pedemonte S, 1998, GENE CHROMOSOME CANC, V22, P257, DOI 10.1002/(SICI)1098-2264(199808)22:4<257::AID-GCC1>3.0.CO;2-U; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; STEWART M, 1972, DEV BIOL, V27, P71, DOI 10.1016/0012-1606(72)90113-3; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867	36	155	158	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2000	19	3					365	372		10.1038/sj.onc.1203309	http://dx.doi.org/10.1038/sj.onc.1203309			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656683				2022-12-17	WOS:000084873700006
J	Chang, CH; Scott, GK; Kuo, WL; Xiong, XH; Suzdaltseva, Y; Park, JW; Sayre, P; Erny, K; Collins, C; Gray, JW; Benz, CC				Chang, CH; Scott, GK; Kuo, WL; Xiong, XH; Suzdaltseva, Y; Park, JW; Sayre, P; Erny, K; Collins, C; Gray, JW; Benz, CC			ESX: A structurally unique Ets overexpressed early during human breast tumorigenesis	ONCOGENE			English	Article						Ets; epithelial-restricted; breast cancer; HER2/neu	TRANSCRIPTION FACTORS; GENE FAMILY; PROTEIN; PROMOTER; BINDING; HYBRIDIZATION; ACTIVATOR; EVOLUTION; PATHWAY; CANCER	The >30 known members of the Ets multigene family of transcriptional regulators are increasingly being recognized for their involvement in early embryonic development and late tissue maturation, directing stage-specific and tissue-restricted programs of target gene expression. Identifiable primarily by their 85 amino acid ETS DNA-binding domain and dispersed across all metazoan lineages into distinct subfamilies, Ets genes also produce malignancies in humans and other vertebrates when overexpressed or rearranged into chimeras retaining the ETS domain, suggesting that their oncogenic potential is determined by the program of target genes they regulate. Searching for Ets factors that regulate expression of the HER2/neu (c-erbB2) oncogene in human breast cancer, we identified a new epithelium-restricted Ets encoding an ETS domain homologous to the Drosophila E74/human Elf-1 subfamily, an amino-terminal region (A-region or Pointed domain) homologous to the distantly related Ets-l subfamily, and a serine-rich box homologous to the transactivating domain of the lymphocyte-restricted High Mobility Group (HMG) protein, SOX4. Recombinant protein encoded by ESX (for epithelial-restricted with serine box) exhibits Ets-like DNA binding specificity in electrophoretic mobility shift assays and, in transient transfection assays, transactivates Ets-responsive promoter elements including that found in the HER2/neu oncogene. ESX is located at chromosome 1q32 in a region known to be amplified in 50% of early breast cancers, is heregulin-inducible and overexpressed in HER2/neu activated breast cancer cells. Tissue hybridization suggests that ESX becomes overexpressed at an early stage of human breast cancer development known as ductal carcinoma in situ (DCIS).	UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV HEMATOL ONCOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV MOL CYTOMETRY,SAN FRANCISCO,CA 94143; LAWRENCE BERKELEY LAB,BERKELEY,CA 94720	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory				Erny-Albrecht, Katrina/0000-0003-3538-1475	NCI NIH HHS [CA44768, CA36773, CA58207] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058207, P01CA044768, R01CA036773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHAGANTI RSK, 1986, CYTOGENET CELL GENET, V43, P181, DOI 10.1159/000132318; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GIOVANE A, 1995, GENOMICS, V29, P769, DOI 10.1006/geno.1995.9938; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; ISOLA JJ, 1995, AM J PATHOL, V147, P905; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KODANDAPANI R, 1996, NATURE, V380, P457; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Li WL, 1996, ONCOGENE, V12, P2473; LIU E, 1992, ONCOGENE, V7, P1027; MORRIS CM, 1991, ONCOGENE, V6, P1093; NOONBERG SB, 1994, GENE, V149, P123, DOI 10.1016/0378-1119(94)90420-0; OHagan RC, 1996, ONCOGENE, V13, P1323; OHAGAN RC, 1996, AM ASS CANC RES, V37, P3575; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SHIPLEY J, 1994, GENOMICS, V23, P710, DOI 10.1006/geno.1994.1564; STOKKE T, 1995, GENOMICS, V26, P134, DOI 10.1016/0888-7543(95)80092-Z; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; Yang BS, 1996, MOL CELL BIOL, V16, P538	31	155	166	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1617	1622		10.1038/sj.onc.1200978	http://dx.doi.org/10.1038/sj.onc.1200978			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129154				2022-12-17	WOS:A1997WQ54800014
J	Oates, AJ; Barraclough, R; Rudland, PS				Oates, AJ; Barraclough, R; Rudland, PS			The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model	ONCOGENE			English	Article						mammary metastasis; subtractive hybridization; osteopontin (OPN)	EPITHELIAL-CELL LINE; RAT; HYBRIDIZATION; TRANSFECTION; VARIANTS; PROTEIN; CANCER; BONE	The rat mammary epithelial cell line, Rama 37, yields benign, non-metastasizing adenomatous tumours in syngeneic Furth-Wistar rats. Transfection of this stably diploid cell line with genomic DNA fragments from a human metastasizing breast cancer cell line yields cells which, when injected subcutaneously in syngeneic rats, give rise to secondary tumours in a number of the animals. From one such secondary lung tumour, a cell line was established designated Ca2-5-LT1. This cell line, when introduced into the syngeneic rat host, also showed the ability to metastasise. To determine key changes in gene expression that occur during the progression from Rama 37, the benign tumour-inducing cell line, to the metastatic derivative Ca2-5-LT1, a general method of subtractive hybridization has been employed. This procedure in conjunction with Northern blotting and nucleic acid sequencing has been used to identify mRNAs expressed differentially between the metastatic and nonmetastatic cell lines described above. So far, of the subtracted cDNAs that have been identified which represent differentially expressed mRNAs, a large proportion of these cDNAs corresponded to the mRNA for rat osteopontin (OPN). The mRNA for OPN was expressed at a ninefold higher level in the metastatic Ca2-5-LT1 cell Une when compared to the nonmetastatic parental Rama 37 cell Line. Rama 37 cells transfected with DNA from a human benign cell line failed to show elevated levels of OPN mRNA. Following transfection of Rama 37 cells with an expression-construct producing elevated levels of OPN, the newly-transfected cells, when introduced into the rat host, developed metastases in 55% of the animals that produced primary tumours. These experiments show that increasing the expression of OPN in a previously benign cell line is sufficient to produce a metastatic phenotype in this particular rat mammary model.	UNIV LIVERPOOL,DEPT BIOCHEM,CANC & POLIO RES FUND LABS,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool			Barraclough, Roger/AAH-6516-2020	Barraclough, Roger/0000-0002-7203-1194				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARRACLOUGH R, 1987, J CELL PHYSIOL, V131, P393, DOI 10.1002/jcp.1041310311; BEHREND EI, 1994, CANCER RES, V54, P832; BROWN LF, 1992, MOL BIOL CELL, V3, P1169, DOI 10.1091/mbc.3.10.1169; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIES BR, 1993, ONCOGENE, V8, P999; DAVIES BR, 1994, CANCER RES, V54, P2785; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DERRICO JA, 1995, J PERIODONTAL RES, V30, P34, DOI 10.1111/j.1600-0765.1995.tb01250.x; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; DUNNINGTON DJ, 1984, CANCER RES, V44, P5338; FELDINGHABERMANN B, 1992, J BIOL CHEM, V267, P5070; FENG B, 1995, CLIN EXP METASTAS, V13, P453, DOI 10.1007/BF00118184; GARDNER HAR, 1994, ONCOGENE, V9, P2321; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; JAMIESON S, 1990, PATHOBIOLOGY, V58, P329, DOI 10.1159/000163605; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; RUBENSTEIN JLR, 1990, NUCLEIC ACIDS RES, V18, P4833, DOI 10.1093/nar/18.16.4833; RUDLAND PS, 1985, CANCER RES, V45, P3864; Sambrook J, 1989, MOL CLONING LAB MANU; SCHWEINFEST CW, 1992, INT J ONCOL, V1, P499; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937	26	155	166	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					97	104						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700559				2022-12-17	WOS:A1996UX31900011
J	ZHOU, P; JIANG, W; ZHANG, YJ; KAHN, SM; SCHIEREN, I; SANTELLA, RM; WEINSTEIN, IB				ZHOU, P; JIANG, W; ZHANG, YJ; KAHN, SM; SCHIEREN, I; SANTELLA, RM; WEINSTEIN, IB			ANTISENSE TO CYCLIN D1 INHIBITS GROWTH AND REVERSES THE TRANSFORMED PHENOTYPE OF HUMAN ESOPHAGEAL CANCER-CELLS	ONCOGENE			English	Article						ANTISENSE; CYCLIN D1; ESOPHAGEAL CANCER; TUMORIGENICITY	RETINOBLASTOMA PROTEIN; NUCLEAR-PROTEIN; AMPLIFICATION; GENE; OVEREXPRESSION; EXPRESSION; FIBROBLASTS; CARCINOMAS; 11Q13; PHASE	The cyclin D1 gene is amplified and overexpressed in a significant fraction of human esophageal tumors, and several other types of human cancer, but the functional significance of this overexpression has not been established. To further address the roles of cyclin D1 in growth control and tumorigenesis, we have overexpressed an antisense cyclin D1 cDNA construct, either constitutively or inducibly, in the HCE7 human esophageal cancer cell line in which cyclin D1 is amplified and expressed at high levels. The expression of antisense cyclin D1 led to decreased expression of cyclin D1 at both the mRNA and protein levels, and this was associated with a marked inhibition of cell proliferation. Antisense cyclin D1 expressing cells displayed a decreased plating efficiency, increased doubling time, decreased saturation density, increased cell size, decreased cyclin D1-associated in vitro kinase activity, decreased anchorage-independent growth, and a loss of tumorigenicity in nude mice. These findings provide direct evidence that the overexpression of cyclin D1 in certain tumor cells contributes to their abnormal growth and tumorigenicity. The ability to revert the transformed phenotype of these cells with antisense cyclin D1 suggests that cyclin D1 may be a useful target in cancer therapy.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PHARMACOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,COLUMBIA PRESBYTERIAN CANC CTR,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,INST CANC RES,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute				Jiang, Wei/0000-0002-2309-9571				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BANKSSCHLEGEL SP, 1986, CANCER RES, V46, P250; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BONHAM L, 1991, ONCOGENE, V6, P1073; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; GILLETT C, 1994, CANCER RES, V54, P1812; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1993, CURR OPIN GENET DEV, V3, P1, DOI 10.1016/S0959-437X(05)80333-8; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, ONCOGENE, V9, P2159; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; OSWALD F, 1994, ONCOGENE, V9, P2029; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHUURING E, 1992, ONCOGENE, V7, P355; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEWING A, 1993, J CELL SCI, V104, P545; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TAM SW, 1994, ONCOGENE, V9, P2663; TOOSHIMA H, 1994, CELL, V78, P67; TSURUTA H, 1993, BIOCHEM BIOPH RES CO, V196, P1529, DOI 10.1006/bbrc.1993.2425; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WON KA, 1992, P NATL ACAD SCI USA, V89, P910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	56	155	168	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					571	580						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630641				2022-12-17	WOS:A1995RN53000018
J	CANN, AJ; KOYANAGI, Y; CHEN, ISY				CANN, AJ; KOYANAGI, Y; CHEN, ISY			HIGH-EFFICIENCY TRANSFECTION OF PRIMARY HUMAN-LYMPHOCYTES AND STUDIES OF GENE-EXPRESSION	ONCOGENE			English	Article									UNIV CALIF LOS ANGELES,SCH MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center				Cann, Alan/0000-0002-9014-3720				BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BOSTON RS, 1987, PLANT PHYSIOL, V83, P742, DOI 10.1104/pp.83.4.742; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CANN AJ, 1988, IN PRESS CONTROL HIV; CHAN JY, 1986, P NATL ACAD SCI USA, V83, P8669, DOI 10.1073/pnas.83.22.8669; CHEN ISY, 1986, CELL, V47, P1, DOI 10.1016/0092-8674(86)90359-4; CHEN ISY, 1983, NATURE, V305, P502, DOI 10.1038/305502a0; CHEN ISY, 1985, SCIENCE, V229, P54, DOI 10.1126/science.2990037; CHEN ISY, 1985, SCIENCE, V230, P570, DOI 10.1126/science.2996140; CHEN ISY, 1983, P NATL ACAD SCI-BIOL, V80, P7006, DOI 10.1073/pnas.80.22.7006; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CHU G, 1981, GENE, V13, P197, DOI 10.1016/0378-1119(81)90008-1; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; FROMM M, 1985, P NATL ACAD SCI USA, V82, P5824, DOI 10.1073/pnas.82.17.5824; GAZDAR AF, 1980, BLOOD, V55, P409; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KITADO H, 1987, SCIENCE, V235, P901, DOI 10.1126/science.3027896; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; LIANYING LY, 1984, CHIN ANTIBIOT, V9, P450; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; RALPH P, 1976, J EXP MED, V143, P1528, DOI 10.1084/jem.143.6.1528; ROSENBLATT JD, 1988, IN PRESS SCIENCE; SCHAFFNER W, 1980, P NATL ACAD SCI-BIOL, V77, P2163, DOI 10.1073/pnas.77.4.2163; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; SHAH NP, 1986, MOL CELL BIOL, V6, P3626, DOI 10.1128/MCB.6.11.3626; SHIVAROVA N, 1983, Z ALLG MIKROBIOL, V23, P595, DOI 10.1002/jobm.3630230915; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; YOSHIYAMA H, 1986, JPN J CANCER RES, V77, P514	37	155	160	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1988	3	1					123	128						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	P0354					2022-12-17	WOS:A1988P035400017
J	Hawinkels, LJAC; Paauwe, M; Verspaget, HW; Wiercinska, E; van der Zon, JM; van der Ploeg, K; Koelink, PJ; Lindeman, JHN; Mesker, W; ten Dijke, P; Sier, CFM				Hawinkels, L. J. A. C.; Paauwe, M.; Verspaget, H. W.; Wiercinska, E.; van der Zon, J. M.; van der Ploeg, K.; Koelink, P. J.; Lindeman, J. H. N.; Mesker, W.; ten Dijke, P.; Sier, C. F. M.			Interaction with colon cancer cells hyperactivates TGF-beta signaling in cancer-associated fibroblasts	ONCOGENE			English	Article						CAF; colorectal cancer; MMP; signaling; TGF-beta; tumor microenvironment	GROWTH-FACTOR-BETA; MUSCLE ACTIN EXPRESSION; MYOFIBROBLAST DIFFERENTIATION; CELLULAR-LOCALIZATION; MAMMARY-GLAND; BREAST-CANCER; TUMOR-CELLS; ACTIVATION; TGF-BETA-1; CARCINOMA	The interaction between epithelial cancer cells and cancer-associated fibroblasts (CAFs) has a major role in cancer progression and eventually in metastasis. In colorectal cancer (CRC), CAFs are present in high abundance, but their origin and functional interaction with epithelial tumor cells has not been elucidated. In this study we observed strong activation of the transforming growth factor-beta (TGF-beta)/ Smad signaling pathway in CRC CAFs, accompanied by decreased signaling in epithelial tumor cells. We evaluated the TGF-beta 1 response and the expression of target genes including matrix metalloproteinases (MMPs) and plasminogen activator inhibitor (PAI)-1 of various epithelial CRC cell lines and primary CAFs in vitro. TGF-beta 1 stimulation caused high upregulation of MMPs, PAI-1 and TGF-beta 1 itself. Next we showed that incubation of CAFs with conditioned medium (CM) from epithelial cancer cells led to hyperactivation of the TGF-beta signaling pathway, enhanced expression of target genes like PAI-1, and the expression of alpha-smooth muscle actin (alpha-SMA). We propose that the interaction of tumor cells with resident fibroblasts results in hyperactivated TGF-beta 1 signaling and subsequent transdifferentiation of the fibroblasts into alpha-SMA-positive CAFs. In turn this leads to cumulative production of TGF-beta and proteinases within the tumor microenvironment, creating a cancer-promoting feedback loop.	[Hawinkels, L. J. A. C.; Verspaget, H. W.; van der Zon, J. M.; Koelink, P. J.; Sier, C. F. M.] Leiden Univ, Med Ctr, Dept Gastroenterol Hepatol, NL-2300 RC Leiden, Netherlands; [Hawinkels, L. J. A. C.; Paauwe, M.; Wiercinska, E.; van der Ploeg, K.; ten Dijke, P.] Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2300 RC Leiden, Netherlands; [Hawinkels, L. J. A. C.; Paauwe, M.; Wiercinska, E.; van der Ploeg, K.; ten Dijke, P.] Leiden Univ, Med Ctr, Ctr Biomed Genet, NL-2300 RC Leiden, Netherlands; [Lindeman, J. H. N.] Leiden Univ, Med Ctr, Dept Vasc Surg, NL-2300 RC Leiden, Netherlands; [Mesker, W.; Sier, C. F. M.] Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands; [ten Dijke, P.] Uppsala Univ, Ludwig Inst Canc Res, Uppsala, Sweden	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Ludwig Institute for Cancer Research; Uppsala University	Hawinkels, LJAC (corresponding author), Leiden Univ, Med Ctr, Dept Mol Cell Biol, Bldg 2,S1-P,POB 9600, NL-2300 RC Leiden, Netherlands.	L.J.A.C.Hawinkels@LUMC.nl	Sier, Cornelis/A-7664-2008; Paauwe, Madelon/C-8244-2018; Dijke, Peter ten/AAG-4660-2021; Hawinkels, Lukas/Q-5098-2019	Sier, Cornelis/0000-0002-4337-2758; Dijke, Peter ten/0000-0002-7234-342X; Hawinkels, Lukas/0000-0002-2274-9325; Wiercinska, Eliza/0000-0002-8434-6492	EC [090773]; Bas Mulder Award [UL2011-5051]	EC(European CommissionEuropean Commission Joint Research Centre); Bas Mulder Award	We thank Dr R Hanemaaijer (TNO Quality of Life BioSciences, Leiden, The Netherlands) for helpful suggestions and reagents. Eveline de Jonge-Muller (Department of Gastroenterology-Hepatology, LUMC), Adri Mulder-Stapel (TNO) and Gabi van Pelt (Department Surgery, LUMC) are acknowledged for excellent technical support. This work was supported by the EC Tumor-host genomic project, the Centre for Biomedical Genetics, the Swedish Cancer Fonden 090773 (EW, PtD) and the Bas Mulder Award 2011 (LJACH, MP, UL2011-5051).	Adegboyega PA, 2002, ARCH PATHOL LAB MED, V126, P829; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Barcellos-Hoff MH, 2000, BREAST CANCER RES, V2, P92, DOI 10.1186/bcr40; BARCELLOSHOFF MH, 1994, J CLIN INVEST, V93, P892, DOI 10.1172/JCI117045; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Cirri P, 2012, CANCER METAST REV, V31, P195, DOI 10.1007/s10555-011-9340-x; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Dooley S, 2003, GASTROENTEROLOGY, V125, P178, DOI 10.1016/S0016-5085(03)00666-8; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Ge GX, 2006, J CELL BIOL, V175, P111, DOI 10.1083/jcb.200606058; Hawinkels LJAC, 2007, BRIT J CANCER, V97, P398, DOI 10.1038/sj.bjc.6603877; Hawinkels LJAC, 2008, EUR J CANCER, V44, P1904, DOI 10.1016/j.ejca.2008.06.031; Hawinkels LJAC, 2007, BIOCHEM BIOPH RES CO, V364, P549, DOI 10.1016/j.bbrc.2007.10.032; Hawinkels LJAC, 2011, GROWTH FACTORS, V29, P140, DOI 10.3109/08977194.2011.595411; Hawinkels LJAC, 2010, CANCER RES, V70, P4141, DOI 10.1158/0008-5472.CAN-09-4466; Hawinkels LJAC, 2009, CANCER SCI, V100, P663, DOI 10.1111/j.1349-7006.2009.01100.x; Huet E, 2008, FASEB J, V22, P1144, DOI 10.1096/fj.07-8748com; Jenkins G, 2008, INT J BIOCHEM CELL B, V40, P1068, DOI 10.1016/j.biocel.2007.11.026; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kankuri E, 2005, CANCER RES, V65, P9914, DOI 10.1158/0008-5472.CAN-05-1559; Kankuri E, 2008, INT J CANCER, V122, P1243, DOI 10.1002/ijc.23179; Kunz-Schughart LA, 2001, EXP CELL RES, V266, P74, DOI 10.1006/excr.2001.5210; Leivonen SK, 2007, INT J CANCER, V121, P2119, DOI 10.1002/ijc.23113; Lewis MP, 2004, BRIT J CANCER, V90, P822, DOI 10.1038/sj.bjc.6601611; Lieubeau B, 1999, INT J CANCER, V81, P629, DOI 10.1002/(SICI)1097-0215(19990517)81:4<629::AID-IJC20>3.3.CO;2-#; Lindeman JHN, 2004, AM J PATHOL, V165, P593, DOI 10.1016/S0002-9440(10)63323-8; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; Mesker WE, 2007, CELL ONCOL, V29, P387; Meulmeester E, 2011, J PATHOL, V223, P205, DOI 10.1002/path.2785; Micke P, 2004, LUNG CANCER, V45, pS163, DOI 10.1016/j.lungcan.2004.07.977; Munoz NM, 2006, CANCER RES, V66, P9837, DOI 10.1158/0008-5472.CAN-06-0890; Nishimura SL, 2009, AM J PATHOL, V175, P1362, DOI 10.2353/ajpath.2009.090393; Pardali E, 2011, ONCOGENE, V30, P334, DOI 10.1038/onc.2010.418; Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Pourreyron C, 2003, INT J CANCER, V104, P28, DOI 10.1002/ijc.10898; Powell DW, 2005, AM J PHYSIOL-GASTR L, V289, pG2, DOI 10.1152/ajpgi.00075.2005; RONNOVJESSEN L, 1995, J CLIN INVEST, V95, P859, DOI 10.1172/JCI117736; Ruiter D, 2002, LANCET ONCOL, V3, P35, DOI 10.1016/S1470-2045(01)00620-9; Shephard P, 2004, AM J PATHOL, V164, P2055, DOI 10.1016/S0002-9440(10)63764-9; Sier CFM, 2008, MATRIX BIOL, V27, P267, DOI 10.1016/j.matbio.2007.10.006; Stolle K, 2005, GENE, V351, P119, DOI 10.1016/j.gene.2005.03.012; ten Dijke P, 2007, NAT REV MOL CELL BIO, V8, P857, DOI 10.1038/nrm2262; Wipff PJ, 2008, EUR J CELL BIOL, V87, P601, DOI 10.1016/j.ejcb.2008.01.012; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Yoshinaga K, 2008, P NATL ACAD SCI USA, V105, P18758, DOI 10.1073/pnas.0805411105	51	154	159	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					97	107		10.1038/onc.2012.536	http://dx.doi.org/10.1038/onc.2012.536			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23208491				2022-12-17	WOS:000329212000011
J	Jung, MJ; Rho, JK; Kim, YM; Jung, JE; Jin, YB; Ko, YG; Lee, JS; Lee, SJ; Lee, JC; Park, MJ				Jung, M-J; Rho, J-K; Kim, Y-M; Jung, J. E.; Jin, Y. B.; Ko, Y-G; Lee, J-S; Lee, S-J; Lee, J. C.; Park, M-J			Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells	ONCOGENE			English	Article						non-small cell lung cancer; cancer stern cell; CXCR4; PI3K/PTEN/Akt/mTOR signaling; STAT3 signaling; tumorigenicity	GROWTH-FACTOR; CHEMOKINE RECEPTOR-4; TUMOR-GROWTH; EXPRESSION; IDENTIFICATION; ACTIVATION; A549; PROLIFERATION; POPULATION; INVASION	The hypothesis of cancer stem cells has been proposed to explain the therapeutic failure in a variety of cancers including lung cancers. Previously, we demonstrated acquisition of epithelial-mesenchymal transition, a feature highly reminiscent of cancer stem-like cells, in gefitinib-resistant A549 cells (A549/GR). Here, we show that A549/GR cells contain a high proportion of CXCR4+ cells that are responsible for having high potential of self-renewal activity in vitro and tumorigenicity in vivo. A549/GR cells exhibited strong sphere-forming activity and high CXCR4 expression and SDF-1 alpha secretion compared with parent cells. Pharmacological inhibition (AMD3100) and/or siRNA transfection targeting CXCR4 significantly suppressed sphere-forming activity in A549 and A549/GR cells, and in various non-small cell lung cancer (NSCLC) cell lines. A549/GR cells showed enhanced Akt, mTOR and STAT3 (Y705) phosphorylation. Pharmacological inhibition of phosphatidyl inositol 3-kinase or transfection with wild-type PTEN suppressed phosphorylation of Akt, mTOR and STAT3 (Y705), sphere formation, and CXCR4 expression in A549/GR cells, whereas mutant PTEN enhanced these events. Inhibition of STAT3 by WP1066 or siSTAT3 significantly suppressed the sphere formation, but not CXCR4 expression, indicating that STAT3 is a downstream effector of CXCR4-mediated signaling. FACS-sorted CXCR4+ A549/GR cells formed many large spheres, had self-renewal capacity, demonstrated radiation resistance in vitro and exhibited stronger tumorigenic potential in vivo than CXCR4 cells. Lentiviral-transduction of CXCR4 enhanced sphere formation and tumorigenicity in H460 and A549 cells, whereas introduction of siCXCR4 suppressed these activities in A549/GR cells. Our data indicate that CXCR4 NSCLC cells are strong candidates for tumorigenic stem-like cancer cells that maintain sternness through a CXCR4-medated STAT3 pathway and provide a potential therapeutic target for eliminating these malignant cells in NSCLC. Oncogene (2013) 32, 209-221; doi:10.1038/onc.2012.37; published online 27 February 2012	[Jung, M-J; Kim, Y-M; Jung, J. E.; Lee, J-S; Park, M-J] Korea Inst Radiol & Med Sci, Div Radiat Canc Res, Seoul 139706, South Korea; [Jung, M-J; Kim, Y-M; Ko, Y-G] Korea Univ, Coll Life Sci & Biotechnol, Seoul, South Korea; [Rho, J-K] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pulm & Crit Care Med, Seoul 138736, South Korea; [Jin, Y. B.] Korea Inst Radiol & Med Sci, Div Radiat Effect, Seoul 139706, South Korea; [Lee, S-J] Hanyang Univ, Dept Chem, Seoul 133791, South Korea; [Lee, S-J] Hanyang Univ, Res Inst Nat Sci, Seoul 133791, South Korea; [Lee, J. C.] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul 138736, South Korea	Korea Institute of Radiological & Medical Sciences; Korea University; University of Ulsan; Asan Medical Center; Korea Institute of Radiological & Medical Sciences; Hanyang University; Hanyang University; University of Ulsan; Asan Medical Center	Park, MJ (corresponding author), Korea Inst Radiol & Med Sci, Div Radiat Canc Res, 215-4 Gongneung Dong, Seoul 139706, South Korea.	jclee@amc.seoul.kr; mjpark@kcch.re.kr	Lee, Jae Cheol/AAA-2678-2021		Mid-career Researcher Program through NRF [2009-0086438]; Nuclear Research and Development Program of Korea Science and Engineering foundation; Korean government (MEST) [2011-0030604]	Mid-career Researcher Program through NRF(National Research Foundation of Korea); Nuclear Research and Development Program of Korea Science and Engineering foundation; Korean government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government)	This work was supported by the Mid-career Researcher Program through NRF grant (2009-0086438) and the Nuclear Research and Development Program of Korea Science and Engineering foundation funded by the Korean government (MEST) (2011-0030604).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Belperio JA, 2004, CHEST, V125, p156S, DOI 10.1378/chest.125.5_suppl.156S; Bertolini G, 2009, P NATL ACAD SCI USA, V106, P16281, DOI 10.1073/pnas.0905653106; Burger M, 2003, ONCOGENE, V22, P8093, DOI 10.1038/sj.onc.1207097; Chen YC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002637; Cho HH, 2006, STEM CELLS DEV, V15, P853, DOI 10.1089/scd.2006.15.853; Ehtesham M, 2009, CANCER LETT, V274, P305, DOI 10.1016/j.canlet.2008.09.034; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Furusato B, 2010, PATHOL INT, V60, P497, DOI 10.1111/j.1440-1827.2010.02548.x; Gilbert CA, 2009, J CELL BIOCHEM, V108, P1031, DOI 10.1002/jcb.22350; Gutova M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000243; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Ho MM, 2007, CANCER RES, V67, P4827, DOI 10.1158/0008-5472.CAN-06-3557; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Jiang F, 2009, MOL CANCER RES, V7, P330, DOI 10.1158/1541-7786.MCR-08-0393; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Kalatskaya I, 2009, MOL PHARMACOL, V75, P1240, DOI 10.1124/mol.108.053389; Kato M, 2003, BREAST CANCER RES, V5, pR144, DOI 10.1186/bcr627; Kijima T, 2002, CANCER RES, V62, P6304; Kim J, 2005, J CLIN ONCOL, V23, P2744, DOI 10.1200/JCO.2005.07.078; Krohn A, 2009, CANCER LETT, V280, P65, DOI 10.1016/j.canlet.2009.02.005; Lam WK, 2007, RESPIROLOGY, V12, P471, DOI 10.1111/j.1440-1843.2007.01105.x; Lancaster GI, 2005, J BIOL CHEM, V280, P23349, DOI 10.1074/jbc.M502017200; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Levina V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003077; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Miki J, 2007, CANCER RES, V67, P3153, DOI 10.1158/0008-5472.CAN-06-4429; Na IK, 2008, HUM PATHOL, V39, P1751, DOI 10.1016/j.humpath.2008.04.017; Nickel W, 2010, CURR OPIN BIOTECH, V21, P621, DOI 10.1016/j.copbio.2010.06.004; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Park CM, 2006, CANCER RES, V66, P8511, DOI 10.1158/0008-5472.CAN-05-4340; Pfeiffer M, 2009, BRIT J CANCER, V100, P1949, DOI 10.1038/sj.bjc.6605068; Phillips RJ, 2005, J BIOL CHEM, V280, P22473, DOI 10.1074/jbc.M500963200; Rho JK, 2009, LUNG CANCER, V63, P219, DOI 10.1016/j.lungcan.2008.05.017; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Santer FR, 2006, CANCER RES, V66, P3024, DOI 10.1158/0008-5472.CAN-05-2013; Schimanski CC, 2006, BRIT J CANCER, V95, P210, DOI 10.1038/sj.bjc.6603251; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Su LP, 2005, CLIN CANCER RES, V11, P8273, DOI 10.1158/1078-0432.CCR-05-0537; Sung JM, 2008, BIOCHEM BIOPH RES CO, V371, P163, DOI 10.1016/j.bbrc.2008.04.038; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Teng Y, 2010, BIOCHEM BIOPH RES CO, V392, P373, DOI 10.1016/j.bbrc.2010.01.028; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499	44	154	159	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2013	32	2					209	221		10.1038/onc.2012.37	http://dx.doi.org/10.1038/onc.2012.37			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22370645				2022-12-17	WOS:000314075500009
J	Geraldo, MV; Yamashita, AS; Kimura, ET				Geraldo, M. V.; Yamashita, A. S.; Kimura, E. T.			MicroRNA miR-146b-5p regulates signal transduction of TGF-beta by repressing SMAD4 in thyroid cancer	ONCOGENE			English	Article						microRNA; TGF-beta; papillary thyroid carcinoma	GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; TRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; PCCL3 CELLS; ACTIVIN-A; THYROTROPIN; ONCOGENE; DIFFERENTIATION; METASTASIS	MicroRNAs (miRNA) are small non-coding RNAs involved in post-transcriptional gene regulation that have crucial roles in several types of tumors, including papillary thyroid carcinoma (PTC). miR-146b-5p is overexpressed in PTCs and is regarded as a relevant diagnostic marker for this type of cancer. A computational search revealed that miR-146b-5p putatively binds to the 3' untranslated region (UTR) of SMAD4, an important member of the transforming growth factor beta (TGF-beta) signaling pathway. The TGF-beta pathway is a negative regulator of thyroid follicular cell growth, and the mechanism by which thyroid cancer cells evade its inhibitory signal remains unclear. We questioned whether the modulation of the TGF-beta pathway by miR-146b-5p can contribute to thyroid tumorigenesis. Luciferase reporter assay confirmed the direct binding of miR-146b-5p on the SMAD4 3'UTR. Specific inhibition of miR-146b-5p with a locked nucleic acid-modified anti-miR-146b oligonucleotide significantly increased SMAD4 levels in the human papillary carcinoma cell lines, TPC-1 and BCPAP. Moreover, suppression of miR-146b-5p increased the cellular response to the TGF-beta anti-proliferative signal, significantly decreasing the proliferation rate. The overexpression of miR-146b-5p in normal rat follicular PCCL3 cells decreased SMAD4 levels and disrupted TGF-beta signal transduction. MiR-146b-5p overexpression in PCCL3 cells also significantly increased cell proliferation in the absence of thyroid-stimulating hormone and conferred resistance to TGF-beta-mediated cell-cycle arrest. Additionally, the activation of thyroid most common oncogenes RET/PTC3 and BRAF in PCCL3 cells upregulated miR-146b-5p expression. Our results confirm the oncogenic role of miR-146b-5p in thyroid follicular cells and contribute to knowledge regarding the modulation of TGF-beta signal transduction by miRNAs in PTCs. Oncogene (2012) 31, 1910-1922; doi:10.1038/onc.2011.381; published online 29 August 2011	[Geraldo, M. V.; Yamashita, A. S.; Kimura, E. T.] Univ Sao Paulo, Inst Biomed Sci, Dept Cell & Dev Biol, Sao Paulo, Brazil	Universidade de Sao Paulo	Kimura, ET (corresponding author), Univ Sao Paulo, Dept Cell & Dev Biol, Inst Biomed Sci, Av Prof Lineu Prestes 1524,Room 414, BR-05508000 So Paulo, Brazil.	etkimura@usp.br	Geraldo, Murilo V/F-7211-2013; Geraldo, Murilo V/C-6427-2016; Yamashita, Alex Shimura/B-3772-2013; Kimura, Edna/D-7334-2012	Geraldo, Murilo V/0000-0002-9418-6103; Kimura, Edna/0000-0001-8403-4459	Fundaco de Amparo A Pesquisa do Estado de So Paulo (FAPESP); Conselho Nacional de Desenvolvimento CientUfico e Tecnoloegico (CNPq)	Fundaco de Amparo A Pesquisa do Estado de So Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento CientUfico e Tecnoloegico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF))	We thank Dr Konstantin D Taganov for donation of pcDNA3.1-miR-146b plasmid, Dr Joan MassaguO for donation of p3TP-Lux plasmid, Dr Nancy Carrasco for donation of anti-NIS antibody, Dr Massimo Santoro for BCPAP, and Dr James A Fagin for PCCL3, PCCL3-rtTA, PTC3-5, TPC-1, and ARO cell lines used in this study. This work was supported by Fundaco de Amparo A Pesquisa do Estado de So Paulo (FAPESP) and Conselho Nacional de Desenvolvimento CientUfico e Tecnoloegico (CNPq).	Adeniran AJ, 2006, AM J SURG PATHOL, V30, P216, DOI 10.1097/01.pas.0000176432.73455.1b; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bhaumik D, 2008, ONCOGENE, V27, P5643, DOI 10.1038/onc.2008.171; Cahill S, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-70; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cerutti JM, 2003, J ENDOCRINOL INVEST, V26, P516, DOI 10.1007/BF03345213; Chou CK, 2010, THYROID, V20, P489, DOI 10.1089/thy.2009.0027; Costamagna E, 2004, J BIOL CHEM, V279, P3439, DOI 10.1074/jbc.M307138200; D'Inzeo S, 2010, J MOL ENDOCRINOL, V45, P229, DOI 10.1677/JME-10-0044; Dykxhoorn DM, 2010, CANCER RES, V70, P6401, DOI 10.1158/0008-5472.CAN-10-1346; Ellenrieder V, 2008, ANTICANCER RES, V28, P1531; Ermak G, 2003, ANAL BIOCHEM, V318, P152, DOI 10.1016/S0003-2697(03)00166-0; FABIEN N, 1994, CANCER, V73, P2206, DOI 10.1002/1097-0142(19940415)73:8<2206::AID-CNCR2820730828>3.0.CO;2-M; Fagin JA, 2002, MOL ENDOCRINOL, V16, P903, DOI 10.1210/me.16.5.903; Franzen A, 1999, ENDOCRINOLOGY, V140, P4300, DOI 10.1210/en.140.9.4300; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Garcia-Jimenez C, 2007, ARQ BRAS ENDOCRINOL, V51, P654, DOI 10.1590/S0004-27302007000500003; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021; Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; JHIANG SM, 1992, ONCOGENE, V7, P1331; Kawaguchi A, 1997, THYROID, V7, P789, DOI 10.1089/thy.1997.7.789; Kimura ET, 2003, CANCER RES, V63, P1454; Kimura ET, 1999, THYROID, V9, P119, DOI 10.1089/thy.1999.9.119; Lazzereschi D, 2005, ONCOGENE, V24, P5344, DOI 10.1038/sj.onc.1208603; Ricarte JCM, 2009, TRANSL ONCOL, V2, P236, DOI 10.1593/tlo.09151; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Matsuo SE, 2010, ARQ BRAS ENDOCRINOL, V54, P406, DOI 10.1590/S0004-27302010000400010; Matsuo SE, 2006, J ENDOCRINOL, V190, P141, DOI 10.1677/joe.1.06713; MORRIS JC, 1988, ENDOCRINOLOGY, V123, P1385, DOI 10.1210/endo-123-3-1385; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Nicolussi A, 2003, MOL CELL ENDOCRINOL, V207, P1, DOI 10.1016/S0303-7207(03)00238-7; Nikiforova MN, 2008, J CLIN ENDOCR METAB, V93, P1600, DOI 10.1210/jc.2007-2696; Nikiforova MN, 2009, ENDOCR PATHOL, V20, P85, DOI 10.1007/s12022-009-9069-z; Pacifico F, 2010, J CLIN ENDOCR METAB, V95, P1421, DOI 10.1210/jc.2009-1128; Paire A, 1997, J BIOL CHEM, V272, P18245, DOI 10.1074/jbc.272.29.18245; Pallante P, 2010, ENDOCR-RELAT CANCER, V17, pF91, DOI 10.1677/ERC-09-0217; Palona I, 2006, ENDOCRINOLOGY, V147, P5699, DOI 10.1210/en.2006-0400; Pei XH, 2005, ONCOGENE, V24, P2787, DOI 10.1038/sj.onc.1208611; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Riesco-Eizaguirre G, 2009, CANCER RES, V69, P8317, DOI 10.1158/0008-5472.CAN-09-1248; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; Santoro M, 2002, ANN NY ACAD SCI, V963, P116, DOI 10.1111/j.1749-6632.2002.tb04102.x; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; TATON M, 1993, MOL CELL ENDOCRINOL, V95, P13, DOI 10.1016/0303-7207(93)90024-E; Wang JW, 2003, MOL ENDOCRINOL, V17, P1425, DOI 10.1210/me.2003-0041; Xia HP, 2009, BRAIN RES, V1269, P158, DOI 10.1016/j.brainres.2009.02.037; Yang G, 2010, INT J BIOL SCI, V6, P1; Zhong H, 2010, INT J HEMATOL, V92, P129, DOI 10.1007/s12185-010-0626-5	53	154	156	0	32	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	15					1910	1922		10.1038/onc.2011.381	http://dx.doi.org/10.1038/onc.2011.381			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	926CW	21874046				2022-12-17	WOS:000302809900004
J	Jelassi, B; Chantome, A; Alcaraz-Perez, F; Baroja-Mazo, A; Cayuela, ML; Pelegrin, P; Surprenant, A; Roger, S				Jelassi, B.; Chantome, A.; Alcaraz-Perez, F.; Baroja-Mazo, A.; Cayuela, M. L.; Pelegrin, P.; Surprenant, A.; Roger, S.			P2X(7) receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness	ONCOGENE			English	Article						P2X(7) receptors; migration; SK3 channels; cancer cell invasion; cystein cathepsins	GATED SODIUM-CHANNELS; EPITHELIAL-CELLS; P2X7 RECEPTOR; ATP RECEPTOR; EXPRESSION; CALCIUM; POLYMORPHISM; MACROPHAGES; PROGRESSION; MECHANISM	ATP-gated P2X(7) receptors (P2X(7)R) are unusual plasma membrane ion channels that have been extensively studied in immune cells. More recently, P2X(7)R have been described as potential cancer cell biomarkers. However, mechanistic links between P2X(7)R and cancer cell processes are unknown. Here, we show, in the highly aggressive human breast cancer cell line MDA-MB-435s, that P2X(7) receptor is highly expressed and fully functional. Its activation is responsible for the extension of neurite-like cellular prolongations, of the increase in cell migration by 35% and in cell invasion through extracellular matrix by 150%. The change in cancer cell morphology and the increased migration appeared to be due to the activation of Ca2+-activated SK3 potassium channels. The enhanced invasion through the extracellular matrix was related to the increase of mature forms of cysteine cathepsins in the extracellular medium, which was independent of SK3 channel activity and not associated with cell death. Pharmacological targeting of P2X(7)R in vivo was crucial for cell invasiveness in a zebrafish model of metastases. Our results demonstrate a novel mechanistic link between P2X(7)R functionality in cancer cells and invasiveness, a key parameter in tumour growth and in the development of metastases. They also suggest a potential therapeutic role for the newly developed P2X(7)R antagonists. Oncogene (2011) 30, 2108-2122; doi:10.1038/onc.2010.593; published online 17 January 2011	[Jelassi, B.; Chantome, A.; Roger, S.] Univ Tours, INSERM, U921, F-37032 Tours, France; [Alcaraz-Perez, F.; Cayuela, M. L.] Univ Hosp Virgen Arrixaca FFIS, Canc & Aging Grp, Carretera Palmar, Murcia, Spain; [Baroja-Mazo, A.; Pelegrin, P.] Univ Hosp Virgen Arrixaca FFIS, Inflammat & Expt Surg Grp, Carretera Palmar, Murcia, Spain; [Pelegrin, P.; Surprenant, A.] Univ Manchester, Fac Life Sci, Manchester, Lancs, England	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; University of Manchester	Roger, S (corresponding author), Univ Tours, INSERM, U921, 10 Blvd Tonnelle, F-37032 Tours, France.	sebastien.roger@univ-tours.fr	Pelegrin, Pablo/M-2007-2014; cayuela, maria l/S-1148-2019; Baroja-Mazo, Alberto/E-6270-2016	Pelegrin, Pablo/0000-0002-9688-1804; Baroja-Mazo, Alberto/0000-0001-5212-5006; Roger, Sebastien/0000-0002-9852-5248; Alcaraz Perez, Francisca/0000-0003-1802-4943	Biotechnology and Biological Sciences Research Council; Ligue Nationale Contre le Cancer Region Centre; Association CANCEN; Ministere de la Recherche et des Technologies; 'Institut National de la Sante et de la Recherche Medicale' (INSERM); 'Partenariat Hubert Curien-Alliance' from the French Foreign and European Ministry; French Embassy in the United Kingdom; Institut National du Cancer (INCa)	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Ligue Nationale Contre le Cancer Region Centre(Ligue nationale contre le cancer); Association CANCEN; Ministere de la Recherche et des Technologies; 'Institut National de la Sante et de la Recherche Medicale' (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); 'Partenariat Hubert Curien-Alliance' from the French Foreign and European Ministry; French Embassy in the United Kingdom; Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France)	We thank Pr Jean-Christophe Pages, Dr Christine Collin and Dr Virginie Joulin for the development of small hairpin RNA cell lines, Elizabeth Martin, Mari C. Banos, Encarnacion Sanchez and Isabelle Domingo for technical assistance. We are grateful to Pr Gilles Lalmanach for helpful discussions and Pierre-Yves Sizaret for his help with confocal microscopy. We thank Dr Michael Jarvis (Abbott Laboratories, USA) for the generous gift of A740003. This work was supported by the Biotechnology and Biological Sciences Research Council, by a grant from the 'Ligue Nationale Contre le Cancer Region Centre', the 'Association CANCEN', the 'Ministere de la Recherche et des Technologies', the 'Institut National de la Sante et de la Recherche Medicale' (INSERM) and the 'Partenariat Hubert Curien-Alliance' from the French Foreign and European Ministry and the French Embassy in the United Kingdom. A C was funded by the 'Institut National du Cancer (INCa)'.	Adinolfi E, 2005, MOL BIOL CELL, V16, P3260, DOI 10.1091/mbc.E04-11-1025; Adinolfi E, 2002, BLOOD, V99, P706, DOI 10.1182/blood.V99.2.706; Adinolfi E, 2010, FASEB J, V24, P3393, DOI 10.1096/fj.09-153601; Burnstock G, 2006, BRIT J PHARMACOL, V147, pS172, DOI 10.1038/sj.bjp.0706429; Cabrini G, 2005, J IMMUNOL, V175, P82, DOI 10.4049/jimmunol.175.1.82; Chantome A, 2009, EXP CELL RES, V315, P3620, DOI 10.1016/j.yexcr.2009.07.021; Deli T, 2007, INT J CANCER, V121, P55, DOI 10.1002/ijc.22621; Di Virgilio F, 1998, CELL DEATH DIFFER, V5, P191; Di Virgilio F, 2009, PURINERG SIGNAL, V5, P251, DOI 10.1007/s11302-009-9145-3; Donnelly-Roberts DL, 2007, BRIT J PHARMACOL, V151, P571, DOI 10.1038/sj.bjp.0707265; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Frosch BA, 1999, APMIS, V107, P28, DOI 10.1111/j.1699-0463.1999.tb01523.x; Gillet L, 2009, J BIOL CHEM, V284, P8671, DOI 10.1074/jbc.M806891200; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hibell AD, 2000, BRIT J PHARMACOL, V130, P167, DOI 10.1038/sj.bjp.0703302; Jedeszko C, 2004, BIOL CHEM, V385, P1017, DOI 10.1515/BC.2004.132; Li X, 2006, CANCER EPIDEM BIOMAR, V15, P1906, DOI 10.1158/1055-9965.EPI-06-0407; Lopez-Castejon G, 2010, J IMMUNOL, V185, P2611, DOI 10.4049/jimmunol.1000436; Marques IJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-128; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378; Pellegatti P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002599; Potier M, 2006, MOL CANCER THER, V5, P2946, DOI 10.1158/1535-7163.MCT-06-0194; Potier M, 2010, BIOCHEM BIOPH RES CO, V397, P42, DOI 10.1016/j.bbrc.2010.05.046; Raffaghello L, 2006, CANCER RES, V66, P907, DOI 10.1158/0008-5472.CAN-05-3185; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93; Roger B, 2008, J NEUROSCI, V28, P6393, DOI 10.1523/JNEUROSCI.0696-08.2008; Roger S, 2007, INT J BIOCHEM CELL B, V39, P774, DOI 10.1016/j.biocel.2006.12.007; Roger S, 2006, CURR PHARM DESIGN, V12, P3681, DOI 10.2174/138161206778522047; Roger S, 2010, J BIOL CHEM, V285, P17514, DOI 10.1074/jbc.M109.053082; Roger S, 2010, J PSYCHIATR RES, V44, P347, DOI 10.1016/j.jpsychires.2009.10.005; Roshy S, 2003, CANCER METAST REV, V22, P271, DOI 10.1023/A:1023007717757; Shemon AN, 2006, J BIOL CHEM, V281, P2079, DOI 10.1074/jbc.M507816200; Slater M, 2005, J MOL HISTOL, V36, P159, DOI 10.1007/s10735-004-6166-7; Slater M, 2004, HISTOPATHOLOGY, V44, P206, DOI 10.1111/j.0309-0167.2004.01798.x; Slater M, 2004, BREAST CANCER RES TR, V83, P1, DOI 10.1023/B:BREA.0000010670.85915.0f; Solini A, 2008, ENDOCRINOLOGY, V149, P389, DOI 10.1210/en.2007-1223; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Wang QF, 2004, AM J PHYSIOL-CELL PH, V287, pC1349, DOI 10.1152/ajpcell.00256.2004; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Zhang XJ, 2004, LEUKEMIA RES, V28, P1313, DOI 10.1016/j.leukres.2004.04.001	43	154	157	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	18					2108	2122		10.1038/onc.2010.593	http://dx.doi.org/10.1038/onc.2010.593			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	759ML	21242969				2022-12-17	WOS:000290249600003
J	Lagadec, C; Meignan, S; Adriaenssens, E; Foveau, B; Vanhecke, E; Romon, R; Toillon, RA; Oxombre, B; Hondermarck, H; Le Bourhis, X				Lagadec, C.; Meignan, S.; Adriaenssens, E.; Foveau, B.; Vanhecke, E.; Romon, R.; Toillon, R-A; Oxombre, B.; Hondermarck, H.; Le Bourhis, X.			TrkA overexpression enhances growth and metastasis of breast cancer cells	ONCOGENE			English	Article						neurotrophins; tyrosine kinase receptors; anoikis	FACTOR RECEPTOR; NEUROTROPHIN RECEPTORS; SIGNALING PATHWAYS; FACTOR EXPRESSION; PROSTATE-CANCER; SINGLE-AGENT; CARCINOMA; SURVIVAL; ANOIKIS; ACTIVATION	The Trk family of neurotrophin tyrosine kinase receptors is emerging as an important player in carcinogenic progression in non-neuronal tissues. Here, we show that breast tumors present high levels of TrkA and phospho-TrkA compared to normal breast tissues. To further evaluate the precise functions of TrkA overexpression in breast cancer development, we have performed a series of biological tests using breast cancer cells that stablyov erexpress TrkA. We show that ( 1) TrkA overexpression promoted cell growth, migration and invasion in vitro; ( 2) overexpression of TrkA per se conferred constitutive activation of its tyrosine kinase activity; ( 3) signal pathways including PI3K-Akt and ERK/p38 MAP kinases were activated byTrkA overexpression and were required for the maintenance of a more aggressive cellular phenotype; and ( 4) TrkA overexpression enhanced tumor growth, angiogenesis and metastasis of xenografted breast cancer cells in immunode efficient mice. Moreover, recovered metastatic cells from the lungs exhibited enhanced anoikis resistance that was abolished by the pharmacological inhibitor K252a, suggesting that TrkA-promoted breast tumor metastasis could be mediated at least in part by enhancing anoikis resistance. Together, these results provide the first direct evidence that TrkA overexpression enhances the tumorigenic properties of breast cancer cells and point to TrkA as a potential target in breast cancer therapy. Oncogene ( 2009) 28, 1960-1970; doi:10.1038/onc.2009.61; published online 30 March 2009	[Lagadec, C.; Meignan, S.; Adriaenssens, E.; Foveau, B.; Vanhecke, E.; Romon, R.; Toillon, R-A; Oxombre, B.; Hondermarck, H.; Le Bourhis, X.] Univ Lille 1, INSERM, U908, IFR 147, F-59655 Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Le Bourhis, X (corresponding author), Univ Lille 1, INSERM, U908, IFR 147, Batiment SN3, F-59655 Villeneuve Dascq, France.	xuefen.lebourhis@univ-lille1.fr	Toillon, Robert-Alain/Q-2286-2018; Meignan, Samuel/E-9628-2017; Lagadec, chann/E-4250-2010; Le+Bourhis, Xuefen/AAL-5141-2021	Toillon, Robert-Alain/0000-0001-5483-2118; Lagadec, chann/0000-0002-5182-2069; 	la Ligue Nationale Contre le Cancer; INSERM; le Ministere de l'Education Nationale and la Region Nord/Pas-de-Calais	la Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); le Ministere de l'Education Nationale and la Region Nord/Pas-de-Calais(Region Hauts-de-France)	We acknowledge the excellent technical assistance of Isabelle Lefebvre. This work was supported by la Ligue Nationale Contre le Cancer ( Equipe Labellisee 2009), INSERM, le Ministere de l'Education Nationale and la Region Nord/Pas-de-Calais plus the FEDER.	Adriaenssens E, 2008, CANCER RES, V68, P346, DOI 10.1158/0008-5472.CAN-07-1183; Aragona M, 2001, CANCER INVEST, V19, P692, DOI 10.1081/CNV-100106144; Campos X, 2007, GYNECOL ONCOL, V104, P168, DOI 10.1016/j.ygyno.2006.07.007; Cantarella G, 2002, FASEB J, V16, P1307, DOI 10.1096/fj.01-1000fje; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; Chiarenza A, 2001, CANCER RES, V61, P3002; Davidson B, 2004, BREAST CANCER RES TR, V83, P119, DOI 10.1023/B:BREA.0000010704.17479.8a; Davidson B, 2003, CLIN CANCER RES, V9, P2248; Descamps S, 2001, CANCER RES, V61, P4337; Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200; Dolle L, 2003, ONCOGENE, V22, P5592, DOI 10.1038/sj.onc.1206805; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Geiger TR, 2007, CANCER RES, V67, P6221, DOI 10.1158/0008-5472.CAN-07-0121; Hedley BD, 2008, CLIN EXP METASTAS, V25, P727, DOI 10.1007/s10585-008-9184-0; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; McGregor LM, 1999, P NATL ACAD SCI USA, V96, P4540, DOI 10.1073/pnas.96.8.4540; Mercurio AM, 2005, J MAMMARY GLAND BIOL, V10, P283, DOI 10.1007/s10911-006-9001-9; Muka J, 2003, VITAM HORM, V66, P385, DOI 10.1016/S0083-6729(03)01011-2; Nakanishi K, 2002, CANCER RES, V62, P2971; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894; Rennebeck G, 2005, CANCER RES, V65, P11230, DOI 10.1158/0008-5472.CAN-05-2763; Ricci A, 2001, AM J RESP CELL MOL, V25, P439, DOI 10.1165/ajrcmb.25.4.4470; Sawaki M, 2004, TUMORI J, V90, P40, DOI 10.1177/030089160409000110; Shen XD, 2004, AM J PATHOL, V165, P1315, DOI 10.1016/S0002-9440(10)63390-1; Tacconelli A, 2004, CANCER CELL, V6, P347, DOI 10.1016/j.ccr.2004.09.011; Tagliabue E, 2000, J BIOL CHEM, V275, P5388, DOI 10.1074/jbc.275.8.5388; Ursini-Siegel J, 2007, NAT REV CANCER, V7, P389, DOI 10.1038/nrc2127; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Weeraratna AT, 2000, PROSTATE, V45, P140, DOI 10.1002/1097-0045(20001001)45:2<140::AID-PROS8>3.0.CO;2-#; Zhu ZW, 1999, J CLIN ONCOL, V17, P2419, DOI 10.1200/JCO.1999.17.8.2419	31	154	159	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2009	28	18					1960	1970		10.1038/onc.2009.61	http://dx.doi.org/10.1038/onc.2009.61			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442DT	19330021				2022-12-17	WOS:000265820900003
J	Kwei, KA; Kim, YH; Girard, L; Kao, J; Pacyna-Gengelbach, M; Salari, K; Lee, J; Choi, YL; Sato, M; Wang, P; Hernandez-Boussard, T; Gazdar, AF; Petersen, I; Minna, JD; Pollack, JR				Kwei, K. A.; Kim, Y. H.; Girard, L.; Kao, J.; Pacyna-Gengelbach, M.; Salari, K.; Lee, J.; Choi, Y-L; Sato, M.; Wang, P.; Hernandez-Boussard, T.; Gazdar, A. F.; Petersen, I.; Minna, J. D.; Pollack, J. R.			Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer	ONCOGENE			English	Article						TITF1; lineage-specific oncogene; genomic profiling; lung cancer; TTF-1; NKX2-1	TRANSCRIPTION FACTOR-I; COPY NUMBER ALTERATION; GENE-EXPRESSION; BREAST-CANCER; PROSTATE-CANCER; REVEALS; ADENOCARCINOMAS; AMPLIFICATION; DEPENDENCY; MICROARRAY	Lung cancer is a leading cause of cancer death, where the amplification of oncogenes contributes to tumorigenesis. Genomic pro. ling of 128 lung cancer cell lines and tumors revealed frequent focal DNA amplification at cytoband 14q13.3, a locus not amplified in other tumor types. The smallest region of recurrent amplification spanned the homeobox transcription factor TITF1 (thyroid transcription factor 1; also called NKX2-1), previously linked to normal lung development and function. When amplified, TITF1 exhibited increased expression at both the RNA and protein levels. Small interfering RNA (siRNA)mediated knockdown of TITF1 in lung cancer cell lines with amplification led to reduced cell proliferation, manifested by both decreased cell-cycle progression and increased apoptosis. Our findings indicate that TITF1 amplification and overexpression contribute to lung cancer cell proliferation rates and survival and implicate TITF1 as a lineage-specific oncogene in lung cancer.	[Pollack, J. R.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Girard, L.; Sato, M.; Gazdar, A. F.; Minna, J. D.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; [Pacyna-Gengelbach, M.; Petersen, I.] Univ Hosp Charite, Inst Pathol, Berlin, Germany; [Salari, K.; Hernandez-Boussard, T.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Choi, Y-L] Sungkyunkwan Univ, Samsung Med Ctr, Dept Pathol, Seoul, South Korea; [Wang, P.] Univ Washington, Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98195 USA	Stanford University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Stanford University; Sungkyunkwan University (SKKU); Samsung Medical Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Pollack, JR (corresponding author), Stanford Univ, Sch Med, Dept Pathol, CCSR-3245A,269 Campus Dr, Stanford, CA 94305 USA.	pollack1@stanford.edu	Sato, MITSUO/I-7280-2014	Sato, MITSUO/0000-0001-5458-9576	NATIONAL CANCER INSTITUTE [R01CA097139, P50CA070907, T32CA009151] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA070907-11, R01 CA097139-02, T32 CA009151-31, T32 CA009151, P50 CA070907-10, R01 CA97139, T32 CA09151, R01 CA097139, P50CA70907, P50 CA070907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bashyam MD, 2005, NEOPLASIA, V7, P556, DOI 10.1593/neo.04586; Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366; Birmingham A, 2006, NAT METHODS, V3, P199, DOI 10.1038/NMETH854; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; Holst F, 2007, NAT GENET, V39, P655, DOI 10.1038/ng2006; Jackson AL, 2006, RNA, V12, P1197, DOI 10.1261/rna.30706; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kao J, 2006, GENE CHROMOSOME CANC, V45, P761, DOI 10.1002/gcc.20339; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lapointe J, 2007, CANCER RES, V67, P8504, DOI 10.1158/0008-5472.CAN-07-0673; Lechner JF, 2001, RADIAT RES, V155, P235, DOI 10.1667/0033-7587(2001)155[0235:PCDTMA]2.0.CO;2; Miccadei S, 2002, MOL ENDOCRINOL, V16, P837, DOI 10.1210/me.16.4.837; Minoo P, 1999, DEV BIOL, V209, P60, DOI 10.1006/dbio.1999.9234; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Puglisi F, 1999, MODERN PATHOL, V12, P318; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Sato M, 2007, J THORAC ONCOL, V2, P327, DOI 10.1097/01.JTO.0000263718.69320.4c; Tan DF, 2003, HUM PATHOL, V34, P597, DOI 10.1016/S0046-8177(03)00180-1; Tanaka H, 2007, CANCER RES, V67, P6007, DOI 10.1158/0008-5472.CAN-06-4774; Tian JM, 2006, CANCER RES, V66, P10399, DOI 10.1158/0008-5472.CAN-06-1564; Tibshirani R, 2008, BIOSTATISTICS, V9, P18, DOI 10.1093/biostatistics/kxm013; Travis WD., 2004, TRAVIS WB WHO CLASSI; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010	31	154	160	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2008	27	25					3635	3640		10.1038/sj.onc.1211012	http://dx.doi.org/10.1038/sj.onc.1211012			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18212743	Green Accepted			2022-12-17	WOS:000256468500015
J	Hamer, PCDW; Van Tilborg, AAG; Eijk, PP; Sminia, P; Troost, D; Van Noorden, CJF; Ylstra, B; Leenstra, S				Hamer, P. C. De Witt; Van Tilborg, A. A. G.; Eijk, P. P.; Sminia, P.; Troost, D.; Van Noorden, C. J. F.; Ylstra, B.; Leenstra, S.			The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids	ONCOGENE			English	Article						glioma; primary cell culture; spheroid; comparative genomic hybridization; microarray	IN-VITRO; PRIMARY TUMORS; GLIOBLASTOMA; DELETIONS; LINES; HYBRIDIZATION	Screening of therapeutics relies on representative cancer models. The representation of human glioblastoma by in vitro cell culture models is questionable. We obtained genomic profiles by array comparative genomic hybridization of both short-and long-term primary cell and spheroid cultures, derived from seven glioblastomas and one anaplastic oligodendroglioma. Chromosomal copy numbers were compared between cell cultures and spheroids and related to the parental gliomas using unsupervised hierarchical clustering and correlation coefficient. In seven out of eight short-term cell cultures, the genomic profiles clustered further apart from their parental tumors than spheroid cultures. In four out of eight samples, the genetic changes in cell culture were substantial. T he average correlation coefficient between parental tumors and spheroid profiles was 0.89 (range: 0.79-0.97), whereas that between parental tumors and cell cultures was 0.62 (range: 0.10-0.96). In two out of three long-term cell cultures progressive genetic changes had developed, whereas the spheroid cultures were genetically stable. It is concluded that genomic profiles of primary cell cultures from glioblastoma are frequently deviant from parental tumor profiles, whereas spheroids are genetically more representative of the glioblastoma. This implies that glioma cell culture data have to be handled with the highest caution.	[Hamer, P. C. De Witt; Van Tilborg, A. A. G.; Leenstra, S.] Univ Amsterdam, Acad Med Ctr, Dept Neurosurg, NL-1100 DD Amsterdam, Netherlands; [Van Tilborg, A. A. G.; Troost, D.] Univ Amsterdam, Acad Med Ctr, Dept Neuropathol, NL-1100 DD Amsterdam, Netherlands; [Eijk, P. P.; Ylstra, B.] Vrije Univ Amsterdam Med Ctr, Dept Pathol, Sect Micro Array Facil, Amsterdam, Netherlands; [Sminia, P.] Vrije Univ Amsterdam Med Ctr, Dept Radiat Oncol, Amsterdam, Netherlands; [Van Noorden, C. J. F.] Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-1100 DD Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Amsterdam; Academic Medical Center Amsterdam	Hamer, PCDW (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurosurg, Room H2-238,POB 22660, NL-1100 DD Amsterdam, Netherlands.	P.C.DeWittHamer@amc.nl	Sminia, Peter/P-3385-2014; van Tilborg, Angela/M-5704-2015; Ylstra, Bauke/D-2906-2012; De Witt Hamer, Philip/E-7630-2013	van Tilborg, Angela/0000-0003-3968-5345; Ylstra, Bauke/0000-0001-9479-3010; De Witt Hamer, Philip/0000-0003-2988-8544; Sminia, Peter/0000-0002-9531-5704				Autio R, 2003, BIOINFORMATICS, V19, P1714, DOI 10.1093/bioinformatics/btg230; Barrett T, 2005, NUCLEIC ACIDS RES, V33, pD562; BIGNER SH, 1987, CANCER GENET CYTOGEN, V24, P163, DOI 10.1016/0165-4608(87)90094-X; BJERKVIG R, 1990, J NEUROSURG, V72, P463, DOI 10.3171/jns.1990.72.3.0463; Burton EC, 2002, CANCER RES, V62, P6205; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Hartmann C, 1999, INT J ONCOL, V15, P975; IZUMOTO S, 1995, CANCER LETT, V97, P241, DOI 10.1016/0304-3835(95)03981-2; Koschny R, 2002, CANCER GENET CYTOGEN, V135, P147, DOI 10.1016/S0165-4608(01)00650-1; Kotliarov Y, 2006, CANCER RES, V66, P9428, DOI 10.1158/0008-5472.CAN-06-1691; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Loeper S, 2001, CYTOGENET CELL GENET, V94, P1, DOI 10.1159/000048773; Pandita A, 2004, GENE CHROMOSOME CANC, V39, P29, DOI 10.1002/gcc.10300; Smeets SJ, 2006, ONCOGENE, V25, P2558, DOI 10.1038/sj.onc.1209275; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Steilen-Gimbel H, 1999, CANCER GENET CYTOGEN, V113, P115, DOI 10.1016/S0165-4608(99)00013-8; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; Voskoglou-Nomikos T, 2003, CLIN CANCER RES, V9, P4227; Wolff JEA, 1999, J CANCER RES CLIN, V125, P481, DOI 10.1007/s004320050305	21	154	157	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2008	27	14					2091	2096		10.1038/sj.onc.1210850	http://dx.doi.org/10.1038/sj.onc.1210850			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17934519				2022-12-17	WOS:000254359100014
J	Weisz, L; Oren, M; Rotter, V				Weisz, L.; Oren, M.; Rotter, V.			Transcription regulation by mutant p53	ONCOGENE			English	Review						mutant p53; gain of function; transcription; mechanism	GAIN-OF-FUNCTION; CELLULAR TUMOR-ANTIGEN; LI-FRAUMENI-SYNDROME; P53-INDEPENDENT APOPTOTIC PATHWAYS; HYDROPHOBIC AMINO-ACIDS; C-TERMINAL DOMAIN; WILD-TYPE P53; GENE-EXPRESSION; FUNCTION PHENOTYPE; SV40-TRANSFORMED CELLS	In addition to the loss of wild-type p53 activity, a high percentage of tumor cells accumulate mutant p53 protein isoforms. Whereas the hallmark of the wild-type p53 is its tumor suppressor activities, tumor-associated mutant p53 proteins acquire novel functions enabling them to promote a large spectrum of cancer phenotypes. During the last years, it became clear that tumor-associated mutant p53 proteins are not only distinct from the wild-type p53, but they also represent a heterogeneous population of proteins with a variety of structure-function features. One of the major mechanisms underlying mutant p53 gain of function is the ability to regulate gene expression. Although a large number of specific target genes were identified, the molecular basis for this regulation is not fully elucidated. This review describes the present knowledge about the transcriptional activities of mutant p53 and the mechanisms that might underlie its target gene specificity.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	varda.rotter@weizmann.ac.il						BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Bossi G, 2006, ONCOGENE, V25, P304, DOI 10.1038/sj.onc.1209026; Buganim Y, 2006, CANCER RES, V66, P10750, DOI 10.1158/0008-5472.CAN-06-0916; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; CHANG C, 1979, J VIROL, V31, P463, DOI 10.1128/JVI.31.2.463-471.1979; Chicas A, 2000, BIOCHEM BIOPH RES CO, V279, P383, DOI 10.1006/bbrc.2000.3965; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; DAVID YB, 1988, ONCOGENE, V3, P179; Deb D, 2002, ONCOGENE, V21, P176, DOI 10.1038/sj/onc/1205035; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; El-Hizawi S, 2002, CANCER RES, V62, P3264; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Gohler T, 2005, NUCLEIC ACIDS RES, V33, P1087, DOI 10.1093/nar/gki252; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HSIAO M, 1994, AM J PATHOL, V145, P702; Hussain SP, 1998, CANCER RES, V58, P4023; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Inga A, 2002, MOL CELL BIOL, V22, P8612, DOI 10.1128/MCB.22.24.8612-8625.2002; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Iwamoto KS, 1996, CANCER RES, V56, P3862; Iwanaga Y, 2002, CANCER RES, V62, P2618; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; Joerger AC, 2005, J BIOL CHEM, V280, P16030, DOI 10.1074/jbc.M500179200; Joerger AC, 2006, P NATL ACAD SCI USA, V103, P15056, DOI 10.1073/pnas.0607286103; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Kim E, 2003, BIOCHEM CELL BIOL, V81, P141, DOI 10.1139/o03-046; Knaup KX, 2004, FEBS LETT, V569, P70, DOI 10.1016/j.febslet.2004.05.052; KRESS M, 1979, J VIROL, V31, P472, DOI 10.1128/JVI.31.2.472-483.1979; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Lee YI, 2000, ONCOGENE, V19, P3717, DOI 10.1038/sj.onc.1203694; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LIN JY, 1995, ONCOGENE, V10, P2387; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LINZER DIH, 1979, VIROLOGY, V98, P308, DOI 10.1016/0042-6822(79)90554-3; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Loging WT, 1999, CANCER EPIDEM BIOMAR, V8, P1011; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; Mizuarai S, 2006, CANCER RES, V66, P6319, DOI 10.1158/0008-5472.CAN-05-4629; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; Muller BF, 1996, ONCOGENE, V12, P1941; MUNROE DG, 1988, ONCOGENE, V2, P621; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; O'Farrell TJ, 2004, CANCER RES, V64, P8199, DOI 10.1158/0008-5472.CAN-03-3639; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; Pan Y, 2000, ONCOGENE, V19, P3095, DOI 10.1038/sj.onc.1203663; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Pastorcic M, 2000, J BIOL CHEM, V275, P34938, DOI 10.1074/jbc.M005411200; Peled A, 1996, CANCER RES, V56, P2148; Preuss U, 2000, INT J CANCER, V88, P162, DOI 10.1002/1097-0215(20001015)88:2<162::AID-IJC3>3.0.CO;2-M; Pugacheva EN, 2002, ONCOGENE, V21, P4595, DOI 10.1038/sj.onc.1205704; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; Scian MJ, 2005, MOL CELL BIOL, V25, P10097, DOI 10.1128/MCB.25.22.10097-10110.2005; Scian MJ, 2004, CANCER RES, V64, P7447, DOI 10.1158/0008-5472.CAN-04-1568; Scian MJ, 2004, ONCOGENE, V23, P4430, DOI 10.1038/sj.onc.1207553; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHOHAT O, 1987, ONCOGENE, V1, P277; Sigal A, 2001, ONCOGENE, V20, P4891, DOI 10.1038/sj.onc.1204724; Sigal A, 2000, CANCER RES, V60, P6788; Soussi T, 2005, BIOCHEM BIOPH RES CO, V331, P834, DOI 10.1016/j.bbrc.2005.03.190; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Trkova M, 2003, CANCER GENET CYTOGEN, V145, P60, DOI 10.1016/S0165-4608(03)00031-1; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weisz L, 2004, CANCER RES, V64, P8318, DOI 10.1158/0008-5472.CAN-04-1145; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Will K, 1998, P NATL ACAD SCI USA, V95, P13681, DOI 10.1073/pnas.95.23.13681; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; Yakovleva T, 2001, J BIOL CHEM, V276, P15650, DOI 10.1074/jbc.M100482200; Yap DBS, 2004, CANCER RES, V64, P4749, DOI 10.1158/0008-5472.CAN-1305-2; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0; Zalcenstein A, 2006, ONCOGENE, V25, P359, DOI 10.1038/sj.onc.1209061; Zalcenstein A, 2003, ONCOGENE, V22, P5667, DOI 10.1038/sj.onc.1206724	98	154	162	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2007	26	15					2202	2211		10.1038/sj.onc.1210294	http://dx.doi.org/10.1038/sj.onc.1210294			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE	17401429				2022-12-17	WOS:000245394800009
J	Taniguchi, H; Yamamoto, H; Hirata, T; Miyamoto, N; Oki, M; Nosho, K; Adachi, Y; Endo, T; Imai, K; Shinomura, Y				Taniguchi, H; Yamamoto, H; Hirata, T; Miyamoto, N; Oki, M; Nosho, K; Adachi, Y; Endo, T; Imai, K; Shinomura, Y			Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers	ONCOGENE			English	Article						WIF-1; Wnt; methylation; gastrointestinal cancers	HUMAN COLORECTAL-CANCER; HISTONE DEACETYLASE INHIBITION; PRIMARY GASTRIC-CANCER; UP-REGULATION; SIGNALING PATHWAY; CELLS; TUMORIGENESIS; EXPRESSION; DEMETHYLATION; CARCINOMA	Aberrant activation and upregulation of the Wnt pathway is a key feature of many cancers. Wnt antagonists have recently attracted wide attention. Wnt inhibitory factor-1 (WIF-1) is a secreted antagonist that can bind to Wnt proteins directly and inhibit Wnt signaling pathway. It has been reported that WIF-1 expression is down regulated in several solid tumors and that WIF-1 is silenced by promoter hypermethylation in lung and colorectal cancer. By using RT-PCR, bisulfite sequence analysis, and methylation-specific PCR, we analysed expression and methylation of WIF-1 in cancer cell lines and freshly resected cancer tissues of the esophagus, stomach, colorectum, and pancreas. Downregulation of WIF-1 mRNA expression was observed in 61 (91.0%) of 67 cancer cell lines, 16 (80.0%) of 20 esophageal, 23 (74.2%) of 31 gastric, 41 (82.0%) of 50 colorectal, and six (75.0%) of eight pancreatic cancer tissues. Downregulation of WIF-1 expression was also observed at protein level. No significant association between WIF-1 downregulation and clinicopathological characteristics was found, suggesting that downregulation of WIF-1 expression is an early event in carcinogenesis of these cancers. Indeed, downregulation of WIF-1 expression was observed in 32 (72.7%) of 44 colorectal adenoma tissues and 18 (78.2%) of 23 early mucosal or submucosal colorectal carcinoma tissues. CpG island hypermethylation in the WIF-1 promoter region correlated with downregulation of WIF-1 expression in cancer cell lines and tissues. Treatment with demethylating agent, 5-aza-2'-deoxycytidine (5-aza-dC), restored WIF-1 expression in cancer cell lines. A combined treatment of 5-aza-dC and a histone deacetylase inhibitor, trichostatinA, restored WIF-1 expression synergistically, indicating the role of cytosine methylation and histone deacetylation in the silencing of the WIF-1 gene. Transfection of the WIF-1 gene construct into TE-1 esophageal cancer cell lines or SW48 colon cancer cell lines lacking WIF-1 expression resulted in a significant inhibition on colony formation, cell proliferation, anchorage-independent growth in soft agar. TOP. ash assay showed WIF-1 inhibits Wnt canonical signaling in these cell lines.These results suggest tumor suppressive function of WIF-1, due to its ability to inhibit Wnt signaling. Our results suggest that WIF-1 silencing due to promoter hypermethylation is an important mechanism underlying aberrant activation of the Wnt signaling pathway in carcinogenesis of the digestive organs. Modulation of the Wnt pathway, through reversal of WIF-1 silencing by demethylating agents, is a potential target for treatment and/or prevention of gastrointestinal cancers.	Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan	Sapporo Medical University	Yamamoto, H (corresponding author), Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan.	h-yama@sapmed.ac.jp	Taniguchi, Hiroaki/AGB-3012-2022; Peng, Bo/A-6920-2009	Taniguchi, Hiroaki/0000-0003-0494-5290; Peng, Bo/0000-0001-8225-2284				Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cebrat M, 2004, CANCER LETT, V206, P107, DOI 10.1016/j.canlet.2003.10.024; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; He BA, 2005, ONCOGENE, V24, P3054, DOI 10.1038/sj.onc.1208511; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Ikenoue T, 2002, JPN J CANCER RES, V93, P1213, DOI 10.1111/j.1349-7006.2002.tb01226.x; Katoh M, 2001, INT J ONCOL, V19, P1003; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kirikoshi H, 2001, INT J ONCOL, V19, P1221; Kolligs FT, 2002, DIGESTION, V66, P131, DOI 10.1159/000066755; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389; Mizushima T, 2002, CANCER RES, V62, P277; Reguart N, 2004, BIOCHEM BIOPH RES CO, V323, P229, DOI 10.1016/j.bbrc.2004.08.075; Saitoh T, 2002, INT J MOL MED, V9, P515; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449	22	154	168	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7946	7952		10.1038/sj.onc.1208910	http://dx.doi.org/10.1038/sj.onc.1208910			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16007117				2022-12-17	WOS:000233463000014
J	Kumar, CC; Madison, V				Kumar, CC; Madison, V			AKT crystal structure and AKT-specific inhibitors	ONCOGENE			English	Article						AKT crystal structure; Akt inhibitors; ATP competitive; PH domain; peptide substrate; apoptosis; chemoresistance	PROTEIN-KINASE-B; PLECKSTRIN HOMOLOGY DOMAIN; SUPPRESSES TUMOR-GROWTH; ETHER LIPID ANALOGS; CANCER-CELLS; SELECTIVE INHIBITORS; LUNG-CANCER; PROMOTES APOPTOSIS; MOLECULAR-BASIS; PKB INHIBITORS	AKT kinases are attractive targets for small molecule drug discovery because of their key role in tumor cell survival/proliferation and their overexpression/activation in many human cancers. This review summarizes studies that support the rationale for targeting AKT kinases in new drug discovery efforts. Structural features of AKT kinase in its inactive and active states, as determined by crystal structure analysis, are described. Recent efforts in the development and biological evaluation of small molecule inhibitors of AKT, and the challenges remaining are summarized. Inhibitors targeting the ATP binding site, PH domain and protein substrate binding site, as well as isoform selective allosteric inhibitors are reviewed. Structure-based design using PKA mutants as surrogates and computer modeling in the discovery of selective inhibitors is discussed. The issues and challenges facing the development of different classes of inhibitors as therapeutics are also discussed.	Schering Plough Res Inst, Dept Tumor Biol, Kenilworth, NJ 07033 USA; Schering Plough Res Inst, Dept Struct Chem, Kenilworth, NJ 07033 USA	Merck & Company; Schering-Plough Research Institute; Merck & Company; Schering-Plough Research Institute	Kumar, CC (corresponding author), Schering Plough Res Inst, Dept Tumor Biol, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.	chandra.kumar@spcorp.com						Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Auguin D, 2004, J BIOMOL NMR, V28, P137, DOI 10.1023/B:JNMR.0000013836.62154.c2; Bacus SS, 2002, ONCOGENE, V21, P3532, DOI 10.1038/sj.onc.1205438; Barnett SF, 2005, CURR TOP MED CHEM, V5, P109, DOI 10.2174/1568026053507714; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; Breitenlechner CB, 2005, J MED CHEM, V48, P163, DOI 10.1021/jm049701n; Breitenlechner CB, 2004, J MED CHEM, V47, P1375, DOI 10.1021/jm0310479; Brognard J, 2001, CANCER RES, V61, P3986; Castillo SS, 2004, CANCER RES, V64, P2782, DOI 10.1158/0008-5472.CAN-03-1530; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; CHENG JQ, 2005, ONCOGENE REV, V24, P7428; Clark AS, 2002, MOL CANCER THER, V1, P707; DeFeo-Jones D, 2005, MOL CANCER THER, V4, P271; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Frolov A, 2003, MOL CANCER THER, V2, P699; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; GARRETT M, 2004, EU J CANC S16, V2; Gills JJ, 2004, EXPERT OPIN INV DRUG, V13, P787, DOI 10.1517/13543784.13.7.787; Hiromura M, 2004, J BIOL CHEM, V279, P53407, DOI 10.1074/jbc.M403775200; Huang X, 2003, STRUCTURE, V11, P21, DOI 10.1016/S0969-2126(02)00937-1; Jetzt A, 2003, CANCER RES, V63, P6697; Kawauchi K, 2003, BLOOD CELL MOL DIS, V31, P11, DOI 10.1016/S1079-9796(03)00070-6; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kumar CC, 2001, BBA-GEN SUBJECTS, V1526, P257, DOI 10.1016/S0304-4165(01)00143-X; Li J, 1998, CANCER RES, V58, P5667; Lindsley CW, 2005, BIOORG MED CHEM LETT, V15, P761, DOI 10.1016/j.bmcl.2004.11.011; Luo Y, 2005, MOL CANCER THER, V4, P977, DOI 10.1158/1535-7163.MCT-05-0005; Luo Y, 2004, BIOCHEMISTRY-US, V43, P1254, DOI 10.1021/bi034515p; Milburn CC, 2003, BIOCHEM J, V375, P531, DOI 10.1042/BJ20031229; Ohashi A, 2004, INT J CANCER, V111, P317, DOI 10.1002/ijc.20305; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pandolfi PP, 2004, NEW ENGL J MED, V351, P2337, DOI 10.1056/NEJMcibr043143; Pearl LH, 2002, CURR OPIN STRUC BIOL, V12, P761, DOI 10.1016/S0959-440X(02)00386-X; Reuveni H, 2002, BIOCHEMISTRY-US, V41, P10304, DOI 10.1021/bi0202530; Saito Y, 2003, GENE THER, V10, P1961, DOI 10.1038/sj.gt.3302100; SCHEID M, 2003, FEBS LETT, P1; She QB, 2003, CLIN CANCER RES, V9, P4340; Shin I, 2005, CANCER RES, V65, P2815, DOI 10.1158/0008-5472.CAN-04-2898; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Thomas CC, 2001, BIOCHEM J, V358, P287, DOI 10.1042/0264-6021:3580287; Xu Z, 2002, CELL GROWTH DIFFER, V13, P285; Xu ZB, 2004, J BIOL CHEM, V279, P50401, DOI 10.1074/jbc.M409216200; Yakes FM, 2002, CANCER RES, V62, P4132; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Zhao ZJ, 2005, BIOORG MED CHEM LETT, V15, P905, DOI 10.1016/j.bmcl.2004.12.062	50	154	169	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 14	2005	24	50					7493	7501		10.1038/sj.onc.1209087	http://dx.doi.org/10.1038/sj.onc.1209087			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982ZW	16288296				2022-12-17	WOS:000233201900012
J	Weber, A; Hengge, UR; Bardenheuer, W; Tischoff, I; Sommerer, F; Markwarth, A; Dietz, A; Wittekind, C; Tannapfel, A				Weber, A; Hengge, UR; Bardenheuer, W; Tischoff, I; Sommerer, F; Markwarth, A; Dietz, A; Wittekind, C; Tannapfel, A			SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition	ONCOGENE			English	Article						SOCS; squamous cell carcinoma; head and neck; precursor lesions; methylation; tumor suppressor	TUMOR-SUPPRESSOR GENES; CPG ISLAND HYPERMETHYLATION; CONSTITUTIVE ACTIVATION; HEPATOCELLULAR-CARCINOMA; ABERRANT METHYLATION; NEGATIVE REGULATOR; SIGNAL TRANSDUCER; IN-VIVO; CANCER; STAT3	The suppressors of cytokine signaling ( SOCS) are inhibitors of cytokine signaling that function via the Janus kinase (JAK)/signal transducers and activators of transcription ( STAT) pathway. Recently, methylation of SOCS-1 and SOCS-3 has been implicated in the tumorigenesis of liver and lung cancer. This study was performed to elucidate the role of SOCS-1 and SOCS-3 in squamous cell carcinoma of the head and neck (HNSCC) and its precursor lesions. HNSCC of 94 patients and corresponding normal mucosa, lymph node metastases as well as 16 high- and 21 low-grade squamous cell dysplasias were studied by using methylation-specific PCR (MSP) for the SOCS-1 and SOCS-3 promoter after microdissection. The presence of SOCS-3 mRNA transcripts was confirmed by semiquantitative real-time PCR, and the SOCS-3 protein was analysed immunohistochemically. SOCS-3 hypermethylation was found in 85/94 HNSCC (90%) and in 10/16 high- grade and 9/21 low-grade dysplasias (63 and 43%, respectively). SOCS-1 promoter hypermethylation was detected in 10/94 HNSCC samples (11%) and in 2/16 high-grade and 1/21 low-grade dysplasias (13 and 5%, respectively). Lymph node metastases exhibited an identical methylation status as the primary tumors. Methylation of the SOCS-3 promoter correlated with downregulation of SOCS-3 transcripts and protein expression in these tumors and various cell lines. In the cell lines tested, SOCS-3 and SOCS-1 transcripts increased upon treatment with the demethylation compound 5-aza-2-deoxycytidine (5-AZA-DC). Overexpression of wild-type SOCS-3 in carcinoma cells with methylated SOCS-3 resulted in the induction of apoptosis and growth suppression as well as downregulation of STAT3, bcl-2 as well as bcl-xL. Our data suggest that promoter methylation and subsequent transcript downregulation of SOCS-3 transcripts and, to a much lesser extent, SOCS-1 are involved in the multistep carcinogenesis of HNSCC. During its involvement in tumor growth, restoration of SOCS-3 may hold treatment potential for HNSCC.	Univ Leipzig, Inst Pathol, D-04103 Leipzig, Germany; Univ Leipzig, Dept Otorhinolaryngol Head & Neck Surg, D-04103 Leipzig, Germany; Univ Dusseldorf, Dept Dermatol, D-40225 Dusseldorf, Germany	Leipzig University; Leipzig University; Heinrich Heine University Dusseldorf	Tannapfel, A (corresponding author), Univ Leipzig, Inst Pathol, D-04103 Leipzig, Germany.	tana@medizin.uni-leipzig.de						Ali S, 2003, J BIOL CHEM, V278, P52021, DOI 10.1074/jbc.M306758200; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365-2141.2000.02127.x; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Fukushima N, 2003, BRIT J CANCER, V89, P338, DOI 10.1038/sj.bjc.6601039; Galm O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Larsen L, 2002, APMIS, V110, P833, DOI 10.1034/j.1600-0463.2002.1101201.x; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Lin SY, 2004, ONCOL REP, V11, P341; Melzner I, 2003, BLOOD, V102, P1554, DOI 10.1182/blood-2003-04-1083; Mora LB, 2002, CANCER RES, V62, P6659; Nagai H, 2003, J HUM GENET, V48, P65, DOI 10.1007/s100380300008; Nagai H, 2002, CANCER LETT, V186, P59, DOI 10.1016/S0304-3835(02)00244-6; Niu GL, 1999, CANCER RES, V59, P5059; Niu GL, 2001, CANCER RES, V61, P3276; Oshimo Y, 2004, INT J CANCER, V112, P1003, DOI 10.1002/ijc.20521; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Shelburne CP, 2003, BLOOD, V102, P1290, DOI 10.1182/blood-2002-11-3490; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Sriuranpong V, 2003, CANCER RES, V63, P2948; Tannapfel A, 2001, EUR ARCH OTO-RHINO-L, V258, P83, DOI 10.1007/s004050000303; Tannapfel A, 2001, VIRCHOWS ARCH, V439, P1, DOI 10.1007/s004280100401; Uehara E, 2003, INT J ONCOL, V23, P693; Union for International Cancer Control, 2017, TNM CLASSIFICATION M; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Weber A, 2003, ONCOGENE, V22, P4757, DOI 10.1038/sj.onc.1206705; Yang B, 2003, AM J PATHOL, V163, P1101, DOI 10.1016/S0002-9440(10)63469-4; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225	34	154	167	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6699	6708		10.1038/sj.onc.1208818	http://dx.doi.org/10.1038/sj.onc.1208818			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007169				2022-12-17	WOS:000232367800011
J	Varga, AC; Wrana, JL				Varga, AC; Wrana, JL			The disparate role of BMP in stem cell biology	ONCOGENE			English	Article						BMP; cell fate; mouse and human embryonic stem cell; neural crest stem cell	NEURAL CREST; SELF-RENEWAL; BETA-CATENIN; MULTILINEAGE DIFFERENTIATION; SIGNAL-TRANSDUCTION; WNT; PLURIPOTENCY; TERATOCARCINOMA; MAINTENANCE; ACTIVATION	Stem cells share several characteristics of cancer cells including loss of contact inhibition and immortality. Therefore, stem cells represent an excellent model system in which to define the molecular mechanisms underlying cancer development and progression. Several signal transduction pathways including leukemia inhibitory factor, Wnt and FGF have been demonstrated to function in stem cell self-renewal and differentiation. However, more recently bone morphogenetic proteins (BMPs) have emerged as key regulators of stem cell fate commitment. Intriguingly, BMPs have disparate roles in regulating the biology of embryonic stem (ES) cells compared with neural crest stem cells (NCSCs). Furthermore, although BMPs block neural differentiation of ES cells from both mouse and human, they contribute to self-renewal specically in mouse ES cells. These observations strongly suggest that combinations of extracellular factors regulate stem cells, and that crosstalk between intracellular signaling pathways precisely defines stem cell fate commitment. In this review, we focus on the role of BMP signaling in mouse and human ES cells compared with NCSCs. We then discuss how the molecular effectors of BMP signaling may contribute to cancer, and thus represent potential targets for therapeutic intervention.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Wrana, JL (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada.	wrana@mshri.on.ca	Wrana, Jeffrey/F-8857-2013					Amit M, 2004, BIOL REPROD, V70, P837, DOI 10.1095/biolreprod.103.021147; Anderson DJ, 1997, COLD SPRING HARB SYM, V62, P493; Anderson DJ, 2000, PHILOS T R SOC B, V355, P953, DOI 10.1098/rstb.2000.0631; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Benchabane H, 2003, MOL CELL BIOL, V23, P6646, DOI 10.1128/MCB.23.18.6646-6661.2003; Brugger SM, 2004, DEVELOPMENT, V131, P5153, DOI 10.1242/dev.01390; Chai Y, 2003, CRIT REV ORAL BIOL M, V14, P78, DOI 10.1177/154411130301400202; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Donovan PJ, 2001, INT J DEV BIOL, V45, P523; Draper JS, 2003, ARCH MED RES, V34, P558, DOI 10.1016/j.arcmed.2003.08.006; Ernst M, 1996, J BIOL CHEM, V271, P30136, DOI 10.1074/jbc.271.47.30136; Gammill LS, 2002, DEVELOPMENT, V129, P5731, DOI 10.1242/dev.00175; Hari L, 2002, J CELL BIOL, V159, P867, DOI 10.1083/jcb.200209039; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Henningfeld KA, 2000, J BIOL CHEM, V275, P21827, DOI 10.1074/jbc.M000978200; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Hussein SM, 2003, J BIOL CHEM, V278, P48805, DOI 10.1074/jbc.M305472200; Joseph NM, 2004, DEVELOPMENT, V131, P5599, DOI 10.1242/dev.01429; Karaulanov E, 2004, EMBO J, V23, P844, DOI 10.1038/sj.emboj.7600101; Kleber M, 2005, J CELL BIOL, V169, P309, DOI 10.1083/jcb.200411095; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Le Douarin NM, 2003, CURR OPIN GENET DEV, V13, P529, DOI 10.1016/j.gde.2003.08.002; Lee HY, 2004, SCIENCE, V303, P1020, DOI 10.1126/science.1091611; Lo KC, 2003, J UROLOGY, V170, P2453, DOI 10.1097/01.ju.0000087170.97532.ff; Martinez CEA, 2002, BIOCHEM BIOPH RES CO, V291, P655, DOI 10.1006/bbrc.2002.6502; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Munoz-Sanjuan I, 2002, NAT REV NEUROSCI, V3, P271, DOI 10.1038/nrn786; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Pera ME, 1998, REPROD FERT DEVELOP, V10, P551, DOI 10.1071/RD98097; Pera MF, 2004, DEVELOPMENT, V131, P5515, DOI 10.1242/dev.01451; Pera MF, 2004, J CELL SCI, V117, P1269, DOI 10.1242/jcs.00970; POMP O, 2005, IN PRESS STEM CELLS; Qi XX, 2004, P NATL ACAD SCI USA, V101, P6027, DOI 10.1073/pnas.0401367101; Sato N, 2003, DEV BIOL, V260, P404, DOI 10.1016/S0012-1606(03)00256-2; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; SCHMIDT C, 2005, IN PRESS ANAT EMBRYO; Sell S, 2004, CRIT REV ONCOL HEMAT, V51, P1, DOI 10.1016/j.critrevonc.2004.04.007; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; Shibamoto S, 2004, EXP CELL RES, V292, P11, DOI 10.1016/j.yexcr.2003.08.009; Tanaka M, 2000, METH MOL B, V158, P135; Tiedemann H, 2001, DEV GROWTH DIFFER, V43, P469; Wang GW, 2005, BIOCHEM BIOPH RES CO, V330, P934, DOI 10.1016/j.bbrc.2005.03.058; Wobus AM, 2005, PHYSIOL REV, V85, P635, DOI 10.1152/physrev.00054.2003; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Xu RH, 2002, NAT BIOTECHNOL, V20, P1261, DOI 10.1038/nbt761; Xu RH, 2005, NAT METHODS, V2, P185, DOI 10.1038/NMETH744; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Zhang WJ, 2002, J BIOL CHEM, V277, P45435, DOI 10.1074/jbc.M208056200	56	154	170	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2005	24	37					5713	5721		10.1038/sj.onc.1208919	http://dx.doi.org/10.1038/sj.onc.1208919			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958MQ	16123804				2022-12-17	WOS:000231452800006
J	Boulanger, CA; Wagner, KU; Smith, GH				Boulanger, CA; Wagner, KU; Smith, GH			Parity-induced mouse mammary epithelial cells are pluripotent, self-renewing and sensitive to TGF-beta 1 expression	ONCOGENE			English	Article						mammary; transplantation; stem cells; TGF-beta 1; cell fate; pregnancy	GLAND; DIFFERENTIATION; CARCINOGENESIS; MORPHOGENESIS; POPULATION; SENESCENCE; PREGNANCY	A parity-induced mammary population, marked by beta-galactosidase expression conditionally activated through cre-lox recombinase originates in WAP-Cre/Rosa-lox-STOP- lox-LacZ (WAP-Cre/Rosa-LacZ) female mice during pregnancy, lactation and involution. During subsequent pregnancies, these parity-induced mammary epithelial cells (PI-MEC) proliferated to produce new secretory acini composed of secretory luminal cells and myoepithelium. In serial transplantation assays, PI-MEC were able to self-renew over several transplant generations and to contribute significantly to the resulting mammary outgrowths. In limiting dilution transplantation, they proliferated to produce both luminal and myoepithelial cells, comprised both lobule-limited and duct-limited epithelial outgrowths, and differentiated into all the cellular subtypes recognized in murine mammary epithelium. TGF-beta1 expression from the whey acidic protein promoter (WAP) in triply transgenic females did not prevent the appearance of PI-MEC after pregnancy despite the absence of full lactation or their ability to proliferate and produce progeny with diverse cellular fates in situ upon subsequent pregnancies. However, in transplants from triple transgenic parous females, the WAP-TGF-beta1-positive PI-MEC did not contribute to the newly recapitulated mammary outgrowths, suggesting that they were incapable of expansive cellular proliferation (self-renewal). This result is consistent with our earlier publication that WAP-TGF-beta1 expression in mammary epithelium induces premature stem cell senescence in mammary transplants and decreases mammary cancer risk in mouse mammary tumor virus (MMTV)-infected females even after multiple pregnancies.	NCI, Mammary Biol & Tumorigenesis Lab, Bethesda, MD 20892 USA; Univ Nebraska, Sch Med, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Nebraska System	Smith, GH (corresponding author), NCI, Mammary Biol & Tumorigenesis Lab, Bldg 10,Room 5B56,9000 Rockville Pike, Bethesda, MD 20892 USA.	gs4d@nih.gov	Wagner, Kay-Uwe/B-6044-2009	Wagner, Kay-Uwe/0000-0002-5081-0226	NATIONAL CANCER INSTITUTE [Z01BC010021, ZIABC010021] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boulanger CA, 2001, ONCOGENE, V20, P2264, DOI 10.1038/sj.onc.1204312; Callahan R, 2000, ONCOGENE, V19, P992, DOI 10.1038/sj.onc.1203276; DANIEL CW, 1968, P NATL ACAD SCI USA, V61, P53, DOI 10.1073/pnas.61.1.53; DEOME K.B., 1959, JNCI-J NATL CANCER I, V78, P751; DEOME KB, 1978, CANCER RES, V38, P2103; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; Kordon EC, 1998, DEVELOPMENT, V125, P1921; Lin HF, 2002, NAT REV GENET, V3, P931, DOI 10.1038/nrg952; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; Robinson GW, 1996, DEV DYNAM, V206, P159, DOI 10.1002/(SICI)1097-0177(199606)206:2<159::AID-AJA5>3.0.CO;2-H; Sivaraman L, 1998, CARCINOGENESIS, V19, P1573, DOI 10.1093/carcin/19.9.1573; Sivaraman L, 2001, P NATL ACAD SCI USA, V98, P12379, DOI 10.1073/pnas.221459098; SMITH GH, 1991, J VIROL, V65, P6365, DOI 10.1128/JVI.65.11.6365-6370.1991; Smith GH, 1996, BREAST CANCER RES TR, V39, P21, DOI 10.1007/BF01806075; Wagner KU, 2002, DEVELOPMENT, V129, P1377; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; WILLIAMS JM, 1983, DEV BIOL, V97, P274, DOI 10.1016/0012-1606(83)90086-6	19	154	156	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					552	560		10.1038/sj.onc.1208185	http://dx.doi.org/10.1038/sj.onc.1208185			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580303	Bronze			2022-12-17	WOS:000226420400003
J	Busino, L; Chiesa, M; Draetta, GF; Donzelli, M				Busino, L; Chiesa, M; Draetta, GF; Donzelli, M			Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis	ONCOGENE			English	Review						Cdc25A; APC/C; SCF; checkpoints	ANAPHASE-PROMOTING COMPLEX; F-BOX PROTEINS; UBIQUITIN-LIGASE COMPLEX; S-PHASE CHECKPOINT; CELL-CYCLE; DNA-DAMAGE; MEDIATED DEGRADATION; G(1)/S TRANSITION; BREAST-CANCER; BETA-CATENIN	In eukaryotic cells, control mechanisms of cell-cycle progression have evolved to accurately monitor the integrity of genetic information to be transferred to the progeny. Cdc25A phosphatase is an essential activator of cell-cycle progression and is targeted by checkpoint signals. Ubiquitylation regulates Cdc25A activity through. ne tuning of its protein levels. Two different ubiquitin ligases (APC/C and SCF complex) are involved in Cdc25A turnover. While APC/C is involved in regulating Cdc25A at the exit of mitosis, SCF regulates the abundance of Cdc25A in S phase and G2. In response to DNA damage or to stalled replication, the activation of the ATM and ATR protein kinases leads to Chk1 and Chk2 activation and to Cdc25A hyperphosphorylation. These events stimulate SCF-mediated ubiquitylation of Cdc25A and its proteolysis. This contributes to delaying cell-cycle progression, thereby preventing genomic instability. Based on recent findings, we discuss the role of Cdc25A ubiquitylation and degradation in cell-cycle progression and in response to DNA damage. Moreover, we discuss the role of phosphorylation at multiple sites in triggering ubiquitylation signals.	European Inst Oncol, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Donzelli, M (corresponding author), European Inst Oncol, 435 Via Ripamonti, I-20141 Milan, Italy.	mdonzell@ieo.it	Donzelli, Maddalena/ABD-3774-2020	DONZELLI, MADDALENA/0000-0002-4045-0802	Telethon [E.0865] Funding Source: Medline	Telethon(Fondazione Telethon)		Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Bernardi R, 2000, ONCOGENE, V19, P2447, DOI 10.1038/sj.onc.1203564; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Broggini M, 2000, ANTICANCER RES, V20, P4835; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Clucas C, 2002, EMBO J, V21, P665, DOI 10.1093/emboj/21.4.665; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Donzelli M, 2002, EMBO J, V21, P4875, DOI 10.1093/emboj/cdf491; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Goloudina A, 2003, CELL CYCLE, V2, P473, DOI 10.4161/cc.2.5.482; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Hassepass I, 2003, J BIOL CHEM, V278, P29824, DOI 10.1074/jbc.M302704200; Hernandez S, 2001, LAB INVEST, V81, P465, DOI 10.1038/labinvest.3780254; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Ito Y, 2002, BRIT J CANCER, V86, P1909, DOI 10.1038/sj.bjc.6600364; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Listovsky T, 2000, EXP CELL RES, V255, P184, DOI 10.1006/excr.1999.4788; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu QH, 2000, GENE DEV, V14, P1448; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Lukas C, 2001, CANCER RES, V61, P4990; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Peters JM, 2003, MOL CELL, V11, P1420, DOI 10.1016/S1097-2765(03)00233-8; Pfleger CM, 2000, GENE DEV, V14, P655; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; Shimuta K, 2002, EMBO J, V21, P3694, DOI 10.1093/emboj/cdf357; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Takai H, 2000, GENE DEV, V14, P1439; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Xu XD, 2003, CLIN CANCER RES, V9, P1764; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	71	154	163	3	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					2050	2056		10.1038/sj.onc.1207394	http://dx.doi.org/10.1038/sj.onc.1207394			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021892				2022-12-17	WOS:000220213400009
J	Liu, T; Brouha, B; Grossman, D				Liu, T; Brouha, B; Grossman, D			Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells	ONCOGENE			English	Article						apoptosis; survivin; caspase; AIF; melanoma; mitochondria	CRYSTAL-STRUCTURE; PROTEIN SURVIVIN; DIRECT INHIBITOR; CYTOCHROME-C; CANCER; DEATH; EXPRESSION; GENE; IAP; AIF	The inhibitor of apoptosis (IAP) protein Survivin is expressed in most cancers and is a key factor in maintaining apoptosis resistance. Although several IAPs have been shown to act as direct inhibitors of caspases, the precise antiapoptotic function of Survivin remains controversial. To clarify the mechanism by which Survivin protects cells, we investigated the kinetics of apoptosis and apoptotic events following Survivin inhibition utilizing a melanoma cell line harboring a tetracycline-regulated Survivin dominant-negative mutant (Survivin-T34A). Blocking Survivin resulted in both caspase activation and apoptosis; however, the level of apoptosis was only partially reduced by caspase inhibition. Survivin blockade also resulted in mitochondrial events that preceded caspase activation, including depolarization and release of cytochrome c and Smac/DIABLO. Levels of other IAPs were not altered in Survivin-targeted cells, although modest cleavage of XIAP and Livin was observed. The earliest proapoptotic event observed in Survivin-targeted cells was nuclear translocation of mitochondrial apoptosis-inducing factor (AIF), known to trigger both apoptotic mitochondrial events and caspase-independent DNA fragmentation. These findings suggest that a key antiapoptotic function of Survivin relates to inhibition of mitochondrial and AIF-dependent apoptotic pathways, and its expression in melanoma and other cancers likely protects against both caspase-independent and -dependent apoptosis.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Dermatol, Salt Lake City, UT 84132 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Grossman, D (corresponding author), Univ Utah, Huntsman Canc Inst, Suite 5243,2000 Circle Hope, Salt Lake City, UT 84112 USA.	doug.grossman@hci.utah.edu			NIAMS NIH HHS [KO8AR48618, R01 AR050102-01A1, R01 AR050102, K08 AR048618, K08 AR048618-04] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050102, K08AR048618] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adida C, 1998, AM J PATHOL, V152, P43; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Altieri DC, 1999, LAB INVEST, V79, P1327; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Banks DP, 2000, BLOOD, V96, P4002, DOI 10.1182/blood.V96.12.4002.h8004000c_4002_4003; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Bowen AR, 2003, J INVEST DERMATOL, V120, P48, DOI 10.1046/j.1523-1747.2003.12010.x; Chantalat L, 2000, MOL CELL, V6, P183, DOI 10.1016/S1097-2765(00)00019-8; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fortugno P, 2002, J CELL SCI, V115, P575; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Grossman D, 1999, LAB INVEST, V79, P1121; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Grossman D, 2001, J CLIN INVEST, V108, P991, DOI 10.1172/JCI200113345; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Mahotka C, 1999, CANCER RES, V59, P6097; Maier JKX, 2002, J NEUROSCI, V22, P2035, DOI 10.1523/JNEUROSCI.22-06-02035.2002; Mate MJ, 2002, NAT STRUCT BIOL, V9, P442, DOI 10.1038/nsb793; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Muchmore SW, 2000, MOL CELL, V6, P173, DOI 10.1016/S1097-2765(00)00018-6; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Olie RA, 2000, CANCER RES, V60, P2805; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Reed JC, 2001, J CLIN INVEST, V108, P965, DOI 10.1172/JCI14123; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Reutelingsperger CPM, 1997, CELL MOL LIFE SCI, V53, P527, DOI 10.1007/s000180050067; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Shankar SL, 2001, J NEUROCHEM, V79, P426, DOI 10.1046/j.1471-4159.2001.00596.x; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tamm I, 1998, CANCER RES, V58, P5315; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030	62	154	170	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					39	48		10.1038/sj.onc.1206978	http://dx.doi.org/10.1038/sj.onc.1206978			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712209	Green Accepted			2022-12-17	WOS:000187895300005
J	Jin, SQ; Tong, T; Fan, WH; Fan, FY; Antinore, MJ; Zhu, XC; Mazzacurati, L; Li, XX; Petrik, KL; Rajasekaran, B; Wu, M; Zhan, QM				Jin, SQ; Tong, T; Fan, WH; Fan, FY; Antinore, MJ; Zhu, XC; Mazzacurati, L; Li, XX; Petrik, KL; Rajasekaran, B; Wu, M; Zhan, QM			GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activity	ONCOGENE			English	Article						p53; GADD45; G2-M arrest; cyclin B1	P53-REGULATED PROTEIN GADD45; HUMAN CANCER-CELLS; DNA-DAMAGE; IONIZING-RADIATION; DEPENDENT KINASES; MAMMALIAN G(1); GROWTH ARREST; HELA-CELLS; P53; CHECKPOINTS	In response to DNA damage, the cell cycle checkpoint is an important biological event in maintaining genomic fidelity. Gadd45, a p53-regulated and DNA damage inducible protein, has recently been demonstrated to play a role in the G2-M checkpoint in response to DNA damage. In the current study, we further investigated the biochemical mechanism(s) involved in the GADD45-activated cell cycle G2-M arrest. Using the tetracycline-controlled system (tet-off), we established GADD45-inducible lines in HCT116 (wild-type p53) and Hela (inactivated p53 status) cells. Following inducible expression of the Gadd45 protein, cell growth was strongly suppressed in both HCT116 and Hela cells. Interestingly, HCT116 cells revealed a significant G2-M arrest but Hela cells failed to arrest at the G2-M phases, indicating that the GADD45-activated G2-M arrest requires normal p53 function. The GADD45-induced G2-M arrest was observed independent of p38 kinase activity. Importantly, induction of Gadd45 protein resulted in a reduction of nuclear cyclin B1 protein, whose nuclear localization is critical for the completion of G2-M transition. The reduced nuclear cyclin B1 levels correlated with inhibition of Cdc2/cyclin 131 kinase activity. Additionally, overexpression of cyclin B1 substantially abrogated the GADD45-induced cell growth suppression. Therefore, GADD45 inhibition of Cdc2 kinase activity through alteration of cyclin B1 subcellular localization may be an essential step in the GADD45-induced cell cycle G2-M arrest and growth suppression.	Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, Pittsburgh, PA 15213 USA; Chinese Acad Med Sci, Inst Canc, Natl Lab Mol Oncol, Beijing 100021, Peoples R China; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of Medical Sciences - Peking Union Medical College; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zhan, QM (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, BST W-945,200 Lothrop St, Pittsburgh, PA 15213 USA.			mazzacurati, lucia/0000-0002-8336-8032	NATIONAL CANCER INSTITUTE [R01CA083874] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-83874] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BERNHARD EJ, 1995, RADIAT ENVIRON BIOPH, V34, P79, DOI 10.1007/BF01275210; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chen IT, 1996, ONCOGENE, V12, P595; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; HALL PA, 1995, ONCOGENE, V10, P2427; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KOHN KW, 1994, J CELL BIOCHEM, V54, P440, DOI 10.1002/jcb.240540411; MUSCHEL RJ, 1992, RADIAT RES, V132, P153, DOI 10.2307/3578520; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; O'Connor P M, 1992, Semin Cancer Biol, V3, P409; O'Connor P M, 1996, Prog Cell Cycle Res, V2, P165; OConnor PM, 1997, CANCER SURV, V29, P151; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Soria JC, 2000, CANCER RES, V60, P4000; STEWART N, 1995, ONCOGENE, V10, P109; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yu M, 2002, MOL IMMUNOL, V38, P981, DOI 10.1016/S0161-5890(02)00026-3; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHANG H, 1994, COLD SPRING HARB SYM, V59, P21, DOI 10.1101/SQB.1994.059.01.005; Zhao HC, 2000, EXP CELL RES, V258, P92, DOI 10.1006/excr.2000.4906	48	154	165	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8696	8704		10.1038/sj.onc.1206034	http://dx.doi.org/10.1038/sj.onc.1206034			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483522				2022-12-17	WOS:000179734400003
J	Schaefer, LK; Ren, ZY; Fuller, GN; Schaefer, TS				Schaefer, LK; Ren, ZY; Fuller, GN; Schaefer, TS			Constitutive activation of Stat3 alpha in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2)	ONCOGENE			English	Article						brain tumor; receptor tyrosine kinase; endothelial cells; VEGF; angiogenesis	GROWTH-FACTOR EXPRESSION; TRANSCRIPTIONAL ACTIVITY; DNA-BINDING; SIGNALING PATHWAY; STAT3 ACTIVATION; SRC; GENE; AMPLIFICATION; INDUCTION; APOPTOSIS	Members of the normally latent family of transcription factors signal/inducers and activators of transcription (Stat) are activated in a number of human tumors and tumor-derived cell lines. In the case of Stat3, it is believed that this activation leads to the induction of survival signals as well as increased proliferation. In this study, we demonstrate that Stat3 is constitutively activated in glioma and medulloblastoma tumors and that the activated protein localizes predominantly to the tumor endothelial cells in the highly vascularized glioma tumors. Our efforts to elucidate potential mechanism(s) for this activated protein have shown that coexpression of Stat3)c and the vascular endothelial growth factor receptor-2 (VEGFR-2) result in ligand-independent activation of Stat3chi tyrosine phosphorylation and subsequent transcriptional activation in non-endothelial cells. We also show that activated Stat3alpha can increase transcription from the vascular endothelial growth factor (VEGF) gene. Taken together, these results suggest that the activated Stat3chi found in brain tumors may be due to the endothelial tyrosine kinase VEGFR-2 and that Stat3chi may play a central role in autocrine VEGF activation.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Schaefer, TS (corresponding author), Box 064,1515 Holcombe Blvd, Houston, TX 77030 USA.	tschaefe@jmdanderson.org		Fuller, Gregory/0000-0001-9447-2647				BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carroll RS, 1999, CANCER-AM CANCER SOC, V86, P1335, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1335::AID-CNCR32>3.0.CO;2-Z; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V131, P207, DOI 10.1016/0006-291X(85)91790-5; Fleming RYD, 1997, SURGERY, V122, P501, DOI 10.1016/S0039-6060(97)90044-1; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; HATVA E, 1995, AM J PATHOL, V146, P368; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; IJICHI A, 1995, GLIA, V14, P87, DOI 10.1002/glia.440140203; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LIBERMANN TA, 1984, CANCER RES, V44, P753; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Ni Z, 2000, CANCER RES, V60, P1225; Nielsen M, 1999, LEUKEMIA, V13, P735, DOI 10.1038/sj.leu.2401415; Pietsch T, 1997, ACTA NEUROPATHOL, V93, P109, DOI 10.1007/s004010050591; Schaefer LK, 2000, CELL SIGNAL, V12, P143, DOI 10.1016/S0898-6568(99)00077-7; Schaefer LK, 1999, BIOCHEM BIOPH RES CO, V266, P481, DOI 10.1006/bbrc.1999.1853; Schaefer LK, 2000, CYTOKINE, V12, P1647, DOI 10.1006/cyto.2000.0774; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHLEGEL J, 1994, INT J CANCER, V56, P72; SCHWECHHEIMER K, 1995, INT J CANCER, V62, P145, DOI 10.1002/ijc.2910620206; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Theurillat JP, 1999, AM J PATHOL, V154, P581, DOI 10.1016/S0002-9440(10)65303-5; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WeberNordt RM, 1996, BLOOD, V88, P809; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Xia Z, 1998, CANCER RES, V58, P3173; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	39	154	167	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2058	2065		10.1038/sj.onc.1205263	http://dx.doi.org/10.1038/sj.onc.1205263			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960378				2022-12-17	WOS:000174827000012
J	Carbone, R; Pearson, M; Minucci, S; Pelicci, PG				Carbone, R; Pearson, M; Minucci, S; Pelicci, PG			PML NBs associate with the hMre11 complex and p53 at sites of irradiation induced DNA damage	ONCOGENE			English	Article						promyelocytic leukaemia nuclear bodies; p53; hMre11; checkpoint; DNA repair	NIJMEGEN BREAKAGE SYNDROME; NUCLEAR-BODIES; PROTEIN COMPLEX; RETINOIC ACID; HISTONE H2AX; REPAIR; GENE; MRE11; ND10; DISRUPTION	PML nuclear bodies (PML NBs) respond to many cellular stresses including viral infection, heat shock, arsenic and oncogenes and have been implicated in the regulation of p53-dependent replicative senescence and apoptosis. Recently, the hMre11/Rad50/NBSI repair complex, involved in Double Strand Breaks (DSBs) repair, was found to colocalize within PML NBs, suggesting a role for these nuclear sub-domains in the DNA repair signalling pathway. We report here that in normal human fibroblasts, after ionizing radiation (IR), the PML NBs are modified and recognize sites of DNA breaks (ssDNA breaks and DSBs). Eight to 12 h after radiation PML NBs associate with hMre11 Ionizing Radiation-Induced Foci (IRIF), and subsequently with p53 within discrete foci. The PML, hMre11 and p53 colocalizing structures mark sites of DSBs as identified by immunolocalization with anti phosphorylated histone gamma-H2AX. Furthermore, we demonstrate that ionizing radiation induces the stable association of p53 with hMre11 and PML. These results suggest that the PML NBs are involved in the recognition and/or processing of DNA breaks and possibly in the recruitment of proteins (p53 and hMre11) required for both checkpoint and DNA-repair responses.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; FIRC Inst Mol Oncol, FIMO, I-20139 Milan, Italy	IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	pgpelicci@ieo.it	Minucci, Saverio/J-9669-2012; Pelicci, Pier Giuseppe/AAL-6572-2020					Ahn JH, 2000, VIROLOGY, V274, P39, DOI 10.1006/viro.2000.0448; Andre C, 1996, EXP CELL RES, V229, P253, DOI 10.1006/excr.1996.0368; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Everett RD, 1999, J CELL SCI, V112, P3443; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; KELLY C, 1995, J GEN VIROL, V76, P2887, DOI 10.1099/0022-1317-76-11-2887; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lombard DB, 2000, CANCER RES, V60, P2331; Lozano G, 2000, NATURE, V404, P24, DOI 10.1038/35003670; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Muller S, 1998, BLOOD, V92, P4308, DOI 10.1182/blood.V92.11.4308.423k36_4308_4316; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Petrini JHJ, 1999, AM J HUM GENET, V64, P1264, DOI 10.1086/302391; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Skalski V, 2000, ONCOGENE, V19, P3321, DOI 10.1038/sj.onc.1203649; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Wang Y, 2000, GENE DEV, V14, P927; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	46	154	157	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1633	1640		10.1038/sj.onc.1205227	http://dx.doi.org/10.1038/sj.onc.1205227			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896594				2022-12-17	WOS:000174214200001
J	Kim, S; Kaminker, P; Campisi, J				Kim, S; Kaminker, P; Campisi, J			Telomeres, aging and cancer: In search of a happy ending	ONCOGENE			English	Review						antagonistic pleiotropy; cellular senescence; genomic instability; immortalization; telomerase; tumor suppression	CELL-CYCLE; POLY(ADP-RIBOSE) POLYMERASE; REPLICATIVE SENESCENCE; LENGTH REGULATION; HUMAN FIBROBLASTS; MOUSE TELOMERASE; LIFE-SPAN; IN-VITRO; EXPRESSION; MICE	Telomeres are distinctive structures, composed of a repetitive DNA sequence and associated proteins, that cap the ends of linear chromosomes. Telomeres are essential for maintaining the integrity and stability of eukaryotic genomes. In addition, under some circumstances, telomeres can influence cellular gene expression. In mammals, the length, structure, and function of telomeres have been proposed to contribute to cellular and organismal phenotypes associated with cancer and aging. Here, we discuss what is known about the basis for the links between telomeres, aging and cancer, and some of the known and proposed consequences of telomere dysfunction and maintenance for mammalian cells and organisms.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Campisi, J (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Mailstop 84-171,1 Cyclotron Rd, Berkeley, CA 94720 USA.	JCAMPISI@LBL.GOV						ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Buchkovich KJ, 1996, MOL BIOL CELL, V7, P1443, DOI 10.1091/mbc.7.9.1443; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Campisi J, 2000, IN VIVO, V14, P183; Campisi J, 1999, MOLECULAR BASIS OF CELL CYCLE AND GROWTH CONTROL, P348; Campisi J, 2001, EXP GERONTOL, V36, P607, DOI 10.1016/S0531-5565(00)00230-8; Campisi Judith, 1996, P121; CHA RS, 1994, P NATL ACAD SCI USA, V91, P3749, DOI 10.1073/pnas.91.9.3749; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chi NW, 2000, J BIOL CHEM, V275, P38437, DOI 10.1074/jbc.M007635200; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; CovielloMcLaughlin GM, 1997, NUCLEIC ACIDS RES, V25, P3051, DOI 10.1093/nar/25.15.3051; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; di Fagagna FD, 1999, NAT GENET, V23, P76; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dolle MET, 1997, NAT GENET, V17, P431, DOI 10.1038/ng1297-431; Dolle MET, 2000, P NATL ACAD SCI USA, V97, P8403, DOI 10.1073/pnas.97.15.8403; Dubrana K, 2001, CURR OPIN CELL BIOL, V13, P281, DOI 10.1016/S0955-0674(00)00210-6; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Effros RB, 1998, AM J HUM GENET, V62, P1003, DOI 10.1086/301845; Funk WD, 2000, EXP CELL RES, V258, P270, DOI 10.1006/excr.2000.4945; Gasser SM, 2000, SCIENCE, V288, P1377, DOI 10.1126/science.288.5470.1377; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Gray JW, 2000, CARCINOGENESIS, V21, P443, DOI 10.1093/carcin/21.3.443; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Hemann MT, 2000, NUCLEIC ACIDS RES, V28, P4474, DOI 10.1093/nar/28.22.4474; Herrera E, 2000, EMBO J, V19, P472, DOI 10.1093/emboj/19.3.472; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Holt SE, 1997, EUR J CANCER, V33, P761, DOI 10.1016/S0959-8049(97)00066-X; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Kakuo S, 1999, BIOCHEM BIOPH RES CO, V263, P308, DOI 10.1006/bbrc.1999.1385; Kaminker PG, 2001, J BIOL CHEM, V276, P35891, DOI 10.1074/jbc.M105968200; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; Klapper W, 2001, MECH AGEING DEV, V122, P695, DOI 10.1016/S0047-6374(01)00223-8; Kohn KW, 1999, MOL BIOL CELL, V10, P2703, DOI 10.1091/mbc.10.8.2703; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Lingner J, 1998, CURR OPIN GENET DEV, V8, P226, DOI 10.1016/S0959-437X(98)80145-7; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; MILLER RA, 1991, CANCER, V68, P2496, DOI 10.1002/1097-0142(19911201)68:11+<2496::AID-CNCR2820681503>3.0.CO;2-B; Mishima K, 1999, INVEST OPHTH VIS SCI, V40, P1590; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Munoz-Jordan JL, 2001, EMBO J, V20, P579, DOI 10.1093/emboj/20.3.579; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Paradis V, 2001, HUM PATHOL, V32, P327, DOI 10.1053/hupa.2001.22747; Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1; Pendergrass WR, 1999, J CELL PHYSIOL, V180, P123, DOI 10.1002/(SICI)1097-4652(199907)180:1<123::AID-JCP14>3.0.CO;2-W; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Rinehart CA, 1997, MOL CARCINOGEN, V18, P187, DOI 10.1002/(SICI)1098-2744(199704)18:4<187::AID-MC1>3.3.CO;2-4; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay J W, 2001, Novartis Found Symp, V235, P116; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Shore D, 1997, TRENDS BIOCHEM SCI, V22, P233, DOI 10.1016/S0968-0004(97)01082-7; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Smith S, 1999, J CELL SCI, V112, P3649; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Song K, 2000, FEBS LETT, V481, P81, DOI 10.1016/S0014-5793(00)01958-X; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wei S, 1999, CANCER RES, V59, P1539; Wellinger RJ, 1997, EUR J CANCER, V33, P735, DOI 10.1016/S0959-8049(97)00067-1; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; Wright Woodring E., 1996, V16, P153; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yang LQ, 2001, MECH AGEING DEV, V122, P1685, DOI 10.1016/S0047-6374(01)00280-9; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu LX, 1998, P NATL ACAD SCI USA, V95, P8648, DOI 10.1073/pnas.95.15.8648; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	105	154	169	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2002	21	4					503	511		10.1038/sj.onc.1205077	http://dx.doi.org/10.1038/sj.onc.1205077			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850775				2022-12-17	WOS:000173390500002
J	Verrecchia, F; Vindevoghel, L; Lechleider, RJ; Uitto, J; Roberts, AB; Mauviel, A				Verrecchia, F; Vindevoghel, L; Lechleider, RJ; Uitto, J; Roberts, AB; Mauviel, A			Smad3/AP-1 interactions control transcriptional responses to TGF-beta in a promoter-specific manner	ONCOGENE			English	Article						TGF-beta; AP-1; Smad; gene regulation; Jun	GROWTH-FACTOR-BETA; COLLAGEN GENE COL7A1; C-JUN; COACTIVATOR P300; SMAD PROTEINS; DNA-BINDING; ACTIVATION; FIBROBLASTS; EXPRESSION; SEQUENCE	Smad proteins transduce signals from TGF-beta receptors and regulate transcription of target genes either directly or in combination with other sequence-specific transcription factors, AP-1 sites and their cognate transcription factors also play important roles in the gene regulatory activities of TGF-beta. In this report, we have investigated the functional interactions of the Smad and AP-1 transcription factors. We demonstrate that Smad and AP-1 complexes specifically bind to their cognate cis-elements and do not interact with each other on-DNA, whereas off-DNA interactions occur between Smad3 and both c-Jun and JunB. Using both artificial constructs specific for either the Smad or AP-1 signaling pathways or natural promoters known to be TGF-beta -responsive, we have determined that Jun family members downregulate Smad3-mediated gene transactivation whereas AP-1-dependent promoters are synergistically activated by Smad3 and Jun proteins, We propose a model where the presence of Smad- and/or AP-1-specific cis-elements within TGF-beta -responsive genes allows dynamic modulation of gene expression, in contrast to the existing model where interactions between Smad and AP-1 proteins are merely an on/off mechanism to regulate TGF-beta /Smad targets.	Hop St Louis, INSERM, U532, Inst Rech Peau, F-75010 Paris, France; Thomas Jefferson Univ, Jefferson Inst Mol Med, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Mauviel, A (corresponding author), Hop St Louis, INSERM, U532, Inst Rech Peau, Pavillon Bazin,1 Ave Claude Vellefaux, F-75010 Paris, France.		Verrecchia, Franck/G-5535-2018; MAUVIEL, Alain/F-6251-2013	Verrecchia, Franck/0000-0003-4920-2554; 	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041439] Funding Source: NIH RePORTER; NIAMS NIH HHS [O1 AR41439] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; FRISCH SM, 1990, ONCOGENE, V5, P75; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Maggirwar SB, 2000, J NEUROCHEM, V74, P527, DOI 10.1046/j.1471-4159.2000.740527.x; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, GENE DEV, V14, P627; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; PIU F, 1993, CR ACAD SCI III-VIE, V316, P772; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Vindevoghel L, 1997, J BIOL CHEM, V272, P10196; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Wong C, 1999, MOL CELL BIOL, V19, P1821; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	38	154	159	0	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2001	20	26					3332	3340		10.1038/sj.onc.1204448	http://dx.doi.org/10.1038/sj.onc.1204448			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423983				2022-12-17	WOS:000169248800003
J	Chen, CA; Manning, DR				Chen, CA; Manning, DR			Regulation of G proteins by covalent modification	ONCOGENE			English	Article						N-myristoylation; palmitoylation; phosphorylation; G protein	PLASMA-MEMBRANE LOCALIZATION; G-BETA-GAMMA; KINASE-C PHOSPHORYLATES; GTP-BINDING-PROTEIN; ALPHA-SUBUNIT; ADENYLYL-CYCLASE; TYROSINE PHOSPHORYLATION; LIPID MODIFICATIONS; HUMAN-PLATELETS; BIOCHEMICAL-CHARACTERIZATION	Heterotrimeric G protein alpha,beta, and gamma subunits are subject to several kinds of co- and post-translational covalent modifications, Among those relevant to G protein-coupled receptor signaling in normal cell function are lipid modifications and phosphorylation, N-myristoylation is a co-translational modification occurring for members of the (G)i family of G alpha subunits, while palmitoylation is a post-translational modification that occurs for these and most other G alpha subunits, One or both modifications are required for plasma membrane targeting and contribute to regulating strength of interaction with the G beta gamma heterodimer, effecters, and regulators of G protein signaling (RGS proteins). G alpha subunits, including those with transforming activity, are often inactive when unable to be modified with lipids, The reversible nature of palmitoylation is intriguing in this regard, as it lends itself to a regulation integrated with the activation state of the G protein, Several G alpha subunits are substrates for phosphorylation by protein kinase C and at least one is a substrate for phosphorylation by the p21-activated protein kinase, Phosphorylation in both instances inhibits the interactions of these subunits with the G beta gamma heterodimer and RGS proteins. Several G alpha subunits are also substrates for tyrosine phosphorylation, A G gamma subunit is phosphorylated by protein kinase C, with the consequence that it interacts tightly with a G alpha subunit but less well with an effector.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Manning, DR (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051196] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51196] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bano MC, 1998, BIOCHEM J, V330, P723, DOI 10.1042/bj3300723; BERTHIAUME L, 1995, J BIOL CHEM, V270, P22399, DOI 10.1074/jbc.270.38.22399; Bhamre S, 1998, J PHARMACOL EXP THER, V286, P1482; Bhatnagar RS, 1997, TRENDS CELL BIOL, V7, P14, DOI 10.1016/S0962-8924(97)10044-7; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BUSHFIELD M, 1990, BIOCHEM J, V268, P449, DOI 10.1042/bj2680449; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; Chen CA, 2000, J BIOL CHEM, V275, P23516, DOI 10.1074/jbc.M003439200; DANIELISSAKANI S, 1989, J BIOL CHEM, V264, P20240; Das AK, 1997, J BIOL CHEM, V272, P11021; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; Fishburn CS, 2000, P NATL ACAD SCI USA, V97, P1085, DOI 10.1073/pnas.97.3.1085; Fishburn CS, 1999, J BIOL CHEM, V274, P18793, DOI 10.1074/jbc.274.26.18793; Fu HW, 1999, RECENT PROG HORM RES, V54, P315; Galbiati F, 1999, J BIOL CHEM, V274, P5843, DOI 10.1074/jbc.274.9.5843; GALBIATI F, 1994, BIOCHEM J, V303, P697, DOI 10.1042/bj3030697; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P9695, DOI 10.1073/pnas.89.20.9695; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; Gurdal H, 1997, MOL PHARMACOL, V52, P1064, DOI 10.1124/mol.52.6.1064; HALLAK H, 1994, J BIOL CHEM, V269, P4571; HALLAK H, 1994, J BIOL CHEM, V269, P4713; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; Hohenegger M, 1996, MOL PHARMACOL, V49, P73; Huang CF, 1999, P NATL ACAD SCI USA, V96, P412, DOI 10.1073/pnas.96.2.412; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; Jones TLZ, 1998, BIOCHEMISTRY-US, V37, P3196, DOI 10.1021/bi972253j; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; Kleuss C, 1997, P NATL ACAD SCI USA, V94, P6116, DOI 10.1073/pnas.94.12.6116; Klinker JF, 1999, EUR J BIOCHEM, V261, P72, DOI 10.1046/j.1432-1327.1999.00209.x; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; KRUPINSKI J, 1988, J BIOL CHEM, V263, P12333; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu WW, 1996, P NATL ACAD SCI USA, V93, P8258, DOI 10.1073/pnas.93.16.8258; Loisel TP, 1999, J BIOL CHEM, V274, P31014, DOI 10.1074/jbc.274.43.31014; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; MILLER T, 1995, BYTE, V20, P18; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; MORISHITA R, 1995, J BIOL CHEM, V270, P29469, DOI 10.1074/jbc.270.49.29469; MOYERS JS, 1995, BIOCHEM J, V305, P411, DOI 10.1042/bj3050411; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; Offermanns S, 1996, J BIOL CHEM, V271, P26044, DOI 10.1074/jbc.271.42.26044; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Schroeder H, 1996, J CELL BIOL, V134, P647, DOI 10.1083/jcb.134.3.647; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; SONG KS, 1997, CELL MOL BIOL, V43, P292; Stanislaus D, 1998, BIOL REPROD, V59, P579, DOI 10.1095/biolreprod59.3.579; Stanislaus D, 1997, MOL ENDOCRINOL, V11, P738, DOI 10.1210/me.11.6.738; STRASSHEIM D, 1994, J BIOL CHEM, V269, P14307; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Ueda H, 1999, J BIOL CHEM, V274, P12124, DOI 10.1074/jbc.274.17.12124; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; Wang J, 1999, J BIOL CHEM, V274, P31641, DOI 10.1074/jbc.274.44.31641; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Wang YR, 1999, J BIOL CHEM, V274, P37435, DOI 10.1074/jbc.274.52.37435; Wedegaertner PB, 1998, BIOL SIGNAL RECEPT, V7, P125; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; Wedegaertner PB, 1996, MOL BIOL CELL, V7, P1225, DOI 10.1091/mbc.7.8.1225; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WIELAND T, 1991, EUR J BIOCHEM, V196, P707, DOI 10.1111/j.1432-1033.1991.tb15869.x; WIELAND T, 1992, J BIOL CHEM, V267, P20791; WIELAND T, 1993, J BIOL CHEM, V268, P18111; Wise A, 1997, FEBS LETT, V407, P257, DOI 10.1016/S0014-5793(97)00300-1; Yasuda H, 1998, J BIOL CHEM, V273, P21958, DOI 10.1074/jbc.273.34.21958; ZICK Y, 1986, P NATL ACAD SCI USA, V83, P9294, DOI 10.1073/pnas.83.24.9294	94	154	155	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	2001	20	13					1643	1652		10.1038/sj.onc.1204185	http://dx.doi.org/10.1038/sj.onc.1204185			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313912				2022-12-17	WOS:000168089800015
J	Maroulakou, IG; Bowe, DB				Maroulakou, IG; Bowe, DB			Expression and function of Ets transcription factors in mammalian development: a regulatory network	ONCOGENE			English	Review						Ets family; development; gene expression; gene regulation; mammalian	STIMULATING FACTOR-I; DNA-BINDING DOMAIN; GENE-EXPRESSION; FAMILY-MEMBER; ONCOGENE FAMILY; MICE LACKING; ERG GENE; T-CELLS; C-ETS; SPI-B	The Ets transcription factor family is involved in a variety of mammalian developmental processes at the cellular, tissue and organ levels. They are implicated in cellular proliferation, differentiation, migration, apoptosis and cell-cell interactions. This article reviews recent studies that demonstrate the integral importance of Ets in the dosage dependent regulation of development. The expression of many Ets genes is associated with mesenchymal - epithelial interactions and changes in extracellular matrix proteins, These inductive processes contribute to tissue remodeling and integrity, particularly during embryonic development. Overlapping as well as unique patterns of Ets expression are evident in developing tissues, including development of the lymphoid and myeloid lineages, brain and central nervous system, bone and mammary gland. Integration of these data will allow the development of predictive models for the regulation of complex developmental processes.	Med Univ S Carolina, Hollings Canc Ctr, Ctr Mol & Struct Biol, Charleston, SC 29403 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29403 USA	Medical University of South Carolina; Medical University of South Carolina	Maroulakou, IG (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Ctr Mol & Struct Biol, Charleston, SC 29403 USA.							AMOUYEL P, 1988, BRAIN RES, V447, P149, DOI 10.1016/0006-8993(88)90976-6; Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; Anderson KL, 1998, BLOOD, V92, P1576, DOI 10.1182/blood.V92.5.1576.417k29_1576_1585; Anderson KL, 1999, BLOOD, V94, P2310, DOI 10.1182/blood.V94.7.2310.419k34_2310_2318; Anderson MK, 1999, DEVELOPMENT, V126, P3131; Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Athanasiou M, 1996, CELL GROWTH DIFFER, V7, P1525; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Bassuk AG, 1998, MOL MED, V4, P392, DOI 10.1007/BF03401746; Bastian LS, 1999, BLOOD, V93, P2637, DOI 10.1182/blood.V93.8.2637.408k20_2637_2644; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BHAT NK, 1994, HYBRIDOMA, V13, P1, DOI 10.1089/hyb.1994.13.1; BOLON I, 1995, AM J PATHOL, V147, P1298; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; Brass AL, 1999, EMBO J, V18, P977, DOI 10.1093/emboj/18.4.977; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Buttice G, 1996, ONCOGENE, V13, P2297; Calmels TPG, 1995, BIOL CELL, V84, P53, DOI 10.1016/0248-4900(96)81318-9; CHEN HM, 1995, ONCOGENE, V11, P1549; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN JM, 1987, DEV BIOL, V120, P311, DOI 10.1016/0012-1606(87)90234-X; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; Davis JN, 1996, GENE, V171, P265, DOI 10.1016/0378-1119(96)00013-3; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; DelannoyCourdent A, 1996, INT J DEV BIOL, V40, P1097; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; FAUST EA, 1993, J EXP MED, V177, P915, DOI 10.1084/jem.177.4.915; Fisher RC, 1998, STEM CELLS, V16, P25, DOI 10.1002/stem.160025; FRIEDMAN LS, 1994, CANCER RES, V54, P6374; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GANAN Y, 1996, INT J DEV BIOL S, pS189; Garrett-Sinha LA, 1999, IMMUNITY, V10, P399, DOI 10.1016/S1074-7613(00)80040-0; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GREVIN D, 1993, INT J DEV BIOL, V37, P519; Guerriero A, 2000, BLOOD, V95, P879, DOI 10.1182/blood.V95.3.879.003k13_879_885; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; Henkel GW, 1999, BLOOD, V93, P2849; Henkel GW, 1996, BLOOD, V88, P2917, DOI 10.1182/blood.V88.8.2917.bloodjournal8882917; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; HROMAS R, 1994, INT J HEMATOL, V59, P257; HROMAS R, 1993, BLOOD, V82, P2998; HROMAS R, 1993, BIOCHIM BIOPHYS ACTA, V1172, P155, DOI 10.1016/0167-4781(93)90283-J; JEON IS, 1995, ONCOGENE, V10, P1229; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kaya M, 1996, ONCOGENE, V12, P221; Kilpatrick LM, 1999, BIOL REPROD, V61, P120, DOI 10.1095/biolreprod61.1.120; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; LaurentHuck FM, 1996, DEV BRAIN RES, V97, P107, DOI 10.1016/S0165-3806(96)00134-4; LEIDEN JM, 1994, CURR OPIN IMMUNOL, V6, P231, DOI 10.1016/0952-7915(94)90096-5; LELIEVRE E, 2000, IN PRESS INT J BIOCH; Lichanska AM, 1999, BLOOD, V94, P127, DOI 10.1182/blood.V94.1.127.413k07_127_138; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Luton D, 1997, EARLY HUM DEV, V47, P147, DOI 10.1016/S0378-3782(96)01775-6; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Mattot V, 2000, ONCOGENE, V19, P762, DOI 10.1038/sj.onc.1203248; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Melet F, 1996, MOL CELL BIOL, V16, P2708; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; Neznanov N, 1999, CANCER RES, V59, P4242; Papas Takis S., 1997, Leukemia (Basingstoke), V11, P557; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; Potter MD, 2000, BLOOD, V95, P3341, DOI 10.1182/blood.V95.11.3341.011k44_3341_3348; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; ROSS IL, 1994, ONCOGENE, V9, P121; ROWE A, 1992, EXP CELL RES, V202, P199, DOI 10.1016/0014-4827(92)90420-D; Sapi E, 1998, CANCER RES, V58, P1027; Spain LM, 1999, J IMMUNOL, V163, P2681; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Su GH, 1996, J EXP MED, V184, P203, DOI 10.1084/jem.184.1.203; Su GH, 1997, EMBO J, V16, P7118, DOI 10.1093/emboj/16.23.7118; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; Vary CPH, 2000, EXP CELL RES, V257, P213, DOI 10.1006/excr.2000.4879; Vlaeminck-Guillem V, 2000, MECH DEVELOP, V91, P331, DOI 10.1016/S0925-4773(99)00272-5; Walunas TL, 2000, J IMMUNOL, V164, P2857, DOI 10.4049/jimmunol.164.6.2857; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; Werb Z, 1998, ANN NY ACAD SCI, V857, P110, DOI 10.1111/j.1749-6632.1998.tb10111.x; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315; Yang BS, 1996, MOL CELL BIOL, V16, P538; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961	131	154	164	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2000	19	55					6432	6442		10.1038/sj.onc.1204039	http://dx.doi.org/10.1038/sj.onc.1204039			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175359				2022-12-17	WOS:000166595000005
J	Ikeda, S; Kishida, M; Matsuura, Y; Usui, H; Kikuchi, A				Ikeda, S; Kishida, M; Matsuura, Y; Usui, H; Kikuchi, A			GSK-3 beta-dependent phosphorylation of adenomatous polyposis coli gene product can be modulated by beta-catenin and protein phosphatase 2A complexed with Axin	ONCOGENE			English	Article						APC; axin; GSK-3 beta; beta-catenin; PP2A	TUMOR-SUPPRESSOR PROTEIN; GLYCOGEN-SYNTHASE KINASE-3; WNT SIGNALING PATHWAY; FUNCTIONAL INTERACTION; NEGATIVE REGULATOR; XENOPUS EMBRYOS; APC; TRANSCRIPTION; ASSOCIATION; GSK3-BETA	Axin forms a complex with adenomatous polyposis coli gene product (APC), glycogen synthase kinase-3 beta (GSK-3 beta), and beta-catenin through different binding sites and downregulates beta-catenin. GSK-3 beta-dependent phosphorylation of APC-(1211-2075) which has the Axin-binding site was facilitated by Axin, but that of APC-(959-1338) which lacks the Axin-binding site was not, Axin-(298-506) or Axin-(298-832), which has the GSK-3 beta- and beta-catenin- but not APC-binding sites, did not enhance GSK-3 beta-dependent phosphorylation of either APC(1211-2075) or APC-(959-1338), Furthermore, beta-catenin stimulated the phosphorylation of APC-(959-1338) and APC-(1211-2075) by GSK-3 beta in the presence of Axin, Consistent with these in vitro observations, expression of beta-catenin or Axin in COS cells promoted an SDS gel band shift of APC. These results indicate that APC complexed with Axin is effectively phosphorylated by GSK-3 beta and that beta-catenin may modulate this phosphorylation, In addition, the heterodimeric form of protein phosphatase 2A (PP2A) directly bound to Axin, and PP2A complexed with Axin dephosphorylated APC phosphorylated by GSK-3 beta. Taken together, these results suggest that GSK-3 beta-dependent phosphorylation of APC can be modulated by beta-catenin and PP2A complexed with Axin.	Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Natl Inst Infect Dis, Dept Virol 2, Shinjuku Ku, Tokyo 1628640, Japan	Hiroshima University; National Institute of Infectious Diseases (NIID)	Kikuchi, A (corresponding author), Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.							Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Dale TC, 1998, BIOCHEM J, V329, P209; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Murai H, 1996, FEBS LETT, V392, P153, DOI 10.1016/0014-5793(96)00806-X; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1997, CANCER RES, V57, P4624; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; USUI H, 1988, J BIOL CHEM, V263, P3752; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zolnierowicz S, 1996, BIOCHEM J, V317, P187, DOI 10.1042/bj3170187	43	154	158	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 27	2000	19	4					537	545		10.1038/sj.onc.1203359	http://dx.doi.org/10.1038/sj.onc.1203359			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698523				2022-12-17	WOS:000085104200007
J	Rosenwald, IB; Chen, JJ; Wang, ST; Savas, L; London, IM; Pullman, J				Rosenwald, IB; Chen, JJ; Wang, ST; Savas, L; London, IM; Pullman, J			Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis	ONCOGENE			English	Article						eIF-4E; translation factors; cyclins; protein synthesis; transformation; colon cancer	CAP-BINDING PROTEIN; RNA 5' CAP; TRANSLATION INITIATION; FACTOR 4E; MESSENGER-RNA; CYCLIN D1; CELL-CYCLE; C-MYC; ORNITHINE DECARBOXYLASE; RETINOBLASTOMA PROTEIN	A general increase in protein synthesis and a specific increase in the synthesis of growth-promoting proteins are necessary for mitogenesis, Regulation of protein synthesis, as well as preferential translation of some mRNAs coding for growth promoting proteins (e.g. cyclin D1), involves the essential protein synthesis initiation factor eIF-4E. This factor is induced by various oncoproteins, and, when overexpressed, it can transform cultured cells. In this report we explore the roles of eIF-4E in human neoplastic disorders of the colon and in the regulation of general and specific protein synthesis, We find that eIF-4E is increased in colon adenomas and carcinomas, and this increase is accompanied in most but not all cases by elevation of cyclin D1 levels. While general protein synthesis is increased by eIF-4E overexpression in cultured cells, only a small proportion of proteins is preferentially upregulated by eIF-4E, as revealed by two-dimensional gel electrophoresis. These results are consistent with the view that eIF-4E plays a role in carcinogenesis by increasing general protein synthesis and by preferentially upregulating a subset of putative growth promoting proteins. Our results, taken together with the recent findings that c-myc transcription is negatively regulated by APC and our earlier data on transcriptional activation of eIF-4E expression by c-Myc suggest that eIF-4E is a downstream target of the APC/beta-catenin/Tcf-4 pathway, and is strongly involved in colon tumorigenesis.	Univ Massachusetts, Med Ctr, Dept Pathol, Worcester, MA 01655 USA; MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA	University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Massachusetts Institute of Technology (MIT)	Rosenwald, IB (corresponding author), Univ Massachusetts, Med Ctr, Dept Pathol, 55 Lake Ave N, Worcester, MA 01655 USA.				NIDDK NIH HHS [DK 16272, R01 DK016272] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016272] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; Epifanova O I, 1977, Int Rev Cytol Suppl, P303; GRAFF JR, 1995, INT J CANCER, V60, P255; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HERSHKO A, 1971, NATURE-NEW BIOL, V232, P206, DOI 10.1038/newbio232206a0; Jones RM, 1996, MOL CELL BIOL, V16, P4754; Kevil C, 1995, ONCOGENE, V11, P2339; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOZAK M, 1994, BIOCHIMIE, V76, P815, DOI 10.1016/0300-9084(94)90182-1; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li BDL, 1997, CANCER-AM CANCER SOC, V79, P2385; Maeda K, 1997, INT J CANCER, V74, P310, DOI 10.1002/(SICI)1097-0215(19970620)74:3<310::AID-IJC13>3.0.CO;2-F; MAKIN CA, 1984, J CLIN PATHOL, V37, P975, DOI 10.1136/jcp.37.9.975; MELHEM MF, 1992, CANCER RES, V52, P5853; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MORRIS DR, 1995, PROG NUCLEIC ACID RE, V51, P339, DOI 10.1016/S0079-6603(08)60883-1; Nathan CAO, 1997, ONCOGENE, V15, P579, DOI 10.1038/sj.onc.1201216; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Rhoads RE, 1995, CURR TOP MICROBIOL, V203, P131; RHOADS RE, 1994, BIOCHIMIE, V76, P831, DOI 10.1016/0300-9084(94)90184-8; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; Rosenwald IB, 1996, BIOESSAYS, V18, P243, DOI 10.1002/bies.950180312; Rosenwald IB, 1995, CANCER LETT, V98, P77, DOI 10.1016/0304-3835(95)90206-6; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Shantz LM, 1996, CANCER RES, V56, P3265; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; ZETTERBERG A, 1991, COLD SH Q B, V56, P137; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0	44	154	173	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	1999	18	15					2507	2517		10.1038/sj.onc.1202563	http://dx.doi.org/10.1038/sj.onc.1202563			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229202				2022-12-17	WOS:000079703300011
J	Yeyati, PL; Shaknovich, R; Boterashvili, S; Li, J; Ball, HJ; Waxman, S; Nason-Burchenal, K; Dmitrovsky, E; Zelent, A; Licht, JD				Yeyati, PL; Shaknovich, R; Boterashvili, S; Li, J; Ball, HJ; Waxman, S; Nason-Burchenal, K; Dmitrovsky, E; Zelent, A; Licht, JD			Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A	ONCOGENE			English	Article						PLZF; acute promyelocytic leukemia; cell cycle; cyclin A	ACUTE PROMYELOCYTIC LEUKEMIA; ACID RECEPTOR-ALPHA; EMBRYONAL CARCINOMA-CELLS; ZINC-FINGER GENE; RETINOIC ACID; RAR-ALPHA; DNA-BINDING; S-PHASE; TRANSCRIPTIONAL PROPERTIES; MAMMALIAN FIBROBLASTS	The PLZF gene was identified by its fusion with the RAR alpha locus in a therapy resistant form of acute promyelocytic leukemia (APL) associated with the t(11;17)(q23;q21) translocation, Here we describe PLZF as a negative regulator of cell cycle progression ultimately leading to growth suppression, PLZF can bind and repress the cyclin A2 promoter while expression of cyclin A2 reverts the growth suppressed phenotype of myeloid cells expressing PLZF, In contrast RAR alpha-PLZF, a fusion protein generated in t(11;17)(q23;q21)APL activates cyclin A2 transcription and allows expression of cyclin A in anchorage-deprived NIH3T3 cells. Therefore, cyclin A2 is a candidate target gene for PLZF and inhibition of cyclin A expression may contribute to the growth suppressive properties of PLZF, Deregulation of cyclin A2 by RAR alpha-PLZF may represent an oncogenic mechanism of this chimeric protein and contribute to the aggressive clinical phenotype of t(11;17)(q23;q21)-associated APL.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Brookdale Ctr Dev & Mol Biol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Inst Canc Res, Leukaemia Res Fund Ctr, London SW3 6JB, England; Mem Sloan Kettering Canc Ctr, Mol Med Lab, New York, NY 10021 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Memorial Sloan Kettering Cancer Center	Licht, JD (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.		Ball, Helen J/A-4242-2010; Zelent, Arthur/B-3532-2009; Licht, Jonathan/L-4239-2019	Ball, Helen J/0000-0003-3733-9748; Zelent, Arthur/0000-0002-7968-9888; Licht, Jonathan/0000-0002-3942-1369	NATIONAL CANCER INSTITUTE [R01CA062275, R01CA059936] Funding Source: NIH RePORTER; NCI NIH HHS [CA62275, CA59936] Funding Source: Medline; NIGMS NIH HHS [GM0707280-17] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1989, SHORT PROTOCOLS MOL; AVANTAGGIATO V, 1995, J NEUROSCI, V15, P4927; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Desdouets C, 1996, FEBS LETT, V385, P34, DOI 10.1016/0014-5793(96)00330-4; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; EAVES CJ, 1991, BLOOD, V78, P110; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GRIGNANI F, 1994, BLOOD, V83, P10; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grimwade D, 1997, BLOOD, V90, P4876; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUIDEZ F, 1994, LEUKEMIA, V8, P312; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Huet X, 1996, MOL CELL BIOL, V16, P3789; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KREIDER BL, 1990, MOL CELL BIOL, V10, P4846, DOI 10.1128/MCB.10.9.4846; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LANOTTE M, 1991, BLOOD, V77, P1080; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Licht JD, 1996, ONCOGENE, V12, P323; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; Meyyappan M, 1998, MOL CELL BIOL, V18, P3163, DOI 10.1128/MCB.18.6.3163; MOASSER MM, 1995, ONCOGENE, V10, P1537; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OTSUKA H, 1976, J CELL PHYSIOL, V87, P213, DOI 10.1002/jcp.1040870209; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pandolfi PP, 1996, HAEMATOLOGICA, V81, P472; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; SCHMID I, 1991, CYTOMETRY, V12, P279, DOI 10.1002/cyto.990120312; SCHUSTERSEWC H, 1992, LETOPIS, V1, P9; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	57	154	156	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					925	934		10.1038/sj.onc.1202375	http://dx.doi.org/10.1038/sj.onc.1202375			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023668				2022-12-17	WOS:000078510600009
J	Chai, YL; Cui, JQ; Shao, NS; Reddy, ESP; Rao, VN				Chai, YL; Cui, JQ; Shao, NS; Reddy, ESP; Rao, VN			The second BRCT domain of BRCA-1 proteins interacts with p53 and stimulates transcription from the p21(WAF1/CIP1) promoter	ONCOGENE			English	Article						BRCA1; BRCA1a; BRCA1b; p53; p21(WAF1/CIP1); BRCT domain; CBP/p300	OVARIAN-CANCER INCIDENCE; CELL-CYCLE; GENE BRCA1; BREAST; EXPRESSION; GROWTH; ACTIVATION; INDUCTION; TISSUES; REGION	Inherited mutations in the breast and ovarian cancer susceptibility gene BRCA1 are associated with high risk for developing breast and ovarian cancers. Several studies link BRCA1 to transcriptional regulation, DNA repair, apoptosis and growth/tumor suppression. BRCA1 associates with p53 and stimulates transcription in both p53 dependent and p53-independent manners. BRCA1 splice variants BRCA1a (p110) and BRCA1b (p100) associates with CBP/p300 co-activators. Here we show that BRCA1a and BRCA1b proteins stimulate p53-dependent transcription from the p21(WAF1/CIP1) promoter. In addition, the C-terminal second BRCA1 (BRCT) domain is sufficient for p53 mediated transactivation of the p21 promoter. Previous studies emphasized the importance of the BRCT domain, which shows homology with p53 binding protein (53BP1), in transcriptional activation, growth inhibition and tumor suppression. Our findings demonstrate an additional function for this domain in protein-protein interaction and co-activation of p53. We also found that BRCA1a and BRCA1b proteins interact with p53 in vitro and in vivo. The p53 interaction domain of BRCA1a/1b maps, in vitro, to the second BRCT domain (aa 1760-1863). The BRCT domain binds to the central domain of p53 which is required for sequence specific DNA binding. These results demonstrate for the first time the presence of a second p53 interaction domain in BRCA1 proteins and suggests that BRCA1a and BRCA1b proteins, like BRCA1, function as p53 co-activators. This BRCT domain also binds in vitro to CBP. These results suggest that one of the mechanisms by which BRCA1 proteins function is through recruitment of CBP/p300 associated HAT/FAT activity for acetylation of p53 to specific promoters resulting in transcriptional activation.	Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, Philadelphia, PA 19102 USA	Drexel University	Rao, VN (corresponding author), Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, MS 481,New Coll Bldg,Broad & Vine St, Philadelphia, PA 19102 USA.				NCI NIH HHS [CA57322, CA50507, CA58642] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050507, R01CA057322, R01CA058642] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Cui JQ, 1998, ONCOL REP, V5, P585; Cui JQ, 1998, ONCOL REP, V5, P591; EASTON DF, 1995, AM J HUM GENET, V56, P265; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FORD D, 1995, AM J HUM GENET, V57, P1457; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Rao VN, 1996, ONCOGENE, V12, P523; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Szabo CI, 1996, HUM MOL GENET, V5, P1289, DOI 10.1093/hmg/5.9.1289; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; WU CJ, 1996, NAT GENET, V14, P430; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	33	154	157	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					263	268		10.1038/sj.onc.1202323	http://dx.doi.org/10.1038/sj.onc.1202323			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926942				2022-12-17	WOS:000078166000029
J	Chernova, OB; Somerville, RPT; Cowell, JK				Chernova, OB; Somerville, RPT; Cowell, JK			A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors	ONCOGENE			English	Article						tumor suppressor gene; human chromosome 10; gene rearrangements; chromosome translocation; glioma; leucine-rich repeat	LEUCINE-RICH REPEATS; HUMAN GLIOMAS; DECREASED EXPRESSION; PROSTATE-CANCER; SUPPRESSOR GENE; HETEROZYGOSITY; CHROMOSOME-10; DROSOPHILA; GROWTH; MOTIF	Loss of heterozygosity for 10q23-26 is seen in over 80% of glioblastoma multiforme tumors. We have used a positional cloning strategy to isolate a novel gene, LGI1 (Leucine-rich gene-Glioma Inactivated), which is rearranged as a result of the t(10;19)(q24;q13) balanced translocation in the T98G glioblastoma cell, line lacking any normal chromosome 10. Rearrangement of the LGI1 gene was also detected in the A172 glioblastoma cell line and several glioblastoma tumors. These rearrangements lead to a complete absence of LGI1 expression in glioblastoma cells. The LGI1 gene encodes a protein with a calculated molecular mass of 60 kD and contains 3.5 leucine-rich repeats (LRR) with conserved flanking sequences. In the LRR domain, LGI1 has the highest homology with a number of transmembrane and extracellular proteins which function as receptors and adhesion proteins. LGI1 is predominantly expressed in neural tissues, especially in brain; its expression is reduced in low grade brain tumors and it is significantly reduced or absent in malignant gliomas. Its localization to the 10q24 region, and rearrangements or inactivation in malignant brain tumors, suggest that LGI1 is a candidate tumor suppressor gene involved in progression of glial tumors.	Cleveland Clin Fdn, Dept Neurosci NC30, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Cowell, JK (corresponding author), Cleveland Clin Fdn, Dept Neurosci NC30, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.			Cowell, John/0000-0002-2079-5950	NATIONAL CANCER INSTITUTE [R01CA076457] Funding Source: NIH RePORTER; NCI NIH HHS [CA76457] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albarosa R, 1996, AM J HUM GENET, V58, P1260; Asamoto M, 1997, JPN J CLIN ONCOL, V27, P22, DOI 10.1093/jjco/27.1.22; ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; BERRY R, 1995, NAT GENET, V10, P415, DOI 10.1038/ng0895-415; Bigner SH, 1990, BRAIN PATHOL, V1, P12, DOI 10.1111/j.1750-3639.1990.tb00633.x; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Buchanan SGS, 1996, PROG BIOPHYS MOL BIO, V65, P1, DOI 10.1016/S0079-6107(96)00003-X; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHANG Z, 1993, DEV BIOL, V160, P315, DOI 10.1006/dbio.1993.1310; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHERNOVA O, 1998, IN PRESS CANC GENET; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; COWELL JK, 1984, INT J CANCER, V33, P657, DOI 10.1002/ijc.2910330517; ElNaggar AK, 1997, AM J PATHOL, V151, P1767; GRAY IC, 1995, CANCER RES, V55, P4800; HALFON MS, 1995, DEV BIOL, V169, P151, DOI 10.1006/dbio.1995.1134; HERBST RA, 1994, CANCER RES, V54, P3111; JAMES CD, 1988, CANCER RES, V48, P5546; KARLBOM AE, 1993, HUM GENET, V92, P169; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Kong XT, 1997, CANCER RES, V57, P3772; KRAUS JA, 1995, J NEUROPATH EXP NEUR, V54, P91, DOI 10.1097/00005072-199501000-00011; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Marchini S, 1997, BRIT J CANCER, V76, P146, DOI 10.1038/bjc.1997.355; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Myohanen SK, 1998, CANCER RES, V58, P591; Nose A, 1997, DEVELOPMENT, V124, P1433; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; PEIFFER SL, 1995, CANCER RES, V55, P1922; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; Raff T, 1997, BIOTECHNIQUES, V23, P456, DOI 10.2144/97233st02; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; Rasheed BKA, 1997, CANCER RES, V57, P4187; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Rosenberg JE, 1996, ONCOGENE, V13, P2483; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; Ryan A, 1998, GYNECOL ONCOL, V68, P14, DOI 10.1006/gyno.1997.4881; Schmidt EE, 1997, BRIT J CANCER, V75, P2, DOI 10.1038/bjc.1997.2; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; VONDEIMLING A, 1994, INT J CANCER, V57, P676, DOI 10.1002/ijc.2910570511; WINDISCH JM, 1995, BIOCHEMISTRY-US, V34, P11256, DOI 10.1021/bi00035a035; WINDISCH JM, 1995, J BIOL CHEM, V270, P28133	47	154	167	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 3	1998	17	22					2873	2881		10.1038/sj.onc.1202481	http://dx.doi.org/10.1038/sj.onc.1202481			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879993				2022-12-17	WOS:000077286400007
